PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Harrison, TM; Blichert-Toft, J; Muller, W; Albarede, F; Holden, P; Mojzsis, SJ				Harrison, TM; Blichert-Toft, J; Muller, W; Albarede, F; Holden, P; Mojzsis, SJ			Heterogeneous Hadean hafnium: Evidence of continental crust at 4.4 to 4.5 Ga	SCIENCE			English	Article							OLD DETRITAL ZIRCONS; LU-HF; JACK HILLS; ISOTOPE EVIDENCE; ND-142 EVIDENCE; EARLY EARTH; MANTLE; CONSTRAINTS; EVOLUTION; DIFFERENTIATION	The long-favored paradigm for the development of continental crust is one of progressive growth beginning at similar to 4 billion years ago (Ga). To test this hypothesis, we measured initial Hf-176/(177) Hf values of 4.01- to 4.37-Ga detrital zircons from Jack Hills, Western Australia. epsilon(Hf) (deviations of Hf-176/Hf-177 from bulk Earth in parts per 104) values show large positive and negative deviations from those of the bulk Earth. Negative values indicate the development of a Lu/Hf reservoir that is consistent with the formation of continental crust (Lu/Hf approximate to 0.01), perhaps as early as 4.5 Ga. Positive epsilon(Hf) deviations require early and likely widespread depletion of the upper mantle. These results support the view that continental crust had formed by 4.4 to 4.5 Ga and was rapidly recycled into the mantle.	Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; Ecole Normale Super Lyon, CNRS, UMR 5570, F-69364 Lyon, France; Royal Holloway Univ London, Dept Geol, Egham TW20 0EX, Surrey, England; Univ Colorado, Dept Geol Sci, Boulder, CO 80309 USA	Australian National University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; Centre National de la Recherche Scientifique (CNRS); Ecole Normale Superieure de Lyon (ENS de LYON); University of London; Royal Holloway University London; University of Colorado System; University of Colorado Boulder	Harrison, TM (corresponding author), Australian Natl Univ, Res Sch Earth Sci, Canberra, ACT 0200, Australia.	mark.harrison@anu.edu.au	Albarede, Francis/A-8871-2011; Blichert-Toft, Janne/C-8280-2012; MOJZSIS, STEPHEN/AAU-9527-2020; Harrison, Timothy M/E-7443-2012	Albarede, Francis/0000-0003-1994-1428; Blichert-Toft, Janne/0000-0002-4932-4079; MOJZSIS, STEPHEN/0000-0003-0000-125X; Muller, Wolfgang/0000-0001-5368-8011				ALBAREDE F, IN PRESS GEOCHIM COS; Amelin Y, 1999, NATURE, V399, P252, DOI 10.1038/20426; ARMSTRONG RL, 1981, PHILOS T R SOC A, V301, P443, DOI 10.1098/rsta.1981.0122; ARMSTRONG RL, 1991, AUST J EARTH SCI, V38, P613, DOI 10.1080/08120099108727995; Blichert-Toft J, 2004, CHEM GEOL, V207, P261, DOI 10.1016/j.chemgeo.2004.03.005; Blichert-Toft J, 1999, EARTH PLANET SC LETT, V171, P439, DOI 10.1016/S0012-821X(99)00151-X; BlichertToft J, 1997, EARTH PLANET SC LETT, V148, P243, DOI 10.1016/S0012-821X(97)00040-X; BLICHERTTOFT J, UNPUB; Bowring SA, 1999, CONTRIB MINERAL PETR, V134, P3, DOI 10.1007/s004100050465; Boyet M, 2003, EARTH PLANET SC LETT, V214, P427, DOI 10.1016/S0012-821X(03)00423-0; Boyet M, 2005, SCIENCE, V309, P576, DOI 10.1126/science.1113634; Caro G, 2003, NATURE, V423, P428, DOI 10.1038/nature01668; CHASE CG, 1988, EARTH PLANET SC LETT, V91, P66, DOI 10.1016/0012-821X(88)90151-3; COMPSTON W, 1986, NATURE, V321, P766, DOI 10.1038/321766a0; Davies GF, 2002, GEOCHIM COSMOCHIM AC, V66, P3125, DOI 10.1016/S0016-7037(02)00915-8; GALER SJG, 1991, GEOCHIM COSMOCHIM AC, V55, P227, DOI 10.1016/0016-7037(91)90413-Y; Hermann J, 2003, J METAMORPH GEOL, V21, P833, DOI 10.1046/j.1525-1314.2003.00484.x; Hoskin PWO, 2003, REV MINERAL GEOCHEM, V53, P27, DOI 10.2113/0530027; MAAS R, 1992, GEOCHIM COSMOCHIM AC, V56, P1281, DOI 10.1016/0016-7037(92)90062-N; MCCULLOCH MT, 1993, LITHOS, V30, P237, DOI 10.1016/0024-4937(93)90038-E; Mojzsis SJ, 2001, NATURE, V409, P178, DOI 10.1038/35051557; Patchett PJ, 2004, EARTH PLANET SC LETT, V222, P29, DOI 10.1016/j.epsl.2004.02.030; Pearson DG, 2004, J PETROL, V45, P439, DOI 10.1093/petrology/egg102; Soderlund U, 2004, EARTH PLANET SC LETT, V219, P311, DOI 10.1016/S0012-821X(04)00012-3; Taylor S.R., 1985, CONTINENTAL CRUST IT; Trail D, 2004, GEOCHIM COSMOCHIM AC, V68, pA743; VEIZER J, 1979, J GEOL, V87, P341, DOI 10.1086/628425; Vervoort JD, 1996, GEOCHIM COSMOCHIM AC, V60, P3717, DOI 10.1016/0016-7037(96)00201-3; Vervoort JD, 1999, EARTH PLANET SC LETT, V168, P79, DOI 10.1016/S0012-821X(99)00047-3; Vervoort JD, 1999, GEOCHIM COSMOCHIM AC, V63, P533, DOI 10.1016/S0016-7037(98)00274-9; Watson EB, 2005, SCIENCE, V308, P841, DOI 10.1126/science.1110873; Wilde SA, 2001, NATURE, V409, P175, DOI 10.1038/35051550	32	397	428	2	82	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 23	2005	310	5756					1947	1950		10.1126/science.1117926	http://dx.doi.org/10.1126/science.1117926			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	997UX	16293721				2022-12-28	WOS:000234275400040
J	Ruotolo, BT; Giles, K; Campuzano, I; Sandercock, AM; Bateman, RH; Robinson, CV				Ruotolo, BT; Giles, K; Campuzano, I; Sandercock, AM; Bateman, RH; Robinson, CV			Evidence for macromolecular protein rings in the absence of bulk water	SCIENCE			English	Article							IONIZATION MASS-SPECTROMETRY; BINDING ATTENUATION PROTEIN; ELECTROSPRAY-IONIZATION; GAS-PHASE; STRUCTURAL-CHANGES; CRYSTAL-STRUCTURES; ION-TRAP; COMPLEXES; CHROMATOGRAPHY; TRANSITIONS	We have examined the architecture of a protein complex in the absence of bulk water. By determining collision cross sections of assemblies of the trp RNA binding protein, TRAP, we established that the 11-membered ring topology of the complex can be maintained within a mass spectrometer. We also found that the binding of tryptophan enhances the stability of the ring structure and that addition of a specific RNA molecule increases the size of the complex and prevents structural collapse. These results provide definitive evidence that protein quaternary structure can be maintained in the absence of bulk water and highlight the potential of ion mobility separation for defining shapes of heterogeneous macromolecular assemblies.	Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England; Waters MS Technol Ctr, Manchester M55 5PP, Lancs, England	University of Cambridge; Waters UK	Robinson, CV (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	cvr24@cam.ac.uk	Ruotolo, Brandon/F-2669-2013	Ruotolo, Brandon/0000-0002-6084-2328; robinson, carol/0000-0001-7829-5505	Engineering and Physical Sciences Research Council [GR/R87703/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Aloy P, 2004, SCIENCE, V303, P2026, DOI 10.1126/science.1092645; Anchordoquy TJ, 2001, ARCH BIOCHEM BIOPHYS, V390, P35, DOI 10.1006/abbi.2001.2351; Antson AA, 1999, NATURE, V401, P235, DOI 10.1038/45730; ANTSON AA, 1995, NATURE, V374, P693, DOI 10.1038/374693a0; Aquilina JA, 2003, P NATL ACAD SCI USA, V100, P10611, DOI 10.1073/pnas.1932958100; Badman ER, 2001, ANAL CHEM, V73, P6000, DOI 10.1021/ac010744a; Bell JA, 1999, PROTEIN SCI, V8, P2033, DOI 10.1110/ps.8.10.2033; Brooijmans N, 2002, PROTEINS, V48, P645, DOI 10.1002/prot.10139; FENN JB, 1989, SCIENCE, V246, P64, DOI 10.1126/science.2675315; Giles K, 2004, RAPID COMMUN MASS SP, V18, P2401, DOI 10.1002/rcm.1641; Hanson CL, 2004, J BIOL CHEM, V279, P24907, DOI 10.1074/jbc.R300037200; Jarrold MF, 2000, ANNU REV PHYS CHEM, V51, P179, DOI 10.1146/annurev.physchem.51.1.179; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; KATTA V, 1991, J AM CHEM SOC, V113, P8534, DOI 10.1021/ja00022a058; Koch MHJ, 2003, Q REV BIOPHYS, V36, P147, DOI 10.1017/S0033583503003871; LIGHTWAHL KJ, 1994, J AM CHEM SOC, V116, P5271, DOI 10.1021/ja00091a035; Loo JA, 2005, J AM SOC MASS SPECTR, V16, P998, DOI 10.1016/j.jasms.2005.02.017; Loo JA, 1997, MASS SPECTROM REV, V16, P1; Mason E., 1988, TRANSPORT PROPERTIES; McCammon MG, 2004, J AM CHEM SOC, V126, P5950, DOI 10.1021/ja0317170; Mesleh MF, 1996, J PHYS CHEM-US, V100, P16082, DOI 10.1021/jp961623v; Myung S, 2002, J PHYS CHEM A, V106, P9976, DOI 10.1021/jp0206368; Nagendra HG, 1998, PROTEINS, V32, P229, DOI 10.1002/(SICI)1097-0134(19980801)32:2<229::AID-PROT9>3.0.CO;2-F; Oomens J, 2005, PHYS CHEM CHEM PHYS, V7, P1345, DOI 10.1039/b502322j; Pace CN, 2004, PHILOS T ROY SOC B, V359, P1225, DOI 10.1098/rstb.2004.1500; Rostom AA, 1999, J AM CHEM SOC, V121, P4718, DOI 10.1021/ja990238r; Sobott F, 2002, CURR OPIN STRUC BIOL, V12, P729, DOI 10.1016/S0959-440X(02)00400-1; Sobott F, 2003, INT J MASS SPECTROM, V230, P193, DOI 10.1016/j.ijms.2003.09.008; van den Heuvel RH, 2004, CURR OPIN CHEM BIOL, V8, P519, DOI 10.1016/j.cbpa.2004.08.006; VON HELDEN G, 1995, SCIENCE, V267, P1483, DOI 10.1126/science.267.5203.1483; WOOD TD, 1995, P NATL ACAD SCI USA, V92, P2451, DOI 10.1073/pnas.92.7.2451; Wyttenbach T, 2003, TOP CURR CHEM, V225, P207, DOI 10.1007/b10470	32	484	487	2	152	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2005	310	5754					1658	1661		10.1126/science.1120177	http://dx.doi.org/10.1126/science.1120177			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	993NV	16293722				2022-12-28	WOS:000233961700038
J	Schmiege, S; Russo, NF				Schmiege, S; Russo, NF			Depression and unwanted first pregnancy: longitudinal cohort study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PARENTHOOD; TRANSITION; ABORTION	Objective To examine the outcomes of an unwanted first pregnancy (abortion v live delivery) and risk of depression and to explain discrepancies with previous research that used the same dataset. Design Longitudinal cohort study. Setting Nationally representative sample of US men and women aged 14-24 in 1979. Participants 1247 women in the US national longitudinal survey of youth who aborted or delivered an unwanted first pregnancy. Main outcome measures Clinical cut-off and continuous scores on a 1992 measure of the Center for Epidemiological Studies depression scale. Results Terminating compared with delivering an unwanted first pregnancy was not directly related to risk of clinically significant depression (odds ratio 1.19, 95% confidence interval 0.85 to 1.66). No evidence was found of a relation between pregnancy outcome and depression in analyses of subgroups known to vary in under-reporting of abortion. In analyses of the characteristics. of non-respondents, refusal to provide information on abortion did not explain die lack of detecting a relation between abortion and mental health. The abortion group had a significantly higher mean education and income and lower total family size, all of which were associated with a lower risk of depression. Conclusions Evidence that choosing to terminate rather than deliver an unwanted first pregnancy puts women at higher risk of depression is inconclusive. Discrepancies between current findings and those of previous research using die same dataset primarily reflect differences in coding of a first pregnancy.	Arizona State Univ, Dept Psychol, Tempe, AZ 85287 USA; Univ Colorado, Dept Psychol UCB 345, Boulder, CO 80309 USA	Arizona State University; Arizona State University-Tempe; University of Colorado System; University of Colorado Boulder	Russo, NF (corresponding author), Arizona State Univ, Dept Psychol, Box 871104, Tempe, AZ 85287 USA.	nancy.russo@asu.edu						CAMPBELL SB, 1992, DEV PSYCHOPATHOL, V4, P29, DOI 10.1017/S095457940000554X; COWAN SP, 2000, J FAM ISSUES, V6, P451; Cox MJ, 1999, J MARRIAGE FAM, V61, P611, DOI 10.2307/353564; GILCHRIST AC, 1995, BRIT J PSYCHIAT, V167, P243, DOI 10.1192/bjp.167.2.243; GILCHRIST AC, 1995, BRIT J PSYCHIAT, V167, P213; GLENN ND, 1982, J MARRIAGE FAM, V44, P63, DOI 10.2307/351263; HORWITZ SM, 1991, PEDIATRICS, V87, P862; JONES EF, 1992, DEMOGRAPHY, V29, P113, DOI 10.2307/2061366; Reardon DC, 2002, BRIT MED J, V324, P151, DOI 10.1136/bmj.324.7330.151; REARDON DC, CLIN DEPRESSION UNIN; RUSSO NF, 1992, PROF PSYCHOL-RES PR, V23, P269, DOI 10.1037/0735-7028.23.4.269; Trad PV, 1999, ADOLESCENCE, V34, P221	12	63	65	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	2005	331	7528					1303	1306A		10.1136/bmj.38623.532384.55	http://dx.doi.org/10.1136/bmj.38623.532384.55			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	990YE	16257993	Green Published, Bronze			2022-12-28	WOS:000233778500016
J	Scott, JT; Rundall, TG; Vogt, TM; Hsu, J				Scott, JT; Rundall, TG; Vogt, TM; Hsu, J			Kaiser Permanente's experience of implementing an electronic medical record: a qualitative study	BRITISH MEDICAL JOURNAL			English	Article								Objective To examine users' attitudes to implementation of an electronic medical record system in Kaiser Permanente Hawaii. Design Qualitative study based on semistructured interviews. Setting Four primary healthcare teams in four clinics, and four specialty departments in one hospital, on Oahu, Hawaii. Shortly before the interviews, Kaiser Permanente stopped implementation of die initial system in favour of a competing one. Participants Twenty six senior clinicians, managers, and project team members. Results Seven key findings emerged: users perceived the decision to adopt the electronic medical record system as flawed; software design problems increased resistance; the system reduced doctors' productivity, especially during initial implementation, which fuelled resistance; the system required clarification of clinical roles and responsibilities, which was traumatic for some individuals; a cooperative culture created trade-offs at varying points in the implementation; no single leadership style was optimal-a participatory, consensus-building style may lead to more effective adoption decisions, whereas decisive leadership could help resolve barriers and resistance during implementation; the process fostered a counter climate of conflict, which was resolved by withdrawal of the initial system. Conclusions Implementation involved several critical components, including perceptions of the system selection, early testing, adaptation of the system to the larger organisation, and adaptation of the organisation to the new electronic environment. Throughout, organisational factors Such as leadership, culture, and professional ideals played complex roles, each facilitating and hindering implementation at various points. A transient climate of conflict was associated with adoption of the system.	Univ St Andrews, Sch Management, St Andrews KY16 9SS, Fife, Scotland; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Kaiser Permanente Ctr Hlth Res, Honolulu, HI 96817 USA; Kaiser Permanente, Div Res, Oakland, CA 94612 USA	University of St Andrews; University of California System; University of California Berkeley; Kaiser Permanente; Kaiser Permanente	Scott, JT (corresponding author), Univ St Andrews, Sch Management, St Andrews KY16 9SS, Fife, Scotland.	jts1@st-andrews.ac.uk	Greiver, Michelle/N-8764-2015	Greiver, Michelle/0000-0001-8957-0285				Aarts J, 2004, J AM MED INFORM ASSN, V11, P207, DOI 10.1197/jamia.M1372; Department of Health, 2001, BUILD INF COR IMPL N; Garrido T, 2005, BMJ-BRIT MED J, V330, P581, DOI 10.1136/bmj.330.7491.581; GIBBS W, 1997, SCI AM, V278, P64; Humber M, 2004, BRIT MED J, V328, P1145, DOI 10.1136/bmj.328.7449.1145; Kaplan B, 1988, J Health Hum Resour Adm, V11, P9; Littlejohns P, 2003, BRIT MED J, V326, P860, DOI 10.1136/bmj.326.7394.860; *NHS INF AUTH, 2002, NHS IA STRAT PLAN 20; [No title captured]	9	164	168	0	19	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 3	2005	331	7528					1313	1316		10.1136/bmj.38638.497477.68	http://dx.doi.org/10.1136/bmj.38638.497477.68			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	990YE	16269467	Green Published, Bronze, Green Submitted			2022-12-28	WOS:000233778500019
J	Galie, N; Ghofrani, HA; Torbicki, A; Barst, RJ; Rubin, LJ; Badesch, D; Fleming, T; Parpia, T; Burgess, G; Branzi, A; Grimminger, F; Kurzyna, M; Simonneau, G				Galie, N; Ghofrani, HA; Torbicki, A; Barst, RJ; Rubin, LJ; Badesch, D; Fleming, T; Parpia, T; Burgess, G; Branzi, A; Grimminger, F; Kurzyna, M; Simonneau, G		SUPER Study Grp	Sildenafil citrate therapy for pulmonary arterial hypertension	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INHALED NITRIC-OXIDE; ORAL SILDENAFIL; 6-MINUTE WALK; DOUBLE-BLIND; VASODILATOR; ILOPROST; PROSTACYCLIN; MECHANISMS; INHIBITORS; PATHWAY	Background Sildenafil inhibits phosphodiesterase type 5, an enzyme that metabolizes cyclic guanosine monophosphate, thereby enhancing the cyclic guanosine monophosphate-mediated relaxation and growth inhibition of vascular smooth-muscle cells, including those in the lung. Methods In this double-blind, placebo-controlled study, we randomly assigned 278 patients with symptomatic pulmonary arterial hypertension (either idiopathic or associated with connective-tissue disease or with repaired congenital systemic-to-pulmonary shunts) to placebo or sildenafil (20, 40, or 80 mg) orally three times daily for 12 weeks. The primary end point was the change from baseline to week 12 in the distance walked in six minutes. The change in mean pulmonary-artery pressure and World Health Organization (WHO) functional class and the incidence of clinical worsening were also assessed, but the study was not powered to assess mortality. Patients completing the 12-week randomized study could enter a long-term extension study. Results The distance walked in six minutes increased from baseline in all sildenafil groups; the mean placebo-corrected treatment effects were 45 m (+13.0 percent), 46 m (+13.3 percent), and 50 m (+14.7 percent) for 20, 40, and 80 mg of sildenafil, respectively (P<0.001 for all comparisons). All sildenafil doses reduced the mean pulmonary-artery pressure (P=0.04, P=0.01, and P<0.001, respectively), improved the WHO functional class (P=0.003, P<0.001, and P<0.001, respectively), and were associated with side effects such as flushing, dyspepsia, and diarrhea. The incidence of clinical worsening did not differ significantly between the patients treated with sildenafil and those treated with placebo. Among the 222 patients completing one year of treatment with sildenafil monotherapy, the improvement from baseline at one year in the distance walked in six minutes was 51 m. Conclusions Sildenafil improves exercise capacity, WHO functional class, and hemodynamics in patients with symptomatic pulmonary arterial hypertension.	Univ Bologna, Inst Cardiol, I-40138 Bologna, Italy; Univ Giessen, Univ Hosp, Giessen, Germany; Inst TB & Lung Dis, Warsaw, Poland; Columbia Presbyterian Med Ctr, Babies & Childrens Hosp, New York, NY 10032 USA; Univ Calif San Diego, La Jolla, CA 92093 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Washington, Seattle, WA 98195 USA; Pfizer Global Res & Dev, Sandwich, Kent, England; Hop Antoine Beclere, Clamart, France	University of Bologna; Justus Liebig University Giessen; Columbia University; NewYork-Presbyterian Hospital; University of California System; University of California San Diego; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Washington; University of Washington Seattle; Pfizer; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Antoine-Beclere - APHP	Galie, N (corresponding author), Univ Bologna, Inst Cardiol, Via Massarenti 9, I-40138 Bologna, Italy.	n.galie@bo.nettuno.it	Simonneau, Gerald/ABE-6614-2020; Kurzyna, Marcin/AAA-1244-2020; Ghofrani, Hossein Ardeschir/AAD-2856-2022; Ghofrani, Ardeschir/AAD-5293-2020; Galie, Nazzareno/F-7004-2014	Kurzyna, Marcin/0000-0002-6746-469X; Ghofrani, Ardeschir/0000-0002-2029-4419; Galie, Nazzareno/0000-0003-4271-8670; Torbicki, Adam/0000-0003-3475-8832; Grimminger, Friedrich/0000-0001-8725-6276				Barst RJ, 2004, J AM COLL CARDIOL, V43, p40S, DOI 10.1016/j.jacc.2004.02.032; Barst RJ, 1996, NEW ENGL J MED, V334, P296, DOI 10.1056/NEJM199602013340504; Bauer P, 1998, STAT MED, V17, P2133, DOI 10.1002/(SICI)1097-0258(19980930)17:18<2133::AID-SIM901>3.0.CO;2-2; Bhatia S, 2003, MAYO CLIN PROC, V78, P1207, DOI 10.4065/78.10.1207; Channick RN, 1996, CHEST, V109, P1545, DOI 10.1378/chest.109.6.1545; Chi GYH, 1998, DRUG INF J, V32, p1347S, DOI 10.1177/00928615980320S131; Cohen AH, 1996, J CLIN INVEST, V97, P172, DOI 10.1172/JCI118386; Corbin JD, 1999, J BIOL CHEM, V274, P13729, DOI 10.1074/jbc.274.20.13729; DALONZO GE, 1991, ANN INTERN MED, V115, P343, DOI 10.7326/0003-4819-115-5-343; Farber HW, 2004, NEW ENGL J MED, V351, P1655, DOI 10.1056/NEJMra035488; Galie N, 2004, J AM COLL CARDIOL, V43, p81S, DOI 10.1016/j.jacc.2004.02.038; Ghofrani HA, 2002, ANN INTERN MED, V136, P515, DOI 10.7326/0003-4819-136-7-200204020-00008; Ghofrani HA, 2004, J AM COLL CARDIOL, V43, p68S, DOI 10.1016/j.jacc.2004.02.031; Ghofrani HA, 2003, J AM COLL CARDIOL, V42, P158, DOI 10.1016/S0735-1097(03)00555-2; GIAID A, 1995, NEW ENGL J MED, V333, P214, DOI 10.1056/NEJM199507273330403; GUYATT GH, 1985, CAN MED ASSOC J, V132, P919; Humbert M, 2004, J AM COLL CARDIOL, V43, p13S, DOI 10.1016/j.jacc.2004.02.029; Humbert M, 2004, NEW ENGL J MED, V351, P1425, DOI 10.1056/NEJMra040291; Ichinose F, 2001, CRIT CARE MED, V29, P1000, DOI 10.1097/00003246-200105000-00024; Jernigan NL, 2002, AM J PHYSIOL-LUNG C, V282, pL1366, DOI 10.1152/ajplung.00273.2001; Klepetko W, 2004, J AM COLL CARDIOL, V43, p73S, DOI 10.1016/j.jacc.2004.02.039; Lepore JJ, 2002, AM J CARDIOL, V90, P677, DOI 10.1016/S0002-9149(02)02586-9; Michelakis E, 2002, CIRCULATION, V105, P2398, DOI 10.1161/01.CIR.0000016641.12984.DC; Michelakis EA, 2003, HEART FAIL REV, V8, P5, DOI 10.1023/A:1022150819223; Miyamoto S, 2000, AM J RESP CRIT CARE, V161, P487, DOI 10.1164/ajrccm.161.2.9906015; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; Olschewski H, 2002, NEW ENGL J MED, V347, P322, DOI 10.1056/NEJMoa020204; PEPKEZABA J, 1991, LANCET, V338, P1173, DOI 10.1016/0140-6736(91)92033-X; RABE KF, 1994, AM J PHYSIOL, V266, pL536, DOI 10.1152/ajplung.1994.266.5.L536; Rondelet B, 2004, CIRCULATION, V110, P2220, DOI 10.1161/01.CIR.0000143836.40431.F5; Ruberg S J, 1995, J Biopharm Stat, V5, P15, DOI 10.1080/10543409508835097; RUBERG SJ, 1996, J BIOPHARM STAT, V6, P375; Rubin LJ, 2002, NEW ENGL J MED, V346, P1258; Rubin LJ, 2002, NEW ENGL J MED, V346, P896, DOI 10.1056/NEJMoa012212; Rubin LJ, 1997, NEW ENGL J MED, V336, P111, DOI 10.1056/NEJM199701093360207; Sastry BKS, 2004, J AM COLL CARDIOL, V43, P1149, DOI 10.1016/j.jacc.2003.10.056; Schermuly RT, 2004, AM J RESP CRIT CARE, V169, P39, DOI 10.1164/rccm.200302-282OC; Simonneau G, 2004, J AM COLL CARDIOL, V43, p5S, DOI 10.1016/j.jacc.2004.02.037; Simonneau G, 2002, AM J RESP CRIT CARE, V165, P800, DOI 10.1164/ajrccm.165.6.2106079; Tantini B, 2005, BASIC RES CARDIOL, V100, P131, DOI 10.1007/s00395-004-0504-5; Wilkens H, 2001, CIRCULATION, V104, P1218, DOI 10.1161/hc3601.096826; Zhao L, 2001, CIRCULATION, V104, P424, DOI 10.1161/hc2901.093117	42	1711	1833	2	118	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2148	2157		10.1056/NEJMoa050010	http://dx.doi.org/10.1056/NEJMoa050010			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291984				2022-12-28	WOS:000233288600007
J	Noel, B; Kunzle, N				Noel, B; Kunzle, N			Lentigo maligna	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									CHU Vaudois, CH-1011 Lausanne, Switzerland	University of Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV)	Noel, B (corresponding author), CHU Vaudois, CH-1011 Lausanne, Switzerland.								0	15	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2176	2176		10.1056/NEJMicm050144	http://dx.doi.org/10.1056/NEJMicm050144			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291987	Green Published			2022-12-28	WOS:000233288600010
J	Wadden, TA; Berkowitz, RI; Womble, LG; Sarwer, DB; Phelan, S; Cato, RK; Hesson, LA; Osei, SY; Kaplan, R; Stunkard, AJ				Wadden, TA; Berkowitz, RI; Womble, LG; Sarwer, DB; Phelan, S; Cato, RK; Hesson, LA; Osei, SY; Kaplan, R; Stunkard, AJ			Randomized trial of lifestyle modification and pharmacotherapy for obesity	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED TRIAL; WEIGHT-LOSS; PHARMACOLOGICAL-TREATMENT; BEHAVIOR-THERAPY; SIBUTRAMINE; PREVENTION	Background Weight-loss medications are recommended as an adjunct to a comprehensive program of diet, exercise, and behavior therapy but are typically prescribed with minimal or no lifestyle modification. This practice is likely to limit therapeutic benefits. Methods In this one-year trial, we randomly assigned 224 obese adults to receive 15 mg of sibutramine per day alone, delivered by a primary care provider in eight visits of 10 to 15 minutes each; lifestyle-modification counseling alone, delivered in 30 group sessions; sibutramine plus 30 group sessions of lifestyle-modification counseling (i.e., combined therapy); or sibutramine plus brief lifestyle-modification counseling delivered by a primary care provider in eight visits of 10 to 15 minutes each. All subjects were prescribed a diet of 1200 to 1500 kcal per day and the same exercise regimen. Results At one year, subjects who received combined therapy lost a mean (+/-SD) of 12.1+/-9.8 kg, whereas those receiving sibutramine alone lost 5.0+/-7.4 kg, those treated by lifestyle modification alone lost 6.7+/-7.9 kg, and those receiving sibutramine plus brief therapy lost 7.5+/-8.0 kg (P<0.001). Those in the combined-therapy group who frequently recorded their food intake lost more weight than those who did so infrequently (18.1+/-9.8 kg vs. 7.7+/-7.5 kg, P=0.04). Conclusions The combination of medication and group lifestyle modification resulted in more weight loss than either medication or lifestyle modification alone. The results underscore the importance of prescribing weight-loss medications in combination with, rather than in lieu of, lifestyle modification.	Univ Penn, Sch Med, Dept Psychiat, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA; Brown Med Sch, Providence, RI USA; GlaxoSmithKline Inc, Philadelphia, PA USA; GlaxoSmithKline Inc, Bryn Mawr, PA USA	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Brown University; GlaxoSmithKline; GlaxoSmithKline	Wadden, TA (corresponding author), Univ Penn, Sch Med, Dept Psychiat, 3535 Market St,Suite 3029, Philadelphia, PA 19104 USA.	wadden@mail.med.upenn.edu		Phelan, Suzanne/0000-0003-2260-0499	NIDDK NIH HHS [DK065018, DK56124] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK065018, R01DK056124] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arterburn DE, 2004, ARCH INTERN MED, V164, P994, DOI 10.1001/archinte.164.9.994; Avenell A, 2004, HEALTH TECHNOL ASSES, V8, P1; Barkeling B, 2003, INT J OBESITY, V27, P693, DOI 10.1038/sj.ijo.0802298; Berkowitz RI, 2003, JAMA-J AM MED ASSOC, V289, P1805, DOI 10.1001/jama.289.14.1805; Bray GA, 1996, OBES RES, V4, P263, DOI 10.1002/j.1550-8528.1996.tb00544.x; BRIGHTWELL DR, 1979, INT J OBESITY, V3, P141; Brownell KD, 1998, LEARN PROGRAM WEIGHT; BROWNELL KD, 1999, LEARN PROGRAM WEIGHT; Brownell KD, 1990, WEIGHT MAINTENANCE S; Connolly HM, 1997, NEW ENGL J MED, V337, P581, DOI 10.1056/NEJM199708283370901; Connolly HM, 1997, NEW ENGL J MED, V337, P1783; CRAIGHEAD LW, 1984, J CONSULT CLIN PSYCH, V52, P190, DOI 10.1037/0022-006X.52.2.190; Haffner SM, 1996, DIABETES CARE, V19, P1138, DOI 10.2337/diacare.19.10.1138; HOLLON SD, 1981, PSYCHOL BULL, V90, P467, DOI 10.1037/0033-2909.90.3.467; James WPT, 2000, LANCET, V356, P2119, DOI 10.1016/S0140-6736(00)03491-7; Kim SH, 2003, OBES RES, V11, P1116, DOI 10.1038/oby.2003.152; Klein S, 2004, DIABETES CARE, V27, P2067, DOI 10.2337/diacare.27.8.2067; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; McTigue KM, 2003, ANN INTERN MED, V139, P933, DOI 10.7326/0003-4819-139-11-200312020-00013; Phelan S, 2002, OBES RES, V10, P560, DOI 10.1038/oby.2002.77; Pi-Sunyer FX, 1998, OBES RES, V6, p51S; Serdula MK, 2003, JAMA-J AM MED ASSOC, V289, P1747, DOI 10.1001/jama.289.14.1747; Sjostrom L, 1998, LANCET, V352, P167, DOI 10.1016/S0140-6736(97)11509-4; *SPSS, 2000, SPSS WIND VERS 11 0; Wadden TA, 1997, OBES RES, V5, P218, DOI 10.1002/j.1550-8528.1997.tb00296.x; Wadden TA, 2000, MED CLIN N AM, V84, P441, DOI 10.1016/j.psc.2004.09.008; Wadden TA, 2001, ARCH INTERN MED, V161, P218, DOI 10.1001/archinte.161.2.218; Wee CC, 2004, J GEN INTERN MED, V19, P1206, DOI 10.1111/j.1525-1497.2004.40063.x; Wing R. R., 2002, Handbook of obesity treatment, P301; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586; 1998, OBES RES, V6, P464; 1996, SHAPE AM YOUR WAY FI	32	535	548	0	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2111	2120		10.1056/NEJMoa050156	http://dx.doi.org/10.1056/NEJMoa050156			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291981				2022-12-28	WOS:000233288600004
J	Reiber, GE; Raugi, GJ				Reiber, GE; Raugi, GJ			Preventing foot ulcers and amputations in diabetes	LANCET			English	Editorial Material							CHRONIC CARE MODEL; CHRONIC ILLNESS; MANAGEMENT		VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA; VA Puget Sound Hlth Care Syst, Dept Dermatol, Seattle, WA 98101 USA; Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA; Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Reiber, GE (corresponding author), VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA 98101 USA.	greiber@u.washington.edu						Bodenheimer T, 2002, JAMA-J AM MED ASSOC, V288, P1909, DOI 10.1001/jama.288.15.1909; Dargis V, 1999, DIABETES CARE, V22, P1428, DOI 10.2337/diacare.22.9.1428; Driver VR, 2005, DIABETES CARE, V28, P248, DOI 10.2337/diacare.28.2.248; Glasgow RE, 2001, MILBANK Q, V79, P579, DOI 10.1111/1468-0009.00222; Grol R, 2005, IMPROVING PATIENT CA; LITZELMAN DK, 1993, ANN INTERN MED, V119, P36, DOI 10.7326/0003-4819-119-1-199307010-00006; MALONE JM, 1989, AM J SURG, V158, P520, DOI 10.1016/0002-9610(89)90183-9; MAZZE R, 1998, STAGED DIABETES MANA; Patout CA, 2000, DIABETES CARE, V23, P1339, DOI 10.2337/diacare.23.9.1339; Renders CM, 2001, DIABETES CARE, V24, P1821, DOI 10.2337/diacare.24.10.1821; Rith-Najarian S, 1998, J FAM PRACTICE, V47, P127; Rith-Najarian S, 2000, DIABETES CARE, V23, P1445, DOI 10.2337/diacare.23.9.1445; UCCIOLI L, 1995, DIABETES CARE, V18, P1376, DOI 10.2337/diacare.18.10.1376; *VISTA OFF EHR, HIGH QUAL PUBL DOM E; Wagner EH, 1996, MILBANK Q, V74, P511, DOI 10.2307/3350391	15	26	28	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 12	2005	366	9498					1676	1677		10.1016/S0140-6736(05)67674-X	http://dx.doi.org/10.1016/S0140-6736(05)67674-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291047				2022-12-28	WOS:000233206400005
J	Kukura, P; McCamant, DW; Yoon, S; Wandschneider, DB; Mathies, RA				Kukura, P; McCamant, DW; Yoon, S; Wandschneider, DB; Mathies, RA			Structural observation of the primary isomerization in vision with femtosecond-stimulated Raman	SCIENCE			English	Article							INFRARED-SPECTROSCOPY; ENERGY-STORAGE; 1ST STEP; DYNAMICS; RHODOPSIN; CHROMOPHORE; MECHANISM; PROTEIN; HEME	The primary event that initiates vision is the light-induced 11-cis to all-trans isomerization of retinal in the visual pigment rhodopsin. Despite decades of study with the traditional tools of chemical reaction dynamics, both the timing and nature of the atomic motions that lead to photoproduct production remain unknown. We used femtosecond-stimulated Raman spectroscopy to obtain time-resolved vibrational spectra of the molecular structures formed along the reaction coordinate. The spectral evolution of the vibrational features from 200 femtoseconds to 1 picosecond after photon absorption reveals the temporal sequencing of the geometric changes in the retinal backbone that activate this receptor.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Mathies, RA (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	rich@zinc.cchem.berkeley.edu		Kukura, Philipp/0000-0003-0136-7704; Yoon, Sangwoon/0000-0001-5705-4569; McCamant, David/0000-0002-9095-040X	NATIONAL EYE INSTITUTE [R37EY002051, R01EY002051] Funding Source: NIH RePORTER; NEI NIH HHS [EY-02051] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		Andruniow T, 2004, P NATL ACAD SCI USA, V101, P17908, DOI 10.1073/pnas.0407997101; Asplund MC, 2000, P NATL ACAD SCI USA, V97, P8219, DOI 10.1073/pnas.140227997; Blomgren F, 2003, CHEM PHYS LETT, V376, P704, DOI 10.1016/S0009-2614(03)01062-5; Bromberg SE, 1997, SCIENCE, V278, P260, DOI 10.1126/science.278.5336.260; FAYER MD, 2001, ULTRAFAST INFRARED R; Fecko CJ, 2003, SCIENCE, V301, P1698, DOI 10.1126/science.1087251; Fleming GR, 1997, CURR OPIN STRUC BIOL, V7, P738, DOI 10.1016/S0959-440X(97)80086-3; FRISCH MJ, 2001, GAUSSIAN 03; HAMAGUCHI H, 1994, ANNU REV PHYS CHEM, V45, P593, DOI 10.1146/annurev.physchem.45.1.593; Kochendoerfer GG, 1996, J PHYS CHEM-US, V100, P14526, DOI 10.1021/jp960509+; Lee SY, 2004, J CHEM PHYS, V121, P3632, DOI 10.1063/1.1777214; Liu RSH, 2001, ACCOUNTS CHEM RES, V34, P555, DOI 10.1021/ar000165c; LOPPNOW GR, 1988, BIOPHYS J, V54, P35, DOI 10.1016/S0006-3495(88)82928-X; Mahet M, 2004, FEMTOCHEMISTRY AND FEMTOBIOLOGY: ULTRAFAST EVENTS IN MOLECULAR SCIENCE, P441, DOI 10.1016/B978-044451656-5/50086-4; Mathies R. A., 2000, HDB BIOL PHYSICS, P55, DOI DOI 10.1016/S1383-8121(00)80005-6; McCamant DW, 2003, J PHYS CHEM A, V107, P8208, DOI 10.1021/jp030147n; Mizutani Y, 1997, SCIENCE, V278, P443, DOI 10.1126/science.278.5337.443; Palczewski K, 2000, SCIENCE, V289, P739, DOI 10.1126/science.289.5480.739; POLLARD WT, 1990, J CHEM PHYS, V92, P4012, DOI 10.1063/1.457815; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; Schotte F, 2003, SCIENCE, V300, P1944, DOI 10.1126/science.1078797; SHANK CV, 1986, SCIENCE, V233, P1276, DOI 10.1126/science.233.4770.1276; WARSHEL A, 1976, NATURE, V260, P679, DOI 10.1038/260679a0; Yan ECY, 2004, BIOCHEMISTRY-US, V43, P10867, DOI 10.1021/bi0400148; ZEWAIL AH, 1994, FEMTOCHEMISTRY; ZHU LY, 1994, SCIENCE, V266, P629, DOI 10.1126/science.7939716	26	527	531	1	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1006	1009		10.1126/science.1118379	http://dx.doi.org/10.1126/science.1118379			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284176				2022-12-28	WOS:000233343400040
J	Mellinghoff, IK; Wang, MY; Vivanco, I; Haas-Kogan, DA; Zhu, SJ; Dia, EQ; Lu, KV; Yoshimoto, K; Huang, JHY; Chute, DJ; Riggs, BL; Horvath, S; Liau, LM; Cavenee, WK; Rao, PN; Beroukhim, R; Peck, TC; Lee, JC; Sellers, WR; Stokoe, D; Prados, M; Cloughesy, TF; Sawyers, CL; Mischel, PS				Mellinghoff, IK; Wang, MY; Vivanco, I; Haas-Kogan, DA; Zhu, SJ; Dia, EQ; Lu, KV; Yoshimoto, K; Huang, JHY; Chute, DJ; Riggs, BL; Horvath, S; Liau, LM; Cavenee, WK; Rao, PN; Beroukhim, R; Peck, TC; Lee, JC; Sellers, WR; Stokoe, D; Prados, M; Cloughesy, TF; Sawyers, CL; Mischel, PS			Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							EPIDERMAL-GROWTH-FACTOR; TUMOR-SUPPRESSOR GENE; ABL TYROSINE KINASE; CELL LUNG-CANCER; PHASE-II TRIAL; FACTOR-RECEPTOR; ANAPLASTIC ASTROCYTOMA; GLIOMA-CELLS; MUTATIONS; GEFITINIB	BACKGROUND: The epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed, or mutated in glioblastomas, but only 10 to 20 percent of patients have a response to EGFR kinase inhibitors. The mechanism of responsiveness of glioblastomas to these inhibitors is unknown. METHODS: We sequenced kinase domains in the EGFR and human EGFR type 2 (Her2/neu) genes and analyzed the expression of EGFR, EGFR deletion mutant variant III (EGFRvIII), and the tumor-suppressor protein PTEN in recurrent malignant gliomas from patients who had received EGFR kinase inhibitors. We determined the molecular correlates of clinical response, validated them in an independent data set, and identified effects of the molecular abnormalities in vitro. RESULTS: Of 49 patients with recurrent malignant glioma who were treated with EGFR kinase inhibitors, 9 had tumor shrinkage of at least 25 percent. Pretreatment tissue was available for molecular analysis from 26 patients, 7 of whom had had a response and 19 of whom had rapid progression during therapy. No mutations in EGFR or Her2/neu kinase domains were detected in the tumors. Coexpression of EGFRvIII and PTEN was significantly associated with a clinical response (P<0.001; odds ratio, 51; 95 percent confidence interval, 4 to 669). These findings were validated in 33 patients who received similar treatment for glioblastoma at a different institution (P=0.001; odds ratio, 40; 95 percent confidence interval, 3 to 468). In vitro, coexpression of EGFRvIII and PTEN sensitized glioblastoma cells to erlotinib. CONCLUSIONS: Coexpression of EGFRvIII and PTEN by glioblastoma cells is associated with responsiveness to EGFR kinase inhibitors.	Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Ctr Hlth Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Mol & Med Pharmacol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Human Genet, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Biostat, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurosurg, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Henry E Singleton Brain Tumor Program, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Howard Hughes Med Inst, David Geffen Sch Med, Los Angeles, CA 90095 USA; Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA 94143 USA; Univ Calif San Diego, Ludwig Inst Canc Res, San Diego, CA 92103 USA; Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Broad Inst, Boston, MA 02115 USA; MIT, Boston, MA USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California San Francisco; Ludwig Institute for Cancer Research; University of California System; University of California San Diego; Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT)	Mischel, PS (corresponding author), Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Ctr Hlth Sci, 10833 Le Conte Ave,Room 13-321, Los Angeles, CA 90095 USA.	pmischel@mednet.ucla.edu	Sawyers, Charles/G-5327-2016; Cloughesy, Timothy Francis/AGV-1013-2022; Vivanco, Igor/GZH-2045-2022; Prados, Michael/N-5220-2019	Vivanco, Igor/0000-0001-6347-9416; Liau, Linda/0000-0002-4053-0052	NCI NIH HHS [CA105695, T32 CA009172, CA108633, CA62399, CA95616, 5T32CA09056, CA097257] Funding Source: Medline; NIGMS NIH HHS [5F31GM067600] Funding Source: Medline; NINDS NIH HHS [NS43147, NS050151] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P50CA097257, T32CA009172, T32CA009056, U01CA062399, U01CA105695, P01CA095616, R01CA108633] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F31GM067600] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS050151, K08NS043147] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aldape KD, 2004, J NEUROPATH EXP NEUR, V63, P700, DOI 10.1093/jnen/63.7.700; Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724; BATRA SK, 1995, CELL GROWTH DIFFER, V6, P1251; Bianco R, 2003, ONCOGENE, V22, P2812, DOI 10.1038/sj.onc.1206388; Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655; Choe G, 2003, CANCER RES, V63, P2742; Dancey JE, 2003, LANCET, V362, P62, DOI 10.1016/S0140-6736(03)13810-X; Demetri GD, 2002, NEW ENGL J MED, V347, P472, DOI 10.1056/NEJMoa020461; Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402; Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401; Druker BJ, 2001, NEW ENGL J MED, V345, P232; EKSTRAND AJ, 1991, CANCER RES, V51, P2164; Ermoian RP, 2002, CLIN CANCER RES, V8, P1100; Fabian MA, 2005, NAT BIOTECHNOL, V23, P329, DOI 10.1038/nbt1068; Frederick L, 2000, CANCER RES, V60, P1383; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Furnari FB, 1997, P NATL ACAD SCI USA, V94, P12479, DOI 10.1073/pnas.94.23.12479; Furnari FB, 1998, CANCER RES, V58, P5002; Goudar RK, 2005, MOL CANCER THER, V4, P101; Han YC, 1996, CANCER RES, V56, P3859; Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100; Huang HJS, 1997, J BIOL CHEM, V272, P2927, DOI 10.1074/jbc.272.5.2927; Isomura M, 2004, J CLIN ONCOL, V22, p200S; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Li B, 2004, ONCOGENE, V23, P4594, DOI 10.1038/sj.onc.1207602; Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943; Liliental J, 2000, CURR BIOL, V10, P401, DOI 10.1016/S0960-9822(00)00417-6; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; MANNING BD, 2002, SCI STKE; Marie Y, 2005, NEUROLOGY, V64, P1444, DOI 10.1212/01.WNL.0000158654.07080.B0; Mellinghoff IK, 2002, CANCER RES, V62, P5254; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Mishima K, 2001, CANCER RES, V61, P5349; Mishima K, 2001, CANCER RES, V61, P7703; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Pawson T, 2003, SCIENCE, V300, P445, DOI 10.1126/science.1083653; PRADOS M, 2003, P AN M AM SOC CLIN, V22, P99; Rich JN, 2004, NEW ENGL J MED, V351, P1260; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110; Sawyers CL, 2003, GENE DEV, V17, P2998, DOI 10.1101/gad.1152403; Smith JS, 2001, JNCI-J NATL CANCER I, V93, P1246, DOI 10.1093/jnci/93.16.1246; Sonoda Y, 2001, CANCER RES, V61, P6674; Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637; Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356; Stephens P, 2004, NATURE, V431, P525, DOI 10.1038/431525b; SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602; Traxler P, 2001, MED RES REV, V21, P499, DOI 10.1002/med.1022; van Oosterom AT, 2001, LANCET, V358, P1421, DOI 10.1016/S0140-6736(01)06535-7; Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965	51	1126	1190	1	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2005	353	19					2012	2024		10.1056/NEJMoa051918	http://dx.doi.org/10.1056/NEJMoa051918			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282176				2022-12-28	WOS:000233119600006
J	Toda, M; Takagaki, A; Okamura, M; Kondo, JN; Hayashi, S; Domen, K; Hara, M				Toda, M; Takagaki, A; Okamura, M; Kondo, JN; Hayashi, S; Domen, K; Hara, M			Green chemistry - Biodiesel made with sugar catalyst	NATURE			English	Editorial Material							SOLID ACID CATALYSTS		Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan; Natl Inst Adv Ind Sci & Technol, Res Inst Instrumentat Frontier, Tsukuba, Ibaraki 3058565, Japan; Univ Tokyo, Sch Engn, Dept Chem Syst Engn, Bunkyo Ku, Tokyo 1138656, Japan	Tokyo Institute of Technology; National Institute of Advanced Industrial Science & Technology (AIST); University of Tokyo	Toda, M (corresponding author), Tokyo Inst Technol, Chem Resources Lab, Yokohama, Kanagawa 2268503, Japan.	mhara@res.titech.ac.jp	KONDO, Junko N./E-8648-2014; Takagaki, Atsushi/E-6788-2010; Hara, Masayuki/AAH-4361-2019; Hara, Michikazu/E-6418-2014	KONDO, Junko N./0000-0002-7940-1266; Takagaki, Atsushi/0000-0002-7829-3451; Hara, Michikazu/0000-0003-3450-5704				Clark JH, 2002, ACCOUNTS CHEM RES, V35, P791, DOI 10.1021/ar010072a; Hara M, 2004, ANGEW CHEM INT EDIT, V43, P2955, DOI 10.1002/anie.200453947; Misono M, 2000, CR ACAD SCI II C, V3, P471, DOI 10.1016/S1387-1609(00)01165-8; Okuhara T, 2002, CHEM REV, V102, P3641, DOI 10.1021/cr0103569; Silverstien R. M., 1991, SPECTROMETRIC IDENTI, P218; Smith K, 2003, ORG BIOMOL CHEM, V1, P1560, DOI 10.1039/b301260c; Tsubouchi N, 2003, ENERG FUEL, V17, P1119, DOI 10.1021/ef020265u; Zhang XQ, 1999, CHEM MATER, V11, P384, DOI 10.1021/cm980605i	8	699	780	12	410	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					178	178		10.1038/438178a	http://dx.doi.org/10.1038/438178a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281026	Bronze			2022-12-28	WOS:000233133500036
J	Weiss, RA				Weiss, RA			Robert Koch: The grandfather of cloning?	CELL			English	Editorial Material								This year marks the centenary of Robert Koch's Nobel Prize for discovering the cause of tuberculosis. Koch was also the first scientist to isolate the anthrax and cholera microbes. Yet perhaps one of his greatest contributions to biology is the least appreciated: his method for propagating individual colonies of bacteria on plates, a technique that came to be called cloning.	UCL, Wohl Vis Ctr, Div Infect & Immun, London W1T 4JF, England	University of London; University College London	Weiss, RA (corresponding author), UCL, Wohl Vis Ctr, Div Infect & Immun, 46 Cleveland St, London W1T 4JF, England.	r.weiss@ucl.ac.uk						Brock T.D., 1999, R KOCH LIFE MED BACT; HARRIS H, 1997, CELLS BODY HIST SOMA; Judson H. F., 1996, 8 DAY CREATION; KLOTZKO AJ, 2004, CLONE YOUR OWN SCI E; Schlich T, 2000, HIST PHIL LIFE SCI, V22, P43	5	9	11	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 8	2005	123	4					539	542		10.1016/j.cell.2005.11.001	http://dx.doi.org/10.1016/j.cell.2005.11.001			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286000	Bronze			2022-12-28	WOS:000233497400001
J	Ruta, V; Chen, JY; MacKinnon, R				Ruta, V; Chen, JY; MacKinnon, R			Calibrated measurement of gating-charge arginine displacement in the KvAP voltage-dependent K+ channel	CELL			English	Article							POTASSIUM CHANNEL; TRANSMEMBRANE MOVEMENT; SODIUM-CHANNELS; ION CHANNELS; S4 SEGMENT; SENSOR; ACTIVATION; DOMAIN; INHIBITION; RESIDUES	Voltage-dependent ion channels open and conduct ions in response to changes in cell-membrane voltage. The voltage sensitivity of these channels arises from the motion of charged arginine residues located on the S4 helices of the channel's voltage sensors. In KvAP, a prokaryotic voltage-dependent K channel, the S4 helix forms part of a helical hairpin structure, the voltage-sensor paddle. We have measured the membrane depth of residues throughout the KvAP channel using avidin accessibility to different-length tethered biotin reagents. From these measurements, we have calibrated the tether lengths and derived the thickness of the membrane that forms a barrier to avidin penetration, allowing us to determine the magnitude of displacement of the voltage-sensor paddles during channel gating. Here we show that the voltagesensor paddles are highly mobile compared to other regions of the channel and transfer the gating-charge arginines 15-20 angstrom through the membrane to open the pore.	Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	MacKinnon, R (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Mol Neurobiol & Biophys, 1230 York Ave, New York, NY 10021 USA.	mackinn@rockefeller.edu		Ruta, Vanessa/0000-0002-4963-2768				Aggarwal SK, 1996, NEURON, V16, P1169, DOI 10.1016/S0896-6273(00)80143-9; Baker OS, 1998, NEURON, V20, P1283, DOI 10.1016/S0896-6273(00)80507-3; Bezanilla F, 2000, PHYSIOL REV, V80, P555, DOI 10.1152/physrev.2000.80.2.555; Cha A, 1999, NATURE, V402, P809, DOI 10.1038/45552; Gandhi CS, 2003, NEURON, V40, P515, DOI 10.1016/S0896-6273(03)00646-9; Gandhi CS, 2002, J GEN PHYSIOL, V120, P455, DOI 10.1085/jgp.20028678; Glauner KS, 1999, NATURE, V402, P813, DOI 10.1038/45561; Gonzalez C, 2005, P NATL ACAD SCI USA, V102, P5020, DOI 10.1073/pnas.0501051102; Heginbotham L, 1999, J GEN PHYSIOL, V114, P551, DOI 10.1085/jgp.114.4.551; Hille B., 2001, ION CHANNELS EXCITAB, V3rd Edn; Hristova K, 1998, BIOPHYS J, V74, P2419, DOI 10.1016/S0006-3495(98)77950-0; Jiang YX, 2003, NATURE, V423, P42, DOI 10.1038/nature01581; Jiang YX, 2003, NATURE, V423, P33, DOI 10.1038/nature01580; Larsson HP, 1996, NEURON, V16, P387, DOI 10.1016/S0896-6273(00)80056-2; Lee SY, 2005, P NATL ACAD SCI USA, V102, P15441, DOI 10.1073/pnas.0507651102; Lee SY, 2004, NATURE, V430, P232, DOI 10.1038/nature02632; Long SB, 2005, SCIENCE, V309, P897, DOI 10.1126/science.1116269; Mannuzzu LM, 1996, SCIENCE, V271, P213, DOI 10.1126/science.271.5246.213; Phillips LR, 2005, NATURE, V436, P857, DOI 10.1038/nature03873; Posson DJ, 2005, NATURE, V436, P848, DOI 10.1038/nature03819; PUGLIESE L, 1993, J MOL BIOL, V231, P698, DOI 10.1006/jmbi.1993.1321; Qiu XQ, 1996, J GEN PHYSIOL, V107, P313, DOI 10.1085/jgp.107.3.313; Ruta V, 2003, NATURE, V422, P180, DOI 10.1038/nature01473; SCHOPPA NE, 1992, SCIENCE, V255, P1712, DOI 10.1126/science.1553560; Senzel L, 1998, J GEN PHYSIOL, V112, P317, DOI 10.1085/jgp.112.3.317; Seoh SA, 1996, NEURON, V16, P1159, DOI 10.1016/S0896-6273(00)80142-7; SIGWORTH FJ, 1994, Q REV BIOPHYS, V27, P1, DOI 10.1017/S0033583500002894; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; Suchyna TM, 2004, NATURE, V430, P235, DOI 10.1038/nature02743; Swartz KJ, 1997, NEURON, V18, P675, DOI 10.1016/S0896-6273(00)80307-4; WIENER MC, 1992, BIOPHYS J, V61, P437; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0; Yang NB, 1996, NEURON, V16, P113, DOI 10.1016/S0896-6273(00)80028-8; Yusaf SP, 1996, PFLUG ARCH EUR J PHY, V433, P91, DOI 10.1007/s004240050253	34	175	178	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					463	475		10.1016/j.cell.2005.08.041	http://dx.doi.org/10.1016/j.cell.2005.08.041			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269337	Bronze			2022-12-28	WOS:000233264300014
J	Schuwirth, BS; Borovinskaya, MA; Hau, CW; Zhang, W; Vila-Sanjurjo, A; Holton, JM; Cate, JHD				Schuwirth, BS; Borovinskaya, MA; Hau, CW; Zhang, W; Vila-Sanjurjo, A; Holton, JM; Cate, JHD			Structures of the bacterial ribosome at 3.5 angstrom resolution	SCIENCE			English	Article							PEPTIDE-BOND FORMATION; AMINOACYL-TRANSFER-RNA; ELONGATION-FACTOR G; ESCHERICHIA-COLI; MESSENGER-RNA; CRYOELECTRON MICROSCOPY; PROTEIN-SYNTHESIS; CRYO-EM; SUBUNIT; TRANSLOCATION	We describe two structures of the intact bacteria[ ribosome from Escherichia coli determined to a resolution of 3.5 angstroms by x-ray crystallography. These structures provide a detailed view of the interface between the small and large ribosomal subunits and the conformation of the peptidyl transferase center in the context of the intact ribosome. Differences between the two ribosomes reveal a high degree of flexibility between the head and the rest of the small subunit. Swiveling of the head of the small subunit observed in the present structures, coupled to-the ratchet-like motion of the two subunits observed previously, suggests a mechanism for the final movements of messenger RNA (mRNA) and transfer RNAs (tRNAs) during translocation.	Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Physiol Biosci Div, Berkeley, CA 94720 USA; Free Univ Berlin, Inst Chem Crystallog, D-14195 Berlin, Germany	University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; Free University of Berlin	Cate, JHD (corresponding author), Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA.	jcate@lbl.gov	Classen, Scott/AAY-8176-2020; Vila-Sanjurjo, Antón/AAS-1007-2020; ZHANG, WEN/HHS-1997-2022; vila-sanjurjo, anton/L-1941-2014	Vila-Sanjurjo, Antón/0000-0001-7820-1644; ZHANG, WEN/0000-0002-4973-1168; vila-sanjurjo, anton/0000-0001-7820-1644	NCI NIH HHS [CA92584] Funding Source: Medline; NIGMS NIH HHS [GM65050] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA092584] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM065050] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Agrawal RK, 2004, P NATL ACAD SCI USA, V101, P8900, DOI 10.1073/pnas.0401904101; Allen GS, 2005, CELL, V121, P703, DOI 10.1016/j.cell.2005.03.023; Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; Bashan A, 2003, MOL CELL, V11, P91, DOI 10.1016/S1097-2765(03)00009-1; Battle DJ, 2002, P NATL ACAD SCI USA, V99, P11676, DOI 10.1073/pnas.182221799; Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Blaha G, 2000, METHOD ENZYMOL, V317, P292; Boeckmann B, 2003, NUCLEIC ACIDS RES, V31, P365, DOI 10.1093/nar/gkg095; Brandi L, 2004, J MOL BIOL, V335, P881, DOI 10.1016/j.jmb.2003.10.067; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Cannone JJ, 2002, BMC BIOINFORMATICS, V3, DOI 10.1186/1471-2105-3-2; Cate JH, 1997, NAT STRUCT BIOL, V4, P553, DOI 10.1038/nsb0797-553; Cate JH, 1996, SCIENCE, V273, P1678, DOI 10.1126/science.273.5282.1678; Cukras AR, 2005, J MOL BIOL, V349, P47, DOI 10.1016/j.jmb.2005.03.075; Cukras AR, 2003, MOL CELL, V12, P321, DOI 10.1016/S1097-2765(03)00275-2; Culver GM, 1999, SCIENCE, V285, P2133, DOI 10.1126/science.285.5436.2133; Draper DE, 2004, RNA, V10, P335, DOI 10.1261/rna.5205404; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Frank J, 2003, BIOPOLYMERS, V68, P223, DOI 10.1002/bip.10210; Gao N, 2005, MOL CELL, V18, P663, DOI 10.1016/j.molcel.2005.05.005; Green R, 1997, ANNU REV BIOCHEM, V66, P679, DOI 10.1146/annurev.biochem.66.1.679; Gromadski KB, 2004, MOL CELL, V13, P191, DOI 10.1016/S1097-2765(04)00005-X; Hagerman PJ, 1997, ANNU REV BIOPH BIOM, V26, P139, DOI 10.1146/annurev.biophys.26.1.139; Halic M, 2004, NATURE, V427, P808, DOI 10.1038/nature02342; Hansen JL, 2002, P NATL ACAD SCI USA, V99, P11670, DOI 10.1073/pnas.172404099; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Hoang L, 2004, P NATL ACAD SCI USA, V101, P12439, DOI 10.1073/pnas.0405227101; HUIBONHOA G, 1980, BIOCHEMISTRY-US, V19, P3080, DOI 10.1021/bi00554a038; JELENC PC, 1979, P NATL ACAD SCI USA, V76, P3174, DOI 10.1073/pnas.76.7.3174; Jenner L, 2005, SCIENCE, V308, P120, DOI 10.1126/science.1105639; Katunin VI, 2002, MOL CELL, V10, P339, DOI 10.1016/S1097-2765(02)00566-X; Khaitovich P, 1999, P NATL ACAD SCI USA, V96, P85, DOI 10.1073/pnas.96.1.85; Kim DF, 1999, MOL CELL, V4, P859, DOI 10.1016/S1097-2765(00)80395-0; Klaholz BP, 2003, NATURE, V421, P90, DOI 10.1038/nature01225; Klaholz BP, 2004, NATURE, V427, P862, DOI 10.1038/nature02332; Klein DJ, 2004, RNA, V10, P1366, DOI 10.1261/rna.7390804; MACON JB, 1968, BIOCHEMISTRY-US, V7, P3453, DOI 10.1021/bi00850a021; Maivali U, 2004, RNA, V10, P600, DOI 10.1261/rna.5220504; Menetret JF, 2005, J MOL BIOL, V348, P445, DOI 10.1016/j.jmb.2005.02.053; MOAZED D, 1987, BIOCHIMIE, V69, P879, DOI 10.1016/0300-9084(87)90215-X; Mohr D, 2002, BIOCHEMISTRY-US, V41, P12520, DOI 10.1021/bi026301y; MONRO RE, 1967, J MOL BIOL, V26, P147, DOI 10.1016/0022-2836(67)90271-9; Moore PB, 2003, ANNU REV BIOCHEM, V72, P813, DOI 10.1146/annurev.biochem.72.110601.135450; Murphy FV, 2004, NAT STRUCT MOL BIOL, V11, P1186, DOI 10.1038/nsmb861; Nissen P, 2001, P NATL ACAD SCI USA, V98, P4899, DOI 10.1073/pnas.081082398; Ogle JM, 2005, ANNU REV BIOCHEM, V74, P129, DOI 10.1146/annurev.biochem.74.061903.155440; Ogle JM, 2002, CELL, V111, P721, DOI 10.1016/S0092-8674(02)01086-3; Ramakrishnan V, 2002, CELL, V108, P557, DOI 10.1016/S0092-8674(02)00619-0; Rawat UBS, 2003, NATURE, V421, P87, DOI 10.1038/nature01224; SAMAHA RR, 1995, NATURE, V377, P309, DOI 10.1038/377309a0; Savelsbergh A, 2003, MOL CELL, V11, P1517, DOI 10.1016/S1097-2765(03)00230-2; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schmeing TM, 2003, RNA, V9, P1345, DOI 10.1261/rna.5120503; Sharma D, 2004, RNA, V10, P102, DOI 10.1261/rna.5148704; Sievers A, 2004, P NATL ACAD SCI USA, V101, P7897, DOI 10.1073/pnas.0402488101; Spahn CMT, 2004, EMBO J, V23, P1008, DOI 10.1038/sj.emboj.7600102; SPIRIN A, 1987, BIOCHIMIE, V69, P949, DOI 10.1016/0300-9084(87)90228-8; Stark H, 2002, NAT STRUCT BIOL, V9, P849, DOI 10.1038/nsb859; Stark H, 2000, CELL, V100, P301, DOI 10.1016/S0092-8674(00)80666-2; TATE WP, 1983, J BIOL CHEM, V258, P2816; Valle M, 2003, CELL, V114, P123, DOI 10.1016/S0092-8674(03)00476-8; Valle M, 2003, NAT STRUCT BIOL, V10, P899, DOI 10.1038/nsb1003; Vila-Sanjurjo A, 2003, P NATL ACAD SCI USA, V100, P8682, DOI 10.1073/pnas.1133380100; Weinger JS, 2004, NAT STRUCT MOL BIOL, V11, P1101, DOI 10.1038/nsmb841; Wilson DN, 2005, EMBO J, V24, P251, DOI 10.1038/sj.emboj.7600525; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Youngman EM, 2004, CELL, V117, P589, DOI 10.1016/S0092-8674(04)00411-8; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089; Yusupova GZ, 2001, CELL, V106, P233, DOI 10.1016/S0092-8674(01)00435-4; Zavialov A. V., 2005, J BIOL-LONDON, V4, P9; Zavialov AV, 2003, CELL, V114, P113, DOI 10.1016/S0092-8674(03)00478-1	72	1006	1089	0	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					827	834		10.1126/science.1117230	http://dx.doi.org/10.1126/science.1117230			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272117				2022-12-28	WOS:000233121800038
J	Xu, PX				Xu, PX			Eppendorf 2005 winner - A Drosophila OBP required for pheromone signaling	SCIENCE			English	Editorial Material							CIS-VACCENYL ACETATE; BINDING PROTEIN; MOTH ANTENNAE; MELANOGASTER; SYSTEM; LUSH		Univ Texas, SW Med Ctr, Dept Basic Neurosci & Pharmacol, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Xu, PX (corresponding author), Univ Texas, SW Med Ctr, Dept Basic Neurosci & Pharmacol, Dallas, TX 75390 USA.	pingxi.xu@utsouthwestern.edu						Angioy AM, 2003, CHEM SENSES, V28, P279, DOI 10.1093/chemse/28.4.279; BARTELT RJ, 1985, J CHEM ECOL, V11, P1747, DOI 10.1007/BF01012124; de Bruyne M, 2001, NEURON, V30, P537, DOI 10.1016/S0896-6273(01)00289-6; HILL DA, 1996, EC IMPORTANCE INSECT; KAISSLIN.KE, 1970, NATURWISSENSCHAFTEN, V57, P23, DOI 10.1007/BF00593550; Kaissling KE, 1998, ANN NY ACAD SCI, V855, P320, DOI 10.1111/j.1749-6632.1998.tb10590.x; Kim MS, 1998, GENETICS, V150, P711; Nakagawa T, 2005, SCIENCE, V307, P1638, DOI 10.1126/science.1106267; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; VANDERMEER RK, 1986, J INSECT PHYSIOL, V32, P681, DOI 10.1016/0022-1910(86)90109-5; VOGT RG, 1981, NATURE, V293, P161, DOI 10.1038/293161a0; Wojtasek H, 1999, J BIOL CHEM, V274, P30950, DOI 10.1074/jbc.274.43.30950; WOODARD C, 1989, GENETICS, V123, P315; Xu PX, 2005, NEURON, V45, P193, DOI 10.1016/j.neuron.2004.12.031; ZAWISTOWSKI S, 1986, J INSECT PHYSIOL, V32, P189, DOI 10.1016/0022-1910(86)90057-0	15	8	9	1	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					798	799		10.1126/science.1121249	http://dx.doi.org/10.1126/science.1121249			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272108				2022-12-28	WOS:000233121800030
J	King-Jones, K; Thummel, CS				King-Jones, K; Thummel, CS			Less steroids make bigger flies	SCIENCE			English	Editorial Material									Univ Utah, Sch Med, Howard Hughes Med Inst, Dept Human Genet, Salt Lake City, UT 84112 USA	Howard Hughes Medical Institute; Utah System of Higher Education; University of Utah	King-Jones, K (corresponding author), Univ Utah, Sch Med, Howard Hughes Med Inst, Dept Human Genet, Salt Lake City, UT 84112 USA.	kirst@genetics.utah.edu; cart.thummel@genetics.utah.edu						Britton JS, 2002, DEV CELL, V2, P239, DOI 10.1016/S1534-5807(02)00117-X; Champlin DT, 1998, DEVELOPMENT, V125, P2009; Colombani J, 2005, SCIENCE, V310, P667, DOI 10.1126/science.1119432; MIRTH C, CURR BIOL; Nijhout HF, 2002, P NATL ACAD SCI USA, V99, P15446, DOI 10.1073/pnas.242548399; Riehle MA, 1999, INSECT BIOCHEM MOLEC, V29, P855, DOI 10.1016/S0965-1748(99)00084-3; Tu MP, 2002, AGING CELL, V1, P158, DOI 10.1046/j.1474-9728.2002.00016.x	7	18	26	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					630	631		10.1126/science.1120410	http://dx.doi.org/10.1126/science.1120410			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254176				2022-12-28	WOS:000232997700027
J	Lunzer, M; Milter, SP; Felsheim, R; Dean, AM				Lunzer, M; Milter, SP; Felsheim, R; Dean, AM			The biochemical architecture of an ancient adaptive landscape	SCIENCE			English	Article							ANTIBIOTIC-RESISTANCE; 3-ISOPROPYLMALATE DEHYDROGENASE; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; FITNESS PEAKS; ADAPTATION; EVOLUTION; PERSPECTIVE; PROTEIN; ADDITIVITY	Molecular evolution is moving from statistical descriptions of adaptive molecular changes toward predicting the fitness effects of mutations. Here, we characterize the fitness landscape of the six amino acids controlling coenzyme use in isopropylmalate dehydrogenase (IMDH). Although all natural IMDHs use, nicotinamide adenine dinucleotide (NAD) as a coenzyme, they can be engineered to use nicotinamide adenine dinucleotide phosphate (NADP) instead. Intermediates between these two phenotypic extremes show that each amino acid contributes additively to enzyme function, with epistatic contributions confined to fitness. The genotype-phenotype-fitness map shows that NAD use is a global optimum.	Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA; Univ Minnesota, Dept Entomol, St Paul, MN 55108 USA; Univ Minnesota, Dept Ecol Evolut & Behav, St Paul, MN 55108 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	Dean, AM (corresponding author), Univ Minnesota, Inst Biotechnol, St Paul, MN 55108 USA.	adean@biosci.umn.edu			NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM060611] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM060611] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Aita T, 2001, PROTEIN ENG, V14, P633, DOI 10.1093/protein/14.9.633; Alon U, 1999, NATURE, V397, P168, DOI 10.1038/16483; Burch CL, 2000, NATURE, V406, P625, DOI 10.1038/35020564; Coyne JA, 1997, EVOLUTION, V51, P643, DOI [10.2307/2411143, 10.1111/j.1558-5646.1997.tb03650.x]; DEAN AM, 1995, GENETICS, V139, P19; DePristo MA, 2005, NAT REV GENET, V6, P678, DOI 10.1038/nrg1672; Fersht A., 1999, STRUCTURE MECH PROTE, DOI 10.1142/10574; Fisher R.A., 1930, GENETICAL THEORY NAT; HARTL DL, 1985, GENETICS, V111, P655; HURLEY JH, 1991, BIOCHEMISTRY-US, V30, P8671, DOI 10.1021/bi00099a026; HURLEY JH, 1994, STRUCTURE, V2, P1007, DOI 10.1016/S0969-2126(94)00104-9; KACSER H, 1981, GENETICS, V97, P639; Lunzer M, 2002, GENETICS, V162, P485; Maisnier-Patin S, 2002, MOL MICROBIOL, V46, P355, DOI 10.1046/j.1365-2958.2002.03173.x; Qasim MA, 2003, BIOCHEMISTRY-US, V42, P6460, DOI 10.1021/bi027186u; SANDBERG WS, 1993, P NATL ACAD SCI USA, V90, P8367, DOI 10.1073/pnas.90.18.8367; Schrag SJ, 1997, P ROY SOC B-BIOL SCI, V264, P1287, DOI 10.1098/rspb.1997.0178; SMITH JM, 1970, NATURE, V225, P563, DOI 10.1038/225563a0; Sokal RR, 1995, BIOMETRY; Wade MJ, 1998, EVOLUTION, V52, P1537, DOI 10.1111/j.1558-5646.1998.tb02235.x; Wallon G, 1997, J MOL BIOL, V266, P1016, DOI 10.1006/jmbi.1996.0797; Wang XJ, 2002, J MOL BIOL, V320, P85, DOI 10.1016/S0022-2836(02)00400-X; Weinreich DM, 2005, EVOLUTION, V59, P1165; Weinreich DM, 2005, EVOLUTION, V59, P1175; WELLS JA, 1990, BIOCHEMISTRY-US, V29, P8509, DOI 10.1021/bi00489a001; WHITLOCK MC, 1995, ANNU REV ECOL SYST, V26, P601, DOI 10.1146/annurev.es.26.110195.003125; WRIGHT S, 1932, P 6 INT C GEN, P356; Zhu GP, 2005, SCIENCE, V307, P1279, DOI 10.1126/science.1106974	28	163	167	1	33	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					499	501		10.1126/science.1115649	http://dx.doi.org/10.1126/science.1115649			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239478				2022-12-28	WOS:000232786000049
J	Nishida, N; Katamine, S; Manuelidis, L				Nishida, N; Katamine, S; Manuelidis, L			Reciprocal interference between specific CJD and scrapie agents in neural cell cultures	SCIENCE			English	Article							CREUTZFELDT-JAKOB-DISEASE; PRION PROTEIN; TRANSMISSION; INFECTIONS; VIRUSES; STRAIN; MICE	Infection of mice with an attenuated Creutzfetdt-Jakob disease agent (SY-CJD) interferes with superinfection by a more virulent human-derived CJD agent (FU-CJD) and does not require pathological prion protein (PrPres). Using a rapid coculture system, we found that a neural cell line free of immune system cells similarly supported substantial CJD agent interference without PrPres. In addition, SY-CJD prevented superinfection by sheep-derived Chandler (Ch) and 22L scrapie agents. However, only 22L and not Ch prevented FU-CJD infection, even though both scrapie strains provoked abundant PrPres. This relationship between particular strains of sheep- and human-derived agents is likely to affect their prevalence and epidemic spread.	Yale Univ, Sch Med, New Haven, CT 06510 USA; Gifu Univ, Ctr Emerging Infect Dis, Gifu 5011193, Japan; Nagasaki Univ, Grad Sch Med, Dept Mol Microbiol & Immunol, Nagasaki 8528523, Japan	Yale University; Gifu University; Nagasaki University	Manuelidis, L (corresponding author), Yale Univ, Sch Med, 333 Cedar St, New Haven, CT 06510 USA.	laura.manuelidis@yale.edu			NINDS NIH HHS [NS12674, R01 NS012674] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012674, R56NS012674] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arjona A, 2004, P NATL ACAD SCI USA, V101, P8768, DOI 10.1073/pnas.0400158101; Baker CA, 2004, J NEUROVIROL, V10, P29, DOI 10.1080/13550280490261761; Baker CA, 2003, P NATL ACAD SCI USA, V100, P675, DOI 10.1073/pnas.0237313100; BARRETT ADT, 1986, CURR TOP MICROBIOL, V128, P55; DICKINSON AG, 1972, NATURE-NEW BIOL, V237, P244, DOI 10.1038/newbio237244a0; Hill AF, 2003, BRAIN, V126, P1333, DOI 10.1093/brain/awg125; Jackson GS, 2001, J CLIN PATHOL-MOL PA, V54, P393; Lasmezas CI, 1997, SCIENCE, V275, P402, DOI 10.1126/science.275.5298.402; Linsell L, 2004, NEUROLOGY, V63, P2077, DOI 10.1212/01.WNL.0000145844.53251.BC; Lu ZY, 2004, J CELL BIOCHEM, V93, P644, DOI 10.1002/jcb.20220; Manuelidis L, 1998, P NATL ACAD SCI USA, V95, P2520, DOI 10.1073/pnas.95.5.2520; Manuelidis L, 2000, NEUROSCI LETT, V293, P163, DOI 10.1016/S0304-3940(00)01514-7; Manuelidis L, 1997, SCIENCE, V277, P94, DOI 10.1126/science.277.5322.94; MANUELIDIS L, 1995, P NATL ACAD SCI USA, V92, P5124, DOI 10.1073/pnas.92.11.5124; Manuelidis L, 2003, P NATL ACAD SCI USA, V100, P5360, DOI 10.1073/pnas.0931192100; Manuelidis L, 2000, J VIROL, V74, P8614, DOI 10.1128/JVI.74.18.8614-8622.2000; MANUELIDIS L, UNPUB; MANUELIDIS L, 1966, TRANSMISSIBLE SUBACU, P375; Nishida N, 2000, J VIROL, V74, P320, DOI 10.1128/JVI.74.1.320-325.2000; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; SKLAVIADIS T, 1992, VIRUS RES, V26, P241, DOI 10.1016/0168-1702(92)90016-3; Smith PG, 2004, CURR TOP MICROBIOL, V284, P161; Waterhouse PM, 2001, NATURE, V411, P834, DOI 10.1038/35081168; Wu JC, 2005, WORLD J GASTROENTERO, V11, P1658; XI YG, 1992, NATURE, V356, P598, DOI 10.1038/356598a0	25	52	54	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					493	496		10.1126/science.1118155	http://dx.doi.org/10.1126/science.1118155			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239476				2022-12-28	WOS:000232786000047
J	Onn, A; Herbst, RS				Onn, A; Herbst, RS			Molecular targeted therapy for lung cancer	LANCET			English	Editorial Material							GROWTH-FACTOR-RECEPTOR; GENE COPY NUMBER; GEFITINIB THERAPY; MUTATIONS; ERLOTINIB; SENSITIVITY; COMBINATION		Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center	Onn, A (corresponding author), Univ Texas, MD Anderson Canc Ctr, 1515 Holcombe Blvd, Houston, TX 77030 USA.	amironn@mdanderson.org						Baker CH, 2002, AM J PATHOL, V161, P929, DOI 10.1016/S0002-9440(10)64253-8; Belldegrun A, 2002, PROSTATE CANCER P D, V5, P2, DOI 10.1038/sj/pcan/4500576; Cappuzzo F, 2005, J CLIN ONCOL, V23, P5007, DOI 10.1200/JCO.2005.09.111; Eberhard DA, 2005, J CLIN ONCOL, V23, P5900, DOI 10.1200/JCO.2005.02.857; Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477; Hirsch FR, 2005, J CLIN ONCOL, V23, P6838, DOI 10.1200/JCO.2005.01.2823; Johnson BE, 2005, CANCER RES, V65, P7525, DOI 10.1158/0008-5472.CAN-05-1257; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Takano T, 2005, J CLIN ONCOL, V23, P6829, DOI 10.1200/JCO.2005.01.0793; Thatcher N, 2005, LANCET, V366, P1527, DOI 10.1016/S0140-6736(05)67625-8	14	7	9	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT-NOV	2005	366	9496					1507	1508		10.1016/S0140-6736(05)67608-8	http://dx.doi.org/10.1016/S0140-6736(05)67608-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257327				2022-12-28	WOS:000232984800004
J	Abbondanzieri, EA; Greenleaf, WJ; Shaevitz, JW; Landick, R; Block, SM				Abbondanzieri, EA; Greenleaf, WJ; Shaevitz, JW; Landick, R; Block, SM			Direct observation of base-pair stepping by RNA polymerase	NATURE			English	Article							OPTICAL FORCE CLAMP; HAND-OVER-HAND; SINGLE-MOLECULE; TRANSCRIPTION ELONGATION; STRUCTURAL BASIS; MECHANISM; DNA; TRANSLOCATION; BACKTRACKING; KINETICS	During transcription, RNA polymerase ( RNAP) moves processively along a DNA template, creating a complementary RNA. Here we present the development of an ultra-stable optical trapping system with angstrom-level resolution, which we used to monitor transcriptional elongation by single molecules of Escherichia coli RNAP. Records showed discrete steps averaging 3.7 +/- 0.6 angstrom, a distance equivalent to the mean rise per base found in B-DNA. By combining our results with quantitative gel analysis, we conclude that RNAP advances along DNA by a single base pair per nucleotide addition to the nascent RNA. We also determined the force-velocity relationship for transcription at both saturating and sub-saturating nucleotide concentrations; fits to these data returned a characteristic distance parameter equivalent to one base pair. Global fits were inconsistent with a model for movement incorporating a power stroke tightly coupled to pyrophosphate release, but consistent with a brownian ratchet model incorporating a secondary NTP binding site.	Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Phys, Stanford, CA 94305 USA; Stanford Univ, Dept Biol Sci, Stanford, CA 94305 USA; Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA	Stanford University; Stanford University; Stanford University; University of Wisconsin System; University of Wisconsin Madison	Block, SM (corresponding author), Stanford Univ, Dept Appl Phys, Stanford, CA 94305 USA.	sblock@stanford.edu			NIGMS NIH HHS [R01 GM057035] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057035] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Adelman K, 2002, P NATL ACAD SCI USA, V99, P13538, DOI 10.1073/pnas.212358999; Altman D, 2004, CELL, V116, P737, DOI 10.1016/S0092-8674(04)00211-9; Artsimovitch I, 2000, P NATL ACAD SCI USA, V97, P7090, DOI 10.1073/pnas.97.13.7090; Asbury CL, 2003, SCIENCE, V302, P2130, DOI 10.1126/science.1092985; Bai L, 2004, J MOL BIOL, V344, P335, DOI 10.1016/j.jmb.2004.08.107; Bar-Nahum G, 2005, CELL, V120, P183, DOI 10.1016/j.cell.2004.11.045; Block SM, 2003, P NATL ACAD SCI USA, V100, P2351, DOI 10.1073/pnas.0436709100; BLOCK SM, 1995, BIOPHYS J, V68, pS230; Cheetham GMT, 1999, SCIENCE, V286, P2305, DOI 10.1126/science.286.5448.2305; Dohoney KM, 2001, NATURE, V409, P370, DOI 10.1038/35053124; Forde NR, 2002, P NATL ACAD SCI USA, V99, P11682, DOI 10.1073/pnas.142417799; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; Gong XQ, 2005, MOL CELL, V18, P461, DOI 10.1016/j.molcel.2005.04.011; GREENLEAF WJ, IN PRESS PHYS REV LE; Guajardo R, 1997, J MOL BIOL, V265, P8, DOI 10.1006/jmbi.1996.0707; Handa N, 2005, MOL CELL, V17, P745, DOI 10.1016/j.molcel.2005.02.011; Harada Y, 2001, NATURE, V409, P113, DOI 10.1038/35051126; Holmes SF, 2003, J BIOL CHEM, V278, P35597, DOI 10.1074/jbc.M304496200; Komissarova N, 1997, J BIOL CHEM, V272, P15329, DOI 10.1074/jbc.272.24.15329; Lang MJ, 2002, BIOPHYS J, V83, P491, DOI 10.1016/S0006-3495(02)75185-0; Li LW, 2005, J MOL BIOL, V345, P817, DOI 10.1016/j.jmb.2004.11.021; Mallik R, 2004, NATURE, V427, P649, DOI 10.1038/nature02293; Marr MT, 2001, P NATL ACAD SCI USA, V98, P8972, DOI 10.1073/pnas.161253298; Mukherjee S, 2003, EMBO J, V22, P6483, DOI 10.1093/emboj/cdg618; Neuman KC, 2003, CELL, V115, P437, DOI 10.1016/S0092-8674(03)00845-6; Nudler E, 1997, CELL, V89, P33, DOI 10.1016/S0092-8674(00)80180-4; Pal M, 2005, MOL CELL, V19, P101, DOI 10.1016/j.molcel.2005.05.024; Perkins TT, 2004, BIOPHYS J, V86, P1640, DOI 10.1016/S0006-3495(04)74232-0; Perkins TT, 2003, SCIENCE, V301, P1914, DOI 10.1126/science.1088047; Purcell TJ, 2002, P NATL ACAD SCI USA, V99, P14159, DOI 10.1073/pnas.182539599; Reeder TC, 1996, CELL, V87, P767, DOI 10.1016/S0092-8674(00)81395-1; RHODES G, 1974, J BIOL CHEM, V249, P6675; Schnitzer MJ, 1995, COLD SPRING HARB SYM, V60, P793, DOI 10.1101/SQB.1995.060.01.085; Schnitzer MJ, 1997, NATURE, V388, P386, DOI 10.1038/41111; Shaevitz JW, 2003, NATURE, V426, P684, DOI 10.1038/nature02191; Simmons RM, 1996, BIOPHYS J, V70, P1813, DOI 10.1016/S0006-3495(96)79746-1; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; Temiakov D, 2005, MOL CELL, V19, P655, DOI 10.1016/j.molcel.2005.07.020; Thomen P, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.128102; Vale RD, 2000, SCIENCE, V288, P88, DOI 10.1126/science.288.5463.88; van Oijen AM, 2003, SCIENCE, V301, P1235, DOI 10.1126/science.1084387; Wang MD, 1998, SCIENCE, V282, P902, DOI 10.1126/science.282.5390.902; WATSON JD, 1953, NATURE, V171, P737, DOI 10.1038/171737a0; Westover KD, 2004, CELL, V119, P481, DOI 10.1016/j.cell.2004.10.016; YANAGI K, 1991, J MOL BIOL, V217, P201, DOI 10.1016/0022-2836(91)90620-L; Yasuda R, 2001, NATURE, V410, P898, DOI 10.1038/35073513; Yildiz A, 2004, SCIENCE, V303, P676, DOI 10.1126/science.1093753; YIN H, 1995, SCIENCE, V270, P1653, DOI 10.1126/science.270.5242.1653; Yin YW, 2004, CELL, V116, P393, DOI 10.1016/S0092-8674(04)00120-5; Zhang CF, 2004, J MOL BIOL, V342, P1085, DOI 10.1016/j.jmb.2004.07.070	50	633	667	2	144	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2005	438	7067					460	465		10.1038/nature04268	http://dx.doi.org/10.1038/nature04268			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986NY	16284617	Green Accepted			2022-12-28	WOS:000233458200041
J	Haynes, JD; Deichmann, R; Rees, G				Haynes, JD; Deichmann, R; Rees, G			Eye-specific effects of binocular rivalry in the human lateral geniculate nucleus	NATURE			English	Article							PRIMARY VISUAL-CORTEX; ALERT MACAQUE; SUPPRESSION; ORGANIZATION; PATHWAY; MONKEY; BRAIN; SIZE; LGN; V1	When dissimilar images are presented to the two eyes, they compete for perceptual dominance so that each image is visible in turn for a few seconds while the other is suppressed. Such binocular rivalry is associated with relative suppression of local, eye-based representations(1-4) that can also be modulated by high-level influences such as perceptual grouping(3,5,6). However, it is currently unclear how early in visual processing the suppression of eye-based signals can occur. Here we use high-resolution functional magnetic resonance imaging (fMRI) in conjunction with a new binocular rivalry stimulus to show that signals recorded from the human lateral geniculate nucleus (LGN) exhibit eye-specific suppression during rivalry. Regions of the LGN that show strong eye-preference independently show strongly reduced activity during binocular rivalry when the stimulus presented in their preferred eye is perceptually suppressed. The human LGN is thus the earliest stage of visual processing that reflects eye-specific dominance and suppression.	UCL, Inst Neurol, Wellcome Dept Imaging Neurosci, London WC1N 3BG, England; UCL, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London; University of London; University College London	Haynes, JD (corresponding author), UCL, Inst Neurol, Wellcome Dept Imaging Neurosci, 12 Queen Sq, London WC1N 3BG, England.	haynes@fil.ion.ucl.ac.uk	Rees, Geraint/C-1493-2008; Haynes, John-Dylan/Q-1148-2016	Rees, Geraint/0000-0002-9623-7007; Haynes, John-Dylan/0000-0003-1786-6954	Wellcome Trust [067453] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Andrews TJ, 1997, J NEUROSCI, V17, P2859; Andrews TJ, 2001, TRENDS COGN SCI, V5, P407, DOI 10.1016/S1364-6613(00)01756-3; BLAKE R, 1980, PERCEPTION, V9, P223, DOI 10.1068/p090223; Blake R, 2002, NAT REV NEUROSCI, V3, P13, DOI 10.1038/nrn701; BLAKE R, 1974, NATURE, V249, P488, DOI 10.1038/249488a0; Fang F, 2005, NAT NEUROSCI, V8, P1380, DOI 10.1038/nn1537; Haynes JD, 2005, NAT NEUROSCI, V8, P686, DOI 10.1038/nn1445; Ichida JM, 2002, J COMP NEUROL, V454, P272, DOI 10.1002/cne.10441; Kamitani Y, 2005, NAT NEUROSCI, V8, P679, DOI 10.1038/nn1444; Kastner S, 2004, J NEUROPHYSIOL, V91, P438, DOI 10.1152/jn.00553.2003; Kovacs I, 1996, P NATL ACAD SCI USA, V93, P15508, DOI 10.1073/pnas.93.26.15508; Lee SH, 2002, J VISION, V2, P618, DOI 10.1167/2.9.4; Lee SH, 2005, NAT NEUROSCI, V8, P22, DOI 10.1038/nn1365; Lee SH, 2004, VISION RES, V44, P983, DOI 10.1016/j.visres.2003.12.007; LEHKY SR, 1988, PERCEPTION, V17, P215, DOI 10.1068/p170215; Lehky SR, 1996, VISION RES, V36, P1225, DOI 10.1016/0042-6989(95)00232-4; LEVELT WJM, 1967, BRIT J PSYCHOL, V58, P143, DOI 10.1111/j.2044-8295.1967.tb01068.x; Logothetis NK, 2004, ANNU REV PHYSIOL, V66, P735, DOI 10.1146/annurev.physiol.66.082602.092845; Logothetis NK, 1996, NATURE, V380, P621, DOI 10.1038/380621a0; MONTERO VM, 1986, EXP BRAIN RES, V62, P215; Polonsky A, 2000, NAT NEUROSCI, V3, P1153, DOI 10.1038/80676; Schneider KA, 2004, J NEUROSCI, V24, P8975, DOI 10.1523/JNEUROSCI.2413-04.2004; SCHROEDER CE, 1990, BRAIN RES, V521, P303, DOI 10.1016/0006-8993(90)91556-V; SCLAR G, 1990, VISION RES, V31, P1148; SENGPIEL F, 1995, VISION RES, V35, P179, DOI 10.1016/0042-6989(94)00125-6; SINGER W, 1977, PHYSIOL REV, V57, P386, DOI 10.1152/physrev.1977.57.3.386; SOBEL KV, 2004, J VIS, V4; Tong F, 2001, NATURE, V411, P195, DOI 10.1038/35075583; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; WALES R, 1970, PERCEPT PSYCHOPHYS, V8, P90, DOI 10.3758/BF03210180; Watanabe K, 2004, VISION RES, V44, P3065, DOI 10.1016/j.visres.2004.07.011	31	256	259	0	21	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2005	438	7067					496	499		10.1038/nature04169	http://dx.doi.org/10.1038/nature04169			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986NY	16244649	Green Accepted, Green Submitted			2022-12-28	WOS:000233458200049
J	Argyris, A; Syvridis, D; Larger, L; Annovazzi-Lodi, V; Colet, P; Fischer, I; Garcia-Ojalvo, J; Mirasso, CR; Pesquera, L; Shore, KA				Argyris, A; Syvridis, D; Larger, L; Annovazzi-Lodi, V; Colet, P; Fischer, I; Garcia-Ojalvo, J; Mirasso, CR; Pesquera, L; Shore, KA			Chaos-based communications at high bit rates using commercial fibre-optic links	NATURE			English	Article							CAVITY SEMICONDUCTOR-LASERS; NONLINEAR DYNAMICS; OPTICAL CHAOS; CLOSED-LOOP; SYNCHRONIZATION; SYSTEMS; DIODES	Chaotic signals have been proposed as broadband information carriers with the potential of providing a high level of robustness and privacy in data transmission(1,2). Laboratory demonstrations of chaos-based optical communications have already shown the potential of this technology(3-5), but a field experiment using commercial optical networks has not been undertaken so far. Here we demonstrate high-speed long-distance communication based on chaos synchronization over a commercial fibre-optic channel. An optical carrier wave generated by a chaotic laser is used to encode a message for transmission over 120 km of optical fibre in the metropolitan area network of Athens, Greece. The message is decoded using an appropriate second laser which, by synchronizing with the chaotic carrier, allows for the separation of the carrier and the message. Transmission rates in the gigabit per second range are achieved, with corresponding bit-error rates below 10(-7). The system uses matched pairs of semiconductor lasers as chaotic emitters and receivers, and off-the-shelf fibre-optic telecommunication components. Our results show that information can be transmitted at high bit rates using deterministic chaos in a manner that is robust to perturbations and channel disturbances unavoidable under real-world conditions.	Univ Illes Balears, Dept Fis, E-07122 Palma De Mallorca, Spain; Univ Athens, Dept Informat, Athens 15784, Greece; Univ Franche Comte, CNRS, UMR 6174, FEMTOST Opt, F-25030 Besancon, France; Univ Pavia, Dept Elect, I-27100 Pavia, Italy; UIB, CSIC, IMEDEA, Inst Mediterraneo Estudios Avanzados, E-07122 Palma de Mallorca, Spain; Tech Univ Darmstadt, Inst Appl Phys, D-64289 Darmstadt, Germany; Univ Politecn Cataluna, Dept Fis & Engn Nucl, E-08222 Terrassa, Spain; Univ Illes Balears, Dept Fis, E-07122 Palma de Mallorca, Spain; Univ Cantabria, CSIC, Inst Fis Cantabria, E-39005 Santander, Spain; Univ Wales, Sch Informat, Bangor LL57 1UT, Gwynedd, Wales	Universitat de les Illes Balears; National & Kapodistrian University of Athens; Centre National de la Recherche Scientifique (CNRS); CNRS - Institute for Engineering & Systems Sciences (INSIS); Universite de Franche-Comte; University of Pavia; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto Mediterraneo de Estudios Avanzados (IMEDEA); Universitat de les Illes Balears; Technical University of Darmstadt; Universitat Politecnica de Catalunya; Universitat de les Illes Balears; Consejo Superior de Investigaciones Cientificas (CSIC); Universidad de Cantabria; CSIC - Instituto de Fisica de Cantabria (IFCA); Bangor University	Mirasso, CR (corresponding author), Univ Illes Balears, Dept Fis, E-07122 Palma De Mallorca, Spain.	claudio@galiota.uib.es	PESQUERA, Luis/I-3087-2015; Argyris, Apostolos/G-1703-2016; Fischer, Ingo/C-2843-2011; Mirasso, Claudio R/B-8661-2008; Larger, Laurent/R-8217-2019; Colet, Pere/A-2472-2011; Shore, Alan/AAT-6367-2021; Garcia-Ojalvo, Jordi/A-4574-2009; Fischer, Ingo/S-9129-2019	PESQUERA, Luis/0000-0003-0615-5751; Argyris, Apostolos/0000-0003-2847-7719; Fischer, Ingo/0000-0003-1881-9842; Larger, Laurent/0000-0003-1245-1602; Colet, Pere/0000-0002-5992-6292; Garcia-Ojalvo, Jordi/0000-0002-3716-7520; Mirasso, Claudio/0000-0003-2980-7038				Annovazzi-Lodi V, 2005, IEEE PHOTONIC TECH L, V17, P1995, DOI 10.1109/LPT.2005.853267; Annovazzi-Lodi V, 2002, IEEE J QUANTUM ELECT, V38, P1171, DOI 10.1109/JQE.2002.801948; Ashwin P, 2003, NATURE, V422, P384, DOI 10.1038/422384a; COLET P, 1994, OPT LETT, V19, P2056, DOI 10.1364/OL.19.002056; CUOMO KM, 1993, IEEE T CIRCUITS-II, V40, P626, DOI 10.1109/82.246163; Donati S, 2002, IEEE J QUANTUM ELECT, V38, P1138, DOI 10.1109/JQE.2002.801951; Garcia-Ojalvo J, 2001, PHYS REV LETT, V86, P5204, DOI 10.1103/PhysRevLett.86.5204; Goedgebuer JP, 1998, PHYS REV LETT, V80, P2249, DOI 10.1103/PhysRevLett.80.2249; Gollub JP, 2000, NATURE, V404, P710, DOI 10.1038/35008168; Heil T, 2002, IEEE J QUANTUM ELECT, V38, P1162, DOI 10.1109/JQE.2002.801950; Kurtsiefer C, 2002, NATURE, V419, P450, DOI 10.1038/419450a; Kusumoto K, 2002, OPT LETT, V27, P989, DOI 10.1364/OL.27.000989; Larger L, 2004, CR PHYS, V5, P609, DOI 10.1016/j.crhy.2004.05.004; Lee MW, 2004, ELECTRON LETT, V40, P614, DOI 10.1049/el:20040429; Lee MW, 2003, OPT LETT, V28, P2168, DOI 10.1364/OL.28.002168; Lee MW, 2003, IEEE J QUANTUM ELECT, V39, P931, DOI 10.1109/JQE.2003.813223; Matsuura T, 2004, OPT LETT, V29, P2731, DOI 10.1364/OL.29.002731; Mirasso CR, 1996, IEEE PHOTONIC TECH L, V8, P299, DOI 10.1109/68.484273; Peil M, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.174101; SHANNON CE, 1949, BELL SYST TECH J, V28, P656, DOI 10.1002/j.1538-7305.1949.tb00928.x; Tang S, 2001, OPT LETT, V26, P1843, DOI 10.1364/OL.26.001843; Uchida A, 2005, PROG OPTICS, V48, P203, DOI 10.1016/S0079-6638(05)48005-1; Vicente R, 2002, IEEE J QUANTUM ELECT, V38, P1197, DOI 10.1109/JQE.2002.802110	24	1243	1310	21	247	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					343	346		10.1038/nature04275	http://dx.doi.org/10.1038/nature04275			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292256				2022-12-28	WOS:000233300200045
J	Wagner, JR; Brunzelle, JS; Forest, KT; Vierstra, RD				Wagner, JR; Brunzelle, JS; Forest, KT; Vierstra, RD			A light-sensing knot revealed by the structure of the chromophore-binding domain of phytochrome	NATURE			English	Article							CRYSTAL-STRUCTURE ANALYSIS; DEEP TREFOIL KNOT; BILIVERDIN CHROMOPHORE; PROTEIN; REFINEMENT; MODEL; CRYSTALLIZATION; AGP1; PR; BACTERIOPHYTOCHROMES	Phytochromes are red/far-red light photoreceptors that direct photosensory responses across the bacterial, fungal and plant kingdoms. These include photosynthetic potential and pigmentation in bacteria as well as chloroplast development and photomorphogenesis in plants. Phytochromes consist of an amino-terminal region that covalently binds a single bilin chromophore, followed by a carboxy-terminal dimerization domain that often transmits the light signal through a histidine kinase relay. Here we describe the three-dimensional structure of the chromophore-binding domain of Deinococcus radiodurans phytochrome assembled with its chromophore biliverdin in the Pr ground state. Our model, refined to 2.5 angstrom resolution, reaffirms Cys 24 as the chromophore attachment site, locates key amino acids that form a solvent-shielded bilin-binding pocket, and reveals an unusually formed deep trefoil knot that stabilizes this region. The structure provides the first three-dimensional glimpse into the photochromic behaviour of these photoreceptors and helps to explain the evolution of higher plant phytochromes from prokaryotic precursors.	Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA; Univ Wisconsin, Dept Genet, Madison, WI 53706 USA; Northwestern Univ, Life Sci Collaborat Access Team, Argonne, IL 60439 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Northwestern University	Forest, KT (corresponding author), Univ Wisconsin, Dept Bacteriol, Madison, WI 53706 USA.	forest@bact.wisc.edu						Bateman A, 2004, NUCLEIC ACIDS RES, V32, pD138, DOI [10.1093/nar/gkh121, 10.1093/nar/gkt1223, 10.1093/nar/gkr1065, 10.1093/nar/gkp985]; Bhoo SH, 2001, NATURE, V414, P776, DOI 10.1038/414776a; Bhoo SH, 1997, J AM CHEM SOC, V119, P11717, DOI 10.1021/ja972875s; Braslavsky SE, 2003, PHOTOCHROMISM: MOLECULES AND SYSTEMS, P738, DOI 10.1016/B978-044451322-9/50023-3; BREJC K, 1995, J MOL BIOL, V249, P424, DOI 10.1006/jmbi.1995.0307; Bricogne G, 2003, ACTA CRYSTALLOGR D, V59, P2023, DOI 10.1107/S0907444903017694; CHAYEN NE, 1992, J CRYST GROWTH, V122, P176, DOI 10.1016/0022-0248(92)90241-A; Chen M, 2005, CURR BIOL, V15, P637, DOI 10.1016/j.cub.2005.02.028; CHERRY JR, 1993, PLANT CELL, V5, P565, DOI 10.1105/tpc.5.5.565; Davis SJ, 1999, SCIENCE, V286, P2517, DOI 10.1126/science.286.5449.2517; DUERRING M, 1991, J MOL BIOL, V217, P577, DOI 10.1016/0022-2836(91)90759-Y; Fischer AJ, 2004, P NATL ACAD SCI USA, V101, P17334, DOI 10.1073/pnas.0407645101; FODOR SPA, 1990, BIOCHEMISTRY-US, V29, P11141, DOI 10.1021/bi00502a018; Gartner W., 2004, PHOTORECEPTORS LIGHT, P136; Grosse-Kunstleve RW, 2003, ACTA CRYSTALLOGR D, V59, P1974, DOI 10.1107/S0907444903021206; Hanzawa H, 2001, P NATL ACAD SCI USA, V98, P3612, DOI 10.1073/pnas.051629698; Inomata K, 2005, J BIOL CHEM, V280, P24491, DOI 10.1074/jbc.M504710200; Karniol B, 2005, BIOCHEM J, V392, P103, DOI 10.1042/BJ20050826; Kneip C, 1999, BIOCHEMISTRY-US, V38, P15185, DOI 10.1021/bi990688w; LAGARIAS JC, 1980, J AM CHEM SOC, V102, P4821, DOI 10.1021/ja00534a042; Lamparter T, 2004, BIOCHEMISTRY-US, V43, P3659, DOI 10.1021/bi035693l; Lamparter T, 2003, J BIOL CHEM, V278, P33786, DOI 10.1074/jbc.M305563200; Liu Y, 2002, PROTEIN SCI, V11, P1285, DOI 10.1110/ps.0201402; Mallam AL, 2005, J MOL BIOL, V346, P1409, DOI 10.1016/j.jmb.2004.12.055; McRee DE, 1999, J STRUCT BIOL, V125, P156, DOI 10.1006/jsbi.1999.4094; Mroginski MA, 2004, J AM CHEM SOC, V126, P16734, DOI 10.1021/ja043959l; Mutsuda M, 2003, J BIOL CHEM, V278, P19102, DOI 10.1074/jbc.M213255200; Nureki O, 2002, ACTA CRYSTALLOGR D, V58, P1129, DOI 10.1107/S0907444902006601; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Perrakis A, 1999, NAT STRUCT BIOL, V6, P458, DOI 10.1038/8263; Quail PH, 2002, NAT REV MOL CELL BIO, V3, P85, DOI 10.1038/nrm728; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; Razeto A, 2004, J MOL BIOL, V336, P319, DOI 10.1016/j.jmb.2003.12.057; Ryu JS, 2005, CELL, V120, P395, DOI 10.1016/j.cell.2004.12.019; SMITH H, 1995, ANNU REV PLANT PHYS, V46, P289, DOI 10.1146/annurev.pp.46.060195.001445; Taylor WR, 2000, NATURE, V406, P916, DOI 10.1038/35022623; Taylor WR, 2003, NATURE, V421, P25, DOI 10.1038/421025a; Terauchi K, 2004, MOL MICROBIOL, V51, P567, DOI 10.1046/j.1365-2958.2003.03853.x; Terwilliger T, 2004, J SYNCHROTRON RADIAT, V11, P49, DOI 10.1107/S0909049503023938; Tu SL, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P121, DOI 10.1002/352760510X.ch6; Vaguine AA, 1999, ACTA CRYSTALLOGR D, V55, P191, DOI 10.1107/S0907444998006684; Vierstra RD, 2005, HANDBOOK OF PHOTOSENSORY RECEPTORS, P171, DOI 10.1002/352760510X.ch8; Winn MD, 2001, ACTA CRYSTALLOGR D, V57, P122, DOI 10.1107/S0907444900014736; Wu SH, 2000, BIOCHEMISTRY-US, V39, P13487, DOI 10.1021/bi001123z; Yeh KC, 1997, SCIENCE, V277, P1505, DOI 10.1126/science.277.5331.1505; Yildiz O, 2005, MOL CELL, V17, P69, DOI 10.1016/j.molcel.2004.11.022; Yoshihara S, 2004, PLANT CELL PHYSIOL, V45, P1729, DOI 10.1093/pcp/pch214; Zarembinski TI, 2003, PROTEINS, V50, P177, DOI 10.1002/prot.10311	48	422	447	3	83	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					325	331		10.1038/nature04118	http://dx.doi.org/10.1038/nature04118			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292304				2022-12-28	WOS:000233300200041
J	Khoshnaw, AI				Khoshnaw, AI			The diabetic foot in Iraq	LANCET			English	Editorial Material											Khoshnaw, AI (corresponding author), 3408 Donna Kay Dr, Nashville, TN 37211 USA.	abdulkhoshnaw@yahoo.com							0	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 12	2005	366	9498					1718	1718		10.1016/S0140-6736(05)67697-0	http://dx.doi.org/10.1016/S0140-6736(05)67697-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291065				2022-12-28	WOS:000233206400027
J	Kong, MF; Jogia, R; Jackson, S; Quinn, M; McNally, P; Davies, M				Kong, MF; Jogia, R; Jackson, S; Quinn, M; McNally, P; Davies, M			Malignant melanoma presenting as a foot ulcer	LANCET			English	Editorial Material							DIAGNOSIS; DELAY		Univ Hosp Leicester, Dept Endocrinol & Diabet, Leicester LE5 4PW, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester	Kong, MF (corresponding author), Univ Hosp Leicester, Dept Endocrinol & Diabet, Leicester LE5 4PW, Leics, England.	marie-france.kong@uhl-tr.nhs.uk		Davies, Melanie/0000-0002-9987-9371				BENNETT DR, 1994, J AM COLL SURGEONS, V179, P279; FORTIN PT, 1995, J BONE JOINT SURG AM, V77, P1396, DOI 10.2106/00004623-199509000-00016; Gregson CL, 2004, DIABETIC MED, V21, P924, DOI 10.1111/j.1464-5491.2004.01338.x; Metzger S, 1998, MELANOMA RES, V8, P181, DOI 10.1097/00008390-199804000-00014; Walsh Susan M, 2003, J Foot Ankle Surg, V42, P193, DOI 10.1016/S1067-2516(03)70028-3	5	19	19	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 12	2005	366	9498					1750	1750		10.1016/S0140-6736(05)67701-X	http://dx.doi.org/10.1016/S0140-6736(05)67701-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291070				2022-12-28	WOS:000233206400032
J	Champion, PM				Champion, PM			Chemistry - Following the flow of energy in biomolecules	SCIENCE			English	Editorial Material							HEME-PROTEINS; SPECTROSCOPY; VISION		Northeastern Univ, Dept Phys, Boston, MA 02115 USA; Northeastern Univ, Ctr Interdisciplinary Res Complex Syst, Boston, MA 02115 USA	Northeastern University; Northeastern University	Champion, PM (corresponding author), Northeastern Univ, Dept Phys, Boston, MA 02115 USA.	p.champion@neu.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK035090] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK035090-23, R01 DK035090] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRETON J, 1986, P NATL ACAD SCI USA, V83, P5121, DOI 10.1073/pnas.83.14.5121; Brixner T, 2005, NATURE, V434, P625, DOI 10.1038/nature03429; CHAMPION PM, 1980, J CHEM PHYS, V73, P5947, DOI 10.1063/1.440153; Kukura P, 2005, SCIENCE, V310, P1006, DOI 10.1126/science.1118379; McCamant DW, 2004, REV SCI INSTRUM, V75, P4971, DOI 10.1063/1.1807566; Rosca F, 2002, J PHYS CHEM A, V106, P3540, DOI 10.1021/jp0129277; SCHOENLEIN RW, 1991, SCIENCE, V254, P412, DOI 10.1126/science.1925597; WANG Q, 1994, SCIENCE, V266, P422, DOI 10.1126/science.7939680; Zewail AH, 2000, PURE APPL CHEM, V72, P2219, DOI 10.1351/pac200072122219; ZHU LY, 1994, SCIENCE, V266, P629, DOI 10.1126/science.7939716; 2004, FARADAY DISCUSS, V127	11	38	38	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2005	310	5750					980	982		10.1126/science.1120280	http://dx.doi.org/10.1126/science.1120280			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284167	Green Accepted			2022-12-28	WOS:000233343400030
J	Heimpel, M; Aurnou, J; Wicht, J				Heimpel, M; Aurnou, J; Wicht, J			Simulation of equatorial and high-latitude jets on Jupiter in a deep convection model	NATURE			English	Article							ZONAL FLOW DRIVEN; ATMOSPHERIC DYNAMICS; SPHERICAL-SHELL; WINDS; TURBULENCE; GALILEO	The bands of Jupiter represent a global system of powerful winds. Broad eastward equatorial jets are flanked by smaller-scale, higher-latitude jets flowing in alternating directions(1,2). Jupiter's large thermal emission suggests that the winds are powered from within(3,4), but the zonal flow depth is limited by increasing density and electrical conductivity in the molecular hydrogen - helium atmosphere towards the centre of the planet(5). Two types of planetary flow models have been explored: shallow-layer models reproduce multiple high-latitude jets, but not the equatorial flow system(6-8), and deep convection models only reproduce an eastward equatorial jet with two flanking neighbours(9-14). Here we present a numerical model of three-dimensional rotating convection in a relatively thin spherical shell that generates both types of jets. The simulated flow is turbulent and quasi-two-dimensional and, as observed for the jovian jets, simulated jet widths follow Rhines' scaling theory(2,12,13,15). Our findings imply that Jupiter's latitudinal transition in jet width corresponds to a separation between the bottom-bounded flow structures in higher latitudes and the deep equatorial flows.	Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada; Univ Calif Los Angeles, Dept Earth & Space Sci, Los Angeles, CA 90095 USA; Max Planck Inst Solar Syst Res, D-37191 Katlenburg Lindau, Germany	University of Alberta; University of California System; University of California Los Angeles; Max Planck Society	Heimpel, M (corresponding author), Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada.	mheimpel@phys.ualberta.ca						Al-Shamali FM, 2004, GEOPHYS ASTRO FLUID, V98, P153, DOI 10.1080/03091920410001659281; Atkinson DH, 1998, J GEOPHYS RES-PLANET, V103, P22911, DOI 10.1029/98JE00060; Aubert J, 2001, PHYS EARTH PLANET IN, V128, P51, DOI 10.1016/S0031-9201(01)00277-1; Aurnou JM, 2004, ICARUS, V169, P492, DOI 10.1016/j.icarus.2004.01.013; Aurnou JM, 2001, GEOPHYS RES LETT, V28, P2557, DOI 10.1029/2000GL012474; BUSSE FH, 1976, ICARUS, V29, P255, DOI 10.1016/0019-1035(76)90053-1; Cho JYK, 1996, SCIENCE, V273, P335, DOI 10.1126/science.273.5273.335; Christensen UR, 2002, J FLUID MECH, V470, P115, DOI 10.1017/S0022112002002008; Christensen UR, 2001, GEOPHYS RES LETT, V28, P2553, DOI 10.1029/2000GL012643; Evonuk M, 2004, GEOPHYS ASTRO FLUID, V98, P241, DOI 10.1080/03091920410001696126; Hubbard WB, 1999, ICARUS, V137, P357, DOI 10.1006/icar.1998.6064; INGERSOLL AP, 1976, ICARUS, V29, P245, DOI 10.1016/0019-1035(76)90052-X; INGERSOLL AP, 1990, SCIENCE, V248, P308, DOI 10.1126/science.248.4953.308; Jones CA, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016980; KIRK RL, 1987, ASTROPHYS J, V316, P836, DOI 10.1086/165248; Kuang WJ, 1999, J COMPUT PHYS, V153, P51, DOI 10.1006/jcph.1999.6274; Manneville JB, 1996, ICARUS, V122, P242, DOI 10.1006/icar.1996.0123; MARTINEZ C, 2005, NASA SELECTS NEW FRO; PIRRAGLIA JA, 1984, ICARUS, V59, P169, DOI 10.1016/0019-1035(84)90020-4; Porco CC, 2003, SCIENCE, V299, P1541, DOI 10.1126/science.1079462; Read PL, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020106; RHINES PB, 1975, J FLUID MECH, V69, P417, DOI 10.1017/S0022112075001504; Schopp R, 1997, GEOPHYS ASTRO FLUID, V86, P43, DOI 10.1080/03091929708245456; Vasavada AR, 2005, REP PROG PHYS, V68, P1935, DOI 10.1088/0034-4885/68/8/R06; Wicht J, 2002, PHYS EARTH PLANET IN, V132, P281, DOI 10.1016/S0031-9201(02)00078-X; WILLIAMS GP, 1978, J ATMOS SCI, V35, P1399, DOI 10.1175/1520-0469(1978)035<1399:PCBROJ>2.0.CO;2; Williams GP, 2003, J ATMOS SCI, V60, P1270, DOI 10.1175/1520-0469(2003)60<1270:JDPIMM>2.0.CO;2; Yano J, 2005, GEOPHYS ASTRO FLUID, V99, P137, DOI 10.1080/03091920412331336398; Yano JI, 2003, NATURE, V421, P36, DOI 10.1038/421036a	30	179	181	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					193	196		10.1038/nature04208	http://dx.doi.org/10.1038/nature04208			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281029	Green Published			2022-12-28	WOS:000233133500041
J	Ng, RWM; Li, GKH				Ng, RWM; Li, GKH			Broken needles	LANCET			English	Editorial Material									Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg,Div Plast & Reconstruct Surg, Hong Kong, Hong Kong, Peoples R China	University of Hong Kong	Ng, RWM (corresponding author), Univ Hong Kong, Med Ctr, Queen Mary Hosp, Dept Surg,Div Plast & Reconstruct Surg, Hong Kong, Hong Kong, Peoples R China.	ngwmr@hkucc.hku.hk							0	3	3	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1652	1652		10.1016/S0140-6736(05)67664-7	http://dx.doi.org/10.1016/S0140-6736(05)67664-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271647	Bronze			2022-12-28	WOS:000233047100027
J	Parker, RJ; Hardinge, M; Jeffries, C				Parker, RJ; Hardinge, M; Jeffries, C			10-minute consultation - Snoring	BRITISH MEDICAL JOURNAL			English	Article									Churchill Hosp, Oxford Ctr Resp Med, Oxford Sleep Unit, Oxford OX3 7LJ, England; Thame Hlth Ctr, Thame OX9 3JZ, England	University of Oxford	Parker, RJ (corresponding author), Churchill Hosp, Oxford Ctr Resp Med, Oxford Sleep Unit, Oxford OX3 7LJ, England.	robertparker@doctors.org.uk							0	5	5	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1063	1063		10.1136/bmj.331.7524.1063	http://dx.doi.org/10.1136/bmj.331.7524.1063			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16269493	Bronze, Green Published			2022-12-28	WOS:000233211200025
J	Lazcano, A				Lazcano, A			Teaching evolution in Mexico: Preaching to the choir	SCIENCE			English	Editorial Material									Univ Nacl Autonoma Mexico, Fac Ciencias, Mexico City 04510, DF, Mexico	Universidad Nacional Autonoma de Mexico	Lazcano, A (corresponding author), Univ Nacl Autonoma Mexico, Fac Ciencias, Apdo Postal 70-407,Cd Univ, Mexico City 04510, DF, Mexico.	alar@correo.unam.mx		Lazcano, Antonio/0000-0001-7365-8557					0	3	3	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					787	789		10.1126/science.1115180	http://dx.doi.org/10.1126/science.1115180			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272103				2022-12-28	WOS:000233121800025
J	Majumder, M; Chopra, N; Andrews, R; Hinds, BJ				Majumder, M; Chopra, N; Andrews, R; Hinds, BJ			Nanoscale hydrodynamics - Enhanced flow in carbon nanotubes	NATURE			English	Editorial Material							MEMBRANES		Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA; Univ Kentucky, Ctr Appl Energy Res, Lexington, KY 40511 USA	University of Kentucky; University of Kentucky	Majumder, M (corresponding author), Univ Kentucky, Dept Chem & Mat Engn, Lexington, KY 40506 USA.	bjhinds@engr.uky.edu	Majumder, Mainak/B-4667-2011; Nitin, Chopra/F-8236-2011					Chopra N, 2005, ADV FUNCT MATER, V15, P858, DOI 10.1002/adfm.200400399; Hille B, 1984, IONIC CHANNELS EXCIT; Hinds BJ, 2004, SCIENCE, V303, P62, DOI 10.1126/science.1092048; Hummer G, 2001, NATURE, V414, P188, DOI 10.1038/35102535; Jirage KB, 1997, SCIENCE, V278, P655, DOI 10.1126/science.278.5338.655; Klein E, 2000, J MEMBRANE SCI, V179, P1, DOI 10.1016/S0376-7388(00)00514-7; Majumder M, 2005, J AM CHEM SOC, V127, P9062, DOI 10.1021/ja043013b; Mao ZG, 2001, J PHYS CHEM B, V105, P6916, DOI 10.1021/jp0103272; Skoulidas AI, 2002, PHYS REV LETT, V89, DOI 10.1103/PhysRevLett.89.185901; Sokhan VP, 2002, J CHEM PHYS, V117, P8531, DOI 10.1063/1.1512643	10	1491	1533	34	704	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					44	44		10.1038/43844a	http://dx.doi.org/10.1038/43844a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267546	Bronze			2022-12-28	WOS:000232979000034
J	Jacobson, PD; Bloche, MG				Jacobson, PD; Bloche, MG			Improving relations between attorneys and physicians	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							AMERICAN HEALTH-CARE		Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ctr Law Eth & Hlth, Ann Arbor, MI 48109 USA; Georgetown Univ, Ctr Law, Brookings Inst, Washington, DC USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA	University of Michigan System; University of Michigan; Brookings Institution; Georgetown University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Jacobson, PD (corresponding author), Univ Michigan, Sch Publ Hlth, Dept Hlth Management & Policy, Ctr Law Eth & Hlth, 109 Observ, Ann Arbor, MI 48109 USA.	pdj@umich.edu						*AM MED ASS, P AM MED ASS 2004 AN; ANNAS GJ, 1989, JURIMETRICS J, V29, P437; BABWIN D, 2005, MALPRACTICE DEBATE T; BLACKMUN HA, 1987, LAW MED HLTH CARE, V14, P175; BLUMENTHAL R, 2004, NY TIMES        0311, pA14; Budetti PP, 2005, JAMA-J AM MED ASSOC, V293, P2660, DOI 10.1001/jama.293.21.2660; *COMM HLTH CAR, 1998, COMM HLTH CAR DISP R; Dickens B M, 1987, Law Med Health Care, V15, P110; FOX DM, 1987, AIDS LAW, P367; HADORN DC, 1992, AM J LAW MED, V18, P73; Havighurst CC, 2000, HEALTH AFFAIR, V19, P84, DOI 10.1377/hlthaff.19.4.84; Kronman Anthony T., 1993, LOST LAWYER FAILING; Leape LL, 2002, NEW ENGL J MED, V347, P1633, DOI 10.1056/NEJMNEJMhpr011493; LIANG B, 2004, HARVARD HLTH POLICY, V5, P6; Sage W M, 1999, Houst Law Rev, V35, P1529; Studdert DM, 2005, JAMA-J AM MED ASSOC, V293, P2609, DOI 10.1001/jama.293.21.2609; 2005, NEW YORKER      0307, P53	17	17	17	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2083	2085		10.1001/jama.294.16.2083	http://dx.doi.org/10.1001/jama.294.16.2083			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249423				2022-12-28	WOS:000232778900029
J	Mann, JJ; Apter, A; Bertolote, J; Beautrais, A; Currier, D; Haas, A; Hegerl, U; Lonnqvist, J; Malone, K; Marusic, A; Mehlum, L; Patton, G; Phillips, M; Rutz, W; Rihmer, Z; Schmidtke, A; Shaffer, D; Silverman, M; Takahashi, Y; Varnik, A; Wasserman, D; Yip, P; Hendin, H				Mann, JJ; Apter, A; Bertolote, J; Beautrais, A; Currier, D; Haas, A; Hegerl, U; Lonnqvist, J; Malone, K; Marusic, A; Mehlum, L; Patton, G; Phillips, M; Rutz, W; Rihmer, Z; Schmidtke, A; Shaffer, D; Silverman, M; Takahashi, Y; Varnik, A; Wasserman, D; Yip, P; Hendin, H			Suicide prevention strategies - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							RANDOMIZED CONTROLLED-TRIAL; MAJOR DEPRESSIVE DISORDER; SEROTONIN REUPTAKE INHIBITORS; DELIBERATE SELF-HARM; SERVICES-TASK-FORCE; PRIMARY-CARE; GENERAL-PRACTITIONERS; YOUTH SUICIDE; FOLLOW-UP; MENTAL-DISORDERS	Context In 2002, an estimated 877000 lives were lost worldwide through suicide. Some developed nations have implemented national suicide prevention plans. Although these plans generally propose multiple interventions, their effectiveness is rarely evaluated. Objectives To examine evidence for the effectiveness of specific suicide-preventive interventions and to make recommendations for future prevention programs and research. Data Sources and Study Selection Relevant publications were identified via electronic searches of MEDLINE, the Cochrane Library, and PsychINFO databases using multiple search terms related to suicide prevention. Studies, published between 1966 and June 2005, included those that evaluated preventative interventions in major domains; education and awareness for the general public and for professionals; screening tools for at-risk individuals; treatment of psychiatric disorders; restricting access to lethal means; and responsible media reporting of suicide. Data Extraction Data were extracted on primary outcomes of interest: suicidal behavior (completion, attempt, ideation), intermediary or secondary outcomes (treatment seeking, identification of at-risk individuals, antidepressant prescription/use rates, referrals), or both. Experts from 15 countries reviewed all studies. Included articles were those that reported on completed and attempted suicide and suicidal ideation; or, where applicable, intermediate outcomes, including help-seeking behavior, identification of at-risk individuals, entry into treatment, and antidepressant prescription rates. We included 3 major types of studies for which the research question was clearly defined: systematic reviews and meta-analyses (n=10); quantitative studies, either randomized controlled trials (n = 18) or cohort studies (n =24); and ecological, or population-based studies (n=41). Heterogeneity of study populations and methodology did not permit formal meta-analysis; thus, a narrative synthesis is presented. Data Synthesis Education of physicians and restricting access to lethal means were found to prevent suicide. Other methods including public education, screening programs, and media education need more testing. Conclusions Physician education in depression recognition and treatment and restricting access to lethal methods reduce suicide rates. Other interventions need more evidence of efficacy. Ascertaining which components of suicide prevention programs are effective in reducing rates of suicide and suicide attempt is essential in order to optimize use of limited resources.	Columbia Univ, New York State Psychiat Inst, Dept Neurosci, Div Neurosci, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, Div Child Psychiat, New York, NY USA; Schneider Childrens Med Ctr Israel, Dept Psychiat, Petah Tiqwa, Israel; WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland; Christchurch Sch Med & Hlth Sci, Canterbury Suicide Project, Christchurch, New Zealand; Amer Fdn Suicide Prevent, New York, NY USA; Univ Munich, Dept Psychiat, D-8000 Munich, Germany; Natl Publ Hlth Inst, Dept Mental Hlth & Alcohol Res, Helsinki, Finland; St Vincents Univ Hosp, Dept Psychiat & Mental Hlth Res, Dublin, Ireland; Inst Publ Hlth Republ Slovenia, Ljubljana, Slovenia; Univ Oslo, Suicide Res & Prevent Unit, Oslo, Norway; Univ Melbourne, Ctr Adolescent Hlth, Melbourne, Vic, Australia; Beijing Suicide Res & Prevent Ctr, Beijing, Peoples R China; Acad Univ Hosp, Div Psychiat, Unit Social Psychiat & Hlth Promot, Uppsala, Sweden; Natl Inst Psychiat & Neurol, Budapest, Hungary; Univ Wurzburg, Dept Psychiat & Psychotherapy, Wurzburg, Germany; Ctr Dis Control & Prevent, Natl Suicide Prevent Tech Resource Ctr, Newton, MA USA; Natl Def Med Coll, Res Inst, Div Behav Sci, Tokyo, Japan; Ctr Behav & Hlth Sci, Estonian Swedish Suicidol Inst, Tallinn, Estonia; Karolinska Inst, Swedish Natl Ctr Suicide Res & prevnet Mental Ill, Dept Publ Hlth Sci, Stockholm, Sweden; Univ Hong Kong, Hong Kong Jockey Club Ctr Suicide Res & Prevent, Hong Kong, Hong Kong, Peoples R China	Columbia University; New York State Psychiatry Institute; Columbia University; World Health Organization; University of Otago; University of Munich; Finland National Institute for Health & Welfare; University College Dublin; Saint Vincent's University Hospital; University of Oslo; University of Melbourne; University of Wurzburg; Centers for Disease Control & Prevention - USA; National Defense Medical College - Japan; Karolinska Institutet; University of Hong Kong	Mann, JJ (corresponding author), Columbia Univ, New York State Psychiat Inst, Dept Neurosci, Div Neurosci, 1051 Riverside Dr,Box 42, New York, NY 10032 USA.	jjm@columbia.edu	Phillips, Michael Robert/AAE-7585-2021; Mehlum, Lars/AAV-9241-2021; Patton, George C/B-5246-2013; Ribeiro, Ana Cristina/HHN-7466-2022	Phillips, Michael Robert/0000-0002-5973-2439; Patton, George C/0000-0001-5039-8326; Ribeiro, Ana Cristina/0000-0002-0493-8376; Currier, Dianne/0000-0002-6614-271X; Hegerl, Ulrich/0000-0002-3039-7470; Schmidtke, Armin/0000-0001-5719-9856; Malone, Kevin M/0000-0001-5665-4706; Phillips, Michael/0000-0003-1040-9080				*AG HLTH CAR POL R, 1999, EV REP TREATM DEPR N; AKROYD S, 2002, PUBLICATION NZ MINIS; ALLARD R, 1992, SUICIDE LIFE-THREAT, V22, P303; *AM FDN SUIC PREV, 2002, REP SUIC REC MED; Andersen UA, 2000, ACTA PSYCHIAT SCAND, V102, P126, DOI 10.1034/j.1600-0447.2000.102002126.x; Angst F, 2002, J AFFECT DISORDERS, V68, P167, DOI 10.1016/S0165-0327(01)00377-9; Aoun S, 1999, Aust N Z J Ment Health Nurs, V8, P65, DOI 10.1046/j.1440-0979.1999.00133.x; Asarnow JR, 2005, JAMA-J AM MED ASSOC, V293, P311, DOI 10.1001/jama.293.3.311; Aseltine RH, 2004, AM J PUBLIC HEALTH, V94, P446, DOI 10.2105/AJPH.94.3.446; Ball C, 1998, LEVELS EVIDENCE GRAD; BARRACLOUGH B, 1974, BRIT J PSYCHIAT, V125, P355, DOI 10.1192/bjp.125.4.355; Bateman A, 2001, AM J PSYCHIAT, V158, P36, DOI 10.1176/appi.ajp.158.1.36; Beaglehole R., 2003, WORLD HLTH REPORT 20; Beautrais AL, 2001, AUST NZ J PSYCHIAT, V35, P557, DOI 10.1080/0004867010060501; Bertolote JM, 2003, BRIT J PSYCHIAT, V183, P382, DOI 10.1192/bjp.183.5.382; BOWLES J, 1995, PREVENTIVE STRATEGIE; BRENT DA, 1994, J AM ACAD CHILD PSY, V33, P1080, DOI 10.1097/00004583-199410000-00003; Bridges FS, 2004, PSYCHOL REP, V94, P819; Bridges FS, 2004, PERCEPT MOTOR SKILL, V98, P594; Brown GK, 2005, JAMA-J AM MED ASSOC, V294, P563, DOI 10.1001/jama.294.5.563; Bruce ML, 2004, JAMA-J AM MED ASSOC, V291, P1081, DOI 10.1001/jama.291.9.1081; Burns JM, 2000, AUST NZ J PSYCHIAT, V34, P388, DOI 10.1046/j.1440-1614.2000.00738.x; CANTOR CH, 1995, MED J AUSTRALIA, V162, P583, DOI 10.5694/j.1326-5377.1995.tb138547.x; Carlsten A, 2001, PHARMACOEPIDEM DR S, V10, P525, DOI 10.1002/pds.618; Carlsten A, 1996, ACTA PSYCHIAT SCAND, V94, P94, DOI 10.1111/j.1600-0447.1996.tb09831.x; Carrington PJ, 1999, ARCH SUICIDE RES, V5, P71, DOI 10.1023/A:1009697214333; Cauffman E, 2004, J AM ACAD CHILD PSY, V43, P430, DOI 10.1097/00004583-200404000-00009; Cedereke M, 2002, EUR PSYCHIAT, V17, P82, DOI 10.1016/S0924-9338(02)00632-6; Centers for Disease Control and Prevention, NAT CTR HLTH STAT SE; Coyle JT, 2003, J AM ACAD CHILD PSY, V42, P1494, DOI 10.1097/00004583-200312000-00017; CROME P, 1993, ACTA PSYCHIAT SCAND, V87, P33, DOI 10.1111/j.1600-0447.1993.tb05371.x; Dieserud G, 2000, SUICIDE LIFE-THREAT, V30, P61; DORPAT TL, 1960, COMPR PSYCHIAT, V1, P349, DOI 10.1016/S0010-440X(60)80058-2; Drake R.E., 1989, DEPRESSION SCHIZOPHR, P171; EGGERT LL, 1995, SUICIDE LIFE-THREAT, V25, P276; Etzersdorfer E, 1998, ARCH SUICIDE RES, V4, P67, DOI 10.1080/13811119808258290; FEIGHTNER J, 1994, CANADIAN GUIDE CLIN; Fergusson D, 2005, BMJ-BRIT MED J, V330, P396, DOI 10.1136/bmj.330.7488.396; Gaynes BN, 2004, ANN INTERN MED, V140, P822, DOI 10.7326/0003-4819-140-10-200405180-00015; Gibbons RD, 2005, ARCH GEN PSYCHIAT, V62, P165, DOI 10.1001/archpsyc.62.2.165; Gilbody S, 2003, JAMA-J AM MED ASSOC, V289, P3145, DOI 10.1001/jama.289.23.3145; Glick ID, 2004, J CLIN PSYCHIAT, V65, P679, DOI 10.4088/jcp.v65n0513; GOLDACRE M, 1993, LANCET, V342, P283, DOI 10.1016/0140-6736(93)91822-4; Goldman LS, 1999, J GEN INTERN MED, V14, P569, DOI 10.1046/j.1525-1497.1999.03478.x; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; Gould MS, 2003, J AM ACAD CHILD PSY, V42, P386, DOI 10.1097/01.CHI.0000046821.95464.CF; Gould MS, 2005, JAMA-J AM MED ASSOC, V293, P1635, DOI 10.1001/jama.293.13.1635; Gould MS, 2001, ANN NY ACAD SCI, V932, P200; Guaiana G, 2005, J CLIN PSYCHIAT, V66, P750, DOI 10.4088/JCP.v66n0612; Gunnell D, 2000, SOC PSYCH PSYCH EPID, V35, P437, DOI 10.1007/s001270050261; Gunnell D, 2005, BMJ-BRIT MED J, V330, P385, DOI 10.1136/bmj.330.7488.385; GUO B, 2002, EFFICACY SUICIDE PRE; Guthrie E, 2001, BRIT MED J, V323, P135, DOI 10.1136/bmj.323.7305.135; Hall WD, 2003, BRIT MED J, V326, P1008, DOI 10.1136/bmj.326.7397.1008; Hannaford PC, 1996, BRIT J GEN PRACT, V46, P333; Hansen V, 2001, BRIT J PSYCHIAT, V179, P438, DOI 10.1192/bjp.179.5.438; Hawton K, 2002, SUICIDE LIFE-THREAT, V32, P223, DOI 10.1521/suli.32.3.223.22169; HAWTON K, 2002, COCHRANE DB SYST REV; Hegerl U, 2003, PHARMACOPSYCHIATRY, V36, P288; Helgason T, 2004, BRIT J PSYCHIAT, V184, P157, DOI 10.1192/bjp.184.2.157; Henriksson S, 2001, ACTA PSYCHIAT SCAND, V103, P301, DOI 10.1034/j.1600-0447.2001.00276.x; Hickie Ian, 2004, Australas Psychiatry, V12 Suppl, pS38; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; Huey SJ, 2004, J AM ACAD CHILD PSY, V43, P183, DOI 10.1097/00004583-200402000-00014; ISOMETSA E, 1995, BRIT MED J, V310, P1366, DOI 10.1136/bmj.310.6991.1366; Joiner TE, 2002, BEHAV RES THER, V40, P471, DOI 10.1016/S0005-7967(01)00017-1; Jorm AF, 2005, AUST NZ J PSYCHIAT, V39, P248, DOI 10.1080/j.1440-1614.2005.01561.x; KAPUR S, 1992, JAMA-J AM MED ASSOC, V268, P3441, DOI 10.1001/jama.268.24.3441; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; KELLER MB, 1986, AM J PSYCHIAT, V143, P24; Kelly C, 1998, ULSTER MED J, V67, P33; Kelly S, 1998, Popul Trends, P29; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Khan A, 2003, AM J PSYCHIAT, V160, P790, DOI 10.1176/appi.ajp.160.4.790; Knox KL, 2003, BMJ-BRIT MED J, V327, P1376, DOI 10.1136/bmj.327.7428.1376; KREITMAN N, 1976, BRIT J PREV SOC MED, V30, P86; Lehfeld Hartmut, 2004, Adv Psychosom Med, V26, P137; Leon AC, 2004, J CLIN PSYCHIAT, V65, P915; LESTER D, 1990, AM J PUBLIC HEALTH, V80, P80, DOI 10.2105/AJPH.80.1.80; LESTER D, 1993, PSYCHOL REP, V72, P787, DOI 10.2466/pr0.1993.72.3.787; LESTER D, 1991, PSYCHOL REP, V68, P202, DOI 10.2466/PR0.68.1.202-202; Lester D, 1999, PSYCHOL REP, V84, P1158, DOI 10.2466/PR0.84.3.1158-1158; LESTER D, 1990, ACTA PSYCHIAT SCAND, V82, P383, DOI 10.1111/j.1600-0447.1990.tb01406.x; Lin EHB, 2001, J GEN INTERN MED, V16, P614, DOI 10.1046/j.1525-1497.2001.016009614.x; LOFTIN C, 1991, NEW ENGL J MED, V325, P1615, DOI 10.1056/NEJM199112053252305; LONNQVIST JK, 1995, PSYCHIAT CLIN NEUROS, V49, pS111, DOI 10.1111/j.1440-1819.1995.tb01912.x; Ludwig J, 2000, JAMA-J AM MED ASSOC, V284, P585, DOI 10.1001/jama.284.5.585; Ludwig J, 2005, J POLICY ANAL MANAG, V24, P249, DOI 10.1002/pam.20089; Luoma JB, 2002, AM J PSYCHIAT, V159, P909, DOI 10.1176/appi.ajp.159.6.909; MALONE KM, 1995, AM J PSYCHIAT, V152, P1601; Mann JJ, 2002, ANN INTERN MED, V136, P302, DOI 10.7326/0003-4819-136-4-200202190-00010; MANN JJ, DEPRESSION RECOGNITI; Marusic A, 2004, 10 EUR S SUIC SUIC B; McClure GMG, 2000, BRIT J PSYCHIAT, V176, P64, DOI 10.1192/bjp.176.1.64; Mehlum L, 2000, 33 INT C MIL MED JUN; Meltzer HY, 2003, ARCH GEN PSYCHIAT, V60, P82, DOI 10.1001/archpsyc.60.1.82; Michel K, 2000, Crisis, V21, P71, DOI 10.1027//0227-5910.21.2.71; MORGAN HG, 1993, BRIT J PSYCHIAT, V163, P111, DOI 10.1192/bjp.163.1.111; Mott JA, 2002, JAMA-J AM MED ASSOC, V288, P988, DOI 10.1001/jama.288.8.988; Motto JA, 2001, PSYCHIATR SERV, V52, P828, DOI 10.1176/appi.ps.52.6.828; MOTTO JA, 1970, ARCH GEN PSYCHIAT, V23, P143; Naismith SL, 2001, MED J AUSTRALIA, V175, pS42; NIELSEN A S, 1992, Ugeskrift for Laeger, V154, P1972; O'Carroll P W, 1994, MMWR Recomm Rep, V43, P9; OHBERG A, 1995, BRIT J PSYCHIAT, V166, P35, DOI 10.1192/bjp.166.1.35; Olfson M, 2003, ARCH GEN PSYCHIAT, V60, P978, DOI 10.1001/archpsyc.60.9.978; OLIVER RG, 1972, MED J AUSTRALIA, V2, P919, DOI 10.5694/j.1326-5377.1972.tb103635.x; Oquendo MA, 2004, AM J PSYCHIAT, V161, P1433, DOI 10.1176/appi.ajp.161.8.1433; Oquendo MA, 2002, AM J PSYCHIAT, V159, P1746, DOI 10.1176/appi.ajp.159.10.1746; Oquendo MA, 1999, AM J PSYCHIAT, V156, P190; ORBACH I, 1993, SUICIDE LIFE-THREAT, V23, P120; Oyama H, 2004, COMMUNITY MENT HLT J, V40, P249, DOI 10.1023/B:COMH.0000026998.29212.17; Paykel ES, 1998, BRIT J PSYCHIAT, V173, P519, DOI 10.1192/bjp.173.6.519; Pfaff JJ, 2001, MED J AUSTRALIA, V174, P222, DOI 10.5694/j.1326-5377.2001.tb143241.x; Phillips MR, 2002, LANCET, V360, P1728, DOI 10.1016/S0140-6736(02)11681-3; Pignone MP, 2002, ANN INTERN MED, V136, P765, DOI 10.7326/0003-4819-136-10-200205210-00013; Pirkis J, 2001, Crisis, V22, P146, DOI 10.1027//0227-5910.22.4.146; Pirkis J, 2001, Crisis, V22, P155, DOI 10.1027//0227-5910.22.4.155; Ploeg J, 1996, CAN J PUBLIC HEALTH, V87, P319; RETTERSTOL N, 1989, ACTA PSYCHIAT SCAND, V80, P61; RICH CL, 1988, ARCH GEN PSYCHIAT, V45, P589, DOI 10.1001/archpsyc.1988.01800300087012; Rihmer Z, 2001, ACTA PSYCHIAT SCAND, V103, P238; ROBINS E, 1959, AM J PUBLIC HEALTH N, V49, P888, DOI 10.2105/AJPH.49.7.888; Rotheram-Borus MJ, 2000, J CONSULT CLIN PSYCH, V68, P1081, DOI 10.1037/0022-006X.68.6.1081; RUTZ W, 1989, ACTA PSYCHIAT SCAND, V80, P151, DOI 10.1111/j.1600-0447.1989.tb01318.x; Rutz W, 2001, J AFFECT DISORDERS, V62, P123, DOI 10.1016/S0165-0327(00)00356-6; SCOTT M, 2004, AM AC CHILD AD PSYCH; Shaffer D, 1996, ARCH GEN PSYCHIAT, V53, P339; Shaffer D, 2004, J AM ACAD CHILD PSY, V43, P71, DOI 10.1097/00004583-200401000-00016; SHELEF M, 1994, SCI TOTAL ENVIRON, V147, P93, DOI 10.1016/0048-9697(94)90224-0; SIMON GE, IN PRESS AM J PSYCHI; SNOWDON J, 1992, MED J AUSTRALIA, V156, P79; Takahashi K, 1998, Seishin Shinkeigaku Zasshi, V100, P469; TAKAHASHI Y, 1999, AMIDST SHARP INCREAS, V88, P2; ThiesFlechtner K, 1996, PHARMACOPSYCHIATRY, V29, P103, DOI 10.1055/s-2007-979553; Thompson C, 2000, LANCET, V355, P185, DOI 10.1016/S0140-6736(99)03171-2; Thompson EA, 2001, AM J PUBLIC HEALTH, V91, P742, DOI 10.2105/AJPH.91.5.742; Valentini W, 2004, REV SAUDE PUBL, V38, P522, DOI 10.1590/S0034-89102004000400007; Valuck RJ, 2004, CNS DRUGS, V18, P1119, DOI 10.2165/00023210-200418150-00006; Vergouwen ACM, 2003, J CLIN PSYCHIAT, V64, P1415, DOI 10.4088/JCP.v64n1203; Wasserman D, 1998, ACTA PSYCHIAT SCAND, V98, P1, DOI 10.1111/j.1600-0447.1998.tb10758.x; Wells K, 2005, AM J PSYCHIAT, V162, P1149, DOI 10.1176/appi.ajp.162.6.1149; WHITLOCK FA, 1975, MED J AUSTRALIA, V1, P737, DOI 10.5694/j.1326-5377.1975.tb111781.x; *WHO, COUNTR REP CHARTS WE; WIEDENMANN A, 1993, ACTA PSYCHIAT SCAND, V88, P364, DOI 10.1111/j.1600-0447.1993.tb03474.x; Yamasawa K, 1980, Acta Med Leg Soc (Liege), V30, P187	147	1878	1924	12	529	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2064	2074		10.1001/jama.294.16.2064	http://dx.doi.org/10.1001/jama.294.16.2064			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	977CB	16249421				2022-12-28	WOS:000232778900027
J	Sanchini, MA; Gunelli, R; Nanni, O; Bravaccini, S; Fabbri, C; Sermasi, A; Bercovich, E; Ravaioli, A; Amadori, D; Calistri, D				Sanchini, MA; Gunelli, R; Nanni, O; Bravaccini, S; Fabbri, C; Sermasi, A; Bercovich, E; Ravaioli, A; Amadori, D; Calistri, D			Relevance of urine telomerase in the diagnosis of bladder cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							REPEAT AMPLIFICATION PROTOCOL; SQUAMOUS-CELL CARCINOMA; NUCLEAR MATRIX PROTEINS; IN-SITU HYBRIDIZATION; BTA STAT; UROTHELIAL CARCINOMA; EXFOLIATED CELLS; ASSAY; TRAP; CYTOLOGY	Context The identification of new molecular markers is one of the most challenging goals for the early detection of bladder cancer because available noninvasive methods have neither sufficient sensitivity nor specificity to be acceptable for routine use. Objective To develop a relatively simple, inexpensive, and accurate test that measures telomerase activity in voided urine to apply to large-scale screening programs for bladder cancer detection. Design, Setting, and Participants Case-control study conducted in 218 men (84 healthy individuals and 134 patients at first diagnosis of histologically confirmed bladder cancer), frequency matched by age and recruited between March 2003 and November 2004 in Italy. Urine telomerase activity was determined using a highly sensitive telomeric repeat amplification protocol (TRAP) assay. Urine samples were processed for cytological diagnosis and TRAP assay. The diagnosis of bladder cancer was based on bioptic and cystoscopic examinations. The performance of the TRAP assay to detect urine telomerase activity was compared with urine cytology as an aid to early cancer detection. Quantification of urine telomerase activity was conducted in a blinded manner. Main Outcome Measure Sensitivity and specificity of TRAP to detect bladder cancer. Results Using a 50 arbitrary enzymatic unit cutoff value, we validated the results obtained in the pilot study. In the overall series, sensitivity was 90% (95% confidence interval [CI], 83%-94%) and specificity was 88% (95% Cl, 79%-93%). Specificity increased to 94% (95% Cl, 85%-98%) for individuals aged 75 years or younger. The same predictive capacity of telomerase activity levels was observed for patients with low-grade tumors or with negative cytology results. Conclusions The present validation study demonstrated the ability of urine telomerase activity levels to accurately detect the presence of bladder tumors in men. This test represents a potentially useful noninvasive diagnostic innovation for bladder cancer detection in high-risk groups such as habitual smokers or in symptomatic patients.	Morgagni Pierantoni Hosp, Div Oncol & Diagnost, I-47100 Forli, Italy; Morgagni Pierantoni Hosp, Dept Urol, I-47100 Forli, Italy; Ist Oncol Romagnolo, Forli, Italy; Infermi Hosp, Dept Oncol, Rimini, Italy; Ist Sci Romagnolo Studio & Cura Tumori, Forli Meldola, Italy	Hospital of Rimini; IRCCS Meldola (IRST)	Calistri, D (corresponding author), Morgagni Pierantoni Hosp, Div Oncol & Diagnost, Via Forlanini 34, I-47100 Forli, Italy.	biomolec@ausl.fo.it	Bravaccini, Sara/C-7023-2016; nanni, oriana/K-3240-2016; Bravaccini, Sara/ABC-8944-2020	nanni, oriana/0000-0001-7338-2896; Bravaccini, Sara/0000-0002-0075-8538; Calistri, Daniele/0000-0002-5064-2023				American Cancer Society, 2004, CANC FACTS FIG 2004; Breslow RA, 1997, J NATL CANCER I, V89, P618, DOI 10.1093/jnci/89.9.618; Califano J, 1996, CANCER RES, V56, P5720; Dalbagni G, 1997, CLIN CANCER RES, V3, P1593; Deeks JJ, 2001, BRIT MED J, V323, P157, DOI 10.1136/bmj.323.7305.157; Dulaimi E, 2004, CLIN CANCER RES, V10, P1887, DOI 10.1158/1078-0432.CCR-03-0127; Fedriga R, 2001, NEOPLASIA, V3, P446, DOI 10.1038/sj.neo.7900191; Gelmini S, 1998, CLIN CHEM, V44, P2133; Getzenberg RH, 1996, CANCER RES, V56, P1690; Glas AS, 2003, J UROLOGY, V169, P1975, DOI 10.1097/01.ju.0000067461.30468.6d; Grossman HB, 2005, JAMA-J AM MED ASSOC, V293, P810, DOI 10.1001/jama.293.7.810; Halling KC, 2002, J UROLOGY, V167, P2001, DOI 10.1016/S0022-5347(05)65072-0; Halling KC, 2000, J UROLOGY, V164, P1768, DOI 10.1016/S0022-5347(05)67104-2; Herr HW., 2001, CANC PRINCIPLES PRAC, V6, P1396; Hirose M, 1997, J CANCER RES CLIN, V123, P337, DOI 10.1007/BF01438310; Hiyama E, 1996, J NATL CANCER I, V88, P116, DOI 10.1093/jnci/88.2.116; Holt SE, 1999, J CELL PHYSIOL, V180, P10, DOI 10.1002/(SICI)1097-4652(199907)180:1<10::AID-JCP2>3.0.CO;2-D; Johansson SL, 1997, SEMIN SURG ONCOL, V13, P291; Kannan S, 1997, CANCER EPIDEM BIOMAR, V6, P413; Kausch I, 2001, EUR UROL, V39, P498, DOI 10.1159/000052495; Keesee SK, 1996, CRIT REV EUKAR GENE, V6, P189, DOI 10.1615/CritRevEukarGeneExpr.v6.i2-3.50; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Kim NW, 1997, NUCLEIC ACIDS RES, V25, P2595, DOI 10.1093/nar/25.13.2595; Kinoshita H, 1997, J NATL CANCER I, V89, P724, DOI 10.1093/jnci/89.10.724; Konety BR, 2001, J UROLOGY, V165, P600, DOI 10.1097/00005392-200102000-00081; Lin Y, 1996, CLIN CANCER RES, V2, P929; Lokeshwar VB, 2001, J UROLOGY, V165, P1067, DOI 10.1016/S0022-5347(05)66428-2; MESSING EM, 1995, UROLOGY, V45, P387, DOI 10.1016/S0090-4295(99)80006-5; Miyoshi Y, 1999, ORAL ONCOL, V35, P283, DOI 10.1016/S1368-8375(98)00117-1; Muller M, 1998, CLIN CANCER RES, V4, P1949; Mutirangura A, 1996, CANCER RES, V56, P3530; Placer J, 2002, EUR UROL, V42, P547, DOI 10.1016/S0302-2838(02)00448-7; Ramakumar S, 1999, J UROLOGY, V161, P388, DOI 10.1016/S0022-5347(01)61899-8; Sanchini MA, 2004, NEOPLASIA, V6, P234, DOI 10.1593/neo.03433; Sarosdy MF, 2002, J UROLOGY, V168, P1950, DOI 10.1016/S0022-5347(05)64270-X; Sarosdy MF, 1997, UROLOGY, V50, P349, DOI 10.1016/S0090-4295(97)00292-6; Sharma S, 1999, J UROLOGY, V162, P53, DOI 10.1097/00005392-199907000-00014; Shay JW, 1997, J CLIN PATHOL, V50, P106, DOI 10.1136/jcp.50.2.106; Shay JW, 1997, EUR J CANCER, V33, P787, DOI 10.1016/S0959-8049(97)00062-2; Smith SD, 2001, JAMA-J AM MED ASSOC, V285, P324, DOI 10.1001/jama.285.3.324; Sourvinos G, 2001, J UROLOGY, V165, P249, DOI 10.1097/00005392-200101000-00073; Tatsumoto N, 2000, CLIN CANCER RES, V6, P2696; WRIGHT WE, 1995, NUCLEIC ACIDS RES, V23, P3794, DOI 10.1093/nar/23.18.3794; Yahata N, 1998, J NATL CANCER I, V90, P684, DOI 10.1093/jnci/90.9.684; Yoshida K, 1997, CANCER, V79, P362, DOI 10.1002/(SICI)1097-0142(19970115)79:2<362::AID-CNCR20>3.0.CO;2-Y	45	85	92	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2052	2056		10.1001/jama.294.16.2052	http://dx.doi.org/10.1001/jama.294.16.2052			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249419	Bronze			2022-12-28	WOS:000232778900025
J	Kuruvilla, S; Mays, N				Kuruvilla, S; Mays, N			Reorienting health-research communication	LANCET			English	Editorial Material							KNOWLEDGE		Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Kuruvilla, S (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England.	Shyama.Kuruvilla@lshtm.ac.uk		Kuruvilla, Shyama/0000-0002-0327-4467				Bowen S, 2005, PLOS MED, V2, P600, DOI 10.1371/journal.pmed.0020166; BUSE K, IN PRESS MAKING HLTH; Eccles M, 2005, J CLIN EPIDEMIOL, V58, P117, DOI 10.1016/j.jclinepi.2004.09.003; Edwards P, 2005, LANCET, V365, P1957; Figueroa ME, 2002, COMMUNICATION SOCIAL; Goodwin N, 2004, MANAGING DIVERSE NET; Haines A, 2004, B WORLD HEALTH ORGAN, V82, P724; Irwin A, 2001, PUBLIC UNDERST SCI, V10, P1, DOI 10.1088/0963-6625/10/1/301; Lasswell H.D., 1948, COMMUNICATION IDEAS, P37; Lavis JN, 2003, MILBANK Q, V81, P221, DOI 10.1111/1468-0009.t01-1-00052; Longino H.E., 2002, FATE KNOWLEDGE; SALWEN MD, 1996, INTEGRATED APPROACH	12	9	9	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1416	1418		10.1016/S0140-6736(05)67580-0	http://dx.doi.org/10.1016/S0140-6736(05)67580-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243076				2022-12-28	WOS:000232724600006
J	Garczarek, F; Gerwert, K				Garczarek, F; Gerwert, K			Functional waters in intraprotein proton transfer monitored by FTIR difference spectroscopy	NATURE			English	Article							HYDROGEN-BONDED NETWORK; ANGSTROM RESOLUTION; STRUCTURAL-CHANGES; ENERGY-STORAGE; EXCESS PROTON; IR-SPECTRA; BACTERIORHODOPSIN; DYNAMICS; ASSIGNMENT; MOLECULES	Much progress has been made in our understanding of water molecule reactions on surfaces(1), proton solvation in gas-phase water clusters(2,3) and proton transfer through liquids(4). Compared with our advanced understanding of these physico-chemical systems, much less is known about individual water molecules and their cooperative behaviour in heterogeneous proteins during enzymatic reactions. Here we use time-resolved Fourier transform infrared(5) spectroscopy (trFTIR) and in situ H-2 O-18/H-2 O-16 exchange FTIR to determine how the membrane protein bacteriorhodopsin(6) uses the interplay among strongly hydrogen-bonded water molecules, a water molecule with a dangling hydroxyl group and a protonated water cluster(7) to transfer protons. The precise arrangement of water molecules in the protein matrix results in a controlled Grotthuss proton transfer, in contrast to the random proton migration that occurs in liquid water. Our findings support the emerging paradigm that intraprotein water molecules are as essential for biological functions as amino acids.	Ruhr Univ Bochum, Lehrstuhl Biophys, D-44780 Bochum, Germany	Ruhr University Bochum	Gerwert, K (corresponding author), Ruhr Univ Bochum, Lehrstuhl Biophys, D-44780 Bochum, Germany.	gerwert@bph.ruhr-uni-bochum.de	Gerwert, Klaus/G-7311-2015					BIRGE RR, 1991, J AM CHEM SOC, V113, P4327, DOI 10.1021/ja00011a043; de Grotthuss C, 1806, ANN CHIM, V58, P54; Dencher NA, 2000, BBA-BIOENERGETICS, V1460, P192, DOI 10.1016/S0005-2728(00)00139-0; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; EIGEN M, 1964, ANGEW CHEM INT EDIT, V3, P1, DOI 10.1002/anie.196400011; Garczarek F, 2005, P NATL ACAD SCI USA, V102, P3633, DOI 10.1073/pnas.0500421102; Garczarek F, 2004, BIOPHYS J, V87, P2676, DOI 10.1529/biophysj.104.046433; GERWERT K, 1989, P NATL ACAD SCI USA, V86, P4943, DOI 10.1073/pnas.86.13.4943; Grudinin S, 2005, BIOPHYS J, V88, P3252, DOI 10.1529/biophysj.104.047993; Hayashi S, 2000, J PHYS CHEM B, V104, P10678, DOI 10.1021/jp001508r; Hayashi S, 2004, J AM CHEM SOC, V126, P10516, DOI 10.1021/ja047506s; Headrick JM, 2005, SCIENCE, V308, P1765, DOI 10.1126/science.1113094; Kandt C, 2004, BIOPHYS J, V86, P705, DOI 10.1016/S0006-3495(04)74149-1; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Kotting C, 2005, CHEMPHYSCHEM, V6, P881, DOI 10.1002/cphc.200400504; Lanyi JK, 2004, ANNU REV PHYSIOL, V66, P665, DOI 10.1146/annurev.physiol.66.032102.150049; LECOUTRE J, 1995, P NATL ACAD SCI USA, V92, P4962, DOI 10.1073/pnas.92.11.4962; Liu K, 1996, SCIENCE, V271, P62, DOI 10.1126/science.271.5245.62; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Marx D, 2004, SCIENCE, V303, P634, DOI 10.1126/science.1094001; Marx D, 1999, NATURE, V397, P601, DOI 10.1038/17579; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Rousseau R, 2004, ANGEW CHEM INT EDIT, V43, P4804, DOI 10.1002/anie.200453857; Rozenberg M, 2000, PHYS CHEM CHEM PHYS, V2, P2699, DOI 10.1039/b002216k; Shibata N, 2005, BIOCHEMISTRY-US, V44, P7406, DOI 10.1021/bi050122+; Spassov VZ, 2001, J MOL BIOL, V312, P203, DOI 10.1006/jmbi.2001.4902; Tanimoto T, 2003, BIOCHEMISTRY-US, V42, P2300, DOI 10.1021/bi026990d; Zundel G., 1976, Hydrogen bond. Recent developments in theory and experiments. II. Structure and spectroscopy, P683; Zwier TS, 2004, SCIENCE, V304, P1119, DOI 10.1126/science.1098129	30	440	445	3	201	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 5	2006	439	7072					109	112		10.1038/nature04231	http://dx.doi.org/10.1038/nature04231			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999HA	16280982				2022-12-28	WOS:000234378700044
J	Piperno, DR; Sues, HD				Piperno, DR; Sues, HD			Dinosaurs dined on grass	SCIENCE			English	Editorial Material							PHYTOLITH		Natl Museum Nat Hist, Washington, DC 20560 USA; Smithsonian Trop Res Inst, Balboa, Panama	Smithsonian Institution; Smithsonian National Museum of Natural History; Smithsonian Institution; Smithsonian Tropical Research Institute	Piperno, DR (corresponding author), Natl Museum Nat Hist, Washington, DC 20560 USA.	pipernod@si.edu						Barker NP, 2001, ANN MO BOT GARD, V88, P373, DOI 10.2307/3298585; Blinnikov M, 2002, PALAEOGEOGR PALAEOCL, V177, P77, DOI 10.1016/S0031-0182(01)00353-4; FREDLUND GG, 1994, J BIOGEOGR, V21, P321, DOI 10.2307/2845533; Fredlund GG, 1997, QUATERNARY RES, V47, P206, DOI 10.1006/qres.1996.1862; Jacobs BF, 1999, ANN MO BOT GARD, V86, P590, DOI 10.2307/2666186; Kellogg EA, 2001, PLANT PHYSIOL, V125, P1198, DOI 10.1104/pp.125.3.1198; Metcalfe CR, 1960, ANATOMY MONOCOTYLEDO, V1; Pascual R, 1999, J VERTEBR PALEONTOL, V19, P373, DOI 10.1080/02724634.1999.10011148; Pearsall DM, 2003, J ARCHAEOL SCI, V30, P611, DOI 10.1016/S0305-4403(02)00237-6; Piperno D.R., 1988, PHYTOLITH ANAL ARCHA; Piperno D.R., 1998, SMITHSONIAN CONTRIBU, P1, DOI [10.5479/si.0081024X.85, DOI 10.5479/SI.0081024X.85]; PIPERNO DR, IN PRESS PHYTOLITHS; Prasad V, 2005, SCIENCE, V310, P1177, DOI 10.1126/science.1118806; SUES H. D., 2000, EVOLUTION HERBIVORY	14	39	48	4	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2005	310	5751					1126	1128		10.1126/science.1121020	http://dx.doi.org/10.1126/science.1121020			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	986GE	16293745				2022-12-28	WOS:000233437300028
J	Meltzer, PS				Meltzer, PS			Genetic diversity in melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									NHGRI, Mol Genet Sect, Canc Genet Branch, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI)	Meltzer, PS (corresponding author), NHGRI, Mol Genet Sect, Canc Genet Branch, Bethesda, MD 20892 USA.							Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; MALDONADO JL, 2001, NATURE, V413, P271; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806	4	4	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2104	2107		10.1056/NEJMp058173	http://dx.doi.org/10.1056/NEJMp058173			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291979				2022-12-28	WOS:000233288600002
J	Rand, TA; Petersen, S; Du, FH; Wang, XD				Rand, TA; Petersen, S; Du, FH; Wang, XD			Argonaute2 cleaves the anti-guide strand of siRNA during RISC activation	CELL			English	Article							INDUCED SILENCING COMPLEX; CAENORHABDITIS-ELEGANS; RNA CLEAVAGE; DROSOPHILA; ENDONUCLEASE; INTERFERENCE; INITIATION; MESSENGER; MICRORNA; ENCODES	The mRNA-cleavage step of RNA interference is mediated by an endonuclease, Argonaute2 (Ago2), within the RNA-induced silencing complex (RISC). Ago2 uses one strand of the small interfering (si) RNA duplex as a guide to find messenger RNAs containing complementary sequences and cleaves the phosphodiester backbone at a specific site measured from the guide strand's 5' end. Here, we show that both strands of siRNA get loaded onto Ago2 protein in Drosophila S2 cell extracts. The anti-guide strand behaves as a RISC substrate and is cleaved by Ago2. This cleavage event is important for the removal of the anti-guide strand from Ago2 protein and activation of RISC.	Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA; Univ Texas, SW Med Ctr Dallas, Med Sci Training Program, Dallas, TX 75390 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Wang, XD (corresponding author), Univ Texas, SW Med Ctr Dallas, Howard Hughes Med Inst, Dept Biochem, Dallas, TX 75390 USA.	xwang@biochem.swmed.edu		Wang, Xiaodong/0000-0001-9885-356X				Baulcombe D, 2004, NATURE, V431, P356, DOI 10.1038/nature02874; Brennecke J, 2003, CELL, V113, P25, DOI 10.1016/S0092-8674(03)00231-9; Carmell MA, 2004, NAT STRUCT MOL BIOL, V11, P214, DOI 10.1038/nsmb729; Dykxhoorn DM, 2003, NAT REV MOL CELL BIO, V4, P457, DOI 10.1038/nrm1129; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Giraldez AJ, 2005, SCIENCE, V308, P833, DOI 10.1126/science.1109020; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Motamedi MR, 2004, CELL, V119, P789, DOI 10.1016/j.cell.2004.11.034; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101; Reinhart BJ, 2000, NATURE, V403, P901, DOI 10.1038/35002607; Rhoades MW, 2002, CELL, V110, P513, DOI 10.1016/S0092-8674(02)00863-2; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Sijen T, 2003, NATURE, V426, P310, DOI 10.1038/nature02107; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Vaucheret H, 2001, J CELL SCI, V114, P3083; Verdel A, 2004, SCIENCE, V303, P672, DOI 10.1126/science.1093686; Volpe TA, 2002, SCIENCE, V297, P1833, DOI 10.1126/science.1074973	29	542	644	0	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					621	629		10.1016/j.cell.2005.10.020	http://dx.doi.org/10.1016/j.cell.2005.10.020			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16271385	Bronze			2022-12-28	WOS:000233497400011
J	Chandra, S; Gallardo, G; Fernandez-Chacon, R; Schluter, OM; Sudhof, TC				Chandra, S; Gallardo, G; Fernandez-Chacon, R; Schluter, OM; Sudhof, TC			alpha-synuclein cooperates with CSP alpha in preventing neurodegeneration	CELL			English	Article							CYSTEINE-STRING PROTEIN; PARKINSONS-DISEASE; MEMBRANE-FUSION; NEUROTRANSMITTER EXOCYTOSIS; CALCIUM-CHANNEL; DROSOPHILA; MICE; DEGENERATION; BRAIN; OVEREXPRESSION	alpha-synuclein and cysteine-string protein-a (CSP alpha) are abundant synaptic vesicle proteins independently linked to neurodegeneration. Dominantly inherited mutations in alpha-synuclein cause Parkinson's disease, but the physiological role of alpha-synuclein remains unknown. Deletion of CSP alpha produces rapidly progressive neurodegeneration in mice, presumably because the cochaperone function of CSP alpha is essential for neuronal survival. Here, we report the surprising finding that transgenic expression of a-synuclein abolishes the lethality and neurodegeneration caused by deletion of CSP alpha. Conversely, ablation of endogenous synucleins exacerbates these phenotypes. Deletion of CSP alpha inhibits SNARE complex assembly; transgenic alpha-synuclein ameliorates this inhibition. In preventing neurodegeneration in CSP alpha-deficient mice, alpha-synuclein does not simply substitute for CSP alpha but acts by a downstream mechanism that requires phospholipid binding by alpha-synuclein. These observations reveal a powerful in vivo activity of alpha-synuclein in protecting nerve terminals against injury and suggest that this activity operates in conjunction with CSP alpha and SNARE proteins on the presynaptic membrane interface.	Univ Texas, Howard Hughes Med Inst, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA; Univ Sevilla, Dept Fisiol Med & Biofis, E-41009 Seville, Spain; MPI Expt Med, D-37070 Gottingen, Germany	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Sevilla	Sudhof, TC (corresponding author), Univ Texas, Howard Hughes Med Inst, SW Med Ctr, Dept Mol Genet, Dallas, TX 75390 USA.	thomas.sudhof@utsouthwestern.edu	Fernandez-Chacon, Rafael/E-6303-2010; IBIS, FISIOLOGIA/O-9485-2015	Fernandez-Chacon, Rafael/0000-0002-9845-9885	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040057] Funding Source: NIH RePORTER; NINDS NIH HHS [5 R01 NS40057-04] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Abeliovich A, 2000, NEURON, V25, P239, DOI 10.1016/S0896-6273(00)80886-7; Andra K, 1996, NEUROBIOL AGING, V17, P183, DOI 10.1016/0197-4580(95)02066-7; Braun JEA, 1996, J BIOL CHEM, V271, P25989, DOI 10.1074/jbc.271.42.25989; Bronk P, 2001, NEURON, V30, P475, DOI 10.1016/S0896-6273(01)00292-6; Brown H, 1998, EMBO J, V17, P5048, DOI 10.1093/emboj/17.17.5048; Chamberlain LH, 1998, MOL BIOL CELL, V9, P2259, DOI 10.1091/mbc.9.8.2259; Chamberlain LH, 1997, BIOCHEM J, V322, P853, DOI 10.1042/bj3220853; Chamberlain LH, 2000, J NEUROCHEM, V74, P1781, DOI 10.1046/j.1471-4159.2000.0741781.x; Chandra S, 2003, J BIOL CHEM, V278, P15313, DOI 10.1074/jbc.M213128200; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Clayton DF, 1998, TRENDS NEUROSCI, V21, P249, DOI 10.1016/S0166-2236(97)01213-7; Cole NB, 2002, J BIOL CHEM, V277, P6344, DOI 10.1074/jbc.M108414200; Dauer W, 2003, NEURON, V39, P889, DOI 10.1016/S0896-6273(03)00568-3; Dawson-Scully K, 2000, J NEUROSCI, V20, P6039, DOI 10.1523/JNEUROSCI.20-16-06039.2000; Eliezer D, 2001, J MOL BIOL, V307, P1061, DOI 10.1006/jmbi.2001.4538; Evans GJO, 2002, BIOCHEM J, V364, P343, DOI 10.1042/BJ20020123; Fernagut PO, 2004, NEUROBIOL DIS, V17, P123, DOI 10.1016/j.nbd.2004.07.001; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Fornai F, 2005, P NATL ACAD SCI USA, V102, P3413, DOI 10.1073/pnas.0409713102; Fortin DL, 2004, J NEUROSCI, V24, P6715, DOI 10.1523/JNEUROSCI.1594-04.2004; Fowler SC, 2001, J NEUROSCI METH, V107, P107, DOI 10.1016/S0165-0270(01)00359-4; Graham ME, 2000, J NEUROSCI, V20, P1281; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; GURNEY ME, 1994, SCIENCE, V264, P1772, DOI 10.1126/science.8209258; Hardy J, 2003, ANN NY ACAD SCI, V991, P167; Jahn R, 2004, ANN NY ACAD SCI, V1014, P170, DOI 10.1196/annals.1294.018; Jensen PH, 1998, J BIOL CHEM, V273, P26292, DOI 10.1074/jbc.273.41.26292; Jo EJ, 2002, J MOL BIOL, V315, P799, DOI 10.1006/jmbi.2001.5269; Katz B., 1969, RELEASE NEURAL TRANS; Leveque C, 1998, J BIOL CHEM, V273, P13488, DOI 10.1074/jbc.273.22.13488; Lin WC, 2001, NATURE, V410, P1057, DOI 10.1038/35074025; Magga JM, 2000, NEURON, V28, P195, DOI 10.1016/S0896-6273(00)00096-9; MAROTEAUX L, 1991, MOL BRAIN RES, V11, P335, DOI 10.1016/0169-328X(91)90043-W; MCMAHON HT, 1995, CELL, V83, P111, DOI 10.1016/0092-8674(95)90239-2; Missler M, 2003, NATURE, V423, P939, DOI 10.1038/nature01755; Nie ZP, 1999, J NEUROSCI, V19, P10270; Ninkina N, 2003, MOL CELL BIOL, V23, P8233, DOI 10.1128/MCB.23.22.8233-8245.2003; Norris EH, 2004, CURR TOP DEV BIOL, V60, P17; Outeiro TF, 2003, SCIENCE, V302, P1772, DOI 10.1126/science.1090439; Perrin RJ, 2000, J BIOL CHEM, V275, P34393, DOI 10.1074/jbc.M004851200; Ranjan R, 1998, J NEUROSCI, V18, P956; ROSAHL TW, 1995, NATURE, V375, P488, DOI 10.1038/375488a0; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Schoch S, 2001, SCIENCE, V294, P1117, DOI 10.1126/science.1064335; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; Spillantini MG, 1997, NATURE, V388, P839, DOI 10.1038/42166; Sudhof TC, 2004, ANNU REV NEUROSCI, V27, P509, DOI 10.1146/annurev.neuro.26.041002.131412; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Umbach JA, 1998, J NEUROSCI, V18, P3233; UMBACH JA, 1994, NEURON, V13, P899, DOI 10.1016/0896-6273(94)90255-0; Washbourne P, 2002, NAT NEUROSCI, V5, P19, DOI 10.1038/nn783; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Zhang H, 1998, FEBS LETT, V437, P267, DOI 10.1016/S0014-5793(98)01233-2; ZINSMAIER KE, 1994, SCIENCE, V263, P977, DOI 10.1126/science.8310297; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150	55	735	750	1	60	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					383	396		10.1016/j.cell.2005.09.028	http://dx.doi.org/10.1016/j.cell.2005.09.028			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269331	Bronze			2022-12-28	WOS:000233264300008
J	Moore, PB				Moore, PB			A ribosomal coup: E-coli at last!	SCIENCE			English	Editorial Material							ANGSTROM RESOLUTION; SUBUNIT		Yale Univ, Dept Chem, New Haven, CT 06520 USA	Yale University	Moore, PB (corresponding author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.	peter.moore@yale.edu						Ban N, 2000, SCIENCE, V289, P905, DOI 10.1126/science.289.5481.905; CATE J, COMMUNICATION; Frank J, 2000, NATURE, V406, P318, DOI 10.1038/35018597; Harms J, 2001, CELL, V107, P679, DOI 10.1016/S0092-8674(01)00546-3; Pioletti M, 2001, EMBO J, V20, P1829, DOI 10.1093/emboj/20.8.1829; Schluenzen F, 2000, CELL, V102, P615, DOI 10.1016/S0092-8674(00)00084-2; Schuwirth BS, 2005, SCIENCE, V310, P827, DOI 10.1126/science.1117230; Wimberly BT, 2000, NATURE, V407, P327, DOI 10.1038/35030006; Yusupov MM, 2001, SCIENCE, V292, P883, DOI 10.1126/science.1060089	9	5	5	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					793	+		10.1126/science.1120539	http://dx.doi.org/10.1126/science.1120539			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272105				2022-12-28	WOS:000233121800027
J	Wadman, M				Wadman, M			Race is on for flu vaccine	NATURE			English	News Item							A/DUCK/SINGAPORE/97 H5N3 VACCINE; MF59-ADJUVANTED INFLUENZA	Drug companies are using adjuvants to boost their vaccines in a bid to be ready for a flu pandemic. The cell-surface proteins of flu viruses change, or drift, over time, so vaccine makers can't develop a vaccine in advance that they know will work if bird flu acquires the ability to pass between humans, triggering a pandemic. What is more, there aren not many companies in the race, afterlow profits drove many to stop producing vaccines at all.										Fedson DS, 2005, J PUBLIC HEALTH POL, V26, P4, DOI 10.1057/palgrave.jphp.3200008; Nicholson KG, 2001, LANCET, V357, P1937, DOI 10.1016/S0140-6736(00)05066-2; Stephenson I, 2005, J INFECT DIS, V191, P1210, DOI 10.1086/428948	3	11	12	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					23	23		10.1038/438023a	http://dx.doi.org/10.1038/438023a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267526				2022-12-28	WOS:000232979000016
J	Tugwell, BD; Patel, PR; Williams, IT; Hedberg, K; Chai, F; Nainan, OV; Thomas, AR; Woll, JE; Bell, BP; Cieslak, PR				Tugwell, BD; Patel, PR; Williams, IT; Hedberg, K; Chai, F; Nainan, OV; Thomas, AR; Woll, JE; Bell, BP; Cieslak, PR			Transmission of hepatitis C virus to several organ and tissue recipients from an antibody-negative donor	ANNALS OF INTERNAL MEDICINE			English	Article							UNITED-STATES; TRANSPLANTATION; ALLOGRAFTS; INFECTION; DISEASE; HCV; PREVALENCE	Background: Although hepatitis C virus (HCV) transmission through tissue transplantation has been rarely reported, a donor with undetected viremia may infect several recipients. A patient developed acute hepatitis C shortly after tissue transplantation. Ninety-one tissues or organs had been recovered from the donor. Objective: To determine whether the donor was the source of infection and the extent of transmission to other organ and tissue recipients. Design: Descriptive epidemiologic study; serum testing for HCV infection. Setting: Recipients were located in 16 states and 2 other countries. Participants: Donor and graft recipients. Measurements: Hepatitis C virus infection was defined as the presence of anti-HCV or HCV RNA. The authors determined the genetic relatedness of viral isolates from the donor and recipients by genotype comparison and quasi-species analysis. Results: The donor was anti-HCV-negative but was HCV RNA-positive (genotype 1a). Forty persons received transplants during 22 months. Five persons were HCV-infected before transplantation or had a genotype other than la, and 5 persons had no post-transplantation serum specimens available. Of the remaining 30 recipients, HCV infection occurred in 8 recipients: 3 of 3 organ recipients, 1 of 2 saphenous vein recipients, 1 of 3 tendon recipients, and 3 of 3 tendon with bone recipients. These 8 recipients had viral isolates genetically related to those of the donor. No cases occurred in recipients of skin (n = 2), cornea (n = 1), or irradiated bone (n = 16). Limitations: Post-transplantation serum specimens were unavailable for 5 recipients. Conclusions: An anti-HCV-negative donor was the source of HCV infection for 8 recipients of organs or tissues. Although HCV transmission from anti-HCV-negative donors is probably uncommon, changes in donor screening to include routine testing for HCV RNA merit further consideration to improve the safety of transplantation.	Ctr Dis Control & Prevent, Atlanta, GA USA; Oregon Dept Human Serv, Portland, OR USA; Community Blood Ctr, Community Tissue Serv, Dayton, OH USA; Wright State Univ, Sch Med, Dayton, OH USA	Centers for Disease Control & Prevention - USA; University System of Ohio; Wright State University Dayton	Tugwell, BD (corresponding author), Queen Elizabeth 2 Hlth Sci Ctr, Div Gen Med, 1278 Tower Rd,406 Bethune Bldg, Halifax, NS B3H 2Y9, Canada.	barna.tugwell@cdha.nshealth.ca						AEDER MI, 1993, TRANSPLANT P, V25, P1469; Alter MJ, 1999, NEW ENGL J MED, V341, P556, DOI 10.1056/NEJM199908193410802; [Anonymous], 1991, MMWR Recomm Rep, V40, P1; ASWAD S, 1993, TRANSPL P, V25, P3072; Busch M. P., 2000, Transfusion (Bethesda), V40, P143; Cody SH, 2002, ARCH INTERN MED, V162, P345, DOI 10.1001/archinte.162.3.345; CONRAD EU, 1995, J BONE JOINT SURG AM, V77A, P214, DOI 10.2106/00004623-199502000-00007; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; EGGEN BM, 1992, NEW ENGL J MED, V326, P411; ENOMOTO N, 1990, BIOCHEM BIOPH RES CO, V170, P1021, DOI 10.1016/0006-291X(90)90494-8; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HUANG CC, 1993, TRANSPLANT P, V25, P1474; Kainer MA, 2004, NEW ENGL J MED, V350, P2564, DOI 10.1056/NEJMoa023222; PELKER RR, 1987, ORTHOP CLIN N AM, V18, P235; PEREIRA BJG, 1994, KIDNEY INT, V46, P886, DOI 10.1038/ki.1994.346; PEREIRA BJG, 1992, NEW ENGL J MED, V327, P910, DOI 10.1056/NEJM199209243271302; PEREIRA BJG, 1991, NEW ENGL J MED, V325, P454, DOI 10.1056/NEJM199108153250702; PEREIRA BJG, 1993, LANCET, V341, P903, DOI 10.1016/0140-6736(93)93118-K; ROTH D, 1992, ANN INTERN MED, V117, P470, DOI 10.7326/0003-4819-117-6-470; SIMMONDS P, 1993, J GEN VIROL, V74, P2391, DOI 10.1099/0022-1317-74-11-2391; Stramer SL, 2004, NEW ENGL J MED, V351, P760, DOI 10.1056/NEJMoa040085; TESI RJ, 1994, TRANSPLANTATION, V57, P826, DOI 10.1097/00007890-199403270-00010; TOMFORD WW, 1995, J BONE JOINT SURG AM, V77A, P1742, DOI 10.2106/00004623-199511000-00017; *US FOOD DRUG ADM, 2004, GUID IND EL DET DON; Zou SM, 2004, NEW ENGL J MED, V351, P751, DOI 10.1056/NEJMoa032510; 2004, FED REG, V69, P29785; 2001, FED REG, V66, P5447; 2004, FED REG, V69, P68611	28	96	100	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					648	654		10.7326/0003-4819-143-9-200511010-00008	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00008			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263887				2022-12-28	WOS:000233030600004
J	Calin, GA; Ferracin, M; Cimmino, A; Di Leva, G; Shimizu, M; Wojcik, SE; Iorio, MV; Visone, R; Sever, NI; Fabbri, M; Iuliano, R; Palumbo, T; Pichiorri, F; Roldo, C; Garzon, R; Sevignani, C; Rassenti, L; Alder, H; Volinia, S; Liu, CG; Kipps, TJ; Negrini, M; Croce, CM				Calin, GA; Ferracin, M; Cimmino, A; Di Leva, G; Shimizu, M; Wojcik, SE; Iorio, MV; Visone, R; Sever, NI; Fabbri, M; Iuliano, R; Palumbo, T; Pichiorri, F; Roldo, C; Garzon, R; Sevignani, C; Rassenti, L; Alder, H; Volinia, S; Liu, CG; Kipps, TJ; Negrini, M; Croce, CM			A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GENE MUTATION STATUS; ZAP-70 EXPRESSION; CANCER; LYMPHOMA; RNA; IDENTIFICATION; ACCUMULATION; APOPTOSIS; DIAGNOSIS; SURVIVAL	BACKGROUND: MicroRNA expression profiles can be used to distinguish normal B cells from malignant B cells in patients with chronic lymphocytic leukemia (CLL). We investigated whether microRNA profiles are associated with known prognostic factors in CLL. METHODS: We evaluated the microRNA expression profiles of 94 samples of CLL cells for which the level of expression of 70-kD zeta-associated protein (ZAP-70), the mutational status of the rearranged immunoglobulin heavy-chain variable-region (IgV(sub H)) gene, and the time from diagnosis to initial treatment were known. We also investigated the genomic sequence of 42 microRNA genes to identify abnormalities. RESULTS: A unique microRNA expression signature composed of 13 genes (of 190 analyzed) differentiated cases of CLL with low levels of ZAP-70 expression from those with high levels and cases with unmutated IgV(sub H) from those with mutated IgV(sub H). The same microRNA signature was also associated with the presence or absence of disease progression. We also identified a germ-line mutation in the miR-16-1-miR-15a primary precursor, which caused low levels of microRNA expression in vitro and in vivo and was associated with deletion of the normal allele. Germ-line or somatic mutations were found in 5 of 42 sequenced microRNAs in 11 of 75 patients with CLL, but no such mutations were found in 160 subjects without cancer (P<0.001). CONCLUSIONS: A unique microRNA signature is associated with prognostic factors and disease progression in CLL. Mutations in microRNA transcripts are common and may have functional importance.	Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA; Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA; Univ Ferrara, Dept Expt & Diagnost Med, Interdept Ctr Canc Res, I-44100 Ferrara, Italy; Thomas Jefferson Univ, Kimmel Canc Ctr, Philadelphia, PA 19107 USA; Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA	James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University of Ferrara; Jefferson University; University of California System; University of California San Diego	Croce, CM (corresponding author), Ohio State Univ, Ctr Comprehens Canc, Wiseman Hall,Rm 385K,400 12th Ave, Columbus, OH 43210 USA.	carlo.croce@osumc.edu	Young, Richard A/F-6495-2012; Volinia, Stefano/AAA-9264-2019; Volinia, Stefano/A-3029-2010; Iorio, Marilena V/K-5446-2016; visone, rosa/K-7910-2016; Negrini, Massimo/J-2377-2016; Ferrua, Camila/F-5439-2015; Garzon, Ramiro/E-3104-2011; Ferracin, Manuela/K-2097-2016; Sever, Nurettin/ABE-4592-2021; Jones, Jeffrey A/E-9827-2013; Calin, George/E-9390-2011	Young, Richard A/0000-0001-8855-8647; Volinia, Stefano/0000-0003-0910-3893; Volinia, Stefano/0000-0003-0910-3893; Iorio, Marilena V/0000-0002-6058-1527; Negrini, Massimo/0000-0002-0007-1920; Ferrua, Camila/0000-0001-8071-377X; Ferracin, Manuela/0000-0002-1595-6887; Di Leva, Gianpiero/0000-0001-6759-8682; Sever, Nurettin Ilter/0000-0002-9320-4146; Calin, George/0000-0001-6704-5615; VISONE, Rosa/0000-0002-4993-0220; Cimmino, Amelia/0000-0002-0004-9299	NCI NIH HHS [P01CA81534, P01CA76259, P30CA56036] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA056036, P01CA081534, P01CA076259] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Berezikov E, 2005, CELL, V120, P21, DOI 10.1016/j.cell.2004.12.031; Bullrich F, 2001, CHRONIC LYMPHOCYTIC, P9; Calin GA, 2005, NEW ENGL J MED, V352, P1667, DOI 10.1056/NEJMoa042280; Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799; Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101; Calin GA, 2004, P NATL ACAD SCI USA, V101, P11755, DOI 10.1073/pnas.0404432101; Catovsky D, 2004, HEMATOL ONCOL CLIN N, V18, P783, DOI 10.1016/j.hoc.2004.04.009; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Cheson BD, 1996, BLOOD, V87, P4990, DOI 10.1182/blood.V87.12.4990.bloodjournal87124990; Chiorazzi N, 2005, NEW ENGL J MED, V352, P804, DOI 10.1056/NEJMra041720; Cimmino A, 2005, P NATL ACAD SCI USA, V102, P13944, DOI 10.1073/pnas.0506654102; Crespo M, 2003, NEW ENGL J MED, V348, P1764, DOI 10.1056/NEJMoa023143; Damle RN, 1999, BLOOD, V94, P1840, DOI 10.1182/blood.V94.6.1840; Dohner H, 2000, NEW ENGL J MED, V343, P1910, DOI 10.1056/NEJM200012283432602; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; Griffiths-Jones S, 2004, NUCLEIC ACIDS RES, V32, pD109, DOI 10.1093/nar/gkh023; Hamblin TJ, 1999, BLOOD, V94, P1848, DOI 10.1182/blood.V94.6.1848; Ishibe N, 2001, LEUKEMIA LYMPHOMA, V42, P99, DOI 10.3109/10428190109097681; Iwai N, 2005, BIOCHEM BIOPH RES CO, V331, P1439, DOI 10.1016/j.bbrc.2005.04.051; KIPPS TJ, 2001, WILLIAMS HEMATOLOGY, P1163; Korz C, 2002, BLOOD, V99, P4554, DOI 10.1182/blood.V99.12.4554; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu CG, 2004, P NATL ACAD SCI USA, V101, P9740, DOI 10.1073/pnas.0403293101; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; McManus MT, 2003, SEMIN CANCER BIOL, V13, P253, DOI 10.1016/S1044-579X(03)00038-5; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Michael MZ, 2003, MOL CANCER RES, V1, P882; Orchard JA, 2004, LANCET, V363, P105, DOI 10.1016/S0140-6736(03)15260-9; Ota A, 2004, CANCER RES, V64, P3087, DOI 10.1158/0008-5472.CAN-03-3773; Rassenti LZ, 2004, NEW ENGL J MED, V351, P893, DOI 10.1056/NEJMoa040857; Takamizawa J, 2004, CANCER RES, V64, P3753, DOI 10.1158/0008-5472.CAN-04-0637	33	1866	2095	0	115	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1793	1801		10.1056/NEJMoa050995	http://dx.doi.org/10.1056/NEJMoa050995			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251535				2022-12-28	WOS:000232813000007
J	Wood, BJ; Halliday, AN				Wood, BJ; Halliday, AN			Cooling of the Earth and core formation after the giant impact	NATURE			English	Article							HF-W CHRONOMETRY; OXIDATION-STATE; TERRESTRIAL ACCRETION; LOWER-MANTLE; ELEMENTS; ORIGIN; METAL; MOON; CONSTRAINTS; TIMESCALE	Kelvin calculated the age of the Earth to be about 24 million years by assuming conductive cooling from being fully molten to its current state(1). Although simplistic(2), his result is interesting in the context of the dramatic cooling that took place after the putative Moon-forming giant impact, which contributed the final similar to 10 per cent of the Earth's mass(3,4). The rate of accretion and core segregation on Earth as deduced from the U - Pb system(5) is much slower than that obtained from Hf - W systematics(6-8), and implies substantial accretion after the Moon-forming impact, which occurred 45 +/- 5 Myr after the beginning of the Solar System. Here we propose an explanation for the two timescales(5,9). We suggest that the Hf - W timescale reflects the principal phase of core-formation before the giant impact. Crystallization of silicate perovskite in the lower mantle during this phase produced Fe3+, which was released during the giant impact(10), and this oxidation resulted in late segregation of sulphur-rich metal into which Pb dissolved readily, setting the younger U - Pb age of the Earth. Separation of the latter metal then occurred 30 +/- 10 Myr after the Moon-forming impact. Over this time span, in surprising agreement with Kelvin's result, the Earth cooled by about 4,000 K in returning from a fully molten to a partially crystalline state.	Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England; Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England	University of Oxford; University of Bristol	Wood, BJ (corresponding author), Macquarie Univ, Dept Earth & Planetary Sci, N Ryde, NSW 2109, Australia.	bwood@els.mq.edu.au	Wood, Bernard J/E-8173-2010	Wood, Bernard J/0000-0003-1038-7301				Abe Y, 1997, PHYS EARTH PLANET IN, V100, P27, DOI 10.1016/S0031-9201(96)03229-3; ALLEGRE CJ, 1995, EARTH PLANET SC LETT, V134, P515, DOI 10.1016/0012-821X(95)00123-T; CAMERON AGW, 1991, ICARUS, V92, P204, DOI 10.1016/0019-1035(91)90046-V; Canup RM, 2001, NATURE, V412, P708, DOI 10.1038/35089010; Canup RM, 2004, ICARUS, V168, P433, DOI 10.1016/j.icarus.2003.09.028; Carslaw H.S., 1986, CONDUCTION HEAT SOLI; Chabot NL, 2005, GEOCHIM COSMOCHIM AC, V69, P2141, DOI 10.1016/j.gca.2004.10.019; Chabot NL, 2003, METEORIT PLANET SCI, V38, P1425, DOI 10.1111/j.1945-5100.2003.tb00248.x; FRANCIS RD, 1990, CHEM GEOL, V85, P199, DOI 10.1016/0009-2541(90)90001-N; Frost DJ, 2004, NATURE, V428, P409, DOI 10.1038/nature02413; Halliday AN, 2004, NATURE, V427, P505, DOI 10.1038/nature02275; HALLIDAY AN, 2003, METEORITES COMETS PL, P509; HALLIDAY AN, IN PRESS METEORITES, V2; Harper CL, 1996, GEOCHIM COSMOCHIM AC, V60, P1131, DOI 10.1016/0016-7037(96)00027-0; Holzheid A, 2002, AM MINERAL, V87, P227; JONES JH, 1993, GEOCHIM COSMOCHIM AC, V57, P453, DOI 10.1016/0016-7037(93)90443-Z; KASTING JF, 1993, J GEOL, V101, P245, DOI 10.1086/648219; KELVIN, 1895, NATURE, V51, P438; KILINC A, 1983, CONTRIB MINERAL PETR, V83, P136, DOI 10.1007/BF00373086; Kleine T, 2002, NATURE, V418, P952, DOI 10.1038/nature00982; KLEINE T, 2005, P LUNAR PLANET SCI C, V36, P1940; MCDONOUGH WF, 1995, CHEM GEOL, V120, P223, DOI 10.1016/0009-2541(94)00140-4; Ohtani E, 1997, PHYS EARTH PLANET IN, V100, P97, DOI 10.1016/S0031-9201(96)03234-7; Righter K, 1997, EARTH PLANET SC LETT, V146, P541, DOI 10.1016/S0012-821X(96)00243-9; Schoenberg R, 2002, GEOCHIM COSMOCHIM AC, V66, P3151, DOI 10.1016/S0016-7037(02)00911-0; STEVENSON DJ, 1981, SCIENCE, V214, P611, DOI 10.1126/science.214.4521.611; Tronnes RG, 2002, EARTH PLANET SC LETT, V197, P117, DOI 10.1016/S0012-821X(02)00466-1; Wade J, 2005, EARTH PLANET SC LETT, V236, P78, DOI 10.1016/j.epsl.2005.05.017; Wetherill G. W., 1986, ORIGIN MOON; WOOD BJ, 1990, SCIENCE, V248, P337, DOI 10.1126/science.248.4953.337; Yi W, 2000, J GEOPHYS RES-SOL EA, V105, P18927, DOI 10.1029/2000JB900152; Yin QZ, 2002, NATURE, V418, P949, DOI 10.1038/nature00995	33	92	94	0	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1345	1348		10.1038/nature04129	http://dx.doi.org/10.1038/nature04129			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251962				2022-12-28	WOS:000232829100051
J	Barton, JH; Emanuel, EJ				Barton, JH; Emanuel, EJ			The patents-based pharmaceutical development process: Rationale, problems, and potential reforms	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DRUG DEVELOPMENT; MARKET; INNOVATION; MEDICINES; INDUSTRY; TRIPS	The pharmaceutical industry is facing substantial criticism from many directions, including financial barriers to access to drugs in both developed and developing countries, high profits, spending on advertising and marketing, and other issues. Underlying these criticisms are fundamental questions about the value of the current patent-based drug development system. Six major problems with the patent system are (1) recovery of research costs by patent monopoly reduces access to drugs; (2) market demand rather than health needs determines research priorities; (3) resources between research and marketing are misallocated; (4) the market for drugs has inherent market failures; (5) overall investment in drug research and development is too low, compared with profits; and (6) the existing system discriminates against US patients. Potential solutions fall into 3 categories: change in drug pricing through either price controls or tiered pricing; change in drug industry structure through a "buy-out" pricing system or with the public sector acting as exclusive research funder; and change in development incentives through a disease burden incentive system, orphan drug approaches, or requiring new drugs to demonstrate improvement over existing products prior to US Food and Drug Administration approval. We recommend 4 complementary reforms: (1) having no requirement to test new drug products against existing products prior to approval but requiring rigorous comparative postapproval testing; (2) international tiered pricing and systematic safeguards to prevent flow-back; (3) increased government-funded research and buy-out for select conditions; and (4) targeted experiments using other approaches for health conditions in which there has been little progress and innovation over the last few decades.	NIH, Dept Clin Bioeth, Ctr Clin, Bethesda, MD 20892 USA; Stanford Univ, Sch Law, Stanford, CA 94305 USA	National Institutes of Health (NIH) - USA; NIH Clinical Center (CC); Stanford University	Emanuel, EJ (corresponding author), NIH, Dept Clin Bioeth, Ctr Clin, Bldg 10,Room 1C118, Bethesda, MD 20892 USA.	eemanuel@nih.gov						Angell M., 2004, TRUTH DRUG CO THEY D; ARNO PS, 1995, MILBANK Q, V73, P231, DOI 10.2307/3350258; Barton JH, 2000, LANCET, V355, P1269, DOI 10.1016/S0140-6736(00)02100-0; Barton John H, 2004, Health Aff (Millwood), V23, P146, DOI 10.1377/hlthaff.23.3.146; Cockburn IM, 2004, HEALTH AFFAIR, V23, P10, DOI 10.1377/hlthaff.23.1.10; *CTR MED MED SERV, NAT HLTH EXP; CUTLER DM, 2001, HEALTH AFFAIR, V20, P11; DiMasi JA, 2003, J HEALTH ECON, V22, P151, DOI 10.1016/S0167-6296(02)00126-1; ELIAS P, 2003, ORPHAN DRUGS SAVE L; Friedman MA, 1999, JAMA-J AM MED ASSOC, V281, P1728, DOI 10.1001/jama.281.18.1728; GRABOWSKI H, 2004, INN LIF SCI INT PROP; Greider K., 2003, BIG FIX PHARM IND RI; *HS TASK FORC DRUG, 2004, REP PRESCR DRUG IMP; *KAIS FAM FDN, 2001, PRESCR DRUG TRENDS; *KAIS FAM FDN, 2003, PRESCR DRUG TRENDS; KREMER M, 1997, PATENT BUY OUTS MECH; KREMER M, 2001, INNOVATION POLICY EC, V1; LANJOUW JO, 2002, HARV J LAW TECHNOL, V16, P2; Lichtenberg FR, 2005, J OCCUP ENVIRON MED, V47, P373, DOI 10.1097/01.jom.0000158724.28302.ac; *MED SANS FRONT, 2003, MSF PUTS DRUG PAT SP; *NAT I HLTH CAR MA, 2000, ISS BRIEF PRESCR DRU; Pammolli F, 2004, HEALTH AFFAIR, V23, P48, DOI 10.1377/hlthaff.23.1.48; Penrose Edith T., 1951, EC INT PATENT SYSTEM; *PHARM RES MAN AM, PHARM IND PROF 2005; Pharmaceutical Research and Manufacturers of America, 2002, PHARM IND PROF 2002; Scherer FM, 2004, NEW ENGL J MED, V351, P927, DOI 10.1056/NEJMhpr040117; Scherer FM, 2002, J INT ECON LAW, V5, P913, DOI 10.1093/jiel/5.4.913; Shulman S. R., 1999, J BIOLAW BUS, V2, P63; Sobel Dava., 2016, GLASS UNIVERSE LADIE; *TUFTS CTR STUD DR, 2003, OUTL; US Food and Drug Administration, 2004, CHALL OPP CRIT PATH; *US OFF TECHN ASS, 1993, PHARM R D COSTS RISK; Whalen J, 2004, WALL STREET J E 1105, pA1; World Health Organization, 2004, WAT SAN HYG LINKS HL; 2004, FED REG, V69, P50386; 2004, FORTUNE         0415, pF26	36	65	67	0	17	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2075	2082		10.1001/jama.294.16.2075	http://dx.doi.org/10.1001/jama.294.16.2075			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249422				2022-12-28	WOS:000232778900028
J	Alvarez-Rosete, A; Bevan, G; Mays, N; Dixon, J				Alvarez-Rosete, A; Bevan, G; Mays, N; Dixon, J			Effect of diverging policy across the NHS	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Econ & Polit Sci, Dept Operat Res, London WC2A 2AE, England; Kings Fund, Policy Directorate, London W1G 0AN, England; Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Serv Res Unit, London WC1E 7HT, England	University of London; London School Economics & Political Science; University of London; London School of Hygiene & Tropical Medicine	Bevan, G (corresponding author), Univ London London Sch Econ & Polit Sci, Dept Operat Res, Houghton St, London WC2A 2AE, England.	R.G.Bevan@lse.ac.uk						*AUD GEN SCOTL, REV MAN WAIT LISTS S; BEVAN G, 1980, HLTH CARE PRIORITIES; BEVAN G, IN PRESS PUBLIC ADM; BIRCH S, 1986, 19 U YORK CTR HLTH E; Dixon J, 1999, BRIT MED J, V318, P522, DOI 10.1136/bmj.318.7182.522; Dixon Sheila, 2004, Health Stat Q, P23; Greer Scott L, 2004, 4 WAY BET DEVOLUTION; LEATHERMAN S, 2005, QUEST QUALITY NHS; *NAT CTR SOC RES, 2004, 4838 NAT CTR SOC RES; *OFF NAT STAT, 2004, POPULATION TRENDS, V116, P45; *OFF NAT STAT, 1997, LIV BRIT 1995 GEN HO; *ORG EC COOP DEV, 2004, HLTH DAT 2004; *RES EV SERV, 2003, PUBL CONS SURV REG S; Shekelle P, 2003, BRIT MED J, V326, P457, DOI 10.1136/bmj.326.7387.457; STEVENS S, 2004, HEALTH AFFAIR, V23, P41	15	36	36	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					946	950		10.1136/bmj.331.7522.946	http://dx.doi.org/10.1136/bmj.331.7522.946			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16239691	Green Accepted, Bronze, Green Published			2022-12-28	WOS:000232970900024
J	Soysal, A; Millington, KA; Bakir, M; Dosanjh, D; Aslan, Y; Deeks, JJ; Efe, S; Staveley, I; Ewer, K; Lalvani, A				Soysal, A; Millington, KA; Bakir, M; Dosanjh, D; Aslan, Y; Deeks, JJ; Efe, S; Staveley, I; Ewer, K; Lalvani, A			Effect of BCG vaccination on risk of Mycobacterium tuberculosis infection in children with household tuberculosis contact: a prospective community-based study	LANCET			English	Article							BACILLUS-CALMETTE-GUERIN; VACCINIA VIRUS ANKARA; SKIN-TEST; BOVIS BCG; T-CELLS; METAANALYSIS; EFFICACY; GAMMA; ENUMERATION; POPULATION	Background Little is known about factors that affect the risk of acquiring infection in children exposed to Mycobacterium tuberculosis. The effect of BCG vaccination has been difficult to ascertain because the tuberculin skin test (TST), until recently the only method for detecting M tuberculosis infection, does not reliably distinguish between tuberculosis infection and BCG vaccination. Methods We investigated risk factors for tuberculosis infection in 979 child household contacts of 414 adult index patients withildren were aged up to 16 years (median 7, IQR 3-11) and 770 of 979 (79%) had a BCG scar. A T-cell-based enzyme-linked immunospot assay (ELISpot), sputum smear-positive pulmonary tuberculosis in Istanbul, Turkey. Chwhich is not confounded by BCG vaccination, and TST were used to assess infection. Independent risk factors for infection were identified through multivariate analysis. Findings Amount of tuberculosis exposure within the household and age (a marker of tuberculosis exposure outside the household) were strongly associated with likelihood of infection as measured by both TST and ELISpot. ELISpot also identified absence of BCG scar as an independent risk factor for infection in tuberculosis-exposed children; BCG-vaccinated children had an odds ratio of 0.60 (95% Cl 0.43-0.83, p=0.003) for tuberculosis infection, compared with unvaccinated children. Interpretation Contrary to the prevailing theory that BCG vaccination protects only against tuberculosis disease, our results suggest that the vaccine also protects against tuberculosis infection. This finding has important implications for our understanding of the biology of tuberculosis infection and development of improved tuberculosis vaccines.	Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, TB Immunol Grp, Oxford OX3 9DU, England; Marmara Univ, Sch Med, Dept Paediat, Istanbul, Turkey; Univ Oxford Wolfson Coll, Ctr Stat Med, Oxford, England	University of Oxford; Marmara University; University of Oxford	Lalvani, A (corresponding author), Univ Oxford, John Radcliffe Hosp, Nuffield Dept Clin Med, TB Immunol Grp, Oxford OX3 9DU, England.	ajit.lalvani@ndm.ox.ac.uk	Ewer, Katie J/B-4328-2011; Aslan, Yasemin/AAP-7713-2020; Deeks, Jon/AAV-5745-2020; Dosanjh, Davinder/ABD-8895-2021; ASLAN, YASEMİN/AAP-7409-2020	Ewer, Katie J/0000-0001-9827-9836; Aslan, Yasemin/0000-0001-6292-2332; Deeks, Jon/0000-0002-8850-1971; Dosanjh, Davinder/0000-0002-9169-5607; Lalvani, Ajit/0000-0002-2396-246X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Almeida LMD, 2001, PEDIATR INFECT DIS J, V20, P1061, DOI 10.1097/00006454-200111000-00011; Aydinlioglu H, 1993, Paediatr Perinat Epidemiol, V7, P334, DOI 10.1111/j.1365-3016.1993.tb00408.x; Behr MA, 1999, SCIENCE, V284, P1520, DOI 10.1126/science.284.5419.1520; Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Briassoulis George, 2005, J Immune Based Ther Vaccines, V3, P1, DOI 10.1186/1476-8518-3-1; COLDITZ GA, 1994, JAMA-J AM MED ASSOC, V271, P698, DOI 10.1001/jama.271.9.698; Deeks J J, 2003, Health Technol Assess, V7, piii; Ewer K, 2003, LANCET, V361, P1168, DOI 10.1016/S0140-6736(03)12950-9; FINE PEM, 1994, LANCET, V344, P1245, DOI 10.1016/S0140-6736(94)90748-X; FINE PEM, 1989, B WORLD HEALTH ORGAN, V67, P35; Gajalakshmi V, 2003, LANCET, V362, P507, DOI 10.1016/S0140-6736(03)14109-8; GEDDEDAHL T, 1952, AM J HYG, V56, P139, DOI 10.1093/oxfordjournals.aje.a119547; Goonetilleke NP, 2003, J IMMUNOL, V171, P1602, DOI 10.4049/jimmunol.171.3.1602; GRZYBOWSKI S, 1975, Bulletin of the International Union Against Tuberculosis, V50, P90; Harboe M, 1996, INFECT IMMUN, V64, P16, DOI 10.1128/IAI.64.1.16-22.1996; Lalvani A, 2003, THORAX, V58, P916, DOI 10.1136/thorax.58.11.916; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Lalvani A, 2001, LANCET, V357, P2017, DOI 10.1016/S0140-6736(00)05115-1; Leung CC, 2004, AM J RESP CRIT CARE, V170, P1027, DOI 10.1164/rccm.200404-512oc; Lienhardt C, 2003, AM J RESP CRIT CARE, V168, P448, DOI 10.1164/rccm.200212-1483OC; Lienhardt C, 2003, PEDIATRICS, V111, pE608, DOI 10.1542/peds.111.5.e608; MADICO G, 1995, LANCET, V345, P416, DOI 10.1016/S0140-6736(95)90401-8; McShane H, 2004, NAT MED, V10, P1240, DOI 10.1038/nm1128; NARAIN R, 1966, B WORLD HEALTH ORGAN, V34, P639; Neuenschwander BE, 2002, AM J EPIDEMIOL, V155, P654, DOI 10.1093/aje/155.7.654; Pai M, 2004, LANCET INFECT DIS, V4, P761, DOI 10.1016/S1473-3099(04)01206-X; Richeldi L, 2004, AM J RESP CRIT CARE, V170, P288, DOI 10.1164/rccm.200403-307OC; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Rom WN, 1996, TUBERCULOSIS, Vxxv; Santiago EM, 2003, PEDIATRICS, V112, pE298, DOI 10.1542/peds.112.4.e298; SEDAGHATIAN MR, 1990, TUBERCLE, V71, P177, DOI 10.1016/0041-3879(90)90072-G; SMITH DW, 1970, AM REV RESPIR DIS, V102, P937; TENDAM HG, 1980, B WORLD HEALTH ORGAN, V58, P37; Vordermeier HM, 2002, INFECT IMMUN, V70, P3026, DOI 10.1128/IAI.70.6.3026-3032.2002; Wang L, 2002, THORAX, V57, P804, DOI 10.1136/thorax.57.9.804; *WHO, 2005, GLOB TB DAT; World Health Organization Website, 2005, IMM PROF TURK; YOUNG TK, 1992, TUBERCLE LUNG DIS, V73, P94, DOI 10.1016/0962-8479(92)90062-O; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	39	222	232	0	9	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2005	366	9495					1443	1451		10.1016/S0140-6736(05)67534-4	http://dx.doi.org/10.1016/S0140-6736(05)67534-4			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243089				2022-12-28	WOS:000232724600023
J	Asner, GP; Knapp, DE; Broadbent, EN; Oliveira, PJC; Keller, M; Silva, JN				Asner, GP; Knapp, DE; Broadbent, EN; Oliveira, PJC; Keller, M; Silva, JN			Selective logging in the Brazilian Amazon	SCIENCE			English	Article							LOGGED FORESTS; CANOPY DAMAGE; DEGRADATION; RECOVERY; DYNAMICS; FRONTIER; IMPACT; FIELD	Amazon deforestation has been measured by remote sensing for three decades. in comparison, selective logging has been mostly invisible to satellites. We developed a large-scale, high-resolution, automated remote-sensing analysis of selective logging in the top five timber-producing states of the Brazilian Amazon. Logged areas ranged from 12,075 to 19,823 square kilometers per year (+/- 14%) between 1999 and 2002, equivalent to 60 to 123% of previously reported deforestation area. Up to 1200 square kilometers per year of logging were observed on conservation lands. Each year, 27 million to 50 million cubic meters of wood were extracted, and a gross flux of similar to 0.1 billion metric tons of carbon was destined for release to the atmosphere by logging.	Carnegie Inst Sci, Dept Global Ecol, Stanford, CA 94305 USA; US Forest Serv, USDA, Int Inst Trop Forestry, Rio Piedras, PR USA; Univ New Hampshire, Complex Syst Res Ctr, Durham, NH 03824 USA; Empresa Brasileira Pesquisa Agropecuaria Amazonia, BR-66095100 Belem, Para, Brazil	Carnegie Institution for Science; United States Department of Agriculture (USDA); United States Forest Service; University System Of New Hampshire; University of New Hampshire; Empresa Brasileira de Pesquisa Agropecuaria (EMBRAPA)	Asner, GP (corresponding author), Carnegie Inst Sci, Dept Global Ecol, Stanford, CA 94305 USA.	gasner@giobalecology.stanford.edu	Asner, Gregory/G-9268-2013; Keller, Michael/A-8976-2012; Broadbent, Eben/H-2965-2013	Asner, Gregory/0000-0001-7893-6421; Keller, Michael/0000-0002-0253-3359; Oliveira, Paulo/0000-0002-4071-3924; Broadbent, Eben/0000-0002-4488-4237; Silva, Jose/0000-0003-4068-2432				Asner GP, 2004, ECOL APPL, V14, pS280; Asner GP, 2004, GLOBAL CHANGE BIOL, V10, P765, DOI 10.1111/j.1529-8817.2003.00756.x; Asner GP, 2002, REMOTE SENS ENVIRON, V80, P483, DOI 10.1016/S0034-4257(01)00326-1; Curran LM, 2004, SCIENCE, V303, P1000, DOI 10.1126/science.1091714; de Wasseige C, 2004, FOREST ECOL MANAG, V188, P161, DOI 10.1016/j.foreco.2003.07.035; DeFries RS, 2002, P NATL ACAD SCI USA, V99, P14256, DOI 10.1073/pnas.182560099; Fimbel R., 2001, CUTTING EDGE CONSERV; Gerwing JJ, 2002, FOREST ECOL MANAG, V157, P131, DOI 10.1016/S0378-1127(00)00644-7; *I SOC, 1999, MAP FOR TYP LAND US; *INPE, 2005, PRODES ASS DEF BRAZ; Keller M, 2004, BIOL RESOURCE MANAGE, P41; Keller M, 2004, GLOBAL CHANGE BIOL, V10, P784, DOI 10.1111/j.1529-8817.2003.00770.x; Keller M, 2001, FOREST ECOL MANAG, V154, P371, DOI 10.1016/S0378-1127(01)00509-6; Lambin EF, 2003, ANNU REV ENV RESOUR, V28, P205, DOI 10.1146/annurev.energy.28.050302.105459; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Pereira R, 2002, FOREST ECOL MANAG, V168, P77, DOI 10.1016/S0378-1127(01)00732-0; Read JM, 2003, PHOTOGRAMM ENG REM S, V69, P275, DOI 10.14358/PERS.69.3.275; SILVA JNM, 1995, FOREST ECOL MANAG, V71, P267, DOI 10.1016/0378-1127(94)06106-S; Souza C, 2003, REMOTE SENS ENVIRON, V87, P494, DOI 10.1016/j.rse.2002.08.002; Souza C, 2000, INT J REMOTE SENS, V21, P173, DOI 10.1080/014311600211064; Stone TA, 1998, INT J REMOTE SENS, V19, P2517, DOI 10.1080/014311698214604; UHL C, 1991, FOREST ECOL MANAG, V46, P243, DOI 10.1016/0378-1127(91)90235-N; VERISSIMO A, 1995, FOREST ECOL MANAG, V72, P39, DOI 10.1016/0378-1127(94)03432-V; VERISSIMO A, 1992, FOREST ECOL MANAG, V55, P169, DOI 10.1016/0378-1127(92)90099-U; [No title captured]	25	664	685	1	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					480	482		10.1126/science.1118051	http://dx.doi.org/10.1126/science.1118051			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239474				2022-12-28	WOS:000232786000043
J	Costantini, DL; Arruda, EP; Agarwal, P; Kim, KH; Zhu, YH; Zhu, W; Lebel, M; Cheng, CW; Park, CY; Pierce, SA; Guerchicoff, A; Pollevick, GD; Chan, TY; Kabir, MG; Cheng, SH; Husain, M; Antzelevitch, C; Srivastava, D; Gross, GJ; Hui, CC; Backx, PH; Bruneau, BG				Costantini, DL; Arruda, EP; Agarwal, P; Kim, KH; Zhu, YH; Zhu, W; Lebel, M; Cheng, CW; Park, CY; Pierce, SA; Guerchicoff, A; Pollevick, GD; Chan, TY; Kabir, MG; Cheng, SH; Husain, M; Antzelevitch, C; Srivastava, D; Gross, GJ; Hui, CC; Backx, PH; Bruneau, BG			The homeodomain transcription factor lrx5 establishes the mouse cardiac ventricular repolarization gradient	CELL			English	Article							MIDBRAIN-HINDBRAIN BOUNDARY; TRANSIENT OUTWARD CURRENT; IROQUOIS HOMEOBOX GENES; KV4 ALPHA-SUBUNIT; SHORT-QT SYNDROME; K+ CURRENTS; I-TO; DEVELOPING HEART; SUDDEN-DEATH; HETEROGENEOUS EXPRESSION	Rhythmic cardiac contractions depend on the organized propagation of depolarizing and repolarizing wavefronts. Repolarization is spatially heterogeneous and depends largely on gradients of potassium currents. Gradient disruption in heart disease may underlie susceptibility to fatal arrhythmias, but it is not known how this gradient is established. We show that, in mice lacking the homeodomain transcription factor Irx5, the cardiac repolarization gradient is abolished due to increased K(v)4.2 potassium-channel expression in endocardial myocardium, resulting in a selective increase of the major cardiac repolarization current, I-to,I-f, and increased susceptibility to arrhythmias. Myocardial Irx5 is expressed in a gradient opposite that of K(v)4.2, and Irx5 represses K(v)4.2 expression by recruiting mBop, a cardiac transcriptional repressor. Thus, an Irx5 repressor gradient negatively regulates potassium-channel-gene expression in the heart, forming an inverse I-to,I-f gradient that ensures coordinated cardiac repolarization while also preventing arrhythmias.	Hosp Sick Children, Program Cardiovasc Res, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Program Dev Biol, Toronto, ON M5G 1X8, Canada; Hosp Sick Children, Div Cardiovasc, Toronto, ON M5G 1X8, Canada; Univ Toronto, Heart & Stroke Richard Lewar Ctr Excellence, Toronto, ON M5G 1A8, Canada; Univ Toronto, Dept Physiol, Toronto, ON M5G 1A8, Canada; Univ Toronto, Dept Mol & Med Genet, Toronto, ON M5G 1A8, Canada; Univ Toronto, Dept Med, Toronto, ON M5G 1A8, Canada; Univ Toronto, Dept Pediat, Toronto, ON M5G 1A8, Canada; Univ Toronto, McLaughlin Ctr Mol Med, Toronto, ON M5G 1A8, Canada; City Univ Hong Kong, Dept Biol & Chem, Hong Kong, Hong Kong, Peoples R China; Univ Texas, SW Med Ctr Dallas, Dept Pediat, Dallas, TX 75230 USA; Univ Texas, SW Med Ctr Dallas, Dept Mol Biol, Dallas, TX 75230 USA; Masonic Med Res Lab, Utica, NY 13501 USA; Toronto Gen Hosp, Inst Res, Div Cellular & Mol Biol, Toronto, ON M5G 2C4, Canada; Univ Hlth Network, Div Cardiol, Toronto, ON M5G 2C4, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; University of Toronto; City University of Hong Kong; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Masonic Medical Research Laboratory; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital; University of Toronto; University Toronto Affiliates; University Health Network Toronto	Backx, PH (corresponding author), Hosp Sick Children, Program Cardiovasc Res, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.	p.backx@utoronto.ca; bbruneau@sickkids.ca	Cheng, Shuk Han/F-9943-2012; Kim, Kyoung-Han/AAZ-4908-2021	Husain, Mansoor/0000-0002-3740-6739; Antzelevitch, Charles/0000-0001-7349-1582; Kim, Kyoung-Han/0000-0002-0433-656X; Bruneau, Benoit/0000-0002-0804-7597; Cheng, Shuk Han/0000-0002-5822-7238	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL047678] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL047678] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Antzelevitch C, 2004, ANN MED, V36, P5, DOI 10.1080/17431380410032553; Bao ZZ, 1999, SCIENCE, V283, P1161, DOI 10.1126/science.283.5405.1161; Barry DM, 1998, CIRC RES, V83, P560, DOI 10.1161/01.RES.83.5.560; Bruneau BG, 2002, CIRC RES, V90, P509, DOI 10.1161/01.RES.0000013072.51957.B7; Bruneau BG, 2001, CELL, V106, P709, DOI 10.1016/S0092-8674(01)00493-7; Bruneau BG, 2000, DEV BIOL, V217, P266, DOI 10.1006/dbio.1999.9548; Bruneau BG, 2001, MOL CELL BIOL, V21, P1730, DOI 10.1128/MCB.21.5.1730-1736.2001; Brunet S, 2004, J PHYSIOL-LONDON, V559, P103, DOI 10.1113/jphysiol.2004.063347; Burglin TR, 1997, NUCLEIC ACIDS RES, V25, P4173, DOI 10.1093/nar/25.21.4173; Cavodeassi F, 2001, DEVELOPMENT, V128, P2847; CHENG CW, 2005, IN PRESS DEV BIOL; Christoffels VM, 2000, DEV BIOL, V224, P263, DOI 10.1006/dbio.2000.9801; Cohen DR, 2000, MECH DEVELOP, V91, P317, DOI 10.1016/S0925-4773(99)00263-4; Danik S, 2002, AM J PHYSIOL-HEART C, V283, pH372, DOI 10.1152/ajpheart.01091.2001; Deschenes I, 2002, CIRCULATION, V106, P423, DOI 10.1161/01.CIR.0000025417.65658.B6; Extramiana F, 2004, CIRCULATION, V110, P3661, DOI 10.1161/01.CIR.0000143078.48699.0C; Gaita F, 2003, CIRCULATION, V108, P965, DOI 10.1161/01.CIR.0000085071.28695.C4; Gomez-Skarmeta JL, 2001, DEVELOPMENT, V128, P551; Gottlieb PD, 2002, NAT GENET, V31, P25, DOI 10.1038/ng866; Guo WN, 2002, J BIOL CHEM, V277, P26436, DOI 10.1074/jbc.M201431200; Guo WN, 2002, CIRC RES, V90, P586, DOI 10.1161/01.RES.0000012664.05949.E0; Guo WN, 1999, J PHYSIOL-LONDON, V521, P587, DOI 10.1111/j.1469-7793.1999.00587.x; Guo WN, 2000, CIRC RES, V87, P73, DOI 10.1161/01.RES.87.1.73; Habets PEMH, 2003, CARDIOVASC RES, V58, P246, DOI 10.1016/S0008-6363(02)00784-8; Itoh M, 2002, DEVELOPMENT, V129, P2317; Jia Y, 2003, CARDIOVASC RES, V60, P278, DOI 10.1016/S0008-6363(03)00528-5; Kaab S, 1998, CIRCULATION, V98, P1383, DOI 10.1161/01.CIR.98.14.1383; Kaprielian R, 2002, AM J PHYSIOL-HEART C, V283, pH1157, DOI 10.1152/ajpheart.00518.2001; Kudoh T, 2001, P NATL ACAD SCI USA, V98, P7852, DOI 10.1073/pnas.141224098; Kuo HC, 2001, CELL, V107, P801, DOI 10.1016/S0092-8674(01)00588-8; Lebel M, 2003, MOL CELL BIOL, V23, P8216, DOI 10.1128/MCB.23.22.8216-8225.2003; Liu G, 2004, J PHYSIOL-LONDON, V555, P267, DOI 10.1113/jphysiol.2003.054064; Matsumoto K, 2004, NAT NEUROSCI, V7, P605, DOI 10.1038/nn1249; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; Mummenhoff J, 2001, MECH DEVELOP, V103, P193, DOI 10.1016/S0925-4773(01)00353-7; Mungrue IN, 2002, J CLIN INVEST, V109, P735, DOI 10.1172/JCI200213265; Nerbonne JM, 2002, J CARDIOVASC ELECTR, V13, P406, DOI 10.1046/j.1540-8167.2002.00406.x; Oudit GY, 2001, J MOL CELL CARDIOL, V33, P851, DOI 10.1006/jmcc.2001.1376; Roberts R, 2003, ANNU REV MED, V54, P257, DOI 10.1146/annurev.med.54.073002.182112; Rosati B, 2003, J PHYSIOL-LONDON, V548, P815, DOI 10.1113/jphysiol.2002.033704; Sah R, 2002, CIRC RES, V90, P165, DOI 10.1161/hh0202.103315; Shibata R, 2003, J BIOL CHEM, V278, P36445, DOI 10.1074/jbc.M306142200; Sun H, 2004, CARDIOVASC RES, V62, P509, DOI 10.1016/j.cardiores.2004.01.029; Tomaselli GF, 2004, CIRC RES, V95, P754, DOI 10.1161/01.RES.0000145047.14691.db; Wickenden AD, 1999, CIRC RES, V85, P1067; Wickenden AD, 1999, AM J PHYSIOL-HEART C, V276, pH1599, DOI 10.1152/ajpheart.1999.276.5.H1599; Xu HD, 1999, J GEN PHYSIOL, V113, P661, DOI 10.1085/jgp.113.5.661; Yan GX, 1998, CIRCULATION, V98, P1928, DOI 10.1161/01.CIR.98.18.1928; Zhu Wei, 2003, J Cardiovasc Electrophysiol, V14, P982, DOI 10.1046/j.1540-8167.2003.02002.x	49	179	183	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					347	358		10.1016/j.cell.2005.08.004	http://dx.doi.org/10.1016/j.cell.2005.08.004			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239150	Bronze, Green Accepted			2022-12-28	WOS:000232794100019
J	Gardai, SJ; McPhillips, KA; Frasch, SC; Janssen, WJ; Starefeldt, A; Murphy-Ullrich, JE; Bratton, DL; Oldenborg, PA; Michalak, M; Henson, PM				Gardai, SJ; McPhillips, KA; Frasch, SC; Janssen, WJ; Starefeldt, A; Murphy-Ullrich, JE; Bratton, DL; Oldenborg, PA; Michalak, M; Henson, PM			Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte	CELL			English	Article							RECEPTOR-RELATED PROTEIN; CLASS-I MOLECULES; MACROPHAGE RECOGNITION; IMMUNE-RESPONSES; DEFICIENT MICE; SIRP-ALPHA; BINDING; PHOSPHATIDYLSERINE; CD47; EXPRESSION	Apoptotic-cell removal is critical for development, tissue homeostasis, and resolution of inflammation. Although many candidate systems exist, only phosphatidylserine has been identified as a general recognition ligand on apoptotic cells. We demonstrate here that calreticulin acts as a second general recognition ligand by binding and activating LDL-receptor-related protein (LRP) on the engulfing cell. Since surface calreticulin is also found on viable cells, a mechanism preventing inadvertent uptake was sought. Disruption of interactions between CD47 (integrin-associated protein) on the target cell and SIRP alpha (SHPS-1), a heavily glycosylated transmembrane protein on the engulfing cell, permitted uptake of viable cells in a calreticulin/LRP-dependent manner. On apoptotic cells, CD47 was altered and/or lost and no longer activated SIRP alpha. These changes on the apoptotic cell create an environment where "don't eat me" signals are rendered inactive and "eat me" signals, including calreticulin and phosphatidylserine, congregate together and signal for removal.	Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, Denver, CO 80206 USA; Univ Colorado, Hlth Sci Ctr, Dept Pathol, Denver, CO 80262 USA; Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care, Denver, CO 80262 USA; Univ Alberta, Dept Biochem, Membrane Prot Res Grp, Edmonton, AB T6G 2H7, Canada; Umea Univ, Sect Histol & Cell Biol, Dept Integrat Med Biol, SE-90187 Umea, Sweden; Univ Alabama, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA; Univ Alabama, Cell Adhes & Matrix Res Ctr, Birmingham, AL 35294 USA	National Jewish Health; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Alberta; Umea University; University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham	Henson, PM (corresponding author), Natl Jewish Med & Res Ctr, Cell Biol Program, Dept Pediat, 1400 Jackson St, Denver, CO 80206 USA.	hensonp@njc.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL068864, R01HL079644, P01HL034303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057573, R01GM061031, R01GM048211] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL34303, R01 HL079644, HL068864, HL079644] Funding Source: Medline; NIGMS NIH HHS [GM61031, GM57573-006, GM48211] Funding Source: Medline; PHS HHS [A1058228] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Arosa FA, 1999, J BIOL CHEM, V274, P16917, DOI 10.1074/jbc.274.24.16917; Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541; Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1; Bu GJ, 2001, INT REV CYTOL, V209, P79; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; Callahan MK, 2000, CELL DEATH DIFFER, V7, P645, DOI 10.1038/sj.cdd.4400690; Cant CA, 2001, CELL MOL LIFE SCI, V58, P117, DOI 10.1007/PL00000771; deCathelineau AM, 2003, ESSAYS BIOCHEM, V39, P105, DOI 10.1042/bse0390105; Dini L, 2000, EUR J HISTOCHEM, V44, P217; Fadok VA, 2001, J BIOL CHEM, V276, P1071, DOI 10.1074/jbc.M003649200; FADOK VA, 1993, J IMMUNOL, V151, P4274; Fadok VA, 2001, J IMMUNOL, V166, P6847, DOI 10.4049/jimmunol.166.11.6847; Frasch SC, 2004, J BIOL CHEM, V279, P17625, DOI 10.1074/jbc.M313414200; Gardai SJ, 2003, CELL, V115, P13, DOI 10.1016/S0092-8674(03)00758-X; Heal R, 1998, BIOCHEM J, V329, P389, DOI 10.1042/bj3290389; Hoffmann PR, 2001, J CELL BIOL, V155, P649, DOI 10.1083/jcb.200108080; Hoffmann PR, 2005, J IMMUNOL, V174, P1393, DOI 10.4049/jimmunol.174.3.1393; Jethmalani SM, 1997, J CELL BIOCHEM, V66, P98; Kharitonenkov A, 1997, NATURE, V386, P181, DOI 10.1038/386181a0; Krause KH, 1997, CELL, V88, P439, DOI 10.1016/S0092-8674(00)81884-X; Li YS, 2000, J BIOL CHEM, V275, P37187, DOI 10.1074/jbc.M000490200; Lindberg FP, 1996, SCIENCE, V274, P795, DOI 10.1126/science.274.5288.795; Manaka J, 2004, J BIOL CHEM, V279, P48466, DOI 10.1074/jbc.M408597200; Mesaeli N, 1999, J CELL BIOL, V144, P857, DOI 10.1083/jcb.144.5.857; Moffatt OD, 1999, J IMMUNOL, V162, P6800; Obermoeller-McCormick LM, 2001, J CELL SCI, V114, P899; Ogden CA, 2001, J EXP MED, V194, P781, DOI 10.1084/jem.194.6.781; Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004; Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855; Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051; Orr AW, 2003, J CELL SCI, V116, P2917, DOI 10.1242/jcs.00600; Orr AW, 2003, J CELL BIOL, V161, P1179, DOI 10.1083/jcb.200302069; OSTWALD TJ, 1974, J BIOL CHEM, V249, P974; Rauch F, 2000, EXP CELL RES, V256, P105, DOI 10.1006/excr.2000.4818; Sadasivan B, 1996, IMMUNITY, V5, P103, DOI 10.1016/S1074-7613(00)80487-2; Savill J, 2002, NAT REV IMMUNOL, V2, P965, DOI 10.1038/nri957; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; Stuart GR, 1997, IMMUNOPHARMACOLOGY, V38, P73, DOI 10.1016/S0162-3109(97)00076-3; Stuart LM, 2005, J IMMUNOL, V174, P3220, DOI 10.4049/jimmunol.174.6.3220; Su HP, 2002, J BIOL CHEM, V277, P11772, DOI 10.1074/jbc.M109336200; Tada K, 2003, J IMMUNOL, V171, P5718, DOI 10.4049/jimmunol.171.11.5718; Vandivier RW, 2002, J IMMUNOL, V169, P3978, DOI 10.4049/jimmunol.169.7.3978; WHITE TK, 1995, J BIOL CHEM, V270, P15926, DOI 10.1074/jbc.270.27.15926	43	975	1058	6	71	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	OCT 21	2005	123	2					321	334		10.1016/j.cell.2005.08.032	http://dx.doi.org/10.1016/j.cell.2005.08.032			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239148	Bronze			2022-12-28	WOS:000232794100017
J	Jones, RB; Gordus, A; Krall, JA; MacBeath, G				Jones, RB; Gordus, A; Krall, JA; MacBeath, G			A quantitative protein interaction network for the ErbB receptors using protein microarrays	NATURE			English	Article							GROWTH-FACTOR RECEPTOR; TYROSINE KINASES; SH2 DOMAINS; SACCHAROMYCES-CEREVISIAE; WIDE PREDICTION; BREAST-CANCER; IDENTIFICATION; TRANSFORMATION; CARCINOMAS; EXPRESSION	Although epidermal growth factor receptor ( EGFR; also called ErbB1) and its relatives initiate one of the most well-studied signalling networks, there is not yet a genome-wide view of even the earliest step in this pathway: recruitment of proteins to the activated receptors. Here we use protein microarrays comprising virtually every Src homology 2 (SH2) and phosphotyrosine binding (PTB) domain encoded in the human genome to measure the equilibrium dissociation constant of each domain for 61 peptides representing physiological sites of tyrosine phosphorylation on the four ErbB receptors. This involved 77,592 independent biochemical measurements and provided a quantitative protein interaction network that reveals many new interactions, including ones that fall outside of our current view of domain selectivity. By slicing through the network at different affinity thresholds, we found surprising differences between the receptors. Most notably, EGFR and ErbB2 become markedly more promiscuous as the threshold is lowered, whereas ErbB3 does not. Because EGFR and ErbB2 are overexpressed in many human cancers, our results suggest that the extent to which promiscuity changes with protein concentration may contribute to the oncogenic potential of receptor tyrosine kinases, and perhaps other signalling proteins as well.	Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA; Harvard Univ, Program Biophys, Cambridge, MA 02138 USA	Harvard University; Harvard University	MacBeath, G (corresponding author), Harvard Univ, Dept Chem & Biol Chem, Cambridge, MA 02138 USA.	macbeath@chemistry.harvard.edu		MacBeath, Gavin/0000-0003-2585-6772				ALIMANDI M, 1995, ONCOGENE, V10, P1813; Bateman A, 2000, NUCLEIC ACIDS RES, V28, P263, DOI 10.1093/nar/28.1.263; Bowers G, 2001, ONCOGENE, V20, P1388, DOI 10.1038/sj.onc.1204255; Burke P, 2001, MOL BIOL CELL, V12, P1897, DOI 10.1091/mbc.12.6.1897; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; GORGOULIS V, 1992, ANTICANCER RES, V12, P1183; HATADA MH, 1995, NATURE, V377, P32, DOI 10.1038/377032a0; Haugh Jason M, 2002, Mol Interv, V2, P292, DOI 10.1124/mi.2.5.292; Hendriks BS, 2005, J BIOL CHEM, V280, P6157, DOI 10.1074/jbc.M410491200; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; IRISH JC, 1993, LARYNGOSCOPE, V103, P42; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; MacBeath G, 2000, SCIENCE, V289, P1760; MOSCATELLO DK, 1995, CANCER RES, V55, P5536; Obenauer JC, 2003, NUCLEIC ACIDS RES, V31, P3635, DOI 10.1093/nar/gkg584; Peri S, 2003, GENOME RES, V13, P2363, DOI 10.1101/gr.1680803; PinkasKramarski R, 1996, EMBO J, V15, P2452, DOI 10.1002/j.1460-2075.1996.tb00603.x; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413; SADOWSKI I, 1986, MOL CELL BIOL, V6, P4396, DOI 10.1128/MCB.6.12.4396; Schoeberl B, 2002, NAT BIOTECHNOL, V20, P370, DOI 10.1038/nbt0402-370; Schultz J, 1998, P NATL ACAD SCI USA, V95, P5857, DOI 10.1073/pnas.95.11.5857; SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; Su AI, 2002, P NATL ACAD SCI USA, V99, P4465, DOI 10.1073/pnas.012025199; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WONG AJ, 1992, P NATL ACAD SCI USA, V89, P2965, DOI 10.1073/pnas.89.7.2965; Woodring PJ, 2003, J CELL SCI, V116, P2613, DOI 10.1242/jcs.00622; Yaffe MB, 2001, NAT BIOTECHNOL, V19, P348, DOI 10.1038/86737; Yan KS, 2002, FEBS LETT, V513, P67, DOI 10.1016/S0014-5793(01)03305-1; Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E; Zhu H, 2001, SCIENCE, V293, P2101, DOI 10.1126/science.1062191	36	558	593	1	59	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 12	2006	439	7073					168	174		10.1038/nature04177	http://dx.doi.org/10.1038/nature04177			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001MT	16273093				2022-12-28	WOS:000234538400032
J	He, CY; Pypaert, M; Warren, G				He, CY; Pypaert, M; Warren, G			Golgi duplication in Trypanosoma brucei requires Centrin2	SCIENCE			English	Article							CELL-CYCLE; GAMMA-TUBULIN; LOCALIZATION; CENTROSOMES; PROTEIN	Centrins are highly conserved components of the centrosome, which in the parasitic protozoan T. brucei comprises the basal body and nucleates the flagellum used for locomotion. Here, we found TbCentrin2 in an additional bi-lobed structure near to the Golgi apparatus. One lobe was associated with the old Golgi, and the other became associated with the newly forming Golgi as the cell grew.. Depletion of TbCentrin1 inhibited duplication of the basal body, whereas depletion of TbCentrin2 also inhibited duplication of the Golgi. Thus, a Centrin2-containing structure distinct from the basal body appears to mark the site for new Golgi assembly.	Yale Univ, Sch Med, Dept Cell Biol, New Haven, CT 06520 USA	Yale University	Warren, G (corresponding author), Yale Univ, Sch Med, Dept Cell Biol, 333 Cedar St, New Haven, CT 06520 USA.	graham.warren@yale.edu	He, Cynthia/H-9789-2012					Bastin P, 1996, MOL BIOCHEM PARASIT, V77, P235, DOI 10.1016/0166-6851(96)02598-4; Bevis BJ, 2002, NAT CELL BIOL, V4, P750, DOI 10.1038/ncb852; Chapman MJ, 2000, Q REV BIOL, V75, P409, DOI 10.1086/393621; Djikeng A, 2004, METH MOL B, V270, P287; Field H, 2000, MOL BIOCHEM PARASIT, V106, P21, DOI 10.1016/S0166-6851(99)00192-9; He CY, 2004, J CELL BIOL, V165, P313, DOI 10.1083/jcb.200311076; Munro S, 2002, NAT CELL BIOL, V4, pE223, DOI 10.1038/ncb1002-e223; Paoletti A, 2003, MOL BIOL CELL, V14, P2793, DOI 10.1091/mbc.E02-10-0661; Rios RM, 2004, CELL, V118, P323; ROBINSON DR, 1991, NATURE, V352, P731, DOI 10.1038/352731a0; Salisbury JL, 2002, CURR BIOL, V12, P1287, DOI 10.1016/S0960-9822(02)01019-9; SALISBURY JL, 1995, CURR OPIN CELL BIOL, V7, P39; SANDERS MA, 1994, J CELL BIOL, V124, P795, DOI 10.1083/jcb.124.5.795; Scott V, 1997, J CELL SCI, V110, P157; Selvapandiyan A, 2004, J BIOL CHEM, V279, P25703, DOI 10.1074/jbc.M402794200; SHERWIN T, 1987, J CELL BIOL, V104, P439, DOI 10.1083/jcb.104.3.439; Striepen B, 2000, J CELL BIOL, V151, P1423, DOI 10.1083/jcb.151.7.1423; WHALEY WG, 1975, GOLGI APPARATUS CELL, V2	18	107	108	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2005	310	5751					1196	1198		10.1126/science.1119969	http://dx.doi.org/10.1126/science.1119969			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GE	16254149				2022-12-28	WOS:000233437300049
J	Heit, JA; Kobbervig, CE; James, AH; Petterson, TM; Bailey, KR; Melton, LJ				Heit, JA; Kobbervig, CE; James, AH; Petterson, TM; Bailey, KR; Melton, LJ			Trends in the incidence of venous thromboembolism during pregnancy or postpartum: A 30-year population-based study	ANNALS OF INTERNAL MEDICINE			English	Article							DEEP-VEIN THROMBOSIS; RISK-FACTORS; PULMONARY-EMBOLISM; CUMULATIVE INCIDENCE; MATERNAL MORTALITY; UNITED-STATES; PUERPERIUM; DISEASE; PREVENTION; WOMEN	Background: The risk for venous thromboembolism during pregnancy or postpartum is uncertain. Objectives: To estimate the relative and absolute risk for deep venous thrombosis and pulmonary embolism during pregnancy and postpartum and to describe trends in incidence. Design: Population-based inception cohort study using the resources of the Rochester Epidemiology Project. Setting: Olmsted County, Minnesota. Patients: women with deep venous thrombosis or pulmonary embolism first diagnosed between 1966 and 1995, including women with venous thromboembolism during pregnancy or the postpartum period (defined as delivery of a newborn no more than 3 months before the deep venous thrombosis or pulmonary embolism event date, including delivery of a stillborn infant after the first trimester). Measurements: The authors obtained yearly counts of live births in Olmsted County between 1966 and 1995 from the Minnesota Department of Health. Results: The relative risk (standardized incidence ratio) for venous thromboembolism among pregnant or postpartum women was 4.29 (95% Cl, 3.49 to 5.22; P < 0.001), and the overall incidence of venous thromboembolism (absolute risk) was 199.7 per 100 000 woman-years. The annual incidence was 5 times higher among postpartum women than pregnant women (511.2 vs. 95.8 per 100 000), and the incidence of deep venous thrombosis was 3 times higher than that of pulmonary embolism (151.8 vs. 47.9 per 100 000). Pulmonary embolism was relatively uncommon during pregnancy versus the postpartum period (10.6 vs. 159.7 per 100 000). Over the 30-year study period, the incidence of venous thromboembolism during pregnancy remained relatively constant whereas the postpartum incidence of pulmonary embolism decreased more than 2-fold. Limitations: Because the Olmsted County population was 98% white and of non-Hispanic ethnicity, the results may not be generalizable to other ethnicities. Conclusions: Among pregnant women, the highest risk period for venous thromboembolism and pulmonary embolism in particular is during the postpartum period. Any prophylaxis against these events should be particularly targeted to postpartum women. Although the incidence of pulmonary embolism has decreased over time, the incidence of deep venous thrombosis remains unchanged, indicating the need to better identify pregnant women at increased risk.	Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA	Mayo Clinic	Heit, JA (corresponding author), Mayo Clin & Mayo Fdn, 200 1st St SW,Stabile 660, Rochester, MN 55905 USA.			James, Andra/0000-0003-4570-6595	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL066216, R01HL060279] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR030582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-66216, HL-60279] Funding Source: Medline; NIAMS NIH HHS [AR-30582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Andersen BS, 1998, ACTA OBSTET GYN SCAN, V77, P170, DOI 10.1034/j.1600-0412.1998.770207.x; Armour R, 2001, AM SURGEON, V67, P641; ATRASH HK, 1990, OBSTET GYNECOL, V76, P1055; BERGQVIST A, 1983, ACTA OBSTET GYN SCAN, V62, P443, DOI 10.3109/00016348309154217; BERGQVIST D, 1983, ACTA OBSTET GYN SCAN, V62, P449, DOI 10.3109/00016348309154218; Bonnar J, 1999, AM J OBSTET GYNECOL, V180, P784, DOI 10.1016/S0002-9378(99)70648-4; Chan LY, 2001, OBSTET GYNECOL, V98, P471, DOI 10.1016/S0029-7844(01)01476-4; Danilenko-Dixon DR, 2001, AM J OBSTET GYNECOL, V184, P104, DOI 10.1067/mob.2001.107919; Geerts WH, 2004, CHEST, V126, p338S, DOI 10.1378/chest.126.3_suppl.338S; Gherman RB, 1999, OBSTET GYNECOL, V94, P730, DOI 10.1016/S0029-7844(99)00426-3; GINSBERG JS, 1992, THROMB HAEMOSTASIS, V67, P519; Heit JA, 1999, ARCH INTERN MED, V159, P445, DOI 10.1001/archinte.159.5.445; HULL RD, 1990, ANN INTERN MED, V112, P663, DOI 10.7326/0003-4819-112-9-663; HUSNI EA, 1967, AM J OBSTET GYNECOL, V97, P901, DOI 10.1016/0002-9378(67)90514-5; James AH, 2005, AM J OBSTET GYNECOL, V193, P216, DOI 10.1016/j.ajog.2004.11.037; James K V, 1996, Cardiovasc Surg, V4, P777, DOI 10.1016/S0967-2109(96)00042-7; KIERKEGAARD A, 1983, ACTA OBSTET GYN SCAN, V62, P239, DOI 10.3109/00016348309155799; Lindqvist P, 1999, OBSTET GYNECOL, V94, P595, DOI 10.1016/S0029-7844(99)00308-7; Macklon NS, 1996, SCOT MED J, V41, P83, DOI 10.1177/003693309604100305; McColl MD, 1997, THROMB HAEMOSTASIS, V78, P1183; McCullagh P., 1989, GEN LINEAR MODELS, V(2nd), DOI [10.1007/978-1-4899-3242-6, https://doi.org/10.1007/978-1-4899-3242-6, DOI 10.1007/978-1-4899-3242-6]; McCullagh P., 1983, GEN LINEAR MODELS, DOI [10.1007/978-1-4899-3244-0, DOI 10.1007/978-1-4899-3244-0]; Melton LJ, 1996, MAYO CLIN PROC, V71, P266, DOI 10.4065/71.3.266; Ray J G, 1999, Obstet Gynecol Surv, V54, P265, DOI 10.1097/00006254-199904000-00023; Res HS, 2001, EPIDEMIOLOGY, V12, P456, DOI 10.1097/00001648-200107000-00016; Rosendaal FR, 1999, THROMB HAEMOSTASIS, V82, P610; RUTHERFORD S, 1991, American Journal of Obstetrics and Gynecology, V164, P286; SACHS BP, 1987, NEW ENGL J MED, V316, P667, DOI 10.1056/NEJM198703123161105; Silverstein MD, 1998, ARCH INTERN MED, V158, P585, DOI 10.1001/archinte.158.6.585; Simpson EL, 2001, BRIT J OBSTET GYNAEC, V108, P56, DOI 10.1111/j.1471-0528.2001.00004.x; Soomro RM, 2002, ANGIOLOGY, V53, P429, DOI 10.1177/000331970205300409; TREFFERS PE, 1983, INT J GYNECOL OBSTET, V21, P327, DOI 10.1016/0020-7292(83)90024-3; Weiss N, 2000, AM J OBSTET GYNECOL, V182, P1073, DOI 10.1067/mob.2000.105441	34	812	870	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					697	706		10.7326/0003-4819-143-10-200511150-00006	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00006			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287790				2022-12-28	WOS:000233486800001
J	Evans, DB; Adam, T; Edejer, TTT; Lim, SS; Cassels, A; Evans, TG				Evans, DB; Adam, T; Edejer, TTT; Lim, SS; Cassels, A; Evans, TG		WHO CHOICE Millennium Dev Goals Te	Achieving the millennium development goals for health - Time to reassess strategies for improving health in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							COST-EFFECTIVENESS; INTERVENTIONS	Making best use of resources is vital in developing countries that are struggling to improve public health with limited funds. The WHO-CHOICE project has developed standardised methods to,evaluate the efficiency of a broad range of interventions. Ibis series starts by assessing die problems with strategies for meeting the millennium development goals. Subsequent articles describe the methods, apply them to maternal and neonatal health, child health, HIV and AIDS, tuberculosis, and malaria, and consider the implications for an overall health strategy. All appear on bmj.com this week.	WHO, Dept Millennium Dev Goals Hlth & Dev Policy, CH-1211 Geneva, Switzerland; Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia	World Health Organization; University of Queensland	Evans, DB (corresponding author), WHO, Dept Millennium Dev Goals Hlth & Dev Policy, CH-1211 Geneva, Switzerland.	evanscl@who.int	Lim, Stephen S/B-4055-2012; Salomon, Joshua A/D-3898-2009	Salomon, Joshua A/0000-0003-3929-5515; Edejer, Tessa/0000-0003-1068-332X				AbouZahr C, 2001, B WORLD HEALTH ORGAN, V79, P561; Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; [Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 1999, WORLD HLTH REPORT 19; [Anonymous], 2005, PREV CHRON DIS VIT I; *DIR GEN DEV EUR C, 2005, FIN DEV; EDEJER TTT, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.39652.550278.7C; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; EVANS DB, IN PRESS ELGAR COMPA; Goodman CA, 1999, HEALTH POLICY PLANN, V14, P301, DOI 10.1093/heapol/14.4.301; Griffiths UK, 2004, B WORLD HEALTH ORGAN, V82, P643; HILL KL, BANGLADESH MATERNAL; HOGAN DR, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38645.660093.68; *INT MON FUND WORL, 2005, GLOB MON REP 2005; Mathers CD, 2003, 54 WHO; MICHAUD CM, 2005, TOUGH CHOICES INVEST; *MILL PROJ, 2005, STAT STAT SUPP INV D; MOREL C, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38639.702384.AE; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Murray CJL, 2000, B WORLD HEALTH ORGAN, V78, P717; Patel Archana B, 2003, Cost Eff Resour Alloc, V1, P7, DOI 10.1186/1478-7547-1-7; SACHS JD, 2005, PLIS MED, V2, pE318; Terris-Prestholt F, 2003, SEX TRANSM INFECT, V79, P375, DOI 10.1136/sti.79.5.375; *UN, 2005, MILL DEV GOALS REP 2, P1; *UN MILL PROJ, GOALS TARG; UN Millennium Project, 2005, INV DEV PRACT PLAN A; United Nations General Assembly, 2000, UN MILL DECL; WHO, 2004, MAT MORT 2000 EST DE; World Health Organisation, 2003, MAK CHOIC HLTH WHO G; World Health Organization, 2005, HLTH MILL DEV GOALS; World Health Organization, 2005, WORLD HLTH REP 2005; Worrall E, 2004, AM J TROP MED HYG, V71, P136, DOI 10.4269/ajtmh.2004.71.136	32	33	35	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1133	1136		10.1136/bmj.331.7525.1133	http://dx.doi.org/10.1136/bmj.331.7525.1133			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	985ZI	16282410	Green Published			2022-12-28	WOS:000233417300021
J	Baron, RJ				Baron, RJ			Personal metrics for practice - How'm I doing?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Greenhouse Internists, Philadelphia, PA USA		Baron, RJ (corresponding author), Greenhouse Internists, Philadelphia, PA USA.							*AM BOARD MED SPEC, 2005, MAIN CERT; Choudhry NK, 2005, ANN INTERN MED, V142, P260, DOI 10.7326/0003-4819-142-4-200502150-00008; LIPNER RS, IN PRESS ANN INTERN	3	11	11	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					1992	1993		10.1056/NEJMp058226	http://dx.doi.org/10.1056/NEJMp058226			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981WV	16282172				2022-12-28	WOS:000233119600002
J	Sheridan, RL; Liu, V; Anupindi, S				Sheridan, RL; Liu, V; Anupindi, S			A 10-year-old girl with a bullous skin eruption and acute respiratory failure - Toxic epidermal necrolysis.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							STEVENS-JOHNSON-SYNDROME; ERYTHEMA MULTIFORME; BURNED CHILDREN; INTRAVENOUS IMMUNOGLOBULIN; MANIFESTATIONS; MANAGEMENT; MORTALITY; SPECTRUM		Shriners Hosp Children, Burn Surg Serv, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Surg, Div Burns, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Sheridan, RL (corresponding author), Shriners Hosp Children, Burn Surg Serv, Boston, MA 02114 USA.			Liu, Vincent/0000-0003-1987-9521				Bachot N, 2003, AM J CLIN DERMATOL, V4, P561, DOI 10.2165/00128071-200304080-00006; Bachot N, 2003, ARCH DERMATOL, V139, P33, DOI 10.1001/archderm.139.1.33; BASTUJIGARIN S, 1993, ARCH DERMATOL, V129, P92, DOI 10.1001/archderm.129.1.92; BASTUJIGARIN S, 1993, AGE AGEING, V22, P450, DOI 10.1093/ageing/22.6.450; BIRCHALL N, 1987, J AM ACAD DERMATOL, V16, P368, DOI 10.1016/S0190-9622(87)70051-6; Brown KM, 2004, J BURN CARE REHABIL, V25, P81, DOI 10.1097/01.BCR.0000105096.93526.27; HEIMBACH DM, 1987, JAMA-J AM MED ASSOC, V258, P1894; HEIMBACH DM, 1987, JAMA-J AM MED ASSOC, V257, P2171; Lebargy F, 1997, INTENS CARE MED, V23, P1237, DOI 10.1007/s001340050492; LYELL A, 1969, LANCET, V1, P1155; LYELL A, 1979, BRIT J DERMATOL, V100, P69, DOI 10.1111/j.1365-2133.1979.tb03571.x; MARVIN JA, 1984, ARCH SURG-CHICAGO, V119, P601; McIvor R. A., 1996, Journal of Burn Care and Rehabilitation, V17, P237, DOI 10.1097/00004630-199605000-00009; Palmieri TL, 2002, J BURN CARE REHABIL, V23, P87, DOI 10.1097/00004630-200203000-00004; POWER WJ, 1995, OPHTHALMOLOGY, V102, P1669; Prelack Kathy, 1997, Journal of Burn Care and Rehabilitation, V18, P177; RASMUSSEN JE, 1995, ARCH DERMATOL, V131, P726, DOI 10.1001/archderm.131.6.726; ROUJEAU JC, 1994, J AM ACAD DERMATOL, V31, P301, DOI 10.1016/S0190-9622(08)81995-0; ROUJEAU JC, 1994, NEW ENGL J MED, V331, P1272, DOI 10.1056/NEJM199411103311906; ROUJEAU JC, 1995, NEW ENGL J MED, V333, P1600, DOI 10.1056/NEJM199512143332404; Schulz JT, 2000, J BURN CARE REHABIL, V21, P199, DOI 10.1097/00004630-200021030-00004; Sheridan R, 1998, J BURN CARE REHABIL, V19, P115, DOI 10.1097/00004630-199803000-00005; Sheridan R. L., 1997, Journal of Burn Care and Rehabilitation, V18, P455; Sheridan RL, 1999, SURGERY, V126, P856, DOI 10.1016/S0039-6060(99)70026-7; SHERIDAN RL, 1995, J TRAUMA, V39, P854, DOI 10.1097/00005373-199511000-00008; Sheridan RL, 2002, PEDIATRICS, V109, P74, DOI 10.1542/peds.109.1.74; Sheridan RL, 1999, J BURN CARE REHABIL, V20, P497, DOI 10.1097/00004630-199920060-00012; Sheridan Robert L., 1995, Journal of Burn Care and Rehabilitation, V16, P62, DOI 10.1097/00004630-199501000-00012; Viard I, 1998, SCIENCE, V282, P490, DOI 10.1126/science.282.5388.490; Weber JM, 2002, INFECT CONT HOSP EP, V23, P549, DOI 10.1086/502106; WILKINS J, 1992, DERMATOL CLIN, V10, P571; Wong K C, 1999, Australas J Dermatol, V40, P131, DOI 10.1046/j.1440-0960.1999.00342.x; Yeh S W, 2003, Dermatol Ther, V16, P214, DOI 10.1046/j.1529-8019.2003.01631.x	33	6	6	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2005	353	19					2057	2066		10.1056/NEJMcpc059029	http://dx.doi.org/10.1056/NEJMcpc059029			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282181				2022-12-28	WOS:000233119600012
J	Fabrizio, P; Gattazzo, C; Battistella, L; Wei, M; Cheng, C; McGrew, K; Longo, VD				Fabrizio, P; Gattazzo, C; Battistella, L; Wei, M; Cheng, C; McGrew, K; Longo, VD			Sir2 blocks extreme life-span extension	CELL			English	Article							POSITION-EFFECT VARIEGATION; FACTOR-BINDING PROTEIN-1; SACCHAROMYCES-CEREVISIAE; CALORIE RESTRICTION; FORKHEAD TRANSCRIPTION; STRESS RESISTANCE; YEAST; GROWTH; GENE; LONGEVITY	Sir2 is a conserved deacetylase that modulates life span in yeast, worms, and files and stress response in mammals. In yeast, Sir2 is required for maintaining replicative life span, and increasing Sir2 dosage can delay replicative aging. We address the role of Sir2 in regulating chronological life span in yeast. Lack of Sir2 along with calorie restriction and/or mutations in the yeast AKT homolog, Sch9, or Ras pathways causes a dramatic chronological life-span extension. Inactivation of Sir2 causes uptake and catabolism of ethanol and upregulation of many stress-resistance and sporulation genes. These changes while sufficient to extend chronological life span in wild-type yeast require severe calorie restriction or additional mutations to extend life span of sir2 Delta mutants. Our results demonstrate that effects of SIR2 on chronological life span are opposite to replicatve life span and suggest that the relevant activities of Sir2-like deacetylases may also be complex in higher eukaryotes.	Univ So Calif, Andrus Gerontol Ctr, Los Angeles, CA 90089 USA; Univ So Calif, Dept Biol Sci, Los Angeles, CA 90089 USA; Univ So Calif, Mol & Computat Biol Dept, Los Angeles, CA 90089 USA	University of Southern California; University of Southern California; University of Southern California	Longo, VD (corresponding author), Univ So Calif, Andrus Gerontol Ctr, 3715 McClintock Ave, Los Angeles, CA 90089 USA.	vlongo@usc.edu	Wei, Min/GSI-8510-2022	Wei, Min/0000-0002-2649-9271; fabrizio, paola/0000-0002-1144-7727	NIA NIH HHS [AG01028, AG20642] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG020642] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aguilaniu H, 2003, SCIENCE, V299, P1751, DOI 10.1126/science.1080418; Anderson RM, 2003, NATURE, V423, P181, DOI 10.1038/nature01578; Astrom SU, 2003, GENETICS, V163, P931; Brachmann CB, 1998, YEAST, V14, P115; Fabrizio P, 2004, J CELL BIOL, V166, P1055, DOI 10.1083/jcb.200404002; Fabrizio P, 2004, FEBS LETT, V557, P136, DOI 10.1016/S0014-5793(03)01462-5; Fabrizio P, 2003, AGING CELL, V2, P73, DOI 10.1046/j.1474-9728.2003.00033.x; Fabrizio P, 2003, GENETICS, V163, P35; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Gay E, 1997, ENDOCRINOLOGY, V138, P2937, DOI 10.1210/en.138.7.2937; Geyskens I, 2000, NATO SCI S A LIF SCI, V316, P117; Guarente L, 1999, NAT GENET, V23, P281, DOI 10.1038/15458; Harris N, 2001, MOL GENET GENOMICS, V265, P258, DOI 10.1007/s004380000409; He JX, 2005, SCIENCE, V307, P1634, DOI 10.1126/science.1107580; Hoppe GJ, 2002, MOL CELL BIOL, V22, P4167, DOI 10.1128/MCB.22.12.4167-4180.2002; Izawa S, 2004, APPL MICROBIOL BIOT, V66, P108, DOI 10.1007/s00253-004-1624-4; Jazwinski SM, 2004, FEMS YEAST RES, V5, P119, DOI 10.1016/j.femsyr.2004.04.005; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; KAISER C, 1994, METHODS YEAST GENETI, V234; Karathanasis E, 2002, GENETICS, V161, P1015; Kenyon C, 2001, CELL, V105, P165, DOI 10.1016/S0092-8674(01)00306-3; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Lin SJ, 2002, NATURE, V418, P344, DOI 10.1038/nature00829; Longo VD, 2003, SCIENCE, V299, P1342, DOI 10.1126/science.1077991; Longo VD, 1997, J CELL BIOL, V137, P1581, DOI 10.1083/jcb.137.7.1581; Lotz GP, 2003, J BIOL CHEM, V278, P17228, DOI 10.1074/jbc.M212761200; McBurney MW, 2003, MOL CELL BIOL, V23, P38, DOI 10.1128/MCB.23.1.38-54.2003; MORTIMER RK, 1959, NATURE, V183, P1751, DOI 10.1038/1831751a0; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Newman BL, 2002, GENETICS, V162, P1675; Nwaka S, 1998, PROG NUCLEIC ACID RE, V58, P197; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583; Rodgers JT, 2005, NATURE, V434, P113, DOI 10.1038/nature03354; Rogina B, 2004, P NATL ACAD SCI USA, V101, P15998, DOI 10.1073/pnas.0404184101; Tanny JC, 2001, P NATL ACAD SCI USA, V98, P415, DOI 10.1073/pnas.031563798; Tanny JC, 1999, CELL, V99, P735, DOI 10.1016/S0092-8674(00)81671-2; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Tomizawa M, 2000, J BIOL CHEM, V275, P7289, DOI 10.1074/jbc.275.10.7289; Tsukamoto Y, 1997, NATURE, V388, P900, DOI 10.1038/42288; Verdone L, 2002, EMBO J, V21, P1101, DOI 10.1093/emboj/21.5.1101; WernerWashburne M, 1996, MOL MICROBIOL, V19, P1159, DOI 10.1111/j.1365-2958.1996.tb02461.x; WILLIAMSON VM, 1980, NATURE, V283, P214, DOI 10.1038/283214a0; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; Yang YH, 2005, EMBO J, V24, P1021, DOI 10.1038/sj.emboj.7600570	46	315	332	0	22	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 8	2005	123	4					655	667		10.1016/j.cell.2005.08.042	http://dx.doi.org/10.1016/j.cell.2005.08.042			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286010	Bronze			2022-12-28	WOS:000233497400014
J	Feldman, DE; Brecht, M				Feldman, DE; Brecht, M			Map plasticity in somatosensory cortex	SCIENCE			English	Review							EXPERIENCE-DEPENDENT PLASTICITY; RAT BARREL CORTEX; DENDRITIC SPINE STABILITY; WHOLE-CELL RECORDINGS; LONG-TERM DEPRESSION; SENSORY DEPRIVATION; SYNAPTIC CONNECTIONS; DEVELOPMENTAL PLASTICITY; COLUMNAR ORGANIZATION; PYRAMIDAL NEURONS	Sensory maps in neocortex are adaptively altered to reflect recent experience and learning. In somatosensory cortex, distinct patterns of sensory use or disuse elicit multiple, functionally distinct forms of map plasticity. Diverse approaches-genetics, synaptic and in vivo physiology, optical imaging and uttrastructural analysis-suggest a distributed model in which plasticity occurs at multiple sites in the cortical circuit with multiple cellular/synaptic mechanisms and multiple likely learning rules for plasticity. This view contrasts with the classical model in which the map plasticity reflects a single Hebbian process acting at a small set of cortical synapses.	Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA; Erasmus MC, Dept Neurosci, NL-3000 DR Rotterdam, Netherlands	University of California System; University of California San Diego; Erasmus University Rotterdam; Erasmus MC	Feldman, DE (corresponding author), Univ Calif San Diego, Div Biol Sci, 9500 Gilman Dr,Room 0357, La Jolla, CA 92093 USA.	dfeldman@ucsd.edu		Brecht, Michael/0000-0002-5387-0953	NINDS NIH HHS [R01 NS046652] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS046652] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Allen CB, 2003, NAT NEUROSCI, V6, P291, DOI 10.1038/nn1012; [Anonymous], 1893, NUEVO CONCEPTO HISTO; Bender KJ, 2003, J NEUROSCI, V23, P8759; BENDER KJ, IN PRESS DEV PLASTIC; BENDER KJ, 2005, SOC NEUR ABSTR; BIENENSTOCK EL, 1982, J NEUROSCI, V2, P32, DOI 10.1523/jneurosci.02-01-00032.1982; Braitenberg V, 1991, ANATOMY CORTEX; Brecht M, 2004, J NEUROSCI, V24, P9223, DOI 10.1523/JNEUROSCI.3344-04.2004; BRECHT M, IN PRESS PLASTICITY; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Bureau I, 2004, NEURON, V42, P789, DOI 10.1016/j.neuron.2004.05.002; Castro-Alamancos MA, 2004, PROG NEUROBIOL, V74, P213, DOI 10.1016/j.pneurobio.2004.09.002; Celikel T, 2004, NAT NEUROSCI, V7, P534, DOI 10.1038/nn1222; Chklovskii DB, 2004, NATURE, V431, P782, DOI 10.1038/nature03012; Cline HT, 2001, CURR OPIN NEUROBIOL, V11, P118, DOI 10.1016/S0959-4388(00)00182-3; Dan Y, 2004, NEURON, V44, P23, DOI 10.1016/j.neuron.2004.09.007; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; Davis GW, 1996, NEURON, V17, P669, DOI 10.1016/S0896-6273(00)80199-3; DENK W, 1990, SCIENCE, V248, P73, DOI 10.1126/science.2321027; DIAMOND ME, 1994, SCIENCE, V265, P1885, DOI 10.1126/science.8091215; Dittgen T, 2004, P NATL ACAD SCI USA, V101, P18206, DOI 10.1073/pnas.0407976101; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Erzurumlu RS, 2001, TRENDS NEUROSCI, V24, P589, DOI 10.1016/S0166-2236(00)01958-5; Feldman DE, 1999, J NEUROBIOL, V41, P92, DOI 10.1002/(SICI)1097-4695(199910)41:1<92::AID-NEU12>3.0.CO;2-U; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; Feldmeyer D, 1999, J PHYSIOL-LONDON, V521, P169, DOI 10.1111/j.1469-7793.1999.00169.x; Feldmeyer D, 2002, J PHYSIOL-LONDON, V538, P803, DOI 10.1113/jphysiol.2001.012959; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Finnerty GT, 1999, NATURE, V400, P367, DOI 10.1038/22553; Foeller E, 2004, CURR OPIN NEUROBIOL, V14, P89, DOI 10.1016/j.conb.2004.01.011; Fox K, 1996, P NATL ACAD SCI USA, V93, P5584, DOI 10.1073/pnas.93.11.5584; Fox K, 2002, NEUROSCIENCE, V111, P799, DOI 10.1016/S0306-4522(02)00027-1; Fukuchi-Shimogori T, 2001, SCIENCE, V294, P1071, DOI 10.1126/science.1064252; Glazewski S, 2000, NAT NEUROSCI, V3, P911, DOI 10.1038/78820; Glazewski S, 1996, J NEUROPHYSIOL, V75, P1714, DOI 10.1152/jn.1996.75.4.1714; GREENBLATT DJ, 1983, CLIN PHARMACOKINET, V8, P233, DOI 10.2165/00003088-198308030-00003; Grutzendler J, 2002, NATURE, V420, P812, DOI 10.1038/nature01276; Haas K, 2001, NEURON, V29, P583, DOI 10.1016/S0896-6273(01)00235-5; Hebb Donald O., 1949, ORG BEHAV; Hickmott PW, 2005, NAT NEUROSCI, V8, P140, DOI 10.1038/nn1384; Holtmaat AJGD, 2005, NEURON, V45, P279, DOI 10.1016/j.neuron.2005.01.003; Katz LC, 1996, SCIENCE, V274, P1133, DOI 10.1126/science.274.5290.1133; Knott GW, 2002, NEURON, V34, P265, DOI 10.1016/S0896-6273(02)00663-3; Kossut M, 1998, EXP BRAIN RES, V123, P110, DOI 10.1007/s002210050551; Lebedev MA, 2000, CEREB CORTEX, V10, P23, DOI 10.1093/cercor/10.1.23; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Maier DL, 2003, EXP NEUROL, V184, P737, DOI 10.1016/S0014-4886(03)00335-2; Maravall M, 2004, CEREB CORTEX, V14, P655, DOI 10.1093/cercor/bhh026; Margrie TW, 2003, NEURON, V39, P911, DOI 10.1016/j.neuron.2003.08.012; Margrie TW, 2002, PFLUG ARCH EUR J PHY, V444, P491, DOI 10.1007/s00424-002-0831-z; Markram H, 1997, J PHYSIOL-LONDON, V500, P409, DOI 10.1113/jphysiol.1997.sp022031; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; McAllister AK, 1999, ANNU REV NEUROSCI, V22, P295, DOI 10.1146/annurev.neuro.22.1.295; Myers WA, 2000, J COMP NEUROL, V418, P373; Petersen CCH, 2003, PFLUG ARCH EUR J PHY, V447, P126, DOI 10.1007/s00424-003-1167-z; Polley DB, 2004, NATURE, V429, P67, DOI 10.1038/nature02469; Polley DB, 1999, NEURON, V24, P623, DOI 10.1016/S0896-6273(00)81117-4; Rema V, 1998, J NEUROSCI, V18, P10196; Ruthazer ES, 2004, J NEUROBIOL, V59, P134, DOI 10.1002/neu.10344; Schierloh A, 2004, EUR J NEUROSCI, V20, P1118, DOI 10.1111/j.1460-9568.2004.03557.x; Shepherd GMG, 2003, NEURON, V38, P277, DOI 10.1016/S0896-6273(03)00152-1; Shimogori T, 2004, DEVELOPMENT, V131, P5639, DOI 10.1242/dev.01428; Shulz DE, 2003, J PHYSIOL-PARIS, V97, P431, DOI 10.1016/j.jphysparis.2004.01.001; Silver RA, 2003, SCIENCE, V302, P1981, DOI 10.1126/science.1087160; SIMONS DJ, 1987, NATURE, V326, P694, DOI 10.1038/326694a0; SIMONS DJ, 1995, BARREL CORTEX RODENT, P262; Siucinska E, 1996, CEREB CORTEX, V6, P506, DOI 10.1093/cercor/6.3.506; Skibinska A, 2000, EXP BRAIN RES, V132, P134, DOI 10.1007/s002210000341; Stern EA, 2001, NEURON, V31, P305, DOI 10.1016/S0896-6273(01)00360-9; Takahashi T, 2003, SCIENCE, V299, P1585, DOI 10.1126/science.1079886; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Turrigiano GG, 2000, CURR OPIN NEUROBIOL, V10, P358, DOI 10.1016/S0959-4388(00)00091-X; VANDERLO.H, 1973, SCIENCE, V179, P395, DOI 10.1126/science.179.4071.395; VOLKMAR FR, 1972, SCIENCE, V176, P1445, DOI 10.1126/science.176.4042.1445; Wallace H, 1999, J NEUROBIOL, V41, P58, DOI 10.1002/(SICI)1097-4695(199910)41:1<58::AID-NEU8>3.0.CO;2-F; WANG XQ, 1995, NATURE, V378, P71, DOI 10.1038/378071a0; WELKER E, 1992, J NEUROSCI, V12, P153; WOOLSEY TA, 1970, BRAIN RES, V17, P205, DOI 10.1016/0006-8993(70)90079-X; Yuste R, 2001, ANNU REV NEUROSCI, V24, P1071, DOI 10.1146/annurev.neuro.24.1.1071; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011; Zuo Y, 2005, NATURE, V436, P261, DOI 10.1038/nature03715; Zuo Y, 2005, NEURON, V46, P181, DOI 10.1016/j.neuron.2005.04.001	82	410	417	2	45	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					810	815		10.1126/science.1115807	http://dx.doi.org/10.1126/science.1115807			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272113				2022-12-28	WOS:000233121800034
J	Sakai, KL				Sakai, KL			Language acquisition and brain development	SCIENCE			English	Article							LEFT PREFRONTAL CORTEX; SIGN LANGUAGE; COMPREHENSION; ENGLISH; FMRI; AGE; SPECIALIZATION; PERCEPTION; SENTENCES; SPEECH	Language acquisition is one of the most fundamental human traits, and it is obviously the brain that undergoes the developmental changes. During the years of language acquisition, the brain not only stores linguistic information but also adapts to the grammatical regularities of Language. Recent advances in functional neuroimaging have substantially contributed to systems-level analyses of brain development. In this Viewpoint, I review the current understanding of how the "final state" of language acquisition is represented in the mature brain and summarize new findings on cortical plasticity for second language acquisition, focusing particularly on the function of the grammar center.	Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Tokyo 1538902, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan	University of Tokyo; Japan Science & Technology Agency (JST)	Sakai, KL (corresponding author), Univ Tokyo, Grad Sch Arts & Sci, Dept Basic Sci, Tokyo 1538902, Japan.	sakai@mind.c.u-tokyo.ac.jp						Ahissar M, 2000, P NATL ACAD SCI USA, V97, P6832, DOI 10.1073/pnas.97.12.6832; Beaton AA, 2004, DYSLEXIA, READING AND THE BRAIN: A SOURCEBOOK OF PSYCHOLOGICAL AND BIOLOGICAL RESEARCH; BOERNIO A, 2005, NAT NEUROSCI, V8, P389; Chee MWL, 1999, NEURON, V23, P127, DOI 10.1016/S0896-6273(00)80759-X; Chomsky N., 2002, NATURE LANGUAGE; CHUGANI HT, 1987, ANN NEUROL, V22, P487, DOI 10.1002/ana.410220408; Dapretto M, 1999, NEURON, V24, P427, DOI 10.1016/S0896-6273(00)80855-7; Dehaene-Lambertz G, 2002, SCIENCE, V298, P2013, DOI 10.1126/science.1077066; Embick D, 2000, P NATL ACAD SCI USA, V97, P6150, DOI 10.1073/pnas.100098897; Epstein SD, 1996, BEHAV BRAIN SCI, V19, P677, DOI 10.1017/S0140525X00043521; Friederici AD, 2000, CEREB CORTEX, V10, P698, DOI 10.1093/cercor/10.7.698; Friederici AD, 2002, P NATL ACAD SCI USA, V99, P529, DOI 10.1073/pnas.012611199; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Guasti M. T., 2002, LANGUAGE ACQUISITION; Hashimoto R, 2002, NEURON, V35, P589, DOI 10.1016/S0896-6273(02)00788-2; Hickok G, 2001, SCI AM, V284, P58, DOI 10.1038/scientificamerican0601-58; Hirsh-Pasek K., 1996, ORIGINS GRAMMAR EVID; Homae F, 2003, NEUROIMAGE, V20, P578, DOI 10.1016/S1053-8119(03)00272-6; Homae F, 2002, NEUROIMAGE, V16, P883, DOI 10.1006/nimg.2002.1138; JOHNSON JS, 1989, COGNITIVE PSYCHOL, V21, P60, DOI 10.1016/0010-0285(89)90003-0; Kim KHS, 1997, NATURE, V388, P171, DOI 10.1038/40623; Kuhl PK, 2000, P NATL ACAD SCI USA, V97, P11850, DOI 10.1073/pnas.97.22.11850; Lenneberg, 1967, BIOL FDN LANGUAGE, DOI 10.1080/21548331.1967.11707799; MacSweeney M, 2002, BRAIN, V125, P1583, DOI 10.1093/brain/awf153; MORGAN G, 2002, DIRECTION SIGN LANGU; Neville HJ, 1998, P NATL ACAD SCI USA, V95, P922, DOI 10.1073/pnas.95.3.922; Pena M, 2003, P NATL ACAD SCI USA, V100, P11702, DOI 10.1073/pnas.1934290100; Perani D, 2003, HUM BRAIN MAPP, V19, P170, DOI 10.1002/hbm.10110; Petitto LA, 2001, NATURE, V413, P35, DOI 10.1038/35092613; Price CJ, 2000, J ANAT, V197, P335, DOI 10.1046/j.1469-7580.2000.19730335.x; Sakai KL, 2005, BRAIN, V128, P1407, DOI 10.1093/brain/awh465; Sakai KL, 2004, CEREB CORTEX, V14, P1233, DOI 10.1093/cercor/bhh084; Sakai KL, 2002, NEURON, V35, P1177, DOI 10.1016/S0896-6273(02)00873-5; Schlaggar BL, 2002, SCIENCE, V296, P1476, DOI 10.1126/science.1069464; Stromswold K, 1996, BRAIN LANG, V52, P452, DOI 10.1006/brln.1996.0024; Suzuki K, 2003, CEREB CORTEX, V13, P517, DOI 10.1093/cercor/13.5.517; Tatsuno Y, 2005, J NEUROSCI, V25, P1637, DOI 10.1523/JNEUROSCI.3978-04.2005; Thompson PM, 2001, NAT NEUROSCI, V4, P1253, DOI 10.1038/nn758; Wartenburger I, 2003, NEURON, V37, P159, DOI 10.1016/S0896-6273(02)01150-9	39	187	192	7	93	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					815	819		10.1126/science.1113530	http://dx.doi.org/10.1126/science.1113530			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	981XR	16272114				2022-12-28	WOS:000233121800035
J	Abidov, A; Rozanski, A; Hachamovitch, R; Hayes, SW; Aboul-Enein, F; Cohen, I; Friedman, JD; Germano, G; Berman, DS				Abidov, A; Rozanski, A; Hachamovitch, R; Hayes, SW; Aboul-Enein, F; Cohen, I; Friedman, JD; Germano, G; Berman, DS			Prognostic significance of dyspnea in patients referred for cardiac stress testing	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	77th Scientific Meeting of the American-Heart-Association	NOV 07-10, 2004	New Orleans, LA	Amer Heart Assoc			CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; ALL-CAUSE MORTALITY; MYOCARDIAL-PERFUSION; HEART-DISEASE; RISK-FACTORS; EXERCISE; MANAGEMENT; SYMPTOMS; MECHANISMS	BACKGROUND: Although dyspnea is a common symptom, there has been only limited investigation of its prognostic significance among patients referred for cardiac evaluation. METHODS: We studied 17,991 patients undergoing myocardial-perfusion single-photon-emission computed tomography during stress and at rest. Patients were divided into five categories on the basis of symptoms at presentation (none, nonanginal chest pain, atypical angina, typical angina, and dyspnea). Multivariable analysis was used to assess the incremental prognostic value of symptom categories in predicting the risk of death from cardiac causes and from any cause. In addition, the prognosis associated with various symptoms at presentation was compared in subgroups selected on the basis of propensity analysis. RESULTS: After a mean (+/-SD) follow-up of 2.7+/-1.7 years, the rate of death from cardiac causes and from any cause was significantly higher among patients with dyspnea (both those previously known to have coronary artery disease and those with no known history of coronary artery disease) than among patients with other or no symptoms at presentation. Among patients with no known history of coronary artery disease, those with dyspnea had four times the risk of sudden death from cardiac causes of asymptomatic patients and more than twice the risk of patients with typical angina. Dyspnea was associated with a significant increase in the risk of death among each clinically relevant subgroup and remained an independent predictor of the risk of death from cardiac causes (P<0.001) and from any cause (P<0.001) after adjustment for other significant factors by multivariable and propensity analysis. CONCLUSIONS: In a large series of patients, self-reported dyspnea identified a subgroup of otherwise asymptomatic patients at increased risk for death from cardiac causes and from any cause. Our results suggest that an assessment of dyspnea should be incorporated into the clinical evaluation of patients referred for cardiac stress testing.	Cedars Sinai Med Ctr, Dept Imaging, Div Nucl Med, Los Angeles, CA 90048 USA; Cedars Sinai Med Ctr, Dept Med, Div Cardiol, Los Angeles, CA 90048 USA; St Joseph Mercy Oakland Med Ctr, Dept Med, Pontiac, MI USA; St Lukes Roosevelt Hosp, Div Cardiol, New York, NY USA; Univ So Calif, Keck Sch Med, Dept Med, Div Cardiovasc, Los Angeles, CA USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA USA	Cedars Sinai Medical Center; Cedars Sinai Medical Center; Saint Joseph Mercy Health System (SJMHS); Mount Sinai St. Luke's; Mount Sinai West; University of Southern California; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Berman, DS (corresponding author), Cedars Sinai Med Ctr, Dept Imaging, Div Nucl Med, 8700 Beverly Blvd, Los Angeles, CA 90048 USA.	bermand@cshs.org						Abidov A, 2003, CIRCULATION, V107, P2894, DOI 10.1161/01.CIR.0000072770.27332.75; Anisman H, 2002, BRAIN BEHAV IMMUN, V16, P513, DOI 10.1016/S0889-1591(02)00009-0; Azarbal B, 2004, J AM COLL CARDIOL, V44, P423, DOI 10.1016/j.jacc.2004.02.060; BERMAN DS, 1993, J AM COLL CARDIOL, V22, P1455, DOI 10.1016/0735-1097(93)90557-H; BONOW RO, 1992, ANN INTERN MED, V117, P502, DOI 10.7326/0003-4819-117-6-502; Cole SR, 1999, AM J CARDIOL, V84, P1401, DOI 10.1016/S0002-9149(99)00585-8; COOK DG, 1988, EUR HEART J, V9, P1215, DOI 10.1093/oxfordjournals.eurheartj.a062432; COX DR, 1972, J R STAT SOC B, V34, P187; DIAMOND GA, 1981, CIRCULATION, V63, P915, DOI 10.1161/01.CIR.63.4.915; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; DIAMOND GA, 1983, J AM COLL CARDIOL, V1, P444, DOI 10.1016/S0735-1097(83)80072-2; GERMANO G, 1995, J NUCL MED, V36, P2138; Gum PA, 2001, JAMA-J AM MED ASSOC, V286, P1187, DOI 10.1001/jama.286.10.1187; Hachamovitch R, 2003, CIRCULATION, V107, P2900, DOI 10.1161/01.CIR.0000072790.23090.41; HAGMAN M, 1987, J CHRON DIS, V40, P265, DOI 10.1016/0021-9681(87)90163-9; HAGMAN M, 1981, ACTA MED SCAND, P16; Jones RC, 2004, AM J MED, V117, P380, DOI 10.1016/j.amjmed.2004.06.004; Leineweber C, 2003, J PSYCHOSOM RES, V54, P121, DOI 10.1016/S0022-3999(02)00475-0; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Montgomery D. C., 1984, DESIGN ANAL EXPT; Morise AP, 2003, J AM COLL CARDIOL, V42, P842, DOI 10.1016/S0735-1097(03)00837-4; PEPINE CJ, 1972, CIRCULATION, V46, P863, DOI 10.1161/01.CIR.46.5.863; Qureshi E, 2002, AM J CARDIOL, V90, P756, DOI 10.1016/S0002-9149(02)02605-X; ROZANSKI A, 1983, NEW ENGL J MED, V309, P518, DOI 10.1056/NEJM198309013090902; Rozanski A, 2005, J AM COLL CARDIOL, V45, P637, DOI 10.1016/j.jacc.2004.12.005; ROZANSKI A, 1984, ANN INTERN MED, V101, P164, DOI 10.7326/0003-4819-101-2-164; Rozanski A, 2001, CIRCULATION, V103, P2084; Rubin DB, 1996, BIOMETRICS, V52, P249, DOI 10.2307/2533160; SUADICANI P, 1993, ATHEROSCLEROSIS, V101, P165, DOI 10.1016/0021-9150(93)90113-9; VASAN RS, 1995, J AM COLL CARDIOL, V26, P1565, DOI 10.1016/0735-1097(95)00381-9; WILHELMSEN L, 1973, CIRCULATION, V48, P950, DOI 10.1161/01.CIR.48.5.950	31	202	207	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1889	1898		10.1056/NEJMoa042741	http://dx.doi.org/10.1056/NEJMoa042741			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	979VJ	16267320				2022-12-28	WOS:000232972800005
J	von Gunten, CF; Ryndes, T				von Gunten, CF; Ryndes, T			The academic hospice	ANNALS OF INTERNAL MEDICINE			English	Article							CARE	The academic hospice is a recent development in health care. Hospice programs and hospitals evolved from the same historical roots in Greek and Roman medicine. The academic hospital emerged as a place where patient care, education, and research are pursued as inextricable parts of the mission. The unique role of the academic medical center in health care is supported by the government, the medical profession, and the public. This article provides a perspective on the emergence of the academic hospice. Dr. Cicely Saunders, who died on 14 July 2005, founded the first such hospice in London, England, in 1967. The authors show that the philosophy of hospice care has the same historical roots as standard health care and describe those elements that distinguish academic hospice programs from other kinds of hospice programs. Finally, the authors note that demographic and economic challenges in the United States and elsewhere only increase the need for academic hospice programs.	San Diego Hospice & Palliat Care, San Diego, CA USA		von Gunten, CF (corresponding author), 4311 3rd Ave, San Diego, CA 92103 USA.	cvongunten@sdhospice.org			NCI NIH HHS [K05CA102582] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K05CA102582] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARING CD, 1971, UNDERSTANDING PHYS; DUNLOP RJ, 1998, HOSP BASED PALLIATIV, P1; Field MJ, 1997, APPROACHING DEATH IM; HINOHARA S, 1993, ANN INTERN MED, V118, P638, DOI 10.7326/0003-4819-118-8-199304150-00012; Kotlikoff LJ, 2004, COMING GENERATIONAL STORM: WHAT YOU NEED TO KNOW ABOUT AMERICA'S ECONOMIC FUTURE, P1; Kubler-Ross Elizabeth, 2011, DEATH DYING WHAT DYI; LORBER J, 1975, J HEALTH SOC BEHAV, V16, P213, DOI 10.2307/2137163; LYONS A, 1987, MED ILLUSTRATED HIST, P185; MOR V, 1988, HOSPICE EXPT, P6; *NAT HOSP ORG, 1979, HOSP STAND; ONEILL WM, 1992, J PAIN SYMPTOM MANAG, V7, P406, DOI 10.1016/0885-3924(92)90020-I; SAUNDERS CM, 1998, OXFORD TXB PALLIATIV, pR6; SAUNDERS CM, 2005, OXFORD TXB PALLIATIV, pR15; STARR P, 1982, SOCIAL TRANSFORMATIO, P362; Teno JM, 2004, JAMA-J AM MED ASSOC, V291, P88, DOI 10.1001/jama.291.1.88; TYLER B, 1997, QUEST DIE DIGNITY AN, P12; Wald F S, 1980, Nurs Outlook, V28, P173; WALSH TD, 1981, NEW ENGL J MED, V305, P1417	18	4	4	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					655	658		10.7326/0003-4819-143-9-200511010-00009	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00009			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263888				2022-12-28	WOS:000233030600005
J	Box, H; Bonney, H; Greenfield, J				Box, H; Bonney, H; Greenfield, J			The patient's journey: the progressive ataxias	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Ataxia UK, London SW9 6EJ, England; Dykebar Hosp, Paisley PA2 7DE, Renfrew, Scotland		Greenfield, J (corresponding author), Ataxia UK, London SW9 6EJ, England.	jgreenfield@ataxia.org.uk							0	3	3	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	2005	331	7523					1007	1009		10.1136/bmj.331.7523.1007	http://dx.doi.org/10.1136/bmj.331.7523.1007			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981AU	16254302	Green Published			2022-12-28	WOS:000233060200020
J	Silk, JB; Brosnan, SF; Vonk, J; Henrich, J; Povinelli, DJ; Richardson, AS; Lambeth, SP; Mascaro, J; Schapiro, SJ				Silk, JB; Brosnan, SF; Vonk, J; Henrich, J; Povinelli, DJ; Richardson, AS; Lambeth, SP; Mascaro, J; Schapiro, SJ			Chimpanzees are indifferent to the welfare of unrelated group members	NATURE			English	Article							AFFILIATION; INEQUITY; KINSHIP	Humans are an unusually prosocial species - we vote, give blood, recycle, give tithes and punish violators of social norms. Experimental evidence indicates that people willingly incur costs to help strangers in anonymous one-shot interactions(1,2), and that altruistic behaviour is motivated, at least in part, by empathy and concern for the welfare of others ( hereafter referred to as other-regarding preferences)(1-3). In contrast, cooperative behaviour in non-human primates is mainly limited to kin and reciprocating partners, and is virtually never extended to unfamiliar individuals(4). Here we present experimental tests of the existence of other-regarding preferences in non-human primates, and show that chimpanzees ( Pan troglodytes) do not take advantage of opportunities to deliver benefits to familiar individuals at no material cost to themselves, suggesting that chimpanzee behaviour is not motivated by other-regarding preferences. Chimpanzees are among the primates most likely to demonstrate prosocial behaviours. They participate in a variety of collective activities, including territorial patrols, coalitionary aggression, cooperative hunting, food sharing and joint mate guarding(5-12). Consolation of victims of aggression(13) and anecdotal accounts of solicitous treatment of injured individuals suggest that chimpanzees may feel empathy(14,15). Chimpanzees sometimes reject exchanges in which they receive less valuable rewards than others, which may be one element of a 'sense of fairness', but there is no evidence that they are averse to interactions in which they benefit more than others(16-18).	Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA; Emory Univ, Dept Anthropol, Atlanta, GA 30322 USA; Univ Texas, MD Anderson Canc Ctr, Michale E Keeling Ctr Comparat Med & Res, Bastrop, TX 78602 USA; Univ Louisiana Lafayette, Cognit Evolut Grp, New Iberia, LA 70560 USA	University of California System; University of California Los Angeles; Emory University; University of Texas System; UTMD Anderson Cancer Center; University of Louisiana Lafayette	Silk, JB (corresponding author), Univ Calif Los Angeles, Dept Anthropol, Los Angeles, CA 90095 USA.	jsilk@anthro.ucla.edu	Vonk, Jennifer/ABB-5385-2021; , jenny/AAC-8282-2019; Vonk, Jennifer/AAB-7316-2020	Vonk, Jennifer/0000-0002-4362-5989; Kaeser, Amanda/0000-0002-0446-4465; Schapiro, Steven J./0000-0001-5406-1739				Boesch C., 2002, CHIMPANZEES TAI FORE; Boyd R, 2003, P NATL ACAD SCI USA, V100, P3531, DOI 10.1073/pnas.0630443100; Brosnan SF, 2005, P ROY SOC B-BIOL SCI, V272, P253, DOI 10.1098/rspb.2004.2947; Brosnan SF, 2003, NATURE, V425, P297, DOI 10.1038/nature01963; Clutton-Brock T, 2002, SCIENCE, V296, P69, DOI 10.1126/science.296.5565.69; Crawford M.P., 1937, COMP PSYCHOL MONOGR, V14, P1; Cronin KA, 2005, ANIM BEHAV, V69, P133, DOI 10.1016/j.anbehav.2004.02.024; de Waal FBM, 2000, NATURE, V404, P563, DOI 10.1038/35007138; De Waal Frans B. M., 1996, P80; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Flack JC, 2000, J CONSCIOUSNESS STUD, V7, P1; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; Greene J, 2002, TRENDS COGN SCI, V6, P517, DOI 10.1016/S1364-6613(02)02011-9; Hauser MD, 2003, P ROY SOC B-BIOL SCI, V270, P2363, DOI 10.1098/rspb.2003.2509; Henrich J, 2004, NATURE, V428, P139, DOI 10.1038/428139a; Henrich J., 2005, FDN HUMAN SOCIALITY; Hohmann G, 1999, BEHAVIOUR, V136, P1219, DOI 10.1163/156853999501739; Mitani JC, 2000, ANIM BEHAV, V59, P885, DOI 10.1006/anbe.1999.1389; Mitani JC, 2001, ANIM BEHAV, V61, P915, DOI 10.1006/anbe.2000.1681; Penner LA, 2005, ANNU REV PSYCHOL, V56, P365, DOI 10.1146/annurev.psych.56.091103.070141; Povinelli DJ, 1999, DEVELOPING THEORIES OF INTENTION, P195; POVINELLI DJ, 1993, EVOLUTIONARY ETHICS, P277; Preston SD, 2002, BEHAV BRAIN SCI, V25, P1, DOI 10.1017/S0140525X02000018; Richerson P. J., 2004, NOT GENES ALONE CULT; Silk J.B., 2005, MORAL SENTIMENTS MAT, P43; Watts DP, 2001, BEHAVIOUR, V138, P299, DOI 10.1163/15685390152032488; Watts DP, 1998, BEHAV ECOL SOCIOBIOL, V44, P43, DOI 10.1007/s002650050513; Watts DP, 2002, BEHAVIOUR, V139, P343, DOI 10.1163/156853902760102708; [No title captured]	29	331	342	5	178	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1357	1359		10.1038/nature04243	http://dx.doi.org/10.1038/nature04243			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251965				2022-12-28	WOS:000232829100054
J	Schlaepfer, TE; Lieb, K				Schlaepfer, TE; Lieb, K			Deep brain stimulation for treatment of refractory depression	LANCET			English	Editorial Material							OBSESSIVE-COMPULSIVE DISORDER; EFFICACY		Univ Hosp, Dept Psychiat & Psychotherapy, D-53105 Bonn, Germany; Johns Hopkins Med Inst, Dept Psychiat, Div Psychiat Neuroimaging, Baltimore, MD 21205 USA; Univ Hosp, Dept Psychiat & Psychotherapy, Freiburg, Germany	University of Bonn; Johns Hopkins University; Johns Hopkins Medicine; University of Freiburg	Schlaepfer, TE (corresponding author), Univ Hosp, Dept Psychiat & Psychotherapy, D-53105 Bonn, Germany.	schlaepf@jhmi.edu	Schlaepfer, Thomas/A-2604-2008	Schlaepfer, Thomas/0000-0003-0612-9692				Bejjani BP, 1999, NEW ENGL J MED, V340, P1476, DOI 10.1056/NEJM199905133401905; Breit S, 2004, CELL TISSUE RES, V318, P275, DOI 10.1007/s00441-004-0936-0; Greenberg BD, 2003, NEUROSURG CLIN N AM, V14, P199, DOI 10.1016/S1042-3680(03)00005-6; Greenberg BD, 2003, CNS SPECTR, V8, P522, DOI 10.1017/S109285290001899X; Hilker R, 2005, J NEUROL NEUROSUR PS, V76, P1217, DOI 10.1136/jnnp.2004.057893; Mayberg HS, 2005, NEURON, V45, P651, DOI 10.1016/j.neuron.2005.02.014; Mayberg HS, 2003, NEUROIMAG CLIN N AM, V13, P805, DOI 10.1016/S1052-5149(03)00104-7; Nestler EJ, 2002, NEURON, V34, P13, DOI 10.1016/S0896-6273(02)00653-0; Nuttin BJ, 2003, NEUROSURGERY, V52, P1263, DOI 10.1227/01.NEU.0000064565.49299.9A; Price BH, 2001, J CLIN PSYCHIAT, V62, P925, DOI 10.4088/JCP.v62n1202; Schatzberg AF, 2000, BIOL PSYCHIAT, V47, P736, DOI 10.1016/S0006-3223(00)00846-5; Schoenen J, 2005, BRAIN, V128, P940, DOI 10.1093/brain/awh411; Stefurak T, 2003, MOVEMENT DISORD, V18, P1508, DOI 10.1002/mds.10593	13	80	82	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1420	1422		10.1016/S0140-6736(05)67582-4	http://dx.doi.org/10.1016/S0140-6736(05)67582-4			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976HQ	16243078				2022-12-28	WOS:000232724600008
J	Sumathipala, A; Siribaddana, S				Sumathipala, A; Siribaddana, S			Research and clinical ethics after the tsunami: Sri Lanka	LANCET			English	Editorial Material									Kings Coll London, Inst Psychiat, Epidemiol Sect, London SE5 8AF, England; Forum Res & Dev, Mulleriyawa, New Town, Sri Lanka	University of London; King's College London	Sumathipala, A (corresponding author), Kings Coll London, Inst Psychiat, Epidemiol Sect, London SE5 8AF, England.	athulasu@sltnet.lk	Sumathipala, Athula/W-2805-2019; Siribaddana, Sisira/I-2295-2016	Siribaddana, Sisira/0000-0001-5821-2557				Ahmad K, 2003, LANCET, V362, P627, DOI 10.1016/S0140-6736(03)14203-1; Angell M, 1997, NEW ENGL J MED, V337, P847, DOI 10.1056/NEJM199709183371209; [Anonymous], INT CLASS DIS 10; Collogan LK, 2004, J TRAUMA STRESS, V17, P363, DOI 10.1023/B:JOTS.0000048949.43570.6a; FERNANDO G, 2003, PSYCHOPHYSIOLOGICAL; FERNANDO G, 2004, TORTURE SRI LANKA PS; FERNANDO G, 2004, MENTAL HLTH SCH CHIL; GAMAGE VM, 2005, LANKADEEPA      0529; GOLDBECK JP, 2004, PERSONAL CONTROL TRA; Kilpatrick DG, 2004, J TRAUMA STRESS, V17, P361, DOI 10.1023/B:JOTS.0000048961.75301.74; Martin R, 2005, LANCET, V366, P275, DOI 10.1016/S0140-6736(05)66964-4; RHODE D, 2005, SUNDAY TIMES    0123; Rose S, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD000560; SANCHEZ S, 2004, VIOLENCE EXPOSURE RE; Silove D, 2005, LANCET, V365, P269; Simpson B, 2001, Ceylon Med J, V46, P54; The National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979, DHEW PUBL, V(OS) 78-0012; van Emmerik AAP, 2002, LANCET, V360, P766, DOI 10.1016/S0140-6736(02)09897-5; World Health Organization, 2003, MENT SOC ASP HLTH PO; 2005, DAILY NEWS      0107	20	20	20	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2005	366	9495					1418	1420		10.1016/S0140-6736(05)67581-2	http://dx.doi.org/10.1016/S0140-6736(05)67581-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976HQ	16243077				2022-12-28	WOS:000232724600007
J	Victora, CG; Fenn, B; Bryce, J; Kirkwood, BR				Victora, CG; Fenn, B; Bryce, J; Kirkwood, BR			Co-coverage of preventive interventions and implications for child-survival strategies: evidence from national surveys	LANCET			English	Article							HEALTH; INEQUITIES; COUNTRIES; POOR; CARE	Background In most low-income countries, several child-survival interventions are being implemented. We assessed how these interventions are clustered at the level of the individual child. Methods We analysed data from Bangladesh, Benin, Brazil, Cambodia, Eritrea, Haiti, Malawi, Nepal, and Nicaragua. A co-coverage score was obtained by adding the number of interventions received by each child (including BCG, diphtheria-pertussis-tetanus, and measles vaccines), tetanus toxoid for the mother, vitamin A supplementation, antenatal care, skilled delivery, and safe water. Socioeconomic status was assessed through principal components analysis of household assets, and concentration indices were calculated. Findings The percentage of children who did not receive a single intervention ranged from 0.3% (14/5495) in Nicaragua to 18.8% (1154/6144) in Cambodia. The proportions receiving all available interventions varied from 0.8% (48/6144) in Cambodia to 13.3% (733/5495) in Nicaragua. There were substantial inequities within all countries. In the poorest wealth quintile, 31% of Cambodian children received no interventions and 17% only one intervention; in Haiti, these figures were 15% and 17%, respectively. Inequities were inversely related to coverage levels. Countries with higher coverage rates tended to show bottom inequity patterns, with the poorest lagging behind all other groups, whereas low-coverage countries showed top inequities with the rich substantially above the rest. Interpretation The inequitable clustering of interventions at the level of the child raises the possibility that the introduction of new technologies might primarily benefit children who are already covered by existing interventions. Packaging several interventions through a single delivery strategy, while making economic sense, could contribute to increased inequities unless population coverage is very high. Co-coverage analyses of child-health surveys provide a way to assess these issues.	Univ Fed Pelotas, BR-96001970 Pelotas, RS, Brazil; London Sch Hyg & Trop Med, London WC1, England	Universidade Federal de Pelotas; University of London; London School of Hygiene & Tropical Medicine	Victora, CG (corresponding author), Univ Fed Pelotas, CP 464, BR-96001970 Pelotas, RS, Brazil.	cvictora@terra.com.br	Victora, Cesar Gomes/Y-2455-2019; Victora, Cesar G/D-4476-2013	Victora, Cesar Gomes/0000-0002-2465-2180; Victora, Cesar G/0000-0002-2465-2180; Fenn, Bridget/0000-0002-8424-4664; Kirkwood, Betty/0000-0001-5274-6072				Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; ETLINGE JL, 1996, STAT TECH B, V31, P3; Filmer D, 2001, DEMOGRAPHY, V38, P115, DOI 10.2307/3088292; Gwatkin DR, 2004, LANCET, V364, P1273, DOI 10.1016/S0140-6736(04)17145-6; GWATKIN DR, 2000, SOCIOECONOMIC DIFFER; James C, 2005, HEALTH CARE ANAL, V13, P33, DOI 10.1007/s10728-005-2568-2; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; Knippenberg R, 2005, LANCET, V365, P1087, DOI 10.1016/S0140-6736(05)74233-1; *MACR INT, DEM HLTH SURV DHS NE; *MACR INT, DEM HLTH SURV DHS BR; *MACR INT, DEM HLTH SURV DHS HA; *MACR INT, DEM HLTH SURV DHS ER; *MACR INT, DEM HLTH SURV DHS MA; *MACR INT, DEM HLTH SURV DHS BE; *MACR INT, DEM HLTH SURV DHS BA; *MACR INT, DEM HLTH SURV DHS NI; *MACR INT, DEM HLTH SURV DHS CA; Macro International, DEM HLTH SURV DHS; Schellenberg JA, 2003, LANCET, V361, P561, DOI 10.1016/S0140-6736(03)12515-9; *UNICEF, MULT IND CLUST SURV, V3; Varmus H, 2003, SCIENCE, V302, P398, DOI 10.1126/science.1091769; Victora CG, 2003, LANCET, V362, P233, DOI 10.1016/S0140-6736(03)13917-7; Victora CG, 2000, LANCET, V356, P1093, DOI 10.1016/S0140-6736(00)02741-0; Wagstaff A, 2004, AM J PUBLIC HEALTH, V94, P726, DOI 10.2105/AJPH.94.5.726; WAGSTAFF A, 2000, SOCIOECONOMIC INEQUA, V1; World Health Organization, 2005, WORLD HLTH REP 2005	26	135	137	0	8	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1460	1466		10.1016/S0140-6736(05)67599-X	http://dx.doi.org/10.1016/S0140-6736(05)67599-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243091				2022-12-28	WOS:000232724600025
J	Ellington, AD; Bull, JJ				Ellington, AD; Bull, JJ			Changing the cofactor diet of an enzyme	SCIENCE			English	Editorial Material							LACTATE-DEHYDROGENASE; SPECIFICITY; MUTAGENESIS		Univ Texas, Inst Cell & Mol Biol, Dept Chem, Austin, TX 78712 USA; Univ Texas, Inst Cell & Mol Biol, Dept Integrat Biol, Austin, TX 78712 USA	University of Texas System; University of Texas Austin; University of Texas System; University of Texas Austin	Ellington, AD (corresponding author), Univ Texas, Inst Cell & Mol Biol, Dept Chem, Austin, TX 78712 USA.	andy.ellington@mail.utexas.edu						BENNER SA, 1982, EXPERIENTIA, V38, P633, DOI 10.1007/BF02327092; Chin JW, 2003, SCIENCE, V301, P964, DOI 10.1126/science.1084772; Flores H, 2005, PROTEIN ENG DES SEL, V18, P369, DOI 10.1093/protein/gzi043; Holmberg N, 1999, PROTEIN ENG, V12, P851, DOI 10.1093/protein/12.10.851; Liu Y, 1998, CHEM BIOL, V5, P91, DOI 10.1016/S1074-5521(98)90143-0; Lunzer M, 2005, SCIENCE, V310, P499, DOI 10.1126/science.1115649; Mushegian A, 1999, CURR OPIN GENET DEV, V9, P709, DOI 10.1016/S0959-437X(99)00023-4; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; Zhu GP, 2005, SCIENCE, V307, P1279, DOI 10.1126/science.1106974	9	10	11	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					454	455		10.1126/science.1120279	http://dx.doi.org/10.1126/science.1120279			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239467				2022-12-28	WOS:000232786000034
J	Khan, J				Khan, J			Eye know it's red	LANCET			English	Editorial Material									Kings Coll Hosp London, Retinal Res Unit, London SE5 9RS, England	King's College Hospital NHS Foundation Trust; King's College Hospital	Khan, J (corresponding author), Kings Coll Hosp London, Retinal Res Unit, Normanby Bldg,Denmark Hill, London SE5 9RS, England.	jaheedkhan@yahoo.co.uk							0	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT-NOV	2005	366	9496					1583	1583		10.1016/S0140-6736(05)67630-1	http://dx.doi.org/10.1016/S0140-6736(05)67630-1			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257346				2022-12-28	WOS:000232984800028
J	Schmitt, AM; Shi, J; Wolf, AM; Lu, CC; King, LA; Zou, YM				Schmitt, AM; Shi, J; Wolf, AM; Lu, CC; King, LA; Zou, YM			Wnt-Ryk signalling mediates medial-lateral retinotectal topographic mapping	NATURE			English	Article							RECEPTOR TYROSINE KINASES; VISUAL-SYSTEM; AXON GUIDANCE; CELL-SURFACE; GROWTH; REQUIREMENT; CONNECTIONS; PROJECTION; PROTEINS; MOLECULE	Computational modelling has suggested that at least two counteracting forces are required for establishing topographic maps. Ephrin-family proteins are required for both anterior - posterior and medial - lateral topographic mapping, but the opposing forces have not been well characterized. Wnt-family proteins are recently discovered axon guidance cues. We find that Wnt3 is expressed in a medial - lateral decreasing gradient in chick optic tectum and mouse superior colliculus. Retinal ganglion cell (RGC) axons from different dorsal - ventral positions showed graded and biphasic response to Wnt3 in a concentration-dependent manner. Wnt3 repulsion is mediated by Ryk, expressed in a ventral-to-dorsal decreasing gradient, whereas attraction of dorsal axons at lower Wnt3 concentrations is mediated by Frizzled(s). Overexpression of Wnt3 in the lateral tectum repelled the termination zones of dorsal RGC axons in vivo. Expression of a dominant-negative Ryk in dorsal RGC axons caused a medial shift of the termination zones, promoting medially directed interstitial branches and eliminating laterally directed branches. Therefore, a classical morphogen, Wnt3, acting as an axon guidance molecule, plays a role in retinotectal mapping along the medial - lateral axis, counterbalancing the medial-directed EphrinB1-EphB activity.	Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA; Univ Chicago, Comm Dev Biol, Chicago, IL 60637 USA; Univ Chicago, Comm Neurobiol, Chicago, IL 60637 USA	University of Chicago; University of Chicago; University of Chicago	Zou, YM (corresponding author), Univ Chicago, Dept Neurobiol Pharmacol & Physiol, Chicago, IL 60637 USA.	yzou@bsd.uchicago.edu	shi, jun/C-2389-2011		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS047484] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS047484] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHENG HJ, 1994, CELL, V79, P157, DOI 10.1016/0092-8674(94)90408-1; Dann CE, 2001, NATURE, V412, P86, DOI 10.1038/35083601; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Feldheim DA, 1998, NEURON, V21, P1303, DOI 10.1016/S0896-6273(00)80650-9; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Flanagan JG, 1998, ANNU REV NEUROSCI, V21, P309, DOI 10.1146/annurev.neuro.21.1.309; FLANAGAN JG, 1990, CELL, V63, P185, DOI 10.1016/0092-8674(90)90299-T; FRASER SE, 1990, J NEUROBIOL, V21, P51, DOI 10.1002/neu.480210105; FRASER SE, 1980, ANNU REV NEUROSCI, V3, P319, DOI 10.1146/annurev.ne.03.030180.001535; Frisen J, 1998, NEURON, V20, P235, DOI 10.1016/S0896-6273(00)80452-3; GIERER A, 1983, PROC R SOC SER B-BIO, V218, P77, DOI 10.1098/rspb.1983.0027; Halford MM, 2000, NAT GENET, V25, P414, DOI 10.1038/78099; Hansen MJ, 2004, NEURON, V42, P717, DOI 10.1016/j.neuron.2004.05.009; Hindges R, 2002, NEURON, V35, P475, DOI 10.1016/S0896-6273(02)00799-7; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; Hsieh JC, 1999, P NATL ACAD SCI USA, V96, P3546, DOI 10.1073/pnas.96.7.3546; Inoue T, 2004, CELL, V118, P795, DOI 10.1016/j.cell.2004.09.001; Liu PT, 1999, NAT GENET, V22, P361, DOI 10.1038/11932; Liu YB, 2005, NAT NEUROSCI, V8, P1151, DOI 10.1038/nn1520; Lyuksyutova AI, 2003, SCIENCE, V302, P1984, DOI 10.1126/science.1089610; Mann F, 2002, NEURON, V35, P461, DOI 10.1016/S0896-6273(02)00786-9; McLaughlin T, 2003, CURR OPIN NEUROBIOL, V13, P57, DOI 10.1016/S0959-4388(03)00014-X; Mey J, 2000, BRAIN RES REV, V32, P343, DOI 10.1016/S0165-0173(99)00022-3; Patthy L, 2000, TRENDS BIOCHEM SCI, V25, P12, DOI 10.1016/S0968-0004(99)01504-2; PRESTIGE MC, 1975, PROC R SOC SER B-BIO, V190, P77, DOI 10.1098/rspb.1975.0080; SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267; Willert K, 2003, NATURE, V423, P448, DOI 10.1038/nature01611; Yoshikawa S, 2003, NATURE, V422, P583, DOI 10.1038/nature01522	28	215	222	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 5	2006	439	7072					31	37		10.1038/nature04334	http://dx.doi.org/10.1038/nature04334			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	999HA	16280981				2022-12-28	WOS:000234378700027
J	Moser, KA; Leon, DA; Gwatkin, DR				Moser, KA; Leon, DA; Gwatkin, DR			How does progress towards the child mortality millennium development goal affect inequalities between the poorest and least poor? Analysis of Demographic and Health Survey data	BRITISH MEDICAL JOURNAL			English	Article									Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England	University of London; London School of Hygiene & Tropical Medicine	Moser, KA (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Epidemiol & Populat Hlth, London WC1E 7HT, England.	kath.moser@ons.gov.uk	Leon, David A/G-2195-2010	Leon, David A/0000-0001-9747-1762				GWATKIN DR, 2000, SOCIOECONOMIC DIFFER; Gwatkin DR., 2003, INITIAL COUNTRY LEVE; Nolen LB, 2005, B WORLD HEALTH ORGAN, V83, P597	3	68	68	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 19	2005	331	7526					1180	1182		10.1136/bmj.38659.588125.79	http://dx.doi.org/10.1136/bmj.38659.588125.79			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	988DG	16284209	Bronze, Green Accepted, Green Published			2022-12-28	WOS:000233571000019
J	Biesecker, LG; Bailey-Wilson, JE; Ballantyne, J; Baum, H; Bieber, FR; Brenner, C; Budowle, B; Butler, JM; Carmody, G; Conneally, PM; Duceman, B; Eisenberg, A; Forman, L; Kidd, KK; Leclair, B; Niezgoda, S; Parsons, TJ; Pugh, E; Shaler, R; Sherry, ST; Sozer, A; Walsh, A				Biesecker, LG; Bailey-Wilson, JE; Ballantyne, J; Baum, H; Bieber, FR; Brenner, C; Budowle, B; Butler, JM; Carmody, G; Conneally, PM; Duceman, B; Eisenberg, A; Forman, L; Kidd, KK; Leclair, B; Niezgoda, S; Parsons, TJ; Pugh, E; Shaler, R; Sherry, ST; Sozer, A; Walsh, A			Epidemiology - DNA identifications after the 9/11 World Trade Center attack	SCIENCE			English	Editorial Material							MITOCHONDRIAL-DNA; STR AMPLICONS; DISASTER; VICTIMS					leslieb@helix.nih.gov	Butler, John M./C-7812-2011; Bieber, Frederick/W-7764-2019; Biesecker, Leslie/AAG-2526-2021	Sherry, Stephen/0000-0002-7982-076X; Bailey-Wilson, Joan/0000-0002-9153-2920; Bieber, Frederick/0000-0002-2120-9829	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [Z01HG000153] Funding Source: NIH RePORTER; NATIONAL LIBRARY OF MEDICINE [Z01LM000160] Funding Source: NIH RePORTER	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		Alonso A, 2005, CROAT MED J, V46, P540; Ballantyne J, 1997, NAT GENET, V15, P329, DOI 10.1038/ng0497-329; BIEBER FR, 2002, HARVARD MED ALUMNI B, V76, P34; BIEBER FR, 2004, DNA CRIMINAL JUSTICE, P23; Brenner CH, 2003, THEOR POPUL BIOL, V63, P173, DOI 10.1016/S0040-5809(03)00008-X; Budimlija ZM, 2003, CROAT MED J, V44, P259; Budowle B, 2003, ANNU REV GENOM HUM G, V4, P119, DOI 10.1146/annurev.genom.4.070802.110352; BUDOWLE B, 1998, 2 EUR S HUM ID 1998, P73; Budowle Bruce, 2005, Legal Medicine, V7, P230, DOI 10.1016/j.legalmed.2005.01.001; Butler JM, 2003, J FORENSIC SCI, V48, P1054; Evett I. W., 1998, INTERPRETING DNA EVI; Hellmann A, 2001, INT J LEGAL MED, V114, P269, DOI 10.1007/s004140000175; Holland MM, 2003, CROAT MED J, V44, P264; Leclair B, 2004, J FORENSIC SCI, V49, P939; Olaisen B, 1997, NAT GENET, V15, P402, DOI 10.1038/ng0497-402; Parsons TJ, 2001, CROAT MED J, V42, P304; Tsukada Kazuhiko, 2002, Leg Med (Tokyo), V4, P239, DOI 10.1016/S1344-6223(02)00049-4; Wiegand P, 2001, INT J LEGAL MED, V114, P285, DOI 10.1007/s004140000162	18	92	95	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2005	310	5751					1122	1123		10.1126/science.1116608	http://dx.doi.org/10.1126/science.1116608			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GE	16293742				2022-12-28	WOS:000233437300025
J	Pedersen, TR; Faergeman, O; Kastelein, JJP; Olsson, AG; Tikkanen, MJ; Holme, I; Larsen, ML; Bendiksen, FS; Lindahl, C; Szarek, M; Tsai, J				Pedersen, TR; Faergeman, O; Kastelein, JJP; Olsson, AG; Tikkanen, MJ; Holme, I; Larsen, ML; Bendiksen, FS; Lindahl, C; Szarek, M; Tsai, J		IDEAL Study Grp	High-dose atorvastatin vs usual dose simvastatin for secondary prevention after myocardial infarction - The IDEAL study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; CHOLESTEROL REDUCTION; IMPACT; RISK	Context Evidence suggests that more intensive lowering of low-density lipoprotein cholesterol (LDL-C) than is commonly applied clinically will provide further benefit in stable coronary artery disease. Objective To compare the effects of 2 strategies of lipid lowering on the risk of cardiovascular disease among patients with a previous myocardial infarction (MI). Design, Setting, and Participants The IDEAL study, a prospective, randomized, open-label, blinded end-point evaluation trial conducted at 190 ambulatory cardiology care and specialist practices in northern Europe between March 1999 and March 2005 with a median follow-up of 4.8 years, which enrolled 8888 patients aged 80 years or younger with a history of acute MI. Interventions Patients were randomly assigned to receive a high dose of atorvastatin (80 mg/d; n=4439), or usual-dose simvastatin (20 mg/d; n=4449). Main Outcome Measure Occurrence of a major coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac arrest with resuscitation. Results During treatment, mean LDL-C levels were 104 (SE, 0.3) mg/dL in the simvastatin group and 81 (SE, 0.3) mg/dL in the atorvastatin group. A major coronary event occurred in 463 simvastatin patients (10.4%) and in 411 atorvastatin patients (9.3%) (hazard ratio [HR], 0.89; 95% Cl, 0.78-1.01; P=.07). Nonfatal acute MI occurred in 321 (7.2%) and M7 (6.0%) in the 2 groups (HR, 0.83; 95% Cl, 0.71-0.98; P=.02), but no differences were seen in the 2 other components of the primary end point. Major cardiovascular events occurred in 608 and 533 in the 2 groups, respectively (HR, 0.87; 95% Cl, 0.77-0.98; P=.02). Occurrence of any coronary event was reported in 1059 simvastatin and 898 atorvastatin patients (HR, 0.84; 95% Cl, 0.76-0.91; P<.001). Non-cardiovascular death occurred in 156 (3.5%) and 143 (3.2%) in the 2 groups (HR, 0.92; 95% Cl, 0.73-1.15; P=.47). Death from any cause occurred in 374 (8.4%) in the simvastatin group and 366 (8.2%) in the atorvastatin group (HR, 0.98; 95% Cl, 0.85-1.13; P=.81). Patients in the atorvastatin group had higher rates of drug discontinuation due to nonserious adverse events; transaminase elevation resulted in 43 (1.0%) vs 5 (0.1%) withdrawals (P<.001). Serious myopathy and rhabdomyolysis were rare in both groups. Conclusions In this study of patients with previous MI, intensive lowering of LDL-C did not result in a significant reduction in the primary outcome of major coronary events, but did reduce the risk of other composite secondary end points and nonfatal acute MI. There were no differences in cardiovascular or all-cause mortality. Patients with MI may benefit from intensive lowering of LDL-C without an increase in noncardiovascular mortality or other serious adverse reactions. Trial Registration ClinicalTrials.gov Identifier: NCT00159835.	Ullevaal Univ Hosp, Ctr Prevent Med, N-0407 Oslo, Norway; Aarhus Univ Hosp, Dept Med Cardiol A, DK-8000 Aarhus, Denmark; Acad Hosp, Amsterdam, Netherlands; Univ Hosp, Dept Internal Med, Linkoping, Sweden; Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; Pfizer Sweden, Taby, Sweden; Pfizer Inc, New York, NY USA	University of Oslo; Aarhus University; University of Helsinki; Helsinki University Central Hospital; Pfizer; Pfizer	Pedersen, TR (corresponding author), Ullevaal Univ Hosp, Ctr Prevent Med, Kirkeveien 166,Bldg 19, N-0407 Oslo, Norway.	t.r.pedersen@medisin.uio.no	Kastelein, John/AAF-7950-2020; Szarek, Michael/ABE-1965-2021	Szarek, Michael/0000-0002-0046-0264; Luotola, Kari/0000-0002-6452-0254				Baigent C, 2005, LANCET, V366, P1267, DOI 10.1016/S0140-6736(05)67394-1; Cannon CP, 2004, NEW ENGL J MED, V350, P1495, DOI 10.1056/NEJMoa040583; COX DR, 1972, J R STAT SOC B, V34, P187; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; Gould AL, 1998, CIRCULATION, V97, P946; Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; HOLME I, 1995, AM J CARDIOL, V76, pC10, DOI 10.1016/S0002-9149(99)80465-2; Koren MJ, 2004, J AM COLL CARDIOL, V44, P1772, DOI 10.1016/j.jacc.2004.07.053; LaRosa JC, 2005, NEW ENGL J MED, V352, P1425, DOI 10.1056/NEJMoa050461; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Nissen SE, 2004, JAMA-J AM MED ASSOC, V291, P1071, DOI 10.1001/jama.291.9.1071; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; Pedersen TR, 2004, AM J CARDIOL, V94, P720, DOI 10.1016/j.amjcard.2004.06.003; Pitt B, 2005, NEW ENGL J MED, V352, P1483, DOI 10.1056/NEJMe058052; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P365; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	18	1195	1280	1	104	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2437	2445		10.1001/jama.294.19.2437	http://dx.doi.org/10.1001/jama.294.19.2437			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287954	Bronze			2022-12-28	WOS:000233277400022
J	Campbell, SM; Roland, MO; Middleton, E; Reeves, D				Campbell, SM; Roland, MO; Middleton, E; Reeves, D			Improvements in quality of clinical care in English general practice 1998-2003: longitudinal observational study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OF-CARE; HEALTH-CARE; UNITED-KINGDOM; GOVERNANCE; CRITERIA; ANGINA; ASTHMA; STATES; UK	Objective To measure changes in quality of care for three major chronic diseases (coronary heart disease, asthma, and type 2 diabetes) between 1998 and 2003. Design Longitudinal cohort study. Setting 42 general practices in six geographical areas of England (Avon, Bury/Rochdale, Enfield, Oldham, Somerset, South Essex). Participants Medical record data for 2300 patients with diabetes, asthma, or coronary heart disease in 1998, and 1495 patients in 2003. Main outcome measure Quality of care assessed against predefined evidence based review criteria. Results Between 1998 and 2003, quality of care improved markedly in terms of maximum possible scores on the review criteria, from 60.5% to 78.1% for coronary heart disease (change = 17.6, 95% confidence interval 13.9 to 21.4; P < 0.001), 60.1% to 70.3% for asthma (10.2, 4.6 to 15.8; P = 0.001), and 70.4% to 77.7% for diabetes (7.3, 3.5 to 11.1; P = 0.001). Important changes occurred to several indicators potentially related to improved health outcomes. These included improved control of serum cholesterol (to <= 5 mmol/l) from 17.6% to 61.4% in coronary heart disease and from 21.5% to 52% in diabetes, and control of blood pressure to <= 150/90 in coronary heart disease from 47.3% to 72.2% and to <= 145/85 in diabetes from 21.8% to 35.8%. A small, non-significant improvement in glycaemic control occurred among diabetic patients (37.9% to 39.7% with HbA(1c) < 7.4%). Significant improvements also occurred in the recording of exercise capacity and diet and weight advice for patients with coronary heart disease; of smoking advice, peak flow, and symptoms for patients with asthma; and of creatinme, weight, and HbA(1c) for patients with diabetes. Over the five years, more improvement in coronary heart disease care occurred in large practices and practices in affluent areas. Conclusions Substantial improvements were seen in quality of care for the three conditions studied between 1998 and 2003, a time of systematic quality improvement initiatives in the NHS. The changes were most marked for coronary heart disease. English general practices could be expected to achieve high clinical quality scores in the initial year of a new contact, which provides financial incentives for-high quality care from 2004.	Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England	University of Manchester	Campbell, SM (corresponding author), Univ Manchester, Natl Primary Care Res & Dev Ctr, Manchester M13 9PL, Lancs, England.	stephen.campbell@manchester.ac.uk	Reeves, David/H-6203-2014; Greiver, Michelle/N-8764-2015	Reeves, David/0000-0001-6377-6859; Greiver, Michelle/0000-0001-8957-0285; Campbell, Stephen/0000-0002-2328-4136				Buetow SA, 1999, QUAL HEALTH CARE, V8, P184, DOI 10.1136/qshc.8.3.184; Campbell SM, 2004, QUAL SAF HEALTH CARE, V13, P115, DOI 10.1136/qshc.2003.007880; Campbell SM, 2001, BMJ-BRIT MED J, V323, P784, DOI 10.1136/bmj.323.7316.784; Campbell SM, 2002, BRIT J GEN PRACT, V52, pS12; Campbell SM, 2002, QUAL SAF HEALTH CARE, V11, P125, DOI 10.1136/qhc.11.2.125; Campbell SM, 1999, QUAL HEALTH CARE, V8, P6, DOI 10.1136/qshc.8.1.6; CAMPBELL SM, 2003, NEW PRIMARY CARE MOD, P101; Campbell Stephen, 2005, J Health Serv Res Policy, V10, P31, DOI 10.1258/1355819052801813; *DEP HLTH, 2001, NAT SERV FRAM DIAB; *DEP HLTH, 2000, NAT SERV FRAM COR HE; Ferlie EB, 2001, MILBANK Q, V79, P281, DOI 10.1111/1468-0009.00206; Holden JD, 1999, J EVAL CLIN PRACT, V5, P313, DOI 10.1046/j.1365-2753.1999.00190.x; Kirk SA, 2003, QUAL SAF HEALTH CARE, V12, P421, DOI 10.1136/qhc.12.6.421; LEATHERMAN S, 2003, QUEST QUALITY NHS; McElduff P, 2004, QUAL SAF HEALTH CARE, V13, P191, DOI 10.1136/qshc.2003.007401; McGlynn EA, 2003, NEW ENGL J MED, V348, P2635, DOI 10.1056/NEJMsa022615; *NAT PRIM CAR RES, QUAL; *NAT PRIM CAR RES, QUAL INC PRACT; Pitman EJG, 1939, BIOMETRIKA, V31, P9, DOI 10.2307/2334971; Roland M, 2004, NEW ENGL J MED, V351, P1448, DOI 10.1056/NEJMhpr041294; ROLAND MO, 2003, QUEST QUALITY NHS, P203; Seddon ME, 2001, QUAL HEALTH CARE, V10, P152, DOI 10.1136/qhc.0100152..; Solomon DH, 2000, MED CARE, V38, P383, DOI 10.1097/00005650-200004000-00005; Stevens CV, 2001, BIOMACROMOLECULES, V2, P1, DOI 10.1021/bm005642t; Stevenson K, 2001, FAM PRACT, V18, P21, DOI 10.1093/fampra/18.1.21	25	131	133	0	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1121	1123		10.1136/bmj.38632.611123.AE	http://dx.doi.org/10.1136/bmj.38632.611123.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	985ZI	16257992	Bronze, Green Published			2022-12-28	WOS:000233417300018
J	Timmins, N				Timmins, N			The NHS revolution: health care in the market place - Use of private health care in the NHS	BRITISH MEDICAL JOURNAL			English	Editorial Material									Financial Times, London SE1 9HL, England		Timmins, N (corresponding author), Kings Coll London, London WC2R 2LS, England.	Nick.Timmins@FT.com						BRAMLEYHARKER E, 2004, COMPARING PHYS EARNI; CARVEL J, 2005, GUARDIAN        0922; Department of Health, 2000, NHS IMPR PLAN; *HEALTHC COMM, 2005, DAY SURG THEATR OP O; REID J, 2005, 120 000 TREATED STAR; SHRIMSLEY R, 2001, FINANCIAL TIMES 1203; TIMMINS N, 2004, FINANCIAL TIMES 1111; TIMMINS N, 2004, FINANCIAL TIMES 0531; Timmins N., 2004, FINANCIAL TIMES 0429, P1; TIMMINS N, 2003, FINANCIAL TIMES 1110; 2005, HLTH SERV J     0120, P5	11	8	8	1	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 12	2005	331	7525					1141	1142		10.1136/bmj.331.7525.1141	http://dx.doi.org/10.1136/bmj.331.7525.1141			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	985ZI	16282412	Green Published			2022-12-28	WOS:000233417300023
J	Zhang, Y; Lu, H; Bargmann, CI				Zhang, Y; Lu, H; Bargmann, CI			Pathogenic bacteria induce aversive olfactory learning in Caenorhabditis elegans	NATURE			English	Article							C-ELEGANS; TRYPTOPHAN-HYDROXYLASE; SIGNALING PATHWAY; NEURONS; GENE; ADAPTATION; PLASTICITY; CHANNEL; MEMORY; FOOD	Food can be hazardous, either through toxicity or through bacterial infections that follow the ingestion of a tainted food source. Because learning about food quality enhances survival, one of the most robust forms of olfactory learning is conditioned avoidance of tastes associated with visceral malaise. The nematode Caenorhabditis elegans feeds on bacteria but is susceptible to infection by pathogenic bacteria in its natural environment. Here we show that C. elegans modifies its olfactory preferences after exposure to pathogenic bacteria, avoiding odours from the pathogen and increasing its attraction to odours from familiar nonpathogenic bacteria. Particular bacteria elicit specific changes in olfactory preferences that are suggestive of associative learning. Exposure to pathogenic bacteria increases serotonin in ADF chemosensory neurons by transcriptional and post-transcriptional mechanisms. Serotonin functions through MOD-1, a serotonin-gated chloride channel expressed in sensory interneurons, to promote aversive learning. An increase in serotonin may represent the negative reinforcing stimulus in pathogenic infection.	Rockefeller Univ, Howard Hughes Med Inst, Lab Neural Circuits & Behav, New York, NY 10021 USA	Howard Hughes Medical Institute; Rockefeller University	Bargmann, CI (corresponding author), Rockefeller Univ, Howard Hughes Med Inst, Lab Neural Circuits & Behav, 1230 York Ave, New York, NY 10021 USA.	cori@rockefeller.edu		Lu, Hang/0000-0002-6881-660X; Bargmann, Cornelia/0000-0002-8484-0618				Avery L, 2003, J EXP BIOL, V206, P2441, DOI 10.1242/jeb.00433; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; Bernhard N, 2000, LEARN MEMORY, V7, P199, DOI 10.1101/lm.7.4.199; Bernstein IL, 1999, NUTRITION, V15, P229, DOI 10.1016/S0899-9007(98)00192-0; CAREW TJ, 1986, ANNU REV NEUROSCI, V9, P435, DOI 10.1146/annurev.ne.09.030186.002251; Chao MY, 2004, P NATL ACAD SCI USA, V101, P15512, DOI 10.1073/pnas.0403369101; Chou JH, 2001, GENETICS, V157, P211; Colbert HA, 1997, LEARN MEMORY, V4, P179, DOI 10.1101/lm.4.2.179; COLBERT HA, 1995, NEURON, V14, P803, DOI 10.1016/0896-6273(95)90224-4; Darmaillacq AS, 2004, ANIM BEHAV, V68, P1291, DOI 10.1016/j.anbehav.2004.01.015; Duerr JS, 1999, J NEUROSCI, V19, P72, DOI 10.1523/JNEUROSCI.19-01-00072.1999; Duffy DC, 1998, ANAL CHEM, V70, P4974, DOI 10.1021/ac980656z; Estevez M, 2004, J NEUROCHEM, V88, P102, DOI 10.1046/j.1471-4159.2003.02140.x; Gershon MD, 2003, CURR OPIN PHARMACOL, V3, P600, DOI 10.1016/j.coph.2003.07.005; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; Kurz CL, 2003, NAT REV GENET, V4, P380, DOI 10.1038/nrg1067; L'Etoile ND, 2002, NEURON, V36, P1079, DOI 10.1016/S0896-6273(02)01066-8; Lints R, 1999, DEVELOPMENT, V126, P5819; Mockus SM, 1998, J MOL NEUROSCI, V10, P163, DOI 10.1007/BF02761772; Nicholas HR, 2004, MOL IMMUNOL, V41, P479, DOI 10.1016/j.molimm.2004.03.037; Nuttley WM, 2002, P NATL ACAD SCI USA, V99, P12449, DOI 10.1073/pnas.192101699; Pujol N, 2001, CURR BIOL, V11, P809, DOI 10.1016/S0960-9822(01)00241-X; Ranganathan R, 2000, NATURE, V408, P470, DOI 10.1038/35044083; Sawin ER, 2000, NEURON, V26, P619, DOI 10.1016/S0896-6273(00)81199-X; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Schwaerzel M, 2003, J NEUROSCI, V23, P10495, DOI 10.1523/jneurosci.23-33-10495.2003; Sze JY, 2000, NATURE, V403, P560, DOI 10.1038/35000609; Tan MW, 1999, P NATL ACAD SCI USA, V96, P2408, DOI 10.1073/pnas.96.5.2408; WEINSHENKER D, 1995, J NEUROSCI, V15, P6975; Wenick AS, 2004, DEV CELL, V6, P757, DOI 10.1016/j.devcel.2004.05.004; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Zhang SY, 2004, DEVELOPMENT, V131, P1629, DOI 10.1242/dev.01047	32	555	581	3	137	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					179	184		10.1038/nature04216	http://dx.doi.org/10.1038/nature04216			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281027				2022-12-28	WOS:000233133500039
J	Preall, JB; Sontheimer, EJ				Preall, JB; Sontheimer, EJ			RNAi: RISC gets loaded	CELL			English	Editorial Material							EMBRYONIC STEM-CELLS; ARGONAUTE2; COMPLEX	When an siRNA or miRNA proceeds through the RNA-induced silencing complex assembly pathway, only one of the two similar to 21-nucleotide RNA strands survives in the final, active complex. In this issue of Cell, Matranga et al. (2005) and Rand et al. (2005) reveal the fate of the rejected passenger siRNA strand. Additionally, Gregory et al. (2005) define a heterotrimeric complex from humans that appears to execute dsRNA loading, strand selection, and target mRNA cleavage activities.	Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, Evanston, IL 60208 USA	Northwestern University	Preall, JB (corresponding author), Northwestern Univ, Dept Biochem Mol Biol & Cell Biol, 2205 Tech Dr, Evanston, IL 60208 USA.			Sontheimer, Erik/0000-0002-0881-0310; Preall, Jonathan/0000-0002-7772-2437				Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023; Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Kanellopoulou C, 2005, GENE DEV, V19, P489, DOI 10.1101/gad.1248505; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Matranga C, 2005, CELL, V123, P607, DOI 10.1016/j.cell.2005.08.044; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Murchison EP, 2005, P NATL ACAD SCI USA, V102, P12135, DOI 10.1073/pnas.0505479102; Pham JW, 2005, J BIOL CHEM, V280, P39278, DOI 10.1074/jbc.M509202200; Rand TA, 2005, CELL, V123, P621, DOI 10.1016/j.cell.2005.10.020; Rose SD, 2005, NUCLEIC ACIDS RES, V33, P4140, DOI 10.1093/nar/gki732	11	76	88	2	11	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 8	2005	123	4					543	545		10.1016/j.cell.2005.11.006	http://dx.doi.org/10.1016/j.cell.2005.11.006			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286001	Bronze			2022-12-28	WOS:000233497400002
J	Conibear, E				Conibear, E			An E-MAP of the ER	CELL			English	Editorial Material							SECRETORY PATHWAY; GENES	Genome-wide phenotype mapping has the potential to provide insights into gene function on an unprecedented scale. In this issue of Cell, Schuldiner et al. (2005) show that saturation epistasis analysis of genes implicated in the early secretory pathway in yeast provides a new strategy for uncovering functional relationships using high-throughput genomic data.	Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada	Child & Family Research Institute; University of British Columbia	Conibear, E (corresponding author), Univ British Columbia, Child & Family Res Inst, Ctr Mol Med & Therapeut, Dept Med Genet, Vancouver, BC V5Z 4H4, Canada.		Conibear, Elizabeth/G-5297-2010	Conibear, Elizabeth/0000-0001-5129-0499				Carpenter AE, 2004, NAT REV GENET, V5, P11, DOI 10.1038/nrg1248; Davierwala AP, 2005, NAT GENET, V37, P1147, DOI 10.1038/ng1640; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; Kelley R, 2005, NAT BIOTECHNOL, V23, P561, DOI 10.1038/nbt1096; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Wong SL, 2005, TRENDS GENET, V21, P424, DOI 10.1016/j.tig.2005.06.006	9	3	4	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					366	368		10.1016/j.cell.2005.10.016	http://dx.doi.org/10.1016/j.cell.2005.10.016			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269327	Bronze			2022-12-28	WOS:000233264300004
J	Danielsen, F; Sorensen, MK; Olwig, MF; Selvam, V; Parish, F; Burgess, ND; Hiraishi, T; Karunagaran, VM; Rasmussen, MS; Hansen, LB; Quarto, A; Suryadiputra, N				Danielsen, F; Sorensen, MK; Olwig, MF; Selvam, V; Parish, F; Burgess, ND; Hiraishi, T; Karunagaran, VM; Rasmussen, MS; Hansen, LB; Quarto, A; Suryadiputra, N			The Asian tsunami: A protective role for coastal vegetation	SCIENCE			English	Article									NORDECO, DK-1159 Copenhagen, Denmark; Univ Copenhagen, Copenhagen, Denmark; MS Swaminathan Res Fdn, Madras 600113, Tamil Nadu, India; Global Environm Ctr, Petaling Jaya 47300, Selangor, Malaysia; Univ Cambridge, Dept Zool, Conservat Biol Grp, Cambridge, England; World Wildlife Fund, Washington, DC 20037 USA; Port & Airport Res Inst, Yokosuka, Kanagawa, Japan; Mangrove Act Project, Port Angeles, WA 98362 USA; Wetlands Int Indonesia, Bogor 16002, Indonesia	University of Copenhagen; University of Cambridge; World Wildlife Fund; Port & Airport Research Institute	Danielsen, F (corresponding author), NORDECO, Skindergade 23, DK-1159 Copenhagen, Denmark.	fd@nordeco.dk	Olwig, Mette Fog/Y-4322-2018	Olwig, Mette Fog/0000-0001-5081-6671; Rasmussen, Michael Schultz/0000-0002-7358-9421; Danielsen, Finn/0000-0003-0229-2847				CHAPMAN VJ, 1977, ECOSYSTEMS WORLD, V1, P3; FAO, 2003, STAT WORLDS FOR; HIRAISHI T, 2003, GREENBELT TSUNAMI PR; Massel SR, 1999, FLUID DYN RES, V24, P219, DOI 10.1016/S0169-5983(98)00024-0; Mumby PJ, 2004, NATURE, V427, P533, DOI 10.1038/nature02286; PARISH F, 2005, ASSESSMENT COST MANG; Valiela I, 2001, BIOSCIENCE, V51, P807, DOI 10.1641/0006-3568(2001)051[0807:MFOOTW]2.0.CO;2	7	500	536	3	258	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					643	643		10.1126/science.1118387	http://dx.doi.org/10.1126/science.1118387			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254180				2022-12-28	WOS:000232997700031
J	Hart, JT				Hart, JT			Evidence not ideology - No evidence is without ideology	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Swansea Univ, Sch Clin, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales	Swansea University	Hart, JT (corresponding author), Swansea Univ, Sch Clin, Primary Care Grp, Swansea SA2 8PP, W Glam, Wales.	julian@tudorhart.freeserve.co.uk						GODLEE F, 2005, BMJ, V331	1	1	1	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					964	964		10.1136/bmj.331.7522.964-a	http://dx.doi.org/10.1136/bmj.331.7522.964-a			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16239698	Green Published			2022-12-28	WOS:000232970900031
J	Lewis, LS				Lewis, LS			Evidence not ideology - The NHS is still working	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									Surgery, Newport SA42 0TJ, Pembrokeshire, Wales		Lewis, LS (corresponding author), Surgery, Newport SA42 0TJ, Pembrokeshire, Wales.	sarn@garthnewydd.freeserve.co.uk						GODLEE F, 2005, BMJ, V331	1	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					964	965		10.1136/bmj.331.7522.964-b	http://dx.doi.org/10.1136/bmj.331.7522.964-b			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16239697	Green Published			2022-12-28	WOS:000232970900032
J	Moschos, MM; Brouzas, D; Mezitis, M; Zachariadis, N				Moschos, MM; Brouzas, D; Mezitis, M; Zachariadis, N			Visual loss due to a carious tooth	LANCET			English	Editorial Material							ORBITAL CELLULITIS; INFECTIONS; DIAGNOSIS		Univ Athens, Dept Ophthalmol, Athens 11527, Greece; KAT Gen Hosp Athens, Dept Oral & Maxillofacial Surg, Athens 14561, Greece	National & Kapodistrian University of Athens	Moschos, MM (corresponding author), Univ Athens, Dept Ophthalmol, 154 Mesogion Ave, Athens 11527, Greece.	moschosmarilita@yahoo.fr						BULLOCK JD, 1985, J ORAL MAXIL SURG, V43, P749, DOI 10.1016/0278-2391(85)90328-3; GOLD RS, 1974, J ORAL SURG, V32, P40; JANAKARAJAH N, 1985, BRIT J ORAL MAX SURG, V23, P140, DOI 10.1016/0266-4356(85)90065-8; ORYAN F, 1988, J ORAL MAXIL SURG, V46, P991, DOI 10.1016/0278-2391(88)90336-9; Rosen D, 2000, Int J Paediatr Dent, V10, P237, DOI 10.1046/j.1365-263x.2000.00198.x	5	6	6	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1504	1504		10.1016/S0140-6736(05)67602-7	http://dx.doi.org/10.1016/S0140-6736(05)67602-7			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243096				2022-12-28	WOS:000232724600030
J	Rollnick, S; Butler, CC; McCambridge, J; Kinnersley, P; Elwyn, G; Resnicow, K				Rollnick, S; Butler, CC; McCambridge, J; Kinnersley, P; Elwyn, G; Resnicow, K			Consultations about changing behaviour	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							PRIMARY-CARE; HEALTH PROMOTION; METAANALYSIS; EFFICACY; OUTCOMES; TRIAL; RISK	Persuading patients to change behaviour that is damaging their health can be difficult. Changing the style of consultation could improve the experience for doctors and patients.	Cardiff Univ, Dept Gen Practice, Ctr Hlth Sci Res, Cardiff CF14 4XN, Wales; Kings Coll London, Inst Psychiat, Natl Addict Ctr, London SE5 8AF, England; Univ Michigan, Hlth Behav & Hlth Educ Sch Publ Hlth, Ann Arbor, MI 48109 USA	Cardiff University; University of London; King's College London; University of Michigan System; University of Michigan	Rollnick, S (corresponding author), Cardiff Univ, Dept Gen Practice, Ctr Hlth Sci Res, Cardiff CF14 4XN, Wales.	rollnick@cf.ac.uk	Elwyn, Glyn/B-4798-2009; Butler, Christopher C/B-5048-2009; Elwyn, G./L-4292-2015	Elwyn, Glyn/0000-0002-0917-6286; Butler, Christopher/0000-0002-0102-3453; McCambridge, Jim/0000-0002-5461-7001				Amrhein PC, 2003, J CONSULT CLIN PSYCH, V71, P862, DOI 10.1037/0022-006X.71.5.862; Britt E, 2004, PATIENT EDUC COUNS, V53, P147, DOI 10.1016/S0738-3991(03)00141-1; Burke BL, 2003, J CONSULT CLIN PSYCH, V71, P843, DOI 10.1037/0022-006X.71.5.843; Conner DB, 2003, BRIT J DEV PSYCHOL, V21, P315, DOI 10.1348/026151003322277720; Department of Health, 2004, CHOOS HLTH MAK HLTH; DiClemente C.C., 2002, MOTIVATIONAL INTERVI, V2nd ed., P201; Elwyn G, 1999, BRIT J GEN PRACT, V49, P477; ELWYN G, 2005, HLTH EXPECT, V7, P1; Gabbay J, 2004, BRIT MED J, V329, P1013, DOI 10.1136/bmj.329.7473.1013; Goldstein MG, 2004, AM J PREV MED, V27, P61, DOI 10.1016/j.amepre.2004.04.023; Gosden T, 2001, J Health Serv Res Policy, V6, P44, DOI 10.1258/1355819011927198; HODGSON R, 1992, PROJECT IDENTIFICATI, P172; Hustedt JT, 2002, INT J BEHAV DEV, V26, P113, DOI 10.1080/01650250042000636; Kok G, 1997, PATIENT EDUC COUNS, V30, P19, DOI 10.1016/S0738-3991(96)00953-6; Lancaster T, 2005, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001292.pub2, 10.1002/14651858.CD001292.pub3]; Lane C, 2005, PATIENT EDUC COUNS, V56, P166, DOI 10.1016/j.pec.2004.01.003; Lane C., 2003, PRACTICAL DIABETES I, V20, P204, DOI [10.1002/pdi.503, DOI 10.1002/PDI.503]; Marteau TM, 2001, BMJ-BRIT MED J, V322, P1056, DOI 10.1136/bmj.322.7293.1056; Miller WR, 2004, J CONSULT CLIN PSYCH, V72, P1050, DOI 10.1037/0022-006X.72.6.1050; MILLER WR, 1993, J CONSULT CLIN PSYCH, V61, P455, DOI 10.1037/0022-006X.61.3.455; Pill R, 1998, FAM PRACT, V15, P229, DOI 10.1093/fampra/15.3.229; PROCHASKA JO, 1992, AM PSYCHOL, V47, P1102, DOI 10.1037/0003-066X.47.9.1102; Rollnick S., 1999, HLTH BEHAV CHANGE GU, V1st; Rubak S, 2005, BRIT J GEN PRACT, V55, P305; Schneider CE, 1998, PRACTICE AUTONOMY PA; STOTT NCH, 1990, FAM PRACT, V7, P125, DOI 10.1093/fampra/7.2.125	26	102	102	2	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 22	2005	331	7522					961	963		10.1136/bmj.331.7522.961	http://dx.doi.org/10.1136/bmj.331.7522.961			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979UR	16239696	Green Published, Green Submitted, Green Accepted			2022-12-28	WOS:000232970900029
J	Chang, Q; Hoefs, S; van der Kemp, AW; Topala, CN; Bindels, RJ; Hoenderop, JG				Chang, Q; Hoefs, S; van der Kemp, AW; Topala, CN; Bindels, RJ; Hoenderop, JG			The beta-glucuronidase klotho hydrolyzes and activates the TRPV5 channel	SCIENCE			English	Article							BONE-DENSITY; GENE; GLYCOSYLATION; RELEASE; KIDNEY; CELL	Blood calcium concentration is maintained within a narrow range despite large variations in dietary input and body demand. The Transient Receptor Potential ion channel TRPV5 has been implicated in this process. We report here that TRPV5 is stimulated by the mammalian hormone klotho. Klotho, a beta-glucuronidase, hydrolyzes extracellular sugar residues on TRPV5, entrapping the channel in the plasma membrane. This maintains durable calcium channel activity and membrane calcium permeability in kidney. Thus, klotho activates a cell surface channel by hydrolysis of its extracellular N-linked oligosaccharides.	Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands	Radboud University Nijmegen	Hoenderop, JG (corresponding author), Radboud Univ Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Physiol, NL-6500 HB Nijmegen, Netherlands.	J.Hoenderop@ncmls.ru.nl	Hoenderop, Joost G.J./H-8047-2014; Bindels, René JM/B-9824-2013	Hoenderop, Joost G.J./0000-0002-1816-8544; Bindels, René JM/0000-0003-1167-1339				Aizawa H, 1998, BIOCHEM BIOPH RES CO, V249, P865, DOI 10.1006/bbrc.1998.9246; BINDELS RJM, 1991, AM J PHYSIOL, V261, pF799, DOI 10.1152/ajprenal.1991.261.5.F799; BRZOBOHATY B, 1993, SCIENCE, V262, P1051, DOI 10.1126/science.8235622; CARSON DD, 1990, J BIOL CHEM, V265, P2947; Clapham DE, 2003, NATURE, V426, P517, DOI 10.1038/nature02196; Henrissat B, 1996, BIOCHEM J, V316, P695, DOI 10.1042/bj3160695; Hoenderop JGJ, 2005, PHYSIOL REV, V85, P373, DOI 10.1152/physrev.00003.2004; Hoenderop JGJ, 2003, J CLIN INVEST, V112, P1906, DOI 10.1172/JCI200319826; Hoenderop JGJ, 2003, EMBO J, V22, P776, DOI 10.1093/emboj/cdg080; Imura A, 2004, FEBS LETT, V565, P143, DOI 10.1016/j.febslet.2004.03.090; Kawano KI, 2002, J BONE MINER RES, V17, P1744, DOI 10.1359/jbmr.2002.17.10.1744; Kuroo M, 1997, NATURE, V390, P45, DOI 10.1038/36285; Nilius B, 2000, J PHYSIOL-LONDON, V527, P239, DOI 10.1111/j.1469-7793.2000.00239.x; Ogata N, 2002, BONE, V31, P37, DOI 10.1016/S8756-3282(02)00786-X; Schiffmann R, 2002, DRUGS, V62, P733, DOI 10.2165/00003495-200262050-00002; Tohyama O, 2004, J BIOL CHEM, V279, P9777, DOI 10.1074/jbc.M312392200; Tsujikawa H, 2003, MOL ENDOCRINOL, V17, P2393, DOI 10.1210/me.2003-0048; Wells L, 2001, SCIENCE, V291, P2376, DOI 10.1126/science.1058714; Wittstock U, 2002, TRENDS PLANT SCI, V7, P263, DOI 10.1016/S1360-1385(02)02273-2	19	483	502	1	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					490	493		10.1126/science.1114245	http://dx.doi.org/10.1126/science.1114245			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239475				2022-12-28	WOS:000232786000046
J	Oliver, WD; Yu, Y; Lee, JC; Berggren, KK; Levitov, LS; Orlando, TP				Oliver, WD; Yu, Y; Lee, JC; Berggren, KK; Levitov, LS; Orlando, TP			Mach-Zehnder interferometry in a strongly driven superconducting qubit	SCIENCE			English	Article							MACROSCOPIC QUANTUM STATES; PHOTON; OSCILLATIONS; SUPERPOSITION; DYNAMICS; PULSE	We demonstrate Mach-Zehnder-type interferometry in a superconducting flux qubit. The qubit is a tunable artificial atom, the ground and excited states of which exhibit an avoided crossing. Strongly driving the qubit with harmonic excitation sweeps it through the avoided crossing two times per period. Because the induced Landau-Zener transitions act as coherent beamsplitters, the accumulated phase between transitions, which varies with microwave amplitude, results in quantum interference fringes for n = 1 to 20 photon transitions. The generalization of optical Mach-Zehnder interferometry, performed in qubit phase space, provides an alternative means to manipulate and characterize the qubit in the strongly driven regime.	MIT, Lincoln Lab, Lexington, MA 02420 USA; MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA	Lincoln Laboratory; Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Oliver, WD (corresponding author), MIT, Lincoln Lab, 244 Wood St, Lexington, MA 02420 USA.	oliver@ll.mit.edu		Levitov, Leonid/0000-0002-4268-731X				BARUCH MC, 1992, PHYS REV LETT, V68, P3515, DOI 10.1103/PhysRevLett.68.3515; Berkley AJ, 2003, SCIENCE, V300, P1548, DOI 10.1126/science.1084528; Chiorescu I, 2004, NATURE, V431, P159, DOI 10.1038/nature02831; Chiorescu I, 2003, SCIENCE, V299, P1869, DOI 10.1126/science.1081045; Claudon J, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.187003; Friedman JR, 2000, NATURE, V406, P43, DOI 10.1038/35017505; Fujisawa T, 1997, JPN J APPL PHYS 1, V36, P4000, DOI 10.1143/JJAP.36.4000; KOUWENHOVEN LP, 1994, PHYS REV LETT, V73, P3443, DOI 10.1103/PhysRevLett.73.3443; Makhlin Y, 2001, REV MOD PHYS, V73, P357, DOI 10.1103/RevModPhys.73.357; McDermott R, 2005, SCIENCE, V307, P1299, DOI 10.1126/science.1107572; NAKAMURA H, 2001, NONADIABATIC TRANSIT; Nakamura Y, 1999, J SUPERCOND, V12, P799, DOI 10.1023/A:1007793228293; Nakamura Y, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.246601; Nakamura Y, 1999, NATURE, V398, P786, DOI 10.1038/19718; Nielsen Michael A., 2002, QUANTUM COMPUTATION; Orlando TP, 1999, PHYS REV B, V60, P15398, DOI 10.1103/PhysRevB.60.15398; Pashkin YA, 2003, NATURE, V421, P823, DOI 10.1038/nature01365; Saito S, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.037001; Shytov AV, 2003, EUR PHYS J B, V36, P263, DOI 10.1140/epjb/e2003-00343-8; Siddiqi I, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.207002; van der Wal CH, 2000, SCIENCE, V290, P773, DOI 10.1126/science.290.5492.773; Vion D, 2002, SCIENCE, V296, P886, DOI 10.1126/science.1069372; Wallraff A, 2004, NATURE, V431, P162, DOI 10.1038/nature02851; Yamamoto T, 2003, NATURE, V425, P941, DOI 10.1038/nature02015; YOAKUM S, 1992, PHYS REV LETT, V69, P1919, DOI 10.1103/PhysRevLett.69.1919; Yu Y, 2002, SCIENCE, V296, P889, DOI 10.1126/science.1069452	27	345	351	3	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 9	2005	310	5754					1653	1657		10.1126/science.1119678	http://dx.doi.org/10.1126/science.1119678			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	993NV	16282527	Green Submitted			2022-12-28	WOS:000233961700037
J	Prosnitz, D				Prosnitz, D			Science and law - WMD sensors - Search and seizure	SCIENCE			English	Editorial Material									Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Prosnitz, D (corresponding author), Lawrence Livermore Natl Lab, Livermore, CA 94550 USA.	dp@llnl.gov						ARONOV R, 2004, QUINNUIPAC L REV, V22, P785; ARONOV RF, 2004, QLR, V22, P769	2	7	7	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					978	978		10.1126/science.1115536	http://dx.doi.org/10.1126/science.1115536			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284165				2022-12-28	WOS:000233343400028
J	Filardi, CE; Moyle, RG				Filardi, CE; Moyle, RG			Single origin of a pan-Pacific bird group and upstream colonization of Australasia	NATURE			English	Article							BIOGEOGRAPHY; ISLANDS; EVOLUTION; MODEL	Oceanic islands have long served as natural laboratories for understanding the diversification of life(1-4). In particular, the many thousands of islands spanning the tropical Pacific support an unparalleled array of terrestrial communities whose patterns of diversity contributed fundamental insights to the development of classical speciation and biogeographic theory(4-8). Much of this work is founded on an assumption derived from traditional taxonomic approaches, namely that faunas on these widely separated archipelagos stem from a simple one-way, downstream flow of colonists from continents to islands(2,4). Here we show, with the use of molecular phylogenetic data from one of the original bird families used to justify this assumption, that a diverse array of endemic island genera and species are the product of a single radiation that diversified across all major Pacific archipelagos in a non-stepping-stone fashion, and recently recolonized continental areas. The geographic scope and lineage-specific approach of this study reveal evolutionary patterns long obscured by traditional taxonomic surveys and indicate thatwidely dispersed archipelagos can be sources of biological diversity.	Amer Museum Nat Hist, Dept Ornithol, New York, NY 10024 USA	American Museum of Natural History (AMNH)	Filardi, CE (corresponding author), Amer Museum Nat Hist, Ctr Biodivers & Conservat, Cent Pk W & 79th St, New York, NY 10024 USA.	filardi@amnh.org						Cibois A, 2004, CONDOR, V106, P837, DOI 10.1650/7491; DIAMOND JM, 1977, SYST ZOOL, V26, P263, DOI 10.2307/2412673; Drovetski SV, 2004, P ROY SOC B-BIOL SCI, V271, P545, DOI 10.1098/rspb.2003.2638; Farris JS, 1995, SYST BIOL, V44, P570, DOI 10.2307/2413663; Filardi CE, 2005, MOL PHYLOGENET EVOL, V37, P776, DOI 10.1016/j.ympev.2005.02.007; FJELDSA J, 2002, TRENDS ECOL EVOL, V17, P292; Gillespie RG, 2002, J BIOGEOGR, V29, P655, DOI 10.1046/j.1365-2699.2002.00714.x; Grant PR, 2001, OIKOS, V92, P385, DOI 10.1034/j.1600-0706.2001.920301.x; Hall Robert, 1998, P99; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Lack D., 1947, DARWINS FINCHES; LOMOLINO MV, 1986, BIOL J LINN SOC, V28, P1, DOI 10.1111/j.1095-8312.1986.tb01746.x; MAC ARTHUR ROBERT H., 1967; Mayr E., 2001, BIRDS NO MELANESIA S; Mayr E, 1942, SYSTEMATICS ORIGIN S; MAYR ERNST, 1939, PROC 6TH PACIFIC SCI CONGR, V4, P197; OLSON S L, 1980, Notornis, V27, P7; Posada D, 1998, BIOINFORMATICS, V14, P817, DOI 10.1093/bioinformatics/14.9.817; Ricklefs RE, 2001, SCIENCE, V294, P1522, DOI 10.1126/science.1065005; Slikas B, 2000, AUK, V117, P355, DOI 10.1642/0004-8038(2000)117[0355:PROMWE]2.0.CO;2; Spironello M, 2003, J BIOGEOGR, V30, P1563, DOI 10.1046/j.1365-2699.2003.00945.x; STEADMAN DW, 1993, P NATL ACAD SCI USA, V90, P818, DOI 10.1073/pnas.90.3.818; STEADMAN DW, 1995, SCIENCE, V267, P1123, DOI 10.1126/science.267.5201.1123; Swofford D.L., 2002, PAUP PHYLOGENETIC AN; TARR CL, 1993, AUK, V110, P825, DOI 10.2307/4088636; Wallace AR, 1855, ANN MAGAZINE NATURAL, V16, P184, DOI DOI 10.1080/037454809495509; Ward SA, 2000, GLOBAL ECOL BIOGEOGR, V9, P7, DOI 10.1046/j.1365-2699.2000.00196.x; WILSON EO, 1959, EVOLUTION, V13, P122, DOI 10.1111/j.1558-5646.1959.tb02996.x; Wright SD, 2000, P NATL ACAD SCI USA, V97, P4118, DOI 10.1073/pnas.050351197	30	166	174	0	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					216	219		10.1038/nature04057	http://dx.doi.org/10.1038/nature04057			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281034				2022-12-28	WOS:000233133500047
J	Olson, EL; Allen, RM				Olson, EL; Allen, RM			The deterministic nature of earthquake rupture	NATURE			English	Article							SEISMIC NUCLEATION PHASE; SOUTHERN CALIFORNIA; 1994 NORTHRIDGE; GROUND-MOTION; SIZE; RIDGECREST; MAGNITUDE; FORESHOCK; SEQUENCE; STRESS	Understanding the earthquake rupture process is central to our understanding of fault systems and earthquake hazards. Multiple hypotheses concerning the nature of fault rupture have been proposed but no unifying theory has emerged(1-12). The conceptual hypothesis most commonly cited is the cascade model for fault rupture(1,3,10,13). In the cascade model, slip initiates on a small fault patch and continues to rupture further across a fault plane as long as the conditions are favourable. Two fundamental implications of this domino-like theory are that small earthquakes begin in the same manner as large earthquakes and that the rupture process is not deterministic - that is, the size of the earthquake cannot be determined until the cessation of rupture. Here we show that the frequency content of radiated seismic energy within the first few seconds of rupture scales with the final magnitude of the event. We infer that the magnitude of an earthquake can therefore be estimated before the rupture is complete. This finding implies that the rupture process is to some degree deterministic and has implications for the physics of the rupture process.	Univ Calif Berkeley, Dept Earth & Planetary Sci, Berkeley, CA 94720 USA; Univ Wisconsin, Dept Geol & Geophys, Madison, WI 53706 USA	University of California System; University of California Berkeley; University of Wisconsin System; University of Wisconsin Madison	Allen, RM (corresponding author), Univ Calif Berkeley, Dept Earth & Planetary Sci, 307 McCone Hall, Berkeley, CA 94720 USA.	rallen@berkeley.edu	Allen, Richard/H-8493-2016	Allen, Richard/0000-0003-4293-9772				ABERCROMBIE R, 1994, B SEISMOL SOC AM, V84, P725; Allen RM, 2003, SCIENCE, V300, P786, DOI 10.1126/science.1080912; Beroza GC, 1996, TECTONOPHYSICS, V261, P209, DOI 10.1016/0040-1951(96)00067-4; BRUNE JN, 1979, J GEOPHYS RES, V84, P2195, DOI 10.1029/JB084iB05p02195; DAS S, 1983, NATURE, V305, P621, DOI 10.1038/305621a0; Dodge DA, 1996, J GEOPHYS RES-SOL EA, V101, P22371, DOI 10.1029/96JB02269; Eberhart-Phillips D, 2003, SCIENCE, V300, P1113, DOI 10.1126/science.1082703; Ellsworth WL, 1998, GEOPHYS RES LETT, V25, P401, DOI 10.1029/97GL53700; ELLSWORTH WL, 1995, SCIENCE, V268, P851, DOI 10.1126/science.268.5212.851; FUKAO Y, 1985, PHYS EARTH PLANET IN, V37, P149, DOI 10.1016/0031-9201(85)90048-2; Kanamori H, 2004, P JPN ACAD B-PHYS, V80, P297, DOI 10.2183/pjab.80.297; KANAMORI H, 1977, J GEOPHYS RES, V82, P2981, DOI 10.1029/JB082i020p02981; Kanamori H, 1999, B SEISMOL SOC AM, V89, P311; Kilb D, 1999, J SEISMOL, V3, P409, DOI 10.1023/A:1009890329925; LOCKMAN A, IN PRESS B SEISMOL S; Mai PM, 2005, B SEISMOL SOC AM, V95, P965, DOI 10.1785/0120040111; Mori J, 1996, B SEISMOL SOC AM, V86, P805; Mori J, 1996, GEOPHYS RES LETT, V23, P2437, DOI 10.1029/96GL02491; Nakamura Y., 1988, P 9 WORLD C EARTHQ E, P673; Nielsen SB, 2000, PURE APPL GEOPHYS, V157, P2029, DOI 10.1007/PL00001073; Oglesby DD, 2002, B SEISMOL SOC AM, V92, P3006, DOI 10.1785/0120010249; Ohnaka M, 2000, PURE APPL GEOPHYS, V157, P2259, DOI 10.1007/PL00001084; Sato T, 1999, B SEISMOL SOC AM, V89, P80; Singh SK, 1998, B SEISMOL SOC AM, V88, P1171; Somerville P., 1999, SEISMOL RES LETT, V70, P59, DOI [10.1785/gssrl.70.1.59, DOI 10.1785/GSSRL.70.1.59]; Steacy SJ, 1998, GEOPHYS J INT, V133, pF11, DOI 10.1046/j.1365-246X.1998.1331548.x; WELLS DL, 1994, B SEISMOL SOC AM, V84, P974; Zhou Y., 2004, P 13 WORLD C EARTHQU	28	188	210	1	25	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					212	215		10.1038/nature04214	http://dx.doi.org/10.1038/nature04214			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281033				2022-12-28	WOS:000233133500046
J	Dove-Edwin, I; Sasieni, P; Adams, J; Thomas, HJW				Dove-Edwin, I; Sasieni, P; Adams, J; Thomas, HJW			Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							COLON-CANCER; RISK; RECOMMENDATIONS; RELATIVES; ADENOMAS	Objective To determine to what extent individuals with various family histories of colorectal cancer (from one to three or more affected first degree relatives) benefit from colonoscopic surveillance. Design Prospective, observational study of high risk families, followed up over 16 years. Setting Tertiary referral family cancer clinic in London. Participants 1678 individuals from families registered with the clinic. Individuals were classified according to the strength of their family history: hereditary non-polyposis colorectal cancer (if they fulfilled the Amsterdam criteria), and one, two, or three affected first degree relatives (moderate risk). Interventions Colonoscopy was initially offered at five year intervals or three year intervals if an adenoma was detected. Main outcome measures The incidence of adenomas with high risk pathological features or cancer. This was analysed by age, the extent of the family history, and findings or previous colonoscopies. The cohort was flagged for cancer and death. Incidence of colorectal cancer and mortality during over 15 000 person years of follow-up were compared with those expected in the absence of surveillance. Results High risk adenomas and cancer were most common in families with hereditary non-polyposis colorectal cancer (on initial colonoscopy 5.7% and 0.9%, respectively). In the families with moderate risk, these findings were particularly uncommon under age 45 (1.1% and 0%) and on follow-up colonoscopy if advanced neoplasia was absent initially (1.7% and 0.1%). The incidence of colorectal cancer was substantially lower-80% in families with moderate risk (P = 0.00004), and 43% in families with hereditary non-polyposis colorectal cancer (P = 0.06)-than the expected incidence in the absence of surveillance when the family history was taken into account. Conclusions Colonoscopic surveillance reduces the risk of colorectal cancer in people with a strong family history, This study confirms that members of families with hereditary non-polyposis colorectal cancer require surveillance with short intervals. Individuals with a lesser family history may not require surveillance under age 45, and if advanced neoplasia is absent on initial colonoscopy, surveillance intervals may be lengthened. This would reduce the demand for colonoscopic surveillance.	Wolfson Inst Prevent Med, Canc Res UK Ctr Epidemiol Math & Stat, London EC1M 6BQ, England; St Marks Hosp, Family Canc Grp, Canc Res UK Colorectal Canc Unit, Harrow HA1 3UJ, Middx, England	Cancer Research UK; University of London; Queen Mary University London; Imperial College London	Sasieni, P (corresponding author), Wolfson Inst Prevent Med, Canc Res UK Ctr Epidemiol Math & Stat, London EC1M 6BQ, England.	peter.sasieni@cancer.org.uk		Sasieni, Peter/0000-0003-1509-8744				Bradshaw N, 2003, GUT, V52, P1748, DOI 10.1136/gut.52.12.1748; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P915, DOI 10.1001/jama.277.11.915; Burt RW, 2000, GASTROENTEROLOGY, V119, P837, DOI 10.1053/gast.2000.16508; FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501; HOULSTON RS, 1990, BRIT MED J, V301, P366, DOI 10.1136/bmj.301.6748.366; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; LOVETT E, 1976, BRIT J SURG, V63, P13, DOI 10.1002/bjs.1800630103; Lynch HT, 1999, J MED GENET, V36, P801; LYNCH HT, 1995, SEMIN SURG ONCOL, V11, P406, DOI 10.1002/ssu.2980110607; *NAT STAT, 2001, CANC STAT REGIS MN1, V28; Rijcken FEM, 2002, GUT, V50, P382, DOI 10.1136/gut.50.3.382; Sasieni P, 2003, EPIDEMIOLOGY, V14, P108, DOI 10.1097/00001648-200301000-00026; STJOHN DJB, 1993, ANN INTERN MED, V118, P785, DOI 10.7326/0003-4819-118-10-199305150-00005; Weber T, 1996, LANCET, V348, P465, DOI 10.1016/S0140-6736(05)64545-X; Winawer SJ, 1996, NEW ENGL J MED, V334, P82, DOI 10.1056/NEJM199601113340204	15	148	150	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2005	331	7524					1047	1049		10.1136/bmj.38606.794560.EB	http://dx.doi.org/10.1136/bmj.38606.794560.EB			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16243849	Green Published, Bronze			2022-12-28	WOS:000233211200017
J	King, H; Keuky, L; Seng, S; Khun, T; Roglic, G; Pinget, M				King, H; Keuky, L; Seng, S; Khun, T; Roglic, G; Pinget, M			Diabetes and associated disorders in Cambodia: two epidemiological surveys	LANCET			English	Article							IMPAIRED GLUCOSE-TOLERANCE; GLOBAL BURDEN; PREVALENCE; MORTALITY; INDIA	Background The Asia-Pacific region is thought to be severely affected by diabetes. However, reliable, standardised data on prevalence and characteristics of glucose. intolerance in Asian populations remain sparse. We describe the results of two field surveys undertaken in Cambodia in 2004. Methods 2246 randomly selected adults aged 25 years and older were examined in two communities, one rural (Siemreap) and one semi-urban (Kampong Cham). The diagnosis of diabetes and impaired glucose tolerance was based on 2-h blood glucose estimation using criteria recommended by the latest report of a WHO Expert Group. Blood pressure, anthropometry, habitual diet, and other relevant characteristics were also recorded. Findings Prevalence of diabetes was 5% in Siemreap and 11% in Kampong Cham. Prevalence of impaired glucose tolerance was 10% in Siemreap and 15% in Kampong Cham. About two-thirds of all cases of diabetes were undiagnosed before the survey. Prevalence of hypertension was 12% at Siemreap and 25% at Kampong Cham. People in Kampong Cham had higher estimates of central obesity than those in Siemreap. Interpretation Diabetes and hypertension are not uncommon in Cambodia. A quarter of all adults in the chosen suburban community had some degree of glucose intolerance. Since Cambodian society is relatively poor, and lifestyle is fairly traditional by international standards, these findings are unexpected.	Ctr Europeen Etud Diabet, F-67200 Strasbourg, France; Cambodian Diabet Assoc, Phnom Penh, Cambodia; WHO, Dept Chron Dis & Hlth Promot, CH-1211 Geneva, Switzerland	World Health Organization	Pinget, M (corresponding author), Ctr Europeen Etud Diabet, F-67200 Strasbourg, France.	association-ceed@wanadoo.fr		Roglic, Gojka/0000-0003-0872-0689				Aekplakorn W, 2003, DIABETES CARE, V26, P2758, DOI 10.2337/diacare.26.10.2758; [Anonymous], 1995, PHYS STAT US INT ANT; Cameron AJ, 2004, ENDOCRIN METAB CLIN, V33, P351, DOI 10.1016/j.ecl.2004.03.005; *DECODE STUD GROUP, 1998, BMJ-BRIT MED J, V3, P371; *GOV CAMB NAT I ST, 2004, CAMB INT POP SURV; International Diabetes Federation, 2000, DIAB ATL 2000; KING H, 1993, DIABETES CARE, V16, P157, DOI 10.2337/diacare.16.1.157; King H, 1998, DIABETES CARE, V21, P1414, DOI 10.2337/diacare.21.9.1414; Lemeshow S., 1990, TITLE ADEQUACY SAMPL; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; Qiao Q, 2000, DIABETOLOGIA, V43, P1470, DOI 10.1007/s001250051557; Ramachandran A, 2001, DIABETOLOGIA, V44, P1094, DOI 10.1007/s001250100627; Roglic G, 2005, DIABETES CARE, V28, P2130, DOI 10.2337/diacare.28.9.2130; Shaw JE, 2003, MED J AUSTRALIA, V179, P379, DOI 10.5694/j.1326-5377.2003.tb05599.x; *US AG INT DEV MIS, QUICK FACTS; Watkins LO, 2004, CLIN CARDIOL, V27, P2, DOI 10.1002/clc.4960271503; *WHO, 1999, WHONCDNCS991; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; *WORLD BANK, 2004, GNI CAP; World Health Organisation, 1996, WHO TECHN REP SER, V862; World Health Organization, 1999, WHONCDNCS992; *WORLD HLTH INF SY, DISMOD II; Yajnik CS, 2004, J NUTR, V134, P205, DOI 10.1093/jn/134.1.205	23	70	70	0	9	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1633	1639		10.1016/S0140-6736(05)67662-3	http://dx.doi.org/10.1016/S0140-6736(05)67662-3			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271644				2022-12-28	WOS:000233047100024
J	Grubb, PJ; Metcalfe, DJ; Coomes, D				Grubb, PJ; Metcalfe, DJ; Coomes, D			Comment on "A brief history of seed size"	SCIENCE			English	Editorial Material							RAIN-FOREST; LEAF SIZE; PHYLOGENY		Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Commonwealth Sci & Ind Res Org, Sustainable Ecosyst & Rainforest Cooperat Res Ctr, Trop Forest Res Ctr, Atherton, Qld 4883, Australia	University of Cambridge; Commonwealth Scientific & Industrial Research Organisation (CSIRO)	Grubb, PJ (corresponding author), Univ Cambridge, Dept Plant Sci, Downing St, Cambridge CB2 3EA, England.	pjg12@cam.ac.uk	Ackerly, David/A-1247-2009; Coomes, David/H-5630-2011; Metcalfe, Daniel J/G-3305-2010; Webb, Campbell/B-1488-2009	Ackerly, David/0000-0002-1847-7398; Metcalfe, Daniel J/0000-0001-6853-7072; Webb, Campbell/0000-0003-1031-3249; Coomes, David/0000-0002-8261-2582; Westoby, Mark/0000-0001-7690-4530				Ackerly DD, 1998, AM NAT, V152, P767, DOI 10.1086/286208; Ashton P. S., 1982, Flora Malesiana, I, Spermatophyta, V9, P237; Charnov Eric L., 1993, P1; COOPER W, 2004, FRUITS AUSTR TROPICA; CORNER EJH, 1949, ANN BOT-LONDON, V13, P367, DOI 10.1093/oxfordjournals.aob.a083225; Grubb PJ, 1998, OIKOS, V82, P467, DOI 10.2307/3546368; Grubb PJ, 1996, FUNCT ECOL, V10, P512, DOI 10.2307/2389944; Kamiya K, 2005, AM J BOT, V92, P775, DOI 10.3732/ajb.92.5.775; Koenker R., 1994, ASYMPTOTIC STAT, P349, DOI [10.1007/978-3-642-57984-4_29, DOI 10.1007/978-3-642-57984-4_29]; Moles AT, 2005, SCIENCE, V307, P576, DOI 10.1126/science.1104863; Newman M. F., 1995, MANUALS DIPTEROCARPS; Westoby M, 2003, OECOLOGIA, V135, P621, DOI 10.1007/s00442-003-1231-6	12	22	27	0	34	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					783A	783A		10.1126/science.1116097	http://dx.doi.org/10.1126/science.1116097			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272102				2022-12-28	WOS:000233121800022
J	Sur, M; Rubenstein, JLR				Sur, M; Rubenstein, JLR			Patterning and plasticity of the cerebral cortex	SCIENCE			English	Review							CAT VISUAL-CORTEX; OCULAR DOMINANCE COLUMNS; DENDRITIC SPINES; ORIENTATION SELECTIVITY; FOREBRAIN DEVELOPMENT; MUTANT MICE; THALAMOCORTICAL PROJECTIONS; HORIZONTAL CONNECTIONS; CORTICAL AREAS; IN-VIVO	The cerebral cortex of the human brain is a sheet of about 10 billion neurons divided into discrete subdivisions or areas that process particular aspects of sensation, movement, and cognition, Recent evidence has begun to transform our understanding of how cortical areas form, make specific connections with other brain regions, develop unique processing networks, and adapt to changes in inputs.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; Univ Calif San Francisco, Nina Ireland Lab Dev Neurobiol, San Francisco, CA 94143 USA	Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	Sur, M (corresponding author), MIT, Dept Brain & Cognit Sci, 77 Massachusetts Ave,46-6237, Cambridge, MA 02139 USA.	msur@mit.edu; john.rubenstein@ucsf.edu						Anderson RM, 2002, DEVELOPMENT, V129, P4975; ANTONINI A, 1993, SCIENCE, V260, P1819, DOI 10.1126/science.8511592; Aoto K, 2002, DEV BIOL, V251, P320, DOI 10.1006/dbio.2002.0811; Berardi N, 2003, TRENDS NEUROSCI, V26, P369, DOI 10.1016/S0166-2236(03)00168-1; Bishop KM, 2003, J COMP NEUROL, V457, P345, DOI 10.1002/cne.10550; Bishop KM, 2002, J NEUROSCI, V22, P7627; Bishop KM, 2000, SCIENCE, V288, P344, DOI 10.1126/science.288.5464.344; Blackshear PJ, 2003, DEVELOPMENT, V130, P4539, DOI 10.1242/dev.00661; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Briggs F, 2001, J NEUROSCI, V21, P3600, DOI 10.1523/JNEUROSCI.21-10-03600.2001; CALLAWAY EM, 1991, P NATL ACAD SCI USA, V88, P745, DOI 10.1073/pnas.88.3.745; Callaway EM, 1998, ANNU REV NEUROSCI, V21, P47, DOI 10.1146/annurev.neuro.21.1.47; Castellani V, 1997, P NATL ACAD SCI USA, V94, P7030, DOI 10.1073/pnas.94.13.7030; CHAPMAN B, 1993, J NEUROSCI, V13, P5251, DOI 10.1523/JNEUROSCI.13-12-05251.1993; Chapman B, 1999, J NEUROBIOL, V41, P18, DOI 10.1002/(SICI)1097-4695(199910)41:1<18::AID-NEU4>3.0.CO;2-V; CLASCA F, 1995, P NATL ACAD SCI USA, V92, P11145, DOI 10.1073/pnas.92.24.11145; Cline H, 2003, TRENDS NEUROSCI, V26, P655, DOI 10.1016/j.tins.2003.10.005; Crair MC, 2001, J COMP NEUROL, V430, P235, DOI 10.1002/1096-9861(20010205)430:2<235::AID-CNE1028>3.0.CO;2-P; Crossley PH, 2001, NEUROSCIENCE, V108, P183, DOI 10.1016/S0306-4522(01)00411-0; Crowley JC, 2000, SCIENCE, V290, P1321, DOI 10.1126/science.290.5495.1321; Crowley JC, 1999, NAT NEUROSCI, V2, P1125, DOI 10.1038/16051; Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878; Dou CL, 1999, CEREB CORTEX, V9, P543, DOI 10.1093/cercor/9.6.543; Dragoi V, 2001, NATURE, V411, P80, DOI 10.1038/35075070; DRAGOI V, 2004, VISUAL NEUROSCIENCES, V2, P1654; Dufour A, 2003, NEURON, V39, P453, DOI 10.1016/S0896-6273(03)00440-9; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fagiolini M, 2004, SCIENCE, V303, P1681, DOI 10.1126/science.1091032; Feldmeyer D, 2005, J NEUROSCI, V25, P3423, DOI 10.1523/JNEUROSCI.5227-04.2005; Ferster D, 2000, ANNU REV NEUROSCI, V23, P441, DOI 10.1146/annurev.neuro.23.1.441; FRIAUF E, 1990, J NEUROSCI, V10, P2601; Fukuchi-Shimogori T, 2003, NAT NEUROSCI, V6, P825, DOI 10.1038/nn1093; Fukuchi-Shimogori T, 2001, SCIENCE, V294, P1071, DOI 10.1126/science.1064252; Furuta Y, 1997, DEVELOPMENT, V124, P2203; Galceran J, 2000, DEVELOPMENT, V127, P469; Garel S, 2004, TRENDS NEUROSCI, V27, P533, DOI 10.1016/j.tins.2004.06.014; Garel S, 2003, DEVELOPMENT, V130, P1903, DOI 10.1242/dev.00416; Garel S, 2002, DEVELOPMENT, V129, P5621, DOI 10.1242/dev.00166; Garel S, 2004, COGNITIVE NEUROSCIENCES III, THIRD EDITION, P69; GHOSH A, 1990, NATURE, V347, P179, DOI 10.1038/347179a0; GILBERT CD, 1989, J NEUROSCI, V9, P2432; GILBERT CD, 1977, J PHYSIOL-LONDON, V268, P391, DOI 10.1113/jphysiol.1977.sp011863; Godecke I, 1996, NATURE, V379, P251, DOI 10.1038/379251a0; Grove EA, 2003, ANNU REV NEUROSCI, V26, P355, DOI 10.1146/annurev.neuro.26.041002.131137; Grove EA, 1998, DEVELOPMENT, V125, P2315; Hamasaki T, 2004, NEURON, V43, P359, DOI 10.1016/j.neuron.2004.07.016; Hensch TK, 2004, ANNU REV NEUROSCI, V27, P549, DOI 10.1146/annurev.neuro.27.070203.144327; Hensch TK, 2004, SCIENCE, V303, P1678, DOI 10.1126/science.1091031; Hentges KE, 2001, P NATL ACAD SCI USA, V98, P13796, DOI 10.1073/pnas.241184198; HERBERT JM, 2002, NEURON, V35, P1029; Hering H, 2001, NAT REV NEUROSCI, V2, P880, DOI 10.1038/35104061; HERRMANN K, 1995, P NATL ACAD SCI USA, V92, P11244, DOI 10.1073/pnas.92.24.11244; Hevner RF, 2002, J COMP NEUROL, V447, P8, DOI 10.1002/cne.10219; HUBEL DH, 1968, J PHYSIOL-LONDON, V195, P215, DOI 10.1113/jphysiol.1968.sp008455; Huffman KJ, 2004, J NEUROSCI, V24, P8917, DOI 10.1523/JNEUROSCI.2086-04.2004; Iwai Y, 2002, MOL CELL NEUROSCI, V19, P375, DOI 10.1006/mcne.2001.1081; Kanold PO, 2003, SCIENCE, V301, P521, DOI 10.1126/science.1084152; KIM DS, 1994, NATURE, V370, P370, DOI 10.1038/370370a0; Kim HJ, 2004, NAT REV MOL CELL BIO, V5, P441, DOI 10.1038/nrm1400; Kozloski J, 2001, SCIENCE, V293, P868, DOI 10.1126/science.293.5531.868; Kuschel S, 2003, DEV BIOL, V260, P484, DOI 10.1016/S0012-1606(03)00252-5; Lagutin OV, 2003, GENE DEV, V17, P368, DOI 10.1101/gad.1059403; Lamprecht R, 2004, NAT REV NEUROSCI, V5, P45, DOI 10.1038/nrn1301; Lee SMK, 2000, DEVELOPMENT, V127, P457; Lendvai B, 2000, NATURE, V404, P876, DOI 10.1038/35009107; Liu GS, 2004, NAT NEUROSCI, V7, P373, DOI 10.1038/nn1206; Lopez-Bendito G, 2003, NAT REV NEUROSCI, V4, P276, DOI 10.1038/nrn1075; Majewska A, 2003, P NATL ACAD SCI USA, V100, P16024, DOI 10.1073/pnas.2636949100; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; Mallamaci A, 2000, NAT NEUROSCI, V3, P679, DOI 10.1038/76630; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Marino J, 2005, NAT NEUROSCI, V8, P194, DOI 10.1038/nn1391; Maruoka Y, 1998, MECH DEVELOP, V74, P175, DOI 10.1016/S0925-4773(98)00061-6; Mataga N, 2004, NEURON, V44, P1031, DOI 10.1016/j.neuron.2004.11.028; Mataga N, 2002, P NATL ACAD SCI USA, V99, P7717, DOI 10.1073/pnas.102088899; Matsuzaki M, 2004, NATURE, V429, P761, DOI 10.1038/nature02617; Miyashita-Lin EM, 1999, SCIENCE, V285, P906, DOI 10.1126/science.285.5429.906; Monuki ES, 2001, NEURON, V32, P591, DOI 10.1016/S0896-6273(01)00504-9; Monuki ES, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn752; Muzio L, 2002, CEREB CORTEX, V12, P129, DOI 10.1093/cercor/12.2.129; Muzio L, 2005, J NEUROSCI, V25, P4435, DOI 10.1523/JNEUROSCI.4804-04.2005; Newton JR, 2004, NAT NEUROSCI, V7, P968, DOI 10.1038/nn1306; O'Leary DDM, 2002, CURR OPIN NEUROBIOL, V12, P14, DOI 10.1016/S0959-4388(02)00285-4; Ohkubo Y, 2002, NEUROSCIENCE, V111, P1, DOI 10.1016/S0306-4522(01)00616-9; Okamoto KI, 2004, NAT NEUROSCI, V7, P1104, DOI 10.1038/nn1311; OLEARY DDM, 1989, TRENDS NEUROSCI, V12, P400, DOI 10.1016/0166-2236(89)90080-5; Oray S, 2004, NEURON, V44, P1021, DOI 10.1016/j.neuron.2004.12.001; Pera EM, 2003, GENE DEV, V17, P3023, DOI 10.1101/gad.1153603; Polleux F, 1998, SCIENCE, V282, P1904, DOI 10.1126/science.282.5395.1904; Polleux F, 2000, NATURE, V404, P567, DOI 10.1038/35007001; Puelles L, 2003, TRENDS NEUROSCI, V26, P469, DOI 10.1016/S0166-2236(03)00234-0; Ragsdale CW, 2001, CURR OPIN NEUROBIOL, V11, P50, DOI 10.1016/S0959-4388(00)00173-2; RAKIC P, 1988, SCIENCE, V241, P170, DOI 10.1126/science.3291116; RAKIC P, 1977, PHILOS T R SOC B, V278, P245, DOI 10.1098/rstb.1977.0040; Rallu M, 2002, DEVELOPMENT, V129, P4963; Ruthazer ES, 1996, J NEUROSCI, V16, P7253; Sawtell NB, 2003, NEURON, V38, P977, DOI 10.1016/S0896-6273(03)00323-4; Schuurmans C, 2004, EMBO J, V23, P2892, DOI 10.1038/sj.emboj.7600278; Sengpiel F, 1999, NAT NEUROSCI, V2, P727, DOI 10.1038/11192; Seoane J, 2004, CELL, V117, P211, DOI 10.1016/S0092-8674(04)00298-3; Shanmugalingam S, 2000, DEVELOPMENT, V127, P2549; Sharma J, 2000, NATURE, V404, P841, DOI 10.1038/35009043; SHATZ CJ, 1978, J PHYSIOL-LONDON, V281, P267, DOI 10.1113/jphysiol.1978.sp012421; SHATZ CJ, 1986, J NEUROSCI, V6, P3655; Shepherd GMG, 2005, NAT NEUROSCI, V8, P782, DOI 10.1038/nn1447; Shimamura K, 1997, DEVELOPMENT, V124, P2709; Shimogori T, 2005, J NEUROSCI, V25, P6550, DOI 10.1523/JNEUROSCI.0453-05.2005; Shimogori T, 2004, DEVELOPMENT, V131, P5639, DOI 10.1242/dev.01428; Shinozaki K, 2004, MECH DEVELOP, V121, P475, DOI 10.1016/j.mod.2004.03.013; Shinya M, 2001, DEVELOPMENT, V128, P4153; Smart IHM, 2002, CEREB CORTEX, V12, P37, DOI 10.1093/cercor/12.1.37; SOMERS DC, 1995, J NEUROSCI, V15, P5448; Song S, 2005, PLOS BIOL, V3, P507, DOI 10.1371/journal.pbio.0030068; Stenman JM, 2003, J NEUROSCI, V23, P10568; Storm EE, 2003, P NATL ACAD SCI USA, V100, P1757, DOI 10.1073/pnas.0337736100; STOYKOVA A, 1994, J NEUROSCI, V14, P1395, DOI 10.1523/JNEUROSCI.14-03-01395.1994; Sun T, 2005, SCIENCE, V308, P1794, DOI 10.1126/science.1110324; Sur M, 2001, NAT REV NEUROSCI, V2, P251, DOI 10.1038/35067562; Sur Mriganka, 2004, HDB MULTISENSORY PRO, P681; Tabuchi K, 2002, GENOMICS, V79, P849, DOI 10.1006/geno.2002.6780; Tole S, 2000, DEV BIOL, V217, P254, DOI 10.1006/dbio.1999.9509; Toresson H, 2001, DEVELOPMENT, V128, P4769; Toresson H, 2000, DEVELOPMENT, V127, P4361; Trachtenberg JT, 2000, SCIENCE, V287, P2029, DOI 10.1126/science.287.5460.2029; Trachtenberg JT, 2002, NATURE, V420, P788, DOI 10.1038/nature01273; Trachtenberg JT, 2001, J NEUROSCI, V21, P3476, DOI 10.1523/JNEUROSCI.21-10-03476.2001; Turrigiano GG, 2004, NAT REV NEUROSCI, V5, P97, DOI 10.1038/nrn1327; Uziel D, 2002, J NEUROSCI, V22, P9352; von Melchner L, 2000, NATURE, V404, P871, DOI 10.1038/35009102; Walshe J, 2003, DEVELOPMENT, V130, P4337, DOI 10.1242/dev.00660; White LE, 2001, NATURE, V411, P1049, DOI 10.1038/35082568; WIESEL TN, 1965, J NEUROPHYSIOL, V28, P1029, DOI 10.1152/jn.1965.28.6.1029; WIESEL TN, 1974, J COMP NEUROL, V158, P307, DOI 10.1002/cne.901580306; Ye WL, 1998, CELL, V93, P755, DOI 10.1016/S0092-8674(00)81437-3; Yoshimura Y, 2005, NATURE, V433, P868, DOI 10.1038/nature03252; Yu H, 2005, NEURON, V47, P267, DOI 10.1016/j.neuron.2005.06.011; Yun K, 2002, DEVELOPMENT, V129, P5029; Yun K, 2001, DEVELOPMENT, V128, P193; Zhou C, 2001, GENE DEV, V15, P2054, DOI 10.1101/gad.913601; Zhou Q, 2004, NEURON, V44, P749, DOI 10.1016/j.neuron.2004.11.011	140	454	461	4	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					805	810		10.1126/science.1112070	http://dx.doi.org/10.1126/science.1112070			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272112	Green Submitted			2022-12-28	WOS:000233121800033
J	Heilbron, JL				Heilbron, JL			Wit and wisdom	NATURE			English	Editorial Material									Museum Hist Sci, Oxford, England		Heilbron, JL (corresponding author), Museum Hist Sci, Broad St, Oxford, England.							LICHTENBERG JC, 1990, WASTE BOOKS; Stern J.P., 1959, LICHTENBERG DOCTRINE	2	1	1	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2005	438	7064					29	29		10.1038/438029a	http://dx.doi.org/10.1038/438029a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	979XS	16267534	Bronze			2022-12-28	WOS:000232979000023
J	Tsai, SP; Wendt, JK; Donnelly, RP; de Jong, G; Ahmed, FS				Tsai, SP; Wendt, JK; Donnelly, RP; de Jong, G; Ahmed, FS			Age at retirement and long term survival of an industrial population: prospective cohort study	BRITISH MEDICAL JOURNAL			English	Article							PHYSICAL HEALTH; CIVIL-SERVANTS; SOCIAL-CLASS; MORTALITY; US; REFINERY	Objective To assess whether early retirement is associated with better survival. Design Long term prospective cohort study. Setting Petroleum and petrochemical industry, United States. Subjects Past employees of Shell Oil who retired at ages 55, 60, and 65 between 1 January 1973 and 31 December 2003. Main outcome measure Hazard ratio of death adjusted for sex, year of entry to study, and socioeconomic status. Results Subjects who retired early at 55 and who were still alive at 65 had a significantly higher mortality than those who retired at 65 (hazard ratio 1.37, 95% confidence interval 1.09 to 1.73). Mortality was also significantly higher for subjects in the first 10 years after retirement at 55 compared with those who continued working (1.89, 1.58 to 2.27). After adjustment, mortality was similar between those who retired at 60 and those who retired at 65 (1.06, 0.92 to 1.22). Mortality did not differ for the first five years after retirement at 60 compared with continuing work at 60 (1.04,0.82 to 1.31). Conclusions Retiring early at 55 or 60 was not associated with better survival than retiring at 65 in a cohort of past employees of the petrochemical industry. Mortality was higher in employees who retired at 55 than in those who continued working.	Shell Oil Co, Shell Hlth Serv, Epidemiol, Houston, TX 77002 USA; Shell Int, The Hague, Netherlands	Royal Dutch Shell; Shell Oil Company; Royal Dutch Shell	Tsai, SP (corresponding author), Shell Oil Co, Shell Hlth Serv, Epidemiol, 910 Louisiana, Houston, TX 77002 USA.	shan.tsai@shell.com		Hess, Judith/0000-0002-9486-1391				ACQUAVELLA JF, 1986, AM J IND MED, V9, P181, DOI 10.1002/ajim.4700090209; Chandola T, 2000, SOC SCI MED, V50, P641, DOI 10.1016/S0277-9536(99)00310-X; Cowper DC, 2002, ANN EPIDEMIOL, V12, P462, DOI 10.1016/S1047-2797(01)00285-X; COX DR, 1972, J R STAT SOC B, V34, P187; EKERDT DJ, 1983, AM J PUBLIC HEALTH, V73, P779, DOI 10.2105/AJPH.73.7.779; HAYNES SG, 1978, J GERONTOL, V33, P269, DOI 10.1093/geronj/33.2.269; JOYNER RE, 1982, J OCCUP ENVIRON MED, V24, P812; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; LIN S, 2002, OPTIMUM STRATEGIES C; Mackenbach JP, 2003, INT J EPIDEMIOL, V32, P830, DOI 10.1093/ije/dyg209; Mein G, 2000, AGE AGEING, V29, P529, DOI 10.1093/ageing/29.6.529; Mein G, 2003, J EPIDEMIOL COMMUN H, V57, P46, DOI 10.1136/jech.57.1.46; MORRIS JK, 1994, BMJ-BRIT MED J, V308, P1135, DOI 10.1136/bmj.308.6937.1135; Muntaner C, 2004, EUR J EPIDEMIOL, V19, P777, DOI 10.1023/B:EJEP.0000036569.39399.68; Padfield A, 1996, BRIT MED J, V312, P1611; Trichopoulos D, 1996, BMJ-BRIT MED J, V312, P632; Tsai SP, 2003, OCCUP ENVIRON MED, V60, P627, DOI 10.1136/oem.60.9.627	17	45	45	0	7	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 29	2005	331	7523					995	997		10.1136/bmj.38586.448704.E0	http://dx.doi.org/10.1136/bmj.38586.448704.E0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981AU	16243848	Green Published, Bronze			2022-12-28	WOS:000233060200016
J	Tanzi, RE				Tanzi, RE			Tangles and neurodegenerative disease - A surprising twist	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							TAU		Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA 02129 USA; Harvard Univ, Sch Med, Charlestown, MA USA	Harvard University; Massachusetts General Hospital; Harvard University	Tanzi, RE (corresponding author), Massachusetts Gen Hosp, Genet & Aging Res Unit, Charlestown, MA 02129 USA.		Tanzi, Rudolph/AAE-9622-2019	Tanzi, Rudolph/0000-0002-7032-1454				FOX M, 2005, REUTERS         0714; GomezIsla T, 1997, ANN NEUROL, V41, P17, DOI 10.1002/ana.410410106; LEE VMY, 1991, SCIENCE, V251, P675, DOI 10.1126/science.1899488; SantaCruz K, 2005, SCIENCE, V309, P476, DOI 10.1126/science.1113694; Tanzi RE, 2005, NAT NEUROSCI, V8, P977, DOI 10.1038/nn0805-977	5	16	18	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1853	1855		10.1056/NEJMcibr055003	http://dx.doi.org/10.1056/NEJMcibr055003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251544				2022-12-28	WOS:000232813000017
J	van Delden, RA; ter Wiel, MKJ; Pollard, MM; Vicario, J; Koumura, N; Feringa, BL				van Delden, RA; ter Wiel, MKJ; Pollard, MM; Vicario, J; Koumura, N; Feringa, BL			Unidirectional molecular motor on a gold surface	NATURE			English	Article							SINGLE STEREOGENIC CENTER; ROTARY MOTION; ROTATION; NANOPARTICLES; ROTOR; SYSTEM	Molecules capable of mimicking the function of a wide range of mechanical devices have been fabricated, with motors that can induce mechanical movement attracting particular attention(1,2). Such molecular motors convert light or chemical energy into directional rotary or linear motion(2-10), and are usually prepared and operated in solution. But if they are to be used as nanomachines that can do useful work, it seems essential to construct systems that can function on a surface, like a recently reported linear artificial muscle(11). Surface-mounted rotors have been realized and limited directionality in their motion predicted(12,13). Here we demonstrate that a light-driven molecular motor capable of repetitive unidirectional rotation(14) can be mounted on the surface of gold nanoparticles. The motor design(14) uses a chiral helical alkene with an upper half that serves as a propeller and is connected through a carbon - carbon double bond ( the rotation axis) to a lower half that serves as a stator. The stator carries two thiol-functionalized 'legs', which then bind the entire motor molecule to a gold surface. NMR spectroscopy reveals that two photo-induced cis-trans isomerizations of the central double bond, each followed by a thermal helix inversion to prevent reverse rotation, induce a full and unidirectional 3608 rotation of the propeller with respect to the surface-mounted lower half of the system.	Univ Groningen, Stratingh Inst, Dept Organ Chem, NL-9747 AG Groningen, Netherlands	University of Groningen	Feringa, BL (corresponding author), Univ Groningen, Stratingh Inst, Dept Organ Chem, Nijenborgh 4, NL-9747 AG Groningen, Netherlands.	B.L.Feringa@rug.nl	Vicario, Javier/C-9893-2012; Feringa, Ben L./C-1665-2013; Koumura, Nagatoshi/M-4947-2018	Vicario, Javier/0000-0002-8976-0991; Koumura, Nagatoshi/0000-0002-2141-0741				ANELLI PL, 1991, J AM CHEM SOC, V113, P5131, DOI 10.1021/ja00013a096; Balzani V., 2003, MOL DEVICES MACHINES, VSecond; BRUST M, 1994, J CHEM SOC CHEM COMM, P801, DOI 10.1039/c39940000801; Kelly TR, 1999, NATURE, V401, P150, DOI 10.1038/43639; Kottas GS, 2005, CHEM REV, V105, P1281, DOI 10.1021/cr0300993; Koumura N, 1999, NATURE, V401, P152, DOI 10.1038/43646; Koumura N, 2002, J AM CHEM SOC, V124, P5037, DOI 10.1021/ja012499i; Koumura N, 2000, J AM CHEM SOC, V122, P12005, DOI 10.1021/ja002755b; Leigh DA, 2003, NATURE, V424, P174, DOI 10.1038/nature01758; Lide D.R., 2003, CRC HDB CHEM PHYS, V84th, P4; Liu Y, 2005, J AM CHEM SOC, V127, P9745, DOI 10.1021/ja051088p; Long B, 2003, J AM CHEM SOC, V125, P15490, DOI 10.1021/ja037592g; Manna A, 2003, CHEM MATER, V15, P20, DOI 10.1021/cm0207696; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Sauvage J.-P., 2001, MOL MACHINES MOTORS, V99; Sherman WB, 2004, NANO LETT, V4, P1203, DOI 10.1021/nl049527q; Thomas KG, 2003, ACCOUNTS CHEM RES, V36, P888, DOI 10.1021/ar030030h; ULLMAN A, 1996, CHEM REV, V96, P1533; van Delden RA, 2002, P NATL ACAD SCI USA, V99, P4945, DOI 10.1073/pnas.062660699; VANDELDEN RA, 2003, MOL MOTORS, P559; Zheng XL, 2004, J AM CHEM SOC, V126, P4540, DOI 10.1021/ja039482f	21	435	435	7	271	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1337	1340		10.1038/nature04127	http://dx.doi.org/10.1038/nature04127			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251960	Green Published, Green Submitted			2022-12-28	WOS:000232829100049
J	Bearhop, S; Fiedler, W; Furness, RW; Votier, SC; Waldron, S; Newton, J; Bowen, GJ; Berthold, P; Farnsworth, K				Bearhop, S; Fiedler, W; Furness, RW; Votier, SC; Waldron, S; Newton, J; Bowen, GJ; Berthold, P; Farnsworth, K			Assortative mating as a mechanism for rapid evolution of a migratory divide	SCIENCE			English	Article							STABLE-HYDROGEN; ISOTOPIC COMPOSITION; SYLVIA-ATRICAPILLA; BIRD; MICROEVOLUTION; POPULATIONS; FEATHERS; BEHAVIOR; SONGBIRD; WINTER	There have been numerous recent observations of changes in the behavior and dynamics of migratory bird populations, but the plasticity of the migratory trait and our inability to track small animals over large distances have hindered investigation of the mechanisms behind migratory change. We used habitat-specific stable isotope signatures to show that recently evolved allopatric wintering populations of European blackcaps Sylvia atricapilla pair assortatively on their sympatric breeding grounds. Birds wintering further north also produce larger clutches and fledge more young. These findings describe an important process in the evolution of migratory divides, new migration routes, and wintering quarters. Temporal segregation of breeding is a way in which subpopulations of vertebrates may become isolated in sympatry.	Queens Univ Belfast, Ctr Med Biol, Sch Biol & Biochem, Belfast BT6 7BL, Antrim, North Ireland; Max Planck Inst Ornithol, Vogelwarte Radolfzell, D-78315 Radolfzell am Bodensee, Germany; Univ Glasgow, Inst Biomed & Life Sci, Glasgow G12 8QQ, Lanark, Scotland; Univ Glasgow, Dept Geog & Geomatics, Ctr Geosci, Glasgow G12 8QQ, Lanark, Scotland; Univ Plymouth, Dept Biol Sci, Plymouth PL4 8AA, Devon, England; Scottish Univ Environm Res Ctr, Life Sci Community Stable Isotope Facil, Glasgow G75 0QF, Lanark, Scotland; Univ Utah, Dept Biol, Salt Lake City, UT 84112 USA	Queens University Belfast; Max Planck Society; University of Glasgow; University of Glasgow; University of Plymouth; Scottish Universities Research & Reactor Center; Utah System of Higher Education; University of Utah	Bearhop, S (corresponding author), Queens Univ Belfast, Ctr Med Biol, Sch Biol & Biochem, Lisburn Rd, Belfast BT6 7BL, Antrim, North Ireland.	s.bearhop@qub.ac.uk	Bowen, Gabriel J/C-1708-2008; Bearhop, Stuart/G-3105-2012; Newton, Jason/A-9536-2009; Farnsworth, Keith D/B-5546-2008; Votier, Stephen C/G-2348-2014; Fiedler, Wolfgang/AAG-4510-2021	Bearhop, Stuart/0000-0002-5864-0129; Newton, Jason/0000-0001-7594-3693; Farnsworth, Keith D/0000-0001-8025-1114; Votier, Stephen C/0000-0002-0976-0167; Fiedler, Wolfgang/0000-0003-1082-4161; WALDRON, SUSAN/0000-0002-2683-0761				Bearhop S, 2003, FUNCT ECOL, V17, P270, DOI 10.1046/j.1365-2435.2003.00725.x; BERTHOLD P, 1992, NATURE, V360, P668, DOI 10.1038/360668a0; BERTHOLD P, 1995, BIRD STUDY, V42, P89, DOI 10.1080/00063659509477155; Bowen GJ, 2003, WATER RESOUR RES, V39, DOI 10.1029/2003WR002086; Chamberlain CP, 1997, OECOLOGIA, V109, P132, DOI 10.1007/s004420050067; Cotton PA, 2003, P NATL ACAD SCI USA, V100, P12219, DOI 10.1073/pnas.1930548100; GLUE D, 2004, BR TRUST ORNITHOL NE, V254, P8; Gorman HE, 2004, P ROY SOC B-BIOL SCI, V271, P1923, DOI 10.1098/rspb.2004.2799; HELBIG AJ, 1991, BEHAV ECOL SOCIOBIOL, V28, P9; Hill GE, 1998, AUK, V115, P240, DOI 10.2307/4089135; Hobson KA, 2004, OECOLOGIA, V141, P477, DOI 10.1007/s00442-004-1671-7; Hobson KA, 1997, OECOLOGIA, V109, P142, DOI 10.1007/s004420050068; Marra PP, 1998, SCIENCE, V282, P1884, DOI 10.1126/science.282.5395.1884; Monteiro LR, 1998, PHILOS T ROY SOC B, V353, P945, DOI 10.1098/rstb.1998.0259; Norris DR, 2004, SCIENCE, V306, P2249, DOI 10.1126/science.1103542; Perez-Tris J, 2004, EVOLUTION, V58, P1819, DOI 10.1554/03-731; Przybylo R, 2001, J AVIAN BIOL, V32, P214, DOI 10.1111/j.0908-8857.2001.320302.x; Reynolds SJ, 2003, OECOLOGIA, V134, P308, DOI 10.1007/s00442-002-1126-y; Rubenstein DR, 2002, SCIENCE, V295, P1062, DOI 10.1126/science.1067124; RYTKONEN S, 1995, OECOLOGIA, V104, P386, DOI 10.1007/BF00328375; Viverette CB, 1996, AUK, V113, P32; Wassenaar LI, 2003, ISOT ENVIRON HEALT S, V39, P211, DOI 10.1080/1025601031000096781; Wassenaar LI, 2000, ENVIRON SCI TECHNOL, V34, P2354, DOI 10.1021/es990804i; Webster MS, 2002, TRENDS ECOL EVOL, V17, P76, DOI 10.1016/S0169-5347(01)02380-1; WEBSTER MS, 2005, BIRDS 2 WORLDS, pCH16	25	288	307	3	185	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					502	504		10.1126/science.1115661	http://dx.doi.org/10.1126/science.1115661			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239479				2022-12-28	WOS:000232786000050
J	Lindholm, LH; Carlberg, B; Samuelsson, O				Lindholm, LH; Carlberg, B; Samuelsson, O			Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis	LANCET			English	Article							LOW-DOSE COMBINATION; RANDOMIZED CONTROLLED-TRIAL; BLOOD-PRESSURE REDUCTION; CHRONIC HEART-FAILURE; END-POINT REDUCTION; CARDIOVASCULAR MORBIDITY; ANTIHYPERTENSIVE TREATMENT; LOSARTAN INTERVENTION; SECONDARY PREVENTION; CALCIUM-ANTAGONIST	Background: beta blockers have been used widely in the treatment of hypertension and are recommended as first-line drugs in hypertension guidelines. However, a preliminary analysis has shown that atenolol is not very effective in hypertension. We aim to substantially enlarge the data on atenolol and analyse the effect of different beta blockers. Methods: The Cochrane Library and PubMed were searched for beta blocker treatment in patients with primary hypertension. Data were then entered into the Cochrane Collaboration Review Manager package and were summarised in meta-analyses. 13 randomised controlled trials (n=105 951) were included in a meta-analysis comparing treatment with beta blockers with other antihypertensive drugs. Seven studies (n=27 433) were included in a comparison of beta blockers and placebo or no treatment. Findings: The relative risk of stroke was 16% higher for beta blockers (95% CI 4-30%) than for other drugs. There was no difference for myocardial infarction. When the effect of beta blockers was compared with that of placebo or no treatment, the relative risk of stroke was reduced by 19% for all beta blockers (7-29%), about half that expected from previous hypertension trials. There was no difference for myocardial infarction or mortality. Interpretation: In comparison with other antihypertensive drugs, the effect of beta blockers is less than optimum, with a raised risk of stroke. Hence, we believe that beta blockers should not remain first choice in the treatment of primary hypertension and should not be used as reference drugs in future randomised controlled trials of hypertension.	Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden; Sahlgrenska Univ Hosp, Dept Nephrol, Gothenburg, Sweden	Umea University; Sahlgrenska University Hospital	Lindholm, LH (corresponding author), Univ Umea Hosp, Dept Publ Hlth & Clin Med, SE-90185 Umea, Sweden.	Larsh.lindholm@fammed.umu.se						ALGRA A, 1993, STROKE, V24, P543; BERGLUND G, 1986, ACTA MED SCAND, V220, P419; Black HR, 2003, JAMA-J AM MED ASSOC, V289, P2073, DOI 10.1001/jama.289.16.2073; BUHLER FR, 1985, J HYPERTENS, V3, P379; Carlberg B, 2004, LANCET, V364, P1684, DOI 10.1016/S0140-6736(04)17355-8; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Dahlof B, 2004, J HUM HYPERTENS, V18, P367, DOI 10.1038/sj.jhh.1001710; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; de Luca N, 2004, J HYPERTENS, V22, P1623, DOI 10.1097/01.hjh.0000125448.28861.fc; EKBOM T, 1992, J HYPERTENS, V10, P1525, DOI 10.1097/00004872-199210120-00013; ERIKSSON S, 1995, CEREBROVASC DIS, V5, P21, DOI 10.1159/000107813; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; FREIS ED, 1982, JAMA-J AM MED ASSOC, V248, P2004; Hansson L, 2000, LANCET, V356, P359, DOI 10.1016/S0140-6736(00)02526-5; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1999, LANCET, V354, P1751, DOI 10.1016/S0140-6736(99)10327-1; HAWKES N, NHS SPENDS 23M YEAR; Hirata K, 2005, J HYPERTENS, V23, P551, DOI 10.1097/01.hjh.0000160211.56103.48; Hjalmarson A, 1999, LANCET, V353, P2001; Kearney PM, 2005, LANCET, V365, P217, DOI 10.1016/S0140-6736(05)70151-3; Klingbeil AU, 2003, AM J MED, V115, P41, DOI 10.1016/S0002-9343(03)00158-X; Law MR, 2003, BRIT MED J, V326, P1427, DOI 10.1136/bmj.326.7404.1427; Lechat P, 1999, LANCET, V353, P9; Lindholm LH, 2003, J HYPERTENS, V21, P1563, DOI 10.1097/00004872-200308000-00022; London GM, 2004, J AM COLL CARDIOL, V43, P92, DOI 10.1016/j.jacc.2003.07.039; Mancia G, 2003, J HYPERTENS, V21, P1011, DOI 10.1097/01.hjh.0000059051.65882.32; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; *MED RES COUNC WOR, 1985, BRIT MED J, V291, P87; Messerli FH, 2003, AM J HYPERTENS, V16, P870, DOI 10.1016/S0895-7061(03)01017-3; Messerli FH, 1998, JAMA-J AM MED ASSOC, V279, P1903, DOI 10.1001/jama.279.23.1903; Morgan T, 2004, AM J HYPERTENS, V17, P118, DOI 10.1016/j.amjhyper.2003.09.012; Packer M, 2002, CIRCULATION, V106, P2194, DOI 10.1161/01.CIR.0000035653.72855.BF; Pepine CJ, 2003, JAMA-J AM MED ASSOC, V290, P2805, DOI 10.1001/jama.290.21.2805; Psaty BN, 2003, JAMA-J AM MED ASSOC, V289, P2534, DOI 10.1001/jama.289.19.2534; Staessen JA, 2001, LANCET, V358, P1305, DOI 10.1016/S0140-6736(01)06411-X; Stearne MR, 1998, BRIT MED J, V317, P713; *SWED COUNC TECHN, 2004, MOD EL BLOOD PRESS, V1; Turnbull F, 2003, LANCET, V362, P1527; WIKSTRAND J, 1988, JAMA-J AM MED ASSOC, V259, P1976, DOI 10.1001/jama.259.13.1976; WIKSTRAND J, 1991, HYPERTENSION, V17, P579, DOI 10.1161/01.HYP.17.4.579; WILHELMSEN L, 1987, J HYPERTENS, V5, P561, DOI 10.1097/00004872-198710000-00009; Williams B, 2004, BMJ-BRIT MED J, V328, P634, DOI 10.1136/bmj.328.7440.634; YURENEV AP, 1992, AM J HYPERTENS, V5, pS182, DOI 10.1093/ajh/5.6.182S; Zanchetti A, 2002, CIRCULATION, V106, P2422, DOI 10.1161/01.CIR.0000039288.86470.DD	47	690	758	1	73	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT-NOV	2005	366	9496					1545	1553		10.1016/S0140-6736(05)67573-3	http://dx.doi.org/10.1016/S0140-6736(05)67573-3			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257341				2022-12-28	WOS:000232984800023
J	Huang, JK; Phillips, GR; Roth, AD; Pedraza, L; Shan, WS; Belkaid, W; Mi, S; Fex-Svenningsen, A; Florens, L; Yates, JR; Colman, DR				Huang, JK; Phillips, GR; Roth, AD; Pedraza, L; Shan, WS; Belkaid, W; Mi, S; Fex-Svenningsen, A; Florens, L; Yates, JR; Colman, DR			Glial membranes at the node of Ranvier prevent neurite outgrowth	SCIENCE			English	Article							OLIGODENDROCYTE-MYELIN GLYCOPROTEIN; CHONDROITIN SULFATE PROTEOGLYCANS; RAT OPTIC-NERVE; AXONAL REGENERATION; CNS MYELIN; LOCALIZATION; CELL; PROTEIN; ADULT; GROWTH	Nodes of Ranvier are regularly placed, nonmyelinated axon segments along myelinated nerves. Here we show that nodal membranes isolated from the central nervous system (CNS) of mammals restricted neurite outgrowth of cultured neurons.. Proteomic analysis of these membranes revealed several inhibitors of neurite outgrowth, including the oligodendrocyte myelin glycoprotein (OMgp). In rat spinal cord, OMgp was not localized to compact myelin, as previously thought, but to oligodendroglia-like cells, whose processes converge to form a ring that completely encircles the nodes. In OMgp-null mice, CNS nodes were abnormally wide and collateral sprouting was observed. Nodal ensheathment in the CNS may stabilize the node and prevent axonal sprouting.	CUNY, Mt Sinai Med Ctr, Fishberg Dept Neurosci, New York, NY 10029 USA; Univ Cambridge, Wellcome Trust Canc Res UK Gurdon Inst, Cambridge CB2 1QR, England; McGill Univ, Montreal Neurol Inst, Montreal, PQ H3A 2B4, Canada; Biogen Idec, Discovery Biol, Cambridge, MA 02142 USA; Uppsala Univ, Dept Genet & Pathol, Rudbeck Lab, SE-75185 Uppsala, Sweden; Stowers Inst, Kansas City, MO 64110 USA; Scripps Res Inst, Dept Cell Biol SR11, La Jolla, CA 92037 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; University of Cambridge; McGill University; Biogen; Uppsala University; Stowers Institute for Medical Research; Scripps Research Institute	Colman, DR (corresponding author), CUNY, Mt Sinai Med Ctr, Fishberg Dept Neurosci, 1 Gustave L Levy Pl, New York, NY 10029 USA.	david.colman@mcgill.ca	Roth, Alejandro D/A-5086-2009; Huang, Jeffrey/J-5248-2017; Svenningsen, Åsa Fex/H-5443-2015; Huang, Jeffrey K./AAH-2418-2021	Roth, Alejandro D/0000-0001-5679-8136; Huang, Jeffrey/0000-0003-0996-9451; Svenningsen, Åsa Fex/0000-0002-5651-265X; Huang, Jeffrey K./0000-0003-0996-9451; Florens, Laurence/0000-0002-9310-6650	NCRR NIH HHS [P41 RR11823] Funding Source: Medline; NINDS NIH HHS [NS20147] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR011823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS020147] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BARTSCH U, 1989, J COMP NEUROL, V284, P451, DOI 10.1002/cne.902840310; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Berry M, 2002, J NEUROCYTOL, V31, P457, DOI 10.1023/A:1025735513560; BRUNNER C, 1989, J NEUROCHEM, V52, P296, DOI 10.1111/j.1471-4159.1989.tb10930.x; Butt AM, 1999, GLIA, V26, P84, DOI 10.1002/(SICI)1098-1136(199903)26:1<84::AID-GLIA9>3.3.CO;2-C; DOU CL, 1994, J NEUROSCI, V14, P7616; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; FFRENCHCONSTANT C, 1986, J CELL BIOL, V102, P844, DOI 10.1083/jcb.102.3.844; Goldsmith AP, 2004, J NEUROSCI RES, V78, P647, DOI 10.1002/jnr.20320; Kottis V, 2002, J NEUROCHEM, V82, P1566, DOI 10.1046/j.1471-4159.2002.01146.x; Lambert S, 1997, J NEUROSCI, V17, P7025; LEVINE JM, 1987, J NEUROSCI, V7, P2711; Levine JM, 2001, TRENDS NEUROSCI, V24, P39, DOI 10.1016/S0166-2236(00)01691-X; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; MIKOL DD, 1990, J CELL BIOL, V111, P2673, DOI 10.1083/jcb.111.6.2673; MIKOL DD, 1988, J CELL BIOL, V106, P1273, DOI 10.1083/jcb.106.4.1273; MILLER RH, 1989, EUR J NEUROSCI, V1, P172, DOI 10.1111/j.1460-9568.1989.tb00785.x; MUKHOPADHYAY G, 1994, NEURON, V13, P757, DOI 10.1016/0896-6273(94)90042-6; Nguyen QT, 2002, NAT NEUROSCI, V5, P861, DOI 10.1038/nn905; Nie DY, 2003, EMBO J, V22, P5666, DOI 10.1093/emboj/cdg570; Niederost BP, 1999, J NEUROSCI, V19, P8979, DOI 10.1523/JNEUROSCI.19-20-08979.1999; NORTON WT, 1973, J NEUROCHEM, V21, P749, DOI 10.1111/j.1471-4159.1973.tb07519.x; Oohashi T, 2002, MOL CELL NEUROSCI, V19, P43, DOI 10.1006/mcne.2001.1061; Pedraza L, 2001, NEURON, V30, P335, DOI 10.1016/S0896-6273(01)00306-3; Peters A., 1991, FINE STRUCTURE NERVO; Phillips GR, 2001, NEURON, V32, P63, DOI 10.1016/S0896-6273(01)00450-0; SCHWAB ME, 1988, J NEUROSCI, V8, P2381; Sivasankaran R, 2004, NAT NEUROSCI, V7, P261, DOI 10.1038/nn1193; SLACK JR, 1979, NATURE, V282, P506, DOI 10.1038/282506a0; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; Wang KC, 2002, NATURE, V417, P941, DOI 10.1038/nature00867; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686	32	127	139	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	2005	310	5755					1813	1817		10.1126/science.1118313	http://dx.doi.org/10.1126/science.1118313			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	995II	16293723				2022-12-28	WOS:000234093600046
J	Salvatori, R				Salvatori, R			Adrenal insufficiency	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INSULIN TOLERANCE-TEST; CORTICOTROPIN-RELEASING HORMONE; ADRENOCORTICOTROPIN ACTH TEST; DOSE METYRAPONE TEST; ADULT GH DEFICIENCY; 250 MU-G; ADDISONS-DISEASE; STIMULATION TEST; GROWTH-HORMONE; HYDROCORTISONE REPLACEMENT	A 44-year-old woman reported several weeks of fatigue, somnolence, pain in the large joints, nausea, and decreased appetite. She had also noted an unintentional 11-kg weight loss over a period of 6 months. She had a remote history of amenorrhea, but she was presently menstruating regularly. She was taking no medications, with the exception of acetaminophen as needed for knee pain. The diagnosis of adrenal insufficiency (AI) was considered. Serum cortisol level after adrenocorticotropin hormone (ACTH) stimulation was abnormal. Because her plasma ACTH level was not increased, a diagnosis of secondary AI (due to deficiency in ACTH) was made. Magnetic resonance imaging of the brain performed to exclude the presence of a sellar or suprasellar mass showed reduction in size of the pituitary gland and an increased cerebrospinal fluid content within the sella, consistent with a partially empty sella. The patient's symptoms improved rapidly with hydrocortisone therapy but during follow-up, the dose of hydrocortisone was found to be excessive. Important differences exist between primary and secondary AI, and the diagnosis of secondary AI may be challenging. The therapy of AI should be carefully tailored to the requirements of the individual patient.	Johns Hopkins Univ, Sch Med, Dept Med, Div Endocrinol, Baltimore, MD 21287 USA	Johns Hopkins University	Salvatori, R (corresponding author), Johns Hopkins Univ, Sch Med, Dept Med, Div Endocrinol, 1830 E Monument St,Suite 333, Baltimore, MD 21287 USA.	salvator@jhmi.edu						Abdu TAM, 1999, J CLIN ENDOCR METAB, V84, P838, DOI 10.1210/jc.84.3.838; Aimaretti G, 2004, CLIN ENDOCRINOL, V61, P320, DOI 10.1111/j.1365-2265.2004.02094.x; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Arlt W, 1999, NEW ENGL J MED, V341, P1013, DOI 10.1056/NEJM199909303411401; Berneis K, 2002, J CLIN ENDOCR METAB, V87, P5470, DOI 10.1210/jc.2001-011959; Chikada N, 2004, ENDOCR J, V51, P355, DOI 10.1507/endocrj.51.355; Cordido F, 2003, EUR J ENDOCRINOL, V149, P117, DOI 10.1530/eje.0.1490117; Courtney CH, 2000, CLIN ENDOCRINOL, V53, P431, DOI 10.1046/j.1365-2265.2000.01106.x; DICKSTEIN G, 1991, J CLIN ENDOCR METAB, V72, P773, DOI 10.1210/jcem-72-4-773; Dickstein G, 1997, ENDOCRINOLOGIST, V7, P285, DOI 10.1097/00019616-199707050-00002; Dokmetas HS, 2000, J CLIN ENDOCR METAB, V85, P3713, DOI 10.1210/jc.85.10.3713; Dorin RI, 2003, ANN INTERN MED, V139, P194, DOI 10.7326/0003-4819-139-3-200308050-00009; Eagling VA, 1997, BRIT J CLIN PHARMACO, V44, P190, DOI 10.1046/j.1365-2125.1997.00644.x; Espinosa G, 2003, MEDICINE, V82, P106, DOI 10.1097/00005792-200303000-00005; Falorni A, 1997, CLIN EXP IMMUNOL, V107, P341, DOI 10.1111/j.1365-2249.1997.262-ce1153.x; FIAD TM, 1994, CLIN ENDOCRINOL, V40, P603, DOI 10.1111/j.1365-2265.1994.tb03011.x; Glowniak JV, 1997, SURGERY, V121, P123, DOI 10.1016/S0039-6060(97)90280-4; Hamrahian AH, 2004, NEW ENGL J MED, V350, P1629, DOI 10.1056/NEJMoa020266; Hartman ML, 2002, J CLIN ENDOCR METAB, V87, P477, DOI 10.1210/jc.87.2.477; HATAZOE T, 1995, INTERNAL MED, V34, P688, DOI 10.2169/internalmedicine.34.688; Kelestimur F, 2004, J ENDOCRINOL INVEST, V27, P380, DOI 10.1007/BF03351067; Krasner AS, 1999, JAMA-J AM MED ASSOC, V282, P671, DOI 10.1001/jama.282.7.671; Lamberts SWJ, 1997, NEW ENGL J MED, V337, P1285, DOI 10.1056/NEJM199710303371807; Laureti S, 2000, CLIN ENDOCRINOL, V53, P107, DOI 10.1046/j.1365-2265.2000.01050.x; Mader R, 2005, ARTHRITIS RHEUM, V52, P924, DOI 10.1002/art.20884; Magill SS, 2004, ANTIMICROB AGENTS CH, V48, P2471, DOI 10.1128/AAC.48.7.2471-2476.2004; Mah PM, 2004, CLIN ENDOCRINOL, V61, P367, DOI 10.1111/j.1365-2265.2004.02106.x; Mahachoklertwattana P, 2004, ARCH DIS CHILD, V89, P1055, DOI 10.1136/adc.2002.020560; MALCHOFF CD, 1997, CURRENT THERAPY ENDO, P142; Mayenknecht J, 1998, J CLIN ENDOCR METAB, V83, P1558, DOI 10.1210/jc.83.5.1558; Moser H, 2004, CURR OPIN NEUROL, V17, P263, DOI 10.1097/00019052-200406000-00005; Nye EJ, 2001, J NEUROENDOCRINOL, V13, P524, DOI 10.1046/j.1365-2826.2001.00664.x; OELKERS W, 1992, J CLIN ENDOCR METAB, V75, P259, DOI 10.1210/jc.75.1.259; Oelkers W, 1996, NEW ENGL J MED, V335, P1206, DOI 10.1056/NEJM199610173351607; Peacey SR, 1997, CLIN ENDOCRINOL, V46, P255, DOI 10.1046/j.1365-2265.1997.780907.x; Pfeifer M, 2001, CLIN ENDOCRINOL, V54, P17, DOI 10.1046/j.1365-2265.2001.01179.x; ROBINSON DB, 1992, ARCH INTERN MED, V152, P1920, DOI 10.1001/archinte.152.9.1920; Ron IG, 2002, EUR J CANCER, V38, P1490, DOI 10.1016/S0959-8049(02)00077-1; SALEM M, 1994, ANN SURG, V219, P416, DOI 10.1097/00000658-199404000-00013; Samaras K, 2005, J CLIN ENDOCR METAB, V90, P4394, DOI 10.1210/jc.2005-0036; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; Schmidt IL, 2003, J CLIN ENDOCR METAB, V88, P4193, DOI 10.1210/jc.2002-021897; SIU SCB, 1990, MAYO CLIN PROC, V65, P664, DOI 10.1016/S0025-6196(12)65129-5; Soule S, 2000, CLIN ENDOCRINOL, V53, P221, DOI 10.1046/j.1365-2265.2000.01057.x; Streeten DHP, 1996, J CLIN ENDOCR METAB, V81, P285, DOI 10.1210/jc.81.1.285; Suliman AM, 2002, CLIN ENDOCRINOL, V56, P533, DOI 10.1046/j.1365-2265.2002.01509.x; Swords FM, 2003, CLIN ENDOCRINOL, V59, P613, DOI 10.1046/j.1365-2265.2003.01894.x; Toogood AA, 2004, GROWTH HORM IGF RES, V14, pS118, DOI 10.1016/j.ghir.2004.03.038; TOUITOU Y, 1990, EUR J APPL PHYSIOL O, V60, P288, DOI 10.1007/BF00379398; VALLOTTON MB, 1992, BAILLIERE CLIN ENDOC, V6, P41, DOI 10.1016/S0950-351X(05)80330-1; XARLI VP, 1978, MEDICINE, V57, P211, DOI 10.1097/00005792-197805000-00002	51	55	60	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2481	2488		10.1001/jama.294.19.2481	http://dx.doi.org/10.1001/jama.294.19.2481			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287959				2022-12-28	WOS:000233277400027
J	Hamaguchi, M; Kojima, T; Takeda, N; Nakagawa, T; Taniguchi, H; Fujii, K; Omatsu, T; Nakajima, T; Sarui, H; Shimazaki, M; Kato, T; Okuda, J; Ida, K				Hamaguchi, M; Kojima, T; Takeda, N; Nakagawa, T; Taniguchi, H; Fujii, K; Omatsu, T; Nakajima, T; Sarui, H; Shimazaki, M; Kato, T; Okuda, J; Ida, K			The metabolic syndrome as a predictor of nonalcoholic fatty liver disease	ANNALS OF INTERNAL MEDICINE			English	Article							INSULIN-RESISTANCE; HEPATIC STEATOSIS; STEATOHEPATITIS; PREVALENCE; ADIPONECTIN; SONOGRAPHY; DIAGNOSIS; HISTOLOGY; NASH	Background: The frequent association of nonalcoholic fatty liver disease with components of the metabolic syndrome such as obesity, hyperglycemia, dyslipidemia, and hypertension is well known. However, no prospective study has examined the role of the metabolic syndrome in the development of this disease. Objective: To characterize the longitudinal relationship between the metabolic syndrome and nonalcoholic fatty liver disease. Design: A prospective observational study. Setting: A medical health checkup program in a general hospital. Participants: 4401 apparently healthy Japanese men and women, 21 to 80 years of age, with a mean body mass index (BMI) of 22.6 kg/m(2) (SD, 3.0). Measurements: Alcohol intake was assessed by using a questionnaire. Biochemical tests for liver and metabolic function and abdominal ultrasonography were done. Modified criteria of the National Cholesterol Education Program Adult Treatment Panel III were used to characterize the metabolic syndrome. Results: At baseline, 812 of 4401 (18%) participants had nonalcoholic fatty liver disease. During the mean follow-up period of 414 days (SD, 128), the authors observed 308 new cases (10%) of nonalcoholic fatty liver disease among 3147 participants who were disease-free at baseline and who completed a second examination. Regression of nonalcoholic fatty liver disease was found in 113 (16%) of 704 participants who had the disease at baseline and who completed a second examination. Men and women who met the criteria for the metabolic syndrome at baseline were more likely to develop the disease during follow-up (adjusted odds ratio, 4.00 [95% Cl, 2.63 to 6.08] and 11.20 [Cl, 4.85 to 25.87], respectively). Nonalcoholic fatty liver disease was less likely to regress in those participants with the metabolic syndrome at baseline. Limitations: Ultrasonography may lead to an incorrect diagnosis of nonalcoholic fatty liver disease in 10% to 30% of cases and cannot distinguish steatolhepatitis from simple steatosis. Self-reported alcohol intake may cause bias. Because all of the participants were Japanese, generalizability to non-Japanese populations is uncertain. Conclusions: The metabolic syndrome is a strong predictor of nonalcoholic fatty liver disease.	Asahi Univ, Murakami Mem Hosp, Dept Gastroenterol, Gifu 5008523, Japan	Asahi University	Hamaguchi, M (corresponding author), Asahi Univ, Murakami Mem Hosp, Dept Gastroenterol, 3-23 Hashimoto Cho, Gifu 5008523, Japan.	seele@mbox.kyotoinet.or.jp						Akbar DH, 2003, DIABETES CARE, V26, P3351, DOI 10.2337/diacare.26.12.3351-a; Angulo P, 2002, NEW ENGL J MED, V346, P1221, DOI 10.1038/nrdp.2015.80; Assy N, 2000, DIGEST DIS SCI, V45, P1929, DOI 10.1023/A:1005661516165; Bellentani S, 2000, ANN INTERN MED, V132, P112, DOI 10.7326/0003-4819-132-2-200001180-00004; Cheal KL, 2004, DIABETES, V53, P1195, DOI 10.2337/diabetes.53.5.1195; Chitturi S, 2004, J GASTROEN HEPATOL, V19, P368, DOI 10.1111/j.1440-1746.2003.03252.x; Chitturi S, 2002, HEPATOLOGY, V35, P373, DOI 10.1053/jhep.2002.30692; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Donati G, 2004, GUT, V53, P1020, DOI 10.1136/gut.2003.027086; Ford ES, 2004, DIABETES CARE, V27, P2444, DOI 10.2337/diacare.27.10.2444; Graif M, 2000, INVEST RADIOL, V35, P319, DOI 10.1097/00004424-200005000-00006; Gupte P, 2004, J GASTROEN HEPATOL, V19, P854, DOI 10.1111/j.1440-1746.2004.03312.x; Hewitt KN, 2004, ENDOCRINOLOGY, V145, P1842, DOI 10.1210/en.2003-1369; Hui JM, 2004, HEPATOLOGY, V40, P46, DOI 10.1002/hep.20280; JOSEPH AEA, 1991, CLIN RADIOL, V43, P26, DOI 10.1016/S0009-9260(05)80350-2; Kojima S, 2003, J GASTROENTEROL, V38, P954, DOI 10.1007/s00535-003-1178-8; Lewis GF, 2002, ENDOCR REV, V23, P201, DOI 10.1210/er.23.2.201; Marchesini G, 2003, HEPATOLOGY, V37, P917, DOI 10.1053/jhep.2003.50161; McCullough Arthur J, 2004, Clin Liver Dis, V8, P521, DOI 10.1016/j.cld.2004.04.004; Mendler MH, 1998, J HEPATOL, V28, P785, DOI 10.1016/S0168-8278(98)80228-6; NEEDLEMAN L, 1986, AM J ROENTGENOL, V146, P1011, DOI 10.2214/ajr.146.5.1011; Neuschwander-Tetri BA, 2003, HEPATOLOGY, V37, P1202, DOI 10.1053/jhep.2003.50193; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; Ryo M, 2004, CIRC J, V68, P975, DOI 10.1253/circj.68.975; Sanyal Arun J, 2002, Gastroenterology, V123, P1705, DOI 10.1053/gast.2002.36572; SAVERYMUTTU SH, 1986, BRIT MED J, V292, P13, DOI 10.1136/bmj.292.6512.13; STEINMAURER HJ, 1984, ULTRASCHALL MED, V5, P98, DOI 10.1055/s-2007-1012076; Teli MR, 1995, HEPATOLOGY, V22, P1714, DOI 10.1002/hep.1840220616; Unger RH, 2003, ENDOCRINOLOGY, V144, P5159, DOI 10.1210/en.2003-0870; *WHO WE PAC REG IN, 2000, AS PAC PERSP RED OB; Xu AM, 2003, J CLIN INVEST, V112, P91, DOI 10.1172/JCI200317797; Yoshiike N, 1998, INT J OBESITY, V22, P684, DOI 10.1038/sj.ijo.0800651	32	781	820	0	34	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					722	728		10.7326/0003-4819-143-10-200511150-00009	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287793				2022-12-28	WOS:000233486800004
J	Wald, A; Langenberg, AGM; Krantz, E; Douglas, JM; Handsfield, HH; DiCarlo, RP; Adimora, AA; Izu, AE; Morrow, RA; Corey, L				Wald, A; Langenberg, AGM; Krantz, E; Douglas, JM; Handsfield, HH; DiCarlo, RP; Adimora, AA; Izu, AE; Morrow, RA; Corey, L			The relationship between condom use and herpes simplex virus acquisition	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	2002 National STD Prevention Conference	MAR 04-07, 2002	San Diego, CA				GENITAL HERPES; TYPE-2 INFECTION; RISK-FACTORS; TRANSMISSION; DISEASE; DESIGN; REDUCE	Background: Few studies have evaluated the relationship be. tween condom use and herpes simplex virus type 2 (HSV-2) and HSV type 1 (HSV-1) acquisition. Objective: To assess the relationship between condom use and acquisition of HSV-2 and HSV-1 among men and women. Design: Analysis of data collected as part of a clinical trial of an ineffective candidate vaccine for HSV-2. Setting: Sexually transmitted disease clinics. Participants: Men and women at risk for HSV-2 acquisition, defined as having 4 or more sexual partners or having a sexually transmitted disease in the past year. Measurement: Acquisition of HSV-2 and HSV-1 as measured by viral culture or change to positive HSV serostatus. Results: Of 1843 participants, 118 (6.4%) became infected with HSV-2. In multivariate analyses, participants reporting more frequent use of condoms were at lower risk for acquiring HSV-2 than participants who used condoms less frequently (hazard ratio, 0.74 [95% Cl, 0.59 to 0.95]); categories of increasing condom use were 0% to 25%, 25% to 75%, and greater than 75% of sexual acts. Nineteen (2.9%) of 659 participants at risk for infection with HSV-1 became infected. No statistically significant association between condom use and infection with HSV-1 was found (hazard ratio, 0.79 [Cl, 0.48 to 1.31]). Limitations: use of condoms was measured by self-report, and persons who used condoms may have differed from those who did not. Conclusions: Consistent use of condoms is associated with lower rates of infection with HSV-2 and should be routinely recommended.	Univ Washington, Virol Res Clin, Seattle, WA 98122 USA; Chiron Corp, Emeryville, CA 94608 USA; Denver Dept Publ Hlth, Denver, CO USA; Louisiana State Univ, Sch Med, New Orleans, LA 70119 USA; Univ N Carolina, Sch Med, Chapel Hill, NC USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA	University of Washington; University of Washington Seattle; Novartis; Louisiana State University System; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Fred Hutchinson Cancer Center	Wald, A (corresponding author), Univ Washington, Virol Res Clin, 600 Broadway,Suite 400, Seattle, WA 98122 USA.	annawald@u.washington.edu	Wald, Anna/B-6272-2012; Corey, Lawrence/AAE-1796-2020	Wald, Anna/0000-0003-3486-6438; Corey, Lawrence/0000-0002-2179-2436	NIAID NIH HHS [AI-30731] Funding Source: Medline; ODCDC CDC HHS [UR6/CCU017828-02] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI030731] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); ODCDC CDC HHS; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ASHLEY RL, 1988, J CLIN MICROBIOL, V26, P662, DOI 10.1128/JCM.26.4.662-667.1988; BRYSON Y, 1993, J INFECT DIS, V167, P942, DOI 10.1093/infdis/167.4.942; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; Cherpes TL, 2005, SEX TRANSM DIS, V32, P84, DOI 10.1097/01.olq.0000151414.64297.46; Corey L, 1999, JAMA-J AM MED ASSOC, V282, P331, DOI 10.1001/jama.282.4.331; Corey L, 2004, NEW ENGL J MED, V350, P11, DOI 10.1056/NEJMoa035144; Coyle PV, 2003, J CLIN VIROL, V27, P22, DOI 10.1016/S1386-6532(02)00105-1; Crosby R, 2002, SEX TRANSM INFECT, V78, P228, DOI 10.1136/sti.78.4.228; Crosby R, 2003, AM J PREV MED, V24, P367, DOI 10.1016/S0749-3797(03)00015-1; Fleming DT, 1997, NEW ENGL J MED, V337, P1105, DOI 10.1056/NEJM199710163371601; Gottlieb SL, 2004, J INFECT DIS, V190, P1059, DOI 10.1086/423323; Holmes KK, 2004, B WORLD HEALTH ORGAN, V82, P454; Kamali A, 1999, SEX TRANSM INFECT, V75, P98, DOI 10.1136/sti.75.2.98; Lafferty WE, 2000, J INFECT DIS, V181, P1454, DOI 10.1086/315395; Manavi K, 2004, SEX TRANSM DIS, V31, P322, DOI 10.1097/01.OLQ.0000123652.88904.9B; McFarland W, 1999, J INFECT DIS, V180, P1459, DOI 10.1086/315076; MERTZ GJ, 1992, ANN INTERN MED, V116, P197, DOI 10.7326/0003-4819-116-3-197; Posavad CM, 2003, J IMMUNOL, V170, P4380, DOI 10.4049/jimmunol.170.8.4380; Roberts CM, 2003, SEX TRANSM DIS, V30, P797, DOI 10.1097/01.OLQ.0000092387.58746.C7; Samra Z, 2003, SEX TRANSM DIS, V30, P794, DOI 10.1097/01.OLQ.0000079517.04451.79; Wald A, 2001, JAMA-J AM MED ASSOC, V285, P3100, DOI 10.1001/jama.285.24.3100; Warner L, 2005, AM J EPIDEMIOL, V161, P765, DOI 10.1093/aje/kwi094; Warner L, 2004, AM J EPIDEMIOL, V159, P242, DOI 10.1093/aje/kwh044	23	101	106	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					707	713		10.7326/0003-4819-143-10-200511150-00007	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00007			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	986YY	16287791				2022-12-28	WOS:000233486800002
J	Raynal, G; Achkar, K				Raynal, G; Achkar, K			Renal colic	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Ctr Hosp, F-60109 Creil, France		Raynal, G (corresponding author), Ctr Hosp, F-60109 Creil, France.								0	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					2056	2056		10.1056/NEJMicm050151	http://dx.doi.org/10.1056/NEJMicm050151			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282180				2022-12-28	WOS:000233119600010
J	Munjuluri, N; Lipman, M; Valentine, A; Hardiman, P; Maclean, AB				Munjuluri, N; Lipman, M; Valentine, A; Hardiman, P; Maclean, AB			Lesson of the week - Postpartum eclampsia of late onset	BRITISH MEDICAL JOURNAL			English	Review								Late onset postpartum eclampsia can occur in normotensive women with uncomplicated pregnancies, not just in women with pre-eclampsia.	N Middlesex Univ Hosp, London N18 1QF, England; Royal Free Hosp, London NW3 2QG, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Munjuluri, N (corresponding author), 71 Lulworth Ave, Goffs Oak EN7 5LB, England.	munjulurinalini@hotmail.com		Lipman, Marc/0000-0001-7501-4448				Chames MC, 2002, AM J OBSTET GYNECOL, V186, P1174, DOI 10.1067/mob.2002.123824; DOUGLAS KA, 1994, BMJ-BRIT MED J, V309, P1395, DOI 10.1136/bmj.309.6966.1395; Felz M W, 2000, J Am Board Fam Pract, V13, P39; Gifford RW, 2000, AM J OBSTET GYNECOL, V183, pS1, DOI 10.1067/mob.2000.107928; Hinchey J, 1996, NEW ENGL J MED, V334, P494, DOI 10.1056/NEJM199602223340803; Khadra Mona, 2003, J Obstet Gynaecol, V23, P201; Leitch CR, 1997, BRIT J OBSTET GYNAEC, V104, P917, DOI 10.1111/j.1471-0528.1997.tb14351.x; LUBRASKY SL, 1994, OBSTET GYNECOL, V83, P502; Matthys LA, 2004, AM J OBSTET GYNECOL, V190, P1464, DOI 10.1016/j.ajog.2004.02.037; Veltkamp R, 2000, J NEUROL NEUROSUR PS, V69, P824, DOI 10.1136/jnnp.69.6.824	10	11	11	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1070	1071		10.1136/bmj.331.7524.1070	http://dx.doi.org/10.1136/bmj.331.7524.1070			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16269495	Green Published, Green Submitted			2022-12-28	WOS:000233211200032
J	Baker, C; Cannon, J				Baker, C; Cannon, J			Traumatic cranial nerve palsy	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center	Baker, C (corresponding author), Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.		Theelen, Thomas/A-3192-2012; Cannon, Jeremy/T-3875-2019; Cruysberg, Johannes R. M./D-4313-2009	Theelen, Thomas/0000-0001-9067-1171; Cannon, Jeremy/0000-0002-2969-9316; Cruysberg, Johannes R. M./0000-0002-5330-0774					0	1	1	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1955	1955		10.1056/NEJMicm040872	http://dx.doi.org/10.1056/NEJMicm040872			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267326				2022-12-28	WOS:000232972800011
J	Okie, S				Okie, S			Betting on a malaria vaccine	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PLASMODIUM-FALCIPARUM INFECTION; EFFICACY; TRIAL											Alonso PL, 2004, LANCET, V364, P1411, DOI 10.1016/S0140-6736(04)17223-1; Bojang KA, 2001, LANCET, V358, P1927, DOI 10.1016/S0140-6736(01)06957-4; Greenwood BM, 2005, LANCET, V365, P1487, DOI 10.1016/S0140-6736(05)66420-3; Moorthy VS, 2004, PLOS MED, V1, P128, DOI 10.1371/journal.pmed.0010033	4	9	9	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1877	1881		10.1056/NEJMp058217	http://dx.doi.org/10.1056/NEJMp058217			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979VJ	16267316				2022-12-28	WOS:000232972800001
J	Graybill, JR				Graybill, JR			Voriconazole for candidosis: an important addition?	LANCET			English	Editorial Material							AMPHOTERICIN-B; FLUCONAZOLE; NEUTROPENIA; CANDIDIASIS; THERAPY		Univ Texas, Hlth Sci Ctr, Div Infect Dis, San Antonio, TX 78229 USA	University of Texas System; University of Texas Health San Antonio	Graybill, JR (corresponding author), Univ Texas, Hlth Sci Ctr, Div Infect Dis, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.	graybill@uthscsa.edu						Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191; Kullberg BJ, 2005, LANCET, V366, P1435, DOI 10.1016/S0140-6736(05)67490-9; Mora-Duarte J, 2002, NEW ENGL J MED, V347, P2020, DOI 10.1056/NEJMoa021585; Pappas PG, 2004, CLIN INFECT DIS, V38, P161, DOI 10.1086/380796; Perfect JR, 2003, CLIN INFECT DIS, V36, P1122, DOI 10.1086/374557; Pfaller MA, 2003, J CLIN MICROBIOL, V41, P1875, DOI 10.1128/JCM.41.5.1875-1880.2003; REBOLI A, 2005, 45 INT C ANT AG CHEM; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; Walsh TJ, 2002, NEW ENGL J MED, V346, P225, DOI 10.1056/NEJM200201243460403	9	6	7	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1413	1414		10.1016/S0140-6736(05)67579-4	http://dx.doi.org/10.1016/S0140-6736(05)67579-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243074				2022-12-28	WOS:000232724600004
J	Light, DW; Lexchin, J				Light, DW; Lexchin, J			Foreign free riders and the high price of US medicines	BRITISH MEDICAL JOURNAL			English	Editorial Material								The US government, backed by the pharmaceutical industry, wants to convince Americans that they're paying more for drugs because they're contributing more than their fair share of the costs of research and development. Not so, argue two researchers who have looked at the evidence.	Univ Med & Dent New Jersey, Dept Psychiat, Stratford, NJ 08084 USA; York Univ, Sch Hlth Policy & Management, Toronto, ON M3J 2R7, Canada	Rutgers State University New Brunswick; Rutgers State University Medical Center; York University - Canada	Light, DW (corresponding author), Univ Med & Dent New Jersey, Dept Psychiat, 40E Laurel Rd, Stratford, NJ 08084 USA.	dlight@princeton.edu						ALDONAS G, 2004, INT TRADE PHARM, P1; BINDRA G, 1996, ASSESSMENT CURRENT C; *DEP HLTH, 2003, 7 DOH; *EUR FED PHARM IND, 2004, PHARM IND FIG; *FAM US, 2001, OFF CHARTS PAY PROF; Families USA, 2004, STICK SHOCK RIS PRES; Gregson N, 2005, NAT REV DRUG DISCOV, V4, P121, DOI 10.1038/nrd1633; GROSS DJ, 2004, TRENDS MANUFACTURER; Light DW, 2003, J HEALTH POLIT POLIC, V28, P473, DOI 10.1215/03616878-28-2-3-473; McClellan M., 2003, 1 INT C GEN MED; *NAT SCI FED, 2002, RES DEV IND 1999; *NIH CAR MAN RES E, 2002, CHANG PATT PHARM INN; *NIH CAR MAN RES E, 2002, PRESCR DRUG EXP 2001; *PAT MED PRIC REV, 2004, 03 PMPRB; *PAT MED PRIC REV, 2002, COMP PHARM RES DEV S; *PAT MED PRIC REV, 2001, 00 PMPRB; *PHARM RES MAN AM, 2004, PHARM IND PROF 2004; SAFIRE W, 2003, NY TIMES        0630, pA21; *STAT CAN, 1996, FIN PERF IND CAN BUS; U.S. Department of Commerce International Trade Administration, 2004, PHARM PRIC CONTR OEC; 2004, PRESCRIBE INT, V13, P71	21	55	55	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 22	2005	331	7522					958	960		10.1136/bmj.331.7522.958	http://dx.doi.org/10.1136/bmj.331.7522.958			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979UR	16239695	Green Published			2022-12-28	WOS:000232970900028
J	Austin, J				Austin, J			United States: Two scientists and a baby	SCIENCE			English	News Item												jaustin@aaas.org							0	0	0	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					518	519		10.1126/science.310.5747.518	http://dx.doi.org/10.1126/science.310.5747.518			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239480				2022-12-28	WOS:000232786000051
J	Carter, LJ; Pigford, TH				Carter, LJ; Pigford, TH			Nuclear waste - Proof of safety at Yucca Mountain	SCIENCE			English	Editorial Material									Univ Calif Berkeley, Dept Nucl Engn, Berkeley, CA 94720 USA	University of California System; University of California Berkeley		lcarter345@aol.com; pig-ford@nuc.berkeley.edu						APTED MJ, 1994, P 5 ANN C HIGH LEV R, P485; BREDEHOEFT JD, 1978, 779 USGS, P3; *DOE, 2002, YUCC MOUNT SCI ENG R, P11; *DOE, 2001, AN TOT SYST LIF CYCL; *DOE, 2001, TOT SYST PERF ASS AN; FORSBERG CW, 2003, P ADV NUCL CYCL MAN, V3, P1; FRI RW, 1995, TECHNICAL BASES YUCC, P2; Long JCS, 2004, ANNU REV EARTH PL SC, V32, P363, DOI 10.1146/annurev.earth.32.092203.122444; Martin Stephen F., COMMUNICATION; PRATT HR, 1981, P WORKSH SEISM PERF, P74; *TRW ENV SAF SYST, 1995, TOT SYST PERF ASS 19, P9; US Department of Education, 2004, M HIGHL QUAL TEACH C, P1; ZHOU W, 1996, 107189 EL POW RES I	13	11	11	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					447	448		10.1126/science.1112786	http://dx.doi.org/10.1126/science.1112786			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239463				2022-12-28	WOS:000232786000030
J	Tulapurkar, AA; Suzuki, Y; Fukushima, A; Kubota, H; Maehara, H; Tsunekawa, K; Djayaprawira, DD; Watanabe, N; Yuasa, S				Tulapurkar, AA; Suzuki, Y; Fukushima, A; Kubota, H; Maehara, H; Tsunekawa, K; Djayaprawira, DD; Watanabe, N; Yuasa, S			Spin-torque diode effect in magnetic tunnel junctions	NATURE			English	Article							ROOM-TEMPERATURE; DRIVEN; MAGNETORESISTANCE; RESONANCE; WAVES	There is currently much interest in the development of 'spin-tronic' devices, in which harnessing the spins of electrons (rather than just their charges) is anticipated to provide new functionalities that go beyond those possible with conventional electronic devices. One widely studied example of an effect that has its roots in the electron's spin degree of freedom is the torque exerted by a spin-polarized electric current on the spin moment of a nanometre-scale magnet. This torque causes the magnetic moment to rotate(1-19) at potentially useful frequencies. Here we report a very different phenomenon that is also based on the interplay between spin dynamics and spin-dependent transport, and which arises from unusual diode behaviour. We show that the application of a small radio-frequency alternating current to a nanometre-scale magnetic tunnel junction(20-22) can generate a measurable direct-current (d.c.) voltage across the device when the frequency is resonant with the spin oscillations that arise from the spin-torque effect: at resonance (which can be tuned by an external magnetic field), the structure exhibits different resistance states depending on the direction of the current. This behaviour is markedly different from that of a conventional semiconductor diode(23), and could form the basis of a nanometre-scale radio-frequency detector in telecommunication circuits.	Natl Inst Adv Ind Sci & Technol, Nanoelectr Res Ctr, Tsukuba, Ibaraki 3058568, Japan; Japan Sci & Technol Agcy, CREST, Kawaguchi 3320012, Japan; Osaka Univ, Grad Sch Engn Sci, Osaka 5608531, Japan; Canon ANELVA Corp, Electron Device Equipment Div, Tokyo 1838508, Japan	National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST); Osaka University; Canon Incorporated	Suzuki, Y (corresponding author), Natl Inst Adv Ind Sci & Technol, Nanoelectr Res Ctr, Tsukuba, Ibaraki 3058568, Japan.	suzuki-y@mp.es.osaka-u.ac.jp	Yuasa, Shinji/H-2804-2016; Kubota, Hitoshi/K-2894-2018; Fukushima, Akio/K-2900-2018; SUZUKI, Yoshishige/D-2652-2013	Yuasa, Shinji/0000-0003-1093-9057; Kubota, Hitoshi/0000-0002-2362-3505; Fukushima, Akio/0000-0002-0769-7897; SUZUKI, Yoshishige/0000-0001-9423-8594; Tulapurkar, Ashwin/0000-0002-6539-5571				Berger L, 1996, PHYS REV B, V54, P9353, DOI 10.1103/PhysRevB.54.9353; Djayaprawira DD, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1871344; Grollier J, 2001, APPL PHYS LETT, V78, P3663, DOI 10.1063/1.1374230; Jiang Y, 2004, NAT MATER, V3, P361, DOI 10.1038/nmat1120; Katine JA, 2000, PHYS REV LETT, V84, P3149, DOI 10.1103/PhysRevLett.84.3149; Kiselev SI, 2003, NATURE, V425, P380, DOI 10.1038/nature01967; KITTEL C, 1996, INTRO SOLID STATE PH, pCH16; KOH RH, 2004, PHYS REV LETT, V92; Lee KJ, 2004, NAT MATER, V3, P877, DOI 10.1038/nmat1237; Manschot J, 2004, APPL PHYS LETT, V85, P3250, DOI 10.1063/1.1801169; Myers EB, 1999, SCIENCE, V285, P867, DOI 10.1126/science.285.5429.867; Nazarov AV, 2002, APPL PHYS LETT, V81, P4559, DOI 10.1063/1.1521578; Ozyilmaz B, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.067203; Parkin SSP, 2004, NAT MATER, V3, P862, DOI 10.1038/nmat1256; Pufall MR, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1875762; Saitoh E, 2004, NATURE, V432, P203, DOI 10.1038/nature03009; Slonczewski JC, 1996, J MAGN MAGN MATER, V159, pL1, DOI 10.1016/0304-8853(96)00062-5; Smith N, 2001, APPL PHYS LETT, V78, P1448, DOI 10.1063/1.1352694; Stiles MD, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.014407; Sun J, 2003, NATURE, V425, P359, DOI 10.1038/425359a; Sze S. M., 1981, PHYS SEMICONDUCTOR D; Tatara G, 2004, PHYS REV LETT, V92, DOI 10.1103/PhysRevLett.92.086601; Tsoi M, 2000, NATURE, V406, P46, DOI 10.1038/35017512; Tulapurkar AA, 2004, APPL PHYS LETT, V85, P5358, DOI 10.1063/1.1828222; Urazhdin S, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.146803; Yagami K, 2004, APPL PHYS LETT, V85, P5634, DOI 10.1063/1.1829140; Yuasa S, 2004, NAT MATER, V3, P868, DOI 10.1038/nmat1257	29	635	675	1	178	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					339	342		10.1038/nature04207	http://dx.doi.org/10.1038/nature04207			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292307				2022-12-28	WOS:000233300200044
J	Stone, PH				Stone, PH			Update in cardiology	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital	Stone, PH (corresponding author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.	pstone@partners.org							0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					737	743		10.7326/0003-4819-143-10-200511150-00011	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00011			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287795				2022-12-28	WOS:000233486800006
J	Novoselov, KS; Geim, AK; Morozov, SV; Jiang, D; Katsnelson, MI; Grigorieva, IV; Dubonos, SV; Firsov, AA				Novoselov, KS; Geim, AK; Morozov, SV; Jiang, D; Katsnelson, MI; Grigorieva, IV; Dubonos, SV; Firsov, AA			Two-dimensional gas of massless Dirac fermions in graphene	NATURE			English	Article							GRAPHITE; STATES	Quantum electrodynamics ( resulting from the merger of quantum mechanics and relativity theory) has provided a clear understanding of phenomena ranging from particle physics to cosmology and from astrophysics to quantum chemistry(1-3). The ideas underlying quantum electrodynamics also influence the theory of condensed matter(4,5), but quantum relativistic effects are usually minute in the known experimental systems that can be described accurately by the non-relativistic Schrodinger equation. Here we report an experimental study of a condensed-matter system (graphene, a single atomic layer of carbon(6,7)) in which electron transport is essentially governed by Dirac's ( relativistic) equation. The charge carriers in graphene mimic relativistic particles with zero rest mass and have an effective 'speed of light' c* approximate to 10(6) m s(-1). Our study reveals a variety of unusual phenomena that are characteristic of two-dimensional Dirac fermions. In particular we have observed the following: first, graphene's conductivity never falls below a minimum value corresponding to the quantum unit of conductance, even when concentrations of charge carriers tend to zero; second, the integer quantum Hall effect in graphene is anomalous in that it occurs at half-integer filling factors; and third, the cyclotron mass m(c) of massless carriers in graphene is described by E = m(c)c(*)(2). This two-dimensional system is not only interesting in itself but also allows access to the subtle and rich physics of quantum electrodynamics in a bench-top experiment.	Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England; Russian Acad Sci, Inst Microelect Technol, Chernogolovka 142432, Russia; Radboud Univ Nijmegen, Inst Mol & Mat, NL-6525 ED Nijmegen, Netherlands	University of Manchester; Russian Academy of Sciences; Radboud University Nijmegen	Geim, AK (corresponding author), Univ Manchester, Manchester Ctr Mesosci & Nanotechnol, Manchester M13 9PL, Lancs, England.	kostya@man.ac.uk; geim@man.ac.uk	Jiang, Da/E-3543-2013; Novoselov, Kostya S/G-9581-2014; Jiang, Da/GZL-0534-2022; Firsov, Anatoly/E-8090-2017; Ma, Jun/D-8971-2011; Katsnelson, Mikhail I./D-4359-2012; Morozov, Sergey V/H-3171-2014; Geim, Andre K/J-7888-2012	Novoselov, Kostya S/0000-0003-4972-5371; Jiang, Da/0000-0002-4341-2289; Morozov, Sergey V/0000-0003-3075-7787; Geim, Andre K/0000-0003-2861-8331; hai yan, he/0000-0003-0366-6185	Engineering and Physical Sciences Research Council [EP/C511875/1, GR/R73621/01] Funding Source: researchfish	Engineering and Physical Sciences Research Council(UK Research & Innovation (UKRI)Engineering & Physical Sciences Research Council (EPSRC))		Berestetskii VB., 1971, RELATIVISTIC QUANTUM; Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f; BRANDT NB, 1988, SEMIMETALS, V1; Bunch JS, 2005, NANO LETT, V5, P287, DOI 10.1021/nl048111+; Dresselhaus MS, 2002, ADV PHYS, V51, P1, DOI [10.1080/00018730110113644, 10.1080/00018738100101367]; FRADKIN E, 1986, PHYS REV B, V33, P3263, DOI 10.1103/PhysRevB.33.3263; Fradkin E., 1997, FIELD THEORIES CONDE; Gusynin VP, 2005, PHYS REV B, V71, DOI 10.1103/PhysRevB.71.125124; Gusynin VP, 2005, UNCONVENTIONAL INTEG; KAKU M, 1988, INTRO SUPERSTRINGS; Lai D, 2001, REV MOD PHYS, V73, P629, DOI 10.1103/RevModPhys.73.629; LEE PA, 1993, PHYS REV LETT, V71, P1887, DOI 10.1103/PhysRevLett.71.1887; Luk'yanchuk IA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166402; Mikitik GP, 1999, PHYS REV LETT, V82, P2147, DOI 10.1103/PhysRevLett.82.2147; Mott N.F., 1979, ELECT PROCESSES NONC, Vsecond; Nakahara M., 1990, GEOMETRY TOPOLOGY PH; NERSESYAN AA, 1994, PHYS REV LETT, V72, P2628, DOI 10.1103/PhysRevLett.72.2628; Novoselov KS, 2005, P NATL ACAD SCI USA, V102, P10451, DOI 10.1073/pnas.0502848102; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Peres NMR, 2005, ELECT PROPERTIES 2 D; Rose M.E., 1961, RELATIVISTIC ELECT T; VANSOVSKY SV, 1989, QUANTUM SOLID STATE; Volovik G.E., 2003, UNIVERSE HELIUM DROP; Zhang YB, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.176803; Zheng YS, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.245420; Ziegler K, 1998, PHYS REV LETT, V80, P3113, DOI 10.1103/PhysRevLett.80.3113	28	16942	17339	223	8354	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					197	200		10.1038/nature04233	http://dx.doi.org/10.1038/nature04233			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281030	Green Submitted			2022-12-28	WOS:000233133500042
J	Yoon, HY; Enquist, LW; Dulac, C				Yoon, HY; Enquist, LW; Dulac, C			Olfactory inputs to hypothalamic neurons controlling reproduction and fertility	CELL			English	Article							GONADOTROPIN-RELEASING-HORMONE; CEREBRAL HEMISPHERE REGULATION; VENTRAL TEGMENTAL AREA; MEDIAL PREOPTIC AREA; LUTEINIZING-HORMONE; PSEUDORABIES VIRUS; CORTICOMEDIAL AMYGDALA; STRIA TERMINALIS; GOLDEN-HAMSTER; NEURAL INPUTS	In order to gain insight into sensory processing modulating reproductive behavioral and endocrine changes, we have aimed at identifying afferent pathways to neurons synthesizing luteinizing hormone-releasing hormone (LHRH, also known as gonadotropin-releasing hormone [GnRH]), a key neurohormone of reproduction. Injection of conditional pseudorabies virus into the brain of an LHRH::CRE mouse line led to the identification of neuronal networks connected to LHRH neurons. Remarkably, and in contrast to established notions on the nature of LHRH neuronal inputs, our data identify major olfactory projection pathways originating from a discrete population of olfactory sensory neurons but fail to document any synaptic connectivity with the vomeronasal system. Accordingly, chemosensory modulation of LHRH neuronal activity and mating behavior are dramatically impaired in absence of olfactory function, while they appear unaffected in mouse mutants lacking vomeronasal signaling. Further visualization of afferents to LHRH neurons across the brain offers a unique opportunity to uncover complex polysynaptic circuits modulating reproduction and fertility.	Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Harvard University; Howard Hughes Medical Institute; Princeton University	Dulac, C (corresponding author), Harvard Univ, Howard Hughes Med Inst, Dept Mol & Cellular Biol, Cambridge, MA 02138 USA.	dulac@fas.harvard.edu	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051; Dulac, Catherine/0000-0001-5024-5418	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033506] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC003903] Funding Source: NIH RePORTER; NIDCD NIH HHS [R01 DC003903] Funding Source: Medline; NINDS NIH HHS [2R01-NS33506] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Baum B.M., 2002, BEHAV ENDOCRINOLOGY, P153; Brittle EE, 2004, J VIROL, V78, P12951, DOI 10.1128/JVI.78.23.12951-12963.2004; Brunet LJ, 1996, NEURON, V17, P681, DOI 10.1016/S0896-6273(00)80200-7; Card JP, 1999, J COMP NEUROL, V407, P438, DOI 10.1002/(SICI)1096-9861(19990510)407:3<438::AID-CNE11>3.0.CO;2-2; COQUELIN A, 1984, J NEUROSCI, V4, P2230; DeFalco J, 2001, SCIENCE, V291, P2608, DOI 10.1126/science.1056602; Dobson H, 2003, REPRODUCTION, V125, P151, DOI 10.1530/rep.0.1250151; Dong HW, 2004, J COMP NEUROL, V471, P396, DOI 10.1002/cne.20002; Dong HW, 2004, J COMP NEUROL, V468, P277, DOI 10.1002/cne.10949; Dulac C, 2003, NAT REV NEUROSCI, V4, P551, DOI 10.1038/nrn1140; Enquist LW, 2003, CURR OPIN NEUROBIOL, V13, P603, DOI 10.1016/j.conb.2003.08.001; FULLE HJ, 1995, P NATL ACAD SCI USA, V92, P3571, DOI 10.1073/pnas.92.8.3571; Genazzani AR, 2000, ANN NY ACAD SCI, V900, P1; JANSEN ASP, 1993, BRAIN RES, V617, P103, DOI 10.1016/0006-8993(93)90619-X; Juilfs DM, 1997, P NATL ACAD SCI USA, V94, P3388, DOI 10.1073/pnas.94.7.3388; Karanth S, 2004, EXP BIOL MED, V229, P72, DOI 10.1177/153537020422900109; KEVETTER GA, 1981, J COMP NEUROL, V197, P81, DOI 10.1002/cne.901970107; KEVETTER GA, 1981, J COMP NEUROL, V197, P99, DOI 10.1002/cne.901970108; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; Liman ER, 1999, P NATL ACAD SCI USA, V96, P5791, DOI 10.1073/pnas.96.10.5791; Lin DY, 2005, NATURE, V434, P470, DOI 10.1038/nature03414; Marson L, 2004, NEUROSCIENCE, V127, P723, DOI 10.1016/j.neuroscience.2004.04.063; MCCARTHY MM, 2002, BEHAV ENDOCRINOLOGY, P117; MERCHENTHALER I, 1989, EXP CLIN ENDOCRINOL, V94, P133, DOI 10.1055/s-0029-1210889; Meredith M, 1998, ANN NY ACAD SCI, V855, P349, DOI 10.1111/j.1749-6632.1998.tb10593.x; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; Mori K, 1999, SCIENCE, V286, P711, DOI 10.1126/science.286.5440.711; Paxinos G., 2001, MOUSE BRAIN STEREOTA; Petrovich GD, 2001, BRAIN RES REV, V38, P247, DOI 10.1016/S0165-0173(01)00080-7; PFAUS JG, 1994, NEUROENDOCRINOLOGY, V60, P283, DOI 10.1159/000126760; Piras E, 2003, J HISTOCHEM CYTOCHEM, V51, P1545, DOI 10.1177/002215540305101114; Preti G, 2003, BIOL REPROD, V68, P2107, DOI 10.1095/biolreprod.102.008268; Richardson HN, 2004, GEN COMP ENDOCR, V138, P211, DOI 10.1016/j.ygcen.2004.06.008; RIZVI TA, 1992, J COMP NEUROL, V315, P1, DOI 10.1002/cne.903150102; SILVERMAN AJ, 1994, PHYSL REPROD, V1; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; SIMERLY RB, 1986, J COMP NEUROL, V246, P312, DOI 10.1002/cne.902460304; Sipos ML, 1996, BRAIN RES, V729, P29, DOI 10.1016/0006-8993(96)00148-5; Sisk CL, 2004, NAT NEUROSCI, V7, P1040, DOI 10.1038/nn1326; Skynner MJ, 1999, J NEUROSCI, V19, P5955, DOI 10.1523/JNEUROSCI.19-14-05955.1999; Srinivas S, 2001, BMC Dev Biol, V1, P4, DOI 10.1186/1471-213X-1-4; St John JA, 2003, CHEM SENSES, V28, P773, DOI 10.1093/chemse/bjg068; Stern K, 1998, NATURE, V392, P177, DOI 10.1038/32408; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Sullivan SL, 1996, P NATL ACAD SCI USA, V93, P884, DOI 10.1073/pnas.93.2.884; Swanson LW, 2000, BRAIN RES, V886, P113, DOI 10.1016/S0006-8993(00)02905-X; SWANSON LW, 1982, BRAIN RES BULL, V9, P321, DOI 10.1016/0361-9230(82)90145-9; VASSAR R, 1993, CELL, V74, P309, DOI 10.1016/0092-8674(93)90422-M; Wang HB, 1998, BRAIN RES, V792, P66, DOI 10.1016/S0006-8993(98)00122-X; WITKIN JW, 1982, NEUROENDOCRINOLOGY, V35, P429, DOI 10.1159/000123419; Wu TJ, 1997, J NEUROBIOL, V33, P983, DOI 10.1002/(SICI)1097-4695(199712)33:7<983::AID-NEU9>3.0.CO;2-4; Yang XDW, 1997, NAT BIOTECHNOL, V15, P859, DOI 10.1038/nbt0997-859; Zhao HQ, 2001, CELL, V104, P651, DOI 10.1016/S0092-8674(02)01107-8	53	304	314	0	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					669	682		10.1016/j.cell.2005.08.039	http://dx.doi.org/10.1016/j.cell.2005.08.039			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16290037	Bronze			2022-12-28	WOS:000233497400015
J	Chinnery, PF; Elliott, HR; Patel, S; Lambert, C; Keers, SM; Durham, SE; McCarthy, MI; Hitman, GA; Hattersley, AT; Walker, M				Chinnery, PF; Elliott, HR; Patel, S; Lambert, C; Keers, SM; Durham, SE; McCarthy, MI; Hitman, GA; Hattersley, AT; Walker, M			Role of the mitochondrial DNA 16184-16193 poly-C tract in type 2 diabetes	LANCET			English	Article							MITOCHONDRIAL-DNA VARIANT; SUSCEPTIBILITY; POPULATION	Recent evidence suggests that polymorphic genetic variation in the non-coding region of mitochondrial DNA (the 16184-16193 polycytosine [poly-C] tract) contributes to the cause of type 2 diabetes, but previous studies only just reached significance. We aimed to investigate this association. We compared patients with type 2 diabetes (n=992) with two independent control groups (n=536, n=1029) from the UK, and saw no difference in the frequency of the 16184-16193 poly-C tract. This finding was confirmed by a meta-analysis of European studies of 1455 patients and 3132 controls (odds ratio 1.16, 95% CI 0.94-1.44). Genetic variation of the 16184-16193 poly-C tract is unlikely to have a major role in the cause of type 2 diabetes.	Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ Newcastle Upon Tyne, Diabet Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Churchill Hosp, Oxford Ctr Diabet Endocrinol & Metab, Oxford OX3 7LJ, England; Barts & London Queen Marys Sch Med & Dent, Inst Cell & Mol Sci, Ctr Diabet & Metab Med, London, England; Peninsula Med Sch, Exeter, Devon, England	Newcastle University - UK; Newcastle University - UK; University of Oxford; University of London; Queen Mary University London; University of Exeter	Chinnery, PF (corresponding author), Univ Newcastle Upon Tyne, Mitochondrial Res Grp, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	P.F.Chinnery@ncl.ac.uk	Elliott, Hannah/AAP-3170-2021; McCarthy, Mark/M-3763-2015	Elliott, Hannah/0000-0002-1500-3533; McCarthy, Mark/0000-0002-4393-0510; Chinnery, Patrick/0000-0002-7065-6617; Patel, Sheila/0000-0002-0626-1899; Hattersley, Andrew/0000-0001-5620-473X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Casteels K, 1999, LANCET, V353, P1499, DOI 10.1016/S0140-6736(98)05817-6; Khogali SS, 2001, LANCET, V357, P1265, DOI 10.1016/S0140-6736(00)04422-6; Liew CF, 2004, DIABETOLOGIA, V47, P2168, DOI 10.1007/s00125-004-1575-4; Livesey KJ, 2004, J MED GENET, V41, P6, DOI 10.1136/jmg.2003.008805; Poulton J, 1998, DIABETOLOGIA, V41, P54, DOI 10.1007/s001250050866; Poulton J, 2002, HUM MOL GENET, V11, P1581, DOI 10.1093/hmg/11.13.1581; Wiltshire S, 2001, AM J HUM GENET, V69, P553, DOI 10.1086/323249	7	54	59	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 5	2005	366	9497					1650	1651		10.1016/S0140-6736(05)67492-2	http://dx.doi.org/10.1016/S0140-6736(05)67492-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271646				2022-12-28	WOS:000233047100026
J	Koren, G				Koren, G			Congenital varicella syndrome in the third trimester	LANCET			English	Editorial Material									Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids)	Koren, G (corresponding author), Hosp Sick Children, Div Clin Pharmacol & Toxicol, Toronto, ON M5G 1X8, Canada.	gkoren@sickkids.on.ca	Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				Enders G., 2000, VARICELLA ZOSTER VIR, P317; Koren G, 2003, CAN FAM PHYSICIAN, V49, P1445; LAFORET EG, 1947, NEW ENGL J MED, V236, P534, DOI 10.1056/NEJM194704102361504; POCOCK N, 2005, DRUGS THER B, V43, P69; Sauerbrei A, 2003, MONATSSCHR KINDERH, V151, P209, DOI 10.1007/s00112-002-0478-z; Tan MP, 2006, REPROD TOXICOL, V21, P410, DOI 10.1016/j.reprotox.2005.04.011	6	15	17	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1591	1592		10.1016/S0140-6736(05)67643-X	http://dx.doi.org/10.1016/S0140-6736(05)67643-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271630				2022-12-28	WOS:000233047100006
J	Adhikary, S; Marinoni, F; Hock, A; Hulleman, E; Popov, N; Beier, R; Bernard, S; Quarto, M; Capra, M; Goettig, S; Kogel, U; Scheffner, M; Helin, K; Eilers, M				Adhikary, S; Marinoni, F; Hock, A; Hulleman, E; Popov, N; Beier, R; Bernard, S; Quarto, M; Capra, M; Goettig, S; Kogel, U; Scheffner, M; Helin, K; Eilers, M			The ubiquitin ligase HectH9 regulates transcriptional activation by myc and is essential for tumor cell proliferation	CELL			English	Article							SMALL-MOLECULE ANTAGONISTS; C-MYC; ONCOGENIC TRANSFORMATION; DEPENDENT DEGRADATION; PROTEIN; PROTEOLYSIS; COMPLEX; INACTIVATION; COFACTOR; PROMOTER	The Myc oncoprotein forms a binary activating complex with its partner protein, Max, and a ternary repressive complex that, in addition to Max, contains the zinc finger protein Miz1. Here we show that the E3 ubiquitin ligase HectH9 ubiquitinates Myc in vivo and in vitro, forming a lysine 63-linked polyubiquitin chain. Miz1 inhibits this ubiquitination. HectH9-mediated ubiquitination of Myc is required for transactivation of multiple target genes, recruitment of the coactivator p300, and induction of cell proliferation by Myc. HectH9 is overexpressed in multiple human tumors and is essential for proliferation of a subset of tumor cells. Our results suggest that site-specific ubiquitination regulates the switch between an activating and a repressive state of the Myc protein, and they suggest a strategy to interfere with Myc function in vivo.	European Inst Oncol, I-20141 Milan, Italy; Univ Marburg, Inst Mol Biol & Tumor Res, D-35033 Marburg, Germany; FIRC Inst Mol Oncol, I-20135 Milan, Italy; Biotech Res & Innovat Ctr, DK-2100 Copenhagen, Denmark; Univ Konstanz, Dept Biol, D-78457 Constance, Germany	IRCCS European Institute of Oncology (IEO); Philipps University Marburg; IFOM - FIRC Institute of Molecular Oncology; University of Konstanz	Helin, K (corresponding author), European Inst Oncol, Via Ripamonti 435, I-20141 Milan, Italy.	kristian.helin@bric.dk; eilers@imt.uni-marburg.de	Helin, Kristian/HDM-8306-2022; Helin, Kristian/K-2526-2019; Hulleman, Esther/AAD-7073-2021; Scheffner, Martin/K-2940-2012	Helin, Kristian/0000-0003-1975-6097; Scheffner, Martin/0000-0003-2229-0128; Hulleman, Esther/0000-0001-9256-947X; Eilers, Martin/0000-0002-0376-6533				Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Berg T, 2002, P NATL ACAD SCI USA, V99, P3830, DOI 10.1073/pnas.062036999; Bres V, 2003, NAT CELL BIOL, V5, P754, DOI 10.1038/ncb1023; Brummelkamp TR, 2002, CANCER CELL, V2, P243, DOI 10.1016/S1535-6108(02)00122-8; Chen DL, 2005, CELL, V121, P1071, DOI 10.1016/j.cell.2005.03.037; Datta A, 2004, J BIOL CHEM, V279, P36698, DOI 10.1074/jbc.M312305200; Eisenman RN, 2001, GENE DEV, V15, P2023, DOI 10.1101/gad928101; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Flick K, 2004, NAT CELL BIOL, V6, P634, DOI 10.1038/ncb1143; Frank SR, 2003, EMBO REP, V4, P575, DOI 10.1038/sj.embor.embor861; GU J, 1994, MOL BRAIN RES, V24, P77, DOI 10.1016/0169-328X(94)90120-1; Herold S, 2002, MOL CELL, V10, P509, DOI 10.1016/S1097-2765(02)00633-0; HUIBREGTSE JM, 1995, P NATL ACAD SCI USA, V92, P2563, DOI 10.1073/pnas.92.7.2563; Jain M, 2002, SCIENCE, V297, P102, DOI 10.1126/science.1071489; Kaiser P, 2000, CELL, V102, P303, DOI 10.1016/S0092-8674(00)00036-2; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; Kononen J, 1998, NAT MED, V4, P844, DOI 10.1038/nm0798-844; Kuras L, 2002, MOL CELL, V10, P69, DOI 10.1016/S1097-2765(02)00561-0; Linares LK, 2003, P NATL ACAD SCI USA, V100, P12009, DOI 10.1073/pnas.2030930100; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RUGARLI EI, 1993, NAT GENET, V4, P19, DOI 10.1038/ng0593-19; Salghetti SE, 1999, EMBO J, V18, P717, DOI 10.1093/emboj/18.3.717; Schuhmacher M, 2001, NUCLEIC ACIDS RES, V29, P397, DOI 10.1093/nar/29.2.397; Vassilev LT, 2004, SCIENCE, V303, P844, DOI 10.1126/science.1092472; Vervoorts J, 2003, EMBO REP, V4, P484, DOI 10.1038/sj.embor.embor821; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X; Walker W, 2005, J CELL BIOL, V169, P405, DOI 10.1083/jcb.200411013; Welcker M, 2004, P NATL ACAD SCI USA, V101, P9085, DOI 10.1073/pnas.0402770101; Wood MA, 2000, MOL CELL, V5, P321, DOI 10.1016/S1097-2765(00)80427-X; Yada M, 2004, EMBO J, V23, P2116, DOI 10.1038/sj.emboj.7600217; Yeh E, 2004, NAT CELL BIOL, V6, P308, DOI 10.1038/ncb1110	32	299	311	1	17	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					409	421		10.1016/j.cell.2005.08.016	http://dx.doi.org/10.1016/j.cell.2005.08.016			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269333	Green Submitted, Bronze			2022-12-28	WOS:000233264300010
J	Zeller, D; Booth, S				Zeller, D; Booth, S			Costs and benefits of regulating mercury	SCIENCE			English	Letter							CHILDREN		Univ British Columbia, Fisheries Ctr, Vancouver, BC V6T 1Z4, Canada	University of British Columbia	Zeller, D (corresponding author), Univ British Columbia, Fisheries Ctr, Vancouver, BC V6T 1Z4, Canada.	d.zeller@fisheries.ubc.ca		Zeller, Dirk/0000-0001-7304-4125				Dietrich KN, 2004, PEDIATRICS, V114, P19, DOI 10.1542/peds.114.1.19; Grandjean P, 1997, NEUROTOXICOL TERATOL, V19, P417, DOI 10.1016/S0892-0362(97)00097-4; Liu XC, 2002, PEDIATRICS, V110, P787, DOI 10.1542/peds.110.4.787; Trasande L, 2005, ENVIRON HEALTH PERSP, V113, P590, DOI 10.1289/ehp.7743	4	8	8	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					777	777						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272100				2022-12-28	WOS:000233121800018
J	Croft, MT; Lawrence, AD; Raux-Deery, E; Warren, MJ; Smith, AG				Croft, MT; Lawrence, AD; Raux-Deery, E; Warren, MJ; Smith, AG			Algae acquire vitamin B-12 through a symbiotic relationship with bacteria	NATURE			English	Article							COBALAMIN VITAMIN-B-12; ESCHERICHIA-COLI; METABOLISM; REDUCTASE; EVOLUTION; FOLATE; GENOME	Vitamin B-12 ( cobalamin) was identified nearly 80 years ago as the anti- pernicious anaemia factor in liver(1), and its importance in human health and disease has resulted in much work on its uptake(2), cellular transport(3) and utilization(4). Plants do not contain cobalamin because they have no cobalamin-dependent enzymes. Deficiencies are therefore common in strict vegetarians(5), and in the elderly, who are susceptible to an autoimmune disorder that prevents its efficient uptake(6). In contrast, many algae are rich in vitamin B-12, with some species, such as Porphyra yezoensis (Nori), containing as much cobalamin as liver(7). Despite this, the role of the cofactor in algal metabolism remains unknown, as does the source of the vitamin for these organisms. A survey of 326 algal species revealed that 171 species require exogenous vitamin B-12 for growth, implying that more than half of the algal kingdom are cobalamin auxotrophs. Here we show that the role of vitamin B-12 in algal metabolism is primarily as a cofactor for vitamin B-12-dependent methionine synthase, and that cobalamin auxotrophy has arisen numerous times throughout evolution, probably owing to the loss of the vitamin B-12-independent form of the enzyme. The source of cobalamin seems to be bacteria, indicating an important and unsuspected symbiosis.	Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England; Univ Kent, Dept Biosci, Canterbury CT2 7NJ, Kent, England	University of Cambridge; University of Kent	Smith, AG (corresponding author), Univ Cambridge, Dept Plant Sci, Cambridge CB2 3EA, England.	as25@cam.ac.uk		Warren, Martin/0000-0002-6028-6456; Smith, Alison Gail/0000-0001-6511-5704				Armbrust EV, 2004, SCIENCE, V306, P79, DOI 10.1126/science.1101156; Banerjee R, 2003, ANNU REV BIOCHEM, V72, P209, DOI 10.1146/annurev.biochem.72.121801.161828; Butler A, 1998, SCIENCE, V281, P207, DOI 10.1126/science.281.5374.207; Cantu C, 2004, STROKE, V35, P1790, DOI 10.1161/01.STR.0000132570.24618.78; Carlucci A. F., 1970, Bull. Scripps Instn Oceanogr. tech. Ser., V17, P23; CARLUCCI A F, 1970, Journal of Phycology, V6, P393, DOI 10.1111/j.1529-8817.1970.tb02413.x; Durnford DG, 1999, J MOL EVOL, V48, P59, DOI 10.1007/PL00006445; Field CB, 1998, SCIENCE, V281, P237, DOI 10.1126/science.281.5374.237; GONZALEZ JC, 1992, BIOCHEMISTRY-US, V31, P6045, DOI 10.1021/bi00141a013; HAMILTON FD, 1974, J BIOL CHEM, V249, P4428; KANAZAWA A, 1963, B JAP SOC SCI FISH, V29, P713; KESHTACHERLIEBSON E, 1995, APPL ENVIRON MICROB, V61, P2439, DOI 10.1128/AEM.61.6.2439-2441.1995; Kurata A., 1986, P185; Lane DJ, 1991, NUCL ACID TECHNIQUES, P115, DOI DOI 10.1007/S00227-012-2133-0; Matsuzaki M, 2004, NATURE, V428, P653, DOI 10.1038/nature02398; Minot George R., 2001, Yale Journal of Biology and Medicine, V74, P341; Miyamoto E, 2004, COMP BIOCHEM PHYS B, V138, P163, DOI 10.1016/j.cbpc.2004.03.006; Murakami A, 2004, SCIENCE, V303, P1633, DOI 10.1126/science.1095459; PROVASOLI L, 1974, ALGAL PHYSL BIOCH, P741; Raux E, 1996, J BACTERIOL, V178, P753, DOI 10.1128/jb.178.3.753-767.1996; Scott J, 1994, ESSAYS BIOCHEM, V28, P63; SEETHARAM B, 1982, ANNU REV NUTR, V2, P343, DOI 10.1146/annurev.nu.02.070182.002015; Seetharam B, 1999, J NUTR, V129, P1761, DOI 10.1093/jn/129.10.1761; Stabler SP, 2004, ANNU REV NUTR, V24, P299, DOI 10.1146/annurev.nutr.24.012003.132440; TROXLER RF, 1972, BIOCHEMISTRY-US, V11, P4235, DOI 10.1021/bi00773a007; Warren MJ, 2002, NAT PROD REP, V19, P390, DOI 10.1039/B108967F; Watanabe F, 2000, BIOSCI BIOTECH BIOCH, V64, P2712, DOI 10.1271/bbb.64.2712; WATANABE F, 1991, BIOCHIM BIOPHYS ACTA, V1075, P36	28	828	871	31	326	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					90	93		10.1038/nature04056	http://dx.doi.org/10.1038/nature04056			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267554				2022-12-28	WOS:000232979000047
J	Kashlinsky, A; Arendt, RG; Mather, J; Moseley, SH				Kashlinsky, A; Arendt, RG; Mather, J; Moseley, SH			Tracing the first stars with fluctuations of the cosmic infrared background	NATURE			English	Article							PROBE WMAP OBSERVATIONS; ARRAY CAMERA IRAC; EXPERIMENT SEARCH; 1ST STARS; MIDINFRARED OBSERVATIONS; DIRBE; EMISSION; GALAXIES; MICRONS; 2MASS	The deepest space- and ground-based observations find metal-enriched galaxies at cosmic times when the Universe was less than 1 Gyr old. These stellar populations had to be preceded by the metal-free first stars, known as 'population III'. Recent cosmic microwave background polarization measurements indicate that stars started forming early - when the Universe was <= 200 Myr old. It is now thought that population III stars were significantly more massive than the present metal-rich stellar populations. Although such sources will not be individually detectable by existing or planned telescopes, they would have produced significant cosmic infrared background radiation in the near-infrared, whose fluctuations reflect the conditions in the primordial density field. Here we report a measurement of diffuse flux fluctuations after removing foreground stars and galaxies. The anisotropies exceed the instrument noise and the more local foregrounds; they can be attributed to emission from population III stars, at an era dominated by these objects.	Observat Cosmol Lab, Greenbelt, MD 20771 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA; SSAI, Greenbelt, MD 20771 USA	National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Kashlinsky, A (corresponding author), Observat Cosmol Lab, Greenbelt, MD 20771 USA.	kashlinsky@stars.gsfc.nasa.gov	Moseley, Harvey/D-5069-2012	Arendt, Richard/0000-0001-8403-8548				Abel T, 2002, SCIENCE, V295, P93, DOI 10.1126/science.1063991; Arendt RG, 1998, ASTROPHYS J, V508, P74, DOI 10.1086/306381; Barmby P, 2004, ASTROPHYS J SUPPL S, V154, P97, DOI 10.1086/422712; Bennett CL, 2003, ASTROPHYS J SUPPL S, V148, P1, DOI 10.1086/377253; Bertin E, 1996, ASTRON ASTROPHYS SUP, V117, P393, DOI 10.1051/aas:1996164; Bromm V, 1999, ASTROPHYS J, V527, pL5, DOI 10.1086/312385; Bromm V, 2004, ANNU REV ASTRON ASTR, V42, P79, DOI 10.1146/annurev.astro.42.053102.134034; Cambresy L, 2001, ASTROPHYS J, V555, P563, DOI 10.1086/321470; Cooray A, 2004, ASTROPHYS J, V606, P611, DOI 10.1086/383137; Cowie LL, 1996, ASTRON J, V112, P839, DOI 10.1086/118058; Dwek E, 1998, ASTROPHYS J, V508, pL9, DOI 10.1086/311714; Eisenhardt PR, 2004, ASTROPHYS J SUPPL S, V154, P48, DOI 10.1086/423180; Fazio GG, 2004, ASTROPHYS J SUPPL S, V154, P39, DOI 10.1086/422585; Fixsen DJ, 2000, ASTROPHYS J SUPPL S, V128, P651, DOI 10.1086/313390; GAUTIER TN, 1992, ASTRON J, V103, P1313, DOI 10.1086/116144; Gorjian V, 2000, ASTROPHYS J, V536, P550, DOI 10.1086/308974; Hauser MG, 1998, ASTROPHYS J, V508, P25, DOI 10.1086/306379; Hauser MG, 2001, ANNU REV ASTRON ASTR, V39, P249, DOI 10.1146/annurev.astro.39.1.249; Hogbom J. A., 1974, Astronomy and Astrophysics Supplement Series, V15, P417; Ingalls JG, 2004, ASTROPHYS J SUPPL S, V154, P281, DOI 10.1086/422718; KAISER N, 1984, ASTROPHYS J, V284, pL9, DOI 10.1086/184341; Kashlinsky A, 2004, ASTROPHYS J, V608, P1, DOI 10.1086/386365; Kashlinsky A, 2005, PHYS REP, V409, P361, DOI 10.1016/j.physrep.2004.12.005; Kashlinsky A, 2002, ASTROPHYS J, V579, pL53, DOI 10.1086/345335; Kashlinsky A, 1998, ASTROPHYS J, V492, P1, DOI 10.1086/305027; Kashlinsky A, 2000, ASTROPHYS J, V528, P74, DOI 10.1086/308172; KASHLINSKY A, 1999, CLUSTERING DIFFUSE I, V4; Kelsall T, 1998, ASTROPHYS J, V508, P44, DOI 10.1086/306380; Kogut A, 2003, ASTROPHYS J SUPPL S, V148, P161, DOI 10.1086/377219; MADDOX SJ, 1990, MON NOT R ASTRON SOC, V242, pP43, DOI 10.1093/mnras/242.1.43P; Magliocchetti M, 2003, MON NOT R ASTRON SOC, V342, pL25, DOI 10.1046/j.1365-8711.2003.06733.x; Matsumoto T, 2005, ASTROPHYS J, V626, P31, DOI 10.1086/429383; Miralda-Escude J, 2003, SCIENCE, V300, P1904, DOI 10.1126/science.1085325; Odenwald S, 2003, ASTROPHYS J, V583, P535, DOI 10.1086/345401; Oliver S, 2004, ASTROPHYS J SUPPL S, V154, P30, DOI 10.1086/422886; PEACOCK JA, 1996, MNRAS, V280, P19; Perlmutter S, 1999, ASTROPHYS J, V517, P565, DOI 10.1086/307221; REES MJ, 1978, NATURE, V275, P35, DOI 10.1038/275035a0; Salvaterra R, 2003, MON NOT R ASTRON SOC, V339, P973, DOI 10.1046/j.1365-8711.2003.06244.x; Santos MR, 2002, MON NOT R ASTRON SOC, V336, P1082, DOI 10.1046/j.1365-8711.2002.05895.x; Shapley AE, 2005, ASTROPHYS J, V626, P698, DOI 10.1086/429990; Springel V, 2005, NATURE, V435, P629, DOI 10.1038/nature03597; Steidel CC, 2005, ASTROPHYS J, V626, P44, DOI 10.1086/429989; Tegmark M, 2004, PHYS REV D, V69, DOI 10.1103/PhysRevD.69.103501; Wright EL, 1998, ASTROPHYS J, V496, P1, DOI 10.1086/305345; Wright EL, 2001, ASTROPHYS J, V553, P538, DOI 10.1086/320942; Wright EL, 2000, ASTROPHYS J, V545, P43, DOI 10.1086/317776	49	158	158	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					45	50		10.1038/nature04143	http://dx.doi.org/10.1038/nature04143			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267547				2022-12-28	WOS:000232979000037
J	Unsworth, MJ; Jones, AG; Wei, W; Marquis, G; Gokarn, SG; Spratt, JE				Unsworth, MJ; Jones, AG; Wei, W; Marquis, G; Gokarn, SG; Spratt, JE		INDEPTH-MT Team	Crustal rheology of the Himalaya and Southern Tibet inferred from magnetotelluric data	NATURE			English	Article							EXPERIMENTAL DEFORMATION; EVOLUTION; PLATEAU; GRANITE; CHANNEL; GROWTH; FLUIDS; MELT	The Cenozoic collision between the Indian and Asian continents formed the Tibetan plateau, beginning about 70 million years ago. Since this time, at least 1,400 km of convergence has been accommodated(1) by a combination of underthrusting of Indian(2) and Asian lithosphere, crustal shortening(3), horizontal extrusion(4) and lithospheric delamination(5). Rocks exposed in the Himalaya show evidence of crustal melting(1,6) and are thought to have been exhumed by rapid erosion and climatically forced crustal flow(7,8). Magnetotelluric data can be used to image subsurface electrical resistivity, a parameter sensitive to the presence of interconnected fluids in the host rock matrix, even at low volume fractions. Here we present magnetotelluric data from the Tibetan - Himalayan orogen from 77 degrees E to 92 degrees E, which show that low resistivity, interpreted as a partially molten layer, is present along at least 1,000 km of the southern margin of the Tibetan plateau. The inferred low viscosity of this layer is consistent with the development of climatically forced crustal flow in Southern Tibet.	Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada; Dublin Inst Adv Studies, Sch Cosm Phys, Dublin 2, Ireland; China Univ Geosci, Minist Educ, Geodetect Lab, Beijing 100083, Peoples R China; Univ Strasbourg, EOST IPGS, EOST ULP, UMR 7516, F-67084 Strasbourg, France; Indian Inst Geomagnetism, Bombay 400005, Maharashtra, India	University of Alberta; Dublin Institute for Advanced Studies; China University of Geosciences; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Earth Sciences & Astronomy (INSU); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg; Department of Science & Technology (India); Indian Institute of Geomagnetism (IIG)	Unsworth, MJ (corresponding author), Univ Alberta, Dept Phys, Edmonton, AB T6G 2J1, Canada.	unsworth@phys.Ualberta.ca	Jones, Alan G/A-3241-2009; Ledo, Juanjo/K-4420-2014; Unsworth, Martyn J/A-6395-2012	Jones, Alan G/0000-0002-3482-2518; Ledo, Juanjo/0000-0003-1548-1575; Unsworth, Martyn J/0000-0001-8282-4174; Bedrosian, Paul/0000-0002-6786-1038				Argand E., 1924, INT GEOL C REP SESS, P171; ARMIJO R, 1986, J GEOPHYS RES-SOLID, V91, P13803, DOI 10.1029/JB091iB14p13803; Beaumont C, 2001, NATURE, V414, P738, DOI 10.1038/414738a; Clark MK, 2000, GEOLOGY, V28, P703, DOI 10.1130/0091-7613(2000)28<703:TOBTEM>2.0.CO;2; DEWEY JF, 1973, J GEOL, V81, P683, DOI 10.1086/627920; FRANCHETEAU J, 1984, NATURE, V307, P32, DOI 10.1038/307032a0; Gaillard F, 2004, GEOLOGY, V32, P801, DOI 10.1130/G20577.1; Gokarn SG, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014325; Grujic D, 2002, EARTH PLANET SC LETT, V198, P177, DOI 10.1016/S0012-821X(02)00482-X; JONES AG, 1989, J GEOPHYS RES-SOLID, V94, P14201, DOI 10.1029/JB094iB10p14201; Lee J, 2000, TECTONICS, V19, P872, DOI 10.1029/1999TC001147; LEFORT P, 1987, TECTONOPHYSICS, V134, P39, DOI 10.1016/0040-1951(87)90248-4; Lemonnier C, 1999, GEOPHYS RES LETT, V26, P3261, DOI 10.1029/1999GL008363; Li SH, 2003, GEOPHYS J INT, V153, P289, DOI 10.1046/j.1365-246X.2003.01850.x; Makovsky Y, 1999, J GEOPHYS RES-SOL EA, V104, P10795, DOI 10.1029/1998JB900074; McNeice GW, 2001, GEOPHYSICS, V66, P158, DOI 10.1190/1.1444891; MOLNAR P, 1993, REV GEOPHYS, V31, P357, DOI 10.1029/93RG02030; Nelson KD, 1996, SCIENCE, V274, P1684, DOI 10.1126/science.274.5293.1684; Owens TJ, 1997, NATURE, V387, P37, DOI 10.1038/387037a0; PHAM VN, 1986, NATURE, V319, P310, DOI 10.1038/319310a0; Renner J, 2000, EARTH PLANET SC LETT, V181, P585, DOI 10.1016/S0012-821X(00)00222-3; Rodi W, 2001, GEOPHYSICS, V66, P174, DOI 10.1190/1.1444893; Rosenberg CL, 2005, J METAMORPH GEOL, V23, P19, DOI 10.1111/j.1525-1314.2005.00555.x; RUTTER EH, 1995, J GEOPHYS RES-SOL EA, V100, P15697, DOI 10.1029/94JB03388; Schilling FR, 1997, PHYS EARTH PLANET IN, V103, P17, DOI 10.1016/S0031-9201(97)00011-3; Spratt JE, 2005, PHYS EARTH PLANET IN, V150, P227, DOI 10.1016/j.pepi.2004.08.035; Tapponnier P, 2001, SCIENCE, V294, P1671, DOI 10.1126/science.105978; VANDERMOLEN I, 1979, CONTRIB MINERAL PETR, V70, P299, DOI 10.1007/BF00375359; Wei WB, 2001, SCIENCE, V292, P716, DOI 10.1126/science.1010580; Yin A, 2000, ANNU REV EARTH PL SC, V28, P211, DOI 10.1146/annurev.earth.28.1.211	30	380	432	11	114	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					78	81		10.1038/nature04154	http://dx.doi.org/10.1038/nature04154			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267552				2022-12-28	WOS:000232979000044
J	Mullan, F				Mullan, F			The metrics of the physician brain drain	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MEDICAL MIGRATION; HEALTH-PROFESSIONALS; HUMAN-RESOURCES; COUNTRIES; CRISIS	BACKGROUND: There has been substantial immigration of physicians to developed countries, much of it coming from lower-income countries. Although the recipient nations and the immigrating physicians benefit from this migration, less developed countries lose important health capabilities as a result of the loss of physicians. METHODS: Data on the countries of origin, based on countries of medical education, of international medical graduates practicing in the United States, the United Kingdom, Canada, and Australia were obtained from sources in the respective countries and analyzed separately and in aggregate. With the use of World Health Organization data, I computed an emigration factor for the countries of origin of the immigrant physicians to provide a relative measure of the number of physicians lost by emigration. RESULTS: International medical graduates constitute between 23 and 28 percent of physicians in the United States, the United Kingdom, Canada, and Australia, and lower-income countries supply between 40 and 75 percent of these international medical graduates. India, the Philippines, and Pakistan are the leading sources of international medical graduates. The United Kingdom, Canada, and Australia draw a substantial number of physicians from South Africa, and the United States draws very heavily from the Philippines. Nine of the 20 countries with the highest emigration factors are in sub-Saharan Africa or the Caribbean. CONCLUSIONS: Reliance on international medical graduates in the United States, the United Kingdom, Canada, and Australia is reducing the supply of physicians in many lower-income countries.	George Washington Univ, Sch Publ Hlth & Hlth Serv, Washington, DC 20006 USA	George Washington University	Mullan, F (corresponding author), George Washington Univ, Sch Publ Hlth & Hlth Serv, Suite 800,2021 K St NW, Washington, DC 20006 USA.	fmullan@gwu.edu						*AM MED ASS, 2005, AMA PHYS MAST; *AUSTR MED WORKF A, 2003, ANN REP; Buchan J., 2004, INT RECRUITMENT HLTH; Bundred PE, 2000, LANCET, V356, P245, DOI 10.1016/S0140-6736(00)02492-2; *CAN I HLTH, 2005, CAN I HLTH INF HOM P; Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; COMMANDER SJ, 2005, BRAIN DRAIN CURSE BO; Cooper RA, 2004, ANN INTERN MED, V141, P705, DOI 10.7326/0003-4819-141-9-200411020-00012; *COUNC GRAD MED ED, 1996, 11 COUNC GRAD MED ED, P9; Ehman AJ, 2001, CAN MED ASSOC J, V164, P387; Emeagwali P., 2010, THE BRAIN DRAIN; *FED PROV TERR ADV, 2004, REP CAN TASK FORC LI; Habte D, 2004, WORLD HOSP HLTH SERV, V40, P40; Habte Demissie, 2004, World Hosp Health Serv, V40, P23; Hawthorne L., 2004, PEOPLE PLACE, V12, P83; Loefler IJP, 2000, LANCET, V356, P1196, DOI 10.1016/S0140-6736(05)72896-8; LOHR K, 1996, NATIONS PHYS WORKFOR, P6; Martineau T, 2004, HEALTH POLICY, V70, P1, DOI 10.1016/j.healthpol.2004.01.006; MEJIA A, 1976, WHO CHRON, V30, P455; MULLAN F, 1995, JAMA-J AM MED ASSOC, V273, P1521, DOI 10.1001/jama.273.19.1521; MULLAN F, 2005, HEALERS ABROAD AM RE, P16; Narasimhan V, 2004, LANCET, V363, P1469, DOI 10.1016/S0140-6736(04)16108-4; *NAT HLTH SERV, 2000, NHS PLAN PLAN INV PL, P50; *ORG EC COOP DEV, 2004, HIGH PERF HLTH SYST, P184; Pang T, 2002, BMJ-BRIT MED J, V324, P499, DOI 10.1136/bmj.324.7336.499; Patel V, 2003, BRIT MED J, V327, P926, DOI 10.1136/bmj.327.7420.926; SIMOENS S, IN PRESS OECD HLTH W; SINGH NK, 2005, INDIAN EXPRESS  0426; Stilwell B, 2004, B WORLD HEALTH ORGAN, V82, P595; Waldman A., 2004, NY TIMES        0724; *WORLD BANK GROUP, DAT STAT RAT COUNTR; World Health Organization, 2005, GLOB ATL HLTH WORKF GLOB ATL HLTH WORKF; YOUNG R, 2003, INT MARKET MED DOCTO; Zurn Pascal, 2004, Hum Resour Health, V2, P13, DOI 10.1186/1478-4491-2-13; 2005, AM MED NEWS     0314	35	510	517	3	60	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1810	1818		10.1056/NEJMsa050004	http://dx.doi.org/10.1056/NEJMsa050004			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251537	Bronze			2022-12-28	WOS:000232813000009
J	Saper, CB; Scammell, TE; Lu, J				Saper, CB; Scammell, TE; Lu, J			Hypothalamic regulation of sleep and circadian rhythms	NATURE			English	Review							VENTROLATERAL PREOPTIC NUCLEUS; SUPRACHIASMATIC NUCLEUS; BASAL FOREBRAIN; TUBEROMAMMILLARY NEURONS; GALANINERGIC NEURONS; WAKING DISCHARGE; LOCUS-COERULEUS; CELL GROUPS; LESIONS; BRAIN	A series of findings over the past decade has begun to identify the brain circuitry and neurotransmitters that regulate our daily cycles of sleep and wakefulness. The latter depends on a network of cell groups that activate the thalamus and the cerebral cortex. A key switch in the hypothalamus shuts off this arousal system during sleep. Other hypothalamic neurons stabilize the switch, and their absence results in inappropriate switching of behavioural states, such as occurs in narcolepsy. These findings explain how various drugs affect sleep and wakefulness, and provide the basis for a wide range of environmental influences to shape wake - sleep cycles into the optimal pattern for survival.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Program Neurosci, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Saper, CB (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.	csaper@bidmc.harvard.edu	Saper, Clifford/L-3815-2019					Achermann P, 2003, FRONT BIOSCI-LANDMRK, V8, pS683, DOI 10.2741/1064; ALLEN LS, 1989, J NEUROSCI, V9, P497; ANCOLIISRAEL S, 1991, BIOFEEDBACK SELF-REG, V16, P349, DOI 10.1007/BF00999989; Aston-Jones G, 2001, NAT NEUROSCI, V4, P732, DOI 10.1038/89522; ASTONJONES G, 1981, J NEUROSCI, V1, P876; BENINGTON JH, 1995, PROG NEUROBIOL, V45, P347, DOI 10.1016/0301-0082(94)00057-O; BORBELY AA, 1985, BRAIN MECH SLEEP, P35; Byne W, 2000, BRAIN RES, V856, P254, DOI 10.1016/S0006-8993(99)02458-0; CASSONE VM, 1986, PHYSIOL BEHAV, V36, P1111, DOI 10.1016/0031-9384(86)90488-9; Chamberlin NL, 2003, NEUROSCIENCE, V119, P913, DOI 10.1016/S0306-4522(03)00246-X; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Chou TC, 2002, J NEUROSCI, V22, P977, DOI 10.1523/JNEUROSCI.22-03-00977.2002; CHOU TC, 2003, THESIS HARVARD U CAM, P82; Chou WB, 2002, ACTA PHARMACOL SIN, V23, P691; De Lecea L, 1998, P NATL ACAD SCI USA, V95, P322, DOI 10.1073/pnas.95.1.322; Deurveilher S, 2005, NEUROSCIENCE, V130, P165, DOI 10.1016/j.neuroscience.2004.08.030; DIJK DJ, 1995, J NEUROSCI, V15, P3526; Doran SM, 2001, ARCH ITAL BIOL, V139, P253; Economo CV, 1930, J NERV MENT DIS, V71, P249, DOI 10.1097/00005053-193003000-00001; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1998, P NATL ACAD SCI USA, V95, P741, DOI 10.1073/pnas.95.2.741; Estabrooke IV, 2001, J NEUROSCI, V21, P1656, DOI 10.1523/JNEUROSCI.21-05-01656.2001; FORNAL C, 1985, EXP NEUROL, V88, P590, DOI 10.1016/0014-4886(85)90074-3; Gallopin T, 2000, NATURE, V404, P992, DOI 10.1038/35010109; Gaus SE, 2002, NEUROSCIENCE, V115, P285, DOI 10.1016/S0306-4522(02)00308-1; Gerashchenko D, 2003, NEUROSCIENCE, V116, P223, DOI 10.1016/S0306-4522(02)00575-4; Gooley JJ, 2003, J NEUROSCI, V23, P7093, DOI 10.1523/JNEUROSCI.23-18-07093.2003; HALLANGER AE, 1987, J COMP NEUROL, V262, P105, DOI 10.1002/cne.902620109; HOFMAN MA, 1989, J ANAT, V164, P55; Jin XW, 1999, CELL, V96, P57, DOI 10.1016/S0092-8674(00)80959-9; John J, 2004, NEURON, V42, P619, DOI 10.1016/S0896-6273(04)00247-8; JOHNSON RF, 1988, BRAIN RES, V460, P297, DOI 10.1016/0006-8993(88)90374-5; Jones BE, 2003, FRONT BIOSCI-LANDMRK, V8, pS438, DOI 10.2741/1074; Ko EM, 2003, BRAIN RES, V992, P220, DOI 10.1016/j.brainres.2003.08.044; KOHLER C, 1986, J COMP NEUROL, V250, P58, DOI 10.1002/cne.902500105; Kong JM, 2002, J NEUROSCI, V22, P5581; Krout KE, 2002, J COMP NEUROL, V448, P53, DOI 10.1002/cne.10236; Krout KE, 2002, NEUROSCIENCE, V110, P73, DOI 10.1016/S0306-4522(01)00551-6; Lancel M, 2001, AM J PHYSIOL-ENDOC M, V281, pE130, DOI 10.1152/ajpendo.2001.281.1.E130; Landrigan CP, 2004, NEW ENGL J MED, V351, P1838, DOI 10.1056/NEJMoa041406; Lee MG, 2005, J NEUROSCI, V25, P6716, DOI 10.1523/JNEUROSCI.1887-05.2005; Lee MG, 2005, J NEUROSCI, V25, P4365, DOI 10.1523/JNEUROSCI.0178-05.2005; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lu J, 2002, J NEUROSCI, V22, P4568, DOI 10.1523/JNEUROSCI.22-11-04568.2002; Lu J, 2001, J NEUROSCI, V21, P4864, DOI 10.1523/JNEUROSCI.21-13-04864.2001; Lu J, 2000, J NEUROSCI, V20, P3830, DOI 10.1523/JNEUROSCI.20-10-03830.2000; Marcus JN, 2001, J COMP NEUROL, V435, P6, DOI 10.1002/cne.1190; Martin-Schild S, 1999, J COMP NEUROL, V405, P450, DOI 10.1002/(SICI)1096-9861(19990322)405:4<450::AID-CNE2>3.0.CO;2-#; MCCORMICK DA, 1989, TRENDS NEUROSCI, V12, P215, DOI 10.1016/0166-2236(89)90125-2; MCEWEN BS, 1993, ARCH INTERN MED, V153, P2093, DOI 10.1001/archinte.153.18.2093; MCGINTY DJ, 1968, SCIENCE, V160, P1253, DOI 10.1126/science.160.3833.1253; Meier-Ewert HK, 2004, J AM COLL CARDIOL, V43, P678, DOI 10.1016/j.jacc.2003.07.050; Mileykovskiy BY, 2005, NEURON, V46, P787, DOI 10.1016/j.neuron.2005.04.035; Mochizuki T, 2004, J NEUROSCI, V24, P6291, DOI 10.1523/JNEUROSCI.0586-04.2004; MOORE RY, 1972, BRAIN RES, V42, P201, DOI 10.1016/0006-8993(72)90054-6; MORUZZI G, 1949, ELECTROEN CLIN NEURO, V1, P455, DOI 10.1016/0013-4694(49)90066-8; NAUTA WJH, 1946, J NEUROPHYSIOL, V9, P285, DOI 10.1152/jn.1946.9.4.285; Nelson LE, 2003, ANESTHESIOLOGY, V98, P428, DOI 10.1097/00000542-200302000-00024; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; NYHOLM H, 1955, ANN ZOOL FENN, V2, P77; Peyron C, 1998, J NEUROSCI, V18, P9996; Peyron C, 2000, NAT MED, V6, P991, DOI 10.1038/79690; Porkka-Heiskanen T, 2000, NEUROSCIENCE, V99, P507, DOI 10.1016/S0306-4522(00)00220-7; Prinz PN, 2004, EXP GERONTOL, V39, P1739, DOI 10.1016/j.exger.2004.06.023; RADULOVACKI M, 1984, J PHARMACOL EXP THER, V228, P268; Ranson SW, 1939, ARCH NEURO PSYCHIATR, V41, P1; Reppert SM, 2002, NATURE, V418, P935, DOI 10.1038/nature00965; Ripley B, 2001, NEUROLOGY, V57, P2253, DOI 10.1212/WNL.57.12.2253; Roth T, 2003, SLEEP MED, V4, P275, DOI 10.1016/S1389-9457(03)00058-3; Rudolph U, 2004, ANNU REV PHARMACOL, V44, P475, DOI 10.1146/annurev.pharmtox.44.101802.121429; Sakurai T, 2005, NEURON, V46, P297, DOI 10.1016/j.neuron.2005.03.010; Sakurai T, 1998, CELL, V92, P573, DOI 10.1016/S0092-8674(00)80949-6; Saper C. B., 2004, RAT NERVOUS SYSTEM, V3rd, P761; Saper CB, 2005, TRENDS NEUROSCI, V28, P152, DOI 10.1016/j.tins.2004.12.009; Saper CB, 2004, SLEEP, V27, P11; SAPER CB, 1985, J COMP NEUROL, V237, P21, DOI 10.1002/cne.902370103; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Scammell TE, 2003, ANN NEUROL, V53, P154, DOI 10.1002/ana.10444; Scammell TE, 2001, NEUROSCIENCE, V107, P653, DOI 10.1016/S0306-4522(01)00383-9; Schachter SC, 1998, EPILEPSIA, V39, P677, DOI 10.1111/j.1528-1157.1998.tb01151.x; Shepel PN, 2005, NEUROL RES, V27, P139, DOI 10.1179/016164105x21832; Sherin JE, 1998, J NEUROSCI, V18, P4705; Sherin JE, 1996, SCIENCE, V271, P216, DOI 10.1126/science.271.5246.216; STARZL TE, 1951, J NEUROPHYSIOL, V14, P461, DOI 10.1152/jn.1951.14.6.461; Steininger TL, 1999, BRAIN RES, V840, P138, DOI 10.1016/S0006-8993(99)01648-0; Stephan FK, 2002, J BIOL RHYTHM, V17, P284, DOI 10.1177/074873002129002591; Strecker RE, 2000, BEHAV BRAIN RES, V115, P183, DOI 10.1016/S0166-4328(00)00258-8; Szymusiak R, 1998, BRAIN RES, V803, P178, DOI 10.1016/S0006-8993(98)00631-3; Thannickal TC, 2000, NEURON, V27, P469, DOI 10.1016/S0896-6273(00)00058-1; Thompson RH, 1996, J COMP NEUROL, V376, P143, DOI 10.1002/(SICI)1096-9861(19961202)376:1<143::AID-CNE9>3.0.CO;2-3; Van Dongen HPA, 2003, SLEEP, V26, P117, DOI 10.1093/sleep/26.2.117; Verret L, 2003, BMC NEUROSCI, V4, DOI 10.1186/1471-2202-4-19; VERRET L, IN PRESS J COMP NEUR; VINCENT SR, 1982, NEUROENDOCRINOLOGY, V34, P117, DOI 10.1159/000123288; WATTS AG, 1987, J COMP NEUROL, V258, P204, DOI 10.1002/cne.902580204; WISDEN W, 1992, J NEUROSCI, V12, P1040; Wisor JP, 2001, J NEUROSCI, V21, P1787, DOI 10.1523/JNEUROSCI.21-05-01787.2001; Yamanaka A, 2003, NEURON, V38, P701, DOI 10.1016/S0896-6273(03)00331-3; YOSHIDA K, IN PRESS J COMP NEUR; [No title captured]	100	1626	1705	13	414	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1257	1263		10.1038/nature04284	http://dx.doi.org/10.1038/nature04284			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251950				2022-12-28	WOS:000232829100038
J	Kullberg, BJ; Sobel, JD; Ruhnke, M; Pappas, PG; Viscoli, C; Rex, JH; Cleary, JD; Rubinstein, E; Church, LWP; Brown, JM; Schlamm, HT; Oborska, IT; Hilton, F; Hodges, MR				Kullberg, BJ; Sobel, JD; Ruhnke, M; Pappas, PG; Viscoli, C; Rex, JH; Cleary, JD; Rubinstein, E; Church, LWP; Brown, JM; Schlamm, HT; Oborska, IT; Hilton, F; Hodges, MR			Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial	LANCET			English	Article; Proceedings Paper	14th European Congress of Clinical Microbiology and Infectious Diseases	MAY 01-04, 2004	Prague, CZECH REPUBLIC				BLOOD-STREAM INFECTIONS; IN-VITRO ACTIVITIES; INTERNATIONAL SURVEILLANCE; INVASIVE ASPERGILLOSIS; FUNGAL-INFECTIONS; MULTICENTER TRIAL; CANDIDIASIS; CANDIDEMIA; THERAPY; AGENTS	Background Voriconazole has proven efficacy against invasive aspergillosis and oesophageal candidiasis. This multicentre, randomised, non-inferiority study compared voriconazole with a regimen of amphotericin B followed by fluconazole for the treatment of candidaemia in non-neutropenic patients. Methods Non-neutropenic patients with a positive blood culture for a species of candida. and clinical evidence of infection were enrolled. Patients were randomly assigned, in a 2:1 ratio, either voriconazole (n=283) or amphotericin B followed by fluconazole (n=139). The primary efficacy analysis was based on clinical and mycological response 12 weeks after the end of treatment, assessed by an independent data-review committee unaware of treatment assignment. Findings Of 422 patients randomised, 370 were included in the modified intention-to-treat population. Voriconazole was non-inferior to amphotericin B/fluconazole in the primary efficacy analysis, with successful outcomes in 41% of patients in both treatment groups (95% Cl for difference -10.6% to 10.6%). At the last evaluable assessment, outcome was successful in 162 (65%) patients assigned voriconazole and 87 (71%) assigned amphotericin B/ fluconazole (p=0.25). Voriconazole cleared blood cultures as quickly as amphotericin B/fluconazole (median time to negative blood culture, 2.0 days). Treatment discontinuations due to all-cause adverse events were more frequent in the voriconazole group, although most discontinuations were due to non-drug-related events and there were significantly fewer serious adverse events and cases of renal toxicity than in the amphotericin B/fluconazole group. Interpretation Voriconazole was as effective as the regimen of amphotericin B followed by fluconazole in the treatment of candidaemia in non-neutropenic patients, and with fewer toxic effects. Relevance to practice There are several options for treatment of candidaemia in non-neutropenic patients, including amphotericin B, fluconazole, voriconazole, and echinocandins. Voriconazole can be given both as initial intravenous treatment and as an oral stepdown agent.	Univ Nijmegen, Radboud Univ Nijmegen Med Ctr, Dept Internal Med 484, Ctr Infect Dis, NL-6500 HB Nijmegen, Netherlands; Wayne State Univ, Sch Med, Detroit, MI USA; Humboldt Univ, Charite, Berlin, Germany; Univ Alabama, Birmingham, AL USA; Univ Genoa, Genoa, Italy; Natl Inst Canc Res, Genoa, Italy; Univ Texas, Sch Med, Houston, TX USA; Univ Mississippi, Sch Pharm, Jackson, MS 39216 USA; Tel Aviv Univ, Tel Hashomer, Israel; Med Univ S Carolina, Charleston, SC 29425 USA; Chris Hani Baragwanath Hosp, Johannesburg, South Africa; Pfizer Global Res & Dev, New York, NY USA; Pfizer Global Res & Dev, Sandwich, Kent, England	Radboud University Nijmegen; Wayne State University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; University of Alabama System; University of Alabama Birmingham; University of Genoa; University of Genoa; IRCCS AOU San Martino IST; University of Texas System; University of Mississippi; Tel Aviv University; Medical University of South Carolina; Pfizer; Pfizer	Kullberg, BJ (corresponding author), Univ Nijmegen, Radboud Univ Nijmegen Med Ctr, Dept Internal Med 484, Ctr Infect Dis, POB 9101, NL-6500 HB Nijmegen, Netherlands.	b.kullberg@aig.umcn.nl	Kullberg, BJ/C-8520-2013	Kullberg, BJ/0000-0002-6813-8167; Rex, John/0000-0003-3265-5872				Ally R, 2001, CLIN INFECT DIS, V33, P1447, DOI 10.1086/322653; Bates DW, 2001, CLIN INFECT DIS, V32, P686, DOI 10.1086/319211; Cuenca-Estrella M, 1999, EUR J CLIN MICROBIOL, V18, P432, DOI 10.1007/s100960050313; Denning DW, 2002, CLIN INFECT DIS, V34, P563, DOI 10.1086/324620; Edwards JE, 1997, CLIN INFECT DIS, V25, P43, DOI 10.1086/514504; Herbrecht R, 2002, NEW ENGL J MED, V347, P408, DOI 10.1056/NEJMoa020191; Mora-Duarte J, 2002, NEW ENGL J MED, V347, P2020, DOI 10.1056/NEJMoa021585; Ostrosky-Zeichner L, 2003, EUR J CLIN MICROBIOL, V22, P651, DOI 10.1007/s10096-003-1014-3; Ostrosky-Zeichner L, 2003, ANTIMICROB AGENTS CH, V47, P3149, DOI 10.1128/AAC.47.10.3149-3154.2003; Pappas PG, 2004, CLIN INFECT DIS, V38, P161, DOI 10.1086/380796; Perfect JR, 2003, CLIN INFECT DIS, V36, P1122, DOI 10.1086/374557; Pfaller MA, 1999, DIAGN MICR INFEC DIS, V35, P19, DOI 10.1016/S0732-8893(99)00046-2; Pfaller MA, 2003, J CLIN MICROBIOL, V41, P78, DOI 10.1128/JCM.41.1.78-83.2003; Pfaller MA, 2001, J CLIN MICROBIOL, V39, P3254, DOI 10.1128/JCM.39.9.3254-3259.2001; Phillips P, 1997, EUR J CLIN MICROBIOL, V16, P337, DOI 10.1007/BF01726360; REX JH, 1994, NEW ENGL J MED, V331, P1325, DOI 10.1056/NEJM199411173312001; Rex JH, 2003, CLIN INFECT DIS, V36, P1221, DOI 10.1086/374850; Ruhnke M, 1997, ANTIMICROB AGENTS CH, V41, P575, DOI 10.1128/AAC.41.3.575; TUIL O, 2003, CRIT CARE S2, V7, pS63; Viscoli C, 1999, CLIN INFECT DIS, V28, P1071, DOI 10.1086/514731; Walsh TJ, 2002, PEDIATR INFECT DIS J, V21, P240, DOI 10.1097/00006454-200203000-00015	21	383	410	2	13	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1435	1442		10.1016/S0140-6736(05)67490-9	http://dx.doi.org/10.1016/S0140-6736(05)67490-9			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243088				2022-12-28	WOS:000232724600022
J	Alley, RB; Clark, PU; Huybrechts, P; Joughin, I				Alley, RB; Clark, PU; Huybrechts, P; Joughin, I			Ice-sheet and sea-level changes	SCIENCE			English	Review							LAST GLACIAL MAXIMUM; PINE ISLAND GLACIER; JAKOBSHAVN ISBR-AE; ANTARCTIC ICE; WEST ANTARCTICA; ATMOSPHERIC CO2; MASS-BALANCE; CLIMATE-CHANGE; SURFACE MELT; BREAK-UP	Future sea-level rise is an important issue related to the continuing buildup of atmospheric greenhouse gas concentrations. The Greenland and Antarctic ice sheets, with the potential to raise sea level similar to 70 meters if completely melted, dominate uncertainties in projected sea-level change. Freshwater fluxes from these ice sheets also may affect oceanic circulation, contributing to climate change. Observational and modeling advances have reduced many uncertainties related to ice-sheet behavior, but recently detected, rapid ice-marginal changes contributing to sea-level rise may indicate greater ice-sheet sensitivity to warming than previously considered.	Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Penn State Univ, Earth & Environm Syst Inst, University Pk, PA 16802 USA; Oregon State Univ, Dept Geosci, Corvallis, OR 97331 USA; Alfred Wegener Inst Polar & Marine Res, D-27515 Bremerhaven, Germany; Vrije Univ Brussels, Dept Geog, B-1050 Brussels, Belgium; Univ Washington, Appl Phys Lab, Polar Sci Ctr, Seattle, WA 98105 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Oregon State University; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research; Vrije Universiteit Brussel; University of Washington; University of Washington Seattle	Alley, RB (corresponding author), Penn State Univ, Dept Geosci, Deike Bldg, University Pk, PA 16802 USA.	rba6@psu.edu	Joughin, Ian/AAR-7778-2021; Joughin, Ian R/A-2998-2008; Huybrechts, Philippe/J-5278-2013	Joughin, Ian/0000-0001-6229-679X; Joughin, Ian R/0000-0001-6229-679X; Huybrechts, Philippe/0000-0003-1406-0525				Abdalati W, 2001, J GEOPHYS RES-ATMOS, V106, P33729, DOI 10.1029/2001JD900192; Ahn J, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004415; ALLEY RB, IN PRESS ANN GLACIOL; BARD E, 1990, NATURE, V345, P405, DOI 10.1038/345405a0; Box JE, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004451; Brachfeld S, 2003, GEOLOGY, V31, P749, DOI 10.1130/G19643.1; Bromwich DH, 2004, J CLIMATE, V17, P427, DOI 10.1175/1520-0442(2004)017<0427:MAPPIS>2.0.CO;2; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; Clark PU, 2004, SCIENCE, V304, P1141, DOI 10.1126/science.1094449; Clark PU, 2002, QUATERNARY SCI REV, V21, P1, DOI 10.1016/S0277-3791(01)00118-4; Clark PU, 2002, SCIENCE, V295, P2438; Davis CH, 2005, SCIENCE, V308, P1898, DOI 10.1126/science.1110662; DeConto RM, 2003, NATURE, V421, P245, DOI 10.1038/nature01290; Dupont TK, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL022024; ECHELMEYER K, 1991, J GLACIOL, V37, P368, DOI 10.3189/S0022143000005803; Etheridge DM, 1996, J GEOPHYS RES-ATMOS, V101, P4115, DOI 10.1029/95JD03410; Fahnestock MA, 2000, J GLACIOL, V46, P652, DOI 10.3189/172756500781832693; FAIRBANKS RG, 1989, NATURE, V342, P637, DOI 10.1038/342637a0; Fichefet T, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017826; Fleming K, 1998, EARTH PLANET SC LETT, V163, P327, DOI 10.1016/S0012-821X(98)00198-8; Gregory JM, 2004, NATURE, V428, P616, DOI 10.1038/428616a; Greve R, 2000, CLIMATIC CHANGE, V46, P289, DOI 10.1023/A:1005647226590; Hanebuth T, 2000, SCIENCE, V288, P1033, DOI 10.1126/science.288.5468.1033; Hanna E, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005641; Hindmarsh RCA, 2001, J GLACIOL, V47, P271, DOI 10.3189/172756501781832269; HUGHES TJ, 1981, J GLACIOL, V27, P518, DOI 10.3189/S002214300001159X; Huybrechts P, 2004, GLOBAL PLANET CHANGE, V42, P83, DOI 10.1016/j.gloplacha.2003.11.011; Huybrechts P, 1999, J CLIMATE, V12, P2169, DOI 10.1175/1520-0442(1999)012<2169:TDROTG>2.0.CO;2; Joughin I, 2004, NATURE, V432, P608, DOI 10.1038/nature03130; Joughin I, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017609; Joughin I, 2002, SCIENCE, V295, P476, DOI 10.1126/science.1066875; Joughin I, 1996, SCIENCE, V274, P228, DOI 10.1126/science.274.5285.228; Keeling CD, 1996, NATURE, V382, P146, DOI 10.1038/382146a0; Krabill W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021533; MacAyeal DR, 2003, J GLACIOL, V49, P22, DOI 10.3189/172756503781830863; Mann ME, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017814; Meehl GA, 2005, SCIENCE, V307, P1769, DOI 10.1126/science.1106663; Munk W, 2003, SCIENCE, V300, P2041, DOI 10.1126/science.1085534; Nakicenovic N., 2000, SPECIAL REPORT EMISS; Pagani M, 2005, SCIENCE, V309, P600, DOI 10.1126/science.1110063; Parizek BR, 2004, QUATERNARY SCI REV, V23, P1013, DOI 10.1016/j.quascirev.2003.12.024; Parizek BR, 2003, ANN GLACIOL-SER, V36, P251, DOI 10.3189/172756403781816167; Pattyn F, 2003, J GEOPHYS RES-SOL EA, V108, DOI 10.1029/2002JB002329; Payne AJ, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021284; Podlech S, 2004, J GLACIOL, V50, P153, DOI 10.3189/172756504781830231; Rignot E, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021947; Rignot E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020697; Rignot E, 2002, SCIENCE, V296, P2020, DOI 10.1126/science.1070942; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Rignot EJ, 1998, SCIENCE, V281, P549, DOI 10.1126/science.281.5376.549; Scambos TA, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020670; Schmeltz M, 2002, J GLACIOL, V48, P552, DOI 10.3189/172756502781831061; Shepherd A, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021106; Shepherd A, 2003, SCIENCE, V302, P856, DOI 10.1126/science.1089768; Shepherd A, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2001GL014183; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Thomas RH, 2004, J GLACIOL, V50, P57, DOI 10.3189/172756504781830321; Thomas RH, 2003, J GLACIOL, V49, P231, DOI 10.3189/172756503781830764; Toniazzo T, 2004, J CLIMATE, V17, P21, DOI 10.1175/1520-0442(2004)017<0021:CIOAGD>2.0.CO;2; Turner J, 2002, NATURE, V418, P291, DOI 10.1038/418291b; Visser K, 2003, NATURE, V421, P152, DOI 10.1038/nature01297; Warner RC, 1998, ANN GLACIOL, V27, P161; Weaver AJ, 2003, SCIENCE, V299, P1709, DOI 10.1126/science.1081002; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456; Yokoyama Y, 2000, NATURE, V406, P713, DOI 10.1038/35021035; Zwally HJ, 2002, SCIENCE, V297, P218, DOI 10.1126/science.1072708	66	389	406	6	298	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					456	460		10.1126/science.1114613	http://dx.doi.org/10.1126/science.1114613			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239468	Green Submitted			2022-12-28	WOS:000232786000035
J	Griffith, CA; Penteado, P; Baines, K; Drossart, P; Barnes, J; Bellucci, G; Bibring, J; Brown, R; Buratti, B; Capaccioni, F; Cerroni, P; Clark, R; Combes, M; Coradini, A; Cruikshank, D; Formisano, V; Jaumann, R; Langevin, Y; Matson, D; McCord, T; Mennella, V; Nelson, R; Nicholson, P; Sicardy, B; Sotin, C; Soderblom, LA; Kursinski, R				Griffith, CA; Penteado, P; Baines, K; Drossart, P; Barnes, J; Bellucci, G; Bibring, J; Brown, R; Buratti, B; Capaccioni, F; Cerroni, P; Clark, R; Combes, M; Coradini, A; Cruikshank, D; Formisano, V; Jaumann, R; Langevin, Y; Matson, D; McCord, T; Mennella, V; Nelson, R; Nicholson, P; Sicardy, B; Sotin, C; Soderblom, LA; Kursinski, R			The evolution of Titan's mid-latitude clouds	SCIENCE			English	Article							TROPOSPHERIC CLOUDS; ATMOSPHERE; TEMPERATURES; WINDS	Spectra from Cassini's Visual and Infrared Mapping Spectrometer reveal that the horizontal structure, height, and optical depth of Titan's clouds are highly dynamic. Vigorous cloud centers are seen to rise from the middle to the upper troposphere within 30 minutes and dissipate within the next hour. Their development indicates that Titan's clouds evolve convectively; dissipate through rain; and, over the next several hours, waft downwind to achieve their great longitude extents. These and other characteristics suggest that temperate clouds originate from circulation-induced convergence, in addition to a forcing at the surface associated with Saturn's tides, geology, and/or surface composition.	Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA; CALTECH, Jet Prop Lab, Pasadena, CA 91109 USA; Observ Paris, Meudon, France; CNR, Inst Fis Spazio Interplanetario, Rome, Italy; Univ Paris 11, Inst Astrophys Spatiale, Orsay, France; CNR, Inst Astrofis Spaziale & Fis Cosm, Rome, Italy; US Geol Survey, Denver, CO 80225 USA; NASA, Ames Res Ctr, Mountain View, CA USA; Univ Washington, Dept Earth & Space Sci, Seattle, WA 98195 USA; Osserv Astron Capodimonte, I-80131 Naples, Italy; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Univ Nantes, Lab Planetol & Geodynam, F-44035 Nantes, France; US Geol Survey, Flagstaff, AZ 86001 USA	University of Arizona; California Institute of Technology; National Aeronautics & Space Administration (NASA); NASA Jet Propulsion Laboratory (JPL); UDICE-French Research Universities; PSL Research University Paris; Observatoire de Paris; Consiglio Nazionale delle Ricerche (CNR); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Saclay; Consiglio Nazionale delle Ricerche (CNR); United States Department of the Interior; United States Geological Survey; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University of Washington; University of Washington Seattle; Istituto Nazionale Astrofisica (INAF); Cornell University; Nantes Universite; United States Department of the Interior; United States Geological Survey	Griffith, CA (corresponding author), Univ Arizona, Lunar & Planetary Lab, Tucson, AZ 85721 USA.		Penteado, Paulo/F-9081-2012; Jaumann, Ralf/N-1001-2018; Bellucci, Giancarlo/ABA-9201-2020; Barnes, Jason W/B-1284-2009; Drossart, Pierre/H-8670-2013	Penteado, Paulo/0000-0001-6759-2037; Jaumann, Ralf/0000-0002-9759-6597; Bellucci, Giancarlo/0000-0003-0867-8679; Barnes, Jason W/0000-0002-7755-3530; Mennella, Vito/0000-0001-9525-895X; Capaccioni, Fabrizio/0000-0003-1631-4314; Cerroni, Priscilla/0000-0003-0239-2741				Adamkovics M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019929; AWAL M, 1994, GEOPHYS RES LETT, V21, P2491, DOI 10.1029/94GL01707; BOUCHEZ A, 2003, THESIS CALTECH PASAD; Bouchez AH, 2005, ASTROPHYS J, V618, pL53, DOI 10.1086/427693; Brown ME, 2002, NATURE, V420, P795, DOI 10.1038/nature01302; Brown RH, 2003, ICARUS, V164, P461, DOI 10.1016/S0019-1035(03)00134-9; Elachi C, 2005, SCIENCE, V308, P970, DOI 10.1126/science.1109919; Flasar FM, 2005, SCIENCE, V308, P975, DOI 10.1126/science.1111150; FLASAR FM, 1981, NATURE, V292, P693, DOI 10.1038/292693a0; Gendron E, 2004, ASTRON ASTROPHYS, V417, pL21, DOI 10.1051/0004-6361:20040027; Gibbard SG, 2004, ICARUS, V169, P429, DOI 10.1016/j.icarus.2003.12.026; Griffith CA, 2000, SCIENCE, V290, P509, DOI 10.1126/science.290.5491.509; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; GRIFFITH CS, UNPUB; LELLOUCH E, 1989, ICARUS, V79, P328, DOI 10.1016/0019-1035(89)90081-X; LORENZ RD, 1993, PLANET SPACE SCI, V41, P647, DOI 10.1016/0032-0633(93)90048-7; MCKELLAR ARW, 1989, ICARUS, V80, P361, DOI 10.1016/0019-1035(89)90146-2; NIEMANN HB, 2005, B AM ASTRON SOC, V37, P621; Porco CC, 2005, NATURE, V434, P159, DOI 10.1038/nature03436; Rannou P, 2004, ICARUS, V170, P443, DOI 10.1016/j.icarus.2004.03.007; Rannou P, 2002, NATURE, V418, P853, DOI 10.1038/nature00961; RANNOU P, 2005, COSPAR SCI ASS 2004, P1272; Roe HG, 2005, ASTROPHYS J, V618, pL49, DOI 10.1086/427499; Roe HG, 2002, ASTROPHYS J, V581, P1399, DOI 10.1086/344403; Rothman LS, 2003, J QUANT SPECTROSC RA, V82, P5, DOI 10.1016/S0022-4073(03)00146-8; STAMNES K, 1988, APPL OPTICS, V27, P2502, DOI 10.1364/AO.27.002502; Tokano T, 2005, ICARUS, V173, P222, DOI 10.1016/j.icarus.2004.08.019; Tokano T, 2002, ICARUS, V158, P499, DOI 10.1006/icar.2002.6883; TOMASKO MG, 1997, ESA SP PUBL, V1177, P345; TOON OB, 1988, ICARUS, V75, P255, DOI 10.1016/0019-1035(88)90005-X	30	121	122	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					474	477		10.1126/science.1117702	http://dx.doi.org/10.1126/science.1117702			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239472				2022-12-28	WOS:000232786000041
J	Armstrong, DG; Lavery, LA				Armstrong, DG; Lavery, LA		Diabet Foot Study Consortium	Negative pressure wound therapy after partial diabetic foot amputation: a multicentre, randomised controlled trial	LANCET			English	Article							MANAGEMENT; ULCERS; RISK; DERMAGRAFT	Background Diabetic foot wounds, particularly those secondary to amputation, are very complex and difficult to treat. We investigated whether negative pressure wound therapy (NPWT) improves the proportion and rate of wound healing after partial foot amputation in patients with diabetes. Methods We enrolled 162 patients into a 16-week, 18-centre, randomised clinical trial in the USA. Inclusion criteria consisted of partial foot amputation wounds up to the transmetatarsal level and evidence of adequate perfusion. Patients who were randomly assigned to NPWT (n=77) received treatment with dressing changes every 48 h. Control patients (n=85) received standard moist wound care according to consensus guidelines. NPWT was delivered through the Vacuum Assisted Closure (VAC) Therapy System. Wounds were treated until healing or completion of the 112-day period of active treatment. Analysis was by intention to treat. This study has been registered with ClinicalTrials.gov, number NCT00224796. Findings More patients healed in the NPWT group than in the control group (43 [56%] vs 33 [39%], p=0.040). The rate of wound healing, based on the time to complete closure, was faster in the NPWT group than in controls (p=0.005). The rate of granulation tissue formation, based on the time to 76-100% formation in the wound bed, was faster in the NPWT group than in controls (p=0.002). The frequency and severity of adverse events (of which the most common was wound infection) were similar in both treatment groups. Interpretation NPWT delivered by the VAC Therapy System seems to be a safe and effective treatment for complex diabetic foot wounds, and could lead to a higher proportion of healed wounds, faster healing rates, and potentially fewer re-amputations than standard care.	Rosalind Franklin Univ Med & Sci, Scholls Ctr Lower Extrem Ambulatory Res, Chicago, IL 60064 USA; Texas A&M Univ, Hlth Sci Ctr, Coll Med, Scott & White Hosp,Dept Surg, Temple, TX USA	Chicago Medical School; Rosalind Franklin University Medical & Science; Texas A&M University System; Texas A&M University College Station; Texas A&M Health Science Center	Armstrong, DG (corresponding author), Rosalind Franklin Univ Med & Sci, Scholls Ctr Lower Extrem Ambulatory Res, Chicago, IL 60064 USA.	Armstrong@usa.net						[Anonymous], 2004, WOUNDS, p3S; [Anonymous], 2001, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858; Armstrong David G, 2004, Int J Low Extrem Wounds, V3, P184, DOI 10.1177/1534734604271963; Armstrong DG, 1998, DIABETES CARE, V21, P855, DOI 10.2337/diacare.21.5.855; Armstrong DG, 2005, DIABETES CARE, V28, P551, DOI 10.2337/diacare.28.3.551; Armstrong DG, 1998, ARCH INTERN MED, V158, P289, DOI 10.1001/archinte.158.3.289; Armstrong DG, 2004, CLIN INFECT DIS, V39, pS92, DOI 10.1086/383269; Armstrong DG, 2003, DIABETIC MED, V20, P329, DOI 10.1046/j.1464-5491.2003.00933.x; Armstrong DG, 2001, DIABETES CARE, V24, P1019, DOI 10.2337/diacare.24.6.1019; Banwell P E, 1999, J Wound Care, V8, P79; Banwell P E, 2003, J Wound Care, V12, P22; Boulton A J, 2000, J Fam Pract, V49, pS3; Boulton AJM, 2005, DIABETES CARE, V28, P956, DOI 10.2337/diacare.28.4.956; COHEN M, 1991, Journal of Foot Surgery, V30, P29; Eginton MT, 2003, ANN VASC SURG, V17, P645, DOI 10.1007/s10016-003-0065-3; Fleischli JG, 1997, J AM PODIAT MED ASSN, V87, P466, DOI 10.7547/87507315-87-10-466; Gentzkow GD, 1996, DIABETES CARE, V19, P350, DOI 10.2337/diacare.19.4.350; Jeffcoate WJ, 2004, DIABETES-METAB RES, V20, pS78, DOI 10.1002/dmrr.476; Jeffcoate WJ, 2003, LANCET, V361, P1545, DOI 10.1016/S0140-6736(03)13169-8; Joseph E, 2000, WOUNDS, V12, P60; Katz IA, 2005, DIABETES CARE, V28, P555, DOI 10.2337/diacare.28.3.555; La Fontaine J, 2001, J AM PODIAT MED ASSN, V91, P533, DOI 10.7547/87507315-91-10-533; LARSSON J, 1998, CLIN ORTHOP RELAT R, V350, P149; Lavery LA, 1996, DIABETES CARE, V19, P818, DOI 10.2337/diacare.19.8.818; Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435; Marston WA, 2003, DIABETES CARE, V26, P1701, DOI 10.2337/diacare.26.6.1701; McCallon S K, 2000, Ostomy Wound Manage, V46, P28; McCallon SK, 2000, OSTOMY WOUND MANAG, V46, P28; Morykwas MJ, 1997, ANN PLAS SURG, V38, P553, DOI 10.1097/00000637-199706000-00001; Mullner T, 1997, BRIT J PLAST SURG, V50, P194, DOI 10.1016/S0007-1226(97)91369-2; Murdoch D P, 1997, J Foot Ankle Surg, V36, P204; PINZUR M, 1986, J BONE JOINT SURG AM, V68A, P1061, DOI 10.2106/00004623-198668070-00013; SAMSON DJ, 2004, PUBLICATION AGENCY H; SANDERS LJ, 1992, J AM PODIAT MED ASSN, V82, P129, DOI 10.7547/87507315-82-3-129; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741-5214(95)70245-8; Thoner B, 1998, Krankenpfl J, V36, P78; Ulbrecht JS, 2004, CLIN INFECT DIS, V39, pS73, DOI 10.1086/383266; Veves A, 2002, ARCH SURG-CHICAGO, V137, P822, DOI 10.1001/archsurg.137.7.822; Veves A, 2001, DIABETES CARE, V24, P290, DOI 10.2337/diacare.24.2.290; *WOUND OST CONT NU, 2004, GUID MAN WOUNDS PAT, P57; Wunderlich RP, 2000, DIABETES RES CLIN PR, V49, P87, DOI 10.1016/S0168-8227(00)00145-5; YOUNG MJ, 1994, DIABETES CARE, V17, P557, DOI 10.2337/diacare.17.6.557	43	586	637	1	96	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1704	1710		10.1016/S0140-6736(05)67695-7	http://dx.doi.org/10.1016/S0140-6736(05)67695-7			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291063				2022-12-28	WOS:000233206400025
J	Mitchell, C; Adebajo, A; Hay, E; Carr, A				Mitchell, C; Adebajo, A; Hay, E; Carr, A			Shoulder pain: diagnosis and management in primary care	BMJ-BRITISH MEDICAL JOURNAL			English	Review							ROTATOR-CUFF; SUBACROMIAL IMPINGEMENT; DISORDERS; TRIALS; PHYSIOTHERAPY; INJECTION; TESTS		Univ Sheffield, No Gen Hosp, ScHARR, Inst Gen Practice & Primary Care, Sheffield S5 7AU, S Yorkshire, England; Univ Sheffield, Sch Med, Div Genom Med, Acad Rheumatol Grp, Sheffield S10 2RX, S Yorkshire, England; Univ Keele, Primary Care Sci Res Ctr, Keele ST5 5BG, Staffs, England; Univ Oxford, Nuffield Dept Orthopaed Surg, Oxford OX3 7LD, England	Northern General Hospital; University of Sheffield; University of Sheffield; Keele University; University of Oxford	Mitchell, C (corresponding author), Univ Sheffield, No Gen Hosp, ScHARR, Inst Gen Practice & Primary Care, Sheffield S5 7AU, S Yorkshire, England.	c.mitchell@sheffield.ac.uk		Mitchell, Caroline/0000-0002-4790-0095				Alasaarela E, 1997, BRIT J RHEUMATOL, V36, P996; Alvarez CM, 2005, AM J SPORT MED, V33, P255, DOI 10.1177/0363546504267345; [Anonymous], 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001156; Bamji AN, 1996, BRIT J RHEUMATOL, V35, P1172; BARRY M, 1995, BRIT MED J, V310, P183, DOI 10.1136/bmj.310.6973.183; Bongers PM, 2001, BMJ-BRIT MED J, V322, P64, DOI 10.1136/bmj.322.7278.64; Buchbinder R., 2003, COCHRANE DB SYST REV, V2003, pCD004016, DOI [DOI 10.1002/14651858.CD004016, 10.1002/14651858.CD004016]; Calis M, 2000, ANN RHEUM DIS, V59, P44, DOI 10.1136/ard.59.1.44; Carette S, 2003, ARTHRITIS RHEUM, V48, P829, DOI 10.1002/art.10954; Chambler AFW, 2003, J BONE JOINT SURG BR, V85B, P789, DOI 10.1302/0301-620X.85B6.14379; Croft P, 1996, BRIT MED J, V313, P601; CROFT P, 1994, BRIT J RHEUMATOL, V33, P942; Daigneault J, 1998, J AM GERIATR SOC, V46, P1144, DOI 10.1111/j.1532-5415.1998.tb06656.x; de Winter AF, 1999, ANN RHEUM DIS, V58, P272, DOI 10.1136/ard.58.5.272; EJNISMAN B, 2003, COCHRANE DATABASE SY, P2758; Glanville J, 1998, BRIT MED J, V317, P200, DOI 10.1136/bmj.317.7152.200; Green S, 1998, BRIT MED J, V316, P354, DOI 10.1136/bmj.316.7128.354; Green S, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005319; Green S, 2003, Cochrane Database Syst Rev, pCD004258; Haahr JP, 2005, ANN RHEUM DIS, V64, P760, DOI 10.1136/ard.2004.021188; Harvie P, 2004, J BONE JOINT SURG BR, V86B, P696, DOI 10.1302/0301-620X.86B5.14747; Hay EM, 2003, ANN RHEUM DIS, V62, P394, DOI 10.1136/ard.62.5.394; KARJALAINEN K, 2001, COCHRANE DB SYST REV; Khan KM, 2002, BRIT MED J, V324, P626, DOI 10.1136/bmj.324.7338.626; MATHERS N, 1989, BRIT MED J, V298, P172, DOI 10.1136/bmj.298.6667.172; MILGROM C, 1995, J BONE JOINT SURG BR, V77B, P296, DOI 10.1302/0301-620X.77B2.7706351; Miniaci A, 2002, AM J SPORT MED, V30, P66, DOI 10.1177/03635465020300012501; Ostor AJK, 2005, RHEUMATOLOGY, V44, P800, DOI 10.1093/rheumatology/keh598; Ostor AJK, 2004, ANN RHEUM DIS, V63, P1288, DOI 10.1136/ard.2003.014712; SHER JS, 1995, J BONE JOINT SURG AM, V77A, P10, DOI 10.2106/00004623-199501000-00002; Sherrington C, 2000, MANUAL THER, V5, P223, DOI 10.1054/math.2000.0372; SPEED C, 2004, CLIN EVID, P1735; Thomas E, 2005, ANN RHEUM DIS, V64, P1056, DOI 10.1136/ard.2004.029959; Urwin M, 1998, ANN RHEUM DIS, V57, P649, DOI 10.1136/ard.57.11.649; vanderWindt DAWM, 1996, BRIT J GEN PRACT, V46, P519; Whiting P, 2004, HEALTH TECHNOL ASSES, V8, P1, DOI 10.3310/hta8250; Winters JC, 1999, RHEUMATOLOGY, V38, P160, DOI 10.1093/rheumatology/38.2.160	37	240	250	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1124	1128A		10.1136/bmj.331.7525.1124	http://dx.doi.org/10.1136/bmj.331.7525.1124			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	985ZI	16282408	Green Published			2022-12-28	WOS:000233417300019
J	Fiocchi, C				Fiocchi, C			One commensal bacterial molecule - All we need for health?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MICROFLORA		Cleveland Clin Fdn, Dept Pathobiol, Lerner Res Inst, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Fiocchi, C (corresponding author), Cleveland Clin Fdn, Dept Pathobiol, Lerner Res Inst, 9500 Euclid Ave, Cleveland, OH 44195 USA.							Backhed F, 2005, SCIENCE, V307, P1915, DOI 10.1126/science.1104816; MacDonald TT, 2005, SCIENCE, V307, P1920, DOI 10.1126/science.1106442; Mazmanian SK, 2005, CELL, V122, P107, DOI 10.1016/j.cell.2005.05.007; Rakoff-Nahoum S, 2004, CELL, V118, P229, DOI 10.1016/j.cell.2004.07.002; Sartor RB, 2004, GASTROENTEROLOGY, V126, P1620, DOI 10.1053/j.gastro.2004.03.024	5	13	15	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					2078	2080		10.1056/NEJMcibr053171	http://dx.doi.org/10.1056/NEJMcibr053171			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282185				2022-12-28	WOS:000233119600016
J	Carrozza, MJ; Li, B; Florens, L; Suganuma, T; Swanson, SK; Lee, KK; Shia, WJ; Anderson, S; Yates, J; Washburn, MP; Workman, JL				Carrozza, MJ; Li, B; Florens, L; Suganuma, T; Swanson, SK; Lee, KK; Shia, WJ; Anderson, S; Yates, J; Washburn, MP; Workman, JL			Histone H3 methylation by Set2 directs deacetylation of coding regions by Rpd3S to suppress spurious intragenic transcription	CELL			English	Article							RNA-POLYMERASE-II; CHROMATIN IN-VIVO; PROTEIN IDENTIFICATION TECHNOLOGY; REGULATES H3 METHYLATION; SACCHAROMYCES-CEREVISIAE; TARGETED RECRUITMENT; SHOTGUN PROTEOMICS; GENE-EXPRESSION; YEAST PROTEOME; DNA-SYNTHESIS	Yeast Rpd3 histone deacetylase plays an important role at actively transcribed genes. We characterized two distinct Rpd3 complexes, Rpd3L and Rpd3S, by MudPIT analysis. Both complexes shared a three subunit core and Rpd3L contains unique subunits consistent with being a promoter targeted corepressor. Rco1 and Eaf3 were subunits specific to Rpd3S. Mutants of RCO1 and EAF3 exhibited increased acetylation in the FLO8 and STE11 open reading frames (ORFs) and the appearance of aberrant transcripts initiating within the body of these ORFs. Mutants in the RNA polymerase II-associated SET2 histone methyltransferase also displayed these defects. Set2 functioned upstream of Rpd3S and the Eaf3 methyl-histone binding chromodomain was important for recruitment of Rpd3S and for deacetylation within the STE11 ORF. These data indicate that Pol ll-associated Set2 methylates H3 providing a transcriptional memory which signals for deacetylation of ORFs by Rpd3S. This erases transcription elongation-associated acetylation to suppress intragenic transcription initiation.	Stowers Inst Med Res, Kansas City, MO 64110 USA; Scripps Res Inst, La Jolla, CA 92037 USA	Stowers Institute for Medical Research; Scripps Research Institute	Workman, JL (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.	jlw@stowers-institute.org		Florens, Laurence/0000-0002-9310-6650; Washburn, Michael/0000-0001-7568-2585	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047867, R01GM047867] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM047867] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Belotserkovskaya R, 2003, SCIENCE, V301, P1090, DOI 10.1126/science.1085703; Bertram MJ, 1999, MOL CELL BIOL, V19, P1479; Bortvin A, 1996, SCIENCE, V272, P1473, DOI 10.1126/science.272.5267.1473; Briggs SD, 2002, NATURE, V418, P498, DOI 10.1038/nature00970; CARROZZA MJ, 2005, IN PRESS BBA GENE ST; de Nadal E, 2004, NATURE, V427, P370, DOI 10.1038/nature02258; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; ENG JK, 1994, J AM SOC MASS SPECTR, V5, P976, DOI 10.1016/1044-0305(94)80016-2; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Guthrie C, 1991, GUIDE YEAST GENETICS; Hecht A, 1999, METHOD ENZYMOL, V304, P399; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Kasten MM, 1997, MOL CELL BIOL, V17, P4852, DOI 10.1128/MCB.17.8.4852; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Kristjuhan A, 2002, MOL CELL, V10, P925, DOI 10.1016/S1097-2765(02)00647-0; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Kurdistani SK, 2003, NAT REV MOL CELL BIO, V4, P276, DOI 10.1038/nrm1075; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Kusch T, 2004, SCIENCE, V306, P2084, DOI 10.1126/science.1103455; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Li B, 2001, J BIOL CHEM, V276, P33788, DOI 10.1074/jbc.M104220200; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Liu HB, 2004, ANAL CHEM, V76, P4193, DOI 10.1021/ac0498563; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Mason PB, 2003, MOL CELL BIOL, V23, P8323, DOI 10.1128/MCB.23.22.8323-8333.2003; McDonald WH, 2002, INT J MASS SPECTROM, V219, P245, DOI 10.1016/S1387-3806(02)00563-8; Moris G, 2003, NEUROLOGIA, V18, P723; Nagy PL, 2002, P NATL ACAD SCI USA, V99, P90, DOI 10.1073/pnas.221596698; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2002, J BIOL CHEM, V277, P34655, DOI 10.1074/jbc.C200433200; Pokholok DK, 2005, CELL, V122, P517, DOI 10.1016/j.cell.2005.06.026; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Puig O, 2001, METHODS, V24, P218, DOI 10.1006/meth.2001.1183; Puig S, 2004, J BIOL CHEM, V279, P30298, DOI 10.1074/jbc.M313463200; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Reid JL, 2004, MOL CELL BIOL, V24, P757, DOI 10.1128/MCB.24.2.757-764.2004; Robyr D, 2002, CELL, V109, P437, DOI 10.1016/S0092-8674(02)00746-8; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Rundlett SE, 1996, P NATL ACAD SCI USA, V93, P14503, DOI 10.1073/pnas.93.25.14503; Sadygov RG, 2002, J PROTEOME RES, V1, P211, DOI 10.1021/pr015514r; Saunders A, 2003, SCIENCE, V301, P1094, DOI 10.1126/science.1085712; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Storici F, 2003, P NATL ACAD SCI USA, V100, P14994, DOI 10.1073/pnas.2036296100; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tabb DL, 2002, J PROTEOME RES, V1, P21, DOI 10.1021/pr015504q; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; Tominaga K, 2005, MOL CELL BIOL, V25, P2924, DOI 10.1128/MCB.25.8.2924-2937.2005; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4; VIDAL M, 1991, MOL CELL BIOL, V11, P6317, DOI 10.1128/MCB.11.12.6317; Vogelauer M, 2000, NATURE, V408, P495, DOI 10.1038/35044127; Washburn MP, 2001, NAT BIOTECHNOL, V19, P242, DOI 10.1038/85686; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Wolters DA, 2001, ANAL CHEM, V73, P5683, DOI 10.1021/ac010617e; Wood A, 2003, J BIOL CHEM, V278, P34739, DOI 10.1074/jbc.C300269200; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Yochum GS, 2002, MOL CELL BIOL, V22, P7868, DOI 10.1128/MCB.22.22.7868-7876.2002; Zhang Y, 1998, MOL CELL, V1, P1021, DOI 10.1016/S1097-2765(00)80102-1	68	952	973	1	49	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					581	592		10.1016/j.cell.2005.10.023	http://dx.doi.org/10.1016/j.cell.2005.10.023			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286007	Bronze			2022-12-28	WOS:000233497400008
J	Shumyatsky, GP; Malleret, G; Shin, RM; Takizawa, S; Tully, K; Tsvetkov, E; Zakharenko, SS; Joseph, J; Vronskaya, S; Yin, DQ; Schubart, UK; Kandel, ER; Bolshakov, VY				Shumyatsky, GP; Malleret, G; Shin, RM; Takizawa, S; Tully, K; Tsvetkov, E; Zakharenko, SS; Joseph, J; Vronskaya, S; Yin, DQ; Schubart, UK; Kandel, ER; Bolshakov, VY			stathmin, a gene enriched in the amygdala, controls both learned and innate fear	CELL			English	Article							LONG-TERM POTENTIATION; STAGE-SPECIFIC EXPRESSION; LATERAL AMYGDALA; PHOSPHOPROTEIN P19; DENDRITIC SPINES; IN-VITRO; NEURONS; MEMORY; RAT; IDENTIFICATION	Little is known about the molecular mechanisms of learned and innate fear. We have identified stathmin, an inhibitor of microtubule formation, as highly expressed in the lateral nucleus (LA) of the amygdala as well as in the thalamic and cortical structures that send information to the LA about the conditioned (learned fear) and unconditioned stimuli (innate fear). Whole-cell recordings from amygdala slices that are isolated from stathmin knockout mice show deficits in spike-timing-dependent long-term potentiation (LTP). The knockout mice also exhibit decreased memory in amygdala-dependent fear conditioning and fail to recognize danger in innately aversive environments. By contrast, these mice do not show deficits in the water maze, a spatial task dependent on the hippocampus, where stathmin is not normally expressed. We therefore conclude that stathmin is required for the induction of LTP in afferent inputs to the amygdala and is essential in regulating both innate and learned fear.	Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA; Columbia Univ, Ctr Neurobiol & Behav, Howard Hughes Med Inst, New York, NY 10032 USA; Harvard Univ, Sch Med, McLean Hosp, Dept Psychiat, Belmont, MA 02478 USA; Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA	Rutgers State University New Brunswick; Columbia University; Howard Hughes Medical Institute; Harvard University; McLean Hospital; Yeshiva University; Albert Einstein College of Medicine	Shumyatsky, GP (corresponding author), Rutgers State Univ, Dept Genet, Piscataway, NJ 08854 USA.	gleb@biology.rutgers.edu	Tsvetkov, Evgeny/C-1085-2016; Zakharenko, Stanislav/D-3287-2013; Tsvetkov, Evgeny A/B-6573-2016	Tsvetkov, Evgeny/0000-0001-9339-1677; Zakharenko, Stanislav/0000-0001-8115-202X; Tsvetkov, Evgeny A/0000-0002-6784-0907; Joseph, Jamie/0000-0002-1012-722X	NIDA NIH HHS [DA15098] Funding Source: Medline; NIMH NIH HHS [MH50733] Funding Source: Medline; NINDS NIH HHS [NS44185] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH050733] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS044185] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSE [R03DA015098] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; Brunzell DH, 2001, BEHAV NEUROSCI, V115, P365, DOI 10.1037//0735-7044.115.2.365; CAMPEAU S, 1995, J NEUROSCI, V15, P2312, DOI 10.1523/JNEUROSCI.15-03-02312.1995; Curmi PA, 1997, J BIOL CHEM, V272, P25029, DOI 10.1074/jbc.272.40.25029; Davis M., 2000, AMYGDALA, P213; Fendt M, 1999, NEUROSCI BIOBEHAV R, V23, P743, DOI 10.1016/S0149-7634(99)00016-0; Feng GP, 2000, NEURON, V28, P41, DOI 10.1016/S0896-6273(00)00084-2; Gavet O, 2002, J NEUROSCI RES, V68, P535, DOI 10.1002/jnr.10234; HANASH SM, 1988, J BIOL CHEM, V263, P12813; Hirokawa N, 2005, NAT REV NEUROSCI, V6, P201, DOI 10.1038/nrn1624; Huang YY, 1998, NEURON, V21, P169, DOI 10.1016/S0896-6273(00)80524-3; Johnson MW, 1997, J NEUROSCI METH, V77, P151, DOI 10.1016/S0165-0270(97)00120-9; Kaech S, 2001, P NATL ACAD SCI USA, V98, P7086, DOI 10.1073/pnas.111146798; Lang C, 2004, P NATL ACAD SCI USA, V101, P16665, DOI 10.1073/pnas.0407581101; Lanuza E, 2004, NEUROSCIENCE, V125, P305, DOI 10.1016/j.neuroscience.2003.12.034; LeDoux JE, 2000, ANNU REV NEUROSCI, V23, P155, DOI 10.1146/annurev.neuro.23.1.155; Mahanty NK, 1998, NATURE, V394, P683, DOI 10.1038/29312; Majak K, 2002, J COMP NEUROL, V451, P236, DOI 10.1002/cne.10346; Maren S, 2004, NAT REV NEUROSCI, V5, P844, DOI 10.1038/nrn1535; Maren S, 2001, ANNU REV NEUROSCI, V24, P897, DOI 10.1146/annurev.neuro.24.1.897; Marklund U, 1996, EMBO J, V15, P5290, DOI 10.1002/j.1460-2075.1996.tb00914.x; McDonald AJ, 2002, J COMP NEUROL, V446, P199, DOI 10.1002/cne.10204; McGregor IS, 2004, J NEUROSCI, V24, P4134, DOI 10.1523/JNEUROSCI.0187-04.2004; McKernan MG, 1997, NATURE, V390, P607, DOI 10.1038/37605; Rodrigues SM, 2004, NEURON, V44, P75, DOI 10.1016/j.neuron.2004.09.014; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Ruiz-Canada C, 2004, NEURON, V42, P567, DOI 10.1016/S0896-6273(04)00255-7; SCHAERENWIEMERS N, 1993, HISTOCHEMISTRY, V100, P431, DOI 10.1007/BF00267823; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; Schubart UK, 1996, J BIOL CHEM, V271, P14062, DOI 10.1074/jbc.271.24.14062; Shi CJ, 1999, J NEUROSCI, V19, P420, DOI 10.1523/JNEUROSCI.19-01-00420.1999; Shumyatsky GP, 2002, CELL, V111, P905, DOI 10.1016/S0092-8674(02)01116-9; Tonegawa S, 2003, PHILOS T R SOC B, V358, P787, DOI 10.1098/rstb.2002.1243; Tsvetkov E, 2004, NEURON, V41, P139, DOI 10.1016/S0896-6273(03)00800-6; Tsvetkov E, 2002, NEURON, V34, P289, DOI 10.1016/S0896-6273(02)00645-1; van Rossum D, 1999, J NEUROCHEM, V72, P962, DOI 10.1046/j.1471-4159.1999.0720962.x; van Rossum D, 1999, TRENDS NEUROSCI, V22, P290, DOI 10.1016/S0166-2236(99)01404-6; Westermann S, 2003, NAT REV MOL CELL BIO, V4, P938, DOI 10.1038/nrm1260	39	176	184	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					697	709		10.1016/j.cell.2005.08.038	http://dx.doi.org/10.1016/j.cell.2005.08.038			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286011	Bronze			2022-12-28	WOS:000233497400017
J	Zilfou, JT; Spector, MS; Lowe, SW				Zilfou, JT; Spector, MS; Lowe, SW			Slugging it out: Fine tuning the p53-PUMA death connection	CELL			English	Editorial Material							TRANSCRIPTION FACTOR; INDUCTION; GROWTH	In response to DNA damage, the tumor suppressor p53 elicits a complex cellular response. In this issue of Cell, Wu et al. (2005) show that the transcription factor SLUG is induced by p53 and protects hematopoletic progenitor cells from apoptosis triggered by DNA damage. SLUG exerts this protective role by repressing Puma, a proapoptotic target of p53. PUMA is also a key coordinator of apoptosis mediated by both nuclear and cytoplasmic functions of p53 (Chipuk et al., 2005).	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory	Zilfou, JT (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.				NATIONAL CANCER INSTITUTE [P30CA008748, P01CA087497] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA008748, P01 CA087497] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aggarwal BB, 2003, NAT REV IMMUNOL, V3, P745, DOI 10.1038/nri1184; Chipuk JE, 2005, SCIENCE, V309, P1732, DOI 10.1126/science.1114297; Fang L, 2001, EMBO J, V20, P1931, DOI 10.1093/emboj/20.8.1931; FEBEYRE G, 2002, NATURE, V415, P26; Ikushima S, 1997, P NATL ACAD SCI USA, V94, P2609, DOI 10.1073/pnas.94.6.2609; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 2005, BLOOD, V105, P4437, DOI 10.1182/blood-2004-08-2976; Komarov PG, 1999, SCIENCE, V285, P1733, DOI 10.1126/science.285.5434.1733; Moll UM, 2005, CURR OPIN CELL BIOL, V17, P631, DOI 10.1016/j.ceb.2005.09.007; Takagi M, 2005, CELL, V123, P49, DOI 10.1016/j.cell.2005.07.034; Wu WS, 2005, CELL, V123, P641, DOI 10.1016/j.cell.2005.09.029; Yee KS, 2005, CARCINOGENESIS, V26, P1317, DOI 10.1093/carcin/bgi122	12	17	17	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					545	548		10.1016/j.cell.2005.11.003	http://dx.doi.org/10.1016/j.cell.2005.11.003			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286002	Bronze, Green Accepted			2022-12-28	WOS:000233497400003
J	Williamson, C				Williamson, C			Withholding policies from patients restricts their autonomy	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Dalby Pld Rectory, Picker Inst, York, N Yorkshire, England		Williamson, C (corresponding author), Dalby Pld Rectory, Picker Inst, York, N Yorkshire, England.	charlotte@wmsn.freeserve.co.uk						Alford R., 1975, HLTH CARE POLITICS I; CHAPMAN C, 1999, B R COLL PATHOL, V105, pR14; CHARLWOOD A, 2004, AIMS J, V16, P5; Coldicott Y, 2003, BRIT MED J, V326, P97, DOI 10.1136/bmj.326.7380.97; DOYAL L, 1993, BRIT MED J, V306, P1593, DOI 10.1136/bmj.306.6892.1593; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P877; General Medical Council (UK), 1998, SEEK PAT CONS ETH CO; HOLLAND PV, 1999, NEW ENGL J MED, V340, P1734; JENSEN UJ, 1990, CHANGING VALUES MED, P1; KAY LA, 1987, BRIT MED J, V294, P137, DOI 10.1136/bmj.294.6565.137; Lukes S., 1974, POWER RADICAL VIEW; Markham R, 2003, BRIT MED J, V326, P863, DOI 10.1136/bmj.326.7394.863; *NBS, 2002, REC BLOOD TRANSF; PARROY S, 2003, RAISING STANDARD INF, P15; Raithatha N, 2004, BMJ-BRIT MED J, V328, P400, DOI 10.1136/bmj.328.7436.400; RHODES P, 1982, AIMS QJ          SPR, P1; Royal Liverpool Children's Inquiry, 2001, ROYAL LIV CHILDR INQ; Sites P., 1973, CONTROL BASIS SOCIAL; Stapleton H, 2002, BMJ-BRIT MED J, V324, P639, DOI 10.1136/bmj.324.7338.639; STUBBS S, 2001, BLOOD MATTERS, V8, P4; Summerton N, 2002, BRIT J GEN PRACT, V52, P5; WILLIAMS C, 1992, WHOSE STANDARDS CONS; Williamson C, 1998, BRIT MED J, V317, P1374, DOI 10.1136/bmj.317.7169.1374; WILLIAMSON C, 2003, RAISING STANDARD INF, P73	24	13	13	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2005	331	7524					1078	1080		10.1136/bmj.331.7524.1078	http://dx.doi.org/10.1136/bmj.331.7524.1078			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	983DL	16269498	Green Published			2022-12-28	WOS:000233211200035
J	Brunet, I; Weinl, C; Piper, M; Trembleau, A; Volovitch, M; Harris, W; Prochiantz, A; Holt, C				Brunet, I; Weinl, C; Piper, M; Trembleau, A; Volovitch, M; Harris, W; Prochiantz, A; Holt, C			The transcription factor Engrailed-2 guides retinal axons	NATURE			English	Article							GANGLION-CELL AXONS; OPTIC TECTUM; TYROSINE KINASES; GROWTH CONES; EXPRESSION; PROTEIN; TRANSLATION; HOMEOPROTEIN; GUIDANCE; LIGANDS	Engrailed-2 (En-2), a homeodomain transcription factor, is expressed in a caudal-to-rostral gradient in the developing midbrain, where it has an instructive role in patterning the optic tectum - the target of topographic retinal input(1,2). In addition to its well-known role in regulating gene expression through its DNA-binding domain, En-2 may also have a role in cell - cell communication, as suggested by the presence of other domains involved in nuclear export, secretion and internalization(3). Consistent with this possibility, here we report that an external gradient of En-2 protein strongly repels growth cones of Xenopus axons originating from the temporal retina and, conversely, attracts nasal axons. Fluorescently tagged En-2 accumulates inside growth cones within minutes of exposure, and a mutant form of the protein that cannot enter cells fails to elicit axon turning. Once internalized, En-2 stimulates the rapid phosphorylation of proteins involved in translation initiation and triggers the local synthesis of new proteins. Furthermore, the turning responses of both nasal and temporal growth cones in the presence of En-2 are blocked by inhibitors of protein synthesis. The differential guidance of nasal and temporal axons reported here suggests that En-2 may participate directly in topographic map formation in the vertebrate visual system.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Ecole Normale Super, CNRS, UMR 8542, F-75230 Paris, France	University of Cambridge; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; Ecole Normale Superieure (ENS)	Holt, C (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.	prochian@biologie.ens.fr; ceh@mole.bio.cam.ac.uk	Piper, Michael J/B-2805-2010	Piper, Michael J/0000-0002-6759-2560; Holt, Christine Elizabeth/0000-0003-2829-121X; Volovitch, Michel/0000-0002-7488-764X; Trembleau, Alain/0000-0002-8290-0795	Wellcome Trust [070568] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Campbell DS, 2001, NEURON, V32, P1013, DOI 10.1016/S0896-6273(01)00551-7; Charron F, 2005, DEVELOPMENT, V132, P2251, DOI 10.1242/dev.01830; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; COHEN J, 1987, DEV BIOL, V122, P407, DOI 10.1016/0012-1606(87)90305-8; de la Torre JR, 1997, NEURON, V19, P1211, DOI 10.1016/S0896-6273(00)80413-4; DEROSSI D, 1994, J BIOL CHEM, V269, P10444; DRESCHER U, 1995, CELL, V82, P359, DOI 10.1016/0092-8674(95)90425-5; Feldheim DA, 2000, NEURON, V25, P563, DOI 10.1016/S0896-6273(00)81060-0; Foucher I, 2003, DEVELOPMENT, V130, P1867, DOI 10.1242/dev.00414; Friedman GC, 1996, J NEUROSCI, V16, P5498; Frisen J, 1999, EMBO J, V18, P5159, DOI 10.1093/emboj/18.19.5159; Gingras AC, 1999, ANNU REV BIOCHEM, V68, P913, DOI 10.1146/annurev.biochem.68.1.913; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Itasaki N, 1996, NEURON, V16, P55, DOI 10.1016/S0896-6273(00)80023-9; Joliot A, 1998, CURR BIOL, V8, P856, DOI 10.1016/S0960-9822(07)00346-6; Kablar B, 1996, MECH DEVELOP, V55, P145, DOI 10.1016/0925-4773(96)00497-2; Logan C, 1996, CURR BIOL, V6, P1006, DOI 10.1016/S0960-9822(02)00645-0; LOHOF AM, 1992, J NEUROSCI, V12, P1253; MACDONALD R, 1994, NEURON, V13, P1039, DOI 10.1016/0896-6273(94)90044-2; Montesinos ML, 2001, J NEUROSCI, V21, P3350, DOI 10.1523/JNEUROSCI.21-10-03350.2001; Nedelec S, 2004, P NATL ACAD SCI USA, V101, P10815, DOI 10.1073/pnas.0403824101; Prochiantz A, 2003, NAT REV MOL CELL BIO, V4, P814, DOI 10.1038/nrm1227; Retaux S, 1996, TRENDS NEUROSCI, V19, P542, DOI 10.1016/S0166-2236(96)10062-X; Shigetani Y, 1997, NEUROSCI RES, V27, P211, DOI 10.1016/S0168-0102(96)01151-0; SPERRY RW, 1963, P NATL ACAD SCI USA, V50, P703, DOI 10.1073/pnas.50.4.703; Topisirovic I, 2005, MOL CELL BIOL, V25, P1100, DOI 10.1128/MCB.25.3.1100-1112.2005; Topisirovic I, 2003, EMBO J, V22, P689, DOI 10.1093/emboj/cdg069	27	199	207	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					94	98		10.1038/nature04110	http://dx.doi.org/10.1038/nature04110			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267555	Green Accepted			2022-12-28	WOS:000232979000048
J	Hillier, SL				Hillier, SL			The complexity of microbial diversity in bacterial vaginosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Pittsburgh, Pittsburgh, PA 15260 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hillier, SL (corresponding author), Univ Pittsburgh, Pittsburgh, PA 15260 USA.								0	40	46	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1886	1887		10.1056/NEJMp058191	http://dx.doi.org/10.1056/NEJMp058191			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267319				2022-12-28	WOS:000232972800004
J	Janssen, WJ; Collard, HR; Saint, S; Weinberger, SE				Janssen, WJ; Collard, HR; Saint, S; Weinberger, SE			A perfect storm	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CONGENITAL MUSCULAR-DYSTROPHY; SPINE; MUTATIONS; RIGIDITY; PHOX2B; GENE		Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, Denver, CO 80262 USA; Univ Calif San Francisco, Dept Med, San Francisco, CA USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA; Dept Vet Affairs, Hlth Serv Res & Dev Ctr Excellence, Ann Arbor, MI USA; Amer Coll Physicians, Philadelphia, PA USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of California System; University of California San Francisco; University of Michigan System; University of Michigan; American College of Physicians	Janssen, WJ (corresponding author), Univ Colorado, Hlth Sci Ctr, Dept Med, Div Pulm Sci & Crit Care Med, 4200 E 9th Ave,Box C-272, Denver, CO 80262 USA.	william.janssen@uchsc.edu	Saint, Sanjay/AAF-5126-2019		AHRQ HHS [P20-HS11540] Funding Source: Medline; AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P20HS011540] Funding Source: NIH RePORTER	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Aldrich TK, 2002, AM J RESP CRIT CARE, V166, P548, DOI 10.1164/rccm.166.4.518; Amiel J, 2003, NAT GENET, V33, P459, DOI 10.1038/ng1130; Dubowitz V, 1997, NEUROMUSCULAR DISORD, V7, P539; DUBOWITZ V, 1965, RES MUSCULAR DYSTROP, P57; FLANIGAN K, 2002, NEUROMUSCULAR DISORD, P1007; GIBSON GJ, 1989, THORAX, V44, P960, DOI 10.1136/thx.44.11.960; Mercuri E, 2002, NEUROMUSCULAR DISORD, V12, P631, DOI 10.1016/S0960-8966(02)00023-8; Moghadaszadeh B, 1998, AM J HUM GENET, V62, P1439, DOI 10.1086/301882; Moghadaszadeh B, 2001, NAT GENET, V29, P17, DOI 10.1038/ng713; Moghadaszadeh B, 1999, NEUROMUSCULAR DISORD, V9, P376, DOI 10.1016/S0960-8966(99)00051-6; RAS GJ, 1994, AM J RESP CRIT CARE, V150, P540, DOI 10.1164/ajrccm.150.2.8049843; Tubridy N, 2001, CURR OPIN NEUROL, V14, P575, DOI 10.1097/00019052-200110000-00005; Venance SL, 2005, NEUROLOGY, V64, P395, DOI 10.1212/01.WNL.0000149755.85666.DB; Weese-Mayer DE, 2005, AM J RESP CRIT CARE, V171, P88, DOI 10.1164/ajrccm.171.1.950	14	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1956	1961		10.1056/NEJMcps050136	http://dx.doi.org/10.1056/NEJMcps050136			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267327				2022-12-28	WOS:000232972800013
J	Veazey, RS; Klasse, PJ; Schader, SM; Hu, QX; Ketas, TJ; Lu, M; Marx, PA; Dufour, J; Colonno, RJ; Shattock, RJ; Springer, MS; Moore, JP				Veazey, RS; Klasse, PJ; Schader, SM; Hu, QX; Ketas, TJ; Lu, M; Marx, PA; Dufour, J; Colonno, RJ; Shattock, RJ; Springer, MS; Moore, JP			Protection of macaques from vaginal SHIV challenge by vaginally delivered inhibitors of virus-cell fusion	NATURE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; HIV-1 INFECTION; ENTRY INHIBITORS; CCR5 INHIBITOR; TRANSMISSION; TYPE-1; ANTAGONISTS; ATTACHMENT; PREVENTION; DISCOVERY	Human immunodeficiency virus type 1 (HIV-1) continues to spread, principally by heterosexual sex, but no vaccine is available(1). Hence, alternative prevention methods are needed to supplement educational and behavioural-modification programmes. One such approach is a vaginal microbicide: the application of inhibitory compounds before intercourse(2). Here, we have evaluated the microbicide concept using the rhesus macaque 'high dose'vaginal transmission model with a CCR5-receptor-using simian - human immunodeficiency virus (SHIV-162P3) and three compounds that inhibit different stages of the virus - cell attachment and entry process. These compounds are BMS-378806, a small molecule that binds the viral gp120 glycoprotein and prevents its attachment to the CD4 and CCR5 receptors(3,4), CMPD167, a small molecule that binds to CCR5 to inhibit gp120 association(5), and C52L, a bacterially expressed peptide inhibitor of gp41-mediated fusion(6). In vitro, all three compounds inhibit infection of T cells and cervical tissue explants, and C52L acts synergistically with CMPD167 or BMS-378806 to inhibit infection of cell lines. In vivo, significant protection was achieved using each compound alone and in combinations. CMPD167 and BMS-378806 were protective even when applied 6 h before challenge.	Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA; Tulane Natl Primate Res Ctr, Covington, LA 70433 USA; Univ London, St Georges, London SW17 0RE, England; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA; Bristol Myers Squibb Co, Inst Pharmaceut, Wallingford, CT 06492 USA; Merck Res Labs, Rahway, NJ 07065 USA	Cornell University; Tulane University; University of London; Cornell University; Bristol-Myers Squibb; Merck & Company	Moore, JP (corresponding author), Cornell Univ, Weill Med Coll, Dept Microbiol & Immunol, New York, NY 10021 USA.	jpm2003@med.cornell.edu	Klasse, P.J./AEX-0142-2022	Klasse, P.J./0000-0001-8222-278X; Hu, Qinxue/0000-0002-4594-9215				Dyer JR, 1998, J INFECT DIS, V177, P1742, DOI 10.1086/517436; Guo Q, 2003, J VIROL, V77, P10528, DOI 10.1128/JVI.77.19.10528-10536.2003; HANNA G, 11 C RETR OPP INF; Harouse JM, 2001, J VIROL, V75, P1990, DOI 10.1128/JVI.75.4.1990-1995.2001; Hu QX, 2004, J EXP MED, V199, P1065, DOI 10.1084/jem.20022212; Ji H, 2000, BIOCHEMISTRY-US, V39, P676, DOI 10.1021/bi991893e; Ketas TJ, 2003, AIDS RES HUM RETROV, V19, P177, DOI 10.1089/088922203763315678; Klausner RD, 2003, SCIENCE, V300, P2036, DOI 10.1126/science.1086916; Lederman MM, 2004, SCIENCE, V306, P485, DOI 10.1126/science.1099288; Lin PF, 2003, P NATL ACAD SCI USA, V100, P11013, DOI 10.1073/pnas.1832214100; LU M, 2004, Patent No. 04106364A1; Marx PA, 1996, NAT MED, V2, P1084, DOI 10.1038/nm1096-1084; Matthews T, 2004, NAT REV DRUG DISCOV, V3, P215, DOI 10.1038/nrd1331; Miller CJ, 2005, J VIROL, V79, P9217, DOI 10.1128/JVI.79.14.9217-9227.2005; Moore JP, 2004, AIDS RES HUM RETROV, V20, P111, DOI 10.1089/088922204322749567; Otten RA, 2005, J INFECT DIS, V191, P164, DOI 10.1086/426452; Pope M, 2003, NAT MED, V9, P847, DOI 10.1038/nm0703-847; Reeves JD, 2002, P NATL ACAD SCI USA, V99, P16249, DOI 10.1073/pnas.252469399; Seibert C, 2004, CURR PHARM DESIGN, V10, P2041, DOI 10.2174/1381612043384312; Shattock RJ, 2003, NAT REV MICROBIOL, V1, P25, DOI 10.1038/nrmicro729; Shen DM, 2004, BIOORG MED CHEM LETT, V14, P941, DOI 10.1016/j.bmcl.2003.12.005; SPARKS S, 2005, 12 C RETR OPP INF; Tremblay C, 2004, CURR PHARM DESIGN, V10, P1861, DOI 10.2174/1381612043384501; Tsai CC, 2004, AIDS RES HUM RETROV, V20, P11, DOI 10.1089/088922204322749459; Veazey RS, 2003, NAT MED, V9, P343, DOI 10.1038/nm833; Veazey RS, 2003, J EXP MED, V198, P1551, DOI 10.1084/jem.20031266; Wang T, 2003, J MED CHEM, V46, P4236, DOI 10.1021/jm034082o; Watson C, 2005, MOL PHARMACOL, V67, P1268, DOI 10.1124/mol.104.008565; Wawer MJ, 2005, J INFECT DIS, V191, P1403, DOI 10.1086/429411; Wolinsky SM, 2004, VIROLOGY, V328, P19, DOI 10.1016/j.virol.2004.07.021	30	255	283	0	15	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					99	102		10.1038/nature04055	http://dx.doi.org/10.1038/nature04055			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16258536				2022-12-28	WOS:000232979000049
J	Dollar, GL; Weber, U; Mlodzik, M; Sokol, SY				Dollar, GL; Weber, U; Mlodzik, M; Sokol, SY			Regulation of Lethal giant larvae by Dishevelled	NATURE			English	Article							ASYMMETRIC CELL-DIVISION; POLARITY; APKC; COMPLEX; LOCALIZATION; POLARIZATION; HOMOLOG; ROLES; CDC42; PAR-6	The establishment of polarity in many cell types depends on Lgl, the tumour suppressor product of lethal giant larvae, which is involved in basolateral protein targeting(1-4). The conserved complex of Par3, Par6 and atypical protein kinase C5-8 phosphorylates and inactivates Lgl at the apical surface; however, the signalling mechanisms that coordinate cell polarization in development are not well defined. Here we show that a vertebrate homologue of Lgl associates with Dishevelled, an essential mediator of Wnt signalling, and that Dishevelled regulates the localization of Lgl in Xenopus ectoderm and Drosophila follicular epithelium. We show that both Lgl and Dsh are required for normal apical - basal polarity of Xenopus ectodermal cells. In addition, we show that the Wnt receptor Frizzled 8, but not Frizzled 7, causes Lgl to dissociate from the cortex with the concomitant loss of its activity in vivo. These findings suggest a molecular basis for the regulation of cell polarity by Frizzled and Dishevelled.	Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, New York, NY 10029 USA	Icahn School of Medicine at Mount Sinai	Sokol, SY (corresponding author), Mt Sinai Sch Med, Dept Mol Cell & Dev Biol, Box 1020,1 Gustave L Levy Pl, New York, NY 10029 USA.	sergei.sokol@mssm.edu		Sokol, Sergei/0000-0002-3963-9202				Baas AF, 2004, CELL, V116, P457, DOI 10.1016/S0092-8674(04)00114-X; Bellaiche Y, 2004, DEVELOPMENT, V131, P469, DOI 10.1242/dev.00928; Benton R, 2003, CELL, V115, P691, DOI 10.1016/S0092-8674(03)00938-3; Betschinger J, 2003, NATURE, V422, P326, DOI 10.1038/nature01486; Bilder D, 2000, SCIENCE, V289, P113, DOI 10.1126/science.289.5476.113; Brott BK, 2005, DEV CELL, V8, P703, DOI 10.1016/j.devcel.2005.02.012; Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286; Chalmers AD, 2005, DEVELOPMENT, V132, P977, DOI 10.1242/dev.01645; Chalmers AD, 2003, DEVELOPMENT, V130, P2657, DOI 10.1242/dev.00490; Chia W, 2002, CURR OPIN GENET DEV, V12, P459, DOI 10.1016/S0959-437X(02)00326-X; Doe CQ, 2001, CURR OPIN CELL BIOL, V13, P68, DOI 10.1016/S0955-0674(00)00176-9; Eaton S, 2003, MECH DEVELOP, V120, P1257, DOI 10.1016/j.mod.2003.07.002; Etienne-Manneville S, 2003, NATURE, V421, P753, DOI 10.1038/nature01423; Hutterer A, 2004, DEV CELL, V6, P845, DOI 10.1016/j.devcel.2004.05.003; Klezovitch O, 2004, GENE DEV, V18, P559, DOI 10.1101/gad.1178004; Lehman K, 1999, J CELL BIOL, V146, P125, DOI 10.1083/jcb.146.1.125; Mlodzik M, 2002, TRENDS GENET, V18, P564, DOI 10.1016/S0168-9525(02)02770-1; Musch A, 2002, MOL BIOL CELL, V13, P158, DOI 10.1091/mbc.01-10-0496; Nakaya M, 2000, DEVELOPMENT, V127, P5021; Ohno S, 2001, CURR OPIN CELL BIOL, V13, P641, DOI 10.1016/S0955-0674(00)00264-7; Ohshiro T, 2000, NATURE, V408, P593, DOI 10.1038/35046087; Plant PJ, 2003, NAT CELL BIOL, V5, P301, DOI 10.1038/ncb948; Sheldahl LC, 2003, J CELL BIOL, V161, P769, DOI 10.1083/jcb.200211094; Shi SH, 2003, CELL, V112, P63, DOI 10.1016/S0092-8674(02)01249-7; Tada M, 2000, DEVELOPMENT, V127, P2227; Wallingford JB, 2000, NATURE, V405, P81, DOI 10.1038/35011077; Wodarz A, 2002, NAT CELL BIOL, V4, pE39, DOI 10.1038/ncb0202-e39; Wu J, 2004, PLOS BIOL, V2, P1004, DOI 10.1371/journal.pbio.0020158; XU T, 1993, DEVELOPMENT, V117, P1223; Yamanaka T, 2003, CURR BIOL, V13, P734, DOI 10.1016/S0960-9822(03)00244-6	30	112	115	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1376	1380		10.1038/nature04116	http://dx.doi.org/10.1038/nature04116			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251968				2022-12-28	WOS:000232829100058
J	Skegg, K				Skegg, K			Self-harm	LANCET			English	Review							RANDOMIZED CONTROLLED-TRIAL; BORDERLINE PERSONALITY-DISORDER; ADOLESCENT SUICIDAL BEHAVIORS; HIGH-SCHOOL-STUDENTS; RISK-FACTORS; SEXUAL ORIENTATION; FOLLOW-UP; YOUNG-PEOPLE; PSYCHIATRIC-PATIENTS; SUBSEQUENT SUICIDE	The term self-harm is commonly used to describe a wide range of behaviours and intentions including attempted hanging, impulsive self-poisoning, and superficial cutting in response to intolerable tension. As with suicide, rates of self-harm vary greatly between countries. 5-9% of adolescents in western countries report having self-harmed within the previous year. Risk factors include socioeconomic disadvantage, and psychiatric illness-particularly depression, substance abuse, and anxiety disorders. Cultural aspects of some societies may protect against suicide and self-harm and explain some of the international variation in rates of these events. Risk of repetition of self-harm and of later suicide is high. More than 5% of people who have been seen at a hospital after self-harm will have committed suicide within 9 years. Assessment after self-harm includes careful consideration of the patient's intent and beliefs about the lethality of the method used. Strong suicidal intent, high lethality, precautions against being discovered, and psychiatric illness are indicators of high suicide risk. Management after self-harm includes forming a trusting relationship with the patient, jointly identifying problems, ensuring support is available in a crisis, and treating psychiatric illness vigorously. Family and friends may also provide support. Large-scale studies of treatments for specific subgroups of people who self-harm might help to identify more effective treatments than are currently available. Although risk factors for self-harm are well established, aspects that protect people from engaging in self-harm need to be further explored.	Univ Otago, Sch Med, Dept Psychol Med, Dunedin, New Zealand	University of Otago	Skegg, K (corresponding author), Univ Otago, Sch Med, Dept Psychol Med, POB 913, Dunedin, New Zealand.	keren.skegg@stonebow.otago.ac.nz						ALDERSON MR, 1974, LANCET, V1, P1040; APPLEBY L, 1993, PSYCHOL MED, V23, P13, DOI 10.1017/S0033291700038800; Baldessarini RJ, 2004, HARVARD REV PSYCHIAT, V12, P1, DOI 10.1080/10673220490425915; BANCROFT JHJ, 1976, BRIT J PSYCHIAT, V128, P538, DOI 10.1192/bjp.128.6.538; Bateman A, 2001, AM J PSYCHIAT, V158, P36, DOI 10.1176/appi.ajp.158.1.36; Beautrais AL, 1997, J AM ACAD CHILD PSY, V36, P1543, DOI 10.1016/S0890-8567(09)66563-1; Beautrais AL, 2003, AUST NZ J PSYCHIAT, V37, P595, DOI 10.1046/j.1440-1614.2003.01236.x; Beautrais AL, 2000, AUST NZ J PSYCHIAT, V34, P420, DOI 10.1080/j.1440-1614.2000.00691.x; Bennewith O, 2004, BMJ-BRIT MED J, V328, P1108, DOI 10.1136/bmj.328.7448.1108; Bennewith O, 2002, BRIT MED J, V324, P1254, DOI 10.1136/bmj.324.7348.1254; Bertolote JM, 2005, AM J MED GENET C, V133C, P8, DOI 10.1002/ajmg.c.30041; Bhugra D, 1999, PSYCHOL MED, V29, P1131, DOI 10.1017/S0033291799008922; Brain KL, 1998, ARCH SUICIDE RES, V4, P227, DOI 10.1080/13811119808258298; Brener ND, 2000, SUICIDE LIFE-THREAT, V30, P304; Brent DA, 2005, AM J MED GENET C, V133C, P13, DOI 10.1002/ajmg.c.30042; Brent DA, 2002, ARCH GEN PSYCHIAT, V59, P801, DOI 10.1001/archpsyc.59.9.801; Briere J, 1998, AM J ORTHOPSYCHIAT, V68, P609, DOI 10.1037/h0080369; Brown J, 1999, J AM ACAD CHILD PSY, V38, P1490, DOI 10.1097/00004583-199912000-00009; BURGESS S, 2005, COCHRANE DATABASE SY, V3; Burns J, 2005, AUST NZ J PSYCHIAT, V39, P121, DOI 10.1111/j.1440-1614.2005.01532.x; Carter G, 2005, BRIT J PSYCHIAT, V186, P253, DOI 10.1192/bjp.186.3.253; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cedereke M, 2002, EUR PSYCHIAT, V17, P82, DOI 10.1016/S0924-9338(02)00632-6; Colman I, 2004, ACTA PSYCHIAT SCAND, V109, P306, DOI 10.1111/j.1600-0447.2003.00282.x; Cooper J, 2005, AM J PSYCHIAT, V162, P297, DOI 10.1176/appi.ajp.162.2.297; Courtet P, 2005, AM J MED GENET C, V133C, P25, DOI 10.1002/ajmg.c.30043; Crowder Rachel, 2004, Crisis, V25, P183, DOI 10.1027/0227-5910.25.4.183; de Leo D, 1999, INT J PSYCHIAT MED, V29, P149, DOI 10.2190/E87K-FG03-CHEE-UJD3; Dervic K, 2004, AM J PSYCHIAT, V161, P2303, DOI 10.1176/appi.ajp.161.12.2303; DESPLAND JN, 1996, SCHWEIZ ARCH NEUROL, V147, P171; Donaldson D, 2005, J AM ACAD CHILD PSY, V44, P113, DOI 10.1097/00004583-200502000-00003; Douglas J, 2004, J AFFECT DISORDERS, V79, P263, DOI 10.1016/S0165-0327(02)00391-9; Dube SR, 2001, JAMA-J AM MED ASSOC, V286, P3089, DOI 10.1001/jama.286.24.3089; DuRant RH, 1998, J PEDIATR-US, V133, P113, DOI 10.1016/S0022-3476(98)70189-1; Eagles JM, 2003, BRIT J PSYCHIAT, V182, P261, DOI 10.1192/bjp.182.3.261; ECKERSLEY R, 1993, J PAEDIATR CHILD H, V29, pS16, DOI 10.1111/j.1440-1754.1993.tb02254.x; Evans E, 2004, CLIN PSYCHOL REV, V24, P957, DOI 10.1016/j.cpr.2004.04.005; Evans J, 2000, INT REV PSYCHIATR, V12, P44, DOI 10.1080/09540260074111; FAVAZZA AR, 1989, ACTA PSYCHIAT SCAND, V79, P283, DOI 10.1111/j.1600-0447.1989.tb10259.x; Favazza AR, 1998, J NERV MENT DIS, V186, P259, DOI 10.1097/00005053-199805000-00001; Fergusson DM, 2000, PSYCHOL MED, V30, P23, DOI 10.1017/S003329179900135X; Forman EM, 2004, AM J PSYCHIAT, V161, P437, DOI 10.1176/appi.ajp.161.3.437; GALA C, 1992, ACTA PSYCHIAT SCAND, V86, P70, DOI 10.1111/j.1600-0447.1992.tb03229.x; Garofalo R, 1999, ARCH PEDIAT ADOL MED, V153, P487; Gladstone GL, 2004, AM J PSYCHIAT, V161, P1417, DOI 10.1176/appi.ajp.161.8.1417; Goldsmith S.K., 2002, REDUCING SUICIDE NAT; GOULD MS, 1994, INT J EPIDEMIOL, V23, P1185, DOI 10.1093/ije/23.6.1185; Gratz KL, 2001, J PSYCHOPATHOL BEHAV, V23, P253, DOI 10.1023/A:1012779403943; Grunbaum JA, 2004, MORBIDITY MORTALITY, P1; GUNNELL DJ, 1995, BRIT MED J, V311, P226, DOI 10.1136/bmj.311.6999.226; Guthrie E, 2001, BRIT MED J, V323, P135, DOI 10.1136/bmj.323.7305.135; Harris J, 2000, QUAL HEALTH RES, V10, P164, DOI 10.1177/104973200129118345; Haw C, 2003, SUICIDE LIFE-THREAT, V33, P353, DOI 10.1521/suli.33.4.353.25232; Haw C, 2001, BRIT J PSYCHIAT, V178, P48, DOI 10.1192/bjp.178.1.48; Hawton K, 2000, BRIT J PSYCHIAT, V177, P463, DOI 10.1192/bjp.177.5.463; Hawton K, 2002, BMJ-BRIT MED J, V325, P1207, DOI 10.1136/bmj.325.7374.1207; Hawton K, 2004, BMJ-BRIT MED J, V329, P1076, DOI 10.1136/bmj.38253.572581.7C; Hawton K, 2003, PSYCHOL MED, V33, P987, DOI 10.1017/S0033291703007943; Hawton K, 2003, PSYCHOL MED, V33, P955, DOI 10.1017/S0033291703008304; Hawton K, 2002, BRIT MED J, V325, P1374, DOI 10.1136/bmj.325.7377.1374; HAWTON K, 1993, BMJ-BRIT MED J, V306, P1641, DOI 10.1136/bmj.306.6893.1641; Hawton K, 1999, J ADOLESCENCE, V22, P369, DOI 10.1006/jado.1999.0228; HAWTON K, 1980, J NEUROL NEUROSUR PS, V43, P168, DOI 10.1136/jnnp.43.2.168; HAWTON K, 2000, HDB SUICIDE ATTEMPTE; HAWTON K, 2004, COCHRANE DATABASE SY, V4; HENDIN H, 1991, AM J PSYCHIAT, V148, P1150; Henriques GR, 2004, PSYCHOL MED, V34, P833, DOI 10.1017/S0033291703001867; Hepp Urs, 2004, Crisis, V25, P108, DOI 10.1027/0227-5910.25.3.108; Hepple J, 1997, BRIT J PSYCHIAT, V171, P42, DOI 10.1192/bjp.171.1.42; Hickey L, 2001, J PSYCHOSOM RES, V50, P87, DOI 10.1016/S0022-3999(00)00225-7; Horesh N, 2004, J NERV MENT DIS, V192, P837, DOI 10.1097/01.nmd.0000146738.78222.e5; Horrocks J, 2003, BRIT J PSYCHIAT, V183, P34, DOI 10.1192/bjp.183.1.34; Houston K, 2003, BRIT J GEN PRACT, V53, P365; Hufford MR, 2001, CLIN PSYCHOL REV, V21, P797, DOI 10.1016/S0272-7358(00)00070-2; HUNTER E, 1990, AUST NZ J PSYCHIAT, V24, P191, DOI 10.3109/00048679009077682; Isacsson G, 2001, BMJ-BRIT MED J, V322, P213, DOI 10.1136/bmj.322.7280.213; Jauregui J, 1999, EUR PSYCHIAT, V14, P205, DOI 10.1016/S0924-9338(99)80743-3; Jick H, 2004, JAMA-J AM MED ASSOC, V292, P338, DOI 10.1001/jama.292.3.338; Johnson JG, 2002, ARCH GEN PSYCHIAT, V59, P741, DOI 10.1001/archpsyc.59.8.741; Jollant F, 2005, AM J PSYCHIAT, V162, P304, DOI 10.1176/appi.ajp.162.2.304; Jorm AF, 2002, BRIT J PSYCHIAT, V180, P423, DOI 10.1192/bjp.180.5.423; Kapur N, 2004, GEN HOSP PSYCHIAT, V26, P36, DOI 10.1016/j.genhosppsych.2003.06.002; Kapur N, 2003, SOC PSYCH PSYCH EPID, V38, P390, DOI 10.1007/s00127-003-0647-y; Kemperman I, 1997, J PERS DISORD, V11, P146, DOI 10.1521/pedi.1997.11.2.146; Kenesi L, 1997, ANN MED-PSYCHOL, V155, P609; KESSEL N, 1965, BRIT MED J, V2, P1265, DOI 10.1136/bmj.2.5473.1265; Kessler RC, 1999, ARCH GEN PSYCHIAT, V56, P617, DOI 10.1001/archpsyc.56.7.617; Klonsky ED, 2003, AM J PSYCHIAT, V160, P1501, DOI 10.1176/appi.ajp.160.8.1501; Laloe V, 2002, BURNS, V28, P475, DOI 10.1016/S0305-4179(02)00047-5; Lin PY, 2004, BIOL PSYCHIAT, V55, P1023, DOI 10.1016/j.biopsych.2004.02.006; MacLeod AK, 2004, J PERS DISORD, V18, P459, DOI 10.1521/pedi.18.5.459.51329; MAGNEINGVAR U, 1992, ACTA PSYCHIAT SCAND, V86, P153, DOI 10.1111/j.1600-0447.1992.tb03244.x; Malone KM, 2000, AM J PSYCHIAT, V157, P1084, DOI 10.1176/appi.ajp.157.7.1084; MANIAM T, 1988, BRIT J PSYCHIAT, V153, P222, DOI 10.1192/bjp.153.2.222; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Mann JJ, 2004, AM J PSYCHIAT, V161, P395, DOI 10.1176/appi.ajp.161.3.395; Martinez C, 2005, BRIT MED J, V330, P389, DOI 10.1136/bmj.330.7488.389; Meltzer HY, 2003, ARCH GEN PSYCHIAT, V60, P82, DOI 10.1001/archpsyc.60.1.82; Menninger K. A, 1938, MAN HIMSELF; MILLER D, 1994, WOMEN HURT THEMSELVE; Mittendorfer-Rutz E, 2004, LANCET, V364, P1135, DOI 10.1016/S0140-6736(04)17099-2; MORGAN HG, 1975, BRIT J PSYCHIAT, V127, P564, DOI 10.1192/bjp.127.6.564; Moscicki EK, 1997, PSYCHIAT CLIN N AM, V20, P499, DOI 10.1016/S0193-953X(05)70327-0; Motto JA, 2001, PSYCHIATR SERV, V52, P828, DOI 10.1176/appi.ps.52.6.828; Nada-Raja S, 2004, SUICIDE LIFE-THREAT, V34, P177, DOI 10.1521/suli.34.2.177.32781; Nada-Raja S, 2003, AUST NZ J PSYCHIAT, V37, P600, DOI 10.1046/j.1440-1614.2003.01252.x; National Institute for Clinical Excellence, 2004, SELF HARM SHORTT PHY; Neeleman J, 1998, LANCET, V351, P93, DOI 10.1016/S0140-6736(97)06364-2; Neeleman J, 2001, J EPIDEMIOL COMMUN H, V55, P85, DOI 10.1136/jech.55.2.85; Nock MK, 2005, J ABNORM PSYCHOL, V114, P140, DOI 10.1037/0021-843X.114.1.140; OCarroll PW, 1996, SUICIDE LIFE-THREAT, V26, P237; ODEJIDE AO, 1986, BRIT J PSYCHIAT, V149, P734, DOI 10.1192/bjp.149.6.734; Oquendo M, 2005, AM J PSYCHIAT, V162, P560, DOI 10.1176/appi.ajp.162.3.560; Ostamo A, 2001, SOC PSYCH PSYCH EPID, V36, P29, DOI 10.1007/s001270050287; Owens D, 2002, BRIT J PSYCHIAT, V181, P193, DOI 10.1192/bjp.181.3.193; Paivio SC, 2004, CHILD ABUSE NEGLECT, V28, P339, DOI 10.1016/j.chiabu.2003.11.018; Paris J, 2002, PSYCHIATR SERV, V53, P738, DOI 10.1176/appi.ps.53.6.738; Patel SP, 1996, PSYCHIATR SERV, V47, P517; PATTISON EM, 1983, AM J PSYCHIAT, V140, P867; Patton GC, 1997, PSYCHOL MED, V27, P715, DOI 10.1017/S003329179600462X; PEARCE CM, 1994, ACTA PSYCHIAT SCAND, V90, P324, DOI 10.1111/j.1600-0447.1994.tb01601.x; Pearson V, 2002, SUICIDE LIFE-THREAT, V32, P359, DOI 10.1521/suli.32.4.359.22345; PETRONIS KR, 1990, SOC PSYCH PSYCH EPID, V25, P193; Pettit JW, 2004, J AFFECT DISORDERS, V83, P249, DOI 10.1016/j.jad.2004.08.010; Platt SHK, 2000, HDB SUICIDE ATTEMPTE; RAMON S, 1980, SOC SCI MED-MED SOC, V14, P317; Redley M, 2003, SOCIOL HEALTH ILL, V25, P348, DOI 10.1111/1467-9566.00350; Roberts RE, 1997, SUICIDE LIFE-THREAT, V27, P208; Rodham K, 2004, J AM ACAD CHILD PSY, V43, P80, DOI 10.1097/00004583-200401000-00017; ROMANS SE, 1995, AM J PSYCHIAT, V152, P1336; ROSEN PM, 1989, AM J PSYCHIAT, V146, P656; Ross S, 2002, J YOUTH ADOLESCENCE, V31, P67, DOI 10.1023/A:1014089117419; Royal College of Psychiatrists, 1994, GEN HOSP MAN AD DEL; Schmidtke A, 1996, ACTA PSYCHIAT SCAND, V93, P327, DOI 10.1111/j.1600-0447.1996.tb10656.x; Schnyder U, 1999, GEN HOSP PSYCHIAT, V21, P62, DOI 10.1016/S0163-8343(98)00064-4; Simon TR, 2001, SUICIDE LIFE-THREAT, V32, P49, DOI 10.1521/suli.32.1.5.49.24212; Skegg K, 2004, SUICIDE LIFE-THREAT, V34, P187, DOI 10.1521/suli.34.2.187.32790; Skegg K, 2003, AM J PSYCHIAT, V160, P541, DOI 10.1176/appi.ajp.160.3.541; Stanley B, 2001, AM J PSYCHIAT, V158, P427, DOI 10.1176/appi.ajp.158.3.427; Statham DJ, 1998, PSYCHOL MED, V28, P839, DOI 10.1017/S0033291798006916; Suominen K, 2004, AM J PSYCHIAT, V161, P562, DOI 10.1176/appi.ajp.161.3.562; Suominen K, 1996, ACTA PSYCHIAT SCAND, V94, P234, DOI 10.1111/j.1600-0447.1996.tb09855.x; Suyemoto KL, 1998, CLIN PSYCHOL REV, V18, P531, DOI 10.1016/S0272-7358(97)00105-0; TANTAM D, 1992, BRIT J PSYCHIAT, V161, P451, DOI 10.1192/bjp.161.4.451; Taylor R, 2004, BRIT J PSYCHIAT, V185, P486, DOI 10.1192/bjp.185.6.486; ThiesFlechtner K, 1996, PHARMACOPSYCHIATRY, V29, P103, DOI 10.1055/s-2007-979553; Townsend E, 2001, PSYCHOL MED, V31, P979, DOI 10.1017/S0033291701004238; TRASKMANBENDZ L, 2002, INT HDB SUICIDE ATTE; Turvill JL, 2000, LANCET, V355, P2048, DOI 10.1016/S0140-6736(00)02355-2; Tyrer P, 2003, PSYCHOL MED, V33, P969, DOI 10.1017/S0033291703008171; Van Heeringen C, 2003, BRIT J PSYCHIAT, V183, P282, DOI 10.1192/bjp.183.4.282; Verheul R, 2003, BRIT J PSYCHIAT, V182, P135, DOI 10.1192/bjp.182.2.135; Verona E, 2004, AM J PSYCHIAT, V161, P444, DOI 10.1176/appi.ajp.161.3.444; Wai B H, 1998, Ethn Health, V3, P255; Weissman MM, 1999, PSYCHOL MED, V29, P9, DOI 10.1017/S0033291798007867; Wewetzer G, 1997, Z KINDER JUG-PSYCH, V25, P95; Wichstrom L, 2002, SUICIDE LIFE-THREAT, V32, P101, DOI 10.1521/suli.32.2.101.24407; Wichstrom L, 2003, J ABNORM PSYCHOL, V112, P144, DOI 10.1037/0021-843X.112.1.144; Williams J. M. G., 2000, INT HDB SUICIDE ATTE; Yuen NYC, 2000, J AM ACAD CHILD PSY, V39, P360, DOI 10.1097/00004583-200003000-00019; Zahl DL, 2004, BRIT J PSYCHIAT, V185, P70, DOI 10.1192/bjp.185.1.70; Zlotnick C, 1999, J NERV MENT DIS, V187, P296, DOI 10.1097/00005053-199905000-00005; Zoroglu SS, 2003, PSYCHIAT CLIN NEUROS, V57, P119, DOI 10.1046/j.1440-1819.2003.01088.x	163	475	492	1	72	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2005	366	9495					1471	1483		10.1016/S0140-6736(05)67600-3	http://dx.doi.org/10.1016/S0140-6736(05)67600-3			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976HQ	16243093				2022-12-28	WOS:000232724600027
J	Brandman, O; Ferrett, JE; Li, R; Meyer, T				Brandman, O; Ferrett, JE; Li, R; Meyer, T			Interlinked fast and slow positive feedback loops drive reliable cell decisions	SCIENCE			English	Article							MAP KINASE; ACTIVATION; DIFFERENTIATION; GTPASE; SPECIFICATION; POLARIZATION; NETWORKS; POLARITY; FATE; MPF	Positive feedback is a ubiquitous signal transduction motif that allows systems to convert graded inputs into decisive, all-or-none outputs. Here we investigate why the positive feedback switches that regulate polarization of budding yeast, calcium signaling, Xenopus oocyte maturation, and various other processes use multiple interlinked loops rather than single positive feedback loops. Mathematical simulations revealed that linking fast and stow positive feedback loops creates a "dual-time" switch that is both rapidly inducible and resistant to noise in the upstream signaling system.	Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA; Marine Biol Lab, Physiol Course 2004, Woods Hole, MA 02543 USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA	Stanford University; Marine Biological Laboratory - Woods Hole; Harvard University; Harvard Medical School; Stowers Institute for Medical Research	Brandman, O (corresponding author), Stanford Univ, Sch Med, Dept Mol Pharmacol, Stanford, CA 94305 USA.	onn@stanford.edu		Meyer, Tobias/0000-0003-4339-3804	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM030179] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM046383, R01 GM057063, R01 GM030179-24A1, R01 GM063702, R01 GM030179] Funding Source: Medline; NIMH NIH HHS [R01 MH064801] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Abrieu A, 2001, J CELL SCI, V114, P257; Acar M, 2005, NATURE, V435, P228, DOI 10.1038/nature03524; Becskei A, 2001, EMBO J, V20, P2528, DOI 10.1093/emboj/20.10.2528; BELTRAMI E, 1995, P NATL ACAD SCI USA, V92, P8744, DOI 10.1073/pnas.92.19.8744; Berridge MJ, 2001, NOVART FDN SYMP, V239, P52; Bhalla US, 2002, SCIENCE, V297, P1018, DOI 10.1126/science.1068873; Butty AC, 2002, EMBO J, V21, P1565, DOI 10.1093/emboj/21.7.1565; Cole F, 2004, DEV CELL, V7, P843, DOI 10.1016/j.devcel.2004.10.009; Ferrell JE, 2001, CHAOS, V11, P227, DOI 10.1063/1.1349894; Gardner TS, 2000, NATURE, V403, P339, DOI 10.1038/35002131; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; HOFFMANN I, 1993, EMBO J, V12, P53, DOI 10.1002/j.1460-2075.1993.tb05631.x; HOLMSEN H, 1991, Proceedings of the National Science Council Republic of China Part B Life Sciences, V15, P147; Isaacs FJ, 2003, P NATL ACAD SCI USA, V100, P7714, DOI 10.1073/pnas.1332628100; Kaneko S, 2002, J BIOL CHEM, V277, P23230, DOI 10.1074/jbc.M201733200; Laurent M, 1999, TRENDS BIOCHEM SCI, V24, P418, DOI 10.1016/S0968-0004(99)01473-5; Levine K, 1995, Prog Cell Cycle Res, V1, P101; Lewis RS, 2001, ANNU REV IMMUNOL, V19, P497, DOI 10.1146/annurev.immunol.19.1.497; Lodish H., 2004, MOL CELL BIOL; Margarit SM, 2003, CELL, V112, P685, DOI 10.1016/S0092-8674(03)00149-1; Medina KL, 2004, DEV CELL, V7, P607, DOI 10.1016/j.devcel.2004.08.006; Reynolds AR, 2003, NAT CELL BIOL, V5, P447, DOI 10.1038/ncb981; Shvartsman SY, 2002, AM J PHYSIOL-CELL PH, V282, pC545, DOI 10.1152/ajpcell.00260.2001; Singh H, 2005, P NATL ACAD SCI USA, V102, P4949, DOI 10.1073/pnas.0500480102; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; THAYER MJ, 1989, CELL, V58, P241, DOI 10.1016/0092-8674(89)90838-6; Wedlich-Soldner R, 2003, SCIENCE, V299, P1231, DOI 10.1126/science.1080944; Wedlich-Soldner R, 2004, J CELL BIOL, V166, P889, DOI 10.1083/jcb.200405061; Weiner OD, 2002, NAT CELL BIOL, V4, P509, DOI 10.1038/ncb811	29	345	349	4	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					496	498		10.1126/science.1113834	http://dx.doi.org/10.1126/science.1113834			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239477	Green Accepted			2022-12-28	WOS:000232786000048
J	Fry, BG; Vidal, N; Norman, JA; Vonk, FJ; Scheib, H; Ramjan, SFR; Kuruppu, S; Fung, K; Hedges, SB; Richardson, MK; Hodgson, WC; Ignjatovic, V; Summerhayes, R; Kochva, E				Fry, BG; Vidal, N; Norman, JA; Vonk, FJ; Scheib, H; Ramjan, SFR; Kuruppu, S; Fung, K; Hedges, SB; Richardson, MK; Hodgson, WC; Ignjatovic, V; Summerhayes, R; Kochva, E			Early evolution of the venom system in lizards and snakes	NATURE			English	Article							TOXINOLOGICAL IMPLICATIONS; PHYLOGENETIC ANALYSIS; TOXIN SEQUENCES; ORIGIN; SPECTROMETRY; APPARATUS	Among extant reptiles only two lineages are known to have evolved venom delivery systems, the advanced snakes and helodermatid lizards ( Gila Monster and Beaded Lizard)(1). Evolution of the venom system is thought to underlie the impressive radiation of the advanced snakes ( 2,500 of 3,000 snake species)(2-5). In contrast, the lizard venom system is thought to be restricted to just two species and to have evolved independently from the snake venom system(1). Here we report the presence of venom toxins in two additional lizard lineages ( Monitor Lizards and Iguania) and show that all lineages possessing toxin-secreting oral glands form a clade, demonstrating a single early origin of the venom system in lizards and snakes. Construction of gland complementary-DNA libraries and phylogenetic analysis of transcripts revealed that nine toxin types are shared between lizards and snakes. Toxinological analyses of venom components from the Lace Monitor Varanus varius showed potent effects on blood pressure and clotting ability, bioactivities associated with a rapid loss of consciousness and extensive bleeding in prey. The iguanian lizard Pogona barbata retains characteristics of the ancestral venom system, namely serial, lobular non-compound venom-secreting glands on both the upper and lower jaws, whereas the advanced snakes and anguimorph lizards ( including Monitor Lizards, Gila Monster and Beaded Lizard) have more derived venom systems characterized by the loss of the mandibular ( lower) or maxillary ( upper) glands. Demonstration that the snakes, iguanians and anguimorphs form a single clade provides overwhelming support for a single, early origin of the venom system in lizards and snakes. These results provide new insights into the evolution of the venom system in squamate reptiles and open new avenues for biomedical research and drug design using hitherto unexplored venom proteins.	Univ Melbourne, Sch Med, Australian Venom Res Unit, Parkville, Vic 3010, Australia; Museum Victoria, Polulat & Evolutionary Genet Unit, Melbourne, Vic 3001, Australia; Penn State Univ, Dept Biol, Mueller Lab 208, University Pk, PA 16802 USA; Penn State Univ, Astrobiol Res Ctr, Mueller Lab 208, University Pk, PA 16802 USA; Museum Natl Hist Nat, Dept Systemat & Evolut, UMS 602, F-75005 Paris, France; Leiden Univ, Inst Biol, NL-2300 RA Leiden, Netherlands; Ctr Med Univ Geneva, Swiss Inst Bioinformat, CH-1211 Geneva 4, Switzerland; Univ Geneva, Dept Struct Biol & Bioinformat, CH-1211 Geneva 4, Switzerland; SBC Lab AG, CH-8185 Winkel, Switzerland; Monash Univ, Dept Pharmacol, Monash Venom Grp, Clayton, Vic 3800, Australia; CSIRO, Mol & Hlth Technol, Parkville, Vic 3010, Australia; Univ Melbourne, Dept Pathol, Parkville, Vic 3010, Australia; Royal Childrens Hosp, Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; Tel Aviv Univ, Dept Zool, IL-69978 Tel Aviv, Israel	University of Melbourne; Museum Victoria; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; Museum National d'Histoire Naturelle (MNHN); Leiden University; Leiden University - Excl LUMC; Swiss Institute of Bioinformatics; University of Geneva; University of Geneva; Monash University; Commonwealth Scientific & Industrial Research Organisation (CSIRO); University of Melbourne; Murdoch Children's Research Institute; Royal Children's Hospital Melbourne; Tel Aviv University	Fry, BG (corresponding author), Univ Melbourne, Sch Med, Australian Venom Res Unit, Level 8, Parkville, Vic 3010, Australia.	bgf@unimelb.edu.au	Kuruppu, Sanjaya/I-2258-2014; Fung, Kim YC/H-3522-2013; Richardson, Michael K/E-8269-2011; Ignjatovic, Vera/F-8598-2011	Kuruppu, Sanjaya/0000-0003-1674-3645; Fung, Kim YC/0000-0002-7205-4206; Richardson, Michael K/0000-0003-1222-8101; Ignjatovic, Vera/0000-0002-5548-5813; Hodgson, Wayne/0000-0002-9919-0144				Evans SE, 2003, BIOL REV, V78, P513, DOI 10.1017/S1464793103006134; Fry BG, 2005, GENOME RES, V15, P403, DOI 10.1101/gr.3228405; Fry BG, 2005, BIOCHEM BIOPH RES CO, V327, P1011, DOI 10.1016/j.bbrc.2004.11.171; Fry BG, 2004, MOL BIOL EVOL, V21, P870, DOI 10.1093/molbev/msh091; Fry BG, 2003, J MOL EVOL, V57, P446, DOI 10.1007/s00239-003-2497-3; Fry BG, 2003, RAPID COMMUN MASS SP, V17, P2047, DOI 10.1002/rcm.1148; Fry BG, 2003, J MOL EVOL, V57, P110, DOI 10.1007/s00239-003-2461-2; Fry BG, 2002, RAPID COMMUN MASS SP, V16, P600, DOI 10.1002/rcm.613; Gabe M, 1971, P65; Gabe M., 1969, Memoires du Museum Nationale d'Histoire Naturelle Paris, V58, P1; GORELOV YUK, 1971, IZV AKAD NAUK TUR BN, V71, P74; Guex N, 1997, ELECTROPHORESIS, V18, P2714, DOI 10.1002/elps.1150181505; Gygax P., 1971, ACTA TROPICA ZOOL, V28, P225; HUANG TF, 1994, BBA-LIPID LIPID MET, V1211, P61, DOI 10.1016/0005-2760(94)90139-2; Jackson K, 2003, ZOOL J LINN SOC-LOND, V137, P337, DOI 10.1046/j.1096-3642.2003.00052.x; Kochva E., 1978, P43; KOCHVA E, 1987, TOXICON, V25, P65, DOI 10.1016/0041-0101(87)90150-4; Kochva E., 2002, Bulletin of the Natural History Museum Zoology Series, V68, P91; KOCHVA E, 1963, ACTA ANAT, V52, P49; Kochva E, 1965, COPEIA, V1965, P147, DOI 10.2307/1440716; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Norell M., 1992, AM MUS NOVIT, V3045, P1; PREGILL G K, 1986, Transactions of the San Diego Society of Natural History, V21, P167; Sopiev O., 1987, IZV AKAD NAUK TURKM, V87, P78; Townsend TM, 2004, SYST BIOL, V53, P735, DOI 10.1080/10635150490522340; UNDERWOOD G, 1993, ZOOL J LINN SOC-LOND, V107, P3, DOI 10.1006/zjls.1993.1002; Underwood Garth, 1996, Symposia of the Zoological Society of London, V70, P1; Vidal N, 2004, P ROY SOC B-BIOL SCI, V271, pS226, DOI 10.1098/rsbl.2003.0151; Vidal N, 2002, CR BIOL, V325, P987, DOI 10.1016/S1631-0691(02)01509-3; Vidal N, 2002, J TOXICOL-TOXIN REV, V21, P21, DOI 10.1081/TXR-120004740	30	395	437	6	356	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	FEB 2	2006	439	7076					584	588		10.1038/nature04328	http://dx.doi.org/10.1038/nature04328			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	008IO	16292255				2022-12-28	WOS:000235033900040
J	Zuber, MT; Garrick-Bethell, I				Zuber, MT; Garrick-Bethell, I			Planetary science - What do we need to know to land on the moon again?	SCIENCE			English	Editorial Material							LUNAR PROSPECTOR; TOPOGRAPHY; WATER; POLES; MARS; ICE		MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT)	Zuber, MT (corresponding author), MIT, Dept Earth Atmospher & Planetary Sci, Cambridge, MA 02139 USA.	zuber@mit.edu; lang@mit.edu	Garrick-Bethell, Ian/E-7051-2013	Garrick-Bethell, Ian/0000-0002-6327-5867				Bussey DBJ, 2005, NATURE, V434, P842, DOI 10.1038/434842a; CHAIKIN A, 1994, MAN MOON, P196; DICKEY JO, 1994, SCIENCE, V265, P482, DOI 10.1126/science.265.5171.482; Feldman WC, 1998, SCIENCE, V281, P1496, DOI 10.1126/science.281.5382.1496; Golombek MP, 2003, J GEOPHYS RES-PLANET, V108, DOI 10.1029/2002JE002035; Golombek MP, 1997, J GEOPHYS RES-PLANET, V102, P3967, DOI 10.1029/96JE03318; Konopliv AS, 2001, ICARUS, V150, P1, DOI 10.1006/icar.2000.6573; Margot JL, 1999, SCIENCE, V284, P1658, DOI 10.1126/science.284.5420.1658; *MISS EV TEAM, 1970, TMX74200 NASA MANN S; Nozette S, 1996, SCIENCE, V274, P1495, DOI 10.1126/science.274.5292.1495; Pieters CM, 1997, GEOPHYS RES LETT, V24, P1903, DOI 10.1029/97GL01718; Simpson RA, 1999, J GEOPHYS RES-PLANET, V104, P3845, DOI 10.1029/1998JE900038; Smith DE, 2001, J GEOPHYS RES-PLANET, V106, P23689, DOI 10.1029/2000JE001364; Smith DE, 1997, J GEOPHYS RES-PLANET, V102, P1591, DOI 10.1029/96JE02940; Squyres SW, 2004, SCIENCE, V306, P1709, DOI 10.1126/science.1104559; Vondrak RR, 2003, AM SCI, V91, P322, DOI 10.1511/2003.26.867	16	7	9	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					983	985		10.1126/science.1115126	http://dx.doi.org/10.1126/science.1115126			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284169				2022-12-28	WOS:000233343400032
J	Braun, H; Christl, M; Rahmstorf, S; Ganopolski, A; Mangini, A; Kubatzki, C; Roth, K; Kromer, B				Braun, H; Christl, M; Rahmstorf, S; Ganopolski, A; Mangini, A; Kubatzki, C; Roth, K; Kromer, B			Possible solar origin of the 1,470-year glacial climate cycle demonstrated in a coupled model	NATURE			English	Article							NORTH-ATLANTIC; STOCHASTIC RESONANCE; VARIABILITY; RECORDS; OZONE; GISP2	Many palaeoclimate records from the North Atlantic region show a pattern of rapid climate oscillations, the so-called Dansgaard Oeschger events, with a quasi-periodicity of similar to 1,470 years for the late glacial period(1-6). Various hypotheses have been suggested to explain these rapid temperature shifts, including internal oscillations in the climate system and external forcing, possibly from the Sun(7). But whereas pronounced solar cycles of similar to 87 and similar to 210 years are well known(8-12), a similar to 1,470-year solar cycle has not been detected(8). Here we show that an intermediate-complexity climate model with glacial climate conditions simulates rapid climate shifts similar to the Dansgaard - Oeschger events with a spacing of 1,470 years when forced by periodic freshwater input into the North Atlantic Ocean in cycles of, 87 and, 210 years. We attribute the robust 1,470-year response time to the superposition of the two shorter cycles, together with strongly nonlinear dynamics and the long characteristic timescale of the thermohaline circulation. For Holocene conditions, similar events do not occur. We conclude that the glacial 1,470-year climate cycles could have been triggered by solar forcing despite the absence of a 1,470-year solar cycle.	Heidelberg Univ, Inst Environm Phys, Heidelberg Acad Sci, D-69120 Heidelberg, Germany; Potsdam Inst Climate Impact Res, D-14412 Potsdam, Germany; Alfred Wegener Inst Polar & Marine Res, D-27570 Bremerhaven, Germany	Ruprecht Karls University Heidelberg; Potsdam Institut fur Klimafolgenforschung; Helmholtz Association; Alfred Wegener Institute, Helmholtz Centre for Polar & Marine Research	Braun, H (corresponding author), Heidelberg Univ, Inst Environm Phys, Heidelberg Acad Sci, Neuenheimer Feld 229, D-69120 Heidelberg, Germany.	holger.braun@iup.uni-heidelberg.de	Christl, Marcus/J-4769-2016; Rahmstorf, Stefan/A-8465-2010; Ganopolski, Andrey/F-6811-2013	Christl, Marcus/0000-0002-3131-6652; Rahmstorf, Stefan/0000-0001-6786-7723; 				Alley RB, 2001, GEOPH MONOG SERIES, V126, P57; Alley RB, 2001, PALEOCEANOGRAPHY, V16, P190, DOI 10.1029/2000PA000518; Beer Jurg, 1994, INT ASTRON UNION CIR, V143, P291, DOI [10.1017/S0252921100024799, DOI 10.1017/S0252921100024799]; Bond G, 2001, SCIENCE, V294, P2130, DOI 10.1126/science.1065680; BOND G, 1993, NATURE, V365, P143, DOI 10.1038/365143a0; Carslaw KS, 2002, SCIENCE, V298, P1732, DOI 10.1126/science.1076964; Ganopolski A, 2001, GEOPH MONOG SERIES, V126, P261; Ganopolski A, 2002, PHYS REV LETT, V88, DOI [10.1103/PhysRevLett.88.038501, 10.1103/PhysRevB.88.038501]; Ganopolski A, 2001, NATURE, V409, P153, DOI 10.1038/35051500; GROOTES PM, 1993, NATURE, V366, P552, DOI 10.1038/366552a0; HAIGH JD, 1994, NATURE, V370, P544, DOI 10.1038/370544a0; Hodell DA, 2001, SCIENCE, V292, P1367, DOI 10.1126/science.1057759; Keeling CD, 2000, P NATL ACAD SCI USA, V97, P3814, DOI 10.1073/pnas.070047197; Lean J, 1998, J CLIMATE, V11, P3069, DOI 10.1175/1520-0442(1998)011<3069:CFBCSR>2.0.CO;2; Lohmann G, 1998, J CLIMATE, V11, P2789, DOI 10.1175/1520-0442(1998)011<2789:SIEOTS>2.0.CO;2; Neff U, 2001, NATURE, V411, P290, DOI 10.1038/35077048; Ogurtsov MG, 2002, SOL PHYS, V211, P371, DOI 10.1023/A:1022411209257; Peristykh AN, 2003, J GEOPHYS RES-SPACE, V108, DOI [10.1029/2002JA009390, 10.1029/2002JAD09390]; Rahmstorf S, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL017115; Ram M, 1999, GEOPHYS RES LETT, V26, P1043, DOI 10.1029/1999GL900199; Sachs JP, 1999, SCIENCE, V286, P756, DOI 10.1126/science.286.5440.756; Schmittner A, 2002, SCIENCE, V295, P1489, DOI 10.1126/science.1066174; Schulz M, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2000PA000571; Shindell D, 1999, SCIENCE, V284, P305, DOI 10.1126/science.284.5412.305; Spotl C, 2002, EARTH PLANET SC LETT, V203, P507, DOI 10.1016/S0012-821X(02)00837-3; Stuiver M., 1993, HOLOCENE, V3, P289, DOI DOI 10.1177/095968369300300401; van Geel B, 1999, QUATERNARY SCI REV, V18, P331, DOI 10.1016/S0277-3791(98)00088-2; Voelker AHL, 2002, QUATERNARY SCI REV, V21, P1185, DOI 10.1016/S0277-3791(01)00139-1; Wagner G, 2001, GEOPHYS RES LETT, V28, P303, DOI 10.1029/2000GL006116; Weber SL, 2004, CLIM DYNAM, V22, P539, DOI 10.1007/s00382-004-0396-y	30	164	175	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					208	211		10.1038/nature04121	http://dx.doi.org/10.1038/nature04121			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281042	Green Published			2022-12-28	WOS:000233133500045
J	Lee, N; Maurange, C; Ringrose, L; Paro, R				Lee, N; Maurange, C; Ringrose, L; Paro, R			Suppression of Polycomb group proteins by JNK signalling induces transdetermination in Drosophila imaginal discs	NATURE			English	Article							METHYLTRANSFERASE ACTIVITY; PATHWAY; COMPLEX; WINGLESS; ENHANCER; ENCODES; CLOSURE; KINASE; DJUN; EYE	During the regeneration of Drosophila imaginal discs, cellular identities can switch fate in a process known as transdetermination(1). For leg-to-wing transdetermination, the underlying mechanism involves morphogens such as Wingless that, when activated outside their normal context, induce ectopic expression of the wing-specific selector gene vestigial(2,3). Polycomb group (PcG) proteins maintain cellular fates by controlling the expression patterns of homeotic genes and other developmental regulators(4). Here we report that transdetermination events are coupled to PcG regulation. We show that the frequency of transdetermination is enhanced in PcG mutant flies. Downregulation of PcG function, as monitored by the reactivation of a silent PcG-regulated reporter gene, is observed in transdetermined cells. This downregulation is directly controlled by the Jun amino-terminal kinase (JNK) signalling pathway, which is activated in cells undergoing regeneration. Accordingly, transdetermination frequency is reduced in a JNK mutant background. This regulatory interaction also occurs in mammalian cells, indicating that the role of this signalling cascade in remodelling cellular fates may be conserved.	Univ Heidelberg, Ctr Mol Biol Heidelberg ZMBH, D-69120 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Paro, R (corresponding author), Univ Heidelberg, Ctr Mol Biol Heidelberg ZMBH, D-69120 Heidelberg, Germany.	paro@zmbh.uni-heidelberg.de	Ringrose, Leonie/AAV-4734-2021	Maurange, Cedric/0000-0001-8931-1419				Bonny C, 2001, DIABETES, V50, P77, DOI 10.2337/diabetes.50.1.77; Bosch M, 2005, DEV BIOL, V280, P73, DOI 10.1016/j.ydbio.2005.01.002; Cavalli G, 1998, CELL, V93, P505, DOI 10.1016/S0092-8674(00)81181-2; Czermin B, 2002, CELL, V111, P185, DOI 10.1016/S0092-8674(02)00975-3; Galko MJ, 2004, PLOS BIOL, V2, P1114, DOI 10.1371/journal.pbio.0020239; Gibson MC, 1999, DEVELOPMENT, V126, P1591; GLISE B, 1995, CELL, V83, P451, DOI 10.1016/0092-8674(95)90123-X; Hadorn E., 1978, P556; Jasper H, 2001, DEV CELL, V1, P579, DOI 10.1016/S1534-5807(01)00045-4; Martin-Blanco E, 1998, GENE DEV, V12, P557, DOI 10.1101/gad.12.4.557; Maves L, 1998, DEVELOPMENT, V125, P115; Maves L, 2003, CURR OPIN GENET DEV, V13, P472, DOI 10.1016/j.gde.2003.08.006; MAVES L, 1995, DEVELOPMENT, V121, P1263; Muller J, 2002, CELL, V111, P197, DOI 10.1016/S0092-8674(02)00976-5; Okubo Tadashi, 2004, J Biol, V3, P11, DOI 10.1186/jbiol3; Otte AP, 2003, CURR OPIN GENET DEV, V13, P448, DOI 10.1016/S0959-437X(03)00108-4; PERKINS KK, 1988, EMBO J, V7, P4265, DOI 10.1002/j.1460-2075.1988.tb03324.x; Ramet M, 2002, DEV BIOL, V241, P145, DOI 10.1006/dbio.2001.0502; RiesgoEscovar JR, 1996, GENE DEV, V10, P2759, DOI 10.1101/gad.10.21.2759; RiesgoEscovar JR, 1997, SCIENCE, V278, P669, DOI 10.1126/science.278.5338.669; Ringrose L, 2003, DEV CELL, V5, P759, DOI 10.1016/S1534-5807(03)00337-X; Ringrose L, 2004, ANNU REV GENET, V38, P413, DOI 10.1146/annurev.genet.38.072902.091907; Shao ZH, 1999, CELL, V98, P37, DOI 10.1016/S0092-8674(00)80604-2; Shaulian E, 2000, CELL, V103, P897, DOI 10.1016/S0092-8674(00)00193-8; Sustar A, 2005, CELL, V120, P383, DOI 10.1016/j.cell.2004.12.008; Valk-Lingbeek ME, 2004, CELL, V118, P409, DOI 10.1016/j.cell.2004.08.005; Weber U, 2000, DEVELOPMENT, V127, P3619; Zeitlinger J, 1999, DEVELOPMENT, V126, P3947	28	170	174	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2005	438	7065					234	237		10.1038/nature04120	http://dx.doi.org/10.1038/nature04120			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281037				2022-12-28	WOS:000233133500051
J	Thomas, SE; Soltani-Bejnood, M; Roth, P; Dorn, R; Logsdon, JM; McKee, BD				Thomas, SE; Soltani-Bejnood, M; Roth, P; Dorn, R; Logsdon, JM; McKee, BD			Identification of two proteins required for conjunction and regular segregation of achiasmate homologs in Drosophila male Meiosis	CELL			English	Article							POSITION-EFFECT VARIEGATION; SYNAPTONEMAL COMPLEX; CHROMATIN INSULATOR; DNA-BINDING; GENE; MOD(MDG4); MELANOGASTER; LOCUS; DYNAMICS; ENHANCER	In Drosophila males, homologous chromosomes segregate by an unusual process involving physical connections not dependent on recombination. We have identified two meiotic proteins specifically required for this process. Stromalin in Melosis (SNM) is a divergent member of the SCC3/SA/STAG family of cohesin proteins, and Modifier of Mdg4 in Melosis (MNM) is one of many BTB-domain proteins expressed from the mod(mdg4) locus. SNM and MNM colocalize along with a repetitive rDNA sequence known to function as an X-Y pairing site to nucleolar foci during meiotic prophase and to a compact structure associated with the X-Y bivalent during prometaphase I and metaphase 1. Additionally, MNM localizes to autosomal foci throughout meiosis 1. These proteins are mutually dependent for their colocalization, and at least MNM requires the function of teflon, another meiotic gene. SNM and MNM do not colocalize with SMC1, suggesting that the homolog conjunction mechanism is independent of cohesin.	Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA; Univ Tennessee, Genome Sci & Technol Program, Knoxville, TN 37996 USA; Univ Halle Wittenberg, Inst Genet, Halle An Der Saale, Germany; Univ Iowa, Roy J Carver Ctr Comparat Genom, Dept Biol Sci, Iowa City, IA 52242 USA	University of Tennessee System; University of Tennessee Knoxville; University of Tennessee System; University of Tennessee Knoxville; Martin Luther University Halle Wittenberg; University of Iowa	McKee, BD (corresponding author), Univ Tennessee, Dept Biochem Cellular & Mol Biol, Knoxville, TN 37996 USA.	bdmckee@utk.edu	Logsdon, John M/B-7812-2009		NIGMS NIH HHS [R01 GM40489] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040489] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ahmad K, 2001, J CELL BIOL, V153, P101, DOI 10.1083/jcb.153.1.101; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Balicky EM, 2002, MOL BIOL CELL, V13, P3890, DOI 10.1091/mbc.E02-06-0332; BONACCORSI S, 2000, DROSOPHILA PROTOCOLS; Buchner K, 2000, GENETICS, V155, P141; CARPENTER ATC, 1994, CELL, V77, P959, DOI 10.1016/0092-8674(94)90434-0; CENCI G, 1994, J CELL SCI, V107, P3521; Cooper KW, 1950, BIOL DROSOPHILA, P1; Dorn R, 2003, GENETICA, V117, P165, DOI 10.1023/A:1022983810016; DORN R, 1993, P NATL ACAD SCI USA, V90, P11376, DOI 10.1073/pnas.90.23.11376; Dorn R, 2001, P NATL ACAD SCI USA, V98, P9724, DOI 10.1073/pnas.151268698; Gerasimova TI, 2000, MOL CELL, V6, P1025, DOI 10.1016/S1097-2765(00)00101-5; GERASIMOVA TI, 1995, CELL, V82, P587, DOI 10.1016/0092-8674(95)90031-4; GETHMANN RC, 1988, J HERED, V79, P344, DOI 10.1093/oxfordjournals.jhered.a110526; Gorczyca M, 1999, J NEUROBIOL, V39, P447, DOI 10.1002/(SICI)1097-4695(19990605)39:3<447::AID-NEU10>3.0.CO;2-Q; GOULDSOMERO M, 1974, ROUX ARCH DEV BIOL, V174, P133, DOI 10.1007/BF00573626; GUNSALUS KC, 1995, J CELL BIOL, V131, P1243, DOI 10.1083/jcb.131.5.1243; Harvey AJ, 1997, MOL CELL BIOL, V17, P2835, DOI 10.1128/MCB.17.5.2835; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Heyting C, 1996, CURR OPIN CELL BIOL, V8, P389, DOI 10.1016/S0955-0674(96)80015-9; Hime GR, 1996, J CELL SCI, V109, P2779; Holt RA, 2002, SCIENCE, V298, P129, DOI 10.1126/science.1076181; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Igarashi K, 1998, J BIOL CHEM, V273, P11783, DOI 10.1074/jbc.273.19.11783; Katsani KR, 1999, EMBO J, V18, P698, DOI 10.1093/emboj/18.3.698; Kitajima TS, 2003, SCIENCE, V300, P1152, DOI 10.1126/science.1083634; Koundakjian EJ, 2004, GENETICS, V167, P203, DOI 10.1534/genetics.167.1.203; MADDISON WP, 2003, MACCLADE; McKee BD, 2004, BBA-GENE STRUCT EXPR, V1677, P165, DOI 10.1016/j.bbaexp.2003.11.017; MEYER GF, 1960, P EUROPEAN REGIONAL, P951; Nasmyth K, 2002, SCIENCE, V297, P559, DOI 10.1126/science.1074757; OCHS RL, 1985, BIOL CELL, V54, P123, DOI 10.1111/j.1768-322X.1985.tb00387.x; Page SL, 2003, SCIENCE, V301, P785, DOI 10.1126/science.1086605; Page SL, 2001, GENE DEV, V15, P3130, DOI 10.1101/gad.935001; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; RASMUSSEN SW, 1977, CHROMOSOMA, V60, P205, DOI 10.1007/BF00329771; Roeder GS, 1997, GENE DEV, V11, P2600, DOI 10.1101/gad.11.20.2600; Strimmer K, 1996, MOL BIOL EVOL, V13, P964, DOI 10.1093/oxfordjournals.molbev.a025664; Thompson JD, 1997, NUCLEIC ACIDS RES, V25, P4876, DOI 10.1093/nar/25.24.4876; Tomkiel JE, 2001, GENETICS, V157, P273; Valdeolmillos A, 1998, DNA CELL BIOL, V17, P699, DOI 10.1089/dna.1998.17.699; Vass S, 2003, CURR BIOL, V13, P208, DOI 10.1016/S0960-9822(03)00047-2; Vazquez J, 2002, CURR BIOL, V12, P1473, DOI 10.1016/S0960-9822(02)01090-4; Wakimoto BT, 2004, GENETICS, V167, P207, DOI 10.1534/genetics.167.1.207; WANDALL A, 1985, CHROMOSOMA, V92, P254, DOI 10.1007/BF00329808; WOLF KW, 1994, BIOESSAYS, V16, P107, DOI 10.1002/bies.950160207	49	65	69	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					555	568		10.1016/j.cell.2005.08.043	http://dx.doi.org/10.1016/j.cell.2005.08.043			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286005	Bronze			2022-12-28	WOS:000233497400006
J	Amelin, Y				Amelin, Y			Meteorite phosphates show constant Lu-176 decay rate since 4557 million years ago	SCIENCE			English	Article							U-PB; LU-HF; ACAPULCO METEORITE; EARLY HISTORY; SYSTEMATICS; CHONDRITES; CHEMISTRY; AGES	The use,of radioactive decay of Lu-176 to Hf-176 to study the evolution of the Earth requires a precise and accurate value for the Lu-176 decay constant. Recent determinations of this decay constant by age comparison to the more precisely calibrated U-Pb isotopic system produced internally consistent but discrepant values between terrestrial minerals and meteorites. New highly radiogenic Lu-Hf data for phosphate minerals from Richardton (ordinary chondrite) and Acapulco (primitive achondrite) yield decay constant values of 1.864 x 10(-11) +/- 0.016 x 10(-11) and 1.832 x 10(-11) +/- 0.029 x 10(-11) year(-1), respectively, identical to the value determined from terrestrial minerals.	Geol Survey Canada, Ottawa, ON K1A 0E8, Canada	Natural Resources Canada; Lands & Minerals Sector - Natural Resources Canada; Geological Survey of Canada	Amelin, Y (corresponding author), Geol Survey Canada, 601 Booth St, Ottawa, ON K1A 0E8, Canada.	yamelin@nrcan.gc.ca						ALBAREDE F, IN PRESS GEOCHIM COS; Amelin Y, 2005, GEOCHIM COSMOCHIM AC, V69, P465, DOI 10.1016/j.gca.2004.04.028; Amelin Y, 2005, GEOCHIM COSMOCHIM AC, V69, P505, DOI 10.1016/j.gca.2004.05.047; Barfod GH, 2005, GEOCHIM COSMOCHIM AC, V69, P1847, DOI 10.1016/j.gca.2004.09.014; Begemann F, 2001, GEOCHIM COSMOCHIM AC, V65, P111, DOI 10.1016/S0016-7037(00)00512-3; Bizzarro M, 2003, NATURE, V421, P931, DOI 10.1038/nature01421; Blichert-Toft J, 2002, EARTH PLANET SC LETT, V204, P167, DOI 10.1016/S0012-821X(02)00976-7; GOPEL C, 1994, EARTH PLANET SC LETT, V121, P153, DOI 10.1016/0012-821X(94)90038-8; GOPEL C, 1992, METEORITICS, V27, P226; Grady M. M., 2000, CATALOGUE METEORITES; Grinyer GF, 2003, PHYS REV C, V67, DOI 10.1103/PhysRevC.67.014302; Ireland TR, 2000, INT GEOL REV, V42, P865, DOI 10.1080/00206810009465116; JAFFEY AH, 1971, PHYS REV C, V4, P1889, DOI 10.1103/PhysRevC.4.1889; Krot AN, 2005, NATURE, V436, P989, DOI 10.1038/nature03830; Ludwig KR, 1998, GEOCHIM COSMOCHIM AC, V62, P665, DOI 10.1016/S0016-7037(98)00059-3; Ludwig KR, 2000, CHEM GEOL, V166, P315, DOI 10.1016/S0009-2541(99)00219-3; McCoy TJ, 1996, GEOCHIM COSMOCHIM AC, V60, P2681, DOI 10.1016/0016-7037(96)00109-3; Min KW, 2003, EARTH PLANET SC LETT, V209, P323, DOI 10.1016/S0012-821X(03)00080-3; Nir-El Y, 2003, PHYS REV C, V68, DOI 10.1103/PhysRevC.68.067301; PALME H, 1981, GEOCHIM COSMOCHIM AC, V45, P727, DOI 10.1016/0016-7037(81)90045-4; Palme H., 2003, TREATISE GEOCHEMISTR, V1, P41, DOI [10.1016/B0-08-043751-6/01060-4, DOI 10.1016/B0-08-043751-6/01060-4]; PATCHETT PJ, 1980, NATURE, V288, P571, DOI 10.1038/288571a0; Patchett PJ, 2004, EARTH PLANET SC LETT, V222, P29, DOI 10.1016/j.epsl.2004.02.030; Scherer E, 2001, SCIENCE, V293, P683, DOI 10.1126/science.1061372; Soderlund U, 2004, EARTH PLANET SC LETT, V219, P311, DOI 10.1016/S0012-821X(04)00012-3; Tera F, 1997, GEOCHIM COSMOCHIM AC, V61, P1713, DOI 10.1016/S0016-7037(97)00018-5	26	86	87	1	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					839	841		10.1126/science.1117919	http://dx.doi.org/10.1126/science.1117919			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272119				2022-12-28	WOS:000233121800041
J	Schiavi, F; Boedeker, CC; Bausch, B; Peczkowska, M; Gomez, CF; Strassburg, T; Pawlu, C; Buchta, M; Salzmann, M; Hoffmann, MM; Berlis, A; Brink, I; Cybulla, M; Muresan, M; Walter, MA; Forrer, F; Valimaki, M; Kawecki, A; Szutkowski, Z; Schipper, J; Walz, MK; Pigny, P; Banters, C; Willet-Brozick, JE; Baysal, BE; Januszewicz, A; Eng, C; Opocher, G; Neumann, HPH				Schiavi, F; Boedeker, CC; Bausch, B; Peczkowska, M; Gomez, CF; Strassburg, T; Pawlu, C; Buchta, M; Salzmann, M; Hoffmann, MM; Berlis, A; Brink, I; Cybulla, M; Muresan, M; Walter, MA; Forrer, F; Valimaki, M; Kawecki, A; Szutkowski, Z; Schipper, J; Walz, MK; Pigny, P; Banters, C; Willet-Brozick, JE; Baysal, BE; Januszewicz, A; Eng, C; Opocher, G; Neumann, HPH		European-American Paraganglioma St	Predictors and prevalence of paraganglioma syndrome associated with mutations of the SDHC gene	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COMPLEX-II GENE; AUTOSOMAL-DOMINANT PARAGANGLIOMA; CAROTID-BODY PARAGANGLIOMA; VONHIPPEL-LINDAU DISEASE; GERM-LINE MUTATIONS; FAMILIAL PHEOCHROMOCYTOMA; NECK PARAGANGLIOMAS; CLINICAL-FEATURES; HEAD; SUSCEPTIBILITY	Context Paraganglioma syndrome includes inherited head and neck paragangliomas (HNPs) and adrenal or extra-adrenal pheochromocytomas and are classified according to the susceptibility genes SDHB, SDHC, and SDHD. In contrast with those with germline mutations of the SDHB and SDHD genes, clinical and genetic data on patients with mutations of SDHC are scarce. Objective To determine the prevalence and clinical characteristics of SDHC mutation carriers compared with patients with SDHB and SDHD mutations and with sporadic cases. Design, Setting, and Patients Genetic screening for SDHC mutations in an international HNP registry of 121 unrelated index cases and in 371 sporadic cases from a pheochromocytoma registry, conducted January 1, 2001, until December 31, 2004. Identified index cases and affected relatives were clinically evaluated. Main Outcome Measures Prevalence of and clinical findings for SDHC mutation-associated HNPs vs those with SDHB and SDHD mutations. Results The prevalence of SDHC carriers was 4% in HNP but 0% in pheochromocytoma index cases. None of the SDHC mutation carriers had signs of pheochromocytoma. We compared HNPs in 22 SDHC mutation carriers with the HNPs of SDHB (n=15) and SDHD (n=42) mutation carriers and with 90 patients with sporadic HNPs. Location, number of tumors, malignancy, and age were different: more carotid body tumors were found in SDHC (13/22 [59%]) than in sporadic HNPs (29/90 [32%], P=.03), as well as fewer instances of multiple tumors in SDHC (2/22) than in SDHD (24/42; P<.001), 0 malignant tumors in SDHC vs 6/15 in SDHB (P=.002), and younger age at diagnosis in SDHC than in sporadic HNPs (45 vs 52 years; P=.03). Conclusions Patients with HNP, but not those with pheochromocytoma, harbor SDHC mutations in addition to those in SDHB and SDHD. In total, more than one quarter of HNP patients carry a mutation in 1 of these 3 genes. Head and neck paragangliomas associated with SDHC mutations are virtually exclusively benign and seldom multifocal. Analysis for germline mutations of SDHC is recommended in apparently sporadic HNP to identify risk of inheritance.	Univ Freiburg, Med Klin, Dept Nephrol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Otorhinolaryngol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Physiol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Lab Med, D-79106 Freiburg, Germany; Univ Freiburg, Dept Neuroradiol, D-79106 Freiburg, Germany; Univ Freiburg, Dept Nucl Med, D-79106 Freiburg, Germany; Univ Padua, Dept Endocrinol, Padua, Italy; Sklodowska Curie Mem Inst Oncol, Inst Cardiol, Dept Hypertens, Warsaw, Poland; Sklodowska Curie Mem Inst Oncol, Dept Head & Neck Canc, Warsaw, Poland; Hosp Navarra, Dept Endocrinol, Pamplona, Spain; Univ Nancy, Hop Brabois, Dept Endocrinol, Nancy, France; Univ Basel, Inst Nucl Med, Basel, Switzerland; Univ Basel, Dept Nucl Med, Div Endocrinol, Basel, Switzerland; Univ Helsinki, Cent Hosp, Dept Med, Helsinki, Finland; Kliniken Essen Mitte, Dept Surg, Essen, Germany; Univ Lille, Univ Hosp, Lab Endocrine Biochem, Lille, France; Univ Lille, Univ Hosp, Dept Endocrinol, Lille, France; Univ Pittsburgh, Sch Med, Dept Obstet Gynecol & Reprod Sci, Pittsburgh, PA USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Cleveland Clin Fdn, Genom Med Inst, Cleveland, OH 44195 USA	University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Freiburg; University of Padua; Institute of Cardiology - Poland; Maria Sklodowska-Curie National Research Institute of Oncology; Maria Sklodowska-Curie National Research Institute of Oncology; Servicio Navarro de Salud - Osasunbidea; CHU de Nancy; Universite de Lorraine; University of Basel; University of Basel; University of Helsinki; Helsinki University Central Hospital; Kliniken Essen-Mitte; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Universite de Lille - ISITE; CHU Lille; Universite de Lille; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Case Western Reserve University; Cleveland Clinic Foundation	Neumann, HPH (corresponding author), Univ Freiburg, Med Klin, Dept Nephrol, Hugstetter Str 55, D-79106 Freiburg, Germany.	neumann@med1.ukl.uni-freiburg.de	Schiavi, Francesca/AAB-9908-2022; Walter, Martin A/B-5203-2017; pigny, pascal/L-7059-2018; Hoffmann, Michael M/D-4074-2015; Berlis, Ansgar/AAN-9734-2020; Opocher, Giuseppe/F-3950-2014; Walz, Martin/AHE-7790-2022	Schiavi, Francesca/0000-0001-8529-4455; Walter, Martin A/0000-0001-6487-5349; Hoffmann, Michael M/0000-0001-8459-6080; Opocher, Giuseppe/0000-0002-9845-9623; Eng, Charis/0000-0002-3693-5145	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD039058] Funding Source: NIH RePORTER; NICHD NIH HHS [R01HD39058-04S1, R01HD39058-04] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Astuti D, 2001, LANCET, V357, P1181, DOI 10.1016/S0140-6736(00)04378-6; Astuti D, 2001, AM J HUM GENET, V69, P49, DOI 10.1086/321282; Badenhop RF, 2004, J MED GENET, V41, DOI 10.1136/jmg.2003.011551; Bauters C, 2003, J MED GENET, V40, DOI 10.1136/jmg.40.6.e75; Baysal BE, 2004, J MED GENET, V41, P703, DOI 10.1136/jmg.2004.019224; Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848; Baysal BE, 2002, J MED GENET, V39, P178, DOI 10.1136/jmg.39.3.178; Birch-Machin MA, 2000, ANN NEUROL, V48, P330, DOI 10.1002/1531-8249(200009)48:3<330::AID-ANA7>3.0.CO;2-A; Eng C, 2003, NAT REV CANCER, V3, P193, DOI 10.1038/nrc1013; Gimm O, 2000, CANCER RES, V60, P6822; HULL MT, 1982, ARCH PATHOL LAB MED, V106, P235; KENNEDY DW, 1986, OTOLARYNG HEAD NECK, V94, P644; KROLL AJ, 1964, NEW ENGL J MED, V270, P6, DOI 10.1056/NEJM196401022700102; Mehta C R, 1994, Stat Methods Med Res, V3, P135, DOI 10.1177/096228029400300203; Mhatre AN, 2004, CLIN GENET, V66, P461, DOI 10.1111/j.1399-0004.2004.00328.x; Neumann HPH, 2002, NEW ENGL J MED, V346, P1459, DOI 10.1056/NEJMoa020152; Neumann HPH, 2004, JAMA-J AM MED ASSOC, V292, P943, DOI 10.1001/jama.292.8.943; Niemann S, 1999, NEUROGENETICS, V2, P167, DOI 10.1007/s100480050078; Niemann S, 2000, NAT GENET, V26, P268, DOI 10.1038/81551; Pawlu C, 2005, FAM CANCER, V4, P49, DOI 10.1007/s10689-004-4227-4; Schimke RN, 1998, AM J MED GENET, V80, P533, DOI 10.1002/(SICI)1096-8628(19981228)80:5<533::AID-AJMG21>3.0.CO;2-C; Zanelli M, 1996, HISTOPATHOLOGY, V29, P178, DOI 10.1046/j.1365-2559.1996.d01-505.x	22	242	252	0	23	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2057	2063		10.1001/jama.294.16.2057	http://dx.doi.org/10.1001/jama.294.16.2057			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249420	Bronze			2022-12-28	WOS:000232778900026
J	Beevers, DG				Beevers, DG			The end of beta blockers for uncomplicated hypertension?	LANCET			English	Editorial Material							RANDOMIZED-TRIAL; ATENOLOL; AMLODIPINE; OUTCOMES		Univ Birmingham, City Hosp, Dept Med, Birmingham B18 7QH, W Midlands, England	University of Birmingham	Beevers, DG (corresponding author), Univ Birmingham, City Hosp, Dept Med, Birmingham B18 7QH, W Midlands, England.	ruby.stone@swbh.nhs.uk						Alderman MH, 2005, HYPERTENSION, V46, P1, DOI 10.1161/01.HYP.0000168924.37091.58; Beevers DG, 1998, J HUM HYPERTENS, V12, P807, DOI 10.1038/sj.jhh.1000701; Carlberg B, 2004, LANCET, V364, P1684, DOI 10.1016/S0140-6736(04)17355-8; Dahlof B, 2002, LANCET, V359, P995, DOI 10.1016/S0140-6736(02)08089-3; Dahlof B, 2005, LANCET, V366, P895, DOI 10.1016/S0140-6736(05)67185-1; Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9; Lindholm LH, 2005, LANCET, V366, P1545, DOI 10.1016/S0140-6736(05)67573-3; *MED RES COUNC WOR, 1985, BRIT MED J, V291, P87; STUTTAFORD T, 2004, TIMES LONDON    1105; Williams B, 2004, J HUM HYPERTENS, V18, P139, DOI 10.1038/sj.jhh.1001683	10	38	44	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1510	1512		10.1016/S0140-6736(05)67575-7	http://dx.doi.org/10.1016/S0140-6736(05)67575-7			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257329				2022-12-28	WOS:000232984800006
J	Sawa, A; Snyder, SH				Sawa, A; Snyder, SH			Two genes link two distinct psychoses	SCIENCE			English	Editorial Material							SCHIZOAFFECTIVE DISORDER; NEURITE OUTGROWTH; SCHIZOPHRENIA; DISC1; DISRUPTED-IN-SCHIZOPHRENIA-1; TRANSLOCATION; MUTATION; PROTEIN; DISEASE; CORTEX		Johns Hopkins Univ, Sch Med, Dept Psychiat, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Program Cellular Mol Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Pharmacol, Baltimore, MD 21205 USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Sawa, A (corresponding author), Johns Hopkins Univ, Sch Med, Dept Psychiat, 725 N Wolfe St, Baltimore, MD 21205 USA.	asawa1@jhmi.edu; ssnyder@jhmi.edu						Baxter MG, 2003, NEURON, V40, P669, DOI 10.1016/S0896-6273(03)00715-3; Blackwood DHR, 2001, AM J HUM GENET, V69, P428, DOI 10.1086/321969; Burdick KE, 2005, NEUROREPORT, V16, P1399, DOI 10.1097/01.wnr.0000175248.25535.f6; Callicott JH, 2005, P NATL ACAD SCI USA, V102, P8627, DOI 10.1073/pnas.0500515102; DAVIS RL, 1995, MOL CELL BIOCHEM, V149, P271, DOI 10.1007/BF01076588; Hamshere ML, 2005, ARCH GEN PSYCHIAT, V62, P1081, DOI 10.1001/archpsyc.62.10.1081; Harrison PJ, 2005, MOL PSYCHIATR, V10, P40, DOI 10.1038/sj.mp.4001558; HENNAH W, MOL PSYCHIAT; ISHIZUKA K, IN PRESS BIOL PSYCHI; KAMIYA A, IN PRESS NAT CELL BI; Lewis DA, 2002, ANNU REV NEUROSCI, V25, P409, DOI 10.1146/annurev.neuro.25.112701.142754; Millar JK, 2005, SCIENCE, V310, P1187, DOI 10.1126/science.1112915; Millar JK, 2000, HUM MOL GENET, V9, P1415, DOI 10.1093/hmg/9.9.1415; Miyoshi K, 2003, MOL PSYCHIATR, V8, P685, DOI 10.1038/sj.mp.4001352; Morris JA, 2003, HUM MOL GENET, V12, P1591, DOI 10.1093/hmg/ddg162; Ozeki Y, 2003, P NATL ACAD SCI USA, V100, P289, DOI 10.1073/pnas.0136913100; Ramos BP, 2003, NEURON, V40, P835, DOI 10.1016/S0896-6273(03)00694-9; Sachs NA, 2005, MOL PSYCHIATR, V10, P758, DOI 10.1038/sj.mp.4001667; Sawa A, 2002, SCIENCE, V296, P692, DOI 10.1126/science.1070532; Sawamura N, 2005, P NATL ACAD SCI USA, V102, P1187, DOI 10.1073/pnas.0406543102; Thomson PA, 2005, NEUROSCI LETT, V389, P41, DOI 10.1016/j.neulet.2005.07.004; WEINBERGER DR, 1987, ARCH GEN PSYCHIAT, V44, P660, DOI 10.1001/archpsyc.1987.01800190080012; Zhu J, 2001, CNS DRUG REV, V7, P387	23	44	45	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2005	310	5751					1128	1129		10.1126/science.1121114	http://dx.doi.org/10.1126/science.1121114			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GE	16293746				2022-12-28	WOS:000233437300029
J	Padian, K; Dial, KP				Padian, K; Dial, KP			Origin of flight - Could 'four-winged' dinosaurs fly?	NATURE			English	Editorial Material							FEATHERS; BIRD		Univ Calif Berkeley, Museum Paleontol, Berkeley, CA 94720 USA; Univ Montana, Div Biol Sci, Missoula, MT 59812 USA	University of California System; University of California Berkeley; University of Montana System; University of Montana	Padian, K (corresponding author), Univ Calif Berkeley, Museum Paleontol, Berkeley, CA 94720 USA.	kpadian@berkeley.edu						Dial KP, 2003, SCIENCE, V299, P402, DOI 10.1126/science.1078237; FEDUCCIA A, 1979, SCIENCE, V203, P1021, DOI 10.1126/science.203.4384.1021; GOULD SJ, 1982, PALEOBIOLOGY, V8, P4, DOI 10.1017/S0094837300004310; Padian K, 2001, NEW PERSPECTIVES ON THE ORIGIN AND EARLY EVOLUTION OF BIRDS, P255; Padian K, 2001, AM ZOOL, V41, P598, DOI 10.1668/0003-1569(2001)041[0598:CTAHPA]2.0.CO;2; Perrins C. M., 1990, ILLUSTRATED ENCY BIR; WITMER LM, 1995, FUNCTIONAL MORPHOLOGY IN VERTEBRATE PALEONTOLOGY, P19; Xu X, 2003, NATURE, V421, P335, DOI 10.1038/nature01342; Zhang FC, 2004, NATURE, V431, P925, DOI 10.1038/431925a	9	15	15	0	56	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2005	438	7066					E3	E3		10.1038/nature04354	http://dx.doi.org/10.1038/nature04354			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292258	Bronze			2022-12-28	WOS:000233300200035
J	Appel, LJ; Sacks, FM; Carey, VJ; Obarzanek, E; Swain, JF; Miller, ER; Conlin, PR; Erlinger, TP; Rosner, BA; Laranjo, NM; Charleston, J; McCarron, P; Bishop, LM				Appel, LJ; Sacks, FM; Carey, VJ; Obarzanek, E; Swain, JF; Miller, ER; Conlin, PR; Erlinger, TP; Rosner, BA; Laranjo, NM; Charleston, J; McCarron, P; Bishop, LM		OmniHeart Collaborative Res Grp	Effects of protein, monounsaturated fat, and carbohydrate intake on blood pressure and serum lipids - Results of the OmniHeart randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY-HEART-DISEASE; DIETARY-PROTEIN; MEDITERRANEAN DIET; GLYCEMIC INDEX; WEIGHT-LOSS; OLIVE OIL; HYPERTENSION; RISK; CHOLESTEROL; SODIUM	Context Reduced intake of saturated fat is widely recommended for prevention of cardiovascular disease. The type of macronutrient that should replace saturated fat remains uncertain. Objective To compare the effects of 3 healthful diets, each with reduced saturated fat intake, on blood pressure and serum lipids. Design, Setting, and Participants Randomized, 3-period, crossover feeding study (April 2003 to June 2005) conducted in Baltimore, Md, and Boston, Mass. Participants were 164 adults with prehypertension or stage 1 hypertension. Each feeding period lasted 6 weeks and body weight was kept constant. Interventions A diet rich in carbohydrates; a diet rich in protein, about half from plant sources; and a diet rich in unsaturated fat, predominantly monounsaturated fat. Main Outcome Measures Systolic blood pressure and low-density lipoprotein cholesterol. Results Blood pressure, low-density lipoprotein cholesterol, and estimated coronary heart disease risk were lower on each diet compared with baseline. Compared with the carbohydrate diet, the protein diet further decreased mean systolic blood pressure by 1.4 mm Hg (P=.002) and by 3.5 mm Hg (P=.006) among those with hypertension and decreased low-density lipoprotein cholesterol by 3.3 mg/dL (0.09 mmol/L; P=.01), high-density lipoprotein cholesterol by 1.3 mg/dL (0.03 mmol/L; P=.02), and triglycerides by 15.7 mg/dL (0.18 mmol/L; P<.001). Compared with the carbohydrate diet, the unsaturated fat diet decreased systolic blood pressure by 1.3 mm Hg (P=.005) and by 2.9 mm Hg among those with hypertension (P=.02), had no significant effect on low-density lipoprotein cholesterol, increased high-density lipoprotein cholesterol by 1.1 mg/dL (0.03 mmol/L; P=.03), and lowered triglycerides by 9.6 mg/dL (0.11 mmol/L; P=.02). Compared with the carbohydrate diet, estimated 10-year coronary heart disease risk was lower and similar on the protein and unsaturated fat diets. Conclusion In the setting of a healthful diet, partial substitution of carbohydrate with either protein or monounsaturated fat can further lower blood pressure, improve lipid levels, and reduce estimated cardiovascular risk. Clinical Trials Registration ClinicalTrials.gov Identifier: NCT00051350.	Johns Hopkins Univ, Sch Med, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Div Gen Internal Med, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Epidemiol, Baltimore, MD 21205 USA; Bloomberg Sch Publ Hlth, Baltimore, MD USA; Brigham & Womens Hosp, Channing Lab, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA; Brigham & Womens Hosp, Gen Clin Res Ctr, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; NHLBI, Div Epidemiol & Clin Applicat, Bethesda, MD 20892 USA; VA Boston Healthcare Syst, Div Endocrinol, Boston, MA USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); US Department of Veterans Affairs; Veterans Health Administration (VHA); Harvard University; VA Boston Healthcare System	Appel, LJ (corresponding author), Johns Hopkins Univ, Sch Med, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-618, Baltimore, MD 21205 USA.	lappel@jhmi.edu	Appel, Larry/GLT-2608-2022		NCRR NIH HHS [RR02635] Funding Source: Medline; NHLBI NIH HHS [HL67098, HL68712] Funding Source: Medline; NIDDK NIH HHS [DK63214] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K23HL068712, R01HL067098] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK063214] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Assmann G, 2002, CIRCULATION, V105, P310, DOI 10.1161/hc0302.102575; Burke V, 2001, HYPERTENSION, V38, P821, DOI 10.1161/hy1001.092614; CAREY VJ, IN PRESS CLIN TRIALS; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cook NR, 2005, J HUM HYPERTENS, V19, P47, DOI 10.1038/sj.jhh.1001775; Cutler JA, 2005, ANN INTERN MED, V143, P74, DOI 10.7326/0003-4819-143-1-200507050-00011; Dietary Guidelines Advisory Committee, 2005, REP DIET GUID ADV CO; ELLIOTT P, IN PRESS ARCH INTERN; Ferrara LA, 2000, ARCH INTERN MED, V160, P837, DOI 10.1001/archinte.160.6.837; Foster GD, 2003, NEW ENGL J MED, V348, P2082, DOI 10.1056/NEJMoa022207; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Harsha DW, 2004, HYPERTENSION, V43, P393, DOI 10.1161/01.HYP.0000113046.83819.a2; He J, 2005, ANN INTERN MED, V143, P1, DOI 10.7326/0003-4819-143-1-200507050-00004; He J, 1999, CLIN EXP HYPERTENS, V21, P785, DOI 10.3109/10641969909061008; HODGES RE, 1983, ANN INTERN MED, V98, P838, DOI 10.7326/0003-4819-98-5-838; Hokanson J E, 1996, J Cardiovasc Risk, V3, P213, DOI 10.1097/00043798-199604000-00014; Hu FB, 1997, NEW ENGL J MED, V337, P1491, DOI 10.1056/NEJM199711203372102; Hu FB, 1999, AM J CLIN NUTR, V70, P221; Institute of Medicine, 2004, DIET REF INT WAT POT; Institute of Medicine Food and Nutrition Board, 2002, DIET REF INT EN CARB; Jones B., 2003, DESIGN ANAL CROSS OV, V2nd; Katan MB, 1997, NEW ENGL J MED, V337, P563; Kelemen LE, 2005, AM J EPIDEMIOL, V161, P239, DOI 10.1093/aje/kwi038; Ludwig DS, 2002, JAMA-J AM MED ASSOC, V287, P2414, DOI 10.1001/jama.287.18.2414; McManus K, 2001, INT J OBESITY, V25, P1503, DOI 10.1038/sj.ijo.0801796; Mensink RP, 2003, AM J CLIN NUTR, V77, P1146, DOI 10.1093/ajcn/77.5.1146; Obarzanek E, 1996, JAMA-J AM MED ASSOC, V275, P1598, DOI 10.1001/jama.275.20.1598; Obarzanek E, 2001, AM J CLIN NUTR, V74, P80; OBRIEN E, 1991, J HYPERTENS, V9, P573, DOI 10.1097/00004872-199106000-00016; Perneger TV, 1999, BRIT MED J, V318, P1288; Psaltopoulou T, 2004, AM J CLIN NUTR, V80, P1012, DOI 10.1093/ajcn/80.4.1012; Rubin D.B., 1987, MULTIPLE IMPUTATION, DOI DOI 10.1002/9780470316696.FMATTER; SACKS FM, 1988, AM J CLIN NUTR, V48, P795, DOI 10.1093/ajcn/48.3.795; Sacks FM, 2001, NEW ENGL J MED, V344, P3, DOI 10.1056/NEJM200101043440101; STAMLER J, 2003, LIFESTYLE MODIFICATI; Stevens VJ, 2001, ANN INTERN MED, V134, P1, DOI 10.7326/0003-4819-134-1-200101020-00007; STRAZZULLO P, 1986, J HYPERTENS, V4, P407, DOI 10.1097/00004872-198608000-00003; Wang YF, 2004, ARCH INTERN MED, V164, P2126, DOI 10.1001/archinte.164.19.2126; White WB, 2001, BLOOD PRESS MONIT, V6, P107, DOI 10.1097/00126097-200104000-00007; Willett W, 2002, AM J CLIN NUTR, V76, p274S, DOI 10.1093/ajcn/76.1.274S; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; WOLFE BM, 1992, CLIN INVEST MED, V15, P349; WOLFE BM, 1991, METABOLISM, V40, P338, DOI 10.1016/0026-0495(91)90142-J; Wolfe BMJ, 1999, CLIN INVEST MED, V22, P140; Zhang HY, 1999, AM J HYPERTENS, V12, P183, DOI 10.1016/S0895-7061(98)00238-6	47	789	811	6	100	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2455	2464		10.1001/jama.294.19.2455	http://dx.doi.org/10.1001/jama.294.19.2455			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287956	Bronze, Green Published			2022-12-28	WOS:000233277400024
J	Falanga, V				Falanga, V			Wound healing and its impairment in the diabetic foot	LANCET			English	Review							GROWTH FACTOR-BB; TISSUE-REPAIR; DERMAL FIBROBLASTS; VASCULAR-DISEASE; VENOUS ULCERS; SKIN; CELLS; EFFICACY; SAFETY; PROLIFERATION	Optimum healing of a cutaneous wound requires a well-orchestrated integration of the complex biological and molecular events of cell migration and proliferation, and of extracellular matrix deposition and remodelling. Cellular responses to inflammatory mediators, growth factors, and cytokines, and to mechanical forces, must be appropriate and precise. However, this orderly progression of the healing process is impaired in chronic wounds, including those due to diabetes. Several pathogenic abnormalities, ranging from disease-specific intrinsic flaws in blood supply, angiogenesis, and matrix turnover to extrinsic factors due to infection and continued trauma, contribute to failure to heal. Yet, despite these obstacles, there is increasing cause for optimism in the treatment of diabetic and other chronic wounds. Enhanced understanding and correction of pathogenic factors, combined with stricter adherence to standards of care and with technological breakthroughs in biological agents, is giving new hope to the problem of impaired healing.	Boston Univ, Dept Dermatol, Boston, MA 02215 USA; Boston Univ, Dept Biochem, Boston, MA 02215 USA; Roger Williams Med Ctr, Dept Dermatol & Skin Surg, Providence, RI 02908 USA	Boston University; Boston University; Roger Williams Medical Center	Falanga, V (corresponding author), Boston Univ, Dept Dermatol, Boston, MA 02215 USA.	vfalanga@bu.edu		Falanga, Vincent/0000-0003-2292-2017	NIAMS NIH HHS [AR42936, AR46557] Funding Source: Medline; NIDDK NIH HHS [DK067836] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042936, R01AR046557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK067836] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Acikgoz G, 2004, J PERIODONTOL, V75, P989, DOI 10.1902/jop.2004.75.7.989; Agren MS, 1999, J INVEST DERMATOL, V112, P463, DOI 10.1046/j.1523-1747.1999.00549.x; Apelqvist J, 2000, DIABETES-METAB RES, V16, pS84, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR113>3.0.CO;2-S; Armstrong DG, 2005, LANCET, V366, P1704, DOI 10.1016/S0140-6736(05)67695-7; Armstrong DG, 2001, DIABETES CARE, V24, P1019, DOI 10.2337/diacare.24.6.1019; Ashcroft GS, 1999, NAT CELL BIOL, V1, P260, DOI 10.1038/12971; Badiavas EV, 2003, ARCH DERMATOL, V139, P510, DOI 10.1001/archderm.139.4.510; Bakker K, 2000, Ned Tijdschr Geneeskd, V144, P409; Bamberger C, 2005, AM J PATHOL, V167, P733, DOI 10.1016/S0002-9440(10)62047-0; Bennett SP, 2003, BRIT J SURG, V90, P133, DOI 10.1002/bjs.4019; Boulton AJM, 2004, NEW ENGL J MED, V351, P48, DOI 10.1056/NEJMcp032966; Brem H, 2004, AM J SURG, V187, p1S, DOI 10.1016/S0002-9610(03)00299-X; Choma DP, 2004, J CELL SCI, V117, P3947, DOI 10.1242/jcs.01251; Conrad C, 2005, J SURG RES, V124, P201, DOI 10.1016/j.jss.2004.09.015; CTERCTEKO GC, 1981, BRIT J SURG, V68, P608, DOI 10.1002/bjs.1800680904; Danen EHJ, 2005, J CELL BIOL, V169, P515, DOI 10.1083/jcb.200412081; Decker Patrice, 2002, Current Pharmaceutical Biotechnology, V3, P275, DOI 10.2174/1389201023378265; Dinh T, 2005, CURR PHARM DESIGN, V11, P2301, DOI 10.2174/1381612054367328; Dinh Thanh L, 2005, Int J Low Extrem Wounds, V4, P154, DOI 10.1177/1534734605280130; Eming SA, 2004, EXPERT OPIN BIOL TH, V4, P1373, DOI 10.1517/14712598.4.9.1373; Falanga V, 2000, WOUNDS, V12, P51; Falanga V, 2002, DIABETIC FOOT: MEDICAL AND SURGICAL MANAGEMENT, P59; Falanga V, 2004, BLOOD CELL MOL DIS, V32, P88, DOI 10.1016/j.bcmd.2003.09.020; FALANGA V, 1993, LANCET, V341, P1006, DOI 10.1016/0140-6736(93)91085-Z; Falanga V, 2002, J INVEST DERMATOL, V119, P653, DOI 10.1046/j.1523-1747.2002.01865.x; Falanga V, 2000, WOUND REPAIR REGEN, V8, P347; Ferrier T M, 1967, Med J Aust, V1, P5; Frykberg RG, 2002, AM FAM PHYSICIAN, V66, P1655; Griffiths M, 2004, TISSUE ENG, V10, P1180, DOI 10.1089/ten.2004.10.1180; Hasan A, 1997, J DERMATOL SCI, V16, P59, DOI 10.1016/S0923-1811(97)00622-1; Hilton JR, 2004, CLIN INFECT DIS, V39, pS100, DOI 10.1086/383270; Iyer V, 2005, J CELL SCI, V118, P1185, DOI 10.1242/jcs.01708; Jeffcoate WJ, 2004, DIABETES-METAB RES, V20, pS78, DOI 10.1002/dmrr.476; Jeffcoate WJ, 2003, LANCET, V361, P1545, DOI 10.1016/S0140-6736(03)13169-8; Kim BC, 2003, J CELL PHYSIOL, V195, P331, DOI 10.1002/jcp.10301; Kranke P, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD004123.PUB2; Kudo FA, 2003, INT ANGIOL, V22, P344; LOGERFO FW, 1984, NEW ENGL J MED, V311, P1615, DOI 10.1056/NEJM198412203112506; Loots MAM, 1998, J INVEST DERMATOL, V111, P850, DOI 10.1046/j.1523-1747.1998.00381.x; Loots MAM, 2002, EUR J CELL BIOL, V81, P153, DOI 10.1078/0171-9335-00228; MACKAAY AJC, 1995, EUR J VASC ENDOVASC, V9, P170, DOI 10.1016/S1078-5884(05)80086-3; Marston WA, 2003, DIABETES CARE, V26, P1701, DOI 10.2337/diacare.26.6.1701; Martin P, 1997, SCIENCE, V276, P75, DOI 10.1126/science.276.5309.75; Martin P, 2004, DEVELOPMENT, V131, P3021, DOI 10.1242/dev.01253; Marutsuka K, 1998, CORONARY ARTERY DIS, V9, P177, DOI 10.1097/00019501-199809040-00002; Mehendale F, 2001, CUTANEOUS WOUND HEAL, P15; NAGHIBI M, 1987, DIABETES RES CLIN PR, V4, P27, DOI 10.1016/S0168-8227(87)80030-X; Nahm WK, 2004, J CELL PHYSIOL, V200, P309, DOI 10.1002/jcp.20010; Patel V, 2005, ANTIOXID REDOX SIGN, V7, P1377, DOI 10.1089/ars.2005.7.1377; PECORARO RE, 1991, DIABETES, V40, P1305, DOI 10.2337/diabetes.40.10.1305; Phillips T, 2002, ARCH DERMATOL, V138, P1079, DOI 10.1001/archderm.138.8.1079; Ramasastry SS, 2005, CLIN PLAST SURG, V32, P195, DOI 10.1016/j.cps.2004.12.001; Robson MC, 2001, CURR PROB SURG, V38, P65; Santoro MM, 2005, EXP CELL RES, V304, P274, DOI 10.1016/j.yexcr.2004.10.033; Schaper Nicolaas C, 2003, Curr Diab Rep, V3, P475, DOI 10.1007/s11892-003-0010-4; Signorelli SS, 2005, VASC MED, V10, P1, DOI 10.1191/1358863x05vm582oa; Singer AJ, 1999, NEW ENGL J MED, V341, P738, DOI 10.1056/NEJM199909023411006; Sivan-Loukianova E, 2003, J VASC RES, V40, P368, DOI 10.1159/000072701; Smiell JM, 1999, WOUND REPAIR REGEN, V7, P335, DOI 10.1046/j.1524-475X.1999.00335.x; Stanley AC, 2005, J SURG RES, V124, P112, DOI 10.1016/j.jss.2004.09.013; STEED DL, 1995, J VASC SURG, V21, P71, DOI 10.1016/S0741-5214(95)70245-8; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; Stephens P, 2003, EXP CELL RES, V283, P22, DOI 10.1016/S0014-4827(02)00021-6; Thomas DW, 2002, BRIT J SURG, V89, P1203, DOI 10.1046/j.1365-2168.2002.02181.x; Tinsley RB, 2006, J GENE MED, V8, P72, DOI 10.1002/jgm.823; Toy L W, 2005, J Wound Care, V14, P20; Vascotto SG, 2005, DEV DYNAM, V233, P347, DOI 10.1002/dvdy.20304; Veves A, 1998, DIABETES, V47, P457, DOI 10.2337/diabetes.47.3.457; Veves A, 2001, DIABETES CARE, V24, P290, DOI 10.2337/diacare.24.2.290; VOWDEN PVK, 2001, MANAGEMENT DIABETIC; Wieman TJ, 1998, DIABETES CARE, V21, P822, DOI 10.2337/diacare.21.5.822; Zykova SN, 2000, DIABETES, V49, P1451, DOI 10.2337/diabetes.49.9.1451	72	1456	1543	51	587	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1736	1743		10.1016/S0140-6736(05)67700-8	http://dx.doi.org/10.1016/S0140-6736(05)67700-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291068				2022-12-28	WOS:000233206400030
J	Kimura, KI; Ote, M; Tazawa, T; Yamamoto, D				Kimura, KI; Ote, M; Tazawa, T; Yamamoto, D			Fruitless specifies sexually dimorphic neural circuitry in the Drosophila brain	NATURE			English	Article							MALE COURTSHIP BEHAVIOR; PROGRAMMED CELL-DEATH; EXPRESSION PATTERNS; GENE; MELANOGASTER; MUSCLE; ORIENTATION; NEURONS; SYSTEM; FLIES	The Drosophila fruitless (fru) gene product Fru has been postulated to be a neural sex determination factor that directs development of the central nervous system (CNS), thereby producing male-typical courtship behaviour and inducing male-specific muscle(1-6). Male-specific Fru protein is expressed in small groups of neurons scattered throughout the CNS of male, but not female, Drosophila(4,7). Collectively, these observations suggest that Fru 'masculinizes' certain neurons, thereby establishing neural substrates for male-typical behaviour. However, specific differences between neurons resulting from the presence or absence of Fru are unknown. Previous studies have suggested that Fru might result in sexual differences in the CNS at the functional level, as no overt sexual dimorphism in CNS structure was discernible(8-10). Here we identify a subset of fru-expressing interneurons in the brain that show marked sexual dimorphism in their number and projection pattern. We also demonstrate that Fru supports the development of neurons with male-specific dendritic fields, which are programmed to die during female development as a result of the absence of Fru. Thus, Fru expression can produce a male-specific neural circuit, probably used during heterosexual courtship, by preventing cell death in identifiable neurons.	Hokkaido Univ, Biol Lab, Iwamizawa 0688642, Japan; Waseda Univ, Adv Inst Sci & Engn, Tokyo 1698555, Japan; Tohoku Univ, Grad Sch Life Sci, Sendai, Miyagi 9808578, Japan	Hokkaido University; Waseda University; Tohoku University	Kimura, KI (corresponding author), Hokkaido Univ, Biol Lab, Iwamizawa Campus, Iwamizawa 0688642, Japan.	kimura@iwa.hokkyodai.ac.jp		, Daisuke/0000-0002-4623-0106; Ote, Manabu/0000-0003-1480-0319				Awasaki T, 1997, J NEUROBIOL, V32, P707, DOI 10.1002/(SICI)1097-4695(19970620)32:7<707::AID-NEU6>3.0.CO;2-8; Demir E, 2005, CELL, V121, P785, DOI 10.1016/j.cell.2005.04.027; Goodwin SF, 2000, GENETICS, V154, P725; Greenspan RJ, 2000, ANNU REV GENET, V34, P205, DOI 10.1146/annurev.genet.34.1.205; GRETHER ME, 1995, GENE DEV, V9, P1694, DOI 10.1101/gad.9.14.1694; HALL JC, 1994, SCIENCE, V264, P1702, DOI 10.1126/science.8209251; Ito H, 1996, P NATL ACAD SCI USA, V93, P9687, DOI 10.1073/pnas.93.18.9687; LAWRENCE PA, 1986, CELL, V45, P505, DOI 10.1016/0092-8674(86)90282-5; Lee G, 2000, J NEUROBIOL, V43, P404, DOI 10.1002/1097-4695(20000615)43:4<404::AID-NEU8>3.0.CO;2-D; Lee T, 1999, NEURON, V22, P451, DOI 10.1016/S0896-6273(00)80701-1; LIENHARD MC, 1987, J EXP ZOOL, V244, P187, DOI 10.1002/jez.1402440203; Manoli DS, 2005, NATURE, V436, P395, DOI 10.1038/nature03859; MURPHEY RK, 1989, J COMP NEUROL, V290, P185, DOI 10.1002/cne.902900203; Nilsson EE, 2000, J NEUROGENET, V13, P213, DOI 10.3109/01677060009084495; Peterson C, 2002, DEVELOPMENT, V129, P1467; Ryner LC, 1996, CELL, V87, P1079, DOI 10.1016/S0092-8674(00)81802-4; STOCKER RF, 1994, CELL TISSUE RES, V275, P3, DOI 10.1007/BF00305372; Stockinger P, 2005, CELL, V121, P795, DOI 10.1016/j.cell.2005.04.026; TAYLOR BJ, 1995, DEVELOPMENT, V121, P3079; Thorne N, 2004, CURR BIOL, V14, P1065, DOI 10.1016/j.cub.2004.05.019; Usui-Aoki K, 2000, NAT CELL BIOL, V2, P500, DOI 10.1038/35019537; Wang ZR, 2004, CELL, V117, P981, DOI 10.1016/j.cell.2004.06.011; WHITE K, 1994, SCIENCE, V264, P677, DOI 10.1126/science.8171319	24	208	213	1	39	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2005	438	7065					229	233		10.1038/nature04229	http://dx.doi.org/10.1038/nature04229			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281036				2022-12-28	WOS:000233133500050
J	Chen, ZM; Pan, HC; Chen, YP; Peto, R; Collins, R; Jiang, LX; Xie, JX; Liu, LS				Chen, ZM; Pan, HC; Chen, YP; Peto, R; Collins, R; Jiang, LX; Xie, JX; Liu, LS		COMMIT Collaborative Grp	Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial	LANCET			English	Article							BETA-BLOCKADE; CARDIOGENIC-SHOCK; TEMPORAL TRENDS; THROMBOLYSIS; BLOCKERS; THERAPY; DEATH	Background Despite previous randomised trials of early beta-blocker therapy in the emergency treatment of myocardial infarction (MI), uncertainty has persisted about the value of adding it to current standard interventions (eg, aspirin and fibrinolytic therapy), and the balance of potential benefits and hazards is still unclear in high-risk patients. Methods 45 852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated metoprolol (up to 15 mg intravenous then 200 mg oral daily; n=22 929) or matching placebo (n=22 923). 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 89% completed it. The two prespecified co-primary outcomes were: (1) composite of death, reinfarction, or cardiac arrest; and (2) death from any cause during the scheduled treatment period. Comparisons were by intention to treat, and used the log-rank method. This study is registered with ClinicalTrials.gov, number NCT 00222573. Findings Neither of the co-primary outcomes was significantly reduced by allocation to metoprolol. For death, reinfarction, or cardiac arrest, 2166 (9.4%) patients allocated metoprolol had at least one such event compared with 2261 (9.9%) allocated placebo (odds ratio [OR] 0.96, 95% CI 0.90-1.01; p=0.1). For death alone, there were 1774 (7.7%) deaths in the metoprolol. group versus 1797 (7.8%) in the placebo group (OR 0.99, 0.92-1.05; p=0.69). Allocation to metoprolol was associated with five fewer people having reinfarction (464 [2.0%] metoprolol vs 568 [2.5%] placebo; OR 0.82, 0.72-0.92; p=0.001) and five fewer having ventricular fibrillation (581 [2.5%] vs 698 [3.0%]; OR 0.83, 0.75-0.93; p=0.001) per 1000 treated. Overall, these reductions were counterbalanced by 11 more per 1000 developing cardiogenic shock (1141 [5.0%] vs 885 [3.9%]; OR 1.30, 1.19-1-41; p<0.00001). This excess of cardiogenic shock was mainly during days 0-1 after admission, whereas the reductions in reinfarction and ventricular fibrillation emerged more gradually. Consequently, the overall effect on death, reinfarction, arrest, or shock was significantly adverse during days 0-1 and significantly beneficial thereafter. There was substantial net hazard in haemodynamically unstable patients, and moderate net benefit in those who were relatively stable (particularly after days 0-1). Interpretation The use of early beta-blocker therapy in acute MI reduces the risks of reinfarction and ventricular fibrillation, but increases the risk of cardiogenic shock, especially during the first day or so after admission. Consequently, it might generally be prudent to consider starting beta-blocker therapy in hospital only when the haemodynamic condition after MI has stabilised.	Clin Trial Serv Unit, Oxford OX3 7LF, England; Beijing Fuwai Hosp, Beijing, Peoples R China	University of Oxford; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS	Xie, JX (corresponding author), Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus, Oxford OX3 7LF, England.	zhengming.chen@ctsu.ox.ac.uk; ccstwo@public3.bta.net.cn						[Anonymous], 1988, LANCET, V1, P921; [Anonymous], 1986, LANCET, V2, P57; APPLEBY P, 1994, LANCET, V343, P311, DOI 10.1016/S0140-6736(94)91161-4; Basu S, 1997, CIRCULATION, V96, P183; CALIFF RM, 1994, NEW ENGL J MED, V330, P1724, DOI 10.1056/NEJM199406163302406; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; COX DR, 1972, J R STAT SOC B, V34, P187; De Backer G, 2003, EUR HEART J, V24, P1601, DOI 10.1016/S0195-668X(03)00347-6; ELTCHANINOFF H, 1995, AM HEART J, V130, P459, DOI 10.1016/0002-8703(95)90352-6; Freemantle N, 1999, BMJ-BRIT MED J, V318, P1730, DOI 10.1136/bmj.318.7200.1730; GOLDBERG RJ, 1991, NEW ENGL J MED, V325, P1117, DOI 10.1056/NEJM199110173251601; Goldberg RJ, 1999, NEW ENGL J MED, V340, P1162, DOI 10.1056/NEJM199904153401504; GURWITZ JH, 1992, AM J MED, V93, P605, DOI 10.1016/0002-9343(92)90192-E; Herlitz J, 1997, AM J CARDIOL, V80, pJ40, DOI 10.1016/S0002-9149(97)00838-2; HJALMARSON A, 1985, EUR HEART J, V6, P199; Hjalmarson A, 1999, LANCET, V353, P2001; KENDALL MJ, 1995, ANN INTERN MED, V123, P358, DOI 10.7326/0003-4819-123-5-199509010-00007; Kennedy HL, 1997, AM J CARDIOL, V80, pJ29, DOI 10.1016/S0002-9149(97)00836-9; Lechat P, 1999, LANCET, V353, P9; LIU LS, 1995, LANCET, V345, P686; Liu LS, 2000, J CARDIOVASC RISK, V7, P435; Lopez-Sendon J, 2004, EUR HEART J, V25, P1341, DOI 10.1016/j.ehj.2004.06.002; Menon V, 2000, AM J MED, V108, P374, DOI 10.1016/S0002-9343(00)00310-7; Owen A, 1998, BMJ-BRIT MED J, V317, P226, DOI 10.1136/bmj.317.7153.226; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Pfisterer M, 1998, J AM COLL CARDIOL, V32, P634, DOI 10.1016/S0735-1097(98)00279-4; Priori SG, 2001, EUR HEART J, V22, P1374, DOI 10.1053/euhj.2001.2824; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Rogers WJ, 2000, J AM COLL CARDIOL, V36, P2056, DOI 10.1016/S0735-1097(00)00996-7; Smith SC, 2001, CIRCULATION, V104, P1577, DOI 10.1161/hc3801.097475; Solomon SD, 2005, NEW ENGL J MED, V352, P2581, DOI 10.1056/NEJMoa043938; Van de Werf F, 1993, J AM COLL CARDIOL, V22, P407, DOI 10.1016/0735-1097(93)90044-2; Woods KL, 1998, EUR HEART J, V19, P74, DOI 10.1053/euhj.1997.0560; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7; ZHOU HH, 1989, NEW ENGL J MED, V320, P565, DOI 10.1056/NEJM198903023200905	35	620	676	2	24	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1622	1632						11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271643				2022-12-28	WOS:000233047100023
J	Baron-Cohen, S; Knickmeyer, RC; Belmonte, MK				Baron-Cohen, S; Knickmeyer, RC; Belmonte, MK			Sex differences in the brain: Implications for explaining autism	SCIENCE			English	Article							HIGH-FUNCTIONING AUTISM; CONGENITAL ADRENAL-HYPERPLASIA; ASPERGER-SYNDROME; CORPUS-CALLOSUM; ANDROGEN RECEPTORS; MENTAL ROTATION; TEMPORAL-LOBE; MONKEY BRAIN; CHILDREN; AMYGDALA	Empathizing is the capacity to predict and to respond to the behavior of agents (usually people) by inferring their mental states and responding to these with an appropriate emotion. Systemizing is the capacity to predict and to respond to the behavior of nonagentive deterministic systems by analyzing input-operation-output relations and inferring the rules that govern such systems. At a population level, females are stronger empathizers and mates are stronger systemizers. The "extreme male brain" theory posits that autism represents an extreme of the male pattern (impaired empathizing and enhanced systemizing). Here we suggest that specific aspects of autistic neuroanatomy may also be extremes of typical male neuroanatomy.	Univ Cambridge, Autism Res Ctr, Dept Psychiat, Cambridge CB2 2AH, England	University of Cambridge	Baron-Cohen, S (corresponding author), Univ Cambridge, Autism Res Ctr, Dept Psychiat, 18b Trumpington Rd, Cambridge CB2 2AH, England.	sb205@cam.ac.uk	Knickmeyer, Rebecca/G-8128-2014; Belmonte, Matthew/G-1170-2015	Knickmeyer, Rebecca/0000-0001-7708-1388; Belmonte, Matthew/0000-0002-4633-9400				Alexander GM, 2002, EVOL HUM BEHAV, V23, P467, DOI 10.1016/S1090-5138(02)00107-1; Allen JS, 2003, NEUROIMAGE, V18, P880, DOI 10.1016/S1053-8119(03)00034-X; ALLEN LS, 1989, J NEUROSCI, V9, P497; Aylward EH, 1999, NEUROLOGY, V53, P2145, DOI 10.1212/WNL.53.9.2145; Baron-Cohen S, 2003, PHILOS T ROY SOC B, V358, P361, DOI 10.1098/rstb.2002.1206; Baron-Cohen S, 2001, J CHILD PSYCHOL PSYC, V42, P241, DOI 10.1111/1469-7610.00715; Baron-Cohen S, 1999, J AUTISM DEV DISORD, V29, P407, DOI 10.1023/A:1023035012436; Baron-Cohen S, 2004, J AUTISM DEV DISORD, V34, P163, DOI 10.1023/B:JADD.0000022607.19833.00; Baron-Cohen S, 2003, J AUTISM DEV DISORD, V33, P509, DOI 10.1023/A:1025879411971; Baron-Cohen S, 1999, BRIT J PSYCHIAT, V175, P484, DOI 10.1192/bjp.175.5.484; Baron-Cohen S, 2002, TRENDS COGN SCI, V6, P248, DOI 10.1016/S1364-6613(02)01904-6; Baron-Cohen S., 2001, J DEV LEARNING DISOR, V5, P47, DOI DOI 10.1111/J.1467-7687.2008.00720.X; Baron -Cohen S., 1997, MINDBLINDNESS ESSAY; Baron -Cohen S., 2003, ESSENTIAL DIFFERENCE; BARONCOHEN S, IN PRESS ARCH DIS CH; Baxter LC, 2003, BRAIN LANG, V84, P264, DOI 10.1016/S0093-934X(02)00549-7; Belmonte MK, 2004, J NEUROSCI, V24, P9228, DOI 10.1523/JNEUROSCI.3340-04.2004; Belmonte MK, 2004, MOL PSYCHIATR, V9, P646, DOI 10.1038/sj.mp.4001499; Berenbaum SA, 2001, ENDOCRIN METAB CLIN, V30, P173, DOI 10.1016/S0889-8529(08)70025-2; BILLINGTON J, UNPUB; Bishop KM, 1997, NEUROSCI BIOBEHAV R, V21, P581, DOI 10.1016/S0149-7634(96)00049-8; Braeutigam S, 2004, EUR J NEUROSCI, V20, P293, DOI 10.1111/j.1460-9568.2004.03467.x; Carrel L, 1999, P NATL ACAD SCI USA, V96, P14440, DOI 10.1073/pnas.96.25.14440; Caviness VS, 1996, CEREB CORTEX, V6, P726, DOI 10.1093/cercor/6.5.726; Connellan J, 2000, INFANT BEHAV DEV, V23, P113, DOI 10.1016/S0163-6383(00)00032-1; Courchesne E, 2005, CURR OPIN NEUROBIOL, V15, P225, DOI 10.1016/j.conb.2005.03.001; Courchesne E, 2004, CURR OPIN NEUROL, V17, P489, DOI 10.1097/01.wco.0000137542.14610.b4; de Vries G.J., 2002, HORMONES BRAIN BEHAV, P137, DOI [10.1016/B978, DOI 10.1016/B978-012532104-4/50066-4]; EGAAS B, 1995, ARCH NEUROL-CHICAGO, V52, P794, DOI 10.1001/archneur.1995.00540320070014; FENSON L, 1994, MONOGR SOC RES CHILD, V59, pR5; Giedd JN, 1996, J COMP NEUROL, V366, P223, DOI 10.1002/(SICI)1096-9861(19960304)366:2<223::AID-CNE3>3.0.CO;2-7; GOLDENFELD N, IN PRESS J CLIN NEUR; Goldstein JM, 2001, CEREB CORTEX, V11, P490, DOI 10.1093/cercor/11.6.490; GRIMSHAW GM, 1995, BRAIN COGNITION, V29, P85, DOI 10.1006/brcg.1995.1269; HANDA RJ, 1988, ENDOCRINOLOGY, V122, P1890, DOI 10.1210/endo-122-5-1890; Herbert MR, 2005, BRAIN, V128, P213, DOI 10.1093/brain/awh330; Herbert MR, 2004, ANN NEUROL, V55, P530, DOI 10.1002/ana.20032; HINES M, 1992, BRAIN RES, V579, P321, DOI 10.1016/0006-8993(92)90068-K; HINES M, 1994, CHILD DEV, V65, P1042; HYDE JS, 1988, PSYCHOL BULL, V104, P53, DOI 10.1037/0033-2909.104.1.53; HYDE JS, 1975, MULTIVAR BEHAV RES, V10, P289, DOI 10.1207/s15327906mbr1003_3; Jancke L, 1997, CEREB CORTEX, V7, P48, DOI 10.1093/cercor/7.1.48; Jolliffe T, 1997, J CHILD PSYCHOL PSYC, V38, P527, DOI 10.1111/j.1469-7610.1997.tb01539.x; Just MA, 2004, BRAIN, V127, P1811, DOI 10.1093/brain/awh199; KIMURA D, 1992, SCI AM, V267, P119; Kimura Doreen, 1999, SEX COGNITION; Knickmeyer R, 2005, J CHILD PSYCHOL PSYC, V46, P198, DOI 10.1111/j.1469-7610.2004.00349.x; KNICKMEYER R, UNPUB; Lawson J, 2004, J AUTISM DEV DISORD, V34, P301, DOI 10.1023/B:JADD.0000029552.42724.1b; LEWIS JD, 2005, 4 INT M AUT RES BOST; Luders E, 2005, NEUROIMAGE, V26, P493, DOI 10.1016/j.neuroimage.2005.02.010; Lutchmaya S, 2002, INFANT BEHAV DEV, V25, P327, DOI 10.1016/S0163-6383(02)00094-2; Lutchmaya S, 2002, INFANT BEHAV DEV, V25, P319, DOI 10.1016/S0163-6383(02)00095-4; Lutchmaya S, 2004, EARLY HUM DEV, V77, P23, DOI 10.1016/j.earlhumdev.2003.12.002; Manning JT, 2001, DEV MED CHILD NEUROL, V43, P160, DOI 10.1017/S0012162201000317; McClure EB, 2000, PSYCHOL BULL, V126, P424, DOI 10.1037/0033-2909.126.3.424; Merke DP, 2003, J CLIN ENDOCR METAB, V88, P1760, DOI 10.1210/jc.2002-021730; Moffat SD, 1998, BRAIN, V121, P2369, DOI 10.1093/brain/121.12.2369; MOSCONI MW, 2005, 4 INT M AUT RES BOST; Ochsner KN, 2004, J COGNITIVE NEUROSCI, V16, P1746, DOI 10.1162/0898929042947829; Pakkenberg B, 1997, J COMP NEUROL, V384, P312, DOI 10.1002/(SICI)1096-9861(19970728)384:2<312::AID-CNE10>3.0.CO;2-K; POMERANTZ SM, 1985, ENDOCRINOLOGY, V116, P83, DOI 10.1210/endo-116-1-83; Rabinowicz T, 2002, J NEUROPATH EXP NEUR, V61, P46, DOI 10.1093/jnen/61.1.46; Rilling JK, 1999, NEUROREPORT, V10, P1453, DOI 10.1097/00001756-199905140-00012; RINGO JL, 1994, CEREB CORTEX, V4, P331, DOI 10.1093/cercor/4.4.331; Rojas DC, 2004, AM J PSYCHIAT, V161, P2038, DOI 10.1176/appi.ajp.161.11.2038; ROOF RL, 1993, BEHAV BRAIN RES, V57, P47, DOI 10.1016/0166-4328(93)90060-4; Schumann CM, 2004, J NEUROSCI, V24, P6392, DOI 10.1523/JNEUROSCI.1297-04.2004; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; SHEPARD RN, 1971, SCIENCE, V171, P701, DOI 10.1126/science.171.3972.701; SHOLL SA, 1990, BRAIN RES, V516, P122, DOI 10.1016/0006-8993(90)90905-Q; SHOLL SA, 1989, ENDOCRINOLOGY, V124, P627, DOI 10.1210/endo-124-2-627; Skuse DH, 2000, PEDIATR RES, V47, P9, DOI 10.1203/00006450-200001000-00006; Sparks BF, 2002, NEUROLOGY, V59, P184, DOI 10.1212/WNL.59.2.184; Tordjman A., 1997, AM J PSYCHIAT, V154, P11; WAKABAYASHI A, UNPUB; WATSON NV, 1991, PERS INDIV DIFFER, V12, P375, DOI 10.1016/0191-8869(91)90053-E; Welchew DE, 2005, BIOL PSYCHIAT, V57, P991, DOI 10.1016/j.biopsych.2005.01.028; Wisniewski AB, 1998, PSYCHONEUROENDOCRINO, V23, P519, DOI 10.1016/S0306-4530(98)00019-5; WITELSON SF, 1995, J NEUROSCI, V15, P3418; Witkin H. A., 1962, PERSONALITY PERCEPTI	81	703	720	7	253	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					819	823		10.1126/science.1115455	http://dx.doi.org/10.1126/science.1115455			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	981XR	16272115	Green Submitted			2022-12-28	WOS:000233121800036
J	Russell, CJ; Webster, RG				Russell, CJ; Webster, RG			The genesis of a pandemic influenza virus	CELL			English	Editorial Material							SINGLE AMINO-ACID; RECEPTOR-BINDING; A VIRUSES; HEMAGGLUTININ; VIRULENCE	Pandemic influenza viruses pose a significant threat to public health worldwide. In a recent Nature paper, Taubenberger et al. (2005) now report remarkable similarities between the polymerase genes of the influenza virus that caused the 1918 Spanish influenza pandemic and those of avian influenza viruses. Meanwhile, Tumpey et al. (2005) reporting in Science show that the reconstructed 1918 Spanish influenza virus kills mice faster than any other influenza virus so far tested.	St Jude Childrens Res Hosp, Dept Infect Dis, Memphis, TN 38105 USA	St Jude Children's Research Hospital	Webster, RG (corresponding author), St Jude Childrens Res Hosp, Dept Infect Dis, 332 N Lauderdale St, Memphis, TN 38105 USA.		Russell, Charles/K-4824-2013; Russell, Charles/AAU-6006-2020	Russell, Charles/0000-0001-5683-3990; Russell, Charles/0000-0001-5683-3990	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [N01AI095357] Funding Source: NIH RePORTER; NCI NIH HHS [CA 21765] Funding Source: Medline; NIAID NIH HHS [AI95357] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Cello J, 2002, SCIENCE, V297, P1016, DOI 10.1126/science.1072266; Gamblin SJ, 2004, SCIENCE, V303, P1838, DOI 10.1126/science.1093155; Garcia-Sastre A, 2001, VIROLOGY, V279, P375, DOI 10.1006/viro.2000.0756; Glaser L, 2005, J VIROL, V79, P11533, DOI 10.1128/JVI.79.17.11533-11536.2005; Ha Y, 2001, P NATL ACAD SCI USA, V98, P11181, DOI 10.1073/pnas.201401198; Hatta M, 2001, SCIENCE, V293, P1840, DOI 10.1126/science.1062882; Kobasa D, 2004, NATURE, V431, P703, DOI 10.1038/nature02951; Skehel JJ, 2000, ANNU REV BIOCHEM, V69, P531, DOI 10.1146/annurev.biochem.69.1.531; Stevens J, 2004, SCIENCE, V303, P1866, DOI 10.1126/science.1093373; SUBBARAO EK, 1993, J VIROL, V67, P1761, DOI 10.1128/JVI.67.4.1761-1764.1993; Taubenberger JK, 2005, NATURE, V437, P889, DOI 10.1038/nature04230; Tumpey TM, 2005, SCIENCE, V310, P77, DOI 10.1126/science.1119392	12	95	113	5	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					368	371		10.1016/j.cell.2005.10.019	http://dx.doi.org/10.1016/j.cell.2005.10.019			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269328	Bronze			2022-12-28	WOS:000233264300005
J	Fredricks, DN; Fiedler, TL; Marrazzo, JM				Fredricks, DN; Fiedler, TL; Marrazzo, JM			Molecular identification of bacteria associated with bacterial vaginosis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	42nd Annual Meeting of the Infectious-Diseases-Society-of-America	SEP 30-OCT 03, 2004	Boston, MA	Infect Dis Soc Amer			IMMUNODEFICIENCY-VIRUS TYPE-1; GRAM STAIN; DIAGNOSTIC-CRITERIA; VAGINAL FLORA; WOMEN; MICROFLORA; INFECTION; VAGINITIS; SYMPTOMS; RISK	BACKGROUND: Bacterial vaginosis affects millions of women and is associated with several serious health conditions. The cause of bacterial vaginosis remains poorly understood despite numerous studies based on cultures. Bacteria in microbial communities can be identified without cultivation by characterizing their ribosomal DNA (rDNA) sequences. METHODS: We identified bacteria in samples of vaginal fluid with a combination of broad-range polymerase-chain-reaction (PCR) amplification of 16S rDNA with clone analysis, bacterium-specific PCR assay of 16S rDNA, and fluorescence in situ hybridization (FISH) performed directly on vaginal fluid from 27 subjects with bacterial vaginosis and 46 without the condition. Twenty-one subjects were studied with the use of broad-range PCR of 16S rDNA, and 73 subjects were studied with the use of bacterium-specific PCR. RESULTS: Women without bacterial vaginosis had 1 to 6 vaginal bacterial species (phylotypes) in each sample (mean, 3.3), as detected by broad-range PCR of 16S rDNA, and lactobacillus species were the predominant bacteria noted (83 to 100 percent of clones). Women with bacterial vaginosis had greater bacterial diversity (P<0.001), with 9 to 17 phylotypes (mean, 12.6) detected per sample and newly recognized species present in 32 to 89 percent of clones per sample library (mean, 58 percent). Thirty-five unique bacterial species were detected in the women with bacterial vaginosis, including several species with no close cultivated relatives. Bacterium-specific PCR assays showed that several bacteria that had not been previously described were highly prevalent in subjects with bacterial vaginosis but rare in healthy controls. FISH confirmed that newly recognized bacteria detected by PCR corresponded to specific bacterial morphotypes visible in vaginal fluid. CONCLUSIONS: Women with bacterial vaginosis have complex vaginal infections with many newly recognized species, including three bacteria in the Clostridiales order that were highly specific for bacterial vaginosis.	Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA; Univ Washington, Dept Med, Div Allergy & Infect Dis, Seattle, WA USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Fredricks, DN (corresponding author), Fred Hutchinson Canc Res Ctr, Program Infect Dis, 1100 Fairview Ave N,D3-100,Box 19024, Seattle, WA 98109 USA.	dfredric@fhcrc.org		Fredricks, David/0000-0003-2735-6800; Marrazzo, Jeanne/0000-0002-9277-7364	NIAID NIH HHS [R01 AI061628, R01AI052228, R03AI053250] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI061628, R03AI053250, R01AI052228] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AMSEL R, 1983, AM J MED, V74, P14, DOI 10.1016/0002-9343(83)91112-9; Berger BJ, 1995, CLIN INFECT DIS, V21, P1402, DOI 10.1093/clinids/21.6.1402; Burton JP, 2004, J CLIN MICROBIOL, V42, P1829, DOI 10.1128/JCM.42.4.1829-1831.2004; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; Ferris MJ, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-5; Fredricks DN, 1996, CLIN MICROBIOL REV, V9, P18, DOI 10.1128/CMR.9.1.18; GARDNER HL, 1955, AM J OBSTET GYNECOL, V69, P962, DOI 10.1016/0002-9378(55)90095-8; HALLEN A, 1987, GENITOURIN MED, V63, P386; HILL GB, 1994, AM J OBSTET GYNECOL, V171, P1198, DOI 10.1016/0002-9378(94)90132-5; HILLIER SL, 1995, CLIN INFECT DIS, V20, pS276, DOI 10.1093/clinids/20.Supplement_2.S276; Hillier SL, 1996, AM J OBSTET GYNECOL, V175, P435, DOI 10.1016/S0002-9378(96)70158-8; HILLIER SL, 1991, GENITOURIN MED, V67, P26; HILLIER SL, 1992, AM J OBSTET GYNECOL, V166, P938, DOI 10.1016/0002-9378(92)91368-K; Hugenholtz P, 1998, J BACTERIOL, V180, P4765, DOI 10.1128/JB.180.18.4765-4774.1998; Hugenholtz P, 1998, J BACTERIOL, V180, P6793, DOI 10.1128/JB.180.24.6793-6793.1998; Klebanoff MA, 2004, OBSTET GYNECOL, V104, P267, DOI 10.1097/01.AOG.0000134783.98382.b0; Leitich H, 2003, AM J OBSTET GYNECOL, V189, P139, DOI 10.1067/mob.2003.339; Marrazzo JM, 2002, J INFECT DIS, V185, P1307, DOI 10.1086/339884; Martin HL, 1999, J INFECT DIS, V180, P1863, DOI 10.1086/315127; Moodley P, 2002, J INFECT DIS, V185, P69, DOI 10.1086/338027; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; Pace NR, 1997, SCIENCE, V276, P734, DOI 10.1126/science.276.5313.734; Peipert JF, 2001, AM J OBSTET GYNECOL, V184, P856, DOI 10.1067/mob.2001.113847; Puapermpoonsiri S, 1996, CLIN INFECT DIS, V23, P748, DOI 10.1093/clinids/23.4.748; SOBEL JD, 1989, ANN INTERN MED, V111, P551, DOI 10.7326/0003-4819-111-7-551; SPIEGEL CA, 1991, CLIN MICROBIOL REV, V4, P485, DOI 10.1128/CMR.4.4.485-502.1991; SPIEGEL CA, 1983, J INFECT DIS, V148, P817, DOI 10.1093/infdis/148.5.817; SPIEGEL CA, 1983, J CLIN MICROBIOL, V18, P170, DOI 10.1128/JCM.18.1.170-177.1983; Verhelst R, 2004, BMC MICROBIOL, V4, DOI 10.1186/1471-2180-4-16; Wang RC, 2000, INT J IND ENG-THEORY, V7, P5; Zhou X, 2004, MICROBIOL-SGM, V150, P2565, DOI 10.1099/mic.0.26905-0	31	817	895	2	82	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1899	1911		10.1056/NEJMoa043802	http://dx.doi.org/10.1056/NEJMoa043802			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	979VJ	16267321				2022-12-28	WOS:000232972800006
J	Haberle, J; Gorg, B; Rutsch, F; Schmidt, E; Toutain, A; Benoist, J; Gelot, A; Suc, A; Hohne, W; Schliess, F; Haussinger, D; Koch, HG				Haberle, J; Gorg, B; Rutsch, F; Schmidt, E; Toutain, A; Benoist, J; Gelot, A; Suc, A; Hohne, W; Schliess, F; Haussinger, D; Koch, HG			Brief report - Congenital glutamine deficiency with glutamine synthetase mutations	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							METABOLISM; LOCALIZATION; BRAIN; GENE; EXPRESSION; MECHANISM; AMMONIA; PROTEIN; GLUL	Glutamine synthetase plays a major role in ammonia detoxification, interorgan nitrogen flux, acid - base homeostasis, and cell signaling. We report on two unrelated newborns who had congenital human glutamine synthetase deficiency with severe brain malformations resulting in multiorgan failure and neonatal death. Glutamine was largely absent from their serum, urine, and cerebrospinal fluid. Each infant had a homozygous mutation in the glutamine synthetase gene (R324C and R341C). Studies that used immortalized lymphocytes expressing R324C glutamine synthetase (R324C-GS) and COS7 cells expressing R341C-GS suggest that these mutations are associated with reduced glutamine synthetase activity.	Univ Klinikum Munster, Klin & Poliklin Kinderheilkunde & Jugendmed, Munster, Germany; Univ Dusseldorf, Clin Gastroenterol Hepatol & Infectiol, D-4000 Dusseldorf, Germany; CHU Bretonneau, Serv Genet, F-37044 Tours, France; Ctr Hosp Univ Clocheville, Dept Pediat, Tours, France; Hop Robert Debre, Serv Biochim Hormonol, F-75019 Paris, France; Hop Armand Trousseau, Unite Neuropathol, Paris, France; Charite Univ Med Berlin, Inst Biochem, Berlin, Germany	University of Munster; Heinrich Heine University Dusseldorf; CHU Tours; CHU Tours; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Armand-Trousseau - APHP; UDICE-French Research Universities; Sorbonne Universite; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin	Haberle, J (corresponding author), Univ Klinikum Munster, Klin & Poliklin Kinderheilkunde & Jugendmed, Munster, Germany.			Gelot, Antoinette/0000-0002-3032-014X; Toutain, Annick/0000-0002-5999-5300; Gorg, Boris/0000-0002-4630-9420; Haberle, Johannes/0000-0003-0635-091X				Boksha IS, 2000, J NEUROCHEM, V75, P2574, DOI 10.1046/j.1471-4159.2000.0752574.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Clancy KP, 1996, GENOMICS, V38, P418, DOI 10.1006/geno.1996.0645; Eid T, 2004, LANCET, V363, P28, DOI 10.1016/S0140-6736(03)15166-5; Eisenberg D, 2000, BBA-PROTEIN STRUCT M, V1477, P122, DOI 10.1016/S0167-4838(99)00270-8; Fumarola C, 2001, CELL DEATH DIFFER, V8, P1004, DOI 10.1038/sj.cdd.4400902; Haussinger D, 1998, ADV ENZYMOL RAMB, V72, P43; Helou K, 1997, MAMM GENOME, V8, P362, DOI 10.1007/s003359900442; Labow BI, 2001, J NUTR, V131, p2467S, DOI 10.1093/jn/131.9.2467S; MARTINEZHERNANDEZ A, 1977, SCIENCE, V195, P1356, DOI 10.1126/science.14400; Purich DL, 1998, ADV ENZYMOL RAMB, V72, P9; Rhoads JM, 2000, GASTROENTEROLOGY, V118, P90, DOI 10.1016/S0016-5085(00)70417-3; Robinson SR, 2000, NEUROCHEM INT, V36, P471, DOI 10.1016/S0197-0186(99)00150-3; Schliess F, 2002, FASEB J, V16, P739, DOI 10.1096/fj.01-0862fje; Self JT, 2004, BIOL REPROD, V70, P1444, DOI 10.1095/biolreprod.103.025486; Shin D, 2003, BIOCHEM J, V374, P175, DOI 10.1042/BJ20030132; Suarez I, 2002, NEUROCHEM INT, V41, P123, DOI 10.1016/S0197-0186(02)00033-5; SUMBILLA CM, 1981, BIOCHIM BIOPHYS ACTA, V675, P301, DOI 10.1016/0304-4165(81)90242-7; Tuchman M, 1997, ANN INTERN MED, V127, P446, DOI 10.7326/0003-4819-127-6-199709150-00005; Wang YM, 1996, GENOMICS, V37, P195, DOI 10.1006/geno.1996.0542; WARD HK, 1979, J NEUROCHEM, V33, P339, DOI 10.1111/j.1471-4159.1979.tb11737.x	21	136	140	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1926	1933		10.1056/NEJMoa050456	http://dx.doi.org/10.1056/NEJMoa050456			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267323				2022-12-28	WOS:000232972800008
J	Hogan, SL; Falk, RJ; Chin, H; Cai, JW; Jennette, CE; Jennette, JC; Nachman, PH				Hogan, SL; Falk, RJ; Chin, H; Cai, JW; Jennette, CE; Jennette, JC; Nachman, PH			Predictors of relapse and treatment resistance in antineutrophil cytoplasmic anti body-associated small-vessel vasculitis	ANNALS OF INTERNAL MEDICINE			English	Article							AUTOANTIBODY-ASSOCIATED GLOMERULONEPHRITIS; WEGENERS-GRANULOMATOSIS; MICROSCOPIC POLYANGIITIS; PULSE CYCLOPHOSPHAMIDE; RANDOMIZED-TRIAL; DISEASE-ACTIVITY; POLYARTERITIS-NODOSA; MAINTENANCE THERAPY; COMPETING RISKS; POOR-PROGNOSIS	Background: Predictors of treatment resistance and relapse have not been well described in antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis. Objective: To identify clinical, pathologic, and serologic predictors of treatment resistance and relapse in a community-based cohort of patients with ANCA-associated vasculitis. Design: Cohort of patients identified at or near the time of biopsy diagnosis and followed as clinically indicated. Setting: The Glomerular Disease Collaborative Network. Patients: 350 patients who received a new diagnosis of ANCA-associated vasculitis between 1985 and 2003 and were followed for a median of 49 months. Measurements: Patients were categorized according to whether they had antiproteinase-3 (anti-PR3) antibodies or antimyeloperoxidase (anti-MPO) antibodies. Organ involvement was determined by biopsy or by well-defined clinical criteria. Treatment resistance was defined as progressive decline in kidney function with active urine sediment or the persistence or appearance of extrarenal manifestations. Relapse was defined as the time to the resurgence of vasculitic symptoms. Results: Treatment resistance affected 23% of 334 treated patients and was associated with female sex, black ethnicity, and presentation with severe kidney disease (odds ratio per serum creatinine elevation of 100 mu mol/L [1.13 mg/dL], 1.28 [95% Ci, 1.16 to 1.39]). The following factors were associated with relapse in 258 (77%) patients who attained remission: seropositivity for anti-PR3 antibodies (hazard ratio, 1.87 [Cl, 1.11 to 3.14]) and disease of the lung (hazard ratio, 1.71 [Cl, 1.04 to 2.81]) or upper respiratory tract (hazard ratio, 1.73 [Cl, 1.04 to 2.88]). Relapses occurred in 26% of patients with no risk factors versus 73% of patients with all 3 risk factors (hazard ratio, 3.7 [Cl, 1.4 to 9.7]). Among 143 patients attaining remission who subsequently stopped all immunosuppressant therapy, relapse rates were similar for those who had received cyclophosphamide therapy for 6 months or less (34%) compared with those treated for a longer duration (35%), even after adjusting for risk factors for relapse (hazard ratio, 1.41 [Cl, 0.80 to 2.50]). Limitations: The cohort mostly included patients with biopsyproven kidney disease. Patients were not followed with uniform treatment protocols, and only limited information about their clinical course before diagnosis was available. Conclusions: Female or black patients, or those with severe kidney disease, may be resistant to initial treatment more often than other patients with ANCA-associated small-vessel vasculitis. increased risk for relapse appears to be related to the presence of lung or upper airway disease and anti-PR3 antibody seropositivity.	Univ N Carolina, Dept Med, Div Nephrol & Hypertens, Kidney Ctr, Chapel Hill, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill	Hogan, SL (corresponding author), Univ N Carolina, Dept Med, Div Nephrol & Hypertens, Kidney Ctr, CB 7156,7024B Burnett Womack, Chapel Hill, NC 27599 USA.	slh@med.unc.edu		Jennette, John Charles/0000-0002-8081-6565; Poulton, Caroline/0000-0002-8462-2661	NIDDK NIH HHS [P01-DK58335] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK058335] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALLISON PD, 1995, COMPETING RISKS SURV, P29; Bacon PA, 2005, NEW ENGL J MED, V352, P330, DOI 10.1056/NEJMp048338; Bajema IM, 1999, KIDNEY INT, V56, P1751, DOI 10.1046/j.1523-1755.1999.00758.x; Boomsma MM, 2000, ARTHRITIS RHEUM-US, V43, P2025, DOI 10.1002/1529-0131(200009)43:9<2025::AID-ANR13>3.0.CO;2-O; Booth AD, 2003, AM J KIDNEY DIS, V41, P776, DOI 10.1016/S0272-6386(03)00025-8; BRIEDIGKEIT L, 1993, POSTGRAD MED J, V69, P856, DOI 10.1136/pgmj.69.817.856; Cotch MF, 1996, ARTHRITIS RHEUM, V39, P87, DOI 10.1002/art.1780390112; DAVENPORT A, 1995, AM J NEPHROL, V15, P201, DOI 10.1159/000168833; de Groot K, 2001, NEPHROL DIAL TRANSPL, V16, P2018, DOI 10.1093/ndt/16.10.2018; DEOLIVIERA J, 1995, AM J KIDNEY DIS, V25, P380, DOI 10.1016/0272-6386(95)90098-5; FALK RJ, 1990, ANN INTERN MED, V113, P656, DOI 10.7326/0003-4819-113-9-656; FAUCI AS, 1978, ANN INTERN MED, V89, P660, DOI 10.7326/0003-4819-89-5-660; Franssen CFM, 2000, KIDNEY INT, V57, P2195, DOI 10.1046/j.1523-1755.2000.00080.x; Gaskin G, 2002, J AM SOC NEPHROL, V13, p2A; Girard T, 2001, RHEUMATOLOGY, V40, P147, DOI 10.1093/rheumatology/40.2.147; Gooley TA, 1999, STAT MED, V18, P695, DOI 10.1002/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O; GUILLEVIN L, 1995, ARTHRITIS RHEUM, V38, P1638, DOI 10.1002/art.1780381116; Guillevin L, 2003, ARTHRIT RHEUM-ARTHR, V49, P93, DOI 10.1002/art.10922; Guillevin L, 1997, ARTHRITIS RHEUM, V40, P2187, DOI 10.1002/art.1780401213; HAGEN EC, 1993, BLOOD, V81, P1996; Han WK, 2003, KIDNEY INT, V63, P1079, DOI 10.1046/j.1523-1755.2003.00821.x; HESS KR, 1995, STAT MED, V14, P1707, DOI 10.1002/sim.4780141510; Hogan SL, 1996, J AM SOC NEPHROL, V7, P23; Jayne D, 2003, NEW ENGL J MED, V349, P36, DOI 10.1056/NEJMoa020286; JAYNE DRW, 1995, QJM-MON J ASSOC PHYS, V88, P127; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; JENNETTE JC, 1989, AM J PATHOL, V135, P921; Kalbfleisch J., 2002, STAT ANAL FAILURE TI, P1, DOI DOI 10.1002/9781118032985; KERR GS, 1993, ADV EXP MED BIOL, V336, P411; Klemmer PJ, 2003, AM J KIDNEY DIS, V42, P1149, DOI 10.1053/j.ajkd.2003.08.015; Koldingsnes W, 2003, J RHEUMATOL, V30, P80; Kyndt X, 1999, AM J MED, V106, P527, DOI 10.1016/S0002-9343(99)00064-9; Langford CA, 2000, ARTHRITIS RHEUM, V43, P1836, DOI 10.1002/1529-0131(200008)43:8<1836::AID-ANR20>3.0.CO;2-R; Langford CA, 2004, CLIN EXP RHEUMATOL, V22, pS3; Langford CA, 2003, AM J MED, V114, P463, DOI 10.1016/S0002-9343(03)00077-9; Levey Andrew S., 2000, Journal of the American Society of Nephrology, V11, p155A; Levey AS, 1999, ANN INTERN MED, V130, P461, DOI 10.7326/0003-4819-130-6-199903160-00002; Lim LCL, 1999, AM J CLIN PATHOL, V111, P363; Metzler C, 2004, RHEUMATOLOGY, V43, P315, DOI 10.1093/rheumatology/keh009; Nachman PH, 1996, J AM SOC NEPHROL, V7, P33; Nowack R, 1999, J AM SOC NEPHROL, V10, P1965; PEPE MS, 1993, STAT MED, V12, P737, DOI 10.1002/sim.4780120803; Popa ER, 2003, CLIN EXP IMMUNOL, V132, P496, DOI 10.1046/j.1365-2249.2003.02157.x; Reinhold-Keller E, 2002, ARTHRIT RHEUM-ARTHR, V47, P326, DOI 10.1002/art.10459; SAVAGE COS, 1985, Q J MED, V56, P467; Segelmark W, 2003, CLIN DIAGN LAB IMMUN, V10, P769, DOI 10.1128/CDLI.10.5.769-774.2003; STEGEMAN CA, 1994, ANN INTERN MED, V120, P12, DOI 10.7326/0003-4819-120-1-199401010-00003; Stone JH, 2005, NEW ENGL J MED, V352, P351; Tervaert JWC, 1996, SARCOIDOSIS VASC DIF, V13, P241; TERVAERT JWC, 1990, LANCET, V336, P709; Therneau TM, 2000, MODELING SURVIVAL DA; VANDERWOUDE FJ, 1985, LANCET, V1, P425; Watts RA, 2001, ANN RHEUM DIS, V60, P1156; Watts RA, 2003, CURR OPIN RHEUMATOL, V15, P11, DOI 10.1097/00002281-200301000-00003	54	323	338	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					621	631		10.7326/0003-4819-143-9-200511010-00005	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00005			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263884				2022-12-28	WOS:000233030600001
J	McCabe, C; Claxton, K; Tsuchiya, A				McCabe, C; Claxton, K; Tsuchiya, A			Orphan drugs and the NHS: should we value rarity?	BRITISH MEDICAL JOURNAL			English	Editorial Material							HEALTH-CARE; RESCUE; RULE		Univ Sheffield, Sch Hlth & Related Res, White Rose Initiat Hlth Technol Assessment Hlth E, Sheffield S1 4DA, S Yorkshire, England; Univ York, White Rose Initiat Hlth Technol Assessment, Ctr Hlth Econ, York YO1 5DD, N Yorkshire, England	University of Sheffield; University of York - UK	McCabe, C (corresponding author), Univ Sheffield, Sch Hlth & Related Res, White Rose Initiat Hlth Technol Assessment Hlth E, Sheffield S1 4DA, S Yorkshire, England.	c.mccabe@sheffield.ac.uk	Tsuchiya, Aki/A-2167-2010	Tsuchiya, Aki/0000-0003-4245-5399; McCabe, Christopher/0000-0001-5728-4129				BOSENQUET N, 2003, PHARM DEV REG, V1, P151; Claxton K, 2002, LANCET, V360, P711, DOI 10.1016/S0140-6736(02)09832-X; *DEP HLTH, NAT DES FUND TREATM; DEVARAX A, 2004, STUD ORPH DRUGS PHAS; *FOOD DRUG ADM, OPH DRUG ACT AM; HADORN DC, 1991, JAMA-J AM MED ASSOC, V265, P2218, DOI 10.1001/jama.265.17.2218; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Jenni KE, 1997, J RISK UNCERTAINTY, V14, P235, DOI 10.1023/A:1007740225484; McKie J, 2003, SOC SCI MED, V56, P2407, DOI 10.1016/S0277-9536(02)00244-7; *NAT I CLIN EXC, 2003, GUID METH HLTH TECHN; *NAT I CLIN EXC, 2004, FIN APPR DET IM TREA; Nord E., 1999, COST VALUE ANAL HLTH; Olsen JA, 1997, J HEALTH ECON, V16, P625, DOI 10.1016/S0167-6296(97)00010-6; RAWLINS M, 2004, MANAGING RARE DIS; *US FDA, GRANTS AW OOPD GRANT	15	143	149	0	11	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 29	2005	331	7523					1016	1019		10.1136/bmj.331.7523.1016	http://dx.doi.org/10.1136/bmj.331.7523.1016			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981AU	16254305	Green Published, Green Accepted			2022-12-28	WOS:000233060200023
J	Lie, DC; Colamarino, SA; Song, HJ; Desire, L; Mira, H; Consiglio, A; Lein, ES; Jessberger, S; Lansford, H; Dearie, AR; Gage, FH				Lie, DC; Colamarino, SA; Song, HJ; Desire, L; Mira, H; Consiglio, A; Lein, ES; Jessberger, S; Lansford, H; Dearie, AR; Gage, FH			Wnt signalling regulates adult hippocampal neurogenesis	NATURE			English	Article							GENE-TRANSFER; IN-VITRO; PROLIFERATION; EXPRESSION; DIFFERENTIATION; TRANSCRIPTION; CELLS; LINKS	The generation of new neurons from neural stem cells is restricted to two regions of the adult mammalian central nervous system: the subventricular zone of the lateral ventricle, and the subgranular zone of the hippocampal dentate gyrus(1). In both regions, signals provided by the microenvironment regulate the maintenance, proliferation and neuronal fate commitment of the local stem cell population(1). The identity of these signals is largely unknown. Here we show that adult hippocampal stem/progenitor cells (AHPs) express receptors and signalling components for Wnt proteins, which are key regulators of neural stem cell behaviour in embryonic development(2). We also show that the Wnt/beta-catenin pathway is active and that Wnt3 is expressed in the hippocampal neurogenic niche. Overexpression of Wnt3 is sufficient to increase neurogenesis from AHPs in vitro and in vivo. By contrast, blockade of Wnt signalling reduces neurogenesis from AHPs in vitro and abolishes neurogenesis almost completely in vivo. Our data show that Wnt signalling is a principal regulator of adult hippocampal neurogenesis and provide evidence that Wnt proteins have a role in adult hippocampal function.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; GSF Natl Res Ctr Environm & Hlth, Inst Dev Genet, D-85764 Neuherberg, Germany; Johns Hopkins Univ, Sch Med, Dept Neurol, Inst Cell Engn, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Neurosci, Inst Cell Engn, Baltimore, MD 21205 USA	Salk Institute; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; Johns Hopkins University; Johns Hopkins University	Gage, FH (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	chichung.lie@gsf.de; gage@salk.edu	consiglio, antonella/G-1815-2016; Lie, Dieter Chichung/AAS-8604-2020; Jessberger, Sebastian/AAJ-4032-2020; Lie, Dieter Chichung/S-7914-2017; consiglio, antonella/AAA-5864-2019	consiglio, antonella/0000-0002-3988-6254; Lie, Dieter Chichung/0000-0002-6035-6442; Lie, Dieter Chichung/0000-0002-6035-6442; consiglio, antonella/0000-0002-3988-6254; Jessberger, Sebastian/0000-0002-0056-8275; Mira, Helena/0000-0001-8574-9544	Telethon [GFP01004] Funding Source: Medline	Telethon(Fondazione Telethon)		Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Cao L, 2004, NAT GENET, V36, P827, DOI 10.1038/ng1395; Consiglio A, 2004, P NATL ACAD SCI USA, V101, P14835, DOI 10.1073/pnas.0404180101; Couillard-Despres S, 2005, EUR J NEUROSCI, V21, P1, DOI 10.1111/j.1460-9568.2004.03813.x; DasGupta R, 1999, DEVELOPMENT, V126, P4557; Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164; Garcia-Castro MI, 2002, SCIENCE, V297, P848, DOI 10.1126/science.1070824; Hoppler S, 1996, GENE DEV, V10, P2805, DOI 10.1101/gad.10.21.2805; Israsena N, 2004, DEV BIOL, V268, P220, DOI 10.1016/j.ydbio.2003.12.024; Jamora C, 2003, NATURE, V422, P317, DOI 10.1038/nature01458; Kitamura T, 2003, EXP HEMATOL, V31, P1007, DOI 10.1016/j.exphem.2003.07.005; Kleber M, 2004, CURR OPIN CELL BIOL, V16, P681, DOI 10.1016/j.ceb.2004.08.006; Kleber M, 2005, J CELL BIOL, V169, P309, DOI 10.1083/jcb.200411095; Lai K, 2003, NAT NEUROSCI, V6, P21, DOI 10.1038/nn983; Lee J, 2002, J NEUROCHEM, V82, P1367, DOI 10.1046/j.1471-4159.2002.01085.x; Lein ES, 2004, J NEUROSCI, V24, P3879, DOI 10.1523/JNEUROSCI.4710-03.2004; Maretto S, 2003, P NATL ACAD SCI USA, V100, P3299, DOI 10.1073/pnas.0434590100; McBeath R, 2004, DEV CELL, V6, P483, DOI 10.1016/S1534-5807(04)00075-9; MOON RT, 2004, SCI STKE, pTR5; Palmer TD, 1997, MOL CELL NEUROSCI, V8, P389, DOI 10.1006/mcne.1996.0595; Rattner A, 1997, P NATL ACAD SCI USA, V94, P2859, DOI 10.1073/pnas.94.7.2859; Sakurada K, 1999, DEVELOPMENT, V126, P4017; Schwartz KA, 1999, MOL CARCINOGEN, V25, P132, DOI 10.1002/(SICI)1098-2744(199906)25:2<132::AID-MC8>3.0.CO;2-2; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; van Praag H, 1999, NAT NEUROSCI, V2, P266, DOI 10.1038/6368; Veeman MT, 2003, CURR BIOL, V13, P680, DOI 10.1016/S0960-9822(03)00240-9; Veeman MT, 2003, DEV CELL, V5, P367, DOI 10.1016/S1534-5807(03)00266-1	27	1130	1230	6	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1370	1375		10.1038/nature04108	http://dx.doi.org/10.1038/nature04108			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251967				2022-12-28	WOS:000232829100057
J	Nielsen, TA; Stenstrom, P				Nielsen, TA; Stenstrom, P			hat are the memory sources of dreaming?	NATURE			English	Article							EYE-MOVEMENT SLEEP; REM-SLEEP; EPISODIC MEMORY; CONSOLIDATION; EVENTS; HIPPOCAMPUS; HUMANS; BRAIN; FMRI	Investigators since Freud have appreciated that memories of the people, places, activities and emotions of daily life are reflected in dreams but are typically so fragmented that their predictability is nil. The mechanisms that translate such memories into dream images remain largely unknown. New research targeting relationships between dreaming, memory and the hippocampus is producing a new theory to explain how, why and when we dream of waking life events.	Hop Sacre Coeur, Dream & Nightmare Lab, Montreal, PQ H4J 1C5, Canada; Hop Sacre Coeur, Dept Psychiat, Montreal, PQ H4J 1C5, Canada; Hop Sacre Coeur, Dept Psychol, Montreal, PQ H4J 1C5, Canada	Universite de Montreal; Universite de Montreal; Universite de Montreal	Nielsen, TA (corresponding author), Hop Sacre Coeur, Dream & Nightmare Lab, 5400 Blvd Gouin Ouest, Montreal, PQ H4J 1C5, Canada.	tore.nielsen@umontreal.ca	Nielsen, Tore/D-2418-2016	Nielsen, Tore/0000-0002-9372-8652				ARKIN AM, 1991, MIND SLEEP PSYCHOL P, P265; Bjorness TE, 2005, LEARN MEMORY, V12, P352, DOI 10.1101/lm.84805; Bodizs R, 2001, HIPPOCAMPUS, V11, P747, DOI 10.1002/hipo.1090; Braun AR, 1998, SCIENCE, V279, P91, DOI 10.1126/science.279.5347.91; Cabeza R, 2004, J COGNITIVE NEUROSCI, V16, P1583, DOI 10.1162/0898929042568578; Cacucci F, 2004, J NEUROSCI, V24, P8265, DOI 10.1523/JNEUROSCI.2635-04.2004; CAVALLERO C, 1990, SLEEP, V13, P449; Cipolli C, 2005, BRAIN RES BULL, V65, P97, DOI 10.1016/j.brainresbull.2004.10.014; Fiss H., 1977, SLEEP RES, V6, P122; Fosse MJ, 2003, J COGNITIVE NEUROSCI, V15, P1, DOI 10.1162/089892903321107774; Freud S., 1965, INTERPRETATION DREAM; Grenier J, 2005, MEM COGNITION, V33, P280, DOI 10.3758/BF03195317; Hall C., 1966, CONTENT ANAL DREAMS, DOI DOI 10.1192/BJP.112.490.963; Hartmann E., 1998, DREAMS NIGHTMARES NE; Heckers S, 2004, HIPPOCAMPUS, V14, P153, DOI 10.1002/hipo.10189; Hobson JA, 1998, CURR OPIN NEUROBIOL, V8, P239, DOI 10.1016/S0959-4388(98)80146-3; Johnson JD, 2005, MED HYPOTHESES, V64, P499, DOI 10.1016/j.mehy.2004.09.004; Kajiwara R, 2003, J NEUROPHYSIOL, V89, P2176, DOI 10.1152/jn.01033.2002; Kesner RP, 2004, REV NEUROSCIENCE, V15, P333; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; Luo J, 2005, HIPPOCAMPUS, V15, P141, DOI 10.1002/hipo.20054; Milner B, 1998, NEURON, V20, P445, DOI 10.1016/S0896-6273(00)80987-3; Misane I, 2005, HIPPOCAMPUS, V15, P418, DOI 10.1002/hipo.20067; Nielsen T. A., 1991, IMAGINATION COGNITIO, V11, P353, DOI [10.2190/3LVV-L5GY-UR5V-N0TG, DOI 10.2190/3LVV-L5GY-UR5V-N0TG]; Nielsen TA, 2004, J SLEEP RES, V13, P327, DOI 10.1111/j.1365-2869.2004.00421.x; Nielsen TA, 2004, SLEEP MED REV, V8, P403, DOI 10.1016/j.smrv.2004.06.005; Paller KA, 2004, LEARN MEMORY, V11, P664, DOI 10.1101/lm.75704; Payne JD, 2004, LEARN MEMORY, V11, P671, DOI 10.1101/lm.77104; Pesant N, 2004, CLIN PSYCHOL REV, V24, P489, DOI 10.1016/j.cpr.2004.05.002; Poe GR, 2000, BRAIN RES, V855, P176, DOI 10.1016/S0006-8993(99)02310-0; Popp CA, 1996, J CONSULT CLIN PSYCH, V64, P1073, DOI 10.1037/0022-006X.64.5.1073; POWELL RA, 1995, PERCEPT MOTOR SKILL, V81, P95, DOI 10.2466/pms.1995.81.1.95; Rauchs G, 2005, J SLEEP RES, V14, P123, DOI 10.1111/j.1365-2869.2005.00450.x; Ribeiro S, 2002, J NEUROSCI, V22, P10914, DOI 10.1523/jneurosci.22-24-10914.2002; Smith C, 2004, SLEEP, V27, P60; Smith C., 2003, SLEEP BRAIN PLASTICI, P117; SQUIRE LR, 1995, CURR OPIN NEUROBIOL, V5, P169, DOI 10.1016/0959-4388(95)80023-9; Stickgold R, 2001, SCIENCE, V294, P1052, DOI 10.1126/science.1063530; Thompson LT, 1996, J NEUROPHYSIOL, V76, P1836, DOI 10.1152/jn.1996.76.3.1836; TORDA C, 1969, ACTA PSYCHIAT SCAND, V45, P277, DOI 10.1111/j.1600-0447.1969.tb07128.x; Tulving E, 2002, ANNU REV PSYCHOL, V53, P1, DOI 10.1146/annurev.psych.53.100901.135114	41	103	103	3	32	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1286	1289		10.1038/nature04288	http://dx.doi.org/10.1038/nature04288			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	977UQ	16251954				2022-12-28	WOS:000232829100042
J	Weber, CP; Gedik, N; Moore, JE; Orenstein, J; Stephens, J; Awschalom, DD				Weber, CP; Gedik, N; Moore, JE; Orenstein, J; Stephens, J; Awschalom, DD			Observation of spin Coulomb drag in a two-dimensional electron gas	NATURE			English	Article							STIMULATED RAMAN-SCATTERING; HETERODYNE-DETECTION	An electron propagating through a solid carries spin angular momentum in addition to its mass and charge. Of late there has been considerable interest in developing electronic devices based on the transport of spin that offer potential advantages in dissipation, size and speed over charge-based devices(1). However, these advantages bring with them additional complexity. Because each electron carries a single, fixed value (-e) of charge, the electrical current carried by a gas of electrons is simply proportional to its total momentum. A fundamental consequence is that the charge current is not affected by interactions that conserve total momentum, notably collisions among the electrons themselves(2). In contrast, the electron's spin along a given spatial direction can take on two values, +/-(h) over bar /2 (conventionally up arrow, down arrow), so that the spin current and momentum need not be proportional. Although the transport of spin polarization is not protected by momentum conservation, it has been widely assumed that, like the charge current, spin current is unaffected by electron - electron ( e - e) interactions. Here we demonstrate experimentally not only that this assumption is invalid, but also that over a broad range of temperature and electron density, the flow of spin polarization in a two-dimensional gas of electrons is controlled by the rate of e - e collisions.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; CALTECH, Arthur Amos Noyes Lab Chem Phys, Lab Mol Sci, Pasadena, CA 91125 USA; Univ Calif Santa Barbara, Ctr Spintron & Quantum Computat, Santa Barbara, CA 93106 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; California Institute of Technology; University of California System; University of California Santa Barbara	Weber, CP (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	cpweber@lbl.gov	Moore, Joel/O-4959-2016; Orenstein, Joseph W/I-3451-2015	Moore, Joel/0000-0002-4294-5761; Weber, Christopher/0000-0002-0372-0324; Orenstein, Joseph/0000-0003-3741-6707				[Anonymous], 1998, QUANTUM TRANSPORT TH; Awschalom DD, 2002, NANOSCI TECHNOL, P147; BARAD S, 1992, PHYS REV LETT, V68, P349, DOI 10.1103/PhysRevLett.68.349; Cameron AR, 1996, PHYS REV LETT, V76, P4793, DOI 10.1103/PhysRevLett.76.4793; CASTELLANI C, 1987, PHYS REV LETT, V59, P477, DOI 10.1103/PhysRevLett.59.477; CHANG YJ, 1995, J PHYS CHEM-US, V99, P7857, DOI 10.1021/j100020a004; D'Amico I, 2003, PHYS REV B, V68, DOI 10.1103/PhysRevB.68.045307; D'Amico I, 2001, EUROPHYS LETT, V55, P566, DOI 10.1209/epl/i2001-00453-y; Flensberg K, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.245308; Gedik N, 2004, OPT LETT, V29, P2109, DOI 10.1364/OL.29.002109; Kato YK, 2004, SCIENCE, V306, P1910, DOI 10.1126/science.1105514; Kikkawa JM, 1999, NATURE, V397, P139, DOI 10.1038/16420; KWON YK, 1994, PHYS REV B, V50, P1684, DOI 10.1103/PhysRevB.50.1684; Meier F., 1984, OPTICAL ORIENTATION; VOHRINGER P, 1995, J PHYS CHEM-US, V99, P2684; Wunderlich J, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.047204; YARLAGADDA S, 1989, PHYS REV B, V40, P5432, DOI 10.1103/PhysRevB.40.5432; Ziman J. M., 2001, ELECT PHONONS THEORY	18	184	185	1	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1330	1333		10.1038/nature04206	http://dx.doi.org/10.1038/nature04206			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251958	Green Submitted			2022-12-28	WOS:000232829100047
J	Smith, GD; Ebrahim, S; Lewis, S; Hansell, AL; Palmer, LJ; Burton, PR				Smith, GD; Ebrahim, S; Lewis, S; Hansell, AL; Palmer, LJ; Burton, PR			Genetic Epidemiology 7 - Genetic epidemiology and public health: hope, hype, and future prospects	LANCET			English	Review							CORONARY-HEART-DISEASE; C-REACTIVE PROTEIN; MENDELIAN RANDOMIZATION; CYSTIC-FIBROSIS; FAMILY-HISTORY; ENVIRONMENT INTERACTION; MYOCARDIAL-INFARCTION; REPLACEMENT THERAPY; LACTASE DEFICIENCY; GENOMIC MEDICINE	Genetic epidemiology is a rapidly expanding research field, but the implications of findings from such studies for individual or population health are unclear. The use of molecular genetic screening currently has some legitimacy in certain monogenic conditions, but no established value with respect to common complex diseases. Personalised medical care based on molecular genetic testing is also as yet undeveloped for common diseases. Genetic epidemiology can contribute to establishing the causal nature of environmentally modifiable risk factors, throught the application of mendelian randomisation approaches and thus contribute to appropriate preventive strategies. Technological and other advances will allow the potential of genetic epidemiology to be revealed over the next few years, and the establishment of large population-based resources for such studies (biobanks) should contribute to this endeavour.	Univ Bristol, Dept Med Sociol, Bristol BS8 2PR, Avon, England; Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol, London, England; Univ Western Australia, Sch Populat Hlth, Lab Genet Epidemiol, Perth, WA 6009, Australia; Univ Western Australia, Western Australia Inst Med Res, Perth, WA 6009, Australia; Univ Western Australia, Med Res Ctr, Perth, WA 6009, Australia; Univ Leicester, Dept Hlth Sci & Genet, Leicester, Leics, England	University of Bristol; Imperial College London; University of Western Australia; University of Western Australia; University of Western Australia; University of Leicester	Smith, GD (corresponding author), Univ Bristol, Dept Med Sociol, Canynge Hall,Whiteladies Rd, Bristol BS8 2PR, Avon, England.	zetkin@bristol.ac.uk	Palmer, Lyle John/N-1948-2019; Davey Smith, George/A-7407-2013; Palmer, Lyle John/K-3196-2014; Burton, Paul R/H-7527-2016	Palmer, Lyle John/0000-0002-1628-3055; Davey Smith, George/0000-0002-1407-8314; Palmer, Lyle John/0000-0002-1628-3055; Hansell, Anna/0000-0001-9904-7447; Lewis, Sarah/0000-0003-4311-6890				Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; *AM COLL OBST GYN, 2001, PREC PREN CARR SCREE; Ames BN, 1999, P NATL ACAD SCI USA, V96, P12216, DOI 10.1073/pnas.96.22.12216; [Anonymous], 1995, JAMA, V274, P1627; Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033; Arnold SE, 2005, PROG BRAIN RES, V147, P319, DOI 10.1016/S0079-6123(04)47023-X; Beaudet AL, 1999, AM J HUM GENET, V64, P1, DOI 10.1086/302217; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; Bell J, 2004, NATURE, V429, P453, DOI 10.1038/nature02624; BELL J, 1998, BMJ-BRIT MED J, V31, P618; BIRGE SJ, 1967, NEW ENGL J MED, V276, P445, DOI 10.1056/NEJM196702232760805; Brennan P, 2004, INT J EPIDEMIOL, V33, P17, DOI 10.1093/ije/dyh033; Brennan P, 2002, CARCINOGENESIS, V23, P381, DOI 10.1093/carcin/23.3.381; BUCHSBAUM DG, 1995, ARCH INTERN MED, V155, P104, DOI 10.1001/archinte.155.1.104; Burke W, 2003, NEW ENGL J MED, V349, P969, DOI 10.1056/NEJMra012479; Burton PR, 2005, LANCET, V366, P941, DOI 10.1016/S0140-6736(05)67322-9; BURTON PR, 2005, UK BIOBANK EXPECTED; Byrnes V, 2001, GENET TEST, V5, P127, DOI 10.1089/109065701753145583; Cardon LR, 2001, NAT REV GENET, V2, P91, DOI 10.1038/35052543; CASKEY CT, 1993, CODE CODES, P112; Chasman DI, 2004, JAMA-J AM MED ASSOC, V291, P2821, DOI 10.1001/jama.291.23.2821; Clarke R, 1998, J EPIDEMIOL COMMUN H, V52, P364, DOI 10.1136/jech.52.6.364; Clausen H, 1996, CLIN GENET, V49, P200; Clayton D, 2001, LANCET, V358, P1356, DOI 10.1016/S0140-6736(01)06418-2; Colhoun HM, 2003, LANCET, V361, P865, DOI 10.1016/S0140-6736(03)12715-8; Collins FS, 1999, NEW ENGL J MED, V341, P28, DOI 10.1056/NEJM199907013410106; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Collins R, 2002, LANCET, V360, P23, DOI 10.1016/S0140-6736(02)09328-5; Correns C. J., 1900, BERICHTE DTSCH BOT G, V18, P158, DOI DOI 10.1111/J.1438-8677.1900.TB04893.X; *CTR LONG STUD, NAT CHILD DEV STUD; Dahlman I, 2002, NAT GENET, V30, P149, DOI 10.1038/ng825; Dekou V, 2001, ATHEROSCLEROSIS, V154, P659, DOI 10.1016/S0021-9150(00)00522-0; Ebrahim S, 2004, BMJ-BRIT MED J, V328, P861, DOI 10.1136/bmj.38034.702836.55; EBY N, 1994, CANCER CAUSE CONTROL, V5, P458, DOI 10.1007/BF01694760; Eccles DM, 2004, ANN ONCOL, V15, P133, DOI 10.1093/annonc/mdh917; Eck P, 2004, HUM GENET, V115, P285, DOI 10.1007/s00439-004-1167-x; Eng CM, 1997, JAMA-J AM MED ASSOC, V278, P1268, DOI 10.1001/jama.278.15.1268; Eng CM, 2001, ADV GENET, V44, P275; Evans WE, 2004, NATURE, V429, P464, DOI 10.1038/nature02626; FALLON UB, 2001, HEART ONLINE    0314; Feder JN, 1996, NAT GENET, V13, P399, DOI 10.1038/ng0896-399; Ferri E., 2003, CHANGING BRITAIN CHA; Frayling IM, 1998, P NATL ACAD SCI USA, V95, P10722, DOI 10.1073/pnas.95.18.10722; FULLER RK, 1988, ALCOHOL CLIN EXP RES, V12, P201, DOI 10.1111/j.1530-0277.1988.tb00180.x; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Godard B, 2003, EUR J HUM GENET, V11, pS49, DOI 10.1038/sj.ejhg.5201113; Goldstein DB, 2003, NAT REV GENET, V4, P937, DOI 10.1038/nrg1229; Goldstein DB, 2003, TRENDS GENET, V19, P615, DOI 10.1016/j.tig.2003.09.006; Gordon C, 2003, AM J MED GENET A, V120A, P199, DOI 10.1002/ajmg.a.20259; Goring HHH, 2001, AM J HUM GENET, V69, P1357, DOI 10.1086/324471; Gormally E, 2004, INT J CANCER, V111, P746, DOI 10.1002/ijc.20327; GRAY R, 1991, BONE MARROW TRANSPL, V7, P9; Griffith GL, 2004, BRIT J CANCER, V90, P1912, DOI 10.1038/sj.bjc.6601794; Grody WW, 2003, ANNU REV MED, V54, P473, DOI 10.1146/annurev.med.54.101601.152127; Grody WW, 2001, GENET MED, V3, P87, DOI 10.1097/00125817-200103000-00001; Guttmacher AE, 2004, NEW ENGL J MED, V351, P2333, DOI 10.1056/NEJMsb042979; Haga SB, 2004, JAMA-J AM MED ASSOC, V291, P2869, DOI 10.1001/jama.291.23.2869; Haga SB, 2003, NAT GENET, V34, P347, DOI 10.1038/ng0803-347; Hahnloser D, 2003, CANCER EPIDEM BIOMAR, V12, P1023; Hartman JL, 2001, SCIENCE, V291, P1001, DOI 10.1126/science.291.5506.1001; HIGHFIELD R, 2004, DAILY TELEGRAPH 0922, P8; Honkanen R, 1996, BONE, V19, P23, DOI 10.1016/8756-3282(96)00107-X; Honnor M, 2000, AM J MED GENET, V93, P198, DOI 10.1002/1096-8628(20000731)93:3<198::AID-AJMG7>3.0.CO;2-Q; Howell RR, 1999, ARCH INTERN MED, V159, P1529; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Humphries SE, 2004, ARTERIOSCL THROM VAS, V24, P628, DOI 10.1161/01.ATV.0000116216.56511.39; HUSEBEKK A, 2003, BIOBANKS HLTH REPORT; Ioannidis JPA, 2003, LANCET, V361, P567, DOI 10.1016/S0140-6736(03)12516-0; Ioannidis JPA, 2001, NAT GENET, V29, P306, DOI 10.1038/ng749; Israel E, 2004, LANCET, V364, P1505, DOI 10.1016/S0140-6736(04)17273-5; Johnson JA, 2003, TRENDS GENET, V19, P660, DOI 10.1016/j.tig.2003.09.008; Juul K, 2004, CIRCULATION, V109, P59, DOI 10.1161/01.CIR.0000105720.28086.6C; Kajinami K, 2004, ATHEROSCLEROSIS, V177, P219, DOI 10.1016/j.atherosclerosis.2004.09.004; Kalow W, 2002, FUND CLIN PHARMACOL, V16, P337, DOI 10.1046/j.1472-8206.2002.00109.x; KATAN MB, 1986, LANCET, V1, P507; Keavney B, 2004, INT J EPIDEMIOL, V33, P1002, DOI 10.1093/ije/dyh275; Keavney B, 2004, INT J EPIDEMIOL, V33, P11, DOI 10.1093/ije/dyh056; Kelada SN, 2003, ENVIRON HEALTH PERSP, V111, P1055, DOI 10.1289/ehp.6065; KELLEHER D, 2004, NOVART FDN SYMP, V263, P211; KELLEHER D, 2004, NOVART FDN SYMP, V263, P53; Kelleher Dermot, 2004, Novartis Found Symp, V263, P41; Khachaturian AS, 2004, ARCH GEN PSYCHIAT, V61, P518, DOI 10.1001/archpsyc.61.5.518; Khaw KT, 2001, LANCET, V357, P657, DOI 10.1016/S0140-6736(00)04128-3; Khoury MJ, 2004, INT J EPIDEMIOL, V33, P936, DOI 10.1093/ije/dyh278; Khoury MJ, 2004, GENET MED, V6, P38, DOI 10.1097/01.GIM.0000105751.71430.79; Khoury MJ, 2003, NEW ENGL J MED, V348, P50, DOI 10.1056/NEJMra013182; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Lawlor DA, 2003, INT J EPIDEMIOL, V32, P239, DOI 10.1093/ije/dyg060; Lewis SJ, 2005, CANCER EPIDEM BIOMAR, V14, P1967, DOI 10.1158/1055-9965.EPI-05-0196; LEWIS SJ, IN PRESS BMJ; Little J, 2003, LANCET, V362, P930, DOI 10.1016/S0140-6736(03)14396-6; Lohmueller KE, 2003, NAT GENET, V33, P177, DOI 10.1038/ng1071; LOWER GM, 1979, ENVIRON HEALTH PERSP, V29, P71, DOI 10.2307/3429048; Mallal S, 2002, LANCET, V359, P727, DOI 10.1016/S0140-6736(02)07873-X; Marteau TM, 1997, HEALTH PSYCHOL, V16, P51; Marteau TM, 1999, AM J OBSTET GYNECOL, V181, P165, DOI 10.1016/S0002-9378(99)70454-0; McCarthy TV, 2000, HUM MUTAT, V15, P410, DOI 10.1002/(SICI)1098-1004(200005)15:5<410::AID-HUMU2>3.0.CO;2-D; McGrath J, 1999, SCHIZOPHR RES, V40, P173, DOI 10.1016/S0920-9964(99)00052-3; McLeod HL, 2000, LEUKEMIA, V14, P567, DOI 10.1038/sj.leu.2401723; Mendel G., EXPT PLANT HYBRIDIZA; Merikangas KR, 2003, SCIENCE, V302, P599, DOI 10.1126/science.1091468; NEWCOMER AD, 1978, ANN INTERN MED, V89, P218, DOI 10.7326/0003-4819-89-2-218; Niederau C, 2002, EUR J GASTROEN HEPAT, V14, P217, DOI 10.1097/00042737-200203000-00003; Norio R, 2003, HUM GENET, V112, P441, DOI 10.1007/s00439-002-0875-3; Oscarson M, 2003, CLIN CHEM LAB MED, V41, P573, DOI 10.1515/CCLM.2003.087; Palmer LJ, 2005, LANCET, V366, P1223, DOI 10.1016/S0140-6736(05)67485-5; Palomaki GE, 2004, GENET MED, V6, P115, DOI 10.1097/01.GIM.0000127272.60548.52; Pastinen T, 2001, HUM MOL GENET, V10, P2961, DOI 10.1093/hmg/10.26.2961; Petitti D, 2004, INT J EPIDEMIOL, V33, P461, DOI 10.1093/ije/dyh192; Qiu C, 2004, J NEUROL NEUROSUR PS, V75, P828, DOI 10.1136/jnnp.2003.021493; Ren R, 2005, NAT REV CANCER, V5, P172, DOI 10.1038/nrc1567; Richards CS, 2004, EXPERT REV MOL DIAGN, V4, P49, DOI 10.1586/14737159.4.1.49; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Risch NJ, 2000, NATURE, V405, P847, DOI 10.1038/35015718; Rosenberg RN, 2003, JAMA-J AM MED ASSOC, V289, P1305, DOI 10.1001/jama.289.10.1305; Roses AD, 2001, HUM MOL GENET, V10, P2261, DOI 10.1093/hmg/10.20.2261; Rothman KJ, 1998, MODERN EPIDEMIOLOGY, P93; Rothman N, 2001, BBA-REV CANCER, V1471, pC1, DOI 10.1016/S0304-419X(00)00021-4; Scheuner MT, 2003, GENET MED, V5, P269, DOI 10.1097/01.GIM.0000079364.98247.26; Severi G, 2003, J NATL CANCER I, V95, P818, DOI 10.1093/jnci/95.11.818; Shekelle PG, 2004, J GEN INTERN MED, V19, P380, DOI 10.1111/j.1525-1497.2004.30090.x; Shostak S, 2003, SOC SCI MED, V56, P2327, DOI 10.1016/S0277-9536(02)00231-9; Silverman EK, 2000, AM J RESP CELL MOL, V22, P645, DOI 10.1165/ajrcmb.22.6.f191; Smith GD, 2004, INT J EPIDEMIOL, V33, P30, DOI 10.1093/ije/dyh132; Smith GD, 2005, ARTERIOSCL THROM VAS, V25, P1051, DOI 10.1161/01.ATV.0000160351.95181.d0; Smith GD, 2004, QJM-INT J MED, V97, P163, DOI 10.1093/qjmed/hch025; Smith GD, 2001, J CLIN EPIDEMIOL, V54, P325, DOI 10.1016/S0895-4356(00)00334-6; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Smith GD, 2005, BMJ-BRIT MED J, V330, P1076, DOI 10.1136/bmj.330.7499.1076; SMITH GD, IN PRESS J EPIDEMIOL; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Strom CM, 2004, GENET MED, V6, P136, DOI 10.1097/01.GIM.0000127268.65149.69; Tabor HK, 2002, NAT REV GENET, V3, P391, DOI 10.1038/nrg796; TAUBES G, 1995, SCIENCE, V269, P164, DOI 10.1126/science.7618077; Terwilliger JD, 2000, HUM BIOL, V72, P63; Thomas DC, 2004, INT J EPIDEMIOL, V33, P21, DOI 10.1093/ije/dyh048; Tobin MD, 2004, INT J EPIDEMIOL, V33, P26, DOI 10.1093/ije/dyh016; *UK NAT SCREEN COM, UK NAT SCREEN COMM C; Vastag B, 2003, JAMA-J AM MED ASSOC, V289, P2923, DOI 10.1001/jama.289.22.2923; VINEIS P, 1995, J CLIN EPIDEMIOL, V48, P189, DOI 10.1016/0895-4356(94)00131-9; Waddington CH, 1942, NATURE, V150, P563, DOI 10.1038/150563a0; WATSON JD, 1993, CODE CODES SCI SOCIA, P164; Weiss KM, 2000, NAT GENET, V26, P151, DOI 10.1038/79866; Wheatley K, 2004, INT J EPIDEMIOL, V33, P15, DOI 10.1093/ije/dyg313; Wilkins AS, 1997, BIOESSAYS, V19, P257, DOI 10.1002/bies.950190312; WILLETT WC, 1990, NUTR REV, V48, P201, DOI 10.1111/j.1753-4887.1990.tb02936.x; Witte DL, 1996, CLIN CHIM ACTA, V245, P139, DOI 10.1016/0009-8981(95)06212-2; Workman P, 2003, CANCER CHEMOTH PHARM, V52, pS45, DOI 10.1007/s00280-003-0593-0; Yoon PW, 2002, GENET MED, V4, P304, DOI 10.1097/00125817-200207000-00009; Youngman LD, 2000, CIRCULATION, V102, P31; Zhou W, 2002, CANCER EPIDEM BIOMAR, V11, P15; Zondervan KT, 2004, NAT REV GENET, V5, P89, DOI 10.1038/nrg1270	153	199	204	1	22	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2005	366	9495					1484	1498		10.1016/S0140-6736(05)67601-5	http://dx.doi.org/10.1016/S0140-6736(05)67601-5			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976HQ	16243094				2022-12-28	WOS:000232724600028
J	Basu, U; Chaudhuri, J; Alpert, C; Dutt, S; Ranganath, S; Li, G; Schrum, JP; Manis, JP; Alt, FW				Basu, U; Chaudhuri, J; Alpert, C; Dutt, S; Ranganath, S; Li, G; Schrum, JP; Manis, JP; Alt, FW			The AID antibody diversification enzyme is regulated by protein kinase A phosphorylation	NATURE			English	Article							CLASS-SWITCH RECOMBINATION; SINGLE-STRANDED-DNA; CYTIDINE DEAMINASE AID; SOMATIC HYPERMUTATION; B-CELLS; MECHANISM; TRANSCRIPTION; EXPRESSION; MYC	Antibodies, which are produced by B-lineage cells, consist of immunoglobulin heavy (IgH) and light (IgL) chains that have amino-terminal variable regions and carboxy-terminal constant regions. In response to antigens, B cells undergo two types of genomic alterations to increase antibody diversity. Affinity for antigen can be increased by introduction of point mutations into IgH and IgL variable regions by somatic hypermutation. In addition, antibody effector functions can be altered by changing the expressed IgH constant region exons through IgH class switch recombination (CSR)(1-3). Somatic hypermutation and CSR both require the B-cell-specific activation-induced cytidine deaminase protein (AID)(4-6), which initiates these reactions through its single-stranded (ss)DNA-specific cytidine deaminase activity(7-11). In biochemical assays, replication protein A (RPA), a ssDNA-binding protein(12), associates with phosphorylated AID from activated B cells and enhances AID activity on transcribed double-stranded (ds)DNA containing somatic hypermutation or CSR target sequences. This AID-RPA association, which requires phosphorylation, may provide a mechanism for allowing AID to access dsDNA targets in activated B cells(13,14). Here we show that AID from B cells is phosphorylated on a consensus protein kinase A (PKA) site and that PKA is the physiological AID kinase. Thus, AID from non-lymphoid cells can be functionally phosphorylated by recombinant PKA to allow interaction with RPA and promote deamination of transcribed dsDNA substrates. Moreover, mutation of the major PKA phosphorylation site of AID preserves ssDNA deamination activity, but markedly reduces RPA-dependent dsDNA deamination activity and severely impairs the ability of AID to effect CSR in vivo. We conclude that PKA has a critical role in post-translational regulation of AID activity in B cells.	Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,CBR Inst Biomed Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Harvard Univ, Sch Med, Childrens Hosp, Joint Program Transfus Med,Dept Pathol, Boston, MA 02115 USA	Harvard University; Boston Children's Hospital; Program in Cellular & Molecular Medicine (PCMM); Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School	Alt, FW (corresponding author), Harvard Univ, Sch Med, Howard Hughes Med Inst, Childrens Hosp,CBR Inst Biomed Res, Boston, MA 02115 USA.	alt@enders.tch.harvard.edu						Barreto VM, 2005, J EXP MED, V202, P733, DOI 10.1084/jem.20051378; Bransteitter R, 2003, P NATL ACAD SCI USA, V100, P4102, DOI 10.1073/pnas.0730835100; Chaudhuri J, 2004, NATURE, V430, P992, DOI 10.1038/nature02821; Chaudhuri J, 2003, NATURE, V422, P726, DOI 10.1038/nature01574; Chaudhuri J, 2004, NAT REV IMMUNOL, V4, P541, DOI 10.1038/nri1395; Dickerson SK, 2003, J EXP MED, V197, P1291, DOI 10.1084/jem.20030481; Dominguez-Sola D, 2004, NAT CELL BIOL, V6, P288, DOI 10.1038/ncb0404-288; Fagarasan S, 2001, NATURE, V413, P639, DOI 10.1038/35098100; Honjo T, 2002, ANNU REV IMMUNOL, V20, P165, DOI 10.1146/annurev.immunol.20.090501.112049; Kotani A, 2005, P NATL ACAD SCI USA, V102, P4506, DOI 10.1073/pnas.0500830102; Manis JP, 1998, J EXP MED, V187, P2081, DOI 10.1084/jem.187.12.2081; Manis JP, 2002, TRENDS IMMUNOL, V23, P31, DOI 10.1016/S1471-4906(01)02111-1; Muramatsu M, 1999, J BIOL CHEM, V274, P18470, DOI 10.1074/jbc.274.26.18470; Muramatsu M, 2000, CELL, V102, P553, DOI 10.1016/S0092-8674(00)00078-7; Nakamura M, 1996, INT IMMUNOL, V8, P193, DOI 10.1093/intimm/8.2.193; Petersen-Mahrt SK, 2002, NATURE, V418, P99, DOI 10.1038/nature00862; Rada C, 2004, MOL CELL, V16, P163, DOI 10.1016/j.molcel.2004.10.011; Ramiro AR, 2004, CELL, V118, P431, DOI 10.1016/j.cell.2004.08.006; Ramiro AR, 2003, NAT IMMUNOL, V4, P452, DOI 10.1038/ni920; Revy P, 2000, CELL, V102, P565, DOI 10.1016/S0092-8674(00)00079-9; Tasken K, 2004, PHYSIOL REV, V84, P137, DOI 10.1152/physrev.00021.2003; Torgersen KM, 2002, CELL SIGNAL, V14, P1, DOI 10.1016/S0898-6568(01)00214-5; Unniraman S, 2004, NAT IMMUNOL, V5, P1117, DOI 10.1038/ni1127; Weill JC, 2004, NAT IMMUNOL, V5, P876, DOI 10.1038/ni0904-876; Wold MS, 1997, ANNU REV BIOCHEM, V66, P61, DOI 10.1146/annurev.biochem.66.1.61; Xu YX, 2003, GENE DEV, V17, P2765, DOI 10.1101/gad.1135503; Yang XJ, 2005, ONCOGENE, V24, P1653, DOI 10.1038/sj.onc.1208173; Zarrin AA, 2004, NAT IMMUNOL, V5, P1275, DOI 10.1038/ni1137; Zhong HH, 1997, CELL, V89, P413, DOI 10.1016/S0092-8674(00)80222-6	29	203	207	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 24	2005	438	7067					508	511		10.1038/nature04255	http://dx.doi.org/10.1038/nature04255			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986NY	16251902				2022-12-28	WOS:000233458200052
J	Despres, JP; Golay, A; Sjostrom, L				Despres, JP; Golay, A; Sjostrom, L		Rimonabant Obesity Lipids Study Gr	Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							C-REACTIVE PROTEIN; WEIGHT-LOSS; PLASMA-LIPOPROTEIN; VISCERAL OBESITY; BODY-FAT; ASSOCIATION; ADIPONECTIN; ENDOCANNABINOIDS; REDUCTION; SYSTEM	Background Rimonabant, a selective cannabinoid-1 receptor (CB1) blocker, has been shown to reduce body weight and improve cardiovascular risk factors in obese patients. The Rimonabant in Obesity-Lipids (RIO-Lipids) study examined the effects of rimonabant on metabolic risk factors, including adiponectin levels, in high-risk patients who are overweight or obese and have dyslipidemia. Methods We randomly assigned 1036 overweight or obese patients (body-mass index [the weight in kilograms divided by the square of the height in meters], 27 to 40) with untreated dyslipidemia (triglyceride levels >1.69 to 7.90 mmol per liter, or a ratio of cholesterol to high-density lipoprotein [HDL] cholesterol of >4.5 among women and >5 among men) to double-blinded therapy with either placebo or rimonabant at a dose of 5 mg or 20 mg daily for 12 months in addition to a hypocaloric diet. Results The rates of completion of the study were 62.6 percent, 60.3 percent, and 63.9 percent in the placebo group, the group receiving 5 mg of rimonabant, and the group receiving 20 mg of rimonabant, respectively. The most frequent adverse events resulting in discontinuation of the drug were depression, anxiety, and nausea. As compared with placebo, rimonabant at a dose of 20 mg was associated with a significant (P<0.001) mean weight loss (repeated-measures method, -6.7+/-0.5 kg, and last-observation-carried-forward analyses, -5.4+/-0.4 kg), reduction in waist circumference (repeated-measures method, -5.8+/-0.5 cm, and last-observation-carried-forward analyses, -4.7+/-0.5 cm), increase in HDL cholesterol (repeated-measures method, +10.0+/-1.6 percent, and last-observation-carried-forward analyses, +8.1+/-1.5 percent), and reduction in triglycerides (repeated-measures method, -13.0+/-3.5 percent, and last-observation-carried-forward analyses, -12.4+/-3.2 percent). Rimonabant at a dose of 20 mg also resulted in an increase in plasma adiponectin levels (repeated-measures method, 57.7 percent, and last-observation-carried-forward analyses, 46.2 percent; P<0.001), for a change that was partly independent of weight loss alone. Conclusions Selective CB1-receptor blockade with rimonabant significantly reduces body weight and waist circumference and improves the profile of several metabolic risk factors in high-risk patients who are overweight or obese and have an atherogenic dyslipidemia.	Laval Hosp Res Ctr, Quebec Heart Inst, Ste Foy, PQ G1V 4G5, Canada; Univ Laval, Dept Prevent & Social Med, Div Kinesiol, Ste Foy, PQ G1K 7P4, Canada; Univ Hosp Geneva, Serv Therapeut Educ Chron Dis, Geneva, Switzerland; Sahlgrens Univ Hosp, Dept Body Composit & Metab, Gothenburg, Sweden	Laval University; University of Geneva; Sahlgrenska University Hospital	Despres, JP (corresponding author), Laval Hosp Res Ctr, Quebec Heart Inst, Pavil Marguerite Dyouville,4th Fl,2725 Chemin Ste, Ste Foy, PQ G1V 4G5, Canada.	jean-pierre.despres@crhl.ulaval.ca	Salas-Salvado, Jordi/C-7229-2017; Adiels, Martin/C-9278-2011	Salas-Salvado, Jordi/0000-0003-2700-7459; 				Albert MA, 2001, JAMA-J AM MED ASSOC, V286, P64, DOI 10.1001/jama.286.1.64; Assmann G, 2001, AM J CARDIOL, V87, p2B, DOI 10.1016/S0002-9149(01)01448-5; Bensaid M, 2003, MOL PHARMACOL, V63, P908, DOI 10.1124/mol.63.4.908; Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486; Cota D, 2003, J CLIN INVEST, V112, P423, DOI 10.1172/JCI17725; Cote M, 2005, J CLIN ENDOCR METAB, V90, P1434, DOI 10.1210/jc.2004-1711; Despres JP, 2001, BRIT MED J, V322, P1379, DOI 10.1136/bmj.322.7299.1379; DESPRES JP, 1990, ARTERIOSCLEROSIS, V10, P497, DOI 10.1161/01.ATV.10.4.497; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; Di Marzo V, 2004, NAT REV DRUG DISCOV, V3, P771, DOI 10.1038/nrd1495; Di Marzo V, 2001, NATURE, V410, P822, DOI 10.1038/35071088; Flier JS, 2004, CELL, V116, P337, DOI 10.1016/S0092-8674(03)01081-X; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Hanus L, 2001, P NATL ACAD SCI USA, V98, P3662, DOI 10.1073/pnas.061029898; Heilbronn LK, 2001, ARTERIOSCL THROM VAS, V21, P968, DOI 10.1161/01.ATV.21.6.968; Horvath TL, 2003, J CLIN INVEST, V112, P323, DOI [10.1172/JCI19376, 10.1172/JCI200319376]; Howlett AC, 2002, PHARMACOL REV, V54, P161, DOI 10.1124/pr.54.2.161; Jbilo O, 2005, FASEB J, V19, P1567, DOI 10.1096/fj.04-3177fje; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; Kanai H, 1996, HYPERTENSION, V27, P125, DOI 10.1161/01.HYP.27.1.125; Kirkham TC, 2002, BRIT J PHARMACOL, V136, P550, DOI 10.1038/sj.bjp.0704767; LaRosa JC, 1999, JAMA-J AM MED ASSOC, V282, P2340, DOI 10.1001/jama.282.24.2340; Lemieux I, 2001, ARTERIOSCL THROM VAS, V21, P961, DOI 10.1161/01.ATV.21.6.961; *LEX, 1996, LAB TEST HDB; Matsuzawa Y, 2004, ARTERIOSCL THROM VAS, V24, P29, DOI 10.1161/01.ATV.0000099786.99623.EF; Meigs JB, 1997, DIABETES, V46, P1594, DOI 10.2337/diabetes.46.10.1594; Pagotto U, 2005, LANCET, V365, P1363, DOI 10.1016/S0140-6736(05)66348-9; Pischon T, 2004, JAMA-J AM MED ASSOC, V291, P1730, DOI 10.1001/jama.291.14.1730; Rainwater DL, 2000, ATHEROSCLEROSIS, V148, P151, DOI 10.1016/S0021-9150(99)00216-6; Ridker PM, 2004, CIRCULATION, V109, P2818, DOI 10.1161/01.CIR.0000132467.45278.59; Ross R, 2000, ANN INTERN MED, V133, P92, DOI 10.7326/0003-4819-133-2-200007180-00008; Spranger J, 2003, LANCET, V361, P226, DOI 10.1016/S0140-6736(03)12255-6; St-Pierre AC, 2001, CIRCULATION, V104, P2295, DOI 10.1161/hc4401.098490; Staels B, 1998, NATURE, V393, P790, DOI 10.1038/31701; Tchernof A, 1996, DIABETES CARE, V19, P629, DOI 10.2337/diacare.19.6.629; Tchernof A, 2002, CIRCULATION, V105, P564, DOI 10.1161/hc0502.103331; Van Gaal LF, 2005, LANCET, V365, P1389, DOI 10.1016/S0140-6736(05)66374-X; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	38	1064	1116	0	39	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2121	2134		10.1056/NEJMoa044537	http://dx.doi.org/10.1056/NEJMoa044537			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291982				2022-12-28	WOS:000233288600005
J	Wing, SL; Harrington, GJ; Smith, FA; Bloch, JI; Boyer, DM; Freeman, KH				Wing, SL; Harrington, GJ; Smith, FA; Bloch, JI; Boyer, DM; Freeman, KH			Transient floral change and rapid global warming at the Paleocene-Eocene boundary	SCIENCE			English	Article							CARBON-ISOTOPE EXCURSION; THERMAL MAXIMUM; NORTH-AMERICA; BIGHORN BASIN; OXYGEN-ISOTOPE; CLIMATE-CHANGE; FOSSIL LEAVES; TEMPERATURE; PLANT; VEGETATION	Rapid global warming of 5 degrees to 10 degrees C during the Paleocene-Eocene Thermal Maximum (PETM) coincided with major turnover in vertebrate faunas, but previous studies have found little floral change. Plant fossils discovered in Wyoming, United States, show that PETM floras were a mixture of native and migrant lineages and that plant range shifts were large and rapid (occurring within 10,000 years). Floral composition and leaf shape and size suggest that climate warmed by similar to 5 degrees C during the PETM and that precipitation was low early in the event and increased later. Floral response to warming and/or increased atmospheric CO2 during the PETM was comparable in rate and magnitude to that seen in postglaciat floras and to the predicted effects of anthropogenic carbon release and climate change on future vegetation.	Smithsonian Museum Nat Hist, Dept Paleobiol, Washington, DC 20560 USA; Univ Birmingham, Dept Geog Earth & Environm Sci, Birmingham B15 2TT, W Midlands, England; Penn State Univ, Dept Geosci, University Pk, PA 16802 USA; Florida Museum Nat Hist, Div Vertebrate Paleontol, Gainesville, FL 32611 USA; SUNY Stony Brook, Dept Anat Sci, Stony Brook, NY 11794 USA	Smithsonian Institution; Smithsonian National Museum of Natural History; University of Birmingham; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Wing, SL (corresponding author), Smithsonian Museum Nat Hist, Dept Paleobiol, 10th St & Constitut Ave NW, Washington, DC 20560 USA.	wings@si.edu	Freeman, Katherine H/H-5140-2011; McInerney, Francesca A/ABE-3639-2020; McInerney, Francesca/B-7894-2009	Freeman, Katherine H/0000-0002-3350-7671; McInerney, Francesca A/0000-0002-2020-6650; McInerney, Francesca/0000-0002-2020-6650; Boyer, Douglas/0000-0002-8697-2999; Wing, Scott/0000-0002-2954-8905; Bloch, Jonathan/0000-0003-1484-6931				Bowen GJ, 2002, SCIENCE, V295, P2062, DOI 10.1126/science.1068700; Bowen GJ, 2004, NATURE, V432, P495, DOI 10.1038/nature03115; Bowen GJ., 2001, PALEOCENE EOCENE STR, P73; BOWN TM, 1993, PALAIOS, V8, P68, DOI 10.2307/3515222; Brown RW., 1962, US GEOL SURV PROF PA, V375, P1; Burnham RJ, 2001, AM J BOT, V88, P1096, DOI 10.2307/2657093; Clyde WC, 1998, GEOLOGY, V26, P1011, DOI 10.1130/0091-7613(1998)026<1011:MCRTTL>2.3.CO;2; Collinson M.E., 2003, GEOLOGICAL SOC AM SP, V369, P333, DOI DOI 10.1130/0-8137-2369-8.333; Crouch EM, 2003, PALAEOGEOGR PALAEOCL, V194, P387, DOI 10.1016/S0031-0182(03)00334-1; Crouch EM, 2001, GEOLOGY, V29, P315, DOI 10.1130/0091-7613(2001)029<0315:GDEAWT>2.0.CO;2; CROUCH EM, 2003, GEOL SOC AM SPEC PAP, V369, P333; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Farley KA, 2003, EARTH PLANET SC LETT, V208, P135, DOI 10.1016/S0012-821X(03)00017-7; Fricke HC, 2004, AM J SCI, V304, P612, DOI 10.2475/ajs.304.7.612; Fricke HC, 1998, EARTH PLANET SC LETT, V160, P193, DOI 10.1016/S0012-821X(98)00088-0; Gingerich P.D., 1989, U MICHIGAN PAPERS PA, V28, P1; GINGERICH PD, 2001, U MICHIGAN PAPERS PA, V33, P37; Gradstein F.M., 2004, GEOLOGIC TIME SCALE; GREENWOOD DR, 1995, GEOLOGY, V23, P1044, DOI 10.1130/0091-7613(1995)023<1044:ECCALT>2.3.CO;2; Harrington G. J., 2003, GEOLOGICAL SOC AM SP, P381, DOI DOI 10.1130/0-8137-2369-8.381; Harrington GJ, 2004, J GEOL SOC LONDON, V161, P173, DOI 10.1144/0016-764903-100; Harrington GJ, 2001, PALAEOGEOGR PALAEOCL, V167, P1, DOI 10.1016/S0031-0182(00)00228-5; Harrington GJ, 2001, PALAIOS, V16, P266, DOI 10.2307/3515604; Harrington GJ., 2001, U MICHIGAN PAPERS PA, V33, P89; Jackson ST, 2000, PALEOBIOLOGY, V26, P194, DOI 10.1666/0094-8373(2000)26[194:ROPPAC]2.0.CO;2; Jacobs BF, 2004, PALAEOGEOGR PALAEOCL, V213, P115, DOI 10.1016/j.palaeo.2004.07.007; Kelly DC, 2002, PALEOCEANOGRAPHY, V17, DOI 10.1029/2002PA000761; KOCH PL, 1995, PALAEOGEOGR PALAEOCL, V115, P61, DOI 10.1016/0031-0182(94)00107-J; Kowalski EA, 2003, P NATL ACAD SCI USA, V100, P167, DOI 10.1073/pnas.232693599; Kurtz AC, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2003PA000908; Magioncalda R, 2004, GEOLOGY, V32, P553, DOI 10.1130/G20476.1; Rohl U, 2000, GEOLOGY, V28, P927, DOI 10.1130/0091-7613(2000)28<927:NCFTLP>2.0.CO;2; ROSE KD, 1981, U MICHIGAN MUSEUM PA, V26, P1; Schmitz B, 2003, GEOLOGY, V31, P689, DOI 10.1130/G19527.1; Strait S.G., 2001, U MICHIGAN PAPERS PA, V33, P127; Svensen H, 2004, NATURE, V429, P542, DOI 10.1038/nature02566; Thomas E, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P214; Wilf P, 1997, PALEOBIOLOGY, V23, P373, DOI 10.1017/S0094837300019746; Wilf P, 2000, GEOL SOC AM BULL, V112, P292, DOI 10.1130/0016-7606(2000)112<0292:LPEECC>2.3.CO;2; Wilf P, 1998, GEOLOGY, V26, P203, DOI 10.1130/0091-7613(1998)026<0203:UFLAPI>2.3.CO;2; Wing S.L., 2000, WARM CLIMATES EARTH, P197; Wing SL, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P380; WING SL, 1995, PALAEOGEOGR PALAEOCL, V115, P117, DOI 10.1016/0031-0182(94)00109-L; Wing SL, 2001, PALEOBIOLOGY, V27, P539, DOI 10.1666/0094-8373(2001)027<0539:FRTRWI>2.0.CO;2; Wing SL., 2003, CAUSES CONSEQUENCES, V369, P425, DOI DOI 10.1130/0-8137-2369-8.425; Wolfe JA, 1979, US GEOLOGICAL SURVEY, V1106, P1, DOI DOI 10.3133/PP1106; Zachos JC, 2005, SCIENCE, V308, P1611, DOI 10.1126/science.1109004; Zachos JC, 2003, SCIENCE, V302, P1551, DOI 10.1126/science.1090110	48	412	431	8	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					993	996		10.1126/science.1116913	http://dx.doi.org/10.1126/science.1116913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284173				2022-12-28	WOS:000233343400036
J	Gregory, RI; Chendrimada, TP; Cooch, N; Shiekhattar, R				Gregory, RI; Chendrimada, TP; Cooch, N; Shiekhattar, R			Human RISC couples microRNA biogenesis and posttranscriptional gene silencing	CELL			English	Article							DOUBLE-STRANDED-RNA; CRYSTAL-STRUCTURE; STRUCTURAL BASIS; DISTINCT ROLES; HUMAN DICER; INTERFERENCE; ARGONAUTE2; BINDING; COMPLEX; MATURATION	RNA interference is implemented through the action of the RNA-induced silencing complex (RISC). Although Argonaute2 has been identified as the catalytic center of RISC, the RISC polypeptide composition and assembly using short interfering RNA (siRNA) duplexes has remained elusive. Here we show that RISC is composed of Dicer, the double-stranded RNA binding protein TRBP, and Argonaute2. We demonstrate that this complex can cleave target RNA using precursor microRNA (pre-miRNA) hairpin as the source of sIRNA. Although RISC can also utilize duplex siRNA, it displays a nearly 10-fold greater activity using the pre-miRNA Dicer substrate. RISC distinguishes the guide strand of the siRNA from the passenger strand and specifically incorporates the guide strand. Importantly, ATP is not required for miRNA processing, RISC assembly, or multiple rounds of target-RNA cleavage. These results define the composition of RISC and demonstrate that miRNA processing and target-RNA cleavage are coupled.	Wistar Inst Anat & Biol, Philadelphia, PA 19104 USA	The Wistar Institute	Shiekhattar, R (corresponding author), Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.	shiekhattar@wistar.org						Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Caudy AA, 2002, GENE DEV, V16, P2491, DOI 10.1101/gad.1025202; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049; Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Filipowicz W, 2005, CELL, V122, P17, DOI 10.1016/j.cell.2005.06.023; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120; Grishok A, 2001, CELL, V106, P23, DOI 10.1016/S0092-8674(01)00431-7; Grishok A, 2000, SCIENCE, V287, P2494, DOI 10.1126/science.287.5462.2494; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504; Hutvagner G, 2001, SCIENCE, V293, P834, DOI 10.1126/science.1062961; Hutvagner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827; Jiang F, 2005, GENE DEV, V19, P1674, DOI 10.1101/gad.1334005; Ketting RF, 2001, GENE DEV, V15, P2654, DOI 10.1101/gad.927801; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Kim DH, 2005, NAT BIOTECHNOL, V23, P222, DOI 10.1038/nbt1051; Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lingel A, 2003, NATURE, V426, P465, DOI 10.1038/nature02123; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Ma JB, 2004, NATURE, V429, P318, DOI 10.1038/nature02519; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Mourelatos Z, 2002, GENE DEV, V16, P720, DOI 10.1101/gad.974702; Novina CD, 2004, NATURE, V430, P161, DOI 10.1038/430161a; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Provost P, 2002, EMBO J, V21, P5864, DOI 10.1093/emboj/cdf578; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Saito K, 2005, PLOS BIOL, V3, P1202, DOI 10.1371/journal.pbio.0030235; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Siolas D, 2005, NAT BIOTECHNOL, V23, P227, DOI 10.1038/nbt1052; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Song JJ, 2003, NAT STRUCT BIOL, V10, P1026, DOI 10.1038/nsb1016; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Tabara H, 2002, CELL, V109, P861, DOI 10.1016/S0092-8674(02)00793-6; Tahbaz N, 2004, EMBO REP, V5, P189, DOI 10.1038/sj.embor.7400070; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Yan KS, 2003, NATURE, V426, P469, DOI 10.1038/nature02129; Zhang HD, 2004, CELL, V118, P57, DOI 10.1016/j.cell.2004.06.017; Zhang HD, 2002, EMBO J, V21, P5875, DOI 10.1093/emboj/cdf582	52	1115	1252	6	139	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					631	640		10.1016/j.cell.2005.10.022	http://dx.doi.org/10.1016/j.cell.2005.10.022			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16271387	Bronze			2022-12-28	WOS:000233497400012
J	Chen, WY; Wang, DH; Yen, RWC; Luo, JY; Gu, W; Baylin, SB				Chen, WY; Wang, DH; Yen, RWC; Luo, JY; Gu, W; Baylin, SB			Tumor suppressor HIC1 directly regulates SIRT1 to modulate p53-dependent DNA-damage responses	CELL			English	Article							TUMOR-SUPPRESSOR GENE; HISTONE DEACETYLASE; SACCHAROMYCES-CEREVISIAE; LIFE-SPAN; P53; HIC1; NAD; EXPRESSION; BINDING; BCL-2	Hypermethylated in cancer 1 (HIC1) is an epigenetically regulated transcriptional repressor that functionally cooperates with p53 to suppress age-dependent development of cancer in mice. Here we show that the mechanism by which the loss of HIC1 function promotes tumorigenesis is via activating the stress-controlling protein SIRT1 and thereby attenuating p53 function. HIC1 forms a transcriptional repression complex with SIRT1 deacetylase, and this complex directly binds the SIRT1 promoter and represses its transcription. Inactivation of HIC1 results in upregulated SIRT1 expression in normal or cancer cells; this deacetylates and inactivates p53, allowing cells to bypass apoptosis and survive DNA damage. Inhibition of SIRT1 function in cells without HIC1 abolishes the resistance to apoptosis. Since aging increases promoter hypermethylation and epigenetic silencing of HIC1, we speculate that the resultant upregulation of SIRT1 may be a double-edged sword that both promotes survival of aging cells and increases cancer risk in mammals.	Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Biol Program, Baltimore, MD 21231 USA; Columbia Univ, Inst Canc Genet, New York, NY 10032 USA	Johns Hopkins University; Johns Hopkins Medicine; Columbia University	Baylin, SB (corresponding author), Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Canc Biol Program, Baltimore, MD 21231 USA.	sbaylin@jhmi.edu	Luo, Jianyuan/ABI-7585-2020; Chen, WenYong/D-6748-2012	Luo, Jianyuan/0000-0001-6057-2914; Chen, WenYong/0000-0001-6913-5729	NATIONAL CANCER INSTITUTE [R01CA043318] Funding Source: NIH RePORTER; NCI NIH HHS [CA043318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; Brunet A, 2004, SCIENCE, V303, P2011, DOI 10.1126/science.1094637; Burma S, 2001, J BIOL CHEM, V276, P42462, DOI 10.1074/jbc.C100466200; Carter MG, 2000, HUM MOL GENET, V9, P413, DOI 10.1093/hmg/9.3.413; Chen WY, 2003, NAT GENET, V33, P197, DOI 10.1038/ng1077; Chen WY, 2004, CANCER CELL, V6, P387, DOI 10.1016/j.ccr.2004.08.030; Chen WY, 2000, P NATL ACAD SCI USA, V97, P377, DOI 10.1073/pnas.97.1.377; Cohen HY, 2004, SCIENCE, V305, P390, DOI 10.1126/science.1099196; De Ruijter AJM, 2003, BIOCHEM J, V370, P737, DOI 10.1042/BJ20021321; Deltour S, 1999, P NATL ACAD SCI USA, V96, P14831, DOI 10.1073/pnas.96.26.14831; Deltour S, 2002, MOL CELL BIOL, V22, P4890, DOI 10.1128/MCB.22.13.4890-4901.2002; Dhordain P, 1997, P NATL ACAD SCI USA, V94, P10762, DOI 10.1073/pnas.94.20.10762; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Grimm C, 1999, HUM MOL GENET, V8, P697, DOI 10.1093/hmg/8.4.697; Guarente L, 2000, GENE DEV, V14, P1021; Guerardel C, 2001, J BIOL CHEM, V276, P3078, DOI 10.1074/jbc.M008690200; HALDAR S, 1994, CANCER RES, V54, P2095; He TC, 1998, P NATL ACAD SCI USA, V95, P2509, DOI 10.1073/pnas.95.5.2509; Hemann MT, 2003, NAT GENET, V33, P396, DOI 10.1038/ng1091; Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960; Imai S, 2000, NATURE, V403, P795, DOI 10.1038/35001622; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; Johnstone RW, 2002, CELL, V108, P153, DOI 10.1016/S0092-8674(02)00625-6; Jones PA, 2002, NAT REV GENET, V3, P415, DOI 10.1038/nrg816; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4; Luo JY, 2004, P NATL ACAD SCI USA, V101, P2259, DOI 10.1073/pnas.0308762101; MIYASHITA T, 1995, CELL, V80, P293; MIYASHITA T, 1994, CANCER RES, V54, P3131; Motta MC, 2004, CELL, V116, P551, DOI 10.1016/S0092-8674(04)00126-6; Nemoto S, 2004, SCIENCE, V306, P2105, DOI 10.1126/science.1101731; North BJ, 2004, GENOME BIOL, V5, DOI 10.1186/gb-2004-5-5-224; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Paull TT, 2000, CURR BIOL, V10, P886, DOI 10.1016/S0960-9822(00)00610-2; Pinte S, 2004, J BIOL CHEM, V279, P38313, DOI 10.1074/jbc.M401610200; Sakamoto J, 2004, FEBS LETT, V556, P281, DOI 10.1016/S0014-5793(03)01444-3; Senawong T, 2003, J BIOL CHEM, V278, P43041, DOI 10.1074/jbc.M307477200; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Sun LQ, 2004, GENE DEV, V18, P1035, DOI 10.1101/gad.1176104; Tissenbaum HA, 2001, NATURE, V410, P227, DOI 10.1038/35065638; Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681; Vaquero A, 2004, MOL CELL, V16, P93, DOI 10.1016/j.molcel.2004.08.031; Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X; WALES MM, 1995, NAT MED, V1, P570, DOI 10.1038/nm0695-570; WEINRUCH R, 1988, RETARDATION AGING DI; Wood JG, 2004, NATURE, V430, P686, DOI 10.1038/nature02789; WRIGHT WE, 1991, MOL CELL BIOL, V11, P4104, DOI 10.1128/MCB.11.8.4104; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1	51	504	541	1	47	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					437	448		10.1016/j.cell.2005.08.011	http://dx.doi.org/10.1016/j.cell.2005.08.011			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269335	Bronze			2022-12-28	WOS:000233264300012
J	Rogulja, D; Irvine, KD				Rogulja, D; Irvine, KD			Regulation of cell proliferation by a morphogen gradient	CELL			English	Article							CONTROLS WING GROWTH; ORGANIZING ACTIVITY; PLANAR POLARITY; GENE-EXPRESSION; DROSOPHILA; PATTERN; APOPTOSIS; TRANSMISSION; COMPARTMENTS; INFORMATION	One model to explain the relationship between patterning and growth during development posits that growth is regulated by the slope of morphogen gradients. The Decapentaplegic (DPP) morphogen controls growth in the Drosophila wing, but the slope of the DPP activity gradient has not been shown to influence growth. By employing a method for spatial, temporal, and quantitative control over gene expression, we show that the juxtaposition of cells perceiving different levels of DPP signaling is essential for medial-wing-cell proliferation and can be sufficient to promote the proliferation of cells throughout the wing. Either activation or inhibition of the DPP pathway in clones at levels distinct from those in surrounding cells stimulates nonautonomous cell proliferation. Conversely, uniform activation of the DPP pathway inhibits cell proliferation in medial wing cells. Our observations provide a direct demonstration that the slope of a morphogen gradient regulates growth during development.	Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA; Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA	Howard Hughes Medical Institute; Rutgers State University New Brunswick; Rutgers State University New Brunswick	Irvine, KD (corresponding author), Rutgers State Univ, Howard Hughes Med Inst, Waksman Inst, Piscataway, NJ 08854 USA.	irvine@waksman.rutgers.edu						Adachi-Yamada T, 2002, DEV BIOL, V251, P74, DOI 10.1006/dbio.2002.0821; Adachi-Yamada T, 1999, NATURE, V400, P166, DOI 10.1038/22112; Amonlirdviman K, 2005, SCIENCE, V307, P423, DOI 10.1126/science.1105471; BOHN H, 1974, J EMBRYOL EXP MORPH, V32, P81; BRAND AH, 1993, DEVELOPMENT, V118, P401; Burke R, 1996, DEVELOPMENT, V122, P2261; Campbell G, 1999, CELL, V96, P553, DOI 10.1016/S0092-8674(00)80659-5; CAPDEVILA J, 1994, EMBO J, V13, P4459, DOI 10.1002/j.1460-2075.1994.tb06768.x; Casal J, 2002, CURR BIOL, V12, P1189, DOI 10.1016/S0960-9822(02)00974-0; Datar SA, 2000, EMBO J, V19, P4543, DOI 10.1093/emboj/19.17.4543; Day SJ, 2000, DEVELOPMENT, V127, P2977; Eaton S, 2003, MECH DEVELOP, V120, P1257, DOI 10.1016/j.mod.2003.07.002; Entchev EV, 2000, CELL, V103, P981, DOI 10.1016/S0092-8674(00)00200-2; FRENCH V, 1976, SCIENCE, V193, P969, DOI 10.1126/science.948762; Garcia-Bellido AC, 1998, INT J DEV BIOL, V42, P353; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GELBART WM, 1989, DEVELOPMENT, V107, P65; Gibson MC, 2002, DEV CELL, V3, P451, DOI 10.1016/S1534-5807(02)00264-2; Haerry TE, 1998, DEVELOPMENT, V125, P3977; Huh JR, 2004, CURR BIOL, V14, P1262, DOI 10.1016/j.cub.2004.06.015; Irvine KD, 2001, ANNU REV CELL DEV BI, V17, P189, DOI 10.1146/annurev.cellbio.17.1.189; Ito K, 1997, DEVELOPMENT, V124, P761; Jazwinska A, 1999, CELL, V96, P563, DOI 10.1016/S0092-8674(00)80660-1; Lawrence P. A., 1970, Adv. Insect Physiol., V7, P197, DOI 10.1016/S0065-2806(08)60242-8; Lawrence PA, 1996, CELL, V85, P951, DOI 10.1016/S0092-8674(00)81297-0; Lawrence PA, 2004, NATURE, V429, P247, DOI 10.1038/429247a; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; Lecuit T, 1998, DEVELOPMENT, V125, P4901; Ma D, 2003, NATURE, V421, P543, DOI 10.1038/nature01366; Martin FA, 2004, DEVELOPMENT, V131, P4921, DOI 10.1242/dev.01385; Martin-Castellanos C, 2002, DEVELOPMENT, V129, P1003; Milan M, 1996, P NATL ACAD SCI USA, V93, P640, DOI 10.1073/pnas.93.2.640; Moreno E, 2002, NATURE, V416, P755, DOI 10.1038/416755a; Muller B, 2003, CELL, V113, P221, DOI 10.1016/S0092-8674(03)00241-1; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Osterwalder T, 2001, P NATL ACAD SCI USA, V98, P12596, DOI 10.1073/pnas.221303298; Padgett RW, 1999, CURR BIOL, V9, pR408, DOI 10.1016/S0960-9822(99)80255-3; Perez-Garijo A, 2004, DEVELOPMENT, V131, P5591, DOI 10.1242/dev.01432; Resino J, 2002, P NATL ACAD SCI USA, V99, P7502, DOI 10.1073/pnas.072208199; Roman G, 2001, P NATL ACAD SCI USA, V98, P12602, DOI 10.1073/pnas.221303998; Ryoo HD, 2004, DEV CELL, V7, P491, DOI 10.1016/j.devcel.2004.08.019; Serrano N, 1997, CURR BIOL, V7, pR186, DOI 10.1016/S0960-9822(97)70085-X; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; Tanimoto H, 2000, MOL CELL, V5, P59, DOI 10.1016/S1097-2765(00)80403-7; Teleman AA, 2000, CELL, V103, P971, DOI 10.1016/S0092-8674(00)00199-9; Thacker SA, 2003, CURR BIOL, V13, P53, DOI 10.1016/S0960-9822(02)01400-8; Tsuneizumi K, 1997, NATURE, V389, P627, DOI 10.1038/39362; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; ZECCA M, 1995, DEVELOPMENT, V121, P2265	50	178	184	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					449	461		10.1016/j.cell.2005.08.030	http://dx.doi.org/10.1016/j.cell.2005.08.030			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269336	Bronze			2022-12-28	WOS:000233264300013
J	Tamblyn, R; Abrahamowicz, M; Dauphinee, D; Girard, N; Bartlett, G; Grand'Maison, P; Brailovsky, C				Tamblyn, R; Abrahamowicz, M; Dauphinee, D; Girard, N; Bartlett, G; Grand'Maison, P; Brailovsky, C			Effect of a community oriented problem based learning curriculum on quality of primary care delivered by graduates: historical cohort comparison study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEBATE CONTINUES; SERVICES; PBL	Objective To assess whether the transition from a traditional curriculum to a community oriented problem based learning curriculum at Sherbrooke University is associated with the expected improvements in preventive care and continuity of care without a decline in diagnosis and management of disease. Design Historical cohort comparison study. Setting Sherbrooke University and three traditional medical schools in Quebec, Canada. Participants 751 doctors from four graduation cohorts (1988-91); three before the transition to community oriented problem based learning (n = 600) and one after the transition (n = 151). Outcome measures Annual performance in preventive care (mammography screening rate), continuity of care, diagnosis (difference in prescribing rates for specific diseases and relief of symptoms), and management (prescribing rate for contraindicated drugs) assessed using provincial health databases for the first 4-7 years of practice. Results After transition to a community oriented problem based learning curriculum, graduates of Sherbrooke University showed a statistically significant improvement in mammography screening rates (55 more women screened per 1000, 95% confidence interval 10.6 to 99.3) and continuity of care (3.3% more visits coordinated by the doctor, 0.9% to 5.8%) compared with graduates of a traditional medical curriculum. Indicators of diagnostic and management performance did not show the hypothesised decline. Sherbrooke graduates showed a significant fourfold increase in disease specific prescribing rates compared with prescribing for symptom relief after the transition. Conclusion Transition to a community oriented problem based learning curriculum was associated with significant improvements in preventive care and continuity of care and an improvement in indicators of diagnostic performance.	McGill Univ, Montreal, PQ H3A 1A3, Canada; McGill Univ, Montreal Gen Hosp, Ctr Hlth, Montreal, PQ H3G 1A4, Canada; Med Council Canada, Ottawa, ON K1G 3H7, Canada; McGill Univ, Clin & Hlth Informat Res Grp, Montreal, PQ H3A 2T5, Canada; Univ Sherbrooke, Fac Med, Sherbrooke, PQ J1K 2R0, Canada; Univ Laval, Ctr Evaluat Sci Sante, Quebec City, PQ G1K 7P4, Canada	McGill University; McGill University; McGill University; University of Sherbrooke; Laval University	Tamblyn, R (corresponding author), McGill Univ, Montreal, PQ H3A 1A3, Canada.	robyn.tamblyn@mcgill.ca	Tamblyn, Robyn/L-6010-2016	Abrahamowicz, Michal/0000-0002-3172-3952				Albanese M, 2000, MED EDUC, V34, P729, DOI 10.1046/j.1365-2923.2000.00753.x; BEERS MH, 1991, ARCH INTERN MED, V151, P1825; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Colliver JA, 2000, ACAD MED, V75, P259, DOI 10.1097/00001888-200003000-00017; DESMARCHAIS JE, 1993, CAN MED ASSOC J, V148, P1567; DESMARCHAIS JE, 2001, LEARNING PHYS SHERBR; Dolmans D, 2003, MED EDUC, V37, P1129, DOI 10.1046/j.1365-2923.2003.01724.x; Farrow R, 2003, MED EDUC, V37, P1131, DOI 10.1046/j.1365-2923.2003.01725.x; GRANDMAISON P, 1992, CAN MED ASSOC J, V146, P1735; Haggerty J, 1999, PREV MED, V29, P391, DOI 10.1006/pmed.1999.0558; Hartert TV, 1996, AM J MED, V100, P386, DOI 10.1016/S0002-9343(97)89513-7; Institute of Medicine, 2000, ERR IS HUM BUILD SAF; Kurth RJ, 2001, J EVAL CLIN PRACT, V7, P325, DOI 10.1046/j.1365-2753.2001.00288.x; Morgan WKC, 1995, BRIT MED J, V311, P1643, DOI 10.1136/bmj.311.7020.1643; Norman GR, 2000, MED EDUC, V34, P721, DOI 10.1046/j.1365-2923.2000.00749.x; PATEL VL, 1991, ACAD MED, V66, P380, DOI 10.1097/00001888-199107000-00002; Salive ME, 1996, PREV MED, V25, P561, DOI 10.1006/pmed.1996.0090; Schmader KE, 1997, ANN PHARMACOTHER, V31, P529, DOI 10.1177/106002809703100501; TAMBLYN R, 1995, J CLIN EPIDEMIOL, V48, P999, DOI 10.1016/0895-4356(94)00234-H; Tamblyn R, 2002, JAMA-J AM MED ASSOC, V288, P3019, DOI 10.1001/jama.288.23.3019; TAMBLYN R, 1994, EVAL HEALTH PROF, V17, P198, DOI 10.1177/016327879401700205; Whitcomb ME, 2002, ACAD MED, V77, P1067, DOI 10.1097/00001888-200211000-00001; Wilchesky M, 2004, J CLIN EPIDEMIOL, V57, P131, DOI 10.1016/S0895-4356(03)00246-4; [No title captured]	24	45	52	1	7	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	OCT 29	2005	331	7523					1002	1005		10.1136/bmj.38636.582546.7C	http://dx.doi.org/10.1136/bmj.38636.582546.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981AU	16239292	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000233060200019
J	Aylward, RB; Sutter, RW; Heymann, DL				Aylward, RB; Sutter, RW; Heymann, DL			OPV cessation - the final step to a "polio-free" world	SCIENCE			English	Article							VACCINE-DERIVED POLIOVIRUS; CERTIFICATION; POLIOMYELITIS; ERADICATION; CIRCULATION		World Hlth Org, Global Polio Eradicat Initiat, Geneva 27, Switzerland	World Health Organization	Aylward, RB (corresponding author), World Hlth Org, Global Polio Eradicat Initiat, Geneva 27, Switzerland.	aylwardb@who.int						[Anonymous], 2000, MMWR Recomm Rep, V49, P1; ASTURIAS EJ, UNPUB; AYLWARD RB, 2004, NEW GENERATION VACCI, P145; *CDC, 2004, MMWR-MORBID MORTAL W, V53, P1113; Debanne SM, 1998, MATH BIOSCI, V150, P83, DOI 10.1016/S0025-5564(98)00007-8; *DEP VACC BIOL, 2002, WHOVB0311 DEP VACC B; Fine PEM, 2004, B WORLD HEALTH ORGAN, V82, P47; FINE PEM, 2001, DEV BIOL SERIES, V105; Halsey NA, 2004, B WORLD HEALTH ORGAN, V82, P3; Henderson DA, 2001, CLIN INFECT DIS, V33, P1057, DOI 10.1086/323808; HENNESSEY KA, UNPUB; Heymann DL, 2005, NATURE, V434, P699, DOI 10.1038/434699a; Kew O, 2002, SCIENCE, V296, P356, DOI 10.1126/science.1068284; Kew OM, 2004, B WORLD HEALTH ORGAN, V82, P16; MacLennan C, 2004, LANCET, V363, P1509, DOI 10.1016/S0140-6736(04)16150-3; *PAHO, 1994, FIN REP INT COMM CER; Rotz LD, 2002, EMERG INFECT DIS, V8, P225, DOI 10.3201/eid0802.010164; Rousset D, 2003, EMERG INFECT DIS, V9, P885; Samba E, 2004, NEW ENGL J MED, V350, P645, DOI 10.1056/NEJMp038210; Sangrujee N, 2004, B WORLD HEALTH ORGAN, V82, P9; Shimizu H, 2004, J VIROL, V78, P13512, DOI 10.1128/JVI.78.24.13512-13521.2004; Smith J, 2004, B WORLD HEALTH ORGAN, V82, P24; Sutter RW, 2003, VACCINES, P651; *TCG, 2002, INT M TECHN CONS GRO; Tebbens RJD, 2005, AM J EPIDEMIOL, V162, P358, DOI 10.1093/aje/kwi206; TEBBENS RJD, UNPUB RISKS PAR DIS; *WHO, 2004, IMM VACC BIOL VACC I; *WHO, 2003, WKLY EPIDEMIOL REC, V78, P241; *WHO, 1997, 2 M GLOB COMM CERT P; *WHO, POL CAS COUNTS; *WHO, 1999, POL ER; *WHO, 2004, REP INF CONS ID MAN; *WHO, 2004, WKLY EPIDEMIOL REC, V79, P401; *WHO, DEC INSTR ASS NOT EV; *WHO TECHN CONS GR, 2001, CLIN INFECT DIS, V34, P72; Yang CF, 2003, J VIROL, V77, P8366, DOI 10.1128/JVI.77.15.8366-8377.2003; 1998, WKLY EPIDEMIOL REC, V73, P113	37	51	53	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					625	626		10.1126/science.1115547	http://dx.doi.org/10.1126/science.1115547			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254173				2022-12-28	WOS:000232997700024
J	Kuo, YH; Lee, YK; Ge, YS; Ren, S; Roth, JE; Kamins, TI; Miller, DAB; Harris, JS				Kuo, YH; Lee, YK; Ge, YS; Ren, S; Roth, JE; Kamins, TI; Miller, DAB; Harris, JS			Strong quantum-confined Stark effect in germanium quantum-well structures on silicon	NATURE			English	Article							ELECTROABSORPTION MODULATORS; OPTICAL INTERCONNECTS; BAND PARAMETERS; TECHNOLOGY; SIGE; ALLOYS; SHIFT	Silicon is the dominant semiconductor for electronics, but there is now a growing need to integrate such components with optoelectronics for telecommunications and computer interconnections(1). Silicon-based optical modulators have recently been successfully demonstrated(2,3); but because the light modulation mechanisms in silicon(4) are relatively weak, long ( for example, several millimetres) devices(2) or sophisticated high-quality-factor resonators(3) have been necessary. Thin quantum-well structures made from III-V semiconductors such as GaAs, InP and their alloys exhibit the much stronger quantum-confined Stark effect (QCSE) mechanism(5), which allows modulator structures with only micrometres of optical path length(6,7). Such III-V materials are unfortunately difficult to integrate with silicon electronic devices. Germanium is routinely integrated with silicon in electronics(8), but previous silicon - germanium structures have also not shown strong modulation effects(9-13). Here we report the discovery of the QCSE, at room temperature, in thin germanium quantum-well structures grown on silicon. The QCSE here has strengths comparable to that in III-V materials. Its clarity and strength are particularly surprising because germanium is an indirect gap semiconductor; such semiconductors often display much weaker optical effects than direct gap materials ( such as the III-V materials typically used for optoelectronics). This discovery is very promising for small, high-speed(14), low-power(15-17) optical output devices fully compatible with silicon electronics manufacture.	Stanford Univ, Dept Elect Engn, Solid State & Photon Lab, Stanford, CA 94305 USA; Hewlett Packard Labs, Quantum Sci Res, Palo Alto, CA 94304 USA	Stanford University; Hewlett-Packard	Kuo, YH (corresponding author), Stanford Univ, Dept Elect Engn, Solid State & Photon Lab, Stanford, CA 94305 USA.	yhkuo@stanford.edu	Miller, David A/C-4829-2009	Miller, David A/0000-0002-3633-7479				Arad U, 2003, IEEE PHOTONIC TECH L, V15, P1531, DOI 10.1109/LPT.2003.818663; Cho H, 2004, J LIGHTWAVE TECHNOL, V22, P2021, DOI 10.1109/JLT.2004.833531; Cressler JD, 1998, IEEE T MICROW THEORY, V46, P572, DOI 10.1109/22.668665; Crow GC, 2000, SEMICOND SCI TECH, V15, P7, DOI 10.1088/0268-1242/15/1/302; DRESSELHAUS G, 1955, PHYS REV, V98, P368, DOI 10.1103/PhysRev.98.368; Galdin S, 2000, SEMICOND SCI TECH, V15, P565, DOI 10.1088/0268-1242/15/6/314; GOOSSEN KW, 1991, APPL PHYS LETT, V59, P1829, DOI 10.1063/1.106212; Helman NC, 2005, IEEE J SEL TOP QUANT, V11, P338, DOI 10.1109/JSTQE.2005.845613; Kibar O, 1999, J LIGHTWAVE TECHNOL, V17, P546, DOI 10.1109/50.754783; Krishnamoorthy AV, 1996, IEEE J SEL TOP QUANT, V2, P55, DOI 10.1109/2944.541875; LAWAETZ P, 1971, PHYS REV B, V4, P3460, DOI 10.1103/PhysRevB.4.3460; Lewen R, 2004, J LIGHTWAVE TECHNOL, V22, P172, DOI 10.1109/JLT.2003.822829; Li C, 2000, J APPL PHYS, V87, P8195, DOI 10.1063/1.373518; Liu AS, 2004, NATURE, V427, P615, DOI 10.1038/nature02310; Liu CP, 2003, IEICE T ELECTRON, VE86C, P1281; Maslov AV, 2003, J APPL PHYS, V93, P10131, DOI 10.1063/1.1574590; MILLER DAB, 1984, PHYS REV LETT, V53, P2173, DOI 10.1103/PhysRevLett.53.2173; Miller DAB, 2000, P IEEE, V88, P728, DOI 10.1109/5.867687; MILLER DAB, 1985, PHYS REV B, V32, P1043, DOI 10.1103/PhysRevB.32.1043; Miyake Y, 1996, APPL PHYS LETT, V68, P2097, DOI 10.1063/1.115596; PARK JS, 1990, J VAC SCI TECHNOL B, V8, P217, DOI 10.1116/1.584813; Qasaimeh O, 1998, IEEE PHOTONIC TECH L, V10, P807, DOI 10.1109/68.681491; RIEGER MM, 1993, PHYS REV B, V48, P14276, DOI 10.1103/PhysRevB.48.14276; Schaffler F, 1997, SEMICOND SCI TECH, V12, P1515, DOI 10.1088/0268-1242/12/12/001; SCHMITTRINK S, 1990, OPT LETT, V15, P60, DOI 10.1364/OL.15.000060; SOREF RA, 1987, IEEE J QUANTUM ELECT, V23, P123, DOI 10.1109/JQE.1987.1073206; Xu QF, 2005, NATURE, V435, P325, DOI 10.1038/nature03569; Yakimov AI, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.125318	28	639	662	4	152	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1334	1336		10.1038/nature04204	http://dx.doi.org/10.1038/nature04204			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251959				2022-12-28	WOS:000232829100048
J	Mann, JJ				Mann, JJ			Drug therapy - The medical management of depression	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SEROTONIN-REUPTAKE INHIBITORS; TREATMENT-RESISTANT-DEPRESSION; PLACEBO-CONTROLLED TRIAL; LONG-TERM TREATMENT; DOUBLE-BLIND; MAJOR DEPRESSION; ANTIDEPRESSANT MEDICATION; PHARMACOLOGICAL-TREATMENT; AFFECTIVE-DISORDERS; PRIMARY-CARE		Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Neurosci, New York, NY 10032 USA	Columbia University; New York State Psychiatry Institute	Mann, JJ (corresponding author), Columbia Univ Coll Phys & Surg, New York State Psychiat Inst, Dept Neurosci, 1051 Riverside Dr,Box 42, New York, NY 10032 USA.	jjm@columbia.edu			NIMH NIH HHS [MH48514, MH40695] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH040695, R01MH048514] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Adli M, 2002, J CLIN PSYCHIAT, V63, P782, DOI 10.4088/JCP.v63n0906; *AG HLTH CAR POL R, 1999, AHCPR PUBL; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; AMSTERDAM JD, 1994, PROG NEURO-PSYCHOPH, V18, P243, DOI 10.1016/0278-5846(94)90057-4; Ananth J, 2004, CURR PHARM DESIGN, V10, P2219, DOI 10.2174/1381612043384088; Anderson IM, 2000, J AFFECT DISORDERS, V58, P19, DOI 10.1016/S0165-0327(99)00092-0; Angst F, 2002, J AFFECT DISORDERS, V68, P167, DOI 10.1016/S0165-0327(01)00377-9; [Anonymous], 2000, Am J Psychiatry, V157, P1; Ansorge MS, 2004, SCIENCE, V306, P879, DOI 10.1126/science.1101678; Barbosa L, 2003, J CLIN PSYCHIAT, V64, P403, DOI 10.4088/JCP.v64n0407; Bauer M, 1999, J CLIN PSYCHOPHARM, V19, P427, DOI 10.1097/00004714-199910000-00006; Bauer M, 2003, EUR ARCH PSY CLIN N, V253, P132, DOI 10.1007/s00406-003-0430-9; Belmaker RH, 2004, NEW ENGL J MED, V351, P476, DOI 10.1056/NEJMra035354; Benkert O, 2002, HUM PSYCHOPHARM CLIN, V17, pS23, DOI 10.1002/hup.397; Bennett AJ, 2002, MOL PSYCHIATR, V7, P118, DOI 10.1038/sj/mp/4000949; Bertolino A, 2003, BIOL PSYCHIAT, V53, P906, DOI 10.1016/S0006-3223(02)01911-X; Bottlender R, 2001, J AFFECT DISORDERS, V63, P79, DOI 10.1016/S0165-0327(00)00172-5; Bowden CL, 2000, ARCH GEN PSYCHIAT, V57, P481, DOI 10.1001/archpsyc.57.5.481; Brannan SK, 2005, J PSYCHIATR RES, V39, P43, DOI 10.1016/j.jpsychires.2004.04.011; Briley M, 2004, HUM PSYCHOPHARM CLIN, V19, pS21, DOI 10.1002/hup.621; Carney S, 2003, LANCET, V361, P799; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Ciechanowski PS, 2000, ARCH INTERN MED, V160, P3278, DOI 10.1001/archinte.160.21.3278; Cohen D, 2004, PHARMACOPSYCHIATRY, V37, P1, DOI 10.1055/s-2004-815468; COYNE JC, 1994, GEN HOSP PSYCHIAT, V16, P267, DOI 10.1016/0163-8343(94)90006-X; DeBattista C, 2003, J CLIN PSYCHOPHARM, V23, P27, DOI 10.1097/00004714-200302000-00005; DEMONTIGNY C, 1994, INT CLIN PSYCHOPHARM, V9, P31, DOI 10.1097/00004850-199406002-00006; Demyttenaere K, 2005, INT J NEUROPSYCHOPH, V8, P93, DOI 10.1017/S1461145704004729; DeRubeis RJ, 1999, AM J PSYCHIAT, V156, P1007; Detke MJ, 2004, EUR NEUROPSYCHOPHARM, V14, P457, DOI 10.1016/j.euroneuro.2004.01.002; Fava M, 2003, J CLIN PSYCHIAT, V64, P13; Feiger A, 1996, J CLIN PSYCHIAT, V57, P53; Feighner J, 1998, J CLIN PSYCHIAT, V59, P246, DOI 10.4088/JCP.v59n0508; Furukawa TA, 2001, J AFFECT DISORDERS, V65, P173, DOI 10.1016/S0165-0327(00)00254-8; Geddes JR, 2003, LANCET, V361, P653, DOI 10.1016/S0140-6736(03)12599-8; GEDDES JR, 2000, COCHRANE DB SYST REV, V2; Gibbons RD, 2005, ARCH GEN PSYCHIAT, V62, P165, DOI 10.1001/archpsyc.62.2.165; Gijsman HJ, 2004, AM J PSYCHIAT, V161, P1537, DOI 10.1176/appi.ajp.161.9.1537; Goldman LS, 1999, J GEN INTERN MED, V14, P569, DOI 10.1046/j.1525-1497.1999.03478.x; Goldstein DJ, 2005, PAIN, V116, P109, DOI 10.1016/j.pain.2005.03.029; Goldstein DJ, 2004, J CLIN PSYCHOPHARM, V24, P389, DOI 10.1097/01.jcp.0000132448.65972.d9; Goodwin F, 1990, MANIC DEPRESSIVE ILL; Greco T, 2004, J GEN INTERN MED, V19, P813, DOI 10.1111/j.1525-1497.2004.30531.x; Guelfi JD, 2001, J CLIN PSYCHOPHARM, V21, P425, DOI 10.1097/00004714-200108000-00010; Hariri AR, 2005, ARCH GEN PSYCHIAT, V62, P146, DOI 10.1001/archpsyc.62.2.146; Hawley CJ, 1998, J AFFECT DISORDERS, V47, P87, DOI 10.1016/S0165-0327(97)00124-9; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; Henry C, 2001, J CLIN PSYCHIAT, V62, P249, DOI 10.4088/JCP.v62n0406; Hirschfield RMA, 1997, JAMA-J AM MED ASSOC, V277, P333, DOI 10.1001/jama.277.4.333; Jiang W, 2002, CNS DRUGS, V16, P111, DOI 10.2165/00023210-200216020-00004; JOHNSON J, 1991, ARCH GEN PSYCHIAT, V48, P1075; Jorge RE, 2003, AM J PSYCHIAT, V160, P1823, DOI 10.1176/appi.ajp.160.10.1823; Judd LL, 1998, ARCH GEN PSYCHIAT, V55, P694, DOI 10.1001/archpsyc.55.8.694; Judd LL, 2000, AM J PSYCHIAT, V157, P1501, DOI 10.1176/appi.ajp.157.9.1501; Kane JM, 2002, AM J PSYCHIAT, V159, P1, DOI 10.1176/appi.ajp.159.1.1; Katona C, 2000, EUR NEUROPSYCHOPHARM, V10, pS427, DOI 10.1016/S0924-977X(00)00109-7; Keck PE, 2005, BIPOLAR DISORD, V7, P34, DOI 10.1111/j.1399-5618.2005.00213.x; KECK PE, 2004, TREATMENT BIPOLAR DI; Keller MB, 2001, J AM ACAD CHILD PSY, V40, P762, DOI 10.1097/00004583-200107000-00010; KELLER MB, 1986, AM J PSYCHIAT, V143, P24; Kendler KS, 1997, BRIT J PSYCHIAT, V170, P541, DOI 10.1192/bjp.170.6.541; Kennedy SH, 2003, BIPOLAR DISORD, V5, P36, DOI 10.1111/j.1399-2406.2003.00058.x; KESSLER RC, 1994, ARCH GEN PSYCHIAT, V51, P8; Kroenke K, 2001, JAMA-J AM MED ASSOC, V286, P2947, DOI 10.1001/jama.286.23.2947; Kroenke K, 1994, Arch Fam Med, V3, P774; Lotufo-Neto F, 1999, NEUROPSYCHOPHARMACOL, V20, P226, DOI 10.1016/S0893-133X(98)00075-X; MacGillivray S, 2003, BMJ-BRIT MED J, V326, P1014, DOI 10.1136/bmj.326.7397.1014; MANN JJ, IN PRESS BASIC NEURO; March J, 2004, JAMA-J AM MED ASSOC, V292, P807; Martin A, 2004, ARCH PEDIAT ADOL MED, V158, P773, DOI 10.1001/archpedi.158.8.773; Masan Prakash S, 2004, Ann Clin Psychiatry, V16, P3, DOI 10.1080/10401230490281410; McEwen BS, 2000, BIOL PSYCHIAT, V48, P721, DOI 10.1016/S0006-3223(00)00964-1; Melfi CA, 1998, ARCH GEN PSYCHIAT, V55, P1128, DOI 10.1001/archpsyc.55.12.1128; Milak MS, 2005, ARCH GEN PSYCHIAT, V62, P397, DOI 10.1001/archpsyc.62.4.397; Misri S, 2000, CAN FAM PHYSICIAN, V46, P626; Montejo AL, 2001, J CLIN PSYCHIAT, V62, P10; Montgomery SA, 1998, INT CLIN PSYCHOPHARM, V13, P63, DOI 10.1097/00004850-199803000-00002; Mueller TI, 1999, AM J PSYCHIAT, V156, P1000; Mulder RT, 2003, J AFFECT DISORDERS, V76, P143, DOI 10.1016/S0165-0327(02)00083-6; Narrow WE, 2002, ARCH GEN PSYCHIAT, V59, P115, DOI 10.1001/archpsyc.59.2.115; Nieuwstraten CE, 2001, ANN PHARMACOTHER, V35, P1608; NOBLER MS, 2001, CONT PSYCHIAT, P425; Olfson M, 2003, ARCH GEN PSYCHIAT, V60, P978, DOI 10.1001/archpsyc.60.9.978; Pampallona S, 2004, ARCH GEN PSYCHIAT, V61, P714, DOI 10.1001/archpsyc.61.7.714; PARSEY RV, IN PRESS AM J PSYCHI; PEET M, 1994, BRIT J PSYCHIAT, V164, P549, DOI 10.1192/bjp.164.4.549; Peretti S, 2000, ACTA PSYCHIAT SCAND, V101, P17, DOI 10.1111/j.1600-0447.2000.tb10944.x; PRIEN RF, 1984, ARCH GEN PSYCHIAT, V41, P1096; Prudic J, 2004, BIOL PSYCHIAT, V55, P301, DOI 10.1016/j.biopsych.2003.09.015; QUITKIN FM, 1993, BRIT J PSYCHIAT, V163, P30, DOI 10.1192/S0007125000292465; Reynolds CF, 1999, JAMA-J AM MED ASSOC, V281, P39, DOI 10.1001/jama.281.1.39; Rothschild AJ, 2004, J CLIN PSYCHOPHARM, V24, P365, DOI 10.1097/01.jcp.0000130557.08996.7a; Rowbotham MC, 2005, PAIN, V113, P248, DOI 10.1016/j.pain.2004.11.021; Rowbotham MC, 2004, PAIN, V110, P697, DOI 10.1016/j.pain.2004.05.010; Rush AJ, 1998, BIOL PSYCHIAT, V44, P3, DOI 10.1016/S0006-3223(98)00092-4; Rush AJ, 2001, TREATMENT PSYCHIAT D, P1417; SACHS GS, 1994, J CLIN PSYCHIAT, V55, P391; Sackeim HA, 2001, JAMA-J AM MED ASSOC, V285, P1299, DOI 10.1001/jama.285.10.1299; Schatzberg AF, 1997, J CLIN PSYCHIAT, V58, P5; Sheline YI, 2003, AM J PSYCHIAT, V160, P1516, DOI 10.1176/appi.ajp.160.8.1516; Shelton RC, 2001, AM J PSYCHIAT, V158, P131, DOI 10.1176/appi.ajp.158.1.131; Simon GE, 1996, JAMA-J AM MED ASSOC, V275, P1897, DOI 10.1001/jama.275.24.1897; Simon JS, 2004, J PSYCHIATR RES, V38, P451, DOI 10.1016/j.jpsychires.2004.04.001; Simon JS, 2004, J PSYCHIATR RES, V38, P249, DOI 10.1016/j.jpsychires.2003.10.004; Smith D, 2002, BRIT J PSYCHIAT, V180, P396, DOI 10.1192/bjp.180.5.396; SPIKER DG, 1985, AM J PSYCHIAT, V142, P430; Stahl SM, 2000, BIOL PSYCHIAT, V48, P894, DOI 10.1016/S0006-3223(00)00957-4; Stahl SM, 2002, BIOL PSYCHIAT, V52, P1166, DOI 10.1016/S0006-3223(02)01425-7; STARK C, 1995, BRIT MED J, V311, P1368, DOI 10.1136/bmj.311.7016.1368c; Suri R, 2005, ARCH WOMEN MENT HLTH, V8, P55, DOI 10.1007/s00737-005-0071-2; Swenson JR, 2003, AM J CARDIOL, V92, P1271, DOI 10.1016/j.amjcard.2003.08.006; Taylor CB, 2005, ARCH GEN PSYCHIAT, V62, P792, DOI 10.1001/archpsyc.62.7.792; Taylor FB, 2003, DEPRESS ANXIETY, V18, P83, DOI 10.1002/da.10115; THASE ME, 1992, AM J PSYCHIAT, V149, P195; Thase ME, 1997, J CLIN PSYCHIAT, V58, P23; Thase ME, 2001, BRIT J PSYCHIAT, V178, P234, DOI 10.1192/bjp.178.3.234; ThiesFlechtner K, 1996, PHARMACOPSYCHIATRY, V29, P103, DOI 10.1055/s-2007-979553; Tohen M, 2002, ARCH GEN PSYCHIAT, V59, P91; Tohen M, 2000, ARCH GEN PSYCHIAT, V57, P841, DOI 10.1001/archpsyc.57.9.841; Tohen M, 2004, ARCH GEN PSYCHIAT, V61, P176; Tohen M, 2003, ARCH GEN PSYCHIAT, V60, P1079, DOI 10.1001/archpsyc.60.11.1079; Trivedi MH, 2004, ARCH GEN PSYCHIAT, V61, P669, DOI 10.1001/archpsyc.61.7.669; Vinkers DJ, 2003, JAMA-J AM MED ASSOC, V290, P2942, DOI 10.1001/jama.290.22.2942; Wecker L, 2003, BIOL PSYCHIAT, V54, P1099, DOI 10.1016/S0006-3223(02)01892-9; Wisner KL, 1999, JAMA-J AM MED ASSOC, V282, P1264, DOI 10.1001/jama.282.13.1264; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Yatham LN, 2004, J CLIN PSYCHIAT, V65, P28; Zisook S, 2004, PSYCHIAT RES, V129, P127, DOI 10.1016/j.psychres.2004.07.004	128	285	298	0	41	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1819	1834		10.1056/NEJMra050730	http://dx.doi.org/10.1056/NEJMra050730			16	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251538				2022-12-28	WOS:000232813000010
J	Steuber, T; Rauch, M; Masse, JP; Graaf, J; Malkoc, M				Steuber, T; Rauch, M; Masse, JP; Graaf, J; Malkoc, M			Low-latitude seasonality of Cretaceous temperatures in warm and cold episodes	NATURE			English	Article							SEA-SURFACE TEMPERATURES; BIVALVES	The Cretaceous period is generally considered to have been a time of warm climate(1-6). Evidence for cooler episodes exists, particularly in the early Cretaceous period(6-8), but the timing and significance of these cool episodes are not well constrained. The seasonality of temperatures is important for constraining equator-to-pole temperature gradients and may indicate the presence of polar ice sheets; however, reconstructions of Cretaceous sea surface temperatures are predominantly based on the oxygen isotopic composition of planktonic foraminifera(1-4) that do not provide information about such intra-annual variations. Here we present intra-shell variations in delta O-18 values of rudist bivalves (Hippuritoidea) from palaeolatitudes between 8 degrees and 31 degrees N, which record the evolution of the seasonality of Cretaceous sea surface temperatures in detail. We find high maximum temperatures (, 35 to 37 degrees C) and relatively low seasonal variability (< 12 degrees C) between 20 degrees and 30 degrees N during the warmer Cretaceous episodes. In contrast, during the cooler episodes our data show seasonal sea surface temperature variability of up to 18 degrees C near 25 degrees N, comparable to the range found today. Such a large seasonal variability is compatible with the existence of polar ice sheets.	Ruhr Univ Bochum, Inst Geol Mineral & Geophys, D-44801 Bochum, Germany; Univ Aix Marseille 1, Ctr Sedimentol Paleontol, F-13331 Marseille, France; Vrije Univ Amsterdam, Dept Earth & Life Sci, NL-1081 HV Amsterdam, Netherlands	Ruhr University Bochum; UDICE-French Research Universities; Aix-Marseille Universite; Vrije Universiteit Amsterdam	Steuber, T (corresponding author), Ruhr Univ Bochum, Inst Geol Mineral & Geophys, D-44801 Bochum, Germany.	thomas.steuber@ruhr-uni-bochum.de	Steuber, Thomas/G-7692-2011	Steuber, Thomas/0000-0003-3342-9885				ANDERSON TF, 1983, SOC EC PALEONT MINER, V10; [Anonymous], CLIMATE MODES PHANER; Camoin G., 1993, ATLAS TETHYS PALAEOE; Clarke LJ, 1999, GEOLOGY, V27, P699, DOI 10.1130/0091-7613(1999)027<0699:NOIEFL>2.3.CO;2; Crowley TJ, 2000, WARM CLIMATES EARTH, P50, DOI DOI 10.1017/CBO9780511564512.004; DeConto R.M., 2000, WARM CLIMATES EARTH, P21; GILI E, 1995, PALAEOGEOGR PALAEOCL, V118, P245, DOI 10.1016/0031-0182(95)00006-X; GRADSTEIN FM, 1994, J GEOPHYS RES-SOL EA, V99, P24051, DOI 10.1029/94JB01889; Huber BT, 2002, GEOLOGY, V30, P123, DOI 10.1130/0091-7613(2002)030<0123:DSPROE>2.0.CO;2; Ivany LC, 2004, J SEDIMENT RES, V74, P7, DOI 10.1306/052803740007; Jenkyns HC, 2004, NATURE, V432, P888, DOI 10.1038/nature03143; Kemper E., 1987, Geologisches Jahrbuch Reihe A, V96, P5; Lecuyer C, 2004, CHEM GEOL, V213, P293, DOI 10.1016/j.chemgeo.2004.02.001; MASSE JP, 1993, ATLAS ETHYS PALAEOEN; McArthur JM, 2001, J GEOL, V109, P155, DOI 10.1086/319243; Norris RD, 2002, GEOLOGY, V30, P299, DOI 10.1130/0091-7613(2002)030<0299:JTTTIT>2.0.CO;2; Obradovich J.D., 1993, GEOL ASSOC CAN SPEC, P379; Pearson PN, 2001, NATURE, V413, P481, DOI 10.1038/35097000; Poulsen CJ, 2004, NATURE, V432, P814, DOI 10.1038/432814a; Poulsen CJ, 1999, GEOL S AM S, P73; Poulsen CJ, 1999, PALEOCEANOGRAPHY, V14, P679, DOI 10.1029/1999PA900034; Price GD, 1999, EARTH-SCI REV, V48, P183, DOI 10.1016/S0012-8252(99)00048-3; Puceat E, 2003, PALEOCEANOGRAPHY, V18, DOI 10.1029/2002PA000823; Schouten S, 2003, GEOLOGY, V31, P1069, DOI 10.1130/G19876.1; SPICER RA, 2003, CRETACEOUS WORLD; Steuber T, 2005, MAR GEOL, V217, P199, DOI 10.1016/j.margeo.2005.02.012; Steuber T, 1999, INT J EARTH SCI, V88, P551, DOI 10.1007/s005310050284; WEFER G, 1991, MAR GEOL, V100, P207, DOI 10.1016/0025-3227(91)90234-U; Wilson PA, 2001, NATURE, V412, P425, DOI 10.1038/35086553; Wilson PA, 1996, GEOLOGY, V24, P555, DOI 10.1130/0091-7613(1996)024<0555:ESSTFT>2.3.CO;2	30	183	188	2	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1341	1344		10.1038/nature04096	http://dx.doi.org/10.1038/nature04096			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251961				2022-12-28	WOS:000232829100050
J	Belda, FJ; Aguilera, L; de la Asuncion, JG; Alberti, J; Vicente, R; Ferrandiz, L; Rodriguez, R; Company, R; Sessler, DI; Aguilar, G; Botello, SG; Orti, R				Belda, FJ; Aguilera, L; de la Asuncion, JG; Alberti, J; Vicente, R; Ferrandiz, L; Rodriguez, R; Company, R; Sessler, DI; Aguilar, G; Botello, SG; Orti, R		Spanish Reduccion Tasa Infeccion Q	Supplemental perioperative oxygen and the risk of surgical wound infection - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							COLORECTAL SURGERY; SITE INFECTION; TISSUE OXYGEN; SMOKING; REDUCE; COMPLICATIONS; PROPHYLAXIS; INDEX	Context Supplemental perioperative oxygen has been variously reported to halve or double the risk of surgical wound infection, Objective To test the hypothesis that supplemental oxygen reduces infection risk in patients following colorectal surgery. Design, Setting, and Patients A double-blind, randomized controlled trial of 300 patients aged 18 to 80 years who underwent elective colorectal surgery in 14 Spanish hospitals from March 1, 2003, to October 31, 2004. Wound infections were diagnosed by blinded investigators using Centers for Disease Control and Prevention criteria. Baseline patient characteristics, anesthetic treatment, and potential confounding factors were recorded. Interventions Patients were randomly assigned to either 30% or 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized. Main Outcome Measures Any surgical site infection (SSI); secondary outcomes included return of bowel function and ability to tolerate solid food, ambulation, suture removal, and duration of hospitalization. Results A total of 143 patients received 30% perioperative oxygen and 148 received 80% perioperative oxygen. Surgical site infection occurred in 35 patients (24.4%) administered 30% FIO2 and in 22 patients (14.9%) administered 80% FIO2 (P=.04). The risk of SSI was 39% lower in the 80% FIO2 group (relative risk [RR], 0.61; 95% confidence interval [CI], 0.38-0.98) vs the 30% FIO2 group. After adjustment for important covariates, the RR of infection in patients administered supplemental oxygen was 0.46 (95% Cl, 0.22-0.95; P=.04). None of the secondary outcomes varied significantly between the 2 treatment groups. Conclusions Patients receiving supplemental inspired oxygen had a significant reduction in the risk of wound infection. Supplemental oxygen appears to be an effective intervention to reduce SSI in patients undergoing colon or rectal surgery. Trial Registration ClinicalTrials.gov Identifier: NCT00235456.	Hosp Clin Univ Valencia, Dept Anesthesiol & Crit Care, Valencia 46010, Spain; Hosp Clin Univ Valencia, Dept Epidemiol & Publ Hlth, Valencia 46010, Spain; Hosp Clin Univ Valencia, Dept Surg, Valencia 46010, Spain; Hosp Galdakao, Dept Anesthesiol & Crit Care, Bizkala, Spain; Hosp Univ Princesa, Dept Anesthesiol & Crit Care, Madrid, Spain; Hosp Univ La Fe, Dept Anesthesiol & Crit Care, Valencia, Spain; Hosp Univ Dr Peset, Dept Anesthesiol & Crit Care, Valencia, Spain; Hosp Univ Virgen Macarena, Dept Anesthesiol & Crit Care, Seville, Spain; Hosp Gen Univ, Dept Anesthesiol & Crit Care, Alicante, Spain; Cleveland Clin Fdn, Dept Outcomes Res, Cleveland, OH 44195 USA; Univ Louisville, Outcomes Res Inst, Louisville, KY 40292 USA	Hospital Clinic Universitari de Valencia; Hospital Clinic Universitari de Valencia; Hospital Clinic Universitari de Valencia; Galdakao Hospital; Hospital de La Princesa; Hospital Universitari i Politecnic La Fe; Hospital Universitario Virgen Macarena; General University Hospital of Alicante; Cleveland Clinic Foundation; University of Louisville	Belda, FJ (corresponding author), Hosp Clin Univ Valencia, Dept Anesthesiol & Crit Care, Ave Blasco Ibanez 17, Valencia 46010, Spain.	fjbelda@uv.es	Lucas, Rafael Manuel Ortí/K-4583-2012; Sessler, Daniel/D-3504-2011	Lucas, Rafael Manuel Ortí/0000-0003-2211-7413; Sessler, Daniel/0000-0001-9932-3077	NIGMS NIH HHS [GM 061655] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Allen DB, 1997, ARCH SURG-CHICAGO, V132, P991; American Society of Anesthesiologists, ASA PHYS STAT CLASS; BURKE JF, 1961, SURGERY, V50, P161; BYRNE DJ, 1989, BIOMED PHARMACOTHER, V43, P669, DOI 10.1016/0753-3322(89)90085-1; CULVER DH, 1991, AM J MED, V91, pS152, DOI 10.1016/0002-9343(91)90361-Z; Delgado-Rodriguez M, 2003, INFECT CONT HOSP EP, V24, P37, DOI 10.1086/502113; Fawcett A, 1996, GUT, V38, P714, DOI 10.1136/gut.38.5.714; Greif R, 2000, NEW ENGL J MED, V342, P161, DOI 10.1056/NEJM200001203420303; HALEY RW, 1980, AM J EPIDEMIOL, V111, P543, DOI 10.1093/oxfordjournals.aje.a112933; HALEY RW, 1985, AM J EPIDEMIOL, V121, P206, DOI 10.1093/oxfordjournals.aje.a113991; Hopf HW, 1997, ARCH SURG-CHICAGO, V132, P997; HORAN TC, 1992, INFECT CONT HOSP EP, V13, P606; Ishida H, 2001, SURG TODAY, V31, P979, DOI 10.1007/s005950170006; JENSEN JA, 1991, ARCH SURG-CHICAGO, V126, P1131; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; Poulsen KB, 1996, J HOSP INFECT, V33, P207, DOI 10.1016/S0195-6701(96)90004-3; Pryor KO, 2004, JAMA-J AM MED ASSOC, V291, P79, DOI 10.1001/jama.291.1.79; Sessler DI, 2000, NEW ENGL J MED, V342, P1613; STOPINSKI J, 1993, J CHIR-PARIS, V130, P422; Todorov Anton T, 2002, Folia Med (Plovdiv), V44, P32; van Geldere D, 2002, J AM COLL SURGEONS, V194, P40, DOI 10.1016/S1072-7515(01)01131-0; WILSON APR, 1986, LANCET, V1, P311	22	363	381	2	18	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2035	2042		10.1001/jama.294.16.2035	http://dx.doi.org/10.1001/jama.294.16.2035			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249417	Bronze			2022-12-28	WOS:000232778900023
J	Curtin, JA; Fridlyand, J; Kageshita, T; Patel, HN; Busam, KJ; Kutzner, H; Cho, KH; Aiba, S; Brocker, EB; LeBoit, PE; Pinkel, D; Bastian, BC				Curtin, JA; Fridlyand, J; Kageshita, T; Patel, HN; Busam, KJ; Kutzner, H; Cho, KH; Aiba, S; Brocker, EB; LeBoit, PE; Pinkel, D; Bastian, BC			Distinct sets of genetic alterations in melanoma	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COMPARATIVE GENOMIC HYBRIDIZATION; CUTANEOUS MELANOMA; MALIGNANT-MELANOMA; BRAF MUTATIONS; SEVERE SUNBURN; SKIN; TUMOR; RISK; NEVI; MICROARRAYS	Background: Exposure to ultraviolet light is a major causative factor in melanoma, although the relationship between risk and exposure is complex. We hypothesized that the clinical heterogeneity is explained by genetically distinct types of melanoma with different susceptibility to ultraviolet light. Methods: We compared genome-wide alterations in the number of copies of DNA and mutational status of BRAF and N-RAS in 126 melanomas from four groups in which the degree of exposure to ultraviolet light differs: 30 melanomas from skin with chronic sun-induced damage and 40 melanomas from skin without such damage; 36 melanomas from palms, soles, and subungual (acral) sites; and 20 mucosal melanomas. Results: We found significant differences in the frequencies of regional changes in the number of copies of DNA and mutation frequencies in BRAF among the four groups of melanomas. Samples could be correctly classified into the four groups with 70 percent accuracy on the basis of the changes in the number of copies of genomic DNA. In two-way comparisons, melanomas arising on skin with signs of chronic sun-induced damage and skin without such signs could be correctly classified with 84 percent accuracy. Acral melanoma could be distinguished from mucosal melanoma with 89 percent accuracy. Eighty-one percent of melanomas on skin without chronic sun-induced damage had mutations in BRAF or N-RAS; the majority of melanomas in the other groups had mutations in neither gene. Melanomas with wild-type BRAF or N-RAS frequently had increases in the number of copies of the genes for cyclin-dependent kinase 4 (CDK4) and cyclin D1 (CCND1), downstream components of the RAS-BRAF pathway. Conclusions: The genetic alterations identified in melanomas at different sites and with different levels of sun exposure indicate that there are distinct genetic pathways in the development of melanoma and implicate CDK4 and CCND1 as independent oncogenes in melanomas without mutations in BRAF or N-RAS.	Univ Calif San Francisco, Ctr Canc, Ctr Comprehens Canc, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Dermatol & Pathol, San Francisco, CA 94143 USA; Kumamoto Univ, Sch Med, Dept Dermatol, Kumamoto 860, Japan; Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10021 USA; DermPath, Friedrichshafen, Germany; Seoul Natl Univ, Coll Med, Dept Dermatol, Seoul, South Korea; Tohoku Univ, Grad Sch Med, Dept Dermatol, Sendai, Miyagi 980, Japan; Univ Wurzburg, Dept Dermatol, D-8700 Wurzburg, Germany	University of California System; University of California San Francisco; UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer Center; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Kumamoto University; Memorial Sloan Kettering Cancer Center; Seoul National University (SNU); Tohoku University; University of Wurzburg	Bastian, BC (corresponding author), Univ Calif San Francisco, Ctr Canc, Ctr Comprehens Canc, Box 0808, San Francisco, CA 94143 USA.	bastian@cc.ucsf.edu		Bastian, Boris/0000-0003-1836-6062; Curtin, John/0000-0001-6299-9110	NATIONAL CANCER INSTITUTE [R01CA094963, R33CA095300] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA094963, R33 CA95300] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ACKERMAN AB, 1980, HUM PATHOL, V11, P591, DOI 10.1016/S0046-8177(80)80069-4; ALBINO AP, 1989, ONCOGENE, V4, P1363; BALCH CM, 1992, SEMIN SURG ONCOL, V8, P400, DOI 10.1002/ssu.2980080611; Barnhill RL, 1997, CANCER, V79, P423; Barnhill RL, 1996, CANCER-AM CANCER SOC, V78, P427; Bastian BC, 2000, CANCER RES, V60, P1968; Bastian BC, 2003, AM J PATHOL, V163, P1765, DOI 10.1016/S0002-9440(10)63536-5; Bastian BC, 1998, CANCER RES, V58, P2170; Bastian BC, 2000, AM J PATHOL, V157, P967, DOI 10.1016/S0002-9440(10)64609-3; BERAL V, 1981, BRIT J CANCER, V44, P886, DOI 10.1038/bjc.1981.288; CLARK WH, 1969, CANCER RES, V29, P705; CLEVELAND WS, 1981, AM STAT, V35, P54, DOI 10.2307/2683591; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Fridlyand J, 2004, J MULTIVARIATE ANAL, V90, P132, DOI 10.1016/j.jmva.2004.02.008; Fridlyand J, PACKAGE ACGH; Lyons JF, 2001, ENDOCR-RELAT CANCER, V8, P219, DOI 10.1677/erc.0.0080219; MACKIE RM, 1982, BRIT J CANCER, V46, P955, DOI 10.1038/bjc.1982.307; Maldonado JL, 2003, J NATL CANCER I, V95, P1878, DOI 10.1093/jnci/djg123; Marks R, 2000, CLIN EXP DERMATOL, V25, P459, DOI 10.1046/j.1365-2230.2000.00693.x; MCGOVERN VJ, 1973, CANCER, V32, P1446, DOI 10.1002/1097-0142(197312)32:6<1446::AID-CNCR2820320623>3.0.CO;2-8; Noonan FP, 2001, NATURE, V413, P271, DOI 10.1038/35095108; Pinkel D, 1998, NAT GENET, V20, P207, DOI 10.1038/2524; Pollock PM, 2003, NAT GENET, V33, P19, DOI 10.1038/ng1054; Rivers JK, 2004, LANCET, V363, P728, DOI 10.1016/S0140-6736(04)15649-3; Sauter ER, 2002, CANCER RES, V62, P3200; Serrano M, 1996, CELL, V85, P27, DOI 10.1016/S0092-8674(00)81079-X; Snijders AM, 2003, ONCOGENE, V22, P4370, DOI 10.1038/sj.onc.1206482; Snijders AM, 2001, NAT GENET, V29, P263, DOI 10.1038/ng754; Tsao H, 2000, CANCER RES, V60, P1800; VAGERO D, 1986, BRIT J CANCER, V53, P507, DOI 10.1038/bjc.1986.80; van Dijk M, 2003, GENE CHROMOSOME CANC, V36, P151, DOI 10.1002/gcc.10156; Whiteman DC, 1998, INT J CANCER, V77, P843, DOI 10.1002/(SICI)1097-0215(19980911)77:6<843::AID-IJC8>3.0.CO;2-U; Whiteman DC, 2003, J NATL CANCER I, V95, P806, DOI 10.1093/jnci/95.11.806; Whiteman DC, 2001, CANCER CAUSE CONTROL, V12, P69, DOI 10.1023/A:1008980919928	34	1927	1988	3	105	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2135	2147		10.1056/NEJMoa050092	http://dx.doi.org/10.1056/NEJMoa050092			13	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291983				2022-12-28	WOS:000233288600006
J	Weir, EK; Lopez-Barneo, J; Buckler, KJ; Archer, SL				Weir, EK; Lopez-Barneo, J; Buckler, KJ; Archer, SL			Mechanisms of disease - Acute oxygen-sensing mechanisms	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							HYPOXIC PULMONARY VASOCONSTRICTION; SMOOTH-MUSCLE-CELLS; RAT CAROTID-BODY; HUMAN DUCTUS-ARTERIOSUS; GATED K+ CHANNELS; SENSITIVE POTASSIUM CHANNEL; CAPACITATIVE CA2+ ENTRY; LONG-TERM TREATMENT; CYCLIC ADP-RIBOSE; GP91 PHOX SUBUNIT		Minneapolis Vet Affairs Med Ctr, Dept Med, Minneapolis, MN USA; Univ Minnesota, Minneapolis, MN 55455 USA; Univ Sevilla, Hosp Virgen Rocio, Lab Invest Biomed, Seville, Spain; Univ Oxford, Dept Physiol, Oxford, England; Univ Alberta, Dept Med, Edmonton, AB, Canada; Univ Alberta, Dept Physiol, Edmonton, AB, Canada	US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System; University of Minnesota System; University of Minnesota Twin Cities; University of Sevilla; Virgen del Rocio University Hospital; University of Oxford; University of Alberta; University of Alberta	Weir, EK (corresponding author), VA Med Ctr, 111C,1 Vet Dr, Minneapolis, MN 55417 USA.	weirx002@umn.edu	IBIS, NEUROBIOLOGIA/O-9922-2015; Archer, Stephen L/C-3621-2013		NHLBI NIH HHS [R01 HL065322-04, R01 HL065322, R01 HL071115, R01-HL071115, R01-HL-65322] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL065322, R01HL071115] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Abe K, 2004, CIRC RES, V94, P385, DOI 10.1161/01.RES.0000111804.34509.94; Abenhaim L, 1996, NEW ENGL J MED, V335, P609, DOI 10.1056/NEJM199608293350901; ALZAMORACASTRO V, 1960, AM J CARDIOL, V5, P761, DOI 10.1016/0002-9149(60)90052-7; ANICHCOV SV, 1963, PHARM CAROTID BODY C; Archer SL, 2004, BIOL CHEM, V385, P205, DOI 10.1515/BC.2004.014; Archer SL, 2004, CIRC RES, V95, P308, DOI 10.1161/01.RES.0000137173.42723.fb; ARCHER SL, 1993, CIRC RES, V73, P1100, DOI 10.1161/01.RES.73.6.1100; Archer SL, 1999, P NATL ACAD SCI USA, V96, P7944, DOI 10.1073/pnas.96.14.7944; Archer SL, 1996, CIRC RES, V78, P431, DOI 10.1161/01.RES.78.3.431; Bartsch P, 2003, SWISS MED WKLY, V133, P377; Baysal BE, 2002, MICROSC RES TECHNIQ, V59, P256, DOI 10.1002/jemt.10200; BENOT AR, 1990, EUR J NEUROSCI, V2, P809, DOI 10.1111/j.1460-9568.1990.tb00473.x; Buckler KJ, 2000, J PHYSIOL-LONDON, V525, P135, DOI 10.1111/j.1469-7793.2000.00135.x; Buckler KJ, 1997, J PHYSIOL-LONDON, V498, P649, DOI 10.1113/jphysiol.1997.sp021890; BUCKLER KJ, 1994, J PHYSIOL-LONDON, V476, P423, DOI 10.1113/jphysiol.1994.sp020143; BURGHUBER OC, 1987, RESPIRATION, V52, P86, DOI 10.1159/000195309; Casalaz D, 2001, NEW ENGL J MED, V344, P457; CHANDER A, 1980, LIFE SCI, V26, P1935, DOI 10.1016/0024-3205(80)90624-4; Cherednichenko G, 2004, CIRC RES, V94, P478, DOI 10.1161/01.RES.0000115554.65513.7C; Conforti L, 2003, J IMMUNOL, V170, P695, DOI 10.4049/jimmunol.170.2.695; Cornfield DN, 1996, P NATL ACAD SCI USA, V93, P8089, DOI 10.1073/pnas.93.15.8089; Curtis TM, 2001, J PHYSIOL-LONDON, V532, P609, DOI 10.1111/j.1469-7793.2001.0609e.x; Dipp M, 2001, CIRC RES, V89, P77, DOI 10.1161/hh1301.093616; Dipp M, 2001, AM J PHYSIOL-LUNG C, V281, pL318, DOI 10.1152/ajplung.2001.281.2.L318; Donnelly DF, 2000, J APPL PHYSIOL, V88, P2296, DOI 10.1152/jappl.2000.88.6.2296; Dorrington KL, 1997, AM J PHYSIOL-HEART C, V273, pH1126, DOI 10.1152/ajpheart.1997.273.3.H1126; Fagan KA, 2004, AM J PHYSIOL-LUNG C, V287, pL656, DOI 10.1152/ajplung.00090.2003; Fu XW, 2000, P NATL ACAD SCI USA, V97, P4374, DOI 10.1073/pnas.97.8.4374; Fu XW, 2002, J PHYSIOL-LONDON, V539, P503, DOI 10.1113/jphysiol.2001.013071; Gauda Estelle B, 2004, Semin Neonatol, V9, P181, DOI 10.1016/j.siny.2003.11.002; Ghofrani HA, 2004, ANN INTERN MED, V141, P169, DOI 10.7326/0003-4819-141-3-200408030-00005; HALES CA, 1978, AM J MED, V65, P911, DOI 10.1016/0002-9343(78)90742-8; HambraeusJonzon K, 1997, ANESTHESIOLOGY, V86, P308, DOI 10.1097/00000542-199702000-00006; Hampl V, 2002, AM J PHYSIOL-HEART C, V283, pH2440, DOI 10.1152/ajpheart.01033.2001; Hogg DS, 2002, CARDIOVASC RES, V55, P349, DOI 10.1016/S0008-6363(02)00411-X; Hong ZG, 2004, AM J PHYSIOL-LUNG C, V286, pL531, DOI 10.1152/ajplung.00247.2003; HOWARD RB, 1987, AM J OBSTET GYNECOL, V157, P1261, DOI 10.1016/S0002-9378(87)80307-1; Hughes FM, 1997, J BIOL CHEM, V272, P30567, DOI 10.1074/jbc.272.48.30567; JIANG C, 1994, J PHYSIOL-LONDON, V481, P15, DOI 10.1113/jphysiol.1994.sp020415; Jovanovic S, 2003, AM J RESP CELL MOL, V28, P363, DOI 10.1165/rcmb.2002-0101OC; Kaplin AI, 1996, J NEUROSCI, V16, P2002; Kemp PJ, 2002, AM J RESP CRIT CARE, V166, pS17, DOI 10.1164/rccm.2206009; Krick S, 2001, AM J PHYSIOL-LUNG C, V281, pL887, DOI 10.1152/ajplung.2001.281.4.L887; Landsberg JW, 2004, NEWS PHYSIOL SCI, V19, P44, DOI 10.1152/nips.01457.2003; LAUWERYNS JM, 1977, CELL TISSUE RES, V182, P425; Leach RM, 2001, J PHYSIOL-LONDON, V536, P211, DOI 10.1111/j.1469-7793.2001.00211.x; Lopez-Barneo J, 2001, ANNU REV PHYSIOL, V63, P259, DOI 10.1146/annurev.physiol.63.1.259; LOPEZBARNEO J, 1988, SCIENCE, V241, P580, DOI 10.1126/science.2456613; MADDEN JA, 1992, AM J PHYSIOL, V263, pL384, DOI 10.1152/ajplung.1992.263.3.L384; Maggiorini M, 2001, CIRCULATION, V103, P2078; MCMURTRY IF, 1978, AM J PHYSIOL, V235, pH104, DOI 10.1152/ajpheart.1978.235.1.H104; McMurtry MS, 2004, CIRC RES, V95, P830, DOI 10.1161/01.RES.0000145360.16770.9f; Michelakis E, 2000, LANCET, V356, P134, DOI 10.1016/S0140-6736(00)02452-1; Michelakis ED, 2003, CIRCULATION, V108, P2066, DOI 10.1161/01.CIR.0000099502.17776.C2; Michelakis ED, 2002, CIRC RES, V90, P1307, DOI 10.1161/01.RES.0000024689.07590.C2; Michelakis ED, 2002, CIRC RES, V91, P478, DOI 10.1161/01.RES.0000035057.63303.D1; Michelakis ED, 2001, AM J PHYSIOL-LUNG C, V280, pL1138, DOI 10.1152/ajplung.2001.280.6.L1138; Michelakis EV, 2004, J MOL CELL CARDIOL, V37, P1119, DOI 10.1016/j.yjmcc.2004.09.007; Montoro RJ, 1996, J GEN PHYSIOL, V107, P133, DOI 10.1085/jgp.107.1.133; Morio Y, 2002, J APPL PHYSIOL, V92, P527, DOI 10.1152/jappl.2002.92.2.527; MOTLEY HL, 1947, AM J PHYSIOL, V150, P315, DOI 10.1152/ajplegacy.1947.150.2.315; Nagaoka T, 2005, AM J RESP CRIT CARE, V171, P494, DOI 10.1164/rccm.200405-637OC; Ng LC, 2005, J PHYSIOL-LONDON, V563, P409, DOI 10.1113/jphysiol.2004.078311; O'Kelly I, 2000, J BIOL CHEM, V275, P7684, DOI 10.1074/jbc.275.11.7684; Olschewski A, 2004, AM J PHYSIOL-LUNG C, V286, pL15, DOI 10.1152/ajplung.00372.2002; Olschewski A, 2002, AM J PHYSIOL-LUNG C, V283, pL1143, DOI 10.1152/ajplung.00104.2002; Ortega-Saenz P, 2003, J PHYSIOL-LONDON, V548, P789, DOI 10.1113/jphysiol.2003.039693; Osipenko ON, 1998, BRIT J PHARMACOL, V124, P1335, DOI 10.1038/sj.bjp.0702006; Osipenko ON, 2000, CIRC RES, V86, P534, DOI 10.1161/01.RES.86.5.534; PEERS C, 1991, BRAIN RES, V568, P116, DOI 10.1016/0006-8993(91)91386-F; Peng W, 1999, AM J RESP CELL MOL, V20, P737, DOI 10.1165/ajrcmb.20.4.3390; PERRIN DG, 1984, LANCET, V2, P535; Piruat JI, 2004, MOL CELL BIOL, V24, P10933, DOI 10.1128/MCB.24.24.10933-10940.2004; POST JM, 1992, AM J PHYSIOL, V262, P882; Pozeg ZI, 2003, CIRCULATION, V107, P2037, DOI 10.1161/01.CIR.0000062688.76508.B3; PRIESTLEY J, 1775, EXPT OBSERVATIONS DI, P101; Reeve HL, 2001, J APPL PHYSIOL, V90, P2249, DOI 10.1152/jappl.2001.90.6.2249; Reeve HL, 2001, J PHYSIOL-LONDON, V533, P253, DOI 10.1111/j.1469-7793.2001.0253b.x; Remillard CV, 2005, P AM THOR SOC, V2, pA723; RICH S, 1987, CIRCULATION, V76, P135, DOI 10.1161/01.CIR.76.1.135; Robertson TP, 2000, J PHYSIOL-LONDON, V525, P669, DOI 10.1111/j.1469-7793.2000.t01-1-00669.x; Robertson TP, 2000, BRIT J PHARMACOL, V131, P5, DOI 10.1038/sj.bjp.0703537; ROBERTSON TP, 1995, AM J PHYSIOL-HEART C, V268, pH301, DOI 10.1152/ajpheart.1995.268.1.H301; Roy A, 2000, BRAIN RES, V872, P188, DOI 10.1016/S0006-8993(00)02458-6; SALVATERRA CG, 1993, AM J PHYSIOL, V264, pL323, DOI 10.1152/ajplung.1993.264.3.L323; SEVERINGHAUS JW, 1966, RESP PHYSIOL, V1, P308, DOI 10.1016/0034-5687(66)90049-1; Shimoda LA, 2001, AM J PHYSIOL-LUNG C, V281, pL202, DOI 10.1152/ajplung.2001.281.1.L202; SMIRNOV SV, 1994, AM J PHYSIOL, V266, pH365, DOI 10.1152/ajpheart.1994.266.1.H365; Somlyo AP, 2003, PHYSIOL REV, V83, P1325, DOI 10.1152/physrev.00023.2003; SULLIVAN CE, 1980, CHEST, V78, P354, DOI 10.1378/chest.78.2.354; Timmers HJLM, 2003, J PHYSIOL-LONDON, V553, P3, DOI 10.1113/jphysiol.2003.052415; Tipparaju SM, 2005, AM J PHYSIOL-CELL PH, V288, pC366, DOI 10.1152/ajpcell.00354.2004; TristaniFirouzi M, 1996, J CLIN INVEST, V98, P1959, DOI 10.1172/JCI118999; Wang DS, 1996, P NATL ACAD SCI USA, V93, P13182, DOI 10.1073/pnas.93.23.13182; Wang J, 2005, AM J PHYSIOL-LUNG C, V288, pL1059, DOI 10.1152/ajplung.00448.2004; Wang ZQ, 2001, AM J RESP CELL MOL, V25, P628, DOI 10.1165/ajrcmb.25.5.4461; Ward JPT, 2004, PHARMACOL THERAPEUT, V104, P207, DOI 10.1016/j.pharmthera.2004.08.009; Waypa GB, 2005, J APPL PHYSIOL, V98, P404, DOI 10.1152/japplphysiol.00722.2004; Waypa GB, 2001, CIRC RES, V88, P1259, DOI 10.1161/hh1201.091960; Weigand L, 2005, AM J PHYSIOL-LUNG C, V289, pL5, DOI 10.1152/ajplung.00044.2005; Weir EK, 1996, CIRCULATION, V94, P2216, DOI 10.1161/01.CIR.94.9.2216; Williams BA, 2004, AM J PHYSIOL-LUNG C, V286, pL221, DOI 10.1152/ajplung.00010.2003; Williams SEJ, 2004, SCIENCE, V306, P2093, DOI 10.1126/science.1105010; Wilson HL, 2001, J BIOL CHEM, V276, P11180, DOI 10.1074/jbc.M004849200; Wyatt CN, 2004, J PHYSIOL-LONDON, V556, P175, DOI 10.1113/jphysiol.2003.058131; WYATT CN, 1995, P NATL ACAD SCI USA, V92, P295, DOI 10.1073/pnas.92.1.295; YOUNGSON C, 1993, NATURE, V365, P153, DOI 10.1038/365153a0; Yu Y, 2004, P NATL ACAD SCI USA, V101, P13861, DOI 10.1073/pnas.0405908101; Yuan JXJ, 1998, CIRCULATION, V98, P1400, DOI 10.1161/01.CIR.98.14.1400; YUAN XJ, 1993, AM J PHYSIOL, V264, pL116, DOI 10.1152/ajplung.1993.264.2.L116; Zhu WH, 1996, AM J PHYSIOL-CELL PH, V271, pC658, DOI 10.1152/ajpcell.1996.271.2.C658; ZULUETA JJ, 1995, AM J RESP CELL MOL, V12, P41, DOI 10.1165/ajrcmb.12.1.7529030	115	351	363	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					2042	2055		10.1056/NEJMra050002	http://dx.doi.org/10.1056/NEJMra050002			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282179	Green Published, Green Accepted, Green Submitted			2022-12-28	WOS:000233119600009
J	Choi, GB; Anderson, DJ				Choi, GB; Anderson, DJ			A nose by any other name (should smell as sweetly)	CELL			English	Editorial Material							SEX-DISCRIMINATION; OLFACTORY-BULB; MICE; CONVERGENCE; VOMERONASAL; BEHAVIORS; AMYGDALA; TRP2; MAIN	The standard view that the control of mating behavior by pheromones is mediated by the vomeronasal organ, and not by the main olfactory epithelium, has recently been called into question. In this issue of Cell, two independent studies (Boehm et al., 2005; Yoon et al., 2005) examine the inputs from each of these olfactory pathways to a population of neurons that plays a central role in mating behavior.	CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA; CALTECH, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; California Institute of Technology; Howard Hughes Medical Institute	Choi, GB (corresponding author), CALTECH, Div Biol 216 76, Pasadena, CA 91125 USA.							Boehm U, 2005, CELL, V123, P683, DOI 10.1016/j.cell.2005.09.027; Choi GB, 2005, NEURON, V46, P647, DOI 10.1016/j.neuron.2005.04.011; Leypold BG, 2002, P NATL ACAD SCI USA, V99, P6376, DOI 10.1073/pnas.082127599; LICHT G, 1987, EXP BRAIN RES, V69, P7; Lin DY, 2005, NATURE, V434, P470, DOI 10.1038/nature03414; Luo MM, 2003, SCIENCE, V299, P1196, DOI 10.1126/science.1082133; Mandiyan VS, 2005, NAT NEUROSCI, V8, P1660, DOI 10.1038/nn1589; Meredith M, 1998, ANN NY ACAD SCI, V855, P349, DOI 10.1111/j.1749-6632.1998.tb10593.x; Pankevich DE, 2004, J NEUROSCI, V24, P9451, DOI 10.1523/JNEUROSCI.2376-04.2004; Stowers L, 2002, SCIENCE, V295, P1493, DOI 10.1126/science.1069259; Yoon HY, 2005, CELL, V123, P669, DOI 10.1016/j.cell.2005.08.039	11	6	6	0	2	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					550	553		10.1016/j.cell.2005.11.004	http://dx.doi.org/10.1016/j.cell.2005.11.004			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286004	Bronze			2022-12-28	WOS:000233497400005
J	Jefford, M; Savulescu, J; Thomson, J; Schofield, P; Mileshkin, L; Agalianos, E; Zalcberg, J				Jefford, M; Savulescu, J; Thomson, J; Schofield, P; Mileshkin, L; Agalianos, E; Zalcberg, J			Medical paternalism and expensive unsubsidised drugs	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							CANCER		Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Melbourne, Vic 8006, Australia; Univ Oxford, Oxford Uehiro Ctr Pract Eth, Oxford, England	Peter Maccallum Cancer Center; University of Oxford	Jefford, M (corresponding author), Peter MacCallum Canc Ctr, Div Haematol & Med Oncol, Locked Bag 1,ABeckett St, Melbourne, Vic 8006, Australia.	Michael.Jefford@petermac.org		Jefford, Michael/0000-0002-8792-7807				*CANCERBACUP, CANCERBACUP DOSS DEL; Federman AD, 2001, JAMA-J AM MED ASSOC, V286, P1732, DOI 10.1001/jama.286.14.1732; Jefford M, 2002, LANCET ONCOL, V3, P629, DOI 10.1016/S1470-2045(02)00877-X; Joensuu H, 2001, NEW ENGL J MED, V344, P1052, DOI 10.1056/NEJM200104053441404; Okie S, 2005, NEW ENGL J MED, V352, P1173, DOI 10.1056/NEJMp058029; OLIVER K, DRUG APPROVAL US PRO; Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143; Scott J A, 2005, Eur J Oncol Nurs, V9, P131, DOI 10.1016/j.ejon.2005.03.012; Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101; SOUMERAI SB, 2004, HLTH AFF MILLWOOD, V239, P135; Tamblyn R, 2001, Can J Clin Pharmacol, V8 Suppl A, p39A; Uyl-De Groot CA, 2005, CURR OPIN ONCOL, V17, P392, DOI 10.1097/01.cco.0000168535.25330.6a; Vickers AJ, 2001, LANCET ONCOL, V2, P226, DOI 10.1016/S1470-2045(00)00293-X; von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068; Ziebland S, 2004, BMJ-BRIT MED J, V328, P564, DOI 10.1136/bmj.328.7439.564; [No title captured]	16	21	21	1	3	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 5	2005	331	7524					1075	1077		10.1136/bmj.331.7524.1075	http://dx.doi.org/10.1136/bmj.331.7524.1075			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16269497	Green Published			2022-12-28	WOS:000233211200034
J	Chen, X; Hiller, M; Sancak, Y; Fuller, MT				Chen, X; Hiller, M; Sancak, Y; Fuller, MT			Tissue-specific TAFs counteract polycomb to turn on terminal differentiation	SCIENCE			English	Article							SPERMATID DIFFERENTIATION; STEM-CELLS; TRANSCRIPTION; DROSOPHILA; PROTEIN; MECHANISMS; COORDINATE; BMI-1	Polycomb transcriptional silencing machinery is implicated in the maintenance of precursor fates, but how this repression is reversed to allow cell differentiation is unknown. Here we show that testis-specific TAF. (TBP-associated factor) homologs required for terminal differentiation of mate germ cells may activate target gene expression in part by counteracting repression by Polycomb. Chromatin immunoprecipitation revealed that testis TAFs bind to target promoters, reduce Polycomb binding, and promote local accumulation of H3K4me3, a mark of Trithorax action. Testis TAFs also promoted relocalization of Polycomb Repression Complex 1 components to the nucleolus in spermatocytes, implicating subnuclear architecture in the regulation of terminal differentiation.	Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, Stanford, CA 94305 USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Stanford University; Stanford University	Fuller, MT (corresponding author), Stanford Univ, Sch Med, Beckman Ctr B300, Dept Dev Biol, 279 Campus Dr, Stanford, CA 94305 USA.	fuller@cmgm.stanford.edu		Fuller, Margaret T/0000-0002-3804-4987	NIGMS NIH HHS [1RO1GM61986] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM061986] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Balicky EM, 2004, CHROMOSOMA, V112, P231, DOI 10.1007/s00412-003-0266-0; CHEN XQ, UNPUB; Dellino GI, 2004, MOL CELL, V13, P887, DOI 10.1016/S1097-2765(04)00128-5; Dietzel S, 1999, CHROMOSOMA, V108, P83, DOI 10.1007/s004120050355; Fischle W, 2003, GENE DEV, V17, P1870, DOI 10.1101/gad.1110503; Francis NJ, 2001, NAT REV MOL CELL BIO, V2, P409, DOI 10.1038/35073039; Freiman RN, 2001, SCIENCE, V293, P2084, DOI 10.1126/science.1061935; Hiller M, 2004, DEVELOPMENT, V131, P5297, DOI 10.1242/dev.01314; Hiller MA, 2001, GENE DEV, V15, P1021, DOI 10.1101/gad.869101; Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572; Lin TY, 1996, DEVELOPMENT, V122, P1331; Maines JZ, 1999, NAT CELL BIOL, V1, P171, DOI 10.1038/11091; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Orlando V, 2003, CELL, V112, P599, DOI 10.1016/S0092-8674(03)00157-0; Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587; Pointud JC, 2003, J CELL SCI, V116, P1847, DOI 10.1242/jcs.00391; Saurin AJ, 2001, NATURE, V412, P655, DOI 10.1038/35088096; Struhl K, 1998, COLD SPRING HARB SYM, V63, P413, DOI 10.1101/sqb.1998.63.413; Wang L, 2004, MOL CELL, V14, P637, DOI 10.1016/j.molcel.2004.05.009; White-Cooper H, 1998, DEVELOPMENT, V125, P125; Witte V, 2004, MOL CELL, V13, P179, DOI 10.1016/S1097-2765(04)00004-8	21	137	142	1	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					869	872		10.1126/science.1118101	http://dx.doi.org/10.1126/science.1118101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272126				2022-12-28	WOS:000233121800050
J	Schueler-Furman, O; Wang, C; Bradley, P; Misura, K; Baker, D				Schueler-Furman, O; Wang, C; Bradley, P; Misura, K; Baker, D			Progress on modeling of protein structures and interactions	SCIENCE			English	Review							COMPUTATIONAL DESIGN; STRUCTURE PREDICTION; ENERGY FUNCTIONS; FORCE-FIELDS; CAPRI; SEQUENCES; DYNAMICS; DOCKING; MINIMIZATION; GENERATION		Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Hebrew Univ Jerusalem, Dept Mol Genet & Biotechnol, Hadassah Med Sch, IL-91120 Jerusalem, Israel; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Hebrew University of Jerusalem; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Baker, D (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.	dabaker@u.washington.edu	wang, chu/GYJ-2191-2022; Wang, Chu/AAE-8759-2021; Wang, Chu/C-4442-2015; Schueler-Furman, Ora/AAC-5932-2020; Baker, David/K-8941-2012	Wang, Chu/0000-0002-6925-1268; Wang, Chu/0000-0002-6925-1268; Schueler-Furman, Ora/0000-0002-1624-0362; Baker, David/0000-0001-7896-6217				ABAGYAN R, 1994, J MOL BIOL, V235, P983, DOI 10.1006/jmbi.1994.1052; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Bava KA, 2004, NUCLEIC ACIDS RES, V32, pD120, DOI 10.1093/nar/gkh082; Bolon DN, 2001, P NATL ACAD SCI USA, V98, P14274, DOI 10.1073/pnas.251555398; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BOWIE JU, 1994, P NATL ACAD SCI USA, V91, P4436, DOI 10.1073/pnas.91.10.4436; Bradley P, 2005, SCIENCE, V309, P1868, DOI 10.1126/science.1113801; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BRYNGELSON JD, 1995, PROTEINS, V21, P167, DOI 10.1002/prot.340210302; Canutescu AA, 2003, PROTEIN SCI, V12, P2001, DOI 10.1110/ps.03154503; Carvalho AL, 2003, P NATL ACAD SCI USA, V100, P13809, DOI 10.1073/pnas.1936124100; Chevalier BS, 2002, MOL CELL, V10, P895, DOI 10.1016/S1097-2765(02)00690-1; Chung S Y, 1996, Pac Symp Biocomput, P126; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; Dahiyat BI, 1997, SCIENCE, V278, P82, DOI 10.1126/science.278.5335.82; Dominguez C, 2003, J AM CHEM SOC, V125, P1731, DOI 10.1021/ja026939x; Dwyer MA, 2004, SCIENCE, V304, P1967, DOI 10.1126/science.1098432; Eisenberg D, 1997, METHOD ENZYMOL, V277, P396, DOI 10.1016/S0076-6879(97)77022-8; Eyal E, 2005, J MOL BIOL, V351, P431, DOI 10.1016/j.jmb.2005.05.066; Fang QJ, 2003, PROTEINS, V53, P486, DOI 10.1002/prot.10541; Feig M, 2004, CURR OPIN STRUC BIOL, V14, P217, DOI 10.1016/j.sbi.2004.03.009; Fiser A, 2003, METHOD ENZYMOL, V374, P461, DOI 10.1016/S0076-6879(03)74020-8; GINALSKI K, 2004, CASP6 ABSTRACT BOOK, P64; Gordon DB, 1999, CURR OPIN STRUC BIOL, V9, P509, DOI 10.1016/S0959-440X(99)80072-4; Graille M, 2004, EMBO J, V23, P1474, DOI 10.1038/sj.emboj.7600162; Hansmann UHE, 1999, CURR OPIN STRUC BIOL, V9, P177, DOI 10.1016/S0959-440X(99)80025-6; Harbury PB, 1998, SCIENCE, V282, P1462, DOI 10.1126/science.282.5393.1462; Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613; Janin J, 2005, PROTEIN SCI, V14, P278, DOI 10.1110/ps.041081905; Janin J, 2003, PROTEINS, V52, P2, DOI 10.1002/prot.10381; Jones DT, 2003, PROTEINS, V53, P480, DOI 10.1002/prot.10542; Jones DT, 1999, J MOL BIOL, V292, P195, DOI 10.1006/jmbi.1999.3091; KANAGAWA M, UNPUB; Kaplan J, 2004, P NATL ACAD SCI USA, V101, P11566, DOI 10.1073/pnas.0404387101; Karplus M, 2002, NAT STRUCT BIOL, V9, P646, DOI 10.1038/nsb0902-646; KATCHALSKIKATZIR E, 1992, P NATL ACAD SCI USA, V89, P2195, DOI 10.1073/pnas.89.6.2195; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; Kortemme T, 2004, CURR OPIN CHEM BIOL, V8, P91, DOI 10.1016/j.cbpa.2003.12.008; Kortemme T, 2004, NAT STRUCT MOL BIOL, V11, P371, DOI 10.1038/nsmb749; Kuhlman B, 2003, SCIENCE, V302, P1364, DOI 10.1126/science.1089427; Lazaridis T, 1999, PROTEINS, V35, P133, DOI 10.1002/(SICI)1097-0134(19990501)35:2<133::AID-PROT1>3.0.CO;2-N; Levinthal C., 1969, MOSSBAUER SPECTROSC, P22; LI ZQ, 1987, P NATL ACAD SCI USA, V84, P6611, DOI 10.1073/pnas.84.19.6611; Looger LL, 2003, NATURE, V423, P185, DOI 10.1038/nature01556; Mackerell AD, 2004, J COMPUT CHEM, V25, P1584, DOI 10.1002/jcc.20082; MATTHEWS BW, 1995, ADV PROTEIN CHEM, V46, P249, DOI 10.1016/S0065-3233(08)60337-X; Mendez R, 2005, PROTEINS, V60, P150, DOI 10.1002/prot.20551; Moore G., 1965, ELECTRONICS, V38, P114, DOI [DOI 10.1109/N-SSC.2006.4785860, DOI 10.1109/JPROC.1998.658762]; Morozov AV, 2004, P NATL ACAD SCI USA, V101, P6946, DOI 10.1073/pnas.0307578101; Moult J, 2005, CURR OPIN STRUC BIOL, V15, P285, DOI 10.1016/j.sbi.2005.05.011; Onuchic JN, 2004, CURR OPIN STRUC BIOL, V14, P70, DOI 10.1016/j.sbi.2004.01.009; Park B, 1996, J MOL BIOL, V258, P367, DOI 10.1006/jmbi.1996.0256; Ponder JW, 2003, ADV PROTEIN CHEM, V66, P27; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; Rohl CA, 2004, METHOD ENZYMOL, V383, P66; Ryter JM, 1998, EMBO J, V17, P7505, DOI 10.1093/emboj/17.24.7505; Schleif R, 2004, METHOD ENZYMOL, V383, P28; Schlosshauer M, 2004, PROTEIN SCI, V13, P1660, DOI 10.1110/ps.03517304; Schueler-Furman O, 2005, PROTEINS, V60, P187, DOI 10.1002/prot.20556; Shifman JM, 2002, J MOL BIOL, V323, P417, DOI 10.1016/S0022-2836(02)00881-1; Simons KT, 1997, J MOL BIOL, V268, P209, DOI 10.1006/jmbi.1997.0959; Skolnick J, 2003, PROTEINS, V53, P469, DOI 10.1002/prot.10551; Tai K, 2004, BIOPHYS CHEM, V107, P213, DOI 10.1016/j.bpc.2003.09.010; Tramontano A, 2003, PROTEINS, V53, P352, DOI 10.1002/prot.10543; Ulmer TS, 2003, J AM CHEM SOC, V125, P9179, DOI 10.1021/ja0350684; von Grotthuss M, 2004, SCIENCE, V304, P1596; Wang GL, 2004, PROTEIN SCI, V13, P1612, DOI 10.1110/ps.03601504; ZHANG XJ, 1995, J MOL BIOL, V250, P527, DOI 10.1006/jmbi.1995.0396	69	231	253	1	69	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					638	642		10.1126/science.1112160	http://dx.doi.org/10.1126/science.1112160			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254179				2022-12-28	WOS:000232997700030
J	Schwartz, JJ; John, BE; Cheadle, MJ; Miranda, EA; Grimes, CB; Wooden, JL; Dick, HJB				Schwartz, JJ; John, BE; Cheadle, MJ; Miranda, EA; Grimes, CB; Wooden, JL; Dick, HJB			Dating the growth of oceanic crust at a slow-spreading ridge	SCIENCE			English	Article							ATLANTIC; DIFFUSION; PB	Nineteen uranium-lead zircon ages of lower crustal gabbros from Atlantis Bank, Southwest Indian Ridge, constrain the growth and construction of oceanic crust at this stow-spreading midocean ridge. Approximately 75% of the gabbros accreted within error of the predicted seafloor magnetic age, whereas similar to 25% are significantly older. These anomalously old samples suggest either spatially varying stochastic intrusion at the ridge axis or, more likely, crystallization of older gabbros at depths of similar to 5 to 18 kilometers below the base of crust in the cold, axial lithosphere, which were uplifted and intruded by shallow-level magmas during the creation of Atlantis Bank.	Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA; US Geol Survey, Menlo Pk, CA 94025 USA; Woods Hole Oceanog Inst, Woods Hole, MA 02543 USA	University of Wyoming; United States Department of the Interior; United States Geological Survey; Woods Hole Oceanographic Institution	Schwartz, JJ (corresponding author), Univ Wyoming, Dept Geol & Geophys, Laramie, WY 82071 USA.			Miranda, Elena/0000-0001-7970-7209				Allerton S, 2000, GEOLOGY, V28, P179, DOI 10.1130/0091-7613(2000)28<179:EAMAOO>2.0.CO;2; BAINES AG, 2004, AM GEOPH UN FALL M S; Cannat M, 1996, J GEOPHYS RES-SOL EA, V101, P2847, DOI 10.1029/95JB03116; Cannat M., 1991, PROC OCEAN DRILL PRO, V118, P399; Cannat M., 1995, P OCEAN DRILLING PRO, V153; Cherniak DJ, 2001, CHEM GEOL, V172, P5, DOI 10.1016/S0009-2541(00)00233-3; Coogan LA, 2002, EARTH PLANET SC LETT, V199, P127, DOI 10.1016/S0012-821X(02)00554-X; Coogan LA, 2001, CHEM GEOL, V178, P1, DOI 10.1016/S0009-2541(00)00424-1; DICK HJB, 1991, P OC DRILL PROGR SCI, V0118; Dick HJB, 2000, EARTH PLANET SC LETT, V179, P31, DOI 10.1016/S0012-821X(00)00102-3; DICK HJB, 1999, P OCEAN DRILLING PRO; FREED AM, 1995, GEOLOGY, V23, P971, DOI 10.1130/0091-7613(1995)023<0971:LTSOTA>2.3.CO;2; Hirth G, 1998, GEOPH MONOG SERIES, V106, P291; HOSFORD A, 2003, J GEOPHYS RES, V108, DOI DOI 10.1029/2001JB00064; John BE, 2004, EARTH PLANET SC LETT, V222, P145, DOI 10.1016/j.epsl.2004.02.014; Kelemen P. B., 2004, P OCEAN DRILLING PRO; Kinoshita H., 2001, MODE 98 LEG 4 CRUISE; KVASSNES A, 2004, THESIS MIT; Lee JKW, 1997, NATURE, V390, P159, DOI 10.1038/36554; Lizarralde D, 2004, NATURE, V432, P744, DOI 10.1038/nature03140; Maclennan J, 2005, GEOLOGY, V33, P357, DOI 10.1130/G21207.1; Magde LS, 2000, EARTH PLANET SC LETT, V175, P55, DOI 10.1016/S0012-821X(99)00281-2; Matsumoto T., 2002, PRELIMINARY REPORT A; Meurer WP, 2002, EARTH PLANET SC LETT, V201, P45, DOI 10.1016/S0012-821X(02)00660-X; NATLAND JH, 2002, P OCEAL DRILL PROGRA, V176, P69; Pilot J, 1998, NATURE, V393, P676, DOI 10.1038/31452; Scharer U, 2000, EARTH PLANET SC LETT, V181, P555, DOI 10.1016/S0012-821X(00)00220-X; Sinha MC, 1998, GEOPHYS J INT, V135, P731, DOI 10.1046/j.1365-246X.1998.00704.x; Small C, 1998, GEOPH MONOG SERIES, V106, P1; STAKES DS, 1991, P OC DRILL PROGR SCI, V0118	30	75	78	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					654	657		10.1126/science.1116349	http://dx.doi.org/10.1126/science.1116349			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254183				2022-12-28	WOS:000232997700035
J	Gendler, LS; Joseph, KA				Gendler, LS; Joseph, KA			Breast cancer of an accessory nipple	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Columbia Univ, Med Ctr, New York, NY 10032 USA	Columbia University	Gendler, LS (corresponding author), Columbia Univ, Med Ctr, New York, NY 10032 USA.			Joseph, Kathie-Ann/0000-0001-8918-9660					0	7	7	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1835	1835		10.1056/NEJMicm050728	http://dx.doi.org/10.1056/NEJMicm050728			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251539				2022-12-28	WOS:000232813000011
J	Murray, CD; Chavez, C; Beurle, K; Cooper, N; Evans, MW; Burns, JA; Porco, CC				Murray, CD; Chavez, C; Beurle, K; Cooper, N; Evans, MW; Burns, JA; Porco, CC			How prometheus creates structure in Saturn's F ring	NATURE			English	Article							CASSINI IMAGING SCIENCE; PERTURBATIONS; SATELLITES; STRANDS; MASSES	Images of Saturn's narrow and contorted F ring returned by the Cassini spacecraft(1) have revealed phenomena not previously detected in any planetary ring system. The perturbing effect of the inner shepherding satellite, Prometheus, seems to introduce channels through the F ring and a 'streamer' - a line of particles that link the ring to the satellite. The detailed mechanism for the formation of these features has been lacking an explanation. Here we show that these phenomena can be understood in terms of a simple gravitational interaction as Prometheus approaches and recedes from the F ring every 14.7 hours. Our numerical models show that as Prometheus recedes from its closest approach to the F ring, it draws out ring material; one orbital period later, this affected region has undergone keplerian shear and is visible as a channel, in excellent agreement with structures seen in the Cassini images. Prometheus' periodic disruption of the F ring will become more pronounced as the two orbits approach their minimum separation in 2009. The model predicts that the appearance of streamers and the associated channels will vary in a regular fashion on a timescale of one orbital period.	Univ London, Queen Mary, Astron Unit, London E1 4NS, England; Cornell Univ, Dept Astron, Ithaca, NY 14853 USA; Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA; Space Sci Inst, Cassini Imaging Cent Lab Operat, Boulder, CO 80301 USA	University of London; Queen Mary University London; Cornell University; Cornell University	Murray, CD (corresponding author), Univ London, Queen Mary, Astron Unit, Mile End Rd, London E1 4NS, England.	C.D.Murray@qmul.ac.uk	Evans, Michael W/AAG-4117-2020	Chavez, Carlos Esteban/0000-0002-6900-1154				BORDERIES N, 1983, ICARUS, V53, P84, DOI 10.1016/0019-1035(83)90022-2; Bosh AS, 2002, ICARUS, V157, P57, DOI 10.1006/icar.2002.6791; Dermott S. F., 1984, PLANETARY RINGS, P589; Jacobson RA, 2004, ICARUS, V172, P382, DOI 10.1016/j.icarus.2004.08.018; KOLVOORD RA, 1990, NATURE, V345, P695, DOI 10.1038/345695a0; KOLVOORD RA, 1992, ICARUS, V95, P253, DOI 10.1016/0019-1035(92)90042-6; Murray CD, 1996, NATURE, V380, P139, DOI 10.1038/380139a0; Murray CD, 1997, ICARUS, V129, P304, DOI 10.1006/icar.1997.5774; Porco CC, 2004, SPACE SCI REV, V115, P363, DOI 10.1007/s11214-004-1456-7; Porco CC, 2005, SCIENCE, V307, P1226, DOI 10.1126/science.1108056; Renner S, 2005, ICARUS, V174, P230, DOI 10.1016/j.icarus.2004.09.005; SHOWALTER MR, 1982, ICARUS, V52, P526, DOI 10.1016/0019-1035(82)90013-6; Winter SMG, 2000, PLANET SPACE SCI, V48, P817, DOI 10.1016/S0032-0633(00)00009-X; WINTER SMG, 1994, THESIS QUEEN MARY WE	14	49	49	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1326	1329		10.1038/nature04212	http://dx.doi.org/10.1038/nature04212			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251957				2022-12-28	WOS:000232829100046
J	Siegel, JM				Siegel, JM			Clues to the functions of mammalian sleep	NATURE			English	Review							SLOW-WAVE SLEEP; REM-SLEEP; PARADOXICAL SLEEP; BRAIN-STEM; TACHYGLOSSUS-ACULEATUS; MEMORY CONSOLIDATION; RETICULAR-FORMATION; ENERGY-METABOLISM; DEPRIVATION; RAT	The functions of mammalian sleep remain unclear. Most theories suggest a role for non-rapid eye movement (NREM) sleep in energy conservation and in nervous system recuperation. Theories of REM sleep have suggested a role for this state in periodic brain activation during sleep, in localized recuperative processes and in emotional regulation. Across mammals, the amount and nature of sleep are correlated with age, body size and ecological variables, such as whether the animals live in a terrestrial or an aquatic environment, their diet and the safety of their sleeping site. Sleep may be an efficient time for the completion of a number of functions, but variations in sleep expression indicate that these functions may differ across species.	Univ Calif Los Angeles, Sch Med, Dept Psychiat, VA GLAHS Sepulveda, North Hills, CA 91343 USA; Univ Calif Los Angeles, Sch Med, Brain Res Inst, North Hills, CA 91343 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Siegel, JM (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Psychiat, VA GLAHS Sepulveda, North Hills, CA 91343 USA.	JSiegel@ucla.edu			NIMH NIH HHS [R01 MH064109] Funding Source: Medline	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Achermann P, 2003, FRONT BIOSCI-LANDMRK, V8, pS683, DOI 10.2741/1064; ALLISON T, 1976, SCIENCE, V194, P732, DOI 10.1126/science.982039; ALLISON T, 1972, ARCH ITAL BIOL, V110, P145; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; ASTONJONES G, 1981, J NEUROSCI, V1, P876; BAKER FC, 2005, AM J PHYSL REGUL INT; Balkin TJ, 2004, AVIAT SPACE ENVIR MD, V75, pA155; Bell-Pedersen D, 2005, NAT REV GENET, V6, P544, DOI 10.1038/nrg1633; BENINGTON JH, 1995, PROG NEUROBIOL, V45, P347, DOI 10.1016/0301-0082(94)00057-O; BERGMANN BM, 1987, SLEEP, V10, P1; Binks PG, 1999, SLEEP, V22, P328, DOI 10.1093/sleep/22.3.328; CARSKADON MA, 2005, PRINCIPLES PRACTICE, V4, P13; CHASE MH, 2005, PRINCIPLES SLEEP MED, V4, P154; Cirelli C, 2005, NATURE, V434, P1087, DOI 10.1038/nature03486; Coleman CG, 2004, NEUROSCIENCE, V126, P821, DOI 10.1016/j.neuroscience.2004.04.029; CZEISLER CA, 2005, PRINCIPLES PRACTICE, V4, P375; Darchia N, 2004, BRAIN RES BULL, V63, P433, DOI 10.1016/j.brainresbull.2003.12.017; Dinges D.F., 2005, PRINCIPLES PRACTICE, V4th ed., P67, DOI DOI 10.1016/B0-72-160797-7/50013-6; Douglas NJ, 2005, PRINCIPLES PRACTICE; Eiland MM, 2002, BRAIN RES, V945, P1, DOI 10.1016/S0006-8993(02)02448-4; EVERSON CA, 1994, J NEUROSCI, V14, P6769; Everson CA, 2005, AM J PHYSIOL-REG I, V288, pR374, DOI 10.1152/ajpregu.00565.2004; Everson CA, 2004, AM J PHYSIOL-ENDOC M, V286, pE1060, DOI 10.1152/ajpendo.00553.2003; Frank MG, 2003, J SLEEP RES, V12, P25, DOI 10.1046/j.1365-2869.2003.00339.x; Franken P, 2003, AM J PHYSIOL-REG I, V285, pR413, DOI 10.1152/ajpregu.00668.2002; Gonzalez MMD, 1995, NEUROSCI LETT, V202, P5; Gopalakrishnan A, 2004, SLEEP, V27, P27, DOI 10.1093/sleep/27.1.27; Grutzner F, 2004, NATURE, V432, P913, DOI 10.1038/nature03021; Guzman-Marin R, 2003, J PHYSIOL-LONDON, V549, P563, DOI 10.1113/jphysiol.2003.041665; Heller C., 2005, PRINCIPLES PRACTICE, P292, DOI DOI 10.1016/B0-72-160797-7/50031-8; Hipolide DC, 2005, PROG NEURO-PSYCHOPH, V29, P297, DOI 10.1016/j.pnpbp.2004.11.015; Hipolide DC, 1998, NEUROSCIENCE, V86, P977, DOI 10.1016/S0306-4522(98)00067-0; Horne JA, 2000, NEUROSCI BIOBEHAV R, V24, P777, DOI 10.1016/S0149-7634(00)00037-3; Horner RL, 1997, BRAIN RES, V778, P127, DOI 10.1016/S0006-8993(97)01045-7; Huber R, 2004, SLEEP, V27, P628, DOI 10.1093/sleep/27.4.628; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; JACOBS BL, 1992, PHYSIOL REV, V72, P165, DOI 10.1152/physrev.1992.72.1.165; John J, 2004, NEURON, V42, P619, DOI 10.1016/S0896-6273(04)00247-8; JOUVET M, 1988, CR ACAD SCI III-VIE, V306, P69; JOUVET M, 1978, INSERM S, V6, P245; Jouvet-Mounier D, 1970, Dev Psychobiol, V2, P216; Karlsson KAE, 2005, PLOS BIOL, V3, P891, DOI 10.1371/journal.pbio.0030143; KLEMM WR, 1966, P SOC EXP BIOL MED, V121, P635, DOI 10.3181/00379727-121-30850; Kong JM, 2002, J NEUROSCI, V22, P5581; Krueger JM, 1999, SLEEP MED REV, V3, P119, DOI 10.1016/S1087-0792(99)90019-9; Kume K, 2005, J NEUROSCI, V25, P7377, DOI 10.1523/JNEUROSCI.2048-05.2005; Lima SL, 2005, ANIM BEHAV, V70, P723, DOI 10.1016/j.anbehav.2005.01.008; Lyamin O, 2005, NATURE, V435, P1177, DOI 10.1038/4351177a; Lyamin OI, 2004, ARCH ITAL BIOL, V142, P557; Lyamin OI, 2002, BEHAV BRAIN RES, V129, P125, DOI 10.1016/S0166-4328(01)00346-1; Lyamin OI, 1996, J SLEEP RES S, V5, P130; Maquet P, 2004, ARCH ITAL BIOL, V142, P413; MCGINTY DJ, 1976, BRAIN RES, V101, P569, DOI 10.1016/0006-8993(76)90480-7; MCGINTY DJ, 2005, PRINCIPLES PRACTICE, V4, P169; MERRICK AW, 1971, AM J VET RES, V32, P1893; Mileykovskiy BY, 2005, NEURON, V46, P787, DOI 10.1016/j.neuron.2005.04.035; MUKHAMETOV LM, 1987, NEUROSCI LETT, V79, P128, DOI 10.1016/0304-3940(87)90684-7; MUKHAMETOV LM, 1992, EXPERIENTIA, V48, P417, DOI 10.1007/BF01923447; MUKHAMETOV LM, 1981, ZH VYSSH NERV DEYAT+, V31, P333; MUKHAMETOV LM, 1977, BRAIN RES, V134, P581, DOI 10.1016/0006-8993(77)90835-6; Mukhametov LM, 2002, P 14 BIENN C BIOL MA, P152; Nakanishi H, 1997, EUR J NEUROSCI, V9, P271, DOI 10.1111/j.1460-9568.1997.tb01397.x; Nofzinger EA, 2004, AM J PSYCHIAT, V161, P2126, DOI 10.1176/appi.ajp.161.11.2126; O'Hara BF, 1999, J NEUROSCI, V19, P3781; Oleksenko A.I., 1992, Journal of Sleep Research, V1, P40; OPP MR, 1994, BRAIN RES, V639, P57, DOI 10.1016/0006-8993(94)91764-7; Parmeggiani PL, 2002, BRAIN RES, V940, P55, DOI 10.1016/S0006-8993(02)02591-X; Paxinos G., 2002, RAT BRAIN STEREOTAXI; Pedrazzoli M, 2004, PHARMACOL BIOCHEM BE, V79, P31, DOI 10.1016/j.pbb.2004.06.001; Ramanathan L, 2002, NEUROREPORT, V13, P1387, DOI 10.1097/00001756-200208070-00007; Rattenborg NC, 2004, PLOS BIOL, V2, P924, DOI 10.1371/journal.pbio.0020212; Rechtschaffen A, 1998, PERSPECT BIOL MED, V41, P359, DOI 10.1353/pbm.1998.0051; Rechtschaffen A, 2002, SLEEP, V25, P18, DOI 10.1093/sleep/25.1.18; Sanford LD, 2003, BEHAV GENET, V33, P43, DOI 10.1023/A:1021051516829; Saper CB, 2001, TRENDS NEUROSCI, V24, P726, DOI 10.1016/S0166-2236(00)02002-6; Schmidt MH, 2000, J NEUROSCI, V20, P6640, DOI 10.1523/JNEUROSCI.20-17-06640.2000; Shaffery JP, 1999, DEV BRAIN RES, V114, P109, DOI 10.1016/S0165-3806(99)00027-9; Shaw PJ, 2000, SCIENCE, V287, P1834, DOI 10.1126/science.287.5459.1834; Siegel J. M., 2005, PRINCIPLES PRACTICE, P120; SIEGEL JM, 1983, J NEUROPHYSIOL, V50, P696, DOI 10.1152/jn.1983.50.3.696; Siegel JM, 2001, SCIENCE, V294, P1058, DOI 10.1126/science.1063049; SIEGEL JM, 1988, BRAIN RES REV, V13, P213, DOI 10.1016/0165-0173(88)90007-0; Siegel JM, 1999, NEUROSCIENCE, V91, P391, DOI 10.1016/S0306-4522(98)00588-0; Siegel JM, 1996, J NEUROSCI, V16, P3500; SNYDER F, 1966, AM J PSYCHIAT, V123, P121, DOI 10.1176/ajp.123.2.121; STERIADE M, 2005, PRINCIPLES PRACTICE, V4, P101; TSAI LL, 1993, BRAIN RES, V602, P221, DOI 10.1016/0006-8993(93)90686-H; Turner N, 2005, J EXP BIOL, V208, P371, DOI 10.1242/jeb.01377; VANDERWOLF CH, 1986, BRAIN RES, V374, P342, DOI 10.1016/0006-8993(86)90428-2; Verret L, 2005, EUR J NEUROSCI, V21, P2488, DOI 10.1111/j.1460-9568.2005.04060.x; Vertes RP, 2004, NEURON, V44, P135, DOI 10.1016/j.neuron.2004.08.034; Vertes RP, 2005, SLEEP, V28, P1232, DOI 10.1093/sleep/28.10.1232; Villablanca JR, 2004, J SLEEP RES, V13, P179, DOI 10.1111/j.1365-2869.2004.00412.x; VOGEL GW, 1978, AM J PSYCHIAT, V135, P1531; Vyazovskiy VV, 2004, EUR J NEUROSCI, V20, P1363, DOI 10.1111/j.1460-9568.2004.03583.x; WEHR TA, 1992, NEUROSCI BIOBEHAV R, V16, P379, DOI 10.1016/S0149-7634(05)80208-8; Xu YL, 2004, NEURON, V43, P487, DOI 10.1016/j.neuron.2004.08.005; Zenko CE, 2000, SLEEP, V23, P341; Zepelin H, 2005, PRINCIPLES PRACTICE, P91, DOI [10.1016/B0-72-160797-7/50015-X, DOI 10.1016/B0-72-160797-7/50015-X]; Zimmerman JE, 2004, J NEUROCHEM, V88, P32, DOI 10.1046/j.1471-4159.2003.02126.x	100	545	560	9	205	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1264	1271		10.1038/nature04285	http://dx.doi.org/10.1038/nature04285			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251951	Green Accepted			2022-12-28	WOS:000232829100039
J	Bild, AH; Yao, G; Chang, JT; Wang, QL; Potti, A; Chasse, D; Joshi, MB; Harpole, D; Lancaster, JM; Berchuck, A; Olson, JA; Marks, JR; Dressman, HK; West, M; Nevins, JR				Bild, AH; Yao, G; Chang, JT; Wang, QL; Potti, A; Chasse, D; Joshi, MB; Harpole, D; Lancaster, JM; Berchuck, A; Olson, JA; Marks, JR; Dressman, HK; West, M; Nevins, JR			Oncogenic pathway signatures in human cancers as a guide to targeted therapies	NATURE			English	Article							GENE-EXPRESSION; BREAST-CANCER; LUNG-CANCER; MUTATIONS; PROFILES; PATTERNS; ASSAYS	The development of an oncogenic state is a complex process involving the accumulation of multiple independent mutations that lead to deregulation of cell signalling pathways central to the control of cell growth and cell fate(1-3). The ability to define cancer subtypes, recurrence of disease and response to specific therapies using DNA microarray-based gene expression signatures has been demonstrated in multiple studies(4). Various studies have also demonstrated the potential for using gene expression profiles for the analysis of oncogenic pathways(5-11). Here we show that gene expression signatures can be identified that reflect the activation status of several oncogenic pathways. When evaluated in several large collections of human cancers, these gene expression signatures identify patterns of pathway deregulation in tumours and clinically relevant associations with disease outcomes. Combining signature-based predictions across several pathways identifies coordinated patterns of pathway deregulation that distinguish between specific cancers and tumour subtypes. Clustering tumours based on pathway signatures further defines prognosis in respective patient subsets, demonstrating that patterns of oncogenic pathway deregulation underlie the development of the oncogenic phenotype and reflect the biology and outcome of specific cancers. Predictions of pathway deregulation in cancer cell lines are also shown to predict the sensitivity to therapeutic agents that target components of the pathway. Linking pathway deregulation with sensitivity to therapeutics that target components of the pathway provides an opportunity to make use of these oncogenic pathway signatures to guide the use of targeted therapeutics.	Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA; Duke Univ, Med Ctr, Dept Obstet & Gynecol, Durham, NC 27710 USA; Duke Univ, Inst Stat & Decis Sci, Durham, NC 27708 USA; Univ S Florida, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	Duke University; Duke University; Duke University; Duke University; Duke University; Duke University; H Lee Moffitt Cancer Center & Research Institute; State University System of Florida; University of South Florida	Nevins, JR (corresponding author), Duke Univ, Inst Genome Sci & Policy, Durham, NC 27708 USA.	j.nevins@duke.edu		, Guang/0000-0003-0167-777X	NATIONAL CANCER INSTITUTE [K23CA106595, R21CA108707] Funding Source: NIH RePORTER; NCI NIH HHS [R21 CA108707, K23 CA106595] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Black EP, 2003, CANCER RES, V63, P3716; Bolstad BM, 2003, BIOINFORMATICS, V19, P185, DOI 10.1093/bioinformatics/19.2.185; CORY AH, 1991, CANCER COMMUN, V3, P207, DOI 10.3727/095535491820873191; D'Cruz CM, 2001, NAT MED, V7, P235, DOI 10.1038/84691; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fearon E., 1990, CELL, V17, P671; Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Huang E, 2003, NAT GENET, V34, P226, DOI 10.1038/ng1167; IRIZARRY RA, IN PRESS BIOSTATISTI; Lamb J, 2003, CELL, V114, P323, DOI 10.1016/S0092-8674(03)00570-1; MITSUDOMI T, 1991, ONCOGENE, V6, P1353; Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180; Ramaswamy S, 2003, NAT GENET, V33, P49, DOI 10.1038/ng1060; Ramaswamy S, 2002, J CLIN ONCOL, V20, P1932, DOI 10.1200/JCO.2002.20.7.1932; Rhodes DR, 2004, P NATL ACAD SCI USA, V101, P9309, DOI 10.1073/pnas.0401994101; RISS TL, 1992, MOL BIOL CELL, V3, pA184; Rodenhuis S, 1997, J CLIN ONCOL, V15, P285, DOI 10.1200/JCO.1997.15.1.285; Salgia R, 1998, J CLIN ONCOL, V16, P1207, DOI 10.1200/JCO.1998.16.3.1207; Segal E, 2004, NAT GENET, V36, P1090, DOI 10.1038/ng1434; Sherr CJ, 1996, SCIENCE, V274, P1672, DOI 10.1126/science.274.5293.1672; STAMPFER MR, 1993, CANCER SURV, V18, P7; Sweet-Cordero A, 2005, NAT GENET, V37, P48, DOI 10.1038/ng1490; West M, 2001, P NATL ACAD SCI USA, V98, P11462, DOI 10.1073/pnas.201162998	24	1538	1627	0	107	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					353	357		10.1038/nature04296	http://dx.doi.org/10.1038/nature04296			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16273092				2022-12-28	WOS:000234682100049
J	Morel, CM; Lauer, JA; Evans, DB				Morel, CM; Lauer, JA; Evans, DB			Achieving the millennium development goals for health - Cost effectiveness analysis of strategies to combat malaria in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INSECTICIDE-TREATED NETS; KWAZULU; DRUG	Objective To determine the cost effectiveness of selected malaria control interventions in the context of reaching the millennium development goals for malaria. Design Generalised cost effectiveness analysis. Data sources Efficacy data came from the literature and authors' calculations supported by expert opinion. Quantities for resource inputs came from the literature and from expert opinion; prices came from the WHO-CHOICE database. Methods Costs were assessed in year 2000 international dollars, and effects were assessed as disability adjusted life years averted by a 10 year implementation programme. Analysis was restricted to sub-Saharan regions where the most deadly form of malaria, Plasmodium falciparum, is most prevalent. The impact on population health for various interventions, and their combinations, was evaluated at selected coverage levels by using a state-transition model. Sensitivity analysis was done for age weights and discounting. Results High coverage with artemisinin based combination treatments was found to be the most cost effective strategy for control of malaria in most countries in sub-Saharan Africa. Conclusions A much larger infusion of resources than those currently available is needed to make headway in the fight to roll back malaria. On cost effectiveness grounds, in most areas in sub-Saharan Africa greater coverage with highly effective combination treatments should be the cornerstone of malaria control. However, treatment alone can achieve less than half the total benefit obtainable through a combination of interventions-and scaling up the use of impregnated mosquito nets or indoor spraying with insecticides is also critical. Intermittent presumptive treatment of pregnant women can bring a small but important additional health gain at relatively low cost.	Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England; WHO, Costs Effectiveness Expenditure & Prior Setting T, Hlth Syst Financing Dept, CH-1211 Geneva, Switzerland	University of London; London School of Hygiene & Tropical Medicine; World Health Organization	Morel, CM (corresponding author), Univ London London Sch Hyg & Trop Med, Dept Publ Hlth & Policy, Hlth Policy Unit, London WC1E 7HT, England.	Chantal.Morel@lshtm.ac.uk	Morel, Chantal M/R-8243-2017	Morel, Chantal M/0000-0003-3984-9741; Lauer, Jeremy A/0000-0003-0652-0691				Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; Bakyaita N, 2005, AM J TROP MED HYG, V72, P573; BALRUSSEN R, 2003, METHODS GEN COST EFF; Chima RI, 2003, HEALTH POLICY, V63, P17, DOI 10.1016/S0168-8510(02)00036-2; Coleman PG, 2004, AM J TROP MED HYG, V71, P196, DOI 10.4269/ajtmh.2004.71.196; Curtis CF, 2000, B WORLD HEALTH ORGAN, V78, P1389; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Goodman CA, 1999, LANCET, V354, P378, DOI 10.1016/S0140-6736(99)02141-8; Goodman CA, 2001, HEALTH ECON, V10, P731, DOI 10.1002/hec.621; Goodman CA, 2001, TROP MED INT HEALTH, V6, P280, DOI 10.1046/j.1365-3156.2001.00700.x; Guyatt HL, 2002, HEALTH POLICY PLANN, V17, P144, DOI 10.1093/heapol/17.2.144; HANSON K, 2004, EC MALARIA CONTROL I; Hay SI, 2004, LANCET INFECT DIS, V4, P327, DOI 10.1016/S1473-3099(04)01043-6; Johns B, 2004, HEALTH ECON, V13, P1117, DOI 10.1002/hec.880; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Lauer Jeremy A, 2003, Cost Eff Resour Alloc, V1, P6, DOI 10.1186/1478-7547-1-6; Sachs J, 2002, NATURE, V415, P680, DOI 10.1038/415680a; SHARP BL, 1990, J AM MOSQUITO CONTR, V6, P197; Staedke SG, 2004, LANCET, V364, P1950, DOI 10.1016/S0140-6736(04)17478-3; Stevens W, 2005, MALARIA J, V4, DOI 10.1186/1475-2875-4-22; United Nations, 2005, MILL DEV GOALS REP; White NJ, 2002, TRENDS PARASITOL, V18, P458, DOI 10.1016/S1471-4922(02)02373-5; White NJ, 1999, LANCET, V353, P1965, DOI 10.1016/S0140-6736(98)07367-X; White NJ, 1999, PARASSITOLOGIA, VOL 41, NOS 1-3, SEPTEMBER 1999, P301; WHITFIELD D, 1999, ED SOCIAL JUSTICE, V1, P1; *WHO, 2002, GLOB BURD DIS EST; *WHO UNICEF, 2003, AFR MAL REP 2003, P120; *WHO UNICEF ROLL B, 2005, WORLD MAL REP 2005	28	86	86	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 3	2005	331	7528					1299	1302B		10.1136/bmj.38639.702384.AE	http://dx.doi.org/10.1136/bmj.38639.702384.AE			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	990YE	16282381	Green Published, Bronze, Green Accepted			2022-12-28	WOS:000233778500015
J	Rine, J				Rine, J			Twists in the tale of the aging yeast	SCIENCE			English	Editorial Material							LIFE-SPAN EXTENSION; RESTRICTION; SIR2		Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Rine, J (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, 229 Stanley Hall, Berkeley, CA 94720 USA.	jrine@berkeley.edu						Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; Lamming DW, 2005, SCIENCE, V309, P1861, DOI 10.1126/science.1113611; Lin SJ, 2000, SCIENCE, V289, P2126, DOI 10.1126/science.289.5487.2126; Sinclair DA, 1997, SCIENCE, V277, P1313, DOI 10.1126/science.277.5330.1313	6	12	12	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2005	310	5751					1124	1125		10.1126/science.1121310	http://dx.doi.org/10.1126/science.1121310			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GE	16293743				2022-12-28	WOS:000233437300026
J	Peterson, HB; Curtis, KM				Peterson, HB; Curtis, KM			Long-acting methods of contraception	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRAUTERINE-DEVICE INSERTION; PELVIC INFLAMMATORY DISEASE; TUBAL-STERILIZATION; UNITED-STATES; IMPLANTABLE CONTRACEPTIVES; ECTOPIC PREGNANCY; PROSTATE-CANCER; VASECTOMY; RISK; WOMEN		Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27514 USA; Univ N Carolina, Sch Med, Dept Obstet & Gynecol, Chapel Hill, NC USA; Ctr Dis Control & Prevent, Div Reprod Hlth, Atlanta, GA USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Centers for Disease Control & Prevention - USA	Peterson, HB (corresponding author), Univ N Carolina, Sch Publ Hlth, Dept Maternal & Child Hlth, Chapel Hill, NC 27514 USA.							*ACOG, 2003, OBSTET GYNECOL, V102, P647; ACOG Committee on Practice Bulletins-Gynecology, 2005, Obstet Gynecol, V105, P223; ALDERMAN PM, 1991, J FAM PRACTICE, V33, P579; [Anonymous], 2001, INT J GYNECOL OBSTET, V75, P93; Backman T, 2002, OBSTET GYNECOL, V99, P608, DOI 10.1016/S0029-7844(01)01764-1; Benshushan A, 2002, EUR J OBSTET GYN R B, V105, P166; Bernal-Delgado E, 1998, FERTIL STERIL, V70, P191, DOI 10.1016/S0015-0282(98)00142-3; Chiou CF, 2003, CONTRACEPTION, V68, P3, DOI 10.1016/S0010-7824(03)00078-7; Choe JM, 1996, J UROLOGY, V155, P1284, DOI 10.1016/S0022-5347(01)66244-X; Costello C, 2002, OBSTET GYNECOL, V100, P511, DOI 10.1016/S0029-7844(02)02042-2; Cox B, 2002, JAMA-J AM MED ASSOC, V287, P3110, DOI 10.1001/jama.287.23.3110; CRAMER DW, 1985, NEW ENGL J MED, V312, P941, DOI 10.1056/NEJM198504113121502; Croxatto HB, 2002, CONTRACEPTION, V65, P21, DOI 10.1016/S0010-7824(01)00294-3; Curtis KM, 2002, CONTRACEPTION, V65, P85, DOI 10.1016/S0010-7824(01)00291-8; DALING JR, 1985, NEW ENGL J MED, V312, P937, DOI 10.1056/NEJM198504113121501; Dennis Jo, 2002, J Fam Plann Reprod Health Care, V28, P61; ESCOBEDO LG, 1989, AM J OBSTET GYNECOL, V160, P147, DOI 10.1016/0002-9378(89)90108-7; FARLEY TMM, 1992, LANCET, V339, P785, DOI 10.1016/0140-6736(92)91904-M; FRANKS AL, 1990, AM J OBSTET GYNECOL, V163, P1120, DOI 10.1016/0002-9378(90)90668-W; Glasier A, 2002, CONTRACEPTION, V65, P29, DOI 10.1016/S0010-7824(01)00284-0; Grimes DA, 1999, CONTRACEPTION, V60, P57, DOI 10.1016/S0010-7824(99)00071-2; Grimes DA, 2001, LANCET, V358, P6, DOI 10.1016/S0140-6736(00)05299-5; Grimes DA, 2000, LANCET, V356, P1013, DOI 10.1016/S0140-6736(00)02699-4; Harrison-Woolrych M, 2003, CONTRACEPTION, V67, P53, DOI 10.1016/S0010-7824(02)00417-1; Henshaw SK, 1998, FAM PLANN PERSPECT, V30, P24, DOI 10.2307/2991522; Hickey M, 2002, CONTRACEPTION, V65, P75, DOI 10.1016/S0010-7824(01)00292-X; Hillis SD, 1998, OBSTET GYNECOL, V91, P241, DOI 10.1016/S0029-7844(97)00648-0; Hillis SD, 1999, OBSTET GYNECOL, V93, P889, DOI 10.1016/S0029-7844(98)00539-0; Hubacher D, 2002, OBSTET GYNECOL SURV, V57, P120, DOI 10.1097/00006254-200202000-00024; Hubacher D, 2001, NEW ENGL J MED, V345, P561, DOI 10.1056/NEJMoa010438; *IUD SAF, 1997, MMWR-MORBID MORTAL W, V46, P969; Jamieson DJ, 2000, OBSTET GYNECOL, V96, P997, DOI 10.1016/S0029-7844(00)01082-6; Jamieson DJ, 2004, OBSTET GYNECOL, V103, P848, DOI 10.1097/01.AOG.0000123246.11511.e4; Jamieson DJ, 2004, OBSTET GYNECOL, V104, P200; Jamieson DJ, 2002, OBSTET GYNECOL, V99, P1073, DOI 10.1016/S0029-7844(02)01981-6; Labrecque M, 2002, J UROLOGY, V168, P2495, DOI 10.1016/S0022-5347(05)64176-6; LEE NC, 1988, OBSTET GYNECOL, V72, P1; MASSEY FJ, 1984, JAMA-J AM MED ASSOC, V252, P1023, DOI 10.1001/jama.252.8.1023; Mastroianni L, 1997, AM J OBSTET GYNECOL, V177, P980, DOI 10.1016/S0002-9378(97)70312-0; MCMAHON AJ, 1992, BRIT J UROL, V69, P188, DOI 10.1111/j.1464-410X.1992.tb15494.x; Mishell DR, 1998, CONTRACEPTION, V58, p45S, DOI 10.1016/S0010-7824(98)00082-1; MOSHER WD, 2004, 350 NAT CTR HLTH STA; Nangia AK, 2000, J UROLOGY, V164, P1939, DOI 10.1016/S0022-5347(05)66923-6; Peterson HB, 2000, NEW ENGL J MED, V343, P1681, DOI 10.1056/NEJM200012073432303; Peterson HB, 1996, AM J OBSTET GYNECOL, V174, P1161, DOI 10.1016/S0002-9378(96)70658-0; Peterson HB, 1997, NEW ENGL J MED, V336, P762, DOI 10.1056/NEJM199703133361104; Rivera R, 1999, AM J OBSTET GYNECOL, V181, P1263, DOI 10.1016/S0002-9378(99)70120-1; Schmidt JE, 2000, FERTIL STERIL, V74, P892, DOI 10.1016/S0015-0282(00)01558-2; Schwingl PJ, 2000, FERTIL STERIL, V73, P923, DOI 10.1016/S0015-0282(00)00482-9; SIVIN I, 1994, FERTIL STERIL, V61, P70; Sivin I, 1997, AM J OBSTET GYNECOL, V177, P718, DOI 10.1016/S0002-9378(97)70175-3; Spinnato JA, 1997, AM J OBSTET GYNECOL, V176, P503, DOI 10.1016/S0002-9378(97)70537-4; Stanford JB, 2002, AM J OBSTET GYNECOL, V187, P1699, DOI 10.1067/mob.2002.128091; Treiman K, 1995, POPULATION REPORTS B; Trussell J, 2004, CONTRACEPTION, V70, P89, DOI 10.1016/j.contraception.2004.03.009; WHO, 2004, MED EL CRIT CONTR US, V3; World Health Organization, 2005, SEL PRACT REC CONTR	57	47	48	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2169	2175		10.1056/NEJMcp044148	http://dx.doi.org/10.1056/NEJMcp044148			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291986	Green Published			2022-12-28	WOS:000233288600009
J	Markel, H				Markel, H			Why America needs a strong FDA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Pediat & Communicable Dis, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, 100 Simpson Mem Inst, Ann Arbor, MI 48109 USA.	howard@umich.edu						Adams S. H., 1905, GREAT AM FRAUD SERIE; Anderson Oscar Edward, 1958, HLTH NATION HW WILEY; Angell M., 2004, TRUTH DRUG CO THEY D; BROPHY JM, 2005, JAMA            1020; BUENKER JD, 2001, OXFORD CO US HIST, P637; FEULNER EJ, 1980, MANDUATE LEADERSHIP; HARRIS G, 2005, NY TIMES        1027; Hilts P, 2003, PROTECTING AM HLTH F; KESSLER D, 2005, COMMUNICATION   0927; KESSLER DA, 2001, GREAT AM BATTLE DEAD; NISSEN SE, 2005, JAMA            1020; Sinclair Upton, 1906, JUNGLE; SWANN JP, 1988, HIST GUIDE AM GOVT, P248; Waxman HA, 2005, NEW ENGL J MED, V352, P2576, DOI 10.1056/NEJMp058136; WHITMAN W, 1959, LEAVES GRASS, P269; WILEY HW, 1930, AUTOBIOGRAPHY; Wood AJJ, 2005, NEW ENGL J MED, V353, P1197, DOI 10.1056/NEJMp058222; Young J.H, 1967, MED MESSIAHS SOCIAL	18	9	11	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2489	2491		10.1001/jama.294.19.2489	http://dx.doi.org/10.1001/jama.294.19.2489			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287960				2022-12-28	WOS:000233277400028
J	Moss, JE; Burtness, B				Moss, JE; Burtness, B			Cetuximab-associated acneiform eruption	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Yale Univ, New Haven, CT 06520 USA	Yale University	Moss, JE (corresponding author), Yale Univ, New Haven, CT 06520 USA.								0	10	10	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					E17	E17		10.1056/NEJMicm050560	http://dx.doi.org/10.1056/NEJMicm050560			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282170				2022-12-28	WOS:000233119600011
J	Doukas, G; Samani, NJ; Alexiou, C; Oc, M; Chin, DT; Stafford, PG; Ng, LL; Spyt, TJ				Doukas, G; Samani, NJ; Alexiou, C; Oc, M; Chin, DT; Stafford, PG; Ng, LL; Spyt, TJ			Left atrial radiofrequency ablation during mitral valve surgery for continuous atrial fibrillation - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAZE PROCEDURE; REPAIR; RISK; CONDUCTION; EFFICACY; DISEASE; TERM	Context Although left atrial radiofrequency ablation (RFA) is increasingly used for the treatment of chronic atrial fibrillation during mitral valve surgery, its efficacy to restore sinus rhythm and any resulting benefits have not been examined in the context of an adequately powered randomized trial. Objective To determine whether intraoperative RFA of the left atrium increases the long-term restoration of sinus rhythm and improves exercise capacity. Design, Setting, and Patients Randomized, double-blind trial performed in a single UK tertiary referral center with enrollment between December 2001 and November 2003. A total of 101 patients referred for mitral valve surgery with at least 6 months' history of uninterrupted atrial fibrillation were assessed for eligibility; 97 were enrolled. Patients were followed up for 12 months. Intervention Patients were randomly assigned to undergo mitral valve surgery and RFA of the left atrium (n=49) or mitral valve surgery alone (controls; n=48). Main Outcome Measures The primary outcome measure was presence of sinus rhythm at 12 months; secondary measures were patient functional status and exercise capacity (assessed by shuttle-walk test), left atrial contractility, and left atrial and left ventricular dimension and function and plasma levels of B-type natriuretic peptide. Results At 12 months, sinus rhythm was present in 20 (44.4%) of 45 RFA patients and in 2 (4.5%) of 44 controls (rate ratio, 9.8; 95% Cl, 2.4-86.3; P<.001). Restoration of sinus rhythm in the RFA group was accompanied by a greater improvement in mean (SD) shuttle-walk distance compared with controls (+94 [102] m vs +48 [82] m; P=.003) and a greater reduction in the plasma level of B-type natriuretic peptide (-104 [87] fmol/mL vs -51 [82] fmol/mL; P=.03). Patients randomized to receive RFA had similar rates of postoperative complications and deaths as control patients. Conclusions Radiofrequency ablation of the left atrium during mitral valve surgery for continuous atrial fibrillation significantly increases the rate of sinus rhythm restoration 1 year postoperatively, improving patient exercise capacity. On the basis of its efficacy and safety, routine use of RFA of the left atrium during mitral valve surgery may be justified. Trial Registration ClinicalTrials.gov Identifier: NCT00238706.	Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Cardiac Surg, Leicester LE3 9QP, Leics, England; Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Cardiol, Leicester LE3 9QP, Leics, England; Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England	University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University Hospitals of Leicester NHS Trust; University of Leicester; Glenfield Hospital; University of Leicester	Doukas, G (corresponding author), Univ Hosp Leicester NHS Trust, Glenfield Hosp, Dept Cardiac Surg, Groby Rd, Leicester LE3 9QP, Leics, England.	doukas_george@hotmail.com	OC, Mehmet/AAA-2342-2020	OC, Mehmet/0000-0002-7832-3067; Ng, Leong/0000-0002-6553-5749				Benjamin EJ, 1998, CIRCULATION, V98, P946, DOI 10.1161/01.CIR.98.10.946; Benussi S, 2002, ANN THORAC SURG, V74, P1050, DOI 10.1016/S0003-4975(02)03850-X; BRODELL GK, 1991, CLEV CLIN J MED, V58, P397, DOI 10.3949/ccjm.58.5.397; CHUA YL, 1994, J THORAC CARDIOV SUR, V107, P408, DOI 10.1016/S0022-5223(12)70085-5; COX JL, 1993, ANN THORAC SURG, V56, P814, DOI 10.1016/0003-4975(93)90338-I; de Lima GG, 2004, ANN THORAC SURG, V77, P2089, DOI 10.1016/j.athoracsur.2003.11.018; Deneke T, 2002, EUR HEART J, V23, P558, DOI 10.1053/euhj.2001.2841; Izumoto H, 1998, ANN THORAC SURG, V66, P800, DOI 10.1016/S0003-4975(98)00590-6; Jalife J, 2002, CARDIOVASC RES, V54, P204, DOI 10.1016/S0008-6363(02)00223-7; KANNEL WB, 1982, NEW ENGL J MED, V306, P1018, DOI 10.1056/NEJM198204293061703; Khargi K, 2005, EUR J CARDIO-THORAC, V27, P258, DOI 10.1016/j.ejcts.2004.11.003; Khargi K, 2001, ANN THORAC SURG, V72, pS1090, DOI 10.1016/S0003-4975(01)02940-X; Large SR, 1997, EUR J CARDIO-THORAC, V11, P76, DOI 10.1016/S1010-7940(96)01012-3; Levin ER, 1998, NEW ENGL J MED, V339, P321; Lim E, 2001, CIRCULATION, V104, pI59; Melo J, 1999, EUR J CARDIO-THORAC, V15, P851, DOI 10.1016/S1010-7940(99)00105-0; Mohr FW, 2002, J THORAC CARDIOV SUR, V123, P919, DOI 10.1067/mtc.2002.120730; Morales FJ, 1999, AM HEART J, V138, P291, DOI 10.1016/S0002-8703(99)70114-6; Ng LL, 2002, CLIN SCI, V102, P411, DOI 10.1042/CS20010265; PARSONNET V, 1989, CIRCULATION, V79, P3; Sie HT, 2004, ANN THORAC SURG, V77, P512, DOI 10.1016/S0003-4975(03)01466-8; SINGH SJ, 1992, THORAX, V47, P1019, DOI 10.1136/thx.47.12.1019; Sueda T, 2001, ANN THORAC SURG, V71, P1189, DOI 10.1016/S0003-4975(00)02606-0; Watanabe M, 2003, J HEART VALVE DIS, V12, P287; Yau TM, 2000, J THORAC CARDIOV SUR, V119, P53, DOI 10.1016/S0022-5223(00)70217-0	25	138	139	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2005	294	18					2323	2329		10.1001/jama.294.18.2323	http://dx.doi.org/10.1001/jama.294.18.2323			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981LI	16278360	Bronze			2022-12-28	WOS:000233089700024
J	Keogh, MC; Kurdistani, SK; Morris, SA; Ahn, SH; Podolny, V; Collins, SR; Schuldiner, M; Chin, KY; Punna, T; Thompson, NJ; Boone, C; Emili, A; Weissman, JS; Hughes, TR; Strahl, BD; Grunstein, M; Greenblatt, JF; Buratowski, S; Krogan, NJ				Keogh, MC; Kurdistani, SK; Morris, SA; Ahn, SH; Podolny, V; Collins, SR; Schuldiner, M; Chin, KY; Punna, T; Thompson, NJ; Boone, C; Emili, A; Weissman, JS; Hughes, TR; Strahl, BD; Grunstein, M; Greenblatt, JF; Buratowski, S; Krogan, NJ			Cotranscriptional Set2 methylation of histone H3 lysine 36 recruits a repressive Rpd3 complex	CELL			English	Article							RNA-POLYMERASE-II; TRANSCRIPTION ELONGATION-FACTORS; CHROMATIN REMODELING COMPLEX; REGULATES H3 METHYLATION; H2A VARIANT HTZ1; SACCHAROMYCES-CEREVISIAE; DEACETYLASE COMPLEX; GENE-EXPRESSION; IN-VIVO; TARGETED RECRUITMENT	The yeast histone deacetylase Rpd3 can be recruited to promoters to repress transcription initiation. Biochemical, genetic, and gene-expression analyses show that Rpd3 exists in two distinct complexes. The smaller complex, Rpd3C(S), shares Sin3 and Ume1 with Rpd3C(L) but contains the unique subunits Rco1 and Eaf3. Rpd3C(S) mutants exhibit phenotypes remarkably similar to those of Set2, a histone methyltransferase associated with elongating RNA polymerase II. Chromatin immunoprecipitation and biochemical experiments indicate that the chromodomain of Eaf3 recruits Rpd3C(S) to nucleosomes methylated by Set2 on histone H3 lysine 36, leading to deacetylation of transcribed regions. This pathway apparently acts to negatively regulate transcription because deleting the genes for Set2 or Rpd3C(S) bypasses the requirement for the positive elongation factor Bur1/ Bur2.	Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Univ Calif Los Angeles, David Geffen Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ N Carolina, Sch Med, Dept Biochem & Biophys, Chapel Hill, NC 27599 USA; Univ Calif San Francisco, Howard Hughes Med Inst, Dept Cellular & Mol Pharmacol, San Francisco, CA 94143 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Harvard University; Harvard Medical School; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University of Toronto	Greenblatt, JF (corresponding author), Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, 240 Longwood Ave, Boston, MA 02115 USA.	jack.greenblatt@utoronto.ca; steveb@hms.harvard.edu	Schuldiner, Maya/C-9488-2009; Strahl, Brian/C-7601-2012	Strahl, Brian/0000-0002-4947-6259; Ahn, Seong-Hoon/0000-0002-9174-4966; Schuldiner, Maya/0000-0001-9947-115X; Collins, Sean/0000-0002-4276-5840; Kurdistani, Siavash/0000-0003-3295-3511; Weissman, Jonathan/0000-0003-2445-670X				ARCHAMBAULT J, 1992, MOL CELL BIOL, V12, P4142, DOI 10.1128/MCB.12.9.4142; Arevalo-Rodriguez M, 2000, EMBO J, V19, P3739, DOI 10.1093/emboj/19.14.3739; Bannister AJ, 2001, NATURE, V410, P120, DOI 10.1038/35065138; Bernstein BE, 2000, P NATL ACAD SCI USA, V97, P13708, DOI 10.1073/pnas.250477697; Briggs SD, 2001, GENE DEV, V15, P3286, DOI 10.1101/gad.940201; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cagney G, 2002, NAT BIOTECHNOL, V20, P163, DOI 10.1038/nbt0202-163; Carrozza MJ, 2005, CELL, V123, P581, DOI 10.1016/j.cell.2005.10.023; Carvin CD, 2004, J BIOL CHEM, V279, P33057, DOI 10.1074/jbc.M405033200; Desmoucelles C, 2002, J BIOL CHEM, V277, P27036, DOI 10.1074/jbc.M111433200; Eisen A, 2001, J BIOL CHEM, V276, P3484, DOI 10.1074/jbc.M008159200; Emili A, 2001, MOL CELL, V7, P13, DOI 10.1016/S1097-2765(01)00150-2; EXINGER F, 1992, CURR GENET, V22, P9, DOI 10.1007/BF00351735; Fischer T, 2002, EMBO J, V21, P5843, DOI 10.1093/emboj/cdf590; Grant PA, 1998, TRENDS CELL BIOL, V8, P193, DOI 10.1016/S0962-8924(98)01263-X; Guglielmi B, 2004, NUCLEIC ACIDS RES, V32, P5379, DOI 10.1093/nar/gkh878; Hampsey M, 2003, CELL, V113, P429, DOI 10.1016/S0092-8674(03)00360-X; Hochstrasser M, 1999, PHILOS T ROY SOC B, V354, P1513, DOI 10.1098/rstb.1999.0495; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Jacobs SA, 2002, SCIENCE, V295, P2080, DOI 10.1126/science.1069473; Jacobs SA, 2001, EMBO J, V20, P5232, DOI 10.1093/emboj/20.18.5232; Kadosh D, 1998, MOL CELL BIOL, V18, P5121, DOI 10.1128/MCB.18.9.5121; Kadosh D, 1997, CELL, V89, P365, DOI 10.1016/S0092-8674(00)80217-2; Kaplan CD, 2003, SCIENCE, V301, P1096, DOI 10.1126/science.1087374; Keogh MC, 2003, MOL CELL BIOL, V23, P7005, DOI 10.1128/MCB.23.19.7005-7018.2003; Keogh MC, 2002, MOL CELL BIOL, V22, P1288, DOI 10.1128/MCB.22.5.1288-1297.2002; KEOGH MC, 2005, IN PRESS NATURE; Keogh Michael-Christopher, 2004, Methods Mol Biol, V257, P1, DOI 10.1385/1-59259-750-5:001; Kizer KO, 2005, MOL CELL BIOL, V25, P3305, DOI 10.1128/MCB.25.8.3305-3316.2005; Kobor MS, 2004, PLOS BIOL, V2, P587, DOI 10.1371/journal.pbio.0020131; Kouzarides T, 2002, CURR OPIN GENET DEV, V12, P198, DOI 10.1016/S0959-437X(02)00287-3; Krogan NJ, 2004, MOL CELL, V16, P1027, DOI 10.1016/j.molcel.2004.11.033; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Krogan NJ, 2004, P NATL ACAD SCI USA, V101, P13513, DOI 10.1073/pnas.0405753101; Krogan NJ, 2003, MOL CELL BIOL, V23, P4207, DOI 10.1128/MCB.23.12.4207-4218.2003; Krogan NJ, 2003, MOL CELL, V12, P1565, DOI 10.1016/S1097-2765(03)00497-0; Krogan NJ, 2003, MOL CELL, V11, P721, DOI 10.1016/S1097-2765(03)00091-1; Krogan NJ, 2002, J BIOL CHEM, V277, P10753, DOI 10.1074/jbc.C200023200; Krogan NJ, 2001, MOL CELL BIOL, V21, P8203, DOI 10.1128/MCB.21.23.8203-8212.2001; Kurdistani SK, 2003, METHODS, V31, P90, DOI 10.1016/S1046-2023(03)00092-6; Kurdistani SK, 2002, NAT GENET, V31, P248, DOI 10.1038/ng907; Lachner M, 2002, CURR OPIN CELL BIOL, V14, P286, DOI 10.1016/S0955-0674(02)00335-6; Lachner M, 2001, NATURE, V410, P116, DOI 10.1038/35065132; Laribee RN, 2005, CURR BIOL, V15, P1487, DOI 10.1016/j.cub.2005.07.028; Lechner T, 2000, J BIOL CHEM, V275, P40961, DOI 10.1074/jbc.M005730200; Lennon JC, 1998, MOL CELL BIOL, V18, P5771, DOI 10.1128/MCB.18.10.5771; Li B, 2003, J BIOL CHEM, V278, P8897, DOI 10.1074/jbc.M212134200; Li JX, 2002, J BIOL CHEM, V277, P49383, DOI 10.1074/jbc.M209294200; Li Y, 2001, J BIOL CHEM, V276, P29628, DOI 10.1074/jbc.C100274200; Linder T, 2004, J BIOL CHEM, V279, P49455, DOI 10.1074/jbc.M409046200; Loewith R, 2001, J BIOL CHEM, V276, P24068, DOI 10.1074/jbc.M102176200; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Moris G, 2003, NEUROLOGIA, V18, P723; Mueller CL, 2002, MOL CELL BIOL, V22, P1971, DOI 10.1128/MCB.22.7.1971-1980.2002; Murray S, 2001, MOL CELL BIOL, V21, P4089, DOI 10.1128/MCB.21.13.4089-4096.2001; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Ng HH, 2002, GENE DEV, V16, P1518, DOI 10.1101/gad.1001502; Nielsen PR, 2002, NATURE, V416, P103, DOI 10.1038/nature722; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; Pijnappel WWMP, 2001, GENE DEV, V15, P2991, DOI 10.1101/gad.207401; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Puig S, 2004, J BIOL CHEM, V279, P30298, DOI 10.1074/jbc.M313463200; Reid JL, 2004, MOL CELL BIOL, V24, P757, DOI 10.1128/MCB.24.2.757-764.2004; Rigaut G, 1999, NAT BIOTECHNOL, V17, P1030, DOI 10.1038/13732; Rundlett SE, 1998, NATURE, V392, P831, DOI 10.1038/33952; Schaft D, 2003, NUCLEIC ACIDS RES, V31, P2475, DOI 10.1093/nar/gkg372; Schuldiner M, 2005, CELL, V123, P507, DOI 10.1016/j.cell.2005.08.031; Simic R, 2003, EMBO J, V22, P1846, DOI 10.1093/emboj/cdg179; Squazzo SL, 2002, EMBO J, V21, P1764, DOI 10.1093/emboj/21.7.1764; Stolinski LA, 1997, MOL CELL BIOL, V17, P4490, DOI 10.1128/MCB.17.8.4490; Strahl BD, 2000, NATURE, V403, P41, DOI 10.1038/47412; Suka N, 2001, MOL CELL, V8, P473, DOI 10.1016/S1097-2765(01)00301-X; Suka N, 2002, NAT GENET, V32, P378, DOI 10.1038/ng1017; Sun ZW, 1999, GENETICS, V152, P921; Sun ZW, 2002, NATURE, V418, P104, DOI 10.1038/nature00883; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; van Leeuwen F, 2002, CELL, V109, P745, DOI 10.1016/S0092-8674(02)00759-6; Wang A, 2002, SCIENCE, V298, P1412, DOI 10.1126/science.1077790; Winkler GS, 2001, J BIOL CHEM, V276, P32743, DOI 10.1074/jbc.M105303200; Wittschieben BO, 1999, MOL CELL, V4, P123, DOI 10.1016/S1097-2765(00)80194-X; Xiao TJ, 2005, MOL CELL BIOL, V25, P637, DOI 10.1128/MCB.25.2.637-651.2005; Xiao TJ, 2003, GENE DEV, V17, P654, DOI 10.1101/gad.1055503; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	84	600	619	1	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					593	605		10.1016/j.cell.2005.10.025	http://dx.doi.org/10.1016/j.cell.2005.10.025			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286008	Bronze, Green Published			2022-12-28	WOS:000233497400009
J	Fleming, D				Fleming, D			Influenza pandemics and avian flu	BRITISH MEDICAL JOURNAL			English	Review								Douglas Fleming is general practitioner in a large suburban practice in Birmingham. In this article he seeks to clarify clinical issues relating to potential pandernics of influenza, including avian influenza.	Royal Coll Gen Practitioners, Birmingham Res Unit, Birmingham, W Midlands, England		Fleming, D (corresponding author), Royal Coll Gen Practitioners, Birmingham Res Unit, Birmingham, W Midlands, England.	dfleming@rcgpbhamresunit.nhs.uk						*DOH, 2005, UK HLTH DEP INFL PAN	1	15	16	2	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1066	1069		10.1136/bmj.331.7524.1066	http://dx.doi.org/10.1136/bmj.331.7524.1066			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16269494	Green Published			2022-12-28	WOS:000233211200031
J	Apai, D; Pascucci, I; Bouwman, J; Natta, A; Henning, T; Dullemond, CP				Apai, D; Pascucci, I; Bouwman, J; Natta, A; Henning, T; Dullemond, CP			The onset of planet formation on brown dwarf disks	SCIENCE			English	Article							STAR-FORMING REGION; T-TAURI STARS; GRAIN-GROWTH; POPULATION; SPECTRA	The onset of planet formation in protoplanetary disks is marked by the growth and crystallization of sub-micrometer-sized dust grains accompanied by dust settling toward the disk mid-plane. Here, we present infrared spectra of disks around brown dwarfs and brown dwarf candidates. We show that all three processes occur in such cool disks in, a way similar or identical to that in disks around low- and intermediate-mass stars. These results indicate that the onset of planet formation extends to disks around brown dwarfs, suggesting that planet formation is a robust process occurring in most young circumstellar disks.	Univ Arizona, Steward Observ, Tucson, AZ 85721 USA; NASA, Ames Res Ctr, NASA Astrobiol Inst, Moffett Field, CA 94035 USA; Max Planck Inst Astron, D-69117 Heidelberg, Germany; Osserv Astrofis Arcetri, Inst Nazl Astrofis, I-50125 Florence, Italy	University of Arizona; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; Max Planck Society; Istituto Nazionale Astrofisica (INAF)	Apai, D (corresponding author), Univ Arizona, Steward Observ, 933 N Cherry Ave, Tucson, AZ 85721 USA.	apai@as.arizona.edu	Henning, Thomas K/O-4372-2018	Henning, Thomas K/0000-0002-1493-300X; Bouwman, Jeroen/0000-0003-4757-2500				Apai D, 2004, ASTRON ASTROPHYS, V426, pL53, DOI 10.1051/0004-6361:200400080; Bouwman J, 2001, ASTRON ASTROPHYS, V375, P950, DOI 10.1051/0004-6361:20010878; Chiang EI, 1999, ASTROPHYS J, V519, P279, DOI 10.1086/307351; Comeron F, 2000, ASTRON ASTROPHYS, V359, P269; Crovisier J, 1997, SCIENCE, V275, P1904, DOI 10.1126/science.275.5308.1904; Dullemond CP, 2004, ASTRON ASTROPHYS, V421, P1075, DOI 10.1051/0004-6361:20040284; Forrest WJ, 2004, ASTROPHYS J SUPPL S, V154, P443, DOI 10.1086/423138; Furlan E, 2005, ASTROPHYS J, V628, pL65, DOI 10.1086/432540; Furlan E, 2005, ASTROPHYS J, V621, pL129, DOI 10.1086/429273; Gail HP, 2004, ASTRON ASTROPHYS, V413, P571, DOI 10.1051/0004-6361:20031554; GOLDREIC.P, 1973, ASTROPHYS J, V183, P1051, DOI 10.1086/152291; HENNING T, IN PRESS PLANET FORM; Klein R, 2003, ASTROPHYS J, V593, pL57, DOI 10.1086/377729; LISSAUER JJ, 1993, ANNU REV ASTRON ASTR, V31, P129, DOI 10.1146/annurev.aa.31.090193.001021; Marti BL, 2004, ASTRON ASTROPHYS, V416, P555, DOI 10.1051/0004-6361:20031720; Pascucci I, 2003, ASTROPHYS J, V590, pL111, DOI 10.1086/376773; PASCUCCI I, UNPUB; Przygodda F, 2003, ASTRON ASTROPHYS, V412, pL43, DOI 10.1051/0004-6361:20034606; van Boekel R, 2005, ASTRON ASTROPHYS, V437, P189, DOI 10.1051/0004-6361:20042339; van Boekel R, 2003, ASTRON ASTROPHYS, V400, pL21, DOI 10.1051/0004-6361:20030141; WEIDENSCHILLING SJ, 1977, ASTROPHYS SPACE SCI, V51, P153, DOI 10.1007/BF00642464	22	160	161	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					834	836		10.1126/science.1118042	http://dx.doi.org/10.1126/science.1118042			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16239438	Green Submitted			2022-12-28	WOS:000233121800039
J	Piana, S; Reyhani, M; Gale, JD				Piana, S; Reyhani, M; Gale, JD			Simulating micrometre-scale crystal growth from solution	NATURE			English	Article							UREA CRYSTALS; KINETICS; DISSOLUTION; MECHANISMS; SURFACES; WATER	Understanding crystal growth is essential for controlling the crystallization used in industrial separation and purification processes. Because solids interact through their surfaces, crystal shape can influence both chemical and physical properties(1). The thermodynamic morphology can readily be predicted(2), but most particle shapes are actually controlled by the kinetics of the atomic growth processes through which assembly occurs(3). Here we study the urea - solvent interface at the nanometre scale and report kinetic Monte Carlo simulations of the micrometre- scale three-dimensional growth of urea crystals. These simulations accurately reproduce experimentally observed crystal growth. Unlike previous models of crystal growth(4-6), no assumption is made that the morphology can be constructed from the results for independently growing surfaces or from an a priori specification of surface defect concentration. This approach offers insights into the role of the solvent, the degree of supersaturation, and the contribution that extended defects ( such as screw dislocations) make to crystal growth. It also connects observations made at the nanometre scale, through in situ atomic force microscopy, with those made at the macroscopic level. If extended to include additives, the technique could lead to the computer-aided design of crystals.	Curtin Univ Technol, Dept Appl Chem, Nanochem Res Inst, Perth, WA 6845, Australia	Curtin University	Gale, JD (corresponding author), Curtin Univ Technol, Dept Appl Chem, Nanochem Res Inst, GPO Box U1987, Perth, WA 6845, Australia.	J.Gale@curtin.edu.au	Gale, Julian D/B-7987-2009; Gale, Julian D./AAC-3668-2019; Curtin, SPM Facility/E-7846-2013	Gale, Julian D/0000-0001-9587-9457; Gale, Julian D./0000-0001-9587-9457; 				Boerrigter SXM, 2004, J PHYS CHEM A, V108, P5894, DOI 10.1021/jp049804h; Boomadevi S, 2002, CRYST RES TECHNOL, V37, P159, DOI 10.1002/1521-4079(200202)37:2/3<159::AID-CRAT159>3.0.CO;2-Y; DAVEY R, 1986, J CRYST GROWTH, V79, P607, DOI 10.1016/0022-0248(86)90527-0; DAVEY RJ, 1982, J CRYST GROWTH, V58, P304, DOI 10.1016/0022-0248(82)90277-9; ESSMANN U, 1995, J CHEM PHYS, V103, P8577, DOI 10.1063/1.470117; Fleming S. D., 2005, Z KRISTALLOGR, V220, P1; Gibbs J.W., 1928, COLLECT WORKS; GILLESPIE DT, 1976, J COMPUT PHYS, V22, P403, DOI 10.1016/0021-9991(76)90041-3; HARTMAN P, 1955, ACTA CRYSTALLOGR, V8, P48; Jonsson H, 2000, ANNU REV PHYS CHEM, V51, P623, DOI 10.1146/annurev.physchem.51.1.623; Land TA, 1999, NATURE, V399, P442, DOI 10.1038/20886; Lindahl E, 2001, J MOL MODEL, V7, P306, DOI 10.1007/s008940100045; LIU XY, 1995, NATURE, V374, P342, DOI 10.1038/374342a0; Piana S, 2005, J AM CHEM SOC, V127, P1975, DOI 10.1021/ja043395l; Pina CM, 1998, NATURE, V395, P483, DOI 10.1038/26718; Pinck LA, 1925, J AM CHEM SOC, V47, P2170, DOI 10.1021/ja01685a502; Rodriguez-Hornedo N, 1999, J PHARM SCI, V88, P651, DOI 10.1021/js980490h; Smith LJ, 2004, J PHYS CHEM B, V108, P1065, DOI 10.1021/jp030534x; SWAMINATHAN S, 1984, ACTA CRYSTALLOGR B, V40, P398, DOI 10.1107/S0108768184002378; van Gunsteren W.F., 1996, BIOMOLECULAR SIMULAT, P1; Winn D, 2000, AICHE J, V46, P1348, DOI 10.1002/aic.690460709; Wulff G, 1901, Z KRYSTALLOGR MINERA, V34, P449, DOI 10.1524/zkri.1901.34.1.449	22	176	180	3	166	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					70	73		10.1038/nature04173	http://dx.doi.org/10.1038/nature04173			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267550				2022-12-28	WOS:000232979000042
J	Hoskin, CJ; Higgie, M; McDonald, KR; Moritz, C				Hoskin, CJ; Higgie, M; McDonald, KR; Moritz, C			Reinforcement drives rapid allopatric speciation	NATURE			English	Article							COMPARATIVE PHYLOGEOGRAPHY; EVOLUTION	Allopatric speciation results from geographic isolation between populations. In the absence of gene flow, reproductive isolation arises gradually and incidentally as a result of mutation, genetic drift and the indirect effects of natural selection driving local adaptation(1-3). In contrast, speciation by reinforcement is driven directly by natural selection against maladaptive hybridization(1,4). This gives individuals that choose the traits of their own lineage greater fitness, potentially leading to rapid speciation between the lineages(1,4). Reinforcing natural selection on a population of one of the lineages in a mosaic contact zone could also result in divergence of the population from the allopatric range of its own lineage outside the zone(4-6). Here we test this with molecular data, experimental crosses, field measurements and mate choice experiments in a mosaic contact zone between two lineages of a rainforest frog. We show that reinforcing natural selection has resulted in significant premating isolation of a population in the contact zone not only from the other lineage but also, incidentally, from the closely related main range of its own lineage. Thus we show the potential for reinforcement to drive rapid allopatric speciation.	Univ Queensland, Sch Integrat Biol, St Lucia, Qld 4072, Australia; Queensland Parks & Wildlife Sci, Atherton, Qld 4883, Australia; Univ Calif Berkeley, Museum Vertebrate Zool, Berkeley, CA 94720 USA	University of Queensland; University of California System; University of California Berkeley	Hoskin, CJ (corresponding author), Univ Queensland, Sch Integrat Biol, St Lucia, Qld 4072, Australia.	c.hoskin@sib.uq.edu.au	Hoskin, Conrad J/A-8407-2012; Higgie, Megan/A-6131-2008; Moritz, Craig/A-7755-2012	Hoskin, Conrad J/0000-0001-8116-6085; Higgie, Megan/0000-0002-2397-0240; Moritz, Craig/0000-0001-5313-7279				AGRESTI A, 1990, CATEGORICAL DATA ANA, P239; Anderson EC, 2002, GENETICS, V160, P1217; BARTON NH, 1989, NATURE, V341, P497, DOI 10.1038/341497a0; BIGELOW RS, 1965, EVOLUTION, V19, P449, DOI 10.2307/2406242; BLAIR WF, 1964, Q REV BIOL, V39, P333, DOI 10.1086/404323; Bridle JR, 2004, EVOLUTION, V58, P1394; BUTLIN RK, 1995, TRENDS ECOL EVOL, V10, P432, DOI 10.1016/S0169-5347(00)89173-9; Butlin RK, 1997, NATURE, V387, P551, DOI 10.1038/42355; Cain ML, 1999, EVOLUTION, V53, P1343, DOI [10.2307/2640881, 10.1111/j.1558-5646.1999.tb05399.x]; Coyne J.A., 2004, SPECIATION; Dobzhansky T., 1951, COPEIA; Dolman G, 2004, MOL ECOL NOTES, V4, P185, DOI 10.1111/j.1471-8286.2004.00609.x; Gerhardt HC., 2002, ACOUSTIC COMMUNICATI; Gosner K. L., 1960, Herpetologica, V16, P183; HOWARD DJ, 1993, HYBRID ZONES AND THE EVOLUTIONARY PROCESS, P46; LIOU LW, 1994, EVOLUTION, V48, P1451, DOI 10.1111/j.1558-5646.1994.tb02187.x; Littlejohn M.J., 1981, P298; LITTLEJOHN MJ, 1968, EVOLUTION, V22, P659, DOI 10.1111/j.1558-5646.1968.tb03467.x; Mayr E, 1963, ANIMAL SPECIES EVOLU, P548; Moore J.A., 1957, SPECIES PROBLEM, P325; Noor MAF, 1999, HEREDITY, V83, P503, DOI 10.1038/sj.hdy.6886320; Phillips BL, 2004, EVOLUTION, V58, P1536; SANDERSON N, 1989, EVOLUTION, V43, P1223, DOI [10.2307/2409358, 10.1111/j.1558-5646.1989.tb02570.x]; Schneider C, 1999, P ROY SOC B-BIOL SCI, V266, P191, DOI 10.1098/rspb.1999.0621; Schneider CJ, 1998, MOL ECOL, V7, P487, DOI 10.1046/j.1365-294x.1998.00334.x; Servedio MR, 2003, ANNU REV ECOL EVOL S, V34, P339, DOI 10.1146/annurev.ecolsys.34.011802.132412; SOKAL RR, 1995, BIOMETRY PRINCIPLES, P724; ZOUROS E, 1980, EVOLUTION, V34, P421, DOI 10.1111/j.1558-5646.1980.tb04830.x	28	332	342	4	216	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1353	1356		10.1038/nature04004	http://dx.doi.org/10.1038/nature04004			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251964				2022-12-28	WOS:000232829100053
J	Oliveira, JG; Barabasi, AL				Oliveira, JG; Barabasi, AL			Human dynamics: Darwin and Einstein correspondence patterns	NATURE			English	Editorial Material									Univ Notre Dame, Ctr Complex Network Res, Notre Dame, IN 46556 USA; Univ Notre Dame, Dept Phys, Notre Dame, IN 46556 USA; Univ Aveiro, Dept Fis, P-3810193 Aveiro, Portugal; Harvard Univ, Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA	University of Notre Dame; University of Notre Dame; Universidade de Aveiro; Harvard University; Dana-Farber Cancer Institute	Oliveira, JG (corresponding author), Univ Notre Dame, Ctr Complex Network Res, Notre Dame, IN 46556 USA.	alb@nd.edu	Barabasi, Albert-Laszlo/S-6474-2017; Oliveira, João/H-3256-2012	Oliveira, João/0000-0002-1199-4667; Barabasi, Albert/0000-0002-4028-3522				Abate J, 1997, QUEUEING SYST, V25, P173, DOI 10.1023/A:1019104402024; Barabasi AL, 2005, NATURE, V435, P207, DOI 10.1038/nature03459; Bunde A, 2004, PHYSICA A, V342, P308, DOI 10.1016/j.physa.2004.01.069; Cobham A., 1954, OPER RES, V2, P70; 1984, CORRES C DARWIN, V1; 1993, COLLECTED PAPERS A E, V5; 1993, COLLECTED PAPERS A E, V8; 1993, COLLECTED PAPERS A E, V9; 1993, COLLECTED PAPERS A E, V1; [No title captured]	10	267	299	2	75	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1251	1251		10.1038/4371251a	http://dx.doi.org/10.1038/4371251a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251946	Green Submitted, Bronze			2022-12-28	WOS:000232829100032
J	Yoo, AS; Greenwald, I				Yoo, AS; Greenwald, I			LIN-12/Notch activation leads to micro RNA-mediated down-regulation of vav in C-elegans	SCIENCE			English	Article							CAENORHABDITIS-ELEGANS; VULVAL DEVELOPMENT; PROTEINS; FAMILY; ENCODES; GENES; GLP-1	Cell-cell interactions and cross-talk between signaling pathways specify Caenorhabditis elegans vulval precursor cells (VPCs) to adopt a spatial pattern: a central "1 degrees" VPC, in which epidermal growth factor receptor (EGFR)-mitogen-activated protein kinase (MAPK) activity is high and LIN-12/Notch activity is low, flanked by two "2 degrees" VPCs, in which LIN-12/Notch activity is high and EGFR-MAPK activity is low. Here, we identify a microRNA gene, mir-61, as a direct transcriptional target of LIN-12 and show that expression of mir-61 promotes the 20 fate. We also identify vav-1, the ortholog of the Vav oncogene, as a target of mir-61, and show that down-regulation of VAV-1 promotes lin-12 activity in specifying the 2 degrees fate. Our results suggest that lin-12, mir-61, and vav-1 form a feedback loop that helps maximize lin-12 activity in the presumptive 2 degrees VPCs.	Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Integrated Program Cellular Mol & Biophys Studies, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute; Columbia University	Greenwald, I (corresponding author), Columbia Univ Coll Phys & Surg, Howard Hughes Med Inst, Dept Biochem & Mol Biophys, 701 W 168th St,Room 720, New York, NY 10032 USA.	greenwaid@cancercenter.columbia.edu		Yoo, Andrew/0000-0002-0304-3247	NATIONAL CANCER INSTITUTE [R01CA095389] Funding Source: NIH RePORTER; NCI NIH HHS [CA095389, R01 CA095389-02, R01 CA095389-06A1, R01 CA095389, R01 CA095389-05, R01 CA095389-04, R01 CA095389-03, R01 CA095389-01A1] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Burdine RD, 1998, DEVELOPMENT, V125, P1083; Chang S, 2004, NATURE, V430, P785, DOI 10.1038/nature02752; Chen CZ, 2004, SCIENCE, V303, P83, DOI 10.1126/science.1091903; Chen N, 2004, DEV CELL, V6, P183, DOI 10.1016/S1534-5807(04)00021-8; Cowan CW, 2005, NEURON, V46, P205, DOI 10.1016/j.neuron.2005.03.019; GREENWALD I, 2005, WORMBOOK; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; Harfe BD, 1998, GENE DEV, V12, P2623, DOI 10.1101/gad.12.16.2623; Hubbard EJA, 1997, GENE DEV, V11, P3182, DOI 10.1101/gad.11.23.3182; Johnston RJ, 2003, NATURE, V426, P845, DOI 10.1038/nature02255; LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y; Loria PM, 2004, J NEUROSCI, V24, P2191, DOI 10.1523/JNEUROSCI.5462-03.2004; Norman KR, 2005, CELL, V123, P119, DOI 10.1016/j.cell.2005.08.001; Rebeiz M, 2002, P NATL ACAD SCI USA, V99, P9888, DOI 10.1073/pnas.152320899; Reddien PW, 2001, NATURE, V412, P198, DOI 10.1038/35084096; Shaye DD, 2005, DEVELOPMENT, V132, P5081, DOI 10.1242/dev.02076; Sternberg PW, 2005, WORMBOOK, DOI 10.1895/wormbook.1.6.1; SUNDARAM M, 1993, GENETICS, V135, P765; Tybulewicz VL, 2005, CURR OPIN IMMUNOL, V17, P267, DOI 10.1016/j.coi.2005.04.003; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165; Yoo AS, 2004, SCIENCE, V303, P663, DOI 10.1126/science.1091639; YOO AS, UNPUB	23	108	134	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	2005	310	5752					1330	1333		10.1126/science.1119481	http://dx.doi.org/10.1126/science.1119481			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988KN	16239437	Green Accepted			2022-12-28	WOS:000233600200042
J	Nissen, SE; Wolski, K; Topol, EJ				Nissen, SE; Wolski, K; Topol, EJ			Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROLIFERATOR-ACTIVATED RECEPTOR; CORONARY-HEART-DISEASE; SECONDARY PREVENTION; RISK-FACTORS; TRIAL; ROSIGLITAZONE; DYSLIPIDEMIA; PIOGLITAZONE; GEMFIBROZIL; MEN	Context Peroxisome proliferator-activated receptors (PPARs) are nuclear transcription factors that modulate gene expression. Therapeutic agents targeting 2 distinct families of PPARs (alpha and gamma) have been introduced in the United States. The first dual-PPAR agonist, muraglitazar, was reviewed by a US Food and Drug Administration (FDA) advisory committee on September 9, 2005, resulting in a vote of 8:1 recommending approval for its use in controlling blood glucose levels in patients with type 2 diabetes. Objective To evaluate the incidence of death, myocardial infarction (MI), stroke, congestive heart failure (CHF), and transient ischemic attack (TIA) in diabetic patients treated with muraglitazar compared with controls. Design, Setting, and Participants The source material for this analysis consisted of documents about phase 2 and 3 clinical trials released under public disclosure laws for the FDA advisory committee meeting. All reviewed trials were prospective, randomized, double-blind, multicenter studies enrolling patients with type 2 diabetes and hemoglobin A,c levels between 7% and 10%. Patients (N=3725) were randomized to receive differing doses of muraglitazar, pioglitazone, or placebo as monotherapy or in combination with metformin or glyburide in trials ranging from 24 to 104 weeks. Main Outcome Measures The primary outcome was the incidence of death, nonfatal MI, or nonfatal stroke. A more comprehensive composite outcome included these events plus the incidence of CHF and TIA. Results In the muraglitazar-treated patients, death, MI, or stroke occurred in 35 of 2374 (1.47%) patients compared with 9 of 1351 (0.67%) patients in the combined placebo and pioglitazone treatment groups (controls) (relative risk [RR], 2.23; 95% confidence interval [CI], 1.07-4.66; P = .03). For the more comprehensive outcome measure that included TIA and CHF, the incidence was 50 of 2374 (2.11%) for muraglitazar compared with 11 of 1351 (0.81%) for controls (RR, 2.62; 95% CI, 1.36-5.05; P = .004). Relative risks for each of the individual components of the composite end point exceeded 2.1 but were not statistically significant. Incidence of adjudicated CHF was 13 of 2374 (0.55%) muraglitazar-treated patients and 1 of 1351 controls (0.07%) (RR, 7.43; 95% CI, 0.97-56.8; P = .053). Conclusions Compared with placebo or pioglitazone, muraglitazar was associated with an excess incidence of the composite end point of death, major adverse cardiovascular events (MI, stroke, TIA), and CHF. This agent should not be approved to treat diabetes based on laboratory end points until safety is documented in a dedicated cardiovascular events trial.	Cleveland Clin Fdn, Dept Cardiovasc Med, Cleveland, OH 44195 USA	Cleveland Clinic Foundation	Nissen, SE (corresponding author), Cleveland Clin Fdn, Dept Cardiovasc Med, 9500 Euclid Ave, Cleveland, OH 44195 USA.	nissens@ccf.org		Topol, Eric/0000-0002-1478-4729				Buse JB, 2005, CLIN THER, V27, P1181, DOI 10.1016/j.clinthera.2005.08.005; Campbell IW, 2005, CURR MOL MED, V5, P349, DOI 10.2174/1566524053766068; Despres JP, 2004, DRUGS, V64, P2177, DOI 10.2165/00003495-200464190-00003; Devasthale PV, 2005, J MED CHEM, V48, P2248, DOI 10.1021/jm0496436; Dormandy JA, 2005, LANCET, V366, P1279, DOI 10.1016/S0140-6736(05)67528-9; *END MET DRUG ADV, 2005, END MET DRUG ADV COM; *END MET DRUGS ADV, TABL CONT; FRICK MH, 1987, NEW ENGL J MED, V317, P1237, DOI 10.1056/NEJM198711123172001; Goldberg RB, 2005, DIABETES CARE, V28, P1547, DOI 10.2337/diacare.28.7.1547; Lygate CA, 2003, CARDIOVASC RES, V58, P632, DOI 10.1016/S0008-6363(03)00289-X; Molavi Behzad, 2002, Journal of Cardiovascular Pharmacology and Therapeutics, V7, P1, DOI 10.1177/107424840200700i101; Nesto RW, 2003, CIRCULATION, V108, P2941, DOI 10.1161/01.CIR.0000103683.99399.7E; Riveline JP, 2003, DIABETES METAB, V29, P207, DOI 10.1016/S1262-3636(07)70030-7; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; SAMBANDAM N, 2005, AM J PHYSL HEART SEP; Staels B, 2005, DIABETES, V54, P2460, DOI 10.2337/diabetes.54.8.2460; Steiner G, 2001, LANCET, V357, P905; Vamecq J, 1999, LANCET, V354, P141, DOI 10.1016/S0140-6736(98)10364-1; VUDAC N, 1995, J CLIN INVEST, V96, P741, DOI 10.1172/JCI118118; Xu Y, 2005, AM J PHYSIOL-HEART C, V288, pH1314, DOI 10.1152/ajpheart.00618.2004	20	435	453	1	16	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 23	2005	294	20					2581	2586		10.1001/JAMA.294.20.JOC50147	http://dx.doi.org/10.1001/JAMA.294.20.JOC50147			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986FT	16239637	Bronze			2022-12-28	WOS:000233436200022
J	Muroyama, Y; Fujiwara, Y; Orkin, SH; Rowitch, DH				Muroyama, Y; Fujiwara, Y; Orkin, SH; Rowitch, DH			Specification of astrocytes by bHLH protein SCL in a restricted region of the neural tube	NATURE			English	Article							SPINAL-CORD; STEM-CELLS; MOTOR-NEURON; GENE-EXPRESSION; V2 INTERNEURONS; SCL/TAL-1; IDENTITY; DIFFERENTIATION; PRECURSORS	Astrocytes are the most abundant and functionally diverse glial population in the vertebrate central nervous system (CNS)(1). However, the mechanisms underlying astrocyte specification are poorly understood. It is well established that cellular diversification of neurons in the embryo is generated by position-dependent extrinsic signals and combinatorial interactions of transcription factors that direct specific cell fates by suppressing alternative fates(2). It is unknown whether a comparable process determines embryonic astrocyte identity. Indeed, astrocyte development is generally thought to take place in a position-independent manner(3,4). Here we show multiple functions of Stem cell leukaemia (Scl, also known as Tal1), which encodes a basic helix-loop-helix (bHLH) transcription factor, in the regulation of both astrocyte versus oligodendrocyte cell fate acquisition and V2b versus V2a interneuron cell fate acquisition in the p2 domain of the developing vertebrate spinal cord. Our findings demonstrate a regionally restricted transcriptional programme necessary for astrocyte and V2b interneuron development, with striking parallels to the involvement of SCL in haematopoiesis. They further indicate that acquisition of embryonic glial subtype identity might be regulated by genetic interactions between SCL and the transcription factor Olig2 in the ventral neural tube.	Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Childrens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Childrens Hosp, Div Hematol, Boston, MA 02115 USA; Childrens Hosp, Div Newborn Med, Boston, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Howard Hughes Medical Institute; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Orkin, SH (corresponding author), Dana Farber Canc Inst, Dept Pediat Oncol, 44 Binney St, Boston, MA 02115 USA.	stuart_orkin@dfci.harvard.edu; david_rowitch@dfci.harvard.edu		Muroyama, Yuko/0000-0002-6697-2123; Rowitch, David/0000-0002-0079-0060				Alvarez-Buylla A, 2001, NAT REV NEUROSCI, V2, P287, DOI 10.1038/35067582; Bachoo RM, 2004, P NATL ACAD SCI USA, V101, P8384, DOI 10.1073/pnas.0402140101; Christopherson KS, 2005, CELL, V120, P421, DOI 10.1016/j.cell.2004.12.020; Doetsch F, 2003, NAT NEUROSCI, V6, P1127, DOI 10.1038/nn1144; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Gering M, 1998, EMBO J, V17, P4029, DOI 10.1093/emboj/17.14.4029; Hermanson O, 2002, NATURE, V419, P934, DOI 10.1038/nature01156; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Karunaratne A, 2002, DEV BIOL, V249, P30, DOI 10.1006/dbio.2002.0754; KETTENMANN H, 1988, GLIA, V1, P64, DOI 10.1002/glia.440010108; Lu QR, 2002, CELL, V109, P75, DOI 10.1016/S0092-8674(02)00678-5; Mikkola HKA, 2003, NATURE, V421, P547, DOI 10.1038/nature01345; Nakashima K, 2001, P NATL ACAD SCI USA, V98, P5868, DOI 10.1073/pnas.101109698; Nieto M, 2001, NEURON, V29, P401, DOI 10.1016/S0896-6273(01)00214-8; Novitch BG, 2001, NEURON, V31, P773, DOI 10.1016/S0896-6273(01)00407-X; Orentas DM, 1999, DEVELOPMENT, V126, P2419; Porcher C, 1999, DEVELOPMENT, V126, P4603; Porcher C, 1996, CELL, V86, P47, DOI 10.1016/S0092-8674(00)80076-8; Pringle NP, 2003, DEVELOPMENT, V130, P93, DOI 10.1242/dev.00184; Ross SE, 2003, NEURON, V39, P13, DOI 10.1016/S0896-6273(03)00365-9; Rowitch DH, 2004, NAT REV NEUROSCI, V5, P409, DOI 10.1038/nrn1389; Schlaeger TM, 2004, MOL CELL BIOL, V24, P7491, DOI 10.1128/MCB.24.17.7491-7502.2004; Smith E, 2002, DEV DYNAM, V224, P231, DOI 10.1002/dvdy.10093; Song MR, 2004, NAT NEUROSCI, V7, P229, DOI 10.1038/nn1192; Stolt CC, 2003, GENE DEV, V17, P1677, DOI 10.1101/gad.259003; Thaler JP, 2002, CELL, V110, P237, DOI 10.1016/S0092-8674(02)00823-1; Tronche F, 1999, NAT GENET, V23, P99, DOI 10.1038/12703; Tzeng SF, 1998, GLIA, V24, P372, DOI 10.1002/(SICI)1098-1136(199812)24:4<372::AID-GLIA2>3.0.CO;2-B; Zhou Q, 2002, CELL, V109, P61, DOI 10.1016/S0092-8674(02)00677-3; Zhou YH, 2000, DEVELOPMENT, V127, P3829	30	126	127	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					360	363		10.1038/nature04139	http://dx.doi.org/10.1038/nature04139			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292311				2022-12-28	WOS:000233300200049
J	Smith, BL; Kopans, DB; Koerner, FC; Morrow, M; Davidson, NE; Partridge, AH; Harris, NL				Smith, BL; Kopans, DB; Koerner, FC; Morrow, M; Davidson, NE; Partridge, AH; Harris, NL			Case 35-2005: A 56-year-old woman with breast cancer and isolated tumor cells in a sentinel lymph node - Invasive ductal carcinoma of the breast with isolated tumor cells in a sentinel lymph node (T1b pN0 (i+))	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							NONSENTINEL AXILLARY NODES; POSTOPERATIVE RADIOTHERAPY; ADJUVANT TREATMENT; NATURAL-HISTORY; DISSECTION; WOMEN; METASTASES; THERAPY; TAMOXIFEN; TRIAL		Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA; Fox Chase Canc Ctr, Philadelphia, PA 19111 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Johns Hopkins University; Fox Chase Cancer Center; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Smith, BL (corresponding author), Johns Hopkins Univ, Sch Med, Baltimore, MD 21218 USA.							Abe O, 2005, LANCET, V365, P1687, DOI 10.1016/s0140-6736(05)66544-0; ATKINS H, 1972, BRIT MED J, V2, P423, DOI 10.1136/bmj.2.5811.423; Carter BA, 2000, AM J CLIN PATHOL, V113, P259, DOI 10.1309/7EF8-F1W7-YVNT-H8H5; Chu KU, 1999, ANN SURG ONCOL, V6, P756, DOI 10.1007/s10434-999-0756-2; Colleoni M, 2005, J CLIN ONCOL, V23, P1379, DOI 10.1200/JCO.2005.07.094; Fant JS, 2003, ANN SURG ONCOL, V10, P126, DOI 10.1245/ASO.2003.04.022; Fisher B, 2002, J CLIN ONCOL, V20, P4141, DOI 10.1200/JCO.2002.11.101; Fisher B, 2002, NEW ENGL J MED, V347, P1233, DOI 10.1056/NEJMoa022152; Fournier K, 2004, ANN SURG, V239, P859, DOI 10.1097/01.sla.0000128302.05898.a7; Galper S, 1999, INT J RADIAT ONCOL, V45, P1157, DOI 10.1016/S0360-3016(99)00334-X; Goldhirsch A, 2005, ANN ONCOL, V16, P1569, DOI 10.1093/annonc/mdi326; Goyal A, 2004, EUR J CANCER, V40, P1731, DOI 10.1016/j.ejca.2004.04.006; Greco M, 2000, ANN SURG, V232, P1, DOI 10.1097/00000658-200007000-00001; Greene FL, 2002, AJCC CANC STAGING MA, DOI DOI 10.1007/978-1-4757-3656-4; Guenther JM, 2003, ARCH SURG-CHICAGO, V138, P52, DOI 10.1001/archsurg.138.1.52; HANSEN NM, 2001, P AN M AM SOC CLIN, V20, pA24; Hayes DF, 2003, BREAST, V12, P543, DOI 10.1016/S0960-9776(03)00164-4; Hayward J L, 1977, World J Surg, V1, P314; Holmberg SB, 2004, J CLIN ONCOL, V22, p4S; Howell A, 2005, LANCET, V365, P60, DOI 10.1016/s0140-6736(04)17666-6; Hwang RF, 2003, ANN SURG ONCOL, V10, P248, DOI 10.1245/ASO.2003.05.020; KAAE S, 1977, INT J RADIAT ONCOL, V2, P1163, DOI 10.1016/0360-3016(77)90126-2; Kamath VJ, 2001, ARCH SURG-CHICAGO, V136, P688, DOI 10.1001/archsurg.136.6.688; Kattan MW, 2004, CANCER-AM CANCER SOC, V101, P2509, DOI 10.1002/cncr.20635; Lambert L, 2005, ANN SURG ONCOL, V12, pS17; Langer I, 2005, ANN SURG, V241, P152, DOI 10.1097/01.sla.0000149305.23322.3c; LANGLANDS AO, 1980, BRIT J SURG, V67, P170, DOI 10.1002/bjs.1800670304; Leidenius MHK, 2005, EJSO, V31, P13, DOI 10.1016/j.ejso.2004.09.012; Louis-Sylvestre C, 2004, J CLIN ONCOL, V22, P97, DOI 10.1200/JCO.2004.12.108; Mansel RE, 2004, BREAST CANCER RES TR, V88, pS12; Menes TS, 2005, J AM COLL SURGEONS, V200, P323, DOI 10.1016/j.jamcollsurg.2004.10.022; Mignotte H, 2002, EUR J SURG ONCOL, V28, P623, DOI 10.1053/ejso.2002.1272; Nos C, 2003, BRIT J SURG, V90, P1354, DOI 10.1002/bjs.4325; Olivotto IA, 2005, J CLIN ONCOL, V23, P2716, DOI 10.1200/JCO.2005.06.178; Orr RK, 1999, ANN SURG ONCOL, V6, P109, DOI 10.1007/s10434-999-0109-1; Overgaard M, 1999, LANCET, V353, P1641, DOI 10.1016/S0140-6736(98)09201-0; Overgaard M, 1997, NEW ENGL J MED, V337, P949, DOI 10.1056/NEJM199710023371401; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; PAIK S, 2004, P 27 ANN SAN ANT BRE; QUIET CA, 1995, J CLIN ONCOL, V13, P1144, DOI 10.1200/JCO.1995.13.5.1144; Quiet CA, 1996, J CLIN ONCOL, V14, P3105, DOI 10.1200/JCO.1996.14.12.3105; Ravdin PM, 2001, J CLIN ONCOL, V19, P980, DOI 10.1200/JCO.2001.19.4.980; Sachdev U, 2002, AM J SURG, V183, P213, DOI 10.1016/S0002-9610(02)00794-8; Shapiro CL, 2001, NEW ENGL J MED, V344, P1997, DOI 10.1056/NEJM200106283442607; Singletary SE, 2003, CANCER, V98, P2740, DOI 10.1002/cncr.11865; Sobin, 2009, UICC TNM CLASSIFICAT; Thurlimann BJ, 2005, J CLIN ONCOL, V23, p6S; Travagli JP, 2003, EUR J SURG ONCOL, V29, P403, DOI 10.1053/ejso.2002.1427; Van Zee KJ, 2003, ANN SURG ONCOL, V10, P1140, DOI 10.1245/ASO.2003.03.015; Veronesi U, 2003, NEW ENGL J MED, V349, P546, DOI 10.1056/NEJMoa012782; Viale G, 2005, ANN SURG, V241, P319, DOI 10.1097/01.sla.0000150255.30665.52; Winer EP, 2005, J CLIN ONCOL, V23, P619, DOI 10.1200/JCO.2005.09.121; Wong SL, 2001, ARCH SURG-CHICAGO, V136, P563, DOI 10.1001/archsurg.136.5.563	53	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2177	2185		10.1056/NEJMcpc059030	http://dx.doi.org/10.1056/NEJMcpc059030			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291988				2022-12-28	WOS:000233288600012
J	Bunker, DE; DeClerck, F; Bradford, JC; Colwell, RK; Perfecto, I; Phillips, OL; Sankaran, M; Naeem, S				Bunker, DE; DeClerck, F; Bradford, JC; Colwell, RK; Perfecto, I; Phillips, OL; Sankaran, M; Naeem, S			Species loss and aboveground carbon storage in a tropical forest	SCIENCE			English	Article							ECOSYSTEM FUNCTION; AMAZONIAN FORESTS; PLANT DIVERSITY; BIODIVERSITY; EXTINCTION; GRASSLAND; TREE; DEFORESTATION; COMMUNITIES; SCENARIOS	Tropical forest biodiversity is declining, but the resulting effects on key ecosystem services, such as carbon storage and sequestration, remain unknown. We assessed the influence of the loss of tropical tree species on carbon storage by simulating 18 possible extinction scenarios within a well-studied 50-hectare tropical forest plot in Panama, which contains 227 tree species. Among extinction scenarios, aboveground carbon stocks varied by more than 600%, and biological insurance varied by more than 400%. These results indicate that future carbon storage in tropical forests will be influenced strongly by future species composition.	Columbia Univ, Dept Ecol Evolut & Environm Biol, New York, NY 10027 USA; Columbia Univ, Earth Inst, New York, NY 10027 USA; Missouri Bot Garden, Ctr Conservat & Sustainable Dev, St Louis, MO 63166 USA; Univ Connecticut, Dept Ecol & Evolutionary Biol, Storrs, CT 06269 USA; Univ Michigan, Sch Nat Resources & Environm, Ann Arbor, MI 48109 USA; Univ Leeds, Sch Geog, Earth & Biosphere Inst, Leeds LS 9JT, W Yorkshire, England; Colorado State Univ, Nat Resource Ecol Lab, Ft Collins, CO 80523 USA	Columbia University; Columbia University; Missouri Botanical Gardens; University of Connecticut; University of Michigan System; University of Michigan; University of Leeds; Colorado State University	Bunker, DE (corresponding author), Columbia Univ, Dept Ecol Evolut & Environm Biol, New York, NY 10027 USA.	deb37@columbia.edu	DeClerck, Fabrice A.J./C-3642-2012; Colwell, Robert K/C-7276-2015; Phillips, Oliver/A-1523-2011	Phillips, Oliver/0000-0002-8993-6168	Natural Environment Research Council [NE/B503384/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Bai YF, 2004, NATURE, V431, P181, DOI 10.1038/nature02850; Brook BW, 2003, NATURE, V424, P420, DOI 10.1038/nature01795; CONDIT R, 1995, ECOL MONOGR, V65, P419, DOI 10.2307/2963497; Condit R, 1998, TROPICAL FOREST CENS; Duraiappah A. K., 2005, MILLENNIUM ECOSYSTEM; Engelhardt KAM, 2001, NATURE, V411, P687, DOI 10.1038/35079573; Gaston K.J., 1994, RARITY, P1; Hector A, 1999, SCIENCE, V286, P1123, DOI 10.1126/science.286.5442.1123; Hooper DU, 1997, SCIENCE, V277, P1302, DOI 10.1126/science.277.5330.1302; Houghton RA, 2000, NATURE, V403, P301, DOI 10.1038/35002062; Hulme M, 1998, CLIMATIC CHANGE, V39, P145, DOI 10.1023/A:1005376007729; Huston MA, 1997, OECOLOGIA, V110, P449, DOI 10.1007/s004420050180; Laurance WF, 1999, BIOL CONSERV, V91, P101, DOI 10.1016/S0006-3207(99)00087-7; Laurance WF, 2004, NATURE, V428, P171, DOI 10.1038/nature02383; Lewis SL, 2004, PHILOS T ROY SOC B, V359, P421, DOI 10.1098/rstb.2003.1431; Loreau M, 2001, NATURE, V412, P72, DOI 10.1038/35083573; Malhi Y, 2004, PHILOS T R SOC B, V359, P311, DOI 10.1098/rstb.2003.1433; Milner-Gulland EJ, 2001, TRENDS ECOL EVOL, V16, P686, DOI 10.1016/S0169-5347(01)02278-9; Nepstad DC, 1999, NATURE, V398, P505, DOI 10.1038/19066; Novacek MJ, 2001, P NATL ACAD SCI USA, V98, P5466, DOI 10.1073/pnas.091093698; Peters HA, 2003, ECOL LETT, V6, P757, DOI 10.1046/j.1461-0248.2003.00492.x; Phillips OL, 2002, NATURE, V418, P770, DOI 10.1038/nature00926; Purvis A, 2000, P ROY SOC B-BIOL SCI, V267, P1947, DOI 10.1098/rspb.2000.1234; Reich PB, 2001, NATURE, V410, P809, DOI 10.1038/35071062; Roscher C, 2005, ECOL LETT, V8, P419, DOI 10.1111/j.1461-0248.2005.00736.x; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Schimel DS, 2001, NATURE, V414, P169, DOI 10.1038/35102500; Schlesinger WH, 1997, BIOGEOCHEMISTRY; Solan M, 2004, SCIENCE, V306, P1177, DOI 10.1126/science.1103960; Symstad AJ, 2000, ECOLOGY, V81, P99, DOI 10.1890/0012-9658(2000)081[0099:ATOTEO]2.0.CO;2; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Uriarte M, 2004, J ECOL, V92, P348, DOI 10.1111/j.0022-0477.2004.00867.x; Wardle DA, 1999, OIKOS, V87, P403, DOI 10.2307/3546757	33	284	318	10	184	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2005	310	5750					1029	1031		10.1126/science.1117682	http://dx.doi.org/10.1126/science.1117682			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16239439				2022-12-28	WOS:000233343400047
J	Calford, MB; Chino, YM; Das, A; Eysel, UT; Gilbert, CD; Heinen, SJ; Kaas, JH; Ullman, S				Calford, MB; Chino, YM; Das, A; Eysel, UT; Gilbert, CD; Heinen, SJ; Kaas, JH; Ullman, S			Neuroscience - Rewiring the adult brain	NATURE			English	Editorial Material							PRIMARY VISUAL-CORTEX; CORTICAL REORGANIZATION; RETINAL LESIONS; FILLING-IN; PLASTICITY; CONNECTIONS; NEURONS		Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2308, Australia; Univ Houston, Coll Optometry, Houston, TX 77004 USA; Columbia Univ, Sch Med, New York, NY 10032 USA; Ruhr Univ Bochum, Fac Med, Dept Neurophysiol, D-44780 Bochum, Germany; Rockefeller Univ, New York, NY 10021 USA; Smith Kettlewell Eye Res Inst, San Francisco, CA 94115 USA; Vanderbilt Univ, Nashville, TN 37240 USA	University of Newcastle; University of Houston System; University of Houston; Columbia University; Ruhr University Bochum; Rockefeller University; The Smith-Kettlewell Eye Research Institute; Vanderbilt University	Calford, MB (corresponding author), Univ Newcastle, Sch Biomed Sci, Newcastle, NSW 2308, Australia.		Calford, Mike/B-4637-2009	Calford, Mike/0000-0002-5727-0234; Eysel, Ulf/0000-0001-6087-957X	NEI NIH HHS [R24 EY015634-03, R01 EY002686, R24 EY015634-02, R24 EY015634-04, R24 EY015634, R24 EY015634-01] Funding Source: Medline; NINDS NIH HHS [R01 NS016446] Funding Source: Medline; NATIONAL EYE INSTITUTE [R24EY015634, R01EY002686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS016446] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Arckens L, 2000, EUR J NEUROSCI, V12, P4222, DOI 10.1046/j.0953-816X.2000.01328.x; Calford MB, 2000, J PHYSIOL-LONDON, V524, P587, DOI 10.1111/j.1469-7793.2000.t01-1-00587.x; Calford MB, 2003, J NEUROSCI, V23, P6434; CHINO YM, 1995, J NEUROSCI, V15, P2417, DOI 10.1523/JNEUROSCI.15-03-02417.1995; CRAIK KJW, 1966, NATURE PSYCHOL, P98; DARIANSMITH C, 1994, NATURE, V368, P737, DOI 10.1038/368737a0; DAS A, 1995, NATURE, V375, P780, DOI 10.1038/375780a0; EYSEL UT, 1982, NATURE, V299, P442, DOI 10.1038/299442a0; GERRITS HJM, 1969, VISION RES, V9, P439, DOI 10.1016/0042-6989(69)90092-3; GILBERT CD, 1990, COLD SPRING HARB SYM, V55, P663; HEINEN SJ, 1991, EXP BRAIN RES, V83, P670; KAAS JH, 1990, SCIENCE, V248, P229, DOI 10.1126/science.2326637; Obata S, 1999, CEREB CORTEX, V9, P238, DOI 10.1093/cercor/9.3.238; Smirnakis SM, 2005, NATURE, V435, P300, DOI 10.1038/nature03495; Zur D, 2003, VISION RES, V43, P971, DOI 10.1016/S0042-6989(03)00038-5	15	38	38	1	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2005	438	7065					E3	E3		10.1038/nature04359	http://dx.doi.org/10.1038/nature04359			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16280984	Bronze			2022-12-28	WOS:000233133500037
J	Kragelund, C; Omland, T				Kragelund, C; Omland, T			A farewell to body-mass index?	LANCET			English	Editorial Material							MYOCARDIAL-INFARCTION; RISK-FACTORS; MORTALITY; OBESITY; IMPACT		Akershus Univ Hosp, Dept Med, NO-1478 Lorenskog, Norway; Univ Oslo, Akershus Univ Hosp, Fac Div, Dept Med, Oslo, Norway	University of Oslo; University of Oslo	Kragelund, C (corresponding author), Akershus Univ Hosp, Dept Med, NO-1478 Lorenskog, Norway.	kragelund@dadlnet.dk						Calle EE, 1999, NEW ENGL J MED, V341, P1097, DOI 10.1056/NEJM199910073411501; Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404; International Diabetes Federation, 2005, IDF CONS WORLDW DEF; Jin RY, 2005, CIRCULATION, V111, P3359, DOI 10.1161/CIRCULATIONAHA.104.489880; Kahn R, 2005, DIABETES CARE, V28, P2289, DOI 10.2337/diacare.28.9.2289; Knowler WC, 2002, NEW ENGL J MED, V346, P393, DOI 10.1056/NEJMoa012512; Kragelund C, 2005, INT J CARDIOL, V98, P123, DOI 10.1016/j.ijcard.2004.03.042; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Snijder MB, 2002, INT J OBESITY, V26, P984, DOI 10.1038/sj.ijo.0801968; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2005, LANCET, V366, P1640, DOI 10.1016/S0140-6736(05)67663-5; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	12	77	82	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 5	2005	366	9497					1589	1591		10.1016/S0140-6736(05)67642-8	http://dx.doi.org/10.1016/S0140-6736(05)67642-8			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271629				2022-12-28	WOS:000233047100005
J	Chernomordik, LV; Kozlov, MM				Chernomordik, LV; Kozlov, MM			Membrane hemifusion: Crossing a chasm in two leaps	CELL			English	Review							INFLUENZA HEMAGGLUTININ; FUSION PROTEIN; BILAYER-MEMBRANES; PHASE-FORMATION; PORE FORMATION; CLASS-I; VIRUS; MODEL; SNARES; INTERMEDIATE	During membrane fusion, the outer leaflets of the two membranes merge first, whereas the distal membrane leaflets remain separate until the opening of a fusion pore. This intermediate stage, called hemifusion, is a critical event shared by exocytosis, protein trafficking, and viral entry.	NICHHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, Sect Membrane Biol,NIH, Bethesda, MD 20892 USA; Tel Aviv Univ, Sackler Fac Med, Dept Physiol & Pharmacol, IL-69978 Tel Aviv, Israel	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Tel Aviv University; Sackler Faculty of Medicine	Chernomordik, LV (corresponding author), NICHHD, Sect Membrane Biol, Lab Cellular & Mol Biophys, Sect Membrane Biol,NIH, Bethesda, MD 20892 USA.	chernoml@mail.nih.gov; michk@post.tau.ac.il			Intramural NIH HHS Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD001501] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD001501] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Armstrong RT, 2000, J CELL BIOL, V151, P425, DOI 10.1083/jcb.151.2.425; Blumenthal R, 2003, CHEM REV, V103, P53, DOI 10.1021/cr000036+; CHERNOMORDIK LV, 1987, BIOCHIM BIOPHYS ACTA, V906, P309, DOI 10.1016/0304-4157(87)90016-5; Chernomordik LV, 2003, ANNU REV BIOCHEM, V72, P175, DOI 10.1146/annurev.biochem.72.121801.161504; Chernomordik LV, 1998, J CELL BIOL, V140, P1369, DOI 10.1083/jcb.140.6.1369; CHERNOMORDIK LV, 1993, FEBS LETT, V318, P71, DOI 10.1016/0014-5793(93)81330-3; COHEN FS, 1980, J GEN PHYSIOL, V75, P251, DOI 10.1085/jgp.75.3.251; Cohen FS, 2004, J MEMBRANE BIOL, V199, P1, DOI 10.1007/s00232-004-0669-8; Coorssen JR, 2003, J CELL SCI, V116, P2087, DOI 10.1242/jcs.00374; Earp LJ, 2005, CURR TOP MICROBIOL, V285, P25; Gaudin Y, 2000, J CELL BIOL, V150, P601, DOI 10.1083/jcb.150.3.601; Gibbons DL, 2004, NATURE, V427, P320, DOI 10.1038/nature02239; Giraudo CG, 2005, J CELL BIOL, V170, P249, DOI 10.1083/jcb.200501093; Grote E, 2000, J CELL BIOL, V151, P453, DOI 10.1083/jcb.151.2.453; Han X, 2004, SCIENCE, V304, P289, DOI 10.1126/science.1095801; Han X, 2005, BIOPHYS J, V88, pL20, DOI 10.1529/biophysj.104.056739; Hu C, 2003, SCIENCE, V300, P1745, DOI 10.1126/science.1084909; Jahn R, 2003, CELL, V112, P519, DOI 10.1016/S0092-8674(03)00112-0; Jahn R, 2002, CURR OPIN CELL BIOL, V14, P488, DOI 10.1016/S0955-0674(02)00356-3; Jones NA, 2004, VIROLOGY, V324, P213, DOI 10.1016/j.virol.2004.03.024; Katsov K, 2004, BIOPHYS J, V87, P3277, DOI 10.1529/biophysj.103.038943; KEMBLE GW, 1994, CELL, V76, P383, DOI 10.1016/0092-8674(94)90344-1; Kozlov MM, 2002, TRAFFIC, V3, P256, DOI 10.1034/j.1600-0854.2002.030403.x; KOZLOV MM, 1983, BIOFIZIKA+, V28, P242; Kozlovsky Y, 2002, BIOPHYS J, V82, P882, DOI 10.1016/S0006-3495(02)75450-7; Kozlovsky Y, 2004, BIOPHYS J, V87, P2508, DOI 10.1529/biophysj.103.038075; Kuzmin PI, 2001, P NATL ACAD SCI USA, V98, P7235, DOI 10.1073/pnas.121191898; Lee J, 1997, BIOCHEMISTRY-US, V36, P6251, DOI 10.1021/bi970404c; Lu XB, 2005, J BIOL CHEM, V280, P30538, DOI 10.1074/jbc.M506862200; Markin VS, 2002, BIOPHYS J, V82, P693, DOI 10.1016/S0006-3495(02)75432-5; Markosyan RM, 2004, BIOPHYS J, V87, P3291, DOI 10.1529/biophysj.104.047696; Marrink SJ, 2004, BIOPHYS J, V87, P3894, DOI 10.1529/biophysj.104.048710; May S, 2002, BIOPHYS J, V83, P2969, DOI 10.1016/S0006-3495(02)75303-4; Mayer A, 2002, ANNU REV CELL DEV BI, V18, P289, DOI 10.1146/annurev.cellbio.18.032202.114809; McNew JA, 2000, J CELL BIOL, V150, P105, DOI 10.1083/jcb.150.1.105; Melikyan GB, 2000, J CELL BIOL, V151, P413, DOI 10.1083/jcb.151.2.413; Melikyan GB, 2005, P NATL ACAD SCI USA, V102, P8728, DOI 10.1073/pnas.0501864102; Mittal A, 2003, BIOPHYS J, V85, P1713, DOI 10.1016/S0006-3495(03)74601-3; Mohler WA, 2002, DEV CELL, V2, P355, DOI 10.1016/S1534-5807(02)00129-6; Reese C, 2005, NATURE, V436, P410, DOI 10.1038/nature03722; Sandre O, 1999, P NATL ACAD SCI USA, V96, P10591, DOI 10.1073/pnas.96.19.10591; Schibli DJ, 2004, MOL MEMBR BIOL, V21, P361, DOI 10.1080/09687860400017784; Shillcock JC, 2005, NAT MATER, V4, P225, DOI 10.1038/nmat1333; Szule JA, 2004, SCIENCE, V306; Tamm LK, 2003, CURR OPIN STRUC BIOL, V13, P453, DOI 10.1016/S0959-440X(03)00107-6; Weber T, 1998, CELL, V92, P759, DOI 10.1016/S0092-8674(00)81404-X; Xu YB, 2005, NAT STRUCT MOL BIOL, V12, P417, DOI 10.1038/nsmb921; Yang L, 2003, BIOCHEMISTRY-US, V42, P6631, DOI 10.1021/bi0344836; Yang L, 2002, SCIENCE, V297, P1877, DOI 10.1126/science.1074354; Yang XZ, 2005, J VIROL, V79, P12132, DOI 10.1128/JVI.79.19.12132-12147.2005; Zaitseva E, 2005, J CELL BIOL, V169, P167, DOI 10.1083/jcb.200412059; Zavorotinskaya T, 2004, J VIROL, V78, P473, DOI 10.1128/JVI.78.1.473-481.2004	52	260	271	2	32	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					375	382		10.1016/j.cell.2005.10.015	http://dx.doi.org/10.1016/j.cell.2005.10.015			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269330	Bronze			2022-12-28	WOS:000233264300007
J	Frenking, G				Frenking, G			Building a quintuple bond	SCIENCE			English	Editorial Material							ANALOG; ALKYNE		Univ Marburg, Fachbereich Chem, D-35039 Marburg, Germany	Philipps University Marburg	Frenking, G (corresponding author), Univ Marburg, Fachbereich Chem, Hans Meerwein Str, D-35039 Marburg, Germany.	frenking@chemie.uni-marburg.de						Cotton F. A., 2005, MULTIPLE BONDS METAL; COTTON FA, 1964, SCIENCE, V145, P1305, DOI 10.1126/science.145.3638.1305; Nguyen T, 2005, SCIENCE, V310, P844, DOI 10.1126/science.1116789; Phillips AD, 2002, J AM CHEM SOC, V124, P5930, DOI 10.1021/ja0257164; Pu LH, 2000, J AM CHEM SOC, V122, P3524, DOI 10.1021/ja993346m; Sekiguchi A, 2004, SCIENCE, V305, P1755, DOI 10.1126/science.1102209; Stender M., 2002, ANGEW CHEM, V114, P1863	7	81	81	2	48	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					796	797		10.1126/science.1120281	http://dx.doi.org/10.1126/science.1120281			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272107				2022-12-28	WOS:000233121800029
J	Yoshihara, M; Adolfsen, B; Galle, KT; Littleton, JT				Yoshihara, M; Adolfsen, B; Galle, KT; Littleton, JT			Retrograde signalling by Syt 4 induces presynaptic release and synapse-specific growth	SCIENCE			English	Article							PROTEIN-KINASE-A; LONG-TERM POTENTIATION; TRANSMITTER RELEASE; SYNAPTOTAGMIN-I; NEUROTRANSMITTER RELEASE; MEMORY STORAGE; DROSOPHILA; CAMP; EXPRESSION; SECRETION	The molecular pathways involved in retrograde signal transduction at synapses and the function of retrograde communication are poorly understood. Here, we demonstrate that postsynaptic calcium 2+ ion (Ca2+) influx through glutamate receptors and subsequent postsynaptic vesicle fusion trigger a robust induction of presynaptic miniature release after high-frequency stimulation at Drosophila neuromuscular. junctions. An isoform of the synaptotagmin family, synaptotagmin 4 (Syt 4), serves as a postsynaptic Ca2+ sensor to release retrograde signals that stimulate enhanced presynaptic function through activation of the cyclic adenosine monophosphate (cAMP)-cAMP-dependent protein kinase pathway. Postsynaptic Ca2+ influx also stimulates local synaptic differentiation and growth through Syt 4-mediated retrograde signals in a synapse-, specific manner.	MIT, Dept Biol, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Northwell Health	Yoshihara, M (corresponding author), MIT, Dept Biol, Picower Inst Learning & Memory, Dept Brain & Cognit Sci, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	motojiro@mit.edu		Littleton, J. Troy/0000-0001-5576-2887	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS040296, R01NS043244] Funding Source: NIH RePORTER; NINDS NIH HHS [R01 NS043244, R01 NS040296-06, R01 NS040296] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Adolfsen B, 2004, J CELL BIOL, V166, P249, DOI 10.1083/jcb.200312054; AGNEL M, 1989, GENE DEV, V3, P85, DOI 10.1101/gad.3.1.85; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Davis GW, 1997, NEURON, V19, P561, DOI 10.1016/S0896-6273(00)80372-4; DiAntonio A, 1999, J NEUROSCI, V19, P3023; Frey U, 1997, NATURE, V385, P533, DOI 10.1038/385533a0; GEPPERT M, 1994, CELL, V79, P717, DOI 10.1016/0092-8674(94)90556-8; Hebb Donald O., 1949, ORG BEHAV; Kalinovsky A, 2004, CURR OPIN NEUROBIOL, V14, P272, DOI 10.1016/j.conb.2004.05.011; Kandel ER, 2001, SCIENCE, V294, P1030, DOI 10.1126/science.1067020; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LANE ME, 1993, GENE DEV, V7, P1229, DOI 10.1101/gad.7.7a.1229; LI W, 1995, CELL, V80, P553, DOI 10.1016/0092-8674(95)90509-X; Littleton JT, 1999, NATURE, V400, P757, DOI 10.1038/23462; Ludwig M, 2003, TRENDS NEUROSCI, V26, P255, DOI 10.1016/S0166-2236(03)00072-9; Martin KC, 1997, CELL, V91, P927, DOI 10.1016/S0092-8674(00)80484-5; Miesenbock G, 1998, NATURE, V394, P192, DOI 10.1038/28190; Neveu D, 1996, NEURON, V16, P619, DOI 10.1016/S0896-6273(00)80081-1; POW DV, 1989, NEUROSCIENCE, V32, P435, DOI 10.1016/0306-4522(89)90091-2; SCHULZE KL, 1995, CELL, V80, P311, DOI 10.1016/0092-8674(95)90414-X; SCHUSTER CM, 1991, SCIENCE, V254, P112, DOI 10.1126/science.1681587; SKOULAKIS EMC, 1993, NEURON, V11, P197, DOI 10.1016/0896-6273(93)90178-T; VICIAN L, 1995, P NATL ACAD SCI USA, V92, P2164, DOI 10.1073/pnas.92.6.2164; Waddell S, 2000, CELL, V103, P805, DOI 10.1016/S0092-8674(00)00183-5; Yoshihara M, 1997, J NEUROSCI, V17, P8408; Yoshihara M, 2002, NEURON, V36, P897, DOI 10.1016/S0896-6273(02)01065-6; Yoshihara M, 2000, J NEUROSCI, V20, P8315, DOI 10.1523/JNEUROSCI.20-22-08315.2000; Yoshihara M, 1999, J NEUROSCI, V19, P2432; ZHONG Y, 1992, J NEUROSCI, V12, P644	29	104	107	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					858	863		10.1126/science.1117541	http://dx.doi.org/10.1126/science.1117541			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272123				2022-12-28	WOS:000233121800047
J	Kinlen, L				Kinlen, L			Richard Doll (1912-2005) Epidemiologist extraordinary. Obituary	NATURE			English	Biographical-Item									Canc Epidemiol Unit, Oxford OX3 7LF, England	University of Oxford	Kinlen, L (corresponding author), Canc Epidemiol Unit, Richard Doll Bldg,Roosevelt Dr, Oxford OX3 7LF, England.	leo.kinlen@dphpc.ox.ac.uk							0	1	1	0	2	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 3	2005	438	7064					41	41		10.1038/438041a	http://dx.doi.org/10.1038/438041a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267544				2022-12-28	WOS:000232979000032
J	Lipford, JR; Smith, GT; Chi, Y; Deshaies, RJ				Lipford, JR; Smith, GT; Chi, Y; Deshaies, RJ			A putative stimulatory role for activator turnover in gene expression	NATURE			English	Article							PROTEASOME INHIBITION; TRANSCRIPTION; GCN4; DEGRADATION; RECRUITMENT; PROTEOLYSIS; GAL4	The ubiquitin - proteasome system (UPS) promotes the destruction of target proteins by attaching to them a ubiquitin chain that is recognized by the 26S proteasome(1). The UPS influences most cellular processes, and its targets include transcriptional activators that are primary determinants of gene expression. Emerging evidence indicates that non-proteolytic functions of the UPS might stimulate transcriptional activity(2,3). Here we show that the proteolysis of some transcriptional activators by the UPS can stimulate their function. We focused on the role of UPS-dependent proteolysis in the function of inducible transcriptional activators in yeast, and found that inhibition of the proteasome(4) reduced transcription of the targets of the activators Gcn4, Gal4 and Ino2/4. In addition, mutations in SCFCdc4, the ubiquitin ligase for Gcn4 (ref. 5), or mutations in ubiquitin that prevent degradation(6), also impaired the transcription of Gcn4 targets. These transcriptional defects were manifested despite the enhanced abundance of Gcn4 on cognate promoters. Proteasome inhibition also decreased the association of RNA polymerase II with Gcn4, Gal4 and Ino2/4 targets, as did mutations in SCFCdc4 for Gcn4 targets. Expression of a stable phospho-site mutant of Gcn4 ( ref. 7) or disruption of the kinases that target Gcn4 for turnover(5,7) alleviated the sensitivity of Gcn4 activity to defects in the UPS.	CALTECH, Div Biol, Howard Hughes Med Inst, Pasadena, CA 91125 USA	California Institute of Technology; Howard Hughes Medical Institute	Deshaies, RJ (corresponding author), CALTECH, Div Biol, Howard Hughes Med Inst, MC 156-29,1200 E Calif Blvd, Pasadena, CA 91125 USA.	deshaies@caltech.edu	Deshaies, Raymond/B-8354-2014	Deshaies, Raymond/0000-0002-3671-9354				Adams J, 2004, CANCER INVEST, V22, P304, DOI 10.1081/CNV-120030218; Albrecht G, 1998, J BIOL CHEM, V273, P12696, DOI 10.1074/jbc.273.21.12696; APARICIO O, 2004, CURRENT PROTOCOLS MO; Chi Y, 2001, GENE DEV, V15, P1078, DOI 10.1101/gad.867501; DRYSDALE CM, 1995, MOL CELL BIOL, V15, P1220, DOI 10.1128/MCB.15.3.1220; FINLEY D, 1994, MOL CELL BIOL, V14, P5501, DOI 10.1128/MCB.14.8.5501; Fleming JA, 2002, P NATL ACAD SCI USA, V99, P1461, DOI 10.1073/pnas.032516399; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Guthrie C, 1991, GUIDE YEAST GENETICS; HILT W, 1993, J BIOL CHEM, V268, P3479; Hinnebusch AG, 2002, EUKARYOT CELL, V1, P22, DOI 10.1128/EC.01.1.22-32.2002; Hirst M, 1999, MOL CELL, V3, P673, DOI 10.1016/S1097-2765(00)80360-3; Kim SY, 2003, MOL CELL, V11, P1177, DOI 10.1016/S1097-2765(03)00173-4; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Lee DH, 1998, TRENDS CELL BIOL, V8, P397, DOI 10.1016/S0962-8924(98)01346-4; Lipford JR, 2003, NAT CELL BIOL, V5, P845, DOI 10.1038/ncb1003-845; Meimoun A, 2000, MOL BIOL CELL, V11, P915, DOI 10.1091/mbc.11.3.915; Mitsiades N, 2002, P NATL ACAD SCI USA, V99, P14374, DOI 10.1073/pnas.202445099; Morris MC, 2003, NATURE, V423, P1009, DOI 10.1038/nature01720; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Pickart CM, 2004, CELL, V116, P181, DOI 10.1016/S0092-8674(03)01074-2; Reid G, 2003, MOL CELL, V11, P695, DOI 10.1016/S1097-2765(03)00090-X; Salghetti SE, 2001, SCIENCE, V293, P1651, DOI 10.1126/science.1062079; Stitzel ML, 2001, GENE DEV, V15, P128, DOI 10.1101/gad.863801; Verma R, 2002, SCIENCE, V298, P611, DOI 10.1126/science.1075898; von der Lehr N, 2003, MOL CELL, V11, P1189, DOI 10.1016/S1097-2765(03)00193-X	27	151	156	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					113	116		10.1038/nature04098	http://dx.doi.org/10.1038/nature04098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267558	Green Accepted			2022-12-28	WOS:000232979000052
J	Sandborn, WJ; Colombel, JF; Enns, R; Feagan, BG; Hanauer, SB; Lawrance, IC; Panaccione, R; Sanders, M; Schreiber, S; Targan, S; van Deventer, S; Goldblum, R; Despain, D; Hogge, GS; Rutgeerts, P				Sandborn, WJ; Colombel, JF; Enns, R; Feagan, BG; Hanauer, SB; Lawrance, IC; Panaccione, R; Sanders, M; Schreiber, S; Targan, S; van Deventer, S; Goldblum, R; Despain, D; Hogge, GS; Rutgeerts, P		ENACT-1 Trial Grp; ENACT-2 Trial Grp	Natalizumab induction and maintenance therapy for Crohn's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PLACEBO-CONTROLLED TRIAL; HUMANIZED MONOCLONAL-ANTIBODY; MULTIPLE-SCLEROSIS; ALPHA-4 INTEGRIN; MODERATE	BACKGROUND: Natalizumab, a humanized monoclonal antibody against alpha(4) integrin, inhibits leukocyte adhesion and migration into inflamed tissue. METHODS: We conducted two controlled trials to evaluate natalizumab as induction and maintenance therapy in patients with active Crohn's disease. In the first trial, 905 patients were randomly assigned to receive 300 mg of natalizumab or placebo at weeks 0, 4, and 8. The primary outcome was response, defined by a decrease in the Crohn's Disease Activity Index (CDAI) score of at least 70 points, at week 10. In the second trial, 339 patients who had a response to natalizumab in the first trial were randomly reassigned to receive 300 mg of natalizumab or placebo every four weeks through week 56. The primary outcome was a sustained response through week 36. A secondary outcome in both trials was disease remission (a CDAI score of less than 150). RESULTS: In the first trial, the natalizumab and placebo groups had similar rates of response (56 percent and 49 percent, respectively; P=0.05) and remission (37 percent and 30 percent, respectively; P=0.12) at 10 weeks. Continuing natalizumab in the second trial resulted in higher rates of sustained response (61 percent vs. 28 percent, P<0.001) and remission (44 percent vs. 26 percent, P=0.003) through week 36 than did switching to placebo. Serious adverse events occurred in 7 percent of each group in the first trial and in 10 percent of the placebo group and 8 percent of the natalizumab group in the second trial. In an open-label extension study, a patient treated with natalizumab died from progressive multifocal leukoencephalopathy, associated with the JC virus, a human polyomavirus. CONCLUSIONS: Induction therapy with natalizumab for Crohn's disease resulted in small, nonsignificant improvements in response and remission rates. Patients who had a response had significantly increased rates of sustained response and remission if natalizumab was continued every four weeks. The benefit of natalizumab will need to be weighed against the risk of serious adverse events, including progressive multifocal leukoencephalopathy. (ClinicalTrials.gov numbers, NCT00032786 and NCT00032799.)	Univ Ziekenhuizen Leuven, B-3000 Louvain, Belgium; Ctr Hosp Reg & Univ Lille, Hop Huriez, F-59037 Lille, France; Univ British Columbia, St Pauls Hosp, Vancouver, BC V5Z 1M9, Canada; Univ Western Ontario, Robarts Res Inst, London, ON, Canada; Univ Chicago, Chicago, IL 60637 USA; Univ Western Australia, Fremantle Hosp, Sch Med & Pharmacol, Fremantle, Australia; Univ Calgary, Calgary, AB, Canada; Propharma Int Ventures, Hillsborough, CA USA; Univ Kiel, Univ Hosp Schleswig Holstein, Kiel, Germany; Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA; Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands; Elan Pharmaceut, San Diego, CA USA; Mayo Clin, Rochester, MN 55905 USA	KU Leuven; University Hospital Leuven; Universite de Lille - ISITE; CHU Lille; St. Paul's Hospital; University of British Columbia; University of Saskatchewan; Western University (University of Western Ontario); University of Chicago; University of Western Australia; University of Calgary; University of Kiel; Schleswig Holstein University Hospital; Cedars Sinai Medical Center; University of Amsterdam; Academic Medical Center Amsterdam; Mayo Clinic	Rutgeerts, P (corresponding author), Univ Ziekenhuizen Leuven, Herestr 49, B-3000 Louvain, Belgium.	sandborn.william@mayo.edu; rutgeerts@uz.kuleuven.ac.be	Panaccione, Remo/ABC-1140-2021; Sandborn, William/ABE-8342-2020; Lawrance, Ian C/H-5252-2014; Pavli, Paul/GZL-0607-2022; Feagan, Brian/G-3292-2011; Feagan, Brian G/M-4283-2015	Panaccione, Remo/0000-0002-5247-940X; 	NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000058] Funding Source: NIH RePORTER; NCRR NIH HHS [M01RR0058] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BEST WR, 1976, GASTROENTEROLOGY, V70, P439; *EL, 2004, TYS NAT; Ghosh S, 2003, NEW ENGL J MED, V348, P24, DOI 10.1056/NEJMoa020732; Gordon FH, 2001, GASTROENTEROLOGY, V121, P268, DOI 10.1053/gast.2001.26260; Hommes D, 2004, GASTROENTEROLOGY, V127, P332, DOI 10.1053/j.gastro.2004.05.011; Kleinschmidt-DeMasters BK, 2005, NEW ENGL J MED, V353, P369, DOI 10.1056/NEJMoa051782; Langer-Gould A, 2005, NEW ENGL J MED, V353, P375, DOI 10.1056/NEJMoa051847; Miller DH, 2003, NEW ENGL J MED, V348, P15, DOI 10.1056/NEJMoa020696; Sandborn WJ, 2003, AM J GASTROENTEROL, V98, P2372, DOI 10.1016/j.amjgastroenterol.2003.08.009; Sandborn WJ, 2004, GUT, V53, P1485, DOI 10.1136/gut.2003.035253; Schreiber S, 2005, GASTROENTEROLOGY, V129, P807, DOI 10.1053/j.gastro.2005.06.064; Su CY, 2004, GASTROENTEROLOGY, V126, P1257, DOI 10.1053/j.gastro.2004.01.024; Tubridy N, 1999, NEUROLOGY, V53, P466, DOI 10.1212/WNL.53.3.466; Van Assche G, 2005, NEW ENGL J MED, V353, P362, DOI 10.1056/NEJMoa051586	14	677	713	0	14	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1912	1925		10.1056/NEJMoa043335	http://dx.doi.org/10.1056/NEJMoa043335			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267322				2022-12-28	WOS:000232972800007
J	Douglas, JA; Gruber, SB; Meister, KA; Bonner, J; Watson, P; Krush, AJ; Lynch, HT				Douglas, JA; Gruber, SB; Meister, KA; Bonner, J; Watson, P; Krush, AJ; Lynch, HT			History and molecular genetics of Lynch syndrome in family G - A century later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONPOLYPOSIS COLORECTAL-CANCER; COLON-CANCER; MUTATION; HOMOLOG; RISK; CARCINOMA; CARRIERS; KINDREDS; MSH2	Context In 1895, Aldred Scott Warthin, MD, PhD, initiated one of the most thoroughly documented and longest cancer family histories ever recorded. The unusually high incidence and segregation of cancers of the colon, rectum, stomach, and endometrium in Dr Warthin's family G was later followed up by his colleagues, most recently by Henry Lynch, AAD. Described today as a Lynch syndrome family, family G was last documented in 1971, prior to the modern era of molecular diagnostics. Objective To update family G. Design, Setting, and Participants Historical prospective cohort study of family G members from 1895 to 2000. Main Outcome Measures The primary outcomes were the frequencies and types of cancers, ages at diagnosis, and presence of the T to G transversion at the splice acceptor site of exon 4 of the mutS homolog 2, colon cancer, nonpolyposis type 1 (E coli) (MSH2) gene in family G members. A secondary analysis compared cancer-specific incidence rates in family G with published national and regional cancer incidence rates through the standardized incidence ratio (SIR). Results Family G now has 929 known descendants of the original progenitor first reported in 1913. Cancers of the colon and rectum (SIR, 3.20; 95% confidence interval [CI], 2.39-4.19) and endometrium (SIR, 3.51; 95% Cl, 1.92-5.89) continue to predominate in family G. Five of 40 tested members of family G carry the MSH2 T to G mutation, as a result, 15 of their living relatives are at increased risk of developing 1 or more colorectal or Lynch syndrome-associated cancers. In contrast, 97 living members of family G can now be excluded as mutation carriers. Conclusion Within the last decade, molecular diagnostic testing has transformed the care of family G and other Lynch syndrome families in which a pathogenic mutation has been identified.	Univ Michigan, Sch Med, Dept Human Genet, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Epidemiol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA; Johns Hopkins Univ, Sch Med, Dept Internal Med & Human Genet, Baltimore, MD USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Creighton University; Johns Hopkins University	Douglas, JA (corresponding author), Univ Michigan, Sch Med, Dept Human Genet, Buhl Bldg,Room 5912, Ann Arbor, MI 48109 USA.	jddoug@umich.edu			NCI NIH HHS [U01 CA86389, R01 CA81488] Funding Source: Medline; NATIONAL CANCER INSTITUTE [U01CA086389, R01CA081488] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Akiyama Y, 1997, CANCER RES, V57, P3920; BRENNER CE, 1994, NATURE, V368, P258; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; GRUBER SB, 2000, MOL PATHOLOGY PROTOC, P263; Hauser IJ, 1936, AM J CANC, V27, P434; Heston JF, 1986, 45 YEARS CANC INCIDE; ITOH H, 1990, BRIT J SURG, V77, P1367, DOI 10.1002/bjs.1800771216; Jarvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5; JARVINEN HJ, 1995, GASTROENTEROLOGY, V108, P1405, DOI 10.1016/0016-5085(95)90688-6; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; Lerman C, 1999, JAMA-J AM MED ASSOC, V281, P1618, DOI 10.1001/jama.281.17.1618; LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M; Lynch HT, 1999, J MED GENET, V36, P801; Lynch HT, 2003, NEW ENGL J MED, V348, P919, DOI 10.1056/NEJMra012242; LYNCH HT, 1971, CANCER, V27, P1505, DOI 10.1002/1097-0142(197106)27:6<1505::AID-CNCR2820270635>3.0.CO;2-L; MARRA G, 1995, J NATL CANCER I, V87, P1114, DOI 10.1093/jnci/87.15.1114; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; NICOLAIDES NC, 1994, NATURE, V371, P75, DOI 10.1038/371075a0; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Parc Y, 2003, J MED GENET, V40, P208, DOI 10.1136/jmg.40.3.208; Rothman KJ, 1979, EPIDEMIOLOGIC ANAL P; Salovaara R, 2000, J CLIN ONCOL, V18, P2193, DOI 10.1200/JCO.2000.18.11.2193; Scott RJ, 2001, AM J HUM GENET, V68, P118, DOI 10.1086/316942; Taeger D, 2000, EPIDEMIOLOGY, V11, P607, DOI 10.1097/00001648-200009000-00019; Vasen HFA, 1998, CANCER, V82, P1632, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1632::AID-CNCR6>3.3.CO;2-X; Vasen HFA, 1999, GASTROENTEROLOGY, V116, P1453, DOI 10.1016/S0016-5085(99)70510-X; VASEN HFA, 1991, DIS COLON RECTUM, V34, P424, DOI 10.1007/BF02053699; Warthin AS, 1913, ARCH INTERN MED, V12, P546; Warthin AS, 1925, J CANCER RES CLIN, V9, P279; Watson P, 2003, J MED GENET, V40, P591, DOI 10.1136/jmg.40.8.591; Yan H, 2000, NATURE, V403, P723, DOI 10.1038/35001659	31	51	56	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2195	2202		10.1001/jama.294.17.2195	http://dx.doi.org/10.1001/jama.294.17.2195			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264161	Bronze			2022-12-28	WOS:000232957700022
J	Korzenik, J; Chung, DC; Digumarthy, S; Badizadegan, K; Moss, JD; Harris, NL; Goldfinger, S; Tso, L; Hung, K				Korzenik, J; Chung, DC; Digumarthy, S; Badizadegan, K; Moss, JD; Harris, NL; Goldfinger, S; Tso, L; Hung, K			A 43-year-old man with lower gastrointestinal bleeding - Hereditary hemorrhagic telangiectasia and atypical juvenile polyposis with dysplasia and intramucosal carcinoma, associated with a germ-line mutation in the MADH4 gene.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PULMONARY ARTERIOVENOUS-MALFORMATIONS; FAMILIAL JUVENILE; BMPR1A MUTATIONS; COLI; SMAD4; ENDOGLIN; CANCER; RISK		Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA; Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Med, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Radiol, Cambridge, MA 02138 USA; Harvard Univ, Sch Med, Dept Pathol, Cambridge, MA 02138 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard University; Harvard University	Korzenik, J (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.							Berg JN, 1996, J MED GENET, V33, P256, DOI 10.1136/jmg.33.3.256; COBURN MC, 1995, ANN SURG ONCOL, V2, P386, DOI 10.1007/BF02306370; Gallione CJ, 2004, LANCET, V363, P852, DOI 10.1016/S0140-6736(04)15732-2; Garcia-Tsao G, 2000, NEW ENGL J MED, V343, P931, DOI 10.1056/NEJM200009283431305; GILINSKY NH, 1986, DIS COLON RECTUM, V29, P417, DOI 10.1007/BF02555065; GROTSKY HW, 1982, GASTROENTEROLOGY, V82, P494; GUTTMACHER AE, 1995, NEW ENGL J MED, V333, P918, DOI 10.1056/NEJM199510053331407; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Howe JR, 1998, SCIENCE, V280, P1086, DOI 10.1126/science.280.5366.1086; Howe JR, 1998, ANN SURG ONCOL, V5, P751, DOI 10.1007/BF02303487; Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919; JARVINEN H, 1984, GUT, V25, P792, DOI 10.1136/gut.25.7.792; JASS JR, 1988, HISTOPATHOLOGY, V13, P619; Johnson DW, 1996, NAT GENET, V13, P189, DOI 10.1038/ng0696-189; Kjeldsen AD, 2000, AM J GASTROENTEROL, V95, P415, DOI 10.1111/j.1572-0241.2000.01792.x; MCALLISTER KA, 1995, HUM MOL GENET, V4, P1983, DOI 10.1093/hmg/4.10.1983; MCCOLL I, 1964, P ROY SOC MED, V57, P896; NUGENT KP, 1993, GASTROENTEROLOGY, V105, P698, DOI 10.1016/0016-5085(93)90885-G; RAMASWAMY G, 1984, DIS COLON RECTUM, V27, P393, DOI 10.1007/BF02553009; Rozen P, 2003, AM J GASTROENTEROL, V98, P2317, DOI 10.1016/S0002-9270(03)00747-0; Sayed MG, 2002, ANN SURG ONCOL, V9, P901, DOI 10.1007/BF02557528; SCOTTCONNER CE, 1995, J AM COLL SURGEONS, V181, P407; Shovlin CL, 2000, AM J MED GENET, V91, P66, DOI 10.1002/(SICI)1096-8628(20000306)91:1<66::AID-AJMG12>3.0.CO;2-P; White RI, 1996, J VASC INTERV RADIOL, V7, P787, DOI 10.1016/S1051-0443(96)70851-5; Woodford-Richens KL, 2001, AM J PATHOL, V159, P1293, DOI 10.1016/S0002-9440(10)62516-3; Xu XL, 2000, ONCOGENE, V19, P1868, DOI 10.1038/sj.onc.1203504	26	4	5	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1836	1844		10.1056/NEJMcpc059028	http://dx.doi.org/10.1056/NEJMcpc059028			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251540				2022-12-28	WOS:000232813000013
J	Markel, H				Markel, H			Just fading away? The closing of Walter Reed	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Markel, H (corresponding author), Univ Michigan, Sch Med, Ctr Hist Med, Ann Arbor, MI 48109 USA.							*DEP DEF, 2005, BAS REAL CLOS; Gawande A, 2004, NEW ENGL J MED, V351, P2471, DOI 10.1056/NEJMp048317; OWENS WA, 1993, JOINT FORCES Q, V3, P7; TRUBY AE, 1943, MEMOIR W REED YELLOW	4	0	0	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1764	1766		10.1056/NEJMp058241	http://dx.doi.org/10.1056/NEJMp058241			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251531				2022-12-28	WOS:000232813000002
J	Hovatta, I; Tennant, RS; Helton, R; Marr, RA; Singer, O; Redwine, JM; Ellison, JA; Schadt, EE; Verma, IM; Lockhart, DJ; Barlow, C				Hovatta, I; Tennant, RS; Helton, R; Marr, RA; Singer, O; Redwine, JM; Ellison, JA; Schadt, EE; Verma, IM; Lockhart, DJ; Barlow, C			Glyoxalase 1 and glutathione reductase 1 regulate anxiety in mice	NATURE			English	Article							MALONDIALDEHYDE LEVELS; ANTIOXIDANT ENZYME; MOUSE; EXPRESSION; BRAIN; IDENTIFICATION; BEHAVIOR; STRAINS; FEAR	Anxiety and fear are normal emotional responses to threatening situations. In human anxiety disorders - such as panic disorder, obsessive - compulsive disorder, post- traumatic stress disorder, social phobia, specific phobias and generalized anxiety disorder - these responses are exaggerated. The molecular mechanisms involved in the regulation of normal and pathological anxiety are mostly unknown. However, the availability of different inbred strains of mice offers an excellent model system in which to study the genetics of certain behavioural phenotypes(1-3). Here we report, using a combination of behavioural analysis of six inbred mouse strains with quantitative gene expression profiling of several brain regions, the identification of 17 genes with expression patterns that correlate with anxiety- like behavioural phenotypes. To determine if two of the genes, glyoxalase 1 and glutathione reductase 1, have a causal role in the genesis of anxiety, we performed genetic manipulation using lentivirus- mediated gene transfer. Local overexpression of these genes in the mouse brain resulted in increased anxiety- like behaviour, while local inhibition of glyoxalase 1 expression by RNA interference decreased the anxiety- like behaviour. Both of these genes are involved in oxidative stress metabolism, linking this pathway with anxiety- related behaviour.	Salk Inst Biol Studies, Genet Lab, La Jolla, CA 92037 USA; BrainCells Inc, San Diego, CA 92121 USA; Neurome Inc, La Jolla, CA 92037 USA; Merck & Co Inc, Rosetta Inpharmat LLC, Seattle, WA 98109 USA	Salk Institute; Merck & Company	Barlow, C (corresponding author), Salk Inst Biol Studies, Genet Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.	cbarlow@braincellsinc.com	Hovatta, Iiris/D-6871-2012	Hovatta, Iiris/0000-0002-5990-7892				Belzung C, 2001, BEHAV BRAIN RES, V125, P141, DOI 10.1016/S0166-4328(01)00291-1; Bilici M, 2001, J AFFECT DISORDERS, V64, P43, DOI 10.1016/S0165-0327(00)00199-3; Bouwknecht J. Adriaan, 2002, Behavioural Brain Research, V136, P489, DOI 10.1016/S0166-4328(02)00200-0; Camargo EE, 2001, J NUCL MED, V42, P611; Carter TA, 2001, PHYSIOL BEHAV, V73, P849, DOI 10.1016/S0031-9384(01)00522-4; Chen F, 2004, P NATL ACAD SCI USA, V101, P7687, DOI 10.1073/pnas.0402338101; Crawley JN, 1997, PSYCHOPHARMACOLOGY, V132, P107, DOI 10.1007/s002130050327; Fernandes C, 2004, EUR J NEUROSCI, V19, P2576, DOI 10.1111/j.0953-816X.2004.03358.x; Gershenfeld HK, 1997, GENOMICS, V46, P1, DOI 10.1006/geno.1997.5002; Gray JA, 2000, NEUROPSYCHOLOGY ANXI; HOVATTA I, 2005, DATABASING BRAIN DAT, P169; Junaid MA, 2004, AM J MED GENET A, V131A, P11, DOI 10.1002/ajmg.a.30349; Karp CL, 2000, NAT IMMUNOL, V1, P221, DOI 10.1038/79759; Kromer SA, 2005, J NEUROSCI, V25, P4375, DOI 10.1523/JNEUROSCI.0115-05.2005; Kuloglu M, 2002, NEUROPSYCHOBIOLOGY, V46, P186, DOI 10.1159/000067810; Kuloglu M, 2002, NEUROPSYCHOBIOLOGY, V46, P27, DOI 10.1159/000063573; LeDoux J, 1998, BIOL PSYCHIAT, V44, P1229, DOI 10.1016/S0006-3223(98)00282-0; Miyoshi H, 1998, J VIROL, V72, P8150, DOI 10.1128/JVI.72.10.8150-8157.1998; PANKSEPP J, 1982, BEHAV BRAIN SCI, V5, P407, DOI 10.1017/S0140525X00012759; Rogers DC, 1999, BEHAV BRAIN RES, V105, P207, DOI 10.1016/S0166-4328(99)00072-8; Sandberg R, 2000, P NATL ACAD SCI USA, V97, P11038, DOI 10.1073/pnas.97.20.11038; Tafti M, 2003, NAT GENET, V34, P320, DOI 10.1038/ng1174; Thornalley PJ, 2003, BIOCHEM SOC T, V31, P1343; Tiscornia G, 2003, P NATL ACAD SCI USA, V100, P1844, DOI 10.1073/pnas.0437912100; Turri MG, 2001, CURR BIOL, V11, P725, DOI 10.1016/S0960-9822(01)00206-8; Yao JK, 2001, CNS DRUGS, V15, P287, DOI 10.2165/00023210-200115040-00004; Zapala MA, 2005, P NATL ACAD SCI USA, V102, P10357, DOI 10.1073/pnas.0503357102	28	370	385	2	46	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 1	2005	438	7068					662	666		10.1038/nature04250	http://dx.doi.org/10.1038/nature04250			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988JY	16244648				2022-12-28	WOS:000233593100049
J	Edejer, TTT; Aikins, M; Black, R; Wolfson, L; Hutubessy, R; Evans, DB				Edejer, TTT; Aikins, M; Black, R; Wolfson, L; Hutubessy, R; Evans, DB			Achieving the millennium development goals for health - Cost effectiveness analysis of strategies for child health in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							IMPROVING HEALTH; MORTALITY; MEASLES	Objective To determine the costs and effectiveness of selected child health interventions-namely, case management of pneumonia, oral rehydration therapy, Supplementation and fortification of staple foods with vitamin A and zinc, provision of supplementary food with counselling on nutrition, and immunisation against measles. Design Cost effectiveness analysis. Data sources Efficacy data came from Published systematic reviews and before and after evaluations of programmes. For resource inputs, quantities came from literature and expert opinion, and prices from the World Health Organization Choosing Interventions that are Cost Effective (WHO-CHOICE) database. Results Cost effectiveness ratios clustered in three groups with fortification with zinc and vitamin A as the most cost effective intervention, and provision of supplementary food and counselling on nutrition as the least cost effective. Between these were oral rehydration therapy case management of pneumonia, vitamin A and zinc supplementation, and measles immunisation. Conclusions On the grounds of cost effectiveness, micronutrients mid measles immunisation should be provided routinely to all children, in addition to oral rehydration therapy and case management of pneumonia for those who are sick. The challenge of malnutrition is not well addressed by existing interventions.	WHO, Costs Effectiveness Expenditure & Prior Setting H, CH-1211 Geneva, Switzerland; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; WHO, Initiat Vaccie Res, Geneva, Switzerland; WHO, Hlth Syst Financing Evidence & Informat Policy, Geneva, Switzerland; Assoc Sci Res Multiple Births, B-9070 Destelbergen, Belgium	World Health Organization; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; World Health Organization; World Health Organization	Edejer, TTT (corresponding author), WHO, Costs Effectiveness Expenditure & Prior Setting H, CH-1211 Geneva, Switzerland.	tantorrest@who.int	Wolfson, Lara/AAC-1400-2019	Wolfson, Lara/0000-0002-6454-3368; Edejer, Tessa/0000-0003-1068-332X; Black, Robert/0000-0001-9926-7984; Aikins, Moses/0000-0002-2370-4006				Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; BEATON GH, 1998, ACC SCN STAT OF THE; Bhutta ZA, 2000, AM J CLIN NUTR, V72, P1516; Black RE, 2003, LANCET, V361, P2226, DOI 10.1016/S0140-6736(03)13779-8; Bryce J, 2005, LANCET, V365, P1147, DOI 10.1016/S0140-6736(05)71877-8; Caulfi eld L. E., 2004, COMP QUANTIFICATION; Caulfield Laura E., 1999, Food and Nutrition Bulletin, V20, P183; DESAVIGNY D, 2004, FIXING HLTH SYSTEMS; Dilraj A, 2000, LANCET, V355, P798, DOI 10.1016/S0140-6736(99)95140-1; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; EVANS DB, 2005, BRIT MED J, V334, P1137; FISHMAN S, 2004, COMP QUANTIFICATION, V1, pCH2; FISHMAN S, 2004, COMP QUANTIFICATIONS, V1; GELBAND H, EVIDENCE BASE INTERV; HORTON S, 1992, WPS952 WORLD BANK PO; HORTON S, 1992, UNIT COSTS COST EFFE; HUMBESSY R, 2003, COST EFF RESOUR ALOC, V1, P8; Jamison D.T., 1993, DIS CONTROL PRIORITI; Jones G, 2003, LANCET, V362, P65, DOI 10.1016/S0140-6736(03)13811-1; MILLER P, 1995, SOC SCI MED, V40, pS1, DOI 10.1016/0277-9536(95)00001-N; Mora J.O., 2000, VITAMIN A SUGAR FORT; Murray CJL, 2000, HEALTH ECON, V9, P235, DOI 10.1002/(SICI)1099-1050(200004)9:3<235::AID-HEC502>3.0.CO;2-O; Murray CJL., 1996, GLOBAL HLTH STAT COM, V1996; PAMPANICH R, 2000, COCHRANE DATABASE SY; Pegurri E, 2005, VACCINE, V23, P1624, DOI 10.1016/j.vaccine.2004.02.029; Perry Robert T., 2004, Journal of Infectious Diseases, V189, pS4, DOI 10.1086/377712; PIECHE S, 1998, CARE SEEKING BEHAV C; Rice A.L., 2004, COMP QUANTIFICATION, V1; SAZAWAL S, 1992, LANCET, V340, P528, DOI 10.1016/0140-6736(92)91720-S; Singh Jagvir, 1997, Journal of Communicable Diseases, V29, P47; *UN, 2005, MILL DEV GOALS REP 2, P1; Victora CG, 1996, HEALTH POLICY PLANN, V11, P132, DOI 10.1093/heapol/11.2.132; *WORLD BANK, 1998, WORLD DEV REP 1993 I; World Health Organisation, 2003, MAK CHOIC HLTH WHO G; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20	36	108	109	0	9	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 19	2005	331	7526					1177	1180		10.1136/bmj.38652.550278.7C	http://dx.doi.org/10.1136/bmj.38652.550278.7C			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	988DG	16282378	Bronze, Green Published			2022-12-28	WOS:000233571000018
J	Clausen, S; Smith, AB				Clausen, S; Smith, AB			Palaeoanatomy and biological affinities of a Cambrian deuterostome (Stylophora)	NATURE			English	Article							ECHINODERMS	Stylophora are a peculiar extinct group of asymmetrical deuterostomes whose biological affinity has been fiercely debated(1-15). Disarticulated skeletal elements of a ceratocystid stylophoran recovered from the earliest Middle Cambrian of Morocco are not only the oldest stylophorans in the fossil record, but their exceptional preservation provides crucial data on the microstructure of its skeleton. Stylophoran plates are constructed of a three-dimensional mesh, termed 'stereom', identical to that of living echinoderms in which stereom microstructure provides a reliable guide to the nature of the investing soft tissues(16-18). Using modern echinoderm anatomy to interpret stereom microstructure of stylophoran elements, here we show that the large proximal lumen of their appendage was filled with muscle and that ligamentary tissues bound distal elements firmly together. We find no evidence for a mouth in the proximal lumen and no evidence that the covering plates of the appendage were articulated. Thus, although skeletal structure suggests that stylophorans are echinoderms, their appendage was not a feeding arm but a muscular locomotory organ.	Univ Sci & Technol Lille, Lab Paleontol & Paleogeog Paleoz, F-59655 Villeneuve Dascq, France; Nat Hist Museum, Dept Paleontol, London SW7 5BD, England	Universite de Lille - ISITE; Universite de Lille; Natural History Museum London	Clausen, S (corresponding author), Univ Sci & Technol Lille, Lab Paleontol & Paleogeog Paleoz, F-59655 Villeneuve Dascq, France.	sebastien.clausen@ed.univ-lille1.fr	CLAUSEN, Sebastien/H-3141-2017; Smith, Andrew B/B-9849-2009	CLAUSEN, Sebastien/0000-0002-2476-1512; 				ALVARO JJ, 2002, THESIS U LILLE 1; BATHER F. A., 1930, ARCH ZOOL ITAL, V14, P431; Benito J, 1997, MICROSCOPICAL ANATOM, V15, P15; BERGMADSEN V, 1986, LETHAIA, V19, P67, DOI 10.1111/j.1502-3931.1986.tb01902.x; Brower JC, 1999, J PALEONTOL, V73, P129, DOI 10.1017/S0022336000027608; CLAUSEN S, 2004, THESIS U LILLE 1; CRIPPS AP, 1991, ZOOL J LINN SOC-LOND, V102, P333, DOI 10.1111/j.1096-3642.1991.tb00005.x; David B, 2000, PALEOBIOLOGY, V26, P529, DOI 10.1666/0094-8373(2000)026<0529:AHEAAF>2.0.CO;2; Gee H., 1996, BACKBONE VIEWS ORIGI; Geyer Gerd, 1995, Beringeria Special Issue, V2, P7; JEFFERIES R. P. S., 1967, SYMP ZOOL SOC LONDON, V20, P163; Jefferies R.P.S., 1986, ANCESTRY VERTEBRATES; Jefferies RPS, 1996, ACTA ZOOL-STOCKHOLM, V77, P101, DOI 10.1111/j.1463-6395.1996.tb01256.x; KOLATA DR, 1991, J PALEONTOL, V65, P844, DOI 10.1017/S0022336000037811; Lefebvre B, 2003, PALAEONTOLOGY, V46, P511, DOI 10.1111/1475-4983.00309; Parsley R.L., 1988, ECHINODERM PHYLOGENY, P345; PHILIP GM, 1979, BIOL REV, V54, P439, DOI 10.1111/j.1469-185X.1979.tb00845.x; Roux M., 1975, Paleontological Contr Univ Kansas (Papers), VNo. 75, P1; Smith A.B., 1990, P413; Smith AB, 2005, GEOL J, V40, P255, DOI 10.1002/gj.1018; Smith AB., 1980, SPEC PAP PALAEONTOL, V25, P1; SPRINKLE J, 1992, ORIGIN EARLY EVOLUTI, P375; Sumrall CD, 1996, J PALEONTOL, V70, P986, DOI 10.1017/S0022336000038683; Sumrall Colin D., 1997, Paleontological Society Papers, V3, P267; UBAGHS G, 1967, PALEONTOL CONTRIB U, V30, P1; UBAGHS G, 1968, TREATISE INVERTEBR S, P495	26	59	62	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					351	354		10.1038/nature04109	http://dx.doi.org/10.1038/nature04109			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292309				2022-12-28	WOS:000233300200047
J	Giles, J				Giles, J			Wisdom of the crowd	NATURE			English	News Item																			0	16	16	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2005	438	7066					281	281		10.1038/438281a	http://dx.doi.org/10.1038/438281a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292279	Bronze			2022-12-28	WOS:000233300200015
J	Wilson, IB; Landon, BE; Hirschhorn, LR; McInnes, K; Ding, L; Marsden, PV; Cleary, PD				Wilson, IB; Landon, BE; Hirschhorn, LR; McInnes, K; Ding, L; Marsden, PV; Cleary, PD			Quality of HIV care provided by nurse practitioners, physician assistants, and physicians	ANNALS OF INTERNAL MEDICINE			English	Article							SOCIETY-USA PANEL; ANTIRETROVIRAL THERAPY; UPDATED RECOMMENDATIONS; NONPHYSICIAN CLINICIAN; RANDOMIZED-TRIAL; UNITED-STATES; SPECIALIZATION; INFECTION; HIV/AIDS; ADOPTION	Background: Nurse practitioners (NPs) and physician assistants (PAs) are primary care providers for patients with HIV in some clinics, but little is known about the quality of care that they provide. Objective: To compare the quality of care provided by NPs and PAs with that provided by physicians. Design: Cross-sectional analysis. Setting: 68 HIV care sites, funded by Ryan White Comprehensive AIDS Resources Emergency (CARE) Act Title III, in 30 different states. Participants: The authors surveyed 243 clinicians (177 physicians and 66 NPs and PAs) and reviewed medical records of 6651 persons with HIV or AIDS. Measurements: 8 quality-of-care measures assessed by medical record review. Results: After adjustments for patient characteristics, 6 of the 8 quality measures did not statistically significantly differ between NPs and PAs and either infectious disease specialists or generalist HIV experts. Adjusted rates of purified protein derivative testing and Papanicolaou smears were statistically significantly higher for NPs and PAs (0.63 and 0.71, respectively) than for infectious disease specialists (0.53 [P = 0.007] and 0.56 [P = 0.001], respectively) or generalist HIV experts (0.47 [P < 0.001] and 0.62 [P = 0.025], respectively). Nurse practitioners and PAs had statistically significantly higher performance scores than generalist non-HIV experts on 6 of the 8 quality measures. Limitations: These results may not be generalizable to care settings where on-site physician HIV experts are not accessible or to measures of more complex clinical processes. Conclusions: For the measures examined, the quality of HIV care provided by NPs and PAs was similar to that of physician HIV experts and generally better than physician non-HIV experts. Nurse practitioners and PAs can provide high-quality care for persons with HIV. Preconditions for this level of performance include high levels of experience, focus on a single condition, and either participation in teams or other easy access to physicians and other clinicians with HIV expertise.	Tufts Univ, New England Med Ctr, Boston, MA 02111 USA; Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA USA; Harvard Univ, Cambridge, MA 02138 USA	Tufts Medical Center; Tufts University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University	Wilson, IB (corresponding author), Tufts Univ, New England Med Ctr, 345,750 Washington St, Boston, MA 02111 USA.	iwilson@tufts-nemc.org	Wilson, Ira/F-9190-2016; Cleary, Paul/AAF-7048-2019	Wilson, Ira/0000-0002-0246-738X; Hirschhorn, Lisa/0000-0002-4355-7437	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [R01HS010227] Funding Source: NIH RePORTER; AHRQ HHS [R-01HS10227] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Binswanger HP, 2000, SCIENCE, V288, P2173, DOI 10.1126/science.288.5474.2173; Carpenter CCJ, 2000, JAMA-J AM MED ASSOC, V283, P381, DOI 10.1001/jama.283.3.381; Cooper RA, 2001, ANNU REV MED, V52, P51, DOI 10.1146/annurev.med.52.1.51; Cooper Richard, 2004, J Health Serv Res Policy, V9 Suppl 1, P39, DOI 10.1258/135581904322724121; CURRAN J, 2004, SCALING UP TREATMENT; Druss BG, 2003, NEW ENGL J MED, V348, P130, DOI 10.1056/NEJMsa020993; Druss BG, 1999, JAMA-J AM MED ASSOC, V282, P651, DOI 10.1001/jama.282.7.651; DUGGER CW, 2004, NY TIMES        1113, P4; Dybul Mark, 2002, MMWR Recomm Rep, V51, P1; HIRSCHHORN LR, IN PRESS HUM RESOUR; Horrocks S, 2002, BRIT MED J, V324, P819, DOI 10.1136/bmj.324.7341.819; Kassaye Seble Getachew, 2003, AIDS Rev, V5, P195; Kober K, 2004, LANCET, V364, P103, DOI 10.1016/S0140-6736(04)16597-5; Koenig SP, 2004, AIDS, V18, pS21, DOI 10.1097/00002030-200406003-00005; Landon BE, 2005, ARCH INTERN MED, V165, P1133, DOI 10.1001/archinte.165.10.1133; Landon BE, 2004, ANN INTERN MED, V140, P887, DOI 10.7326/0003-4819-140-11-200406010-00010; Landon BE, 2003, J GEN INTERN MED, V18, P233, DOI 10.1046/j.1525-1497.2003.20705.x; Landon BE, 2002, J GEN INTERN MED, V17, P12, DOI 10.1046/j.1525-1497.2002.10401.x; Mundinger MO, 2000, JAMA-J AM MED ASSOC, V283, P59, DOI 10.1001/jama.283.1.59; RABEHESKETH S, 2001, 200101 DEP BIOST COM; SACKETT DL, 1974, ANN INTERN MED, V80, P137, DOI 10.7326/0003-4819-80-2-137; Sox HC, 2000, JAMA-J AM MED ASSOC, V283, P106, DOI 10.1001/jama.283.1.106; TUMOLO J, 2004, 2003 NAT SAL SURV NU; *US DEP HHS, 2004, GUID US ANT AG HIV 1; *US DEP HHS, 2004, COMP CHANG PROF PRAC; Venning P, 2000, BMJ-BRIT MED J, V320, P1048, DOI 10.1136/bmj.320.7241.1048; *WHO, 2002, SCAL UP ANT THER RES; Wilson IB, 2005, MED CARE, V43, P12; Wilson IB, 2002, MED CARE, V40, P1149, DOI 10.1097/00005650-200212000-00003; Yeni PG, 2002, JAMA-J AM MED ASSOC, V288, P222, DOI 10.1001/jama.288.2.222; Yeni PG, 2004, JAMA-J AM MED ASSOC, V292, P251, DOI 10.1001/jama.292.2.251	31	112	112	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					729	736		10.7326/0003-4819-143-10-200511150-00010	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287794				2022-12-28	WOS:000233486800005
J	Watts, G				Watts, G			More men (and women) on the Moon?	LANCET			English	Editorial Material											Watts, G (corresponding author), 28 New End Sq, London NW3 1LS, England.	geoff@scileg.freeserve.co.uk						FOUST J, 2004, SPACE REV       0209; *NASA, 2005, WELL GET BACK MOON; PARK R, 2004, NEW ATLANTIS, V4, P90; PARK R, 2000, VOODOO SCI	4	0	0	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1681	1682		10.1016/S0140-6736(05)67677-5	http://dx.doi.org/10.1016/S0140-6736(05)67677-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291050				2022-12-28	WOS:000233206400008
J	Grimm, V; Revilla, E; Berger, U; Jeltsch, F; Mooij, WM; Railsback, SF; Thulke, HH; Weiner, J; Wiegand, T; DeAngelis, DL				Grimm, V; Revilla, E; Berger, U; Jeltsch, F; Mooij, WM; Railsback, SF; Thulke, HH; Weiner, J; Wiegand, T; DeAngelis, DL			Pattern-oriented modeling of agent-based complex systems: Lessons from ecology	SCIENCE			English	Review							NATURAL BEECH FORESTS; SPATIAL-DISTRIBUTION; MULTIAGENT MODEL; SIMULATION; UNCERTAINTY; SPREAD	Agent-based complex systems are dynamic networks of many interacting agents; examples include ecosystems, financial markets, and cities. The search for general principles underlying the internal organization of such systems often uses bottom-up simulation models such as cellular automata and agent-based models. No general framework for designing, testing, and analyzing bottom-up models has yet been established, but recent advances in ecological modeling have come together in a general strategy we call pattern-oriented modeling. This strategy provides a unifying framework for decoding the internal organization of agent-based complex systems and may lead toward unifying algorithmic theories of the relation between adaptive behavior and system complexity.	UFZ Helmholtz Ctr Environm Res, Dept Okol Syst Anal, D-04301 Leipzig, Germany; CSIC, Spanish Council Sci Res, Estac Biol Donana, Dept Appl Biol, E-41013 Seville, Spain; Zentrum Marine Tropenokol, D-28359 Bremen, Germany; Univ Potsdam, Inst Biochem & Biol, D-14469 Potsdam, Germany; Netherlands Inst Ecol, Ctr Limnol, NL-3631 AC Nieuwersluis, Netherlands; Humboldt State Univ, Lang Railsback & Associates, Arcata, CA 95521 USA; Humboldt State Univ, Dept Math, Arcata, CA 95521 USA; Royal Vet & Agr Univ, Dept Ecol, Bot Sect, DK-1958 Frederiksberg, Denmark; Univ Miami, US Geol Survey, Florida Integrated Sci Ctr, Coral Gables, FL 33124 USA; Univ Miami, Dept Biol, Coral Gables, FL 33124 USA	Helmholtz Association; Helmholtz Center for Environmental Research (UFZ); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Estacion Biologica de Donana (EBD); Leibniz Zentrum fur Marine Tropenforschung (ZMT); University of Bremen; University of Potsdam; Royal Netherlands Academy of Arts & Sciences; Netherlands Institute of Ecology (NIOO-KNAW); California State University System; California State Polytechnic University, Humboldt; California State University System; California State Polytechnic University, Humboldt; University of Copenhagen; United States Department of the Interior; United States Geological Survey; University of Miami; University of Miami	Grimm, V (corresponding author), UFZ Helmholtz Ctr Environm Res, Dept Okol Syst Anal, PF 500 136, D-04301 Leipzig, Germany.	volker.grimm@ufz.de	Wiegand, Thorsten/AAP-9709-2021; Weiner, Jacob/E-1839-2011; Mooij, Wolf M/C-2677-2008; Wiegand, Thorsten/H-5877-2016; Thulke, Hans-Hermann/I-6923-2013; Revilla, Eloy/B-5100-2008	Wiegand, Thorsten/0000-0002-3721-2248; Weiner, Jacob/0000-0002-0736-7943; Mooij, Wolf M/0000-0001-5586-8200; Wiegand, Thorsten/0000-0002-3721-2248; Thulke, Hans-Hermann/0000-0002-7670-2231; Revilla, Eloy/0000-0001-5534-5581; Railsback, Steven/0000-0002-5923-9847; Jeltsch, Florian/0000-0002-4670-6469				Auyang S.Y., 1998, FDN COMPLEX SYSTEM T, DOI DOI 10.1017/CBO9780511626135; Axtell RL, 2002, P NATL ACAD SCI USA, V99, P7275, DOI 10.1073/pnas.092080799; Bankes SC, 2002, P NATL ACAD SCI USA, V99, P7199, DOI 10.1073/pnas.072081299; Burgman M, 2000, CONSERV BIOL SER, V4, P97; Burnham K.P., 2002, MODEL SELECTION MULT, V2nd, DOI [10.1007/b97636, DOI 10.1007/B97636]; DeAngelis DL, 2005, ANNU REV ECOL EVOL S, V36, P147, DOI 10.1146/annurev.ecolsys.36.102003.152644; Dennett Daniel C., 1995, DARWINS DANGEROUS ID; Epstein J.M., 1996, GROWING ARTIFICIAL S; Grimm V, 1996, SCI TOTAL ENVIRON, V183, P151, DOI 10.1016/0048-9697(95)04966-5; HUTH A, 1994, ECOL MODEL, V75, P135, DOI 10.1016/0304-3800(94)90013-2; HUTH A, 1992, THESIS U MARBURG GER; Jeltsch F, 1997, P ROY SOC B-BIOL SCI, V264, P495, DOI 10.1098/rspb.1997.0071; Korpel S., 1995, URWALDER WESTKARPATE; LeBaron B, 2001, IEEE T EVOLUT COMPUT, V5, P442, DOI 10.1109/4235.956709; Lempert R, 2002, P NATL ACAD SCI USA, V99, P7195, DOI 10.1073/pnas.072079399; Lenth R., 2019, Journal of Statistical Software, V60, P1; LIU JG, 1995, FOREST ECOL MANAG, V73, P157, DOI 10.1016/0378-1127(94)03490-N; LOEHLE C, 1990, BIOSCIENCE, V40, P123, DOI 10.2307/1311345; Mooij WM, 2003, ECOL APPL, V13, P794, DOI 10.1890/1051-0761(2003)013[0794:UISEAD]2.0.CO;2; Moss S, 2002, P NATL ACAD SCI USA, V99, P7267, DOI 10.1073/pnas.092080699; NEUERT C, 2001, NATURSCHUTZ LANDSCHA, V33, P173; Peck SL, 2004, TRENDS ECOL EVOL, V19, P530, DOI 10.1016/j.tree.2004.07.019; Pitt WC, 2003, ECOL MODEL, V166, P109, DOI 10.1016/S0304-3800(03)00130-3; PLATT JR, 1964, SCIENCE, V146, P347, DOI 10.1126/science.146.3642.347; Rademacher C, 2003, FORSTWISS CENTRALBL, V122, P337, DOI 10.1007/s10342-003-0002-6; Rademacher C, 2004, FOREST ECOL MANAG, V194, P349, DOI 10.1016/j.foreco.2004.02.022; Rademacher C, 2001, FORSTWISS CENTRALBL, V120, P288; Railsback SF, 2002, ECOLOGY, V83, P1817, DOI 10.2307/3071767; Remmert H, 1991, MOSAIC CYCLE CONCEPT; Reynolds C.W., 1987, ACM SIGGRAPH COMPUTE, V21, P25, DOI DOI 10.1145/37402.37406; Rouchier J, 2001, J ECON DYN CONTROL, V25, P527, DOI 10.1016/S0165-1889(00)00035-X; Schweitzer F., 2003, SPRINGER SERIES SYNE; Thulke HH, 1999, ECOL MODEL, V117, P179, DOI 10.1016/S0304-3800(98)00198-7; Watson J.D., 1968, DOUBLE HELIX PERSONA; Wiegand T, 2004, BIODIVERS CONSERV, V13, P53, DOI 10.1023/B:BIOC.0000004313.86836.ab; Wiegand T, 2003, OIKOS, V100, P209, DOI 10.1034/j.1600-0706.2003.12027.x; WISSEL C, 1992, ECOL MODEL, V63, P29, DOI 10.1016/0304-3800(92)90060-R; Wissel C., 1989, THEORETISCHE OKOLOGI; ZEIGLER BP, 1985, THEORY MODELING SIMU	39	1340	1376	25	648	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					987	991		10.1126/science.1116681	http://dx.doi.org/10.1126/science.1116681			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284171	Green Submitted			2022-12-28	WOS:000233343400034
J	Johannessen, OM; Khvorostovsky, K; Miles, MW; Bobylev, LP				Johannessen, OM; Khvorostovsky, K; Miles, MW; Bobylev, LP			Recent ice-sheet growth in the interior of Greenland	SCIENCE			English	Article							NORTH-ATLANTIC OSCILLATION; MASS-BALANCE	A continuous data set of Greenland Ice Sheet altimeter height from European Remote Sensing satellites (ERS-1 and ERS-2), 1992 to 2003, has been analyzed. An increase of 6.4 +/- 0.2 centimeters per year (cm/year) is found in the vast interior areas above 1500 meters, in contrast to previous reports of high-elevation balance. Below 1500 meters, the elevation-change rate is -2.0 +/- 0.9 cm/year, in qualitative agreement with reported thinning in the ice-sheet margins. Averaged over the study area, the increase is 5.4 +/- 0.2 cm/year, or similar to 60 cm over 11 years, or similar to 54 cm when corrected for isostatic uplift. Winter elevation changes are shown to be linked to the North Atlantic Oscillation.	Nansen Environm & Remote Sensing Ctr, Mohn Sverdrup Ctr Global Ocean Studies & Operat O, N-5006 Bergen, Norway; Univ Bergen, Inst Geophys, N-5007 Bergen, Norway; Nansen Int Environm & Remote Sensing Ctr, St Petersburg 197101, Russia; Bjerknes Ctr Climate Res, N-5007 Bergen, Norway; Environm Syst Anal Res Ctr, Boulder, CO 80303 USA	Nansen Environmental & Remote Sensing Center (NERSC); University of Bergen; Nansen Environmental & Remote Sensing Center (NERSC); Bjerknes Centre for Climate Research	Johannessen, OM (corresponding author), Nansen Environm & Remote Sensing Ctr, Mohn Sverdrup Ctr Global Ocean Studies & Operat O, N-5006 Bergen, Norway.	ola.johannessen@nersc.no	Khvorostovsky, Kirill/ABD-7783-2020; Bobylev, Leonid/L-4816-2017	Bobylev, Leonid/0000-0002-2341-9088	Natural Environment Research Council [NE/C51631X/1] Funding Source: researchfish	Natural Environment Research Council(UK Research & Innovation (UKRI)Natural Environment Research Council (NERC))		Abdalati W, 2001, J GEOPHYS RES-ATMOS, V106, P33729, DOI 10.1029/2001JD900192; Abdalati W, 2001, J GEOPHYS RES-ATMOS, V106, P33983, DOI 10.1029/2001JD900181; Arctic Climate Impact Assessment, 2004, IMP WARM ARCT; BRENNER AC, 2000, P ERS ENVISAT S 16 2; Bromwich DH, 1999, J GEOPHYS RES-ATMOS, V104, P22103, DOI 10.1029/1999JD900373; Chylek P, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL023552; Davis CH, 2001, J GEOPHYS RES-ATMOS, V106, P33743, DOI 10.1029/2001JD900167; Femenias P., 1996, ERTNRSRA0022; FICHEFET T, 2003, GEOPHYS RES LETT, V30, DOI DOI 10.1029/2003GL017826; Gregory JM, 2004, NATURE, V428, P616, DOI 10.1038/428616a; Hanna E, 2005, J GEOPHYS RES-ATMOS, V110, DOI 10.1029/2004JD005641; HURRELL J, 1932, N ATLANTIC OSCILLATI; HUYBRECHTS P, 1991, GLOBAL PLANET CHANGE, V89, P399, DOI 10.1016/0921-8181(91)90119-H; *INT PAN CLIM CHAN, 2001, CLIM CHANG 2000 3 AS; Jones PD, 1997, INT J CLIMATOL, V17, P1433, DOI 10.1002/(SICI)1097-0088(19971115)17:13<1433::AID-JOC203>3.0.CO;2-P; Joughin I, 2004, NATURE, V432, P608, DOI 10.1038/nature03130; Kalnay E, 1996, B AM METEOROL SOC, V77, P437, DOI 10.1175/1520-0477(1996)077<0437:TNYRP>2.0.CO;2; KHOROSTOVSKY K, 2003, ARCTIC ENV VARIABILI, P270; Krabill W, 2000, SCIENCE, V289, P428, DOI 10.1126/science.289.5478.428; Krabill W, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL021533; Kuzmina SI, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021064; Layberry RL, 2001, J GEOPHYS RES-ATMOS, V106, P33781, DOI 10.1029/2001JD900053; McConnell JR, 2000, NATURE, V406, P877, DOI 10.1038/35022555; Osborn TJ, 2004, CLIM DYNAM, V22, P605, DOI 10.1007/s00382-004-0405-1; Rahmstorf S, 2000, CLIMATIC CHANGE, V46, P247, DOI 10.1023/A:1005648404783; Rignot E, 2002, SCIENCE, V297, P1502, DOI 10.1126/science.1073888; Rogers JC, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018728; Steffen K, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020444; Thomas R, 2001, J GEOPHYS RES-ATMOS, V106, P33707, DOI 10.1029/2001JD900033; Wadhams P, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020039; Wahr J, 2001, J GEOPHYS RES-ATMOS, V106, P33755, DOI 10.1029/2001JD900154; Wingham DJ, 1998, SCIENCE, V282, P456, DOI 10.1126/science.282.5388.456; ZWALLY HJ, 1989, SCIENCE, V246, P1587, DOI 10.1126/science.246.4937.1587	33	124	128	0	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1013	1016		10.1126/science.1115356	http://dx.doi.org/10.1126/science.1115356			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16239440	Green Submitted			2022-12-28	WOS:000233343400042
J	Nogueiras, R; Tschop, M				Nogueiras, R; Tschop, M			Biomedicine - Separation of conjoined hormones yields appetite rivals	SCIENCE			English	Editorial Material							FOOD-INTAKE; GHRELIN; RECEPTORS; PITUITARY; DELETION		Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45237 USA; German Inst Human Nutr, Dept Pharmacol, D-14558 Nuthetal, Germany	University System of Ohio; University of Cincinnati; Deutsches Institut fur Ernahrungsforschung Potsdam-Rehbrucke (DIfE)	Nogueiras, R (corresponding author), Univ Cincinnati, Dept Psychiat, Cincinnati, OH 45237 USA.	tschoemh@ucmail.uc.edu	Tschoep, Matthias H/I-5443-2014; Nogueiras, Ruben/AAS-9427-2021	Nogueiras, Ruben/0000-0002-9976-9930; Tschoep, Matthias/0000-0002-4744-371X				Bagnol D, 2004, CURR OPIN DRUG DISC, V7, P665; Berthoud HR, 2002, NEUROSCI BIOBEHAV R, V26, P393, DOI 10.1016/S0149-7634(02)00014-3; Castro MG, 1997, CRIT REV NEUROBIOL, V11, P35; Cummings DE, 2005, CURR DRUG TARGETS, V6, P153, DOI 10.2174/1389450053174569; Guo L, 2004, P NATL ACAD SCI USA, V101, P11797, DOI 10.1073/pnas.0403165101; Halatchev IG, 2005, CELL METAB, V1, P159, DOI 10.1016/j.cmet.2005.02.003; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; Peeters TL, 2005, GUT, V54, P1638, DOI 10.1136/gut.2004.062604; Pemberton C, 2003, BIOCHEM BIOPH RES CO, V310, P567, DOI 10.1016/j.bbrc.2003.09.045; Strader AD, 2005, GASTROENTEROLOGY, V128, P175, DOI 10.1053/j.gastro.2004.10.043; Sun YX, 2003, MOL CELL BIOL, V23, P7973, DOI 10.1128/MCB.23.22.7973-7981.2003; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Zhang JV, 2005, SCIENCE, V310, P996, DOI 10.1126/science.1117255	17	34	38	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					985	986		10.1126/science.1121214	http://dx.doi.org/10.1126/science.1121214			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284170				2022-12-28	WOS:000233343400033
J	Bradley, TD; Logan, AG; Kimoff, RJ; Series, F; Morrison, D; Ferguson, K; Belenkie, I; Pfeifer, M; Fleetham, J; Hanly, P; Smilovitch, M; Tomlinson, G; Floras, JS				Bradley, TD; Logan, AG; Kimoff, RJ; Series, F; Morrison, D; Ferguson, K; Belenkie, I; Pfeifer, M; Fleetham, J; Hanly, P; Smilovitch, M; Tomlinson, G; Floras, JS		CANPAP Investigators	Continuous positive airway pressure for central sleep apnea and heart failure	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CHEYNE-STOKES RESPIRATION; NASAL CPAP; TRIAL; CARVEDILOL; MORTALITY; SURVIVAL	BACKGROUND: The Canadian Continuous Positive Airway Pressure for Patients with Central Sleep Apnea and Heart Failure trial tested the hypothesis that continuous positive airway pressure (CPAP) would improve the survival rate without heart transplantation of patients who have central sleep apnea and heart failure. METHODS: After medical therapy was optimized, 258 patients who had heart failure (mean age [+/-SD], 63+/-10 years; ejection fraction, 24.5+/-7.7 percent) and central sleep apnea (number of episodes of apnea and hypopnea per hour of sleep, 40+/-16) were randomly assigned to receive CPAP (128 patients) or no CPAP (130 patients) and were followed for a mean of two years. During follow-up, sleep studies were conducted and measurements of the ejection fraction, exercise capacity, quality of life, and neurohormones were obtained. RESULTS: Three months after undergoing randomization, the CPAP group, as compared with the control group, had greater reductions in the frequency of episodes of apnea and hypopnea (-21+/-16 vs. -2+/-18 per hour, P<0.001) and in norepinephrine levels (-1.03+/-1.84 vs. 0.02+/-0.99 nmol per liter, P=0.009), and greater increases in the mean nocturnal oxygen saturation (1.6+/-2.8 percent vs. 0.4+/-2.5 percent, P<0.001), ejection fraction (2.2+/-5.4 percent vs. 0.4+/-5.3 percent, P=0.02), and the distance walked in six minutes (20.0+/-55 vs. -0.8+/-64.8 m, P=0.016). There were no differences between the control group and the CPAP group in the number of hospitalizations, quality of life, or atrial natriuretic peptide levels. An early divergence in survival rates without heart transplantation favored the control group, but after 18 months the divergence favored the CPAP group, yet the overall event rates (death and heart transplantation) did not differ (32 vs. 32 events, respectively; P=0.54). CONCLUSIONS: Although CPAP attenuated central sleep apnea, improved nocturnal oxygenation, increased the ejection fraction, lowered norepinephrine levels, and increased the distance walked in six minutes, it did not affect survival. Our data do not support the use of CPAP to extend life in patients who have central sleep apnea and heart failure.	Univ Toronto, Dept Med, Toronto, ON, Canada; McGill Univ, Dept Med, Montreal, PQ, Canada; Univ Laval, Dept Med, Quebec City, PQ G1K 7P4, Canada; Dalhousie Univ, Dept Med, Halifax, NS, Canada; Univ Western Ontario, Dept Med, London, ON, Canada; Univ Calgary, Dept Med, Calgary, AB, Canada; Univ British Columbia, Dept Med, Vancouver, BC, Canada; Univ Regensburg, Dept Med, D-8400 Regensburg, Germany	University of Toronto; McGill University; Laval University; Dalhousie University; Western University (University of Western Ontario); University of Calgary; University of British Columbia; University of Regensburg	Bradley, TD (corresponding author), Univ Hlth Network, Toronto Gen Hosp, Dept Med, Room 9N-943,200 Elizabeth St, Toronto, ON M5G 2C4, Canada.	douglas.bradley@utoronto.ca	Tomlinson, George A/L-5432-2016; Floras, John S./D-4042-2015; Logan, Alexander G/E-4626-2013	Tomlinson, George A/0000-0002-9328-6399; 				BONNET MH, 1992, SLEEP, V15, P526; Bradley TD, 2003, CIRCULATION, V107, P1671, DOI 10.1161/01.CIR.0000061757.12581.15; Bradley TD, 2003, CIRCULATION, V107, P1822, DOI 10.1161/01.CIR.0000061758.05044.64; Bradley TD, 2001, CAN J CARDIOL, V17, P677; BRADLEY TD, 1992, AM REV RESPIR DIS, V145, P377, DOI 10.1164/ajrccm/145.2_Pt_1.377; BUCKLE P, 1992, CHEST, V102, P31, DOI 10.1378/chest.102.1.31; Clark SA, 1998, AM J RESP CRIT CARE, V158, P713, DOI 10.1164/ajrccm.158.3.9708056; DAVIES RJO, 1993, AM REV RESPIR DIS, V147, P630, DOI 10.1164/ajrccm/147.3.630; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; FRANKLIN KA, 1995, LANCET, V345, P1085, DOI 10.1016/S0140-6736(95)90820-X; Freedman NJ, 2004, J CLIN INVEST, V113, P1379, DOI 10.1172/JCI200421748; GUILLEMINAULT C, 1993, SLEEP, V16, P524; GUYATT GH, 1989, J GEN INTERN MED, V4, P101, DOI 10.1007/BF02602348; Hanly PJ, 1996, AM J RESP CRIT CARE, V153, P272, DOI 10.1164/ajrccm.153.1.8542128; Javaheri S, 1998, CIRCULATION, V97, P2154, DOI 10.1161/01.CIR.97.21.2154; JOHNSTONE DE, 1994, CAN J CARDIOL, V10, P613; Kaneko Y, 2003, NEW ENGL J MED, V348, P1233, DOI 10.1056/NEJMoa022479; Kaye DM, 2001, CIRCULATION, V103, P2336; Lanfranchi PA, 1999, CIRCULATION, V99, P1435, DOI 10.1161/01.CIR.99.11.1435; Leung RST, 2001, AM J RESP CRIT CARE, V164, P2147, DOI 10.1164/ajrccm.164.12.2107045; MALONE S, 1991, LANCET, V338, P1480; Mansfield DR, 2004, AM J RESP CRIT CARE, V169, P361, DOI 10.1164/rccm.200306-752OC; McCullagh P., 1989, GEN LINEAR MODELS, V(2nd), DOI [10.1007/978-1-4899-3242-6, https://doi.org/10.1007/978-1-4899-3242-6, DOI 10.1007/978-1-4899-3242-6]; NAUGHTON MT, 1995, CIRCULATION, V91, P1725, DOI 10.1161/01.CIR.91.6.1725; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V152, P473, DOI 10.1164/ajrccm.152.2.7633695; NAUGHTON MT, 1995, AM J RESP CRIT CARE, V151, P92, DOI 10.1164/ajrccm.151.1.7812579; O'Keeffe ST, 1998, HEART, V80, P377, DOI 10.1136/hrt.80.4.377; Packer M, 1996, CIRCULATION, V94, P2793, DOI 10.1161/01.CIR.94.11.2793; Packer M, 2001, NEW ENGL J MED, V344, P1651, DOI 10.1056/NEJM200105313442201; Pitt B, 1999, NEW ENGL J MED, V341, P709, DOI 10.1056/NEJM199909023411001; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; Redfield MM, 2003, JAMA-J AM MED ASSOC, V289, P194, DOI 10.1001/jama.289.2.194; SCHOENFELD DA, 1982, BIOMETRICS, V38, P163, DOI 10.2307/2530299; Sin DD, 1999, AM J RESP CRIT CARE, V160, P1101, DOI 10.1164/ajrccm.160.4.9903020; Sin DD, 2000, CIRCULATION, V102, P61, DOI 10.1161/01.CIR.102.1.61; STAATS BA, 1984, AM REV RESPIR DIS, V130, P59; Tkacova R, 1997, J AM COLL CARDIOL, V30, P739, DOI 10.1016/S0735-1097(97)00199-X; Usui K, 2005, J AM COLL CARDIOL, V45, P2008, DOI 10.1016/j.jacc.2004.12.080	38	755	784	1	21	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2005	353	19					2025	2033		10.1056/NEJMoa051001	http://dx.doi.org/10.1056/NEJMoa051001			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282177				2022-12-28	WOS:000233119600007
J	Wadman, M				Wadman, M			Path to approval proves rocky for copycat biodrugs	NATURE			English	News Item								The road to approval for the production of biogeneric drugs is proving to be an extremely difficult one as the original pharmaceutical producing companies doubt the efficacy and safety of the new drugs that may be approved by the European Medicines Agency next year. Possible generic drugs include erythropoietin, interferon-alpha and interferon-beta.											0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2005	438	7065					154	155		10.1038/438154a	http://dx.doi.org/10.1038/438154a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281004				2022-12-28	WOS:000233133500016
J	Linder, JA; Bates, DW; Lee, GM; Finkelstein, JA				Linder, JA; Bates, DW; Lee, GM; Finkelstein, JA			Antibiotic treatment of children with sore throat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; ADVERSE DRUG EVENTS; STREPTOCOCCAL PHARYNGITIS; UNITED-STATES; PRIMARY-CARE; MANAGEMENT; SCORE; INTERVENTION; PRINCIPLES; GUIDELINES	Context Of children with sore throat, 15% to 36% have pharyngitis caused by group A beta-hemolytic streptococci (GABHS). Performance of a GABHS test prior to antibiotic prescribing is recommended for children with sore throat. Penicillin, amoxicillin, erythromycin, and first-generation cephalosporins are the recommended antibiotics for treatment of sore throat due to GABHS. Objectives To measure rates of antibiotic prescribing and GABHS testing and to evaluate the association between testing and antibiotic treatment for children with sore throat. Design, Setting, and Participants Analysis of visits by children aged 3 to 17 years with sore throat to office-based physicians, hospital outpatient departments, and emergency departments in the National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, 1995 to 2003 (N=4158) and of a subset of visits with GABHS testing data (n=2797). Main Outcome Measures National rates of antibiotic prescribing, prescribing of antibiotics recommended and not recommended for GABHS, and GABHS testing. Results Physicians prescribed antibiotics in 53% (95% confidence interval [CI],49%-56%) of an estimated 7.3 million annual visits for sore throat and nonrecommended antibiotics to 27% (95% Cl, 24%-31%) of children who received an antibiotic. Antibiotic prescribing decreased from 66% of visits in 1995 to 54% of visits in 2003 (P=.01 for trend). This decrease was attributable to a decrease in the prescribing of recommended antibiotics (49% to 38%; P=.002). Physicians performed a GABHS test in 53% (95% CI,48%-57%)of visits and in 51% (95% Cl, 45%-57%)of visits at which an antibiotic was prescribed. GABHS testing was not associated with a lower antibiotic prescribing rate overall (48% tested vs 51% not tested; P=.40), but testing was associated with a lower antibiotic prescribing rate for children with diagnosis codes for pharyngitis, tonsillitis, and streptococcal sore throat (57% tested vs 73% not tested; P<.001). Conclusions Physicians prescribed antibiotics to 53% of children with sore throat, in excess of the maximum expected prevalence of GABHS. Although there was a decrease in the proportion of children receiving antibiotics between 1995 and 2003, this was due to decreased prescribing of agents recommended for GABHS. Although GABHS testing was associated with a lower rate of antibiotic prescribing for children with diagnosis codes of pharyngitis, tonsillitis, and streptococcal sore throat, GABHS testing was underused.	Brigham & Womens Hosp, Div Gen Med, Boston, MA 02120 USA; Harvard Univ, Sch Med, Ctr Child Hlth Care Studies, Boston, MA USA; Harvard Univ, Sch Med, Dept Ambulatory Care & Prevent, Boston, MA USA; Harvard Pilgrim Hlth Care, Boston, MA USA; Childrens Hosp, Div Infect Dis, Boston, MA 02115 USA; Childrens Hosp, Div Gen Pediat, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard Pilgrim Health Care; Harvard University; Boston Children's Hospital; Harvard University; Boston Children's Hospital	Linder, JA (corresponding author), Brigham & Womens Hosp, Div Gen Med, 1620 Tremont St,BC-3-2X, Boston, MA 02120 USA.	jlinder@partners.org	Linder, Jeffrey/AAF-3424-2021	Linder, Jeffrey/0000-0003-2217-184X	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [K08HS014563, K08HS013908] Funding Source: NIH RePORTER; AHRQ HHS [K08 HS014563, K08 HS013908] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Belongia EA, 2001, PEDIATRICS, V108, P575, DOI 10.1542/peds.108.3.575; Benin AL, 2003, PEDIATR INFECT DIS J, V22, P1043, DOI 10.1097/01.inf.0000100577.76542.af; Bisno AL, 2003, ANN INTERN MED, V139, P150, DOI 10.7326/0003-4819-139-2-200307150-00015; Bisno AL, 2002, CLIN INFECT DIS, V35, P113, DOI 10.1086/340949; Bisno AL, 2001, NEW ENGL J MED, V344, P205, DOI 10.1056/NEJM200101183440308; CAPLAN C, 1979, J FAM PRACTICE, V8, P485; Centor R M, 1981, Med Decis Making, V1, P239, DOI 10.1177/0272989X8100100304; COHEN ML, 1992, SCIENCE, V257, P1050, DOI 10.1126/science.257.5073.1050; Critchley IA, 2002, DIAGN MICR INFEC DIS, V42, P129, DOI 10.1016/S0732-8893(01)00327-3; Ebell MH, 2000, JAMA-J AM MED ASSOC, V284, P2912, DOI 10.1001/jama.284.22.2912; Finkelstein JA, 2001, PEDIATRICS, V108, pU113; Gandhi TK, 2003, NEW ENGL J MED, V348, P1556, DOI 10.1056/NEJMsa020703; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Gurwitz JH, 2003, JAMA-J AM MED ASSOC, V289, P1107, DOI 10.1001/jama.289.9.1107; HING E, 2004, ADV DATA VITAL HLTH, V338; Huang ES, 2002, ARCH INTERN MED, V162, P41, DOI 10.1001/archinte.162.1.41; Hyde TB, 2001, JAMA-J AM MED ASSOC, V286, P1857, DOI 10.1001/jama.286.15.1857; KAPLAN EL, 1971, J INFECT DIS, V123, P490, DOI 10.1093/infdis/123.5.490; KLJAKOVIC M, 1993, NEW ZEAL MED J, V106, P381; KOMAROFF AL, 1986, J GEN INTERN MED, V1, P1, DOI 10.1007/BF02596317; Linder JA, 2005, AM J MED, V118, P259, DOI 10.1016/j.amjmed.2004.09.015; Linder JA, 2003, CLIN THER, V25, P2419, DOI 10.1016/S0149-2918(03)80284-9; Linder JA, 2004, AM J MANAG CARE, V10, P661; LINDER JA, IN PRESS PHARMACOEPI; Mainous AG, 1996, PEDIATR INFECT DIS J, V15, P806, DOI 10.1097/00006454-199609000-00014; Mangione-Smith R, 2005, ARCH PEDIAT ADOL MED, V159, P491, DOI 10.1001/archpedi.159.5.491; Martin JM, 2002, NEW ENGL J MED, V346, P1200, DOI 10.1056/NEJMoa013169; Mather J. L., 1994, Canadian Journal of Hospital Pharmacy, V47, P111; McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096; MCCAIG LF, 2004, ADV DATA VITAL HLTH, V335; McIsaac WJ, 2000, CAN MED ASSOC J, V163, P811; McIsaac WJ, 2004, JAMA-J AM MED ASSOC, V291, P1587, DOI 10.1001/jama.291.13.1587; McIsaac WJ, 2002, J FAM PRACTICE, V51, P339; McIsaac WJ, 1998, CAN MED ASSOC J, V158, P75; Nash DR, 2002, ARCH PEDIAT ADOL MED, V156, P1114, DOI 10.1001/archpedi.156.11.1114; *NAT COMM QUAL ASS, HEDIS 2004 SUMM TABL; *NAT CTR HLTH STAT, 2005, PUBL US MICR FIL DOC; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Perz JF, 2002, JAMA-J AM MED ASSOC, V287, P3103, DOI 10.1001/jama.287.23.3103; PICKERING LK, 2003, RED BOOK 2003 REPORT; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; Schwartz B, 1998, PEDIATRICS, V101, P171; Snow V, 2001, ANN INTERN MED, V134, P506, DOI 10.7326/0003-4819-134-6-200103200-00018; Solomon DH, 2001, ARCH INTERN MED, V161, P1897, DOI 10.1001/archinte.161.15.1897; Steinman MA, 2003, JAMA-J AM MED ASSOC, V289, P719, DOI 10.1001/jama.289.6.719; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Stille CJ, 2004, PEDIATRICS, V114, P1206, DOI 10.1542/peds.2004-0311; *US FDA, 1995, NAT DRUG COD DIR; WALSH BT, 1975, ARCH INTERN MED, V135, P1493, DOI 10.1001/archinte.135.11.1493; Woodwell DA, 2004, ADV DATA VITAL HLTH	50	133	151	9	21	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2005	294	18					2315	2322		10.1001/jama.294.18.2315	http://dx.doi.org/10.1001/jama.294.18.2315			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981LI	16278359	Bronze			2022-12-28	WOS:000233089700023
J	Ha, EM; Oh, CT; Bae, YS; Lee, WJ				Ha, EM; Oh, CT; Bae, YS; Lee, WJ			A direct role for dual oxidase in Drosophila gut immunity	SCIENCE			English	Article							INNATE IMMUNITY; NADPH OXIDASE; CLONING; SYSTEM; MYELOPEROXIDASE; RECOGNITION; FAMILY; CDNAS; CELLS; BURST	Because the mucosal epithelia are in constant contact with large numbers of microorganisms, these surfaces must be armed with efficient microbial control systems. Here, we show that the Drosophila nicotinamide adenine dinucleotide phosphate (NADPH) oxidase enzyme, dual oxidase (dDuox), is indispensable for gut antimicrobial activities. Adult flies in which dDuox expression is silenced showed a marked increase in mortality rate even after a minor infection through ingestion of microbe-contaminated food. This could be restored by the specific reintroduction of dDuox, demonstrating that this oxidase generates a unique epithelia[ oxidative burst that limits microbial proliferation in the gut. Thus, oxidant-mediated antimicrobial responses are not restricted to the phagocytes, but rather are used more broadly, including in mucosal barrier epithelia.	Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Cell Signaling Res, Seoul 120750, South Korea; Inst Pasteur Korea, Lab Innate Immun, Seoul 136791, South Korea	Ewha Womans University; Ewha Womans University; Institut Pasteur Korea	Lee, WJ (corresponding author), Ewha Womans Univ, Div Mol Life Sci, Seoul 120750, South Korea.	lwj@ewha.ac.kr						Babior B M, 1995, Curr Opin Hematol, V2, P55; Bokoch GM, 2003, TRENDS BIOCHEM SCI, V28, P502, DOI 10.1016/S0968-0004(03)00194-4; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; De Deken X, 2000, J BIOL CHEM, V275, P23227, DOI 10.1074/jbc.M000916200; Dupuy C, 1999, J BIOL CHEM, V274, P37265, DOI 10.1074/jbc.274.52.37265; Edens WA, 2001, J CELL BIOL, V154, P879, DOI 10.1083/jcb.200103132; El Hassani RA, 2005, AM J PHYSIOL-GASTR L, V288, pG933, DOI 10.1152/ajpgi.00198.2004; Forteza R, 2005, AM J RESP CELL MOL, V32, P462, DOI 10.1165/rcmb.2004-0302OC; Geiszt M, 2004, J BIOL CHEM, V279, P51715, DOI 10.1074/jbc.R400024200; Geiszt M, 2003, FASEB J, V17, P1502, DOI 10.1096/fj.02-1104fje; GRAY GR, 1973, LANCET, V2, P530; Ha EM, 2005, DEV CELL, V8, P125, DOI 10.1016/j.devcel.2004.11.007; Hampton MB, 1998, BLOOD, V92, P3007, DOI 10.1182/blood.V92.9.3007.421k47_3007_3017; Hoffmann JA, 2002, NAT IMMUNOL, V3, P121, DOI 10.1038/ni0202-121; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; KLEBANOFF SJ, 1974, J BIOL CHEM, V249, P3724; Lambeth JD, 2004, NAT REV IMMUNOL, V4, P181, DOI 10.1038/nri1312; Lemaitre B, 2004, NAT REV IMMUNOL, V4, P521, DOI 10.1038/nri1390; Medzhitov R, 1997, CELL, V91, P295, DOI 10.1016/S0092-8674(00)80412-2; Moreno JC, 2002, NEW ENGL J MED, V347, P95, DOI 10.1056/NEJMoa012752; Pullar JM, 2000, IUBMB LIFE, V50, P259, DOI 10.1080/15216540051080958; Quinn MT, 2004, J LEUKOCYTE BIOL, V76, P760, DOI 10.1189/jlb.0404216; Rhee S.G., 2000, SCI STKE; Rosen H, 2002, J BIOL CHEM, V277, P30463, DOI 10.1074/jbc.M202331200; Silverman N, 2001, GENE DEV, V15, P2321, DOI 10.1101/gad.909001; Wong JL, 2004, DEV CELL, V7, P801, DOI 10.1016/j.devcel.2004.10.014	27	558	581	2	72	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					847	850		10.1126/science.1117311	http://dx.doi.org/10.1126/science.1117311			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272120				2022-12-28	WOS:000233121800044
J	Patzold, M; Tellman, S; Hausler, B; Hinson, D; Schaa, R; Tyler, GL				Patzold, M; Tellman, S; Hausler, B; Hinson, D; Schaa, R; Tyler, GL			A sporadic third layer in the ionosphere of Mars	SCIENCE			English	Article							IONS; ATMOSPHERE	The daytime martian ionosphere has been observed as a two-layer structure with electron densities that peak at attitudes between about 110 and 130 kilometers. The Mars Express Orbiter Radio Science Experiment on the European Mars Express spacecraft observed, in 10 out of 120 electron density profiles, a third ionospheric layer at attitude ranges of 65 to 110 kilometers, where electron densities, on average, peaked at 0.8 x 10(10) per cubic meter. Such a layer has been predicted to be permanent and continuous. Its origin has been attributed to ablation of meteors and charge exchange of magnesium and iron. Our observations imply that this layer is present sporadically and locally.	Univ Cologne, Inst Geophys & Meteorol, D-5000 Cologne, Germany; Univ Bundeswehr Munchen, Inst Raumfahrttech, Neubiberg, Germany; Stanford Univ, Dept Elect Engn, Stanford, CA 94305 USA	University of Cologne; Bundeswehr University Munich; Stanford University	Patzold, M (corresponding author), Univ Cologne, Inst Geophys & Meteorol, D-5000 Cologne, Germany.	paetzold@geo.uni-koeln.de		Hinson, David/0000-0002-1620-4011				BERTAUX JL, COMMUNICATION; FJELDBO G, 1965, J GEOPHYS RES, V70, P3701, DOI 10.1029/JZ070i015p03701; Fox JL, 2004, ADV SPACE RES-SERIES, V33, P132, DOI 10.1016/j.asr.2003.08.014; HANSON WB, 1977, J GEOPHYS RES, V82, P4352; Kopp E, 1997, J GEOPHYS RES-SPACE, V102, P9667, DOI 10.1029/97JA00384; LINDAL GF, 1979, J GEOPHYS RES, V84, P8443, DOI 10.1029/JB084iB14p08443; Molina-Cuberos GJ, 2003, PLANET SPACE SCI, V51, P239, DOI 10.1016/S0032-0633(02)00197-6; Patzold M, 2004, ESA SPEC PUBL, P141; Pesnell WD, 2000, J GEOPHYS RES-PLANET, V105, P1695, DOI 10.1029/1999JE001115; RISBETH EG, 2003, PLANET SPACE SCI, V52, P849; Rishbeth H, 2004, PLANET SPACE SCI, V52, P849, DOI 10.1016/j.pss.2004.02.007; Zasova L, 2005, PLANET SPACE SCI, V53, P1065, DOI 10.1016/j.pss.2004.12.010	12	147	150	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					837	839		10.1126/science.1117755	http://dx.doi.org/10.1126/science.1117755			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272118				2022-12-28	WOS:000233121800040
J	Platten, M; Ho, PP; Youssef, S; Fontoura, P; Garren, H; Hur, EM; Gupta, R; Lee, LY; Kidd, BA; Robinson, WH; Sobel, RA; Selley, ML; Steinman, L				Platten, M; Ho, PP; Youssef, S; Fontoura, P; Garren, H; Hur, EM; Gupta, R; Lee, LY; Kidd, BA; Robinson, WH; Sobel, RA; Selley, ML; Steinman, L			Treatment of autoimmune neuroinflammation with a synthetic tryptophan metabolite	SCIENCE			English	Article							ALTERED PEPTIDE LIGAND; MYELIN BASIC-PROTEIN; MULTIPLE-SCLEROSIS; T-CELL; INDOLEAMINE 2,3-DIOXYGENASE; IMMUNE-RESPONSES; NERVOUS SYSTEMS; DENDRITIC CELLS; INHIBITION; CATABOLISM	Local catabolism of, the amino acid tryptophan (Trp) by indoleamine 2,3-dioxygenase ([DO) is considered an important mechanism of regulating T cell immunity. We show that IDO transcription was increased when myelin-specific T cells were stimulated with tolerogenic altered self-peptides. Catabolites of Trp suppressed proliferation of myelin-specific T cells and inhibited production of proinflammatory T helper-1 (T(H)1) cytokines. N-(3,4,-Dimethoxycinnamoyl) anthranilic acid (3,4-DAA), an orally active syntihetic derivative of the Trp metabolite anthranilic acid, reversed paralysis in mice with experimental autoimmune encephalomyelitis, a model of multiple sclerosis (MS). Trp catabolites and their derivatives offer a new strategy for treating T(H)1-mediated autoimmune diseases such as MS.	Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Stanford, CA 94305 USA; Stanford Univ, Dept Pathol Neuropathol, Stanford, CA 94305 USA; Univ Tubingen, Dept Gen Neurol, D-72076 Tubingen, Germany; Univ Tubingen, Hertie Inst Clin Brain Res, D-72076 Tubingen, Germany; Univ Nova Lisboa, Fac Med Sci, Dept Immunol, P-1169056 Lisbon, Portugal; Bayhill Therapeut Inc, Palo Alto, CA 94303 USA; Vet Affairs Hlth Syst, Ctr Geriatr Res Educ & Clin, Palo Alto, CA 94304 USA; Angiogen Pharmaceut Pty Ltd, Sydney, NSW 2000, Australia	Stanford University; Stanford University; Eberhard Karls University of Tubingen; Eberhard Karls University of Tubingen; Eberhard Karls University Hospital; Universidade Nova de Lisboa; Geriatric Research Education & Clinical Center	Platten, M (corresponding author), Stanford Univ, Dept Neurol & Neurol Sci, Beckman Ctr Mol Med, Stanford, CA 94305 USA.	michael.platten@uni-tuebingen.de; steinman@stanford.edu	Fontoura, Paulo/A-2315-2010; Platten, Michael/F-2902-2013	Platten, Michael/0000-0002-4746-887X; Sobel, Raymond/0000-0002-0477-9002; Robinson, William/0000-0003-4385-704X; Kidd, Brian/0000-0003-2110-1145; Steinman, Lawrence/0000-0002-2437-2250; /0000-0002-6848-318X; Gupta, Rohit/0000-0002-6897-7083				Aaronson DS, 2002, SCIENCE, V296, P1653, DOI 10.1126/science.1071545; Bielekova B, 2000, NAT MED, V6, P1167, DOI 10.1038/80516; Brocke S, 1996, NATURE, V379, P343, DOI 10.1038/379343a0; Carreno BM, 2002, ANNU REV IMMUNOL, V20, P29, DOI 10.1146/annurev.immunol.20.091101.091806; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Duda PW, 2000, J CLIN INVEST, V105, P967, DOI 10.1172/JCI8970; EVAVOLD BD, 1993, IMMUNOL TODAY, V14, P602, DOI 10.1016/0167-5699(93)90200-5; Feldmann M, 2005, NATURE, V435, P612, DOI 10.1038/nature03727; Frumento G, 2002, J EXP MED, V196, P459, DOI 10.1084/jem.20020121; Garren H, 2001, IMMUNITY, V15, P15, DOI 10.1016/S1074-7613(01)00171-6; Genain CP, 2000, NAT MED, V6, P1098, DOI 10.1038/80424; Grohmann U, 2003, TRENDS IMMUNOL, V24, P242, DOI 10.1016/S1471-4906(03)00072-3; Isaji M, 1998, CARDIOVASC DRUG REV, V16, P288, DOI 10.1111/j.1527-3466.1998.tb00359.x; Kappos L, 2000, NAT MED, V6, P1176, DOI 10.1038/80525; Mellor AL, 2004, NAT REV IMMUNOL, V4, P762, DOI 10.1038/nri1457; Munn DH, 1998, SCIENCE, V281, P1191, DOI 10.1126/science.281.5380.1191; Munn DH, 2004, TRENDS MOL MED, V10, P15, DOI 10.1016/j.molmed.2003.11.003; NICHOLSON LB, 1995, IMMUNITY, V3, P397, DOI 10.1016/1074-7613(95)90169-8; Pearson CI, 1997, J EXP MED, V185, P583, DOI 10.1084/jem.185.4.583; Platten M, 2005, NAT MED, V11, P252, DOI 10.1038/nm0305-252; Polman C, 2005, NEUROLOGY, V64, P987, DOI 10.1212/01.WNL.0000154520.48391.69; Schwarcz R, 2004, CURR OPIN PHARMACOL, V4, P12, DOI 10.1016/j.coph.2003.10.006; Steinman L, 2004, SCIENCE, V305, P212, DOI 10.1126/science.1099896; Steinman L, 2004, NAT IMMUNOL, V5, P575, DOI 10.1038/ni1078; Steinman L, 2001, NAT IMMUNOL, V2, P762, DOI 10.1038/ni0901-762; Stone TW, 2002, NAT REV DRUG DISCOV, V1, P609, DOI 10.1038/nrd870; Tan IL, 2000, MULT SCLER, V6, P99, DOI 10.1191/135245800678827626; TAYLOR MW, 1991, FASEB J, V5, P2516, DOI 10.1096/fasebj.5.11.1907934; Terness P, 2002, J EXP MED, V196, P447, DOI 10.1084/jem.20020052; Youssef S, 2002, NATURE, V420, P78, DOI 10.1038/nature01158	30	342	365	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					850	855		10.1126/science.1117634	http://dx.doi.org/10.1126/science.1117634			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272121				2022-12-28	WOS:000233121800045
J	Suthram, S; Sittler, T; Ideker, T				Suthram, S; Sittler, T; Ideker, T			The Plasmodium protein network diverges from those of other eukaryotes	NATURE			English	Article							INTERACTION MAP; FALCIPARUM; ANNOTATION; YEAST; TOOL	Plasmodium falciparum is the pathogen responsible for over 90% of human deaths from malaria(1). Therefore, it has been the focus of a considerable research initiative, involving the complete DNA sequencing of the genome(2), large-scale expression analyses(3,4), and protein characterization of its life-cycle stages(5). The Plasmodium genome sequence is relatively distant from those of most other eukaryotes, with more than 60% of the 5,334 encoded proteins lacking any notable sequence similarity to other organisms(2). To systematically elucidate functional relationships among these proteins, a large two-hybrid study has recently mapped a network of 2,846 interactions involving 1,312 proteins within Plasmodium6. This network adds to a growing collection of available interaction maps for a number of different organisms, and raises questions about whether the divergence of Plasmodium at the sequence level is reflected in the configuration of its protein network. Here we examine the degree of conservation between the Plasmodium protein network and those of model organisms. Although we find 29 highly connected protein complexes specific to the network of the pathogen, we find very little conservation with complexes observed in other organisms ( three in yeast, none in the others). Overall, the patterns of protein interaction in Plasmodium, like its genome sequence, set it apart from other species.	Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Suthram, S (corresponding author), Univ Calif San Diego, Bioinformat Program, La Jolla, CA 92093 USA.	ssuthram@ucsd.edu		Sittler, Taylor/0000-0001-7495-4147; Ideker, Trey/0000-0002-1708-8454	NIEHS NIH HHS [R01 ES014811, R01 ES014811-01A1] Funding Source: Medline; NIGMS NIH HHS [R01 GM070743, R01 GM070743-01] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES014811] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070743] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Conant GC, 2003, NAT GENET, V34, P264, DOI 10.1038/ng1181; Engqvist-Goldstein AEY, 2003, ANNU REV CELL DEV BI, V19, P287, DOI 10.1146/annurev.cellbio.19.111401.093127; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Gagny B, 2000, J CELL SCI, V113, P3309; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Goodson HV, 1996, J CELL BIOL, V133, P1277, DOI 10.1083/jcb.133.6.1277; Hoppe HC, 2004, ANTIMICROB AGENTS CH, V48, P2370, DOI 10.1128/AAC.48.7.2370-2378.2004; Kelley BP, 2003, P NATL ACAD SCI USA, V100, P11394, DOI 10.1073/pnas.1534710100; LaCount DJ, 2005, NATURE, V438, P103, DOI 10.1038/nature04104; Langst G, 2001, J CELL SCI, V114, P2561; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Mewes HW, 2004, NUCLEIC ACIDS RES, V32, pD41, DOI 10.1093/nar/gkh092; Miller LH, 2002, NATURE, V415, P673, DOI 10.1038/415673a; Rain JC, 2001, NATURE, V409, P211, DOI 10.1038/35051615; SALISBURY JL, 1981, NATURE, V294, P163, DOI 10.1038/294163a0; Sanchez CP, 2004, BIOCHEMISTRY-US, V43, P16365, DOI 10.1021/bi048241x; SCHEIBEL LW, 1987, P NATL ACAD SCI USA, V84, P7310, DOI 10.1073/pnas.84.20.7310; Shanmugam KS, 1979, DIGITAL ANALOG COMMU; Sharan R, 2005, P NATL ACAD SCI USA, V102, P1974, DOI 10.1073/pnas.0409522102; Sollars V, 2003, NAT GENET, V33, P70, DOI 10.1038/ng1067; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303; Yu HY, 2004, GENOME RES, V14, P1107, DOI 10.1101/gr.1774904	30	97	104	1	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					108	112		10.1038/nature04135	http://dx.doi.org/10.1038/nature04135			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267557	Green Accepted			2022-12-28	WOS:000232979000051
J	Sable-Fourtassou, G; Cohen, P; Mahr, A; Pagnoux, C; Mouthon, L; Jayne, D; Blockmans, D; Cordier, JF; Delaval, P; Puechal, X; Lauque, D; Viallard, JF; Zoulim, A; Guillevin, L				Sable-Fourtassou, G; Cohen, P; Mahr, A; Pagnoux, C; Mouthon, L; Jayne, D; Blockmans, D; Cordier, JF; Delaval, P; Puechal, X; Lauque, D; Viallard, JF; Zoulim, A; Guillevin, L		French Vasculitis Study Grp	Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome	ANNALS OF INTERNAL MEDICINE			English	Article							TERM-FOLLOW-UP; SYSTEMIC VASCULITIS; GRANULOMATOSIS; EOSINOPHILIA; MONTELUKAST; ZAFIRLUKAST; ANGIITIS; ASTHMA; CELLS	Background: since testing for antineutrophil cytoplasmic antibodies (ANCA) became available for routine evaluation, no large homogeneous cohort of patients with the Churg-Strauss syndrome has been studied. Objective: To define the clinical and biological characteristics of newly diagnosed Churg-Strauss syndrome, according to the presence or absence of ANCA. Design: Cross-sectional analysis of manifestations of participants who were enrolled in treatment trials between December 1995 and December 2002. Setting: Multicenter study in 63 clinical centers in France, Belgium, Latvia, and the United Kingdom, coordinated by the French Vasculitis Study Group. Participants: 112 patients with Churg-Strauss syndrome that was recently diagnosed on the basis of current classifications. Measurements: The authors compared principal demographic, clinical, and laboratory features according to ANCA status at diagnosis. Results: The authors detected ANCA in 43 (38%) patients. Positive ANCA status at diagnosis was associated with renal involvement, peripheral neuropathy, and biopsy-proven vasculitis, whereas negative ANCA status was associated with heart disease and fever. Limitations: The authors assessed ANCA by immunofluorescence, but they did not assess ANCA centrally or systematically retest if ANCA was undetected at diagnosis. Conclusions: Phenotypically, ANCA-positive and ANCA-negative Churg-Strauss syndrome might differ. The association of ANCA positivity with clinical symptoms that indicate inflammation and necrosis of small vessels might characterize a predominantly vasculitic pattern of the Churg-Strauss syndrome.	Univ Paris 05, Hop Cochin, Dept Internal Med, APHP, F-75014 Paris, France; Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium; Addenbrookes Hosp, Cambridge, England; Hop Pontchaillou, Rennes, France; Hop Louis Pradel, Hospices Civils Lyon, Lyon, France; Ctr Hosp, Le Mans, France; Hop Purpan, Toulouse, France; Hop Haut Leveque, Bordeaux, France; Ctr Hosp Cote Nacre, Caen, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Ambroise-Pare - APHP; Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; KU Leuven; University Hospital Leuven; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; CHU Rennes; CHU Lyon; Centre Hospitalier Le Mans; CHU de Toulouse; CHU Bordeaux; CHU de Caen NORMANDIE	Guillevin, L (corresponding author), Univ Paris 05, Hop Cochin, Dept Internal Med, APHP, 27 Rue Faubourg St Jacques, F-75014 Paris, France.	loic.guillevin@cch.ap-hop-paris.fr	Puéchal, Xavier/P-1555-2017; Pagnoux, Christian/C-4612-2015	Puéchal, Xavier/0000-0003-3573-9203; Mahr, Alfred/0000-0002-1564-9115; Jayne, David/0000-0002-1712-0637				Della Rossa A, 2002, RHEUMATOLOGY, V41, P1286, DOI 10.1093/rheumatology/41.11.1286; Elena C, 1999, INTERNAL MED, V38, P759, DOI 10.2169/internalmedicine.38.759; FIENBERG R, 1993, HUM PATHOL, V24, P160, DOI 10.1016/0046-8177(93)90295-R; Gross WL, 2002, CURR OPIN RHEUMATOL, V14, P11, DOI 10.1097/00002281-200201000-00003; GUILLEVIN L, 1987, LUNG, V165, P165, DOI 10.1007/BF02714432; Guillevin L, 1996, MEDICINE, V75, P17, DOI 10.1097/00005792-199601000-00003; Guillevin L, 1999, MEDICINE, V78, P26, DOI 10.1097/00005792-199901000-00003; Guilpain P, 2002, RHEUMATOLOGY, V41, P535, DOI 10.1093/rheumatology/41.5.535; Hagen EC, 1998, KIDNEY INT, V53, P743, DOI 10.1046/j.1523-1755.1998.00807.x; JENNETTE JC, 1994, ARTHRITIS RHEUM-US, V37, P187, DOI 10.1002/art.1780370206; Kallenberg Cees G. M., 2002, Autoimmunity Reviews, V1, P61, DOI 10.1016/S1568-9972(01)00008-8; Keogh KA, 2003, AM J MED, V115, P284, DOI 10.1016/S0002-9343(03)00359-0; Kiene A, 2001, ARTHRITIS RHEUM-US, V44, P469, DOI 10.1002/1529-0131(200102)44:2<469::AID-ANR66>3.0.CO;2-0; Lane SE, 2003, ARTHRITIS RHEUM-US, V48, P814, DOI 10.1002/art.10830; Leigh J, 1997, ENVIRON HEALTH PERSP, V105, P1241, DOI 10.2307/3433540; Levy Y, 1999, SOUTHERN MED J, V92, P412, DOI 10.1097/00007611-199904000-00012; LUQMANI RA, 1994, Q J MED, V87, P671; MASI AT, 1990, ARTHRITIS RHEUM, V33, P1094, DOI 10.1002/art.1780330806; Reid AJC, 1998, QJM-MON J ASSOC PHYS, V91, P219, DOI 10.1093/qjmed/91.3.219; Rothenberg ME, 1998, NEW ENGL J MED, V338, P1592, DOI 10.1056/NEJM199805283382206; Solans R, 2002, THORAX, V57, P183, DOI 10.1136/thorax.57.2.183; Solans R, 2001, RHEUMATOLOGY, V40, P763, DOI 10.1093/rheumatology/40.7.763; Tatsis E, 1998, ANN INTERN MED, V129, P370, DOI 10.7326/0003-4819-129-5-199809010-00004; Umetsu DT, 1997, J ALLERGY CLIN IMMUN, V100, P1, DOI 10.1016/S0091-6749(97)70186-6; Wechsler ME, 1998, JAMA-J AM MED ASSOC, V279, P455, DOI 10.1001/jama.279.6.455; Wechsler ME, 1999, CHEST, V116, P266, DOI 10.1378/chest.116.1.266-a; Wills-Karp M, 1999, ANNU REV IMMUNOL, V17, P255, DOI 10.1146/annurev.immunol.17.1.255; Xiao H, 2002, J CLIN INVEST, V110, P955, DOI 10.1172/JCI200215918	28	439	467	1	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					632	638		10.7326/0003-4819-143-9-200511010-00006	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00006			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263885				2022-12-28	WOS:000233030600002
J	Tomlins, SA; Rhodes, DR; Perner, S; Dhanasekaran, SM; Mehra, R; Sun, XW; Varambally, S; Cao, XH; Tchinda, J; Kuefer, R; Lee, C; Montie, JE; Shah, RB; Pienta, KJ; Rubin, MA; Chinnaiyan, AM				Tomlins, SA; Rhodes, DR; Perner, S; Dhanasekaran, SM; Mehra, R; Sun, XW; Varambally, S; Cao, XH; Tchinda, J; Kuefer, R; Lee, C; Montie, JE; Shah, RB; Pienta, KJ; Rubin, MA; Chinnaiyan, AM			Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer	SCIENCE			English	Article							EWINGS-SARCOMA TRANSLOCATION; EXPRESSION PROFILES; MULTIPLE-MYELOMA; EWS GENE; LEUKEMIA; CLASSIFICATION; FAMILY; TUMOR; FUSES	Recurrent chromosomal rearrangements have not been well characterized in common carcinomas. We used a bioinformatics approach to discover candidate oncogenic chromosomal aberrations on the basis of outlier gene expression. Two ETS transcription factors, ERG and ETV1, were identified as outliers in prostate cancer. We identified recurrent gene fusions of the 5' untranslated region of TMPRSS2 to ERG or ETV1 in prostate cancer tissues with outlier expression. By using fluorescence in situ hybridization, we demonstrated that 23 of 29 prostate cancer samples harbor rearrangements in ERG or ETV1. Cell line experiments suggest that the androgen-responsive promoter elements of TMPRSS2 mediate the overexpression of ETS family members in prostate cancer. These results have implications in the development of carcinomas and the molecular diagnosis and treatment of prostate cancer.	Univ Michigan, Sch Med, Dept Pathol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Bioinformat Program, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Urol, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Michigan Urol Ctr, Ann Arbor, MI 48109 USA; Univ Michigan, Sch Med, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA; Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Univ Ulm, Fac Med, Dept Urol, D-89075 Ulm, Germany	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Ulm University	Chinnaiyan, AM (corresponding author), Univ Michigan, Sch Med, Dept Pathol, 1301 Catherine St, Ann Arbor, MI 48109 USA.	arul@umich.edu	; Pienta, Kenneth/E-7679-2015	Rubin, Mark/0000-0002-8321-9950; Varambally, Sooryanarayana/0000-0002-2277-1127; Pienta, Kenneth/0000-0002-4138-2186; Dhanasekaran, saravana mohan/0000-0002-0489-2224; Tomlins, Scott/0000-0001-8661-9821	NCI NIH HHS [UO1 CA111275-01, 5P30 CA46592, P50CA69568, R01 CA97063] Funding Source: Medline; NIA NIH HHS [R01AG21404] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA097063, U01CA111275, P30CA046592, P50CA069568] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG021404] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Afar DEH, 2001, CANCER RES, V61, P1686; Deininger M, 2005, BLOOD, V105, P2640, DOI 10.1182/blood-2004-08-3097; DEKLEIN A, 1982, NATURE, V300, P765, DOI 10.1038/300765a0; Dhanasekaran SM, 2001, NATURE, V412, P822, DOI 10.1038/35090585; Dhanasekaran SM, 2004, FASEB J, V18, P243, DOI 10.1096/fj.04-2415fje; Fonseca Rafael, 2004, Cancer Research, V64, P1546, DOI 10.1158/0008-5472.CAN-03-2876; Futreal PA, 2004, NAT REV CANCER, V4, P177, DOI 10.1038/nrc1299; Glinsky GV, 2004, J CLIN INVEST, V113, P913, DOI 10.1172/JCI200420032; Hsu T, 2004, J CELL BIOCHEM, V91, P896, DOI 10.1002/jcb.20012; Huang E, 2003, LANCET, V361, P1590, DOI 10.1016/S0140-6736(03)13308-9; Jacquinet E, 2001, EUR J BIOCHEM, V268, P2687, DOI 10.1046/j.1432-1327.2001.02165.x; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; JEON IS, 1995, ONCOGENE, V10, P1229; Lapointe J, 2004, P NATL ACAD SCI USA, V101, P811, DOI 10.1073/pnas.0304146101; Lin BY, 1999, CANCER RES, V59, P4180; Mitelman F, 2000, MUTAT RES-REV MUTAT, V462, P247, DOI 10.1016/S1383-5742(00)00006-5; Nielsen TO, 2002, LANCET, V359, P1301, DOI 10.1016/S0140-6736(02)08270-3; Oikawa T, 2003, GENE, V303, P11, DOI 10.1016/S0378-1119(02)01156-3; Petrovics G, 2005, ONCOGENE, V24, P3847, DOI 10.1038/sj.onc.1208518; RABBITTS TH, 1994, NATURE, V372, P143, DOI 10.1038/372143a0; Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2; Ross ME, 2003, BLOOD, V102, P2951, DOI 10.1182/blood-2003-01-0338; ROWLEY JD, 1973, NATURE, V243, P290, DOI 10.1038/243290a0; Rowley JD, 2001, NAT REV CANCER, V1, P245, DOI 10.1038/35106108; SORENSEN PHB, 1994, NAT GENET, V6, P146, DOI 10.1038/ng0294-146; Sotiriou C, 2003, P NATL ACAD SCI USA, V100, P10393, DOI 10.1073/pnas.1732912100; Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847; Valk PJM, 2004, NEW ENGL J MED, V350, P1617, DOI 10.1056/NEJMoa040465; Vasselli JR, 2003, P NATL ACAD SCI USA, V100, P6958, DOI 10.1073/pnas.1131754100; Welsh JB, 2001, CANCER RES, V61, P5974; Yu YP, 2004, J CLIN ONCOL, V22, P2790, DOI 10.1200/JCO.2004.05.158; Zhan FH, 2002, BLOOD, V99, P1745, DOI 10.1182/blood.V99.5.1745	32	2888	3046	3	213	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					644	648		10.1126/science.1117679	http://dx.doi.org/10.1126/science.1117679			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254181				2022-12-28	WOS:000232997700032
J	Stickgold, R				Stickgold, R			Sleep-dependent memory consolidation	NATURE			English	Review							LONG-TERM POTENTIATION; LATE NOCTURNAL SLEEP; REM-SLEEP; EXPRESSION; TIME; HIPPOCAMPUS; IMPROVEMENT; ACTIVATION; PLASTICITY; WORKING	The concept of 'sleeping on a problem' is familiar to most of us. But with myriad stages of sleep, forms of memory and processes of memory encoding and consolidation, sorting out how sleep contributes to memory has been anything but straightforward. Nevertheless, converging evidence, from the molecular to the phenomenological, leaves little doubt that offline memory reprocessing during sleep is an important component of how our memories are formed and ultimately shaped.	Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA; Beth Israel Deaconess Med Ctr, Ctr Sleep & Cognit, Boston, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Stickgold, R (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, 330 Brookline Ave,FD-861, Boston, MA 02215 USA.	rstickgold@hms.harvard.edu			NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH092638] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Atienza M, 2004, J COGNITIVE NEUROSCI, V16, P53, DOI 10.1162/089892904322755557; BrashersKrug T, 1996, NATURE, V382, P252, DOI 10.1038/382252a0; Buzsaki G, 1996, CEREB CORTEX, V6, P81, DOI 10.1093/cercor/6.2.81; Cirelli C, 2004, NEURON, V41, P35, DOI 10.1016/S0896-6273(03)00814-6; Clemens Z, 2005, NEUROSCIENCE, V132, P529, DOI 10.1016/j.neuroscience.2005.01.011; Datta S, 2000, J NEUROSCI, V20, P8607, DOI 10.1523/JNEUROSCI.20-22-08607.2000; Dave AS, 2000, SCIENCE, V290, P812, DOI 10.1126/science.290.5492.812; Deregnaucourt S, 2005, NATURE, V433, P710, DOI 10.1038/nature03275; Dudai Y, 2004, ANNU REV PSYCHOL, V55, P51, DOI 10.1146/annurev.psych.55.090902.142050; DUNCAN CP, 1949, J COMP PHYSIOL PSYCH, V42, P32, DOI 10.1037/h0058173; Ebbinghaus, 1885, GEDACHTNIS; Fischer S, 2002, P NATL ACAD SCI USA, V99, P11987, DOI 10.1073/pnas.182178199; Fosse MJ, 2003, J COGNITIVE NEUROSCI, V15, P1, DOI 10.1162/089892903321107774; Frank MG, 2001, NEURON, V30, P275, DOI 10.1016/S0896-6273(01)00279-3; Gais S, 2004, P NATL ACAD SCI USA, V101, P2140, DOI 10.1073/pnas.0305404101; Gais S, 2002, J NEUROSCI, V22, P6830; Gais S, 2000, NAT NEUROSCI, V3, P1335, DOI 10.1038/81881; Ghilardi MF, 2000, BRAIN RES, V871, P127, DOI 10.1016/S0006-8993(00)02365-9; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; *I OR, QUINTILIAN; KARNI A, 1994, SCIENCE, V265, P679, DOI 10.1126/science.8036518; Kuriyama K, 2004, LEARN MEMORY, V11, P705, DOI 10.1101/lm.76304; Louie K, 2001, NEURON, V29, P145, DOI 10.1016/S0896-6273(01)00186-6; Manoach DS, 2004, BIOL PSYCHIAT, V56, P951, DOI 10.1016/j.biopsych.2004.09.012; Manoach DS, 2003, SCHIZOPHR RES, V60, P285, DOI 10.1016/S0920-9964(02)00294-3; Maquet P, 2000, NAT NEUROSCI, V3, P831, DOI 10.1038/77744; Maquet P, 2000, J SLEEP RES, V9, P207; MCCLELLAND JL, 1995, PSYCHOL REV, V102, P419, DOI 10.1037/0033-295X.102.3.419; Muller G. E., 1900, Z PSYCHOLOGIE, V1, P1; Peigneux P, 2004, NEURON, V44, P535, DOI 10.1016/j.neuron.2004.10.007; Plihal W, 1997, J COGNITIVE NEUROSCI, V9, P534, DOI 10.1162/jocn.1997.9.4.534; Plihal W, 1999, NEUROREPORT, V10, P2741, DOI 10.1097/00001756-199909090-00009; Plihal W, 1999, PSYCHOPHYSIOLOGY, V36, P571, DOI 10.1111/1469-8986.3650571; Ribeiro S, 1999, LEARN MEMORY, V6, P500, DOI 10.1101/lm.6.5.500; Ribeiro S, 2002, J NEUROSCI, V22, P10914, DOI 10.1523/jneurosci.22-24-10914.2002; Robertson EM, 2004, CURR BIOL, V14, P208, DOI 10.1016/j.cub.2004.01.027; Roth DAE, 2005, LEARN MEMORY, V12, P159, DOI 10.1101/87505; Schabus M, 2004, SLEEP, V27, P1479, DOI 10.1093/sleep/27.7.1479; Schacter D., 1994, MEMORY SYSTEMS; Schwartz S, 2002, P NATL ACAD SCI USA, V99, P17137, DOI 10.1073/pnas.242414599; Shaffery JP, 2002, NEUROSCIENCE, V110, P431, DOI 10.1016/S0306-4522(01)00589-9; Smith C, 2001, SLEEP MED REV, V5, P491, DOI 10.1053/smrv.2001.0164; Smith Carlyle, 1996, Physiology and Behavior, V59, P93, DOI 10.1016/0031-9384(95)02054-3; Smith CT, 1998, NEUROBIOL LEARN MEM, V69, P211, DOI 10.1006/nlme.1997.3809; Steriade M, 2001, ARCH ITAL BIOL, V139, P37; Stickgold R, 2000, NAT NEUROSCI, V3, P1237, DOI 10.1038/81756; Stickgold R, 2000, SCIENCE, V290, P350, DOI 10.1126/science.290.5490.350; Stickgold R, 2000, J COGNITIVE NEUROSCI, V12, P246, DOI 10.1162/089892900562075; Stickgold R, 2005, SLEEP, V28, P1225, DOI 10.1093/sleep/28.10.1225; Stickgold R, 1998, TRENDS COGN SCI, V2, P484, DOI 10.1016/S1364-6613(98)01258-3; Vertes RP, 2005, SLEEP, V28, P1228, DOI 10.1093/sleep/28.10.1228; Wagner U, 2001, LEARN MEMORY, V8, P112, DOI 10.1101/lm.36801; Wagner U, 2004, NATURE, V427, P352, DOI 10.1038/nature02223; Walker MP, 2005, CEREB CORTEX, V15, P1666, DOI 10.1093/cercor/bhi043; Walker MP, 2004, NEURON, V44, P121, DOI 10.1016/j.neuron.2004.08.031; Walker MP, 2005, NEUROSCIENCE, V133, P911, DOI 10.1016/j.neuroscience.2005.04.007; Walker MP, 2003, LEARN MEMORY, V10, P275, DOI 10.1101/lm.58503; Walker MP, 2002, NEURON, V35, P205, DOI 10.1016/S0896-6273(02)00746-8; Walker MP, 2003, NATURE, V425, P616, DOI 10.1038/nature01930; WALKER MP, IN PRESS CLIN SPORTS; WILSON MA, 1994, SCIENCE, V265, P676, DOI 10.1126/science.8036517; Wixted JT, 2004, ANNU REV PSYCHOL, V55, P235, DOI 10.1146/annurev.psych.55.090902.141555	63	1042	1077	6	345	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1272	1278		10.1038/nature04286	http://dx.doi.org/10.1038/nature04286			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	977UQ	16251952	Green Published			2022-12-28	WOS:000232829100040
J	Fuster, V; Voute, J				Fuster, V; Voute, J			MDGs: chronic diseases are not on the agenda	LANCET			English	Editorial Material									World Hlth Federat, CH-1205 Geneva, Switzerland		Fuster, V (corresponding author), World Hlth Federat, CH-1205 Geneva, Switzerland.	Eileen.Durniak@msnyuhealth.org	Fuster, Valentin/H-4319-2015	Fuster, Valentin/0000-0002-9043-9986				Eckel Robert H, LANCET, V365, P1415, DOI [10.1016/S0140-6736(05)66378-7, DOI 10.1016/S0140-6736(05)67342-4, DOI 10.1016/S0140-6736(05)66378-7]; LEEDER S, 2004, RACE TIME; Nichols William C, LANCET, V365, P410, DOI [10.1016/S0140-6736(05)17828-3, DOI 10.1016/S0140-6736(05)67343-6, DOI 10.1016/S0140-6736(05)17828-3]; OBASANJO O, 2005, WHO PREV CHRON DIS V, pR8; Sacha J, 2004, B WORLD HEALTH ORGAN, V82, P891; Smith SC, 2004, CIRCULATION, V109, P3112, DOI 10.1161/01.CIR.0000133427.35111.67; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; Travis P, 2004, LANCET, V364, P900, DOI 10.1016/S0140-6736(04)16987-0; Unwin N, 2001, B WORLD HEALTH ORGAN, V79, P947; WANG L, 2005, LANCET          1005, DOI DOI 10.1016/S0140-6736(05)67344-8; WHO, 2005, CHRON DIS HLTH PROM; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	12	99	107	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1512	1514		10.1016/S0140-6736(05)67610-6	http://dx.doi.org/10.1016/S0140-6736(05)67610-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257330				2022-12-28	WOS:000232984800007
J	Hayashi, K; Yoshida, K; Matsui, Y				Hayashi, K; Yoshida, K; Matsui, Y			A histone H3 methyltransferase controls epigenetic events required for meiotic prophase	NATURE			English	Article							CHROMOSOME SYNAPSIS; METHYLATION PATTERNS; ACTIVE GENES; MOUSE; MICE; HETEROCHROMATIN; PROTEINS; COMPLEX; TRANSCRIPTION; CHROMATIN	Epigenetic modifications of histones regulate gene expression and chromatin structure(1,2). Here we show that Meisetz (meiosis-induced factor containing a PR/SET domain and zinc-finger motif) is a histone methyltransferase that is important for the progression of early meiotic prophase. Meisetz transcripts are detected only in germ cells entering meiotic prophase in female fetal gonads and in postnatal testis. Notably, Meisetz has catalytic activity for trimethylation, but not mono- or dimethylation, of lysine 4 of histone H3, and a transactivation activity that depends on its methylation activity. Mice in which the Meisetz gene is disrupted show sterility in both sexes due to severe impairment of the double-stranded break repair pathway, deficient pairing of homologous chromosomes and impaired sex body formation. In Meisetz-deficient testis, trimethylation of lysine 4 of histone H3 is attenuated and meiotic gene transcription is altered. These findings indicate that meiosis-specific epigenetic events in mammals are crucial for proper meiotic progression.	Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Mol Embryol, Osaka 5941101, Japan; Japan Sci & Technol Agcy, CREST, Saitama 3320012, Japan; Osaka City Univ, Grad Sch Med, Dept Mol Genet, Abeno Ku, Osaka 5458585, Japan; Tohoku Univ, Inst Dev Aging & Canc, Cell Resource Ctr Biomed Res, Sendai, Miyagi 9808575, Japan	Japan Science & Technology Agency (JST); Osaka Metropolitan University; Tohoku University	Matsui, Y (corresponding author), Osaka Med Ctr Maternal & Child Hlth, Res Inst, Dept Mol Embryol, Murodo Cho 840, Osaka 5941101, Japan.	ymatsui@idac.tohoku.ac.jp		Matsui, Yasuhisa/0000-0001-7026-6355				Baarends WM, 2005, MOL CELL BIOL, V25, P1041, DOI 10.1128/MCB.25.3.1041-1053.2005; Baudat F, 2000, MOL CELL, V6, P989, DOI 10.1016/S1097-2765(00)00098-8; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Dutta R, 2000, TRENDS BIOCHEM SCI, V25, P24, DOI 10.1016/S0968-0004(99)01503-0; Goo YH, 2003, MOL CELL BIOL, V23, P140, DOI 10.1128/MCB.23.1.140-149.2003; Jenuwein T, 2001, SCIENCE, V293, P1074, DOI 10.1126/science.1063127; Mahadevaiah SK, 2001, NAT GENET, V27, P271, DOI 10.1038/85830; Miller T, 2001, P NATL ACAD SCI USA, V98, P12902, DOI 10.1073/pnas.231473398; Milne TA, 2002, MOL CELL, V10, P1107, DOI 10.1016/S1097-2765(02)00741-4; Nakamura T, 2002, MOL CELL, V10, P1119, DOI 10.1016/S1097-2765(02)00740-2; Nishioka K, 2002, GENE DEV, V16, P479, DOI 10.1101/gad.967202; Noma K, 2001, SCIENCE, V293, P1150, DOI 10.1126/science.1064150; O'Carroll D, 2000, MOL CELL BIOL, V20, P9423, DOI 10.1128/MCB.20.24.9423-9433.2000; Peters AHFM, 2001, CELL, V107, P323, DOI 10.1016/S0092-8674(01)00542-6; Pittman DL, 1998, MOL CELL, V1, P697, DOI 10.1016/S1097-2765(00)80069-6; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Roguev A, 2001, EMBO J, V20, P7137, DOI 10.1093/emboj/20.24.7137; Romanienko PJ, 2000, MOL CELL, V6, P975, DOI 10.1016/S1097-2765(00)00097-6; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Schneider R, 2004, NAT CELL BIOL, V6, P73, DOI 10.1038/ncb1076; Tachibana M, 2001, J BIOL CHEM, V276, P25309, DOI 10.1074/jbc.M101914200; Turner JMA, 2005, NAT GENET, V37, P41, DOI 10.1038/ng1484; Wang HB, 2001, MOL CELL, V8, P1207, DOI 10.1016/S1097-2765(01)00405-1; WATANABE D, 1992, MOL REPROD DEV, V33, P307, DOI 10.1002/mrd.1080330312; Wysocka J, 2003, GENE DEV, V17, P896, DOI 10.1101/gad.252103; Yoshida K, 1998, MOL CELL, V1, P707, DOI 10.1016/S1097-2765(00)80070-2; Zhang Y, 2001, GENE DEV, V15, P2343, DOI 10.1101/gad.927301	28	353	372	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					374	378		10.1038/nature04112	http://dx.doi.org/10.1038/nature04112			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292313				2022-12-28	WOS:000233300200052
J	Clifford, DB; Evans, S; Yang, YJ; Acosta, EP; Goodkin, K; Tashima, K; Simpson, D; Dorfman, D; Ribaudo, H; Gulick, RM				Clifford, DB; Evans, S; Yang, YJ; Acosta, EP; Goodkin, K; Tashima, K; Simpson, D; Dorfman, D; Ribaudo, H; Gulick, RM		A5097 Study Team	Impact of efavirenz on neuropsychological performance and symptoms in HIV-infected individuals	ANNALS OF INTERNAL MEDICINE			English	Article							CENTRAL-NERVOUS-SYSTEM; HIV-1-INFECTED PATIENTS; ZIDOVUDINE TREATMENT; CONTAINING REGIMENS; INDUCED PSYCHOSIS; AIDS; INHIBITORS; COMPLEX	Background: Efavirenz is a commonly used antiretroviral drug that causes neurologic side effects in more than 50% of patients. Objective: To characterize efavirenz-associated neurologic Symptoms in a randomized, controlled study of initial antiretroviral treatment. Design: Substudy of a randomized, double-blind, controlled trial of combination antiretroviral regimens (A5095) that was performed between March 2001 and January 2002. Setting: Multicenter academic clinical trial units. Participants: HIV-infected patients who were initiating therapy in the context of a controlled trial. Measurements: Neuropsychological performance measures, including the Digit Symbol Substitution Test and the Trail Making Test (Parts A and B); symptom questionnaires; standardized assessments of sleep quality, anxiety, and depression; and efavirenz plasma concentrations. Results: Twenty of 303 (6.6%) enrolled participants prematurely discontinued the study. Neuropsychological performance improved in both groups over time without significant differences between patients who were receiving efavirenz and those who were not. The efavirenz group experienced more neurologic symptoms at week 1 (P < 0.001) but not at weeks 4, 12, or 24. A sleep index revealed that participants receiving efavirenz had more "bad dreams" during the first week of therapy (P = 0.038). No significant changes in anxiety or depressed mood were noted. Changes in efavirenz-associated neurologic symptoms were correlated to efavirenz plasma concentrations at week 1 but not at later time points. Twelve (6%) patients receiving efavirenz stopped taking the drug before the end of the study because of central nervous system symptoms. Limitations: Participant selection may have been biased in favor of patients with fewer psychiatric complications. The study design permitted substitution of a new drug in place of efavirenz in cases of treatment-limiting toxicity. Conclusions: in a large controlled trial, efavirenz use was associated with neurologic symptoms distinct from depression and anxiety that began early in therapy but resolved by week 4. Improvement in neuropsychological performance was comparable in patients who were receiving efavirenz and those who were not.	Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA	Washington University (WUSTL)	Clifford, DB (corresponding author), Washington Univ, Sch Med, Dept Neurol, Box 8111,660 S Euclid Ave, St Louis, MO 63110 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR002635, M01RR000865] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI046386, P30AI042848, P30AI042851, U01AI038858, U01AI027658, P30AI027767, U01AI046381, U01AI025879, U01AI046370, U01AI027673, U01AI025868, U01AI027670, U01AI039156, U01AI032775, K24AI051966, U01AI027664, U01AI027661, U01AI034832, P30AI028697, U01AI025924, U01AI027659, U01AI032782, U01AI027668, U01AI025903, U01AI027660, U01AI025915, U01AI038855, U01AI046339, U01AI027675, U01AI046376, U01AI025897, K23AI001781, P30AI050410] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS032228, R01NS032228] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 02635, RR00096, RR00044, RR00052, RR00865, RR00047, RR00046] Funding Source: Medline; NIAID NIH HHS [AI 42848, AI 27668, AI 39156, AI 25868, AI 25915, AI 46386, AI 25903, AI 27670, AI 51966, AI 42851, AI 46339, AI 38858, AI 27659, AI 27673, AI 27675, AI 27767, AI 27664, AI 38855, AI 25924, AI 34832, AI 27658, AI 46376, AI 46370, AI 25897, AI 27660, AI 01781, AI 27661, AI 32782, AI 46381, AI 32775, AI 28697, AI 50410, AI 25879] Funding Source: Medline; NINDS NIH HHS [NS 32228] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Army Individual Test Battery, 1944, ARM COMB FITN TEST; Blanch J, 2001, J ACQ IMMUN DEF SYND, V27, P336, DOI 10.1097/00126334-200108010-00003; *BRIST MYERS SQUIB, 2002, SUST EF MON ONL; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; DAVES CS, 2002, STAT METHODS ANAL RE; de la Garza CLS, 2001, AIDS, V15, P1911, DOI 10.1097/00002030-200109280-00033; Ferrando S, 1998, AIDS, V12, pF65, DOI 10.1097/00002030-199808000-00002; Fumaz CR, 2002, J ACQ IMMUN DEF SYND, V29, P244, DOI 10.1097/00042560-200203010-00004; Gallego L, 2004, CLIN INFECT DIS, V38, P430, DOI 10.1086/380791; Gulick RM, 2004, NEW ENGL J MED, V350, P1850, DOI 10.1056/NEJMoa031772; Haas DW, 2004, AIDS, V18, P2391; LANDOVITZ R, 2003, P 10 C RETR OPP INF, P314; Lezak MD, 2012, NEUROPSYCHOLOGICAL A, V5; Lochet P, 2003, HIV Med, V4, P62, DOI 10.1046/j.1468-1293.2003.00136.x; Marzolini C, 2001, AIDS, V15, P71, DOI 10.1097/00002030-200101050-00011; MAXWELL S, 1988, JAMA-J AM MED ASSOC, V259, P3406, DOI 10.1001/jama.259.23.3406; Peyriere H, 2001, AIDS, V15, P1323, DOI 10.1097/00002030-200107060-00025; Poulsen HD, 2003, AIDS, V17, P451, DOI 10.1097/00002030-200302140-00026; Puzantian T, 2002, PHARMACOTHERAPY, V22, P930, DOI 10.1592/phco.22.11.930.33624; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Reitan R., 1995, HALSTEAD REITAN NEUR; RIBAUDO H, 2004, 11 C RETR OPP INF AL; Sabato S, 2002, AIDS, V16, P1841, DOI 10.1097/00002030-200209060-00024; Sacktor NC, 2000, J NEUROVIROL, V6, P84, DOI 10.3109/13550280009006385; SCHMITT FA, 1988, NEW ENGL J MED, V319, P1573, DOI 10.1056/NEJM198812153192404; SIDTIS JJ, 1993, ANN NEUROL, V33, P343, DOI 10.1002/ana.410330403; Spielberger C. D., 1983, MIND GARDEN; Staszewski S, 1999, NEW ENGL J MED, V341, P1865, DOI 10.1056/NEJM199912163412501; Treisman GJ, 2002, AIDS, V16, P1201, DOI 10.1097/00002030-200206140-00002; Turner ML, 2003, J CHROMATOGR B, V784, P331, DOI 10.1016/S1570-0232(02)00822-X; *US DEP HHS, 2005, PAN CLIN PRACT TREAT; von Giesen HJ, 2003, HIV CLIN TRIALS, V4, P382; von Giesen HJ, 2002, J ACQ IMMUN DEF SYND, V29, P363, DOI 10.1097/00126334-200204010-00006; Wechsler D., 2008, WECHSLER ADULT INTEL, P257; Wechsler D, 1997, WECHSLER ADULT INTEL, VIII	36	198	202	0	6	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					714	721		10.7326/0003-4819-143-10-200511150-00008	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287792				2022-12-28	WOS:000233486800003
J	Yamamoto, JK; Fairchild, TR; Boggiani, PC; Montanheiro, TJ; de Araujo, CC; Kiyohara, PK; de Matos, SLF; Soares, PC				Yamamoto, JK; Fairchild, TR; Boggiani, PC; Montanheiro, TJ; de Araujo, CC; Kiyohara, PK; de Matos, SLF; Soares, PC			A record of Permian subaqueous vent activity in southeastern Brazil	NATURE			English	Article								The remarkable occurrence of more than 4,500 conical siliceous mounds in an area of less than 1.5 square kilometres has been reported in the Parana basin, near Anhembi, Sao Paulo, in southeastern Brazil(1). These structures, which are up to two metres high, are thought to have been formed at the margin of a very shallow, broad but waning internal sea(1), and it was originally suggested that they are stromatolites(2). Yet their restricted occurrence, unusual abundance and nearly pure siliceous composition have never been satisfactorily explained by this hypothesis. Here we report field and laboratory observations on their shape, construction, composition and mineralogy. On the basis of our data we suggest that the conical mounds are the result of subaqueous Late Permian vent activity in southwestern Gondwana. The present siliceous cone field differs considerably from other Palaeozoic siliceous hot spring deposits, such as those at Rhynie, Scotland(3), and the Drummond basin, Australia(4), and therefore represents an unusual occurrence of vent activity.	Univ Sao Paulo, Inst Geosci, BR-05508080 Sao Paulo, Brazil; State Secretary Environm, Inst Geol, BR-04301903 Sao Paulo, Brazil; PETROBRAS SA, BR-20031912 Rio De Janeiro, Brazil; Univ Sao Paulo, Inst Phys, BR-05508900 Sao Paulo, Brazil; Univ Fed Parana, Dept Geol, BR-81531990 Curitiba, Parana, Brazil	Universidade de Sao Paulo; Petrobras; Universidade de Sao Paulo; Universidade Federal do Parana	Yamamoto, JK (corresponding author), Univ Sao Paulo, Inst Geosci, Rua Lago 562, BR-05508080 Sao Paulo, Brazil.	jkyamamo@usp.br	Fairchild, Thomas Rich/AAE-1835-2021; Yamamoto, Jorge/C-3385-2013					[Anonymous], 1976, STROMATOLITES DEV SE; BRYAN TS, 1995, GEYSERS YELLOWSTONE, P1; COUTINHO JMV, 1991, P INT GONDWANA S, V7, P147; CUNNEEN R, 1989, ECON GEOL, V84, P135, DOI 10.2113/gsecongeo.84.1.135; Guidry SA, 2003, SEDIMENT GEOL, V157, P71, DOI 10.1016/S0037-0738(02)00195-1; HAYMON RM, 1983, NATURE, V301, P695, DOI 10.1038/301695a0; HOFMANN HJ, 1975, AM J SCI, V275, P1121, DOI 10.2475/ajs.275.10.1121; Matos S.L.F. de, 2001, GONDWANA RES, V4, P421, DOI DOI 10.1016/S1342-937X(05)70341-5; MATOS SLF, 1995, THESIS U SAO PAULO, P1; RAGONHA EW, 1974, ANAIS, V2, P271; Rice CM, 2002, J GEOL SOC LONDON, V159, P203, DOI 10.1144/0016-764900-181; SOARES PC, 1972, RES COMUN SESS TECNI, V1, P249; Souza Paulo A., 2003, Revista del Museo Argentino de Ciencias Naturales Nueva Serie, V5, P205; THURMAN HV, 2001, INTRO OCEANOGRAPHY, P1; Tivey MK, 1998, OCEANUS, V41, P22; Walter M.R., 1976, STROMATOLITES, P273	16	12	12	1	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					205	207		10.1038/nature04252	http://dx.doi.org/10.1038/nature04252			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281032				2022-12-28	WOS:000233133500044
J	Wu, WS; Heinrichs, S; Xu, D; Garrison, SP; Zambetti, GP; Adams, JM; Look, AT				Wu, WS; Heinrichs, S; Xu, D; Garrison, SP; Zambetti, GP; Adams, JM; Look, AT			Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma	CELL			English	Article							TRANSCRIPTION FACTORS SNAIL; RADIATION-THERAPY; BCL-2 FAMILY; CELL-DEATH; C-ELEGANS; P53; EXPRESSION; GENE; SURVIVAL; PROTEIN	In response to DNA damage, the p53 tumor suppressor can elicit either apoptosis or cell-cycle arrest and repair, but how this critical decision is made in specific cell types remains largely undefined. We investigated the mechanism by which the transcriptional repressor Slug specifically rescues hematopoietic progenitor cells from lethal doses of gamma radiation. We show that Slug is transcriptionally induced by p53 upon irradiation and then protects the damaged cell from apoptosis by directly repressing p53-mediated transcription of puma, a key BH3-only antagonist of the antiapoptotic Bcl-2 proteins. We established the physiologic significance of Slug-mediated repression of puma by demonstrating that mice deficient in both genes survive doses of total-body irradiation that lethally deplete hematopoietic progenitor populations in mice lacking only slug. Thus, Slug functions downstream of p53 in developing blood cells as a critical switch that prevents their apoptosis by antagonizing the trans-activation of puma by p53.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; St Jude Childrens Res Hosp, Dept Biochem, Memphis, TN 38105 USA; Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; St Jude Children's Research Hospital; Walter & Eliza Hall Institute	Look, AT (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.	thomas_look@dfci.harvard.edu	Zambetti, Gerard/N-8093-2018; Adams, Jerry M/E-1199-2013; Wu, Wen-Shu/I-1258-2014	Zambetti, Gerard/0000-0002-0929-5007; Wu, Wen-Shu/0000-0002-0225-2522; Adams, Jerry/0000-0002-4360-8628	NATIONAL CANCER INSTITUTE [F32CA103726, R01CA059571] Funding Source: NIH RePORTER; NCI NIH HHS [CA103726, CA-059571] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Balint E, 2001, BRIT J CANCER, V85, P1813, DOI 10.1054/bjoc.2001.2128; Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907; Bouillet P, 1999, SCIENCE, V286, P1735, DOI 10.1126/science.286.5445.1735; Cory S, 2003, ONCOGENE, V22, P8590, DOI 10.1038/sj.onc.1207102; Domen J, 1998, BLOOD, V91, P2272, DOI 10.1182/blood.V91.7.2272.2272_2272_2282; Egle A, 2004, P NATL ACAD SCI USA, V101, P6164, DOI 10.1073/pnas.0401471101; Grimes HL, 1996, MOL CELL BIOL, V16, P6263; Gupta PB, 2005, NAT GENET, V37, P1047, DOI 10.1038/ng1634; Hajra KM, 2002, CANCER RES, V62, P1613; Han JW, 2001, P NATL ACAD SCI USA, V98, P11318, DOI 10.1073/pnas.201208798; Harris SL, 2005, ONCOGENE, V24, P2899, DOI 10.1038/sj.onc.1208615; Hemann MT, 2005, NATURE, V436, P807, DOI 10.1038/nature03845; Hemann MT, 2004, P NATL ACAD SCI USA, V101, P9333, DOI 10.1073/pnas.0403286101; Hemavathy K, 2000, GENE, V257, P1, DOI 10.1016/S0378-1119(00)00371-1; Hemavathy K, 2000, MOL CELL BIOL, V20, P5087, DOI 10.1128/MCB.20.14.5087-5095.2000; Hofmann ER, 2002, CURR BIOL, V12, P1908, DOI 10.1016/S0960-9822(02)01262-9; Hoh J, 2002, P NATL ACAD SCI USA, V99, P8467, DOI 10.1073/pnas.132268899; Inoue A, 2002, CANCER CELL, V2, P279, DOI 10.1016/S1535-6108(02)00155-1; Inukai T, 1999, MOL CELL, V4, P343, DOI 10.1016/S1097-2765(00)80336-6; Jeffers JR, 2003, CANCER CELL, V4, P321, DOI 10.1016/S1535-6108(03)00244-7; Kajita M, 2004, MOL CELL BIOL, V24, P7559, DOI 10.1128/MCB.24.17.7559-7566.2004; Kurrey NK, 2005, GYNECOL ONCOL, V97, P155, DOI 10.1016/j.ygyno.2004.12.043; LEDOUARIN NM, 1994, CURR OPIN GENET DEV, V4, P685, DOI 10.1016/0959-437X(94)90135-P; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; Martin TA, 2005, ANN SURG ONCOL, V12, P488, DOI 10.1245/ASO.2005.04.010; Metzstein MM, 1999, MOL CELL, V4, P309, DOI 10.1016/S1097-2765(00)80333-0; Nakano K, 2001, MOL CELL, V7, P683, DOI 10.1016/S1097-2765(01)00214-3; Nakorn TN, 2002, J CLIN INVEST, V109, P1579, DOI 10.1172/JCI200215272; Oda E, 2000, SCIENCE, V288, P1053, DOI 10.1126/science.288.5468.1053; Ogilvy S, 1999, P NATL ACAD SCI USA, V96, P14943, DOI 10.1073/pnas.96.26.14943; Perez-Mancera PA, 2005, ONCOGENE, V24, P3073, DOI 10.1038/sj.onc.1208505; Shibue T, 2003, GENE DEV, V17, P2233, DOI 10.1101/gad.1103603; Slee EA, 2004, ONCOGENE, V23, P2809, DOI 10.1038/sj.onc.1207516; Thellmann M, 2003, DEVELOPMENT, V130, P4057, DOI 10.1242/dev.00597; Villunger A, 2003, SCIENCE, V302, P1036, DOI 10.1126/science.1090072; Werner-Wasik M, 2004, HEMATOL ONCOL CLIN N, V18, P131, DOI 10.1016/S0889-8588(03)00150-3; Yoshizawa H, 2003, BRIT J CANCER, V89, P803, DOI 10.1038/sj.bjc.6601227; Yu J, 2001, MOL CELL, V7, P673, DOI 10.1016/S1097-2765(01)00213-1; Yu J, 2003, P NATL ACAD SCI USA, V100, P1931, DOI 10.1073/pnas.2627984100; Zhou BBS, 2000, NATURE, V408, P433, DOI 10.1038/35044005	40	335	363	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					641	653		10.1016/j.cell.2005.09.029	http://dx.doi.org/10.1016/j.cell.2005.09.029			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286009	Bronze			2022-12-28	WOS:000233497400013
J	Sabatine, MS				Sabatine, MS			Something old, something new: beta blockers and clopidogrel in acute myocardial infarction	LANCET			English	Editorial Material							REPERFUSION THERAPY; THROMBOLYSIS; MORTALITY		Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Thrombolysis Myocardial Infarct Study Grp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Sabatine, MS (corresponding author), Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Thrombolysis Myocardial Infarct Study Grp, Boston, MA 02115 USA.	msabatine@partners.org	Sabatine, Marc/AAJ-6751-2020	Sabatine, Marc/0000-0002-0691-3359				[Anonymous], 1988, LANCET, V2, P349; [Anonymous], 1986, LANCET, V2, P57; Antman Elliott M., 2004, J Am Coll Cardiol, V44, pE1, DOI 10.1016/j.jacc.2004.07.014; BRAUNWALD E, 1993, NEW ENGL J MED, V329, P1650, DOI 10.1056/NEJM199311253292211; Chen ZM, 2005, LANCET, V366, P1622; Chen ZM, 2005, LANCET, V366, P1607, DOI 10.1016/s0140-6736(05)67660-x; FRIEDMAN LM, 1982, JAMA-J AM MED ASSOC, V247, P1707; *GISSI, 1986, LANCET, V1, P65; Leon MB, 1998, NEW ENGL J MED, V339, P1665, DOI 10.1056/NEJM199812033392303; Mehta SR, 2005, JAMA-J AM MED ASSOC, V293, P437; OHMAN EM, 1990, CIRCULATION, V82, P781, DOI 10.1161/01.CIR.82.3.781; PEDERSEN TR, 1981, NEW ENGL J MED, V304, P801; ROBERTS R, 1991, CIRCULATION, V83, P422, DOI 10.1161/01.CIR.83.2.422; Sabatine MS, 2005, AM HEART J, V149, P227, DOI 10.1016/j.ahj.2004.11.006; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Sabatine MS, 2005, JAMA-J AM MED ASSOC, V294, P1224, DOI 10.1001/jama.294.10.1224; SNOW PJD, 1965, LANCET, V2, P551; Topol EJ, 2001, LANCET, V357, P1905; Van de Werf F, 2003, EUR HEART J, V24, P28, DOI 10.1016/S0195-668X(02)00618-8; Van de Werf F, 1993, J AM COLL CARDIOL, V22, P407, DOI 10.1016/0735-1097(93)90044-2; Yusuf S, 2005, JAMA-J AM MED ASSOC, V293, P427; Yusuf S, 2001, NEW ENGL J MED, V345, P494; YUSUF S, 1984, STAT MED, V3, P409, DOI 10.1002/sim.4780030421; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	24	10	10	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1587	1589		10.1016/S0140-6736(05)67641-6	http://dx.doi.org/10.1016/S0140-6736(05)67641-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271628				2022-12-28	WOS:000233047100004
J	Eisenmesser, EZ; Millet, O; Labeikovsky, W; Korzhnev, DM; Wolf-Watz, M; Bosco, DA; Skalicky, JJ; Kay, LE; Kern, D				Eisenmesser, EZ; Millet, O; Labeikovsky, W; Korzhnev, DM; Wolf-Watz, M; Bosco, DA; Skalicky, JJ; Kay, LE; Kern, D			Intrinsic dynamics of an enzyme underlies catalysis	NATURE			English	Article							CIS-TRANS-ISOMERIZATION; TRIOSEPHOSPHATE ISOMERASE; CHEMICAL-EXCHANGE; PROTEIN DYNAMICS; LOOP MOTION; NMR; FLEXIBILITY; STATES	A unique feature of chemical catalysis mediated by enzymes is that the catalytically reactive atoms are embedded within a folded protein. Although current understanding of enzyme function has been focused on the chemical reactions and static three-dimensional structures, the dynamic nature of proteins has been proposed to have a function in catalysis(1-5). The concept of conformational substates has been described(6); however, the challenge is to unravel the intimate linkage between protein flexibility and enzymatic function. Here we show that the intrinsic plasticity of the protein is a key characteristic of catalysis. The dynamics of the prolyl cis - trans isomerase cyclophilin A ( CypA) in its substrate-free state and during catalysis were characterized with NMR relaxation experiments. The characteristic enzyme motions detected during catalysis are already present in the free enzyme with frequencies corresponding to the catalytic turnover rates. This correlation suggests that the protein motions necessary for catalysis are an intrinsic property of the enzyme and may even limit the overall turnover rate. Motion is localized not only to the active site but also to a wider dynamic network. Whereas coupled networks in proteins have been proposed previously(3,7-10), we experimentally measured the collective nature of motions with the use of mutant forms of CypA. We propose that the pre-existence of collective dynamics in enzymes before catalysis is a common feature of biocatalysts and that proteins have evolved under synergistic pressure between structure and dynamics.	Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA; Univ Toronto, Dept Med Genet, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Biochem, Toronto, ON M5S 1A8, Canada; Univ Toronto, Dept Chem, Toronto, ON M5S 1A8, Canada; Florida State Univ, Natl High Magnet Field Lab, Tallahassee, FL 32310 USA	Brandeis University; Howard Hughes Medical Institute; University of Toronto; University of Toronto; University of Toronto; State University System of Florida; Florida State University	Kern, D (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Dept Biochem, Waltham, MA 02454 USA.	dkern@brandeis.edu	Millet, Oscar/F-9696-2011; Labeikovsky, Wladimir/K-1648-2019	Millet, Oscar/0000-0001-8748-4105; Labeikovsky, Wladimir/0000-0001-6074-3269				Agarwal PK, 2004, BIOCHEMISTRY-US, V43, P10605, DOI 10.1021/bi0495228; AUSTIN RH, 1975, BIOCHEMISTRY-US, V14, P5355, DOI 10.1021/bi00695a021; Benkovic SJ, 2003, SCIENCE, V301, P1196, DOI 10.1126/science.1085515; Berendsen HJC, 2000, CURR OPIN STRUC BIOL, V10, P165, DOI 10.1016/S0959-440X(00)00061-0; CARVER JP, 1972, J MAGN RESON, V6, P89, DOI 10.1016/0022-2364(72)90090-X; Cole R, 2002, BIOCHEMISTRY-US, V41, P6072, DOI 10.1021/bi025655m; Eisenmesser EZ, 2002, SCIENCE, V295, P1520, DOI 10.1126/science.1066176; FISCHER G, 1984, BIOMED BIOCHIM ACTA, V43, P1101; Garcia-Viloca M, 2004, SCIENCE, V303, P186, DOI 10.1126/science.1088172; Goff DC, 2004, PREV MED, V38, P85, DOI 10.1016/j.ypmed.2003.09.037; Hammes GG, 2002, BIOCHEMISTRY-US, V41, P8221, DOI 10.1021/bi0260839; Ishima R, 1999, STRUCTURE, V7, P1047, DOI 10.1016/S0969-2126(99)80172-5; Jencks W. P., 1987, CATALYSIS CHEM ENZYM; KERN D, 1995, BIOCHEMISTRY-US, V34, P13594, DOI 10.1021/bi00041a039; Loria JP, 1999, J BIOMOL NMR, V15, P151, DOI 10.1023/A:1008355631073; McElheny D, 2005, P NATL ACAD SCI USA, V102, P5032, DOI 10.1073/pnas.0500699102; Mulder FAA, 2001, NAT STRUCT BIOL, V8, P932, DOI 10.1038/nsb1101-932; Ottiger M, 1997, J MOL BIOL, V272, P64, DOI 10.1006/jmbi.1997.1220; Palmer AG, 2004, CHEM REV, V104, P3623, DOI 10.1021/cr030413t; Rod TH, 2003, P NATL ACAD SCI USA, V100, P6980, DOI 10.1073/pnas.1230801100; Rosen MK, 1996, J MOL BIOL, V263, P627, DOI 10.1006/jmbi.1996.0603; Rozovsky S, 2001, J MOL BIOL, V310, P271, DOI 10.1006/jmbi.2001.4673; Schmid FX, 2002, ADV PROTEIN CHEM, V59, P243; Schnell JR, 2004, ANNU REV BIOPH BIOM, V33, P119, DOI 10.1146/annurev.biophys.33.110502.133613; Skrynnikov NR, 2002, J AM CHEM SOC, V124, P12352, DOI 10.1021/ja0207089; Suel GM, 2003, NAT STRUCT BIOL, V10, P59, DOI 10.1038/nsb881; Volkman BF, 2001, SCIENCE, V291, P2429, DOI 10.1126/science.291.5512.2429; WILLIAMS JC, 1995, BIOCHEMISTRY-US, V34, P8309, DOI 10.1021/bi00026a012; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Zhao YD, 1996, BIOCHEMISTRY-US, V35, P7356, DOI 10.1021/bi9602775	30	869	887	3	258	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					117	121		10.1038/nature04105	http://dx.doi.org/10.1038/nature04105			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267559				2022-12-28	WOS:000232979000053
J	Henry, SG				Henry, SG			Playing doctor	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CLINICAL-SKILLS EXAMINATION; COMPETENCE					stephen.henry@vanderbilt.edu			NCRR NIH HHS [M01 RR00095, M01 RR000095] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000095] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Barzansky B, 2004, JAMA-J AM MED ASSOC, V292, P1025, DOI 10.1001/jama.292.9.1025; Gaur L, 2004, JAMA-J AM MED ASSOC, V291, P2143, DOI 10.1001/jama.291.17.2143; GOLDMAN GM, 1990, YALE J BIOL MED, V63, P47; Holmboe ES, 2004, ACAD MED, V79, P16, DOI 10.1097/00001888-200401000-00006; Hubbard JP, 1985, NATL BOARD MED EXAMI; MALTERUD K, 1995, THEOR MED, V16, P183, DOI 10.1007/BF00998544; Newble D, 2004, MED EDUC, V38, P199, DOI 10.1111/j.1365-2923.2004.01755.x; Papadakis MA, 2004, NEW ENGL J MED, V350, P1703, DOI 10.1056/NEJMp038246; POLANYI M, 1970, AM SCHOLAR, V39, P655; Polanyi M., 1962, PERSONAL KNOWLEDGE; Polanyi M., 1966, TACIT DIMENSION; Schutz A., 1973, STRUCTURES LIFE WORL, V1; *USMLE, 2005, SCOR STEP 2 CS EX; Wettach GR, 2003, ACAD MED, V78, P1240, DOI 10.1097/00001888-200312000-00008; Williams RG, 2004, TEACH LEARN MED, V16, P215, DOI 10.1207/s15328015tlm1602_16	15	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2138	2140		10.1001/jama.294.17.2138	http://dx.doi.org/10.1001/jama.294.17.2138			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264147				2022-12-28	WOS:000232957700001
J	Altshuler, D; Brooks, LD; Chakravarti, A; Collins, FS; Daly, MJ; Donnelly, P; Gibbs, RA; Belmont, JW; Boudreau, A; Leal, SM; Hardenbol, P; Pasternak, S; Wheeler, DA; Willis, TD; Yu, FL; Yang, HM; Zeng, CQ; Gao, Y; Hu, HR; Hu, WT; Li, CH; Lin, W; Liu, SQ; Pan, H; Tang, XL; Wang, J; Wang, W; Yu, J; Zhang, B; Zhang, QR; Zhao, HB; Zhao, H; Zhou, J; Gabriel, SB; Barry, R; Blumenstiel, B; Camargo, A; Defelice, M; Faggart, M; Goyette, M; Gupta, S; Moore, J; Nguyen, H; Onofrio, RC; Parkin, M; Roy, J; Stahl, E; Winchester, E; Ziaugra, L; Shen, Y; Yao, ZJ; Huang, W; Chu, X; He, YG; Jin, L; Liu, YF; Shen, YY; Sun, WW; Wang, HF; Wang, Y; Wang, Y; Wang, Y; Xiong, XY; Xu, L; Waye, MMY; Tsui, SKW; Xue, H; Wong, JTF; Galver, ILM; Fan, JB; Murray, SS; Oliphant, AR; Chee, MS; Montpetit, A; Chagnon, F; Ferretti, V; Leboeuf, M; Olivier, JF; Phillips, MS; Roumy, S; Sallee, C; Verner, A; Hudson, TJ; Frazer, KA; Ballinger, DG; Cox, DR; Hinds, DA; Stuve, LL; Kwok, PY; Cai, DM; Koboldt, DC; Miller, RD; Pawlikowska, L; Taillon-Miller, P; Xiao, M; Tsui, LC; Mak, W; Sham, PC; Song, YQ; Tam, PKH; Nakamura, Y; Kawaguchi, T; Kitamoto, T; Morizono, T; Nagashima, A; Ohnishi, Y; Sekine, A; Tanaka, T; Tsunoda, T; Deloukas, P; Bird, CP; Delgado, M; Dermitzakis, ET; Gwilliam, R; Hunt, S; Morrison, J; Powell, D; Stranger, BE; Whittaker, P; Bentley, DR; Daly, MJ; de Bakker, PIW; Barrett, J; Fry, B; Maller, J; McCarroll, S; Patterson, N; Pe'er, I; Purcell, S; Richter, DJ; Sabeti, P; Saxena, R; Schaffner, SF; Varilly, P; Stein, LD; Krishnan, L; Smith, AV; Thorisson, GA; Chen, PE; Cutler, DJ; Kashuk, CS; Lin, S; Abecasis, GR; Guan, WH; Munro, HM; Qin, ZHS; Thomas, DJ; McVean, G; Bottolo, L; Eyheramendy, S; Freeman, C; Marchini, J; Myers, S; Spencer, C; Stephens, M; Cardon, LR; Clarke, G; Evans, DM; Morris, AP; Weir, BS; Tsunoda, T; Mullikin, JC; Sherry, ST; Feolo, M; Zhang, HC; Zeng, CQ; Zhao, H; Matsuda, I; Fukushima, Y; Macer, DR; Suda, E; Rotimi, CN; Adebamowo, CA; Ajayi, I; Aniagwu, T; Marshall, PA; Nkwodimmah, C; Royal, CDM; Leppert, MF; Dixon, M; Peiffer, A; Qiu, RZ; Kent, A; Kato, K; Niikawa, N; Adewole, IF; Knoppers, BM; Foster, MW; Clayton, EW; Muzny, D; Nazareth, L; Sodergren, E; Weinstock, GM; Wheeler, DA; Yakub, I; Gabriel, SB; Richter, DJ; Ziaugra, L; Birren, BW; Wilson, RK; Fulton, LL; Rogers, J; Burton, J; Carter, NP; Clee, CM; Griffiths, M; Jones, MC; McLay, K; Plumb, RW; Ross, MT; Sims, SK; Willey, DL; Chen, Z; Han, H; Kang, L; Godbout, M; Wallenburg, JC; Archeveque, PL; Bellemare, G; Saeki, K; Wang, HG; An, DC; Fu, HB; Li, Q; Wang, Z; Wang, RW; Holden, AL; Brooks, LD; McEwen, JE; Bird, CR; Guyer, MS; Nailer, PJ; Wang, VO; Peterson, JL; Shi, M; Spiegel, J; Sung, LM; Witonsky, J; Zacharia, LF; Kennedy, K; Jamieson, R; Stewart, J				Altshuler, D; Brooks, LD; Chakravarti, A; Collins, FS; Daly, MJ; Donnelly, P; Gibbs, RA; Belmont, JW; Boudreau, A; Leal, SM; Hardenbol, P; Pasternak, S; Wheeler, DA; Willis, TD; Yu, FL; Yang, HM; Zeng, CQ; Gao, Y; Hu, HR; Hu, WT; Li, CH; Lin, W; Liu, SQ; Pan, H; Tang, XL; Wang, J; Wang, W; Yu, J; Zhang, B; Zhang, QR; Zhao, HB; Zhao, H; Zhou, J; Gabriel, SB; Barry, R; Blumenstiel, B; Camargo, A; Defelice, M; Faggart, M; Goyette, M; Gupta, S; Moore, J; Nguyen, H; Onofrio, RC; Parkin, M; Roy, J; Stahl, E; Winchester, E; Ziaugra, L; Shen, Y; Yao, ZJ; Huang, W; Chu, X; He, YG; Jin, L; Liu, YF; Shen, YY; Sun, WW; Wang, HF; Wang, Y; Wang, Y; Wang, Y; Xiong, XY; Xu, L; Waye, MMY; Tsui, SKW; Xue, H; Wong, JTF; Galver, ILM; Fan, JB; Murray, SS; Oliphant, AR; Chee, MS; Montpetit, A; Chagnon, F; Ferretti, V; Leboeuf, M; Olivier, JF; Phillips, MS; Roumy, S; Sallee, C; Verner, A; Hudson, TJ; Frazer, KA; Ballinger, DG; Cox, DR; Hinds, DA; Stuve, LL; Kwok, PY; Cai, DM; Koboldt, DC; Miller, RD; Pawlikowska, L; Taillon-Miller, P; Xiao, M; Tsui, LC; Mak, W; Sham, PC; Song, YQ; Tam, PKH; Nakamura, Y; Kawaguchi, T; Kitamoto, T; Morizono, T; Nagashima, A; Ohnishi, Y; Sekine, A; Tanaka, T; Tsunoda, T; Deloukas, P; Bird, CP; Delgado, M; Dermitzakis, ET; Gwilliam, R; Hunt, S; Morrison, J; Powell, D; Stranger, BE; Whittaker, P; Bentley, DR; Daly, MJ; de Bakker, PIW; Barrett, J; Fry, B; Maller, J; McCarroll, S; Patterson, N; Pe'er, I; Purcell, S; Richter, DJ; Sabeti, P; Saxena, R; Schaffner, SF; Varilly, P; Stein, LD; Krishnan, L; Smith, AV; Thorisson, GA; Chen, PE; Cutler, DJ; Kashuk, CS; Lin, S; Abecasis, GR; Guan, WH; Munro, HM; Qin, ZHS; Thomas, DJ; McVean, G; Bottolo, L; Eyheramendy, S; Freeman, C; Marchini, J; Myers, S; Spencer, C; Stephens, M; Cardon, LR; Clarke, G; Evans, DM; Morris, AP; Weir, BS; Tsunoda, T; Mullikin, JC; Sherry, ST; Feolo, M; Zhang, HC; Zeng, CQ; Zhao, H; Matsuda, I; Fukushima, Y; Macer, DR; Suda, E; Rotimi, CN; Adebamowo, CA; Ajayi, I; Aniagwu, T; Marshall, PA; Nkwodimmah, C; Royal, CDM; Leppert, MF; Dixon, M; Peiffer, A; Qiu, RZ; Kent, A; Kato, K; Niikawa, N; Adewole, IF; Knoppers, BM; Foster, MW; Clayton, EW; Muzny, D; Nazareth, L; Sodergren, E; Weinstock, GM; Wheeler, DA; Yakub, I; Gabriel, SB; Richter, DJ; Ziaugra, L; Birren, BW; Wilson, RK; Fulton, LL; Rogers, J; Burton, J; Carter, NP; Clee, CM; Griffiths, M; Jones, MC; McLay, K; Plumb, RW; Ross, MT; Sims, SK; Willey, DL; Chen, Z; Han, H; Kang, L; Godbout, M; Wallenburg, JC; Archeveque, PL; Bellemare, G; Saeki, K; Wang, HG; An, DC; Fu, HB; Li, Q; Wang, Z; Wang, RW; Holden, AL; Brooks, LD; McEwen, JE; Bird, CR; Guyer, MS; Nailer, PJ; Wang, VO; Peterson, JL; Shi, M; Spiegel, J; Sung, LM; Witonsky, J; Zacharia, LF; Kennedy, K; Jamieson, R; Stewart, J		Int HapMap Consortium	A haplotype map of the human genome	NATURE			English	Review							SINGLE-NUCLEOTIDE POLYMORPHISM; RECENT POSITIVE SELECTION; FACTOR-H POLYMORPHISM; LINKAGE-DISEQUILIBRIUM; RECOMBINATION RATES; SEGMENTAL DUPLICATIONS; MEIOTIC RECOMBINATION; TYROSINE-PHOSPHATASE; SCALE VARIATION; SPASTIC ATAXIA	Inherited genetic variation has a critical but as yet largely uncharacterized role in human disease. Here we report a public database of common variation in the human genome: more than one million single nucleotide polymorphisms ( SNPs) for which accurate and complete genotypes have been obtained in 269 DNA samples from four populations, including ten 500-kilobase regions in which essentially all information about common DNA variation has been extracted. These data document the generality of recombination hotspots, a block-like structure of linkage disequilibrium and low haplotype diversity, leading to substantial correlations of SNPs with many of their neighbours. We show how the HapMap resource can guide the design and analysis of genetic association studies, shed light on structural variation and recombination, and identify loci that may have been subject to natural selection during human evolution.	Harvard Univ, Broad Inst, Cambridge, MA 02139 USA; MIT, Cambridge, MA 02139 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Simches Res Ctr, Boston, MA 02114 USA; Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA; Baylor Coll Med, Human Genome Sequencing Ctr, Dept Mol & Human Genet, Houston, TX 77030 USA; ParAllele Biosci Inc, San Francisco, CA 94080 USA; Chinese Acad Sci, Beijing Genom Inst, Beijing 100300, Peoples R China; Chinese Natl Human Genome Ctr, Beijing Econ Technol Dev Area, Beijing 100176, Peoples R China; Chinese Natl Human Genome Ctr Shanghai, Shanghai 201203, Peoples R China; Chinese Univ Hong Kong, Dept Biochem, Croucher Lab Human Genom, Shatin, Hong Kong, Peoples R China; Hong Kong Univ Sci & Technol, Dept Biochem, Kowloon, Hong Kong, Peoples R China; Illumina, San Diego, CA 92121 USA; Prognosys Biosci Inc, San Diego, CA 92121 USA; McGill Univ, Montreal, PQ H3A 1A4, Canada; Genome Quebec Innovat Ctr, Montreal, PQ H3A 1A4, Canada; Univ Montreal, Publ Law Res Ctr CRDP, Montreal, PQ H3C 3J7, Canada; Perlegen Sci Inc, Mountain View, CA 94043 USA; Univ Calif San Francisco, Cardiovasc Res Inst, San Francisco, CA 94143 USA; Washington Univ, Sch Med, Dept Genet, St Louis, MO 63110 USA; Univ Hong Kong, Genome Res Ctr, Pokfulam, Hong Kong, Peoples R China; Univ Tokyo, Inst Med Sci, Minato Ku, Tokyo 1088639, Japan; RIKEN, SNP Res Ctr, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan; Wellcome Trust Sanger Inst, Cambridge CB10 1SA, England; Solexa Ltd, Saffron Walden CB10 1XL, Essex, England; Cold Spring Harbor Lab, New York, NY 11724 USA; Univ Michigan, Ctr Stat Genet, Dept Biostat, Ann Arbor, MI 48109 USA; Univ Calif Santa Cruz, Ctr Biomol Sci & Engn, Santa Cruz, CA 95064 USA; Univ Washington, Dept Stat, Washington, DC 98195 USA; Univ Oxford, Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England; N Carolina State Univ, Bioinformat Res Ctr, Raleigh, NC 27695 USA; Natl Human Genome Res Inst, US Natl Inst Hlth, Bethesda, MD 20892 USA; US Natl Inst Hlth, Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Beijing Normal Univ, Beijing 100875, Peoples R China; Hlth Sci Univ Hokkaido, Ishikari, Hokkaido, Japan; Shinshu Univ, Sch Med, Dept Med Genet, Matsumoto, Nagano 3908621, Japan; UNESCO, Bangkok 10110, Thailand; Univ Tsukuba, Eubios Eth Inst, Tsukuba 3058691, Japan; Howard Univ, Natl Human Genome Ctr, Washington, DC 20059 USA; Univ Ibadan, Coll Med, Ibadan, Oyo State, Nigeria; Case Western Reserve Univ, Sch Med, Dept Bioeth, Cleveland, OH 44106 USA; Univ Utah, Eccles Inst Human Genet, Dept Human Genet, Salt Lake City, UT 84112 USA; Chinese Acad Social Sci, Ctr Appl Eth, Beijing 100054, Peoples R China; Genet Interest Grp, London N1 3QP, England; Kyoto Univ, Inst Res Humanities, Sakyo Ku, Kyoto 6068501, Japan; Grad Sch Biostudies, Sakyo Ku, Kyoto 6068501, Japan; Nagasaki Univ, Grad Sch Biomed Sci, Dept Human Genet, Nagasaki 8528523, Japan; Univ Oklahoma, Dept Anthropol, Norman, OK 73019 USA; Vanderbilt Univ, Ctr Genet & Hlth Policy, Nashville, TN 37232 USA; Wellcome Trust Res Labs, London NW1 2BE, England; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Chinese Acad Sci, Beijing 100864, Peoples R China; Genome Canada, Ottawa, ON K2P 1P1, Canada; McGill Univ, Off Technol Transfer, Montreal, PQ H3A 2A7, Canada; Genome Quebec, Montreal, PQ H3B 1S6, Canada; Minist Educ Culture Sports Sci & Technol, Chiyoda Ku, Tokyo 1008959, Japan; Minist Sci & Technol, Beijing 100862, Peoples R China; Human Genet Resource Adm China, Beijing 100081, Peoples R China; SNP Consortium, Deerfield, IL 60015 USA; Novartis Pharmaceut, Biomarker Dev, E Hanover, NJ 07936 USA; US Natl Inst Hlth, Off Technol Transfer, Rockville, MD 20852 USA; Univ Maryland, Sch Law, Baltimore, MD 21201 USA; Frost & Sullivan, Palo Alto, CA 94303 USA	Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Johns Hopkins University; Baylor College of Medicine; Beijing Genomics Institute (BGI); Chinese Academy of Sciences; Chinese University of Hong Kong; Hong Kong University of Science & Technology; Illumina; McGill University; Universite de Montreal; University of California System; University of California San Francisco; Washington University (WUSTL); University of Hong Kong; University of Tokyo; RIKEN; Wellcome Trust Sanger Institute; Cold Spring Harbor Laboratory; University of Michigan System; University of Michigan; University of California System; University of California Santa Cruz; University of Washington; University of Oxford; Wellcome Centre for Human Genetics; University of North Carolina; North Carolina State University; National Institutes of Health (NIH) - USA; NIH National Human Genome Research Institute (NHGRI); National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Beijing Normal University; Health Sciences University of Hokkaido; Shinshu University; University of Tsukuba; Howard University; University of Ibadan; Case Western Reserve University; Utah System of Higher Education; University of Utah; Chinese Academy of Social Sciences; Kyoto University; Nagasaki University; University of Oklahoma System; University of Oklahoma - Norman; Vanderbilt University; Washington University (WUSTL); Chinese Academy of Sciences; McGill University; Novartis; National Institutes of Health (NIH) - USA; University System of Maryland; University of Maryland Baltimore	Altshuler, D (corresponding author), Harvard Univ, Broad Inst, 1 Kendall Sq, Cambridge, MA 02139 USA.	altshuler@molbio.mgh.harvard.edu; donnelly@stats.ox.ac.uk	Smith, Albert Vernon/K-5150-2015; Abecasis, Goncalo R/B-7840-2010; Peng, Bo/A-6920-2009; Tsui, Stephen Kwok-Wing/E-4385-2015; Thorisson, Gudmundur/E-7359-2010; Daly, Mark J/B-2453-2017; Altshuler, David M/A-4476-2009; Song, You-Qiang/E-5207-2011; Belmont, John/AAH-6084-2021; Xiao, Ming/E-7448-2012; Ganesh, Dunna Sai/AGX-5170-2022; 韋妙宜教授, Mary Miu Yee Waye/A-9674-2008; Tsui, Lap-chee/A-1081-2010; Evans, David M/H-6325-2013; Jin, Li/M-5063-2019; Adebamowo, Clement/C-8778-2011; Song, You-qiang/C-4401-2009; Sabeti, Pardis/GQH-8610-2022; Marchini, Jonathan/ABE-9024-2020; Belmont, John W/AAI-2494-2019; Qin, Zhaohui/Q-3133-2019; de Bakker, Paul IW/B-8730-2009; Tanaka, Toshihiro/J-9310-2014; Qin, Zhaohui S/E-8196-2011; Weinstock, George M/C-6314-2013; Dermitzakis, Emmanouil/B-7687-2013; Saxena, Richa/AAG-7279-2020; Tsunoda, Tatsuhiko/K-2061-2014; 郑, 征/C-8514-2011; Kwok, Pui-Yan/F-7725-2014; Schaffner, Stephen F/D-1189-2011; Deloukas, Panos/B-2922-2013; Wheeler, David A/M-9740-2018; Jin, Li/C-1468-2009; maller, julian B/A-9323-2009; /C-4405-2009; Varilly, Patrick/C-8118-2013; Myers, Simon/A-6792-2015	Smith, Albert Vernon/0000-0003-1942-5845; Peng, Bo/0000-0001-8225-2284; Tsui, Stephen Kwok-Wing/0000-0003-0686-4259; Thorisson, Gudmundur/0000-0001-5635-1860; Daly, Mark J/0000-0002-0949-8752; Altshuler, David M/0000-0002-7250-4107; 韋妙宜教授, Mary Miu Yee Waye/0000-0002-2582-4917; Evans, David M/0000-0003-0663-4621; Adebamowo, Clement/0000-0002-6571-2880; Marchini, Jonathan/0000-0003-0610-8322; Belmont, John W/0000-0001-7409-3578; Qin, Zhaohui/0000-0002-1583-146X; de Bakker, Paul IW/0000-0001-7735-7858; Tanaka, Toshihiro/0000-0001-6201-9784; Qin, Zhaohui S/0000-0002-1583-146X; Weinstock, George M/0000-0002-2997-4592; Tsunoda, Tatsuhiko/0000-0002-5439-7918; Kwok, Pui-Yan/0000-0002-5087-3059; Deloukas, Panos/0000-0001-9251-070X; Wheeler, David A/0000-0002-9056-6299; Jin, Li/0000-0002-4546-2415; He, Yungang/0000-0002-2931-2871; /0000-0001-6231-3035; Abecasis, Goncalo/0000-0003-1509-1825; Song, You-Qiang/0000-0001-9407-2256; Schaffner, Stephen/0000-0001-6699-3568; Frazer, Kelly/0000-0002-6060-8902; Wong, J. Tze-Fei/0000-0001-8539-8537; Hudson, Thomas/0000-0002-1376-4849; Kitamoto, Takuya/0000-0002-4008-5497; Varilly, Patrick/0000-0003-4619-8174; Xue, Hong/0000-0002-8133-9828; Saxena, Richa/0000-0003-2233-1065; ajayi, Ikeoluwapo/0000-0001-7719-8746; Macer, Darryl/0000-0001-9335-4235; Wang, Haifeng/0000-0001-5022-0720; Witonsky, Jonathan/0000-0001-8264-0244; Stranger, Barbara/0000-0001-9021-7331; Eyheramendy, Susana/0000-0003-4723-9660; Myers, Simon/0000-0002-2585-9626; Kato, Kazuto/0000-0001-9006-9551; Richter, Daniel/0000-0002-9238-5571; Lin, Shin/0000-0003-0118-0413; Hunt, Sarah/0000-0002-8350-1235; Sherry, Stephen/0000-0002-7982-076X; Bottolo, Leonardo/0000-0002-6381-2327	NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG001720] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01 HG001720, R01 HG001720-06] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		Altshuler D, 2000, NAT GENET, V26, P76, DOI 10.1038/79216; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bailey JA, 2002, SCIENCE, V297, P1003, DOI 10.1126/science.1072047; Begovich AB, 2004, AM J HUM GENET, V75, P330, DOI 10.1086/422827; BEGUN DJ, 1992, NATURE, V356, P519, DOI 10.1038/356519a0; BELL GI, 1984, DIABETES, V33, P176, DOI 10.2337/diabetes.33.2.176; Bersaglieri T, 2004, AM J HUM GENET, V74, P1111, DOI 10.1086/421051; Bottini N, 2004, NAT GENET, V36, P337, DOI 10.1038/ng1323; Brem RB, 2005, NATURE, V436, P701, DOI 10.1038/nature03865; Broman KW, 1998, AM J HUM GENET, V63, P861, DOI 10.1086/302011; Carlson CS, 2004, AM J HUM GENET, V74, P106, DOI 10.1086/381000; CHAKRABORTY R, 1988, P NATL ACAD SCI USA, V85, P9119, DOI 10.1073/pnas.85.23.9119; Chapman JM, 2003, HUM HERED, V56, P18, DOI 10.1159/000073729; *CHIMP SEQ AN CONS, 2005, NATURE, V0437; Crawford DC, 2004, NAT GENET, V36, P700, DOI 10.1038/ng1376; Dahlback B, 1997, THROMB HAEMOSTASIS, V78, P483; Daly MJ, 2001, NAT GENET, V29, P229, DOI 10.1038/ng1001-229; Dawson E, 2002, NATURE, V418, P544, DOI 10.1038/nature00864; de Bakker PIW, 2005, NAT GENET, V37, P1217, DOI 10.1038/ng1669; De La Chapelle A, 1998, P NATL ACAD SCI USA, V95, P12416, DOI 10.1073/pnas.95.21.12416; Deeb SS, 1998, NAT GENET, V20, P284, DOI 10.1038/3099; Dermitzakis ET, 2002, NATURE, V420, P578, DOI 10.1038/nature01251; Edwards AO, 2005, SCIENCE, V308, P421, DOI 10.1126/science.1110189; Ellis N, 2002, GENOME RES, V12, P339; Emison ES, 2005, NATURE, V434, P857, DOI 10.1038/nature03467; Enattah NS, 2002, NAT GENET, V30, P233, DOI 10.1038/ng826; Engert JC, 2000, NAT GENET, V24, P120, DOI 10.1038/72769; Feingold EA, 2004, SCIENCE, V306, P636, DOI 10.1126/science.1105136; Florez JC, 2003, ANNU REV GENOM HUM G, V4, P257, DOI 10.1146/annurev.genom.4.070802.110436; Foster MW, 2004, NAT REV GENET, V5, P467, DOI 10.1038/nrg1351; Frazer KA, 2007, NATURE, V449, P851, DOI 10.1038/nature06258; Fullerton SM, 2001, MOL BIOL EVOL, V18, P1139, DOI 10.1093/oxfordjournals.molbev.a003886; Gabriel SB, 2002, SCIENCE, V296, P2225, DOI 10.1126/science.1069424; Gonzalez E, 2005, SCIENCE, V307, P1434, DOI 10.1126/science.1101160; Haines JL, 2005, SCIENCE, V308, P419, DOI 10.1126/science.1110359; HASTBACKA J, 1992, NAT GENET, V2, P204, DOI 10.1038/ng1192-204; Herrnstadt C, 2002, AM J HUM GENET, V70, P1152, DOI 10.1086/339933; HILL WG, 1994, AM J HUM GENET, V54, P705; Hinds DA, 2005, SCIENCE, V307, P1072, DOI 10.1126/science.1105436; Huang Jing, 2004, Human Genomics, V1, P287; HUDSON RR, 1985, GENETICS, V111, P147; Hugot JP, 2001, NATURE, V411, P599, DOI 10.1038/35079107; Iafrate AJ, 2004, NAT GENET, V36, P949, DOI 10.1038/ng1416; Istrail S, 2004, P NATL ACAD SCI USA, V101, P1916, DOI 10.1073/pnas.0307971100; Jeffreys AJ, 2001, NAT GENET, V29, P217, DOI 10.1038/ng1001-217; Jobling MA, 2003, NAT REV GENET, V4, P598, DOI 10.1038/nrg1124; Johnson GCL, 2001, NAT GENET, V29, P233, DOI 10.1038/ng1001-233; Jorde LB, 2000, GENOME RES, V10, P1435, DOI 10.1101/gr.144500; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Kong A, 2002, NAT GENET, V31, P241, DOI 10.1038/ng917; Kruglyak L, 1999, NAT GENET, V22, P139, DOI 10.1038/9642; LECHLER R, 2005, HLA HLTH DIS; Li N, 2003, GENETICS, V165, P2213; Lichten M, 1995, ANNU REV GENET, V29, P423, DOI 10.1146/annurev.ge.29.120195.002231; Lin S, 2004, NAT GENET, V36, P1181, DOI 10.1038/ng1457; MARCHINI J, IN PRESS AM J HUM GE; Margulies EH, 2003, GENOME RES, V13, P2507, DOI 10.1101/gr.1602203; Matsuzaki H, 2004, NAT METHODS, V1, P109, DOI 10.1038/nmeth718; MCCARROLL SA, IN PRESS NATURE GENE; McVean GAT, 2004, SCIENCE, V304, P581, DOI 10.1126/science.1092500; Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533; Mootha VK, 2003, P NATL ACAD SCI USA, V100, P605, DOI 10.1073/pnas.242716699; Myers S, 2005, SCIENCE, V310, P321, DOI 10.1126/science.1117196; Myers SR, 2003, GENETICS, V163, P375; Need AC, 2005, NAT GENET, V37, P671, DOI 10.1038/ng1593; Nickerson DA, 1998, NAT GENET, V19, P233, DOI 10.1038/907; Nielsen R, 2005, NATURE, V434, P288, DOI 10.1038/434288a; Ogura Y, 2001, NATURE, V411, P603, DOI 10.1038/35079114; Patil N, 2001, SCIENCE, V294, P1719, DOI 10.1126/science.1065573; PEER I, UNPUB GENOME RES; Pehrson JR, 1998, NUCLEIC ACIDS RES, V26, P2837, DOI 10.1093/nar/26.12.2837; Phillips MS, 2003, NAT GENET, V33, P382, DOI 10.1038/ng1100; Pritchard JK, 2001, AM J HUM GENET, V69, P1, DOI 10.1086/321275; PUFFENBERGER EG, 1994, CELL, V79, P1257, DOI 10.1016/0092-8674(94)90016-7; Reich DE, 2001, NATURE, V411, P199, DOI 10.1038/35075590; Richter A, 1999, AM J HUM GENET, V64, P768, DOI 10.1086/302274; Rosenberg NA, 2002, SCIENCE, V298, P2381, DOI 10.1126/science.1078311; Sabeti PC, 2002, NATURE, V419, P832, DOI 10.1038/nature01140; Sebat J, 2004, SCIENCE, V305, P525, DOI 10.1126/science.1098918; Singleton AB, 2003, SCIENCE, V302, P841, DOI 10.1126/science.1090278; Smith AV, 2005, GENOME RES, V15, P1519, DOI 10.1101/gr.4421405; Smith MW, 2005, NAT REV GENET, V6, P623, DOI 10.1038/nrg1657; Smith MW, 2004, AM J HUM GENET, V74, P1001, DOI 10.1086/420856; Stankiewicz P, 2002, TRENDS GENET, V18, P74, DOI 10.1016/S0168-9525(02)02592-1; Stefansson H, 2005, NAT GENET, V37, P129, DOI 10.1038/ng1508; Stephens M, 2003, AM J HUM GENET, V73, P1162, DOI 10.1086/379378; Stram DO, 2003, HUM HERED, V55, P27, DOI 10.1159/000071807; Strittmatter WJ, 1996, ANNU REV NEUROSCI, V19, P53, DOI 10.1146/annurev.ne.19.030196.000413; Trachtenberg E, 2003, NAT MED, V9, P928, DOI 10.1038/nm893; Ueda H, 2003, NATURE, V423, P506, DOI 10.1038/nature01621; Underhill PA, 2001, ANN HUM GENET, V65, P43, DOI 10.1046/j.1469-1809.2001.6510043.x; Venter JC, 2001, SCIENCE, V291, P1304, DOI 10.1126/science.1058040; Waterston RH, 2002, NATURE, V420, P520, DOI 10.1038/nature01262; Weale ME, 2003, AM J HUM GENET, V73, P551, DOI 10.1086/378098; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; Wigginton JE, 2005, AM J HUM GENET, V76, P887, DOI 10.1086/429864; Winckler W, 2005, SCIENCE, V308, P107, DOI 10.1126/science.1105322; WRIGHT S, 1969, EVOLUTION GENETICS P, V2, P294; Yu A, 2001, NATURE, V409, P951, DOI 10.1038/35057185; Zhao XJ, 2004, CANCER RES, V64, P3060, DOI 10.1158/0008-5472.CAN-03-3308; Zhu XF, 2000, AM J HUM GENET, V67, P1144; Zhu XF, 2005, NAT GENET, V37, P177, DOI 10.1038/ng1510	103	4312	4487	9	554	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1299	1320		10.1038/nature04226	http://dx.doi.org/10.1038/nature04226			22	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16255080	hybrid, Green Accepted			2022-12-28	WOS:000232829100044
J	Berry, DA; Cronin, KA; Plevritis, SK; Fryback, DG; Clarke, L; Zelen, M; Mandelblatt, JS; Yakovlev, AY; Habbema, JDF; Feuer, EJ				Berry, DA; Cronin, KA; Plevritis, SK; Fryback, DG; Clarke, L; Zelen, M; Mandelblatt, JS; Yakovlev, AY; Habbema, JDF; Feuer, EJ		CISNET Collaborators	Effect of screening and adjuvant therapy on mortality from breast cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RANDOMIZED-TRIALS; UNITED-STATES; SOCIETY GUIDELINES; FOLLOW-UP; MAMMOGRAPHY; TAMOXIFEN; PROGRESS	BACKGROUND: We used modeling techniques to assess the relative and absolute contributions of screening mammography and adjuvant treatment to the reduction in breast-cancer mortality in the United States from 1975 to 2000. METHODS: A consortium of investigators developed seven independent statistical models of breast-cancer incidence and mortality. All seven groups used the same sources to obtain data on the use of screening mammography, adjuvant treatment, and benefits of treatment with respect to the rate of death from breast cancer. RESULTS: The proportion of the total reduction in the rate of death from breast cancer attributed to screening varied in the seven models from 28 to 65 percent (median, 46 percent), with adjuvant treatment contributing the rest. The variability across models in the absolute contribution of screening was larger than it was for treatment, reflecting the greater uncertainty associated with estimating the benefit of screening. CONCLUSIONS: Seven statistical models showed that both screening mammography and treatment have helped reduce the rate of death from breast cancer in the United States.	Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Unit 447, Houston, TX 77030 USA; NCI, Bethesda, MD 20892 USA; Stanford Univ, Stanford, CA 94305 USA; Univ Wisconsin, Madison, WI USA; Cornerstone Syst, Lynden, WA USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Georgetown Univ, Washington, DC USA; Univ Rochester, Rochester, NY USA; Erasmus Univ, Med Ctr, Rotterdam, Netherlands	University of Texas System; UTMD Anderson Cancer Center; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Stanford University; University of Wisconsin System; University of Wisconsin Madison; Harvard University; Dana-Farber Cancer Institute; Georgetown University; University of Rochester; Erasmus University Rotterdam; Erasmus MC	Berry, DA (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Biostat & Appl Math, Unit 447, 1515 Holcombe Blvd, Houston, TX 77030 USA.	dberry@mdanderson.org	Boer, Robert/AFM-0525-2022; Boer, Rob/E-6473-2015; Boer, Robert/AAH-2901-2022	Boer, Robert/0000-0003-0680-001X; Boer, Rob/0000-0003-0680-001X; Boer, Robert/0000-0003-0680-001X	NATIONAL CANCER INSTITUTE [U01CA088177, U01CA069976, U01CA088202, U01CA063736, U01CA070013, U01CA088278, U01CA088270, U01CA088283, U01CA063740, U01CA063731, U01CA086082, U01CA088248, U01CA070040, U01CA088211, U01CA086076] Funding Source: NIH RePORTER; NCI NIH HHS [U01CA86082, CA88177, CA88270, U01CA63740, CA88248, U01CA70013, U01CA63731, U01CA86076, CA88202, U01CA63736, U01CA70040, CA88211, U01CA69976, CA88283, CA88278] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Abe O, 1998, LANCET, V352, P930; [Anonymous], HUM MORT DAT; [Anonymous], CANC INT SURV MOD NE; BallardBarbash R, 1997, AM J ROENTGENOL, V169, P1001, DOI 10.2214/ajr.169.4.9308451; Breen N, 2001, J NATL CANCER I, V93, P1704, DOI 10.1093/jnci/93.22.1704; Clarke M, 1998, LANCET, V351, P1451; Cronin KA, 2005, CANCER CAUSE CONTROL, V16, P701, DOI 10.1007/s10552-005-0693-8; Early Breast Cancer Trialists' Collaborative Group, 2002, COCHRANE DB SYST REV, V1; Goodman SN, 2002, ANN INTERN MED, V137, P363, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00015; Harlan LC, 2002, J CLIN ONCOL, V20, P1809, DOI 10.1200/JCO.2002.07.052; Humphrey LL, 2002, ANN INTERN MED, V137, P347, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00012; Leitch AM, 1997, CA-CANCER J CLIN, V47, P150, DOI 10.3322/canjclin.47.3.150; Mariotto A, 2002, J NATL CANCER I, V94, P1626; Miller AB, 2000, JNCI-J NATL CANCER I, V92, P1490, DOI 10.1093/jnci/92.18.1490; Miller AB, 2002, ANN INTERN MED, V137, P305, DOI 10.7326/0003-4819-137-5_Part_1-200209030-00005; Nystrom L, 2002, LANCET, V360, P724; Nystrom L, 2002, LANCET, V359, P909, DOI 10.1016/S0140-6736(02)08020-0; Olsen O, 2001, LANCET, V358, P1340, DOI 10.1016/S0140-6736(01)06449-2; Parkin DM, 2003, EUR J CANCER, V39, P848, DOI 10.1016/S0959-8049(02)00739-6; Parkin DM, 2001, EUR J CANCER, V37, pS4, DOI 10.1016/S0959-8049(01)00267-2; Ries L, 2004, SEER CANC STAT REV 1; Smith RA, 2003, CA-CANCER J CLIN, V53, P141, DOI 10.3322/canjclin.53.3.141; Swan J, 2003, CANCER, V97, P1528, DOI 10.1002/cncr.11208; Tabar L, 2000, RADIOL CLIN N AM, V38, P625, DOI 10.1016/S0033-8389(05)70191-3; Tabar L, 1999, CANCER, V86, P449, DOI 10.1002/(SICI)1097-0142(19990801)86:3<449::AID-CNCR13>3.0.CO;2-Q; Wand M.P., 1994, KERNEL SMOOTHING; 2005, CANC INTERVENTION SU	27	1759	1805	3	119	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1784	1792		10.1056/NEJMoa050518	http://dx.doi.org/10.1056/NEJMoa050518			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251534				2022-12-28	WOS:000232813000006
J	Phimister, EG				Phimister, EG			Genomic cartography - Presenting the HapMap	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material																		Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226	1	8	8	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1766	1768		10.1056/NEJMp058255	http://dx.doi.org/10.1056/NEJMp058255			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251532				2022-12-28	WOS:000232813000003
J	Lexau, CA; Lynfield, R; Danila, R; Pilishvili, T; Facklam, R; Farley, MM; Harrison, LH; Schaffner, W; Reingold, A; Bennett, NM; Hadler, J; Cieslak, PR; Whitney, CG				Lexau, CA; Lynfield, R; Danila, R; Pilishvili, T; Facklam, R; Farley, MM; Harrison, LH; Schaffner, W; Reingold, A; Bennett, NM; Hadler, J; Cieslak, PR; Whitney, CG		Active Bacterial Core Surveillance	Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STREPTOCOCCUS-PNEUMONIAE; NASOPHARYNGEAL CARRIAGE; MORTALITY; SURVEILLANCE; INFECTIONS; RESISTANCE; IMPACT	Context A conjugate vaccine targeting 7 pneumococcal serotypes was licensed for young children in 2000. In contrast to the 23-valent polysaccharide vaccine used in adults, the 7-valent conjugate vaccine affects pneumococcal carriage and transmission. Early after its introduction, incidence of invasive pneumococcal disease declined among older adults, a group at high risk for pneumococcal disease. Objective To determine among adults aged 50 years or older whether incidence of invasive pneumococcal disease, disease characteristics, or the spectrum of patients acquiring these illnesses have changed over the 4 years since pneumococcal conjugate vaccine licensure. Design, Setting, and Population Population-based surveillance of invasive pneumococcal disease in 8 US geographic areas (total population, 18 813 000), 1998-2003. Main Outcome Measures Incidence of invasive pneumococcal disease by pneumococcal serotype and other characteristics; frequency among case patients of comorbid conditions and other factors influencing mortality. Results Incidence of invasive pneumococcal disease among adults aged 50 years or older declined 28% (95% confidence interval [CI], -31% to -24%), from 40.8 cases/ 100 000 in 1998-1999 to 29.4 in 2002-2003. Among those aged 65 years or older, the 2002-2003 rate (41.7 cases/100 000) was lower than the Healthy People 2010 goal (42 cases/100000). Among adults aged 50 years or older, incidence of disease caused by the 7 conjugate vaccine serotypes declined 55% (95% Cl, -58% to -51%) from 22.4 to 10.2 cases/100 000. In contrast, disease caused by any of the 16 serotypes only in polysaccharide vaccine did not change, and disease caused by serotypes not in either vaccine increased somewhat, from 6.0 to 6.8 cases/100000 (13%; 95% Cl, 1% to 27%). Between 1998-1999 and 2002-2003, the proportion of case-patients with human immunodeficiency virus infection increased from 1.7% (47/ 2737) to 5.6% (124/2231) (P<.001), and those with any comorbid condition that is an indication for pneumococcal polysaccharide vaccination increased from 62.3% (1842/ 2955) to 72.0% (1721/2390) (P<.001). Conclusions Our findings indicate that use of conjugate vaccine in children has substantially benefited older adults. However, persons with certain comorbid conditions may benefit less than healthier persons from the indirect effects of the new vaccine.	Minnesota Dept Hlth, St Paul, MN 55155 USA; Ctr Dis Control & Prevent, Div Bacterial & Mycot Dis, Natl Ctr Infect Dis, Atlanta, GA USA; Emory Univ, Sch Med, Decatur, GA 30033 USA; Atlanta Vet Affairs Med Ctr, Decatur, GA 30033 USA; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA; Vanderbilt Univ, Sch Med, Dept Prevent Med, Nashville, TN 37212 USA; Univ Calif Berkeley, Sch Publ Hlth, Berkeley, CA 94720 USA; Monroe Cty Hlth Dept, Rochester, NY USA; Connecticut Dept Publ Hlth, Program Epidemiol, Hartford, CT USA; Dept Human Serv, Off Dis Prevent & Epidemiol, Portland, OR USA	Minnesota Department of Health (MHD); Centers for Disease Control & Prevention - USA; Emory University; US Department of Veterans Affairs; Veterans Health Administration (VHA); Atlanta VA Health Care System; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health; Vanderbilt University; University of California System; University of California Berkeley	Lexau, CA (corresponding author), Minnesota Dept Hlth, 625 Robert St N, St Paul, MN 55155 USA.	catherine.lexau@health.state.mn.us						[Anonymous], 2000, MMWR Recomm Rep, V49, P1; [Anonymous], 1997, MMWR MORB MORT WKLY, V46, P1; Black S, 2004, PEDIATR INFECT DIS J, V23, P485, DOI 10.1097/01.inf.0000129685.04847.94; Bogaert D, 2004, LANCET INFECT DIS, V4, P144, DOI 10.1016/S1473-3099(04)00938-7; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P783; *CDCP, 1997, STREPT PNEUM; *CDCP, 2001, MMWR-MORBID MORTAL W, V50, P1140; *CDCP, 2003, MMWR-MORBID MORTAL W, V52, P446; Centers for Disease Control and Prevention, BEH RISK FACT SURV S; Centers for Disease Control and Prevention (CDC), 2004, MMWR Morb Mortal Wkly Rep, V53, P658; Dagan R, 1996, J INFECT DIS, V174, P1271, DOI 10.1093/infdis/174.6.1271; Feikin DR, 2000, AM J PUBLIC HEALTH, V90, P223, DOI 10.2105/AJPH.90.2.223; FLANNERY BL, 2004, INF DIS SOC AM C SEP; Fry AM, 2002, VACCINE, V21, P303, DOI 10.1016/S0264-410X(02)00451-6; Givon-Lavi N, 2003, PEDIATR INFECT DIS J, V22, P524, DOI 10.1097/00006454-200306000-00008; HOOK EW, 1983, JAMA-J AM MED ASSOC, V249, P1055, DOI 10.1001/jama.249.8.1055; Ingram Deborah D, 2003, Vital Health Stat 2, P1; Leino T, 2004, EPIDEMIOL INFECT, V132, P959, DOI 10.1017/S095026880400250X; Martens P, 2004, BMC INFECT DIS, V4, DOI 10.1186/1471-2334-4-21; Mbelle N, 1999, J INFECT DIS, V180, P1171, DOI 10.1086/315009; Moore MR, 2004, J INFECT DIS, V190, P2031, DOI 10.1086/425422; MUFSON MA, 1974, ARCH INTERN MED, V134, P505, DOI 10.1001/archinte.134.3.505; Obaro SK, 1996, LANCET, V348, P271, DOI 10.1016/S0140-6736(05)65585-7; Robinson KA, 2001, JAMA-J AM MED ASSOC, V285, P1729, DOI 10.1001/jama.285.13.1729; Rubins JB, 1999, INFECT IMMUN, V67, P5979, DOI 10.1128/IAI.67.11.5979-5984.1999; Rubins JB, 2001, DRUG AGING, V18, P305, DOI 10.2165/00002512-200118050-00001; Schuchat A, 1997, NEW ENGL J MED, V337, P970, DOI 10.1056/NEJM199710023371404; Schuchat A, 2001, EMERG INFECT DIS, V7, P92, DOI 10.3201/eid0701.010114; SHAPIRO ED, 1991, NEW ENGL J MED, V325, P1453, DOI 10.1056/NEJM199111213252101; Talbot TR, 2004, PEDIATR INFECT DIS J, V23, P726, DOI 10.1097/01.inf.0000133046.60555.de; U.S. Department of Health and Human Services, 2000, HLTH PEOPL 2010 UND; *US DHHS, NAT IMM SURV 2002 20; Whitney CG, 2003, NEW ENGL J MED, V348, P1737, DOI 10.1056/NEJMoa022823; Yu VL, 2003, CLIN INFECT DIS, V37, P230, DOI 10.1086/377534	34	519	549	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2043	2051		10.1001/jama.294.16.2043	http://dx.doi.org/10.1001/jama.294.16.2043			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249418				2022-12-28	WOS:000232778900024
J	Patel, HC; Bouamra, O; Woodford, M; King, AT; Yates, DW; Lecky, FE				Patel, HC; Bouamra, O; Woodford, M; King, AT; Yates, DW; Lecky, FE		Trauma Audit Res Network	Trends in head injury outcome from 1989 to 2003 and the effect of neurosurgical care: an observational study	LANCET			English	Article							TRAUMA CARE; MANAGEMENT; ENGLAND; CENTERS; WALES	Background Case fatality rates after all types of blunt injury have not improved since 1994 in England and Wales, possibly because not all patients with severe head injury are treated in a neurosurgical Centre. Our aims were to investigate the case fatality trends in major trauma patients with and without head injury, and to establish the effect of neurosurgical care on mortality after severe head injury. Methods We analysed prospectively collected data from the Trauma Audit and Research Network database for patients presenting between 1989 and 2003. Mortality and odds of death adjusted for case mix were compared for patients with and without head injury, and for those treated in a neurosurgical versus a non-neurosurgical Centre. Findings Patients with head injury (n=22 216) had a ten-fold higher mortality and showed less improvement in the adjusted odds of death since 1989 than did patients without head injury (n=154 231). 2305 (33%) of patients with severe head injury (presenting between 1996 and 2003) were treated only in non-neurosurgical centres; such treatment was associated with a 26% increase in mortality and a 2.15-fold increase (95% Cl 1.77-2.60) in the odds of death adjusted for case mix compared with patients treated at a neurosurgical Centre. Interpretation Since 1989 trauma system changes in England and Wales have delivered greater benefit to patients without head injury. Our data lend support to current guidelines, suggesting that treatment in a neurosurgical Centre represents an important strategy in the management of severe head injury.	Univ Manchester, Hope Hosp, Trauma Audit & Res Network, Salford M6 8HD, Lancs, England; Hope Hosp, Dept Neurosurg, Salford M6 8HD, Lancs, England	University of Manchester	Lecky, FE (corresponding author), Univ Manchester, Hope Hosp, Trauma Audit & Res Network, Salford M6 8HD, Lancs, England.	flecky@fs1.ho.man.ac.uk	Patel, Hiren/AAL-3811-2021; King, Andrew/AAR-1656-2020	Patel, Hiren/0000-0002-1439-8801; bouamra, omar/0000-0002-3155-4634; King, Andrew/0000-0002-6546-7248				Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; [Anonymous], 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BRIGGS M, 1984, BRIT MED J, V288, P983; Cairns H, 1947, NOTES NEUROSURGICAL; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; Crimmins DW, 2000, J NEUROL NEUROSUR PS, V68, P8, DOI 10.1136/jnnp.68.1.8; D'Agostino RB, 1998, STAT MED, V17, P2265, DOI 10.1002/(SICI)1097-0258(19981015)17:19<2265::AID-SIM918>3.0.CO;2-B; GENNARELLI TA, 1989, J TRAUMA, V29, P1193, DOI 10.1097/00005373-198909000-00002; GENTLEMAN D, 1992, INJURY, V23, P471, DOI 10.1016/0020-1383(92)90066-2; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; HOLLIS S, 1995, J TRAUMA, V38, P763, DOI 10.1097/00005373-199505000-00015; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; MacKenzie EJ, 1999, J TRAUMA, V47, pS34, DOI 10.1097/00005373-199909001-00008; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; Matta B, 1996, CRIT CARE MED, V24, P1743, DOI 10.1097/00003246-199610000-00023; McKeating EG, 1998, BRIT J NEUROSURG, V12, P7; Muzha I, 2004, LANCET, V364, P1321, DOI 10.1016/S0140-6736(04)17188-2; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Piek Jurgen, 2002, Curr Opin Crit Care, V8, P134, DOI 10.1097/00075198-200204000-00008; Royal College of Surgeons, 1999, REP WORK PART MAN PA; SAMPALIS JS, 1995, J TRAUMA, V39, P232, DOI 10.1097/00005373-199508000-00008; Sherman HF, 2001, J TRAUMA, V50, P784, DOI 10.1097/00005373-200105000-00003; Stocchetti N, 1999, INTENS CARE MED, V25, P371, DOI 10.1007/s001340050860; The Brain Trauma Foundation, 2000, J NEUROTRAUM, V17, P457; *TRAUM AUD RES NET, PS 04; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110	30	237	247	0	11	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1538	1544		10.1016/S0140-6736(05)67626-X	http://dx.doi.org/10.1016/S0140-6736(05)67626-X			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257340				2022-12-28	WOS:000232984800022
J	Backus, EHG; Eichler, A; Kleyn, AW; Bonn, M				Backus, EHG; Eichler, A; Kleyn, AW; Bonn, M			Real-time observation of molecular motion on a surface	SCIENCE			English	Article							CO; DIFFUSION; CHEMISORPTION; DESORPTION; TRANSITION; ADSORPTION; VIBRATION; DYNAMICS; PT(335)	The laser-induced movement of CO molecules over a platinum surface was followed in real time by means of ultrafast vibrational spectroscopy. Because the CO molecules bound on different surface sites exhibit different C-O stretch vibrational frequencies, the site-to-site hopping, triggered by excitation with a laser pulse, can be determined from subpicosecond changes in the vibrational spectra. The unexpectedly fast motion-characterized by a 500-femtosecond time constant-reveals that a rotational motion of the CO molecules, rather than pure translation, is required for this diffusion process. This conclusion is corroborated by density functional theory calculations.	Leiden Univ, Leiden Inst Chem, NL-2300 RA Leiden, Netherlands; Univ Vienna, Inst Materialphys, A-1090 Vienna, Austria; Univ Vienna, Ctr Computat Mat Sci, A-1090 Vienna, Austria; FOM, Inst Plasma Phys Rijnhuizen, NL-3430 BE Nieuwegein, Netherlands; FOM, Inst Atom & Mol Phys, NL-1098 SJ Amsterdam, Netherlands	Leiden University; Leiden University - Excl LUMC; University of Vienna; University of Vienna; AMOLF	Backus, EHG (corresponding author), Leiden Univ, Leiden Inst Chem, POB 9502, NL-2300 RA Leiden, Netherlands.							Backus EHG, 2005, CHEM PHYS LETT, V412, P152, DOI 10.1016/j.cplett.2005.06.118; BACKUS EHG, UNPUB; Bartels L, 2004, SCIENCE, V305, P648, DOI 10.1126/science.1099770; Bartels L, 1998, CHEM PHYS LETT, V291, P573, DOI 10.1016/S0009-2614(98)00644-7; Bauer M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.025501; Bonn M, 2000, PHYS REV LETT, V84, P4653, DOI 10.1103/PhysRevLett.84.4653; Bonn M, 1999, SCIENCE, V285, P1042, DOI 10.1126/science.285.5430.1042; Briner BG, 1997, SCIENCE, V278, P257, DOI 10.1126/science.278.5336.257; BUDDE F, 1993, SURF SCI, V283, P143, DOI 10.1016/0039-6028(93)90973-N; Denzler DN, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.226102; Fournier F, 2004, J CHEM PHYS, V121, P4839, DOI 10.1063/1.1778138; GERMER TA, 1993, J CHEM PHYS, V98, P9986, DOI 10.1063/1.464324; JANSCH HJ, 1993, J CHEM PHYS, V99, P721, DOI 10.1063/1.465744; Komeda T, 2002, SCIENCE, V295, P2055, DOI 10.1126/science.1069016; Kresse G, 1999, PHYS REV B, V59, P1758, DOI 10.1103/PhysRevB.59.1758; Kubota J, 2003, J PHYS CHEM B, V107, P10329, DOI 10.1021/jp030123g; Ma JW, 1998, PHYS REV B, V58, P4977, DOI 10.1103/PhysRevB.58.4977; MILLS G, 1995, SURF SCI, V324, P305, DOI 10.1016/0039-6028(94)00731-4; Pascual JI, 2003, NATURE, V423, P525, DOI 10.1038/nature01649; PERDEW JP, 1992, PHYS REV B, V46, P6671, DOI 10.1103/PhysRevB.46.6671; Petek H, 2000, SCIENCE, V288, P1402, DOI 10.1126/science.288.5470.1402; REUTTROBEY JE, 1988, PHYS REV LETT, V61, P2778, DOI 10.1103/PhysRevLett.61.2778; SCHWEIZER E, 1989, SURF SCI, V213, P49, DOI 10.1016/0039-6028(89)90252-5; Stepan K, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.236103; Stipe BC, 1998, SCIENCE, V279, P1907, DOI 10.1126/science.279.5358.1907; XU JZ, 1995, SURF SCI, V327, P193, DOI 10.1016/0039-6028(94)00849-3; YATES JT, 1992, SCIENCE, V255, P1397, DOI 10.1126/science.255.5050.1397; Yoshinobu J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.248301	28	146	147	0	95	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 16	2005	310	5755					1790	1793		10.1126/science.1120693	http://dx.doi.org/10.1126/science.1120693			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	995II	16282524				2022-12-28	WOS:000234093600039
J	Castellone, MD; Teramoto, H; Williams, BO; Druey, KM; Gutkind, JS				Castellone, MD; Teramoto, H; Williams, BO; Druey, KM; Gutkind, JS			Prostaglandin E-2 promotes colon cancer cell growth through a G(s)-axin-beta-catenin signaling axis	SCIENCE			English	Article							ACTIVATED PROTEIN-KINASE; BETA-CATENIN; ALPHA-SUBUNITS; PHOSPHORYLATION; RECEPTOR; MECHANISM; COMPLEX; INACTIVATION; CARCINOMA; TRANSCRIPTION	How cyclooxygenase-2 (COX-2) and its proinflammatory metabolite prostaglandin E2 (PGE2) enhance colon cancer progression remains poorly understood. We show that PGE2 stimulates colon cancer cell growth through its heterotrimeric guanine nucleotide-binding protein (G protein)-coupled receptor, EP2, by a signaling route that involves the activation of phosphoinositide 3-kinase and the protein kinase Akt by free G protein beta gamma subunits and the direct association of the G protein a. subunit with the regulator of G protein signaling (RGS) domain of axin. This leads to the inactivation and release of glycogen synthase kinase 3 beta from its complex with axin, thereby relieving the inhibitory phosphorytation of beta-catenin and activating its signaling pathway. These findings may provide a molecular framework for the future evaluation of chemopreventive strategies for colorectal cancer.	Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA; Kojin Hosp, Nagoya, Aichi 4638530, Japan; Van Andel Res Inst, Lab Cell Signaling & Carcinogenesis, Grand Rapids, MI 49503 USA; NIAID, Mol Signal Transduct Sect, Lab Allerg Dis, NIH, Rockville, MD 20852 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); Van Andel Institute; National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID)	Gutkind, JS (corresponding author), Natl Inst Dent & Craniofacial Res, Oral & Pharyngeal Canc Branch, NIH, Bethesda, MD 20892 USA.	sg39v@nih.gov	Gutkind, J. Silvio/A-1053-2009; Williams, Bart/A-3539-2013; Gutkind, J. Silvio/J-1201-2016	Williams, Bart/0000-0002-5261-5301; Gutkind, J. Silvio/0000-0002-5150-4482; CASTELLONE, MARIADOMENICA/0000-0003-0507-8037	Intramural NIH HHS Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [ZIAAI000939, Z01AI000939] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH [ZIADE000551] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000551] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF DENTAL & CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR))		Berman DM, 1998, J BIOL CHEM, V273, P1269, DOI 10.1074/jbc.273.3.1269; Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051; Cong F, 2003, BMC MOL BIOL, V4, DOI 10.1186/1471-2199-4-10; CRESPO P, 1995, J BIOL CHEM, V270, P25259, DOI 10.1074/jbc.270.42.25259; DAY RN, 1989, J BIOL CHEM, V264, P431; Ding VW, 2000, J BIOL CHEM, V275, P32475, DOI 10.1074/jbc.M005342200; Fang XJ, 2000, P NATL ACAD SCI USA, V97, P11960, DOI 10.1073/pnas.220413597; Fujino H, 2002, J BIOL CHEM, V277, P2614, DOI 10.1074/jbc.M109440200; Hansen-Petrik MB, 2002, CANCER RES, V62, P403; Hart MJ, 1998, CURR BIOL, V8, P573, DOI 10.1016/S0960-9822(98)70226-X; He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117; Ikeda S, 1998, EMBO J, V17, P1371, DOI 10.1093/emboj/17.5.1371; Ingi T, 1998, J NEUROSCI, V18, P7178; Jemal A, 2005, CA-CANCER J CLIN, V55, P10, DOI 10.3322/canjclin.55.1.10; Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784; LEVY DB, 1994, CANCER RES, V54, P5953; Liu GZ, 2003, MOL CELL BIOL, V23, P5825, DOI 10.1128/MCB.23.16.5825-5835.2003; Liu T, 2001, SCIENCE, V292, P1718, DOI 10.1126/science.1060100; McManus EJ, 2005, EMBO J, V24, P1571, DOI 10.1038/sj.emboj.7600633; Murga C, 1998, J BIOL CHEM, V273, P19080, DOI 10.1074/jbc.273.30.19080; OSHIMA M, 1995, P NATL ACAD SCI USA, V92, P4482, DOI 10.1073/pnas.92.10.4482; Pai R, 2002, NAT MED, V8, P289, DOI 10.1038/nm0302-289; Pierce KL, 2002, NAT REV MOL CELL BIO, V3, P639, DOI 10.1038/nrm908; QIAO L, 1995, BBA-LIPID LIPID MET, V1258, P215, DOI 10.1016/0005-2760(95)00100-Q; Rubinfeld B, 1996, SCIENCE, V272, P1023, DOI 10.1126/science.272.5264.1023; Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; Shao JY, 2005, J BIOL CHEM, V280, P26565, DOI 10.1074/jbc.M413056200; Sonoshita M, 2001, NAT MED, V7, P1048, DOI 10.1038/nm0901-1048; Spink KE, 2000, EMBO J, V19, P2270, DOI 10.1093/emboj/19.10.2270; STAMBOLIC V, 1994, BIOCHEM J, V303, P701, DOI 10.1042/bj3030701; Sterne-Marr R, 2003, J BIOL CHEM, V278, P6050, DOI 10.1074/jbc.M208787200; Tanabe S, 2004, METHOD ENZYMOL, V390, P285; Tesmer JJG, 1997, CELL, V89, P251, DOI 10.1016/S0092-8674(00)80204-4; Tetsu O, 1999, NATURE, V398, P422, DOI 10.1038/18884; Torrance CJ, 2000, NAT MED, V6, P1024, DOI 10.1038/79534; Vogelstein B, 2004, NAT MED, V10, P789, DOI 10.1038/nm1087; Wang DZ, 2005, CANCER RES, V65, P1822, DOI 10.1158/0008-5472.CAN-04-3671; Watson N, 1996, NATURE, V383, P172, DOI 10.1038/383172a0; Xing Y, 2003, GENE DEV, V17, P2753, DOI 10.1101/gad.1142603	40	728	767	1	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 2	2005	310	5753					1504	1510		10.1126/science.1116221	http://dx.doi.org/10.1126/science.1116221			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	990PU	16293724				2022-12-28	WOS:000233756500047
J	Schiffman, M; Castle, PE				Schiffman, M; Castle, PE			The promise of global cervical-cancer prevention	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							PARTICLE VACCINE; YOUNG-WOMEN; EFFICACY; TYPE-18		NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Prevent, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Schiffman, M (corresponding author), NCI, Hormonal & Reprod Epidemiol Branch, Div Canc Epidemiol & Prevent, NIH, Bethesda, MD 20892 USA.		Castle, Philip/AAP-6395-2020; Schiffman, Mark/B-9766-2015	Castle, Philip/0000-0003-1082-6554; 				Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7	3	170	192	0	10	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2101	2104		10.1056/NEJMp058171	http://dx.doi.org/10.1056/NEJMp058171			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	984FT	16291978				2022-12-28	WOS:000233288600001
J	Zhang, JV; Ren, PG; Avsian-Kretchmer, O; Luo, CW; Rauch, R; Klein, C; Hsueh, AJW				Zhang, JV; Ren, PG; Avsian-Kretchmer, O; Luo, CW; Rauch, R; Klein, C; Hsueh, AJW			Obestatin, a peptide encoded by the ghrelin gene, opposes ghrelin's effects on food intake	SCIENCE			English	Article							RECEPTOR; FAMILY; OBESITY; DELETION; NEURONS; PROTEIN; MEMBER; RATS	Ghrelin, a circulating appetite-inducing hormone, is derived from a prohormone by posttranslational processing. On the basis of the bioinformatic prediction that another peptide also derived from proghrelin exists, we isolated a hormone from rat stomach and named it obestatin-a contraction of obese, from the Latin "obedere," meaning to devour, and "statin," denoting suppression. Contrary to the appetite-stimulating effects of ghrelin, treatment of rats with obestatin suppressed food intake, inhibited jejunal contraction, and decreased body-weight gain. Obestatin bound to the orphan G protein-coupled receptor GPR39. Thus, two peptide hormones with opposing action in weight regulation are derived from the same ghrelin gene. After differential modification, these hormones activate distinct receptors.	Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA	Stanford University	Hsueh, AJW (corresponding author), Stanford Univ, Sch Med, Dept Obstet & Gynecol, Div Reprod Biol, Stanford, CA 94305 USA.	aaron.hsueh@stanford.edu	Ren, Pei-Gen/A-4099-2009; ZHANG, Jian/B-5157-2009					Ariyasu H, 2005, ENDOCRINOLOGY, V146, P355, DOI 10.1210/en.2004-0629; Badman MK, 2005, SCIENCE, V307, P1909, DOI 10.1126/science.1109951; BOWERS CY, 1980, ENDOCRINOLOGY, V106, P663, DOI 10.1210/endo-106-3-663; Conklin BR, 1996, MOL PHARMACOL, V50, P885; Edholm T, 2004, REGUL PEPTIDES, V121, P25, DOI 10.1016/j.regpep.2004.04.001; EIPPER BA, 1993, PROTEIN SCI, V2, P489; Fan W, 1997, NATURE, V385, P165, DOI 10.1038/385165a0; Gnanapavan S, 2002, J CLIN ENDOCR METAB, V87, P2988, DOI 10.1210/jc.87.6.2988; Holst B, 2004, J BIOL CHEM, V279, P53806, DOI 10.1074/jbc.M407676200; Howard AD, 1996, SCIENCE, V273, P974, DOI 10.1126/science.273.5277.974; Hsu SY, 2001, NAT MED, V7, P605, DOI 10.1038/87936; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Kojima M, 2005, PHYSIOL REV, V85, P495, DOI 10.1152/physrev.00012.2004; Lewis K, 2001, P NATL ACAD SCI USA, V98, P7570, DOI 10.1073/pnas.121165198; McKee KK, 1997, GENOMICS, V46, P426, DOI 10.1006/geno.1997.5069; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Pemberton C, 2003, BIOCHEM BIOPH RES CO, V310, P567, DOI 10.1016/j.bbrc.2003.09.045; Reyes TM, 2001, P NATL ACAD SCI USA, V98, P2843, DOI 10.1073/pnas.051626398; Seidah NG, 1999, BRAIN RES, V848, P45, DOI 10.1016/S0006-8993(99)01909-5; Smith RG, 1997, ENDOCR REV, V18, P621, DOI 10.1210/er.18.5.621; Smith RG, 1999, HORM RES, V51, P1; Sun YX, 2003, MOL CELL BIOL, V23, P7973, DOI 10.1128/MCB.23.22.7973-7981.2003; Tschop M, 2000, NATURE, V407, P908, DOI 10.1038/35038090; van der Lely AJ, 2004, ENDOCR REV, V25, P426, DOI 10.1210/er.2002-0029; Wortley KE, 2004, P NATL ACAD SCI USA, V101, P8227, DOI 10.1073/pnas.0402763101; Wren AM, 2001, DIABETES, V50, P2540, DOI 10.2337/diabetes.50.11.2540	26	893	954	2	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					996	999		10.1126/science.1117255	http://dx.doi.org/10.1126/science.1117255			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284174				2022-12-28	WOS:000233343400037
J	Lee, WY; Sine, SM				Lee, WY; Sine, SM			Principal pathway coupling agonist binding to channel gating in nicotinic receptors	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; EXTRACELLULAR DOMAIN; CONFORMATIONAL-CHANGES; CHARGED RESIDUES; GLYCINE RECEPTOR; GABA(A) RECEPTOR; ASPARTIC-ACID; ACH-BINDING; ACTIVATION; SUBUNIT	Synaptic receptors respond to neurotransmitters by opening an intrinsic ion channel in the final step in synaptic transmission. How binding of the neurotransmitter is conveyed over the long distance to the channel remains a central question in neurobiology. Here we delineate a principal pathway that links neurotransmitter binding to channel gating by using a structural model of the Torpedo acetylcholine receptor at 4-angstrom resolution(1), recordings of currents through single receptor channels and determinations of energetic coupling between pairs of residues. We show that a pair of invariant arginine and glutamate residues in each receptor alpha-subunit electrostatically links peripheral and inner beta-sheets from the binding domain and positions them to engage with the channel. The key glutamate and flanking valine residues energetically couple to conserved proline and serine residues emerging from the top of the channel-forming alpha-helix, suggesting that this is the point at which the binding domain triggers opening of the channel. The series of interresidue couplings identified here constitutes a primary allosteric pathway that links neurotransmitter binding to channel gating.	Mayo Clin & Mayo Fdn, Coll Med, Dept Physiol & Biomed Engn, Receptor Biol Lab, Rochester, MN 55905 USA; Mayo Clin & Mayo Fdn, Coll Med, Mol Neurosci Grad Program, Rochester, MN 55905 USA	Mayo Clinic; Mayo Clinic	Sine, SM (corresponding author), Mayo Clin & Mayo Fdn, Coll Med, Dept Physiol & Biomed Engn, Receptor Biol Lab, 200 1st St SW, Rochester, MN 55905 USA.	sine@mayo.edu		Lee, Won Yong/0000-0001-7915-1829	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS031744] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Absalom NL, 2003, J BIOL CHEM, V278, P50151, DOI 10.1074/jbc.M305357200; Bouzat C, 2004, NATURE, V430, P896, DOI 10.1038/nature02753; Castaldo P, 2004, J BIOL CHEM, V279, P25598, DOI 10.1074/jbc.M311021200; Celie PHN, 2004, NEURON, V41, P907, DOI 10.1016/S0896-6273(04)00115-1; Chakrapani S, 2004, J GEN PHYSIOL, V123, P341, DOI 10.1085/jgp.200309004; COLQUHOUN D, 1981, NATURE, V294, P464, DOI 10.1038/294464a0; Croxen R, 1997, HUM MOL GENET, V6, P767, DOI 10.1093/hmg/6.5.767; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; Grosman C, 2000, NATURE, V403, P773, DOI 10.1038/35001586; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; Hu XQ, 2003, J BIOL CHEM, V278, P46583, DOI 10.1074/jbc.M308974200; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Kash TL, 2004, J BIOL CHEM, V279, P4887, DOI 10.1074/jbc.M311441200; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Law RJ, 2005, P NATL ACAD SCI USA, V102, P6813, DOI 10.1073/pnas.0407739102; Lee WY, 2004, J GEN PHYSIOL, V124, P555, DOI 10.1085/jgp.200409077; Lyford LK, 2003, MOL PHARMACOL, V64, P650, DOI 10.1124/mol.64.3.650; Qin F, 1996, BIOPHYS J, V70, P264, DOI 10.1016/S0006-3495(96)79568-1; Sala F, 2005, J BIOL CHEM, V280, P6642, DOI 10.1074/jbc.M411048200; Schofield CM, 2003, J BIOL CHEM, V278, P34079, DOI 10.1074/jbc.M302416200; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; Shen XM, 2003, J CLIN INVEST, V111, P497, DOI 10.1172/JC1200316997; SINE SM, 1990, J GEN PHYSIOL, V96, P395, DOI 10.1085/jgp.96.2.395; Sine SM, 2002, J NEUROBIOL, V53, P431, DOI 10.1002/neu.10139; Sine SM, 2002, J GEN PHYSIOL, V120, P483, DOI 10.1085/jgp.20028568; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Unwin N, 2002, J MOL BIOL, V319, P1165, DOI 10.1016/S0022-2836(02)00381-9; Vaughan CK, 2002, ACTA CRYSTALLOGR D, V58, P591, DOI 10.1107/S0907444902001567; Vicente-Agullo F, 2001, BIOCHEMISTRY-US, V40, P8300, DOI 10.1021/bi010087g; Wilson GG, 1998, NEURON, V20, P1269, DOI 10.1016/S0896-6273(00)80506-1	30	235	236	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					243	247		10.1038/nature04156	http://dx.doi.org/10.1038/nature04156			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281039				2022-12-28	WOS:000233133500053
J	Samore, MH; Bateman, K; Alder, SC; Hannah, E; Donnelly, S; Stoddard, GJ; Haddadin, B; Rubin, MA; Williamson, J; Stults, B; Rupper, R; Stevenson, K				Samore, MH; Bateman, K; Alder, SC; Hannah, E; Donnelly, S; Stoddard, GJ; Haddadin, B; Rubin, MA; Williamson, J; Stults, B; Rupper, R; Stevenson, K			Clinical decision support and appropriateness of antimicrobial prescribing - A randomized trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RESPIRATORY-TRACT INFECTIONS; UNCOMPLICATED ACUTE BRONCHITIS; OUTPATIENT ANTIBIOTIC USE; AMBULATORY-CARE SETTINGS; STREPTOCOCCUS-PNEUMONIAE; DRUG PRESCRIPTIONS; RELATIVE RISK; UNITED-STATES; RESISTANCE; COMMUNITY	Context The impact of clinical decision support systems (CDSS) on antimicrobial prescribing in ambulatory settings has not previously been evaluated. Objective To measure the added value of CDSS when coupled with a community intervention to reduce inappropriate prescribing of antimicrobial drugs for acute respiratory tract infections. Design, Participants and Setting Cluster randomized trial that included 407 460 inhabitants and 334 primary care clinicians in 12 rural communities in Utah and Idaho (6 with 1 shared characteristic and 6 with another), and a third group of 6 communities that served as nonstudy controls. The preintervention period was January to December 2001 and the postintervention period was January 2002 to September 2003. Acute respiratory tract infection diagnoses were classified into groups based on indication for antimicrobial use. Multilevel regression methods were applied to account for the clustered design. Intervention Six communities received a community intervention alone and 6 communities received community intervention plus CDSS that were targeted toward primary care clinicians. The CDSS comprised decision support tools on paper and a handheld computer to guide diagnosis and management of acute respiratory tract infection. Main Outcome Measure Community-wide antimicrobial usage was assessed using retail pharmacy data. Diagnosis-specific antimicrobial use was compared by chart review. Results Within CDSS communities, 71% of primary care clinicians participated in the use of CDSS. The prescribing rate decreased from 84.1 to 75.3 per 100 person-years in the CDSS arm vs 84.3 to 85.2 in community intervention alone, and remained stable in the other communities (P=.03). A total of 13 081 acute respiratory tract infection visits were abstracted. The relative decrease in antimicrobial prescribing for visits in the antibiotics "never-indicated" category during the postintervention period was 32% in CDSS communities and 5% in community intervention-alone communities (P=.03). Use of macrolides decreased significantly in CDSS communities but not in community intervention-alone communities. Conclusion CDSS implemented in rural primary care settings reduced overall antimicrobial use and improved appropriateness of antimicrobial selection for acute respiratory tract infections. Trial Registration ClinicalTrials.gov Identifier: NCT00235703.	Univ Utah, Sch Med, Dept Internal Med, Salt Lake City, UT 84132 USA; VA Salt Lake City Hlth Care Syst, Salt Lake City, UT USA; HealthInsight, Salt Lake City, UT USA; Qualis Hlth, Boise, ID USA	Utah System of Higher Education; University of Utah; US Department of Veterans Affairs	Samore, MH (corresponding author), Univ Utah, Sch Med, Dept Internal Med, 50 N Med Dr,AC230A SOM, Salt Lake City, UT 84132 USA.	matthew.samore@hsc.utah.edu			DRS NIH HHS [RS1 CCR820631] Funding Source: Medline	DRS NIH HHS		Alder SC, 2005, AM J HEALTH EDUC, V36, P132, DOI 10.1080/19325037.2005.10608174; Austin DJ, 1999, P NATL ACAD SCI USA, V96, P1152, DOI 10.1073/pnas.96.3.1152; Barden LS, 1998, CLIN PEDIATR, V37, P665, DOI 10.1177/000992289803701104; Barratt A, 2004, CAN MED ASSOC J, V171, P353, DOI 10.1503/cmaj.1021197; Bates DW, 2003, NEW ENGL J MED, V348, P2526, DOI 10.1056/NEJMsa020847; Bauraind I, 2004, JAMA-J AM MED ASSOC, V292, P2468, DOI 10.1001/jama.292.20.2468-b; Bell DS, 2004, J AM MED INFORM ASSN, V11, P60, DOI 10.1197/jamia.M1374; Bellamy SL, 2000, STAT METHODS MED RES, V9, P135, DOI 10.1191/096228000672549488; Belongia EA, 2001, PEDIATRICS, V108, P575, DOI 10.1542/peds.108.3.575; Belongia EA, 2002, PREV MED, V34, P346, DOI 10.1006/pmed.2001.0992; Besser RE, 2003, ANN INTERN MED, V138, P605, DOI 10.7326/0003-4819-138-7-200304010-00020; Bingenheimer JB, 2004, ANNU REV PUBL HEALTH, V25, P53, DOI 10.1146/annurev.publhealth.25.050503.153925; Cabana MD, 1999, JAMA-J AM MED ASSOC, V282, P1458, DOI 10.1001/jama.282.15.1458; Campbell MK, 2001, STAT MED, V20, P391, DOI 10.1002/1097-0258(20010215)20:3<391::AID-SIM800>3.0.CO;2-Z; Cantrell R, 2002, CLIN THER, V24, P170, DOI 10.1016/S0149-2918(02)85013-5; Cimino JJ, 2005, NEW ENGL J MED, V352, P860, DOI 10.1056/NEJMp048149; Davey P, 2002, CLIN MICROBIOL INFEC, V8, P43, DOI 10.1046/j.1469-0691.8.s.2.6.x; Dean NC, 2004, INFECT DIS CLIN N AM, V18, P975, DOI 10.1016/j.idc.2004.07.005; Donner A, 2004, AM J PUBLIC HEALTH, V94, P416, DOI 10.2105/AJPH.94.3.416; Dorsch JL, 2000, B MED LIBR ASSOC, V88, P346; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P341, DOI 10.1097/00006454-199904000-00006; Dowell SF, 1999, PEDIATR INFECT DIS J, V18, P1, DOI 10.1097/00006454-199901000-00002; Elder JP, 1999, AM J PREV MED, V17, P275, DOI 10.1016/S0749-3797(99)00094-X; Finch RG, 2004, LANCET INFECT DIS, V4, P44, DOI 10.1016/S1473-3099(03)00860-0; Finch RG, 2002, CLIN MICROBIOL INFEC, V8, P69, DOI 10.1046/j.1469-0691.8.s.2.7.x; Finkelstein JA, 2003, PEDIATRICS, V112, P620, DOI 10.1542/peds.112.3.620; Finkelstein JA, 2001, PEDIATRICS, V108, pU113; Gonzales R, 2001, ANN INTERN MED, V134, P490, DOI 10.7326/0003-4819-134-6-200103200-00015; Gonzales R, 2001, ANN INTERN MED, V134, P521, DOI 10.7326/0003-4819-134-6-200103200-00021; Gonzales R, 2001, ANN INTERN MED, V134, P479, DOI 10.7326/0003-4819-134-6-200103200-00013; Gonzales R, 2005, HEALTH SERV RES, V40, P101, DOI 10.1111/j.1475-6773.2005.00344.x; GONZALES R, 1995, LANCET, V345, P665, DOI 10.1016/S0140-6736(95)90861-7; Gonzales R, 2001, CLIN INFECT DIS, V33, P757, DOI 10.1086/322627; Gonzales R, 1999, JAMA-J AM MED ASSOC, V281, P1512, DOI 10.1001/jama.281.16.1512; Gonzales R, 1997, JAMA-J AM MED ASSOC, V278, P901, DOI 10.1001/jama.278.11.901; Goossens H, 2005, LANCET, V365, P579, DOI 10.1016/S0140-6736(05)17907-0; Harbarth S, 2002, EMERG INFECT DIS, V8, P1460, DOI 10.3201/eid0812.010533; Hastie R, 2001, ANNU REV PSYCHOL, V52, P653, DOI 10.1146/annurev.psych.52.1.653; Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; Jackson W Clay, 2002, Prim Care Companion J Clin Psychiatry, V4, P100; Kawamoto K, 2005, BMJ-BRIT MED J, V330, P765, DOI 10.1136/bmj.38398.500764.8F; Kiefe CI, 2001, JAMA-J AM MED ASSOC, V285, P2871, DOI 10.1001/jama.285.22.2871; Koch HJ, 2001, EUR J CLIN PHARMACOL, V56, P943, DOI 10.1007/s002280000258; Kuyvenhoven MM, 2003, J ANTIMICROB CHEMOTH, V52, P675, DOI 10.1093/jac/dkg412; Lipsitch M, 2002, EMERG INFECT DIS, V8, P347, DOI 10.3201/eid0804.010312; Lipsitch M, 2001, TRENDS MICROBIOL, V9, P438, DOI 10.1016/S0966-842X(01)02130-8; Macfarlane J, 1997, BMJ-BRIT MED J, V315, P1211, DOI 10.1136/bmj.315.7117.1211; Mainous AG, 1997, J FAM PRACTICE, V45, P75; Mangione-Smith R, 2001, ARCH PEDIAT ADOL MED, V155, P800, DOI 10.1001/archpedi.155.7.800; Mangione-Smith R, 2003, SOC SCI MED, V56, P313, DOI 10.1016/S0277-9536(02)00029-1; McCaig LF, 2002, JAMA-J AM MED ASSOC, V287, P3096, DOI 10.1001/jama.287.23.3096; McCaig LF, 2003, EMERG INFECT DIS, V9, P432; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Morris AH, 2000, ANN INTERN MED, V132, P373, DOI 10.7326/0003-4819-132-5-200003070-00007; Murray DM, 2004, AM J PUBLIC HEALTH, V94, P423, DOI 10.2105/AJPH.94.3.423; Neuhaus J M, 1992, Stat Methods Med Res, V1, P249, DOI 10.1177/096228029200100303; NEUHAUS JM, 1993, STAT MED, V12, P1259, DOI 10.1002/sim.4780121107; Nyquist AC, 1998, JAMA-J AM MED ASSOC, V279, P875, DOI 10.1001/jama.279.11.875; Parsons Jacqueline E, 2003, Aust J Rural Health, V11, P242, DOI 10.1111/j.1440-1584.2003.00527.x; Perz JF, 2002, JAMA-J AM MED ASSOC, V287, P3103, DOI 10.1001/jama.287.23.3103; Raudenbush SW, 2002, HIERARCHICAL LINEAR; Rodriguez G, 2001, J ROY STAT SOC A STA, V164, P339, DOI 10.1111/1467-985X.00206; Rosenstein N, 1998, PEDIATRICS, V101, P181; ROSENSTOCK IM, 1988, HEALTH EDUC QUART, V15, P175, DOI 10.1177/109019818801500203; Rubin MA, 2005, CLIN INFECT DIS, V40, P546, DOI 10.1086/427500; Samore MH, 2001, PEDIATRICS, V108, P856, DOI 10.1542/peds.108.4.856; SCHAFFNER W, 1983, JAMA-J AM MED ASSOC, V250, P1728, DOI 10.1001/jama.250.13.1728; Schwartz B, 1998, PEDIATRICS, V101, P171; Scopelliti J, 2004, AUST NZ J PSYCHIAT, V38, P953, DOI 10.1111/j.1440-1614.2004.01486.x; Sim I, 2001, J AM MED INFORM ASSN, V8, P527, DOI 10.1136/jamia.2001.0080527; Spellberg B, 2004, CLIN INFECT DIS, V38, P1279, DOI 10.1086/420937; Steinman MA, 2003, ANN INTERN MED, V138, P525, DOI 10.7326/0003-4819-138-7-200304010-00008; Stivers T, 2003, J FAM PRACTICE, V52, P140; Taylor CT, 2003, AM J HEALTH-SYST PH, V60, P1123, DOI 10.1093/ajhp/60.11.1123; Weissman JT, 2001, METHOD ENZYMOL, V329, P431; Worrall G, 2005, CAN J RURAL MED, V10, P86; Wyatt J, 1991, Proc Annu Symp Comput Appl Med Care, P3	77	155	157	0	10	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2005	294	18					2305	2314		10.1001/jama.294.18.2305	http://dx.doi.org/10.1001/jama.294.18.2305			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981LI	16278358	Bronze			2022-12-28	WOS:000233089700022
J	Winkelmayer, WC; Stampfer, MJ; Willett, WC; Curhan, GC				Winkelmayer, WC; Stampfer, MJ; Willett, WC; Curhan, GC			Habitual caffeine intake and the risk of hypertension in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; ANALGESIC USE; QUESTIONNAIRE; FREQUENCY; COFFEE; REPRODUCIBILITY; VALIDATION; RESPONSES; VALIDITY	Context Caffeine acutely increases blood pressure, but the association between habitual consumption of caffeinated beverages and incident hypertension is uncertain. Objective To examine the association between caffeine intake and incident hypertension in women. Design, Setting, and Participants Prospective cohort study conducted in the Nurses' Health Studies (NHSs) I and II of 155 594 US women free from physician-diagnosed hypertension followed up over 12 years (1990-1991 to 2002-2003 questionnaires). Caffeine intake and possible confounders were ascertained from regularly administered questionnaires. We also tested the associations with types of caffeinated beverages. Main Outcome Measure Incident physician-diagnosed hypertension. Results During follow-up, 19 541 incident cases of physician-diagnosed hypertension were reported in NHS I and 13 536 in NHS II. In both cohorts, no linear association between caffeine consumption and risk of incident hypertension was observed after multivariate adjustment (NHS I, P for trend=.29; NHS II, P for trend =.53). Using categorical analysis, an inverse U-shaped association between caffeine consumption and incident hypertension was found. Compared with participants in the lowest quintile of caffeine consumption, those in the third quintile had a 13% and 12% increased risk of hypertension, respectively (95% confidence interval in NHS I, 8%-18%; in NHS II, 6%-18%). When studying individual classes of caffeinated beverages, habitual coffee consumption was not associated with increased risk of hypertension. By contrast, consumption of cola beverages was associated with an increased risk of hypertension, independent of whether it was sugared or diet cola (P for trend <.001). Conclusion No linear association between caffeine consumption and incident hypertension was found. Even though habitual coffee consumption was not associated with an increased risk of hypertension, consumption of sugared or diet cola was associated with it. Further research to elucidate the role of cola beverages in hypertension is warranted.	Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02120 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Renal Div, Boston, MA 02120 USA; Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02120 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Winkelmayer, WC (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Div Pharmacoepidemiol & Pharmacoecon, 1620 Tremont St,Suite 3030, Boston, MA 02120 USA.	wwinkelmayer@partners.org			NCI NIH HHS [CA050385, CA87969] Funding Source: Medline; NIDDK NIH HHS [DK66574, DK52866] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA050385, P01CA087969] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK052866, R01DK066574] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; *AM HEART ASS, 2001, 2002 HEART STROK STA; Choi SB, 2002, J NUTR BIOCHEM, V13, P727, DOI 10.1016/S0955-2863(02)00216-4; Colditz G A, 1995, J Am Med Womens Assoc (1972), V50, P40; COLDITZ GA, 1986, AM J EPIDEMIOL, V123, P894, DOI 10.1093/oxfordjournals.aje.a114319; Curhan GC, 2002, ARCH INTERN MED, V162, P2204, DOI 10.1001/archinte.162.19.2204; Dedier J, 2002, HYPERTENSION, V40, P604, DOI 10.1161/01.HYP.0000035856.77718.DA; FIEBACH NH, 1989, AM J EPIDEMIOL, V130, P646; Forman JP, 2005, JAMA-J AM MED ASSOC, V293, P320, DOI 10.1001/jama.293.3.320; GROBBEE DE, 1990, NEW ENGL J MED, V323, P1026, DOI 10.1056/NEJM199010113231504; Jee SH, 1999, HYPERTENSION, V33, P647, DOI 10.1161/01.HYP.33.2.647; JEE SH, 1997, CAN J CARDIOL SB, V13, pB36; Klag MJ, 2002, ARCH INTERN MED, V162, P657, DOI 10.1001/archinte.162.6.657; LANE JD, 1990, PSYCHOSOM MED, V52, P320, DOI 10.1097/00006842-199005000-00006; Levy D, 1996, JAMA-J AM MED ASSOC, V275, P1557, DOI 10.1001/jama.275.20.1557; LOVALLO WR, 1989, HYPERTENSION, V14, P170, DOI 10.1161/01.HYP.14.2.170; RIMM EB, 1992, AM J EPIDEMIOL, V135, P1114, DOI 10.1093/oxfordjournals.aje.a116211; ROBERTSON D, 1978, NEW ENGL J MED, V298, P181, DOI 10.1056/NEJM197801262980403; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; Schulze MB, 2004, JAMA-J AM MED ASSOC, V292, P927, DOI 10.1001/jama.292.8.927; Willett W., 2012, NUTR EPIDEMIOLOGY; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; Yang YC, 2004, ARCH INTERN MED, V164, P1534, DOI 10.1001/archinte.164.14.1534	23	205	214	0	32	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2005	294	18					2330	2335		10.1001/jama.294.18.2330	http://dx.doi.org/10.1001/jama.294.18.2330			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981LI	16278361	Bronze			2022-12-28	WOS:000233089700025
J	Chen, ZM; Jiang, LX; Chen, YP; Xie, JX; Pan, HC; Peto, R; Collins, R; Liu, LS; Chen, ZM; Liu, LS; Collins, R; Jiang, LX; Chen, YP; Xie, JX; Pan, HC; Peto, R; Cai, NS; Chen, YZ; Cui, JJ; Dai, GZ; Feng, JZ; Fu, SY; Gent, M; Gong, LS; Hu, DY; Huang, DJ; Huang, J; Huang, TG; Huang, ZW; Hui, RT; Jiang, BQ; Li, DY; Li, SM; Li, TD; Li, YQ; Li, ZQ; Liu, YH; Meng, QY; Qian, TJ; San, J; Tao, SQ; Wang, DW; Wang, LH; Wang, W; Wu, HA; Xi, WH; Xu, CB; Yang, DC; Yang, XF; Yin, JQ; Zeng, DY; Zhang, F; Zhou, JC; Zhu, DQ; Zhu, J; Sleight, P; MacMahon, S; Lam, TH; Sandercock, P				Chen, ZM; Jiang, LX; Chen, YP; Xie, JX; Pan, HC; Peto, R; Collins, R; Liu, LS; Chen, ZM; Liu, LS; Collins, R; Jiang, LX; Chen, YP; Xie, JX; Pan, HC; Peto, R; Cai, NS; Chen, YZ; Cui, JJ; Dai, GZ; Feng, JZ; Fu, SY; Gent, M; Gong, LS; Hu, DY; Huang, DJ; Huang, J; Huang, TG; Huang, ZW; Hui, RT; Jiang, BQ; Li, DY; Li, SM; Li, TD; Li, YQ; Li, ZQ; Liu, YH; Meng, QY; Qian, TJ; San, J; Tao, SQ; Wang, DW; Wang, LH; Wang, W; Wu, HA; Xi, WH; Xu, CB; Yang, DC; Yang, XF; Yin, JQ; Zeng, DY; Zhang, F; Zhou, JC; Zhu, DQ; Zhu, J; Sleight, P; MacMahon, S; Lam, TH; Sandercock, P		COMMIT Collaborative Grp	Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial	LANCET			English	Article							ANTIPLATELET THERAPY; CORONARY; TICLOPIDINE; DESIGN; RISK	Background Despite improvements in the emergency treatment of myocardial infarction (MI), early mortality and morbidity remain high. The antiplatelet agent clopidogrel adds to the benefit of aspirin in acute coronary syndromes without ST-segment elevation, but its effects in patients with ST-elevation MI were unclear. Methods 45 852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated clopidogrel 75 mg daily (n = 22 961) or matching placebo (n=22 891) in addition to aspirin 162 mg daily. 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment depression. Treatment was to continue until discharge or up to 4 weeks in hospital (mean 15 days in survivors) and 93% of patients completed it. The two prespecified co-primary outcomes were: (1) the composite of death, reinfarction, or stroke; and (2) death from any cause during the scheduled treatment period. Comparisons were by intention to treat, and used the log-rank method. This trial is registered with ClinicalTrials.gov, number NCT00222573. Findings Allocation to clopidogrel produced a highly significant 9% (95% CI 3-14) proportional reduction in death, reinfarction, or stroke (2121 [9.2%] clopidogrel vs 2310 [10.1%] placebo; p=0.002), corresponding to nine (SE 3) fewer events per 1000 patients treated for about 2 weeks. There was also a significant 7% (1-13) proportional reduction in any death (1726 [7.5%] vs 1845 [8.1%]; p=0.03). These effects on death, reinfarction, and stroke seemed consistent across a wide range of patients and independent of other treatments being used. Considering all fatal, transfused, or cerebral bleeds together, no significant excess risk was noted with clopidogrel, either overall (134 [0.58%] vs 125 [0.55%]; p=0.59), or in patients aged older than 70 years or in those given fibrinolytic therapy. Interpretation In a wide range of patients with acute MI, adding clopidogrel 75 mg daily to aspirin and other standard treatments (such as fibrinolytic therapy) safely reduces mortality and major vascular events in hospital, and should be considered routinely.	Univ Oxford, Clin Trial Serv Unit, Oxford OX3 7LF, England; Epidemiol Studies Unit, Oxford OX3 7LF, England; Fuwai Hosp, Beijing 100037, Peoples R China	University of Oxford; University of Oxford; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS	Chen, ZM (corresponding author), Univ Oxford, Clin Trial Serv Unit, Richard Doll Bldg,Old Rd Campus, Oxford OX3 7LF, England.	zhengming.chen@ctsu.ox.ac.uk; ccstwo@public3.bta.net.cn						Angiolillo DJ, 2004, EUR HEART J, V25, P1903, DOI 10.1016/j.ehj.2004.07.036; [Anonymous], 1988, LANCET, V2, P349; Baigent C, 2002, BMJ-BRIT MED J, V324, P71, DOI 10.1136/bmj.324.7329.71; Baigent C, 1998, BMJ-BRIT MED J, V316, P1337, DOI 10.1136/bmj.316.7141.1337; Bhatt DL, 2004, AM HEART J, V148, P263, DOI 10.1016/j.ahj.2004.03.028; Cadroy Y, 2000, CIRCULATION, V101, P2823, DOI 10.1161/01.CIR.101.24.2823; Chen ZM, 2005, LANCET, V366, P1622; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; Gregorini L, 1997, HEART, V77, P11, DOI 10.1136/hrt.77.1.11; HERBERT JM, 1993, CARDIOVASC DRUG REV, V11, P180, DOI 10.1111/j.1527-3466.1993.tb00275.x; LIU LS, 1995, LANCET, V345, P686; Liu LS, 2000, J CARDIOVASC RISK, V7, P435; Mishkel GJ, 1999, J AM COLL CARDIOL, V34, P1884, DOI 10.1016/S0735-1097(99)00443-X; PETO R, 1976, BRIT J CANCER, V34, P585, DOI 10.1038/bjc.1976.220; Quinn MJ, 1999, CIRCULATION, V100, P1667, DOI 10.1161/01.CIR.100.15.1667; ROUX S, 1992, J AM COLL CARDIOL, V19, P671, DOI 10.1016/S0735-1097(10)80290-6; Sabatine MS, 2005, NEW ENGL J MED, V352, P1179, DOI 10.1056/NEJMoa050522; Steinhubl SR, 2002, JAMA-J AM MED ASSOC, V288, P2411, DOI 10.1001/jama.288.19.2411; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2003, CIRCULATION, V107, P966, DOI 10.1161/01.CIR.0000051362.96946.15; Yusuf S, 2001, NEW ENGL J MED, V345, P494	21	1417	1546	4	56	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1607	1621		10.1016/s0140-6736(05)67660-x	http://dx.doi.org/10.1016/s0140-6736(05)67660-x			15	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271642				2022-12-28	WOS:000233047100022
J	Sequist, TD				Sequist, TD			Paving the way - Providing opportunities for Native American students	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Harvard Univ, Sch Med, Direct Summer Res Program 4, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA USA; Brigham & Womens Hosp, Div Gen Med & Primary Care, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	Sequist, TD (corresponding author), Harvard Univ, Sch Med, Direct Summer Res Program 4, Boston, MA 02115 USA.							*AG HEALTHC RES QU, 2004, NAT HEALTHC DISP REP; [Anonymous], MIN MED ED FACTS FIG; *IND HLTH SERV, FACT SHEET 2004; Zuckerman S, 2004, AM J PUBLIC HEALTH, V94, P53, DOI 10.2105/AJPH.94.1.53	4	5	5	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1884	1886		10.1056/NEJMp058218	http://dx.doi.org/10.1056/NEJMp058218			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979VJ	16267318				2022-12-28	WOS:000232972800003
J	Shen, ZQ; Lo, KY; Liang, MC; Ho, PTP; Zhao, JH				Shen, ZQ; Lo, KY; Liang, MC; Ho, PTP; Zhao, JH			A size of similar to 1 AU for the radio source Sgr A* at the centre of the Milky Way	NATURE			English	Article							SUPERMASSIVE BLACK-HOLE; X-RAY; MILLIMETER; MODELS	Although it is widely accepted that most galaxies have supermassive black holes at their centres(1-3), concrete proof has proved elusive. Sagittarius A* (Sgr A*)(4), an extremely compact radio source at the centre of our Galaxy, is the best candidate for proof(5-7), because it is the closest. Previous very-long-baseline interferometry observations ( at 7 mm wavelength) reported that Sgr A* is similar to 2 astronomical units (AU) in size(8), but this is still larger than the 'shadow' ( a remarkably dim inner region encircled by a bright ring) that should arise from general relativistic effects near the event horizon of the black hole(9). Moreover, the measured size is wavelength dependent(10). Here we report a radio image of Sgr A* at a wavelength of 3.5 mm, demonstrating that its size is similar to 1 AU. When combined with the lower limit on its mass(11), the lower limit on the mass density is 6.5 x 10(21) M-. pc(-3) (where M-. is the solar mass), which provides strong evidence that Sgr A* is a supermassive black hole. The power-law relationship between wavelength and intrinsic size ( size proportional to wavelength(1.09)) explicitly rules out explanations other than those emission models with stratified structure, which predict a smaller emitting region observed at a shorter radio wavelength.	Shanghai Astron Observ, Shanghai 200030, Peoples R China; Natl Radio Astron Observ, Charlottesville, VA 22903 USA; CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; Harvard Smithsonian Ctr Astrophys, Cambridge, MA 02138 USA; Acad Sinica, Inst Astron & Astrophys, Taipei 106, Taiwan	Chinese Academy of Sciences; Shanghai Astronomical Observatory, CAS; National Radio Astronomy Observatory (NRAO); California Institute of Technology; Harvard University; Smithsonian Astrophysical Observatory; Smithsonian Institution; Academia Sinica - Taiwan	Shen, ZQ (corresponding author), Shanghai Astron Observ, 80 Nandan Rd, Shanghai 200030, Peoples R China.	zshen@shao.ac.cn	Ho, Paul/AAZ-5108-2020; Liang, Mao-Chang/AAG-4305-2021; Liang, Mao-Chang/P-9796-2018	Ho, Paul/0000-0002-3412-4306; Liang, Mao-Chang/0000-0002-5294-9344				ALBERDI A, 1993, ASTRON ASTROPHYS, V277, pL1; BALICK B, 1974, ASTROPHYS J, V194, P265, DOI 10.1086/153242; Begelman MC, 2003, SCIENCE, V300, P1898, DOI 10.1126/science.1085325; Bower GC, 2004, SCIENCE, V304, P704, DOI 10.1126/science.1094023; Bower GC, 1998, ASTROPHYS J, V496, pL97, DOI 10.1086/311259; DAVIES RD, 1976, MON NOT R ASTRON SOC, V177, P319, DOI 10.1093/mnras/177.2.319; Doeleman SS, 2001, ASTRON J, V121, P2610, DOI 10.1086/320376; Falcke H, 2000, ASTRON ASTROPHYS, V362, P113; Falcke H, 1998, ASTROPHYS J, V499, P731, DOI 10.1086/305687; Falcke H, 2000, ASTROPHYS J, V528, pL13, DOI 10.1086/312423; Genzel R, 2003, NATURE, V425, P934, DOI 10.1038/nature02065; GWINN CR, 1991, ASTROPHYS J, V381, pL43, DOI 10.1086/186192; KONIGL A, 1981, ASTROPHYS J, V243, P700, DOI 10.1086/158638; KORMENDY J, 1995, ANNU REV ASTRON ASTR, V33, P581, DOI 10.1146/annurev.aa.33.090195.003053; LO KY, 1985, NATURE, V315, P124, DOI 10.1038/315124a0; Maoz E, 1998, ASTROPHYS J, V494, pL181, DOI 10.1086/311194; MELIA F, 1994, ASTROPHYS J, V426, P577, DOI 10.1086/174094; Melia F, 2001, ANNU REV ASTRON ASTR, V39, P309, DOI 10.1146/annurev.astro.39.1.309; MIYOSHI M, 1995, NATURE, V373, P127, DOI 10.1038/373127a0; Ozel F, 2000, ASTROPHYS J, V541, P234, DOI 10.1086/309396; REES MJ, 1984, ANNU REV ASTRON ASTR, V22, P471, DOI 10.1146/annurev.aa.22.090184.002351; Reid MJ, 2003, ASTRON NACHR, V324, P505, DOI 10.1002/asna.200385084; Schodel R, 2002, NATURE, V419, P694, DOI 10.1038/nature01121; Shen ZQ, 2003, ASTRON NACHR, V324, P383, DOI 10.1002/asna.200385090; Shen ZQ, 2004, PROG THEOR PHYS SUPP, P413, DOI 10.1143/PTPS.155.413; Torres DF, 2000, PHYS REV D, V62, DOI 10.1103/PhysRevD.62.104012; Yuan F, 2003, ASTROPHYS J, V598, P301, DOI 10.1086/378716; [No title captured]	29	193	200	1	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					62	64		10.1038/nature04205	http://dx.doi.org/10.1038/nature04205			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267548	Green Accepted			2022-12-28	WOS:000232979000040
J	Barker, DJP; Osmond, C; Forsen, TJ; Kajantie, E; Eriksson, JG				Barker, DJP; Osmond, C; Forsen, TJ; Kajantie, E; Eriksson, JG			Trajectories of growth among children who have coronary events as adults	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ISCHEMIC-HEART-DISEASE; BODY-MASS INDEX; CARDIOVASCULAR-DISEASE; BIRTH-WEIGHT; CHILDHOOD; COHORT; DEATH; WOMEN; OVERWEIGHT; INSULIN	BACKGROUND: Low birth weight is a risk factor for coronary heart disease. It is uncertain how postnatal growth affects disease risk. METHODS: We studied 8760 people born in Helsinki from 1934 through 1944. Childhood growth had been recorded. A total of 357 men and 87 women had been admitted to the hospital with coronary heart disease or had died from the disease. Coronary risk factors were measured in a subset of 2003 people. RESULTS: The mean body size of children who had coronary events as adults was below average at birth. At two years of age the children were thin; subsequently, their body-mass index (BMI) increased relative to that of other children and had reached average values by 11 years of age. In simultaneous regressions, the hazard ratios associated with a 1 SD increase in BMI were 0.76 (95 percent confidence interval, 0.66 to 0.87; P<0.001) at 2 years and 1.14 (95 percent confidence interval, 1.00 to 1.31; P=0.05) at 11 years among the boys. The corresponding figures for the girls were 0.62 (95 percent confidence interval, 0.46 to 0.82; P=0.001) and 1.35 (95 percent confidence interval, 1.02 to 1.78; P=0.04). Low BMI at 2 years of age and increased BMI from 2 to 11 years of age were also associated with raised fasting insulin concentrations (P<0.001 for both). CONCLUSIONS: On average, adults who had a coronary event had been small at birth and thin at two years of age and thereafter put on weight rapidly. This pattern of growth during childhood was associated with insulin resistance in later life. The risk of coronary events was more strongly related to the tempo of childhood gain in BMI than to the BMI attained at any particular age.	Univ Southampton, Southampton Gen Hosp, Dev Origins Hlth & Dis Div, Southampton, Hants, England; Univ Southampton, Southampton Gen Hosp, MRC, Epidemiol Resource Ctr, Southampton, Hants, England; Natl Publ Hlth Inst, Helsinki, Finland	University of Southampton; University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Princess Anne Hosp, DOHaD Div, Level F 887,Coxford Rd, Southampton SO16 5YA, Hants, England.	djpb@mrc.soton.ac.uk	Barker, David JP/A-5671-2013	Eriksson, Johan/0000-0002-2516-2060; Osmond, Clive/0000-0002-9054-4655				BARKER DJP, 1989, LANCET, V2, P577; Barker DJP, 2001, BMJ-BRIT MED J, V323, P1273, DOI 10.1136/bmj.323.7324.1273; Bhargava SK, 2004, NEW ENGL J MED, V350, P865, DOI 10.1056/NEJMoa035698; Dietz WH, 2004, NEW ENGL J MED, V350, P855, DOI 10.1056/NEJMp048008; Eriksson JG, 2001, BRIT MED J, V322, P949, DOI 10.1136/bmj.322.7292.949; Forsen T, 2004, HEART, V90, P20, DOI 10.1136/heart.90.1.20; FOSSATI P, 1982, CLIN CHEM, V28, P2077; Frankel S, 1996, LANCET, V348, P1478, DOI 10.1016/S0140-6736(96)03482-4; Harding JE, 2001, INT J EPIDEMIOL, V30, P15, DOI 10.1093/ije/30.1.15; KUCZMARSKI RJ, 2002, VITAL HLTH STAT S 11, V246; KUNST A, 1983, METHOD ENZYMAT AN, P163; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; LIE RF, 1976, CLIN CHEM, V22, P1627; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; Phillips DIW, 1996, DIABETOLOGIA, V39, P1119; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROBINSON SM, 1991, BRIT J OBSTET GYNAEC, V98, P1223, DOI 10.1111/j.1471-0528.1991.tb15393.x; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; SINGHAL A, 2004, LANCET, V363, P1462; SOBEY WJ, 1989, BIOCHEM J, V260, P535, DOI 10.1042/bj2600535; Stettler N, 2002, PEDIATRICS, V109, P194, DOI 10.1542/peds.109.2.194; WIDDOWSON EM, 1972, ARCH DIS CHILD, V47, P652, DOI 10.1136/adc.47.254.652	22	1046	1082	1	43	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1802	1809		10.1056/NEJMoa044160	http://dx.doi.org/10.1056/NEJMoa044160			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251536				2022-12-28	WOS:000232813000008
J	Page-Shafer, K; Saphonn, V; Sun, LP; Vun, MC; Cooper, DA; Kaldor, JM				Page-Shafer, K; Saphonn, V; Sun, LP; Vun, MC; Cooper, DA; Kaldor, JM			HIV prevention research in a resource-limited setting: the experience of planning a trial in Cambodia	LANCET			English	Editorial Material							RISK BEHAVIOR; INFECTION; MACAQUES		Univ Calif San Francisco, Dept Med, Ctr AIDS Prevent Studies, San Francisco, CA USA; Minist Hlth, Natl Ctr HIV AIDS Dermatol & STDS, Phnom Penh, Cambodia; Univ New S Wales, Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW, Australia	University of California System; University of California San Francisco; University of New South Wales Sydney; Kirby Institute	Kaldor, JM (corresponding author), Natl Ctr HIV Epidemiol & Clin Res, Darlinghurst, NSW 2010, Australia.	jkaldor@nchecr.unsw.edu.au	Kaldor, John M/D-4545-2011	Page, Kimberly/0000-0002-7120-1673	PHS HHS [5UO154241] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		Ahmad K, 2004, LANCET INFECT DIS, V4, P597, DOI 10.1016/S1473-3099(04)01159-4; *AIDS VACC ADV COA, PILL DAY PREV HIV; Balant LP, 2000, INT J CLIN PHARM TH, V38, P47; Bartholow BN, 2005, JAIDS-J ACQ IMM DEF, V39, P90, DOI 10.1097/01.qai.0000143600.41363.78; Bjornsson TD, 2003, J CLIN PHARMACOL, V43, P943, DOI 10.1177/0091270003256065; *CAMB MIN HLTH, 2002, NAT GUID SEL PEOPL L; *CAMB MIN HLTH, 2002, ETH GUID HLTH RES IN; Cardo DM, 1997, NEW ENGL J MED, V337, P1485, DOI 10.1056/NEJM199711203372101; CHASE M, 2004, WALL STREET J   0812, pB1; Cohen J, 2004, SCIENCE, V305, P1092; Council for International Organizations of Medical Sciences WHO, 2002, INT ETH GUID BIOM RE; Gallant JE, 2003, CLIN INFECT DIS, V37, P944, DOI 10.1086/378068; JAMES JS, 2004, AIDS TREAT NEWS 0723, P4; Loff B, 2005, LANCET, V365, P1618, DOI 10.1016/S0140-6736(05)66502-6; Nolan ML, 2002, AIDS, V16, P1991, DOI 10.1097/00002030-200210180-00003; Ojcius David, 2004, Nat Rev Microbiol, V2, P776; Saphonn V, 2004, AIDS EDUC PREV, V16, P64, DOI 10.1521/aeap.16.3.5.64.35522; TSAI CC, 1995, SCIENCE, V270, P1197, DOI 10.1126/science.270.5239.1197; UNAIDS and WHO, 2000, ETH CONS HIV PREV VA; van Griensven F, 2004, AIDS, V18, P295, DOI 10.1097/00002030-200401230-00020; Van Rompay KKA, 2001, J INFECT DIS, V184, P429, DOI 10.1086/322781; WHO/UNAIDS, 2004, AIDS, V18, pW1; World Health Organization, 2002, SCAL ANT THER RES LT	23	35	36	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2005	366	9495					1499	1503		10.1016/S0140-6736(05)67146-2	http://dx.doi.org/10.1016/S0140-6736(05)67146-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	976HQ	16243095				2022-12-28	WOS:000232724600029
J	Platon, A; Poletti, PA				Platon, A; Poletti, PA			Pulmonary sequestration	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Hosp Geneva, Geneva, Switzerland	University of Geneva	Platon, A (corresponding author), Univ Hosp Geneva, Geneva, Switzerland.								0	2	4	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					E18	E18		10.1056/NEJMicm041010	http://dx.doi.org/10.1056/NEJMicm041010			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291977				2022-12-28	WOS:000233288600011
J	Adam, T; Lim, SS; Mehta, S; Bhutta, ZA; Fogstad, H; Mathai, M; Zupan, J; Darmstadt, GL				Adam, T; Lim, SS; Mehta, S; Bhutta, ZA; Fogstad, H; Mathai, M; Zupan, J; Darmstadt, GL			Achieving the millennium development goals for health - Cost effectiveness analysis of strategies for. maternal and neonatal health in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							EFFECTIVE INTERVENTIONS; IMPROVING HEALTH	Objective To determine the costs and benefits of interventions for maternal and newborn health to assess the appropriateness of current strategies and guide future plans to attain the millennium development goals. Design Cost effectiveness analysis. Setting Two regions classified by the World Health Organization according to their epidemiological grouping: Afr-E, those countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, comprising countries in South East Asia with high adult and high child mortality. Data sources Effectiveness data from several sources, including trials, observational studies, and expert opinion. For resource inputs, quantifies came from WHO guidelines, literature, and expert opinion, and prices from the WHO choosing interventions that are cost effective database. Main outcome measures Cost per disability adjusted life year (DALY) averted in year 2000 international dollars. Results The most cost effective mix of interventions was similar in Afr-E and Sear-D. These were the community based newborn care package, followed by antenatal care (tetanus toxoid, screening for pre-eclampsia, screening and treatment of asymptomatic bacteriuria and syphilis); skilled attendance at birth, offering first level maternal and neonatal care around childbirth; and emergency obstetric and neonatal care around and after birth. Screening and treatment of maternal syphilis, community based management of neonatal pneumonia, and steroids given during the antenatal period were relatively less cost effective in Sear-D. Scaling up all of the included interventions to 95% coverage would halve neonatal and maternal deaths. Conclusion Preventive interventions at the community level for newborn babies and at the primary care level for mothers and newborn babies are extremely cost effective, but the millennium development goals for maternal and child health will not be achieved without universal access to clinical services as well.	Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia; WHO, Dept Making Pregnancy Safer, CH-1211 Geneva, Switzerland; Hlth Effects Inst, Boston, MA USA; Aga Khan Univ, Karachi, Pakistan; Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Int Hlth, Baltimore, MD USA	University of Queensland; World Health Organization; Health Effects Institute (HEI); Aga Khan University; Johns Hopkins University; Johns Hopkins Bloomberg School of Public Health	Lim, SS (corresponding author), Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia.	s.lim@sph.uq.edu.au	Darmstadt, Gary/AAU-7488-2020; Lim, Stephen S/B-4055-2012	Darmstadt, Gary/0000-0002-7522-5824				ALUER JA, 2003, COS EFF RESOUR ALLOC, V1; [Anonymous], 2022, BMJ, V378, DOI [DOI 10.1136/BMJ.38643.368692.68, 10.1136/bmj-2021-068384, DOI 10.1136/BMJ.O2284]; Baltussen R, 2004, J NUTR, V134, P2678, DOI 10.1093/jn/134.10.2678; BALTUSSEN R, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38645.660093.68; Darmstadt GL, 2005, LANCET, V365, P977, DOI 10.1016/S0140-6736(05)71088-6; Department of Reproductive Health and Research World Health Organization, 2004, MAT MORT 2000 EST DE; EDEJER TTT, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38652.550278.7C; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; EVANS DB, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38658.675243.94; Griffiths UK, 2004, B WORLD HEALTH ORGAN, V82, P643; Horton S, 1996, HEALTH POLICY PLANN, V11, P156, DOI 10.1093/heapol/11.2.156; Kulier R, 2004, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002855.PUB3; Lawn JE, 2005, LANCET, V365, P891, DOI 10.1016/S0140-6736(05)71048-5; MOREL C, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38639.702384.AE; NAKHAEE N, 2002, E MEDITERR HLTH J, V8, P53; Nanda G., 2005, ACCELERATING PROGR A; Stevens TP, 2004, COCHRANE DB SYST REV, V3; Terris-Prestholt F, 2003, SEX TRANSM INFECT, V79, P375, DOI 10.1136/sti.79.5.375; WHO UNICEF UNFPA, 2003, PREGN CHILDB POSTP N; World Health Organization, 2002, WHORHR0130; World Health Organization, 2003, WHORHR007; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization, 2003, MAN NEWB PROBL GUID	24	215	221	1	23	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1107	1110		10.1136/bmj.331.7525.1107	http://dx.doi.org/10.1136/bmj.331.7525.1107			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	985ZI	16282407	Green Published, Bronze			2022-12-28	WOS:000233417300012
J	Greenman, RL; Panasyuk, S; Wang, X; Lyons, TE; Dinh, T; Longoria, L; Giurini, JM; Freeman, J; Khaodhiar, L; Veves, A				Greenman, RL; Panasyuk, S; Wang, X; Lyons, TE; Dinh, T; Longoria, L; Giurini, JM; Freeman, J; Khaodhiar, L; Veves, A			Early changes in the skin microcirculation and muscle metabolism of the diabetic foot	LANCET			English	Article							MAGNETIC-RESONANCE-SPECTROSCOPY; NEUROPATHIC FOOT; SKELETAL-MUSCLE; OXYGENATION; QUANTIFICATION; RISK; H-1	Background Changes in the large vessels and microcirculation of the diabetic foot are important in the development of foot ulceration and subsequent failure to heal existing ulcers. We investigated whether oxygen delivery and muscle metabolism of the lower extremity were factors in diabetic foot disease. Methods We studied 108 patients (21 control individuals who did not have diabetes, 36 patients with diabetes who did not have neuropathy, and 51 patients with both diabetes and neuropathy). We used medical hyperspectral imaging (MHSI) to investigate the haemoglobin saturation (SHSIO2; % of oxyhaemoglobin in total haemoglobin [the sum of oxyhaemoglobin and deoxyhaemoglobin]) in the forearm and foot; we also used P-31-MRI scans to study the cellular metabolism of the foot muscles by measuring the concentrations of inorganic phosphate and phosphocreatine and calculating the ratio of inorganic phosphate to phosphocreatine (Pi/PCr). Findings The forearm SHSIO2 during resting was different in all three groups, with the highest value in controls (mean 42 [SD 17]), followed by the non-neuropathic (32 [8]) and neuropathic (28 [8]) groups (p<0.0001). In the foot at resting, SHSIO2 was higher in the control (38 [22]) and non-neuropathic groups (37 [12]) than in the neuropathic group (30 [12]; p=0.027). The Pi/PCr ratio was higher in the non-neuropathic (0.41 [0.10]) and neuropathic groups (0.58 [0.26]) than in controls (0.20 [0.06]; p<0.0001). Interpretation Our results indicate that tissue SHSIO2 is reduced in the skin of patients with diabetes, and that this impairment is accentuated in the presence of neuropathy in the diabetic foot. Additionally, energy reserves of the foot muscles are reduced in the presence of diabetes, suggesting that microcirculation could be a major reason for this difference.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Microcirculat Lab, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Radiol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Joslin Beth Israel Deaconess Foot Ctr, Boston, MA 02215 USA; HyperMed Inc, Watertown, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Joslin Diabetes Center, Inc.	Veves, A (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Microcirculat Lab, Palmer 321A,West Campus,1 Deaconess Rd, Boston, MA 02215 USA.	aveves@bidmc.harvard.edu		Khaodhiar, Lalita/0000-0002-3899-9847	NCRR NIH HHS [RR 01032] Funding Source: Medline; NHLBI NIH HHS [R01 HL0 75678-01] Funding Source: Medline; NIDDK NIH HHS [R41 DK69871, R21 DK58651] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL075678] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R21DK058651, R41DK069871] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		[Anonymous], 1988, DIABETES, V37, P1000; Arora S, 1998, DIABETES CARE, V21, P1339, DOI 10.2337/diacare.21.8.1339; BOSKA M, 1991, NMR BIOMED, V4, P173, DOI 10.1002/nbm.1940040404; BOULTON AJM, 1982, DIABETOLOGIA, V22, P6, DOI 10.1007/BF00253861; Caballero AE, 1999, DIABETES, V48, P1856, DOI 10.2337/diabetes.48.9.1856; Colarusso P, 1998, APPL SPECTROSC, V52, p106A, DOI 10.1366/0003702981943545; DYCK PJ, 1989, NEUROLOGY, V39, P111, DOI 10.1212/WNL.39.1.111; Economides PA, 2004, METABOLISM, V53, P222, DOI 10.1016/j.metabol.2003.09.019; Epstein FH, 2002, DIABETES CARE, V25, P575, DOI 10.2337/diacare.25.3.575; Gavin JR, 1997, DIABETES CARE, V20, P1183; Gillies Robert, 2003, Diabetes Technol Ther, V5, P847, DOI 10.1089/152091503322527058; Greenman RL, 2005, J MAGN RESON IMAGING, V22, P427, DOI 10.1002/jmri.20372; Greenman RL, 2005, DIABETES CARE, V28, P1425, DOI 10.2337/diacare.28.6.1425; Greenman RL, 2004, MAGN RESON MED, V52, P1036, DOI 10.1002/mrm.20258; Greenman RL, 2002, J MAGN RESON IMAGING, V15, P467, DOI 10.1002/jmri.10081; Hamdy O, 2001, DIABETES CARE, V24, P344, DOI 10.2337/diacare.24.2.344; Ibrahim S, 1999, DIABETOLOGIA, V42, P737, DOI 10.1007/s001250051222; MORRIS SJ, 1995, DIABETOLOGIA, V38, P1337, DOI 10.1007/BF00401767; Pham H, 2000, DIABETES CARE, V23, P606, DOI 10.2337/diacare.23.5.606; Prasad PV, 1996, CIRCULATION, V94, P3271, DOI 10.1161/01.CIR.94.12.3271; RAYMAN G, 1986, BRIT MED J, V292, P1295, DOI 10.1136/bmj.292.6531.1295; Schunk K, 1999, INVEST RADIOL, V34, P116, DOI 10.1097/00004424-199902000-00004; Smith DG, 1999, FOOT ANKLE INT, V20, P258, DOI 10.1177/107110079902000409; Suzuki E, 2000, DIABETOLOGIA, V43, P165, DOI 10.1007/s001250050025; TESFAYE S, 1994, DIABETOLOGIA, V37, P847, DOI 10.1007/BF00400938; Veves A, 1998, DIABETES, V47, P457, DOI 10.2337/diabetes.47.3.457; WIENER DH, 1986, J AM COLL CARDIOL, V7, P793, DOI 10.1016/S0735-1097(86)80338-2; ZATINA MA, 1986, J VASC SURG, V3, P411; Zimny S, 2001, DIABETES CARE, V24, P1810, DOI 10.2337/diacare.24.10.1810	29	147	160	1	33	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1711	1717		10.1016/S0140-6736(05)67696-9	http://dx.doi.org/10.1016/S0140-6736(05)67696-9			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291064				2022-12-28	WOS:000233206400026
J	Sullivan, F; Wyatt, JC				Sullivan, F; Wyatt, JC			ABC of health informatics - Referral or follow-up?	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Sullivan, F (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Wyatt, Jeremy/F-8160-2010; Sullivan, Frank m/A-7767-2009; Sullivan, Frank/L-8286-2019	Wyatt, Jeremy/0000-0001-7008-1473; Sullivan, Frank/0000-0002-6623-4964				Hunt DL, 1998, JAMA-J AM MED ASSOC, V280, P1339, DOI 10.1001/jama.280.15.1339; *NHS CONF, GEN MED SERV CONTR N; Perlin JB, 2004, AM J MANAG CARE, V10, P828; Sullivan FM, 1996, LANCET, V348, P941, DOI 10.1016/S0140-6736(96)05219-1; Wagner E H, 1998, Eff Clin Pract, V1, P2; WILLIAMS GJ, 2001, COCHRANE DB SYST REV, V4	6	1	1	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 5	2005	331	7524					1072	1074		10.1136/bmj.331.7524.1072	http://dx.doi.org/10.1136/bmj.331.7524.1072			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983DL	16269496	Green Published			2022-12-28	WOS:000233211200033
J	Hung, CP; Kreiman, G; Poggio, T; DiCarlo, JJ				Hung, CP; Kreiman, G; Poggio, T; DiCarlo, JJ			Fast readout of object identity from macaque inferior temporal cortex	SCIENCE			English	Article							SINGLE NEURONS; REPRESENTATION; CATEGORIZATION; RECOGNITION; RESPONSES; IMAGES; FACE	Understanding the brain computations leading to object recognition requires quantitative characterization of the information represented in inferior temporal (IT) cortex. We used a biologically plausible, classifier-based readout technique to investigate the neural coding of selectivity and invariance at the IT population level. The activity of small neuronal populations (similar to 100 randomly selected cells) over very short time intervals (as small as 12.5 milliseconds) contained unexpectedly accurate and robust information about both object "identity" and "category." This information generalized over a range of object positions and scales, even for novel objects. Coarse information about position and scale could also be read out from the same population.	MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA; MIT, Ctr Biol & Computat Learning, Cambridge, MA 02139 USA; MIT, CSBI, Cambridge, MA 02139 USA; MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Hung, CP (corresponding author), MIT, McGovern Inst Brain Res, 77 Massachusetts Ave, Cambridge, MA 02139 USA.	chouhung@mit.edu						ABBOTT LF, 1994, Q REV BIOPHYS, V27, P291, DOI 10.1017/S0033583500003024; Abbott LF, 1996, CEREB CORTEX, V6, P498, DOI 10.1093/cercor/6.3.498; Aggelopoulos NC, 2005, J NEUROPHYSIOL, V93, P1342, DOI 10.1152/jn.00553.2004; Brincat SL, 2004, NAT NEUROSCI, V7, P880, DOI 10.1038/nn1278; deCharms RC, 2000, ANNU REV NEUROSCI, V23, P613, DOI 10.1146/annurev.neuro.23.1.613; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Fabre-Thorpe M, 1998, NEUROREPORT, V9, P303, DOI 10.1097/00001756-199801260-00023; Freedman DJ, 2001, SCIENCE, V291, P312, DOI 10.1126/science.291.5502.312; GOCHIN PM, 1994, J NEUROPHYSIOL, V71, P2325, DOI 10.1152/jn.1994.71.6.2325; Ishai A, 1999, P NATL ACAD SCI USA, V96, P9379, DOI 10.1073/pnas.96.16.9379; ITO M, 1995, J NEUROPHYSIOL, V73, P218, DOI 10.1152/jn.1995.73.1.218; Keysers C, 2001, J COGNITIVE NEUROSCI, V13, P90, DOI 10.1162/089892901564199; Koch Christof, 1999, P1; LOGOTHETIS NK, 1995, CURR BIOL, V5, P552, DOI 10.1016/S0960-9822(95)00108-4; Logothetis NK, 1996, ANNU REV NEUROSCI, V19, P577, DOI 10.1146/annurev.ne.19.030196.003045; PERRETT DI, 1992, PHILOS T ROY SOC B, V335, P23, DOI 10.1098/rstb.1992.0003; Poggio T, 2004, NATURE, V431, P768, DOI 10.1038/nature03014; Poggio Tomaso, 2003, NOTICES AM MATH SOC, V50, P537; Pouget A, 2003, ANNU REV NEUROSCI, V26, P381, DOI 10.1146/annurev.neuro.26.041002.131112; Quiroga RQ, 2005, NATURE, V435, P1102, DOI 10.1038/nature03687; RICHMOND BJ, 1983, J NEUROPHYSIOL, V50, P1415, DOI 10.1152/jn.1983.50.6.1415; Riesenhuber M, 1999, NAT NEUROSCI, V2, P1019, DOI 10.1038/14819; Rolls E T, 1991, Curr Opin Neurobiol, V1, P274, DOI 10.1016/0959-4388(91)90090-T; Shenoy KV, 2003, NEUROREPORT, V14, P591, DOI 10.1097/00001756-200303240-00013; Sugase Y, 1999, NATURE, V400, P869, DOI 10.1038/23703; Tanaka K, 1996, ANNU REV NEUROSCI, V19, P109, DOI 10.1146/annurev.ne.19.030196.000545; Tjan BS, 2001, ADV NEUR IN, V13, P66; TOLIAS AS, 2002, SOC NEUR ABSTR; Tomita H, 1999, NATURE, V401, P699, DOI 10.1038/44372; VanRullen R, 2002, VISION RES, V42, P2593, DOI 10.1016/S0042-6989(02)00298-5; Vogels R, 1999, EUR J NEUROSCI, V11, P1239, DOI 10.1046/j.1460-9568.1999.00531.x; Wallis G, 1997, PROG NEUROBIOL, V51, P167, DOI 10.1016/S0301-0082(96)00054-8; YOUNG MP, 1992, SCIENCE, V256, P1327, DOI 10.1126/science.1598577	34	534	540	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					863	866		10.1126/science.1117593	http://dx.doi.org/10.1126/science.1117593			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272124	Green Submitted			2022-12-28	WOS:000233121800048
J	Church, JA; White, NJ; Arblaster, JM				Church, JA; White, NJ; Arblaster, JM			Significant decadal-scale impact of volcanic eruptions on sea level and ocean heat content	NATURE			English	Article							20TH-CENTURY TEMPERATURE; CLIMATE SIMULATIONS; RISE	Ocean thermal expansion contributes significantly to sea-level variability and rise(1). However, observed decadal variability in ocean heat content(2,3) and sea level(4) has not been reproduced well in climate models(5). Aerosols injected into the stratosphere during volcanic eruptions scatter incoming solar radiation, and cause a rapid cooling of the atmosphere(6,7) and a reduction in rainfall(6,8,9,) as well as other changes in the climate system(7). Here we use observations of ocean heat content(2,3) and a set of climate simulations to show that large volcanic eruptions result in rapid reductions in ocean heat content and global mean sea level. For the Mt Pinatubo eruption, we estimate a reduction in ocean heat content of about 3 x 10(22) J and a global sea-level fall of about 5 mm. Over the three years following such an eruption, we estimate a decrease in evaporation of up to 0.1 mm d(-1), comparable to observed changes in mean land precipitation(6,8,9). The recovery of sea level following the Mt Pinatubo eruption in 1991 explains about half of the difference between the long-termrate of sea-level rise(4) of 1.8 mm yr(-1) ( for 1950 - 2000), and the higher rate estimated for the more recent period where satellite altimeter data are available (1993 - 2000)(4,10).	CSIRO Marine & Atmospher Res, Hobart, Tas 7001, Australia; Antarctic Climate & Ecosyst Cooperat Res Ctr, Hobart, Tas 7001, Australia; Natl Ctr Atmospher Res, Boulder, CO 80307 USA; Bur Meteorol Res Ctr, Melbourne, Vic 3001, Australia	Commonwealth Scientific & Industrial Research Organisation (CSIRO); Antarctic Climate & Ecosystems Cooperative Research Centre (ACE CRC); National Center Atmospheric Research (NCAR) - USA; Bureau of Meteorology - Australia	Church, JA (corresponding author), CSIRO Marine & Atmospher Res, GPO Box 1538, Hobart, Tas 7001, Australia.	John.Church@csiro.au	Arblaster, Julie/C-1342-2010; White, Neil/B-2077-2013; Church, John A/A-1541-2012	Arblaster, Julie/0000-0002-4287-2363; Church, John A/0000-0002-7037-8194				Ammann CM, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2003GL016875; Arendt AA, 2002, SCIENCE, V297, P382, DOI 10.1126/science.1072497; Broccoli AJ, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2003JD003812; Church JA, 2001, CLIMATE CHANGE 2001: THE SCIENTIFIC BASIS, P639; Church JA, 2004, J CLIMATE, V17, P2609, DOI 10.1175/1520-0442(2004)017<2609:EOTRDO>2.0.CO;2; DELWORTH TL, UNPUB GEOPHYS RES LE; Gillett NP, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020876; Gregory JM, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020258; Gregory JM, 2001, CLIM DYNAM, V18, P225, DOI 10.1007/s003820100180; Hansen J, 2005, SCIENCE, V308, P1431, DOI 10.1126/science.1110252; Ishii M, 2003, MON WEATHER REV, V131, P51, DOI 10.1175/1520-0493(2003)131<0051:HOSTAW>2.0.CO;2; KRAYBILL W, 2004, GEOPHYS RES LETT, V31, P24402, DOI DOI 10.1029/2004GL021533; Lambert FH, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL019545; Leuliette EW, 2004, MAR GEOD, V27, P79, DOI 10.1080/01490410490465193; Levitus S, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2004GL021592; Meehl GA, 2004, J CLIMATE, V17, P3721, DOI 10.1175/1520-0442(2004)017<3721:CONAAF>2.0.CO;2; MINNIS P, 1993, SCIENCE, V259, P1411, DOI 10.1126/science.259.5100.1411; NOZAWA T, IN PRESS GEOPHYS RES; Rayner NA, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002670; Rignot E, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2004GL020697; Rignot E, 2003, SCIENCE, V302, P434, DOI 10.1126/science.1087393; ROBOCK A, 1994, J CLIMATE, V7, P44, DOI 10.1175/1520-0442(1994)007<0044:TVSIGI>2.0.CO;2; Robock A, 2000, REV GEOPHYS, V38, P191, DOI 10.1029/1998RG000054; SATO M, 1993, J GEOPHYS RES-ATMOS, V98, P22987, DOI 10.1029/93JD02553; Stott PA, 2000, SCIENCE, V290, P2133, DOI 10.1126/science.290.5499.2133; Sun S, 2003, J CLIMATE, V16, P2807, DOI 10.1175/1520-0442(2003)016<2807:CSFWAC>2.0.CO;2; Thomas R, 2004, SCIENCE, V306, P255, DOI 10.1126/science.1099650; Washington WM, 2000, CLIM DYNAM, V16, P755, DOI 10.1007/s003820000079	28	166	172	0	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					74	77		10.1038/nature04237	http://dx.doi.org/10.1038/nature04237			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267551				2022-12-28	WOS:000232979000043
J	LaCount, DJ; Vignali, M; Chettier, R; Phansalkar, A; Bell, R; Hesselberth, JR; Schoenfeld, LW; Ota, I; Sahasrabudhe, S; Kurschner, C; Fields, S; Hughes, RE				LaCount, DJ; Vignali, M; Chettier, R; Phansalkar, A; Bell, R; Hesselberth, JR; Schoenfeld, LW; Ota, I; Sahasrabudhe, S; Kurschner, C; Fields, S; Hughes, RE			A protein interaction network of the malaria parasite Plasmodium falciparum	NATURE			English	Article							YEAST; GENOMICS; ACETYLTRANSFERASE; EXPRESSION; VIRULENCE; BIOLOGY; MAP	Plasmodium falciparum causes the most severe form of malaria and kills up to 2.7 million people annually(1). Despite the global importance of P. falciparum, the vast majority of its proteins have not been characterized experimentally. Here we identify P. falciparum protein - protein interactions using a high-throughput version of the yeast two-hybrid assay that circumvents the difficulties in expressing P. falciparum proteins in Saccharomyces cerevisiae. From more than 32,000 yeast two-hybrid screens with P. falciparum protein fragments, we identified 2,846 unique interactions, most of which include at least one previously uncharacterized protein. Informatic analyses of network connectivity, coexpression of the genes encoding interacting fragments, and enrichment of specific protein domains or Gene Ontology annotations(2) were used to identify groups of interacting proteins, including one implicated in chromatin modification, transcription, messenger RNA stability and ubiquitination, and another implicated in the invasion of host cells. These data constitute the first extensive description of the protein interaction network for this important human pathogen.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA; Prolexys Pharmaceut Inc, Salt Lake City, UT 84111 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Fields, S (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357730, Seattle, WA 98195 USA.	fields@u.washington.edu; rhughes@buckinstitute.org		Hesselberth, Jay/0000-0002-6299-179X; Vignali, Marissa/0000-0002-7319-3371				Aravind L, 2003, CELL, V115, P771, DOI 10.1016/S0092-8674(03)01023-7; Ashburner M, 2000, NAT GENET, V25, P25, DOI 10.1038/75556; Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2; Barabasi AL, 2004, NAT REV GENET, V5, P101, DOI 10.1038/nrg1272; Bozdech Z, 2003, PLOS BIOL, V1, P85, DOI 10.1371/journal.pbio.0000005; Breman JG, 2001, AM J TROP MED HYG, V64, P1; Collart MA, 2003, GENE, V313, P1, DOI 10.1016/S0378-1119(03)00672-3; Cooke BM, 2004, TRENDS PARASITOL, V20, P581, DOI 10.1016/j.pt.2004.09.008; Coulson RMR, 2004, GENOME RES, V14, P1548, DOI 10.1101/gr.2218604; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Fan Q, 2004, EUKARYOT CELL, V3, P264, DOI 10.1128/EC.3.2.264-276.2004; Florens L, 2002, NATURE, V419, P520, DOI 10.1038/nature01107; Formstecher E, 2005, GENOME RES, V15, P376, DOI 10.1101/gr.2659105; Gardner MJ, 2002, NATURE, V419, P498, DOI 10.1038/nature01097; Ge H, 2003, TRENDS GENET, V19, P551, DOI 10.1016/j.tig.2003.08.009; Giot L, 2003, SCIENCE, V302, P1727, DOI 10.1126/science.1090289; Hiller NL, 2004, SCIENCE, V306, P1934, DOI 10.1126/science.1102737; Huynh KD, 1998, ONCOGENE, V17, P2473, DOI 10.1038/sj.onc.1202197; Iida T, 2004, MOL CELL BIOL, V24, P217, DOI 10.1128/MCB.24.1.217-227.2004; Kissinger JC, 2002, NATURE, V419, P490, DOI 10.1038/419490a; Le Roch KG, 2004, GENOME RES, V14, P2308, DOI 10.1101/gr.2523904; Le Roch KG, 2003, SCIENCE, V301, P1503, DOI 10.1126/science.1087025; Li L, 2003, GENOME RES, V13, P2178, DOI 10.1101/gr.1224503; Li SM, 2004, SCIENCE, V303, P540, DOI 10.1126/science.1091403; Li XR, 2004, J BIOL CHEM, V279, P5765, DOI 10.1074/jbc.M308716200; Marti M, 2004, SCIENCE, V306, P1930, DOI 10.1126/science.1102452; Ragvin A, 2004, J MOL BIOL, V337, P773, DOI 10.1016/j.jmb.2004.01.051; Rea S, 2000, NATURE, V406, P593, DOI 10.1038/35020506; Rives AW, 2003, P NATL ACAD SCI USA, V100, P1128, DOI 10.1073/pnas.0237338100; Sibley CH, 1997, METHODS, V13, P190, DOI 10.1006/meth.1997.0511	30	396	422	0	40	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					103	107		10.1038/nature04104	http://dx.doi.org/10.1038/nature04104			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267556				2022-12-28	WOS:000232979000050
J	Burls, A; Austin, D; Moore, D				Burls, A; Austin, D; Moore, D			Commissioning for rare diseases: view from the frontline	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Birmingham, Dept Epidemiol & Publ Hlth, W Midlands Hlth Technol Assessment Collaborat, Birmingham B15 2TT, W Midlands, England; W Midlands Specialised Serv Agcy, Birmingham B16 9RG, W Midlands, England	University of Birmingham	Burls, A (corresponding author), Univ Birmingham, Dept Epidemiol & Publ Hlth, W Midlands Hlth Technol Assessment Collaborat, Birmingham B15 2TT, W Midlands, England.	AJ.Burls@bham.ac.uk	Burls, Amanda J.E./D-7641-2011	Moore, David/0000-0002-4163-4080; Burls, Amanda/0000-0001-9540-622X				*AGGR RES INT FAC, 2004, REC HUM ALPH L ID TR; *AGGR RES INT FAC, 2004, REC HUM ALPH GAL TRE; *CAN COORD OFF HLT, 2005, LAR CEDAC FIN REC RE; CONNOCK MJ, IN PRESS HLTH TECHNO; *DEP HLTH, MECH FUND NSCAG; *DEP HLTH, 2003, GUID COMM RANG SPEC; *DEP HLTH, 2005, NATL SPEC COMM ADV G; McCabe C, 2005, BRIT MED J, V331, P1016, DOI 10.1136/bmj.331.7523.1016; MCIVER S, 2004, VIEWS PUBLIC FUNDING; *NAT SPEC COMM ADV, 2005, LYS STOR DIS NSCAGS; National Institute for Clinical Excellence, 2004, NICE CIT COUNC REP U; SHEEHAN MP, 2004, ENZYME REPLACEMENT T	12	31	31	0	4	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 29	2005	331	7523					1019	1021		10.1136/bmj.331.7523.1019	http://dx.doi.org/10.1136/bmj.331.7523.1019			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981AU	16254306	Green Published			2022-12-28	WOS:000233060200024
J	Chen, CZ				Chen, CZ			MicroRNAs as oncogenes and tumor suppressors	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							EXPRESSION		Stanford Univ, Sch Med,Inst Canc Stem Cell Biol & Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA	Stanford University	Chen, CZ (corresponding author), Stanford Univ, Sch Med,Inst Canc Stem Cell Biol & Med, Dept Microbiol & Immunol, Baxter Lab Genet Pharmacol, Stanford, CA 94305 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL081612] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL081612, R01 HL081612-02, R01 HL081612-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; O'Donnell KA, 2005, NATURE, V435, P839, DOI 10.1038/nature03677	3	636	707	0	33	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1768	1771		10.1056/NEJMp058190	http://dx.doi.org/10.1056/NEJMp058190			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251533				2022-12-28	WOS:000232813000004
J	Ju, TZ; Cummings, RD				Ju, TZ; Cummings, RD			Protein glycosylation - Chaperone mutation in Tn syndrome	NATURE			English	Editorial Material							BETA-1,3-GALACTOSYLTRANSFERASE		Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA; Univ Oklahoma, Hlth Sci Ctr, Oklahoma Ctr Med Glycobiol, Oklahoma City, OK 73104 USA	University of Oklahoma System; University of Oklahoma Health Sciences Center; University of Oklahoma System; University of Oklahoma Health Sciences Center	Ju, TZ (corresponding author), Univ Oklahoma, Hlth Sci Ctr, Dept Biochem & Mol Biol, Oklahoma City, OK 73104 USA.	richard-cummings@ouhsc.edu		Ju, Tongzhong/0000-0002-4429-1976				Berger EG, 1999, BBA-MOL BASIS DIS, V1455, P255, DOI 10.1016/S0925-4439(99)00069-1; CARTRON JP, 1979, NATURE, V282, P621, DOI 10.1038/282621a0; CARTRON JP, 1978, LANCET, V1, P856; Felner KM, 1998, BBA-MOL BASIS DIS, V1406, P115; Ju TZ, 2002, P NATL ACAD SCI USA, V99, P16613, DOI 10.1073/pnas.262438199; Ju TZ, 2002, J BIOL CHEM, V277, P178, DOI 10.1074/jbc.M109060200; Julian BA, 2004, CURR OPIN NEPHROL HY, V13, P171, DOI 10.1097/00041552-200403000-00005; MOREAU R, 1957, Bull Mem Soc Med Hop Paris, V73, P569; Xia LJ, 2004, J CELL BIOL, V164, P451, DOI 10.1083/jcb.200311112	9	196	217	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1252	1252		10.1038/4371252a	http://dx.doi.org/10.1038/4371252a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251947	Bronze			2022-12-28	WOS:000232829100033
J	Eddleston, M; Eyer, P; Worek, F; Mohamed, F; Senarathna, L; von Meyer, L; Juszczak, E; Hittarage, A; Azhar, S; Dissanayake, W; Sheriff, MHR; Szinicz, L; Dawson, AH; Buckley, NA				Eddleston, M; Eyer, P; Worek, F; Mohamed, F; Senarathna, L; von Meyer, L; Juszczak, E; Hittarage, A; Azhar, S; Dissanayake, W; Sheriff, MHR; Szinicz, L; Dawson, AH; Buckley, NA			Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study	LANCET			English	Article							DEVELOPING-WORLD; SRI-LANKA; PESTICIDE; MANAGEMENT	Background Although more than 100 organophosphorus insecticides exist, organophosphorus poisoning is usually regarded as a single entity, distinguished only by the compound's lethal dose in animals. We aimed to determine whether the three most common organophosphorus insecticides used for self-poisoning in Sri Lanka differ in the clinical features and severity of poisoning they cause. Methods We prospectively studied 802 patients with chlorpyrifos, dimethoate, or fenthion self-poisoning admitted to three hospitals. Blood cholinesterase activity and insecticide concentration were measured to determine the compound and the patients' response to insecticide and therapy. We recorded clinical outcomes for each patient. Findings Compared with chlorpyrifos (35 of 439, 8.0%), the proportion dying was significantly higher with dimethoate (61 of 264, 23.1%, odds ratio [OR] 3.5, 95% Cl 2.2-5.4) or fenthion (16 of 99, 16.2%, OR 2.2, 1.2-4.2), as was the proportion requiring endotracheal intubation (66 of 439 for chlorpyrifos, 15.0%; 93 of 264 for dimethoate, 3 5.2%, OR 3.11 2.1-4.4; 31 of 99 for fenthion, 31.3%, 2.6, 1.6-4-2). Dimethoate-poisoned patients died sooner than those ingesting other pesticides and often from hypotensive shock. Fenthion poisoning initially caused few symptoms but many patients subsequently required intubation. Acetylcholinesterase inhibited by fenthion or dimethoate responded poorly to pralidoxime treatment compared with chlorpyrifos-inhibited acetylcholinesterase. Interpretation Organophosphorus insecticide poisoning is not a single entity, with substantial variability in clinical course, response to oximes, and outcome. Animal toxicity does not predict human toxicity since, although chlorpyrifos is generally the most toxic in rats, it is least toxic in people. Each organophosphorus insecticide should be considered as an individual poison and, consequently, patients might benefit from management protocols developed for particular organophosphorus insecticides.	Univ Oxford, Ctr Trop Med, S Asian Clin Toxicol Res Collaborat, Oxford, England; Univ Colombo, Ox Col Collaborat, Dept Clin Med, Colombo, Sri Lanka; Univ Munich, Walther Straub Inst Pharmacol & Toxicol, Munich, Germany; Univ Munich, Inst Legal Med, Munich, Germany; Bundeswehr Inst Pharmacol & Toxicol, Munich, Germany; Univ Oxford, Wolfson Coll, Ctr Stat Med, Oxford, England; Anuradhapura Gen Hosp, Anuradhapura, N Cent Province, Sri Lanka; Polonnaruwa Gen Hosp, Polonnaruwa, N Cent Province, Sri Lanka; Univ Peradeniya, Dept Clin Med, Peradeniya, Sri Lanka; Canberra Clin Sch, Dept Clin Pharmacol & Toxicol, Canberra, ACT, Australia	University of Oxford; University of Colombo; University of Munich; University of Munich; University of Oxford; University of Peradeniya	Eddleston, M (corresponding author), Churchill Hosp, Ctr Clin Vaccinol & Trop Med, Old Rd, Oxford OX3 7LJ, England.	eddlestonm@eureka.lk	Buckley, Nicholas A/D-4030-2012; Dawson, Andrew H/U-8041-2019; Dawson, Andrew/D-5085-2012	Buckley, Nicholas A/0000-0002-6326-4711; Dawson, Andrew H/0000-0002-8047-397X; Dawson, Andrew/0000-0002-8047-397X; Senarathna, Lalith/0000-0002-7073-5788; Mohamed, Fahim/0000-0003-2849-7269; Worek, Franz/0000-0003-3531-3616	Wellcome Trust [063560] Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Altman D.G., 2000, STAT CONFIDENCE, Vsecond; Ballantyne B., 1992, CLIN EXPT TOXICOLOGY, P3; Benfenati E, 2003, CHEMOSPHERE, V53, P1155, DOI 10.1016/S0045-6535(03)00609-X; Bruyndonckx R B, 2002, Eur J Emerg Med, V9, P238, DOI 10.1097/00063110-200209000-00006; Buckley NA, 2004, J TOXICOL-CLIN TOXIC, V42, P113, DOI 10.1081/CLT-120028756; Caravati E, 2004, MED TOXICOLOGY, P1475; Dart RC, 2003, MED TOXICOLOGY; DESILVA HJ, 1992, LANCET, V339, P1136, DOI 10.1016/0140-6736(92)90733-J; Eddleston M, 2000, QJM-INT J MED, V93, P715, DOI 10.1093/qjmed/93.11.715; Eddleston M, 2004, CRIT CARE, V8, pR391, DOI 10.1186/cc2953; Eddleston M, 2002, QJM-INT J MED, V95, P275, DOI 10.1093/qjmed/95.5.275; Eddleston M, 2004, BMJ-BRIT MED J, V328, P42, DOI 10.1136/bmj.328.7430.42; Eddleston M, 2002, LANCET, V360, P1163, DOI 10.1016/S0140-6736(02)11204-9; EDDLESTON M, IN PRESS CLIN TOXICO; Eddleston Michael, 2005, Clin Evid, P1744; Eyer Florian, 2003, Toxicological Reviews, V22, P143, DOI 10.2165/00139709-200322030-00003; Eyer Peter, 2003, Toxicological Reviews, V22, P165, DOI 10.2165/00139709-200322030-00004; JEYARATNAM J, 1990, World Health Statistics Quarterly, V43, P139; Johnson MK., 2000, EMERGEN MED, V12, P22, DOI [DOI 10.1046/J.1442-2026.2000.00087.X, 10.1046/j.1442-2026.2000.00087.x]; Lotti M, 2001, HDB PESTICIDE TOXICO, V2, P1043, DOI DOI 10.1016/B978-012426260-7.50054-9; Occupational Safety & Health Administration, CHEM SAMPL INF; Peter JV, 2000, ANAESTH INTENS CARE, V28, P11, DOI 10.1177/0310057X0002800102; Peter JV., 2004, CRITICAL CARE UPDATE, P153; Roberts DM, 2003, B WORLD HEALTH ORGAN, V81, P789; Van der Hoek W, 1998, SOC SCI MED, V46, P495, DOI 10.1016/S0277-9536(97)00193-7; WADIA RS, 1977, INDIAN J MED RES, V66, P460; Worek F, 1999, CLIN CHIM ACTA, V288, P73, DOI 10.1016/S0009-8981(99)00144-8; World Health Organization (WHO), 2001, GUID DOC US DAT DEV; 2003, CROP PROTECTION HDB	29	242	250	0	34	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1452	1459		10.1016/S0140-6736(05)67598-8	http://dx.doi.org/10.1016/S0140-6736(05)67598-8			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243090				2022-12-28	WOS:000232724600024
J	Leonard, H; Davis, MR; Turbett, GR; Laing, NG; Bower, C; Ravine, D				Leonard, H; Davis, MR; Turbett, GR; Laing, NG; Bower, C; Ravine, D			Effectiveness of posthumous molecular diagnosis from a kept baby tooth	LANCET			English	Editorial Material							RETT-SYNDROME; DATABASE; MECP2; DNA		Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia; Royal Perth Hosp, Dept Anat Pathol, Neurogenet Lab, Perth, WA, Australia; Western Australian Ctr Pathol & Med Res, Forens Serv, Forens Biol Lab, Nedlands, WA, Australia; Univ Western Australia, Med Res Ctr, Western Australian Inst Med Res, Perth, WA 6009, Australia; Univ Western Australia, Sch Med & Pharmacol, Western Australian Inst Med Res, Perth, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; Royal Perth Hospital; University of Western Australia; University of Western Australia; University of Western Australia; University of Western Australia	Leonard, H (corresponding author), Univ Western Australia, Ctr Child Hlth Res, Telethon Inst Child Hlth Res, Perth, WA 6009, Australia.	hleonard@worra.ichr.uwa.edu.au	Ravine, David/A-6797-2008; Leonard, Helen/A-1010-2013	Leonard, Helen/0000-0001-6405-5834; TURBETT, Gavin/0000-0001-6522-6498; Laing, Nigel/0000-0001-5111-3732	NICHD NIH HHS [1 R01HD43100-01A1] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD043100] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Christodoulou J, 2003, HUM MUTAT, V21, P466, DOI 10.1002/humu.10194; Colvin L, 2003, ARCH DIS CHILD, V88, P38, DOI 10.1136/adc.88.1.38; Moog UTE, 2003, EUR J PAEDIATR NEURO, V7, P5, DOI 10.1016/S1090-3798(02)00134-4; RESTAGNO G, 1995, PRENATAL DIAG, V15, P672, DOI 10.1002/pd.1970150715; WALSH PS, 1991, BIOTECHNIQUES, V10, P506, DOI 10.2144/000114018	5	3	3	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT-NOV	2005	366	9496					1584	1584		10.1016/S0140-6736(05)67631-3	http://dx.doi.org/10.1016/S0140-6736(05)67631-3			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257347				2022-12-28	WOS:000232984800029
J	Evans, DB; Lim, SS; Adam, T; Edejer, TTT				Evans, DB; Lim, SS; Adam, T; Edejer, TTT		WHO CHOICE Millennium Dev Goals Te	Achieving the millennium development goals for health - Evaluation of current strategies and future priorities for improving health in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia	University of Queensland	Evans, DB (corresponding author), WHO, CH-1211 Geneva, Switzerland.	evansd@who.int	Lim, Stephen S/B-4055-2012; Salomon, Joshua A/D-3898-2009	Salomon, Joshua A/0000-0003-3929-5515; Edejer, Tessa/0000-0003-1068-332X				Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; [Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 2022, BMJ, V378, DOI [DOI 10.1136/BMJ.38643.368692.68, 10.1136/bmj-2021-068384, DOI 10.1136/BMJ.O2284]; Baltussen R., 2003, GEN COST EFFECTIVENE; BALTUSSEN R, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38645.660093.68; BROCK DW, 2003, HLTH CARE SOCIAL JUS; EDEJER TTT, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38652.550278.7C; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; EVANS DB, 2004, GLOBAL CRISES GLOBAL, P115; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Kim JY, 2005, SOC SCI MED, V61, P847, DOI 10.1016/j.socscimed.2004.08.046; Lauer Jeremy A, 2003, Cost Eff Resour Alloc, V1, P6, DOI 10.1186/1478-7547-1-6; MOREL C, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38639.702384.AE; Nanda G., 2005, ACCELERATING PROGR A	16	43	43	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 17	2005	331	7530					1457	1461		10.1136/bmj.38658.675243.94	http://dx.doi.org/10.1136/bmj.38658.675243.94			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	996EE	16282377	Green Published			2022-12-28	WOS:000234156400028
J	Pasare, C; Medzhitov, R				Pasare, C; Medzhitov, R			Control of B-cell responses by Toll-like receptors	NATURE			English	Article							GERMINAL CENTER FORMATION; T-CELL; IMMUNE-RESPONSES; PLASMA-CELLS; BLIMP-1; LYMPHOCYTES; ACTIVATION; EXPRESSION; DIFFERENTIATION; MEMORY	Toll-like receptors (TLRs) detect microbial infection and have an essential role in the induction of immune responses(1-3). TLRs can directly induce innate host defence responses, but the mechanisms of TLR-mediated control of adaptive immunity are not fully understood. Although TLR-induced dendritic cell maturation is required for activation of T-helper (T-H) cells(4), the role of TLRs in B-cell activation and antibody production in vivo is not yet known. Here we show that activation and differentiation of TH cells is not sufficient for the induction of T-dependent B-cell responses. We find that, in addition to CD4(+) T-cell help, generation of T-dependent antigen-specific antibody responses requires activation of TLRs in B cells.	Yale Univ, Sch Med, Howard Hughes Med Inst, New Haven, CT 06510 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA	Howard Hughes Medical Institute; Yale University; Yale University	Medzhitov, R (corresponding author), Yale Univ, Sch Med, Howard Hughes Med Inst, 300 Cedar St, New Haven, CT 06510 USA.	ruslan.medzhitov@yale.edu	Eckhardt, Erik/G-1567-2010					Angelin-Duclos C, 2000, J IMMUNOL, V165, P5462, DOI 10.4049/jimmunol.165.10.5462; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barton GM, 2002, CURR OPIN IMMUNOL, V14, P380, DOI 10.1016/S0952-7915(02)00343-6; Bernasconi NL, 2002, SCIENCE, V298, P2199, DOI 10.1126/science.1076071; Bondada S, 2000, VACCINE, V19, P557, DOI 10.1016/S0264-410X(00)00161-4; Dent AL, 1997, SCIENCE, V276, P589, DOI 10.1126/science.276.5312.589; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; GOODNOW CC, 1988, NATURE, V334, P676, DOI 10.1038/334676a0; Hayashi F, 2001, NATURE, V410, P1099, DOI 10.1038/35074106; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Kawai T, 1999, IMMUNITY, V11, P115, DOI 10.1016/S1074-7613(00)80086-2; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; LASZLO G, 1993, J IMMUNOL, V150, P5252; Leadbetter EA, 2002, NATURE, V416, P603, DOI 10.1038/416603a; McHeyzer-Williams LJ, 2005, ANNU REV IMMUNOL, V23, P487, DOI 10.1146/annurev.immunol.23.021704.115732; MOLLER G, 1972, CELL IMMUNOL, V4, P416, DOI 10.1016/0008-8749(72)90043-3; Pasare C, 2004, IMMUNITY, V21, P733, DOI 10.1016/j.immuni.2004.10.006; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; Rui LX, 2003, NAT IMMUNOL, V4, P594, DOI 10.1038/ni924; Schliephake DE, 1996, EUR J IMMUNOL, V26, P268, DOI 10.1002/eji.1830260142; Schnare M, 2001, NAT IMMUNOL, V2, P947, DOI 10.1038/ni712; Shaffer AL, 2000, IMMUNITY, V13, P199, DOI 10.1016/S1074-7613(00)00020-0; Shaffer AL, 2002, IMMUNITY, V17, P51, DOI 10.1016/S1074-7613(02)00335-7; Shapiro-Shelef M, 2003, IMMUNITY, V19, P607, DOI 10.1016/S1074-7613(03)00267-X; Soro PG, 1999, J IMMUNOL, V163, P611; Takeda K, 2003, ANNU REV IMMUNOL, V21, P335, DOI 10.1146/annurev.immunol.21.120601.141126; TURNER CA, 1994, CELL, V77, P297, DOI 10.1016/0092-8674(94)90321-2; Vos Q, 2000, IMMUNOL REV, V176, P154	30	580	602	1	37	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					364	368		10.1038/nature04267	http://dx.doi.org/10.1038/nature04267			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292312				2022-12-28	WOS:000233300200050
J	Haumann, M; Liebisch, P; Muller, C; Barra, M; Grabolle, M; Dau, H				Haumann, M; Liebisch, P; Muller, C; Barra, M; Grabolle, M; Dau, H			Photosynthetic O-2 formation tracked by time-resolved X-ray experiments	SCIENCE			English	Article							BIOLOGICAL METAL CENTERS; II-MANGANESE COMPLEX; PHOTOSYSTEM-II; WATER OXIDATION; ABSORPTION SPECTROSCOPY; ROOM-TEMPERATURE; ELECTRONIC-STRUCTURE; CRYSTAL-STRUCTURE; PROTON RELEASE; OXYGEN	Plants and cyanobacteria produce atmospheric dioxygen from water, powered by sunlight and catalyzed by a manganese complex in photosystem II. A classic S-cycle model for oxygen evolution involves five states, but only four have been identified. The missing S-4 state is particularly important because it is directly involved in dioxygen formation. Now progress comes from an x-ray technique that can monitor redox and structural changes in metal centers in real time with 10-microsecond resolution. We show that in the O-2-formation step, an intermediate is formed-the enigmatic S-4 state. Its creation is identified with a deprotonation process rather than the expected electron-transfer mechanism. Subsequent electron transfer would give an additional S-4' state, thus extending the fundamental S-state cycle of dioxygen formation.	Free Univ Berlin, FB Phys, D-14195 Berlin, Germany	Free University of Berlin	Haumann, M (corresponding author), Free Univ Berlin, FB Phys, Arnimallee 14, D-14195 Berlin, Germany.	haumann@physik.fu-berlin.de; holger.dau@physik.fu-berlin.de	MIchael, Haumann/A-7087-2013	Dau, Holger/0000-0001-6482-7494				Ahlbrink R, 1998, BIOCHEMISTRY-US, V37, P1131, DOI 10.1021/bi9719152; BABCOCK GT, 1976, FEBS LETT, V61, P286; Barber J, 2004, BBA-BIOENERGETICS, V1655, P123, DOI 10.1016/j.bbabio.2003.10.011; Clausen J, 2004, NATURE, V430, P480, DOI 10.1038/nature02676; Dau H, 2005, PHOTOSYNTH RES, V84, P325, DOI 10.1007/s11120-004-7080-2; Dau H, 2003, ANAL BIOANAL CHEM, V376, P562, DOI 10.1007/s00216-003-1982-2; Ferreira KN, 2004, SCIENCE, V303, P1831, DOI 10.1126/science.1093087; Haumann M, 2005, BIOCHEMISTRY-US, V44, P1894, DOI 10.1021/bi048697e; Haumann M, 2005, J SYNCHROTRON RADIAT, V12, P35, DOI 10.1107/S0909049504027803; Haumann M, 2002, FEBS LETT, V512, P116, DOI 10.1016/S0014-5793(02)02237-8; HAUMANN M, 1994, BIOCHEMISTRY-US, V33, P864, DOI 10.1021/bi00170a003; Hays AMA, 1999, BIOCHEMISTRY-US, V38, P11851, DOI 10.1021/bi990716a; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; JOLIOT P, 1968, BIOCHIM BIOPHYS ACTA, V153, P625, DOI 10.1016/0005-2728(68)90190-4; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; Kleifeld O, 2003, NAT STRUCT BIOL, V10, P98, DOI 10.1038/nsb889; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; LAVERGNE J, 1993, PHOTOSYNTH RES, V38, P279, DOI 10.1007/BF00046752; Mamedov F, 1998, BIOCHEMISTRY-US, V37, P14245, DOI 10.1021/bi980194j; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; McEvoy JP, 2004, PHYS CHEM CHEM PHYS, V6, P4754, DOI 10.1039/b407500e; Meinke C, 2000, BIOCHEMISTRY-US, V39, P7033, DOI 10.1021/bi9924258; ONO T, 1992, SCIENCE, V258, P1335, DOI 10.1126/science.258.5086.1335; Penner-Hahn JE, 2003, NAT STRUCT BIOL, V10, P75, DOI 10.1038/nsb0203-75; RAPPAPORT F, 1994, BBA-BIOENERGETICS, V1184, P178, DOI 10.1016/0005-2728(94)90222-4; Razeghifard MR, 1997, BIOCHEMISTRY-US, V36, P86, DOI 10.1021/bi9614287; Rutherford AW, 2001, TRENDS BIOCHEM SCI, V26, P341, DOI 10.1016/S0968-0004(01)01874-6; YACHANDRA VK, 1995, METHOD ENZYMOL, V246, P638; Zouni A, 2001, NATURE, V409, P739, DOI 10.1038/35055589; 2001, BIOCH BIOPHYS ACTA, V1503	30	377	383	3	136	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1019	1021		10.1126/science.1117551	http://dx.doi.org/10.1126/science.1117551			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284178				2022-12-28	WOS:000233343400044
J	He, MM; Smith, AS; Oslob, JD; Flanagan, WM; Braisted, AC; Whitty, A; Cancilla, MT; Wang, J; Lugovskoy, AA; Yoburn, JC; Fung, AD; Farrington, G; Eldredge, JK; Day, ES; Cruz, LA; Cachero, TG; Miller, SK; Friedman, JE; Choong, IC; Cunningham, BC				He, MM; Smith, AS; Oslob, JD; Flanagan, WM; Braisted, AC; Whitty, A; Cancilla, MT; Wang, J; Lugovskoy, AA; Yoburn, JC; Fung, AD; Farrington, G; Eldredge, JK; Day, ES; Cruz, LA; Cachero, TG; Miller, SK; Friedman, JE; Choong, IC; Cunningham, BC			Small-molecule inhibition of TNF-alpha	SCIENCE			English	Article							NECROSIS-FACTOR-ALPHA; DIMERIZATION; DERIVATIVES; DISCOVERY; RECEPTOR	We have identified a small-molecule inhibitor of tumor necrosis factor a (TNF-alpha) that promotes subunit disassembly of this trimeric cytokine family member. The compound inhibits TNF-alpha activity in biochemical and cell-based assays with median inhibitory concentrations of 22 and 4.6 micromolar, respectively. Formation of an intermediate complex between the compound and the intact trimer results in a 600-fold accelerated subunit dissociation rate that leads to trimer dissociation. A structure solved by x-ray crystallography reveals that a single compound molecule displaces a subunit of the trimer to form a complex with a dimer of TNF-alpha subunits.	Sunesis Pharmaceut Inc, San Francisco, CA 94080 USA; CUNY Mt Sinai Sch Med, Kravis Childrens Hosp, New York, NY 10029 USA; Biogenldec, Dept Drug Discovery, Cambridge, MA 02142 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; Univ Calif San Francisco, Chem & Chem Biol Program, San Francisco, CA 94143 USA	City University of New York (CUNY) System; Icahn School of Medicine at Mount Sinai; Massachusetts Institute of Technology (MIT); University of California System; University of California San Francisco	Cunningham, BC (corresponding author), Sunesis Pharmaceut Inc, 341 Oyster Point Blvd, San Francisco, CA 94080 USA.	bcc@sunesis.com	Stroustrup, Annemarie/ABB-5846-2020; Day, Eric S/C-5020-2009	Stroustrup, Annemarie/0000-0002-5667-6195; 				Berg T, 2003, ANGEW CHEM INT EDIT, V42, P2462, DOI 10.1002/anie.200200558; Blasko E, 2002, J BIOL CHEM, V277, P295, DOI 10.1074/jbc.M105691200; Capps KJ, 2005, BIOORG MED CHEM LETT, V15, P2840, DOI 10.1016/j.bmcl.2005.03.094; Cheng JF, 2003, BIOORG MED CHEM LETT, V13, P3647, DOI 10.1016/j.bmcl.2003.08.025; Clark MP, 2004, J MED CHEM, V47, P2724, DOI 10.1021/jm049968m; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; CUNNINGHAM BC, 1991, SCIENCE, V254, P821, DOI 10.1126/science.1948064; DELANO WL, 2004, PRACTICAL APPROACH S, V266, P85; ECK MJ, 1989, J BIOL CHEM, V264, P17595; Jackson RW, 2003, BIOORG MED CHEM LETT, V13, P205, DOI 10.1016/S0960-894X(02)00877-6; Jackson RW, 2002, BIOORG MED CHEM LETT, V12, P1093, DOI 10.1016/S0960-894X(02)00098-7; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; Levin JI, 2001, BIOORG MED CHEM LETT, V11, P2189, DOI 10.1016/S0960-894X(01)00419-X; McMillan K, 2000, P NATL ACAD SCI USA, V97, P1506, DOI 10.1073/pnas.97.4.1506; Niwayama S, 1996, J MED CHEM, V39, P3044, DOI 10.1021/jm960284r; Niwayama S, 1998, BIOORG MED CHEM LETT, V8, P1071, DOI 10.1016/S0960-894X(98)00171-1; Palladino MA, 2003, NAT REV DRUG DISCOV, V2, P736, DOI 10.1038/nrd1175; SAMPAIO EP, 1991, J EXP MED, V173, P699, DOI 10.1084/jem.173.3.699; Toogood PL, 2002, J MED CHEM, V45, P1543, DOI 10.1021/jm010468s	19	344	393	3	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1022	1025		10.1126/science.1116304	http://dx.doi.org/10.1126/science.1116304			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	984YN	16284179				2022-12-28	WOS:000233343400045
J	Huang, CC; Tang, M; Zhang, MY; Majeed, S; Montabana, E; Stanfield, RL; Dimitrov, DS; Korber, B; Sodroski, J; Wilson, IA; Wyatt, R; Kwong, PD				Huang, CC; Tang, M; Zhang, MY; Majeed, S; Montabana, E; Stanfield, RL; Dimitrov, DS; Korber, B; Sodroski, J; Wilson, IA; Wyatt, R; Kwong, PD			Structure of a V3-containing HIV-1 gp120 core	SCIENCE			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ENVELOPE GLYCOPROTEIN; SOLUBLE CD4; V3 LOOP; CRYSTAL-STRUCTURE; TYPE-1; RECEPTOR; ANTIBODY; BINDING; NEUTRALIZATION	The third variable region (V3) of the HIV-1 gp120 envelope glycoprotein is immunodominant and contains features essential for coreceptor binding. We determined the structure of V3 in the context of an HIV-1 gp120 core complexed to the CD4 receptor and to the X5 antibody at 3.5 angstrom resolution. Binding of gp120 to cell-surface CD4 would position V3 so that its coreceptor-binding tip protrudes 30 angstroms from the core toward the target cell membrane. The extended nature and antibody accessibility of V3 explain its immunodominance. Together, the results provide a structural rationale for the role of V3 in HIV entry and neutralization.	NIAID, Vaccine Res Ctr, Bethesda, MD 20892 USA; SAIC Frederick, Basic Res Program, Frederick, MD USA; NCI, Prot Interact Grp, Ctr Canc Res, Nanobiol Program, Frederick, MD 21702 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA; Los Alamos Natl Lab, Los Alamos, NM 87545 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02115 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Scripps Research Institute; Scripps Research Institute; United States Department of Energy (DOE); Los Alamos National Laboratory; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	Wyatt, R (corresponding author), NIAID, Vaccine Res Ctr, Bethesda, MD 20892 USA.	richw@mail.nih.gov; pdkwong@nih.gov	Abrams, William R/A-5782-2008; Stanfield, Robyn/AAH-3190-2019	Korber, Bette/0000-0002-2026-5757	Intramural NIH HHS [Z99 AI999999] Funding Source: Medline; NIAID NIH HHS [AI24755, AI31783, AI40895, AI39429] Funding Source: Medline; NIGMS NIH HHS [GM46192] Funding Source: Medline; NATIONAL CANCER INSTITUTE [Z01BC010701] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [Z01AI005022, R01AI040895, R01AI031783, R37AI024755, Z01AI005050, R01AI024755] Funding Source: NIH RePORTER	Intramural NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Chen B, 2005, NATURE, V433, P834, DOI 10.1038/nature03327; Cormier EG, 2002, J VIROL, V76, P8953, DOI 10.1128/JVI.76.17.8953-8957.2002; Cormier EG, 2001, J VIROL, V75, P5541, DOI 10.1128/JVI.75.12.5541-5549.2001; DALGLEISH AG, 1984, NATURE, V312, P763, DOI 10.1038/312763a0; Darbha R, 2004, BIOCHEMISTRY-US, V43, P1410, DOI 10.1021/bi035323x; Feng Y, 1996, SCIENCE, V272, P872, DOI 10.1126/science.272.5263.872; Hartley O, 2005, AIDS RES HUM RETROV, V21, P171, DOI 10.1089/aid.2005.21.171; Huang CC, 2005, STRUCTURE, V13, P755, DOI 10.1016/j.str.2005.03.006; HWANG SS, 1991, SCIENCE, V253, P71, DOI 10.1126/science.1905842; JAVAHERIAN K, 1990, SCIENCE, V250, P1590, DOI 10.1126/science.1703322; Klco JM, 2005, NAT STRUCT MOL BIOL, V12, P320, DOI 10.1038/nsmb913; Koch M, 2003, VIROLOGY, V313, P387, DOI 10.1016/S0042-6822(03)00294-0; KUIKEN CL, 2002, SEQUENCE COMPENDIUM; Kwong PD, 2000, J VIROL, V74, P1961, DOI 10.1128/JVI.74.4.1961-1972.2000; Kwong PD, 1999, J BIOL CHEM, V274, P4115, DOI 10.1074/jbc.274.7.4115; Kwong PD, 2000, STRUCTURE, V8, P1329, DOI 10.1016/S0969-2126(00)00547-5; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LIN G, 2005, 12 C RETR OPP INF BO; Moulard M, 2002, P NATL ACAD SCI USA, V99, P6913, DOI 10.1073/pnas.102562599; Resch W, 2001, VIROLOGY, V288, P51, DOI 10.1006/viro.2001.1087; Rizzuto C, 2000, AIDS RES HUM RETROV, V16, P741, DOI 10.1089/088922200308747; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; RYU SE, 1990, NATURE, V348, P419, DOI 10.1038/348419a0; SATTENTAU QJ, 1991, J EXP MED, V174, P407, DOI 10.1084/jem.174.2.407; Stanfield RL, 2003, VIROLOGY, V315, P159, DOI 10.1016/S0042-6822(03)00525-7; Stevens RC, 2001, SCIENCE, V293, P519, DOI 10.1126/science.293.5529.519; Sullivan N, 1998, J VIROL, V72, P6332, DOI 10.1128/JVI.72.8.6332-6338.1998; Trkola A, 1996, NATURE, V384, P184, DOI 10.1038/384184a0; WANG JH, 1990, NATURE, V348, P411, DOI 10.1038/348411a0; Wei XP, 2003, NATURE, V422, P307, DOI 10.1038/nature01470; WERNER A, 1993, J VIROL, V67, P2566, DOI 10.1128/JVI.67.5.2566-2574.1993; Wu H, 1997, NATURE, V387, P527, DOI 10.1038/387527a0; Wu LJ, 1996, NATURE, V384, P179, DOI 10.1038/384179a0; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Wyatt R, 1998, SCIENCE, V280, P1884, DOI 10.1126/science.280.5371.1884	35	609	640	1	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1025	1028		10.1126/science.1118398	http://dx.doi.org/10.1126/science.1118398			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284180	Green Accepted			2022-12-28	WOS:000233343400046
J	Audi, J; Belson, M; Patel, M; Schier, J; Osterloh, J				Audi, J; Belson, M; Patel, M; Schier, J; Osterloh, J			Ricin poisoning - A comprehensive review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							TOXIC PROTEINS ABRIN; CASTOR BEAN DUST; ABRUS-PRECATORIUS; IMMUNOCYTOCHEMICAL DETECTION; DIPHTHERIA-TOXIN; LECTINS ABRIN; ORAL TOXICITY; PROTECTS MICE; A-CHAIN; INHALATION	Context The recent discoveries of ricin, a deadly biologic toxin, at a South Carolina postal facility, a White House mail facility, and a US senator's office has raised concerns among public health officials, physicians, and citizens. Ricin is one of the most potent and lethal substances known, particularly when inhaled. The ease with which the native plant (Ricinus communis) can be obtained and the toxin extracted makes ricin an attractive weapon. Objectives To summarize the literature on ricin poisoning and provide recommendations based on our best professional judgment for clinicians and public health officials that are faced with deliberate release of ricin into the environment. Literature Acquisition Using PubMed, we searched MEDLINE and OLDMEDLINE databases (January 1950-August 2005). The Chemical and Biological Information Analysis Center database was searched for historical and military literature related to ricin toxicity. Book chapters, unpublished reports, monographs, relevant news reports, and Web material were also reviewed to find nonindexed articles. Results Most literature on ricin poisoning involves castor bean ingestion and experimental animal research. Aerosol release of ricin into the environment or adulteration of food and beverages are pathways to exposure likely to be exploited. Symptoms after ingestion (onset within 12 hours) are nonspecific and may include nausea, vomiting, diarrhea, and abdominal pain and may progress to hypotension, liver failure, renal dysfunction, and death due to multiorgan failure or cardiovascular collapse. Inhalation (onset of symptoms is likely within 8 hours) of ricin is expected to produce cough, dyspnea, arthralgias, and fever and may progress to respiratory distress and death, with few other organ system manifestations. Biological analytic methods for detecting ricin exposure are undergoing investigation and may soon be available through reference laboratories. Testing of environmental samples is available through federal reference laboratories. Currently, no antidote, vaccine, or other specific effective therapy is available for ricin poisoning or prevention. Prompt treatment with supportive care is necessary to limit morbidity and mortality. Conclusion Healthcare workers and public health officials should consider ricin poisoning in patients with gastrointestinal or respiratory tract illness in the setting a credible threat. Poison control centers and public health authorities should be notified of any known illness associated with ricin exposure.	Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Environm Hazards & Hlth Effects, Hlth Studies Branch, Atlanta, GA USA; Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Div Sci Lab, Atlanta, GA USA; Emory Univ, Dept Emergency Med, Atlanta, GA 30322 USA; Georgia Poison Control Ctr, Sect Toxicol, Atlanta, GA USA	Centers for Disease Control & Prevention - USA; Centers for Disease Control & Prevention - USA; Emory University	Audi, J (corresponding author), Univ Nebraska Med Ctr, Nebraska Reg Poison Ctr, 8401 W Dodge Rd,Suite 115, Omaha, NE 68154 USA.	cza7@cdc.gov	Schier, Joshua G/F-9861-2013					[Anonymous], 2000, MMWR Recomm Rep, V49, P1; BALE JM, 2003, RICIN FOUND LONDON A; BALINT GA, 1974, TOXICOLOGY, V2, P77, DOI 10.1016/0300-483X(74)90044-4; Bies C, 2004, ADV DRUG DELIVER REV, V56, P425, DOI 10.1016/j.addr.2003.10.030; BINGEN A, 1987, J SUBMICR CYTOL PATH, V19, P247; Bispham WN, 1903, AM J MED SCI, V126, P319; BLAKEY DC, 1988, CANCER RES, V48, P7072; Bradberry Sally M., 2003, Toxicological Reviews, V22, P65, DOI 10.2165/00139709-200322010-00007; Brown RFR, 1997, INT J EXP PATHOL, V78, P267, DOI 10.1046/j.1365-2613.1997.300363.x; BRUGSCH HG, 1960, NEW ENGL J MED, V262, P1039, DOI 10.1056/NEJM196005192622016; Burrows WD, 1999, ENVIRON HEALTH PERSP, V107, P975, DOI 10.1289/ehp.99107975; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P1129; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P938; CHALLONER KR, 1990, ANN EMERG MED, V19, P1177, DOI 10.1016/S0196-0644(05)81525-2; Chyka P A, 1997, J Toxicol Clin Toxicol, V35, P721; CMIECH HA, 1985, HISTOCHEM J, V17, P859, DOI 10.1007/BF01004181; Cope A. C, 1945, CHEM WARFARE AGENT 1, P179; CORWIN AH, 1961, J MED PHARMACEUT CH, V4, P483, DOI 10.1021/jm50019a007; Crompton R, 1980, Med Leg J, V48, P51; Darby SM, 2001, J FORENSIC SCI, V46, P1033; Day PJ, 2002, BIOCHEMISTRY-US, V41, P2836, DOI 10.1021/bi012012i; DOEBLER JA, 1995, TOXICOLOGY, V98, P137, DOI 10.1016/0300-483X(94)02978-4; EITZEN E, 1998, MED MANAGEMENT BIOL, P101; Endo Y, 1988, Cancer Treat Res, V37, P75; Ferraz AC, 2002, PHARMACOL BIOCHEM BE, V72, P779, DOI 10.1016/S0091-3057(02)00750-5; FIGLEY KD, 1950, J ALLERGY, V21, P545, DOI 10.1016/0021-8707(50)90106-7; Figley KD, 1928, J AMER MED ASSOC, V90, P79, DOI 10.1001/jama.1928.02690290009003; FINE DR, 1992, MED SCI LAW, V32, P70, DOI 10.1177/002580249203200117; Flexner S, 1897, J Exp Med, V2, P197, DOI 10.1084/jem.2.2.197; FODSTAD O, 1976, BRIT J CANCER, V34, P418, DOI 10.1038/bjc.1976.187; FODSTAD O, 1979, J TOXICOL ENV HEALTH, V5, P1073, DOI 10.1080/15287397909529815; Franz DR, 2001, CLIN LAB MED, V21, P435; Furbee B, 1997, CRIT CARE CLIN, V13, P849, DOI 10.1016/S0749-0704(05)70372-9; GODAL A, 1984, CANCER CHEMOTH PHARM, V13, P157, DOI 10.1007/BF00269021; GODAL A, 1981, J TOXICOL ENV HEALTH, V8, P409, DOI 10.1080/15287398109530079; GRANT WM, 1993, TOXICOLOGY EYE EFFEC, P246; GRIFFITHS GD, 1986, HISTOCHEM J, V18, P189, DOI 10.1007/BF01676120; GRIFFITHS GD, 1995, HUM EXP TOXICOL, V14, P155, DOI 10.1177/096032719501400201; GRIFFITHS GD, 1994, TOXICOLOGY, V90, P11, DOI 10.1016/0300-483X(94)90201-1; GRIFFITHS GD, 1987, J PATHOL, V151, P221, DOI 10.1002/path.1711510310; GRIFFITHS GD, 1986, J FORENSIC SCI SOC, V26, P349, DOI 10.1016/S0015-7368(86)72516-4; Griffiths GD, 1999, VACCINE, V17, P2562, DOI 10.1016/S0264-410X(99)00054-7; GRIFFITHS GD, 1995, INHAL TOXICOL, V7, P269, DOI 10.3109/08958379509029098; HEGDE R, 1992, EUR J BIOCHEM, V204, P155, DOI 10.1111/j.1432-1033.1992.tb16618.x; HOUSTON LL, 1982, J TOXICOL-CLIN TOXIC, V19, P385, DOI 10.3109/15563658208992492; Hughes JN, 1996, HUM EXP TOXICOL, V15, P443, DOI 10.1177/096032719601500513; ISHIGURO M, 1983, CHEM PHARM BULL, V31, P3222; ISHIGURO M, 1976, TOXICON, V14, P157, DOI 10.1016/0041-0101(76)90001-5; ISHIGURO M, 1992, J PHARMACOBIO-DYNAM, V15, P147, DOI 10.1248/bpb1978.15.147; Johnson RC, 2005, J ANAL TOXICOL, V29, P149, DOI 10.1093/jat/29.3.149; KANERVA L, 1990, J AM ACAD DERMATOL, V23, P351, DOI 10.1016/0190-9622(90)70220-C; KATHREN R L, 1959, AMA Arch Ind Health, V19, P487; KEMENY DM, 1981, CLIN ALLERGY, V11, P463, DOI 10.1111/j.1365-2222.1981.tb01620.x; Kende M, 2002, VACCINE, V20, P1681, DOI 10.1016/S0264-410X(01)00484-4; KINAMORE PA, 1980, CLIN TOXICOL, V17, P401, DOI 10.3109/15563658008989989; KLAIM GJ, 1990, 453 LETT ARM I RES; KNIGHT B, 1979, BRIT MED J, V1, P350; Koch LA, 1942, AM J DIS CHILD, V64, P485; KOPFERSCHMITT J, 1983, HUM TOXICOL, V2, P239, DOI 10.1177/096032718300200211; Kumar O, 2003, TOXICON, V41, P333, DOI 10.1016/S0041-0101(02)00313-6; LAYTON LL, 1962, J ALLERGY, V33, P232, DOI 10.1016/0021-8707(62)90089-8; LEEK MD, 1989, J PATHOL, V159, P329, DOI 10.1002/path.1711590411; LEITH AG, 1988, J FORENSIC SCI SOC, V28, P227, DOI 10.1016/S0015-7368(88)72840-6; Lombard S, 2001, BIOCHEM J, V358, P773, DOI 10.1042/0264-6021:3580773; Lord J M, 1987, Prog Med Chem, V24, P1, DOI 10.1016/S0079-6468(08)70418-1; LORD JM, 1994, FASEB J, V8, P201, DOI 10.1096/fasebj.8.2.8119491; Lord Michael J., 2003, Toxicological Reviews, V22, P53, DOI 10.2165/00139709-200322010-00006; MALIZIA E, 1977, ACTA PHARMACOL TOX, V41, P351; Mayor Susan, 2003, BMJ, V326, P126, DOI 10.1136/bmj.326.7381.126; MELDRUM WP, 1900, BRIT MED J, V8, P317; Metz G, 2001, CONTACT DERMATITIS, V44, P367, DOI 10.1034/j.1600-0536.2001.440609-2.x; Morino H, 1995, BIOL PHARM BULL, V18, P1770, DOI 10.1248/bpb.18.1770; Morlon-Guyot J, 2003, J BIOL CHEM, V278, P17006, DOI 10.1074/jbc.M209516200; OLSNES S, 1974, J BIOL CHEM, V249, P803; Olsnes S, 2004, TOXICON, V44, P361, DOI 10.1016/j.toxicon.2004.05.003; OLSNES S, 1976, J BIOL CHEM, V251, P3985; OLSNES S, 1972, FEBS LETT, V28, P48, DOI 10.1016/0014-5793(72)80674-4; OLSNES S, 1975, BIOCHIM BIOPHYS ACTA, V405, P1, DOI 10.1016/0005-2795(75)90308-6; ORDMAN D, 1955, INT ARCH ALLER A IMM, V7, P10, DOI 10.1159/000228201; Palatnick W, 2000, J TOXICOL-CLIN TOXIC, V38, P67, DOI 10.1081/CLT-100100920; PAPPENHEIMER AM, 1974, J IMMUNOL, V113, P835; Park DC, 1996, ADV COMPOS MATER, V6, P1, DOI 10.1163/156855196X00167; Poli MA, 1996, TOXICON, V34, P1037, DOI 10.1016/0041-0101(96)00047-5; POLI MA, 1994, TOXICON, V32, P1371, DOI 10.1016/0041-0101(94)90409-X; RAMSDEN CS, 1989, TOXICOLOGY, V55, P161, DOI 10.1016/0300-483X(89)90183-2; RAUBER A, 1985, VET HUM TOXICOL, V27, P498; Reed RP, 1998, MED J AUSTRALIA, V168, P423, DOI 10.5694/j.1326-5377.1998.tb139017.x; Roy CJ, 2003, INHAL TOXICOL, V15, P619, DOI 10.1080/08958370390205092; Sandvig K, 2000, EMBO J, V19, P5943, DOI 10.1093/emboj/19.22.5943; SANDVIG K, 1982, J BIOL CHEM, V257, P7495; SANDVIG K, 1982, J BIOL CHEM, V257, P7504; Satpathy R, 1979, J Indian Med Assoc, V73, P190; SCARPA A, 1982, J ETHNOPHARMACOL, V5, P117, DOI 10.1016/0378-8741(82)90038-1; SEKINE I, 1986, ACTA PATHOL JAPON, V36, P1205; Shyu HF, 2002, HYBRIDOMA HYBRIDOM, V21, P69, DOI 10.1089/15368590252917665; Shyu RH, 2002, TOXICON, V40, P255, DOI 10.1016/S0041-0101(01)00193-3; SKILLETER DN, 1981, BIOCHIM BIOPHYS ACTA, V677, P495, DOI 10.1016/0304-4165(81)90264-6; Smallshaw JE, 2005, VACCINE, V23, P4775, DOI 10.1016/j.vaccine.2005.04.037; Smallshaw JE, 2002, VACCINE, V20, P3422, DOI 10.1016/S0264-410X(02)00312-2; Targosz D, 2002, J TOXICOL CLIN TOXIC, V40, P398; THORPE SC, 1989, IMMUNOLOGY, V68, P307; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P67, DOI 10.1016/0091-6749(88)90053-X; THORPE SC, 1988, J ALLERGY CLIN IMMUN, V82, P62, DOI 10.1016/0091-6749(88)90052-8; Vale J A, 1997, J Toxicol Clin Toxicol, V35, P711; VITETTA ES, 1985, CELL, V41, P653, DOI 10.1016/S0092-8674(85)80042-8; Vogel P, 1996, LAB ANIM SCI, V46, P516; WALLER GR, 1965, PLANT PHYSIOL, V40, P803, DOI 10.1104/pp.40.5.803; WANNEMACHER RW, 1993, TREATMENT REMOVAL BI; WEDIN GP, 1986, AM J EMERG MED, V4, P259, DOI 10.1016/0735-6757(86)90080-X; Wilhelmsen CL, 1996, VET PATHOL, V33, P296, DOI 10.1177/030098589603300306; Zilinskas RA, 1997, JAMA-J AM MED ASSOC, V278, P418, DOI 10.1001/jama.278.5.418	111	437	458	7	140	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2005	294	18					2342	2351		10.1001/jama.294.18.2342	http://dx.doi.org/10.1001/jama.294.18.2342			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981LI	16278363	Bronze			2022-12-28	WOS:000233089700027
J	Schmitt, R; Weichert, W; Schneider, W; Luft, FC; Kettritz, R				Schmitt, R; Weichert, W; Schneider, W; Luft, FC; Kettritz, R			Pseudo-pseudo Meigs' syndrome	LANCET			English	Article							CANCER; OVARY		Franz Volhard Clin, Fac Med Charite, D-13125 Berlin, Germany; HELIOS Klinikum Berlin, Dept Pathol, D-13122 Berlin, Germany	Franz-Volhard Clinical Research Center; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Helios Kliniken	Kettritz, R (corresponding author), Franz Volhard Clin, Fac Med Charite, Wiltberg Str 50, D-13125 Berlin, Germany.	kettritz@fvk-berlin.de	Schmitt, Roland/AAP-4609-2021	Schmitt, Roland/0000-0003-4415-8355; Luft, Friedrich/0000-0002-8635-1199; Kettritz, Ralph/0000-0001-5821-6718				BAST RC, 1981, J CLIN INVEST, V68, P1331, DOI 10.1172/JCI110380; Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842; KALSTONE CE, 1969, OBSTET GYNECOL, V34, P564; MEIGS JV, 1954, AM J OBSTET GYNECOL, V67, P962, DOI 10.1016/0002-9378(54)90258-6; Zeimet AG, 1996, GYNECOL ONCOL, V62, P384, DOI 10.1006/gyno.1996.0253	5	27	28	0	2	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1672	1672		10.1016/S0140-6736(05)67666-0	http://dx.doi.org/10.1016/S0140-6736(05)67666-0			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271650				2022-12-28	WOS:000233047100030
J	Mignot, T; Merlie, JP; Zusman, DR				Mignot, T; Merlie, JP; Zusman, DR			Regulated pole-to-pole oscillations of a bacterial gliding motility protein	SCIENCE			English	Article							MYXOCOCCUS-XANTHUS; SIGNAL-TRANSDUCTION; SOCIAL MOTILITY; IV PILI; RETRACTION; REVERSAL; SYSTEM	Little is known about directed motility of bacteria that move by type IV,pilus-mediated (twitching) motility. Here, we found that during periodic cell reversals of Myxoccocus xanthus, type IV pili were disassembled at one pole and reassembled at the other pole. Accompanying these reversals, FrzS, a protein required for directed motility, moved in an oscillatory pattern between the cell poles. The frequency of the oscillations was controlled by the Frz chemosensory system, which is essential for directed motility. Pole-to-pole migration of FrzS appeared to involve movement along a filament running the length of the cell. FrzS dynamics may thus regulate cell polarity during directed motility.	Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Zusman, DR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Berkeley, CA 94720 USA.	zusman@uclink.berkeley.edu		Mignot, Tam/0000-0003-4338-9063	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM020509] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM20509] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bhaya D, 2004, MOL MICROBIOL, V53, P745, DOI 10.1111/j.1365-2958.2004.04160.x; BLACKHART BD, 1985, P NATL ACAD SCI USA, V82, P8767, DOI 10.1073/pnas.82.24.8767; Bustamante VH, 2004, MOL MICROBIOL, V53, P1501, DOI 10.1111/j.1365-2958.2004.04221.x; Gitai Z, 2005, CELL, V120, P577, DOI 10.1016/j.cell.2005.02.026; Igoshin OA, 2004, P NATL ACAD SCI USA, V101, P15760, DOI 10.1073/pnas.0407111101; Kaiser D, 2003, NAT REV MICROBIOL, V1, P45, DOI 10.1038/nrmicro733; Mattick JS, 2002, ANNU REV MICROBIOL, V56, P289, DOI 10.1146/annurev.micro.56.012302.160938; Skerker JM, 2001, P NATL ACAD SCI USA, V98, P6901, DOI 10.1073/pnas.121171698; Spormann AM, 1999, J BACTERIOL, V181, P2593, DOI 10.1128/JB.181.8.2593-2601.1999; Sun H, 2000, CURR BIOL, V10, P1143, DOI 10.1016/S0960-9822(00)00705-3; Ward MJ, 2000, MOL MICROBIOL, V37, P1357, DOI 10.1046/j.1365-2958.2000.02079.x	12	108	109	1	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					855	857		10.1126/science.1119052	http://dx.doi.org/10.1126/science.1119052			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272122				2022-12-28	WOS:000233121800046
J	Giovannoni, SJ; Bibbs, L; Cho, JC; Stapels, MD; Desiderio, R; Vergin, KL; Rappe, MS; Laney, S; Wilhelm, LJ; Tripp, HJ; Mathur, EJ; Barofsky, DF				Giovannoni, SJ; Bibbs, L; Cho, JC; Stapels, MD; Desiderio, R; Vergin, KL; Rappe, MS; Laney, S; Wilhelm, LJ; Tripp, HJ; Mathur, EJ; Barofsky, DF			Proteorhodopsin in the ubiquitous marine bacterium SAR11	NATURE			English	Article							IDENTIFICATION; PHOTOTROPHY	Proteorhodopsins are light-dependent proton pumps that are predicted to have an important role in the ecology of the oceans by supplying energy for microbial metabolism(1,2). Proteorhodopsin genes were first discovered through the cloning and sequencing of large genomic DNA fragments from seawater(1). They were later shown to be widely distributed, phylogenetically diverse, and active in the oceans(3-7). Proteorhodopsin genes have not been found in cultured bacteria, and on the basis of environmental sequence data, it has not yet been possible to reconstruct the genomes of uncultured bacterial strains that have proteorhodopsin genes. Although the metabolic effect of proteorhodopsins is uncertain, they are thought to function in cells for which the primary mode of metabolism is the heterotrophic assimilation of dissolved organic carbon. Here we report that SAR11 strain HTCC1062 ('Pelagibacter ubique')(8), the first cultivated member of the extraordinarily abundant SAR11 clade, expresses a proteorhodopsin gene when cultured in autoclaved seawater and in its natural environment, the ocean. The Pelagibacter proteorhodopsin functions as a light-dependent proton pump. The gene is expressed by cells grown in either diurnal light or in darkness, and there is no difference between the growth rates or cell yields of cultures grown in light or darkness.	Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA; Oregon State Univ, Dept Chem, Corvallis, OR 97331 USA; Oregon State Univ, Coll Ocean & Atmospher Sci, Corvallis, OR 97331 USA; Diversa Corp, San Diego, CA 92121 USA	Oregon State University; Oregon State University; Oregon State University	Giovannoni, SJ (corresponding author), Oregon State Univ, Dept Microbiol, Corvallis, OR 97331 USA.	steve.giovannoni@oregonstate.edu	chen, qi/C-8585-2011; Barofsky, Douglas F/D-2044-2017	Barofsky, Douglas F/0000-0002-5437-5778; VERGIN, KEVIN/0000-0002-8972-2813; Cho, Jang-Cheon/0000-0002-0666-3791				Beja O, 2000, SCIENCE, V289, P1902, DOI 10.1126/science.289.5486.1902; Beja O, 2001, NATURE, V411, P786, DOI 10.1038/35081051; de la Torre JR, 2003, P NATL ACAD SCI USA, V100, P12830, DOI 10.1073/pnas.2133554100; Field KG, 1997, APPL ENVIRON MICROB, V63, P63, DOI 10.1128/AEM.63.1.63-70.1997; Giovannoni SJ, 2005, SCIENCE, V309, P1242, DOI 10.1126/science.1114057; Huelsenbeck JP, 2001, BIOINFORMATICS, V17, P754, DOI 10.1093/bioinformatics/17.8.754; Kimura M., 1983, NEUTRAL THEORY MOL E; Man DL, 2003, EMBO J, V22, P1725, DOI 10.1093/emboj/cdg183; Man-Aharonovich D, 2004, PHOTOCH PHOTOBIO SCI, V3, P459, DOI 10.1039/b316071h; Morris RM, 2002, NATURE, V420, P806, DOI 10.1038/nature01240; Peck RF, 2002, J BACTERIOL, V184, P2889, DOI 10.1128/JB.184.11.2889-2897.2002; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Ram RJ, 2005, SCIENCE, V308, P1915, DOI 10.1126/science. 1109070; Rappe MS, 2002, NATURE, V418, P630, DOI 10.1038/nature00917; Sabehi G, 2004, ENVIRON MICROBIOL, V6, P903, DOI 10.1111/j.1462-2920.2004.00676.x; Sabehi G, 2003, ENVIRON MICROBIOL, V5, P842, DOI 10.1046/j.1462-2920.2003.00493.x; Stapels Martha D, 2004, J Biomol Tech, V15, P191; Stapels MD, 2004, ANAL CHEM, V76, P5423, DOI 10.1021/ac030427z; Venter JC, 2004, SCIENCE, V304, P66, DOI 10.1126/science.1093857; Wang WW, 2003, J BIOL CHEM, V278, P33985, DOI 10.1074/jbc.M305716200; Whitman WB, 1998, P NATL ACAD SCI USA, V95, P6578, DOI 10.1073/pnas.95.12.6578	21	229	241	3	94	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					82	85		10.1038/nature04032	http://dx.doi.org/10.1038/nature04032			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267553				2022-12-28	WOS:000232979000045
J	Ness, KK; Mertens, AC; Hudson, MM; Wall, MM; Leisenring, WM; Oeffinger, KC; Sklar, CA; Robison, LL; Gurney, JG				Ness, KK; Mertens, AC; Hudson, MM; Wall, MM; Leisenring, WM; Oeffinger, KC; Sklar, CA; Robison, LL; Gurney, JG			Limitations on physical performance and daily activities among long-term survivors of childhood cancer	ANNALS OF INTERNAL MEDICINE			English	Article							QUALITY-OF-LIFE; HEALTH-STATUS; BRAIN-TUMORS; ADOLESCENT CANCER; ADULT SURVIVORS; RADIATION-THERAPY; NEURO-BLASTOMA; CHILDREN; COMPLICATIONS; NEUROBLASTOMA	Background: Survivors of childhood cancer may experience important disease- and treatment-related late effects, including functional limitations. Objective: This study evaluated performance limitations and restricted abilities to participate in personal care, to engage in routine activities like shopping or housework, and to attend work or school (participation restrictions) in a cohort of survivors of childhood cancer. Setting: Epidemiologic survey and 26 institutions that treat childhood cancer. Patients: Participants included 11 481 persons who were treated for primary brain cancer, leukemia, Hodgkin disease, non-Hodgkin lymphoma, kidney tumor, neuroblastoma, soft-tissue sarcoma, or malignant bone tumor before the age of 21 years and who survived at least 5 years after diagnosis. The comparison group included 3839 siblings of survivors of childhood cancer. Measurement: Medical data were abstracted, and participants or parents (if the participants were < 18 years of age at survey completion) completed a 24-page questionnaire. Results: Compared with siblings, survivors were more likely to report performance limitations (risk ratio, 1.8 [95% Cl, 1.7 to 2.0]) and to report restricted participation in personal care skills (risk ratio, 4.7 [Cl, 3.0 to 7.2]), routine activities (risk ratio, 4.7 [Cl, 3.6 to 6.2]), and the ability to attend work or school (risk ratio, 5.9 [Cl, 4.5 to 7.6]). Survivors of brain (26.6%) and bone (36.9%) cancer were most likely to report performance limitations, restricted ability to do routine activities (20.9% and 8.5%, respectively), and restricted ability to attend work or school (20.0% and 11.2%, respectively). Survivors of brain cancer were also most likely to report restricted abilities to perform personal care (10.5%). Limitations: There was the potential for participants to be healthier or more physically capable than nonparticipants or for persons to be more motivated to participate in this study if they had functional deficits. In addition, the nature of the questionnaire did not allow specific physical limitations to be measured. Conclusion: Long-term survivors of childhood cancer are at increased risk for functional limitations in physical performance and in participation in activities needed for daily living.	Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Minneapolis, MN 55455 USA; St Jude Childrens Res Hosp, Memphis, TN 38105 USA; Univ Tennessee, Coll Med, Memphis, TN USA; Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA; Univ Texas, SW Med Ctr, Dallas, TX USA; Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA	University of Minnesota System; University of Minnesota Twin Cities; St Jude Children's Research Hospital; University of Tennessee System; University of Tennessee Health Science Center; Fred Hutchinson Cancer Center; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Memorial Sloan Kettering Cancer Center	Ness, KK (corresponding author), Univ Minnesota, Dept Pediat, Div Epidemiol & Clin Res, Mayo Mail Code 715,420 Delaware St SE, Minneapolis, MN 55455 USA.	ness@epi.umn.edu	Ness, Kirsten K/N-2550-2018; Hudson, Melissa M/N-4441-2018; Robison, Leslie/N-8122-2018; Wall, Melanie/AAE-7828-2019	Ness, Kirsten K/0000-0002-2084-1507; Hudson, Melissa M/0000-0001-6984-2407; 	NATIONAL CANCER INSTITUTE [U24CA055727, U01CA055727] Funding Source: NIH RePORTER; NCI NIH HHS [CA 55727, U24 CA055727] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Alcoser Pat Wills, 2003, J Pediatr Nurs, V18, P103, DOI 10.1053/jpdn.2003.10; Anderson DM, 2001, CANCER-AM CANCER SOC, V92, P2709, DOI 10.1002/1097-0142(20011115)92:10<2709::AID-CNCR1625>3.0.CO;2-D; AZIZKHAN RG, 1985, SURGERY, V97, P514; Balis FM, 2002, PRINCIPLES PRACTICE, V4th, P237; Boulad F, 1998, Curr Probl Pediatr, V28, P273; Crom DB, 1999, INT J CANCER, P25; Cruccetti A, 2000, J PEDIATR SURG, V35, P724, DOI 10.1053/jpsu.2000.6076; Damron TA, 1997, SEMIN SURG ONCOL, V13, P3, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<3::AID-SSU2>3.3.CO;2-5; DREYER ZE, 2002, PRINCIPLES PRACTICE, P1431; Felder-Puig R, 1998, CANCER, V83, P69, DOI 10.1002/(SICI)1097-0142(19980701)83:1<69::AID-CNCR10>3.0.CO;2-A; Foreman NK, 1999, J NEURO-ONCOL, V41, P47, DOI 10.1023/A:1006145724500; Freeman CR, 2002, MED PEDIATR ONCOL, V39, P99, DOI 10.1002/mpo.10116; GARRE ML, 1994, AM J PEDIAT HEMATOL, V16, P143; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Gurney JG, 2003, J CLIN ENDOCR METAB, V88, P4731, DOI 10.1210/jc.2003-030784; Gurney JG, 2003, CANCER-AM CANCER SOC, V97, P663, DOI 10.1002/cncr.11095; Gustavsson A, 2003, ACTA ONCOL, V42, P589, DOI 10.1080/02841860310013346; Habrand JL, 2001, CHILD NERV SYST, V17, P121, DOI 10.1007/s003810000365; Hejna MJ, 1997, SEMIN SURG ONCOL, V13, P18, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<18::AID-SSU4>3.0.CO;2-7; Hudson Melissa M, 2004, J Pediatr Oncol Nurs, V21, P170, DOI 10.1177/1043454204264388; Hudson MM, 2003, JAMA-J AM MED ASSOC, V290, P1583, DOI 10.1001/jama.290.12.1583; Ilveskoski I, 1996, NEUROPEDIATRICS, V27, P124, DOI 10.1055/s-2007-973762; Jenkin D, 1998, MED PEDIATR ONCOL, V31, P506, DOI 10.1002/(SICI)1096-911X(199812)31:6<506::AID-MPO7>3.0.CO;2-X; Kaaijk Patricia, 2003, Expert Rev Anticancer Ther, V3, P79, DOI 10.1586/14737140.3.1.79; KAJANTI M, 1983, ANN CLIN RES, V15, P1; Kalapurakal JA, 2004, LANCET ONCOL, V5, P37, DOI 10.1016/S1470-2045(03)01322-6; Kennedy CR, 1999, INT J CANCER, P106; LANNERING B, 1990, MED PEDIATR ONCOL, V18, P304, DOI 10.1002/mpo.2950180410; Laverdiere C, 2005, PEDIATR BLOOD CANCER, V45, P324, DOI 10.1002/pbc.20331; Laverdiere C, 2005, PEDIAT ONCOL, P277; Macedoni-Luksic M, 2003, PEDIATR HEMAT ONCOL, V20, P89, DOI 10.1080/0880010390158595; MANKIN HJ, 1992, ORTHOPEDICS, V15, P1147; Marina N, 1997, PEDIATR CLIN N AM, V44, P1021, DOI 10.1016/S0031-3955(05)70543-5; Massey B, 2001, PHYS THER, V81, P9; MAYFIELD JK, 1981, J BONE JOINT SURG AM, V63, P183, DOI 10.2106/00004623-198163020-00002; McGoveran BM, 1999, CAN J SURG, V42, P37; McNutt LA, 2003, AM J EPIDEMIOL, V157, P940, DOI 10.1093/aje/kwg074; Meister L A, 1993, Curr Probl Pediatr, V23, P102, DOI 10.1016/0045-9380(93)90019-9; Mertens AC, 2002, CANCER, V95, P2431, DOI 10.1002/cncr.10978; Meyer WH, 2004, CANCER TREAT REV, V30, P269, DOI 10.1016/j.ctrv.2003.11.001; Nagarajan R, 2002, J CLIN ONCOL, V20, P4493, DOI 10.1200/JCO.2002.09.006; Ng Andrea K, 2004, Curr Hematol Rep, V3, P27; NITSCHKE R, 1988, J CLIN ONCOL, V6, P1271, DOI 10.1200/JCO.1988.6.8.1271; Oeffinger KC, 2004, CA-CANCER J CLIN, V54, P208, DOI 10.3322/canjclin.54.4.208; Packer RJ, 2003, J CLIN ONCOL, V21, P3255, DOI 10.1200/JCO.2003.01.202; PASTORE G, 1987, MED PEDIATR ONCOL, V15, P1, DOI 10.1002/mpo.2950150102; PASTORE G, 1982, MED PEDIATR ONCOL, V10, P369, DOI 10.1002/mpo.2950100407; Rao BN, 2003, MED PEDIATR ONCOL, V41, P584, DOI 10.1002/mpo.10405; Refaat Y, 2002, CLIN ORTHOP RELAT R, P298; Robison LL, 2004, CANCER EPIDEM BIOMAR, V13, P1093; Robison LL, 2003, BRIT J HAEMATOL, V122, P345, DOI 10.1046/j.1365-2141.2003.04499.x; Robison LL, 2003, CURR PROB CANCER, V27, P212, DOI 10.1016/S0147-0272(03)00029-1; Robison LL, 2002, MED PEDIATR ONCOL, V38, P229, DOI 10.1002/mpo.1316; Scarborough MT, 1997, SEMIN SURG ONCOL, V13, P25, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<25::AID-SSU5>3.0.CO;2-6; Schindler OS, 1998, CLIN ORTHOP RELAT R, P157; Schwartz CL, 2003, CURR OPIN PEDIATR, V15, P10, DOI 10.1097/00008480-200302000-00003; SHAMBERGER RC, 2002, PRINCIPLES PRACTICE, P351; SIM FH, 1987, CLIN ORTHOP RELAT R, P188; Sklar C, 2002, J PEDIATR ENDOCR MET, V15, P669; Sklar CA, 2000, UROL CLIN N AM, V27, P563, DOI 10.1016/S0094-0143(05)70103-8; SMITH MA, 2002, PRINCIPLES PRACTICE, P1; Smith Malcolm, 2004, J Pediatr Oncol Nurs, V21, P160, DOI 10.1177/1043454204264407; Springfield DS, 1997, SEMIN SURG ONCOL, V13, P11, DOI 10.1002/(SICI)1098-2388(199701/02)13:1<11::AID-SSU3>3.3.CO;2-L; TARBELL NJ, 2002, PRINCIPLES PRACTICE, P369; van den Berg Hendrik, 2003, Cancer Chemother Biol Response Modif, V21, P683; WHO, 2002, WHOEIPGPECAS013; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	67	232	234	0	20	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					639	647		10.7326/0003-4819-143-9-200511010-00007	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00007			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980PN	16263886				2022-12-28	WOS:000233030600003
J	Dobson, AP				Dobson, AP			What links bats to emerging infectious diseases?	SCIENCE			English	Editorial Material							ACUTE RESPIRATORY SYNDROME; VIRUS		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Dobson, AP (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	dobber@princeton.edu						Aguirre A.A., 2002, CONSERVATION MED ECO; DIEKMANN O, 1990, J MATH BIOL, V28, P365; Dobson A, 2004, AM NAT, V164, pS64, DOI 10.1086/424681; Hsu VP, 2004, EMERG INFECT DIS, V10, P2082, DOI 10.3201/eid1012.040701; Hyatt A.D., 2004, ECOHEALTH, V1, P25, DOI [10.1007/s10393-004-0017-6, DOI 10.1007/S10393-004-0017-6]; Jones KE, 2002, BIOL REV, V77, P223, DOI 10.1017/S1464793101005899; Lau SKP, 2005, P NATL ACAD SCI USA, V102, P14040, DOI 10.1073/pnas.0506735102; Li WD, 2005, SCIENCE, V310, P676, DOI 10.1126/science.1118391; McLean AR., 2005, SARS CASE STUDY EMER, DOI [10.1093/shm/hki055, DOI 10.1093/SHM/HKI055]; *MILL EC ASS, 2003, ECO HUM WELL BEING F; NOKES DJ, 1988, LANCET, V2, P1374; Parashar UD, 2004, INT J EPIDEMIOL, V33, P628, DOI 10.1093/ije/dyh198; WOOLHOUSE MEJ, IN PRESS EMERG INFEC	13	110	120	3	32	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					628	629		10.1126/science.1120872	http://dx.doi.org/10.1126/science.1120872			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254175				2022-12-28	WOS:000232997700026
J	Verstraelen, H; Goetgeluk, S; Derom, C; Vansteelandt, S; Derom, R; Goetghebeur, E; Temmerman, NA				Verstraelen, H; Goetgeluk, S; Derom, C; Vansteelandt, S; Derom, R; Goetghebeur, E; Temmerman, NA			Preterm birth in twins after subfertility treatment: population based cohort study	BRITISH MEDICAL JOURNAL			English	Article							IN-VITRO FERTILIZATION; PREGNANCIES; SINGLETONS; DELIVERY; WEIGHT	Objectives To assess gestational length and prevalence of preterm birth among medically and naturally conceived twins; to establish the role of zygosity and chorionicity in assessing gestational length in twins born after subfertility treatment. Design Population based cohort study. Setting Collaborative network of 19 maternity facilities in East Flanders, Belgium (East Flanders prospective twin survey). Participants 4368 twin pairs born between 1976 and 2002, including 2915 spontaneous twin pairs, 710 twin pairs born after ovarian stimulation, and 743 twin pairs born after in vitro fertilisation or intracytoplasmic sperm injection. Main outcome measures Gestational length and prevalence of preterm birth. Results Compared with naturally conceived twins, twins resulting from subfertility treatment had on average a slightly decreased gestational age at birth (mean difference 4.0 days, 95% confidence interval 2.7 to 5.2), corresponding to an odds ratio of 1.6 (1.4 to 1.8) for preterm birth, albeit confined to mild preterm birth (34-36 weeks). The adjusted odds ratios of preterm birth after subfertility treatment were 13 (1.1 to 1.5) when controlled for birth year, maternal age, and parity and 1.6 (1.3 to 1.8) with additional control for fetal sex, caesarean section, zygosity, and chorionicity. Although an increased risk of preterm birth was therefore seen among twins resulting from subfertility treatment, the risk was largely caused by a first birth effect among subfertile couples; conversely, the risk of prematurity was substantially levelled off by the protective effect of dizygotic twinning. Conclusions Twins resulting from subfertility treatment have an increased risk of preterm birth, but the risk is limited to mild preterm birth, primarily by virtue of dizygotic twinning.	State Univ Ghent Hosp, Dept Obstet & Gynaecol, B-9000 Ghent, Belgium; State Univ Ghent, Dept Appl Math & Informat, B-9000 Ghent, Belgium; Katholieke Univ Leuven, Univ Hosp Gasthuisberg, Ctr Human Genet, B-3000 Louvain, Belgium; Assoc Sci Res Multiple Births, B-9070 Destelbergen, Belgium	Ghent University; Ghent University Hospital; Ghent University; KU Leuven; University Hospital Leuven	Verstraelen, H (corresponding author), State Univ Ghent Hosp, Dept Obstet & Gynaecol, 1P3 De Pintelaan, B-9000 Ghent, Belgium.	hans.verstraelen@UGent.be	Vansteelandt, Stijn/J-4072-2017; Verstraelen, Hans/A-5602-2008; Verstraelen, Hans/AAA-8694-2019; Goetghebeur, Els J/H-7939-2016	Vansteelandt, Stijn/0000-0002-4207-8733; Verstraelen, Hans/0000-0002-4070-1587; Derom, Catherine/0000-0001-5574-796X				Andersen AN, 2004, HUM REPROD, V19, P490, DOI 10.1093/humrep/deh129; Barrett JFR, 2004, BEST PRACT RES CL OB, V18, P625, DOI 10.1016/j.bpobgyn.2004.04.010; Basso O, 2003, HUM REPROD, V18, P2478, DOI 10.1093/humrep/deg444; Blondel B, 2003, EUR J PUBLIC HEALTH, V13, P83, DOI 10.1093/eurpub/13.1.83; Blondel B, 2002, SEMIN PERINATOL, V26, P239, DOI 10.1053/sper.2002.34775; Davies HTO, 1998, BRIT MED J, V316, P989, DOI 10.1136/bmj.316.7136.989; DEROM C, 2005, MULTIPLE PREGNANCY E, P39; Dhont M, 1999, AM J OBSTET GYNECOL, V181, P688, DOI 10.1016/S0002-9378(99)70514-4; DIGGLE PJ, 1994, OXFORD STAT SCI SERI, V13; Fauser BCJM, 2005, LANCET, V365, P1807, DOI 10.1016/S0140-6736(05)66478-1; Hall JG, 2003, LANCET, V362, P735, DOI 10.1016/S0140-6736(03)14237-7; Helmerhorst FM, 2004, BRIT MED J, V328, P261, DOI 10.1136/bmj.37957.560278.EE; Jackson RA, 2004, OBSTET GYNECOL, V103, P551, DOI 10.1097/01.AOG.0000114989.84822.51; Koudstaal J, 2000, HUM REPROD, V15, P935, DOI 10.1093/humrep/15.4.935; Kramer MS, 2000, JAMA-J AM MED ASSOC, V284, P843, DOI 10.1001/jama.284.7.843; Lambalk CB, 2001, FERTIL STERIL, V75, P731, DOI 10.1016/S0015-0282(01)01679-X; Loos R, 1998, Twin Res, V1, P167, DOI 10.1375/twin.1.4.167; Machin GA, 2004, BEST PRACT RES CL OB, V18, P515, DOI 10.1016/j.bpobgyn.2004.04.013; Moise J, 1998, HUM REPROD, V13, P1702, DOI 10.1093/humrep/13.6.1702; Pinborg A, 2004, HUM REPROD, V19, P435, DOI 10.1093/humrep/deh063; Schieve LA, 2002, NEW ENGL J MED, V346, P731, DOI 10.1056/NEJMoa010806; Taylor A, 2003, BRIT MED J, V327, P434, DOI 10.1136/bmj.327.7412.434; Wright Victoria C, 2003, MMWR Surveill Summ, V52, P1	23	53	53	0	5	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 19	2005	331	7526					1173	1176A		10.1136/bmj.38625.685706.AE	http://dx.doi.org/10.1136/bmj.38625.685706.AE			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	988DG	16249191	Bronze, Green Published			2022-12-28	WOS:000233571000017
J	Grigorenko, AN; Geim, AK; Gleeson, HF; Zhang, Y; Firsov, AA; Khrushchev, IY; Petrovic, J				Grigorenko, AN; Geim, AK; Gleeson, HF; Zhang, Y; Firsov, AA; Khrushchev, IY; Petrovic, J			Nanofabricated media with negative permeability at visible frequencies	NATURE			English	Article							LEFT-HANDED MATERIALS; NANOWIRES	A great deal of attention has recently been focused on a new class of smart materials-so-called left-handed media-that exhibit highly unusual electromagnetic properties and promise new device applications(1-6). Left-handed materials require negative permeability m, an extreme condition that has so far been achieved only for frequencies in the microwave to terahertz range(7-11). Extension of the approach described in ref. 7 to achieve the necessary high-frequency magnetic response in visible optics presents a formidable challenge(12-15), as no material-natural or artificial-is known to exhibit any magnetism at these frequencies. Here we report a nanofabricated medium consisting of electromagnetically coupled pairs of gold dots with geometry carefully designed at a 10-nm level. The medium exhibits a strong magnetic response at visible-light frequencies, including a band with negative m. The magnetism arises owing to the excitation of an antisymmetric plasmon resonance. The high-frequency permeability qualitatively reveals itself via optical impedance matching. Our results demonstrate the feasibility of engineering magnetism at visible frequencies and pave the way towards magnetic and left-handed components for visible optics.	Univ Manchester, Dept Phys & Astron, Manchester M13 9PL, Lancs, England; Russian Acad Sci, Inst Microelect Technol, Chernogolovka 142432, Russia; Aston Univ, Dept Elect Engn, Birmingham B4 7ET, W Midlands, England	University of Manchester; Russian Academy of Sciences; Aston University	Grigorenko, AN (corresponding author), Univ Manchester, Dept Phys & Astron, Manchester M13 9PL, Lancs, England.	sasha@man.ac.uk	Geim, Andre K/J-7888-2012; Firsov, Anatoly/E-8090-2017; Petrovic, Jovana/F-9019-2015	Geim, Andre K/0000-0003-2861-8331; Sanchez-Fernandez, Gregorio Esteban/0000-0002-6059-7182; Petrovic, Jovana/0000-0002-1002-241X				ABELES F, 1971, PHYS THIN FILMS, V6, pCH5; Aizpurua J, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.057401; Barron L. D., 1982, MOL LIGHT SCATTERING; Born M., 1980, PRINCIPLES OPTICS; Dimmock JO, 2003, OPT EXPRESS, V11, P2397, DOI 10.1364/OE.11.002397; Ebbesen TW, 1998, NATURE, V391, P667, DOI 10.1038/35570; Felidj N, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.245407; Gademann A, 2003, J PHYS D APPL PHYS, V36, P2193, DOI 10.1088/0022-3727/36/18/003; Houck AA, 2003, PHYS REV LETT, V90, DOI 10.1103/PhysRevLett.90.137401; Jin RC, 2003, NATURE, V425, P487, DOI 10.1038/nature02020; Kottmann JP, 2001, OPT EXPRESS, V8, P655, DOI 10.1364/OE.8.000655; Landau LD., 1984, ELECTRODYNAMICS CONT; Linden S, 2004, SCIENCE, V306, P1351, DOI 10.1126/science.1105371; Mock JJ, 2003, NANO LETT, V3, P485, DOI 10.1021/nl0340475; O'Brien S, 2002, J PHYS-CONDENS MAT, V14, P6383, DOI 10.1088/0953-8984/14/25/307; Panina LV, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.155411; Pendry J, 2003, NATURE, V423, P22, DOI 10.1038/423022a; Pendry JB, 2000, PHYS REV LETT, V85, P3966, DOI 10.1103/PhysRevLett.85.3966; Pendry JB, 1999, IEEE T MICROW THEORY, V47, P2075, DOI 10.1109/22.798002; Podolskiy VA, 2002, J NONLINEAR OPT PHYS, V11, P65, DOI 10.1142/S0218863502000833; PROKHOROV AM, 1958, ZH EKSP TEOR FIZ, V34, P1658; SCHAWLOW AL, 1958, PHYS REV, V112, P1940, DOI 10.1103/PhysRev.112.1940; Shelby RA, 2001, SCIENCE, V292, P77, DOI 10.1126/science.1058847; Smith DR, 2000, PHYS REV LETT, V84, P4184, DOI 10.1103/PhysRevLett.84.4184; VESELAGO VG, 1968, SOV PHYS USPEKHI, V10, P509, DOI 10.1070/PU1968v010n04ABEH003699; Wiltshire MCK, 2001, SCIENCE, V291, P849, DOI 10.1126/science.291.5505.849; Yen TJ, 2004, SCIENCE, V303, P1494, DOI 10.1126/science.1094025	27	534	548	3	217	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					335	338		10.1038/nature04242	http://dx.doi.org/10.1038/nature04242			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292306	Green Submitted			2022-12-28	WOS:000233300200043
J	Cavanagh, PR; Lipsky, BA; Bradbury, AW; Botek, G				Cavanagh, PR; Lipsky, BA; Bradbury, AW; Botek, G			Treatment for diabetic foot ulcers	LANCET			English	Review							PERIPHERAL ARTERIAL-DISEASE; LOWER-EXTREMITY AMPUTATION; RESISTANT STAPHYLOCOCCUS-AUREUS; SEVERE LIMB ISCHEMIA; TOTAL CONTACT CAST; NEUROPATHIC FOOT; COST-EFFECTIVENESS; THERAPEUTIC FOOTWEAR; PLANTAR PRESSURE; ANTIMICROBIAL AGENTS	People with diabetes develop foot ulcers because of neuropathy (sensory, motor, and autonomic deficits), ischaemia, or both. The initiating injury may be from acute mechanical or thermal trauma or from repetitively or continuously applied mechanical stress. Patients with clinically significant limb ischaemia should be assessed by a vascular surgeon to determine the need for angioplasty, stenting, or femorodistal bypass. When infection complicates a foot ulcer, the combination can be limb or life-threatening. Infection is defined clinically, but wound cultures reveal the causative pathogens. Tissue specimens are strongly preferred to wound swabs for wound cultures. Antimicrobial therapy should be guided by culture results, and should aim to cure the infection, not to heal the wound. Alleviation of the mechanical load on ulcers (off-loading) should always be a part of treatment. Neuropathic ulcers typically heal in 6 weeks with total contact casting, because it effectively relieves pressure at the ulcer site and enforces patient compliance. The success of other approaches to off-loading similarly depends on the patients' adherence to the effectiveness of pressure relief. Surgery to heal ulcers and prevent recurrence can include tenotomy, tendon lengthening, reconstruction, or removal of bony prominences. However, these procedures may result in secondary ulceration and other complications. Ulcer recurrence rates are high, but appropriate education for patients, the provision of posthealing footwear, and regular foot care can reduce rates of re-ulceration.	Cleveland Clin Fdn, Dept Biomed Engn, Diabet Foot Care Program, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Dept Orthopaed Surg, Diabet Foot Care Programme, Cleveland, OH 44195 USA; Cleveland Clin Fdn, Orthopaed Res Ctr, Cleveland, OH 44195 USA; Case Western Reserve Univ, Cleveland Clin, Lerner Coll Med, Cleveland, OH 44106 USA; Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Gen Internal Med Clin, Seattle, WA USA; Univ Birmingham, Dept Vasc Surg, Birmingham, W Midlands, England; Heart England NHS Fdn Trust, Birmingham, W Midlands, England	Cleveland Clinic Foundation; Cleveland Clinic Foundation; Cleveland Clinic Foundation; Case Western Reserve University; Cleveland Clinic Foundation; University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; University of Birmingham; Heart of England NHS Foundation Trust	Cavanagh, PR (corresponding author), Cleveland Clin Fdn, Dept Biomed Engn, Diabet Foot Care Program, ND20,9500 Euclid Ave, Cleveland, OH 44195 USA.	cavanap@ccf.org	Lipsky, Benjamin A/B-4645-2013	Lipsky, Benjamin A./0000-0001-9886-5114				Abbas ZG, 2005, DIABETIC MED, V22, P631, DOI 10.1111/j.1464-5491.2005.01488.x; Abbott CA, 2005, DIABETES CARE, V28, P1869, DOI 10.2337/diacare.28.8.1869; Abdulrazak A, 2005, J DIABETES COMPLICAT, V19, P138, DOI 10.1016/j.jdiacomp.2004.06.001; Abidia A, 2003, EUR J VASC ENDOVASC, V25, P513, DOI 10.1053/ejvs.2002.1911; Adam DJ, 2006, EUR J VASC ENDOVASC, V31, P151, DOI 10.1016/j.ejvs.2005.05.039; Akbari CM, 2000, ARCH SURG-CHICAGO, V135, P452, DOI 10.1001/archsurg.135.4.452; Aksoy DY, 2004, EXP CLIN ENDOCR DIAB, V112, P526, DOI 10.1055/s-2004-821310; Al-Khawari HA, 2005, MED PRIN PRACT, V14, P165, DOI 10.1159/000084634; American Diabetes Association, 1999, DIABETES CARE, V22, P354; Andros G, 2004, DIABETES-METAB RES, V20, pS29, DOI 10.1002/dmrr.468; Apelqvist J, 1998, Clin Podiatr Med Surg, V15, P21; ARMMSTRONG DG, 1996, J FOOT ANKLE SURG, V35, P280; Armstrong D G, 1996, J Foot Ankle Surg, V35, P585; Armstrong D G, 1996, J Foot Ankle Surg, V35, P280; Armstrong David G, 2004, Int J Low Extrem Wounds, V3, P12, DOI 10.1177/1534734604263291; Armstrong David G, 2004, Diabetes Technol Ther, V6, P167, DOI 10.1089/152091504773731357; Armstrong DG, 2005, J AM PODIAT MED ASSN, V95, P353, DOI 10.7547/0950353; Armstrong DG, 2005, J AM PODIAT MED ASSN, V95, P254, DOI 10.7547/0950254; Armstrong DG, 2004, DIABETES CARE, V27, P1980, DOI 10.2337/diacare.27.8.1980; Armstrong DG, 2003, DIABETIC MED, V20, P329, DOI 10.1046/j.1464-5491.2003.00933.x; Armstrong DG, 2005, LANCET, V366, P1704, DOI 10.1016/S0140-6736(05)67695-7; Armstrong DG, 2001, DIABETES CARE, V24, P1019, DOI 10.2337/diacare.24.6.1019; Armstrong DG, 2003, DIABETES CARE, V26, P2595, DOI 10.2337/diacare.26.9.2595; Aronow Wilbert S, 2005, Cardiol Rev, V13, P61, DOI 10.1097/01.crd.0000126082.86717.12; Aronow WS, 2004, J GERONTOL A-BIOL, V59, P172; Attinger CE, 2002, PLAST RECONSTR SURG, V110, P1047, DOI 10.1097/01.PRS.0000021448.57210.52; Aulivola B, 2004, ARCH SURG-CHICAGO, V139, P395, DOI 10.1001/archsurg.139.4.395; Aye Mo, 2002, Am J Clin Dermatol, V3, P463, DOI 10.2165/00128071-200203070-00003; Badiavas EV, 2003, J CELL PHYSIOL, V196, P245, DOI 10.1002/jcp.10260; Bailey CMH, 2003, EUR J VASC ENDOVASC, V25, P131, DOI 10.1053/ejvs.2002.1817; Balbierz JM, 2004, ARCH PHYS MED REHAB, V85, P1205, DOI 10.1016/j.apmr.2003.12.024; Baravarian Babak, 2004, Clin Podiatr Med Surg, V21, P271, DOI 10.1016/j.cpm.2004.01.007; Bates MC, 2004, J ENDOVASC THER, V11, P107, DOI 10.1583/04-1324.1; Baumhauer JF, 1997, FOOT ANKLE INT, V18, P26, DOI 10.1177/107110079701800106; Becker W, 1999, Q J NUCL MED, V43, P9; Berendt Anthony R, 2004, Curr Diab Rep, V4, P424, DOI 10.1007/s11892-004-0051-3; Berglund J, 2005, EUR J VASC ENDOVASC, V29, P412, DOI 10.1016/j.ejvs.2004.12.023; BIRKE JA, 1991, PHYS THER, V71, P116, DOI 10.1093/ptj/71.2.116; Bockler D, 2005, J ENDOVASC THER, V12, P13, DOI 10.1583/04-1252.1; Bolia A, 2004, ACTA CHIR BELG, V104, P547; Bots Th C M, 2004, J Wound Care, V13, P375; Bowler PG, 1999, INT J DERMATOL, V38, P573, DOI 10.1046/j.1365-4362.1999.00738.x; Bowler PG, 2001, CLIN MICROBIOL REV, V14, P244, DOI 10.1128/CMR.14.2.244-269.2001; Bradbury A, 2004, J VASC SURG, V39, P1026, DOI 10.1016/j.jvs.2004.01.031; Bradbury AW, 2002, EUR J VASC ENDOVASC, V24, P411, DOI 10.1053/ejvs.2002.1709; Bradbury AW, 1996, LANCET, V347, P277, DOI 10.1016/S0140-6736(96)90460-2; Brem H, 2004, AM J SURG, V187, p1S, DOI 10.1016/S0002-9610(03)00299-X; Brown D, 2004, ARCH PHYS MED REHAB, V85, P81, DOI 10.1016/S0003-9993(03)00374-5; Burns P, 2002, EUR J VASC ENDOVASC, V24, P6, DOI 10.1053/ejvs.2002.1684; Burns P, 2003, BMJ-BRIT MED J, V326, P584, DOI 10.1136/bmj.326.7389.584; Bus SA, 2002, DIABETES CARE, V25, P1444, DOI 10.2337/diacare.25.8.1444; Bus SA, 2004, CLIN BIOMECH, V19, P629, DOI 10.1016/j.clinbiomech.2004.02.010; Busch K, 2003, DIABETIC MED, V20, P665, DOI 10.1046/j.1464-5491.2003.01003.x; Caravaggi C, 2000, DIABETES CARE, V23, P1746, DOI 10.2337/diacare.23.12.1746; Caruana MF, 2005, EUR J VASC ENDOVASC, V29, P443, DOI 10.1016/j.ejvs.2005.01.015; Caselli A, 2002, DIABETES CARE, V25, P1066, DOI 10.2337/diacare.25.6.1066; Cavanagh PR, 2004, DIABETES-METAB RES, V20, pS51, DOI 10.1002/dmrr.435; Chang B B, 1996, Cardiovasc Surg, V4, P792, DOI 10.1016/S0967-2109(96)00045-2; CHANTELAU E, 1990, DIABETIC MED, V7, P355, DOI 10.1111/j.1464-5491.1990.tb01404.x; Chantelau E, 2001, DIABETES CARE, V24, P2016, DOI 10.2337/diacare.24.11.2016; Chatha DS, 2005, RADIOL CLIN N AM, V43, P747, DOI 10.1016/j.rcl.2005.02.008; Chaytor ER, 2000, DIABETES-METAB RES, V16, pS66, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR140>3.0.CO;2-Y; Chen SL, 2005, ANN PLAS SURG, V54, P44, DOI 10.1097/01.sap.0000141377.00807.16; Chipchase SY, 2005, DIABETIC MED, V22, P1258, DOI 10.1111/j.1464-5491.2005.01665.x; Coello R, 2005, J HOSP INFECT, V60, P93, DOI 10.1016/j.jhin.2004.10.019; Connor H, 2004, DIABETES-METAB RES, V20, pS23, DOI 10.1002/dmrr.446; Coughlin Michael J, 2003, Instr Course Lect, V52, P421; Crenshaw SJ, 2004, FOOT ANKLE INT, V25, P69, DOI 10.1177/107110070402500206; Cruz CP, 2003, AM J SURG, V186, P449, DOI 10.1016/j.amjsurg.2003.07.027; Cunha B A, 2000, J Foot Ankle Surg, V39, P253; Czerny M, 2004, EUR J VASC ENDOVASC, V27, P635, DOI 10.1016/j.ejvs.2004.02.028; Dang CN, 2003, DIABETIC MED, V20, P159, DOI 10.1046/j.1464-5491.2003.00860.x; Davis BL, 2004, DIABETES-METAB RES, V20, pS45, DOI 10.1002/dmrr.445; de Noordhout BM, 2004, ACTA CHIR BELG, V104, P393, DOI 10.1080/00015458.2004.11679580; Dijkstra S, 1997, DIABETIC MED, V14, P1080, DOI 10.1002/(SICI)1096-9136(199712)14:12<1080::AID-DIA496>3.0.CO;2-N; Dillingham TR, 2005, AM J PHYS MED REHAB, V84, P147, DOI 10.1097/01.PHM.0000154899.49528.05; Dorrucci V, 2004, J CARDIOVASC SURG, V45, P193; Dyet JF, 2000, DIABETES-METAB RES, V16, pS16, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR131>3.3.CO;2-N; Edmonds M, 2004, AM J SURG, V187, p25S, DOI 10.1016/S0002-9610(03)00300-3; Edmonds ME, 1999, LANCET, V354, P270, DOI 10.1016/S0140-6736(99)90012-0; El-Tahawy AT, 2000, SAUDI MED J, V21, P344; Eldor R, 2004, DIABETIC MED, V21, P1161, DOI 10.1111/j.1464-5491.2004.01358.x; Falanga V, 2005, LANCET, V366, P1736, DOI 10.1016/S0140-6736(05)67700-8; Faries PL, 2004, AM J SURG, V187, p34S, DOI 10.1016/S0002-9610(03)00302-7; Feinglass J, 2005, J VASC SURG, V41, P823, DOI 10.1016/j.jvs.2005.01.040; Fleischli JE, 1999, FOOT ANKLE INT, V20, P80, DOI 10.1177/107110079902000203; Flynn James, 2003, Br J Community Nurs, V8, pS36; Frykberg R G, 1998, Adv Wound Care, V11, P329; Game F, 2004, DIABETIC MED, V21, P16, DOI 10.1111/j.1464-5491.2004.1424-8.x; Garapati R, 2004, AM J SURG, V187, p81S, DOI 10.1016/S0002-9610(03)00309-X; GERDING DN, 1995, CLIN INFECT DIS, V20, pS283, DOI 10.1093/clinids/20.Supplement_2.S283; Giacalone V F, 1997, J Foot Ankle Surg, V36, P28; Gibbons GW, 2003, SURG CLIN N AM, V83, P659, DOI 10.1016/S0039-6109(02)00199-8; Gil HC, 2004, SEMIN MUSCULOSKEL R, V8, P189, DOI 10.1055/s-2004-835359; Gilcreast DM, 2005, J WOUND OSTOMY CONT, V32, P112, DOI 10.1097/00152192-200503000-00008; GIURINI J M, 1987, Journal of Foot Surgery, V26, P249; Goldstein EJC, 1996, DIABETES CARE, V19, P638, DOI 10.2337/diacare.19.6.638; GRAYSON ML, 1995, JAMA-J AM MED ASSOC, V273, P721, DOI 10.1001/jama.273.9.721; Greenspan A, 1997, SEMIN NUCL MED, V27, P372, DOI 10.1016/S0001-2998(97)80010-4; Harkless Lawrence, 2005, Surg Infect (Larchmt), V6, P27, DOI 10.1089/sur.2005.6.27; HaVan G, 1996, DIABETES CARE, V19, P1257, DOI 10.2337/diacare.19.11.1257; Heggers J P, 1998, J Wound Care, V7, P452; Henke PK, 2005, ANN SURG, V241, P885, DOI 10.1097/01.sla.0000164172.28918.3f; Hirsh J, 2004, ARCH INTERN MED, V164, P2106, DOI 10.1001/archinte.164.19.2106; Hissink RJ, 2000, FOOT ANKLE INT, V21, P320, DOI 10.1177/107110070002100408; Ho V, 2005, J VASC SURG, V42, P81, DOI 10.1016/j.jvs.2005.03.023; Hobbs SD, 2005, EUR J VASC ENDOVASC, V29, P301, DOI 10.1016/j.ejvs.2004.11.002; Hobbs SD, 2005, J VASC SURG, V41, P451, DOI 10.1016/j.jvs.2004.12.039; Hobbs SD, 2004, EUR J VASC ENDOVASC, V28, P573, DOI 10.1016/j.ejvs.2004.08.003; Hobbs SD, 2003, EUR J VASC ENDOVASC, V26, P341, DOI 10.1016/S1078-5884(03)00356-3; Hobbs SD, 2003, EUR J VASC ENDOVASC, V26, P267, DOI 10.1053/ejvs.2002.2011; Holstein P, 2004, DIABETES-METAB RES, V20, pS37, DOI 10.1002/dmrr.452; Horgan O, 2004, DISABIL REHABIL, V26, P837, DOI 10.1080/09638280410001708869; Horobin AJ, 2003, BRIT J DERMATOL, V148, P923, DOI 10.1046/j.1365-2133.2003.05314.x; Huang ME, 2005, ARCH PHYS MED REHAB, V86, P73, DOI 10.1016/j.apmr.2003.12.029; Illig KA, 2001, J VASC SURG, V33, P17, DOI 10.1067/mva.2001.112301; Inderbitzi R, 2003, EUR J VASC ENDOVASC, V26, P59, DOI 10.1053/ejvs.2002.1868; Jeffcoate WJ, 2004, DIABETOLOGIA, V47, P2051, DOI 10.1007/s00125-004-1584-3; Jeffcoate WJ, 2004, DIABETES-METAB RES, V20, pS78, DOI 10.1002/dmrr.476; Jeffcoate WJ, 2004, CLIN INFECT DIS, V39, pS115, DOI 10.1086/383272; JOHNSON S, 1995, CLIN INFECT DIS, V20, pS289, DOI 10.1093/clinids/20.Supplement_2.S289; Jude EB, 2004, DRUG AGING, V21, P833, DOI 10.2165/00002512-200421130-00002; Kaleta JL, 2001, J AM PODIAT MED ASSN, V91, P445, DOI 10.7547/87507315-91-9-445; Kantor J, 2001, DERMATOL SURG, V27, P347, DOI 10.1046/j.1524-4725.2001.00280.x; Karr JC, 2002, J AM PODIAT MED ASSN, V92, P314, DOI 10.7547/87507315-92-5-314; Katz IA, 2005, DIABETES CARE, V28, P555, DOI 10.2337/diacare.28.3.555; Kaye ET, 2000, CURR CLIN TOPICS INF, V20, P43; Khatri G, 2001, AM J MED SCI, V321, P367, DOI 10.1097/00000441-200106000-00002; Kidmas A T, 2004, East Afr Med J, V81, P427; Knowles E Ann, 2002, Ostomy Wound Manage, V48, P50; Lauterbach SR, 2005, ARCH SURG-CHICAGO, V140, P487, DOI 10.1001/archsurg.140.5.487; Lavery LA, 1996, DIABETES CARE, V19, P818, DOI 10.2337/diacare.19.8.818; Lazaris AM, 2004, J ENDOVASC THER, V11, P447, DOI 10.1583/03-1159.1; Lepantalo M, 2000, DIABETES-METAB RES, V16, pS27, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR107>3.0.CO;2-H; Lew DP, 2004, LANCET, V364, P369, DOI 10.1016/S0140-6736(04)16727-5; Lioupis Christos, 2005, Int J Low Extrem Wounds, V4, P45; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; Lipsky BA, 2005, J ANTIMICROB CHEMOTH, V55, P240, DOI 10.1093/jac/dkh531; Lipsky BA, 1999, FEMS IMMUNOL MED MIC, V26, P267, DOI 10.1111/j.1574-695X.1999.tb01398.x; Lipsky BA, 2004, CLIN INFECT DIS, V38, P17, DOI 10.1086/380449; Lipsky BA, 2004, CLIN INFECT DIS, V39, P885, DOI 10.1086/383271; Lipsky BA, 1997, CLIN INFECT DIS, V25, P1318, DOI 10.1086/516148; Lipsky BA, 2004, DIABETES-METAB RES, V20, pS68, DOI 10.1002/dmrr.453; Lipsky BA, 2005, LANCET, V366, P1695, DOI 10.1016/S0140-6736(05)67694-5; LOGERFO FW, 1997, ADV SURG, V30, P417; Macfarlane RM, 1997, DIABETIC MED, V14, P867, DOI 10.1002/(SICI)1096-9136(199710)14:10<867::AID-DIA475>3.0.CO;2-L; Machan Lindsay, 2004, Tech Vasc Interv Radiol, V7, P28, DOI 10.1053/j.tvir.2004.01.004; Mader J T, 1996, Clin Podiatr Med Surg, V13, P701; Maluf KS, 2004, J BIOMECH, V37, P897, DOI 10.1016/j.jbiomech.2003.10.009; Maluf KS, 2003, CLIN BIOMECH, V18, P567, DOI 10.1016/S0268-0033(03)00118-9; Mantey I, 1999, DIABETIC MED, V16, P245, DOI 10.1046/j.1464-5491.1999.00032.x; Margolis DJ, 2005, WOUND REPAIR REGEN, V13, P230, DOI 10.1111/j.1067-1927.2005.130303.x; Margolis DJ, 1999, DIABETES CARE, V22, P692, DOI 10.2337/diacare.22.5.692; Margolis DJ, 2005, DIABETIC MED, V22, P172, DOI 10.1111/j.1464-5491.2004.01375.x; Margolis DJ, 2003, AM J MED, V115, P627, DOI 10.1016/j.amjmed.2003.06.006; Margolis DJ, 2003, DIABETES CARE, V26, P1696, DOI 10.2337/diacare.26.6.1696; Morrison WB, 2002, RADIOL CLIN N AM, V40, P1171, DOI 10.1016/S0033-8389(02)00036-2; Mueller MJ, 2003, J BONE JOINT SURG AM, V85A, P1436, DOI 10.2106/00004623-200308000-00003; MUELLER MJ, 1989, DIABETES CARE, V12, P384, DOI 10.2337/diacare.12.6.384; Murray HJ, 1996, DIABETIC MED, V13, P979, DOI 10.1002/(SICI)1096-9136(199611)13:11<979::AID-DIA267>3.3.CO;2-1; Nabuurs-Franssen MH, 2005, DIABETOLOGIA, V48, P1906, DOI 10.1007/s00125-005-1856-6; Nabuurs-Ranssen MH, 2005, DIABETES CARE, V28, P243, DOI 10.2337/diacare.28.2.243; O'Meara S, 2000, Health Technol Assess, V4, P1; O'Meara SM, 2001, BRIT J SURG, V88, P4, DOI 10.1046/j.1365-2168.2001.01631.x; Ortegon MM, 2004, DIABETES CARE, V27, P901, DOI 10.2337/diacare.27.4.901; Oyibo SO, 2001, DIABETES CARE, V24, P84, DOI 10.2337/diacare.24.1.84; Ozkan O, 2005, MICROSURG, V25, P107, DOI 10.1002/micr.20094; Pathare N A, 1998, Indian J Pathol Microbiol, V41, P437; PECORARO RE, 1990, DIABETES CARE, V13, P513, DOI 10.2337/diacare.13.5.513; Perry JE, 2002, GAIT POSTURE, V15, P101, DOI 10.1016/S0966-6362(01)00176-X; Petre M, 2005, DIABETES CARE, V28, P929, DOI 10.2337/diacare.28.4.929; Petrov O, 1996, J Foot Ankle Surg, V35, P573; Piaggesi A, 1998, DIABETIC MED, V15, P412, DOI 10.1002/(SICI)1096-9136(199805)15:5<412::AID-DIA584>3.3.CO;2-T; Pinzur M, 2004, FOOT ANKLE INT, V25, P545, DOI 10.1177/107110070402500806; Pinzur MS, 2005, FOOT ANKLE INT, V26, P113, DOI 10.1177/107110070502600112; Pittet D, 1999, ARCH INTERN MED, V159, P851, DOI 10.1001/archinte.159.8.851; Ploeg AJ, 2005, EUR J VASC ENDOVASC, V29, P633, DOI 10.1016/j.ejvs.2005.02.014; Prisant LM, 2004, J CLIN PHARMACOL, V44, P423, DOI 10.1177/0091270004263016; Ramachandran A, 2004, DIABETES-METAB RES, V20, pS19, DOI 10.1002/dmrr.440; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; Rayman G, 2005, Br J Nurs, V14, P109; Redekop W, 2004, DIABETES METAB, V30, P549, DOI 10.1016/S1262-3636(07)70154-4; Redekop WK, 2003, PHARMACOECONOMICS, V21, P1171, DOI 10.2165/00019053-200321160-00003; Reiber GE, 2002, JAMA-J AM MED ASSOC, V287, P2552, DOI 10.1001/jama.287.19.2552; Resch S, 2004, DIABETES-METAB RES, V20, pS34, DOI 10.1002/dmrr.436; Resnick HE, 2004, DIABETES CARE, V27, P1286, DOI 10.2337/diacare.27.6.1286; Robertson DD, 2002, J BONE JOINT SURG AM, V84A, P1395, DOI 10.2106/00004623-200208000-00016; Roeckl-Wiedmann I, 2005, BRIT J SURG, V92, P24, DOI 10.1002/bjs.4863; Roghmann MC, 2001, J HOSP INFECT, V47, P98, DOI 10.1053/jhin.2000.0903; Rosales A, 2004, J AM PODIAT MED ASSN, V94, P353, DOI 10.7547/0940353; Rosenthal D, 2004, J CARDIOVASC SURG, V45, P185; RUEF J, 2004, J INTERV CARDIOL, V17, P4427; Saap LJ, 2004, DERMATOL SURG, V30, P1095, DOI 10.1111/j.1524-4725.2004.30334.x; Saar WE, 2005, FOOT ANKLE INT, V26, P27, DOI 10.1177/107110070502600105; Sandnes DK, 2004, J AM COLL SURGEONS, V199, P394, DOI 10.1016/j.jamcollsurg.2004.05.270; Schaper NC, 2004, DIABETES-METAB RES, V20, pS90, DOI 10.1002/dmrr.464; Schweitzer ME, 2004, RADIOL CLIN N AM, V42, P61, DOI 10.1016/S0033-8389(03)00163-5; Sibbald R Gary, 2003, Ostomy Wound Manage, V49, P14; Sibbald R Gary, 2003, Ostomy Wound Manage, V49, P52; Sibbald R Gary, 2003, Ostomy Wound Manage, V49, P76; SIBBALD RG, 2003, OSTOMY WOUND MANAG, V49, P23; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Smiell JM, 1999, WOUND REPAIR REGEN, V7, P335, DOI 10.1046/j.1524-475X.1999.00335.x; SNYDER RJ, 2002, OSTOMY WOUND MANAG, V48, P30; SNYDER RJ, 2002, OSTOMY WOUND MANAG, V48, P32; Snyder Robert J, 2002, Ostomy Wound Manage, V48, P22; Stanley Stephanie, 2004, Br J Nurs, V13, P788; Steed DL, 1996, J AM COLL SURGEONS, V183, P61; Subramaniam B, 2005, ANESTH ANALG, V100, P1241, DOI 10.1213/01.ANE.0000147705.94738.31; Sumpio BE, 2000, NEW ENGL J MED, V343, P787, DOI 10.1056/NEJM200009143431107; Tan JS, 1996, CLIN INFECT DIS, V23, P286, DOI 10.1093/clinids/23.2.286; TASC Working Group, 2000, EUR J VASC ENDOVASC, V19, pS1; TAYLOR LM, 1987, J VASC SURG, V6, P454, DOI 10.1067/mva.1987.avs0060454; Temple ME, 2000, J AM GERIATR SOC, V48, P822, DOI 10.1111/j.1532-5415.2000.tb04760.x; Tennvall GR, 2004, CLIN INFECT DIS, V39, pS132, DOI 10.1086/383275; Tennvall GR, 2001, DIABETOLOGIA, V44, P2077; Tentolouris N, 1999, DIABETIC MED, V16, P767, DOI 10.1046/j.1464-5491.1999.00132.x; Teodorescu VJ, 2004, AM J SURG, V187, p75S, DOI 10.1016/S0002-9610(03)00308-8; Teppler Hedy, 2002, Surg Infect (Larchmt), V3, P337, DOI 10.1089/109629602762539553; TILLO TH, 1990, J AM PODIAT MED ASSN, V80, P211, DOI 10.7547/87507315-80-4-211; Treece KA, 2004, DIABETIC MED, V21, P987, DOI 10.1111/j.1464-5491.2004.01275.x; UCCIOLI L, 1995, DIABETES CARE, V18, P1376, DOI 10.2337/diacare.18.10.1376; Urbancic-Rovan V, 2000, DIABETIC MED, V17, P814, DOI 10.1046/j.1464-5491.2000.00374-2.x; VALK GD, 2001, COCHRANE DB SYST REV, V4; Van Damme H, 2005, Rev Med Liege, V60, P516; Van Damme H, 2001, ACTA CHIR BELG, V101, P123; van Deursen R, 2004, CLIN INFECT DIS, V39, pS87, DOI 10.1086/383268; Venturi ML, 2005, AM J CLIN DERMATOL, V6, P185, DOI 10.2165/00128071-200506030-00005; VEVES A, 1992, DIABETOLOGIA, V35, P660, DOI 10.1007/BF00400259; Vileikyte L, 2001, DIABETES-METAB RES, V17, P246, DOI 10.1002/dmrr.216; Viswanathan V, 2002, J Assoc Physicians India, V50, P1013; Wendelken ME, 2003, WOUNDS, V15, P351; Whaley-Connell A, 2005, ENDOCRIN METAB CLIN, V34, P63, DOI 10.1016/j.ecl.2004.11.007; Wolff H, 2003, CLIN EXP DERMATOL, V28, P134, DOI 10.1046/j.1365-2230.2003.01226.x; WRIAHG PR, 2005, DIABETIC MED, V22, P127; Yildirim S, 2002, ANN PLAS SURG, V48, P258, DOI 10.1097/00000637-200203000-00005; Zimny S, 2004, EXP CLIN ENDOCR DIAB, V112, P191, DOI 10.1055/s-2004-817932; Zimny S, 2004, DIABETES CARE, V27, P942, DOI 10.2337/diacare.27.4.942; Zimny S, 2003, DIABETIC MED, V20, P622, DOI 10.1046/j.1464-5491.2003.01011.x; Zuluaga AF, 2002, BMC INFECT DIS, V2, DOI 10.1186/1471-2334-2-8	240	306	321	2	90	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1725	1735		10.1016/S0140-6736(05)67699-4	http://dx.doi.org/10.1016/S0140-6736(05)67699-4			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291067				2022-12-28	WOS:000233206400029
J	Turner, A; Beales, J; Faure, S; Dunford, RP; Laurie, DA				Turner, A; Beales, J; Faure, S; Dunford, RP; Laurie, DA			The pseudo-response regulator Ppd-H1 provides adaptation to photoperiod in barley	SCIENCE			English	Article							QUANTITATIVE TRAIT LOCUS; CIRCADIAN CLOCK; FLOWERING TIME; APRR1/TOC1 QUINTET; ARABIDOPSIS; RICE; GENE; CONSTANS; RHYTHM; ROLES	Plants commonly use photoperiod (day length) to control the timing of flowering during the year, and variation in photoperiod response has been selected in many crops to provide adaptation to different environments and farming practices. Positional cloning identified Ppd-H1, the major determinant of barley photoperiod response, as a pseudo-response regulator, a class of genes involved in circadian clock function. Reduced photoperiod responsiveness of the ppd-H1 mutant, which is highly advantageous in spring-sown varieties, is explained by altered circadian expression of the photoperiod pathway gene CONSTANS and reduced expression of its downstream target, FT, a key regulator of flowering.	John Innes Ctr Plant Sci Res, Crop Genet Dept, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Laurie, DA (corresponding author), John Innes Ctr Plant Sci Res, Crop Genet Dept, Norwich Res Pk, Norwich NR4 7UH, Norfolk, England.	david.laurie@bbsrc.ac.uk		faure, sebastien/0000-0002-1094-3999				Decousset L, 2000, THEOR APPL GENET, V101, P1202, DOI 10.1007/s001220051598; Doi K, 2004, GENE DEV, V18, P926, DOI 10.1101/gad.1189604; Farre EM, 2005, CURR BIOL, V15, P47, DOI 10.1016/j.cub.2004.12.067; Griffiths S, 2003, PLANT PHYSIOL, V131, P1855, DOI 10.1104/pp.102.016188; Hayama R, 2004, PLANT PHYSIOL, V135, P677, DOI 10.1104/pp.104.042614; Hayama R, 2003, NATURE, V422, P719, DOI 10.1038/nature01549; Kaczorowski KA, 2003, PLANT CELL, V15, P2654, DOI 10.1105/tpc.015065; Kojima S, 2002, PLANT CELL PHYSIOL, V43, P1096, DOI 10.1093/pcp/pcf156; LAURIE DA, 1995, GENOME, V38, P575, DOI 10.1139/g95-074; Laurie DA, 1997, PLANT MOL BIOL, V35, P167, DOI 10.1023/A:1005726329248; Makino S, 2001, PLANT CELL PHYSIOL, V42, P334, DOI 10.1093/pcp/pce036; Michael TP, 2003, SCIENCE, V302, P1049, DOI 10.1126/science.1082971; Mizuno T, 2005, PLANT CELL PHYSIOL, V46, P677, DOI 10.1093/pcp/pci087; Murakami M, 2003, PLANT CELL PHYSIOL, V44, P1229, DOI 10.1093/pcp/pcg135; Nakamichi N, 2005, PLANT CELL PHYSIOL, V46, P686, DOI 10.1093/pcp/pci086; Suarez-Lopez P, 2001, NATURE, V410, P1116, DOI 10.1038/35074138; Valverde F, 2004, SCIENCE, V303, P1003, DOI 10.1126/science.1091761; Yamamoto T, 2000, GENETICS, V154, P885; Yamamoto Y, 2003, PLANT CELL PHYSIOL, V44, P1119, DOI 10.1093/pcp/pcg148; Yano M, 2000, PLANT CELL, V12, P2473, DOI 10.1105/tpc.12.12.2473	20	611	660	1	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1031	1034		10.1126/science.1117619	http://dx.doi.org/10.1126/science.1117619			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284181				2022-12-28	WOS:000233343400048
J	Malone, FD; Canick, JA; Ball, RH; Nyberg, DA; Comstock, CH; Bukowski, R; Berkowitz, RL; Gross, SJ; Dugoff, L; Craigo, SD; Timor-Tritsch, IE; Carr, SR; Wolfe, HM; Dukes, K; Bianchi, DW; Rudnicka, AR; Hackshaw, AK; Lambert-Messerlian, G; Wald, NJ; D'Alton, ME				Malone, FD; Canick, JA; Ball, RH; Nyberg, DA; Comstock, CH; Bukowski, R; Berkowitz, RL; Gross, SJ; Dugoff, L; Craigo, SD; Timor-Tritsch, IE; Carr, SR; Wolfe, HM; Dukes, K; Bianchi, DW; Rudnicka, AR; Hackshaw, AK; Lambert-Messerlian, G; Wald, NJ; D'Alton, ME		FASTER Res Consortium	First-trimester or second-trimester screening, or both, for Down's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETAL NUCHAL-TRANSLUCENCY; MATERNAL AGE; ULTRASOUND; DEFECTS; 1ST	BACKGROUND: It is uncertain how best to screen pregnant women for the presence of fetal Down's syndrome: to perform first-trimester screening, to perform second-trimester screening, or to use strategies incorporating measurements in both trimesters. METHODS: Women with singleton pregnancies underwent first-trimester combined screening (measurement of nuchal translucency, pregnancy-associated plasma protein A [PAPP-A], and the free beta subunit of human chorionic gonadotropin at 10 weeks 3 days through 13 weeks 6 days of gestation) and second-trimester quadruple screening (measurement of alpha-fetoprotein, total human chorionic gonadotropin, unconjugated estriol, and inhibin A at 15 through 18 weeks of gestation). We compared the results of stepwise sequential screening (risk results provided after each test), fully integrated screening (single risk result provided), and serum integrated screening (identical to fully integrated screening, but without nuchal translucency). RESULTS: First-trimester screening was performed in 38,167 patients; 117 had a fetus with Down's syndrome. At a 5 percent false positive rate, the rates of detection of Down's syndrome were as follows: with first-trimester combined screening, 87 percent, 85 percent, and 82 percent for measurements performed at 11, 12, and 13 weeks, respectively; with second-trimester quadruple screening, 81 percent; with stepwise sequential screening, 95 percent; with serum integrated screening, 88 percent; and with fully integrated screening with first-trimester measurements performed at 11 weeks, 96 percent. Paired comparisons found significant differences between the tests, except for the comparison between serum integrated screening and combined screening. CONCLUSIONS: First-trimester combined screening at 11 weeks of gestation is better than second-trimester quadruple screening but at 13 weeks has results similar to second-trimester quadruple screening. Both stepwise sequential screening and fully integrated screening have high rates of detection of Down's syndrome, with low false positive rates.	Columbia Univ Coll Phys & Surg, New York, NY 10032 USA; Royal Coll Surgeons Ireland, Dublin 2, Ireland; Brown Univ, Sch Med, Providence, RI 02912 USA; Univ Utah, Salt Lake City, UT USA; Intermt HealthCare, Salt Lake City, UT USA; William Beaumont Hosp, Royal Oak, MI 48072 USA; Univ Texas, Med Branch, Galveston, TX 77550 USA; Mt Sinai Sch Med, New York, NY USA; Montefiore Med Ctr, Bronx, NY 10467 USA; Albert Einstein Coll Med, Bronx, NY 10467 USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Tufts Univ, Sch Med, Boston, MA 02111 USA; NYU, Sch Med, New York, NY USA; Univ N Carolina, Med Ctr, Chapel Hill, NC USA; DM STAT, Boston, MA USA; Wolfson Inst Prevent Med, London, England; UCL, London, England	Columbia University; Royal College of Surgeons - Ireland; Brown University; Utah System of Higher Education; University of Utah; Intermountain Healthcare; Intermountain Medical Center; Beaumont Health; University of Texas System; University of Texas Medical Branch Galveston; Icahn School of Medicine at Mount Sinai; Montefiore Medical Center; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Tufts University; New York University; University of North Carolina; University of North Carolina Chapel Hill; University of London; Queen Mary University London; University of London; University College London	Malone, FD (corresponding author), Royal Coll Surgeons Ireland, Rotunda Hosp, Dept Obstet & Gynaecol, Parnell Sq, Dublin 1, Ireland.	fmalone@rcsi.ie	Malone, Fergal/D-6233-2012; Wald, Nicholas/AAY-8924-2021; Wald, Nicholas/AAY-2814-2021	Rudnicka, Alicja R/0000-0003-0369-8574; Messerlian, Geralyn/0000-0002-9440-3411; Timor-Tritsch, Ilan/0000-0001-9774-3107	NCRR NIH HHS [M01 RR 00054] Funding Source: Medline; NICHD NIH HHS [R01 HD 38652] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD038652] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000054] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		*CDCP, 2002, SERIES CDCP, V20; Egan JFX, 2002, AM J OBSTET GYNECOL, V187, P1230, DOI 10.1067/mob.2002.126980; HADLOCK FP, 1992, RADIOLOGY, V182, P501, DOI 10.1148/radiology.182.2.1732970; Malone FD, 2003, OBSTET GYNECOL, V102, P1066, DOI 10.1016/j.obstetgynecol.2003.08.004; Malone TD, 2005, OBSTET GYNECOL, V106, P288, DOI 10.1097/01.AOG.0000173318.54978.1f; Morris JK, 2002, J MED SCREEN, V9, P2, DOI 10.1136/jms.9.1.2; NICOLAIDES KH, 1992, BRIT MED J, V304, P867, DOI 10.1136/bmj.304.6831.867; Snijders RJM, 1998, LANCET, V352, P343, DOI 10.1016/S0140-6736(97)11280-6; Wald N, 2004, PRENATAL DIAG, V24, P150, DOI 10.1002/pd.840; Wald N J, 2003, Health Technol Assess, V7, P1; Wald N J, 1997, J Med Screen, V4, P181; Wald NJ, 2000, J MED SCREEN, V7, P168; Wald NJ, 2000, J MED SCREEN, V7, P74, DOI 10.1136/jms.7.2.74; Wald NJ, 1997, PRENATAL DIAG, V17, P821, DOI 10.1002/(SICI)1097-0223(199709)17:9<821::AID-PD154>3.3.CO;2-X; Wald NJ, 1999, NEW ENGL J MED, V341, P461, DOI 10.1056/NEJM199908123410701; Wald NJ, 1998, J MED SCREEN, V5, P110; Wald NJ, 1998, J MED SCREEN, V5, P166; Wald NJ, 2000, ANTENATAL NEONATAL S, P23; Wapner R, 2003, NEW ENGL J MED, V349, P1405, DOI 10.1056/NEJMoa025273; Wright D, 2004, PRENATAL DIAG, V24, P762, DOI 10.1002/pd.974	20	728	799	3	92	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 10	2005	353	19					2001	2011		10.1056/NEJMoa043693	http://dx.doi.org/10.1056/NEJMoa043693			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282175	Green Published, Bronze			2022-12-28	WOS:000233119600005
J	Steingrimsdottir, L; Gunnarsson, O; Indridason, OS; Franzson, L; Sigurdsson, G				Steingrimsdottir, L; Gunnarsson, O; Indridason, OS; Franzson, L; Sigurdsson, G			Relationship between serum parathyroid hormone levels, vitamin D sufficiency, and calcium intake	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL DENSITY; ELDERLY-WOMEN; FRACTURES; CHOLECALCIFEROL; POPULATION; PREGNANCY; SEASON; MEN	Context Adequate vitamin D status for optimum bone health has received increased recognition in recent years; however, the ideal intake is not known. Serum 25-hydroxyvitamin D is the generally accepted indicator of vitamin D status, but no Universal reference level has been reached. Objective To investigate the relative importance of high calcium intake and serum 25-hydroxyvitamin D for calcium homeostasis, as determined by serum intact parathyroid hormone (PTH). Design, Setting, and Participants Cross-sectional study of 2310 healthy Icelandic adults who were divided equally into 3 age groups (30-45 years, 50-65 years, or 70-85 years) and recruited from February 2001 to January 2003. They were administered a semi-quantitative food frequency questionnaire, which assessed vitamin D and calcium intake. Participants were further divided into groups according to calcium intake (<800 mg/d, 800-1200 mg/d, and >1200 mg/d) and serum 25-hydroxyvitamin D level (<10 ng/mL, 10-18 ng/mL, and >18 ng/mL). Main Outcome Measure Serum intact PTH as determined by calcium intake and vitamin D. Results A total of 944 healthy participants completed all parts of the study. After adjusting for relevant factors, serum PTH was lowest in the group with a serum 25-hydroxyvitamin D level of more than 18 ng/mL but highest in the group with a serum 25-hydroxyvitamin D level of less than 10 ng/mL. At the low serum 25-hydroxyvitamin D level (<10 ng/mL), calcium intake of less than 800 mg/d vs more than 1200 mg/d was significantly associated with higher serum PTH (P=.04); and at a calcium intake of more than 1200 mg/d, there was a significant difference between the lowest and highest vitamin D groups (P=.04). Conclusions As long as vitamin D status is ensured, calcium intake levels of more than 800 mg/d may be unnecessary for maintaining calcium metabolism. Vitamin D supplements are necessary for adequate vitamin D status in northern climates.	Landspitali Univ Hosp, Dept Med, Div Endocrinol & Metab, IS-101 Reykjavik, Iceland; Publ Hlth Inst Iceland, Reykjavik, Iceland; Univ Iceland, Reykjavik, Iceland	Landspitali National University Hospital; University of Iceland	Gunnarsson, O (corresponding author), Landspitali Univ Hosp, Dept Med, Div Endocrinol & Metab, IS-101 Reykjavik, Iceland.	gunnars@landspitali.is	Steingrimsdottir, Laufey/L-3150-2015					Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204; Bates CJ, 2003, OSTEOPOROSIS INT, V14, P152, DOI 10.1007/s00198-002-1338-3; Chapuy MC, 1997, OSTEOPOROSIS INT, V7, P439, DOI 10.1007/s001980050030; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; DawsonHughes B, 1997, AM J CLIN NUTR, V65, P67, DOI 10.1093/ajcn/65.1.67; Harkness L, 2005, OSTEOPOROSIS INT, V16, P109, DOI 10.1007/s00198-004-1656-8; Heaney RP, 2005, VITAMIN D: VOLS 1 AND 2, 2ND EDITION, P773; Heaney RP, 2003, BONE, V33, P457, DOI 10.1016/S8756-3282(03)00236-9; Heaney RP, 2003, AM J CLIN NUTR, V77, P204, DOI 10.1093/ajcn/77.1.204; Heaney RP, 2002, NUTR RES, V22, P153, DOI 10.1016/S0271-5317(01)00358-X; Hollis BW, 2004, AM J CLIN NUTR, V79, P717; Kinyamu HK, 1998, AM J CLIN NUTR, V67, P342, DOI 10.1093/ajcn/67.2.342; Lips P, 2001, ENDOCR REV, V22, P477, DOI 10.1210/er.22.4.477; Lips P, 1998, SERONO SYMP, P262; LIPS P, 1991, CLIN ENDOCRINOL, V35, P35, DOI 10.1111/j.1365-2265.1991.tb03493.x; Lips P, 1999, OSTEOPOROSIS INT, V9, P394, DOI 10.1007/s001980050162; Nutrition and Bone Health: With Particular Reference to Calcium and Vitamin D Report of the Subgroup on Bone Health, 1998, REP HLTH SOC SUBJ LO, V49, P1; Olafsdottir AS, 2005, BJOG-INT J OBSTET GY, V112, P424, DOI 10.1111/j.1471-0528.2005.00477.x; OOMS ME, 1995, J BONE MINER RES, V10, P1177; Sigurdsson G, 1999, Laeknabladid, V85, P398; Sigurdsson G, 2000, OSTEOPOROSIS INT, V11, P1031, DOI 10.1007/s001980070024; STEINGRIMSDOTTI.L, 2003, ICELANDIC NATL NUTR; Thornorsdottir Inga, 2004, Laeknabladid, V90, P37; Trivedi DP, 2003, BMJ-BRIT MED J, V326, P469, DOI 10.1136/bmj.326.7387.469; Vieth R, 2001, AM J CLIN NUTR, V73, P288; WEBB AR, 1988, J CLIN ENDOCR METAB, V67, P373, DOI 10.1210/jcem-67-2-373; Zittermann A, 2003, BRIT J NUTR, V89, P552, DOI 10.1079/BJN2003837	28	349	356	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 9	2005	294	18					2336	2341		10.1001/jama.294.18.2336	http://dx.doi.org/10.1001/jama.294.18.2336			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981LI	16278362				2022-12-28	WOS:000233089700026
J	Boehm, U; Zou, ZH; Buck, LB				Boehm, U; Zou, ZH; Buck, LB			Feedback loops link odor and pheromone signaling with reproduction	CELL			English	Article							GREEN FLUORESCENT PROTEIN; LUTEINIZING-HORMONE; MALE-MICE; VOMERONASAL SYSTEM; OLFACTORY CORTEX; BRAIN; GLUTAMATE; LOCALIZATION; RECEPTORS; RESPONSES	Pheromones can have profound effects on reproductive physiology and behavior in mammals. To investigate the neural circuits underlying these effects, we used a genetic transneuronal tracer to identify neurons that synapse with GnRH (LHRH) neurons, the key regulators of reproduction. We then asked whether the connected neurons are presynaptic or postsynaptic to GnRH neurons and analyzed their responses to chemosensory cues. Surprisingly, these experiments indicate that GnRH neurons receive pheromone signals from both odor and pheromone relays in the brain and may also receive common odor signals. Moreover, feedback loops are evident whereby GnRH neurons could influence both odor and pheromone processing. Remarkably, similar to 800 GnRH neurons communicate with similar to 50,000 neurons in 53 functionally diverse brain areas, with some connections exhibiting sexual dimorphism. These studies reveal a complex interplay between reproduction and other functions in which GnRH neurons appear to integrate information from multiple sources and modulate a variety of brain functions.	Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Howard Hughes Medical Institute	Buck, LB (corresponding author), Fred Hutchinson Canc Res Ctr, Howard Hughes Med Inst, 1100 Fairview Ave N, Seattle, WA 98109 USA.	lbuck@fhcrc.org	Oka, Yoshitaka/C-9670-2010	Oka, Yoshitaka/0000-0002-3482-3051				BADR M, 1987, SYNAPSE, V1, P567, DOI 10.1002/syn.890010609; Buck LB, 2000, CELL, V100, P611, DOI 10.1016/S0092-8674(00)80698-4; COQUELIN A, 1980, ENDOCRINOLOGY, V106, P1224, DOI 10.1210/endo-106-4-1224; COQUELIN A, 1984, J NEUROSCI, V4, P2230; Dong HW, 2001, BRAIN RES REV, V38, P192, DOI 10.1016/S0165-0173(01)00079-0; Dulac C, 2003, NAT REV NEUROSCI, V4, P551, DOI 10.1038/nrn1140; ERLANDER MG, 1991, NEURON, V7, P91, DOI 10.1016/0896-6273(91)90077-D; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; Gore A. C, 2002, GNRH MASTER MOL REPR; Halpern M, 2003, PROG NEUROBIOL, V70, P245, DOI 10.1016/S0301-0082(03)00103-5; Horowitz LF, 1999, P NATL ACAD SCI USA, V96, P3194, DOI 10.1073/pnas.96.6.3194; Jennes L, 1997, RECENT PROG HORM RES, V52, P475; JENNES L, 1988, BRAIN RES, V452, P156, DOI 10.1016/0006-8993(88)90020-0; Jones Barbara E., 1995, P155; Kandel E., 2000, PRINCIPLES NEURAL SC; Keverne EB, 1999, SCIENCE, V286, P716, DOI 10.1126/science.286.5440.716; Ma WD, 1999, CHEM SENSES, V24, P289, DOI 10.1093/chemse/24.3.289; MARUNIAK JA, 1976, ENDOCRINOLOGY, V99, P963, DOI 10.1210/endo-99-4-963; Meisel Robert L., 1994, P3; Meredith M, 1998, ANN NY ACAD SCI, V855, P349, DOI 10.1111/j.1749-6632.1998.tb10593.x; Novotny MV, 2003, BIOCHEM SOC T, V31, P117, DOI 10.1042/BST0310117; Pfaff Donald W., 1994, P107; Shipley Michael T., 1995, P899; Silverman Ann-Judith, 1994, P1683; Simerly RB, 2002, ANNU REV NEUROSCI, V25, P507, DOI 10.1146/annurev.neuro.25.112701.142745; Simerly Richard B., 1995, P353; Simmons DA, 2003, J COMP NEUROL, V459, P290, DOI 10.1002/cne.10605; Spergel DJ, 1999, J NEUROSCI, V19, P2037; Suter KJ, 2000, ENDOCRINOLOGY, V141, P412, DOI 10.1210/en.141.1.412; Swanson LW, 2000, BRAIN RES, V886, P113, DOI 10.1016/S0006-8993(00)02905-X; Swanson LW, 2000, TRENDS NEUROSCI, V23, P519, DOI 10.1016/S0166-2236(00)01639-8; West AE, 2001, P NATL ACAD SCI USA, V98, P11024, DOI 10.1073/pnas.191352298; WRAY S, 1989, P NATL ACAD SCI USA, V86, P8132, DOI 10.1073/pnas.86.20.8132; WYSOCKI CJ, 1991, J STEROID BIOCHEM, V39, P661, DOI 10.1016/0960-0760(91)90265-7; Zou ZH, 2005, P NATL ACAD SCI USA, V102, P7724, DOI 10.1073/pnas.0503027102; Zou ZH, 2001, NATURE, V414, P173, DOI 10.1038/35102506	36	236	240	0	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					683	695		10.1016/j.cell.2005.09.027	http://dx.doi.org/10.1016/j.cell.2005.09.027			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16290036	Bronze			2022-12-28	WOS:000233497400016
J	Gilliland, WD; Hawley, RS				Gilliland, WD; Hawley, RS			Cohesin and the maternal age effect	CELL			English	Editorial Material							HUMAN OOCYTES; RECOMBINATION; ANEUPLOIDY; MEIOSIS	During melosis in human oocytes, chromosome nondisjunction increases with maternal age, leading to disorders such as Down's syndrome. In a recent study in Nature Genetics, Hodges et al. (2005) show that mice with a mutation in the melosis-specific cohesin protein SMC1 beta exhibit age-dependent defects in meiosis. These defects are similar to those observed in oocytes of older human mothers. Their results implicate an age-dependent loss of function in SMC1 beta (or related proteins) in the maternal age effect of humans.	Stowers Inst Med Res, Kansas City, MO 64110 USA	Stowers Institute for Medical Research	Gilliland, WD (corresponding author), Stowers Inst Med Res, 1000 E 50th St, Kansas City, MO 64110 USA.			Hawley, R. Scott/0000-0002-6478-0494				ANGELL RR, 1995, CYTOGENET CELL GENET, V69, P266, DOI 10.1159/000133977; Hassold T, 2001, NAT REV GENET, V2, P280, DOI 10.1038/35066065; Hunt PA, 2003, CURR BIOL, V13, P546, DOI 10.1016/S0960-9822(03)00189-1; Jeffreys CA, 2003, CURR BIOL, V13, P498, DOI 10.1016/S0960-9822(03)00134-9; Lamb NE, 2005, CYTOGENET GENOME RES, V111, P250, DOI 10.1159/000086896; Pellestor F, 2003, HUM GENET, V112, P195, DOI 10.1007/s00439-002-0852-x; Petronczki M, 2003, CELL, V112, P423, DOI 10.1016/S0092-8674(03)00083-7; Revenkova E, 2004, NAT CELL BIOL, V6, P555, DOI 10.1038/ncb1135; Wolstenholme J, 2000, CHROMOSOMA, V109, P435, DOI 10.1007/s004120000088	9	15	15	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					371	373		10.1016/j.cell.2005.10.018	http://dx.doi.org/10.1016/j.cell.2005.10.018			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269329	Bronze			2022-12-28	WOS:000233264300006
J	Sawaya, GF				Sawaya, GF			A 21-year-old woman with atypical squamous cells of undetermined significance	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CERVICAL INTRAEPITHELIAL NEOPLASIA; HUMAN-PAPILLOMAVIRUS TYPE-16; 2001 CONSENSUS GUIDELINES; FOLLOW-UP; MANAGEMENT STRATEGIES; SCREENING PRACTICES; PARTICLE VACCINE; YOUNG-WOMEN; RISK; TRIAGE		Univ Calif San Francisco, Dept Obstet Gynecol & Reprod Sci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; San Francisco Gen Hosp, Cerv Dysplasia Clin, San Francisco, CA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; San Francisco General Hospital Medical Center	Sawaya, GF (corresponding author), 3333 Calif St,Suite 335, San Francisco, CA 94118 USA.	sawayag@obgyn.ucsf.edu			AGENCY FOR HEALTHCARE RESEARCH AND QUALITY [P01HS010856] Funding Source: NIH RePORTER; AHRQ HHS [1 P01 HS10856] Funding Source: Medline	AGENCY FOR HEALTHCARE RESEARCH AND QUALITY(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		*ACOG, 2005, OBSTET GYNECOL, V106, P645; *AM COLL OBST GYN, 2004, ETH OBST GYN PAT TES; American College of Obstetricians and Gynecologists, 2003, Int J Gynaecol Obstet, V83, P237; Anhang R, 2004, CANCER-AM CANCER SOC, V100, P315, DOI 10.1002/cncr.20007; Arbyn M, 2004, JNCI-J NATL CANCER I, V96, P280, DOI 10.1093/jnci/djh037; Bernstein SJ, 2001, AM J OBSTET GYNECOL, V185, P308, DOI 10.1067/mob.2001.116736; Castle PE, 2005, JNCI-J NATL CANCER I, V97, P1066, DOI 10.1093/jnci/dji186; Chan PG, 2003, OBSTET GYNECOL, V102, P765, DOI 10.1016/S0029-7844(03)00696-3; Ferris DG, 1997, ARCH FAM MED, V6, P348, DOI 10.1001/archfami.6.4.348; FLANNELLY G, 1994, BRIT MED J, V308, P1399, DOI 10.1136/bmj.308.6941.1399; Guido R, 2003, AM J OBSTET GYNECOL, V188, P1401, DOI 10.1067/mob.2003.456; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; Hogewoning CJA, 2003, INT J CANCER, V107, P811, DOI 10.1002/ijc.11474; Kim JJ, 2002, JAMA-J AM MED ASSOC, V287, P2382, DOI 10.1001/jama.287.18.2382; Kjaer SK, 2001, CANCER EPIDEM BIOMAR, V10, P101; Koutsky LA, 2000, J NATL CANCER I, V92, P397, DOI 10.1093/jnci/92.5.397; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Kulasingam SL, 2002, JAMA-J AM MED ASSOC, V288, P1749, DOI 10.1001/jama.288.14.1749; Le T, 2004, J Obstet Gynaecol Can, V26, P788; Levi AW, 2003, CANCER CYTOPATHOL, V99, P191, DOI 10.1002/cncr.11507; Maissi E, 2004, BMJ-BRIT MED J, V328, P1293, DOI 10.1136/bmj.328.7451.1293; Manhart LE, 2002, SEX TRANSM DIS, V29, P725, DOI 10.1097/00007435-200211000-00018; Maxwell GL, 2002, OBSTET GYNECOL, V100, P740, DOI 10.1016/S0029-7844(02)02195-6; McGoogan E, 1998, ACTA CYTOL, V42, P25, DOI 10.1159/000331532; McIntyre-Seltman K, 2005, CANCER EPIDEM BIOMAR, V14, P1165, DOI 10.1158/1055-9965.EPI-04-0918; Moscicki AB, 2004, LANCET, V364, P1678, DOI 10.1016/S0140-6736(04)17354-6; Munoz N, 2003, NEW ENGL J MED, V348, P518, DOI 10.1056/NEJMoa021641; Noller KL, 2003, OBSTET GYNECOL, V102, P259, DOI 10.1016/S0029-7844(03)00565-9; Obwegeser JH, 2001, ACTA CYTOL, V45, P709, DOI 10.1159/000328292; Ries L., 2005, SEER CANC STAT REV 1; Sadler L, 2004, JAMA-J AM MED ASSOC, V291, P2100, DOI 10.1001/jama.291.17.2100; Saint M, 2005, AM J OBSTET GYNECOL, V192, P414, DOI 10.1016/j.ajog.2004.09.026; Samson SLA, 2005, OBSTET GYNECOL, V105, P325, DOI 10.1097/01.AOG.0000151991.09124.bb; Saslow D, 2002, CA-CANCER J CLIN, V52, P342, DOI 10.3322/canjclin.52.6.342; Sawaya GF, 1999, OBSTET GYNECOL, V94, P307, DOI 10.1016/S0029-7844(99)00289-6; Sawaya GF, 2002, JAMA-J AM MED ASSOC, V288, P1350; Schiffman M, 2005, J NATL CANCER I, V97, P147, DOI 10.1093/jnci/dji014; Schiffman M, 2000, ACTA CYTOL, V44, P726, DOI 10.1159/000328554; Schiffman Mark, 2003, J Natl Cancer Inst Monogr, P14; Schwarz EB, 2005, CONTRACEPTION, V72, P179, DOI 10.1016/j.contraception.2005.04.009; Sherman ME, 2002, J NATL CANCER I, V94, P102, DOI 10.1093/jnci/94.2.102; Shlay JC, 2000, OBSTET GYNECOL, V96, P410, DOI 10.1016/S0029-7844(00)00907-8; Solomon D, 2001, J NATL CANCER I, V93, P293, DOI 10.1093/jnci/93.4.293; Solomon D, 2003, AM J OBSTET GYNECOL, V188, P1383, DOI 10.1067/mob.2003.457; Solomon D, 2002, JAMA-J AM MED ASSOC, V287, P2114, DOI 10.1001/jama.287.16.2114; STEVENS IM, 2002, JAMA-J AM MED ASSOC, V287, P2452; Stewart FH, 2001, JAMA-J AM MED ASSOC, V285, P2232, DOI 10.1001/jama.285.17.2232; Stoler MH, 2001, JAMA-J AM MED ASSOC, V285, P1500, DOI 10.1001/jama.285.11.1500; Stuart Gavin, 2004, J Obstet Gynaecol Can, V26, P1004; U. S. Preventive Services Task Force, 2003, SCREEN CERV CANC; Villa LL, 2005, LANCET ONCOL, V6, P271, DOI 10.1016/S1470-2045(05)70101-7; Wang SS, 2004, CANCER-AM CANCER SOC, V100, P1035, DOI 10.1002/cncr.20064; Winer RL, 2003, AM J EPIDEMIOL, V157, P218, DOI 10.1093/aje/kwf180; Wright TC, 2003, AM J OBSTET GYNECOL, V189, P295, DOI 10.1067/mob.2003.633; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 2003, NEW ENGL J MED, V348, P489, DOI 10.1056/NEJMp020178	56	14	14	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2210	2218		10.1001/jama.294.17.2210	http://dx.doi.org/10.1001/jama.294.17.2210			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264163				2022-12-28	WOS:000232957700024
J	Luquet, S; Perez, FA; Hnasko, TS; Palmiter, RD				Luquet, S; Perez, FA; Hnasko, TS; Palmiter, RD			NPY/AgRP neurons are essential for feeding in adult mice but can be ablated in neonates	SCIENCE			English	Article							NEUROPEPTIDE-Y; FOOD-INTAKE; RECEPTOR; LEPTIN; OBESITY; DEFICIENCY; GENE; AGRP	Hypothalamic neurons that express neuropeptide Y (NPY) and agouti-related protein (AgRP) are thought to be critical regulators of feeding behavior and body weight. To determine whether NPY/AgRP neurons are essential in mice, we targeted the human diphtheria toxin receptor to the Agrp locus, which allows temporally controlled ablation of NPY/AgRP neurons to occur after an injection of diphtheria toxin. Neonatal ablation of NPY/AgRP neurons had minimal effects on feeding, whereas their ablation in adults caused rapid starvation. These results suggest that network-based compensatory mechanisms can develop after the ablation of NPY/AgRP neurons in neonates but do not readily occur when these neurons become essential in adults.	Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Palmiter, RD (corresponding author), Univ Washington, Howard Hughes Med Inst, Box 357370, Seattle, WA 98195 USA.	palmiter@u.washington.edu	Luquet, serge/AAT-1809-2021	Luquet, serge/0000-0001-8668-6645; Hnasko, Thomas/0000-0001-6176-8513	NATIONAL INSTITUTE ON DRUG ABUSE [K01DA026504] Funding Source: NIH RePORTER; NIDA NIH HHS [K01 DA026504] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		Bewick GA, 2005, FASEB J, V19, P1680, DOI 10.1096/fj.04-3434fje; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Broberger C, 1998, P NATL ACAD SCI USA, V95, P15043, DOI 10.1073/pnas.95.25.15043; Buch T, 2005, NAT METHODS, V2, P419, DOI 10.1038/NMETH762; Chen HY, 2004, ENDOCRINOLOGY, V145, P2607, DOI 10.1210/en.2003-1596; CLARK JT, 1984, ENDOCRINOLOGY, V115, P427, DOI 10.1210/endo-115-1-427; Cone RD, 1996, RECENT PROG HORM RES, V51, P287; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Elmquist JK, 1998, J COMP NEUROL, V395, P535; Erickson JC, 1996, NATURE, V381, P415, DOI 10.1038/381415a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; Gropp E, 2005, NAT NEUROSCI, V8, P1289, DOI 10.1038/nn1548; Hahn TM, 1998, NAT NEUROSCI, V1, P271, DOI 10.1038/1082; Hinney A, 1999, J CLIN ENDOCR METAB, V84, P1483, DOI 10.1210/jc.84.4.1483; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Krude H, 1999, ANN NY ACAD SCI, V885, P419; Marsh DJ, 1998, NAT MED, V4, P718, DOI 10.1038/nm0698-718; Marsh DJ, 1999, BRAIN RES, V848, P66, DOI 10.1016/S0006-8993(99)01962-9; Palmiter RD, 1998, RECENT PROG HORM RES, V53, P163; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; Qian S, 2002, MOL CELL BIOL, V22, P5027, DOI 10.1128/MCB.22.14.5027-5035.2002; Saito M, 2001, NAT BIOTECHNOL, V19, P746, DOI 10.1038/90795; Schwartz MW, 2000, NATURE, V404, P661, DOI 10.1038/35007534; Schwartz MW, 2005, SCIENCE, V307, P375, DOI 10.1126/science.1104344; Woods SC, 1998, SCIENCE, V280, P1378, DOI 10.1126/science.280.5368.1378; Yaswen L, 1999, NAT MED, V5, P1066, DOI 10.1038/12506; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	27	770	788	3	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					683	685		10.1126/science.1115524	http://dx.doi.org/10.1126/science.1115524			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254186				2022-12-28	WOS:000232997700044
J	Premawardhena, A; Fisher, CA; Olivieri, NF; de Silva, S; Arambepola, M; Perera, W; O'Donnell, A; Peto, TEA; Viprakasit, V; Merson, L; Muraca, G; Weatherall, DJ				Premawardhena, A; Fisher, CA; Olivieri, NF; de Silva, S; Arambepola, M; Perera, W; O'Donnell, A; Peto, TEA; Viprakasit, V; Merson, L; Muraca, G; Weatherall, DJ			Haemoglobin E beta thalassaemia in Sri Lanka	LANCET			English	Article								Haemoglobin E beta thalassaemia is the commonest form of severe thalassaemia in many Asian countries, but little is known about its natural history, the reasons for clinical diversity, or its management. We studied 109 Sri Lankan patients with the disorder over 5 years. 25 patients were not receiving transfusion; transfusion was stopped with no deleterious effect in a further 37. We identified several genetic and environmental factors that might contribute to the phenotypic diversity of the disorder, including modifiers of haemoglobin F production, malaria, and age-related changes in adaptive function. Our findings suggest that haemoglobin E beta thalassaemia can be managed without transfusion in many patients, even with low haemoglobin levels. Age-related changes in the pattern of adaptation to anaemia suggest that different and more cost-effective approaches to management should be explored.	Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England; Natl Thalassaemia Ctr, Gen Hosp, Kurunegala, Sri Lanka; Univ Hlth Network, Hemoglobinopathy Res, Toronto, ON, Canada; Mahidol Univ, Siriraj Hosp, Dept Paediat, Div Haematol Oncol, Bangkok 10700, Thailand	University of Oxford; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Mahidol University	Weatherall, DJ (corresponding author), Univ Oxford, John Radcliffe Hosp, Weatherall Inst Mol Med, Oxford OX3 9DS, England.	liz.rose@imm.ox.ac.uk	Premawardhena, Anuja/GLN-5388-2022; Olivieri, Nancy/AAI-2250-2020	Premawardhena, Anuja/0000-0003-0605-9081; peto, tim/0000-0003-3477-8307; Muraca, Giulia/0000-0003-4618-0839; Merson, Laura/0000-0002-4168-1960	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Fisher CA, 2003, BRIT J HAEMATOL, V121, P662, DOI 10.1046/j.1365-2141.2003.04346.x; Fucharoen S, 1997, HEMOGLOBIN, V21, P299, DOI 10.3109/03630269709000664; Premawardhena A, 2001, LANCET, V357, P1945, DOI 10.1016/S0140-6736(00)05082-0; SNOUNOU G, 1993, MOL BIOCHEM PARASIT, V61, P315, DOI 10.1016/0166-6851(93)90077-B; Viprakasit V, 2004, BLOOD, V103, P3296, DOI 10.1182/blood-2003-11-3957; Walker S. R., 1993, QUALITY LIFE ASSESSM; Weatherall D.J., 2001, THALASSAEMIA SYNDROM, Vfourth	7	73	75	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT 22	2005	366	9495					1467	1470		10.1016/S0140-6736(05)67396-5	http://dx.doi.org/10.1016/S0140-6736(05)67396-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243092				2022-12-28	WOS:000232724600026
J	Brennan, P; Hsu, CC; Moullan, N; Szeszenia-Dabrowska, N; Lissowska, J; Zaridze, D; Rudnai, P; Fabianova, E; Mates, D; Bencko, V; Foretova, L; Janout, V; Gemignani, F; Chabrier, A; Hall, J; Hung, RJ; Boffetta, P; Canzian, F				Brennan, P; Hsu, CC; Moullan, N; Szeszenia-Dabrowska, N; Lissowska, J; Zaridze, D; Rudnai, P; Fabianova, E; Mates, D; Bencko, V; Foretova, L; Janout, V; Gemignani, F; Chabrier, A; Hall, J; Hung, RJ; Boffetta, P; Canzian, F			Effect of cruciferous vegetables on lung cancer in patients stratified by genetic status: a mendelian randomisation approach	LANCET			English	Article							POLYMORPHISMS; ISOTHIOCYANATES; RISK; SHANGHAI; WOMEN; CHINA	Whether consumption of cruciferous vegetables protects against lung cancer is unclear, largely because of potential confounding factors. We therefore studied the role of cruciferous vegetables in lung cancer after stratifying by GSTM1 and GSTT1 status, two genes implicated in the elimination of isothiocyanates, the likely chemopreventative compound. In 2141 cases and 2168 controls, weekly consumption of cruciferous vegetables protected against lung cancer in those who were GSTM1 null (odds ratio=0.67, 95% CI 0.49-0.91), GSTT1 null (0.63, 0.37-1.07), or both (0.28, 0.11-0.67). No protective effect was seen in people who were both GSTM1 and GSTT1 positive (0.88, 0.65-1.21). Similar protective results were noted for consumption of cabbage and a combination of broccoli and brussels sprouts. These data provide strong evidence for a substantial protective effect of cruciferous vegetable consumption on lung cancer.	Int Agcy Res Canc, F-69008 Lyon, France; Inst Occupat Med, Dept Epidemiol, Lodz, Poland; Ctr Canc, Dept Canc Epidemiol & Prevent, Warsaw, Poland; M Sklodowska Curie Inst Oncol, Warsaw, Poland; Russian Acad Med Sci, Canc Res Ctr, Inst Carcinogenesis, Moscow, Russia; Foder Jozsef Natl Ctr Publ Hlth, Budapest, Hungary; Reg Author Publ Hlth, Banska Bystrika, Slovakia; Inst Publ Hlth, Bucharest, Romania; Charles Univ, Inst Hyg & Epidemiol, Fac Med 1, CR-11636 Prague, Czech Republic; Masaryk Mem Canc Inst, Dept Canc Epidemiol & Genet, Brno, Czech Republic; Palacky Univ Med, Dept Prevent Med, Olomouc, Czech Republic	World Health Organization; International Agency for Research on Cancer (IARC); Nofer Institute of Occupational Medicine; Maria Sklodowska-Curie National Research Institute of Oncology; Russian Academy of Medical Sciences; Regional Authority of Public Health Banska Bystrica; Charles University Prague; Masaryk Memorial Cancer Institute; Palacky University Olomouc	Brennan, P (corresponding author), Int Agcy Res Canc, F-69008 Lyon, France.	brennan@iarc.fr	Janout, Vladimir/M-5133-2014; Bencko, Vladimir/H-8598-2017; hall, janet/G-1372-2013; Boffetta, Paolo/AAI-7767-2021; Hung, Rayjean J/A-7439-2013; Szeszenia-Dabrowska, Neonila/F-7190-2010; Lissowska, Jolanta/AAH-3252-2020; Canzian, Federico/I-2804-2014	Bencko, Vladimir/0000-0003-1935-2228; hall, janet/0000-0002-4397-6295; Boffetta, Paolo/0000-0002-3811-2791; Lissowska, Jolanta/0000-0003-2695-5799; Canzian, Federico/0000-0002-4261-4583; Hung, Rayjean/0000-0002-4486-7496; mates, dana/0000-0002-6219-9807; Foretova, Lenka/0000-0003-0494-2620; GEMIGNANI, Federica/0000-0003-1297-0701	NCI NIH HHS [R01 CA 092039-01A2] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA092039] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 2004, IARC HDB CANC PREVEN; Fowke JH, 2003, CANCER EPIDEM BIOMAR, V12, P1536; Hecht SS, 1996, ADV EXP MED BIOL, V401, P1; Hung RJ, 2005, JNCI-J NATL CANCER I, V97, P567, DOI 10.1093/jnci/dji101; London SJ, 2000, LANCET, V356, P724, DOI 10.1016/S0140-6736(00)02631-3; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Spitz MR, 2000, CANCER EPIDEM BIOMAR, V9, P1017; [World Cancer Research Fund American Institute for Cancer Research], 1997, FOOD NUTR PREV CANC; Zhao B, 2001, CANCER EPIDEM BIOMAR, V10, P1063	9	101	107	0	14	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	OCT-NOV	2005	366	9496					1558	1560		10.1016/S0140-6736(05)67628-3	http://dx.doi.org/10.1016/S0140-6736(05)67628-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257343				2022-12-28	WOS:000232984800025
J	Harris, RA; de Ibarra, NH; Graham, P; Collett, TS				Harris, RA; de Ibarra, NH; Graham, P; Collett, TS			Ant navigation - Priming of visual route memories	NATURE			English	Editorial Material							DESERT ANTS; HONEY-BEES; VECTORS; INFORMATION; LANDMARKS; INSECTS		Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England	University of Sussex	Harris, RA (corresponding author), Univ Sussex, Sch Life Sci, Brighton BN1 9QG, E Sussex, England.	t.s.collett@sussex.ac.uk	de Ibarra, Natalie Hempel/A-1962-2013; Graham, Paul/C-6420-2009	de Ibarra, Natalie Hempel/0000-0002-0859-8217; Graham, Paul/0000-0002-3745-0940				Beugnon G, 2005, J INSECT BEHAV, V18, P415, DOI 10.1007/s10905-005-3700-8; Bisch-Knaden S, 2003, J COMP PHYSIOL A, V189, P181, DOI 10.1007/s00359-003-0389-z; Collett M, 1998, NATURE, V394, P269, DOI 10.1038/28378; COLLETT TS, 1992, J COMP PHYSIOL A, V170, P435; Dyer FC, 2002, NATURWISSENSCHAFTEN, V89, P262, DOI 10.1007/s00114-002-0311-5; Graham P, 2002, J EXP BIOL, V205, P2499; Kohler M, 2005, NEUROBIOL LEARN MEM, V83, P1, DOI 10.1016/j.nlm.2004.05.011; KOLTERMANN R, 1971, Z VERGL PHYSIOL, V75, P49, DOI 10.1007/BF00335137; Menzel R, 1998, ANIM BEHAV, V55, P139, DOI 10.1006/anbe.1997.0574; Reinhard J, 2004, J EXP BIOL, V207, P4371, DOI 10.1242/jeb.01306; Santschi F., 1913, Revue Suisse de Zoologie, V21; Wahl O., 1932, Zeitschrift fuer Vergleichende Physiologie Berlin, V16, P529; Wehner R, 1996, J EXP BIOL, V199, P129	13	53	56	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					302	302		10.1038/438302a	http://dx.doi.org/10.1038/438302a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292300	Bronze			2022-12-28	WOS:000233300200034
J	Rifkin, SA; Houle, D; Kim, J; White, KP				Rifkin, SA; Houle, D; Kim, J; White, KP			A mutation accumulation assay reveals a broad capacity for rapid evolution of gene expression	NATURE			English	Article							SELECTION; PROFILES; TISSUE	Mutation is the ultimate source of biological diversity because it generates the variation that fuels evolution(1). Gene expression is the first step by which an organism translates genetic information into developmental change. Here we estimate the rate at which mutation produces new variation in gene expression by measuring transcript abundances across the genome during the onset of metamorphosis in 12 initially identical Drosophila melanogaster lines that independently accumulated mutations for 200 generations(2). We find statistically significant mutational variation for 39% of the genome and a wide range of variability across corresponding genes. As genes are upregulated in development their variability decreases, and as they are downregulated it increases, indicating that developmental context affects the evolution of gene expression. A strong correlation between mutational variance and environmental variance shows that there is the potential for widespread canalization(3). By comparing the evolutionary rates that we report here with differences between species(4,5), we conclude that gene expression does not evolve according to strictly neutral models. Although spontaneous mutations have the potential to generate abundant variation in gene expression, natural variation is relatively constrained.	Univ Penn, Dept Biol, Goddard Labs 203, Philadelphia, PA 19104 USA; Yale Univ, Dept Ecol & Evolutionary Biol, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Genet, New Haven, CT 06520 USA; Florida State Univ, Dept Biol Sci, Tallahassee, FL 32306 USA	University of Pennsylvania; Yale University; Yale University; State University System of Florida; Florida State University	Kim, J (corresponding author), Univ Penn, Dept Biol, Goddard Labs 203, 415 S Univ Ave, Philadelphia, PA 19104 USA.	junhyong@sas.upenn.edu; kevin.white@yale.edu		Rifkin, Scott/0000-0001-8476-3256; Houle, David/0000-0002-8095-3156				BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Benton MJ, 2003, SCIENCE, V300, P1698, DOI 10.1126/science.1077795; Denver DR, 2005, NAT GENET, V37, P544, DOI 10.1038/ng1554; Fry JD, 2004, GENETIC ANAL COMPLEX, P11; Gu ZL, 2004, NAT GENET, V36, P577, DOI 10.1038/ng1355; HARTL DL, 1985, GENETICS, V111, P655; Houle D, 1996, GENETICS, V143, P1467; Houle D, 1998, GENETICA, V102-3, P241, DOI 10.1023/A:1017034925212; Houle D, 2004, GENET RES, V83, P7, DOI 10.1017/S0016672303006505; Hsieh WP, 2003, GENETICS, V165, P747; Kacser H, 1973, Symp Soc Exp Biol, V27, P65; Khaitovich P, 2004, PLOS BIOL, V2, P682, DOI 10.1371/journal.pbio.0020132; LANDE R, 1975, GENET RES, V26, P221, DOI 10.1017/S0016672300016037; Lemos B, 2005, EVOLUTION, V59, P126; Li TR, 2003, DEV CELL, V5, P59, DOI 10.1016/S1534-5807(03)00192-8; Littell R. C., 2006, SAS SYSTEMS MIXED MO, V2nd; Lynch M, 1999, EVOLUTION, V53, P645, DOI 10.1111/j.1558-5646.1999.tb05361.x; LYNCH M, 1986, EVOLUTION, V40, P915, DOI 10.1111/j.1558-5646.1986.tb00561.x; Lynch Michael, 1998; Meiklejohn CD, 2002, TRENDS ECOL EVOL, V17, P468, DOI 10.1016/S0169-5347(02)02596-X; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Oleksiak MF, 2005, NAT GENET, V37, P67, DOI 10.1038/ng1483; Rifkin SA, 2003, NAT GENET, V33, P138, DOI 10.1038/ng1086; Sokal R.R., 2012, BIOMETRY; WADDINGTON CH, 1953, EVOLUTION, V7, P118, DOI 10.2307/2405747; Wagner GP, 1997, EVOLUTION, V51, P329, DOI [10.2307/2411105, 10.1111/j.1558-5646.1997.tb02420.x]; White KP, 1999, SCIENCE, V286, P2179, DOI 10.1126/science.286.5447.2179; Wolfinger RD, 2001, J COMPUT BIOL, V8, P625, DOI 10.1089/106652701753307520; Yanai I, 2004, OMICS, V8, P15, DOI 10.1089/153623104773547462; Yang HP, 2001, GENETICS, V157, P1285	30	154	154	0	17	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					220	223		10.1038/nature04114	http://dx.doi.org/10.1038/nature04114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281035				2022-12-28	WOS:000233133500048
J	Matranga, C; Tomari, Y; Shin, C; Bartel, DP; Zamore, PD				Matranga, C; Tomari, Y; Shin, C; Bartel, DP; Zamore, PD			Passenger-strand cleavage facilitates assembly of siRNA into Ago2-containing RNAi enzyme complexes	CELL			English	Article							INDUCED SILENCING COMPLEX; MESSENGER-RNA; DROSOPHILA-MELANOGASTER; MICRORNA TARGETS; DISTINCT ROLES; INTERFERENCE; ARGONAUTE2; PATHWAYS; PROTEIN; RISC	In the Drosophila and mammalian RNA interference pathways, sIRNAs direct the protein Argonaute2 (Ago2) to cleave corresponding mRNA targets, silencing their expression. Ago2 is the catalytic component of the RNAi enzyme complex, RISC. For each siRNA duplex, only one strand, the guide, is assembled into the active RISC; the other strand, the passenger, is destroyed. An ATP-dependent helicase has been proposed first to separate the two siRNA strands, then the resulting single-stranded guide is thought to bind Ago2. Here, we show that Ago2 instead directly receives the double-stranded siRNA from the RISC assembly machinery. Ago2 then cleaves the siRNA passenger strand, thereby liberating the single-stranded guide. For siRNAs, virtually all RISC is assembled through this cleavage-assisted mechanism. In contrast, passenger-strained cleavage is not important for the incorporation of mIRNAs that derive from mismatched duplexes.	Univ Massachusetts, Sch Med, Dept Biol Chem & Mol Pharmacol, Worcester, MA 01605 USA; MIT, Dept Biol, Whitehead Inst Biomed Res, Cambridge, MA 02142 USA	University of Massachusetts System; University of Massachusetts Worcester; Massachusetts Institute of Technology (MIT); Whitehead Institute	Zamore, PD (corresponding author), Univ Massachusetts, Sch Med, Dept Biol Chem & Mol Pharmacol, Worcester, MA 01605 USA.	phillip.zamore@umassmed.edu	Zamore, Phillip D/A-8941-2013; Tomari, Yukihide/A-8009-2009	Tomari, Yukihide/0000-0001-8442-0851; Zamore, Phillip/0000-0002-4505-9618; Matranga, Christian/0000-0002-9037-5468	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM062862, R01GM065236, R01GM062862, R01GM067031] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM67031, GM65236, GM62862] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Baumberger N, 2005, P NATL ACAD SCI USA, V102, P11928, DOI 10.1073/pnas.0505461102; Bernstein E, 2001, NATURE, V409, P363, DOI 10.1038/35053110; Brennecke J, 2005, PLOS BIOL, V3, P404, DOI 10.1371/journal.pbio.0030085; Caudy AA, 2003, NATURE, V425, P411, DOI 10.1038/nature01956; Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868; Davis E, 2005, CURR BIOL, V15, P743, DOI 10.1016/j.cub.2005.02.060; Deshpande G, 2005, GENE DEV, V19, P1680, DOI 10.1101/gad.1316805; Doench JG, 2004, GENE DEV, V18, P504, DOI 10.1101/gad.1184404; Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301; Elbashir SM, 2001, NATURE, V411, P494, DOI 10.1038/35078107; Elbashir SM, 2001, EMBO J, V20, P6877, DOI 10.1093/emboj/20.23.6877; Forstemann K, 2005, PLOS BIOL, V3, P1187, DOI 10.1371/journal.pbio.0030236; Haley B, 2004, NAT STRUCT MOL BIOL, V11, P599, DOI 10.1038/nsmb780; Haley B, 2003, METHODS, V30, P330, DOI 10.1016/S1046-2023(03)00052-5; Hamilton AJ, 1999, SCIENCE, V286, P950, DOI 10.1126/science.286.5441.950; Hammond SM, 2001, SCIENCE, V293, P1146, DOI 10.1126/science.1064023; Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Leaman D, 2005, CELL, V121, P1097, DOI 10.1016/j.cell.2005.04.016; Lee YS, 2004, CELL, V117, P69, DOI 10.1016/S0092-8674(04)00261-2; Lewis BP, 2003, CELL, V115, P787, DOI 10.1016/S0092-8674(03)01018-3; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513; Liu QH, 2003, SCIENCE, V301, P1921, DOI 10.1126/science.1088710; Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514; Martinez J, 2004, GENE DEV, V18, P975, DOI 10.1101/gad.1187904; Martinez J, 2002, CELL, V110, P563, DOI 10.1016/S0092-8674(02)00908-X; Meister G, 2004, MOL CELL, V15, P185, DOI 10.1016/j.molcel.2004.07.007; Meister G, 2004, NATURE, V431, P343, DOI 10.1038/nature02873; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Nykanen A, 2001, CELL, V107, P309, DOI 10.1016/S0092-8674(01)00547-5; Okamura K, 2004, GENE DEV, V18, P1655, DOI 10.1101/gad.1210204; Parker JS, 2005, NATURE, V434, P663, DOI 10.1038/nature03462; Pham JW, 2004, CELL, V117, P83, DOI 10.1016/S0092-8674(04)00258-2; Qi Y, 2005, MOL CELL, V19, P421, DOI 10.1016/j.molcel.2005.06.014; Rand TA, 2004, P NATL ACAD SCI USA, V101, P14385, DOI 10.1073/pnas.0405913101; Rivas FV, 2005, NAT STRUCT MOL BIOL, V12, P340, DOI 10.1038/nsmb918; Schwarz DS, 2004, CURR BIOL, V14, P787, DOI 10.1016/j.cub.2004.03.008; Schwarz DS, 2003, CELL, V115, P199, DOI 10.1016/S0092-8674(03)00759-1; Schwarz DS, 2002, MOL CELL, V10, P537, DOI 10.1016/S1097-2765(02)00651-2; Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514; Sontheimer EJ, 2005, NAT REV MOL CELL BIO, V6, P127, DOI 10.1038/nrm1568; Tahbaz N, 2004, EMBO REP, V5, P189, DOI 10.1038/sj.embor.7400070; Tomari Y, 2005, GENE DEV, V19, P517, DOI 10.1101/gad.1284105; Tomari Y, 2004, SCIENCE, V306, P1377, DOI 10.1126/science.1102755; Tomari Y, 2004, CELL, V116, P831, DOI 10.1016/S0092-8674(04)00218-1; Verma S, 1998, ANNU REV BIOCHEM, V67, P99, DOI 10.1146/annurev.biochem.67.1.99; Yekta S, 2004, SCIENCE, V304, P594, DOI 10.1126/science.1097434; Zamore PD, 2000, CELL, V101, P25, DOI 10.1016/S0092-8674(00)80620-0	53	797	920	2	85	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 8	2005	123	4					607	620		10.1016/j.cell.2005.08.044	http://dx.doi.org/10.1016/j.cell.2005.08.044			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16271386	Green Published, Bronze			2022-12-28	WOS:000233497400010
J	Cottam, R				Cottam, R			Is public health coercive health?	LANCET			English	Editorial Material									Croydon PCT, Croydon CR0 6SR, England		Cottam, R (corresponding author), Croydon PCT, Croydon CR0 6SR, England.	rachel.cottam@croydonpct.nhs.uk						Aristotle, 2002, NICOMACHEAN ETHICS; BLAIRS T, 2004, COMMUNICATION   1203; *DEP HLTH, 2004, RED RISK COT DEATH E; *EUROPHEN, 2004, ATT GOV INT PUBL HLT; HAWKES C., 2004, MARKETING FOOD CHILD; HERBERT N, 2004, SPECTATOR       1204; Hobsbawm E, 1969, BANDITS; JONES G, 2004, DAILY TELEGRAPH 1005; Zatonski WA, 2005, BMJ-BRIT MED J, V331, P187, DOI 10.1136/bmj.331.7510.187	9	3	3	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 5	2005	366	9497					1592	1594		10.1016/S0140-6736(05)67644-1	http://dx.doi.org/10.1016/S0140-6736(05)67644-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271631				2022-12-28	WOS:000233047100007
J	Epping-Jordan, JE; Galea, G; Tukuitonga, C; Beaglehole, R				Epping-Jordan, JE; Galea, G; Tukuitonga, C; Beaglehole, R			Chronic diseases 2 - Preventing chronic diseases: taking stepwise action	LANCET			English	Article							CORONARY-HEART-DISEASE; MORTALITY; REDUCTION; DECLINE; RISK	The scientific knowledge to achieve a new global goal for the prevention. of chronic diseases-a 2% yearly reduction in rates of death from chronic disease over and above projected declines during the next 10 years-already exists. However, many low-income and middle-income countries must deal with the practical realities of limited resources and a double burden of infectious and chronic diseases. This paper presents a novel planning framework that can be used in these contexts: the stepwise framework for preventing chronic diseases. The framework offers a flexible and practical public health approach to assist ministries of health in balancing diverse needs and priorities while implementing evidence-based interventions such as those recommended by the WHO Framework Convention on Tobacco Control and the WHO Global Strategy on Diet, Physical Activity and Health. Countries such as Indonesia, the Philippines, Tonga, and Vietnam have applied the stepwise planning framework: their experiences illustrate how the stepwise approach has general applicability to solving chronic disease problems without sacrificing specificity for any particular country.	WHO, Dept Chron Dis & Hlth Promot, CH-1211 Geneva, Switzerland; WHO, Reg Off Western Pacific, Manila, Philippines	World Health Organization; WHO Western Pacific Regional Office; World Health Organization	Epping-Jordan, JE (corresponding author), WHO, Dept Chron Dis & Hlth Promot, 20 Ave Appia, CH-1211 Geneva, Switzerland.	eppingj@who.int		Galea, Gauden/0000-0002-2257-6014				[Anonymous], WORLD HLTH REP 2002; [Anonymous], 2005, PREV CHRON DIS VIT I; Capewell S, 2000, CIRCULATION, V102, P1511, DOI 10.1161/01.CIR.102.13.1511; Critchley JA, 2003, J CLIN EPIDEMIOL, V56, P583, DOI 10.1016/S0895-4356(03)00059-3; Ezzati M, 2005, PLOS MED, V2, P404, DOI 10.1371/journal.pmed.0020133; Fichtenberg CM, 2000, NEW ENGL J MED, V343, P1772, DOI 10.1056/NEJM200012143432406; Joint WHO/FAO Expert Consultation on Diet Nutrition and the Prevention of Chronic Diseases, 2002, WHO TECHN REP SER, V916; Murray CJL, 2003, LANCET, V361, P717, DOI 10.1016/S0140-6736(03)12655-4; Pietinen P, 2001, J Nutr Health Aging, V5, P150; Sargent RP, 2004, BMJ-BRIT MED J, V328, P977, DOI 10.1136/bmj.38055.715683.55; Son LENTD, 2004, DIABETIC MED, V21, P371, DOI 10.1111/j.1464-5491.2004.01159.x; STRONG K, 2005, LANCET          1005; *TONG MIN HLTH, 2003, NAT STRAT PREV CONTR; Unal B, 2004, CIRCULATION, V109, P1101, DOI 10.1161/01.CIR.0000118498.35499.B2; *VIET NAM DEP THER, 2004, WORKSH DEV NAT NCD S; WANG L, 2005, LANCET          1005; *WHO, 2005, SURF REP 2; *WHO, 2003, TONG COMM PROM HLTH; *WORLD CANC RES FU, 1997, FOOD NUTR PREV CANC, P530; World Health Organization, 2003, STEPS FRAM SURV; World Health Organization, 2003, WHO FRAM CONV TOB CO; World Health Organization, 2003, WHO COUNTR COOP STRA; Zatonski WA, 2005, BMJ-BRIT MED J, V331, P187, DOI 10.1136/bmj.331.7510.187	23	119	123	1	11	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 5	2005	366	9497					1667	1671		10.1016/S0140-6736(05)67342-4	http://dx.doi.org/10.1016/S0140-6736(05)67342-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271649				2022-12-28	WOS:000233047100029
J	Balthasar, N; Dalgaard, LT; Lee, CE; Yu, J; Funahashi, H; Williams, T; Ferreira, M; Tang, V; McGovern, RA; Kenny, CD; Christiansen, LM; Edelstein, E; Choi, B; Boss, O; Aschkenasi, C; Zhang, CY; Mountjoy, K; Kishi, T; Elmquist, JK; Lowell, BB				Balthasar, N; Dalgaard, LT; Lee, CE; Yu, J; Funahashi, H; Williams, T; Ferreira, M; Tang, V; McGovern, RA; Kenny, CD; Christiansen, LM; Edelstein, E; Choi, B; Boss, O; Aschkenasi, C; Zhang, CY; Mountjoy, K; Kishi, T; Elmquist, JK; Lowell, BB			Divergence of melanocortin pathways in the control of food intake and energy expenditure	CELL			English	Article							DORSAL VAGAL COMPLEX; PARAVENTRICULAR NUCLEUS; SPINAL-CORD; TRANSGENE EXPRESSION; FRAMESHIFT MUTATION; MESSENGER-RNA; RECEPTOR; OBESITY; RAT; NEURONS	Activation of melanocortin-4-receptors (MC4Rs) reduces body fat stores by decreasing food intake and increasing energy expenditure. MC4Rs are expressed in multiple CNS sites, any number of which could mediate these effects. To identify the functionally relevant sites of MC4R expression, we generated a IoxPmodified, null Mc4r allele (IoxTB Mc4r) that can be reactivated by Cre-recombinase. Mice homozygous for the IoxTB Mc4r allele do not express MC4Rs and are markedly obese. Restoration of MC4R expression in the paraventricular hypothalamus (PVH) and a subpopulation of amygdala neurons, using Sim1-Cre transgenic mice, prevented 60% of the obesity. Of note, increased food intake, typical of Mc4r null mice, was completely rescued while reduced energy expenditure was unaffected. These findings demonstrate that MC4Rs in the PVH and/or the amygdala control food intake but that MC4Rs elsewhere control energy expenditure. Disassociation of food intake and energy expenditure reveals unexpected divergence in melanocortin pathways controlling energy balance.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Neurol,Program Neurosci, Boston, MA 02215 USA; Shimane Univ, Sch Med, Dept Anat & Morphol Neurosci, Izumo, Shimane 6938501, Japan; Univ Auckland, Fac Med & Hlth Sci, Dept Physiol, Auckland 1, New Zealand	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Shimane University; University of Auckland	Elmquist, JK (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div Endocrinol, 99 Brookline Dr, Boston, MA 02215 USA.	jelmquis@bidmc.harvard.edu; blowell@bidmc.harvard.edu	Mountjoy, Kathy/L-4473-2019; Dalgaard, Louise/O-3788-2015	Dalgaard, Louise/0000-0002-3598-2775	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Bachman ES, 2002, SCIENCE, V297, P843, DOI 10.1126/science.1073160; BACON SJ, 1990, EXP BRAIN RES, V79, P589; Bagnol D, 1999, J NEUROSCI, V19; Balthasar N, 2004, NEURON, V42, P983, DOI 10.1016/j.neuron.2004.06.004; BARNSHAD M, 1999, AM J PHYSIOL, V276, pR1569; Blevins JE, 2004, AM J PHYSIOL-REG I, V287, pR87, DOI 10.1152/ajpregu.00604.2003; Butler AA, 2001, NAT NEUROSCI, V4, P605, DOI 10.1038/88423; Chamberlin NL, 1998, BRAIN RES, V793, P169, DOI 10.1016/S0006-8993(98)00169-3; Chen AS, 2000, TRANSGENIC RES, V9, P145, DOI 10.1023/A:1008983615045; Cone RD, 2005, NAT NEUROSCI, V8, P571, DOI 10.1038/nn1455; Cowley MA, 1999, NEURON, V24, P155, DOI 10.1016/S0896-6273(00)80829-6; Elias CF, 1998, NEURON, V21, P1375, DOI 10.1016/S0896-6273(00)80656-X; Fan CM, 1996, MOL CELL NEUROSCI, V7, P1, DOI 10.1006/mcne.1996.0001; Fan W, 2005, PEPTIDES, V26, P1800, DOI 10.1016/j.peptides.2004.11.033; Giraudo SQ, 1998, BRAIN RES, V809, P302, DOI 10.1016/S0006-8993(98)00837-3; GOLD RM, 1973, SCIENCE, V182, P488, DOI 10.1126/science.182.4111.488; Harris M, 2001, J CLIN INVEST, V107, P111, DOI 10.1172/JCI10741; HOGAN B, 1986, MANIPULATING MOUSE E; Holder JL, 2000, HUM MOL GENET, V9, P101; Huszar D, 1997, CELL, V88, P131, DOI 10.1016/S0092-8674(00)81865-6; Kask A, 2000, BRAIN RES, V887, P460, DOI 10.1016/S0006-8993(00)03034-1; Kishi T, 2005, J COMP NEUROL, V482, P217, DOI 10.1002/cne.20432; Kishi T, 2003, J COMP NEUROL, V457, P213, DOI 10.1002/cne.10454; LANDSBERG L, 1984, AM J PHYSIOL, V247, pE181, DOI 10.1152/ajpendo.1984.247.2.E181; Lee EC, 2001, GENOMICS, V73, P56, DOI 10.1006/geno.2000.6451; Liu HY, 2003, J NEUROSCI, V23, P7143, DOI 10.1523/JNEUROSCI.23-18-07143.2003; LOEWY AD, 1981, BRAIN RES, V222, P129, DOI 10.1016/0006-8993(81)90946-X; Mao XH, 2001, BLOOD, V97, P324, DOI 10.1182/blood.V97.1.324; Marsh DJ, 1999, NAT GENET, V21, P119, DOI 10.1038/5070; MCCANN MJ, 1990, J PHYSIOL-LONDON, V428, P95, DOI 10.1113/jphysiol.1990.sp018202; Michaud JL, 1998, GENE DEV, V12, P3264, DOI 10.1101/gad.12.20.3264; Michaud JL, 2001, HUM MOL GENET, V10, P1465, DOI 10.1093/hmg/10.14.1465; Morrison SF, 2001, AM J PHYSIOL-REG I, V281, pR683, DOI 10.1152/ajpregu.2001.281.3.R683; Morrison SF, 2001, CLIN EXP PHARMACOL P, V28, P138, DOI 10.1046/j.1440-1681.2001.03406.x; Mountjoy KG, 2003, ENDOCRINOLOGY, V144, P5488, DOI 10.1210/en.2003-0570; MOUNTJOY KG, 1994, MOL ENDOCRINOL, V8, P1298, DOI 10.1210/me.8.10.1298; Saper CB, 2002, NEURON, V36, P199, DOI 10.1016/S0896-6273(02)00969-8; SAPER CB, 1976, BRAIN RES, V117, P305, DOI 10.1016/0006-8993(76)90738-1; Sawchenko PE, 1998, J COMP NEUROL, V402, P435; Ste Marie L, 2000, P NATL ACAD SCI USA, V97, P12339, DOI 10.1073/pnas.220409497; SWANSON LW, 1980, J COMP NEUROL, V194, P555, DOI 10.1002/cne.901940306; Vaisse C, 1998, NAT GENET, V20, P113, DOI 10.1038/2407; WEINGARTEN HP, 1985, BRAIN RES BULL, V14, P551, DOI 10.1016/0361-9230(85)90104-2; Williams DL, 2000, ENDOCRINOLOGY, V141, P1332, DOI 10.1210/en.141.4.1332; Yeo GSH, 1998, NAT GENET, V20, P111, DOI 10.1038/2404; ZIMMERMAN L, 1994, NEURON, V12, P11, DOI 10.1016/0896-6273(94)90148-1	46	786	804	1	63	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					493	505		10.1016/j.cell.2005.08.035	http://dx.doi.org/10.1016/j.cell.2005.08.035			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269339	Bronze			2022-12-28	WOS:000233264300016
J	Bonini, NM; Glasson, BI				Bonini, NM; Glasson, BI			Snaring the function of alpha-synuclein	CELL			English	Editorial Material							PARKINSONS-DISEASE; PROTEIN; PATHWAYS	It is well established that the abundant neuronal protein a-synuclein has a causal role in Parkinson's disease, yet the normal functions of this protein remain unclear. In this issue of Cell, Chandra et al. (2005) reveal that a-synuclein acts as a molecular chaperone, assisting in the folding and refolding of synaptic proteins called SNAREs. These proteins are crucial for release of neurotransmitters at the neuronal synapse, vesicle recycling, and synaptic integrity.	Univ Penn, Sch Med, Dept Biol, Philadelphia, PA 19104 USA; Univ Penn, Howard Hughes Med Inst, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pharmacol, Philadelphia, PA 19104 USA	University of Pennsylvania; Howard Hughes Medical Institute; University of Pennsylvania; University of Pennsylvania	Bonini, NM (corresponding author), Univ Penn, Sch Med, Dept Biol, Philadelphia, PA 19104 USA.			Bonini, Nancy/0000-0003-0226-5291				Auluck PK, 2002, SCIENCE, V295, P865, DOI 10.1126/science.1067389; Buchner E, 1997, TRENDS NEUROSCI, V20, P223, DOI 10.1016/S0166-2236(96)10082-5; Chandra S, 2005, CELL, V123, P383, DOI 10.1016/j.cell.2005.09.028; Chandra S, 2004, P NATL ACAD SCI USA, V101, P14966, DOI 10.1073/pnas.0406283101; Cookson MR, 2005, ANNU REV BIOCHEM, V74, P29, DOI 10.1146/annurev.biochem.74.082803.133400; Dawson TM, 2003, SCIENCE, V302, P819, DOI 10.1126/science.1087753; Fernandez-Chacon R, 2004, NEURON, V42, P237, DOI 10.1016/S0896-6273(04)00190-4; Giasson BI, 2003, CELL, V114, P1, DOI 10.1016/S0092-8674(03)00509-9; Tobaben S, 2001, NEURON, V31, P987, DOI 10.1016/S0896-6273(01)00427-5; Ungar D, 2003, ANNU REV CELL DEV BI, V19, P493, DOI 10.1146/annurev.cellbio.19.110701.155609	10	122	126	1	26	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					359	361		10.1016/j.cell.2005.10.017	http://dx.doi.org/10.1016/j.cell.2005.10.017			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269324	Bronze			2022-12-28	WOS:000233264300001
J	Dasen, JS; Tice, BC; Brenner-Morton, S; Jessell, TM				Dasen, JS; Tice, BC; Brenner-Morton, S; Jessell, TM			A Hox regulatory network establishes motor neuron pool identity and target-muscle connectivity	CELL			English	Article							DEVELOPING SPINAL-CORD; SUBTYPE IDENTITY; NERVOUS-SYSTEM; HOMEOBOX GENES; EXPRESSION; SPECIFICATION; LIMB; MOTONEURONS; HINDBRAIN; PROJECTIONS	Spinal motor neurons acquire specialized "pool" identities that determine their ability to form selective connections with target muscles in the limb, but the molecular basis of this striking example of neuronal specificity has remained unclear. We show here that a Hox transcriptional regulatory network specifies motor neuron pool identity and connectivity. Two interdependent sets of Hox regulatory interactions operate within motor neurons, one assigning rostrocaudal motor pool position and a second directing motor pool diversity at a single segmental level. This Hox regulatory network directs the downstream transcriptional identity of motor neuron pools and defines the pattern of target-muscle connectivity.	Columbia Univ, Howard Hughes Med Inst, Ctr Med, Dept Biochem & Mol Biophys, New York, NY 10032 USA	Columbia University; Howard Hughes Medical Institute	Jessell, TM (corresponding author), Columbia Univ, Howard Hughes Med Inst, Ctr Med, Dept Biochem & Mol Biophys, 701 W 168th St, New York, NY 10032 USA.	tmj1@columbia.edu						Arber S, 2000, CELL, V101, P485, DOI 10.1016/S0092-8674(00)80859-4; Bel-Vialar S, 2002, DEVELOPMENT, V129, P5103; Bell E, 1999, SCIENCE, V284, P2168, DOI 10.1126/science.284.5423.2168; Belting HG, 1998, J EXP ZOOL, V282, P196, DOI 10.1002/(SICI)1097-010X(199809/10)282:1/2&lt;196::AID-JEZ22&gt;3.0.CO;2-R; Carpenter EM, 2002, DEV NEUROSCI-BASEL, V24, P24, DOI 10.1159/000064943; Dasen JS, 2003, NATURE, V425, P926, DOI 10.1038/nature02051; Elowitz MB, 2000, NATURE, V403, P335, DOI 10.1038/35002125; Ensini M, 1998, DEVELOPMENT, V125, P969; FRANK E, 1993, NEURON, V10, P779, DOI 10.1016/0896-6273(93)90194-V; Gaufo GO, 2003, DEVELOPMENT, V130, P5191, DOI 10.1242/dev.00730; Gavalas A, 2003, DEVELOPMENT, V130, P5663, DOI 10.1242/dev.00802; Gavalas A, 1998, DEVELOPMENT, V125, P1123; Helmbacher F, 2003, NEURON, V39, P767, DOI 10.1016/S0896-6273(03)00493-8; HOLLYDAY M, 1990, J COMP NEUROL, V302, P575, DOI 10.1002/cne.903020313; IZPISUABELMONTE JC, 1992, DEV BIOL, V152, P26, DOI 10.1016/0012-1606(92)90153-8; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kania A, 2003, NEURON, V38, P581, DOI 10.1016/S0896-6273(03)00292-7; Lance-Jones C, 2001, DEVELOPMENT, V128, P2255; LANDMESSER L, 1978, J PHYSIOL-LONDON, V284, P391, DOI 10.1113/jphysiol.1978.sp012546; Landmesser LT, 2001, INT J DEV NEUROSCI, V19, P175, DOI 10.1016/S0736-5748(00)00090-3; Lin JH, 1998, CELL, V95, P393, DOI 10.1016/S0092-8674(00)81770-5; Liu JP, 2001, NEURON, V32, P997, DOI 10.1016/S0896-6273(01)00544-X; Livet J, 2002, NEURON, V35, P877, DOI 10.1016/S0896-6273(02)00863-2; Mann RS, 1998, CURR OPIN GENET DEV, V8, P423, DOI 10.1016/S0959-437X(98)80113-5; Marin O, 2003, ANNU REV NEUROSCI, V26, P441, DOI 10.1146/annurev.neuro.26.041002.131058; Nonchev S, 1997, COLD SPRING HARB SYM, V62, P313; Pearson BJ, 2004, ANNU REV CELL DEV BI, V20, P619, DOI 10.1146/annurev.cellbio.19.111301.115142; Price SR, 2002, CELL, V109, P205, DOI 10.1016/S0092-8674(02)00695-5; ROMANES GJ, 1942, J ANAT, V76, P112; Shah V, 2004, DEV DYNAM, V231, P43, DOI 10.1002/dvdy.20103; Sockanathan S, 1998, CELL, V94, P503, DOI 10.1016/S0092-8674(00)81591-3; Solomin L, 1998, NATURE, V395, P398, DOI 10.1038/26515; STIRLING RV, 1988, DEVELOPMENT, V103, P97; Studer M, 1996, NATURE, V384, P630, DOI 10.1038/384630a0; SULLIVAN G. E., 1962, AUSTRALIAN JOUR ZOOL, V10, P458, DOI 10.1071/ZO9620458; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Theriault FM, 2004, P NATL ACAD SCI USA, V101, P10343, DOI 10.1073/pnas.0400768101; Tiret L, 1998, DEVELOPMENT, V125, P279; TOSNEY KW, 1985, DEV BIOL, V109, P193, DOI 10.1016/0012-1606(85)90360-4; TSUCHIDA T, 1994, CELL, V79, P957, DOI 10.1016/0092-8674(94)90027-2; Vermot J, 2005, DEVELOPMENT, V132, P1611, DOI 10.1242/dev.01718; Yamagata M, 2002, CELL, V110, P649, DOI 10.1016/S0092-8674(02)00910-8	42	318	321	0	15	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					477	491		10.1016/j.cell.2005.09.009	http://dx.doi.org/10.1016/j.cell.2005.09.009			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269338	Bronze			2022-12-28	WOS:000233264300015
J	Fischer, J; Baumgartner, J; Marschner, C				Fischer, J; Baumgartner, J; Marschner, C			Synthesis and structure of sila-adamantane	SCIENCE			English	Article							OLIGOSILANES; POLYSILANES		Graz Tech Univ, Inst Anorgan Chem, A-8010 Graz, Austria	Graz University of Technology	Marschner, C (corresponding author), Graz Tech Univ, Inst Anorgan Chem, Stremayrgasse 16, A-8010 Graz, Austria.	christoph.marschner@tugraz.at		Baumgartner, Judith/0000-0002-9938-1813; Marschner, Christoph/0000-0001-8586-2889				Fischer R, 2003, J ORGANOMET CHEM, V685, P79, DOI 10.1016/j.jorganchem.2003.02.002; Ghosh AW, 2004, MRS BULL, V29, P391, DOI 10.1557/mrs2004.121; ISHIKAWA M, 1981, J AM CHEM SOC, V103, P4845, DOI 10.1021/ja00406a029; SCHLEYER PV, 1957, J AM CHEM SOC, V79, P3292; Schnepf A, 2004, ANGEW CHEM INT EDIT, V43, P664, DOI 10.1002/anie.200301706; SEKIGUCHI A, 2002, CHEM ORGANIC GERMA 2, V2, pCH15; Tsuji H, 2003, J ORGANOMET CHEM, V685, P9, DOI 10.1016/S0022-328X(03)00162-1; Tsuji H, 2003, J AM CHEM SOC, V125, P7486, DOI 10.1021/ja034500e; WEST R, 1972, J AM CHEM SOC, V94, P6110, DOI 10.1021/ja00772a030	9	87	87	1	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					825	825		10.1126/science.1118981	http://dx.doi.org/10.1126/science.1118981			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC); Current Chemical Reactions (CCR-EXPANDED)	Science & Technology - Other Topics	981XR	16272116				2022-12-28	WOS:000233121800037
J	Cadena, CD; Ricklefs, RE; Jimenez, I; Bermingham, E				Cadena, CD; Ricklefs, RE; Jimenez, I; Bermingham, E			Ecology - Is speciation driven by species diversity?	NATURE			English	Editorial Material							MOLECULAR PHYLOGENIES; AREA RELATIONSHIP; ISLAND; DIVERSIFICATION; AGE		Univ Missouri, Dept Biol, St Louis, MO 63121 USA; Missouri Bot Garden, Ctr Conservat & Sustainable Dev, St Louis, MO 63166 USA; Smithsonian Trop Res Inst, Balboa, Panama	University of Missouri System; University of Missouri Saint Louis; Missouri Botanical Gardens; Smithsonian Institution; Smithsonian Tropical Research Institute	Cadena, CD (corresponding author), Univ Missouri, Dept Biol, 8001 Nat Bridge Rd, St Louis, MO 63121 USA.	cdc35b@umsl.edu	Cadena, Carlos Daniel/G-1313-2010					Baldwin BG, 1998, P NATL ACAD SCI USA, V95, P9402, DOI 10.1073/pnas.95.16.9402; Emerson BC, 2005, EVOLUTION, V59, P586; Emerson BC, 2005, NATURE, V434, P1015, DOI 10.1038/nature03450; Goldberg EE, 2005, AM NAT, V165, P623, DOI 10.1086/430012; Johnson KP, 2000, EVOLUTION, V54, P387; Losos JB, 2000, NATURE, V408, P847, DOI 10.1038/35048558; MAC ARTHUR ROBERT H., 1967; MAYR E, 1965, SCIENCE, V150, P1587, DOI 10.1126/science.150.3703.1587; NEE S, 1992, P NATL ACAD SCI USA, V89, P8322, DOI 10.1073/pnas.89.17.8322; Pybus OG, 2000, P ROY SOC B-BIOL SCI, V267, P2267, DOI 10.1098/rspb.2000.1278; Ricklefs RE, 2004, AM NAT, V163, P227, DOI 10.1086/381002	11	33	36	1	27	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					E1	E2		10.1038/nature04308	http://dx.doi.org/10.1038/nature04308			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267504				2022-12-28	WOS:000232979000035
J	Denny, L; Kuhn, L; De Souza, M; Pollack, AE; Dupree, W; Wright, TC				Denny, L; Kuhn, L; De Souza, M; Pollack, AE; Dupree, W; Wright, TC			Screen-and-treat approaches for cervical cancer prevention in low-resource settings - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STRATEGIES; MANAGEMENT; BENEFITS	Context Non-cytology-based screen-and-treat approaches for cervical cancer prevention have been developed for low-resource settings, but few have directly addressed efficacy. Objective To determine the safety and efficacy of 2 screen-and-treat approaches for cervical cancer prevention that were designed to be more resource-appropriate than conventional cytology-based screening programs. Design, Setting, and Patients Randomized clinical trial of 6555 nonpregnant women, aged 35 to 65 years, recruited through community outreach and conducted between June 2000 and December 2002 at ambulatory women's health clinics in Khayelitsha, South Africa. Interventions All patients were screened using human papillomavirus (HPV) DNA testing and visual inspection with acetic acid (VIA). Women were subsequently randomized to 1 of 3 groups: cryotherapy if she had a positive HPV DNA test result; cryotherapy if she had a positive VIA test result; or to delayed evaluation. Main Outcome Measures Biopsy-confirmed high-grade cervical cancer precursor lesions and cancer at 6 and 12 months in the HPV DNA and VIA groups compared with the delayed evaluation (control) group; complications after cryotherapy. Results The prevalence of high-grade cervical intraepithelial neoplasia and cancer (ClN 2+) was significantly lower in the 2 screen-and-treat groups at 6 months after randomization than in the delayed evaluation group. At 6 months, CIN 2+ was diagnosed in 0.80% (95% confidence interval [CI], 0.40%-1.20%) of the women in the HPV DNA group and 2.23% (95% Cl, 1.57%-2.89%) in the VIA group compared with 3.55% (95% Cl, 2.71 %-4.39%) in the delayed evaluation group (P<.001 and P=.02 for the HPV DNA and VIA groups, respectively). A subset of women underwent a second colposcopy 12 months after enrollment. At 12 months the cumulative detection of CIN 2+ among women in the HPV DNA group was 1.42% (95% Cl, 0.88%-1.97%),2.91% (95% Cl, 2.12%-3.69%) in the VIA group, and 5.41% (95% Cl, 4.32%-6.50%) in the delayed evaluation group. Although minor complaints, such as discharge and bleeding, were common after cryotherapy, major complications were rare. Conclusion Both screen-and-treat approaches are safe and result in a lower prevalence of high-grade cervical cancer precursor lesions compared with delayed evaluation at both 6 and 12 months. Trial Registration Clinicaltrials.gov Identifier: NCT00233727.	Columbia Univ, Dept Pathol, New York, NY 10032 USA; Univ Cape Town, Dept Obstet & Gynaecol, Cape Town, South Africa; Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10032 USA; Columbia Univ, Dept Epidemiol, New York, NY 10032 USA; EngenderHealth, New York, NY USA; HealthNetwork Lab, Allentown, PA USA	Columbia University; University of Cape Town; Columbia University; Columbia University	Wright, TC (corresponding author), Columbia Univ, Dept Pathol, Room 16-404,P&S Bldg,630 W 168th St, New York, NY 10032 USA.	tcw1@columbia.edu						Cox JT, 1999, LANCET, V353, P857, DOI 10.1016/S0140-6736(98)00392-4; Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4&lt;826::AID-CNCR15&gt;3.0.CO;2-5; Denny L, 2002, CANCER-AM CANCER SOC, V94, P1699, DOI 10.1002/cncr.10381; FERENCZY A, 1996, INT J GYNECOL CANCER, V2, P14; FERLAY J, 1998, GLOBOCAN CANC INCIDE; FERRIS D, 2005, MODERN COLPOSCOPY; Gaffikin L, 2003, LANCET, V361, P814, DOI 10.1016/S0140-6736(03)12707-9; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107; Goldie SJ, 2003, INT J CANCER, V106, P896, DOI 10.1002/ijc.11334; Greenland S, 1998, MODERN EPIDEMIOLOGY, P286; Jha P, 2002, SCIENCE, V295, P2036, DOI 10.1126/science.295.5562.2036; Kundel HL, 2003, RADIOLOGY, V228, P303, DOI 10.1148/radiol.2282011860; Mandelblatt JS, 2002, JNCI-J NATL CANCER I, V94, P1469, DOI 10.1093/jnci/94.19.1469; Miller AB, 1992, CERVICAL CANC SCREEN; Monsonego J, 2004, INT J CANCER, V108, P329, DOI 10.1002/ijc.11530; Parkin DM, 2001, LANCET ONCOL, V2, P533, DOI 10.1016/S1470-2045(01)00486-7; RICHART RM, 1995, CANCER, V76, P1919, DOI 10.1002/1097-0142(19951115)76:10+<1919::AID-CNCR2820761308>3.0.CO;2-9; Rohan TE, 2003, AM J OBSTET GYNECOL, V189, pS37, DOI 10.1067/S0002-9378(03)01079-2; Sankaranarayanan R, 2004, INT J CANCER, V110, P907, DOI 10.1002/ijc.20190; Sellors JW, 2002, OBSTET GYNECOL, V99, P635, DOI 10.1016/S0029-7844(01)01767-7; *WHO, WHO C JAN 24 2005 NE; Witkiewicz AK, 2011, BLAUSTEIN'S PATHOLOGY OF THE FEMALE GENITAL TRACT, SIXTH EDITION, P253, DOI 10.1007/978-1-4419-0489-8_6; Wright TC, 2000, JAMA-J AM MED ASSOC, V283, P81, DOI 10.1001/jama.283.1.81; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Wright TC, 2004, OBSTET GYNECOL, V103, P304, DOI 10.1097/01.AOG.0000109426.82624.f8; Wright Thomas C Jr, 2003, J Natl Cancer Inst Monogr, P66	26	237	245	0	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2173	2181		10.1001/jama.294.17.2173	http://dx.doi.org/10.1001/jama.294.17.2173			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264158	Bronze			2022-12-28	WOS:000232957700019
J	Insel, TR; Quirion, R				Insel, TR; Quirion, R			Psychiatry as a clinical neuroscience discipline	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							MAJOR DEPRESSION; PREFRONTAL CORTEX; SCHIZOPHRENIA; LIFE; INTERSECTION; POLYMORPHISM; PATHWAYS; DISORDER; PROTEIN		NIMH, NIH, Bethesda, MD 20892 USA; Douglas Hosp, Inst Neurosci Mental Hlth & Addict, Canadian Inst Hlth Res, Montreal, PQ, Canada	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Institute for Work & Health; McGill University	Insel, TR (corresponding author), NIMH, NIH, 6001 Execut Blvd,Room 8235, Bethesda, MD 20892 USA.	tinsel@mail.nih.gov						Abi-Dargham A, 2000, P NATL ACAD SCI USA, V97, P8104, DOI 10.1073/pnas.97.14.8104; Alberts B., 2008, MOL BIOL CEL, V5th ed.; AMARAL DG, 2005, 4 INT M AUT RES MAY; Anderson MC, 2004, SCIENCE, V303, P232, DOI 10.1126/science.1089504; Bast RC, 2004, NEW ENGL J MED, V351, P2865, DOI 10.1056/NEJMe048300; Boguski MS, 2004, NAT NEUROSCI, V7, P429, DOI 10.1038/nn1232; Caspi A, 2003, SCIENCE, V301, P386, DOI 10.1126/science.1083968; Cole TB, 2005, JAMA-J AM MED ASSOC, V294, P623, DOI 10.1001/jama.294.5.623; Cowan WM, 2002, ANNU REV NEUROSCI, V25, P1, DOI 10.1146/annurev.neuro.25.112701.142853; Coyle JT, 2003, NEURON, V38, P157, DOI 10.1016/S0896-6273(03)00195-8; Drevets WC, 1997, NATURE, V386, P824, DOI 10.1038/386824a0; Duman RS, 2004, BIOL PSYCHIAT, V56, P140, DOI 10.1016/j.biopsych.2004.02.033; Goldapple K, 2004, ARCH GEN PSYCHIAT, V61, P34, DOI 10.1001/archpsyc.61.1.34; Insel TR, 2003, AM J PSYCHIAT, V160, P616, DOI 10.1176/appi.ajp.160.4.616; Kandel ER, 1998, AM J PSYCHIAT, V155, P457, DOI 10.1176/ajp.155.4.457; Kendler KS, 2005, ARCH GEN PSYCHIAT, V62, P529, DOI 10.1001/archpsyc.62.5.529; Kessler RC, 2005, JAMA-J AM MED ASSOC, V293, P2487, DOI 10.1001/jama.293.20.2487; Lesperance F, 2004, AM J PSYCHIAT, V161, P271, DOI 10.1176/appi.ajp.161.2.271; Marcotte ER, 2003, PHARMACOL THERAPEUT, V100, P63, DOI 10.1016/S0163-7258(03)00086-X; Martin JB, 2002, AM J PSYCHIAT, V159, P695, DOI 10.1176/appi.ajp.159.5.695; Mayberg HS, 2003, BRIT MED BULL, V65, P193, DOI 10.1093/bmb/65.1.193; Moffitt TE, 2005, ARCH GEN PSYCHIAT, V62, P473, DOI 10.1001/archpsyc.62.5.473; Neumeister A, 2004, J NEUROSCI, V24, P589, DOI 10.1523/JNEUROSCI.4921-03.2004; Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588; Pennington K, 2005, BRIT J PSYCHIAT, V187, P4, DOI 10.1192/bjp.187.1.4; Pezawas L, 2005, NAT NEUROSCI, V8, P828, DOI 10.1038/nn1463; Prabakaran S, 2004, MOL PSYCHIATR, V9, P684, DOI 10.1038/sj.mp.4001511; Sandberg R, 2000, P NATL ACAD SCI USA, V97, P11038, DOI 10.1073/pnas.97.20.11038; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Schacter DL, 2004, NEURON, V44, P149, DOI 10.1016/j.neuron.2004.08.017; Segman RH, 2005, MOL PSYCHIATR, V10, P500, DOI 10.1038/sj.mp.4001636; Sheps DS, 2004, PSYCHOSOM MED, V66, P797, DOI 10.1097/01.psy.0000147479.29050.0a; Spedding M, 2005, NAT REV DRUG DISCOV, V4, P467, DOI 10.1038/nrd1753; Swatton JE, 2004, MOL PSYCHIATR, V9, P128, DOI 10.1038/sj.mp.4001475; Tsuang MT, 2005, AM J MED GENET B, V133B, P1, DOI 10.1002/ajmg.b.30161; Varnas K, 2004, HUM BRAIN MAPP, V22, P246, DOI 10.1002/hbm.20035; Volkow ND, 2005, J NEUROSCI, V25, P3932, DOI 10.1523/JNEUROSCI.0433-05.2005; Vollmayr B, 2003, BIOL PSYCHIAT, V54, P1035, DOI 10.1016/S0006-3223(03)00527-4; Weaver ICG, 2004, NAT NEUROSCI, V7, P847, DOI 10.1038/nn1276; WHO, 2002, RED RISKS PROM HLTH; Yung AR, 2004, SCHIZOPHR RES, V67, P131, DOI 10.1016/S0920-9964(03)00192-0	41	167	176	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2221	2224		10.1001/jama.294.17.2221	http://dx.doi.org/10.1001/jama.294.17.2221			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264165	Green Accepted			2022-12-28	WOS:000232957700026
J	Koenig, R				Koenig, R			Profile - Phillip Tobias - South Africa's bone man: 80 and still digging into the past	SCIENCE			English	Biographical-Item																		TOBIAS PV, PUBLICATION LIST	1	0	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2005	310	5748					608	609		10.1126/science.310.5748.608	http://dx.doi.org/10.1126/science.310.5748.608			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254161				2022-12-28	WOS:000232997700010
J	Mahowald, MW; Schenck, CH				Mahowald, MW; Schenck, CH			Insights from studying human sleep disorders	NATURE			English	Review							RESTLESS LEGS SYNDROME; BEHAVIOR DISORDER; CHRONIC INSOMNIA; REM-SLEEP; NIGHT-TERRORS; CIRCADIAN-RHYTHM; PHASE SYNDROME; DOPAMINE TRANSPORTERS; PARKINSONS-DISEASE; NOCTURNAL SLEEP	Problems with sleep are one of the commonest reasons for seeking medical attention. Knowledge gained from basic research into sleep in animals has led to marked advances in the understanding of human sleep, with important diagnostic and therapeutic implications. At the same time, research guided by human sleep disorders is leading to important basic sleep concepts. For example, sleep may not be a global, but rather a local, brain phenomenon. Furthermore, contrary to common assumptions, wakefulness, rapid eye movement (REM) and non-REM sleep are not mutually exclusive states. This striking realization explains a fascinating range of clinical phenomena.	Hennepin Cty Med Ctr, Minnesota Reg Sleep Disorders Ctr, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Neurol, Minneapolis, MN 55415 USA; Hennepin Cty Med Ctr, Dept Psychiat, Minneapolis, MN 55415 USA; Univ Minnesota, Sch Med, Minneapolis, MN 55415 USA	Hennepin County Medical Center; Hennepin County Medical Center; Hennepin County Medical Center; University of Minnesota System; University of Minnesota Twin Cities	Mahowald, MW (corresponding author), Hennepin Cty Med Ctr, Minnesota Reg Sleep Disorders Ctr, Minneapolis, MN 55415 USA.	mahow002@umn.edu						Albin RL, 2000, NEUROLOGY, V55, P1410, DOI 10.1212/WNL.55.9.1410; Allen RP, 2001, J CLIN NEUROPHYSIOL, V18, P128, DOI 10.1097/00004691-200103000-00004; Archer SN, 2003, SLEEP, V26, P413, DOI 10.1093/sleep/26.4.413; Bassetti C, 1996, NEUROL CLIN, V14, P545, DOI 10.1016/S0733-8619(05)70273-5; Boeve B, 2003, NEUROLOGY, V61, P40, DOI 10.1212/01.WNL.0000073619.94467.B0; Bonnet MH, 2000, SLEEP, V23, P205; Bucher SF, 1997, ANN NEUROL, V41, P639, DOI 10.1002/ana.410410513; Caples SM, 2005, ANN INTERN MED, V142, P187, DOI 10.7326/0003-4819-142-3-200502010-00010; Cirelli C, 2005, NATURE, V434, P1087, DOI 10.1038/nature03486; CZEISLER CA, 1981, SLEEP, V4, P1; Dagan Y, 1998, CHRONOBIOL INT, V15, P181, DOI 10.3109/07420529808998682; Dauviltiers Y, 2005, SLEEP MED REV, V9, P91, DOI 10.1016/j.smrv.2004.06.001; Dawson D, 1998, ANN MED, V30, P95, DOI 10.3109/07853899808999390; Desautels A, 2005, ARCH NEUROL-CHICAGO, V62, P591, DOI 10.1001/archneur.62.4.591; Eisensehr I, 2000, BRAIN, V123, P1155, DOI 10.1093/brain/123.6.1155; Eisensehr I, 2003, SLEEP, V26, P507, DOI 10.1093/sleep/26.5.507; Fantini ML, 2003, ANN NEUROL, V53, P774, DOI 10.1002/ana.10547; FISHER C, 1973, J NERV MENT DIS, V157, P75, DOI 10.1097/00005053-197308000-00001; FISHER C, 1974, J NERV MENT DIS, V158, P174, DOI 10.1097/00005053-197403000-00002; Gilman S, 2003, NEUROLOGY, V61, P29, DOI 10.1212/01.WNL.0000073745.68744.94; GUILLEMIAULT C, 2005, PRINCIPLES PRACTICE, P780, DOI DOI 10.1016/B0-72-160797-7/50072-0; GUILLEMINAULT C, 1995, SLEEP, V18, P740, DOI 10.1093/sleep/18.9.740; Hajak Goran, 2002, Ann Clin Psychiatry, V14, P1; Hendricks JC, 2004, SLEEP, V27, P334, DOI 10.1093/sleep/27.2.334; Huber R, 2004, SLEEP, V27, P628, DOI 10.1093/sleep/27.4.628; John J, 2000, Sleep Res Online, V3, P23; KAHN E, 1991, MIND SLEEP PSYCHOL P, P437; KLACKENBERG G, 1982, ACTA PAEDIATR SCAND, V71, P495, DOI 10.1111/j.1651-2227.1982.tb09458.x; LASAGNA L, 1995, J CLIN PSYCHOPHARM, V15, P383, DOI 10.1097/00004714-199512000-00001; LLORENTE MD, 1992, J CLIN PSYCHIAT, V53, P392; Mahowald M, 2000, PRINCIPLES PRACTICE, P786; Mahowald MW, 2001, ARCH ITAL BIOL, V139, P269; MAHOWALD MW, 2005, PRINCIPLES PRACTICE, P960; MAHOWALD MW, 2005, PRINCIPLES PRACTICE; Mahowald MW, 2005, PRINCIPLES PRACTICE, P897; Mendelson WB, 2004, SLEEP MED REV, V8, P7, DOI 10.1016/S1087-0792(03)00042-X; Mignot E, 2002, ARCH NEUROL-CHICAGO, V59, P1553, DOI 10.1001/archneur.59.10.1553; Mignot E, 1998, NEUROLOGY, V50, pS16, DOI 10.1212/WNL.50.2_Suppl_1.S16; Miyamoto M, 2000, PSYCHIAT CLIN NEUROS, V54, P350, DOI 10.1046/j.1440-1819.2000.00710.x; Moore-Ede MFMS., 1982, CLOCKS TIME US PHYSL; Morin CM, 2003, HUM PSYCHOPHARM CLIN, V18, P75, DOI 10.1002/hup.454; Morton AJ, 2005, J NEUROSCI, V25, P157, DOI 10.1523/JNEUROSCI.3842-04.2005; *NAT COMM SLEEP DI, 1992, RES DHHS PUB; NINOMURCIA G, 1987, PSYCHOPHARMACOLOGY 3, P873; Nobili L, 1996, NEUROPHYSIOL CLIN, V26, P51, DOI 10.1016/0987-7053(96)81534-6; Ohayon MM, 1999, J CLIN PSYCHIAT, V60, P268, DOI 10.4088/JCP.v60n0413; Perlis ML, 2001, SLEEP MED REV, V5, P365, DOI 10.1053/smrv.2001.0151; Petersen A, 2005, HUM MOL GENET, V14, P39, DOI 10.1093/hmg/ddi004; Phillips B, 2000, ARCH INTERN MED, V160, P2137, DOI 10.1001/archinte.160.14.2137; Reid KJ, 2005, PRINCIPLES PRACTICE, P691, DOI DOI 10.1016/B0-72-160797-7/50065-3; ROSEN G, 1995, PRINCIPLES PRACTICE, P99; Rosenfeld DS, 1998, ARCH SEX BEHAV, V27, P269, DOI 10.1023/A:1018651018224; SACK RL, 1992, J CLIN ENDOCR METAB, V75, P127, DOI 10.1210/jcem.75.1.1619000; Sack RL, 1998, ANN MED, V30, P115, DOI 10.3109/07853899808999393; SCHENCK CH, 1989, AM J PSYCHIAT, V146, P1166; Schenck CH, 1996, AM J MED, V100, P333, DOI 10.1016/S0002-9343(97)89493-4; SCHENCK CH, 1992, ANN NEUROL, V32, P3, DOI 10.1002/ana.410320103; SCHENCK CH, 1994, INT J EAT DISORDER, V15, P343, DOI 10.1002/eat.2260150405; Schenck CH, 1990, CLEVE CLIN J MED INT, V57, pS; SCHENCK CH, 2003, ENCY NEUROLOGICAL SC, P146; Shapiro CM, 2003, CAN J PSYCHIAT, V48, P311, DOI 10.1177/070674370304800506; Shirakawa S, 2002, PSYCHIAT CLIN NEUROS, V56, P291, DOI 10.1046/j.1440-1819.2002.00961.x; Smith MT, 2002, SLEEP, V25, P325; STEPANSKI E, 1988, SLEEP, V11, P54, DOI 10.1093/sleep/11.1.54; Stiasny-Kolster K, 2004, BRAIN, V127, P773, DOI 10.1093/brain/awh079; Taheri S, 2002, ANNU REV NEUROSCI, V25, P283, DOI 10.1146/annurev.neuro.25.112701.142826; Tergau F, 1999, NEUROLOGY, V52, P1060, DOI 10.1212/WNL.52.5.1060; Toh KL, 2001, SCIENCE, V291, P1040, DOI 10.1126/science.1057499; Trenkwalder C, 1999, MOVEMENT DISORD, V14, P102, DOI 10.1002/1531-8257(199901)14:1<102::AID-MDS1017>3.0.CO;2-E; Turjanski N, 1999, NEUROLOGY, V52, P932, DOI 10.1212/WNL.52.5.932; Vgontzas AN, 2001, J CLIN ENDOCR METAB, V86, P3787, DOI 10.1210/jc.86.8.3787; von Spiczak S, 2005, BRAIN, V128, P906, DOI 10.1093/brain/awh441; Winkelman JW, 1999, PSYCHOL MED, V29, P1461, DOI 10.1017/S0033291799008272; Winkelmann J, 2005, J NEUROL, V252, P67, DOI 10.1007/s00415-005-0604-7; Wisor JP, 2005, NEUROSCIENCE, V131, P375, DOI 10.1016/j.neuroscience.2004.11.018; Xu Y, 2005, NATURE, V434, P640, DOI 10.1038/nature03453; Yamadera H, 1996, PSYCHIAT CLIN NEUROS, V50, P195, DOI 10.1111/j.1440-1819.1996.tb02742.x	77	194	199	5	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1279	1285		10.1038/nature04287	http://dx.doi.org/10.1038/nature04287			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	977UQ	16251953				2022-12-28	WOS:000232829100041
J	Myong, S; Rasnik, I; Joo, C; Lohman, TM; Ha, T				Myong, S; Rasnik, I; Joo, C; Lohman, TM; Ha, T			Repetitive shuttling of a motor protein on DNA	NATURE			English	Article							RESONANCE ENERGY-TRANSFER; SINGLE-STRANDED-DNA; ESCHERICHIA-COLI; REP HELICASE; CRYSTAL-STRUCTURES; MOLECULE; REPLICATION; RECOMBINATION; DOMAIN; TRANSLOCATION	Many helicases modulate recombination, an essential process that needs to be tightly controlled. Mutations in some human disease helicases cause increased recombination, genome instability and cancer. To elucidate the potential mode of action of these enzymes, here we developed a single-molecule fluorescence assay that can visualize DNA binding and translocation of Escherichia coli Rep, a superfamily 1 DNA helicase homologous to Saccharomyces cerevisiae Srs2. Individual Rep monomers were observed to move on single-stranded ( ss) DNA in the 30 to 50 direction using ATP hydrolysis. Strikingly, on hitting a blockade, such as duplex DNA or streptavidin, the protein abruptly snapped back close to its initial position, followed by further cycles of translocation and snapback. This repetitive shuttling is likely to be caused by a blockade-induced protein conformational change that enhances DNA affinity for the protein's secondary DNA binding site, thereby resulting in a transient DNA loop. Repetitive shuttling was also observed on ssDNA bounded by a stalled replication fork and an Okazaki fragment analogue, and the presence of Rep delayed formation of a filament of recombination protein RecA on ssDNA. Thus, the binding of a single Rep monomer to a stalled replication fork can lead to repetitive shuttling along the single-stranded region, possibly keeping the DNA clear of toxic recombination intermediates.	Univ Illinois, Dept Phys, Urbana, IL 61801 USA; Howard Hughes Med Inst, Urbana, IL 61801 USA; Washington Univ, Sch Med, Dept Biochem & Mol Biophys, St Louis, MO 63110 USA	University of Illinois System; University of Illinois Urbana-Champaign; Howard Hughes Medical Institute; Washington University (WUSTL)	Ha, T (corresponding author), Univ Illinois, Dept Phys, 1110 W Green St, Urbana, IL 61801 USA.	tjha@uiuc.edu	Ha, Taekjip/B-9506-2009; Joo, Chirlmin/B-9294-2008	Ha, Taekjip/0000-0003-2195-6258; Joo, Chirlmin/0000-0003-2803-0335	NIGMS NIH HHS [R01 GM045948, R01 GM065367] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045948, R01GM065367] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Blanchard SC, 2004, P NATL ACAD SCI USA, V101, P12893, DOI 10.1073/pnas.0403884101; Brendza KM, 2005, P NATL ACAD SCI USA, V102, P10076, DOI 10.1073/pnas.0502886102; Byrd AK, 2004, NAT STRUCT MOL BIOL, V11, P531, DOI 10.1038/nsmb774; Cheng W, 2002, P NATL ACAD SCI USA, V99, P16006, DOI 10.1073/pnas.242479399; Cheng W, 2001, J MOL BIOL, V310, P327, DOI 10.1006/jmbi.2001.4758; DENHARDT DT, 1967, P NATL ACAD SCI USA, V57, P813, DOI 10.1073/pnas.57.3.813; Dessinges MN, 2004, P NATL ACAD SCI USA, V101, P6439, DOI 10.1073/pnas.0306713101; Fairman ME, 2004, SCIENCE, V304, P730, DOI 10.1126/science.1095596; Ha T, 1996, P NATL ACAD SCI USA, V93, P6264, DOI 10.1073/pnas.93.13.6264; Ha T, 2002, NATURE, V419, P638, DOI 10.1038/nature01083; Ha T, 2001, METHODS, V25, P78, DOI 10.1006/meth.2001.1217; Kaplan DL, 2002, MOL CELL, V10, P647, DOI 10.1016/S1097-2765(02)00642-1; Kawaoka J, 2004, NAT STRUCT MOL BIOL, V11, P526, DOI 10.1038/nsmb771; Korolev S, 1997, CELL, V90, P635, DOI 10.1016/S0092-8674(00)80525-5; Krejci L, 2003, NATURE, V423, P305, DOI 10.1038/nature01577; LEE MS, 1990, J BIOL CHEM, V265, P17078; Lohman TM, 1996, ANNU REV BIOCHEM, V65, P169, DOI 10.1146/annurev.bi.65.070196.001125; Margittai M, 2003, P NATL ACAD SCI USA, V100, P15516, DOI 10.1073/pnas.2331232100; Marians KJ, 2004, PHILOS T ROY SOC B, V359, P71, DOI 10.1098/rstb.2003.1366; Morimatsu K, 2003, MOL CELL, V11, P1337, DOI 10.1016/S1097-2765(03)00188-6; Mukhopadhyay J, 2001, CELL, V106, P453, DOI 10.1016/S0092-8674(01)00464-0; Murphy MC, 2004, BIOPHYS J, V86, P2530, DOI 10.1016/S0006-3495(04)74308-8; Perkins TT, 2004, BIOPHYS J, V86, P1640, DOI 10.1016/S0006-3495(04)74232-0; Petit MA, 2002, EMBO J, V21, P3137, DOI 10.1093/emboj/cdf317; Rasnik I, 2004, J MOL BIOL, V336, P395, DOI 10.1016/j.jmb.2003.12.031; Sandler SJ, 2000, GENETICS, V155, P487; SCOTT JF, 1978, J BIOL CHEM, V253, P3292; SCOTT JF, 1977, P NATL ACAD SCI USA, V74, P193, DOI 10.1073/pnas.74.1.193; Veaute X, 2005, EMBO J, V24, P180, DOI 10.1038/sj.emboj.7600485; Veaute X, 2003, NATURE, V423, P309, DOI 10.1038/nature01585; Velankar SS, 1999, CELL, V97, P75, DOI 10.1016/S0092-8674(00)80716-3; von Hippel PH, 2004, NAT STRUCT MOL BIOL, V11, P494, DOI 10.1038/nsmb0604-494; Weiss S, 1999, SCIENCE, V283, P1676, DOI 10.1126/science.283.5408.1676; Zhuang XW, 2000, SCIENCE, V288, P2048, DOI 10.1126/science.288.5473.2048	34	220	222	0	44	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1321	1325		10.1038/nature04049	http://dx.doi.org/10.1038/nature04049			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251956				2022-12-28	WOS:000232829100045
J	Seeberger, PH				Seeberger, PH			Exploring life's sweet spot	NATURE			English	Editorial Material									ETH, Organ Chem Lab, CH-8093 Zurich, Switzerland; Burnham Inst, La Jolla, CA 92037 USA	Swiss Federal Institutes of Technology Domain; ETH Zurich; Sanford Burnham Prebys Medical Discovery Institute	Seeberger, PH (corresponding author), ETH, Organ Chem Lab, Wolfgang Pauli Str 10, CH-8093 Zurich, Switzerland.							Seeberger PH, 2003, CHEM COMMUN, P1115, DOI 10.1039/b210230g; Varki A., 1999, ESSENTIALS GLYCOBIOL	2	41	42	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1239	1239		10.1038/4371239a	http://dx.doi.org/10.1038/4371239a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251936	Bronze			2022-12-28	WOS:000232829100023
J	Murray, HW; Berman, JD; Davies, CR; Saravia, NG				Murray, HW; Berman, JD; Davies, CR; Saravia, NG			Advances in leishmaniasis	LANCET			English	Review							INDIAN VISCERAL LEISHMANIASIS; LIPOSOMAL AMPHOTERICIN-B; LOCALIZED CUTANEOUS LEISHMANIASIS; DIRECT AGGLUTINATION-TEST; HIV-INFECTED PATIENTS; INTRALESIONAL MEGLUMINE ANTIMONIATE; MACROPHAGE GENE-EXPRESSION; CONTROLLED CLINICAL-TRIAL; PLACEBO-CONTROLLED TRIAL; VACCINE PLUS BCG	Governed by parasite and host factors and immunoinflammatory responses, the clinical spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions), and disseminated infection (cutaneous, mucosal, or visceral). Symptomatic disease is subacute or chronic and diverse in presentation and outcome. Clinical characteristics vary further by endemic region. Despite T-cell-dependent immune responses, which produce asymptomatic and self-healing infection, or appropriate treatment, intracellular infection is probably life-long since targeted cells (tissue macrophages) allow residual parasites to persist. There is an epidemic of cutaneous leishmaniasis in Afghanistan and Pakistan and of visceral infection in India and Sudan. Diagnosis relies on visualising parasites in tissue or serology; culture and detection of parasite DNA are useful in the laboratory. Pentavalent antimony is the conventional treatment; however, resistance of visceral infection in India has spawned new treatment approaches-amphotericin B and its lipid formulations, injectable paromomycin, and oral miltefosine. Despite tangible advances in diagnosis, treatment, and basic scientific research, leishmaniasis is embedded in poverty and neglected. Current obstacles to realistic prevention and proper management include inadequate vector (sandfly) control, no vaccine, and insufficient access to or impetus for developing affordable new drugs.	Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; NIH, Natl Ctr Complementary & Alternat Med, Bethesda, MD 20892 USA; London Sch Hyg & Trop Med, Dept Infect & Trop Dis, London WC1, England; Ctr Int Entrenamiento & Invest Med, Cali, Colombia	Cornell University; National Institutes of Health (NIH) - USA; NIH National Center for Complementary & Alternative Medicine; University of London; London School of Hygiene & Tropical Medicine	Murray, HW (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA.	hwmurray@med.cornell.edu	Murray, Heather/GQY-8016-2022		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI016963, R01AI016963] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 16963] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		Abdallah KAA, 2004, TROP MED INT HEALTH, V9, P1127, DOI 10.1111/j.1365-3156.2004.01308.x; Ahluwalia IB, 2003, AM J TROP MED HYG, V69, P624, DOI 10.4269/ajtmh.2003.69.624; Ahluwalia S, 2004, BMJ-BRIT MED J, V329, P842, DOI 10.1136/bmj.329.7470.842; Ajdary S, 2000, INFECT IMMUN, V68, P1760, DOI 10.1128/IAI.68.4.1760-1764.2000; Aliaga L, 2003, MEDICINE, V82, P147, DOI 10.1097/00005792-200305000-00001; Alkhawajah AM, 1997, ANN TROP MED PARASIT, V91, P899, DOI 10.1080/00034989760284; Alrajhi AA, 2002, NEW ENGL J MED, V346, P891, DOI 10.1056/NEJMoa011882; Alvar J, 2004, ADV PARASIT, V57, P1, DOI 10.1016/S0065-308X(04)57001-X; Andersen EM, 2005, AM J TROP MED HYG, V72, P133, DOI 10.4269/ajtmh.2005.72.133; Arana BA, 2001, AM J TROP MED HYG, V65, P466, DOI 10.4269/ajtmh.2001.65.466; ARANA BA, 1994, CLIN INFECT DIS, V18, P381, DOI 10.1093/clinids/18.3.381; Armijos RX, 2004, VACCINE, V22, P1320, DOI 10.1016/j.vaccine.2003.06.002; Armijos RX, 2003, J INFECT DIS, V187, P1959, DOI 10.1086/375399; Aronson NE, 1998, CLIN INFECT DIS, V27, P1457, DOI 10.1086/515027; Asilian A, 2003, ANN TROP MED PARASIT, V97, P493, DOI 10.1179/000349803225001373; Asilian A, 2003, J CLIN PHARM THER, V28, P175, DOI 10.1046/j.1365-2710.2003.00476.x; Asilian A, 1995, AM J TROP MED HYG, V53, P648, DOI 10.4269/ajtmh.1995.53.648; Bacellar O, 2002, INFECT IMMUN, V70, P6734, DOI 10.1128/IAI.70.12.6734-6740.2002; BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BARRAL A, 1995, AM J TROP MED HYG, V53, P256, DOI 10.4269/ajtmh.1995.53.256; Belkaid Y, 2000, J IMMUNOL, V165, P969, DOI 10.4049/jimmunol.165.2.969; Belkaid Y, 2001, J EXP MED, V194, P1497, DOI 10.1084/jem.194.10.1497; BENSALAH A, 1995, AM J TROP MED HYG, V53, P162, DOI 10.4269/ajtmh.1995.53.162; Berenguer J, 2000, AIDS, V14, P2946, DOI 10.1097/00002030-200012220-00020; Bern C, 2005, EMERG INFECT DIS, V11, P655, DOI 10.3201/eid1105.040718; Bern C, 2000, AM J TROP MED HYG, V63, P184, DOI 10.4269/ajtmh.2000.63.184; Bertholet S, 2003, INFECT IMMUN, V71, P2095, DOI 10.1128/IAI.71.4.2095-2101.2003; Beutler B, 2004, MOL IMMUNOL, V40, P845, DOI 10.1016/j.molimm.2003.10.005; Bhattacharya SK, 2004, CLIN INFECT DIS, V38, P217, DOI 10.1086/380638; Blackwell JM, 2004, TRENDS PARASITOL, V20, P268, DOI 10.1016/j.pt.2004.04.003; Blum J, 2004, J ANTIMICROB CHEMOTH, V53, P158, DOI 10.1093/jac/dkh058; Boelaert M, 2004, AM J TROP MED HYG, V70, P72, DOI 10.4269/ajtmh.2004.70.72; Borj-Cabrera GP, 2002, VACCINE, V20, P3277, DOI 10.1016/S0264-410X(02)00294-3; Bourreau E, 2001, J INFECT DIS, V184, P1628, DOI 10.1086/324665; Bourreau E, 2001, J INFECT DIS, V183, P953, DOI 10.1086/319249; Brandonisio O, 2004, MICROBES INFECT, V6, P1402, DOI 10.1016/j.micinf.2004.10.004; BRYCESON AD, 1969, T ROY SOC TROP MED H, V63, P708, DOI 10.1016/0035-9203(69)90116-3; Buates S, 2001, J IMMUNOL, V166, P3416, DOI 10.4049/jimmunol.166.5.3416; Buxbaum LU, 2003, J IMMUNOL, V171, P3711, DOI 10.4049/jimmunol.171.7.3711; CABRERA M, 1995, J EXP MED, V182, P1259, DOI 10.1084/jem.182.5.1259; CARVALHO EM, 1992, J INFECT DIS, V165, P535, DOI 10.1093/infdis/165.3.535; Cascio A, 2004, J ANTIMICROB CHEMOTH, V54, P217, DOI 10.1093/jac/dkh279; CERF BJ, 1987, J INFECT DIS, V156, P1030, DOI 10.1093/infdis/156.6.1030; Coler RN, 2005, TRENDS PARASITOL, V21, P244, DOI 10.1016/j.pt.2005.03.006; Collin S, 2004, CLIN INFECT DIS, V38, P612, DOI 10.1086/381203; Convit J, 2004, MEM I OSWALDO CRUZ, V99, P57, DOI 10.1590/S0074-02762004000100010; CONVIT J, 1993, T ROY SOC TROP MED H, V87, P444, DOI 10.1016/0035-9203(93)90030-T; Costa CHN, 2000, J INFECT DIS, V182, P997, DOI 10.1086/315795; Cotarelo MJF, 2003, CLIN INFECT DIS, V37, P973, DOI 10.1086/377607; Couppie P, 2004, BRIT J DERMATOL, V151, P1165, DOI 10.1111/j.1365-2133.2004.06226.x; Courtenay O, 2002, J INFECT DIS, V186, P1314, DOI 10.1086/344312; Cruz I, 2002, LANCET, V359, P1124, DOI 10.1016/S0140-6736(02)08160-6; Luz Zélia Maria Profeta da, 2003, Cad. Saúde Pública, V19, P561, DOI 10.1590/S0102-311X2003000200023; Davidson RN, 1998, DRUGS, V56, P1009, DOI 10.2165/00003495-199856060-00005; Davies C R, 2000, Cad Saude Publica, V16, P925, DOI 10.1590/S0102-311X2000000400013; Davies CR, 2000, T ROY SOC TROP MED H, V94, P631, DOI 10.1016/S0035-9203(00)90214-1; Davies CR, 1999, PARASITOLOGY, V119, P247, DOI 10.1017/S0031182099004680; Davies CR, 2003, BRIT MED J, V326, P377, DOI 10.1136/bmj.326.7385.377; de Oliveira CI, 2003, CLIN INFECT DIS, V37, pE149, DOI 10.1086/379610; de Souza EP, 2001, ACTA TROP, V80, P69, DOI 10.1016/S0001-706X(01)00150-4; Dereure J, 2003, J INFECTION, V47, P77, DOI 10.1016/S0163-4453(03)00002-1; Desjeux P, 2004, COMP IMMUNOL MICROB, V27, P305, DOI 10.1016/j.cimid.2004.03.004; Desjeux P, 2001, T ROY SOC TROP MED H, V95, P239, DOI 10.1016/S0035-9203(01)90223-8; DILLON RJ, 2005, ARCH I PASTEUR TUNIS, V82, P39; Dowlati Y, 1996, CLIN DERMATOL, V14, P425, DOI 10.1016/0738-081X(96)00058-2; El-Hassan AM, 2001, T ROY SOC TROP MED H, V95, pS1, DOI 10.1016/S0035-9203(01)90216-0; El-Sayed NM, 2005, SCIENCE, V309, P404, DOI 10.1126/science.1112181; ELAMIN EM, 1986, CLIN EXP IMMUNOL, V64, P14; ELON J, 1985, BRIT MED J, V291, P1280, DOI 10.1136/bmj.291.6504.1280-b; Elso CM, 2004, GENES IMMUN, V5, P93, DOI 10.1038/sj.gene.6364042; Engwerda CR, 2004, TRENDS PARASITOL, V20, P524, DOI 10.1016/j.pt.2004.08.009; Faber WR, 2003, J AM ACAD DERMATOL, V49, P70, DOI 10.1067/mjd.2003.492; Fernandez-Guerrero ML, 2004, ACTA TROP, V90, P11, DOI 10.1016/j.actatropica.2003.09.009; Fissore C, 2004, J CLIN MICROBIOL, V42, P5332, DOI 10.1128/JCM.42.11.5332-5333.2004; Follador I, 2002, CLIN INFECT DIS, V34, pE54, DOI 10.1086/340261; FRANKE ED, 1990, ANN INTERN MED, V113, P934, DOI 10.7326/0003-4819-113-12-934; Gama MEA, 2004, MEM I OSWALDO CRUZ, V99, P889, DOI 10.1590/S0074-02762004000800018; Gama MEA, 2004, BRAZ J MED BIOL RES, V37, P129, DOI 10.1590/S0100-879X2004000100018; Gantt KR, 2003, J IMMUNOL, V170, P2613, DOI 10.4049/jimmunol.170.5.2613; Gasim S, 1998, CLIN EXP IMMUNOL, V111, P64; Gatti S, 2004, ANN TROP MED PARASIT, V98, P667, DOI 10.1179/000349804225011488; Gomes RB, 2002, J INFECT DIS, V186, P1530, DOI 10.1086/344733; Gradoni L., 2004, Parassitologia (Rome), V46, P199; Guerin PJ, 2002, LANCET INFECT DIS, V2, P494, DOI 10.1016/S1473-3099(02)00347-X; Gurunathan S, 2000, J IMMUNOL, V165, P915, DOI 10.4049/jimmunol.165.2.915; Hailu A, 2004, AM J TROP MED HYG, V71, P561, DOI 10.4269/ajtmh.2004.71.561; Handman E, 2001, CLIN MICROBIOL REV, V14, P229, DOI 10.1128/CMR.14.2.229-243.2001; HERWALDT BL, 1992, J INFECT DIS, V165, P518, DOI 10.1093/infdis/165.3.518; Herwaldt BL, 1999, LANCET, V354, P1191, DOI 10.1016/S0140-6736(98)10178-2; Hoebe K, 2004, NAT IMMUNOL, V5, P971, DOI 10.1038/ni1004-971; Islam MZ, 2004, AM J TROP MED HYG, V70, P78, DOI 10.4269/ajtmh.2004.70.78; Ivens AC, 2005, SCIENCE, V309, P436, DOI 10.1126/science.1112680; Jha TK, 1998, BRIT MED J, V316, P1200, DOI 10.1136/bmj.316.7139.1200; JHA TK, 1983, T ROY SOC TROP MED H, V77, P167, DOI 10.1016/0035-9203(83)90058-5; Joshi PB, 2002, MOL BIOCHEM PARASIT, V120, P33, DOI 10.1016/S0166-6851(01)00432-7; Junior AD, 1997, MEM I OSWALDO CRUZ, V92, P15, DOI 10.1590/S0074-02761997000100003; Karplus TM, 2002, INFECT IMMUN, V70, P6919, DOI 10.1128/IAI.70.12.6919-6925.2002; Kelly BL, 2003, J EXP MED, V198, P1689, DOI 10.1084/jem.20031162; Kenney RT, 1998, J INFECT DIS, V177, P815, DOI 10.1086/517817; Khalil EAG, 2000, LANCET, V356, P1565, DOI 10.1016/S0140-6736(00)03128-7; Khamesipour A, 2005, VACCINE, V23, P3642, DOI 10.1016/j.vaccine.2005.02.015; King RJ, 2004, EMERG INFECT DIS, V10, P598, DOI 10.3201/eid1004.030241; Kroeger A, 2002, BMJ-BRIT MED J, V325, P810, DOI 10.1136/bmj.325.7368.810; Laguna F, 2003, ANN TROP MED PARASIT, V97, P135, DOI 10.1179/000349803225002606; le Fichoux Y, 1999, J CLIN MICROBIOL, V37, P1953, DOI 10.1128/JCM.37.6.1953-1957.1999; Lessa HA, 2001, AM J TROP MED HYG, V65, P87, DOI 10.4269/ajtmh.2001.65.87; Louzir H, 1998, J INFECT DIS, V177, P1687, DOI 10.1086/515297; Lyons S, 2003, TROP MED INT HEALTH, V8, P733, DOI 10.1046/j.1365-3156.2003.01088.x; Machado P, 2002, CLIN INFECT DIS, V34, pE69, DOI 10.1086/340526; Machado-Coelho GLL, 2005, T ROY SOC TROP MED H, V99, P55, DOI 10.1016/j.trstmh.2003.08.001; Magill AJ, 2005, INFECT DIS CLIN N AM, V19, P241, DOI 10.1016/j.idc.2004.11.005; Marlet MVL, 2003, T ROY SOC TROP MED H, V97, P515, DOI 10.1016/S0035-9203(03)80012-3; Maroli M, 2001, MED VET ENTOMOL, V15, P358, DOI 10.1046/j.0269-283x.2001.00321.x; MAZLOUMIGAVGANI AS, 2002, LANCET, V360, P374; McDowell MA, 2002, INFECT IMMUN, V70, P3994, DOI 10.1128/IAI.70.8.3994-4001.2002; McMahon-Pratt D, 2004, IMMUNOL REV, V201, P206, DOI 10.1111/j.0105-2896.2004.00190.x; Melby PC, 2001, INFECT IMMUN, V69, P4719, DOI 10.1128/IAI.69.8.4719-4725.2001; MELLERMELLOUL C, 1991, PARASITE IMMUNOL, V13, P531, DOI 10.1111/j.1365-3024.1991.tb00549.x; Mendonca MG, 2004, J INFECT DIS, V189, P1018, DOI 10.1086/382135; Miranda-Verastegui C, 2005, CLIN INFECT DIS, V40, P1395, DOI 10.1086/429238; Mohebali M, 2004, VACCINE, V22, P4097, DOI 10.1016/j.vaccine.2004.03.058; Momeni AZ, 1999, VACCINE, V17, P466, DOI 10.1016/S0264-410X(98)00220-5; Morales MA, 2002, J INFECT DIS, V185, P1533, DOI 10.1086/340219; Moreira ED, 2004, VET PARASITOL, V122, P245, DOI 10.1016/j.vetpar.2004.05.019; Morillas-Marquez F, 2002, EXP PARASITOL, V100, P71, DOI 10.1006/expr.2001.4678; Murray Henry W, 2004, Expert Rev Anti Infect Ther, V2, P279, DOI 10.1586/14787210.2.2.279; Murray HW, 2002, INFECT IMMUN, V70, P6284, DOI 10.1128/IAI.70.11.6284-6293.2002; Murray HW, 2001, ANTIMICROB AGENTS CH, V45, P2185, DOI 10.1128/AAC.45.8.2185-2197.2001; Murray HW, 2001, INT J EXP PATHOL, V82, P249, DOI 10.1046/j.1365-2613.2001.00199.x; Nassiri-Kashani M, 2005, J EUR ACAD DERMATOL, V19, P80, DOI 10.1111/j.1468-3083.2004.01133.x; NAVIN TR, 1992, J INFECT DIS, V165, P528, DOI 10.1093/infdis/165.3.528; Oliveira JGS, 2005, ACTA TROP, V94, P55, DOI 10.1016/j.actatropica.2004.12.003; Osman OF, 2000, TROP MED INT HEALTH, V5, P553, DOI 10.1046/j.1365-3156.2000.00598.x; Pagliano P, 2005, J ANTIMICROB CHEMOTH, V55, P229, DOI 10.1093/jac/dkh538; Pagliano P, 2003, J ANTIMICROB CHEMOTH, V52, P264, DOI 10.1093/jac/dkg340; Palacios R, 2001, AM J TROP MED HYG, V64, P187, DOI 10.4269/ajtmh.2001.64.187; Pattanayak S, 2001, Indian J Public Health, V45, P41; Pintado V, 2001, MEDICINE, V80, P54, DOI 10.1097/00005792-200101000-00006; Rabello A, 2003, Ann Trop Med Parasitol, V97 Suppl 1, P17; Ramirez JR, 2000, J CLIN MICROBIOL, V38, P3768; Ray M, 2000, J INFECT DIS, V181, P1121, DOI 10.1086/315330; Reithinger R, 2005, EMERG INFECT DIS, V11, P634, DOI 10.3201/eid1104.040945; Reithinger R, 2005, CLIN INFECT DIS, V40, P1148, DOI 10.1086/428736; Reithinger R, 2001, EMERG INFECT DIS, V7, P872; Requena JM, 2004, EXPERT OPIN BIOL TH, V4, P1505, DOI 10.1517/14712598.4.9.1505; Reyburn H, 2003, T ROY SOC TROP MED H, V97, P170, DOI 10.1016/S0035-9203(03)90111-8; Reyburn H, 2000, T ROY SOC TROP MED H, V94, P361, DOI 10.1016/S0035-9203(00)90104-4; Riera C, 2004, T ROY SOC TROP MED H, V98, P102, DOI 10.1016/S0035-9203(03)00015-4; Rijal S, 2003, T ROY SOC TROP MED H, V97, P350, DOI 10.1016/S0035-9203(03)90167-2; Rodriguez NE, 2004, INFECT IMMUN, V72, P2111, DOI 10.1128/IAI.72.4.2111-2122.2004; Rogers ME, 2004, NATURE, V430, P463, DOI 10.1038/nature02675; Romero GAS, 2005, ACTA TROP, V93, P49, DOI 10.1016/j.actatropica.2004.09.005; Romero GAS, 2001, AM J TROP MED HYG, V65, P456, DOI 10.4269/ajtmh.2001.65.456; Sacks D, 2002, NAT REV IMMUNOL, V2, P845, DOI 10.1038/nri933; Sacks D, 2004, IMMUNOL REV, V201, P225, DOI 10.1111/j.0105-2896.2004.00185.x; Sacks D, 2002, NAT IMMUNOL, V3, P1041, DOI 10.1038/ni1102-1041; Sacks DL, 2001, CELL MICROBIOL, V3, P189, DOI 10.1046/j.1462-5822.2001.00115.x; SAENZ RE, 1990, AM J MED, V89, P147, DOI 10.1016/0002-9343(90)90292-L; Salmanpour R, 2001, J DERMATOL TREAT, V12, P159, DOI 10.1080/09546630152607899; SAMPAIO S A P, 1971, International Journal of Dermatology, V10, P179, DOI 10.1111/j.1365-4362.1971.tb01694.x; Santos JB, 2004, J INFECT DIS, V190, P1793, DOI 10.1086/424848; Sharifi I, 1998, LANCET, V351, P1540, DOI 10.1016/S0140-6736(98)09552-X; Soto J, 2004, CLIN INFECT DIS, V38, P1266, DOI 10.1086/383321; Soto J, 2004, AM J TROP MED HYG, V71, P577, DOI 10.4269/ajtmh.2004.71.577; Soto J, 1998, CLIN INFECT DIS, V26, P56, DOI 10.1086/516267; SOTOMANCIPE J, 1993, CLIN INFECT DIS, V16, P417, DOI 10.1093/clind/16.3.417; Spath GF, 2003, P NATL ACAD SCI USA, V100, P9536, DOI 10.1073/pnas.1530604100; Sundar S, 2005, AM J TROP MED HYG, V73, P269, DOI 10.4269/ajtmh.2005.73.269; Sundar S, 2004, CLIN INFECT DIS, V38, P377, DOI 10.1086/380971; Sundar S, 2003, CLIN INFECT DIS, V37, P800, DOI 10.1086/377542; Sundar S, 2002, CLIN INFECT DIS, V35, P581, DOI 10.1086/342057; Sundar S, 2002, NEW ENGL J MED, V347, P1739, DOI 10.1056/NEJMoa021556; Sundar S, 2002, AM J TROP MED HYG, V66, P143, DOI 10.4269/ajtmh.2002.66.143; Sundar S, 2001, TROP MED INT HEALTH, V6, P849, DOI 10.1046/j.1365-3156.2001.00778.x; Sundar S, 2001, BRIT MED J, V323, P419, DOI 10.1136/bmj.323.7310.419; Sundar S, 1997, AM J TROP MED HYG, V56, P522, DOI 10.4269/ajtmh.1997.56.522; Sundar S, 2000, CLIN INFECT DIS, V31, P1104, DOI 10.1086/318121; Sundar Shyam, 2003, J Assoc Physicians India, V51, P195; Syriopoulou V, 2003, CLIN INFECT DIS, V36, P560, DOI 10.1086/367843; Tayeh A, 1997, WHOLEISH9741; Thakur CP, 2004, ANN TROP MED PARASIT, V98, P129, DOI 10.1179/000349804225003154; Thompson RA, 2002, AM J TROP MED HYG, V67, P648, DOI 10.4269/ajtmh.2002.67.648; Turetz ML, 2002, J INFECT DIS, V186, P1829, DOI 10.1086/345772; Uzun S, 2004, J PARASITOL, V90, P853, DOI 10.1645/GE-185R; Veeken H, 2000, TROP MED INT HEALTH, V5, P312, DOI 10.1046/j.1365-3156.2000.00555.x; Veeken H, 2003, TROP MED INT HEALTH, V8, P164, DOI 10.1046/j.1365-3156.2003.00996.x; Vega-Lopez F, 2003, CURR OPIN INFECT DIS, V16, P97, DOI 10.1097/00001432-200304000-00006; Velez I, 1997, ANN INTERN MED, V126, P232, DOI 10.7326/0003-4819-126-3-199702010-00010; von Stebut E, 2004, MICROBES INFECT, V6, P1102, DOI 10.1016/j.micinf.2004.05.024; Weigle K, 1996, CLIN DERMATOL, V14, P433, DOI 10.1016/0738-081X(96)00036-3; Weina PJ, 2004, CLIN INFECT DIS, V39, P1674, DOI 10.1086/425747; Werneck GL, 2002, EPIDEMIOLOGY, V13, P364, DOI 10.1097/00001648-200205000-00020; WHOPES, 2005, WHOCDSWHOPESGCDPP200; Wise J, 2004, B WORLD HEALTH ORGAN, V82, P884; Yamey G, 2002, BRIT MED J, V325, P176, DOI 10.1136/bmj.325.7357.176; Yanik M, 2004, CLIN EXP DERMATOL, V29, P464, DOI 10.1111/j.1365-2230.2004.01605.x; Zhang WW, 2003, J BIOL CHEM, V278, P35508, DOI 10.1074/jbc.M305030200; Zijistra EE, 2003, LANCET INFECT DIS, V3, P87, DOI 10.1016/S1473-3099(03)00517-6	199	1226	1275	1	170	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1561	1577		10.1016/S0140-6736(05)67629-5	http://dx.doi.org/10.1016/S0140-6736(05)67629-5			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257344				2022-12-28	WOS:000232984800026
J	Mavromaras, K; Scott, A				Mavromaras, K; Scott, A			Promotion to hospital consultant: regression analysis using NHS administrative data	BRITISH MEDICAL JOURNAL			English	Article								Objectives To examine factors influencing promotion to hospital consultant. Design Multivariate logistic regression analysis of NHS administrative data between 1991 and 2000. Setting Hospitals in NHS Scotland. Population All registrars, senior registrars, and specialist registrars in Scotland. Main outcome measure The proportion of doctors promoted to NHS consultant. Results Compared with doctors who graduated in Scotland, graduates from the rest of the United Kingdom and from overseas were less likely to be promoted to consultant (odds ratio 0.65, 95% confidence interval 0.52 to 0.82; and 0.37, 0.28 to 0.50, respectively). Promotion and holding an honorary contract before promotion were positively associated (1.37, 1.03 to 1.83); and the number of years since graduation (5.98 per year, 4.94 to 7.23). Women were less likely to be promoted (0.73, 0.60 to 0.90), as were doctors who worked part time (0.27, 0.17 to 0.42). Probabilities of promotion did not have a clear time trend between 1993 and 2000, and NHS boards in non-metropolitan areas of Scotland were more likely to offer promotions than NHS boards in metropolitan areas, presumably reflecting a higher gap between demand. and supply in these boards. Conclusion As the proportion of women in hospital medicine increases, government targets for the recruitment of consultants are unlikely to be met unless the promotion process is examined. It is unclear whether more recent reforms of die medical career structure will deal with these issues.	Univ Melbourne, Melbourne Inst Appl Econ & Social Res, Parkville, Vic 3010, Australia	University of Melbourne	Mavromaras, K (corresponding author), Univ Melbourne, Melbourne Inst Appl Econ & Social Res, Parkville, Vic 3010, Australia.	k.mavromaras@unimelb.edu.au	Scott, Anthony/E-6636-2010	Scott, Anthony/0000-0002-2851-5378	Chief Scientist Office [HERU1] Funding Source: Medline	Chief Scientist Office		BALRAGI B, 2001, ECONOMETRIC ANAL PAN, P11; Baltagi Badi H., 2001, ECONOMETRIC ANAL PAN, P11; Department of Health, 2000, 48181 DEP HLTH STAT; ELLIOTT R, 2002, NHS LABOUR MARKETS S; Lambert TW, 2004, BMJ-BRIT MED J, V328, P1347, DOI 10.1136/bmj.38062.639190.44; Scottish Executive, 2000, OUR NAT HLTH PLAN AC; *STAT CORP, 2003, STAT CROSS SECT TIM; UK Department of Health, 2004, MOD MED CAR NEXT STE; WOOLDRIDGE JM, 2002, ECONOMETRIC ANAL CRO, P453	9	10	10	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	JAN 21	2006	332	7534					148	151		10.1136/bmj.38628.738935.3A	http://dx.doi.org/10.1136/bmj.38628.738935.3A			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	006OC	16260457	Bronze, Green Published			2022-12-28	WOS:000234905800017
J	Solit, DB; Garraway, LA; Pratilas, CA; Sawai, A; Getz, G; Basso, A; Ye, Q; Lobo, JM; She, YH; Osman, I; Golub, TR; Sebolt-Leopold, J; Sellers, WR; Rosen, N				Solit, DB; Garraway, LA; Pratilas, CA; Sawai, A; Getz, G; Basso, A; Ye, Q; Lobo, JM; She, YH; Osman, I; Golub, TR; Sebolt-Leopold, J; Sellers, WR; Rosen, N			BRAF mutation predicts sensitivity to MEK inhibition	NATURE			English	Article							CYCLIN D1; PROTEIN-KINASE; RAS MUTATIONS; IN-VIVO; MELANOMA; CANCER; EXPRESSION; PATHWAY; GENE; PROTEOLYSIS	The kinase pathway comprising RAS, RAF, mitogen-activated protein kinase kinase (MEK) and extracellular signal regulated kinase (ERK) is activated in most human tumours, often through gain-of-function mutations of RAS and RAF family members(1). Using small-molecule inhibitors of MEK and an integrated genetic and pharmacologic analysis, we find that mutation of BRAF is associated with enhanced and selective sensitivity to MEK inhibition when compared to either 'wild-type' cells or cells harbouring a RAS mutation. This MEK dependency was observed in BRAF mutant cells regardless of tissue lineage, and correlated with both downregulation of cyclin D1 protein expression and the induction of G1 arrest. Pharmacological MEK inhibition completely abrogated tumour growth in BRAF mutant xenografts, whereas RAS mutant tumours were only partially inhibited. These data suggest an exquisite dependency on MEK activity in BRAF mutant tumours, and offer a rational therapeutic strategy for this genetically defined tumour subtype.	Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Pediat, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Mol Pharmacol & Chem, New York, NY 10021 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA; Harvard Univ, Broad Inst, Cambridge, MA 02141 USA; MIT, Cambridge, MA 02141 USA; NYU Med Ctr, Dept Med, New York, NY 10016 USA; NYU Med Ctr, Dept Urol, New York, NY 10016 USA; Pfizer Global Res & Dev, Ann Arbor, MI 48105 USA	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Massachusetts Institute of Technology (MIT); Broad Institute; Massachusetts Institute of Technology (MIT); New York University; New York University; Pfizer	Rosen, N (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, 1275 York Ave, New York, NY 10021 USA.	rosenn@mskcc.org	Solit, David B./AAC-5309-2019; Rosen, Neal/ABF-2677-2020		NCI NIH HHS [T32 CA009172, P01 CA094060-01A1, P01 CA094060] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA094060, T32CA009172] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Aktas H, 1997, MOL CELL BIOL, V17, P3850, DOI 10.1128/MCB.17.7.3850; ALBANESE C, 1995, J BIOL CHEM, V270, P23589, DOI 10.1074/jbc.270.40.23589; ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Brose MS, 2002, CANCER RES, V62, P6997; Cheng MG, 1998, P NATL ACAD SCI USA, V95, P1091, DOI 10.1073/pnas.95.3.1091; Chopra AP, 2003, J BIOL CHEM, V278, P9402, DOI 10.1074/jbc.M211262200; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766; Diehl JA, 1998, GENE DEV, V12, P3499, DOI 10.1101/gad.12.22.3499; Dombrowski A, 1999, J ANTIBIOT, V52, P1077, DOI 10.7164/antibiotics.52.1077; FILMUS J, 1994, ONCOGENE, V9, P3627; Garraway LA, 2005, NATURE, V436, P117, DOI 10.1038/nature03664; Golub TR, 1999, SCIENCE, V286, P531, DOI 10.1126/science.286.5439.531; Gonzalez-Garcia A, 2005, CANCER CELL, V7, P219, DOI 10.1016/j.ccr.2005.01.029; Gorden A, 2003, CANCER RES, V63, P3955; Hamad NM, 2002, GENE DEV, V16, P2045, DOI 10.1101/gad.993902; Karasarides M, 2004, ONCOGENE, V23, P6292, DOI 10.1038/sj.onc.1207785; Kerkhoff E, 1997, MOL CELL BIOL, V17, P2576, DOI 10.1128/MCB.17.5.2576; LIU JJ, 1995, MOL CELL BIOL, V15, P3654; Mody N, 2001, FEBS LETT, V502, P21, DOI 10.1016/S0014-5793(01)02651-5; Muise-Helmericks RC, 1998, J BIOL CHEM, V273, P29864, DOI 10.1074/jbc.273.45.29864; Ohren JF, 2004, NAT STRUCT MOL BIOL, V11, P1192, DOI 10.1038/nsmb859; Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533; Sebolt-Leopold JS, 2004, NAT REV CANCER, V4, P937, DOI 10.1038/nrc1503; STINSON SF, 1992, ANTICANCER RES, V12, P1035; Weber JD, 1997, BIOCHEM J, V326, P61, DOI 10.1042/bj3260061; Wellbrock C, 2004, CANCER RES, V64, P2338, DOI 10.1158/0008-5472.CAN-03-3433; Zhao A, 1999, J ANTIBIOT, V52, P1086, DOI 10.7164/antibiotics.52.1086	28	1067	1116	1	51	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JAN 19	2006	439	7074					358	362		10.1038/nature04304	http://dx.doi.org/10.1038/nature04304			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	003LA	16273091	Green Accepted			2022-12-28	WOS:000234682100050
J	Klass, P				Klass, P			So where's my medal?	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Boston Univ, Med Ctr, Boston, MA 02215 USA; Reach Out & Read Natl Ctr, Somerville, MA USA	Boston University	Klass, P (corresponding author), Boston Univ, Med Ctr, Boston, MA 02215 USA.								0	4	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2107	2109		10.1056/NEJMp048155	http://dx.doi.org/10.1056/NEJMp048155			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291980				2022-12-28	WOS:000233288600003
J	Baum, DA; Smith, SD; Donovan, SSS				Baum, DA; Smith, SD; Donovan, SSS			Evolution - The tree-thinking challenge	SCIENCE			English	Editorial Material							SCIENCE		Univ Wisconsin, Dept Bot, Madison, WI 53706 USA; Univ Pittsburgh, Dept Instruct & Learning, Pittsburgh, PA 15260 USA	University of Wisconsin System; University of Wisconsin Madison; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Baum, DA (corresponding author), Univ Wisconsin, Dept Bot, 430 Lincoln Dr, Madison, WI 53706 USA.	dbaum@wisc.edu; sdsmith4@wisc.edu; sdonovan@pitt.edu	Baum, David/D-6804-2015	Baum, David/0000-0001-8334-6311; Donovan, Sam/0000-0003-4021-9878				Cracraft J., 2004, ASSEMBLING TREE LIFE; Crandall KA, 1999, EVOLUTION OF HIV, P153; Crisp MD, 2005, TRENDS ECOL EVOL, V20, P122, DOI 10.1016/j.tree.2004.11.010; DAWKINS R, 2004, ANCESTORS TALE PILMG; Gilbert SF, 2003, NAT REV GENET, V4, P735, DOI 10.1038/nrg1159; Goldsmith DW, 2003, AM BIOL TEACH, V65, P679, DOI 10.1662/0002-7685(2003)065[0679:TGCR]2.0.CO;2; HERRON J, 2005, EVOBEAKER 1 0; Metzker ML, 2002, P NATL ACAD SCI USA, V99, P14292, DOI 10.1073/pnas.222522599; Nee S, 2005, NATURE, V435, P429, DOI 10.1038/435429a; O'Hara RJ, 1997, ZOOL SCR, V26, P323, DOI 10.1111/j.1463-6409.1997.tb00422.x; OHARA RJ, 1988, SYST ZOOL, V37, P142, DOI 10.2307/2992272; PENNY D, 1982, NATURE, V297, P197, DOI 10.1038/297197a0; Rudolph JL, 1998, J RES SCI TEACH, V35, P1069, DOI 10.1002/(SICI)1098-2736(199812)35:10<1069::AID-TEA2>3.0.CO;2-A; Sober E, 2002, J THEOR BIOL, V218, P395, DOI 10.1006/jtbi.2002.3086	14	161	163	2	161	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					979	980		10.1126/science.1117727	http://dx.doi.org/10.1126/science.1117727			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284166				2022-12-28	WOS:000233343400029
J	Lu, ET; Love, SG				Lu, ET; Love, SG			Gravitational tractor for towing asteroids - A spacecraft could deflect an Earth-bound asteroid without having to dock to its surface first	NATURE			English	Editorial Material									NASA, Lyndon B Johnson Space Ctr, Houston, TX 77058 USA	National Aeronautics & Space Administration (NASA); NASA JOHNSON SPACE CENTER	Lu, ET (corresponding author), NASA, Lyndon B Johnson Space Ctr, Mail Code CB, Houston, TX 77058 USA.	edward.t.lu@nasa.gov						Carusi A, 2002, ICARUS, V159, P417, DOI 10.1006/icar.2002.6906; Chapman CR, 2004, EARTH PLANET SC LETT, V222, P1, DOI 10.1016/j.epsl.2004.03.004; Chesley S. R., 2004, MITIGATION HAZARDOUS, P22; SCHEERES DJ, 2004, 20041446 AM I AER AS; Schweickart RL, 2003, SCI AM, V289, P54, DOI 10.1038/scientificamerican1103-54	5	137	143	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					177	178		10.1038/438177a	http://dx.doi.org/10.1038/438177a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281025	Green Submitted			2022-12-28	WOS:000233133500035
J	Steinbrook, R				Steinbrook, R			Renewing board certification	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							QUALITY											Brennan TA, 2004, JAMA-J AM MED ASSOC, V292, P1038, DOI 10.1001/jama.292.9.1038; Choudhry NK, 2005, ANN INTERN MED, V142, P260, DOI 10.7326/0003-4819-142-4-200502150-00008; *FED STAT MED BOAR, 2004, INT REP SPEC COMM MA; Institute of Medicine, 2001, CROSSING QUALITY CHA; Kohn L.T., 2000, ERR IS HUMAN BUILDIN, DOI 10.17226/9728	5	29	30	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					1994	1997		10.1056/NEJMp058067	http://dx.doi.org/10.1056/NEJMp058067			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981WV	16282173				2022-12-28	WOS:000233119600003
J	Bloodgood, BL; Sabatini, BL				Bloodgood, BL; Sabatini, BL			Neuronal activity regulates diffusion across the neck of dendritic spines	SCIENCE			English	Article							DEPENDENT SYNAPTIC PLASTICITY; PROTEIN-KINASE-II; LTP; ACTIN; CELLS; INDUCTION; STRENGTH; CAMKII	In mammalian excitatory neurons, dendritic spines are separated from dendrites by thin necks. Diffusion across the neck limits the chemical and electrical isolation of each spine. We found that 'spine/dendrite diffusional coupling is heterogeneous and uncovered a class of diffusionally isolated spines. The barrier to diffusion posed by the neck and the number of diffusionally isolated spines is bidirectionally regulated by neuronal activity. Furthermore, coincident synaptic activation and postsynaptic action potentials rapidly restrict diffusion across the neck. The regulation of diffusional. coupling provides a possible mechanism for determining the amplitude of postsynaptic potentials and the accumulation of plasticity-inducing molecules within the spine head.	Harvard Univ, Sch Med, Dept Neurobiol, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Sabatini, BL (corresponding author), Harvard Univ, Sch Med, Dept Neurobiol, 220 Longwood Ave, Boston, MA 02115 USA.	bsabatini@hms.harvard.edu		Bloodgood, Brenda/0000-0002-4797-9119				Andrasfalvy BK, 2004, J PHYSIOL-LONDON, V559, P543, DOI 10.1113/jphysiol.2004.065219; Bi GQ, 1998, J NEUROSCI, V18, P10464, DOI 10.1523/jneurosci.18-24-10464.1998; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; Canepari M, 2001, J NEUROSCI METH, V112, P29, DOI 10.1016/S0165-0270(01)00451-4; Capani F, 2001, J COMP NEUROL, V435, P156, DOI 10.1002/cne.1199; Colbran RJ, 2004, CURR OPIN NEUROBIOL, V14, P318, DOI 10.1016/j.conb.2004.05.008; DUDEK SM, 1993, J NEUROSCI, V13, P2910; Feldman DE, 2000, NEURON, V27, P45, DOI 10.1016/S0896-6273(00)00008-8; Fischer M, 2000, NAT NEUROSCI, V3, P887, DOI 10.1038/78791; Froemke RC, 2005, NATURE, V434, P221, DOI 10.1038/nature03366; Kiskin NI, 2002, EUR BIOPHYS J BIOPHY, V30, P588, DOI 10.1007/s00249-001-0187-x; KOCH C, 1993, J NEUROSCI, V13, P413; Li Z, 2004, CELL, V119, P873, DOI 10.1016/j.cell.2004.11.003; Malenka RC, 2004, NEURON, V44, P5, DOI 10.1016/j.neuron.2004.09.012; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; Murase S, 2002, NEURON, V35, P91, DOI 10.1016/S0896-6273(02)00764-X; Patterson GH, 2002, SCIENCE, V297, P1873, DOI 10.1126/science.1074952; Post JN, 2005, FEBS LETT, V579, P325, DOI 10.1016/j.febslet.2004.11.092; SEGEV I, 1988, J NEUROPHYSIOL, V60, P499, DOI 10.1152/jn.1988.60.2.499; Shen K, 2000, NAT NEUROSCI, V3, P881, DOI 10.1038/78783; Star EN, 2002, NAT NEUROSCI, V5, P239, DOI 10.1038/nn811; Svoboda K, 1996, SCIENCE, V272, P716, DOI 10.1126/science.272.5262.716; Swaminathan R, 1997, BIOPHYS J, V72, P1900, DOI 10.1016/S0006-3495(97)78835-0; Thiagarajan TC, 2002, NEURON, V36, P1103, DOI 10.1016/S0896-6273(02)01049-8; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Zucker RS, 1999, CURR OPIN NEUROBIOL, V9, P305, DOI 10.1016/S0959-4388(99)80045-2	26	252	258	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					866	869		10.1126/science.1114816	http://dx.doi.org/10.1126/science.1114816			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272125				2022-12-28	WOS:000233121800049
J	Bullock, TH; Bennett, MVL; Johnston, D; Josephson, R; Marder, E; Fields, RD				Bullock, TH; Bennett, MVL; Johnston, D; Josephson, R; Marder, E; Fields, RD			The Neuron Doctrine, redux	SCIENCE			English	Editorial Material							ACTION-POTENTIALS; TRIGGERS; DYNAMICS; CELLS		Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA; Univ Calif San Diego, Dept Neurosci, La Jolla, CA 92093 USA; Albert Einstein Coll Med, Dept Neurosci, Bronx, NY 10461 USA; Univ Texas, Ctr Learning & Memory, Austin, TX 78712 USA; Univ Calif Irvine, Dept Neurobiol & Behav, Irvine, CA 92697 USA; Brandeis Univ, Dept Biol, Waltham, MA 02454 USA; NICHHD, Nervous Syst Dev & Plast Sect, Bethesda, MD 20892 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of California System; University of California San Diego; Yeshiva University; Albert Einstein College of Medicine; University of Texas System; University of Texas Austin; University of California System; University of California Irvine; Brandeis University; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bullock, TH (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, La Jolla, CA 92093 USA.	fieldsd@mail.nih.gov			EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [ZIAHD000713] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD000713] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Alvarez-Maubecin V, 2000, J NEUROSCI, V20, P4091; Bennett MVL, 2004, NEURON, V41, P495, DOI 10.1016/S0896-6273(04)00043-1; Bergles DE, 2000, NATURE, V405, P187, DOI 10.1038/35012083; Bucher D, 2003, J NEUROSCI, V23, P6866; BULLOCK TH, 1959, SCIENCE, V129, P997, DOI 10.1126/science.129.3355.997; Bullock TH, 1997, P NATL ACAD SCI USA, V94, P1, DOI 10.1073/pnas.94.1.1; Bullock TH, 2003, NEURAL COMPUT, V15, P2013, DOI 10.1162/089976603322297269; Coggan JS, 2005, SCIENCE, V309, P446, DOI 10.1126/science.1108239; DANI JW, 1992, NEURON, V8, P429, DOI 10.1016/0896-6273(92)90271-E; DEROBERTIS EDP, 1955, J BIOPHYS BIOCHEM CY, V1, P47, DOI 10.1083/jcb.1.1.47; Dupree JL, 2004, NEURON GLIA BIOL, V1, P179, DOI 10.1017/S1740925X04000304; FICK A, 2004, NAT NEUROSCI, V7, P126; Fields RD, 2002, SCIENCE, V298, P556, DOI 10.1126/science.298.5593.556; Goaillard JM, 2004, J NEUROSCI, V24, P7063, DOI 10.1523/JNEUROSCI.2078-04.2004; Golding NL, 1998, NEURON, V21, P1189, DOI 10.1016/S0896-6273(00)80635-2; Johnston D, 1996, ANNU REV NEUROSCI, V19, P165, DOI 10.1146/annurev.ne.19.030196.001121; Matsui K, 2004, J NEUROSCI, V24, P8932, DOI 10.1523/JNEUROSCI.2650-04.2004; Noctor SC, 2001, NATURE, V409, P714, DOI 10.1038/35055553; Nusbaum MP, 2001, TRENDS NEUROSCI, V24, P146, DOI 10.1016/S0166-2236(00)01723-9; Pereda AE, 2004, BRAIN RES REV, V47, P227, DOI 10.1016/j.brainresrev.2004.06.010; Ramon y Cajal S, 1995, HISTOLOGY NERVOUS SY; Stevens B, 2002, NEURON, V36, P855, DOI 10.1016/S0896-6273(02)01067-X; Stevens B, 2000, SCIENCE, V287, P2267, DOI 10.1126/science.287.5461.2267; STUART GJ, 1993, PFLUG ARCH EUR J PHY, V423, P511, DOI 10.1007/BF00374949	24	96	98	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 4	2005	310	5749					791	793		10.1126/science.1114394	http://dx.doi.org/10.1126/science.1114394			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272104				2022-12-28	WOS:000233121800026
J	Gordon, RJ; Lowy, FD				Gordon, RJ; Lowy, FD			Current concepts - Bacterial infections in drug users	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							RESISTANT STAPHYLOCOCCUS-AUREUS; IMMUNODEFICIENCY-VIRUS-INFECTION; DETROIT-MEDICAL-CENTER; BLACK-TAR HEROIN; RISK-FACTORS; NECROTIZING FASCIITIS; NARCOTIC ADDICTS; WOUND BOTULISM; ENDOCARDITIS; INJECTION		Columbia Univ Coll Phys & Surg, Div Infect Dis, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pathol, New York, NY 10032 USA	Columbia University; Columbia University	Gordon, RJ (corresponding author), Columbia Univ Coll Phys & Surg, Div Infect Dis, Dept Med, Box 82,630 W 168th St, New York, NY 10032 USA.	rj216@columbia.edu			NIDA NIH HHS [DA-15018, DA-09655] Funding Source: Medline; ODCDC CDC HHS [CCR223380-01] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA015018] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); ODCDC CDC HHS; NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ALCABES P, 1995, CLIN INFECT DIS, V20, P1467, DOI 10.1093/clinids/20.6.1467; Baddour LM, 2005, CIRCULATION, V111, pE394, DOI 10.1161/CIRCULATIONAHA.105.165564; Bassetti S, 2004, INFECTION, V32, P163, DOI 10.1007/s15010-004-3106-0; Binswanger IA, 2000, CLIN INFECT DIS, V30, P579, DOI 10.1086/313703; Bohlen LM, 2000, EMERG INFECT DIS, V6, P175; Boschini A, 1996, CLIN INFECT DIS, V23, P107, DOI 10.1093/clinids/23.1.107; Centers for Disease Control and Prevention (CDC), 2003, MMWR Recomm Rep, V52, P1; Centers for Disease Control and Prevention (CDC), 2001, MMWR Morb Mortal Wkly Rep, V50, P919; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P88; Centers for Disease Control and Prevention (CDC), 2016, DEV WAT MAN PROGR RE; CHAMBERS HF, 1988, ANN INTERN MED, V109, P619, DOI 10.7326/0003-4819-109-8-619; CHAMBERS HF, 1987, ANN INTERN MED, V106, P833, DOI 10.7326/0003-4819-106-6-833; CHANDRASEKAR PH, 1986, REV INFECT DIS, V8, P904; Charlebois ED, 2002, CLIN INFECT DIS, V34, P425, DOI 10.1086/338069; CHERUBIN CE, 1993, ANN INTERN MED, V119, P1017, DOI 10.7326/0003-4819-119-10-199311150-00009; Chin DP, 2000, JAMA-J AM MED ASSOC, V283, P2968, DOI 10.1001/jama.283.22.2968; Cicalini S, 2001, J INFECTION, V42, P267, DOI 10.1053/jinf.2001.0812; CRANE LR, 1986, REV INFECT DIS, V8, P364; CRAVEN DE, 1986, AM J MED, V80, P770, DOI 10.1016/0002-9343(86)90614-5; DWORKIN RJ, 1989, LANCET, V2, P1071; Fleisch F, 2001, CLIN INFECT DIS, V32, P581, DOI 10.1086/318716; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; Havlir DV, 1999, NEW ENGL J MED, V340, P367, DOI 10.1056/NEJM199902043400507; HECHT SR, 1992, ANN INTERN MED, V117, P560, DOI 10.7326/0003-4819-117-7-560; HEMINGWAY DM, 1992, SCOT MED J, V37, P116, DOI 10.1177/003693309203700407; HIND CRK, 1990, THORAX, V45, P957, DOI 10.1136/thx.45.12.957; Hoeger PH, 1996, ACTA DERM-VENEREOL, V76, P239; Kimura AC, 2004, CLIN INFECT DIS, V38, pE87, DOI 10.1086/383471; Kluytmans J, 1997, CLIN MICROBIOL REV, V10, P505, DOI 10.1128/CMR.10.3.505; LEVINE DP, 1986, REV INFECT DIS, V8, P374; LEVINE DP, 2005, MANDELL DOUGLAS BENN, V2, P3462; Levine DP., 1991, INFECT INTRAVENOUS D; Li JS, 2000, CLIN INFECT DIS, V30, P633, DOI 10.1086/313753; Lina G, 1999, CLIN INFECT DIS, V29, P1128, DOI 10.1086/313461; LOURIA DB, 1967, ANN INTERN MED, V67, P1, DOI 10.7326/0003-4819-67-1-1; LY LT, 2004, ANN M INF DIS SOC AM; MAENZA JR, 2004, INFECT DIS, P1297; Malakmadze N, 2005, CLIN INFECT DIS, V40, P366, DOI 10.1086/427112; MARANTZ PR, 1987, ANN INTERN MED, V106, P823, DOI 10.7326/0003-4819-106-6-823; Miller LG, 2005, NEW ENGL J MED, V352, P1445, DOI 10.1056/NEJMoa042683; Miro JM, 2002, INFECT DIS CLIN N AM, V16, P273, DOI 10.1016/S0891-5520(01)00008-3; Murphy EL, 2001, CLIN INFECT DIS, V33, P35, DOI 10.1086/320879; NELSON KE, 1991, J INFECT DIS, V164, P457, DOI 10.1093/infdis/164.3.457; Palepu A, 2001, CAN MED ASSOC J, V165, P415; Pascual F Brian, 2003, MMWR Surveill Summ, V52, P1; Passaro DJ, 1998, JAMA-J AM MED ASSOC, V279, P859, DOI 10.1001/jama.279.11.859; Perlman DC, 1999, SOC SCI MED, V48, P1441, DOI 10.1016/S0277-9536(98)00448-1; Perper J A, 1992, Recent Dev Alcohol, V10, P363; Petrosillo N, 2002, CLIN INFECT DIS, V34, P677, DOI 10.1086/338813; Quagliarello B, 2002, CLIN INFECT DIS, V35, P671, DOI 10.1086/342196; SAPICO FL, 1980, REV INFECT DIS, V2, P196; SARAVOLATZ LD, 1982, ANN INTERN MED, V96, P11, DOI 10.7326/0003-4819-96-1-11; SCHEIDEGGER C, 1990, REV INFECT DIS, V12, P165; SCHEIDEGGER C, 1989, REV INFECT DIS, V11, P486; SELWYN PA, 1993, ANN INTERN MED, V119, P1044, DOI 10.7326/0003-4819-119-10-199311150-00013; SHEKAR R, 1985, J INFECT DIS, V151, P203, DOI 10.1093/infdis/151.2.203; SILVERMAN HS, 1985, NEW ENGL J MED, V312, P1706; Spijkerman IJB, 1996, J CLIN EPIDEMIOL, V49, P1149, DOI 10.1016/0895-4356(96)00180-1; STEIN MD, 1990, J GEN INTERN MED, V5, P249, DOI 10.1007/BF02600544; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; *SUBST AB MENT HLT, 2004, 2003 NAT SURV DRUG U; SUMMANEN PH, 1995, CLIN INFECT DIS, V20, pS279, DOI 10.1093/clinids/20.Supplement_2.S279; TORRESTORTOSA M, 1994, EUR J CLIN MICROBIOL, V13, P559, DOI 10.1007/BF01971306; TUAZON CU, 1975, ANN INTERN MED, V82, P788, DOI 10.7326/0003-4819-82-6-788; Tumbarello M, 1998, J ACQ IMMUN DEF SYND, V18, P39, DOI 10.1097/00042560-199805010-00006; *UN OFF DRUGS CRIM, 2005, WORLD DRUG REP, V1; *UN OFF DRUGS CRIM, 2004, WORLD DRUG REP, V1; VLAHOV D, 1992, PUBLIC HEALTH REP, V107, P595; Werner SB, 2000, CLIN INFECT DIS, V31, P1018, DOI 10.1086/318134; Wilson LE, 2002, J INFECT DIS, V185, P1761, DOI 10.1086/340827; Zetola N, 2005, LANCET INFECT DIS, V5, P275, DOI 10.1016/S1473-3099(05)70112-2; Zinderman CE, 2004, EMERG INFECT DIS, V10, P941, DOI 10.3201/eid1005.030604; 2003, EUROSURVELL WKLY, V7, P5; 1998, MMWR MORB MORTAL WKL, V47, P149; 1997, MMWR MORB MORTAL WKL, V46, P510; 2001, MMWR MORB MORTAL WKL, V50, P381; 2003, MMWR MORB MORTAL WKL, V52, P992; 1991, MMWR MORB MORTAL WKL, V40, P485; 2000, MMWR MORB MORTAL WKL, V49, P543	79	219	221	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1945	1954		10.1056/NEJMra042823	http://dx.doi.org/10.1056/NEJMra042823			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267325				2022-12-28	WOS:000232972800010
J	Strogatz, SH; Abrams, DM; McRobie, A; Eckhardt, B; Ott, E				Strogatz, SH; Abrams, DM; McRobie, A; Eckhardt, B; Ott, E			Crowd synchrony on the Millennium Bridge	NATURE			English	Editorial Material							EXCITATION		Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA; Univ Maryland, College Pk, MD 20742 USA; Univ Marburg, Fachbereich Phys, D-35032 Marburg, Germany	Cornell University; University System of Maryland; University of Maryland College Park; Philipps University Marburg	Strogatz, SH (corresponding author), Cornell Univ, Dept Theoret & Appl Mech, Ithaca, NY 14853 USA.	strogatz@cornell.edu	Eckhardt, Bruno/D-5948-2012; Abrams, Daniel M/F-2297-2011; Strogatz, Steven H/A-1641-2014; Abrams, Daniel M/H-5532-2012; O, E/F-1630-2015	Eckhardt, Bruno/0000-0003-4050-3254; Abrams, Daniel M/0000-0002-6015-8358; Strogatz, Steven H/0000-0003-2923-3118; 				DALLARD P., 2001, J BRIDGE ENG, V6, P412, DOI [10.1061/(ASCE)1084-0702(2001)6:6(412), DOI 10.1061/(ASCE)1084-0702(2001)6:6(412)]; Dallard P., 2001, STRUCT ENG, V79, P17; Glass L, 1988, CLOCKS CHAOS RHYTHMS; Kuramoto Y., 1984, CHEM OSCILLATIONS WA; McRobie A., 2003, BRIDGE ENG, V156, P71, DOI DOI 10.1680/BREN.2003.156.2.71); Nakamura S, 2004, J STRUCT ENG-ASCE, V130, P32, DOI 10.1061/(ASCE)0733-9445(2004)130:1(32); Newland DE, 2004, P I MECH ENG C-J MEC, V218, P477, DOI 10.1243/095440604323052274; Roberts T. M., 2003, P ICE BRIDGE ENG, V156, P155, DOI [10.1680/bren.2003.156.4.155, DOI 10.1680/BREN.2003.156.4.155]; Strogatz SH, 2000, PHYSICA D, V143, P1, DOI 10.1016/S0167-2789(00)00094-4; Winfree AT., 1980, GEOMETRY BIOL TIME	10	402	414	10	127	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					43	44		10.1038/438043a	http://dx.doi.org/10.1038/438043a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267545				2022-12-28	WOS:000232979000033
J	Bernal, D; Donley, JM; Shadwick, RE; Syme, DA				Bernal, D; Donley, JM; Shadwick, RE; Syme, DA			Mammal-like muscles power swimming in a cold-water shark	NATURE			English	Article							METABOLIC BIOCHEMISTRY; CONTRACTILE PROPERTIES; BODY-TEMPERATURE; LAMNA-DITROPIS; TUNA; PERFORMANCE; FISH; DESIGN; FIBERS; TUNNEL	Effects of temperature on muscle contraction and powering movement are profound, outwardly obvious, and of great consequence to survival(1,2). To cope with the effects of environmental temperature fluctuations, endothermic birds and mammals maintain a relatively warm and constant body temperature, whereas most fishes and other vertebrates are ectothermic and conform to their thermal niche, compromising performance at colder temperatures(2,3). However, within the fishes the tunas and lamnid sharks deviate from the ectothermic strategy, maintaining elevated core body temperatures(4,5) that presumably confer physiological advantages for their roles as fast and continuously swimming pelagic predators. Here we show that the salmon shark, a lamnid inhabiting cold, north Pacific waters, has become so specialized for endothermy that its red, aerobic, locomotor muscles, which power continuous swimming, seem mammal-like, functioning only within a markedly elevated temperature range ( 20 - 30 degrees C). These muscles are ineffectual if exposed to the cool water temperatures, and when warmed even 10 degrees C above ambient they still produce only 25 - 50% of the power produced at 26 degrees C. In contrast, the white muscles, powering burst swimming, do not show such a marked thermal dependence and work well across a wide range of temperatures.	Univ Massachusetts, Dept Biol, N Dartmouth, MA 02747 USA; Univ Calif San Diego, Scripps Inst Oceanog, Div Marine Biol Res, La Jolla, CA 92093 USA; Miracosta Coll, Dept Biol Sci, Oceanside, CA 92056 USA; Univ Calgary, Dept Biol Sci, Calgary, AB T2N 1N4, Canada	University of Massachusetts System; University Massachusetts Dartmouth; University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Calgary	Shadwick, RE (corresponding author), Univ British Columbia, Dept Zool, 6270 Univ Blvd, Vancouver, BC V6T 1Z4, Canada.	dbernal@umassd.edu; shadwick@zoology.ubc.ca						Altringham JD, 1997, J EXP BIOL, V200, P2617; Anderson SD, 2001, COPEIA, P794; BENNETT AF, 1985, J EXP BIOL, V115, P333; Bennett AF, 1990, AM J PHYSIOL, V250, P253; Bernal D, 2003, J EXP BIOL, V206, P2845, DOI 10.1242/jeb.00504; Bernal D, 2001, COMP BIOCHEM PHYS A, V129, P695, DOI 10.1016/S1095-6433(01)00333-6; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P205, DOI 10.1016/0010-406X(69)91336-X; CAREY FG, 1969, COMP BIOCHEM PHYSIOL, V28, P199, DOI 10.1016/0010-406X(69)91335-8; CURTIN NA, 1988, J EXP BIOL, V140, P187; DEWAR H, 1994, J EXP BIOL, V192, P13; DICKSON KA, 1995, ENVIRON BIOL FISH, V42, P65, DOI 10.1007/BF00002352; Donley JM, 2004, NATURE, V429, P61, DOI 10.1038/nature02435; GRAHAM JB, 1990, J EXP BIOL, V151, P175; HULBERT L, 2002, SALMON SHARK LAMNA D; James RS, 1998, J EXP BIOL, V201, P901; JOHNSON TP, 1991, J COMP PHYSIOL B, V161, P27, DOI 10.1007/BF00258743; Johnston IA, 2002, J EXP BIOL, V205, P2305; Katz SL, 2002, J EXP BIOL, V205, P2251; Katz SL, 2001, NATURE, V410, P770, DOI 10.1038/35071170; PAUST B, 1989, 8601 U AL SEA GRANT; SMITH RL, 1983, J MAR BIOL ASSOC UK, V63, P243, DOI 10.1017/S0025315400049936; Syme DA, 2002, J EXP BIOL, V205, P189	22	71	72	3	63	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1349	1352		10.1038/nature04007	http://dx.doi.org/10.1038/nature04007			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251963				2022-12-28	WOS:000232829100052
J	Loppin, B; Bonnefoy, E; Anselme, C; Laurencon, A; Karr, TL; Couble, P				Loppin, B; Bonnefoy, E; Anselme, C; Laurencon, A; Karr, TL; Couble, P			The histone H3.3 chaperone HIRA is essential for chromatin assembly in the male pronucleus	NATURE			English	Article							DROSOPHILA-MELANOGASTER; GENE; METHYLATION; EXPRESSION; VARIANTS; SESAME; CHROMOSOME; ACTIVATION; ASYMMETRY; PROTEINS	In sexually reproducing animals, a crucial step in zygote formation is the decondensation of the fertilizing spermnucleus into a DNA replication-competent male pronucleus. Genome-wide nucleosome assembly on paternal DNA implies the replacement of sperm chromosomal proteins, such as protamines, by maternally provided histones(1,2). This fundamental process is specifically impaired in sesame (ssm), a unique Drosophila maternal effect mutant that prevents male pronucleus formation(3). Here we show that ssm is a point mutation in the Hira gene, thus demonstrating that the histone chaperone protein HIRA is required for nucleosome assembly during sperm nucleus decondensation. In vertebrates, HIRA has recently been shown to be critical for a nucleosome assembly pathway independent of DNA synthesis that specifically involves the H3.3 histone variant(4,5). We also show that nucleosomes containing H3.3, and not H3, are specifically assembled in paternal Drosophila chromatin before the first round of DNA replication. The exclusive marking of paternal chromosomes with H3.3 represents a primary epigenetic distinction between parental genomes in the zygote, and underlines an important consequence of the critical and highly specialized function of HIRA at fertilization.	Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France; Inst Natl Sci Appl, INRA, UMR, F-69621 Villeurbanne, France; Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite Claude Bernard Lyon 1; INRAE; Institut National des Sciences Appliquees de Lyon - INSA Lyon; University of Bath	Loppin, B (corresponding author), Univ Lyon 1, CNRS, UMR 5534, Ctr Genet Mol & Cellulaire, F-69622 Villeurbanne, France.	loppin@cgmc.univ-lyon1.fr	Karr, Timothy L/G-1693-2011	LAURENCON, Anne/0000-0003-1791-1882				Ahmad K, 2002, MOL CELL, V9, P1191, DOI 10.1016/S1097-2765(02)00542-7; Ahmad K, 2002, P NATL ACAD SCI USA, V99, P16477, DOI 10.1073/pnas.172403699; AKHMANOVA AS, 1995, GENOME, V38, P586, DOI 10.1139/g95-075; Arney KL, 2002, INT J DEV BIOL, V46, P317; Cowell IG, 2002, CHROMOSOMA, V111, P22, DOI 10.1007/s00412-002-0182-8; Drysdale RA, 2005, NUCLEIC ACIDS RES, V33, pD390, DOI 10.1093/nar/gki046; Foe Victoria E., 1993, P149; Henikoff S, 2004, TRENDS GENET, V20, P320, DOI 10.1016/j.tig.2004.05.004; Huynh KD, 2003, NATURE, V426, P857, DOI 10.1038/nature02222; Janicki SM, 2004, CELL, V116, P683, DOI 10.1016/S0092-8674(04)00171-0; Kirov N, 1998, GENE, V212, P323, DOI 10.1016/S0378-1119(98)00143-7; KLEMENZ R, 1987, NUCLEIC ACIDS RES, V15, P3947, DOI 10.1093/nar/15.10.3947; Lepikhov Konstantin, 2004, BMC Developmental Biology, V4, P1; Llevadot R, 1998, BIOCHEM BIOPH RES CO, V249, P486, DOI 10.1006/bbrc.1998.9165; Loppin B, 2000, DEV BIOL, V222, P392, DOI 10.1006/dbio.2000.9718; Loppin B, 2001, CHROMOSOMA, V110, P430, DOI 10.1007/s004120100161; Loppin B, 2004, COMPREHENSIVE INSECT, P213; Mayer W, 2000, NATURE, V403, P501, DOI 10.1038/35000656; McLay DW, 2003, REPRODUCTION, V125, P625, DOI 10.1530/rep.0.1250625; Okamoto I, 2004, SCIENCE, V303, P644, DOI 10.1126/science.1092727; Raja SJ, 2005, MOL CELL BIOL, V25, P6165, DOI 10.1128/MCB.25.14.6165-6177.2005; Ray-Gallet D, 2002, MOL CELL, V9, P1091, DOI 10.1016/S1097-2765(02)00526-9; Roberts C, 2002, MOL CELL BIOL, V22, P2318, DOI 10.1128/MCB.22.7.2318-2328.2002; Schwartz BE, 2005, GENE DEV, V19, P804, DOI 10.1101/gad.1259805; Smith TF, 1999, TRENDS BIOCHEM SCI, V24, P181, DOI 10.1016/S0968-0004(99)01384-5; Tagami H, 2004, CELL, V116, P51, DOI 10.1016/S0092-8674(03)01064-X; van der Heijden GW, 2005, MECH DEVELOP, V122, P1008, DOI 10.1016/j.mod.2005.04.009; Wright SJ, 1999, CURR TOP DEV BIOL, V46, P133, DOI 10.1016/S0070-2153(08)60328-2; YAMAGUCHI M, 1991, J CELL SCI, V100, P729	29	259	276	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1386	1390		10.1038/nature04059	http://dx.doi.org/10.1038/nature04059			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251970				2022-12-28	WOS:000232829100060
J	Hunt, N; McHale, S				Hunt, N; McHale, S			The psychological impact of alopecia	BRITISH MEDICAL JOURNAL			English	Review							LIFE EVENTS; AREATA; WOMEN; CHILDREN; CANCER; HAIR		Univ Nottingham, Inst Work Hlth & Org, Nottingham NG7 2RQ, England; Sheffield Hallam Univ, Psychol Grp, Sheffield S1 1WB, S Yorkshire, England	University of Nottingham; Sheffield Hallam University	Hunt, N (corresponding author), Univ Nottingham, Inst Work Hlth & Org, Nottingham Sci & Technol Pk, Nottingham NG7 2RQ, England.	nigel.hunt@nottingham.ac.uk		Hunt, Nigel/0000-0002-8492-6577				Carpenter J S, 1994, Oncol Nurs Forum, V21, P751; EGELE UT, 1987, PSYCHOTER PSYCHOSOMM, V37, P31; FREEDMAN TG, 1994, CANCER NURS, V17, P334; Garcia-Hernandez Maria Jose, 1999, Journal of Dermatology (Tokyo), V26, P625; Hunt N, 2005, J LOSS TRAUMA, V10, P33, DOI 10.1080/15325020490890633; Hunt N, 2004, UNDERSTANDING ALOPEC; Kalish RS, 2003, J INVEST DERM SYMP P, V8, P164, DOI 10.1046/j.1087-0024.2003.00802.x; Koo John Y. M., 1994, International Journal of Dermatology, V33, P849, DOI 10.1111/j.1365-4362.1994.tb01018.x; KOSE O, 2000, KLIN PSIKOFARMAKOL B, V10, P21; Lenane P, 2005, J AM ACAD DERMATOL, V52, pS8, DOI 10.1016/j.jaad.2004.06.024; Liakopoulou M, 1997, J AM ACAD CHILD PSY, V36, P678, DOI 10.1097/00004583-199705000-00019; Madani S, 2000, J AM ACAD DERMATOL, V42, P549, DOI 10.1016/S0190-9622(00)90164-6; McGarvey EL, 2001, CANCER PRACT, V9, P283, DOI 10.1046/j.1523-5394.2001.96007.x; Meidan VM, 2001, DRUGS, V61, P53, DOI 10.2165/00003495-200161010-00006; NERENZ DR, 1986, HLTH SERV RES, V20, P960; Prickitt Joe, 2004, Dermatol Nurs, V16, P237; Reeve EA, 1996, J AM ACAD CHILD PSY, V35, P1518, DOI 10.1097/00004583-199611000-00021; Ruiz-Doblado S, 2003, INT J DERMATOL, V42, P434, DOI 10.1046/j.1365-4362.2003.01340.x; WEITZ R, 2004, RAPUNZELS DAUGHTER W; Wolf Naomi, 1991, BEAUTY MYTH; York J, 1998, PSYCHOL REP, V82, P1044	21	218	228	1	13	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 22	2005	331	7522					951	953		10.1136/bmj.331.7522.951	http://dx.doi.org/10.1136/bmj.331.7522.951			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979UR	16239692	Green Published			2022-12-28	WOS:000232970900025
J	Lienhardt, C; Zumla, A				Lienhardt, C; Zumla, A			BCG: the story continues	LANCET			English	Editorial Material							MYCOBACTERIUM-TUBERCULOSIS INFECTION; ANTIGENS ESAT-6; VACCINATION; PROTECTION; DIAGNOSIS; CONTACT		Inst Rech Dev, TB Res Programme, UMR 145, Dakar, Senegal; UCL Royal Free & UCL Med Sch, Windeyer Inst Med Sci, Ctr Infect Dis & Int Hlth, London, England	Institut de Recherche pour le Developpement (IRD); University of London; University College London	Lienhardt, C (corresponding author), Inst Rech Dev, TB Res Programme, UMR 145, Dakar, Senegal.	lienhardt@ird.sn	Lienhardt, Christian/AAU-4969-2021; ZUMLA, Alimuddin/ABA-8208-2020	Lienhardt, Christian/0000-0003-0233-893X; ZUMLA, Alimuddin/0000-0002-5111-5735				Black GF, 2002, LANCET, V359, P1393, DOI 10.1016/S0140-6736(02)08353-8; Brock I, 2001, INT J TUBERC LUNG D, V5, P462; FINE PEM, 1995, LANCET, V346, P1339, DOI 10.1016/S0140-6736(95)92348-9; FINE PEM, 1989, REV INFECT DIS S2, V11, P353; Hill PC, 2005, CLIN INFECT DIS, V40, P273, DOI 10.1086/427030; HUEBNER RE, 1993, CLIN INFECT DIS, V17, P968, DOI 10.1093/clinids/17.6.968; Lalvani A, 2001, AM J RESP CRIT CARE, V163, P824, DOI 10.1164/ajrccm.163.4.2009100; Langermans JAM, 2005, VACCINE, V23, P2740, DOI 10.1016/j.vaccine.2004.11.051; Mittal S. K., 1996, Indian Journal of Pediatrics, V63, P659, DOI 10.1007/BF02730815; Pym AS, 2002, MOL MICROBIOL, V46, P709, DOI 10.1046/j.1365-2958.2002.03237.x; RODRIGUES LC, 1993, INT J EPIDEMIOL, V22, P1154, DOI 10.1093/ije/22.6.1154; Soysal A, 2005, LANCET, V366, P1443, DOI 10.1016/S0140-6736(05)67534-4; SUTHERLAND I, 1979, TUBERCLE, V60, P225, DOI 10.1016/0041-3879(79)90003-5; van Pinxteren LAH, 2000, CLIN DIAGN LAB IMMUN, V7, P155, DOI 10.1128/CDLI.7.2.155-160.2000; Vekemans J, 2001, EUR J IMMUNOL, V31, P1531, DOI 10.1002/1521-4141(200105)31:5<1531::AID-IMMU1531>3.0.CO;2-1; 2004, GLOBAL TUBERCULOSIS, P181	16	13	13	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	OCT 22	2005	366	9495					1414	1416		10.1016/S0140-6736(05)67535-6	http://dx.doi.org/10.1016/S0140-6736(05)67535-6			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	976HQ	16243075				2022-12-28	WOS:000232724600005
J	Kocks, C; Cho, JH; Nehme, N; Ulvila, J; Pearson, AM; Meister, M; Strom, C; Conto, SL; Hetru, C; Stuart, LM; Stehle, T; Hoffmann, JA; Reichhart, JM; Ferrandon, D; Ramet, M; Ezekowitz, RAB				Kocks, C; Cho, JH; Nehme, N; Ulvila, J; Pearson, AM; Meister, M; Strom, C; Conto, SL; Hetru, C; Stuart, LM; Stehle, T; Hoffmann, JA; Reichhart, JM; Ferrandon, D; Ramet, M; Ezekowitz, RAB			Eater, a transmembrane protein mediating phagocytosis of bacterial pathogens in Drosophila	CELL			English	Article							SCAVENGER RECEPTOR; INNATE IMMUNITY; CELL-DEATH; RECOGNITION; HEMOCYTES; IDENTIFICATION; HEMATOPOIESIS; MECHANISMS; ENGULFMENT; COMPLEXITY	Phagocytosis is a complex, evolutionarily conserved process that plays a central role in host defense against infection. We have identified a predicted transmembrane protein, Eater, which is involved in phagocytosis in Drosophila. Transcriptional silencing of the eater gene in a macrophage cell line led to a significant reduction in the binding and internalization of bacteria. Moreover, the N terminus of the Eater protein mediated direct microbial binding which could be inhibited with scavenger receptor ligands, acetylated, and oxidized low-density lipoprotein. In vivo, eater expression was restricted to blood cells. Files lacking the eater gene displayed normal responses in NF-kappa B-like Toll and IMD signaling pathways but showed impaired phagocytosis and decreased survival after bacterial infection. Our results suggest that Eater is a major phagocytic receptor for a broad range of bacterial pathogens in Drosophila and provide a powerful model to address the role of phagocytosis in vivo.	Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Dev Immunol,Dept Pediat, Boston, MA 02114 USA; Inst Biol Mol & Cellulaire, Ctr Natl Rech Sci, UPR9022, F-67084 Strasbourg, France; Oulu Univ, Dept Pediat, SF-90220 Oulu, Finland; Oulu Univ, Bioctr, SF-90220 Oulu, Finland; Tampere Univ, Inst Med Technol, FIN-33101 Tampere, Finland; Tampere Univ Hosp, Dept Pediat, Tampere, Finland	Harvard University; Harvard Medical School; Massachusetts General Hospital; Centre National de la Recherche Scientifique (CNRS); CNRS - National Institute for Biology (INSB); University of Oulu; University of Oulu; Tampere University; Tampere University; Tampere University Hospital	Kocks, C (corresponding author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Lab Dev Immunol,Dept Pediat, Boston, MA 02114 USA.	christine_kocks@hms.harvard.edu		FERRANDON, Dominique/0000-0001-7680-7773	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI044220] Funding Source: NIH RePORTER; NIAID NIH HHS [P01 AI 44220] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Adachi H, 1997, J BIOL CHEM, V272, P31217, DOI 10.1074/jbc.272.50.31217; Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; BRAND AH, 1993, DEVELOPMENT, V118, P401; Braun A, 1998, P NATL ACAD SCI USA, V95, P14337, DOI 10.1073/pnas.95.24.14337; Brennan CA, 2004, ANNU REV IMMUNOL, V22, P457, DOI 10.1146/annurev.immunol.22.012703.104626; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; Crozatier M, 2004, PLOS BIOL, V2, P1107, DOI 10.1371/journal.pbio.0020196; Elrod-Erickson M, 2000, CURR BIOL, V10, P781, DOI 10.1016/S0960-9822(00)00569-8; Evans CJ, 2003, DEV CELL, V5, P673, DOI 10.1016/S1534-5807(03)00335-6; Ferrandon D, 2004, SEMIN IMMUNOL, V16, P43, DOI 10.1016/j.smim.2003.10.008; Franc NC, 1999, SCIENCE, V284, P1991, DOI 10.1126/science.284.5422.1991; Gobert V, 2003, SCIENCE, V302, P2126, DOI 10.1126/science.1085432; Goto A, 2003, DEV BIOL, V264, P582, DOI 10.1016/j.ydbio.2003.06.001; Greaves DR, 2005, J LIPID RES, V46, P11, DOI 10.1194/jlr.R400011-JLR200; Greenberg S, 2002, CURR OPIN IMMUNOL, V14, P136, DOI 10.1016/S0952-7915(01)00309-0; Herz J, 2001, J CLIN INVEST, V108, P779, DOI 10.1172/JCI200113992; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Hoffmann JA, 2003, NATURE, V426, P33, DOI 10.1038/nature02021; Holz A, 2003, DEVELOPMENT, V130, P4955, DOI 10.1242/dev.00702; Horan P K, 1990, Methods Cell Biol, V33, P469; Hori S, 2000, EUR J BIOCHEM, V267, P5397, DOI 10.1046/j.1432-1327.2000.01578.x; Hultmark D, 2003, CURR OPIN IMMUNOL, V15, P12, DOI 10.1016/S0952-7915(02)00005-5; Irving P, 2005, CELL MICROBIOL, V7, P335, DOI 10.1111/j.1462-5822.2004.00462.x; Krieger M, 2001, J CLIN INVEST, V108, P645, DOI 10.1172/JCI13932; Kurz CL, 2003, EMBO J, V22, P1451, DOI 10.1093/emboj/cdg159; Lanot R, 2001, DEV BIOL, V230, P243, DOI 10.1006/dbio.2000.0123; METCHNIKOFF II, 1908, PRESENT STATE QUESTI; Moita LF, 2005, IMMUNITY, V23, P65, DOI 10.1016/j.immuni.2005.05.006; Pearson AM, 2003, MICROBES INFECT, V5, P815, DOI 10.1016/S1286-4579(03)00157-6; Ramet M, 2002, NATURE, V416, P644, DOI 10.1038/nature735; Ramet M, 2001, IMMUNITY, V15, P1027, DOI 10.1016/S1074-7613(01)00249-7; Reddien PW, 2004, ANNU REV CELL DEV BI, V20, P193, DOI 10.1146/annurev.cellbio.20.022003.114619; Rizki T.M., 1984, P579; ROBB JA, 1969, J CELL BIOL, V41, P876, DOI 10.1083/jcb.41.3.876; Stuart LM, 2005, IMMUNITY, V22, P539, DOI 10.1016/j.immuni.2005.05.002; TEPASS U, 1994, DEVELOPMENT, V120, P1829; Underhill DM, 2002, ANNU REV IMMUNOL, V20, P825, DOI 10.1146/annurev.immunol.20.103001.114744; Waltzer L, 2002, EMBO J, V21, P5477, DOI 10.1093/emboj/cdf545; Weber JR, 2003, IMMUNITY, V19, P269, DOI 10.1016/S1074-7613(03)00205-X; Xiong JP, 2001, SCIENCE, V294, P339, DOI 10.1126/science.1064535; Zhou Z, 2001, CELL, V104, P43, DOI 10.1016/S0092-8674(01)00190-8	41	288	300	0	24	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	OCT 21	2005	123	2					335	346		10.1016/j.cell.2005.08.034	http://dx.doi.org/10.1016/j.cell.2005.08.034			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	977HN	16239149	Bronze			2022-12-28	WOS:000232794100018
J	Johnson, N; Fletcher, O; Naceur-Lombardelli, C; Silva, ID; Ashworth, A; Peto, J				Johnson, N; Fletcher, O; Naceur-Lombardelli, C; Silva, ID; Ashworth, A; Peto, J			Interaction between CHEK2*1100delC and other low-penetrance breast-cancer susceptibility genes: a familial study	LANCET			English	Article							PROSTATE-CANCER; MUTATIONS; RELATIVES; RISK; BRCA1; WOMEN	Background The allele CHEK2*1100delC doubles the risk of breast cancer in unselected women, but could confer a greater risk in women with a family history of the disease, particularly of bilateral breast cancer. Our aim was to measure the risk of breast cancer in relatives of women with bilateral breast cancer who were carriers of this allele. Methods A population-based series of 469 bilateral breast cancer cases ascertained through English cancer registries were genotyped for CHEK2*1100delC. Standardised incidence ratios (SIRs) and cumulative risks were calculated for breast cancer, prostate cancer, and all other cancers in the first-degree relatives of carriers and non-carriers. Findings The relatives of bilateral cases who were wild-type for CHEK2 had three times the population risk of female breast cancer (145 cases: SIR 3.48 (95% CI 2.96-4.09), twice the risk of prostate cancer (34 cases: SIR 2.41, 1.67-3.36) and a large excess of male breast cancer (five cases: SIR 15.06, 4.92-35.36). Relatives of those who were carriers of CHEK2*1100delC had a substantially higher risk of breast cancer (eight cases: SIR 12.11, 5.23-23.88) and possibly prostate cancer (two cases: SIR 9.87, 1.20-35.67). Interpretation These data suggest a multiplicative interaction between CHEK2*1100delC and other unknown susceptibility genes. in women with a family history of bilateral disease, CHEK2*1100delC confers a high lifetime risk and might be useful for predictive testing. Bilateral breast cancer cases and their families are likely to provide an efficient basis for identification of additional low-penetrance breast-cancer genes.	Univ London London Sch Hyg & Trop Med, Noncommunicable Dis Epidemiol Unit, Canc Res UK Epidemiol & Genet Grp, London WC1E 7HT, England; Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England; Inst Canc Res, Surrey, England	University of London; London School of Hygiene & Tropical Medicine; Royal Marsden NHS Foundation Trust; University of London; Institute of Cancer Research - UK; University of London; Institute of Cancer Research - UK	Peto, J (corresponding author), Univ London London Sch Hyg & Trop Med, Noncommunicable Dis Epidemiol Unit, Canc Res UK Epidemiol & Genet Grp, Keppel St, London WC1E 7HT, England.	julian.peto@lshtm.ac.uk		Fletcher, Olivia/0000-0001-9387-7116; dos Santos Silva, Isabel/0000-0002-6596-8798	Breast Cancer Now [BREAST CANCER NOW RESEARCH CENTRE] Funding Source: Medline	Breast Cancer Now		Cybulski C, 2004, CANCER RES, V64, P2677, DOI 10.1158/0008-5472.CAN-04-0341; Dong XY, 2003, AM J HUM GENET, V72, P270, DOI 10.1086/346094; Easton D, 2004, AM J HUM GENET, V74, P1175, DOI 10.1086/421251; GOLDGAR DE, 1994, J NATL CANCER I, V86, P1600, DOI 10.1093/jnci/86.21.1600; Hemminki K, 2000, INT J CANCER, V88, P87, DOI 10.1002/1097-0215(20001001)88:1<87::AID-IJC14>3.0.CO;2-F; Lee SB, 2001, CANCER RES, V61, P8062; Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879; Murff HJ, 2004, JAMA-J AM MED ASSOC, V292, P1480, DOI 10.1001/jama.292.12.1480; Peto J, 2000, NAT GENET, V26, P411, DOI 10.1038/82533; Peto J, 1999, J NATL CANCER I, V91, P943, DOI 10.1093/jnci/91.11.943; Peto J, 1996, INT J CANCER, V65, P275, DOI 10.1002/(SICI)1097-0215(19960126)65:3&lt;275::AID-IJC1&gt;3.0.CO;2-X; Pharoah PDP, 2002, NAT GENET, V31, P33, DOI 10.1038/ng853; Seppala EH, 2003, BRIT J CANCER, V89, P1966, DOI 10.1038/sj.bjc.6601425; Sodha N, 2000, Science, V289, P359	14	62	63	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1554	1557		10.1016/S0140-6736(05)67627-1	http://dx.doi.org/10.1016/S0140-6736(05)67627-1			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257342				2022-12-28	WOS:000232984800024
J	Thatcher, N; Chang, A; Parikh, P; Pereira, JR; Ciuleanu, T; von Pawel, J; Thongprasert, S; Tan, EH; Pemberton, K; Archer, V; Carroll, K				Thatcher, N; Chang, A; Parikh, P; Pereira, JR; Ciuleanu, T; von Pawel, J; Thongprasert, S; Tan, EH; Pemberton, K; Archer, V; Carroll, K			Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)	LANCET			English	Article							RECEPTOR TYROSINE KINASE; CHEMOTHERAPY REGIMENS; GENE-MUTATIONS; TRIAL; INHIBITOR; SENSITIVITY; ERLOTINIB; PLATINUM; ZD1839; DOCETAXEL	Background This placebo-controlled phase III study investigated the effect on survival of gefitinib as second-line or third-line treatment for patients with locally advanced or metastatic non-small-cell lung cancer. Methods 1692 patients who were refractory to or intolerant of their latest chemotherapy regimen were randomly assigned in a ratio of two to one either gefitinib (250 mg/day) or placebo, plus best supportive care. The primary endpoint was survival in the overall population of patients and those with adenocarcinoma. The primary analysis of the population for survival was by intention to treat. This study has been submitted for registration with ClinicalTrials.gov, number 1839IL/709. Findings 1129 patients were assigned gefitinib and 563 placebo. At median follow-up of 7.2 months, median survival did not differ significantly between the groups in the overall population (5.6 months for gefitinib and 5.1 months for placebo; hazard ratio 0.89 [95% CI 0.77-1.02], p=0.087) or among the 812 patients with adenocarcinoma (6.3 months vs 5.4 months; 0.84 [0.68-1.03], p=0.089). Preplanned subgroup analyses showed significantly longer survival in the gefitinib group than the placebo group for never-smokers (n=375; 0.67 [0.49-0.92], p=0.012; median survival 8.9 vs 6.1 months) and patients of Asian origin (n=342; 0.66 [0.48-0.91], p=0.01; median survival 9.5 vs 5.5 months). Gefitinib was well tolerated, as in previous studies. Interpretation Treatment with gefitinib was not associated with significant improvement in survival in either coprimary population. There was pronounced heterogeneity in survival outcomes between groups of patients, with some evidence of benefit among never-smokers and patients of Asian origin.	Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England; Johns Hopkins NUH Int Med Ctr, Singapore, Singapore; Tata Mem Hosp, Bombay 400012, Maharashtra, India; Arnaldo Vieira de Carvalho Canc Inst, Sao Paulo, Brazil; Oncol Inst Ion Chiricuta, Cluj Napoca, Romania; Asklepios Fachkliniken, Gauting, Germany; Maharaj Nakorn Chiang Mai Hosp, Chiang Mai, Thailand; Natl Canc Ctr, Singapore, Singapore; AstraZeneca, Macclesfield, Cheshire, England	Christie NHS Foundation Trust; Christie Hospital; National University of Singapore; Tata Memorial Centre (TMC); Tata Memorial Hospital; Oncology Institute Prof. Dr. Ion Chiricuta; Chiang Mai University; National Cancer Centre Singapore (NCCS); AstraZeneca	Thatcher, N (corresponding author), Christie Hosp NHS Trust, Manchester M20 4BX, Lancs, England.	nick.thatcher@christie-tr.nwest.nhs.uk	Ciuleanu, Tudor Eliade/C-3996-2011; Ciuleanu, Tudor-Eliade/ABH-8452-2020	Ciuleanu, Tudor Eliade/0000-0003-0958-5597				Bailey L. Renee, 2003, Proceedings of the American Association for Cancer Research Annual Meeting, V44, P1362; Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100; Cappuzzo F, 2005, JNCI-J NATL CANCER I, V97, P643, DOI 10.1093/jnci/dji112; Cella D, 2002, J CLIN EPIDEMIOL, V55, P285, DOI 10.1016/S0895-4356(01)00477-2; Forsythe B, 2004, DRUG SAFETY, V27, P1081, DOI 10.2165/00002018-200427140-00002; Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038; Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038; Kelly K, 2001, J CLIN ONCOL, V19, P3210, DOI 10.1200/JCO.2001.19.13.3210; Kris MG, 2003, JAMA-J AM MED ASSOC, V290, P2149, DOI 10.1001/jama.290.16.2149; Lynch TJ, 2005, J CLIN ONCOL, V23, p622S; Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938; Massarelli E, 2003, LUNG CANCER-J IASLC, V39, P55, DOI 10.1016/S0169-5002(02)00308-2; Miller VA, 2004, J CLIN ONCOL, V22, P1103, DOI 10.1200/JCO.2004.08.158; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; Nakagawa K, 2003, ANN ONCOL, V14, P922, DOI 10.1093/annonc/mdg250; *NAT CANC I CANC T, COMM TOX CRIT MAN CO; *NORTHR GRUMM CORP, 2004, MED DICT REG ACT VER; OCHS J, 2004, P AN M AM SOC CLIN, V23, P628; Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314; Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101; Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74; Perez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Scagliotti GV, 2002, J CLIN ONCOL, V20, P4285, DOI 10.1200/JCO.2002.02.068; Schiller JH, 2002, NEW ENGL J MED, V346, P92, DOI 10.1056/NEJMoa011954; Schulz KF, 2005, LANCET, V365, P1657, DOI 10.1016/S0140-6736(05)66516-6; Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753; Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095; SHEPHERD FA, 2004, P AN M AM SOC CLIN, V23, P18; Shigematsu H, 2005, JNCI-J NATL CANCER I, V97, P339, DOI 10.1093/jnci/dji055; Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038	33	1742	1852	2	113	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1527	1537		10.1016/S0140-6736(05)67625-8	http://dx.doi.org/10.1016/S0140-6736(05)67625-8			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257339				2022-12-28	WOS:000232984800021
J	Baltussen, R; Floyd, K; Dye, C				Baltussen, R; Floyd, K; Dye, C			Achieving the millennium development goals for health - Cost effectiveness analysis of strategies for tuberculosis control in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARE FACILITY INVOLVEMENT; INCREASED COMMUNITY; IMPROVING HEALTH; INTERVENTIONS; PROSPECTS; DISTRICT	Objective To assess the costs and health effects of tuberculosis control interventions in Africa and South East Asia in the context of the millennium development goals. Design Cost effectiveness analysis based on an epidemiological model. Setting Analyses undertaken for two regions classified by WHO according to their epidemiological grouping-Afr-E, countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, countries in South East Asia with high adult and high child mortality. Data sources Published studies, costing databases, expert opinion. Main outcome measures Costs per disability adjusted life year (DALY) averted in 2000 international dollars ($Int). Results Treatment of new cases of smear-positive tuberculosis in DOTS programmes cost $Int6-8 per DALY averted in Afr-E and $Int7 per DALY averted in Sear-D at coverage levels of 50-95%. In Afr-E, adding treatment of smear-negative and extra-pulmonary cases at a coverage level of 95% cost $Int95 per DALY averted; the addition of DOTS-Plus treatment for multidrug resistant cases cost $Int123. In Sear-D, these costs were $Int52 and $Int226, respectively. The full combination of interventions could reduce prevalence and mortality by over 50% in Sear-D between 1990 mid 2010, and by almost 50% between 2000 and 2010 in Afr-E. Conclusions DOTS treatment of new smear-positive cases is the first priority in tuberculosis control, including in countries with high HINT prevalence. DOTS treatment of smear-negative and extra-pulmonary cases and DOTS-Plus treatment of multidrug resistant cases are also highly cost effective. To achieve the millennium development goal for tuberculosis control, substantial extra investment is needed to increase case finding and implement interventions on a wider scale.	Erasmus MC, Inst Med Technol Assessment, NL-3000 DR Rotterdam, Netherlands; WHO, STOP TB Dept, CH-1211 Geneva, Switzerland	Erasmus University Rotterdam; Erasmus MC; World Health Organization	Baltussen, R (corresponding author), Erasmus MC, Inst Med Technol Assessment, POB 1738, NL-3000 DR Rotterdam, Netherlands.	r.baltusen@erasmusmc.nl	Dye, Christopher/AIC-4659-2022; Baltussen, R.M.P.M./L-4181-2015	Dye, Christopher/0000-0002-2957-1793				Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; [Anonymous], 2022, BMJ, V378, DOI [DOI 10.1136/BMJ.38643.368692.68, 10.1136/bmj-2021-068384, DOI 10.1136/BMJ.O2284]; [Anonymous], 1996, GLOBAL BURDEN DIS CO; Borgdorff MW, 2002, B WORLD HEALTH ORGAN, V80, P217; Dye C, 2005, JAMA-J AM MED ASSOC, V293, P2767, DOI 10.1001/jama.293.22.2767; Dye C, 1998, LANCET, V352, P1886, DOI 10.1016/S0140-6736(98)03199-7; EDEJER TTT, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38652.550278.7C; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; EVANS DB, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38658.675243.94; Floyd K, 2003, TUBERCULOSIS, V83, P187, DOI 10.1016/S1472-9792(02)00077-X; Floyd K, 2003, INT J TUBERC LUNG D, V7, pS29; International Programme on Chemical S., 2005, 3 IPCS; Johns B, 2004, HEALTH ECON, V13, P1117, DOI 10.1002/hec.880; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Lauer Jeremy A, 2003, Cost Eff Resour Alloc, V1, P6, DOI 10.1186/1478-7547-1-6; MAHER D, 1999, WHAT IS DOTS GUIDE U; MOREL GM, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38639.702384.AE; MURRAY CJL, 1991, LANCET, V338, P1305, DOI 10.1016/0140-6736(91)92600-7; Nganda B, 2003, INT J TUBERC LUNG D, V7, pS14; STOVER J, 1998, TB HIV SPREADSHEET M; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; UN, 2000, ARES552 UN; *WHO, WHO CHOICE CHOOS INT; WHO, POP DEATH RAT REPR R; *WHO, 2005, GLOB TUB CONTR SURV	27	90	96	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 10	2005	331	7529					1364	1368		10.1136/bmj.38645.660093.68	http://dx.doi.org/10.1136/bmj.38645.660093.68			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	993ZO	16282379	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000233999300016
J	McMillan, PF				McMillan, PF			A stranger in paradise	SCIENCE			English	Editorial Material							GENERAL-ANESTHESIA; XENON		UCL, Dept Chem, London WC1H 0AJ, England; UCL, Mat Chem Ctr, London WC1H 0AJ, England; UCL Royal Inst Great Britain, Davy Faraday Res Lab, London WBX 4BS, England	University of London; University College London; University of London; University College London; University of London; University College London	McMillan, PF (corresponding author), UCL, Dept Chem, 20 Gordon St, London WC1H 0AJ, England.	p.f.mcmillan@ucl.ac.uk	McMillan, Paul/AAI-9067-2020					ANDERS E, 1977, SCIENCE, V198, P453, DOI 10.1126/science.198.4316.453; BARTLETT N, 1962, P CHEM SOC LONDON, P218; BENNETT PE, 2003, PHYSL MED DIVING; Cousteau Jacques-Yves, 1953, SILENT WORLD; Franks NP, 1998, NATURE, V396, P324, DOI 10.1038/24525; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; Greenwood N.N., 1984, CHEM ELEMENTS; Jephcoat AP, 1998, NATURE, V393, P355, DOI 10.1038/30712; Lewis GN, 1916, J AM CHEM SOC, V38, P762, DOI 10.1021/ja02261a002; PAULING L, 1961, SCIENCE, V134, P15, DOI 10.1126/science.134.3471.15; RAMSAY W, 1915, GASES ATMOSPHERE HIS; Sanloup C, 2005, SCIENCE, V310, P1174, DOI 10.1126/science.1119070; Wilson George, 1851, LIFE H CAVENDISH	13	3	4	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 18	2005	310	5751					1125	1126		10.1126/science.1121022	http://dx.doi.org/10.1126/science.1121022			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GE	16293744				2022-12-28	WOS:000233437300027
J	Fisher, B; Costanza, R				Fisher, B; Costanza, R			Regional commitment to reducing emissions - Local policy in the United States goes some way towards countering anthropogenic climate change	NATURE			English	Editorial Material									Univ Vermont, Rubenstein Sch Environm & Nat Resources, Gund Inst Ecol Econ, Burlington, VT 05405 USA	University of Vermont	Fisher, B (corresponding author), Univ Vermont, Rubenstein Sch Environm & Nat Resources, Gund Inst Ecol Econ, Burlington, VT 05405 USA.	brendan.fisher@uvm.edu	Costanza, Robert/AAJ-3546-2021; Costanza, Robert/A-4912-2008	Costanza, Robert/0000-0001-6348-8734				Babiker M. H., 1997, 977 U COL; Babiker MH, 2005, J INT ECON, V65, P421, DOI 10.1016/j.jinteco.2004.01.003; Butler D, 2005, NATURE, V436, P156, DOI 10.1038/436156a; *DEP EN, 2003, EM GREENH GAS US 200; Haag A, 2004, NATURE, V432, P936, DOI 10.1038/432936b; Marland G., 2003, TRENDS COMPENDIUM DA; *PEW CTR GLOB CLIM, 2002, AN PRES BUSHS CLIM C; SUBAK SE, 1995, NATURE, V374, P300, DOI 10.1038/374300b0; VICTOR DG, 1995, NATURE, V373, P280, DOI 10.1038/373280a0; 2004, NATURE, V431, P613	10	11	11	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2005	438	7066					301	302		10.1038/438301a	http://dx.doi.org/10.1038/438301a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	984JR	16292299				2022-12-28	WOS:000233300200033
J	Kabat, P; van Vierssen, W; Veraart, J; Vellinga, P; Aerts, J				Kabat, P; van Vierssen, W; Veraart, J; Vellinga, P; Aerts, J			Climate proofing the Netherlands	NATURE			English	Editorial Material									Univ Wageningen & Res Ctr, Environm Sci Grp, NL-6700 AA Wageningen, Netherlands; Free Univ Amsterdam, Fac Earth Sci, Amsterdam, Netherlands	Wageningen University & Research; Vrije Universiteit Amsterdam	Kabat, P (corresponding author), Univ Wageningen & Res Ctr, Environm Sci Grp, POB 47, NL-6700 AA Wageningen, Netherlands.		Aerts, Jeroen Cjh/M-8431-2013; Kabat, Pavel/AAJ-2245-2020					BOUWER LM, IN PRESS FLOODING EU; KABAT P, 2003, SYNTHESIS REPORT INT, P2; KONNEN G, 2001, CLIMATE SCENARIOS IM; Milly PCD, 2002, NATURE, V415, P514, DOI 10.1038/415514a; Stott PA, 2004, NATURE, V432, P610, DOI 10.1038/nature03089; TIELROOY F, 2000, WATER MANAGEMENT 21; VANDENBORN GJ, 2002, R0205 FREE U AMST; 2004, ESPACE GUIDING MODEL	8	113	113	3	33	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					283	284		10.1038/438283a	http://dx.doi.org/10.1038/438283a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	984JR	16292285	Green Published			2022-12-28	WOS:000233300200021
J	Robinson, A				Robinson, A			A polymath's dilemma	NATURE			English	Editorial Material																			0	2	2	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2005	438	7066					291	291		10.1038/438291a	http://dx.doi.org/10.1038/438291a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292291	Bronze			2022-12-28	WOS:000233300200026
J	Wyatt, JC; Sullivan, F				Wyatt, JC; Sullivan, F			ABC of health informatics - Keeping up: learning in the workplace	BRITISH MEDICAL JOURNAL			English	Review									Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Wyatt, JC (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Wyatt, Jeremy/F-8160-2010; Sullivan, Frank m/A-7767-2009; Sullivan, Frank/L-8286-2019	Wyatt, Jeremy/0000-0001-7008-1473; Sullivan, Frank/0000-0002-6623-4964				EBELL MH, 2003, J CONTIN ED HLTH PRO, V23, P53; Ely JW, 2002, BRIT MED J, V324, P710, DOI 10.1136/bmj.324.7339.710; General Medical Council, 2003, LIC PRACT REV; Harker N, 2004, BMJ-BRIT MED J, V328, P503, DOI 10.1136/bmj.328.7438.503; Mazmanian PE, 2002, JAMA-J AM MED ASSOC, V288, P1057, DOI 10.1001/jama.288.9.1057; Pitkin RM, 1999, JAMA-J AM MED ASSOC, V281, P1110, DOI 10.1001/jama.281.12.1110; Smith R, 1996, BRIT MED J, V313, P1062; WYATT J, 1991, LANCET, V338, P1368, DOI 10.1016/0140-6736(91)92245-W; [No title captured]	9	24	25	0	6	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	NOV 12	2005	331	7525					1129	1132		10.1136/bmj.331.7525.1129	http://dx.doi.org/10.1136/bmj.331.7525.1129			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	985ZI	16282409	Green Published			2022-12-28	WOS:000233417300020
J	Friedman, HS; Bigner, DD				Friedman, HS; Bigner, DD			Gliobastoma multiforme and the epidermal growth factor receptor	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Duke Univ, Durham, NC 27706 USA	Duke University	Friedman, HS (corresponding author), Duke Univ, Durham, NC 27706 USA.							PRADOS M, 2003, P AN M AM SOC CLIN, V22, P99; Rich JN, 2004, J CLIN ONCOL, V22, P133, DOI 10.1200/JCO.2004.08.110	2	34	46	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					1997	1999		10.1056/NEJMp058186	http://dx.doi.org/10.1056/NEJMp058186			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282174				2022-12-28	WOS:000233119600004
J	Kohane, IS; Altman, RB				Kohane, IS; Altman, RB			Health-information altruists - A potentially critical resource	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							GENETICS; PRIVACY; US		Childrens Hosp, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA; Stanford Univ, Dept Genet, Stanford, CA 94305 USA	Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Stanford University	Kohane, IS (corresponding author), Childrens Hosp, Dept Pediat, Boston, MA 02115 USA.		Kohane, Isaac Kohane/K-3716-2012	Kohane, Isaac Kohane/0000-0003-2192-5160				Barlow-Stewart KK, 2003, MED J AUSTRALIA, V178, P515, DOI 10.5694/j.1326-5377.2003.tb05333.x; CLAYTON P, 1997, RECORD PROTECTING EL; Collins FS, 2004, NATURE, V429, P475, DOI 10.1038/nature02628; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Henneman L, 2004, COMMUNITY GENET, V7, P33, DOI 10.1159/000080302; Kaiser J, 2002, SCIENCE, V298, P1158, DOI 10.1126/science.298.5596.1158; Lin Z, 2004, SCIENCE, V305, P183, DOI 10.1126/science.1095019; Malin B, 2004, J BIOMED INFORM, V37, P179, DOI 10.1016/j.jbi.2004.04.005; Mandl KD, 2001, BMJ-BRIT MED J, V322, P283, DOI 10.1136/bmj.322.7281.283; SHERMAN E, 2001, HARVARD U EXTENSION; Sifri R, 2003, CLIN GENET, V64, P355, DOI 10.1034/j.1399-0004.2003.00131.x; Simons WW, 2005, J AM MED INFORM ASSN, V12, P47, DOI 10.1197/jamia.M1592; STRASSMAN M, 2004, CALIFORNIA POLI 0906; WADE N, 2002, NY TIMES        0427, pA15; Wade Nicholas, 2002, N Y Times Web, pA15; 2004, MMWR MORB MORTAL WKL, V53, P603	16	83	83	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					2074	2077		10.1056/NEJMsb051220	http://dx.doi.org/10.1056/NEJMsb051220			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282184				2022-12-28	WOS:000233119600015
J	Schuldiner, M; Collins, SR; Thompson, NJ; Denic, V; Bhamidipati, A; Punna, T; Ihmels, J; Andrews, B; Boone, C; Greenblatt, JF; Weissman, JS; Krogan, NJ				Schuldiner, M; Collins, SR; Thompson, NJ; Denic, V; Bhamidipati, A; Punna, T; Ihmels, J; Andrews, B; Boone, C; Greenblatt, JF; Weissman, JS; Krogan, NJ			Exploration of the function and organization of the yeast early secretory pathway through an epistatic miniarray profile	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; ENDOPLASMIC-RETICULUM; PROTEIN COMPLEXES; GLOBAL ANALYSIS; EXPRESSION; GENOME; GENE; LOCALIZATION; NETWORK	We present a strategy for generating and analyzing comprehensive genetic-interaction maps, termed E-MAPs (epistatic miniarray profiles), comprising quantitative measures of aggravating or alleviating interactions between gene pairs. Crucial to the interpretation of E-MAPs is their high-density nature made possible by focusing on logically connected gene subsets and including essential genes. Described here is the analysis of an E-MAP of genes acting in the yeast early secretory pathway. Hierarchical clustering, together with novel analytical strategies and experimental verification, revealed or clarified the role of many proteins involved in extensively studied processes such as sphingolipid metabolism and retention of HDEL proteins. At a broader level, analysis of the E-MAP delineated pathway organization and components of physical complexes and illustrated the interconnection between the various secretory processes. Extension of this strategy to other logically connected gene subsets in yeast and higher eukaryotes should provide critical insights into the functional/organizational principles of biological systems.	Univ Calif San Francisco, Howard Hughes Med Inst, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA; Univ Toronto, Banting & Best Dept Med Res, Toronto, ON M5G 1L6, Canada; Univ Toronto, Dept Med Genet & Microbiol, Toronto, ON M5S 1A8, Canada	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Toronto; University of Toronto	Weissman, JS (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, Dept Mol & Cellular Pharmacol, San Francisco, CA 94143 USA.	weissman@cmp.ucsf.edu	Schuldiner, Maya/C-9488-2009	Collins, Sean/0000-0002-4276-5840; Schuldiner, Maya/0000-0001-9947-115X; Weissman, Jonathan/0000-0003-2445-670X				Balakrishnan R, 2005, NUCLEIC ACIDS RES, V33, pD374, DOI 10.1093/nar/gki023; Bhamidipati A, 2005, MOL CELL, V19, P741, DOI 10.1016/j.molcel.2005.07.027; BOHNI PC, 1987, PROTEASES BIOL CONTR, P255; de Martin PE, 2005, J CELL SCI, V118, P65, DOI 10.1242/jcs.01583; Dimmer KS, 2002, MOL BIOL CELL, V13, P847, DOI 10.1091/mbc.01-12-0588; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Elena SF, 1997, NATURE, V390, P395, DOI 10.1038/37108; Enyenihi AH, 2003, GENETICS, V163, P47; Gavin AC, 2002, NATURE, V415, P141, DOI 10.1038/415141a; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; Giaever G, 2004, P NATL ACAD SCI USA, V101, P793, DOI 10.1073/pnas.0307490100; Giaever G, 2002, NATURE, V418, P387, DOI 10.1038/nature00935; Ho Y, 2002, NATURE, V415, P180, DOI 10.1038/415180a; Hughes TR, 2000, CELL, V102, P109, DOI 10.1016/S0092-8674(00)00015-5; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Ito T, 2001, P NATL ACAD SCI USA, V98, P4569, DOI 10.1073/pnas.061034498; Kelley R, 2005, NAT BIOTECHNOL, V23, P561, DOI 10.1038/nbt1096; Krogan NJ, 2002, MOL CELL BIOL, V22, P6979, DOI 10.1128/MCB.22.20.6979-6992.2002; Kumar A, 2002, GENE DEV, V16, P707, DOI 10.1101/gad.970902; Kupperman E, 2000, NATURE, V406, P192, DOI 10.1038/35018092; Lester RL, 2001, ANAL BIOCHEM, V298, P283, DOI 10.1006/abio.2001.5368; Li DX, 2000, GENE, V256, P237, DOI 10.1016/S0378-1119(00)00347-4; Lipke PN, 1998, J BACTERIOL, V180, P3735, DOI 10.1128/JB.180.15.3735-3740.1998; Mnaimneh S, 2004, CELL, V118, P31, DOI 10.1016/j.cell.2004.06.013; Muhlrad D, 1999, RNA, V5, P1299, DOI 10.1017/S1355838299990829; Norman TC, 1999, SCIENCE, V285, P591, DOI 10.1126/science.285.5427.591; Pan XW, 2004, MOL CELL, V16, P487, DOI 10.1016/j.molcel.2004.09.035; Parsons AB, 2004, NAT BIOTECHNOL, V22, P62, DOI 10.1038/nbt919; Patil C, 2001, CURR OPIN CELL BIOL, V13, P349, DOI 10.1016/S0955-0674(00)00219-2; Phillips PC., 2000, EPISTASIS EVOLUTIONA, P20; Sato K, 2002, MOL BIOL CELL, V13, P2518, DOI 10.1091/mbc.E02-01-0027; Segre D, 2005, NAT GENET, V37, P77, DOI 10.1038/ng1489; SEMENZA JC, 1990, CELL, V61, P1349, DOI 10.1016/0092-8674(90)90698-E; Shahinian S, 1998, GENETICS, V149, P843; Shen J, 2003, BIOMETALS, V16, P369, DOI 10.1023/A:1022504311669; Simons JF, 1998, EMBO J, V17, P396, DOI 10.1093/emboj/17.2.396; Siniossoglou S, 2000, EMBO J, V19, P4885, DOI 10.1093/emboj/19.18.4885; Sutterlin C, 2002, CELL, V109, P359, DOI 10.1016/S0092-8674(02)00720-1; Tipper DJ, 2002, MOL BIOL CELL, V13, P1158, DOI 10.1091/mbc.01-10-0488; Tong AHY, 2004, SCIENCE, V303, P808, DOI 10.1126/science.1091317; Tong AHY, 2001, SCIENCE, V294, P2364, DOI 10.1126/science.1065810; Tu BP, 2004, J CELL BIOL, V164, P341, DOI 10.1083/jcb.200311055; Uetz P, 2000, NATURE, V403, P623, DOI 10.1038/35001009; Vashist S, 2002, MOL BIOL CELL, V13, P3955, DOI 10.1091/mbc.02-06-0090; Whyte JRC, 2002, J CELL SCI, V115, P2627	45	660	679	0	31	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					507	519		10.1016/j.cell.2005.08.031	http://dx.doi.org/10.1016/j.cell.2005.08.031			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269340	Bronze			2022-12-28	WOS:000233264300017
J	Chaguturu, S; Vallabhaneni, S				Chaguturu, S; Vallabhaneni, S			Aiding and abetting - Nursing crises at home and abroad	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA; Brown Med Sch, Providence, RI USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; Brown University	Chaguturu, S (corresponding author), Massachusetts Gen Hosp, Boston, MA 02114 USA.							Chen L, 2004, LANCET, V364, P1984, DOI 10.1016/S0140-6736(04)17482-5; *DEP HHS, 2002, PROJ SUPPL DEM SHORT; Needleman J, 2002, NEW ENGL J MED, V346, P1715, DOI 10.1056/NEJMsa012247; Oberoi A, 2003, LANCET, V362, P329, DOI 10.1016/S0140-6736(03)13980-3; 2005, GLOBAL HLTH PROFESSI	5	32	34	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					1761	1763		10.1056/NEJMp058201	http://dx.doi.org/10.1056/NEJMp058201			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251530				2022-12-28	WOS:000232813000001
J	Perls, TT; Reisman, NR; Olshansky, SJ				Perls, TT; Reisman, NR; Olshansky, SJ			Provision or distribution of growth hormone for "antiaging": Clinical and legal issues	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PLACEBO-CONTROLLED TRIAL; RANDOMIZED CONTROLLED-TRIAL; FACTOR-I; LIFE-SPAN; MEN; DEFICIENCY; THERAPY; REPLACEMENT; CANCER		Boston Med Ctr, Dept Med, Geriatr Sect, Boston, MA 02118 USA; Boston Univ, Sch Med, Boston, MA 02118 USA; Baylor Coll Med, Dept Plast Surg, Houston, TX 77030 USA; St Lukes Episcopal Hosp, Houston, TX 77030 USA; Univ Illinois, Sch Publ Hlth, Chicago, IL USA	Boston Medical Center; Boston University; Baylor College of Medicine; Saint Lukes Episcopal Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Perls, TT (corresponding author), Boston Med Ctr, Dept Med, Geriatr Sect, Robinson 2400,88 E Newton St, Boston, MA 02118 USA.	thperls@bu.edu		Perls, Thomas/0000-0002-2492-4334	NATIONAL INSTITUTE ON AGING [K02AG000785] Funding Source: NIH RePORTER; NIA NIH HHS [K02 AG00785-05] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Aimaretti G, 2004, HORM RES, V62, P26, DOI 10.1159/000080755; Bartke A, 2003, NEUROENDOCRINOLOGY, V78, P210, DOI 10.1159/000073704; Bartke A, 2001, J GERONTOL A-BIOL, V56, pB340, DOI 10.1093/gerona/56.8.B340; BIBBY K, BIOPEOPLE; Blackman MB, 2002, JAMA-J AM MED ASSOC, V288, P2282, DOI 10.1001/jama.288.18.2282; CHAPPELL MA, 2004, FDA WARNING LETT ADD; COSTELLO G, FDA WARNING LETT A B; de Zegher F, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1934; GHARIB H, 2003, ENDOCR PRACT, V9, P65; Harman SM, 2004, J GERONTOL A-BIOL, V59, P652; JAMES J, 2005, AIDS TREAT NEWS, V411, P2; KAUFMAN M, 2002, WASHINGTON POST 1102, pA2; Koutkia P, 2004, JAMA-J AM MED ASSOC, V292, P210, DOI 10.1001/jama.292.2.210; Lange KHW, 2002, J CLIN ENDOCR METAB, V87, P513, DOI 10.1210/jc.87.2.513; LANGRETH R, 2000, FORBES          1211; Lee PDK, 1996, J CLIN ENDOCR METAB, V81, P2968, DOI 10.1210/jc.81.8.2968; Lyle WG, 2002, PLAST RECONSTR SURG, V110, P1585, DOI 10.1097/00006534-200211000-00032; MARCUS R, 1990, J CLIN ENDOCR METAB, V70, P519, DOI 10.1210/jcem-70-2-519; Mehlman MJ, 2004, GERONTOLOGIST, V44, P304, DOI 10.1093/geront/44.3.304; Mukhina S, 2004, P NATL ACAD SCI USA, V101, P15166, DOI 10.1073/pnas.0405881101; Papadakis MA, 1996, ANN INTERN MED, V124, P708, DOI 10.7326/0003-4819-124-8-199604150-00002; Perls TT, 2004, J GERONTOL A-BIOL, V59, P682; Pugeat M, 2004, Horm Res, V62 Suppl 4, P2, DOI 10.1159/000080902; Roehr Bob, 2003, BETA, V15, P12; ROTHENBERG R, 2001, FOREVER AGELESS; Schambelan M, 1996, ANN INTERN MED, V125, P873, DOI 10.7326/0003-4819-125-11-199612010-00002; Sonntag WE, 2005, ENDOCRINOLOGY, V146, P2920, DOI 10.1210/en.2005-0058; SULLIVAN M, 1998, ANTIAGING HORMONES P; Swerdlow AJ, 2002, LANCET, V360, P273, DOI 10.1016/S0140-6736(02)09519-3; TRAN D, FDA WARNING LETT GEN; U.S. Senate Special Committee on Aging, 2001, SWINDL HUCKST SNAK O; *US HOUS REPR, 1984, PUBL US HOUS REPR; Vance ML, 2003, NEW ENGL J MED, V348, P779, DOI 10.1056/NEJMp020186; Verhelst J, 1997, CLIN ENDOCRINOL, V47, P485, DOI 10.1046/j.1365-2265.1997.3041112.x; Waters D, 1996, ANN INTERN MED, V125, P865, DOI 10.7326/0003-4819-125-11-199612010-00001; Wilson TA, 2003, J PEDIATR-US, V143, P415, DOI 10.1067/S0022-3476(03)00246-4; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	37	53	53	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	OCT 26	2005	294	16					2086	2090		10.1001/jama.294.16.2086	http://dx.doi.org/10.1001/jama.294.16.2086			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977CB	16249424				2022-12-28	WOS:000232778900030
J	Takano, T; Ohe, Y				Takano, T; Ohe, Y			Erlotinib in lung cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Letter							GEFITINIB		Natl Canc Ctr, Tokyo 1040045, Japan	National Cancer Center - Japan	Takano, T (corresponding author), Natl Canc Ctr, Tokyo 1040045, Japan.	yohe@ncc.go.jp						Han SW, 2005, J CLIN ONCOL, V23, P2493, DOI 10.1200/JCO.2005.01.388; Mitsudomi T, 2005, J CLIN ONCOL, V23, P2513, DOI 10.1200/JCO.2005.00.992; TAKANO T, IN PRESS J CLIN ONCO; Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736	4	1	1	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 20	2005	353	16					1739	1740						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	975IC	16240472				2022-12-28	WOS:000232653200018
J	Horton, R				Horton, R			The neglected epidemic of chronic disease	LANCET			English	Editorial Material							TOBACCO USE		The Lancet, London NW1 7BY, England		Horton, R (corresponding author), The Lancet, London NW1 7BY, England.							Eckel Robert H, LANCET, V365, P1415, DOI [10.1016/S0140-6736(05)66378-7, DOI 10.1016/S0140-6736(05)67342-4, DOI 10.1016/S0140-6736(05)66378-7]; Nichols William C, LANCET, V365, P410, DOI [10.1016/S0140-6736(05)17828-3, DOI 10.1016/S0140-6736(05)67343-6, DOI 10.1016/S0140-6736(05)17828-3]; Pampel FC, 2005, AM J PUBLIC HEALTH, V95, P1009, DOI 10.2105/AJPH.2004.056895; REDDY KS, 2005, LANCET          1005, DOI DOI 10.1016/S0140-6736(05)67342-4; Sorensen G, 2005, AM J PUBLIC HEALTH, V95, P1003, DOI 10.2105/AJPH.2004.045039; Strong K, 2005, LANCET, V366, P1578, DOI 10.1016/S0140-6736(05)67341-2; WANG L, 2005, LANCET          1005, DOI DOI 10.1016/S0140-6736(05)67344-8; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	8	112	115	0	4	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1514	1514		10.1016/S0140-6736(05)67454-5	http://dx.doi.org/10.1016/S0140-6736(05)67454-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257331				2022-12-28	WOS:000232984800008
J	Rosenfeld, JV; Cooper, DJ				Rosenfeld, JV; Cooper, DJ			Management of severe head injury: can we do better?	LANCET			English	Editorial Material							TRENDS; CARE		Alfred Univ, Dept Neurosurg, Melbourne, Vic 3004, Australia; Alfred Univ, Dept Surg, Melbourne, Vic 3004, Australia; Alfred Univ, Dept Intens Care, Melbourne, Vic 3004, Australia; Monash Univ, Melbourne, Vic 3004, Australia; Natl Trauma Res Inst, Melbourne, Vic, Australia	Monash University	Rosenfeld, JV (corresponding author), Alfred Univ, Dept Neurosurg, Melbourne, Vic 3004, Australia.	j.rosenfeld@alfred.org.au	Cooper, D. James/G-7961-2013; Rosenfeld, Jeffrey V/B-7249-2011	Cooper, D. James/0000-0002-5872-9051; 				*AM ASS NEUR SURG, 2000, MAN PROGN SEV TRAU 1; GANN WF, 2005, SHORTAGE NEUROTRAUMA, P4; Lecky F, 2000, LANCET, V355, P1771, DOI 10.1016/S0140-6736(00)02264-9; McDermott FT, 2004, J TRAUMA, V56, P137, DOI 10.1097/01.TA.0000056163.58047.74; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; *RCS, 1999, REP WORK PART MAN PA; Rose SPR, 2000, LEARN MEMORY, V7, P1, DOI 10.1101/lm.7.1.1; Seeley HM, 2001, EMERG MED J, V18, P358, DOI 10.1136/emj.18.5.358; Shackford SR, 2005, J TRAUMA, V58, P663, DOI 10.1097/01.TA.0000159704.96037.63; White BD, 1998, BRIT J NEUROSURG, V12, P329	11	2	2	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1509	1510		10.1016/S0140-6736(05)67609-X	http://dx.doi.org/10.1016/S0140-6736(05)67609-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257328				2022-12-28	WOS:000232984800005
J	Gasparini, Z; Pol, D; Spalletti, LA				Gasparini, Z; Pol, D; Spalletti, LA			An unusual marine crocodyliform from the Jurassic-Cretaceous boundary of Patagonia	SCIENCE			English	Article							THALATTOSUCHIA; PALEOCENE; ARGENTINA	Remains of the marine crocodyliform Dakosaurus andiniensis from western South America reveal a lineage that drastically deviated from the skull morphology that characterizes marine crocodyliforms. The snout and lower jaw are extremely robust, short, and high and only bear a few large teeth with serrated edges (resembling those of some terrestrial carnivorous archosaurs). This unusual morphology contrasts with the long and gracile snout and tower jaws bearing numerous teeth, which are present in the closest relatives of D. andiniensis (and interpreted as indicating feeding on small fish or mollusks). Thus, the morphological diversity of pelagic marine crocodyliforms was wider than had been thought.	Natl Univ La Plata, Fac Ciencias Nat & Museo, Dept Palaeontol Vertebrados, CONICET, RA-1900 La Plata, Argentina; Ohio State Univ, Math Biosci Inst, Columbus, OH 43210 USA; Natl Univ La Plata, Fac Ciencias Nat & Museo, Ctr Invest Geol, CONICET, RA-1900 La Plata, Argentina	National University of La Plata; University System of Ohio; Ohio State University; National University of La Plata	Gasparini, Z (corresponding author), Natl Univ La Plata, Fac Ciencias Nat & Museo, Dept Palaeontol Vertebrados, CONICET, Paseo Bosque S-N, RA-1900 La Plata, Argentina.	zgaspari@museo.fcnym.unip.edu.ar	Pol, Diego/A-8007-2008	Pol, Diego/0000-0002-9690-7517				Brochu CA, 2001, AM ZOOL, V41, P564, DOI 10.1668/0003-1569(2001)041[0564:CSISAT]2.0.CO;2; Buckley GA, 2000, NATURE, V405, P941, DOI 10.1038/35016061; BUSBEY AB, 1995, FUNCTIONAL MORPHOLOGY IN VERTEBRATE PALEONTOLOGY, P173; CARVALHO IS, 2004, GONDWANA RES, V8, P11; CLARK JM, 1994, IN THE SHADOW OF THE DINOSAURS, P84; Delfino M, 2005, ACTA PALAEONTOL POL, V50, P565; Farlow J.O., 1991, Modern Geology, V16, P161; Fernandez M, 2000, LETHAIA, V33, P269; Fraas E., 1902, PALAEONTOGRAPHICA, V49, P1; Gasparini Z, 2005, GEOL SOC SPEC PUBL, V252, P279, DOI 10.1144/GSL.SP.2005.252.01.14; Gasparini Z, 1976, ACT 1 C GEOL CHIL, V1, pC1; GOLOBOFF P, 2003, TNT VER 1 0 PROGRAM; Goloboff PA, 2004, CLADISTICS, V20, P595; Howell JA, 2005, GEOL SOC SPEC PUBL, V252, P1, DOI 10.1144/GSL.SP.2005.252.01.01; Hua S, 1996, J VERTEBR PALEONTOL, V16, P703, DOI 10.1080/02724634.1996.10011359; Iordansky N.N., 1973, P201; Jouve S, 2005, PALAEONTOLOGY, V48, P359, DOI 10.1111/j.1475-4983.2005.00442.x; Langston W. Jr., 1973, P263; Legasa O., 1994, STUDIA GEOLOGICA SAL, V29, P127; MARTILL DM, 1986, NEUES JB GEOLOGIE PA, P621; Pol D, 2004, AM MUS NOVIT, P1, DOI 10.1206/0003-0082(2004)458<0001:ANGCTF>2.0.CO;2; Prasad Guntupalli V.R., 2002, Annales de Paleontologie, V88, P19, DOI 10.1016/S0753-3969(02)01036-4; Riff Douglas, 2001, Boletim do Museu Nacional Nova Serie Geologia, V59, P1; Spalletti LA, 2000, J GEOL SOC LONDON, V157, P433, DOI 10.1144/jgs.157.2.433; Vignaud P, 1996, CR ACAD SCI II A, V322, P245; Vignaud P., 1995, THESIS U POITIERS	26	79	82	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 6	2006	311	5757					70	73		10.1126/science.1120803	http://dx.doi.org/10.1126/science.1120803			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	001ON	16282526	Bronze, Green Submitted			2022-12-28	WOS:000234546300034
J	Glass, J; Lanctot, KL; Herrmann, N; Sproule, BA; Busto, UE				Glass, J; Lanctot, KL; Herrmann, N; Sproule, BA; Busto, UE			Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits	BMJ-BRITISH MEDICAL JOURNAL			English	Review							DOUBLE-BLIND; ELDERLY-PATIENTS; GERIATRIC-PATIENTS; BENZODIAZEPINE USE; SUBJECTIVE SLEEP; TRIAZOLAM; NITRAZEPAM; ZOPICLONE; ZOLPIDEM; PLACEBO	Objectives To quantify and compare potential benefits (subjective reports of sleep variables) and risks (adverse events and morning-after psychomotor impairment) of short term treatment with sedative hypnotics in older people with insomnia. Data sources Medline, Embase, the Cochrane clinical trials database, PubMed, and PsychLit, 1966 to 2003; bibliographies of published reviews and meta-analyses; manufacturers of newer sedative hypnotics (zaleplon, zolpidem, zopiclone) regarding unpublished studies. Selection criteria Randomised controlled trials of any pharmacological treatment for insomnia for at least five consecutive nights in people aged 60 cor over with insomnia and otherwise free of psychiatric or psychological disorders. Results 24 Studies (involving 2417 participants) with extractable data met inclusion and exclusion criteria. Sleep quality improved (effect size 0.14, P < 0.05), total sleep time increased (mean 25.2 minutes, P < 0.001), and the number of night time awakenings decreased (0.63 P < 0.001) with sedative use compared with placebo. Adverse events were more common with sedatives than with placebo: adverse cognitive events were 4.78 times more common (95% confidence interval 1.47 to 15.47, P < 0.01); adverse psychomotor events were 2.61 times more common (1.12 to 6.09, P > 0.05). and reports of daytime fatigue were 3.82 times more common (1.88 to 7.80, P < 0.001) in people using any sedative compared with placebo. Conclusions Improvements in sleep with sedative use are statistically significant, but the magnitude of effect is small. The increased risk of adverse events is statistically significant and potentially clinically relevant in older people at risk of falls and cognitive impairment. In people over 60, the benefits of these drugs may not justify the increased risk, particularly if the patient has additional risk factors for cognitive or psychomotor adverse events. prescribed a benzodiazepine or a benzodiazepine receptor agonist for sleep problems.(5,6) Adverse events that are associated with sedative use, Such as ataxia, falls, or memory impairment, are thought to be particularly detrimental for older people.(7 8) Despite the widespread use of sedative hypnotics in older people, the risk-benefit relation is not known. This meta-analysis aims to study the benefits of sedative rise, as determined by subjective reported changes in sleep variables, and the risks, as determined by adverse events.	Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada; Univ Toronto, Dept Pharmaceut Sci, Toronto, ON M5S 2S2, Canada; Univ Toronto, Dept Psychiat, Neurosci Res Program,Hlth Sci Ctr, Sunnybrook & Womens Coll, Toronto, ON M4N 3M5, Canada; Univ Toronto, Dept Med, Div Geriatr Med, Sunnybrook & Womens Coll,Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	University of Toronto; University Toronto Affiliates; Centre for Addiction & Mental Health - Canada; University of Toronto; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; University of Manitoba; Children's Hospital Research Institute of Manitoba; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center	Busto, UE (corresponding author), Ctr Addict & Mental Hlth, Toronto, ON M5S 2S1, Canada.	usoa_busto@camh.net	Lanctot, Krista L./AAY-4820-2020; l, l/GZH-2874-2022; L, L/HGA-1686-2022	Lanctot, Krista L./0000-0001-7024-6637; Sproule, Beth/0000-0001-7960-3696				American Sleep Disorders Association. Diagnostic Classification Steering Committee, 1990, INT CLASS SLEEP DIS, pxii, 396; Ancoli-Israel S, 1999, PRIM CARE COMPANION, V1, P114; Aparasu RR, 2003, J AM GERIATR SOC, V51, P671, DOI 10.1034/j.1600-0579.2003.00212.x; Barbone F, 1998, LANCET, V352, P1331, DOI 10.1016/S0140-6736(98)04087-2; BAYER AJ, 1986, ACTA PSYCHIAT SCAND, V73, P104, DOI 10.1111/j.1600-0447.1986.tb10544.x; BAYER AJ, 1986, CURR MED RES OPIN, V10, P17, DOI 10.1185/03007998609111088; BAYER AJ, 1983, PHARMATHERAPEUTICA, V3, P468; BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446; Brostrom Anders, 2004, J Cardiovasc Nurs, V19, P234; Byles JE, 2003, AGE AGEING, V32, P154, DOI 10.1093/ageing/32.2.154; CALDWELL JR, 1982, PHARMATHERAPEUTICA, V3, P278; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Craig D, 2003, PHARMACOEPIDEM DR S, V12, P383, DOI 10.1002/pds.865; de Craen AJM, 1998, LANCET, V351, P310, DOI 10.1016/S0140-6736(05)78341-0; DEHLIN O, 1983, ACTA PSYCHIAT SCAND, V67, P290, DOI 10.1111/j.1600-0447.1983.tb00345.x; Dehlin O, 1995, CURR MED RES OPIN, V13, P317, DOI 10.1185/03007999509110492; Duval S, 2000, BIOMETRICS, V56, P455, DOI 10.1111/j.0006-341X.2000.00455.x; ELIE R, 1990, INT CLIN PSYCHOPHARM, V5, P39; FAIRWEATHER DB, 1992, EUR J CLIN PHARMACOL, V43, P597, DOI 10.1007/BF02284957; FLEMING JAE, 2003, THERAPEUTIC CHOICES, P54; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Greenblatt DJ, 2004, CLIN PHARMACOL THER, V76, P467, DOI 10.1016/j.clpt.2004.07.009; GREENBLATT DJ, 1991, NEW ENGL J MED, V324, P1691, DOI 10.1056/NEJM199106133242403; GREENBLATT DJ, 1989, J CLIN PHARMACOL, V29, P866, DOI 10.1002/j.1552-4604.1989.tb03246.x; Hedner J, 2000, INT J GERIATR PSYCH, V15, P704, DOI 10.1002/1099-1166(200008)15:8<704::AID-GPS183>3.3.CO;2-J; Hemmelgarn B, 1997, JAMA-J AM MED ASSOC, V278, P27, DOI 10.1001/jama.278.1.27; Holbrook AM, 2000, CAN MED ASSOC J, V162, P225; HOLBROOK AM, 2000, CMAJ, V162, P206; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; Kallin K, 2004, J FAM PRACTICE, V53, P41; KLIMM HD, 1987, SLEEP, V10, P73, DOI 10.1093/sleep/10.suppl_1.73; KRIPKE DF, 1990, J CLIN PSYCHOPHARM, V10, pS32; LACHNIT KS, 1983, BRIT J CLIN PHARMACO, V16, pS173, DOI 10.1111/j.1365-2125.1983.tb02291.x; Leppik IE, 1997, DRUG DEVELOP RES, V40, P230, DOI 10.1002/(SICI)1098-2299(199703)40:3<230::AID-DDR3>3.3.CO;2-Y; MAMELAK M, 1989, J CLIN PSYCHOPHARM, V9, P260; McAlister FA, 2000, JAMA-J AM MED ASSOC, V283, P2829, DOI 10.1001/jama.283.21.2829; METTLEMAN JR, 1987, DRUG INTELL CLIN PHA, V21, P716; MEULEMAN JR, 1987, DRUG INTEL CLIN PHAR, V21, P716; MORIN CM, 1994, AM J PSYCHIAT, V151, P1172; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Mort JR, 2002, CNS DRUGS, V16, P99, DOI 10.2165/00023210-200216020-00003; MOURET J, 1990, INT CLIN PSYCHOPHARM, V5, P47; MOURGUIART P, 1990, GEODYNAMIQUE, V5, P2; Murphy P, 1982, Age Ageing, V11, P222, DOI 10.1093/ageing/11.4.222; MURTAGH DRR, 1995, J CONSULT CLIN PSYCH, V63, P79, DOI 10.1037/0022-006X.63.1.79; Neutel CI, 2002, PHARMACOEPIDEM DR S, V11, P97, DOI 10.1002/pds.686; Nowell PD, 1997, JAMA-J AM MED ASSOC, V278, P2170; Ohayon MM, 2002, SLEEP MED REV, V6, P97, DOI 10.1053/smrv.2002.0186; OVERSTALL PW, 1987, AGE AGEING, V16, P45, DOI 10.1093/ageing/16.1.45; Ray WA, 1997, JAMA-J AM MED ASSOC, V278, P66, DOI 10.1001/jama.278.1.66; REEVES RL, 1977, J CLIN PHARMACOL, V17, P319, DOI 10.1002/j.1552-4604.1977.tb04611.x; RICHARDS HH, 1988, CURR MED RES OPIN, V11, P48, DOI 10.1185/03007998809111131; ROGER M, 1993, CLIN THER, V15, P127; Roth TG, 1997, J CLIN PSYCHOPHARM, V17, P401, DOI 10.1097/00004714-199710000-00009; Smith A, 2002, NAT REV DRUG DISCOV, V1, P5, DOI 10.1038/nrd714; Smith MT, 2002, AM J PSYCHIAT, V159, P5, DOI 10.1176/appi.ajp.159.1.5; VINKARI M, 1984, NEUROPSYCHOBIOLOGY, V12, P130; VIUKARI M, 1984, NEUROPSYCHOBIOLOGY, V12, P130, DOI 10.1159/000118125; WYSOWSKI DK, 1991, ARCH INTERN MED, V151, P2003, DOI 10.1001/archinte.151.10.2003; 2002, COCHRANE COLLABORATI	60	658	673	2	83	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X	1756-1833		BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 19	2005	331	7526					1169	1173		10.1136/bmj.38623.768588.47	http://dx.doi.org/10.1136/bmj.38623.768588.47			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	988DG	16284208	Green Published, Bronze			2022-12-28	WOS:000233571000016
J	Lloyd-Smith, JO; Schreiber, SJ; Kopp, PE; Getz, WM				Lloyd-Smith, JO; Schreiber, SJ; Kopp, PE; Getz, WM			Superspreading and the effect of individual variation on disease emergence	NATURE			English	Article							ACUTE RESPIRATORY SYNDROME; TRANSMISSION DYNAMICS; SARS TRANSMISSION; MODELS; COMMUNITY; WORKERS	Population-level analyses often use average quantities to describe heterogeneous systems, particularly when variation does not arise from identifiable groups(1,2). A prominent example, central to our current understanding of epidemic spread, is the basic reproductive number, R-0, which is defined as the mean number of infections caused by an infected individual in a susceptible population(3,4). Population estimates of R-0 can obscure considerable individual variation in infectiousness, as highlighted during the global emergence of severe acute respiratory syndrome (SARS) by numerous 'superspreading events' in which certain individuals infected unusually large numbers of secondary cases(5-10). For diseases transmitted by non-sexual direct contacts, such as SARS or smallpox, individual variation is difficult to measure empirically, and thus its importance for outbreak dynamics has been unclear(2,10,11). Here we present an integrated theoretical and statistical analysis of the influence of individual variation in infectiousness on disease emergence. Using contact tracing data from eight directly transmitted diseases, we show that the distribution of individual infectiousness around R-0 is often highly skewed. Model predictions accounting for this variation differ sharply from average-based approaches, with disease extinction more likely and outbreaks rarer but more explosive. Using these models, we explore implications for outbreak control, showing that individual-specific control measures outperform population-wide measures. Moreover, the dramatic improvements achieved through targeted control policies emphasize the need to identify predictive correlates of higher infectiousness. Our findings indicate that superspreading is a normal feature of disease spread, and to frame ongoing discussion we propose a rigorous definition for superspreading events and a method to predict their frequency.	Univ Calif Berkeley, Dept Environm Sci Policy & Management, Berkeley, CA 94720 USA; Univ Calif Berkeley, Biophys Grad Grp, Berkeley, CA 94720 USA; Coll William & Mary, Dept Math, Williamsburg, VA 23187 USA; Univ Hull, Ctr Math, Kingston Upon Hull HU6 7RX, N Humberside, England	University of California System; University of California Berkeley; University of California System; University of California Berkeley; William & Mary; University of Hull	Lloyd-Smith, JO (corresponding author), Univ Calif Berkeley, Dept Environm Sci Policy & Management, 140 Mulford Hall, Berkeley, CA 94720 USA.	jls@nature.berkeley.edu	Lloyd-Smith, James/AAG-4463-2021; /K-4080-2012; Getz, Wayne/I-4521-2013	/0000-0001-7941-502X; Getz, Wayne/0000-0001-8784-9354				ANDERSON R M, 1991; Anderson RM, 2004, PHILOS T R SOC B, V359, P1091, DOI 10.1098/rstb.2004.1490; BAILEY NTJ, 1975, MATH THEORY INFECT D, P263; Bauch CT, 2005, EPIDEMIOLOGY, V16, P791, DOI 10.1097/01.ede.0000181633.80269.4c; Becker N., 1990, STOCHASTIC PROCESSES, P90; BECKER N, 1989, AAL INFECT DIS DATA, P48; Becker NG, 1999, J ROY STAT SOC B, V61, P287, DOI 10.1111/1467-9868.00177; BOSWELL MT, 1970, RANDOM COUNTS MODEL, P7; BURNHAM K.P., 2002, MODEL SELECTION MULT, V2nd, DOI DOI 10.1007/B97636; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P405; Diekmann O., 2000, MATH EPIDEMIOLOGY IN; Dye C, 2003, SCIENCE, V300, P1884, DOI 10.1126/science.1086925; Farrington CP, 2003, BIOSTATISTICS, V4, P279, DOI 10.1093/biostatistics/4.2.279; Ferguson NM, 2004, SCIENCE, V304, P968, DOI 10.1126/science.1096898; Gani R, 2004, EMERG INFECT DIS, V10, P608, DOI 10.3201/eid1004.030509; Ha LD, 2004, EMERG INFECT DIS, V10, P265, DOI 10.3201/eid1002.030707; Keeling MJ, 1997, SCIENCE, V275, P65, DOI 10.1126/science.275.5296.65; Koopman J, 2004, ANNU REV PUBL HEALTH, V25, P303, DOI 10.1146/annurev.publhealth.25.102802.124353; Levin SA, 1997, SCIENCE, V275, P334, DOI 10.1126/science.275.5298.334; Lipsitch M, 2003, SCIENCE, V300, P1966, DOI 10.1126/science.1086616; Lloyd AL, 2001, P ROY SOC B-BIOL SCI, V268, P985, DOI 10.1098/rspb.2001.1599; Lloyd-Smith JO, 2003, P ROY SOC B-BIOL SCI, V270, P1979, DOI 10.1098/rspb.2003.2481; Lloyd-Smith JO, 2004, P ROY SOC B-BIOL SCI, V271, P625, DOI 10.1098/rspb.2003.2632; MAY RM, 1987, NATURE, V326, P137, DOI 10.1038/326137a0; Meyers LA, 2005, J THEOR BIOL, V232, P71, DOI 10.1016/j.jtbi.2004.07.026; Park BJ, 2004, EMERG INFECT DIS, V10, P244; Riley S, 2003, SCIENCE, V300, P1961, DOI 10.1126/science.1086478; Shen Z, 2004, EMERG INFECT DIS, V10, P256, DOI 10.3201/eid1002.030732; Wallinga J, 2004, AM J EPIDEMIOL, V160, P509, DOI 10.1093/aje/kwh255; Woolhouse MEJ, 1997, P NATL ACAD SCI USA, V94, P338, DOI 10.1073/pnas.94.1.338	30	1437	1454	3	249	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					355	359		10.1038/nature04153	http://dx.doi.org/10.1038/nature04153			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292310	Bronze, Green Submitted, Green Published			2022-12-28	WOS:000233300200048
J	Patrinos, A; Bamzai, A				Patrinos, A; Bamzai, A			Policy needs robust climate science	NATURE			English	Editorial Material									US DOE, Off Sci, Washington, DC 20585 USA	United States Department of Energy (DOE)	Patrinos, A (corresponding author), US DOE, Off Sci, Washington, DC 20585 USA.							Barnett TP, 2005, NATURE, V438, P303, DOI 10.1038/nature04141; Patz JA, 2005, NATURE, V438, P310, DOI 10.1038/nature04188	2	9	10	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 17	2005	438	7066					285	285		10.1038/438285a	http://dx.doi.org/10.1038/438285a			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	984JR	16292286				2022-12-28	WOS:000233300200022
J	Sweet, K; Willis, J; Zhou, XP; Gallione, C; Sawada, T; Alhopuro, P; Khoo, SK; Patocs, A; Martin, C; Bridgeman, S; Heinz, J; Pilarski, R; Lehtonen, R; Prior, TW; Frebourg, T; Teh, BT; Marchuk, DA; Aaltonen, LA; Eng, C				Sweet, K; Willis, J; Zhou, XP; Gallione, C; Sawada, T; Alhopuro, P; Khoo, SK; Patocs, A; Martin, C; Bridgeman, S; Heinz, J; Pilarski, R; Lehtonen, R; Prior, TW; Frebourg, T; Teh, BT; Marchuk, DA; Aaltonen, LA; Eng, C			Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							JUVENILE POLYPOSIS; SERRATED ADENOMAS; KRAS MUTATIONS; BETA; METHYLATION; EXPRESSION; ENDOGLIN; COWDEN; COLON; BRAF	Context Significant proportions of patients with hamartomatous polyposis or with hyperplastic/mixed polyposis remain without specific clinical and molecular diagnosis or present atypically. Assigning a syndromic diagnosis is important because it guides management, especially surveillance and prophylactic surgery. Objective To systematically classify patients with unexplained hamartomatous or hyperplastic/mixed polyposis by extensive molecular analysis in the context of central rereview of histopathology results. Design, Setting, and Patients Prospective, referral-based study of 49 unrelated patients from outside institutions (n=28) and at a comprehensive cancer center (n=21), conducted from May 2, 2002, until December 15, 2004. Germline analysis of PTEN, BMPR1A, STK11 (sequence, deletion), SMAD4, and ENG (sequence), specific exon screening of BRAF, MYH, and BHD, and rereview of polyp histology results were performed. Main Outcome Measures Molecular, clinical, and histopathological findings in patients with unexplained polyposis. Results Of the 49 patients, 11 (22%) had germline mutations. Of 14 patients with juvenile polyposis, 2 with early-onset disease had mutations in ENG, encoding endoglin, previously only associated with hereditary hemorrhagic telangiectasia; 1 had hemizygous deletion encompassing PTEN and BMPR1A; and 1 had an SMAD4 mutation. One individual previously classified with Peutz-Jeghers syndrome had a PTEN deletion. Among 9 individuals with an unknown hamartomatous polyposis, 4 had mutations in STK11 (1), BMPR1A (2), and SMAD4 (1). Of the 23 patients with hyperplastic/mixed polyposis, 2 had PTEN mutations. Substantial discrepancies in histopathology results were seen. Conclusions Systematic molecular classification of 49 patients with unexplained hamartomatous or hyperplastic polyposis uncovered a potential novel susceptibility gene, ENG, for juvenile polyposis. Importantly, given the substantial proportion of patients found to have germline mutations, more extensive analysis of the known susceptibility genes is indicated. Rereview of histology results by a dedicated gastrointestinal pathologist should be considered routinely, as organ-specific surveillance rests on defining syndromic diagnosis.	Cleveland Clin Fdn, Genom Med Inst, Lerner Res Inst, Cleveland, OH 44195 USA; Ohio State Univ, Ctr Comprehens Canc, Human Canc Genet Program, Clin Canc Genet Program, Columbus, OH 43210 USA; Ohio State Univ, Dept Internal Med, Div Human Genet, Columbus, OH 43210 USA; Ohio State Univ, Dept Pathol, Columbus, OH 43210 USA; Case Western Reserve Univ, Sch Med, Univ Hosp Hlth Syst, Dept Pathol, Cleveland, OH USA; Case Western Reserve Univ, Sch Med, Dept Genet, Cleveland, OH 44106 USA; Duke Univ, Med Ctr, Dept Mol Genet & Microbiol, Durham, NC USA; Univ Helsinki, Biomedicum Helsinki, Dept Med Genet, Helsinki, Finland; Univ Helsinki, Biomedicum Helsinki, Mol & Canc Biol Res Program, Helsinki, Finland; Van Andel Res Inst, Canc Genet Lab, Grand Rapids, MI USA; Univ Hosp Rouen, Fac Med, Dept Genet, Rouen, France; Univ Cambridge, Canc Res UK Human Canc Genet Res Grp, Cambridge, England	Cleveland Clinic Foundation; James Cancer Hospital & Solove Research Institute; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University; Case Western Reserve University; University Hospitals of Cleveland; Case Western Reserve University; Duke University; University of Helsinki; University of Helsinki; Van Andel Institute; CHU de Rouen; University of Cambridge	Eng, C (corresponding author), Cleveland Clin Fdn, Genom Med Inst, Lerner Res Inst, 9500 Euclid Ave,Mailstop NE-30, Cleveland, OH 44195 USA.	engc@ccf.org	Pilarski, Robert/X-3256-2019; Pilarski, Robert/E-3871-2011; Sweet, Kevin/E-4172-2011; Frebourg, Thierry/AAK-8390-2020; Aaltonen, Lauri/A-5375-2010	Aaltonen, Lauri/0000-0001-6839-4286; Patocs, Attila/0000-0001-7506-674X; Teh, Bin Tean/0000-0003-1514-1124; Frebourg, Thierry/0000-0003-0399-4007; Eng, Charis/0000-0002-3693-5145; Marchuk, Douglas/0000-0002-3110-6671; Lehtonen, Rainer Juhani/0000-0002-8343-0318				AALTONEN LA, 2000, PATHOLOGY GENETICS T, P74; Akagi K, 2002, SURGERY, V131, pS109, DOI 10.1067/msy.2002.119361; Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828; Aotake T, 1999, CLIN CANCER RES, V5, P135; BARGMANN CI, 1986, CELL, V45, P649, DOI 10.1016/0092-8674(86)90779-8; Bariol C, 2003, MODERN PATHOL, V16, P417, DOI 10.1097/01.MP.0000068236.47471.DB; Blobe GC, 2000, NEW ENGL J MED, V342, P1350, DOI 10.1056/NEJM200005043421807; Chan TL, 2003, CANCER RES, V63, P4878; DISARIO JA, 1991, AM J GASTROENTEROL, V86, P941; Eng C, 2000, J MED GENET, V37, P828, DOI 10.1136/jmg.37.11.828; Fonsatti Ester, 2004, J Transl Med, V2, P18, DOI 10.1186/1479-5876-2-18; Gallione CJ, 2004, LANCET, V363, P852, DOI 10.1016/S0140-6736(04)15732-2; Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307; Hawkins NJ, 2002, PATHOLOGY, V34, P548, DOI 10.1080/0031302021000035965; Hemminki A, 1998, NATURE, V391, P184, DOI 10.1038/34432; Hohenstein P, 2003, GENE CHROMOSOME CANC, V36, P273, DOI 10.1002/gcc.10169; Howe JR, 2004, J MED GENET, V41, P484, DOI 10.1136/jmg.2004.018598; Imperiale TF, 2002, NEW ENGL J MED, V346, P1781, DOI 10.1056/NEJM200206063462304; JASS J, 2000, PATHOLOGY GENETICS T, P136; Jass JR, 2000, GUT, V47, P43, DOI 10.1136/gut.47.1.43; JASS JR, 1988, HISTOPATHOLOGY, V13, P619; Jass JR, 2002, GASTROENTEROLOGY, V123, P862, DOI 10.1053/gast.2002.35392; Jass JR, 2003, AM J PATHOL, V162, P705, DOI 10.1016/S0002-9440(10)63865-5; JEGHERS H, 1949, NEW ENGL J MED, V241, P993, DOI 10.1056/NEJM194912222412501; Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671; LASHNER BA, 1986, DIGEST DIS SCI, V31, P213, DOI 10.1007/BF01300711; Le Meur N, 2004, EUR J HUM GENET, V12, P415, DOI 10.1038/sj.ejhg.5201155; Lebrin F, 2004, EMBO J, V23, P4018, DOI 10.1038/sj.emboj.7600386; Leggett BA, 2001, AM J SURG PATHOL, V25, P177, DOI 10.1097/00000478-200102000-00005; Lux A, 2000, HUM MOL GENET, V9, P745, DOI 10.1093/hmg/9.5.745; Marsh DJ, 1998, HUM MOL GENET, V7, P507, DOI 10.1093/hmg/7.3.507; Miller DW, 1999, INT J CANCER, V81, P568, DOI 10.1002/(SICI)1097-0215(19990517)81:4<568::AID-IJC11>3.3.CO;2-O; Mutter GL, 2000, JNCI-J NATL CANCER I, V92, P924, DOI 10.1093/jnci/92.11.924; Nagy R, 2004, ONCOGENE, V23, P6445, DOI 10.1038/sj.onc.1207714; Naski MC, 1996, NAT GENET, V13, P233, DOI 10.1038/ng0696-233; *NAT CTR BIOT INF, ON LIN MEND INH MAN; Newman JH, 2001, NEW ENGL J MED, V345, P319, DOI 10.1056/NEJM200108023450502; Rashid A, 2000, GASTROENTEROLOGY, V119, P323, DOI 10.1053/gast.2000.9361; Roth S, 1999, GENE CHROMOSOME CANC, V26, P54, DOI 10.1002/(SICI)1098-2264(199909)26:1<54::AID-GCC8>3.0.CO;2-D; Saad RS, 2004, MODERN PATHOL, V17, P197, DOI 10.1038/modpathol.3800034; Shpitz B, 2003, ANTICANCER RES, V23, P5153; Snover DC, 2005, AM J CLIN PATHOL, V124, P380, DOI 10.1309/V2EPTPLJRB3FGHJL; Torlakovic E, 2003, AM J SURG PATHOL, V27, P65, DOI 10.1097/00000478-200301000-00008; Waite KA, 2003, NAT REV GENET, V4, P763, DOI 10.1038/nrg1178; Wali RK, 2005, GUT, V54, P654, DOI 10.1136/gut.2004.056010; Weber HC, 1998, GASTROENTEROLOGY, V114, pA702, DOI 10.1016/S0016-5085(98)82880-1; Wong SH, 2000, EUR J BIOCHEM, V267, P5550, DOI 10.1046/j.1432-1327.2000.01621.x; Wynter CVA, 2004, GUT, V53, P573, DOI 10.1136/gut.2003.030841; Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a; Zhou XP, 2003, AM J HUM GENET, V73, P404, DOI 10.1086/377109; Zhou XP, 2001, AM J HUM GENET, V69, P704, DOI 10.1086/323703	51	175	179	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2465	2473		10.1001/jama.294.19.2465	http://dx.doi.org/10.1001/jama.294.19.2465			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287957	Bronze			2022-12-28	WOS:000233277400025
J	Penner-Hahn, JE; Yocum, CF				Penner-Hahn, JE; Yocum, CF			Biochemistry - The photosynthesis "oxygen clock" gets a new number	SCIENCE			English	Editorial Material							PHOTOSYSTEM-II; CRYSTAL-STRUCTURE; EVOLVING COMPLEX; WATER OXIDATION; MECHANISM; S-3; INTERMEDIATE; TRANSITION; RESOLUTION; MODEL		Univ Michigan, Dept Chem, Ann Arbor, MI 48109 USA; Univ Michigan, Dept Mol Cellular & Dev Biol, Ann Arbor, MI 48109 USA; Univ Michigan, Div Biophys Res, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan	Penner-Hahn, JE (corresponding author), Univ Michigan, Dept Chem, 930 N Univ Ave, Ann Arbor, MI 48109 USA.	jeph@umich.edu	Penner-Hahn, James/GYD-3750-2022	Penner-Hahn, James/0000-0003-0314-1274				Barber J, 2004, PHYS CHEM CHEM PHYS, V6, P4737, DOI 10.1039/b407981g; Biesiadka J, 2004, PHYS CHEM CHEM PHYS, V6, P4733, DOI 10.1039/b406989g; Clausen J, 2004, NATURE, V430, P480, DOI 10.1038/nature02676; Cruickshank DWJ, 1999, ACTA CRYSTALLOGR D, V55, P583, DOI 10.1107/S0907444998012645; Haumann M, 2005, SCIENCE, V310, P1019, DOI 10.1126/science.1117551; Hoganson CW, 1997, SCIENCE, V277, P1953, DOI 10.1126/science.277.5334.1953; JOLIOT P, 1969, PHOTOCHEM PHOTOBIOL, V10, P309, DOI 10.1111/j.1751-1097.1969.tb05696.x; Kamiya N, 2003, P NATL ACAD SCI USA, V100, P98, DOI 10.1073/pnas.0135651100; KOK B, 1970, PHOTOCHEM PHOTOBIOL, V11, P457, DOI 10.1111/j.1751-1097.1970.tb06017.x; Messinger J, 2001, J AM CHEM SOC, V123, P7804, DOI 10.1021/ja004307+; RAPPAPORT F, 1994, BBA-BIOENERGETICS, V1184, P178, DOI 10.1016/0005-2728(94)90222-4; Razeghifard MR, 1999, BIOCHEMISTRY-US, V38, P1252, DOI 10.1021/bi9811765; Weng TC, 2004, J AM CHEM SOC, V126, P8070, DOI 10.1021/ja0494104; Yano J, 2005, P NATL ACAD SCI USA, V102, P12047, DOI 10.1073/pnas.0505207102	14	12	12	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					982	983		10.1126/science.1120919	http://dx.doi.org/10.1126/science.1120919			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284168				2022-12-28	WOS:000233343400031
J	Brennan, TA				Brennan, TA			Recertification for internists - One "grandfather's" experience	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Brigham & Womens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School	Brennan, TA (corresponding author), Brigham & Womens Hosp, Boston, MA 02115 USA.							Brennan TA, 2004, JAMA-J AM MED ASSOC, V292, P1038, DOI 10.1001/jama.292.9.1038; Lukes Steven, 1973, E DURKHEIM HIS LIFE	2	15	16	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					1989	1992		10.1056/NEJMp058223	http://dx.doi.org/10.1056/NEJMp058223			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981WV	16282171				2022-12-28	WOS:000233119600001
J	Brewster, WR; Hubbell, FA; Largent, J; Ziogas, A; Lin, F; Howe, S; Ganiats, TG; Anton-Culver, H; Manetta, A				Brewster, WR; Hubbell, FA; Largent, J; Ziogas, A; Lin, F; Howe, S; Ganiats, TG; Anton-Culver, H; Manetta, A			Feasibility of management of high-grade cervical lesions in a single visit - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ABNORMAL PAPANICOLAOU SMEARS; FOLLOW-UP; CANCER PREVENTION; POPULATION; WOMEN; INTERVENTIONS; LATINOS; PROGRAM; RISK; CARE	Context The incidence of cervical cancer is higher among low-income and minority women who have never undergone a conventional Papanicolaou test or who do not follow up after testing. Screening has been shown to reduce cervical cancer incidence rates. Objectives To determine the feasibility and acceptability of immediately treating women with severely abnormal Papanicolaou test results by using a single-visit cervical cancer screening and treatment program and to compare treatment rates and 12-month follow-up rates with those of women who received usual care. Design, Setting, and Participants Randomized controlled trial conducted among 3521 women aged 18 years or older recruited between January 1999 and April 2002 at US community health centers located in predominantly Latino underserved areas. Interventions Women randomized to usual care (n = 1805) were discharged immediately after examination. Women randomized to the single-visit group (n = 1716) remained at the clinic until the results of their conventional Papanicolaou test were available. Large loop electrosurgical excision procedure was performed in single-visit patients with either a diagnosis of a high-grade squamous intraepithelial lesion (HGSIL)/ atypical glandular cells of undetermined significance (AGUS) or suspicion of carcinoma. All other patients with abnormal Papanicolaou test results were referred to abnormal cytology clinics or elected to receive follow-up care outside the study's medical system. Main Outcome Measures Treatment rates for HGSIL/AGUS at 6 months, follow-up rates at 6 months for lower-grade lesions, and 1-year follow-up rates for all patients. Results The rate of abnormal Papanicolaou test results was 4.1%. One percent of results showed high-grade lesions. In the single-visit group, the mean visit time was 2.8 hours and the mean time for delivery and processing of the Papanicolaou tests was 66 minutes. Six months after randomization, 14 (88%) of 16 single-visit and 10 (53%) of 19 usual care patients with HGSIL/AGUS had completed treatment. Fifty percent in the single-visit program and 53% of usual care with less abnormal Papanicolaou tests completed treatment within 6 months. Overall, 36% in each group presented for a follow-up Papanicolaou test 1 year later. Women in the single-visit group with high-grade lesions (10/16; 63%) were significantly more likely to attend follow-up for Papanicolaou tests 12 months later than women with similar lesions in the usual care group (4/19; 21%). Conclusions For cervical cancer screening, the single-visit program was feasible and the degree of acceptability was high in this underserved population. Single visit programs provide an opportunity to increase the rate of immediate treatment and follow-up of women with severely abnormal Papanicolaou test results. This strategy did not improve follow-up rates for women with less-abnormal results. Trial Registration ClinicalTrials.govldentifier: NCT00237562.	Univ Calif Irvine, Sch Med, Off Educ Affairs, Dept Med, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Obstet & Gynecol, Irvine, CA 92697 USA; Univ Calif Irvine, Sch Med, Dept Pathol, Irvine, CA 92697 USA; Project Concern Int, San Diego, CA USA; Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA	University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California Irvine; University of California System; University of California San Diego	Brewster, WR (corresponding author), Univ Calif Irvine, Sch Med, Off Educ Affairs, Dept Med, 802 Berk Hall, Irvine, CA 92697 USA.	amanetta@uci.edu			NATIONAL CANCER INSTITUTE [R01CA076502] Funding Source: NIH RePORTER; NCI NIH HHS [R01CA 76502-01] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Belinson JL, 2001, OBSTET GYNECOL, V98, P441, DOI 10.1016/S0029-7844(01)01454-5; Brewster WR, 2002, GYNECOL ONCOL, V85, P250, DOI 10.1006/gyno.2002.6592; BURGER RA, 1995, OBSTET GYNECOL, V86, P491; CAREY P, 1993, J FAM PRACTICE, V37, P583; Henson R M, 1996, J Public Health Manag Pract, V2, P36; Howe SL, 1998, PREV MED, V27, P674, DOI 10.1006/pmed.1998.0343; Hubbell FA, 1996, ARCH INTERN MED, V156, P2353, DOI 10.1001/archinte.156.20.2353; HUBBELL FA, 1991, WESTERN J MED, V154, P414; Mandelblatt J, 1996, ANN EMERG MED, V28, P493, DOI 10.1016/S0196-0644(96)70111-7; McKee MD, 1999, ARCH FAM MED, V8, P129, DOI 10.1001/archfami.8.2.129; Miller BA, 1996, NIH PUBLICATION, V96-4104; PEREZSTABLE EJ, 1994, ARCH INTERN MED, V154, P1073, DOI 10.1001/archinte.154.10.1073; Peterson NB, 2003, J NATL MED ASSOC, V95, P825; ROBERTS RE, 1980, MED CARE, V18, P266, DOI 10.1097/00005650-198003000-00002; SAMET JM, 1988, J NATL CANCER I, V80, P432, DOI 10.1093/jnci/80.6.432; Shinn E, 2004, PREV MED, V39, P404, DOI 10.1016/j.ypmed.2004.02.004; Wertlake PT, 1997, OBSTET GYNECOL, V90, P421, DOI 10.1016/S0029-7844(97)00288-3; Wright TC, 2002, JAMA-J AM MED ASSOC, V287, P2120, DOI 10.1001/jama.287.16.2120; Yabroff KR, 2000, PREV MED, V31, P429, DOI 10.1006/pmed.2000.0722	19	21	21	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2182	2187		10.1001/jama.294.17.2182	http://dx.doi.org/10.1001/jama.294.17.2182			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264159	Bronze			2022-12-28	WOS:000232957700020
J	Holdren, JP				Holdren, JP			Joseph Rotblat (1908-2005)	SCIENCE			English	Biographical-Item									Woods Hole Res Ctr, Woods Hole, MA 02543 USA; Harvard Univ, Cambridge, MA 02138 USA	Woods Hole Research Center; Harvard University	Holdren, JP (corresponding author), Woods Hole Res Ctr, POB 296, Woods Hole, MA 02543 USA.	john_holdren@harvard.edu							0	2	2	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2005	310	5748					633	633		10.1126/science.1121081	http://dx.doi.org/10.1126/science.1121081			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254178				2022-12-28	WOS:000232997700029
J	Conroy, S; O'Malley, B				Conroy, S; O'Malley, B			Lesson of the week - Hypercalcaemia in cancer	BRITISH MEDICAL JOURNAL			English	Review							PRIMARY HYPERPARATHYROIDISM; BREAST-CANCER		Queens Med Ctr, Sch Med, Div Rehabil & Ageing, Nottingham NG7 2UH, England; Gen Hosp Kettering, Kettering NN16 8UZ, England	University of Nottingham	Conroy, S (corresponding author), Queens Med Ctr, Sch Med, Div Rehabil & Ageing, Nottingham NG7 2UH, England.	simon.conroy@nottingham.ac.uk	Conroy, Simon/B-8832-2009	Conroy, Simon/0000-0002-4306-6064				Conroy S, 2003, AGE AGEING, V32, P571, DOI 10.1093/ageing/afg122; Honda M, 2004, INTERNAL MED, V43, P310, DOI 10.2169/internalmedicine.43.310; HUTCHESSON ACJ, 1995, POSTGRAD MED J, V71, P28, DOI 10.1136/pgmj.71.831.28; Marx SJ, 2000, NEW ENGL J MED, V343, P1863, DOI 10.1056/NEJM200012213432508; Michels KB, 2004, INT J CANCER, V110, P449, DOI 10.1002/ijc.20155; SCHNEIDER AB, 1995, J CLIN ENDOCR METAB, V80, P254, DOI 10.1210/jc.80.1.254; STRODEL WE, 1988, J SURG ONCOL, V37, P10, DOI 10.1002/jso.2930370104	7	6	6	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 22	2005	331	7522					954	954		10.1136/bmj.331.7522.954	http://dx.doi.org/10.1136/bmj.331.7522.954			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16239693	Green Published			2022-12-28	WOS:000232970900026
J	Sullivan, F; Wyatt, JC				Sullivan, F; Wyatt, JC			ABC of health informatics - How informatics tools help deal with patients' problems	BRITISH MEDICAL JOURNAL			English	Review							CARE		Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Sullivan, F (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Sullivan, Frank/L-8286-2019; Wyatt, Jeremy/F-8160-2010; Sullivan, Frank m/A-7767-2009	Sullivan, Frank/0000-0002-6623-4964; Wyatt, Jeremy/0000-0001-7008-1473; 				ELY JW, 2002, BRIT MED J, V324, P71; Little P, 2002, BMJ-BRIT MED J, V325, P254, DOI 10.1136/bmj.325.7358.254; Peck C, 2000, BRIT MED J, V320, P432, DOI 10.1136/bmj.320.7232.432; Poon EG, 2003, J BIOMED INFORM, V36, P80, DOI 10.1016/S1532-0464(03)00061-3; Smith R, 1997, BRIT MED J, V314, P1495, DOI 10.1136/bmj.314.7093.1495; Wyatt JC, 2001, CLIN KNOWLEDGE PRACT	6	5	5	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 22	2005	331	7522					955	957		10.1136/bmj.331.7522.955	http://dx.doi.org/10.1136/bmj.331.7522.955			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979UR	16239694	Green Published			2022-12-28	WOS:000232970900027
J	Forde, A				Forde, A			Germany: Deciphering cellular processes	SCIENCE			English	News Item																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					519	520		10.1126/science.310.5747.519	http://dx.doi.org/10.1126/science.310.5747.519			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239481				2022-12-28	WOS:000232786000052
J	Murray, RZ; Kay, JG; Sangermani, DG; Stow, JL				Murray, RZ; Kay, JG; Sangermani, DG; Stow, JL			A role for the phagosome in cytokine secretion	SCIENCE			English	Article							TUMOR-NECROSIS-FACTOR; FACTOR-ALPHA; RECYCLING ENDOSOMES; PLASMA-MEMBRANE; MACROPHAGES; PHAGOCYTOSIS; GOLGI; CELLS; EXOCYTOSIS; TRANSPORT	Membrane traffic in activated macrophages is required for two critical events in innate immunity: proinflammatory cytokine secretion and phagocytosis of pathogens. We found a joint trafficking pathway linking both actions, which may economize membrane transport and augment the immune response. Tumor necrosis factor alpha (TNF alpha) is trafficked from the Golgi to the recycling endosome (RE), where vesicle-associated membrane protein 3 mediates its delivery to the cell surface at the site of phagocytic cup formation. Fusion of the RE at the cup simultaneously allows rapid release of TNF alpha and expands the membrane for phagocytosis.	Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia	University of Queensland	Stow, JL (corresponding author), Univ Queensland, Inst Mol Biosci, Brisbane, Qld 4072, Australia.	j.stow@imb.uq.edu.au	Murray, Rachael/J-1370-2012; Stow, Jennifer L/I-4723-2013	Murray, Rachael/0000-0002-4935-7794; Stow, Jennifer L/0000-0002-5409-9101; Kay, Jason/0000-0001-8944-6612				Allen LAH, 2002, J LEUKOCYTE BIOL, V72, P217; Ang AL, 2004, J CELL BIOL, V167, P531, DOI 10.1083/jcb.200408165; Bajno L, 2000, J CELL BIOL, V149, P697, DOI 10.1083/jcb.149.3.697; Becker T, 2005, P NATL ACAD SCI USA, V102, P4022, DOI 10.1073/pnas.0409219102; Beutler BA, 1999, J RHEUMATOL, V26, P16; Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0; Braun V, 2004, EMBO J, V23, P4166, DOI 10.1038/sj.emboj.7600427; Cox D, 2000, P NATL ACAD SCI USA, V97, P680, DOI 10.1073/pnas.97.2.680; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; Gagnon E, 2002, CELL, V110, P119, DOI 10.1016/S0092-8674(02)00797-3; Hackam DJ, 1998, P NATL ACAD SCI USA, V95, P11691, DOI 10.1073/pnas.95.20.11691; Hong WJ, 2005, BBA-MOL CELL RES, V1744, P120, DOI 10.1016/j.bbamcr.2005.03.014; Lock JG, 2005, MOL BIOL CELL, V16, P1744, DOI 10.1091/mbc.E04-10-0867; MURRAY R, UNPUB; Murray RZ, 2005, J BIOL CHEM, V280, P10478, DOI 10.1074/jbc.M414420200; Netea MG, 2004, MICROBES INFECT, V6, P985, DOI 10.1016/j.micinf.2004.05.013; Pagan JK, 2003, CURR BIOL, V13, P156, DOI 10.1016/S0960-9822(03)00006-X; Polishchuk RS, 2000, J CELL BIOL, V148, P45, DOI 10.1083/jcb.148.1.45; Pryor PR, 2004, EMBO REP, V5, P590, DOI 10.1038/sj.embor.7400150; Shurety W, 2000, J INTERF CYTOK RES, V20, P427, DOI 10.1089/107999000312379; Touret N, 2005, CELL, V123, P157, DOI 10.1016/j.cell.2005.08.018; Vieira OV, 2002, BIOCHEM J, V366, P689, DOI 10.1042/BJ20020691	22	239	245	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 2	2005	310	5753					1492	1495		10.1126/science.1120225	http://dx.doi.org/10.1126/science.1120225			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	990PU	16282525				2022-12-28	WOS:000233756500044
J	Krumholz, MR; McKee, CF; Klein, RI				Krumholz, MR; McKee, CF; Klein, RI			The formation of stars by gravitational collapse rather than competitive accretion	NATURE			English	Article							GAUSSIAN CLOUD CONDITIONS; INITIAL MASS FUNCTION; STELLAR CLUSTERS; MOLECULAR CLOUDS; TURBULENCE	There are two dominant models of how stars form. Under gravitational collapse, star-forming molecular clumps, of typically hundreds to thousands of solar masses (M.), fragment into gaseous cores that subsequently collapse to make individual stars or small multiple systems(1-3). In contrast, competitive accretion theory suggests that at birth all stars are much smaller than the typical stellar mass (similar to 0.5M.), and that final stellar masses are determined by the subsequent accretion of unbound gas from the clump(4-8). Competitive accretion models interpret brown dwarfs and free-floating planets as protostars ejected from star-forming clumps before they have accreted much mass; key predictions of this model are that such objects should lack disks, have high velocity dispersions, form more frequently in denser clumps(9-11), and that the mean stellar mass should vary within the Galaxy(8). Here we derive the rate of competitive accretion as a function of the star-forming environment, based partly on simulation(12), and determine in what types of environments competitive accretion can occur. We show that no observed star-forming region can undergo significant competitive accretion, and that the simulations that show competitive accretion do so because the assumed properties differ from those determined by observation. Our result shows that stars form by gravitational collapse, and explains why observations have failed to confirm predictions of the competitive accretion model.	Princeton Univ, Dept Astrophys, Princeton, NJ 08544 USA; Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA; Lawrence Livermore Natl Lab, Livermore, CA 94550 USA	Princeton University; University of California System; University of California Berkeley; University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Livermore National Laboratory	Krumholz, MR (corresponding author), Princeton Univ, Dept Astrophys, Princeton, NJ 08544 USA.	krumholz@astro.princeton.edu		Krumholz, Mark/0000-0003-3893-854X				Bate MR, 2002, MON NOT R ASTRON SOC, V336, P705, DOI 10.1046/j.1365-8711.2002.05775.x; Bate MR, 2005, MON NOT R ASTRON SOC, V356, P1201, DOI 10.1111/j.1365-2966.2004.08593.x; Bate MR, 2003, MON NOT R ASTRON SOC, V339, P577, DOI 10.1046/j.1365-8711.2003.06210.x; BERTOLDI F, 1992, ASTROPHYS J, V395, P140, DOI 10.1086/171638; Beuther H, 2004, SCIENCE, V303, P1167, DOI 10.1126/science.1094014; Bonnell IA, 2002, MON NOT R ASTRON SOC, V336, P659, DOI 10.1046/j.1365-8711.2002.05794.x; Bonnell IA, 1998, MON NOT R ASTRON SOC, V298, P93, DOI 10.1046/j.1365-8711.1998.01590.x; Bonnell IA, 2004, MON NOT R ASTRON SOC, V349, P735, DOI 10.1111/j.1365-2966.2004.07543.x; Bonnell IA, 2001, MON NOT R ASTRON SOC, V324, P573, DOI 10.1046/j.1365-8711.2001.04311.x; Bonnell IA, 2001, MON NOT R ASTRON SOC, V323, P785, DOI 10.1046/j.1365-8711.2001.04270.x; Cho JY, 2003, MON NOT R ASTRON SOC, V345, P325, DOI 10.1046/j.1365-8711.2003.06941.x; Edgar R, 2004, MON NOT R ASTRON SOC, V349, P678, DOI 10.1111/j.1365-2966.2004.07533.x; Fiege JD, 2000, MON NOT R ASTRON SOC, V311, P85, DOI 10.1046/j.1365-8711.2000.03066.x; Johnstone D, 2001, ASTROPHYS J, V559, P307, DOI 10.1086/322323; Klessen RS, 2001, ASTROPHYS J, V549, P386, DOI 10.1086/319053; Klessen RS, 2000, ASTROPHYS J SUPPL S, V128, P287, DOI 10.1086/313371; KRAMER C, 1991, ASTRON ASTROPHYS SUP, V89, P421; KRUMHOLZ MR, 2005, IN PRESS ASTROPHYS J; LARSON RB, 1981, MON NOT R ASTRON SOC, V194, P809, DOI 10.1093/mnras/194.4.809; McKee CF, 2003, ASTROPHYS J, V585, P850, DOI 10.1086/346149; Mohanty S, 2005, ASTROPHYS J, V626, P498, DOI 10.1086/429794; Motte F, 1998, ASTRON ASTROPHYS, V336, P150; Padoan P, 2002, ASTROPHYS J, V576, P870, DOI 10.1086/341790; Padoan P, 2005, ASTROPHYS J, V622, pL61, DOI 10.1086/429562; Plume R, 1997, ASTROPHYS J, V476, P730, DOI 10.1086/303654; QUILLEN AC, IN PRESS ASTROPHYS J; RUFFERT M, 1994, ASTROPHYS J, V427, P351, DOI 10.1086/174145; SHU FH, 1987, ANNU REV ASTRON ASTR, V25, P23, DOI 10.1146/annurev.aa.25.090187.000323; TESTI L, 1998, APJ, V508, P91	30	116	116	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					332	334		10.1038/nature04280	http://dx.doi.org/10.1038/nature04280			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292305				2022-12-28	WOS:000233300200042
J	Milly, PCD; Dunne, KA; Vecchia, AV				Milly, PCD; Dunne, KA; Vecchia, AV			Global pattern of trends in streamflow and water availability in a changing climate	NATURE			English	Article								Water availability on the continents is important for human health(1,2), economic activity(3), ecosystem function(4) and geophysical processes(5). Because the saturation vapour pressure of water in air is highly sensitive to temperature, perturbations in the global water cycle are expected to accompany climate warming(6). Regional patterns of warming-induced changes in surface hydroclimate are complex and less certain than those in temperature, however, with both regional increases and decreases expected in precipitation and runoff. Here we show that an ensemble of 12 climate models exhibits qualitative and statistically significant skill in simulating observed regional patterns of twentieth-century multidecadal changes in streamflow. These models project 10-40% increases in runoff in eastern equatorial Africa, the La Plata basin and high-latitude North America and Eurasia, and 10-30% decreases in runoff in southern Africa, southern Europe, the Middle East and mid-latitude western North America by the year 2050. Such changes in sustainable water availability would have considerable regional-scale consequences for economies as well as ecosystems.	US Geol Survey, NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; US Geol Survey, Bismarck, ND 58503 USA	National Oceanic Atmospheric Admin (NOAA) - USA; United States Department of the Interior; United States Geological Survey; United States Department of the Interior; United States Geological Survey	Milly, PCD (corresponding author), US Geol Survey, NOAA, Geophys Fluid Dynam Lab, POB 308, Princeton, NJ 08542 USA.	cmilly@usgs.gov	Dunne, Krista/N-4230-2019; Milly, Paul C. D./H-1169-2019	Dunne, Krista/0000-0002-1220-6140; Milly, Paul C. D./0000-0003-4389-3139				Adler RF, 2003, J HYDROMETEOROL, V4, P1147, DOI 10.1175/1525-7541(2003)004<1147:TVGPCP>2.0.CO;2; Allen MR, 2002, NATURE, V419, P224, DOI 10.1038/nature01092; [Anonymous], 2003, WAT PEOPL WAT LIF UN; BROCKWELL PJ, 1987, TIME SERIES THEORY M, pCH7; CAZENAVE A, 2004, EOS, V48, P59; Darnell W.L., 1996, SURFACE RAD BUDGET L; Fekete BM, 2002, GLOBAL BIOGEOCHEM CY, V16, DOI 10.1029/1999GB001254; Manabe S, 2004, CLIMATIC CHANGE, V64, P59, DOI 10.1023/B:CLIM.0000024674.37725.ca; Mooney H, 2005, NATURE, V434, P561, DOI 10.1038/434561a; Reiter L., 2004, SOURCE WATER DRINKIN; Shiklomanov IA., 2004, WORLD WATER RESOURCE; Vorosmarty CJ, 2000, GLOBAL BIOGEOCHEM CY, V14, P599, DOI 10.1029/1999GB900092; [No title captured]	13	1430	1500	42	685	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					347	350		10.1038/nature04312	http://dx.doi.org/10.1038/nature04312			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292308				2022-12-28	WOS:000233300200046
J	Patz, JA; Campbell-Lendrum, D; Holloway, T; Foley, JA				Patz, JA; Campbell-Lendrum, D; Holloway, T; Foley, JA			Impact of regional climate change on human health	NATURE			English	Review							EARLY WARNING SYSTEM; ROSS RIVER VIRUS; LAND-USE CHANGE; EL-NINO; TEMPERATURE VARIABILITY; MALARIA TRANSMISSION; FOOD-PRODUCTION; GLOBAL CLIMATE; VECTOR-BORNE; DENGUE-FEVER	The World Health Organisation estimates that the warming and precipitation trends due to anthropogenic climate change of the past 30 years already claim over 150,000 lives annually. Many prevalent human diseases are linked to climate fluctuations, from cardiovascular mortality and respiratory illnesses due to heatwaves, to altered transmission of infectious diseases and malnutrition from crop failures. Uncertainty remains in attributing the expansion or resurgence of diseases to climate change, owing to lack of long-term, high-quality data sets as well as the large influence of socio-economic factors and changes in immunity and drug resistance. Here we review the growing evidence that climate-health relationships pose increasing health risks under future projections of climate change and that the warming trend over recent decades has already contributed to increased morbidity and mortality in many regions of the world. Potentially vulnerable regions include the temperate latitudes, which are projected to warm disproportionately, the regions around the Pacific and Indian oceans that are currently subjected to large rainfall variability due to the El Nino/Southern Oscillation sub-Saharan Africa and sprawling cities where the urban heat island effect could intensify extreme climatic events.	Univ Wisconsin, Nelson Inst Environm Studies, Ctr Sustainabil & Global Environm, Madison, WI 53726 USA; Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI 53726 USA; WHO, Dept Protect Human Environm, CH-1211 Geneva, Switzerland	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; World Health Organization	Patz, JA (corresponding author), Univ Wisconsin, Nelson Inst Environm Studies, Ctr Sustainabil & Global Environm, 1710 Univ Ave, Madison, WI 53726 USA.	patz@wisc.edu	Foley, Jonathan A/GRS-5522-2022					ANIELLO C, 1995, COMPUT GEOSCI-UK, V21, P965, DOI 10.1016/0098-3004(95)00033-5; Anyamba A, 2001, Cad Saude Publica, V17 Suppl, P133, DOI 10.1590/S0102-311X2001000700022; Arnell NW, 2002, CLIMATIC CHANGE, V53, P413, DOI 10.1023/A:1015277014327; Beniston M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL018857; Bentham G, 2001, INT J BIOMETEOROL, V45, P22, DOI 10.1007/s004840000083; Bouma MJ, 1997, JAMA-J AM MED ASSOC, V278, P1772, DOI 10.1001/jama.278.21.1772; Bouma MJ, 1996, TROP MED INT HEALTH, V1, P86, DOI 10.1046/j.1365-3156.1996.d01-7.x; Cazelles B, 2005, PLOS MED, V2, P313, DOI 10.1371/journal.pmed.0020106; Checkley W, 2000, LANCET, V355, P442, DOI 10.1016/S0140-6736(00)82010-3; Colwell RR, 1996, SCIENCE, V274, P2025, DOI 10.1126/science.274.5295.2025; Cummings DAT, 2004, NATURE, V427, P344, DOI 10.1038/nature02225; Curriero FC, 2002, AM J EPIDEMIOL, V155, P80, DOI 10.1093/aje/155.1.80; Ebi KL, 2004, B AM METEOROL SOC, V85, P1067, DOI 10.1175/BAMS-85-8-1067; Frumkin H, 2002, PUBLIC HEALTH REP, V117, P201, DOI 10.1016/S0033-3549(04)50155-3; Githeko A.K., 2001, GLOB CHANGE HUM HLTH, V2, P54, DOI [10.1023/A:1011943131643, DOI 10.1023/A:1011943131643]; Glass GE, 2002, P NATL ACAD SCI USA, V99, P16817, DOI 10.1073/pnas.252617999; Glass GE, 2000, EMERG INFECT DIS, V6, P238, DOI 10.3201/eid0603.000303; Gouveia N, 2003, INT J EPIDEMIOL, V32, P390, DOI 10.1093/ije/dyg077; Gubler DJ, 2001, ENVIRON HEALTH PERSP, V109, P223, DOI 10.2307/3435012; Hajat S, 2002, J EPIDEMIOL COMMUN H, V56, P367, DOI 10.1136/jech.56.5.367; Hales S, 2002, LANCET, V360, P830, DOI 10.1016/S0140-6736(02)09964-6; Hay SI, 2002, NATURE, V415, P905, DOI 10.1038/415905a; Hay SI, 2005, TRENDS PARASITOL, V21, P52, DOI 10.1016/j.pt.2004.11.007; Hayhoe K, 2004, P NATL ACAD SCI USA, V101, P12422, DOI 10.1073/pnas.0404500101; Hogrefe C, 2004, J GEOPHYS RES, V109, P2627; Hopp MJ, 2003, CLIM RES, V25, P85, DOI 10.3354/cr025085; Houghton J. T., 2001, CLIM CHANG 2001 SCI, P1; *INT FED RED CROSS, 2004, WORLD DIS REP 2004, pCH2; *INT PAN CLIM CHAN, 2001, 11000 INT PAN CLIM C; Kalnay E, 2003, NATURE, V423, P528, DOI 10.1038/nature01675; Knowlton K, 2004, ENVIRON HEALTH PERSP, V112, P1557, DOI 10.1289/ehp.7163; Koelle K, 2005, NATURE, V436, P696, DOI 10.1038/nature03820; KOSATSKY T, 2005, EURO SURVEILL, V10; Kovats RS, 2004, EPIDEMIOL INFECT, V132, P443, DOI 10.1017/S0950268804001992; Kovats RS, 2001, PHILOS T R SOC B, V356, P1057, DOI 10.1098/rstb.2001.0894; Kuhn KG, 2003, P NATL ACAD SCI USA, V100, P9997, DOI 10.1073/pnas.1233687100; Lindblade KA, 2000, TROP MED INT HEALTH, V5, P263, DOI 10.1046/j.1365-3156.2000.00551.x; Lindblade KA, 1999, T ROY SOC TROP MED H, V93, P480, DOI 10.1016/S0035-9203(99)90344-9; Linthicum KJ, 1999, SCIENCE, V285, P397, DOI 10.1126/science.285.5426.397; Luterbacher J, 2004, SCIENCE, V303, P1499, DOI 10.1126/science.1093877; Martens WJM, 1998, ENVIRON HEALTH PERSP, V106, P241, DOI 10.2307/3433924; McMichael A., 2004, COMP QUANTIFICATION, V2, P1543; McMichael A.J., 2003, HUMAN HLTH CLIMATE C; McMichael AJ, 2001, P NUTR SOC, V60, P195, DOI 10.1079/PNS200090; Meehl GA, 2005, B AM METEOROL SOC, V86, P89, DOI 10.1175/BAMS-86-1-89; Meehl GA, 2004, SCIENCE, V305, P994, DOI 10.1126/science.1098704; Michelozzi P, 2004, JAMA-J AM MED ASSOC, V291, P2537; MICMICHAEL AJ, 1996, CLIMATE CHANGE HUMAN; Mouchet J, 1998, B SOC PATHOL EXOT, V91, P64; Mouchet J, 1998, J AM MOSQUITO CONTR, V14, P121; Parmenter RR, 1999, AM J TROP MED HYG, V61, P814, DOI 10.4269/ajtmh.1999.61.814; Parry ML, 2004, GLOBAL ENVIRON CHANG, V14, P53, DOI 10.1016/j.gloenvcha.2003.10.008; Pascual M, 2000, SCIENCE, V289, P1766, DOI 10.1126/science.289.5485.1766; Patz JA, 1996, JAMA-J AM MED ASSOC, V275, P217, DOI 10.1001/jama.275.3.217; PATZ JA, 2004, HEAT ADVISORY CLIMAT; Poveda G, 2001, ENVIRON HEALTH PERSP, V109, P489, DOI 10.2307/3454707; Purse BV, 2005, NAT REV MICROBIOL, V3, P171, DOI 10.1038/nrmicro1090; Reiter P, 2004, LANCET INFECT DIS, V4, P323, DOI 10.1016/S1473-3099(04)01038-2; Rodo X, 2002, P NATL ACAD SCI USA, V99, P12901, DOI 10.1073/pnas.182203999; Rogers DJ, 2000, SCIENCE, V289, P1763, DOI 10.1126/science.289.5485.1763; Ropelewski C. F., 1987, MONTHLY WEATHER REV, V111, P517; Schar C, 2004, NATURE, V427, P332, DOI 10.1038/nature02300; Shanks GD, 2002, EMERG INFECT DIS, V8, P1404, DOI 10.3201/eid0812.020077; Sheridan S. C., 1998, WORLD RESOURCE REV, V10, P375; Sheridan SC, 2004, B AM METEOROL SOC, V85, P1931, DOI 10.1175/BAMS-85-12-1931; Stott PA, 2004, NATURE, V432, P610, DOI 10.1038/nature03089; Tan JG, 2004, INT J BIOMETEOROL, V48, P157, DOI 10.1007/s00484-003-0193-z; Tanser FC, 2003, LANCET, V362, P1792, DOI 10.1016/S0140-6736(03)14898-2; Thomson MC, 2005, AM J TROP MED HYG, V73, P214, DOI 10.4269/ajtmh.2005.73.214; Tong SL, 2004, TROP MED INT HEALTH, V9, P298, DOI 10.1046/j.1365-3156.2003.01175.x; TULU AN, 1996, THESIS U LONDON; Weisskopf MG, 2002, AM J PUBLIC HEALTH, V92, P830, DOI 10.2105/AJPH.92.5.830; Woodruff R, 2003, EPIDEMIOLOGY, V14, pS94, DOI 10.1097/00001648-200309001-00223; World Health Organization (WHO), 2013, WORLD HLTH REPORT 20; Zhou LM, 2004, P NATL ACAD SCI USA, V101, P9540, DOI 10.1073/pnas.0400357101	75	1747	1840	81	1575	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					310	317		10.1038/nature04188	http://dx.doi.org/10.1038/nature04188			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292302				2022-12-28	WOS:000233300200039
J	Tsukuda, T; Fleming, AB; Nickoloff, JA; Osley, MA				Tsukuda, T; Fleming, AB; Nickoloff, JA; Osley, MA			Chromatin remodelling at a DNA double-strand break site in Saccharomyces cerevisiae	NATURE			English	Article							IN-VIVO; DAMAGE RESPONSE; HISTONE H2A; REPAIR; COMPLEX; PROTEINS; PHOSPHORYLATION; RECOMBINATION; RPA; RECRUITMENT	The repair of DNA double-strand breaks (DSBs) is crucial for maintaining genome stability. Eukaryotic cells repair DSBs by both non-homologous end joining and homologous recombination. How chromatin structure is altered in response to DSBs and how such alterations influence DSB repair processes are important issues. In vertebrates, phosphorylation of the histone variant H2A.X occurs rapidly after DSB formation(1), spreads over mega-base chromatin domains, and is required for stable accumulation of repair proteins at damage foci(2). In Saccharomyces cerevisiae, phosphorylation of the two principal H2A species is also signalled by DSB formation, which spreads similar to 40 kb in either direction from the DSB3. Here we show that near a DSB phosphorylation of H2A is followed by loss of histones H2B and H3 and increased sensitivity of chromatin to digestion by micrococcal nuclease; however, phosphorylation of H2A and nucleosome loss occur independently. The DNA damage sensor MRX4 is required for histone loss, which also depends on INO80, a nucleosome remodelling complex(5). The repair protein Rad51 (ref. 6) shows delayed recruitment to DSBs in the absence of histone loss, suggesting that MRX-dependent nucleosome remodelling regulates the accessibility of factors directly involved in DNA repair by homologous recombination. Thus, MRX may regulate two pathways of chromatin changes: nucleosome displacement for efficient recruitment of homologous recombination proteins; and phosphorylation of H2A, which modulates checkpoint responses to DNA damage(2).	Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, Albuquerque, NM 87131 USA	University of New Mexico	Osley, MA (corresponding author), Univ New Mexico, Sch Med, Dept Mol Genet & Microbiol, 915 Camino de Salud, Albuquerque, NM 87131 USA.	mosley@salud.unm.edu		Fleming, Alastair/0000-0003-0083-3240	NIGMS NIH HHS [R01 GM040118] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM040118] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARKADY C, 2003, NATURE CELL BIOL, V5, P675; Chai B, 2005, GENE DEV, V19, P1656, DOI 10.1101/gad.1273105; Downs JA, 2004, MOL CELL, V16, P979, DOI 10.1016/j.molcel.2004.12.003; Downs JA, 2000, NATURE, V408, P1001, DOI 10.1038/35050000; Fleming AB, 2001, EMBO J, V20, P5219, DOI 10.1093/emboj/20.18.5219; Frank-Vaillant M, 2002, MOL CELL, V10, P1189, DOI 10.1016/S1097-2765(02)00705-0; Kantake N, 2003, J BIOL CHEM, V278, P23410, DOI 10.1074/jbc.M302995200; Kristjuhan A, 2004, EMBO J, V23, P4243, DOI 10.1038/sj.emboj.7600433; Kuo MH, 1999, METHODS, V19, P425, DOI 10.1006/meth.1999.0879; Lee SE, 1998, CELL, V94, P399, DOI 10.1016/S0092-8674(00)81482-8; LICHTEN W, 1988, DATA ERROR ANAL INTR; Lisby M, 2004, CELL, V118, P699, DOI 10.1016/j.cell.2004.08.015; Miyazaki T, 2004, EMBO J, V23, P939, DOI 10.1038/sj.emboj.7600091; Mizuguchi G, 2004, SCIENCE, V303, P343, DOI 10.1126/science.1090701; Morrison AJ, 2004, CELL, V119, P767, DOI 10.1016/j.cell.2004.11.037; Nakamura TM, 2004, MOL CELL BIOL, V24, P6215, DOI 10.1128/MCB.24.14.6215-6230.2004; PALTER KB, 1979, CELL, V18, P451, DOI 10.1016/0092-8674(79)90064-3; Reinke H, 2003, MOL CELL, V11, P1599, DOI 10.1016/S1097-2765(03)00186-2; Rogakou EP, 1998, J BIOL CHEM, V273, P5858, DOI 10.1074/jbc.273.10.5858; Schwabish MA, 2004, MOL CELL BIOL, V24, P10111, DOI 10.1128/MCB.24.23.10111-10117.2004; Shen XT, 2000, NATURE, V406, P541, DOI 10.1038/35020123; Shen XT, 2003, MOL CELL, V12, P147, DOI 10.1016/S1097-2765(03)00264-8; Shroff R, 2004, CURR BIOL, V14, P1703, DOI 10.1016/j.cub.2004.09.047; Sugawara N, 2003, MOL CELL, V12, P209, DOI 10.1016/S1097-2765(03)00269-7; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Usui T, 2001, MOL CELL, V7, P1255, DOI 10.1016/S1097-2765(01)00270-2; Uziel T, 2003, EMBO J, V22, P5612, DOI 10.1093/emboj/cdg541; van Attikum H, 2004, CELL, V119, P777, DOI 10.1016/j.cell.2004.11.033; Wang X, 2004, PLOS BIOL, V2, P104, DOI 10.1371/journal.pbio.0020021; Weiss K, 1998, MOL CELL BIOL, V18, P5392, DOI 10.1128/MCB.18.9.5392	30	340	346	2	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					379	383		10.1038/nature04148	http://dx.doi.org/10.1038/nature04148			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292314	Green Accepted			2022-12-28	WOS:000233300200053
J	Alexander, JH; Hafley, G; Harrington, R; Peterson, ED; Ferguson, TB; Lorenz, TJ; Goyal, A; Gibson, M; Mack, MJ; Gennevois, D; Califf, RM; Kouchoukos, NT				Alexander, JH; Hafley, G; Harrington, R; Peterson, ED; Ferguson, TB; Lorenz, TJ; Goyal, A; Gibson, M; Mack, MJ; Gennevois, D; Califf, RM; Kouchoukos, NT		PREVENT IV Investigators	Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery - PREVENT IV: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INTERNAL MAMMARY ARTERY; SAPHENOUS-VEIN; SURGICAL THERAPY; GENE-THERAPY; SURVIVAL; DISEASE; PATENCY; TRANSFECTION; PATHOGENESIS; REOPERATION	Context Coronary artery bypass graft (CABG) surgery with autologous vein grafting is commonly performed. Progressive neointimal hyperplasia, however, contributes to considerable vein graft failure. Edifoligicle is an oligonucleotide decoy that binds to and inhibits E2F transcription factors and thus may prevent neointimal hyperplasia and vein graft failure. Objective To assess the efficacy and safety of pretreating vein grafts with edifoligide for patients undergoing CABG surgery. Design, Setting, and Participants A phase 3 randomized, double-blind, placebo-controlled trial of 3014 patients undergoing primary CABG surgery with at least 2 planned saphenous vein grafts and without concomitant valve surgery, who were enrolled between August 2002 and October 2003 at 107 US sites. Intervention Vein grafts were treated ex vivo with either eclifoligide or placebo in a pressure-mediated delivery system. The first 2400 patients enrolled were scheduled for 12- to 18-month follow-up angiography. Main Outcome Measures The primary efficacy end point was angiographic vein graft failure (>= 75% vein graft stenosis) occurring 12 to 18 months after CABG surgery. Other end points included other angiographic variables, adverse events through 30 days, and major adverse cardiac events. Results A total of 1920 patients (80%) either died (n=91) or underwent follow-up angiography (n=1829). Edifoligide had no effect on the primary end point of per patient vein graft failure (436 [45.2%] of 965 patients in the edifoligide group vs 442 [46.3%] of 955 patients in the placebo group; odds ratio, 0.96 [95% confidence interval {CI}, 0.80-1.14]; P=.66), on any secondary angiographic end point, or on the incidence of major adverse cardiac events at 1 year (101 [6.7%] of 1508 patients in the edifoligide group vs 121 [8.1%] of 1506 patients in the placebo group; hazard ratio, 0.83 [95% Cl, 0.64-1.08]; P=.16). Conclusions Failure of at least 1 vein graft is quite common within 12 to 18 months after CABG surgery. Edifoligicle is no more effective than placebo in preventing these events. Longer-term follow-up and additional research are needed to determine whether edifoligide has delayed beneficial effects; to understand the mechanisms and clinical consequences of vein graft failure, and to improve the durability of CABG surgery. Clinical Trial Registration ClinicalTrials.gov Identifier: NCT00042081.	Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27715 USA; Louisiana State Univ, New Orleans, LA USA; Corgentech Inc, San Francisco, CA USA; PERFUSE Angiog Core Lab, Boston, MA USA; Cardiopulm Res Sci & Technol Inst, Dallas, TX USA; Missouri Baptist Med Ctr, St Louis, MO USA	Duke University; Louisiana State University System	Alexander, JH (corresponding author), Duke Univ, Med Ctr, Duke Clin Res Inst, Box 3300, Durham, NC 27715 USA.	john.h.alexander@duke.edu	Alexander, John/GVS-7271-2022; Peterson, Eric David/ABF-5033-2021; Goyal, Abhinav/J-5086-2012	Goyal, Abhinav/0000-0002-6286-2349; Alexander, John/0000-0002-1444-2462				Alderman EL, 2000, J AM COLL CARDIOL, V35, P1122; Alexander JH, 2005, AM HEART J, V150, P643, DOI 10.1016/j.ahj.2005.05.021; *AM HEART ASS, 2003, HEART STROK FACTS; Braun-Dullaeus RC, 1998, CIRCULATION, V98, P82, DOI 10.1161/01.CIR.98.1.82; CALIFF RM, 1989, JAMA-J AM MED ASSOC, V261, P2077, DOI 10.1001/jama.261.14.2077; CAMERON A, 1988, CIRCULATION, V78, P158; Campeau L, 1997, NEW ENGL J MED, V336, P153; CHEN SJ, 1994, CIRCULATION, V89, P1922, DOI 10.1161/01.CIR.89.5.1922; *CORG INC BRIST MY, 2004, CORG BRIST MYERS SQU; COX DR, 1972, J R STAT SOC B, V34, P187; COX JL, 1991, PROG CARDIOVASC DIS, V34, P45, DOI 10.1016/0033-0620(91)90019-I; Dahmen G, 2004, BIOMETRICAL J, V46, P214, DOI 10.1002/bimj.200310018; Desai ND, 2004, NEW ENGL J MED, V351, P2302, DOI 10.1056/NEJMoa040982; EAGLE KA, 2004, ACC AHA GUIDELINE UP; Ehsan A, 2001, J THORAC CARDIOV SUR, V121, P714, DOI 10.1067/mtc.2001.111204; Ferguson TB, 2002, ANN THORAC SURG, V73, P480, DOI 10.1016/S0003-4975(01)03339-2; FITZGIBBON GM, 1986, J THORAC CARDIOV SUR, V91, P773; FitzGibbon GM, 1996, J AM COLL CARDIOL, V28, P616, DOI 10.1016/0735-1097(96)00206-9; Fleiss J. L., 1981, STAT METHODS RATES P, V2; GIBSON M, 1992, AM J CARDIOL, V69, P1286, DOI 10.1016/0002-9149(92)91222-P; GOLDMAN S, 1989, CIRCULATION, V80, P1190, DOI 10.1161/01.CIR.80.5.1190; Goldman S, 2004, J AM COLL CARDIOL, V44, P2149, DOI 10.1016/j.jacc.2004.08.064; GRONDIN CM, 1984, CIRCULATION, V70, P208; GRONDIN CM, 1989, CIRCULATION, V79, P24; GRUBE E, 2001, AM HEART ASS SCI SES; HALABI A, IN PRESS AM J CARDIO; Jones RH, 1996, J THORAC CARDIOV SUR, V111, P1013, DOI 10.1016/S0022-5223(96)70378-1; Kalbfleisch D., 1980, STAT ANAL FAILURE TI; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Knatterud GL, 2000, CIRCULATION, V102, P157, DOI 10.1161/01.CIR.102.2.157; LEFKOVITS J, 1995, CIRCULATION, V92, P734, DOI 10.1161/01.CIR.92.4.734; Maiti B, 2005, J BIOL CHEM, V280, P18211, DOI 10.1074/jbc.M501410200; Mann MJ, 2000, J CLIN INVEST, V106, P1071, DOI 10.1172/JCI11459; Mann MJ, 1999, LANCET, V354, P1493, DOI 10.1016/S0140-6736(99)09405-2; Mann MJ, 2004, BIODRUGS, V18, P1, DOI 10.2165/00063030-200418010-00001; Mann MJ, 1999, P NATL ACAD SCI USA, V96, P6411, DOI 10.1073/pnas.96.11.6411; MANN MJ, 1995, P NATL ACAD SCI USA, V92, P4502, DOI 10.1073/pnas.92.10.4502; MORISHITA R, 1995, P NATL ACAD SCI USA, V92, P5855, DOI 10.1073/pnas.92.13.5855; Motwani JG, 1998, CIRCULATION, V97, P916, DOI 10.1161/01.CIR.97.9.916; MUHLBAIER LH, 1992, CIRCULATION, V86, P198; Satava RM, 2003, SURG ENDOSC, V17, P1833, DOI 10.1007/s00464-003-8168-z; Savage MP, 1997, NEW ENGL J MED, V337, P740, DOI 10.1056/NEJM199709113371103; Stokes ME, 2000, CATEGORICAL DATA ANA; VANDERMEER J, 1993, LANCET, V342, P257, DOI 10.1016/0140-6736(93)91815-4; Widimsky P, 2004, CIRCULATION, V110, P3418, DOI 10.1161/01.CIR.0000148139.79580.36; YUSUF S, 1994, LANCET, V344, P563, DOI 10.1016/S0140-6736(94)91963-1; ZWOLAK RM, 1987, J VASC SURG, V5, P126, DOI 10.1067/mva.1987.avs0050126; 1999, APPROVAL BASED SURRO	48	497	533	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2446	2454						9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287955				2022-12-28	WOS:000233277400023
J	Evans, DB; Edejer, TTT; Adam, T; Lim, SS				Evans, DB; Edejer, TTT; Adam, T; Lim, SS		WHO CHOICE Millennium Dev Goals Te	Achieving the millennium development goals for health - Methods to assess the costs and health effects of interventions for improving health in developing countries	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material							SENSITIVITY-ANALYSIS; STRATEGIES; DISEASE		WHO, CH-1211 Geneva, Switzerland; Univ Queensland, St Lucia, Qld 4067, Australia	World Health Organization; University of Queensland	Evans, DB (corresponding author), WHO, CH-1211 Geneva, Switzerland.	evansd@who.int	Salomon, Joshua A/D-3898-2009; Lim, Stephen S/B-4055-2012	Salomon, Joshua A/0000-0003-3929-5515; Edejer, Tessa/0000-0003-1068-332X				Adam T, 2005, BMJ-BRIT MED J, V331, P1107, DOI 10.1136/bmj.331.7525.1107; Adam Taghreed, 2003, Cost Eff Resour Alloc, V1, P3, DOI 10.1186/1478-7547-1-3; [Anonymous], 2001, MACR HLTH INV HLTH E; [Anonymous], 2022, BMJ, V378, DOI [DOI 10.1136/BMJ.38643.368692.68, 10.1136/bmj-2021-068384, DOI 10.1136/BMJ.O2284]; BALTUSSEN R, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38645.660093.68; BALTUSSEN R, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38643.368692.68; Briggs AH, 2002, MED DECIS MAKING, V22, P290, DOI 10.1177/027298902400448867; Claxton K, 2005, HEALTH ECON, V14, P339, DOI 10.1002/hec.985; Devarajan S., 2002, PROSPECTS COSTS APRI; EDEJER TTT, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38652.550278.7C; Evans DB, 2005, BMJ-BRIT MED J, V331, P1133, DOI 10.1136/bmj.331.7525.1133; Gold MR, 1996, COST EFFECTIVENESS H; Gutierrez JP, 2004, LANCET, V364, P63, DOI 10.1016/S0140-6736(04)16590-2; JAMISON DT, 1991, AM J PUBLIC HEALTH, V81, P15, DOI 10.2105/AJPH.81.1.15; Johns B, 2004, HEALTH ECON, V13, P1117, DOI 10.1002/hec.880; JOHNS B, 2005, ENHANCING COMP COSTI; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Lauer Jeremy A, 2003, Cost Eff Resour Alloc, V1, P6, DOI 10.1186/1478-7547-1-6; MOREL C, 2005, BMJ             1110, DOI DOI 10.1136/BMJ.38639.702384.AE; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P495; MURRAY CJL, 2000, GLOBAL BURDEN DIS 20; Olsen JA, 1999, SOC SCI MED, V49, P17, DOI 10.1016/S0277-9536(99)00116-1; TENGS TO, 1995, RISK ANAL, V15, P369, DOI 10.1111/j.1539-6924.1995.tb00330.x; UN Millennium Project, 2005, INV DEV PRACT PLAN A; WHO UNICEF UNFPA, 2003, PREGN CHILDB POSTP N; WHO United Nations Population Fund Unicef World Bank, 2003, MAN COMPL PREGN CHIL; World Health Organisation, 2003, MAK CHOIC HLTH WHO G; World Health Organization, 2002, ANT CAR RAND TRIAL M; World Health Organization, 2005, WORLD HLTH REP 2005; World Health Organization, 2003, MAN NEWB PROBL GUID	30	96	97	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1137	1140		10.1136/bmj.331.7525.1137	http://dx.doi.org/10.1136/bmj.331.7525.1137			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	985ZI	16282411	Green Published			2022-12-28	WOS:000233417300022
J	Urbancic-Rovan, V				Urbancic-Rovan, V			Causes of diabetic foot lesions	LANCET			English	Editorial Material							MELLITUS; RISK; COMPLICATIONS; ULCERS		Univ Med Ctr, Dept Endocrinol Diabet & Metab Dis, Ljubljana 1525, Slovenia	University Medical Centre Ljubljana	Urbancic-Rovan, V (corresponding author), Univ Med Ctr, Dept Endocrinol Diabet & Metab Dis, Ljubljana 1525, Slovenia.	vilma.urbancic@kclj.si						Armstrong DG, 2004, DIABETES CARE, V27, P1980, DOI 10.2337/diacare.27.8.1980; Boyko EJ, 1999, DIABETES CARE, V22, P1036, DOI 10.2337/diacare.22.7.1036; BRAND FN, 1989, DIABETES, V38, P504, DOI 10.2337/diabetes.38.4.504; Chantelau E, 2002, GERONTOLOGY, V48, P241, DOI 10.1159/000058357; Eldor R, 2004, DIABETIC MED, V21, P1161, DOI 10.1111/j.1464-5491.2004.01358.x; Engel S, 2003, NEW ENGL J MED, V348, P2294; Grundy SM, 1999, CIRCULATION, V100, P1134, DOI 10.1161/01.CIR.100.10.1134; LeMaster JW, 2003, MED SCI SPORT EXER, V35, P1093, DOI 10.1249/01.MSS.0000074459.41029.75; Lipsky BA, 2004, DIABETES-METAB RES, V20, pS56, DOI 10.1002/dmrr.441; Lipsky BA, 2004, DIABETES-METAB RES, V20, pS68, DOI 10.1002/dmrr.453; MOSS SE, 1992, ARCH INTERN MED, V152, P610, DOI 10.1001/archinte.152.3.610; Pataky Z, 2002, DIABETES METAB, V28, P356; Peters EJG, 2005, J DIABETES COMPLICAT, V19, P107, DOI 10.1016/j.jdiacomp.2004.06.002; SANDERS LJ, 2004, DIABETES-METAB RES S, V20, P54; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; ULTRECHT JS, 2004, CLIN INFECT DIS   S2, V39, pS73	17	22	23	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 12	2005	366	9498					1675	1676		10.1016/S0140-6736(05)67673-8	http://dx.doi.org/10.1016/S0140-6736(05)67673-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291046				2022-12-28	WOS:000233206400004
J	Zhang, YB; Tan, YW; Stormer, HL; Kim, P				Zhang, YB; Tan, YW; Stormer, HL; Kim, P			Experimental observation of the quantum Hall effect and Berry's phase in graphene	NATURE			English	Article							CARBON NANOTUBES; GRAPHITE	When electrons are confined in two-dimensional materials, quantum-mechanically enhanced transport phenomena such as the quantum Hall effect can be observed. Graphene, consisting of an isolated single atomic layer of graphite, is an ideal realization of such a two-dimensional system. However, its behaviour is expected to differ markedly from the well-studied case of quantum wells in conventional semiconductor interfaces. This difference arises from the unique electronic properties of graphene, which exhibits electron - hole degeneracy and vanishing carrier mass near the point of charge neutrality(1,2). Indeed, a distinctive half-integer quantum Hall effect has been predicted(3-5) theoretically, as has the existence of a non-zero Berry's phase ( a geometric quantum phase) of the electron wavefunction - a consequence of the exceptional topology of the graphene band structure(6,7). Recent advances in micromechanical extraction and fabrication techniques for graphite structures(8-12) now permit such exotic two-dimensional electron systems to be probed experimentally. Here we report an experimental investigation of magneto-transport in a high-mobility single layer of graphene. Adjusting the chemical potential with the use of the electric field effect, we observe an unusual half-integer quantum Hall effect for both electron and hole carriers in graphene. The relevance of Berry's phase to these experiments is confirmed by magneto-oscillations. In addition to their purely scientific interest, these unusual quantum transport phenomena may lead to new applications in carbon-based electronic and magneto-electronic devices.	Columbia Univ, Dept Phys, New York, NY 10027 USA; Columbia Univ, Dept Appl Phys & Appl Math, New York, NY 10027 USA	Columbia University; Columbia University	Kim, P (corresponding author), Columbia Univ, Dept Phys, 538 W 120th St, New York, NY 10027 USA.	pkim@phys.columbia.edu	Li, jiayu/H-3827-2014; Tan, Yan-Wen/GQZ-0713-2022; Kim, Philip/N-1886-2013	Li, jiayu/0000-0003-2639-213X; Tan, Yan-Wen/0000-0002-5522-7996; Kim, Philip/0000-0002-8255-0086				Ando T, 1998, J PHYS SOC JPN, V67, P2857, DOI 10.1143/JPSJ.67.2857; Berger C, 2004, J PHYS CHEM B, V108, P19912, DOI 10.1021/jp040650f; Bunch JS, 2005, NANO LETT, V5, P287, DOI 10.1021/nl048111+; Fang Z, 2003, SCIENCE, V302, P92, DOI 10.1126/science.1089408; Gusynin VP, 2005, UNCONVENTIONAL INTEG; HALDANE FDM, 1988, PHYS REV LETT, V61, P2015, DOI 10.1103/PhysRevLett.61.2015; KANE CL, 2005, QUANTUM SPIN HALL EF; Luk'yanchuk IA, 2004, PHYS REV LETT, V93, DOI 10.1103/PhysRevLett.93.166402; McEuen PL, 1999, PHYS REV LETT, V83, P5098, DOI 10.1103/PhysRevLett.83.5098; Mikitik GP, 1999, PHYS REV LETT, V82, P2147, DOI 10.1103/PhysRevLett.82.2147; MOROZOV SV, 2005, 2 DIMENSIONAL ELECT; Novoselov KS, 2004, SCIENCE, V306, P666, DOI 10.1126/science.1102896; Peres NMR, 2005, ELECT PROPERTIES 2 D; ROUKES ML, 1990, PHYS REV LETT, V64, P1154, DOI 10.1103/PhysRevLett.64.1154; SEMENOFF GW, 1984, PHYS REV LETT, V53, P2449, DOI 10.1103/PhysRevLett.53.2449; Sharapov SG, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.075104; Shoenberg D., 1984, MAGNETIC OSCILLATION; Zhang YB, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.176803; Zhang YB, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1862334; Zheng YS, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.245420	20	11089	11413	143	5365	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					201	204		10.1038/nature04235	http://dx.doi.org/10.1038/nature04235			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281031	Green Submitted			2022-12-28	WOS:000233133500043
J	Holz, MK; Ballif, BA; Gygi, SP; Blenis, J				Holz, MK; Ballif, BA; Gygi, SP; Blenis, J			mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events	CELL			English	Article							MESSENGER-RNA TRANSLATION; INITIATION-FACTOR 4B; CELL-GROWTH; EUKARYOTIC TRANSLATION; MAMMALIAN TARGET; HELICASE ACTIVITY; TOS MOTIF; IN-VITRO; RAPAMYCIN; KINASE	In response to nutrients, energy sufficiency, hormones, and mitogenic agents, S6K1 phosphorylates several targets linked to translation. However, the molecular mechanisms whereby S6K1 is activated, encounters substrate, and contributes to translation initiation are poorly understood. We show that mTOR and S6K1 maneuver on and off the eukaryotic initiation factor 3 (eIF3) translation initiation complex in a signal-dependent, choreographed fashion. When inactive, S6K1 associates with the eIF3 complex, while the S6K1 activator mTOR/raptor does not. Cell stimulation promotes mTOR/raptor binding to the eIF3 complex and phosphorylation of S6K1 at its hydrophobic motif. Phosphorylation results in S6K1 dissociation, activation, and subsequent phosphorylation of its translational targets, including eIF4B, which is then recruited into the complex in a phosphorylation-dependent manner. Thus, the eIF3 preinitiation complex acts as a scaffold to coordinate a dynamic sequence of events in response to stimuli that promote efficient protein synthesis.	Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Program Biol & Biomed Sci, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	Blenis, J (corresponding author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.	jblenis@hms.harvard.edu			NATIONAL CANCER INSTITUTE [R37CA046595, R01CA046595] Funding Source: NIH RePORTER; NCI NIH HHS [CA046595] Funding Source: Medline; NHGRI NIH HHS [HG00041] Funding Source: Medline; NIGMS NIH HHS [GM051405] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Alessi DR, 1998, CURR BIOL, V8, P69, DOI 10.1016/S0960-9822(98)70037-5; Ballif BA, 2004, CURR BIOL, V14, P606, DOI 10.1016/j.cub.2004.03.038; Bjornsti MA, 2004, CANCER CELL, V5, P519, DOI 10.1016/j.ccr.2004.05.027; Bordeleau ME, 2005, P NATL ACAD SCI USA, V102, P10460, DOI 10.1073/pnas.0504249102; Brunn GJ, 1997, J BIOL CHEM, V272, P32547, DOI 10.1074/jbc.272.51.32547; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; Fingar DC, 2004, ONCOGENE, V23, P3151, DOI 10.1038/sj.onc.1207542; Frodin M, 2002, EMBO J, V21, P5396, DOI 10.1093/emboj/cdf551; Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201; Hay N, 2004, GENE DEV, V18, P1926, DOI 10.1101/gad.1212704; Inoki K, 2005, MICROBIOL MOL BIOL R, V69, P79, DOI 10.1128/MMBR.69.1.79-100.2005; Jefferies HBJ, 1997, EMBO J, V16, P3693, DOI 10.1093/emboj/16.12.3693; Kelleher RJ, 2004, NEURON, V44, P59, DOI 10.1016/j.neuron.2004.09.013; Kim DH, 2002, CELL, V110, P163, DOI 10.1016/S0092-8674(02)00808-5; Kruger M, 2001, MOL CELL BIOL, V21, P8357, DOI 10.1128/MCB.21.24.8357-8364.2001; LAWSON TG, 1988, J BIOL CHEM, V263, P7266; Martin KA, 2002, ADV CANCER RES, V86, P1, DOI 10.1016/S0065-230X(02)86001-8; Martin KA, 2001, J BIOL CHEM, V276, P7892, DOI 10.1074/jbc.M009972200; Mayeur GL, 2003, EUR J BIOCHEM, V270, P4133, DOI 10.1046/j.1432-1033.2003.03807.x; Methot N, 1996, RNA, V2, P38; Miyamoto S, 2005, J BIOL CHEM, V280, P28251, DOI 10.1074/jbc.M414129200; Nilsson J, 2004, EMBO REP, V5, P1137, DOI 10.1038/sj.embor.7400291; Nojima H, 2003, J BIOL CHEM, V278, P15461, DOI 10.1074/jbc.C200665200; Pende M, 2004, MOL CELL BIOL, V24, P3112, DOI 10.1128/MCB.24.8.3112-3124.2004; Rajasekhar VK, 2004, ONCOGENE, V23, P3248, DOI 10.1038/sj.onc.1207546; Raught B, 2004, EMBO J, V23, P1761, DOI 10.1038/sj.emboj.7600193; Richardson CJ, 2004, SEMIN CELL DEV BIOL, V15, P147, DOI 10.1016/j.semcdb.2003.12.023; Rogers GW, 1999, J BIOL CHEM, V274, P12236, DOI 10.1074/jbc.274.18.12236; Rogers GW, 2001, J BIOL CHEM, V276, P30914, DOI 10.1074/jbc.M100157200; Romanelli A, 1999, MOL CELL BIOL, V19, P2921; Romanelli A, 2002, J BIOL CHEM, V277, P40281, DOI 10.1074/jbc.M205168200; Schaim SS, 2003, CURR BIOL, V13, P797, DOI 10.1016/S0960-9822(03)00329-4; Schalm SS, 2005, J BIOL CHEM, V280, P11101, DOI 10.1074/jbc.M413995200; Schalm SS, 2002, CURR BIOL, V12, P632, DOI 10.1016/S0960-9822(02)00762-5; Schmelzle T, 2000, CELL, V103, P253, DOI 10.1016/S0092-8674(00)00117-3; Tang H, 2001, MOL CELL BIOL, V21, P8671, DOI 10.1128/MCB.21.24.8671-8683.2001; Tee AR, 2005, SEMIN CELL DEV BIOL, V16, P29, DOI 10.1016/j.semcdb.2004.11.005; Wang XM, 2001, EMBO J, V20, P4370, DOI 10.1093/emboj/20.16.4370	38	850	882	1	53	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 8	2005	123	4					569	580		10.1016/j.cell.2005.10.024	http://dx.doi.org/10.1016/j.cell.2005.10.024			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286006	Bronze			2022-12-28	WOS:000233497400007
J	Baker, SP; Grant, PA				Baker, SP; Grant, PA			The proteasome: Not just degrading anymore	CELL			English	Editorial Material							HISTONE H2B; UBIQUITYLATION; TRANSCRIPTION; METHYLATION; COMPLEX	The proteasome is a large multiprotein complex that has a critical role in the degradation of ubiquitylated proteins. A fascinating paper in this issue of Cell (Lee et al., 2005) now reveals that the proteasome recruits the SAGA histone acetyltransferase complex to a target promoter during gene activation. This finding adds to the growing body of evidence indicating that the proteasome has nonproteolytic functions.	Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA	University of Virginia	Baker, SP (corresponding author), Univ Virginia, Sch Med, Dept Biochem & Mol Genet, Charlottesville, VA 22908 USA.							Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Gillette TG, 2004, P NATL ACAD SCI USA, V101, P5904, DOI 10.1073/pnas.0305411101; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Kinyamu HK, 2005, J MOL ENDOCRINOL, V34, P281, DOI 10.1677/jme.1.01680; Lee DY, 2005, CELL, V123, P423, DOI 10.1016/j.cell.2005.08.015; Muratani M, 2003, NAT REV MOL CELL BIO, V4, P192, DOI 10.1038/nrm1049; Muratani M, 2005, CELL, V120, P887, DOI 10.1016/j.cell.2004.12.025; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Russell SJ, 1999, MOL CELL, V3, P687, DOI 10.1016/S1097-2765(01)80001-0; Torok MS, 2004, ADV PROTEIN CHEM, V67, P181	11	23	23	0	1	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					361	363		10.1016/j.cell.2005.10.013	http://dx.doi.org/10.1016/j.cell.2005.10.013			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269325	Bronze			2022-12-28	WOS:000233264300002
J	Cess, RD				Cess, RD			Water vapor feedback in climate models	SCIENCE			English	Editorial Material							GENERAL-CIRCULATION MODELS		SUNY Stony Brook, Marine Sci Res Ctr, Inst Terr & Planetary Atmospheres, Stony Brook, NY 11794 USA	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Cess, RD (corresponding author), SUNY Stony Brook, Marine Sci Res Ctr, Inst Terr & Planetary Atmospheres, Stony Brook, NY 11794 USA.	rcess@notes.cc.sunysb.edu	Keyes, Dennis/AAZ-9285-2021					CESS RD, 1989, SCIENCE, V245, P513, DOI 10.1126/science.245.4917.513; Dai A, 2001, J CLIMATE, V14, P485, DOI 10.1175/1520-0442(2001)014<0485:COTTAT>2.0.CO;2; HARRISON EF, 1990, J GEOPHYS RES-ATMOS, V95, P18687, DOI 10.1029/JD095iD11p18687; MANABE S, 1967, J ATMOS SCI, V24, P241, DOI 10.1175/1520-0469(1967)024<0241:TEOTAW>2.0.CO;2; Potter GL, 2004, J GEOPHYS RES-ATMOS, V109, DOI 10.1029/2003JD004018; Soden BJ, 2005, SCIENCE, V310, P841, DOI 10.1126/science.1115602	6	15	17	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 4	2005	310	5749					795	796		10.1126/science.1119258	http://dx.doi.org/10.1126/science.1119258			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	981XR	16272106				2022-12-28	WOS:000233121800028
J	Song, MR; Pfaff, SL				Song, MR; Pfaff, SL			Hox genes: The instructors working at motor pools	CELL			English	Editorial Material							IDENTITY	Motor neurons are assigned unique subidentities preceding their axon navigation. This ensures proper innervation of muscle targets and is accompanied by a stereotypical clustering of motor neuron cell bodies into "motor pools" within the spinal cord. However, the mechanisms that drive motor neuron diversification have been poorly understood. A new study by Dasen et al. (2005) in this issue of Cell shows that a network of Hox genes is responsible for instructing motor pool development.	Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA	Salk Institute	Song, MR (corresponding author), Salk Inst Biol Studies, Gene Express Lab, La Jolla, CA 92037 USA.							Dasen JS, 2003, NATURE, V425, P926, DOI 10.1038/nature02051; Goulding M, 2005, CURR OPIN NEUROBIOL, V15, P14, DOI 10.1016/j.conb.2005.01.017; Haase G, 2002, NEURON, V35, P893, DOI 10.1016/S0896-6273(02)00864-4; Jessell TM, 2000, NAT REV GENET, V1, P20, DOI 10.1038/35049541; Kania A, 2000, CELL, V102, P161, DOI 10.1016/S0092-8674(00)00022-2; Landmesser LT, 2001, INT J DEV NEUROSCI, V19, P175, DOI 10.1016/S0736-5748(00)00090-3; Liu JP, 2001, NEURON, V32, P997, DOI 10.1016/S0896-6273(01)00544-X	7	9	9	0	0	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					363	365		10.1016/j.cell.2005.10.014	http://dx.doi.org/10.1016/j.cell.2005.10.014			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269326	Bronze			2022-12-28	WOS:000233264300003
J	Plaut, M; Valentine, MD				Plaut, M; Valentine, MD			Clinical practice - Allergic rhinitis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PLACEBO-CONTROLLED IMMUNOTHERAPY; GRASS-POLLEN ALLERGOIDS; INTRANASAL CORTICOSTEROIDS; DOUBLE-BLIND; RECEPTOR ANTAGONISTS; BECLOMETHASONE DIPROPIONATE; PERENNIAL RHINITIS; NASAL SPRAY; ASTHMA; EFFICACY	A Baltimore college student has rhinorrhea, sneezing, nasal congestion, and itchy, watery eyes in the spring. He reports having had similar symptoms the previous spring. Over-the-counter allergy pills have failed to help his symptoms and caused dry mouth and somnolence. He wants relief and assurance that he will not be ill, have dry mouth, or feel drowsy during final examinations. On physical examination, his conjunctivae are injected, and his nasal mucous membranes are pale, wet, and boggy. What are your recommendations?	NIAID, Asthma Allergy & Inflmmat Branch, Div Allergy Immunol & Transplantat, NIH, Bethesda, MD 20892 USA; Johns Hopkins Univ, Sch Med, Div Allergy & Immunol, Baltimore, MD USA	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Johns Hopkins University	Plaut, M (corresponding author), NIAID, Asthma Allergy & Inflmmat Branch, Div Allergy Immunol & Transplantat, NIH, 6610 Rockledge Dr,Rm 3093,MSC-6601, Bethesda, MD 20892 USA.	mplaut@niaid.nih.gov						Adelroth E, 2000, J ALLERGY CLIN IMMUN, V106, P253, DOI 10.1067/mai.2000.108310; Allen BM, 1938, BIOL REV CAMB PHILOS, V13, P1, DOI 10.1111/j.1469-185X.1938.tb00505.x; *AM AC ALL ASTHM I, ALL REP; [Anonymous], 2004, SUMMARY HLTH STAT US; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bender BG, 2003, J ALLERGY CLIN IMMUN, V111, P770, DOI 10.1067/mai.2003.1408; BESWICK KBJ, 1985, CURR MED RES OPIN, V9, P560, DOI 10.1185/03007998509109635; Blaiss MS, 2003, ANN ALLERG ASTHMA IM, V90, P16, DOI 10.1016/S1081-1206(10)61655-9; BOUSQUET J, 1989, J ALLERGY CLIN IMMUN, V84, P546, DOI 10.1016/0091-6749(89)90369-2; BOUSQUET J, 1990, J ALLERGY CLIN IMMUN, V85, P490, DOI 10.1016/0091-6749(90)90160-6; Bousquet J, 2003, ALLERGY, V58, P733, DOI 10.1034/j.1398-9995.2003.00076.x; Bousquet J, 2001, J ALLERGY CLIN IMMUN, V108, pS147, DOI 10.1067/mai.2001.118891; BROOKS CD, 1993, J CLIN PHARMACOL, V33, P816, DOI 10.1002/j.1552-4604.1993.tb01957.x; Casale TB, 2003, J ALLERGY CLIN IMMUN, V111, pS835, DOI 10.1067/mai.2003.1550; Casale TB, 2001, JAMA-J AM MED ASSOC, V286, P2956, DOI 10.1001/jama.286.23.2956; Corren J, 1997, J ALLERGY CLIN IMMUN, V100, P781, DOI 10.1016/S0091-6749(97)70274-4; Corren J, 2005, CLIN THER, V27, P543, DOI 10.1016/j.clinthera.2005.04.012; Demoly P, 2003, DRUGS, V63, P1813, DOI 10.2165/00003495-200363170-00004; DesRoches A, 1997, J ALLERGY CLIN IMMUN, V99, P450, DOI 10.1016/S0091-6749(97)70069-1; Djukanovic R, 1996, CLIN EXP ALLERGY, V26, P44, DOI 10.1111/j.1365-2222.1996.tb00659.x; Donshik PC, 2000, ADV THER, V17, P94, DOI 10.1007/BF02854842; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Dykewicz MS, 1998, ANN ALLERG ASTHMA IM, V81, P478, DOI 10.1016/S1081-1206(10)63155-9; Ewbank PA, 2003, J ALLERGY CLIN IMMUN, V111, P155, DOI 10.1067/mai.2003.41; Garbe E, 1997, JAMA-J AM MED ASSOC, V277, P722, DOI 10.1001/jama.277.9.722; Holgate ST, 2003, NAT REV DRUG DISCOV, V2, P903, DOI 10.1038/nrd1224; *JOINT TASK FORC P, 2005, J ALLERGY CLIN IM S2, V0115, pS 483; Juniper Elizabeth F, 2005, J Allergy Clin Immunol, V115, pS390, DOI 10.1016/j.jaci.2004.12.014; Kay GG, 1997, AM J MANAG CARE, V3, P1843; Kuehr J, 2002, J ALLERGY CLIN IMMUN, V109, P274, DOI 10.1067/mai.2002.121949; LaForce C, 1999, J ALLERGY CLIN IMMUN, V103, pS388, DOI 10.1016/S0091-6749(99)70218-6; LAURSEN LC, 1987, ALLERGY, V42, P168, DOI 10.1111/j.1398-9995.1987.tb02194.x; Lipworth BJ, 2000, DRUG SAFETY, V23, P11, DOI 10.2165/00002018-200023010-00002; Lipworth BJ, 1999, ARCH INTERN MED, V159, P941, DOI 10.1001/archinte.159.9.941; MELTZER EO, 1995, J ALLERGY CLIN IMMUN, V95, P1097, DOI 10.1016/S0091-6749(95)70213-X; METZGER WJ, 1978, J ALLERGY CLIN IMMUN, V61, P268, DOI 10.1016/0091-6749(78)90202-6; Milgrom H, 1999, ANN ALLERG ASTHMA IM, V83, P105, DOI 10.1016/S1081-1206(10)62620-8; Moller C, 2002, J ALLERGY CLIN IMMUN, V109, P251, DOI 10.1067/mai.2002.121317; Morgan WJ, 2004, NEW ENGL J MED, V351, P1068, DOI 10.1056/NEJMoa032097; NEGRINI AC, 1995, CLIN EXP ALLERGY, V25, P60, DOI 10.1111/j.1365-2222.1995.tb01003.x; Pajno GB, 2001, CLIN EXP ALLERGY, V31, P1392, DOI 10.1046/j.1365-2222.2001.01161.x; PIPKORN U, 1985, ALLERGY, V40, P491, DOI 10.1111/j.1398-9995.1985.tb00255.x; PLAUT M, 2004, ALLERGENS ALLERGEN I, P681; Pleskow W, 2005, ANN ALLERG ASTHMA IM, V94, P348, DOI 10.1016/S1081-1206(10)60986-6; SHEIKH A, 2001, COCHRANE DB SYST REV, V4; Simons FER, 2004, NEW ENGL J MED, V351, P2203, DOI 10.1056/NEJMra033121; Simons FER, 2004, J ALLERGY CLIN IMMUN, V113, P1144, DOI 10.1016/j.jaci.2004.03.003; Till SJ, 2004, J ALLERGY CLIN IMMUN, V113, P1025, DOI 10.1016/j.jaci.2004.03.024; VALENTINE MD, 2003, PRINCIPLES AMBULATOR, P387; van Cauwenberge P, 2000, ALLERGY, V55, P116, DOI 10.1034/j.1398-9995.2000.00526.x; Verster JC, 2005, ANN ALLERG ASTHMA IM, V94, P409, DOI 10.1016/S1081-1206(10)60998-2; Verster JC, 2004, ANN ALLERG ASTHMA IM, V92, P675; Verster JC, 2004, ANN ALLERG ASTHMA IM, V92, P294, DOI 10.1016/S1081-1206(10)61566-9; Weiner JM, 1998, BMJ-BRIT MED J, V317, P1624, DOI 10.1136/bmj.317.7173.1624; Wheeler AW, 2004, EXPERT OPIN BIOL TH, V4, P1473, DOI 10.1517/14712598.4.9.1473; Wilson AM, 2004, AM J MED, V116, P338, DOI 10.1016/j.amjmed.2003.10.030; Wilson DR, 2003, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD002893; Yanez A, 2002, ANN ALLERG ASTHMA IM, V89, P479, DOI 10.1016/S1081-1206(10)62085-6	58	132	140	2	7	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1934	1944		10.1056/NEJMcp044141	http://dx.doi.org/10.1056/NEJMcp044141			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267324				2022-12-28	WOS:000232972800009
J	Roubideaux, Y				Roubideaux, Y			Beyond Red Lake - The persistent crisis in American Indian healthcare	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Univ Arizona, Coll Publ Hlth, Tucson, AZ 85721 USA; Univ Arizona, Coll Med, Tucson, AZ USA	University of Arizona; University of Arizona	Roubideaux, Y (corresponding author), Univ Arizona, Coll Publ Hlth, Tucson, AZ 85721 USA.							*IND HLTH SERV, 2002, FIN REP RESTR IN WOR; *IND HLTH SERV, 2000, TRENDS IND HLTH 2000; LEE ET, 1995, DIABETES CARE, V18, P599, DOI 10.2337/diacare.18.5.599; *PROGR STAT TEAM, 1998, IND HLTH FOC YOUTH 1; 1998, MMWR MORB MORTAL WKL, V47, P901	5	28	28	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					1881	1883		10.1056/NEJMp058095	http://dx.doi.org/10.1056/NEJMp058095			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	979VJ	16267317				2022-12-28	WOS:000232972800002
J	Hill, LD; Madara, JL				Hill, LD; Madara, JL			Role of the urban academic medical center in US health care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Chicago, Div Biol Sci, Chicago, IL 60637 USA; Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Madara, JL (corresponding author), Univ Chicago, Div Biol Sci, 5841 S Maryland Ave,MC 1000, Chicago, IL 60637 USA.	jmadara@bsd.uchicago.edu						BURROWS J, 2004, CAMBRIDGE HLTH ALLIA; *COMM FUNK TASK FO, 2003, ENV FUT AC HLTH CTR; FOGEL RW, 2003, SECULAR TRENDS PHYSL; Foreman S, 2004, ACAD MED, V79, P1154, DOI 10.1097/00001888-200412000-00007; Guerra FA, 2004, ACAD MED, V79, P1148, DOI 10.1097/00001888-200412000-00006; Leviton LC, 2000, AM J PUBLIC HEALTH, V90, P863, DOI 10.2105/AJPH.90.6.863; Mallon W. T., 2004, HDB ACAD MED MED SCH; Mathie A., 2002, CLIENTS CITIZENS ASS	8	11	11	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2219	2220		10.1001/jama.294.17.2219	http://dx.doi.org/10.1001/jama.294.17.2219			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264164				2022-12-28	WOS:000232957700025
J	Roe, HG; Brown, ME; Schaller, EL; Bouchez, AH; Trujillo, CA				Roe, HG; Brown, ME; Schaller, EL; Bouchez, AH; Trujillo, CA			Geographic control of Titan's mid-latitude clouds	SCIENCE			English	Article							TROPOSPHERIC CLOUDS; ATMOSPHERE; PHOTOCHEMISTRY; GEMINI	Observations of Titan's mid-latitude clouds from the W. M. Keck and Gemini Observatories show that they cluster near 350 degrees W longitude, 40 degrees S latitude. These clouds cannot be explained by a seasonal shift in global circulation and thus presumably reflect a mechanism on Titan such as geysering or cryovolcanism in this region. The rate of volatile release necessary to trigger cloud formation could easily supply enough methane to balance the loss to photolysis in the upper atmosphere.	CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA; CALTECH, Opt Observ, Pasadena, CA 91125 USA; Gemini Observ, Hilo, HI 96720 USA	California Institute of Technology; California Institute of Technology	Roe, HG (corresponding author), CALTECH, Div Geol & Planetary Sci, Pasadena, CA 91125 USA.	hroe@gps.caltech.edu		Trujillo, Chadwick/0000-0001-9859-0894; Brown, Michael E./0000-0002-8255-0545; Schaller, Emily/0000-0001-8967-5423				Bouchez AH, 2005, ASTROPHYS J, V618, pL53, DOI 10.1086/427693; Brown ME, 2002, NATURE, V420, P795, DOI 10.1038/nature01302; Griffith CA, 2000, SCIENCE, V290, P509, DOI 10.1126/science.290.5491.509; Griffith CA, 1998, NATURE, V395, P575, DOI 10.1038/26920; Hodapp KW, 2003, PUBL ASTRON SOC PAC, V115, P1388, DOI 10.1086/379669; JOHNSON TV, 1984, SCIENCE, V226, P134, DOI 10.1126/science.226.4671.134; Lara LM, 2002, ICARUS, V158, P191, DOI 10.1006/icar.2002.6861; LUNINE JI, 1983, SCIENCE, V222, P1229, DOI 10.1126/science.222.4629.1229; MCKAY CP, 1989, ICARUS, V80, P23, DOI 10.1016/0019-1035(89)90160-7; Porco CC, 2005, NATURE, V434, P159, DOI 10.1038/nature03436; Roe HG, 2005, ASTROPHYS J, V618, pL49, DOI 10.1086/427499; Roe HG, 2002, ASTROPHYS J, V581, P1399, DOI 10.1086/344403; Sotin C, 2005, NATURE, V435, P786, DOI 10.1038/nature03596; STROBEL DF, 1974, ICARUS, V21, P466, DOI 10.1016/0019-1035(74)90149-3; Tokano T, 2002, ICARUS, V158, P499, DOI 10.1006/icar.2002.6883; Wilson EH, 2004, J GEOPHYS RES-PLANET, V109, DOI 10.1029/2003JE002181; Wizinowich P, 2000, PUBL ASTRON SOC PAC, V112, P315, DOI 10.1086/316543	17	73	73	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					477	479		10.1126/science.1116760	http://dx.doi.org/10.1126/science.1116760			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239473				2022-12-28	WOS:000232786000042
J	Barnett, TP; Adam, JC; Lettenmaier, DP				Barnett, TP; Adam, JC; Lettenmaier, DP			Potential impacts of a warming climate on water availability in snow-dominated regions	NATURE			English	Review							GLACIER-MELT; HYDROLOGICAL CYCLE; TROPICAL GLACIER; PAN EVAPORATION; RIVER; RESOURCES; EVAPOTRANSPIRATION; SENSITIVITY; AEROSOLS; RUNOFF	All currently available climate models predict a near-surface warming trend under the influence of rising levels of greenhouse gases in the atmosphere. In addition to the direct effects on climate-for example, on the frequency of heatwaves-this increase in surface temperatures has important consequences for the hydrological cycle, particularly in regions where water supply is currently dominated by melting snow or ice. In a warmer world, less winter precipitation falls as snow and the melting of winter snow occurs earlier in spring. Even without any changes in precipitation intensity, both of these effects lead to a shift in peak river runoff to winter and early spring, away from summer and autumn when demand is highest. Where storage capacities are not sufficient, much of the winter runoff will immediately be lost to the oceans. With more than one-sixth of the Earth's population relying on glaciers and seasonal snow packs for their water supply, the consequences of these hydrological changes for future water availability-predicted with high confidence and already diagnosed in some regions-are likely to be severe.	Univ Calif San Diego, Scripps Inst Oceanog, Div Climate Res, La Jolla, CA 92093 USA; Univ Washington, Dept Civil & Environm Engn, Seattle, WA 98195 USA	University of California System; University of California San Diego; Scripps Institution of Oceanography; University of Washington; University of Washington Seattle	Barnett, TP (corresponding author), Univ Calif San Diego, Scripps Inst Oceanog, Div Climate Res, La Jolla, CA 92093 USA.	timdotbarnett@ucsd.edu; dennisl@u.washington.edu	Ebersole, Joseph L/A-8371-2009; lettenmaier, dennis p/F-8780-2011	lettenmaier, dennis p/0000-0003-3317-1327				ADAM JC, IN PRESS J CLIM; [Anonymous], CLIM CHANGE; Barnett T, 2004, CLIMATIC CHANGE, V62, P1, DOI 10.1023/B:CLIM.0000013695.21726.b8; Borys RD, 2003, GEOPHYS RES LETT, V30, DOI 10.1029/2002GL016855; Brutsaert W, 1998, NATURE, V396, P30, DOI 10.1038/23845; BURN DH, 1994, J HYDROL, V160, P53, DOI 10.1016/0022-1694(94)90033-7; Cayan DR, 2001, B AM METEOROL SOC, V82, P399, DOI 10.1175/1520-0477(2001)082<0399:CITOOS>2.3.CO;2; Chattopadhyay N, 1997, AGR FOREST METEOROL, V87, P55, DOI 10.1016/S0168-1923(97)00006-3; *CHIN AC SCI, 2004, CHIN GLAC INV; CIESIN, 2004, SOC DAT APPL CTR SED; COMBES S, 2004, GOING GOING GONE CLI, P1; DAI A, UNPUB J CLIM; de Loe R, 2001, GLOBAL ENVIRON CHANG, V11, P231, DOI 10.1016/S0959-3780(00)00053-4; Dettinger MD, 2004, CLIMATIC CHANGE, V62, P283, DOI 10.1023/B:CLIM.0000013683.13346.4f; Douville H, 2002, CLIM DYNAM, V20, P45, DOI 10.1007/s00382-002-0259-3; Francou B, 2003, J GEOPHYS RES-ATMOS, V108, DOI 10.1029/2002JD002959; Gan TY, 2000, WATER RESOUR MANAG, V14, P111, DOI 10.1023/A:1008195827031; GAO Q, 1992, J DESERT RES, V12, P1; Giorgi F, 2005, GEOPHYS RES LETT, V32, DOI 10.1029/2005GL024288; Giorgi F, 2001, GEOPHYS RES LETT, V28, P3317, DOI 10.1029/2001GL013150; Givati A, 2004, J APPL METEOROL, V43, P1038, DOI [10.1175/1520-0450(2004)043<1038:QPSDTA>2.0.CO;2, 10.1175/1520-0450(2004)043&lt;1038:QPSDTA&gt;2.0.CO;2]; Golubev VS, 2001, GEOPHYS RES LETT, V28, P2665, DOI 10.1029/2000GL012851; HAMLET AF, IN PRESS J CLIM; Hansen J, 2005, SCIENCE, V308, P1431, DOI 10.1126/science.1110252; Hansen J, 2004, P NATL ACAD SCI USA, V101, P423, DOI 10.1073/pnas.2237157100; HOBBINS MT, 2004, GEOPHYS RES LETT, V31, DOI DOI 10.1029/2004G6019846; HOU S, 2000, CHINESE SCI BULL, V45, P256; Houghton J. T., 2001, CLIMATE CHANGE 2001; Kaser G, 2005, ADV GLOB CHANGE RES, P185, DOI 10.1007/1-4020-3508-X_19; Kaufman YJ, 2002, NATURE, V419, P215, DOI 10.1038/nature01091; Kiehl JT, 2000, J GEOPHYS RES-ATMOS, V105, P1441, DOI 10.1029/1999JD900495; Krishnan R, 2002, GEOPHYS RES LETT, V29, DOI 10.1029/2002GL014687; Lawrimore JH, 2000, J HYDROMETEOROL, V1, P543, DOI 10.1175/1525-7541(2000)001<0543:PETIDA>2.0.CO;2; Liang X, 1994, J GEOPHYS RES-ATMOS, V99, P14415, DOI 10.1029/94JD00483; Liniger H., 1998, MOUNTAINS WORLD WATE, P1; Mark BG, 2003, J GLACIOL, V49, P271, DOI 10.3189/172756503781830746; MARK BG, 2005, ADV GLOB CHANGE RES, V23, P205; MARK BG, IN PRESS QUAT SCI RE; McCarthy J.J., 2001, CLIMATE CHANGE 2001; Meier MF, 2002, SCIENCE, V297, P350, DOI 10.1126/science.1073591; Middelkoop H, 2001, CLIMATIC CHANGE, V49, P105, DOI 10.1023/A:1010784727448; Mote PW, 2005, B AM METEOROL SOC, V86, P39, DOI 10.1175/BAMS-86-1-39; Nijssen B, 2001, CLIMATIC CHANGE, V50, P143, DOI 10.1023/A:1010616428763; Ohmura A, 2002, SCIENCE, V298, P1345, DOI 10.1126/science.1078972; Payne JT, 2004, CLIMATIC CHANGE, V62, P233, DOI 10.1023/B:CLIM.0000013694.18154.d6; PETERSON TC, 1995, NATURE, V377, P687, DOI 10.1038/377687b0; Ramanathan V, 2001, SCIENCE, V294, P2119, DOI 10.1126/science.1064034; Roderick ML, 2002, SCIENCE, V298, P1410; Rosenfeld D, 1999, GEOPHYS RES LETT, V26, P3105, DOI 10.1029/1999GL006066; Rosenfeld D, 2000, SCIENCE, V287, P1793, DOI 10.1126/science.287.5459.1793; RUIZBARRADAS A, UNPUB J CLIM; Schindler DW, 2001, CAN J FISH AQUAT SCI, V58, P18, DOI 10.1139/cjfas-58-1-18; Singh P, 1997, MT RES DEV, V17, P49, DOI 10.2307/3673913; Singh P, 1997, J HYDROL, V193, P316, DOI 10.1016/S0022-1694(96)03142-3; Singh P, 2004, HYDROL PROCESS, V18, P2363, DOI 10.1002/hyp.1468; Singh P, 2003, HYDROLOG SCI J, V48, P413, DOI 10.1623/hysj.48.3.413.45280; Singh P, 2002, HYDROLOG SCI J, V47, P93, DOI 10.1080/02626660209492910; Stewart IT, 2004, CLIMATIC CHANGE, V62, P217, DOI 10.1023/B:CLIM.0000013702.22656.e8; Thomas A, 2000, INT J CLIMATOL, V20, P381, DOI 10.1002/(SICI)1097-0088(20000330)20:4&lt;381::AID-JOC477&gt;3.0.CO;2-K; Thompson LG, 2003, CLIMATIC CHANGE, V59, P137, DOI 10.1023/A:1024472313775; Vorosmarty CJ, 1997, AMBIO, V26, P210; Vorosmarty CJ, 2003, GLOBAL PLANET CHANGE, V39, P169, DOI 10.1016/S0921-8181(03)00023-7; Vuille M, 2000, GEOPHYS RES LETT, V27, P3885, DOI 10.1029/2000GL011871; Vuille M, 2003, CLIMATIC CHANGE, V59, P75, DOI 10.1023/A:1024406427519; Walter MT, 2004, J HYDROMETEOROL, V5, P405, DOI 10.1175/1525-7541(2004)005<0405:IEFTCU>2.0.CO;2; Wild M, 2004, GEOPHYS RES LETT, V31, DOI 10.1029/2003GL019188	66	2791	2908	99	1757	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					303	309		10.1038/nature04141	http://dx.doi.org/10.1038/nature04141			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292301				2022-12-28	WOS:000233300200038
J	Cnattingius, S; Torrang, A; Ekbom, A; Granath, F; Petersson, G; Lambe, M				Cnattingius, S; Torrang, A; Ekbom, A; Granath, F; Petersson, G; Lambe, M			Pregnancy characteristics and maternal risk of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PLACENTAL WEIGHT; BIRTH-WEIGHT; REPLACEMENT THERAPY; ALPHA-FETOPROTEIN; FETAL; PREECLAMPSIA; GROWTH; EPIDEMIOLOGY; ESTROGEN; ESTRIOL	Context During pregnancy, serum levels of estrogen, progesterone, and other hormones are markedly higher than during other periods of life. Pregnancy hormones primarily are produced in the placenta, and signs of placental impairment may serve as indirect markers of hormone exposures during pregnancy. During pregnancy, these markers have been inconsistently associated with subsequent risk of breast cancer in the mother. Objective To examine associations between indirect markers of hormonal exposures, such as placental weight and other pregnancy characteristics, and maternal risk of developing breast cancer. Design and Setting Population-based cohort study using data from the Swedish Birth Register, the Swedish Cancer Register, the Swedish Cause of Death Register, and the Swedish Register of Population and Population Changes. Participants Women included in the Sweden Birth Register who delivered singletons between 1982 and 1989, with complete information on date of birth and gestational age. Women were followed up until the occurrence of breast cancer, death, or end of follow-up (December 31, 2001). Cox proportional hazards models were used to estimate associations between hormone exposures and risks of breast cancer. Main Outcome Measure Incidence of invasive breast cancer. Results. Of 314,019 women in the cohort, 2216 (0.7%) developed breast cancer during the follow-up through 2001, of whom 2100 (95%) were diagnosed before age 50 years. Compared with women who had placentas weighing less than 500 g in 2 consecutive pregnancies, the risk of breast cancer was increased among women whose placentas weighed between 500 and 699 g in their first pregnancy and at least 700 g in their second pregnancy (or vice versa) (adjusted hazard ratio, 1.82; 95% confidence interval [CI], 1.07-3.08), and the corresponding risk was doubled among women whose placentas weighed at least 700 g in both pregnancies (adjusted hazard ratio, 2.05; 95% Cl, 1.15-3.64). A high birth weight (>= 4000 g) in 2 successive births was associated with an increased risk of breast cancer before but not after adjusting for placental weight and other covariates (adjusted hazard ratio, 1.10; 95% Cl, 0.76-1.59). Conclusions Placental weight is positively associated with maternal risk of breast cancer. These results further support the hypothesis that pregnancy hormones are important modifiers of subsequent maternal breast cancer risk..	Karolinska Inst, Karolinska Hosp, Dept Med Epidemiol & Biostat, SE-17177 Stockholm, Sweden; Karolinska Inst, Karolinska Hosp, Dept Med, Clin Epidemiol Unit, SE-17177 Stockholm, Sweden; AstraZeneca R&D, Molndal, Sweden	Karolinska Institutet; Karolinska University Hospital; Karolinska Institutet; Karolinska University Hospital; AstraZeneca	Cnattingius, S (corresponding author), Karolinska Inst, Karolinska Hosp, Dept Med Epidemiol & Biostat, POB 281, SE-17177 Stockholm, Sweden.	sven.cnattingius@mep.ki.se		Lambe, Mats/0000-0002-4624-3767				Acromite MT, 1999, AM J OBSTET GYNECOL, V180, P60, DOI 10.1016/S0002-9378(99)70150-X; Becroft DMO, 2002, PLACENTA, V23, P343, DOI 10.1053/plac.2001.0777; Beral V, 1997, LANCET, V350, P1047, DOI 10.1016/S0140-6736(97)08233-0; Clapp JF, 2004, AM J OBSTET GYNECOL, V190, P730, DOI 10.1016/j.ajog.2003.09.061; Clausson B, 2000, BRIT J OBSTET GYNAEC, V107, P375, DOI 10.1111/j.1471-0528.2000.tb13234.x; CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Cohn BA, 2001, J NATL CANCER I, V93, P1133, DOI 10.1093/jnci/93.15.1133; GODFREY KM, 1991, BRIT J OBSTET GYNAEC, V98, P886, DOI 10.1111/j.1471-0528.1991.tb13510.x; GRUENWALD P, 1963, BIOL NEONATORUM, V5, P215; HANKINSON S, 2002, TXB CANC EPIDEMIOLOG, P301; Hoover RN, 2001, J NATL CANCER I, V93, P1119, DOI 10.1093/jnci/93.15.1119; Innes KE, 1999, EPIDEMIOLOGY, V10, P722, DOI 10.1097/00001648-199911000-00013; Kaijser M, 2000, EPIDEMIOLOGY, V11, P315, DOI 10.1097/00001648-200005000-00015; KAIJSER M, 2002, THESIS KAROLINSKA I; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; Kinnunen Tarja I, 2004, BMC Womens Health, V4, P7, DOI 10.1186/1472-6874-4-7; LAMBE M, 1994, NEW ENGL J MED, V331, P5, DOI 10.1056/NEJM199407073310102; LIPWORTH L, 1995, EUR J CANCER PREV, V4, P7, DOI 10.1097/00008469-199502000-00002; Magnusson C, 1999, INT J CANCER, V81, P339, DOI 10.1002/(SICI)1097-0215(19990505)81:3<339::AID-IJC5>3.3.CO;2-Y; Melbye M, 2000, JNCI-J NATL CANCER I, V92, P1001, DOI 10.1093/jnci/92.12.1001; MOLTENI RA, 1978, J REPROD MED, V21, P327; MOLTENI RA, 1984, SEMIN PERINATOL, V8, P94; Mucci LA, 2003, CANCER CAUSE CONTROL, V14, P311, DOI 10.1023/A:1023966813330; NAEYE RL, 1987, HUM PATHOL, V18, P387, DOI 10.1016/S0046-8177(87)80170-3; *NAT BOARD HLTH WE, 2000, CANC INC SWED 1998; Salonen RH, 2000, AM J MED GENET, V91, P256; Thame M, 2001, OBSTET GYNECOL, V98, P279, DOI 10.1016/S0029-7844(01)01414-4; TRICHOPOULOS D, 1990, LANCET, V335, P939, DOI 10.1016/0140-6736(90)91000-Z; Troisi R, 1998, EPIDEMIOLOGY, V9, P641, DOI 10.1097/00001648-199811000-00014; Troisi R, 2003, INT J EPIDEMIOL, V32, P455, DOI 10.1093/ije/dyg094; Vatten LJ, 2002, BRIT J CANCER, V87, P971, DOI 10.1038/sj.bjc.6600581; Wenstrom KD, 1996, OBSTET GYNECOL, V87, P213, DOI 10.1016/0029-7844(95)00377-0; Wohlfahrt J, 1999, EPIDEMIOLOGY, V10, P441, DOI 10.1097/00001648-199907000-00017; Yu H, 2000, JNCI-J NATL CANCER I, V92, P1472, DOI 10.1093/jnci/92.18.1472	34	60	61	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610-0946 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 16	2005	294	19					2474	2480		10.1001/jama.294.19.2474	http://dx.doi.org/10.1001/jama.294.19.2474			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984BL	16287958	Bronze			2022-12-28	WOS:000233277400026
J	Crotty, M; Whitehead, CH; Wundke, R; Giles, LC; Ben-Tovim, D; Phillips, PA				Crotty, M; Whitehead, CH; Wundke, R; Giles, LC; Ben-Tovim, D; Phillips, PA			Transitional care facility for elderly people in hospital awaiting a long term care bed: randomised controlled trial	BMJ-BRITISH MEDICAL JOURNAL			English	Article							INTERMEDIATE CARE; OUTCOMES; DESIGNS; STROKE	Objective To assess the effectiveness of moving patients who are waiting in hospital for a lone term care bed to an off-site transitional care facility. Design Randomised controlled trial. Setting Three public hospitals in Southern Adelaide. Participants 320 elderly patients (mean age 83 years) in acute hospital beds (212 randomised to intervention, 108 to control). Interventions A transitional care facility where all patients received a single assessment from a specialist elder care team and appropriate ongoing therapy. Main outcome measures Length of stay in hospital, rates of readmission, deaths, and patient's functional level (modified Barthel index), quality of life (assessment of quality of life), and care needs (residential classification scale) at four months. Results From admission, those in the intervention group stayed a median of 32.5 days (95% confidence interval 29 to 36 days) in hospital. In the control group the median length of stay was 43.5 days (41 to 51 days) (95% confidence interval for difference 6 to 16 days). Patients in the intervention g roup took a median of 21 days (6 to 27 days) longer to be admitted to permanent care than those in the control group. In both groups few patients went home (14 (7%) in the intervention group v 9 (9%) in the control group). There were no significant differences in death rates (28% v 27%) or rates of transfer back to hospital (28% v 25%). Conclusions For frail elderly patients who are awaiting a residential care bed transfer out of hospital to an off-site transitional care unit with focus on aged care "unblocks beds" without adverse effects.	Flinders Univ S Australia, Repatriat Gen Hosp, Dept Rehabil & Aged Care, Daw Pk, SA 5041, Australia; Flinders Med Ctr, Clin Epidemiol & Hlth Outcomes Unit, Bedford Pk, SA 5042, Australia; Flinders Univ S Australia, Dept Med, Adelaide, SA 5001, Australia	Flinders University South Australia; Flinders Medical Centre; Flinders University South Australia	Crotty, M (corresponding author), Flinders Univ S Australia, Repatriat Gen Hosp, Dept Rehabil & Aged Care, Daw Pk, SA 5041, Australia.	maria.crotty@flinders.edu.au	Giles, Lynne/C-8789-2009	Giles, Lynne/0000-0001-9054-9088; Crotty, Maria/0000-0002-2996-5135				*BRIT GER SOC, 1998, INT CAR GUID COMM PR; Carpenter I, 2002, AGE AGEING, V31, P97, DOI 10.1093/ageing/31.2.97; CONOVER WJ, 1999, PRACTICAL NONPARAMET, P143; Ebrahim S, 2001, BMJ-BRIT MED J, V323, P337; ELLENBERG SS, 1984, NEW ENGL J MED, V310, P1404, DOI 10.1056/NEJM198405243102141; Evans JG, 2001, BRIT MED J, V322, P807, DOI 10.1136/bmj.322.7290.807; GRIFFITHS PD, 2004, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD002214.PUB2; Hawthorne G, 1999, QUAL LIFE RES, V8, P209, DOI 10.1023/A:1008815005736; Kane RL, 1996, J AM GERIATR SOC, V44, P545, DOI 10.1111/j.1532-5415.1996.tb01440.x; Kramer AM, 1997, JAMA-J AM MED ASSOC, V277, P396, DOI 10.1001/jama.277.5.396; Marshall Adele H, 2004, Health Care Manag Sci, V7, P27, DOI 10.1023/B:HCMS.0000005395.77308.d1; McClean S I, 1998, Health Care Manag Sci, V1, P159, DOI 10.1023/A:1019002804381; Pencheon D, 2002, BRIT MED J, V324, P1347, DOI 10.1136/bmj.324.7350.1347; SHAH S, 1989, STROKE, V20, P766, DOI 10.1161/01.STR.20.6.766; Steiner A, 2001, BRIT MED J, V322, P453, DOI 10.1136/bmj.322.7284.453; WARD D, 2004, COCHRANE DATABASE SY; ZELEN M, 1979, NEW ENGL J MED, V300, P1242, DOI 10.1056/NEJM197905313002203; ZELEN M, 1990, STAT MED, V9, P645, DOI 10.1002/sim.4780090611	18	29	29	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 12	2005	331	7525					1110	1113		10.1136/bmj.38638.441933.63	http://dx.doi.org/10.1136/bmj.38638.441933.63			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	985ZI	16267077	Green Published, Bronze			2022-12-28	WOS:000233417300013
J	Haak, W; Forster, P; Bramanti, B; Matsumura, S; Brandt, G; Tanzer, M; Villems, R; Renfrew, C; Gronenborn, D; Alt, KW; Burger, J				Haak, W; Forster, P; Bramanti, B; Matsumura, S; Brandt, G; Tanzer, M; Villems, R; Renfrew, C; Gronenborn, D; Alt, KW; Burger, J			Ancient DNA from the first European farmers in 7500-year-old Neolithic sites	SCIENCE			English	Article							EXPANSION; DIVERSITY; PATTERNS	The ancestry of modern Europeans is a subject of debate among geneticists, archaeologists, and anthropologists. A crucial question is the extent to which Europeans are descended from the first European farmers in the Neolithic Age 7500 years ago or from Paleolithic hunter-gatherers who were present in Europe since 40,000 years ago. Here we present an analysis of ancient DNA from early European farmers. We successfully extracted and sequenced intact stretches of maternally inherited mitochondrial DNA (mtDNA) from 24 out of 57 Neolithic skeletons from various locations in Germany, Austria, and Hungary. We found that 25% of the Neolithic farmers had one characteristic mtDNA type and that this type formerly was widespread among Neolithic farmers in Central Europe. Europeans today have a 150-times lower frequency (0.2%) of this mtDNA type, revealing that these first Neolithic farmers did not have a strong genetic influence on modern European female lineages. Our finding lends weight to a proposed Paleolithic ancestry for modern Europeans.	Johannes Gutenberg Univ Mainz, Inst Anthropol, D-55099 Mainz, Germany; Univ Cambridge, McDonald Inst Archaeol Res, Cambridge CB2 3ER, England; Univ Tartu, Estonian Bioctr, EE-51010 Tartu, Estonia; Romisch German Zent Museum, D-55116 Mainz, Germany	Johannes Gutenberg University of Mainz; University of Cambridge; Estonian Biocentre; University of Tartu	Haak, W (corresponding author), Mol Archaeol Grp, Inst Anthropol, Colonel Kleinmann Weg 2,SBII 02, D-55128 Mainz, Germany.	haakw@uni-mainz.de	Matsumura, Shuichi/C-7986-2013; Bramanti, Barbara/A-9112-2015; Bramanti, Barbara/AAF-8542-2019; Haak, Wolfgang/Z-4947-2019	Matsumura, Shuichi/0000-0002-0368-006X; Bramanti, Barbara/0000-0002-5433-663X; Bramanti, Barbara/0000-0002-5433-663X; Haak, Wolfgang/0000-0003-2475-2007; Gronenborn, Detlef/0000-0002-6467-5643				Ammermann A.J., 1984, NEOLITHIC TRANSITION; ANDERSON S, 1981, NATURE, V290, P457, DOI 10.1038/290457a0; BANFFY E, 2004, 6 MILLENIUM BC BOUND; Barbujani G, 1998, AM J HUM GENET, V62, P488, DOI 10.1086/301719; Barbujani G, 2004, ANNU REV GENOM HUM G, V5, P119, DOI 10.1146/annurev.genom.5.061903.180021; Bentley RA, 2002, CURR ANTHROPOL, V43, P799, DOI 10.1086/344373; Bogucki P., 2000, EUROPES 1 FARMERS, P197, DOI DOI 10.1017/CBO9780511607851.009; Chikhi L, 1998, P NATL ACAD SCI USA, V95, P9053, DOI 10.1073/pnas.95.15.9053; Chikhi L, 2002, P NATL ACAD SCI USA, V99, P11008, DOI 10.1073/pnas.162158799; Currat M, 2005, P ROY SOC B-BIOL SCI, V272, P679, DOI 10.1098/rspb.2004.2999; Diamond J, 2003, SCIENCE, V300, P597, DOI 10.1126/science.1078208; Dupanloup I, 2004, MOL BIOL EVOL, V21, P1361, DOI 10.1093/molbev/msh135; Forster L, 2002, P NATL ACAD SCI USA, V99, P13950, DOI 10.1073/pnas.202400499; Gilbert MTP, 2003, AM J HUM GENET, V72, P32, DOI 10.1086/345378; Gronenborn D, 1999, J WORLD PREHIST, V13, P123, DOI 10.1023/A:1022374312372; GRONENBORN D, 2004, BEFORE FARMING; Harris DR, 1996, ORIGINS SPREAD AGR P, P552; Hofreiter M, 2001, NUCLEIC ACIDS RES, V29, P4793, DOI 10.1093/nar/29.23.4793; PAVUK J, 2004, LBK DIALOGUES STUDIE, P71; RENFREW C, 1987, ARCHAEOLOGY LANGUAGE; Ricaut FX, 2004, HUM BIOL, V76, P109, DOI 10.1353/hub.2004.0025; Richards M, 2000, AM J HUM GENET, V67, P1251, DOI 10.1016/S0002-9297(07)62954-1; Rohl A, 2001, INT J LEGAL MED, V115, P29, DOI 10.1007/s004140100217; Semino O, 2000, SCIENCE, V290, P1155, DOI 10.1126/science.290.5494.1155; Simoni L, 2000, AM J HUM GENET, V66, P262, DOI 10.1086/302706; Torroni A, 1998, AM J HUM GENET, V62, P1137, DOI 10.1086/301822; VILLEMS R, 2005, UNPUB; Whittle A., 1996, EUROPE NEOLITHIC CRE; Zvelebil M., 2004, LBK DIALOGUES STUDIE, P183	29	307	317	0	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1016	1018		10.1126/science.1118725	http://dx.doi.org/10.1126/science.1118725			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284177				2022-12-28	WOS:000233343400043
J	Furukawa, H; Singh, SK; Mancusso, R; Gouaux, E				Furukawa, H; Singh, SK; Mancusso, R; Gouaux, E			Subunit arrangement and function in NMDA receptors	NATURE			English	Article							D-ASPARTATE RECEPTORS; LIGAND-BINDING CORE; GLUTAMATE-RECEPTOR; CRYSTAL-STRUCTURES; MOLECULAR DETERMINANTS; CHANNEL KINETICS; AMPA RECEPTORS; ACTIVATION; KAINATE; MECHANISM	Excitatory neurotransmission mediated by NMDA (N-methyl-D-aspartate) receptors is fundamental to the physiology of the mammalian central nervous system. These receptors are heteromeric ion channels that for activation require binding of glycine and glutamate to the NR1 and NR2 subunits, respectively. NMDA receptor function is characterized by slow channel opening and deactivation, and the resulting influx of cations initiates signal transduction cascades that are crucial to higher functions including learning and memory. Here we report crystal structures of the ligand-binding core of NR2A with glutamate and that of the NR1 - NR2A heterodimer with glutamate and glycine. The NR2A - glutamate complex defines the determinants of glutamate and NMDA recognition, and the NR1 - NR2A heterodimer suggests a mechanism for ligand-induced ion channel opening. Analysis of the heterodimer interface, together with biochemical and electrophysiological experiments, confirms that the NR1 - NR2A heterodimer is the functional unit in tetrameric NMDA receptors and that tyrosine 535 of NR1, located in the subunit interface, modulates the rate of ion channel deactivation.	Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10032 USA; Columbia Univ, Howard Hughes Med Inst, New York, NY 10032 USA	Columbia University; Columbia University; Howard Hughes Medical Institute	Gouaux, E (corresponding author), Oregon Hlth & Sci Univ, Vollum Inst, Portland, OR 97239 USA.	jeg52@columbia.edu	Gouaux, Eric/Y-4370-2019	Gouaux, Eric/0000-0002-8549-2360				Armstrong N, 2000, NEURON, V28, P165, DOI 10.1016/S0896-6273(00)00094-5; Armstrong N, 1998, NATURE, V395, P913, DOI 10.1038/27692; Ayalon G, 2001, NEURON, V31, P103, DOI 10.1016/S0896-6273(01)00333-6; BENVENISTE M, 1991, BIOPHYS J, V59, P560, DOI 10.1016/S0006-3495(91)82272-X; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Choi YB, 2001, J NEUROSCI, V21, P392, DOI 10.1523/JNEUROSCI.21-02-00392.2001; CLEMENTS JD, 1991, NEURON, V7, P605, DOI 10.1016/0896-6273(91)90373-8; Cowtan KD, 1996, ACTA CRYSTALLOGR D, V52, P43, DOI 10.1107/S090744499500761X; Cull-Candy S, 2001, CURR OPIN NEUROBIOL, V11, P327, DOI 10.1016/S0959-4388(00)00215-4; Erreger K, 2005, J PHYSIOL-LONDON, V563, P345, DOI 10.1113/jphysiol.2004.080028; Erreger Kevin, 2004, Critical Reviews in Neurobiology, V16, P187; Folta-Stogniew E, 1999, J Biomol Tech, V10, P51; FORSYTHE ID, 1988, J PHYSIOL-LONDON, V396, P515, DOI 10.1113/jphysiol.1988.sp016975; Furukawa H, 2003, EMBO J, V22, P2873, DOI 10.1093/emboj/cdg303; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; Inanobe A, 2005, NEURON, V47, P71, DOI 10.1016/j.neuron.2005.05.022; Jin RS, 2005, J NEUROSCI, V25, P9027, DOI 10.1523/JNEUROSCI.2567-05.2005; Jin RS, 2002, BIOCHEMISTRY-US, V41, P15635, DOI 10.1021/bi020583k; JOHNSON JW, 1987, NATURE, V325, P529, DOI 10.1038/325529a0; Jones TA, 1997, METHOD ENZYMOL, V277, P173, DOI 10.1016/S0076-6879(97)77012-5; KABSCH W, 1976, ACTA CRYSTALLOGR A, V32, P922, DOI 10.1107/S0567739476001873; KANDEL ER, 1995, ESSENTIALS NEURAL SC, P219; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Laube B, 2004, NEUROPHARMACOLOGY, V47, P994, DOI 10.1016/j.neuropharm.2004.07.041; LAURIE DJ, 1994, EUR J PHARM-MOLEC PH, V268, P335, DOI 10.1016/0922-4106(94)90058-2; LESTER RAJ, 1990, NATURE, V346, P565, DOI 10.1038/346565a0; MACDERMOTT AB, 1986, NATURE, V321, P519, DOI 10.1038/321519a0; Mayer ML, 2005, NEURON, V45, P539, DOI 10.1016/j.neuron.2005.01.031; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Meddows E, 2001, J BIOL CHEM, V276, P18795, DOI 10.1074/jbc.M101382200; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; Nanao MH, 2005, P NATL ACAD SCI USA, V102, P1708, DOI 10.1073/pnas.0409573102; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Regalado MP, 2001, NEURON, V32, P1085, DOI 10.1016/S0896-6273(01)00539-6; Schorge S, 2003, J NEUROSCI, V23, P1151, DOI 10.1523/JNEUROSCI.23-04-01151.2003; Schuck P, 2000, BIOPHYS J, V78, P1606, DOI 10.1016/S0006-3495(00)76713-0; Stern-Bach Y, 1998, NEURON, V21, P907, DOI 10.1016/S0896-6273(00)80605-4; Sun Y, 2002, NATURE, V417, P245, DOI 10.1038/417245a; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Vicini S, 1998, J NEUROPHYSIOL, V79, P555, DOI 10.1152/jn.1998.79.2.555; WATANABE M, 1992, NEUROREPORT, V3, P1138, DOI 10.1097/00001756-199212000-00027; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WATKINS JC, 1990, TRENDS PHARMACOL SCI, V11, P25, DOI 10.1016/0165-6147(90)90038-A; Waxman EA, 2005, NEUROSCIENTIST, V11, P37, DOI 10.1177/1073858404269012; WERNER P, 1991, NATURE, V351, P742, DOI 10.1038/351742a0; YPHANTIS D, 1997, WINNONLIN106 PROGRAM	50	566	593	0	64	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					185	192		10.1038/nature04089	http://dx.doi.org/10.1038/nature04089			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281028				2022-12-28	WOS:000233133500040
J	Lummis, SCR; Beene, DL; Lee, LW; Lester, HA; Broadhurst, RW; Dougherty, DA				Lummis, SCR; Beene, DL; Lee, LW; Lester, HA; Broadhurst, RW; Dougherty, DA			Cis-trans isomerization at a proline opens the pore of a neurotransmitter-gated ion channel	NATURE			English	Article							RECEPTOR M2-M3 LOOP; ACETYLCHOLINE-RECEPTOR; 5-HT3 RECEPTOR; NICOTINIC RECEPTOR; GATING MECHANISM; GABA(A) RECEPTOR; AGONIST-BINDING; RESIDUES; ACCESSIBILITY; CONFORMATION	5-Hydroxytryptamine type 3 (5-HT3) receptors are members of the Cys-loop receptor superfamily(1). Neurotransmitter binding in these proteins triggers the opening (gating) of an ion channel by means of an as-yet-uncharacterized conformational change. Here we show that a specific proline ( Pro 8*), located at the apex of the loop between the second and third transmembrane helices (M2 - M3)(2,3), can link binding to gating through a cis-trans isomerization of the protein backbone. Using unnatural amino acid mutagenesis, a series of proline analogues with varying preference for the cis conformer was incorporated at the 8* position. Proline analogues that strongly favour the trans conformer produced nonfunctional channels. Among the functional mutants there was a strong correlation between the intrinsic cis - trans energy gap of the proline analogue and the activation of the channel, suggesting that cis - trans isomerization of this single proline provides the switch that interconverts the open and closed states of the channel. Consistent with this proposal, nuclear magnetic resonance studies on an M2 - M3 loop peptide reveal two distinct, structured forms. Our results thus confirm the structure of the M2 - M3 loop and the critical role of Pro 8* in the 5-HT3 receptor. In addition, they suggest that a molecular rearrangement at Pro 8* is the structural mechanism that opens the receptor pore.	CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA; Univ Cambridge, Dept Biochem, Cambridge CB2 1GA, England; CALTECH, Div Biol, Pasadena, CA 91125 USA	California Institute of Technology; University of Cambridge; California Institute of Technology	Dougherty, DA (corresponding author), CALTECH, Div Chem & Chem Engn, Pasadena, CA 91125 USA.	dadougherty@caltech.edu	Broadhurst, Bill William/J-6710-2017	Broadhurst, Bill William/0000-0002-0264-4593	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		An SSA, 1999, J AM CHEM SOC, V121, P11558, DOI 10.1021/ja9930317; Beene DL, 2004, J NEUROSCI, V24, P9097, DOI 10.1523/JNEUROSCI.2429-04.2004; Beene DL, 2002, BIOCHEMISTRY-US, V41, P10262, DOI 10.1021/bi020266d; Bera AK, 2002, J BIOL CHEM, V277, P43002, DOI 10.1074/jbc.M206321200; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; Breitinger HGA, 2001, BIOCHEMISTRY-US, V40, P8419, DOI 10.1021/bi0106890; Brejc K, 2001, NATURE, V411, P269, DOI 10.1038/35077011; Colquhoun D, 1998, BRIT J PHARMACOL, V125, P924; Cox C, 1998, J AM CHEM SOC, V120, P10660, DOI 10.1021/ja9815071; Dang H, 2000, MOL PHARMACOL, V57, P1114; Dugave C, 2003, CHEM REV, V103, P2475, DOI 10.1021/cr0104375; Gao F, 2005, J BIOL CHEM, V280, P8443, DOI 10.1074/jbc.M412389200; Grosman C, 2000, J GEN PHYSIOL, V116, P327, DOI 10.1085/jgp.116.3.327; Halab L, 1999, J ORG CHEM, V64, P3312, DOI 10.1021/jo990294a; Jabs A, 1999, J MOL BIOL, V286, P291, DOI 10.1006/jmbi.1998.2459; Kash TL, 2003, NATURE, V421, P272, DOI 10.1038/nature01280; Kelley SP, 2003, NATURE, V424, P321, DOI 10.1038/nature01788; Kern D, 1997, J AM CHEM SOC, V119, P8403, DOI 10.1021/ja970606w; Lester HA, 2004, TRENDS NEUROSCI, V27, P329, DOI 10.1016/j.tins.2004.04.002; Lummis SCR, 2004, BIOCHEM SOC T, V32, P535, DOI 10.1042/BST0320535; Lynch JW, 2001, J NEUROSCI, V21, P2589, DOI 10.1523/JNEUROSCI.21-08-02589.2001; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MEEUS N, 2003, PA2ONLINE, V1; Miyazawa A, 2003, NATURE, V423, P949, DOI 10.1038/nature01748; Nowak MW, 1998, METHOD ENZYMOL, V293, P504; Reeves DC, 2003, BIOPHYS J, V84, P2338, DOI 10.1016/S0006-3495(03)75039-5; Sansom MSP, 2000, TRENDS PHARMACOL SCI, V21, P445; Taly A, 2005, BIOPHYS J, V88, P3954, DOI 10.1529/biophysj.104.050229; Unwin N, 2005, J MOL BIOL, V346, P967, DOI 10.1016/j.jmb.2004.12.031; Zhong WG, 1998, P NATL ACAD SCI USA, V95, P12088, DOI 10.1073/pnas.95.21.12088	30	379	382	0	66	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 10	2005	438	7065					248	252		10.1038/nature04130	http://dx.doi.org/10.1038/nature04130			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281040				2022-12-28	WOS:000233133500054
J	Kennedy, BK; Smith, ED; Kaeberlein, M				Kennedy, BK; Smith, ED; Kaeberlein, M			The enigmatic role of Sir2 in aging	CELL			English	Editorial Material							REPLICATIVE LIFE-SPAN; SACCHAROMYCES-CEREVISIAE; LONGEVITY; STRESS; YEAST; SCH9	In this issue of Cell, Longo and colleagues (Fabrizio et al., 2005) examine the role of Sir2, a histone deacetylase, in chronological aging in yeast by measuring the long-term survival of nondividing cells. In contrast to measurements of aging for mitotic cells, cell survival in the nonmitotic state is decreased by Sir2 activity under conditions that mimic calorie restriction.	Univ Washington, Dept Biochem, Seattle, WA 98195 USA; Univ Washington, Dept Genome Sci & Med, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Kennedy, BK (corresponding author), Univ Washington, Dept Biochem, Seattle, WA 98195 USA.			Kennedy, Brian/0000-0002-5754-1874				Blander G, 2004, ANNU REV BIOCHEM, V73, P417, DOI 10.1146/annurev.biochem.73.011303.073651; Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007; Fabrizio P, 2005, CELL, V123, P655, DOI 10.1016/j.cell.2005.08.042; Fabrizio P, 2004, FEBS LETT, V557, P136, DOI 10.1016/S0014-5793(03)01462-5; Fabrizio P, 2001, SCIENCE, V292, P288, DOI 10.1126/science.1059497; Kaeberlein M, 1999, GENE DEV, V13, P2570, DOI 10.1101/gad.13.19.2570; Kaeberlein M, 2004, PLOS BIOL, V2, P1381, DOI 10.1371/journal.pbio.0020296; Kaeberlein M, 2005, SCIENCE, V310, P1193, DOI 10.1126/science.1115535; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; Lemieux ME, 2005, MECH AGEING DEV, V126, P1097, DOI 10.1016/j.mad.2005.04.006; Picard F, 2004, NATURE, V429, P771, DOI 10.1038/nature02583	11	42	43	0	7	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 8	2005	123	4					548	550		10.1016/j.cell.2005.11.002	http://dx.doi.org/10.1016/j.cell.2005.11.002			3	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	987DA	16286003	Bronze			2022-12-28	WOS:000233497400004
J	Saad, M; Moorman, J				Saad, M; Moorman, J			Actinomyces hepatic abscess with cutaneous fistula	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									James H Quillen Vet Affairs Med Ctr, Johnson City, TN 37614 USA		Saad, M (corresponding author), James H Quillen Vet Affairs Med Ctr, Johnson City, TN 37614 USA.								0	8	8	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 3	2005	353	18					E16	E16		10.1056/NEJMicm050528	http://dx.doi.org/10.1056/NEJMicm050528			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979VJ	16267315				2022-12-28	WOS:000232972800012
J	Vlasov, YA; O'Boyle, M; Hamann, HF; McNab, SJ				Vlasov, YA; O'Boyle, M; Hamann, HF; McNab, SJ			Active control of slow light on a chip with photonic crystal waveguides	NATURE			English	Article							THERMOOPTICAL SWITCH	It is known that light can be slowed down in dispersive materials near resonances(1). Dramatic reduction of the light group velocity and even bringing light pulses to a complete halt - has been demonstrated recently in various atomic(2-5) and solid state systems(6-8), where the material absorption is cancelled via quantum optical coherent effects(3-5,7). Exploitation of slow light phenomena has potential for applications ranging from all-optical storage to all-optical switching(9,10). Existing schemes, however, are restricted to the narrow frequency range of the material resonance, which limits the operation frequency, maximum data rate and storage capacity(10). Moreover, the implementation of external lasers, low pressures and/or low temperatures prevents miniaturization and hinders practical applications. Here we experimentally demonstrate an over 300-fold reduction of the group velocity on a silicon chip via an ultra-compact photonic integrated circuit using low-loss silicon photonic crystal waveguides(11,12) that can support an optical mode with a submicrometre cross-section(13,14). In addition, we show fast (similar to 100 ns) and efficient (2 mW electric power) active control of the group velocity by localized heating of the photonic crystal waveguide with an integrated micro-heater.	IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA	International Business Machines (IBM)	Vlasov, YA (corresponding author), IBM Corp, Thomas J Watson Res Ctr, Yorktown Hts, NY 10598 USA.	yvlasov@us.ibm.com	Vlasov, Yurii A/E-8209-2011	Vlasov, Yurii A/0000-0002-5864-3346; Hamann, Hendrik/0000-0001-9049-1330				Altug H, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1882755; Astratov VN, 2000, APPL PHYS LETT, V77, P178, DOI 10.1063/1.126916; Bajcsy M, 2003, NATURE, V426, P638, DOI 10.1038/nature02176; Bendickson JM, 1996, PHYS REV E, V53, P4107, DOI 10.1103/PhysRevE.53.4107; Bigelow MS, 2003, SCIENCE, V301, P200, DOI 10.1126/science.1084429; Brillouin L., 1960, WAVE PROPAGATION GRO; Camargo EA, 2004, OPT EXPRESS, V12, P588, DOI 10.1364/OPEX.12.000588; COCORULLO G, 1992, ELECTRON LETT, V28, P83, DOI 10.1049/el:19920051; Dulkeith E, 2005, PHYS REV B, V72, DOI 10.1103/PhysRevB.72.115102; Espinola RL, 2003, IEEE PHOTONIC TECH L, V15, P1366, DOI 10.1109/LPT.2003.818246; Geis MW, 2004, IEEE PHOTONIC TECH L, V16, P2514, DOI 10.1109/LPT.2004.835194; Gersen H, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.073903; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; Johnson SG, 2001, OPT EXPRESS, V8, P173, DOI 10.1364/OE.8.000173; Khurgin JB, 2005, J OPT SOC AM B, V22, P1062, DOI 10.1364/JOSAB.22.001062; Krauss TF, 1996, NATURE, V383, P699, DOI 10.1038/383699a0; Ku PC, 2004, OPT LETT, V29, P2291, DOI 10.1364/OL.29.002291; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Lukin MD, 2001, NATURE, V413, P273, DOI 10.1038/35095000; McNab SJ, 2003, OPT EXPRESS, V11, P2927, DOI 10.1364/OE.11.002927; MCNAB SJ, 2004, Patent No. 20050084213A1; MCNAB SJ, 2003, Patent No. 20050084195A1; Mok JT, 2005, NATURE, V433, P811, DOI 10.1038/433811a; Notomi M, 2001, PHYS REV LETT, V87, DOI 10.1103/PhysRevLett.87.253902; Turukhin AV, 2002, PHYS REV LETT, V88, DOI 10.1103/PhysRevLett.88.023602; Vlasov YA, 2004, OPT EXPRESS, V12, P1622, DOI 10.1364/OPEX.12.001622; Vlasov YA, 1999, PHYS REV E, V60, P1030, DOI 10.1103/PhysRevE.60.1030; VLASOV YA, 2005, IN PRESS OPT LETT	28	1096	1137	14	358	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 3	2005	438	7064					65	69		10.1038/nature04210	http://dx.doi.org/10.1038/nature04210			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	979XS	16267549				2022-12-28	WOS:000232979000041
J	Carter, SG; Birkedal, V; Wang, CS; Coldren, LA; Maslov, AV; Citrin, DS; Sherwin, MS				Carter, SG; Birkedal, V; Wang, CS; Coldren, LA; Maslov, AV; Citrin, DS; Sherwin, MS			Quantum coherence in an optical modulator	SCIENCE			English	Article							FANO INTERFERENCE; WELLS DRIVEN; ABSORPTION; LIGHT; TRANSPARENCY; STORAGE	Semiconductor quantum well electroabsorption modulators are widely used to modulate near-infrared (NIR) radiation at frequencies below 0.1 terahertz (THz). Here, the NIR absorption of undoped quantum welts was modulated by strong electric fields with frequencies between 1.5 and 3.9 THz. The THz field coupled two excited states (excitons) of the quantum wells, as manifested by a new THz frequency- and power-dependent NIR absorption line. Nonperturbative theory and experiment indicate that the THz field generated a coherent quantum superposition of an absorbing and a nonabsorbing exciton. This quantum coherence may yield new applications for quantum well modulators in. optical communications.	Univ Calif Santa Barbara, Dept Phys, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Quantum & Complex Dynam, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Dept Elect & Comp Engn, Santa Barbara, CA 93106 USA; NASA, Ames Res Ctr, Ctr Nanotechnol, Moffett Field, CA 94035 USA; Georgia Inst Technol, Atlanta, GA 30332 USA; Georgia Tech Lorraine, Metz Technopole, F-57070 Metz, France	University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; National Aeronautics & Space Administration (NASA); NASA Ames Research Center; University System of Georgia; Georgia Institute of Technology	Sherwin, MS (corresponding author), Univ Calif Santa Barbara, Dept Phys, Broida Hall Bldg 572,Room 3410, Santa Barbara, CA 93106 USA.	sherwin@physics.ucsb.edu	Maslov, Alexey V/E-5158-2011; Sherwin, Mark S/Q-4762-2017; Carter, Sam G/G-4589-2012; Birkedal, Victoria/C-8899-2015	Maslov, Alexey V/0000-0002-7835-2474; Sherwin, Mark S/0000-0002-3869-1893; Carter, Sam G/0000-0001-8842-2053; Birkedal, Victoria/0000-0002-1360-8870				AUTLER SH, 1955, PHYS REV, V100, P703, DOI 10.1103/PhysRev.100.703; Davies J.H., 1998, PHYS LOW DIMENSIONAL; Dynes JF, 2005, PHYS REV LETT, V94, DOI 10.1103/PhysRevLett.94.157403; Faist J, 1996, OPT LETT, V21, P985, DOI 10.1364/OL.21.000985; Harris SE, 1997, PHYS TODAY, V50, P36, DOI 10.1063/1.881806; Hau LV, 1999, NATURE, V397, P594, DOI 10.1038/17561; Haug H., 2004, QUANTUM THEORY OPTIC, V4th ed.; Hughes S, 1999, PHYS REV B, V59, pR5288, DOI 10.1103/PhysRevB.59.R5288; Liu AS, 2000, J OPT SOC AM B, V17, P433, DOI 10.1364/JOSAB.17.000433; Liu C, 2001, NATURE, V409, P490, DOI 10.1038/35054017; Maslov AV, 2002, IEEE J SEL TOP QUANT, V8, P457, DOI 10.1109/JSTQE.2002.1016348; Maslov AV, 2002, J OPT SOC AM B, V19, P1905, DOI 10.1364/JOSAB.19.001905; Maslov AV, 2000, PHYS REV B, V62, P16686, DOI 10.1103/PhysRevB.62.16686; MILLER GA, 1990, PSYCHOL SCI, V1, P7, DOI 10.1111/j.1467-9280.1990.tb00059.x; Nordstrom KB, 1998, PHYS REV LETT, V81, P457, DOI 10.1103/PhysRevLett.81.457; Phillips DF, 2001, PHYS REV LETT, V86, P783, DOI 10.1103/PhysRevLett.86.783; Phillips MC, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.183602; Schmidt H, 1997, APPL PHYS LETT, V70, P3455, DOI 10.1063/1.119199; SCHMITTRINK S, 1989, ADV PHYS, V38, P89, DOI 10.1080/00018738900101102; SCULLY MO, 1997, QUANTUM OPT, pCH7; Serapiglia GB, 2000, PHYS REV LETT, V84, P1019, DOI 10.1103/PhysRevLett.84.1019	21	112	113	1	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					651	653		10.1126/science.1116195	http://dx.doi.org/10.1126/science.1116195			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254182				2022-12-28	WOS:000232997700034
J	Shiber, JR				Shiber, JR			Angioedema of the arytenoids	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									E Carolina Univ, Greenville, NC 27834 USA	University of North Carolina; East Carolina University	Shiber, JR (corresponding author), E Carolina Univ, Greenville, NC 27834 USA.								0	3	4	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	OCT 27	2005	353	17					E15	E15		10.1056/NEJMicm040964	http://dx.doi.org/10.1056/NEJMicm040964			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	977OL	16251529				2022-12-28	WOS:000232813000012
J	O'Shea, JN				O'Shea, JN			Molecular orbitals tell the story	SCIENCE			English	Editorial Material							SUPERCONDUCTIVITY		Univ Nottingham, Sch Phys & Astron, Nanosci Grp, Nottingham NG7 2RD, England	University of Nottingham	O'Shea, JN (corresponding author), Univ Nottingham, Sch Phys & Astron, Nanosci Grp, Nottingham NG7 2RD, England.	james.oshea@nottingham.ac.uk	O'Shea, James/B-5881-2016	O'Shea, James/0000-0003-4687-7257				Dahlke P, 2002, CHEM MATER, V14, P1285, DOI 10.1021/cm010386s; Durand P, 2003, NAT MATER, V2, P605, DOI 10.1038/nmat953; Fabrizio M, 1997, PHYS REV B, V55, P13465, DOI 10.1103/PhysRevB.55.13465; Gunnarsson O, 1997, REV MOD PHYS, V69, P575, DOI 10.1103/RevModPhys.69.575; HADDON RC, 1991, NATURE, V350, P320, DOI 10.1038/350320a0; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; Jahn HA, 1937, PROC R SOC LON SER-A, V161, P220, DOI 10.1098/rspa.1937.0142; MANINI N, 1994, PHYS REV B, V49, P13008, DOI 10.1103/PhysRevB.49.13008; Wachowiak A, 2005, SCIENCE, V310, P468, DOI 10.1126/science.1117303; Zhu ZT, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.045409	10	6	6	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					453	454		10.1126/science.1119274	http://dx.doi.org/10.1126/science.1119274			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239466				2022-12-28	WOS:000232786000033
J	Hogan, DR; Baltussen, R; Hayashi, C; Lauer, JA; Salomon, JA				Hogan, DR; Baltussen, R; Hayashi, C; Lauer, JA; Salomon, JA			Achieving the millennium development goals for health - Cost effectiveness analysis of strategies to combat HIV/AIDS in developing countries	BRITISH MEDICAL JOURNAL			English	Article							SEXUALLY-TRANSMITTED-DISEASES; HIV-PREVENTION; BEHAVIOR-CHANGE; TRIAL; INTERVENTIONS; IMPACT; RAKAI; TRANSMISSION; AFRICA; MWANZA	Objective To assess the costs and health effects of a range of interventions for preventing the spread of HIV and for treating people with HIV/AIDS in the context of the millennium development goal for combating HIV/AIDS. Design Cost effectiveness analysis based on an epidemiological model. Setting Analyses undertaken for two regions classified using the WHO epidemiological grouping-Afr-E, countries in sub-Saharan Africa with very high adult and high child mortality, and Sear-D, countries in South East Asia with high adult and high child mortality. Data sources Biological and behavioural parameters from clinical and observational studies and population based surveys. Intervention effects and resource inputs based on published reports, expert opinion, and the WHO-CHOICE database. Main outcome measures Costs per disability adjusted life year (DALY) averted in 2000 international dollars ($Int). Results In both regions interventions focused on mass media, education and treatment of sexually transmitted infections for female sex workers, amid treatment of sexually transmitted infections in the general population cost < $Int150 per DALY averted. Voluntary counselling and testing costs < $Int350 per DALY averted in both regions, while prevention of mother to child transmission costs < $Int50 per DALY averted in Afr-E but around $Int850 per DALY in Sear-D. School based education strategies and various antiretroviral treatment strategies cost between $Int500 and $Int5000 per DALY averted. Conclusions Reducing HIV transmission could be done most efficiently through mass media campaigns, interventions for sex workers and treatment of sexually transmitted infections where resources are most scarce. However, prevention of mother to child transmission, voluntary counselling and testing, and school based education would yield further health gains at higher budget levels and would be regarded as cost effective or highly cost effective based on standard international benchmarks. Antiretroviral therapy is at least as cost effective in improving population health as some of these interventions.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Harvard Ctr Populat & Dev Studies, Cambridge, MA 02138 USA; Erasmus MC, Inst Med Technol Assessment, Rotterdam, Netherlands; WHO, Strateg Informat & Res, Dept HIV AIDS, CH-1211 Geneva, Switzerland; WHO, Costs Effectiveness Expenditure & Prior Setting T, Hlth Syst Financing Dept, CH-1211 Geneva, Switzerland	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Erasmus University Rotterdam; Erasmus MC; World Health Organization; World Health Organization	Salomon, JA (corresponding author), Harvard Univ, Sch Publ Hlth, Harvard Univ Initiat Global Hlth, 104 Mt Auburn St,3rd Floor, Cambridge, MA 02138 USA.	jsalomon@hsph.harvard.edu	Salomon, Joshua/S-1929-2019; Salomon, Joshua A/D-3898-2009; Baltussen, R.M.P.M./L-4181-2015	Salomon, Joshua/0000-0003-3929-5515; Salomon, Joshua A/0000-0003-3929-5515; Lauer, Jeremy A/0000-0003-0652-0691	NIA NIH HHS [P01 AG17625] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P01AG017625] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bollinger L, 2004, STUD FAMILY PLANN, V35, P27, DOI 10.1111/j.1728-4465.2004.00003.x; Creese A, 2002, LANCET, V359, P1635, DOI 10.1016/S0140-6736(02)08595-1; Dixon S, 2002, BRIT MED J, V324, P232, DOI 10.1136/bmj.324.7331.232; Evans DB, 2005, BMJ-BRIT MED J, V331, P1137, DOI 10.1136/bmj.331.7525.1137; Grosskurth H, 2000, LANCET, V355, P1981, DOI 10.1016/S0140-6736(00)02336-9; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; Gutierrez JP, 2004, LANCET, V364, P63, DOI 10.1016/S0140-6736(04)16590-2; GUTIERREZ JP, 2004, 15 INT AIDS C SAT SE; GUTIERREZ JP, 2004, 15 IN AIDS C SAT SES; Kamali A, 2003, LANCET, V361, P645, DOI 10.1016/S0140-6736(03)12598-6; Koopman JS, 1997, J ACQ IMMUN DEF SYND, V14, P249, DOI 10.1097/00042560-199703010-00009; Korenromp EL, 2002, AIDS, V16, P2209, DOI 10.1097/00002030-200211080-00014; KOREURONIP EL, 2002, AIDS, V16, P2299; Marseille E, 2002, LANCET, V359, P1851, DOI 10.1016/S0140-6736(02)08705-6; Mukherjee JS, 2003, BMJ-BRIT MED J, V327, P1104, DOI 10.1136/bmj.327.7423.1104; Orroth KK, 2003, SEX TRANSM INFECT, V79, P98, DOI 10.1136/sti.79.2.98; Quinn TC, 2000, NEW ENGL J MED, V342, P921, DOI 10.1056/NEJM200003303421303; Salomon JA, 2005, PLOS MED, V2, P50, DOI 10.1371/journal.pmed.0020016; Schwartlander B, 2001, SCIENCE, V292, P2434, DOI 10.1126/science.1062876; Stover J, 2002, LANCET, V360, P73, DOI 10.1016/S0140-6736(02)09339-X; *UNAIDS, 2004, AIDS EP UPD DEC 2004; Walker D, 2003, HEALTH POLICY PLANN, V18, P4, DOI 10.1093/heapol/18.1.4; Wawer MJ, 1999, LANCET, V353, P525, DOI 10.1016/S0140-6736(98)06439-3; White RG, 2004, JAIDS-J ACQ IMM DEF, V37, P1500, DOI 10.1097/01.qai.0000127062.94627.31; World Health Organization (WHO), 2005, ANT DRUGS PREV MOTH	25	116	118	0	23	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	DEC 17	2005	331	7530					1431	1435		10.1136/bmj.38643.368692.68	http://dx.doi.org/10.1136/bmj.38643.368692.68			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	996EE	16282380	Green Published, Bronze, Green Accepted, Green Submitted			2022-12-28	WOS:000234156400017
J	Tu, BP; Kudlicki, A; Rowicka, M; McKnight, SL				Tu, BP; Kudlicki, A; Rowicka, M; McKnight, SL			Logic of the yeast metabolic cycle: Temporal compartmentalization of cellular processes	SCIENCE			English	Article							REDUCED PYRIDINE-NUCLEOTIDE; CIRCADIAN GENE-EXPRESSION; SACCHAROMYCES-CEREVISIAE; GLOBAL ANALYSIS; TRANSCRIPTION; OSCILLATIONS; CLOCK; ORCHESTRATION; LOCALIZATION; DIVISION	Budding yeast grown under continuous, nutrient-limited conditions exhibit robust, highly periodic cycles in the form of respiratory bursts. Microarray studies reveal that over half of the yeast genome is expressed periodically during these metabolic cycles. Genes encoding proteins having a common function exhibit similar temporal expression patterns, and genes specifying functions associated with energy and metabolism tend to be expressed with exceptionally robust periodicity. Essential cellular and metabolic events occur in synchrony with the metabolic cycle, demonstrating that key processes in a simple eukaryotic cell are compartmentalized in time.	Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75390 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	McKnight, SL (corresponding author), Univ Texas, SW Med Ctr, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	smckni@biochem.swmed.edu	Rowicka, Maga/E-2496-2012; Kudlicki, Andrzej/AAG-8537-2019; Kudlicki, Andrzej/C-7612-2012	Rowicka, Maga/0000-0002-4011-071X; Kudlicki, Andrzej/0000-0001-8158-9600; 				BAILEY TL, 1994, P 2 INT C INT SYST M, P28; CHANCE B, 1964, P NATL ACAD SCI USA, V52, P337, DOI 10.1073/pnas.52.2.337; CHANCE B, 1964, P NATL ACAD SCI USA, V51, P1244, DOI 10.1073/pnas.51.6.1244; Claridge-Chang A, 2001, NEURON, V32, P657, DOI 10.1016/S0896-6273(01)00515-3; Conibear E, 2002, METHOD ENZYMOL, V351, P408; Correa A, 2003, P NATL ACAD SCI USA, V100, P13597, DOI 10.1073/pnas.2233734100; Damiola F, 2000, GENE DEV, V14, P2950, DOI 10.1101/gad.183500; Dioum EM, 2002, SCIENCE, V298, P2385, DOI 10.1126/science.1078456; Gerber AP, 2004, PLOS BIOL, V2, P342, DOI 10.1371/journal.pbio.0020079; Ghaemmaghami S, 2003, NATURE, V425, P737, DOI 10.1038/nature02046; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; Golden SS, 2003, NAT REV MICROBIOL, V1, P191, DOI 10.1038/nrmicro774; Henke JM, 2004, TRENDS CELL BIOL, V14, P648, DOI 10.1016/j.tcb.2004.09.012; HOMMES FA, 1964, ARCH BIOCHEM BIOPHYS, V108, P36, DOI 10.1016/0003-9861(64)90352-2; Huh WK, 2003, NATURE, V425, P686, DOI 10.1038/nature02026; Klevecz RR, 2004, P NATL ACAD SCI USA, V101, P1200, DOI 10.1073/pnas.0306490101; Kuge S, 1997, EMBO J, V16, P1710, DOI 10.1093/emboj/16.7.1710; LIU Y, 1995, GENE DEV, V9, P1469, DOI 10.1101/gad.9.12.1469; Lloyd D, 2005, TRENDS BIOCHEM SCI, V30, P373, DOI 10.1016/j.tibs.2005.05.005; Maeta K, 2004, MOL CELL BIOL, V24, P8753, DOI 10.1128/MCB.24.19.8753-8764.2004; MARGULIS L, 1981, SYMBIOSIS CELL EVOLU, pR22; Matsuo T, 2003, SCIENCE, V302, P255, DOI 10.1126/science.1086271; Mori T, 1996, P NATL ACAD SCI USA, V93, P10183, DOI 10.1073/pnas.93.19.10183; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/S0092-8674(04)01054-2; Palkova Z, 2002, MOL BIOL CELL, V13, P3901, DOI 10.1091/mbc.E01-12-0149; Panda S, 2002, CELL, V109, P307, DOI 10.1016/S0092-8674(02)00722-5; PORRO D, 1988, BIOTECHNOL BIOENG, V32, P411, DOI 10.1002/bit.260320402; Pramila T, 2002, GENE DEV, V16, P3034, DOI 10.1101/gad.1034302; Princiotta MF, 2003, IMMUNITY, V18, P343, DOI 10.1016/S1074-7613(03)00051-7; Richard P, 2003, FEMS MICROBIOL REV, V27, P547, DOI 10.1016/S0168-6445(03)00065-2; Rutter J, 2002, ANNU REV BIOCHEM, V71, P307, DOI 10.1146/annurev.biochem.71.090501.142857; Rutter J, 2001, SCIENCE, V293, P510, DOI 10.1126/science.1060698; SATROUTDINOV AD, 1992, FEMS MICROBIOL LETT, V98, P261, DOI 10.1016/0378-1097(92)90167-M; Stokkan KA, 2001, SCIENCE, V291, P490, DOI 10.1126/science.291.5503.490; STRYER L, 1995, BIOCHEMISTRY-US, pR34; van Dijken JP, 2000, ENZYME MICROB TECH, V26, P706, DOI 10.1016/S0141-0229(00)00162-9; VONMEYEN HK, 1969, ARCH MIKROBIOL, V66, P289; Wu J, 2000, EMBO J, V19, P5672, DOI 10.1093/emboj/19.21.5672	38	654	689	1	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 18	2005	310	5751					1152	1158		10.1126/science.1120499	http://dx.doi.org/10.1126/science.1120499			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	986GE	16254148				2022-12-28	WOS:000233437300037
J	Grishchuk, EL; Molodtsov, MI; Ataullakhanov, FI; McIntosh, JR				Grishchuk, EL; Molodtsov, MI; Ataullakhanov, FI; McIntosh, JR			Force production by disassembling microtubules	NATURE			English	Article							SLOWLY HYDROLYZABLE ANALOG; INDIVIDUAL MICROTUBULES; DYNAMIC INSTABILITY; GTP HYDROLYSIS; IN-VITRO; DEPOLYMERIZATION; COMPLEX; CHROMOSOMES; INFORMATION; GENERATION	Microtubules (MTs) are important components of the eukaryotic cytoskeleton: they contribute to cell shape and movement, as well as to the motions of organelles including mitotic chromosomes. MTs bind motor enzymes that drive many such movements, but MT dynamics can also contribute to organelle motility(1-8). Each MT polymer is a store of chemical energy that can be used to do mechanical work, but how this energy is converted to motility remains unknown. Here we show, by conjugating glass microbeads to tubulin polymers through strong inert linkages, such as biotin-avidin, that depolymerizing MTs exert a brief tug on the beads, as measured with laser tweezers. Analysis of these interactions with a molecular-mechanical model of MT structure and force production(9,10) shows that a single depolymerizing MT can generate about ten times the force that is developed by a motor enzyme; thus, this mechanism might be the primary driving force for chromosome motion. Because even the simple coupler used here slows MT disassembly, physiological couplers may modulate MT dynamics in vivo.	Univ Colorado, MCD Biol Dept, Boulder, CO 80309 USA; Inst Gen Pathol & Pathophysiol, Moscow 125315, Russia; Natl Res Ctr Haematol, Moscow 125167, Russia; Moscow MV Lomonosov State Univ, Dept Phys, Moscow 119992, Russia; Russian Acad Sci, Inst Theoret & Expt Biophys, Pushchino 142292, Russia	University of Colorado System; University of Colorado Boulder; Russian Academy of Medical Sciences; Institute of General Pathology & Pathophysiology, RAMS; Russian Academy of Medical Sciences; National Medical Research Center for Hematology; Lomonosov Moscow State University; Russian Academy of Sciences; Pushchino Scientific Center for Biological Research (PSCBI) of the Russian Academy of Sciences; Institute of Theoretical & Experimental Biophysics	McIntosh, JR (corresponding author), Univ Colorado, MCD Biol Dept, Boulder, CO 80309 USA.	richard.mcintosh@colorado.edu	McIntosh, Richard/GLN-3533-2022; Ataullakhanov, Fazoil/J-8076-2012; Ataullakhanov, Fazoil/O-3458-2019	Molodtsov, Maxim/0000-0002-3066-0515				Allersma MW, 1998, BIOPHYS J, V74, P1074, DOI 10.1016/S0006-3495(98)74031-7; Brouhard GJ, 2003, IEEE T BIO-MED ENG, V50, P121, DOI 10.1109/TBME.2002.805463; CAPLOW M, 1994, J CELL BIOL, V127, P779, DOI 10.1083/jcb.127.3.779; COUE M, 1991, J CELL BIOL, V112, P1165, DOI 10.1083/jcb.112.6.1165; Dogterom M, 2005, CURR OPIN CELL BIOL, V17, P67, DOI 10.1016/j.ceb.2004.12.011; FYGENSON DK, 1994, PHYS REV E, V50, P1579, DOI 10.1103/PhysRevE.50.1579; Gigant B, 2000, CELL, V102, P809, DOI 10.1016/S0092-8674(00)00069-6; GILDERSLEEVE RF, 1992, J BIOL CHEM, V267, P7995; Howard J, 2003, NATURE, V422, P753, DOI 10.1038/nature01600; Hunt AJ, 1998, MOL BIOL CELL, V9, P2857, DOI 10.1091/mbc.9.10.2857; HYMAN AA, 1992, MOL BIOL CELL, V3, P1155, DOI 10.1091/mbc.3.10.1155; INOUE S, 1995, MOL BIOL CELL, V6, P1619, DOI 10.1091/mbc.6.12.1619; KOSHLAND DE, 1988, NATURE, V331, P499, DOI 10.1038/331499a0; LOMBILLO VA, 1995, NATURE, V373, P161, DOI 10.1038/373161a0; LOMBILLO VA, 1995, J CELL BIOL, V128, P107, DOI 10.1083/jcb.128.1.107; MANDELKOW EM, 1991, J CELL BIOL, V114, P977, DOI 10.1083/jcb.114.5.977; McIntosh JR, 2002, ANNU REV CELL DEV BI, V18, P193, DOI 10.1146/annurev.cellbio.18.032002.132412; Miranda JJL, 2005, NAT STRUCT MOL BIOL, V12, P138, DOI 10.1038/nsmb896; Molodtsov MI, 2005, BIOPHYS J, V88, P3167, DOI 10.1529/biophysj.104.051789; Molodtsov MI, 2005, P NATL ACAD SCI USA, V102, P4353, DOI 10.1073/pnas.0501142102; Muller-Reichert T, 1998, P NATL ACAD SCI USA, V95, P3661, DOI 10.1073/pnas.95.7.3661; Nicklas RB, 1997, SCIENCE, V275, P632, DOI 10.1126/science.275.5300.632; OBRIEN ET, 1990, BIOCHEMISTRY-US, V29, P6648, DOI 10.1021/bi00480a014; SVOBODA K, 1994, CELL, V77, P773, DOI 10.1016/0092-8674(94)90060-4; VIGERS GPA, 1988, J CELL BIOL, V107, P1011, DOI 10.1083/jcb.107.3.1011; Visscher K, 1998, METHOD ENZYMOL, V298, P460, DOI 10.1016/S0076-6879(98)98040-5; WALKER RA, 1988, J CELL BIOL, V107, P1437, DOI 10.1083/jcb.107.4.1437; Waterman-Storer CM, 1999, NAT CELL BIOL, V1, P45, DOI 10.1038/9018; Waterman-Storer CM, 1998, CURR BIOL, V8, P798, DOI 10.1016/S0960-9822(98)70321-5; Westermann S, 2005, MOL CELL, V17, P277, DOI 10.1016/j.molcel.2004.12.019	30	211	218	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					384	388		10.1038/nature04132	http://dx.doi.org/10.1038/nature04132			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292315				2022-12-28	WOS:000233300200054
J	Hughes, RAC; Cornblath, DR				Hughes, RAC; Cornblath, DR			Guillain-Barre syndrome	LANCET			English	Review							INFLAMMATORY DEMYELINATING POLYNEUROPATHY; MOTOR AXONAL NEUROPATHY; CAMPYLOBACTER-JEJUNI INFECTION; MILLER-FISHER SYNDROME; EXPERIMENTAL AUTOIMMUNE NEURITIS; EXPERIMENTAL ALLERGIC NEURITIS; ACUTE IDIOPATHIC POLYNEURITIS; ACUTE QUADRIPLEGIC MYOPATHY; RANDOMIZED CONTROLLED-TRIAL; ANTI-GLYCOLIPID ANTIBODIES	Guillain-Barre syndrome consists of at least four subtypes of acute peripheral neuropathy. Major advances have been made in understanding the mechanisms of some of the subtypes. The histological appearance of the acute inflammatory demyelinating polyradiculoneuropathy (AIDP) subtype resembles experimental autoimmune neuritis, which is predominantly caused by T cells directed against peptides from the myelin proteins P0, P2, and PMP22. The role of T-cell-mediated immunity in AIDP remains unclear and there is evidence for the involvement of antibodies and complement. Strong evidence now exists that axonal subtypes of Guillain-Barre syndrome, acute motor axonal neuropathy (AMAN), and acute motor and sensory axonal neuropathy (AMSAN), are caused by antibodies to gangliosides on the axolemma that target macrophages to invade the axon at the node of Ranvier. About a quarter of patients with Guillain-Barre syndrome have had a recent Campylobacter jejuni infection, and axonal forms of the disease are especially common in these people. The lipo-oligosaccharide from the C jejuni bacterial wall contains ganglioside-like structures and its injection into rabbits induces a neuropathy that resembles acute motor axonal neuropathy. Antibodies to GM1, GM1b, GD1a, and Ga1Nac-GD1a are in particular implicated in acute motor axonal neuropathy and, with the exception of Ga1NacGD1a, in acute motor and sensory axonal neuropathy. The Fisher's syndrome subtype is especially associated with antibodies to GQ1b, and similar cross-reactivity with ganglioside structures in the wall of C jejuni has been discovered. Anti-GQ1b antibodies have been shown to damage the motor nerve terminal in vitro by a complement-mediated mechanism. Results of international randomised trials have shown equivalent efficacy of both plasma exchange and intravenous immunoglobulin, but not corticosteroids, in hastening recovery from Guillain-Barre syndrome. Further research is needed to discover treatments to prevent 20% of patients from being left with persistent and significant disability.	Guys Hosp, Kings Coll London Sch Med, Dept Clin Neurosci, London, England; Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA	Guy's & St Thomas' NHS Foundation Trust; University of London; King's College London; Johns Hopkins University	Hughes, RAC (corresponding author), Guys Hosp, Kings Coll London Sch Med, Dept Clin Neurosci, London, England.	richard.a.hughes@kcl.ac.uk						ALBERS JW, 1985, MUSCLE NERVE, V8, P528, DOI 10.1002/mus.880080609; ALBERS JW, 1989, MUSCLE NERVE, V12, P435, DOI 10.1002/mus.880120602; ALDIN AN, 1982, BRAIN, V105, P481, DOI 10.1093/brain/105.3.481; Ammache Z, 2001, J CHILD NEUROL, V16, P477; Ang CW, 2004, TRENDS IMMUNOL, V25, P61, DOI 10.1016/j.it.2003.12.004; Annane D, 1997, ANN NEUROL, V41, P298; ANNANE D, 2005, COCHRANE COLLABORATI, V2; [Anonymous], 1985, Neurology, V35, P1096; Asahina M, 2002, ACTA NEUROL SCAND, V105, P44, DOI 10.1034/j.1600-0404.2002.00099.x; ASBURY AK, 1990, ANN NEUROL, V27, pS21, DOI 10.1002/ana.410270707; ASBURY AK, 1969, MEDICINE, V48, P173, DOI 10.1097/00005792-196905000-00001; Bechtold DA, 2005, BRAIN, V128, P18, DOI 10.1093/brain/awh328; Bensa S, 2000, EUR J NEUROL, V7, P423, DOI 10.1046/j.1468-1331.2000.00096.x; BenSmith A, 1996, J NEUROL NEUROSUR PS, V61, P362, DOI 10.1136/jnnp.61.4.362; Berciano J, 1997, MUSCLE NERVE, V20, P846; Bernsen RAJAM, 2002, J NEUROL SCI, V201, P13, DOI 10.1016/S0022-510X(02)00158-2; Bernsen RAJAM, 1999, NEUROLOGY, V53, P409, DOI 10.1212/WNL.53.2.409; Bernsen RAJAM, 1997, J NEUROL NEUROSUR PS, V62, P637, DOI 10.1136/jnnp.62.6.637; BLASER MJ, 1991, LANCET, V338, P308, DOI 10.1016/0140-6736(91)90447-W; Bogliun G, 2004, ACTA NEUROL SCAND, V110, P100, DOI 10.1111/j.1600-0404.2004.00272.x; BRADSHAW DY, 1992, MUSCLE NERVE, V15, P500, DOI 10.1002/mus.880150415; BROWN WF, 1984, BRAIN, V107, P219, DOI 10.1093/brain/107.1.219; BROWN WF, 1991, J NEUROL NEUROSUR PS, V54, P768, DOI 10.1136/jnnp.54.9.768; Bulsara KR, 2001, TRANSPLANTATION, V71, P1169, DOI 10.1097/00007890-200104270-00026; Cheng Q, 2002, J NEUROL, V249, P25, DOI 10.1007/PL00007844; Chiba A, 1997, BRAIN RES, V745, P32, DOI 10.1016/S0006-8993(96)01123-7; Chio A, 2003, NEUROLOGY, V60, P1146, DOI 10.1212/01.WNL.0000055091.96905.D0; COMBLATH DR, 1993, WHPIRENMNHEPI933; CORNBLATH DR, 1991, NEUROLOGY, V41, P617; CORNBLATH DR, 1990, ANN NEUROL, V27, pS17, DOI 10.1002/ana.410270706; Creange A, 1999, NEUROLOGY, V53, P1683, DOI 10.1212/WNL.53.8.1683; Dahle C, 1997, J NEUROL SCI, V153, P54, DOI 10.1016/S0022-510X(97)00178-0; Dalakas MC, 2004, JAMA-J AM MED ASSOC, V291, P2367, DOI 10.1001/jama.291.19.2367; De La Cour CD, 2005, MUSCLE NERVE, V31, P70, DOI 10.1002/mus.20240; de la Cour CD, 2005, NEUROLOGY, V64, P246, DOI 10.1212/01.WNL.0000149521.65474.83; Esperou H, 2000, INTENS CARE MED, V26, P1094, DOI 10.1007/s001340051323; Farcas P, 1997, LANCET, V350, P1747, DOI 10.1016/S0140-6736(97)24050-X; FISHER M, 1956, NEW ENGL J MED, V255, P57, DOI 10.1056/NEJM195607122550201; FROSS RD, 1987, NEUROLOGY, V37, P1493, DOI 10.1212/WNL.37.9.1493; Gabriel CM, 2000, J NEUROIMMUNOL, V104, P139, DOI 10.1016/S0165-5728(99)00269-6; Gabriel CM, 1998, BRAIN, V121, P1895, DOI 10.1093/brain/121.10.1895; Garssen MPJ, 2004, NEUROLOGY, V63, P2393, DOI 10.1212/01.WNL.0000148589.87107.9C; Geleijns K, 2004, J NEUROIMMUNOL, V150, P132, DOI 10.1016/j.jneuroim.2004.01.003; Geleijns K, 2005, NEUROLOGY, V64, P44, DOI 10.1212/01.WNL.0000148727.02732.01; GOLDSCHALK PC, 2004, J CLIN INVEST, V114, P1659; Gong Y, 2002, BRAIN, V125, P2491, DOI 10.1093/brain/awf258; Goodfellow JA, 2005, J NEUROSCI, V25, P1620, DOI 10.1523/JNEUROSCI.4279-04.2005; Goodyear CS, 1999, J CLIN INVEST, V104, P697, DOI 10.1172/JCI6837; Gordon PH, 2001, ARCH NEUROL-CHICAGO, V58, P913, DOI 10.1001/archneur.58.6.913; GORODEZKY C, 1983, J NEUROIMMUNOL, V4, P1, DOI 10.1016/0165-5728(83)90058-9; Govoni V, 2003, J NEUROL SCI, V216, P99, DOI 10.1016/S0022-510X(03)00215-6; Govoni V, 2001, CURR OPIN NEUROL, V14, P605, DOI 10.1097/00019052-200110000-00009; Green DM, 2001, ARCH NEUROL-CHICAGO, V58, P1098, DOI 10.1001/archneur.58.7.1098; GRIFFIN JW, 1995, BRAIN, V118, P577, DOI 10.1093/brain/118.3.577; Griffin JW, 1996, J NEUROCYTOL, V25, P33, DOI 10.1007/BF02284784; Griffin JW, 1996, ANN NEUROL, V39, P17, DOI 10.1002/ana.410390105; Guillain G., 1916, B MEM SOC MED HOP P, V40, P1462; GUILOFF RJ, 1977, J NEUROL NEUROSUR PS, V40, P801, DOI 10.1136/jnnp.40.8.801; Haber P, 2004, JAMA-J AM MED ASSOC, V292, P2478, DOI 10.1001/jama.292.20.2478; Hadden RDM, 1998, ANN NEUROL, V44, P780, DOI 10.1002/ana.410440512; Hadden RDM, 2002, NEUROPATH APPL NEURO, V28, P489, DOI 10.1046/j.1365-2990.2002.00421.x; Hadden RDM, 2001, NEUROLOGY, V56, P758, DOI 10.1212/WNL.56.6.758; Hadden RDM, 1999, ANN NEUROL, V46, P484; HaferMacko C, 1996, ANN NEUROL, V40, P635, DOI 10.1002/ana.410400414; HaferMacko CE, 1996, ANN NEUROL, V39, P627, DOI 10.1002/ana.410390512; HALL SM, 1992, ANN NEUROL, V31, P441, DOI 10.1002/ana.410310416; Halstead SK, 2004, BRAIN, V127, P2109, DOI 10.1093/brain/awh231; Hao Q, 1998, J NEUROIMMUNOL, V81, P116, DOI 10.1016/S0165-5728(97)00166-5; HARVEY GK, 1995, MUSCLE NERVE, V18, P388, DOI 10.1002/mus.880180404; HEMACHUDHA T, 1988, NEUROLOGY, V38, P375, DOI 10.1212/WNL.38.3.375; Hiraga A, 2005, J NEUROL NEUROSUR PS, V76, P719, DOI 10.1136/jnnp.2004.051136; Hiraga A, 2005, NEUROLOGY, V64, P856, DOI 10.1212/01.WNL.0000153071.71335.E9; Hiraga A, 2003, NEUROLOGY, V61, P471, DOI 10.1212/01.WNL.0000081231.08914.A1; Hirota N, 1997, BRAIN, V120, P2159, DOI 10.1093/brain/120.12.2159; Ho TW, 1997, NEUROLOGY, V48, P695, DOI 10.1212/WNL.48.3.695; HO TW, 1995, BRAIN, V118, P597, DOI 10.1093/brain/118.3.597; Ho TW, 1999, ANN NEUROL, V45, P168, DOI 10.1002/1531-8249(199902)45:2<168::AID-ANA6>3.0.CO;2-6; HUGHES R, 1992, ARCH NEUROL-CHICAGO, V49, P612, DOI 10.1001/archneur.1992.00530300044009; Hughes R., 2000, COCHRANE DB SYST REV, V2; Hughes R.A., 1990, GUILLAIN BARRE SYNDR; HUGHES RA, 2001, COCHRANE DB SYST REV, V2, P2063; Hughes RAC, 2005, ARCH NEUROL-CHICAGO, V62, P1194, DOI 10.1001/archneur.62.8.1194; Hughes RAC, 2003, NEUROLOGY, V61, P736, DOI 10.1212/WNL.61.6.736; Hughes RAC, 1999, J NEUROIMMUNOL, V100, P74, DOI 10.1016/S0165-5728(99)00195-2; Hughes RAC, 1997, J INFECT DIS, V176, pS92, DOI 10.1086/513793; ILLA I, 1995, ANN NEUROL, V38, P218, DOI 10.1002/ana.410380214; KADLUBOWSKI M, 1979, NATURE, V277, P140, DOI 10.1038/277140a0; Kaida K, 2003, NEUROLOGY, V61, P465, DOI 10.1212/01.WNL.0000081229.88862.C6; KAPLAN JE, 1982, JAMA-J AM MED ASSOC, V248, P698, DOI 10.1001/jama.248.6.698; KAPLAN JE, 1983, NEUROLOGY, V33, P633, DOI 10.1212/WNL.33.5.633; Khalili-Shirazi A, 1999, J NEUROL NEUROSUR PS, V66, P376, DOI 10.1136/jnnp.66.3.376; Khalili-Shirazi A, 1998, J NEUROL SCI, V158, P154, DOI 10.1016/S0022-510X(98)00121-X; KHALILISHIRAZI A, 1993, J NEUROIMMUNOL, V46, P245, DOI 10.1016/0165-5728(93)90255-W; KHALILISHIRAZI A, 1992, J NEUROL SCI, V111, P200, DOI 10.1016/0022-510X(92)90069-W; Kieseier BC, 2004, MUSCLE NERVE, V30, P131, DOI 10.1002/mus.20076; Koga M, 2005, NEUROLOGY, V64, P1605, DOI 10.1212/01.WNL.0000160399.08456.7C; Koga M, 2003, J NEUROIMMUNOL, V141, P112, DOI 10.1016/S0165-5728(03)00212-1; Koga M, 2001, NEUROLOGY, V57, P686, DOI 10.1212/WNL.57.4.686; Korinthenberg R, 2005, PEDIATRICS, V116, P8, DOI 10.1542/peds.2004-1324; Kusunoki S, 1996, ANN NEUROL, V39, P424, DOI 10.1002/ana.410390404; Kusunoki S, 2003, MUSCLE NERVE, V27, P302, DOI 10.1002/mus.10307; Kuwabara S, 2004, NEUROLOGY, V63, P529, DOI 10.1212/01.WNL.0000133205.05169.04; Kuwabara S, 2003, MUSCLE NERVE, V28, P683, DOI 10.1002/mus.10488; Kuwabara S, 1999, MUSCLE NERVE, V22, P840, DOI 10.1002/(SICI)1097-4598(199907)22:7<840::AID-MUS5>3.3.CO;2-U; Kwa MSG, 2001, J NEUROIMMUNOL, V116, P220, DOI 10.1016/S0165-5728(01)00307-1; LAMBERT EH, 1964, ELECTROEN CLIN NEURO, V17, P86; LAMPERT P, 1967, ACTA NEUROPATHOL, V9, P99, DOI 10.1007/BF00691436; LANGMUIR AD, 1984, AM J EPIDEMIOL, V119, P841, DOI 10.1093/oxfordjournals.aje.a113809; Lasky T, 1998, NEW ENGL J MED, V339, P1797, DOI 10.1056/NEJM199812173392501; Ma JJ, 1998, NEUROLOGY, V51, P379, DOI 10.1212/WNL.51.2.379; Ma JJ, 1998, ANN NEUROL, V44, P815, DOI 10.1002/ana.410440517; Magira EE, 2003, J IMMUNOL, V170, P3074, DOI 10.4049/jimmunol.170.6.3074; MCKHANN GM, 1988, ANN NEUROL, V23, P347, DOI 10.1002/ana.410230406; MCKHANN GM, 1993, ANN NEUROL, V33, P333, DOI 10.1002/ana.410330402; MCKHANN GM, 1991, LANCET, V338, P593, DOI 10.1016/0140-6736(91)90606-P; MCLEOD JG, 1981, ANN NEUROL, V9, P20, DOI 10.1002/ana.410090705; Merkies ISJ, 1999, NEUROLOGY, V53, P1648, DOI 10.1212/WNL.53.8.1648; Meulstee J, 1997, J Peripher Nerv Syst, V2, P143; Meythaler JM, 1997, ARCH PHYS MED REHAB, V78, P872, DOI 10.1016/S0003-9993(97)90203-3; MILNER P, 1987, J NEUROL SCI, V79, P275, DOI 10.1016/0022-510X(87)90235-8; Monos DS, 1997, J INFECT DIS, V176, pS180, DOI 10.1086/513786; Mori K, 2002, NEUROLOGY, V58, P979, DOI 10.1212/WNL.58.6.979; Mori M, 1999, NEUROLOGY, V52, P1282, DOI 10.1212/WNL.52.6.1282; MURRAY NMF, 1980, MUSCLE NERVE, V3, P444; Nachamkin I, 2002, INFECT IMMUN, V70, P5299, DOI 10.1128/IAI.70.9.5299-5303.2002; Nappi G, 2000, NEUROL SCI, V21, P229; O'Hanlon GM, 2001, BRAIN, V124, P893, DOI 10.1093/brain/124.5.893; Odaka M, 2003, J NEUROL, V250, P913, DOI 10.1007/s00415-003-1096-y; Ogawara K, 2000, ANN NEUROL, V48, P624, DOI 10.1002/1531-8249(200010)48:4<624::AID-ANA9>3.3.CO;2-F; Oh SJ, 2003, NEUROLOGY, V61, P1507, DOI 10.1212/01.WNL.0000096166.28131.4C; OLNEY RK, 1990, NEUROLOGY, V40, P471, DOI 10.1212/WNL.40.3_Part_1.471; Paradiso G, 1999, ANN NEUROL, V46, P701, DOI 10.1002/1531-8249(199911)46:5<701::AID-ANA4>3.0.CO;2-7; PETTE M, 1994, J NEUROIMMUNOL, V54, P29, DOI 10.1016/0165-5728(94)90227-5; PHILLIPS MS, 1984, J NEUROL NEUROSUR PS, V47, P492, DOI 10.1136/jnnp.47.5.492; Plomp JJ, 1999, ANN NEUROL, V45, P189, DOI 10.1002/1531-8249(199902)45:2<189::AID-ANA9>3.0.CO;2-T; PRINEAS JW, 1981, ANN NEUROL, V9, P6, DOI 10.1002/ana.410090704; PRINEAS JW, 1972, LAB INVEST, V26, P133; Pritchard J, 2004, LANCET, V363, P2186, DOI 10.1016/S0140-6736(04)16512-4; Pritchard J, 2003, NEUROLOGY, V61, P1282, DOI 10.1212/01.WNL.0000092019.53628.88; Pritchard J, 2002, J NEUROL NEUROSUR PS, V73, P348, DOI 10.1136/jnnp.73.3.348; Raphael JC, 2002, COCHRANE DB SYST REV, V2; REES JH, 1995, J NEUROIMMUNOL, V62, P53, DOI 10.1016/0165-5728(95)00102-8; REES JH, 1995, NEW ENGL J MED, V333, P1374, DOI 10.1056/NEJM199511233332102; Rees JH, 1998, J NEUROL NEUROSUR PS, V64, P74, DOI 10.1136/jnnp.64.1.74; Rich MM, 2001, ANN NEUROL, V50, P26, DOI 10.1002/ana.1016; Rich MM, 1998, ANN NEUROL, V43, P171, DOI 10.1002/ana.410430207; ROBERTS M, 1994, LANCET, V343, P454, DOI 10.1016/S0140-6736(94)92694-8; ROMAN GC, 1995, PERIPHERAL NEUROPA 1, P469; ROPPER AH, 1990, ARCH NEUROL-CHICAGO, V47, P881, DOI 10.1001/archneur.1990.00530080065012; Ruts L, 2005, NEUROLOGY, V65, P138, DOI 10.1212/01.wnl.0000167549.09664.b8; Salomon B, 2001, J EXP MED, V194, P677, DOI 10.1084/jem.194.5.677; Scelsa SN, 2004, MUSCLE NERVE, V30, P423, DOI 10.1002/mus.20105; Sheikh KA, 2004, ANN NEUROL, V56, P228, DOI 10.1002/ana.20173; Susuki K, 2004, NEUROLOGY, V62, P949, DOI 10.1212/01.WNL.0000115123.42929.FD; Susuki K, 2003, ANN NEUROL, V54, P383, DOI 10.1002/ana.33333; Taguchi K, 2004, J NEUROL SCI, V225, P91, DOI 10.1016/j.jns.2004.07.011; TAKIGAWA T, 1995, ANN NEUROL, V37, P436, DOI 10.1002/ana.410370405; Van Den Bergh PYK, 2004, MUSCLE NERVE, V29, P565, DOI 10.1002/mus.20022; van Koningsveld R, 2004, LANCET, V363, P192, DOI 10.1016/S0140-6736(03)15324-X; van Koningsveld R, 2001, NEUROLOGY, V56, P1467, DOI 10.1212/WNL.56.11.1467; Van Koningsveld R, 2000, NEUROLOGY, V54, P620, DOI 10.1212/WNL.54.3.620; van Sorge NM, 2005, J NEUROIMMUNOL, V162, P157, DOI 10.1016/j.jneuroim.2005.01.016; van Sorge NM, 2004, AUTOIMMUN REV, V3, P151, DOI 10.1016/S1568-9972(03)00089-2; van Sorge NM, 2003, ANN NEUROL, V53, P570, DOI 10.1002/ana.10503; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705; Visser LH, 1999, NEUROLOGY, V53, P598, DOI 10.1212/WNL.53.3.598; Willison HJ, 2004, BRAIN, V127, P680, DOI 10.1093/brain/awh083; Willison HJ, 2002, BRAIN, V125, P2591, DOI 10.1093/brain/awf272; WINER JB, 1988, J NEUROL NEUROSUR PS, V51, P613, DOI 10.1136/jnnp.51.5.613; Yuki N, 2004, P NATL ACAD SCI USA, V101, P11404, DOI 10.1073/pnas.0402391101; YUKI N, 1994, ANN NEUROL, V36, P791, DOI 10.1002/ana.410360517; Yuki N, 2001, ANN NEUROL, V49, P712, DOI 10.1002/ana.1012; YUKI N, 1992, MUSCLE NERVE, V15, P968	173	989	1059	4	189	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1653	1666		10.1016/S0140-6736(05)67665-9	http://dx.doi.org/10.1016/S0140-6736(05)67665-9			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271648				2022-12-28	WOS:000233047100028
J	Yu, HG; Koshland, D				Yu, HG; Koshland, D			Chromosome morphogenesis: Condensin-dependent cohesin removal during meiosis	CELL			English	Article							SISTER-CHROMATID COHESION; POLO-LIKE KINASE; SACCHAROMYCES-CEREVISIAE; CENTROMERIC COHESION; MEIOTIC CHROMOSOMES; VERTEBRATE COHESIN; XENOPUS-OOCYTES; DNA-DAMAGE; PROTEIN; ANAPHASE	During meiosis, segregation of homologous chromosomes necessitates the coordination of sister chromatid cohesion, chromosome condensation, and recombination. Cohesion and condensation require the SMC complexes, cohesin and condensin, respectively. Here we use budding yeast Saccharomyces cerevisiae to show that condensin and Cdc5, a Polo-like kinase, facilitate the removal of cohesin from chromosomes prior to the onset of anaphase I when homologs segregate. This cohesin removal is critical for homolog segregation because it helps dissolve the recombination-dependent links between homologs that form during prophase I. Condensin enhances the association of Cdc5 with chromosomes and its phosphorylation of cohesin, which in turn likely stimulates cohesin removal. Condensin/Cdc5-dependent removal of cohesin underscores the potential importance of crosstalk between chromosome structural components in chromosome morphogenesis and provides a mechanism to couple chromosome morphogenesis with other meiotic events.	Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Carnegie Inst,Dept Embryol, Baltimore, MD 21218 USA	Carnegie Institution for Science; Howard Hughes Medical Institute; Johns Hopkins University	Koshland, D (corresponding author), Johns Hopkins Univ, Sch Med, Howard Hughes Med Inst, Carnegie Inst,Dept Embryol, Baltimore, MD 21218 USA.	koshland@ciwemb.edu		Yu, Hong-Guo/0000-0002-1311-7043				Buonomo SBC, 2000, CELL, V103, P387, DOI 10.1016/S0092-8674(00)00131-8; Cha RS, 2000, GENE DEV, V14, P493; Chan RC, 2004, J CELL BIOL, V167, P613, DOI 10.1083/jcb.200408061; Clyne RK, 2003, NAT CELL BIOL, V5, P480, DOI 10.1038/ncb977; D'Amours D, 2004, CELL, V117, P455, DOI 10.1016/S0092-8674(04)00413-1; Glynn EF, 2004, PLOS BIOL, V2, P1325, DOI 10.1371/journal.pbio.0020259; Guacci V, 1997, CELL, V91, P47, DOI 10.1016/S0092-8674(01)80008-8; Hauf S, 2005, PLOS BIOL, V3, P419, DOI 10.1371/journal.pbio.0030069; Hirota T, 2004, J CELL SCI, V117, P6435, DOI 10.1242/jcs.01604; Hornig NCD, 2004, EMBO J, V23, P3144, DOI 10.1038/sj.emboj.7600303; Katis VL, 2004, CURR BIOL, V14, P560, DOI 10.1016/j.cub.2004.03.001; KERREBROCK AW, 1995, CELL, V83, P247, DOI 10.1016/0092-8674(95)90166-3; Kim JS, 2002, J BIOL CHEM, V277, P45149, DOI 10.1074/jbc.M209123200; Kitajima TS, 2003, EMBO J, V22, P5643, DOI 10.1093/emboj/cdg527; Kitajima TS, 2004, NATURE, V427, P510, DOI 10.1038/nature02312; Kleckner N, 2004, P NATL ACAD SCI USA, V101, P12592, DOI 10.1073/pnas.0402724101; Klein F, 1999, CELL, V98, P91, DOI 10.1016/S0092-8674(00)80609-1; Laloraya S, 2000, J CELL BIOL, V151, P1047, DOI 10.1083/jcb.151.5.1047; Lavoie BD, 2002, J CELL BIOL, V156, P805, DOI 10.1083/jcb.200109056; Lee BH, 2003, SCIENCE, V300, P482, DOI 10.1126/science.1081846; Lee J, 2003, J CELL SCI, V116, P2781, DOI 10.1242/jcs.00495; Losada A, 2002, GENE DEV, V16, P3004, DOI 10.1101/gad.249202; Losada A, 1998, GENE DEV, V12, P1986, DOI 10.1101/gad.12.13.1986; Losada A, 2005, GENE DEV, V19, P1269, DOI 10.1101/gad.1320505; Marston AL, 2004, SCIENCE, V303, P1367, DOI 10.1126/science.1094220; Nasmyth K, 2005, ANNU REV BIOCHEM, V74, P595, DOI 10.1146/annurev.biochem.74.082803.133219; Pasierbek P, 2001, GENE DEV, V15, P1349, DOI 10.1101/gad.192701; Peter M, 2001, NAT CELL BIOL, V3, P83, DOI 10.1038/35050607; Prieto I, 2001, NAT CELL BIOL, V3, P761, DOI 10.1038/35087082; Revenkova E, 2001, MOL CELL BIOL, V21, P6984, DOI 10.1128/MCB.21.20.6984-6998.2001; Rogers E, 2002, J CELL BIOL, V157, P219, DOI 10.1083/jcb.200110045; SCHNEIDER BL, 1995, YEAST, V11, P1265, DOI 10.1002/yea.320111306; Sullivan M, 2004, CELL, V117, P471, DOI 10.1016/S0092-8674(04)00415-5; Sumara I, 2002, MOL CELL, V9, P515, DOI 10.1016/S1097-2765(02)00473-2; Taieb FE, 2001, CURR BIOL, V11, P508, DOI 10.1016/S0960-9822(01)00145-2; Unal E, 2004, MOL CELL, V16, P991, DOI 10.1016/j.molcel.2004.11.027; Vagnarelli P, 2004, EMBO REP, V5, P167, DOI 10.1038/sj.embor.7400077; van Heemst D, 1999, CELL, V98, P261, DOI 10.1016/S0092-8674(00)81020-X; Yu HG, 2003, J CELL BIOL, V163, P937, DOI 10.1083/jcb.200308027; Zickler D, 1999, ANNU REV GENET, V33, P603, DOI 10.1146/annurev.genet.33.1.603	42	79	82	1	5	CELL PRESS	CAMBRIDGE	1100 MASSACHUSETTS AVE, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 4	2005	123	3					397	407		10.1016/j.cell.2005.09.014	http://dx.doi.org/10.1016/j.cell.2005.09.014			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269332	Bronze			2022-12-28	WOS:000233264300009
J	Keren, R; Zaoutis, TE; Bridges, CB; Herrera, G; Watson, BM; Wheeler, AB; Licht, DJ; Luan, XQ; Coffin, SE				Keren, R; Zaoutis, TE; Bridges, CB; Herrera, G; Watson, BM; Wheeler, AB; Licht, DJ; Luan, XQ; Coffin, SE			Neurological and neuromuscular disease as a risk factor for respiratory failure in children hospitalized with influenza infection	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OUTPATIENT VISITS; COMPLICATIONS; EPIDEMIC; INFANTS	Context The Advisory Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for children with certain chronic medical conditions to prevent serious complications of influenza infection. Little is known about the relative contribution of each of these chronic medical conditions to the development of serious influenza-associated complications. Objective To identify chronic medical conditions that are associated with respiratory failure in children hospitalized with community-acquired laboratory-confirmed influenza. Design, Setting, and Patients A retrospective cohort study of patients aged 21 years or younger hospitalized at The Children's Hospital of Philadelphia with community-acquired laboratory-confirmed influenza during 4 consecutive influenza seasons (June 2000 through May 2004). We examined 9 ACIP-designated high-risk chronic medical conditions and 3 additional chronic medical conditions (neurological and neuromuscular disease [NNMD], gastroesophageal reflux disease [GERD], and history of prematurity) that in recent studies have been associated with influenza hospitalization and severe influenza-related complications. Main Outcome Measures Rate and odds ratio (OR) of respiratory failure, defined as need for mechanical ventilation. Results Of 745 children hospitalized with community-acquired laboratory-confirmed influenza, 322 (43%) had 1 or more ACIP-designated high-risk chronic medical conditions. Neurological and neuromuscular disease, GERD, and history of prematurity were present in 12%, 14%, and 3%, of children, respectively. Thirty-two children (4.3%) developed respiratory failure. In multivariate logistic regression analyses, conditions associated with respiratory failure included NNMID (OR, 6.0 95% confidence interval [CI], 2.7-13.5), chronic pulmonary disease other than asthma (OR, 4.8; 95% Cl, 1.5-15.1), and cardiac disease (OR, 4.0; 95% Cl, 1.6-10.2). The predicted probabilities of respiratory failure derived from the multivariate model were 12% (95% Cl, 7%-20%), 9% (95% Cl, 3%-23%), and 8% (95% Cl, 4%-18%) for children with NNMD, chronic pulmonary disease, and cardiac disease, respectively. Conclusions These results support the ACIP's recent decision to add NNMID to the list of conditions for which annual influenza vaccine is recommended in children. Neurologists and primary care pediatricians should be alerted to the increased risk of respiratory failure and the importance of influenza vaccination in children with NNMD.	Childrens Hosp Philadelphia, Div Gen Pediat, Pediat Gen Res Grp, Dept Med, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Med, Div Infect Dis, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Med, Div Neurol, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Dept Med, Div Biostat & Epidemiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Ctr Clin Epidemiol & Biostat, Philadelphia, PA 19104 USA; Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA; Philadelphia Dept Publ Hlth, Philadelphia, PA USA; Ctr Dis Control & Prevent, Natl Immunizat Program, Atlanta, GA USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; University of Pennsylvania; Centers for Disease Control & Prevention - USA	Keren, R (corresponding author), Childrens Hosp Philadelphia, Div Gen Pediat, Pediat Gen Res Grp, Dept Med, 3535 Market St,Room 1524, Philadelphia, PA 19104 USA.	keren@email.chop.edu	Licht, Daniel J/I-3370-2013	Licht, Daniel J/0000-0002-4080-843X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [K23HD043179] Funding Source: NIH RePORTER; NICHD NIH HHS [K23 HD043179] Funding Source: Medline; ODCDC CDC HHS [H23/CCH32253-02] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); ODCDC CDC HHS		[Anonymous], MMWR MORB MORTAL WKL; Collins SDW., 1957, REV STUDY ILLNESS ME; CONNOLLY AM, 1993, BRIT MED J, V306, P1452, DOI 10.1136/bmj.306.6890.1452; EICKHOFF TC, 1961, JAMA-J AM MED ASSOC, V176, P776, DOI 10.1001/jama.1961.03040220024005; Erhart LM, 2004, J PEDIATR-US, V144, P191, DOI 10.1016/j.jpeds.2003.11.007; Griffin MR, 2002, ARCH INTERN MED, V162, P1229, DOI 10.1001/archinte.162.11.1229; Harper Scott A., 2005, Morbidity and Mortality Weekly Report, V54, P1; Kroger Andrew T., 2011, Morbidity and Mortality Weekly Report, V60, P3; Izurieta HS, 2000, NEW ENGL J MED, V342, P232, DOI 10.1056/NEJM200001273420402; Lehmann, 1953, EXCESS DEATHS INFLUE; Loughlin J, 2003, PHARMACOECONOMICS, V21, P273, DOI 10.2165/00019053-200321040-00005; Meury S, 2004, EUR J PEDIATR, V163, P359, DOI 10.1007/s00431-004-1445-6; MULLOOLY JP, 1982, AM J PUBLIC HEALTH, V72, P1008, DOI 10.2105/AJPH.72.9.1008; Neuzil KM, 2000, NEW ENGL J MED, V342, P225, DOI 10.1056/NEJM200001273420401; Neuzil KM, 2000, J PEDIATR-US, V137, P856, DOI 10.1067/mpd.2000.110445; O'Brien MA, 2004, PEDIATRICS, V113, P585, DOI 10.1542/peds.113.3.585; Quach C, 2003, PEDIATRICS, V112, pE197, DOI 10.1542/peds.112.3.e197; Thompson WW, 2004, JAMA-J AM MED ASSOC, V292, P1333, DOI 10.1001/jama.292.11.1333; Vaudry W, 2004, Can Commun Dis Rep, V30, P157; Wang Ying-Hsiang, 2003, Journal of Microbiology Immunology and Infection, V36, P111	20	122	130	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2188	2194		10.1001/jama.294.17.2188	http://dx.doi.org/10.1001/jama.294.17.2188			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264160				2022-12-28	WOS:000232957700021
J	Clark, AM; Harding, L; Vandermeer, B; McAlister, FA				Clark, AM; Harding, L; Vandermeer, B; McAlister, FA			Meta-analysis: Secondary prevention programs for patients with coronary artery disease	ANNALS OF INTERNAL MEDICINE			English	Review							RANDOMIZED CONTROLLED-TRIAL; ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-LIFE; CARDIAC REHABILITATION PROGRAM; MULTIFACTORIAL INTERVENTION PROGRAM; HIGH CARDIOVASCULAR RISK; ISCHEMIC-HEART-DISEASE; FOLLOW-UP; PRIMARY-CARE; BYPASS-SURGERY	Background: Although supervised exercise programs reduce mortality in survivors of myocardial infarction, the effects of other types of cardiac secondary prevention programs are unknown. Purpose: To determine the effectiveness of secondary cardiac prevention programs with and without exercise components. Data Sources: The authors searched MEDLINE (1966-2004), the Cochrane Central Register of Controlled Trials, EMBASE, CINAHL, SIGLE, and the Cochrane Effective Practice and Organization of Care Study Registry. They also contacted primary study authors and hand-searched bibliographies provided by the Centers for Medicare & Medicaid Services. Study Selection: Randomized clinical trials. Data Extraction: Two reviewers chose studies and extracted data independently; random-effects summary risk ratios were calculated. Data Synthesis: The authors identified 63 randomized trials (21 295 patients with coronary disease). The summary risk ratio was 0.85 (95% Cl, 0.77 to 0.94) for all-cause mortality, but this result differed over time with a risk ratio of 0.97 (Cl, 0.82 to 1.14) at 12 months and 0.53 (Cl, 0.35 to 0.81) at 24 months. The summary risk ratio was 0.83 (Cl, 0.74 to 0.94) for recurrent myocardial infarction over a median follow-up of 12 months. Effects were similar for programs that included risk factor education or counseling with a structured exercise component (risk ratio, 0.88 [Cl, 0.74 to 1.04] for mortality and 0.62 [Cl, 0.44 to 0.87] for myocardial infarction), for programs that included risk factor education or counseling without an exercise component (risk ratio, 0.87 [Cl, 0.76 to 0.99] for mortality and 0.86 [Cl, 0.72 to 1.03] for myocardial infarction), and for programs that were solely exercise-based (risk ratio, 0.72 [Cl, 0.54 to 0.95] for mortality and 0.76 [Cl, 0.57 to 1.01] for myocardial infarction). Most of these programs improved quality of life or functional status, but effect sizes were small. Limitations: Although these programs may reduce total health care costs, published data on the costs of the programs are inadequate to conclusively comment on their cost-effectiveness. Conclusions: A wide variety of secondary prevention programs improve health outcomes in patients with coronary disease.	Univ Alberta Evidence Based Practice Ctr, Edmonton, AB, Canada	University of Alberta	McAlister, FA (corresponding author), Univ Alberta Hosp, Div Gen Internal Med, 2E3-24 WMC,8440 112th St, Edmonton, AB T6G 2R7, Canada.	Finlay.McAlister@ualberta.ca	McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341	PHS HHS [290-02-0023] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AGREN B, 1989, EUR HEART J, V10, P451, DOI 10.1093/oxfordjournals.eurheartj.a059509; Allen JK, 2002, AM HEART J, V144, P678, DOI 10.1067/mhj.2002.124837; Allison TG, 2000, AM J CARDIOL, V86, P133, DOI 10.1016/S0002-9149(00)00848-1; Allison TG, 1999, MAYO CLIN PROC, V74, P466; *AM HEART ASS, 2004, HEART DIS STROK STAT; Balady GJ, 2000, CIRCULATION, V102, P1069, DOI 10.1161/01.CIR.102.9.1069; BALLANTYNE FC, 1982, CIRCULATION, V65, P913, DOI 10.1161/01.CIR.65.5.913; Belardinelli R, 2001, J AM COLL CARDIOL, V37, P1891, DOI 10.1016/S0735-1097(01)01236-0; BELL J, 1998, THESIS U LONDON LOND; BENGTSSON K, 1983, SCAND J REHABIL MED, V15, P1; BERTIE J, 1992, J ROY COLL PHYS LOND, V26, P147; BETHELL HJN, 1990, BRIT HEART J, V64, P370; Campbell NC, 1998, HEART, V80, P447, DOI 10.1136/hrt.80.5.447; Campbell NC, 1998, BMJ-BRIT MED J, V316, P1434, DOI 10.1136/bmj.316.7142.1434; Carlsson R, 1998, SCAND CARDIOVASC J, V32, P1, DOI 10.1080/140174398427956-1; Carlsson R, 1997, HEART, V77, P256, DOI 10.1136/hrt.77.3.256; CARSON P, 1982, J ROY COLL PHYS LOND, V16, P147; Cooper AF, 2002, CLIN REHABIL, V16, P541, DOI 10.1191/0269215502cr524oa; CUPPLES ME, 1994, BRIT MED J, V309, P993, DOI 10.1136/bmj.309.6960.993; Cupples ME, 1999, BMJ-BRIT MED J, V319, P687, DOI 10.1136/bmj.319.7211.687; DEBUSK RF, 1994, ANN INTERN MED, V120, P721, DOI 10.7326/0003-4819-120-9-199405010-00001; Dinnes J, 1999, QUAL HEALTH CARE, V8, P65, DOI 10.1136/qshc.8.1.65; DOROSSIEV D, 1983, EURO REPORTS STUDIES, V84; Dugmore LD, 1999, HEART, V81, P359, DOI 10.1136/hrt.81.4.359; Engblom E, 1997, J Cardiopulm Rehabil, V17, P29, DOI 10.1097/00008483-199701000-00004; ENGBLOM E, 1992, EUR HEART J, V13, P232, DOI 10.1093/oxfordjournals.eurheartj.a060152; ERDMAN RAM, 1986, J CARDIOPULM REHABIL, V6, P206, DOI DOI 10.1097/00008483-198606000-00001; FITZGERALD JF, 1994, ARCH INTERN MED, V154, P1721, DOI 10.1001/archinte.154.15.1721; FLETCHER BJ, 1994, AM J CARDIOL, V73, P170, DOI 10.1016/0002-9149(94)90209-7; FrasureSmith N, 1997, LANCET, V350, P473, DOI 10.1016/S0140-6736(97)02142-9; Fridlund B, 1991, Scand J Caring Sci, V5, P23; HAMALAINEN H, 1989, EUR HEART J, V10, P55; Hamalainen H, 1995, EUR HEART J, V16, P1839; HASKELL WL, 1994, CIRCULATION, V89, P975, DOI 10.1161/01.CIR.89.3.975; Heldal M, 2000, SCAND CARDIOVASC J, V34, P59; Higgins HC, 2001, PATIENT EDUC COUNS, V43, P219, DOI 10.1016/S0738-3991(00)00164-6; HOLMBACK AM, 1994, ARCH PHYS MED REHAB, V75, P551; Johnston M, 1999, PSYCHOSOM MED, V61, P225, DOI 10.1097/00006842-199903000-00015; Jolly K, 1999, BMJ-BRIT MED J, V318, P706; Jones DA, 1996, BRIT MED J, V313, P1517, DOI 10.1136/bmj.313.7071.1517; KALLIO V, 1979, LANCET, V2, P1091; Lavie Carl J., 1999, Cardiology Clinics, V17, P233, DOI 10.1016/S0733-8651(05)70067-9; Lear SA, 2003, EUR HEART J, V24, P1920, DOI 10.1016/j.ehj.2003.08.015; LEIZOROVICZ A, 1991, EUR HEART J, V12, P612; Lichtman JH, 2004, AM HEART J, V147, P522, DOI 10.1016/j.ahj.2003.06.003; Linfante A, 2004, CIRCULATION, V110, P664; Lisspers J, 1999, J PSYCHOSOM RES, V46, P143, DOI 10.1016/S0022-3999(98)00074-9; Majeed FA, 1996, PUBLIC HEALTH, V110, P7, DOI 10.1016/S0033-3506(96)80027-8; Majumdar SR, 2004, J AM COLL CARDIOL, V43, P1738, DOI 10.1016/j.jacc.2003.12.043; MANT J, 1995, BMJ-BRIT MED J, V311, P793, DOI 10.1136/bmj.311.7008.793; Marchionni N, 2003, CIRCULATION, V107, P2201, DOI 10.1161/01.CIR.0000066322.21016.4A; Masley S, 2001, J FAM PRACTICE, V50, P235; McAlister FA, 2001, BRIT MED J, V323, P957, DOI 10.1136/bmj.323.7319.957; McHugh F, 2001, HEART, V86, P317, DOI 10.1136/heart.86.3.317; Milani RV, 1998, AM J CARDIOL, V81, P1233, DOI 10.1016/S0002-9149(98)00121-0; MILLER NH, 1984, CIRCULATION, V70, P645, DOI 10.1161/01.CIR.70.4.645; Moher M, 2001, BMJ-BRIT MED J, V322, P1338, DOI 10.1136/bmj.322.7298.1338; Murchie P, 2004, FAM PRACT, V21, P567, DOI 10.1093/fampra/cmh514; Murchie P, 2003, BRIT MED J, V326, P84, DOI 10.1136/bmj.326.7380.84; NAYLOR M, 1994, ANN INTERN MED, V120, P999, DOI 10.7326/0003-4819-120-12-199406150-00005; Naylor M D, 1999, J Cardiovasc Nurs, V14, P44; Naylor MD, 1999, JAMA-J AM MED ASSOC, V281, P613, DOI 10.1001/jama.281.7.613; Niebauer J, 1997, CIRCULATION, V96, P2534, DOI 10.1161/01.CIR.96.8.2534; OCONNOR GT, 1989, CIRCULATION, V80, P234, DOI 10.1161/01.CIR.80.2.234; OLDRIDGE N, 1991, AM J CARDIOL, V67, P1084, DOI 10.1016/0002-9149(91)90870-Q; OLDRIDGE NB, 1988, JAMA-J AM MED ASSOC, V260, P945, DOI 10.1001/jama.260.7.945; Oliver S, 2004, HEALTH TECHNOL ASSES, V8, P1; Ornish D, 1998, JAMA-J AM MED ASSOC, V280, P2001, DOI 10.1001/jama.280.23.2001; ORNISH D, 1983, JAMA-J AM MED ASSOC, V249, P54, DOI 10.1001/jama.249.1.54; ORNISH D, 1990, LANCET, V336, P129, DOI 10.1016/0140-6736(90)91656-U; Raftery JP, 2005, BRIT MED J, V330, P707, DOI 10.1136/bmj.38342.665417.8F; ROVIARO S, 1984, J BEHAV MED, V7, P61, DOI 10.1007/BF00845347; SCHULER G, 1992, CIRCULATION, V86, P1, DOI 10.1161/01.CIR.86.1.1; Seki E, 2003, CIRC J, V67, P73, DOI 10.1253/circj.67.73; SHAW LW, 1981, AM J CARDIOL, V48, P39, DOI 10.1016/0002-9149(81)90570-1; Shephard RJ, 1999, CIRCULATION, V99, P963, DOI 10.1161/01.CIR.99.7.963; SIVARAJAN ES, 1982, CIRCULATION, V65, P1420, DOI 10.1161/01.CIR.65.7.1420; Song F, 2003, BMJ-BRIT MED J, V326, P472, DOI 10.1136/bmj.326.7387.472; Stagmo M, 2001, J CARDIOVASC RISK, V8, P243, DOI 10.1097/00043798-200108000-00009; Stahle A, 2000, SCAND J REHABIL MED, V32, P111; STERN MJ, 1983, ARCH INTERN MED, V143, P1719, DOI 10.1001/archinte.143.9.1719; Sundin O, 2003, INT J BEHAV MED, V10, P191, DOI 10.1207/S15327558IJBM1003_01; Taylor C B, 1997, J Cardiopulm Rehabil, V17, P157, DOI 10.1097/00008483-199705000-00002; Taylor RS, 2004, AM J MED, V116, P682, DOI 10.1016/j.amjmed.2004.01.009; Toobert DJ, 2000, ANN BEHAV MED, V22, P1, DOI 10.1007/BF02895162; Vale MJ, 2003, ARCH INTERN MED, V163, P2775, DOI 10.1001/archinte.163.22.2775; Vale MJ, 2002, J CLIN EPIDEMIOL, V55, P245, DOI 10.1016/S0895-4356(01)00460-7; VERMEULEN A, 1983, AM HEART J, V105, P798, DOI 10.1016/0002-8703(83)90243-0; WILHELMSEN L, 1975, PREV MED, V4, P491, DOI 10.1016/0091-7435(75)90035-3; Witt BJ, 2004, J AM COLL CARDIOL, V44, P988, DOI 10.1016/j.jacc.2004.05.062; Wosornu D, 1996, EUR HEART J, V17, P854; Young W, 2003, CAN MED ASSOC J, V169, P905; Yu CM, 2003, AM J CARDIOL, V91, P321, DOI 10.1016/S0002-9149(02)03159-4; Yusuf S, 2002, LANCET, V360, P2, DOI 10.1016/S0140-6736(02)09358-3; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9; 2003, EUR J CARDIOVASC PRE, V10, P429	96	689	726	1	66	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 1	2005	143	9					659	672		10.7326/0003-4819-143-9-200511010-00010	http://dx.doi.org/10.7326/0003-4819-143-9-200511010-00010			14	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	980PN	16263889				2022-12-28	WOS:000233030600006
J	Knight, PL				Knight, PL			The observation of matter wave fluctuations	SCIENCE			English	Editorial Material									Univ London Imperial Coll Sci Technol & Med, Blackett Lab, London SW7 2AZ, England	Imperial College London	Knight, PL (corresponding author), Univ London Imperial Coll Sci Technol & Med, Blackett Lab, Prince Consort Rd, London SW7 2AZ, England.	p.knight@imperial.ac.uk						[Anonymous], 1965, QUANTUM OPTICS ELECT; BARNETT SM, 1985, J OPT SOC AM B, V2, P467, DOI 10.1364/JOSAB.2.000467; Dirac P. A. M., 1982, PRINCIPLES QUANTUM M; Gerry C. C., 2005, INTRO QUANTUM OPTICS; HANBURYBROWN R, 1956, NATURE, V178, P1046, DOI DOI 10.1038/1781046A0; Ottl A, 2005, PHYS REV LETT, V95, DOI 10.1103/PhysRevLett.95.090404; Schellekens M, 2005, SCIENCE, V310, P648, DOI 10.1126/science.1118024; Yasuda M, 1996, PHYS REV LETT, V77, P3090, DOI 10.1103/PhysRevLett.77.3090; [No title captured]	9	8	8	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 28	2005	310	5748					631	632		10.1126/science.1120023	http://dx.doi.org/10.1126/science.1120023			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254177				2022-12-28	WOS:000232997700028
J	Hirano, Y; Hendil, KB; Yashiroda, H; Iemura, S; Nagane, R; Hioki, Y; Natsume, T; Tanaka, K; Murata, S				Hirano, Y; Hendil, KB; Yashiroda, H; Iemura, S; Nagane, R; Hioki, Y; Natsume, T; Tanaka, K; Murata, S			A heterodimeric complex that promotes the assembly of mammalian 20S proteasomes	NATURE			English	Article							BETA-SUBUNITS; MATURATION; RESOLUTION; PROTEIN	The 26S proteasome is a multisubunit protease responsible for regulated proteolysis in eukaryotic cells(1,2). It comprises one catalytic 20S proteasome and two axially positioned 19S regulatory complexes(3). The 20S proteasome is composed of 28 subunits arranged in a cylindrical particle as four heteroheptameric rings, alpha(1-7)beta(1-7)beta(1-7)alpha(1-7) ( refs 4, 5), but the mechanism responsible for the assembly of such a complex structure remains elusive. Here we report two chaperones, designated proteasome assembling chaperone-1 (PAC1) and PAC2, that are involved in the maturation of mammalian 20S proteasomes. PAC1 and PAC2 associate as heterodimers with proteasome precursors and are degraded after formation of the 20S proteasome is completed. Overexpression of PAC1 or PAC2 accelerates the formation of precursor proteasomes, whereas knockdown by short interfering RNA impairs it, resulting in poor maturation of 20S proteasomes. Furthermore, the PAC complex provides a scaffold for alpha-ring formation and keeps the alpha-rings competent for the subsequent formation of half-proteasomes. Thus, our results identify a mechanism for the correct assembly of 20S proteasomes.	Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Core Technol & Res Ctr, Bunkyo Ku, Tokyo 1138613, Japan; Univ Copenhagen, Inst Mol Biol & Physiol, DK-2100 Copenhagen, Denmark; Natl Inst Adv Ind SCi & Technol, Biol Informat Res Ctr, Kohtoh Ku, Tokyo 1350064, Japan; Japan Sci & Technol Agcy, PRESTO, Kawaguchi, Saitama 3320012, Japan	Tokyo Metropolitan Institute of Medical Science; University of Copenhagen; National Institute of Advanced Industrial Science & Technology (AIST); Japan Science & Technology Agency (JST)	Murata, S (corresponding author), Tokyo Metropolitan Inst Med Sci, Lab Frontier Sci, Core Technol & Res Ctr, Bunkyo Ku, Tokyo 1138613, Japan.	tanakak@rinshoken.or.jp; smurata@rinshoken.or.jp	Yashiroda, Hideki/Y-7641-2019; Murata, Shigeo/A-1426-2010	Murata, Shigeo/0000-0002-3177-3503				Ahn K, 1996, J BIOL CHEM, V271, P18237, DOI 10.1074/jbc.271.30.18237; Bahar R, 2002, J BIOL CHEM, V277, P40012, DOI 10.1074/jbc.M205345200; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Burri L, 2000, P NATL ACAD SCI USA, V97, P10348, DOI 10.1073/pnas.190268597; Chen P, 1996, CELL, V86, P961, DOI 10.1016/S0092-8674(00)80171-3; Gerards WLH, 1997, J BIOL CHEM, V272, P10080; Glickman MH, 2002, PHYSIOL REV, V82, P373, DOI 10.1152/physrev.00027.2001; Griffin Thomas A., 2000, Molecular Cell Biology Research Communications, V3, P212, DOI 10.1006/mcbr.2000.0213; Groll M, 1997, NATURE, V386, P463, DOI 10.1038/386463a0; Murata S, 2001, EMBO J, V20, P5898, DOI 10.1093/emboj/20.21.5898; Nandi D, 1997, EMBO J, V16, P5363, DOI 10.1093/emboj/16.17.5363; Natsume T, 2002, ANAL CHEM, V74, P4725, DOI 10.1021/ac020018n; Pickart CM, 2001, ANNU REV BIOCHEM, V70, P503, DOI 10.1146/annurev.biochem.70.1.503; Ramos PC, 1998, CELL, V92, P489, DOI 10.1016/S0092-8674(00)80942-3; Schmidtke G, 1996, EMBO J, V15, P6887, DOI 10.1002/j.1460-2075.1996.tb01081.x; Schmidtke G, 1997, J MOL BIOL, V268, P95, DOI 10.1006/jmbi.1997.0947; Tanahashi N, 2000, J BIOL CHEM, V275, P14336, DOI 10.1074/jbc.275.19.14336; Unno M, 2002, STRUCTURE, V10, P609, DOI 10.1016/S0969-2126(02)00748-7; Vidal-Taboada JM, 2000, BIOCHEM BIOPH RES CO, V272, P156, DOI 10.1006/bbrc.2000.2726; Witt E, 2000, J MOL BIOL, V301, P1, DOI 10.1006/jmbi.2000.3959; YANG Y, 1995, J BIOL CHEM, V270, P27687, DOI 10.1074/jbc.270.46.27687; Yao Y, 1999, BIOCHEM J, V344, P349, DOI 10.1042/0264-6021:3440349; ZWICKL P, 1994, NAT STRUCT BIOL, V1, P765, DOI 10.1038/nsb1194-765	23	181	192	1	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1381	1385		10.1038/nature04106	http://dx.doi.org/10.1038/nature04106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251969				2022-12-28	WOS:000232829100059
J	Graham, LA; Davies, PL				Graham, LA; Davies, PL			Glycine-rich antifreeze proteins from snow fleas	SCIENCE			English	Article							EVOLUTION		Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada; Queens Univ, Prot Funct Discovery Grp, Kingston, ON K7L 3N6, Canada	Queens University - Canada; Queens University - Canada	Davies, PL (corresponding author), Queens Univ, Dept Biochem, Kingston, ON K7L 3N6, Canada.	daviesp@post.queensu.ca						Baardsnes J, 2001, TRENDS BIOCHEM SCI, V26, P468, DOI 10.1016/S0968-0004(01)01879-5; Bellinger P.F., 1996, CHECKLIST COLLEMBOLA; Cheng CHC, 1999, NATURE, V401, P443, DOI 10.1038/46721; Ewart KV, 1999, CELL MOL LIFE SCI, V55, P271, DOI 10.1007/s000180050289; Jia ZC, 2002, TRENDS BIOCHEM SCI, V27, P101, DOI 10.1016/S0968-0004(01)02028-X; Kuiper MJ, 2003, BIOCHEM BIOPH RES CO, V300, P645, DOI 10.1016/S0006-291X(02)02900-5; ZETTEL J, 1984, REV ECOL BIOL SOL, V21, P189	7	121	141	1	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					461	461		10.1126/science.1115145	http://dx.doi.org/10.1126/science.1115145			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239469				2022-12-28	WOS:000232786000036
J	Pain, E				Pain, E			Belgium: A particle physicist on track	SCIENCE			English	News Item																			0	0	0	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					521	521						1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239485				2022-12-28	WOS:000232786000056
J	Strong, K; Mathers, C; Leeder, S; Beaglehole, R				Strong, K; Mathers, C; Leeder, S; Beaglehole, R			Chronic diseases 1 - Preventing chronic diseases: how many lives can we save?	LANCET			English	Article								35 million people will die in 2005 from heart disease, stroke, cancer, and other chronic diseases. Only 20% of these deaths will be in high-income countries-while 80% will occur in low-income and middle-income countries. The death rates from these potentially preventable diseases are higher in low-income and middle-income countries than in high-income countries, especially among adults aged 30-69 years. The impact on men and women is similar. We propose a new goal for reducing deaths from chronic disease to focus prevention and control efforts among those concerned about international health. This goal-to reduce chronic disease death rates by an additional 2% annually-would avert 36 million deaths by 2015. An additional benefit will be a gain of about 500 million years of life over the 10 years from 2006 to 2015. Most of these averted deaths and life-years gained will be in low-income and middle-income countries, and just under half will be in people younger than 70 years. We base the global goal on worldwide projections of deaths by cause for 2005 and 2015. The data are presented for the world, selected countries, and World Bank income groups.	WHO, Dept Chron Dis & Hlth Promot, CH-1211 Geneva, Switzerland; WHO, Dept Measurement & Hlth Informat Syst, CH-1211 Geneva, Switzerland; Univ Sydney, Coll Hlth Sci, Australian Hlth Policy Inst, Sydney, NSW 2006, Australia	World Health Organization; World Health Organization; University of Sydney	Strong, K (corresponding author), WHO, Dept Chron Dis & Hlth Promot, 20 Ave Appia, CH-1211 Geneva, Switzerland.	strongk@who.int		Mathers, Colin/0000-0002-0617-6731; Strong, Kathleen/0000-0002-8092-1955				[Anonymous], 2005, PREV CHRON DIS VIT I; BULATAO RA, 1993, EPIDEMIOLOGICAL TRAN; Eckel Robert H, LANCET, V365, P1415, DOI [10.1016/S0140-6736(05)66378-7, DOI 10.1016/S0140-6736(05)67342-4, DOI 10.1016/S0140-6736(05)66378-7]; Ezzati M, 2004, COMP QUANTIFICATION; Greenberg H, 2005, HEALTH AFFAIR, V24, pW531, DOI 10.1377/hlthaff.W5.31; Hulme D, 2003, WORLD DEV, V31, P403, DOI 10.1016/S0305-750X(02)00222-X; Leeder S, 2004, RACE TIME CHALLENGE; Murray CJL, 1997, LANCET, V349, P1498, DOI 10.1016/S0140-6736(96)07492-2; Murray CJL, 1996, GLOBAL BURDEN DIS IN, V1; Narayan D., 2000, VOICES POOR CRYING O; OMRAN AR, 1971, MILBANK MEML FUND Q, V49, P509, DOI 10.2307/3349375; RAYMOND SU, 2004, DEVELOPMENT, V47, P94; ROGERS A, 2000, J HYPERTENS S1, V18, pS3; Savedoff W., 2003, HLTH SYSTEMS PERFORM; SHIBUYA K, 2005, INT J CANC      0519, DOI DOI 10.1002/IJE.21078; *WHO, BURD DIS PROJ; *WORLD BANK, 2003, 2003 WORLD DEV IND; World Health Organization, 2004, WORLD HLTH REP 2004; World Health Organization (WHO), WORLD HLTH REP	19	432	459	0	15	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	OCT-NOV	2005	366	9496					1578	1582		10.1016/S0140-6736(05)67341-2	http://dx.doi.org/10.1016/S0140-6736(05)67341-2			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979ZX	16257345				2022-12-28	WOS:000232984800027
J	Krutzfeldt, J; Rajewsky, N; Braich, R; Rajeev, KG; Tuschl, T; Manoharan, M; Stoffel, M				Krutzfeldt, J; Rajewsky, N; Braich, R; Rajeev, KG; Tuschl, T; Manoharan, M; Stoffel, M			Silencing of microRNAs in vivo with 'antagomirs'	NATURE			English	Article							RNA; INHIBITION; BIOGENESIS; EXPRESSION; TARGETS; MIRNAS	MicroRNAs ( miRNAs) are an abundant class of non- coding RNAs that are believed to be important in many biological processes through regulation of gene expression(1-3). The precise molecular function of miRNAs in mammals is largely unknown and a better understanding will require loss- of- function studies in vivo. Here we show that a novel class of chemically engineered oligonucleotides, termed ' antagomirs', are efficient and specific silencers of endogenous miRNAs in mice. Intravenous administration of antagomirs against miR- 16, miR- 122, miR- 192 and miR- 194 resulted in a marked reduction of corresponding miRNA levels in liver, lung, kidney, heart, intestine, fat, skin, bone marrow, muscle, ovaries and adrenals. The silencing of endogenous miRNAs by this novel method is specific, efficient and long-lasting. The biological significance of silencing miRNAs with the use of antagomirs was studied for miR- 122, an abundant liver-specific miRNA. Gene expression and bioinformatic analysis of messenger RNA from antagomir- treated animals revealed that the 3' untranslated regions of upregulated genes are strongly enriched in miR- 122 recognition motifs, whereas downregulated genes are depleted in these motifs. Analysis of the functional annotation of downregulated genes specifically predicted that cholesterol biosynthesis genes would be affected by miR- 122, and plasma cholesterol measurements showed reduced levels in antagomir-122- treated mice. Our findings show that antagomirs are powerful tools to silence specific miRNAs in vivo and may represent a therapeutic strategy for silencing miRNAs in disease.	Rockefeller Univ, Lab Metab Dis, New York, NY 10021 USA; Rockefeller Univ, Howard Hughes Med Inst, Lab RNA Mol Biol, New York, NY 10021 USA; NYU, Dept Biol, Ctr Comparat Funct Genom, New York, NY 10003 USA; Alnylam Pharmaceut Inc, Cambridge, MA 02142 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; New York University	Stoffel, M (corresponding author), Rockefeller Univ, Lab Metab Dis, 1230 York Ave, New York, NY 10021 USA.	stoffel@rockefeller.edu	yang, xiao-jun/B-1927-2009	Rajewsky, Nikolaus/0000-0002-4785-4332; Stoffel, Markus/0000-0003-1304-5817				Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871; Bagga S, 2005, CELL, V122, P553, DOI 10.1016/j.cell.2005.07.031; Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Chang Jinhong, 2004, RNA Biol, V1, P106, DOI 10.4161/rna.1.2.1066; Chen CZ, 2005, SEMIN IMMUNOL, V17, P155, DOI 10.1016/j.smim.2005.01.001; Cheng AM, 2005, NUCLEIC ACIDS RES, V33, P1290, DOI 10.1093/nar/gki200; Eis PS, 2005, P NATL ACAD SCI USA, V102, P3627, DOI 10.1073/pnas.0500613102; He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552; He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379; Hutvagner G, 2004, PLOS BIOL, V2, P465, DOI 10.1371/journal.pbio.0020098; John B, 2004, PLOS BIOL, V2, P1862, DOI 10.1371/journal.pbio.0020363; Jopling CL, 2005, SCIENCE, V309, P1577, DOI 10.1126/science.1113329; Krek A, 2005, NAT GENET, V37, P495, DOI 10.1038/ng1536; Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035; Lim LP, 2005, NATURE, V433, P769, DOI 10.1038/nature03315; Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702; MANOHARAN M, 2005, Patent No. 2005107325; Meister G, 2004, RNA, V10, P544, DOI 10.1261/rna.5235104; Metzler M, 2004, GENE CHROMOSOME CANC, V39, P167, DOI 10.1002/gcc.10316; Poy MN, 2004, NATURE, V432, P226, DOI 10.1038/nature03076; Pruitt KD, 2005, NUCLEIC ACIDS RES, V33, pD501, DOI 10.1093/nar/gki025; Soutschek J, 2004, NATURE, V432, P173, DOI 10.1038/nature03121; Tomari Y, 2005, CURR BIOL, V15, pR61, DOI 10.1016/j.cub.2004.12.057; Weiler J, 2006, GENE THER, V13, P496, DOI 10.1038/sj.gt.3302654; Zhao Y, 2005, NATURE, V436, P214, DOI 10.1038/nature03817	25	3087	3527	5	312	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 1	2005	438	7068					685	689		10.1038/nature04303	http://dx.doi.org/10.1038/nature04303			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988JY	16258535				2022-12-28	WOS:000233593100054
J	Goldie, SJ; Gaffikin, L; Goldhaber-Fiebert, JD; Gordillo-Tobar, A; Levin, C; Mahe, C; Wright, TC				Goldie, SJ; Gaffikin, L; Goldhaber-Fiebert, JD; Gordillo-Tobar, A; Levin, C; Mahe, C; Wright, TC		Alliance Cervical Canc Prevention	Cost-effectiveness of cervical-cancer screening in five developing countries	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HUMAN-PAPILLOMAVIRUS TYPE-16; LOW-INCOME; STRATEGIES; BENEFITS	Background: Cervical-cancer screening strategies that involve the use of conventional cytology and require multiple visits have been impractical in developing countries. Methods: We used computer-based models to assess the cost-effectiveness of a variety of cervical-cancer screening strategies in India, Kenya, Peru, South Africa, and Thailand. Primary data were combined with data from the literature to estimate age-specific incidence and mortality rates for cancer and the effectiveness of screening for and treatment of precancerous lesions. We assessed the direct medical, time, and program-related costs of strategies that differed according to screening test, targeted age and frequency, and number of clinic visits required. Single-visit strategies involved the assumption that screening and treatment could be provided in the same day. Outcomes included the lifetime risk of cancer, years of life saved, lifetime costs, and cost-effectiveness ratios (cost per year of life saved). Results: The most cost-effective strategies were those that required the fewest visits, resulting in improved follow-up testing and treatment. Screening women once in their lifetime, at the age of 35 years, with a one-visit or two-visit screening strategy involving visual inspection of the cervix with acetic acid or DNA testing for human papillomavirus (HPV) in cervical cell samples, reduced the lifetime risk of cancer by approximately 25 to 36 percent, and cost less than $500 per year of life saved. Relative cancer risk declined by an additional 40 percent with two screenings (at 35 and 40 years of age), resulting in a cost per year of life saved that was less than each country's per capita gross domestic product - a very cost-effective result, according to the Commission on Macroeconomics and Health. Conclusions: Cervical-cancer screening strategies incorporating visual inspection of the cervix with acetic acid or DNA testing for HPV in one or two clinical visits are cost-effective alternatives to conventional three-visit cytology-based screening programs in resource-poor settings.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Harvard Univ Initiat Global Hlth, Cambridge, MA 02138 USA; Harvard Univ, PhD Program Hlth Policy, Cambridge, MA 02138 USA; JHPIEGO, Baltimore, MD USA; WHO, Pan Amer Hlth Org, Washington, DC USA; Program Appropriate Technol Hlth, Seattle, WA USA; WHO, Int Agcy Res Canc, Lyon, France; Columbia Univ, Coll Phys & Surg, New York, NY USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Jhpiego; Pan American Health Organization; World Health Organization; World Health Organization; International Agency for Research on Cancer (IARC); Columbia University	Goldie, SJ (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Harvard Univ Initiat Global Hlth, 104 Mt Auburn St,3rd Fl, Cambridge, MA 02138 USA.	sue_goldie@harvard.edu		Goldhaber-Fiebert, Jeremy/0000-0002-4007-5192	NATIONAL CANCER INSTITUTE [R01CA093435] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA93435] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		*ACCP, EFF SAF ACC CRYOTH S; Aggarwal R, 2003, J HEPATOL, V38, P215, DOI 10.1016/S0168-8278(02)00382-3; BOSCH FX, 2003, NCI MONOGRAPH, V31; Denny L, 2000, CANCER-AM CANCER SOC, V89, P826, DOI 10.1002/1097-0142(20000815)89:4&lt;826::AID-CNCR15&gt;3.0.CO;2-5; *DEP COMM, 1999 INC DAT; *DEP LAB, WAG BEN POV LIN M WO; Disease control priorities in developing countries, DIS CONTROL PRIORITI; Ferlay J, 2001, GLOBOCAN 2000 CANC I; Gaffikin L, 1999, LANCET, V353, P869; Gold MR, 1996, COST EFFECTIVENESS H; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V285, P3107, DOI 10.1001/jama.285.24.3107; Goldie SJ, 2001, JAMA-J AM MED ASSOC, V286, P1026; Harper DM, 2004, LANCET, V364, P1757, DOI 10.1016/S0140-6736(04)17398-4; *INT CTR TROP AGR, ACC TRANSP TRAV TIM; *INT LAB OFF, WOM MEN INF EC STAT; Johns Benjamin, 2003, Cost Eff Resour Alloc, V1, P1, DOI 10.1186/1478-7547-1-1; Koutsky LA, 2002, NEW ENGL J MED, V347, P1645, DOI 10.1056/NEJMoa020586; Kuhn L, 2000, JNCI-J NATL CANCER I, V92, P818, DOI 10.1093/jnci/92.10.818; Mandelblatt JS, 2002, JNCI-J NATL CANCER I, V94, P1469, DOI 10.1093/jnci/94.19.1469; Sankaranarayanan R, 2001, B WORLD HEALTH ORGAN, V79, P954; Sankaranarayanan R, 1999, INT J CANCER, V80, P161, DOI 10.1002/(SICI)1097-0215(19990105)80:1<161::AID-IJC28>3.3.CO;2-#; Suarez PG, 2002, LANCET, V359, P1980, DOI 10.1016/S0140-6736(02)08830-X; VANBALLEGOOIJEN M, 1992, EUR J CANCER, V28A, P1703, DOI 10.1016/0959-8049(92)90072-A; Waggoner SE, 2003, LANCET, V361, P2217, DOI 10.1016/S0140-6736(03)13778-6; *WHO, WHO STAT INF SYST CH; *WHO, LIF TABL 191 COUNTR; Wiseman V, 2003, AM J TROP MED HYG, V68, P161, DOI 10.4269/ajtmh.2003.68.161; World Health Organization, 2001, MACR HLTH INV HLTH E; NOMINAL INTERBANK EX	29	437	450	1	45	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 17	2005	353	20					2158	2168		10.1056/NEJMsa044278	http://dx.doi.org/10.1056/NEJMsa044278			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	984FT	16291985	Bronze			2022-12-28	WOS:000233288600008
J	Mitra, K; Schaffitzel, C; Shaikh, T; Tama, F; Jenni, S; Brooks, CL; Ban, N; Frank, J				Mitra, K; Schaffitzel, C; Shaikh, T; Tama, F; Jenni, S; Brooks, CL; Ban, N; Frank, J			Structure of the E-coli protein-conducting channel bound to a translating ribosome	NATURE			English	Article							ENDOPLASMIC-RETICULUM; TRANSLOCATION CHANNEL; CROSS-LINKING; ANGSTROM RESOLUTION; ELECTRON-MICROSCOPY; BACTERIAL PROTEIN; MEMBRANE-VESICLES; PLASMA-MEMBRANE; SIGNAL SEQUENCE; SEC61 COMPLEX	Secreted and membrane proteins are translocated across or into cell membranes through a protein-conducting channel (PCC). Here we present a cryo-electron microscopy reconstruction of the Escherichia coli PCC, SecYEG, complexed with the ribosome and a nascent chain containing a signal anchor. This reconstruction shows a messenger RNA, three transfer RNAs, the nascent chain, and detailed features of both a translocating PCC and a second, non-translocating PCC bound to mRNA hairpins. The translocating PCC forms connections with ribosomal RNA hairpins on two sides and ribosomal proteins at the back, leaving a frontal opening. Normal mode-based flexible fitting of the archaeal SecYE beta structure into the PCC electron microscopy densities favours a front-to-front arrangement of two SecYEG complexes in the PCC, and supports channel formation by the opening of two linked SecY halves during polypeptide translocation. On the basis of our observation in the translocating PCC of two segregated pores with different degrees of access to bulk lipid, we propose a model for co-translational protein translocation.	New York State Dept Hlth, Wadsworth Ctr Labs & Res, Hlth Res Inc, Howard Hughes Med Inst, Albany, NY 12201 USA; ETH Honggerberg, Inst Mol Biol & Biophys, CH-8093 Zurich, Switzerland; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; SUNY Albany, Dept Biomed Sci, Albany, NY 12201 USA	Health Research Inc; Howard Hughes Medical Institute; State University of New York (SUNY) System; Wadsworth Center; Swiss Federal Institutes of Technology Domain; ETH Zurich; Scripps Research Institute; State University of New York (SUNY) System; State University of New York (SUNY) Albany	Frank, J (corresponding author), New York State Dept Hlth, Wadsworth Ctr Labs & Res, Hlth Res Inc, Howard Hughes Med Inst, Empire State Plaza, Albany, NY 12201 USA.	Joachim@wadsworth.org	tama, florence/S-2733-2019; Tama, Florence/A-7077-2016	tama, florence/0000-0003-2021-5618; Tama, Florence/0000-0003-2021-5618; Berger-Schaffitzel, Christiane Helene/0000-0002-1516-9760	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012255, P41RR001219] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM055440, R37GM029169] Funding Source: NIH RePORTER; NCRR NIH HHS [P41 RR012255, P41 RR001219] Funding Source: Medline; NIGMS NIH HHS [R01 GM055440, R37 GM029169] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Beckmann R, 2001, CELL, V107, P361, DOI 10.1016/S0092-8674(01)00541-4; Beckmann R, 1997, SCIENCE, V278, P2123, DOI 10.1126/science.278.5346.2123; Bessonneau P, 2002, EMBO J, V21, P995, DOI 10.1093/emboj/21.5.995; Breyton C, 2002, NATURE, V418, P662, DOI 10.1038/nature00827; BRUNDAGE L, 1990, CELL, V62, P649, DOI 10.1016/0092-8674(90)90111-Q; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHAPMAN MS, 1995, ACTA CRYSTALLOGR A, V51, P69, DOI 10.1107/S0108767394007130; Cheng ZL, 2005, J CELL BIOL, V168, P67, DOI 10.1083/jcb.200408188; Frank J, 1996, J STRUCT BIOL, V116, P190, DOI 10.1006/jsbi.1996.0030; Gabashvili IS, 2000, CELL, V100, P537, DOI 10.1016/S0092-8674(00)80690-X; Gao HX, 2003, CELL, V113, P789, DOI 10.1016/S0092-8674(03)00427-6; GILMORE R, 1985, CELL, V42, P497, DOI 10.1016/0092-8674(85)90107-2; GO N, 1983, P NATL ACAD SCI-BIOL, V80, P3696, DOI 10.1073/pnas.80.12.3696; GORLICH D, 1993, CELL, V75, P615, DOI 10.1016/0092-8674(93)90483-7; Harms JM, 2004, BMC BIOL, V2, DOI 10.1186/1741-7007-2-4; Hessa T, 2005, NATURE, V433, P377, DOI 10.1038/nature03216; HIGH S, 1993, J BIOL CHEM, V268, P26745; Kalies KU, 1998, J CELL BIOL, V141, P887, DOI 10.1083/jcb.141.4.887; Kaufmann A, 1999, BIOCHEMISTRY-US, V38, P9115, DOI 10.1021/bi990539d; Laird V, 1997, J BIOL CHEM, V272, P1983, DOI 10.1074/jbc.272.3.1983; Levy R, 2001, J BIOL CHEM, V276, P2340, DOI 10.1074/jbc.M004867200; MARTOGLIO B, 1995, CELL, V81, P207, DOI 10.1016/0092-8674(95)90330-5; Menetret JF, 2000, MOL CELL, V6, P1219, DOI 10.1016/S1097-2765(00)00118-0; Morgan DG, 2002, J MOL BIOL, V324, P871, DOI 10.1016/S0022-2836(02)01111-7; Mothes W, 1997, CELL, V89, P523, DOI 10.1016/S0092-8674(00)80234-2; Nakatogawa H, 2002, CELL, V108, P629, DOI 10.1016/S0092-8674(02)00649-9; Neumann-Haefelin C, 2000, EMBO J, V19, P6419, DOI 10.1093/emboj/19.23.6419; NISHIYAMA K, 1993, EMBO J, V12, P3409, DOI 10.1002/j.1460-2075.1993.tb06015.x; Plath K, 1998, CELL, V94, P795, DOI 10.1016/S0092-8674(00)81738-9; Prinz A, 2000, EMBO J, V19, P1900, DOI 10.1093/emboj/19.8.1900; Raden D, 2000, J CELL BIOL, V150, P53, DOI 10.1083/jcb.150.1.53; Rapoport TA, 2004, TRENDS CELL BIOL, V14, P568, DOI 10.1016/j.tcb.2004.09.002; SCHATZ PJ, 1991, EMBO J, V10, P1749, DOI 10.1002/j.1460-2075.1991.tb07699.x; Scotti PA, 2000, EMBO J, V19, P542, DOI 10.1093/emboj/19.4.542; SIMON SM, 1989, P NATL ACAD SCI USA, V86, P6176, DOI 10.1073/pnas.86.16.6176; SIMON SM, 1991, CELL, V65, P371, DOI 10.1016/0092-8674(91)90455-8; Tama F, 2004, J STRUCT BIOL, V147, P315, DOI 10.1016/j.jsb.2004.03.002; TANI K, 1990, J BIOL CHEM, V265, P17341; Tirion MM, 1996, PHYS REV LETT, V77, P1905, DOI 10.1103/PhysRevLett.77.1905; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Valent QA, 1998, EMBO J, V17, P2504, DOI 10.1093/emboj/17.9.2504; Valle M, 2002, EMBO J, V21, P3557, DOI 10.1093/emboj/cdf326; van den Berg B, 2004, NATURE, V427, P36, DOI 10.1038/nature02218; van der Sluis EO, 2002, FEBS LETT, V527, P159, DOI 10.1016/S0014-5793(02)03202-7; Veenendaal AKJ, 2001, J BIOL CHEM, V276, P32559, DOI 10.1074/jbc.M103912200; WAGENKNECHT T, 1988, J MOL BIOL, V199, P137, DOI 10.1016/0022-2836(88)90384-1; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; Wirth A, 2003, MOL CELL, V12, P261, DOI 10.1016/S1097-2765(03)00283-1; Zito CR, 2003, J BIOL CHEM, V278, P40640, DOI 10.1074/jbc.M308025200	49	214	227	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 17	2005	438	7066					318	324		10.1038/nature04133	http://dx.doi.org/10.1038/nature04133			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984JR	16292303	Green Accepted			2022-12-28	WOS:000233300200040
J	Wilson, JF				Wilson, JF			Why prion diseases are a mystery, and why they matter	ANNALS OF INTERNAL MEDICINE			English	News Item												jenwilson@acponline.org	Wilson, Jennifer/Q-3623-2019	Wilson, Jennifer/0000-0003-4025-3136					0	1	1	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					773	776						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287812				2022-12-28	WOS:000233486800027
J	Boulton, AJM; Vileikyte, L; Ragnarson-Tennvall, G; Apelqvist, J				Boulton, AJM; Vileikyte, L; Ragnarson-Tennvall, G; Apelqvist, J			The global burden of diabetic foot disease	LANCET			English	Review							LOWER-EXTREMITY AMPUTATIONS; RISK-FACTORS; AUSTRALIAN POPULATION; CARE; ULCERS; COST; PREVALENCE; ULCERATION; COMPLICATIONS; PREVENTION	Diabetic foot problems are common throughout the world, resulting in major economic consequences for the patients, their families, and society. Foot ulcers are more likely to be of neuropathic origin, and therefore eminently preventable, in developing countries, which will experience the greatest rise in the prevalence of type 2 diabetes in the next 20 years. People at greatest risk of ulceration can easily be identified by careful clinical examination of the feet: education and frequent follow-up is indicated for these patients. When assessing the economic effects of diabetic foot disease, it is important to remember that rates of recurrence of foot ulcers are very high, being greater than 50% after 3 years. Costing should therefore include not only the immediate ulcer episode, but also social services, home care, and subsequent ulcer episodes. A broader view of total resource use should include some estimate of quality of life and the final outcome. An integrated care approach with regular screening and education of patients at risk requires low expenditure and has the potential to reduce the cost of health care.	Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England; Univ Miami, Div Endocrinol Diabet & Metab, Miami, FL 33152 USA; Swedish Inst Hlth Econ, Lund, Sweden; Lund Univ, Malmo Univ Hosp, Dept Endocrinol, S-22100 Lund, Sweden	University of Manchester; University of Miami; Lund University; Skane University Hospital	Boulton, AJM (corresponding author), Univ Manchester, Manchester Royal Infirm, Dept Med, Manchester M13 9WL, Lancs, England.	aboulton@med.miami.edu						Abbas ZG, 2005, MED SCI MONITOR, V11, pRA262; Abbas ZG, 2005, AM J CLIN DERMATOL, V6, P21, DOI 10.2165/00128071-200506010-00003; Abbott CA, 2005, DIABETES CARE, V28, P1869, DOI 10.2337/diacare.28.8.1869; Abbott CA, 2002, DIABETIC MED, V19, P377, DOI 10.1046/j.1464-5491.2002.00698.x; ALPIZAR M, 1995, DIABETIC MED, V12, P14; ANICHINI R, 2005, DIABETOLOGIA S1, V48, pA254; [Anonymous], 2005, TIM ACT DIAB FOOT CA; APELQVIST J, 1994, J INTERN MED, V235, P463, DOI 10.1111/j.1365-2796.1994.tb01104.x; APELQVIST J, 1995, FOOT ANKLE INT, V16, P388, DOI 10.1177/107110079501600702; BELHADJ M, 1998, DIABETES METAB S, V24, pR67; Boulton AJM, 2004, NEW ENGL J MED, V351, P48, DOI 10.1056/NEJMcp032966; Boulton AJM, 2004, DIABETOLOGIA, V47, P1343, DOI 10.1007/s00125-004-1463-y; Dargis V, 1999, DIABETES CARE, V22, P1428, DOI 10.2337/diacare.22.9.1428; Donohoe ME, 2000, DIABETIC MED, V17, P581, DOI 10.1046/j.1464-5491.2000.00336.x; Eneroth M., 2004, FOOT, V14, P198; Gale EA., 2002, DIABETES, V51, P363; Girod I, 2003, DIABETES METAB, V29, P269, DOI 10.1016/S1262-3636(07)70036-8; Gordois A, 2003, DIABETES CARE, V26, P1790, DOI 10.2337/diacare.26.6.1790; Gordois A, 2003, DIABET FOOT, V6, P62; Gulam-Abbas Z, 2002, DIABETIC MED, V19, P575, DOI 10.1046/j.1464-5491.2002.00740.x; Gulliford MC, 2002, DIABETES RES CLIN PR, V56, P35, DOI 10.1016/S0168-8227(01)00343-6; Harrington C, 2000, DIABETES CARE, V23, P1333, DOI 10.2337/diacare.23.9.1333; HEURTIER A, 1998, DIABET METAB S1, V24, pR66; Holzer SES, 1998, CLIN THER, V20, P169; Humphrey ARG, 1996, DIABETES CARE, V19, P710, DOI 10.2337/diacare.19.7.710; Jaramillo O, 1997, WOUNDS, V9, P94; Jeffcoate W, 2005, LANCET, V365, P1527, DOI 10.1016/S0140-6736(05)66437-9; Jimenez JT, 1998, DIABETIC MED, V15, P334, DOI 10.1002/(SICI)1096-9136(199804)15:4<334::AID-DIA575>3.0.CO;2-Z; Kidmas A T, 2004, East Afr Med J, V81, P427; KUMAR S, 1994, DIABETIC MED, V11, P480, DOI 10.1111/j.1464-5491.1994.tb00310.x; Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435; *LEA STUD GROUP, 2000, BRIT J SURG, V87, P328; LESLIE PJ, 1992, DIABETIC MED, V9, P379, DOI 10.1111/j.1464-5491.1992.tb01801.x; Manes C, 2002, WOUNDS, V14, P11; MASSON EA, 1992, DIABETIC MED, V9, P753, DOI 10.1111/j.1464-5491.1992.tb01886.x; McCabe CJ, 1998, DIABETIC MED, V15, P80, DOI 10.1002/(SICI)1096-9136(199801)15:1<80::AID-DIA517>3.0.CO;2-K; MCGILL M, 2003, DIABET FOOT, V6, P165; McGill MN, 2003, DIABET FOOT, V6, P172; Mehta SS, 1999, DIABETES CARE, V22, P1110, DOI 10.2337/diacare.22.7.1110; Morbach S, 2004, DIABETIC MED, V21, P91, DOI 10.1046/j.1464-5491.2003.01069.x; Muller IS, 2002, DIABETES CARE, V25, P570, DOI 10.2337/diacare.25.3.570; New JP, 1998, DIABETIC MED, V15, P760, DOI 10.1002/(SICI)1096-9136(199809)15:9<760::AID-DIA672>3.0.CO;2-I; Ortegon MM, 2004, DIABETES CARE, V27, P901, DOI 10.2337/diacare.27.4.901; Payne CB, 1998, DIABETES RES CLIN PR, V39, P69, DOI 10.1016/S0168-8227(97)00110-1; Pedrosa HC, 2004, INT DIABETES MONITOR, V16, P10; PENDSEY S, 1994, INT J DIABETES DEV C, V2, P37; Pinzur MS, 2005, FOOT ANKLE INT, V26, P113, DOI 10.1177/107110070502600112; RAGNARSONTENNVA.WH, 2001, DIABETOLOGIA, V44, P2077; Ramachandran A, 2004, DIABETES-METAB RES, V20, pS19, DOI 10.1002/dmrr.440; Ramsey SD, 1999, DIABETES CARE, V22, P382, DOI 10.2337/diacare.22.3.382; RAUNER MS, 2004, SCS SOC MODELING SIM; Reiber G, 2002, EVIDENCE BASE DIABET, P642; Resnick HE, 1999, ARCH INTERN MED, V159, P2470, DOI 10.1001/archinte.159.20.2470; Richard J-L, 1997, J PLAIES CICATRISATI, V7, P127; Saar WE, 2005, FOOT ANKLE INT, V26, P27, DOI 10.1177/107110070502600105; Shearer A, 2003, DIABETES CARE, V26, P2305, DOI 10.2337/diacare.26.8.2305; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Tapp RJ, 2004, DIABETES CARE, V27, P688, DOI 10.2337/diacare.27.3.688; Tapp RJ, 2003, DIABETIC MED, V20, P105, DOI 10.1046/j.1464-5491.2003.00881.x; Tchakonte B, 2005, Bull Soc Pathol Exot, V98, P94; Tennvall GR, 2000, J INTERN MED, V248, P397; Tennvall GR, 2004, CLIN INFECT DIS, V39, pS132, DOI 10.1086/383275; Tennvall GR, 2000, PHARMACOECONOMICS, V18, P225, DOI 10.2165/00019053-200018030-00003; Trautner C, 2001, DIABETES CARE, V24, P855, DOI 10.2337/diacare.24.5.855; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6; Van Acker K, 2000, DIABETES RES CLIN PR, V50, P87, DOI 10.1016/S0168-8227(00)00157-1; van Houtum WH, 2004, DIABETES CARE, V27, P1042, DOI 10.2337/diacare.27.5.1042; vanHoutum WH, 1996, J INTERN MED, V240, P227, DOI 10.1046/j.1365-2796.1996.42868000.x; VANHOUTUM WH, 1995, DIABETIC MED, V12, P777; VEVES A, 1994, DIABETIC MED, V11, P709, DOI 10.1111/j.1464-5491.1994.tb00338.x; Vileikyte L, 2004, DIABETES-METAB RES, V20, pS13, DOI 10.1002/dmrr.437; Vozar J., 1997, Diabetologia, V40, pA465; Walrond E R, 2001, West Indian Med J, V50 Suppl 1, P24; Wild S, 2004, DIABETES CARE, V27, P1047, DOI 10.2337/diacare.27.5.1047; ZHANGRONG X, 1997, NATL MED J CHINA, V77, P119	75	1397	1479	8	211	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1719	1724		10.1016/S0140-6736(05)67698-2	http://dx.doi.org/10.1016/S0140-6736(05)67698-2			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291066				2022-12-28	WOS:000233206400028
J	Lipsky, BA; Armstrong, DG; Citron, DM; Tice, AD; Morgenstern, DE; Abramson, MA				Lipsky, BA; Armstrong, DG; Citron, DM; Tice, AD; Morgenstern, DE; Abramson, MA			Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial	LANCET			English	Article							RESISTANT STAPHYLOCOCCUS-AUREUS; SKIN-STRUCTURE INFECTIONS; ANTIBIOTIC-THERAPY; ANTIMICROBIAL THERAPY; COMPLICATED SKIN; MANAGEMENT; ULCERS; PATHOGENS; PREVALENCE; AMPUTATION	Background Diabetic foot infections are a common and serious problem, yet few randomised trials of adequate quality have compared the efficacy of the various antibiotic regimens available for their treatment. Our aim was to assess the efficacy and safety of ertapenem versus piperacillin/tazobactam for foot infections. Methods We did a randomised, double-blinded, multicentre trial in adults (n=586) with diabetes and a foot infection classified as moderate-to-severe and requiring intravenous antibiotics. We assigned patients intravenous ertapenem (1 g daily; n=295) or piperacillin/tazobactam (3.375 g every 6 h; n=291) given for a minimum of 5 days, after which oral amoxicillin/clavulanic acid (875/125 mg every 12 h) could be given for up to 23 days. Investigators retained the option to administer vancomycin to patients in either group to ensure adequate coverage for potentially antibiotic resistant Enterococcus spp and meticillin-resistant Staphylococcus aureus (MRSA). Our primary outcome was the proportion of patients with a favourable clinical response (cure or improvement) on the day that intravenous antibiotic was discontinued. Analyses were by an evaluable-patient only approach. This study is registered with ClinicalTrials.gov, number NCT00229112. Findings Of the 576 patients treated, 445 were available for assessment at the end of intravenous therapy. Both baseline characteristics and favourable clinical response rates were similar for the 226 who received ertapenem and the 219 who received piperacillin/tazobactam. (94% vs 92%, respectively; between treatment difference 1.9%, 95% CI -2.9 to 6.9). Rates of favourable microbiological responses (eradication rates and clinical outcomes, by pathogen) and adverse events did not differ between groups. Interpretation Clinical and microbiological outcomes for patients treated with ertapenem were equivalent to those for patients treated with piperacillin/tazobactam, suggesting that this once-daily antibiotic should be considered for parenteral. therapy of diabetic foot infections, when deemed appropriate.	Univ Washington, Sch Med, Seattle, WA 98108 USA; Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA; Rosalind Franklin Univ Med & Sci, Scholl Coll Podiatr Med, Chicago, IL USA; Rosalind Franklin Univ Med & Sci, Ctr Lower Extrem Ambulatory Res, Chicago, IL USA; RM Alden Res Lab, Santa Monica, CA USA; Univ Hawaii, John A Burns Sch Med, Honolulu, HI 96822 USA; Merck & Co Inc, West Point, PA USA	University of Washington; University of Washington Seattle; US Department of Veterans Affairs; Veterans Health Administration (VHA); Vet Affairs Puget Sound Health Care System; Chicago Medical School; Rosalind Franklin University Medical & Science; Chicago Medical School; Rosalind Franklin University Medical & Science; University of Hawaii System; Merck & Company	Lipsky, BA (corresponding author), Univ Washington, Sch Med, 1660 S Columbian Way, Seattle, WA 98108 USA.	Benjamin.Lipsky@med.va.gov	Lipsky, Benjamin A/B-4645-2013	Morgenstern, Dave/0000-0003-0554-3947; Lipsky, Benjamin A./0000-0001-9886-5114				Abdulrazak A, 2005, J DIABETES COMPLICAT, V19, P138, DOI 10.1016/j.jdiacomp.2004.06.001; Apelqvist J, 2000, DIABETES-METAB RES, V16, pS75, DOI 10.1002/1520-7560(200009/10)16:1+<::AID-DMRR139>3.0.CO;2-8; Armstrong DG, 1998, DIABETES CARE, V21, P855, DOI 10.2337/diacare.21.5.855; ARMSTRONG DG, 1996, J FOOT ANKLE SURG, V35, P528; Boulton AJM, 2004, NEW ENGL J MED, V351, P48, DOI 10.1056/NEJMcp032966; Caputo GM, 1997, AM FAM PHYSICIAN, V56, P195; Carvalho Cibele B.M., 2004, Arq Bras Endocrinol Metab, V48, P398, DOI 10.1590/S0004-27302004000300012; Cunha B A, 2000, J Foot Ankle Surg, V39, P253; Dang CN, 2003, DIABETIC MED, V20, P159, DOI 10.1046/j.1464-5491.2003.00860.x; FARRINGTON CP, 1990, STAT MED, V9, P1447, DOI 10.1002/sim.4780091208; FILE TM, 1983, AM J MED, V75, P100, DOI 10.1016/0002-9343(83)90103-1; Fridkin SK, 2005, NEW ENGL J MED, V352, P1436, DOI 10.1056/NEJMoa043252; GERDING DN, 1995, CLIN INFECT DIS, V20, pS283, DOI 10.1093/clinids/20.Supplement_2.S283; GIBBONS GW, 1984, MANAGEMENT DIABETIC, P97; Goldstein EJC, 1996, DIABETES CARE, V19, P638, DOI 10.2337/diacare.19.6.638; Graham DR, 2002, CLIN INFECT DIS, V34, P1460, DOI 10.1086/340348; GRAYSON ML, 1994, CLIN INFECT DIS, V18, P683, DOI 10.1093/clinids/18.5.683; GRAYSON ML, 1995, INFECT DIS CLIN N AM, V9, P143; Hartemann-Heurtier A, 2000, DIABETES METAB, V26, P219; HUGHES C E, 1987, Clinical Therapeutics, V10, P36; *INT C HARM TECHN, E6 GOOD CLIN PRACT C; *INT WORK GROUP DI, 2003, INT CONS DIAT FOOT; Jeffcoate WJ, 2003, LANCET, V361, P1545, DOI 10.1016/S0140-6736(03)13169-8; KARCHMER AW, 1994, CURRENT CLIN TOPICS, P1; Lavery LA, 2003, DIABETES CARE, V26, P1435, DOI 10.2337/diacare.26.5.1435; Lipsky B A, 1990, Infect Dis Clin North Am, V4, P409; Lipsky BA, 2005, J ANTIMICROB CHEMOTH, V55, P240, DOI 10.1093/jac/dkh531; Lipsky BA, 1999, FEMS IMMUNOL MED MIC, V26, P267, DOI 10.1111/j.1574-695X.1999.tb01398.x; LIPSKY BA, 1990, ARCH INTERN MED, V150, P790, DOI 10.1001/archinte.150.4.790; Lipsky BA, 1997, CLIN INFECT DIS, V24, P643, DOI 10.1093/clind/24.4.643; Lipsky BA, 2004, CLIN INFECT DIS, V38, P17, DOI 10.1086/380449; Lipsky BA, 2004, CLIN INFECT DIS, V39, P885, DOI 10.1086/383271; MIETTINEN O, 1985, STAT MED, V4, P213, DOI 10.1002/sim.4780040211; MOUTON Y, 1992, POSTGRAD MED J, V68, pS68; *NCCLS, 2000, M7A5 NCCLS CLIN LAB; *NCCLS, 2000, M11A5 NCCLS CLIN LAB; Pathare N A, 1998, Indian J Pathol Microbiol, V41, P437; Pinzur MS, 2005, FOOT ANKLE INT, V26, P113, DOI 10.1177/107110070502600112; SAPICO FL, 1984, REV INFECT DIS, V6, pS171; Senneville E, 2005, EXPERT OPIN PHARMACO, V6, P263, DOI 10.1517/14656566.6.2.263; SENVEVILLE E, 2005, EXPERT OPINION PHARM, V6, P263; Shah P, 2003, DIABETES, V52, P38, DOI 10.2337/diabetes.52.1.38; Singh N, 2005, JAMA-J AM MED ASSOC, V293, P217, DOI 10.1001/jama.293.2.217; Slater RA, 2004, DIABETIC MED, V21, P705, DOI 10.1111/j.1464-5491.2004.01221.x; SMITH PG, 1981, APPLIED STATISTICS, V30, P190; Tentolouris N, 1999, DIABETIC MED, V16, P767, DOI 10.1046/j.1464-5491.1999.00132.x; Tice AD, 2004, J ANTIMICROB CHEMOTH, V53, P83, DOI 10.1093/jac/dkh210; *US CDCP, NUMB 1000 HOSP DISCH; Viswanathan V, 2002, J Assoc Physicians India, V50, P1013; Wagner A, 2001, DEUT MED WOCHENSCHR, V126, P1353, DOI 10.1055/s-2001-18655; WHEAT LJ, 1986, ARCH INTERN MED, V146, P1935, DOI 10.1001/archinte.146.10.1935; Williams R, 2000, FOOT DIABETES, P3; Zeillemaker AM, 1998, FOOT ANKLE INT, V19, P169, DOI 10.1177/107110079801900311	53	176	180	0	11	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1695	1703		10.1016/S0140-6736(05)67694-5	http://dx.doi.org/10.1016/S0140-6736(05)67694-5			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291062				2022-12-28	WOS:000233206400024
J	Smith, GD; Ebrahim, S				Smith, GD; Ebrahim, S			Folate supplementation and cardiovascular disease	LANCET			English	Editorial Material							CORONARY-HEART-DISEASE; ESTROGEN REPLACEMENT THERAPY; QUANTITATIVE ASSESSMENT; FOLIC-ACID; VITAMIN-E; RISK; HOMOCYSTEINE; PREVENTION; MTHFR		Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England	University of Bristol	Smith, GD (corresponding author), Univ Bristol, Dept Social Med, Bristol BS8 2PR, Avon, England.	George.Davey-Smith@bristol.ac.uk	Davey Smith, George/A-7407-2013	Davey Smith, George/0000-0002-1407-8314				*B VIT TREATM TRIA, IN PRESS AM HEART; Baker F, 2002, CIRCULATION, V106, P741; BONAA KH, 2005, NORVIT RANDOMISED TR; Charles D, 2004, BMJ-BRIT MED J, V329, P1375, DOI 10.1136/bmj.329.7479.1375; Cronin S, 2005, STROKE, V36, P1581, DOI 10.1161/01.STR.0000169946.31639.af; Eidelman RS, 2004, ARCH INTERN MED, V164, P1552, DOI 10.1001/archinte.164.14.1552; Hultdin J, 2005, INT J CANCER, V113, P819, DOI 10.1002/ijc.20646; Klerk M, 2002, JAMA-J AM MED ASSOC, V288, P2023, DOI 10.1001/jama.288.16.2023; Lange H, 2004, NEW ENGL J MED, V350, P2673, DOI 10.1056/NEJMoa032845; Lewis SJ, 2005, BMJ-BRIT MED J, V331, P1053, DOI 10.1136/bmj.38611.658947.55; Liem A, 2003, J AM COLL CARDIOL, V41, P2105, DOI 10.1016/S0735-1097(03)00485-6; MANSON JE, 1991, CIRCULATION S2, V84, P546; Osganian SK, 2003, J AM COLL CARDIOL, V42, P246, DOI 10.1016/S0735-1097(03)00575-8; Potter JD, 2005, LANCET, V366, P527, DOI 10.1016/S0140-6736(05)67077-8; Rimm EB, 1998, JAMA-J AM MED ASSOC, V279, P359, DOI 10.1001/jama.279.5.359; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; Smith GD, 2003, INT J EPIDEMIOL, V32, P1, DOI 10.1093/ije/dyg070; Stampfer MJ, 2004, INT J EPIDEMIOL, V33, P445, DOI 10.1093/ije/dyh125; STAMPFER MJ, 1991, PREV MED, V20, P47, DOI 10.1016/0091-7435(91)90006-P; Toole JF, 2004, JAMA-J AM MED ASSOC, V291, P565, DOI 10.1001/jama.291.5.565; Wald DS, 2002, BMJ-BRIT MED J, V325, P1202, DOI 10.1136/bmj.325.7374.1202; Wald NJ, 2003, BMJ-BRIT MED J, V326, P1419, DOI 10.1136/bmj.326.7404.1419; Willett W.C., 2001, EAT DRINK HLTH HARVA	23	47	49	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1679	1681		10.1016/S0140-6736(05)67676-3	http://dx.doi.org/10.1016/S0140-6736(05)67676-3			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291049				2022-12-28	WOS:000233206400007
J	van Houtum, WH				van Houtum, WH			Barriers to the delivery of diabetic foot care	LANCET			English	Editorial Material									Spaarne Hosp Hoofddorp, Dept Internal Med, NL-2134 TM Hoofddorp, Netherlands	Spaarne Hospital	van Houtum, WH (corresponding author), Spaarne Hosp Hoofddorp, Dept Internal Med, NL-2134 TM Hoofddorp, Netherlands.	houtum@tiscali.nl						BAKKER K, 2005, DIABETES FOOT CARE T; Chin MH, 2001, DIABETES CARE, V24, P268, DOI 10.2337/diacare.24.2.268; Hendricks LE, 1998, DIABETES EDUCATOR, V24, P168, DOI 10.1177/014572179802400206; *INT WORK GROUP DI, 2003, INT CONS DIAB FOOT P; Jeffcoate WJ, 2004, DIABETOLOGIA, V47, P2051, DOI 10.1007/s00125-004-1584-3; Mayfield JA, 2004, DIABETES CARE, V27, pB39, DOI 10.2337/diacare.27.suppl_2.B39; MILLS JL, 1991, SOUTHERN MED J, V84, P970, DOI 10.1097/00007611-199108000-00009; Ortegon MM, 2004, DIABETES CARE, V27, P901, DOI 10.2337/diacare.27.4.901; Ramachandran A, 2004, DIABETES-METAB RES, V20, pS19, DOI 10.1002/dmrr.440; Tsalikian E, 2004, DIABETES CARE, V27, P722; VANHOUTUM WH, 2001, DIABETIC FOOT, V4, P185; Vileikyte L, 2004, DIABETES-METAB RES, V20, pS13, DOI 10.1002/dmrr.437	12	28	28	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 12	2005	366	9498					1678	1679		10.1016/S0140-6736(05)67675-1	http://dx.doi.org/10.1016/S0140-6736(05)67675-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	983BP	16291048				2022-12-28	WOS:000233206400006
J	Bukowski, MR; Koehntop, KD; Stubna, A; Bominaar, EL; Halfen, JA; Munck, E; Nam, W; Que, L				Bukowski, MR; Koehntop, KD; Stubna, A; Bominaar, EL; Halfen, JA; Munck, E; Nam, W; Que, L			A thiolate-ligated nonheme oxoiron(IV) complex relevant to cytochrome P450	SCIENCE			English	Article							FE-IV=O COMPLEX; ENZYMES; LIGAND; CHEMISTRY; MECHANISM; P450CAM; MODELS; QM/MM; EPR	Thiolate-ligated oxoiron(IV) centers are postulated to be the key oxidants in the catalytic cycles of oxygen-activating cytochrome P450 and related enzymes. Despite considerable synthetic efforts, chemists have not succeeded in preparing an appropriate model complex. Here we report the synthesis and spectroscopic characterization of [Fe-IV(O)(TMCS)](+) where TMCS is a pentadentate ligand that provides a square pyramidal N-4(SR)(apical), where SR is thiotate, ligand environment about the iron center, which is similar to that of cytochrome P450. The rigidity of the ligand framework stabilizes the thiolate in an oxidizing environment. Reactivity studies suggest that thiolate coordination favors hydrogen-atom abstraction chemistry over oxygen-atom transfer pathways in the presence of reducing substrates.	Univ Wisconsin, Dept Chem, Eau Claire, WI 54702 USA; Univ Minnesota, Dept Chem, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Met Biocatalysis, Minneapolis, MN 55455 USA; Carnegie Mellon Univ, Dept Chem, Pittsburgh, PA 15213 USA; Ewha Womans Univ, Dept Chem, Div Nano Sci, Seoul 120750, South Korea; Ewha Womans Univ, Ctr Biomimet Syst, Seoul 120750, South Korea	University of Wisconsin System; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; Carnegie Mellon University; Ewha Womans University; Ewha Womans University	Halfen, JA (corresponding author), Univ Wisconsin, Dept Chem, Eau Claire, WI 54702 USA.	halfenja@uwec.edu; emunck@cmu.edu; que@chem.umn.edu		Nam, Wonwoo/0000-0001-8592-4867; Bukowski, Michael/0000-0001-8381-4429	NIBIB NIH HHS [EB-001475] Funding Source: Medline; NIGMS NIH HHS [GM-33162, T32 GM-08700] Funding Source: Medline; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING [R01EB001475] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033162, T32GM008700, R37GM033162] Funding Source: NIH RePORTER	NIBIB NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Costas M, 2004, CHEM REV, V104, P939, DOI 10.1021/cr020628n; Davydov R, 2001, J AM CHEM SOC, V123, P1403, DOI 10.1021/ja003583l; Debrunner P. G., 1989, IRON PORPHYRINS, V3, P137; Decker A, 2004, J AM CHEM SOC, V126, P5378, DOI 10.1021/ja0498033; Denisov IG, 2005, CHEM REV, V105, P2253, DOI 10.1021/cr0307143; Fiedler AT, 2005, J AM CHEM SOC, V127, P1675, DOI 10.1021/ja046939s; Green MT, 2004, SCIENCE, V304, P1653, DOI 10.1126/science.1096897; Groves J. T., 2005, CYTOCHROME P450, P1, DOI DOI 10.1007/0-387-27447-2_1; Kaizer J, 2004, J AM CHEM SOC, V126, P472, DOI 10.1021/ja037288n; Lim MH, 2003, P NATL ACAD SCI USA, V100, P3665, DOI 10.1073/pnas.0636830100; Meunier B, 2004, CHEM REV, V104, P3947, DOI 10.1021/cr020443g; Nam W, 2000, ANGEW CHEM INT EDIT, V39, P3646, DOI 10.1002/1521-3773(20001016)39:20<3646::AID-ANIE3646>3.0.CO;2-Q; Ogliaro F, 2002, J INORG BIOCHEM, V91, P554, DOI 10.1016/S0162-0134(02)00437-3; Rohde JU, 2004, J AM CHEM SOC, V126, P16750, DOI 10.1021/ja047667w; Rohde JU, 2003, SCIENCE, V299, P1037, DOI 10.1126/science.299.5609.1037; Rohde JU, 2005, ANGEW CHEM INT EDIT, V44, P2255, DOI 10.1002/anie.200462631; Sastri CV, 2005, J AM CHEM SOC, V127, P12494, DOI 10.1021/ja0540573; Schlichting I, 2000, SCIENCE, V287, P1615, DOI 10.1126/science.287.5458.1615; Schoneboom JC, 2005, J AM CHEM SOC, V127, P5840, DOI 10.1021/ja0424732; Schoneboom JC, 2002, J AM CHEM SOC, V124, P8142, DOI 10.1021/ja026279w; Shaik S, 2005, CHEM REV, V105, P2279, DOI 10.1021/cr030722j; Stuehr DJ, 1999, BBA-BIOENERGETICS, V1411, P217, DOI 10.1016/S0005-2728(99)00016-X; Tani F, 2002, COORDIN CHEM REV, V226, P219, DOI 10.1016/S0010-8545(01)00444-1; Westre TE, 1997, J AM CHEM SOC, V119, P6297, DOI 10.1021/ja964352a	24	214	214	1	75	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 11	2005	310	5750					1000	1002		10.1126/science.1119092	http://dx.doi.org/10.1126/science.1119092			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16254150				2022-12-28	WOS:000233343400038
J	Yaggi, HK; Concato, J; Kernan, WN; Lichtman, JH; Brass, LM; Mohsenin, V				Yaggi, HK; Concato, J; Kernan, WN; Lichtman, JH; Brass, LM; Mohsenin, V			Obstructive sleep apnea as a risk factor for stroke and death	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POSITIVE AIRWAY PRESSURE; CARDIOVASCULAR-DISEASE; BREATHING DISORDERS; BRAIN INFARCTION; BLOOD-PRESSURE; MORTALITY; ADULTS; HYPERTENSION; HYPOPNEA; 1ST-EVER	BACKGROUND: Previous studies have suggested that the obstructive sleep apnea syndrome may be an important risk factor for stroke. It has not been determined, however, whether the syndrome is independently related to the risk of stroke or death from any cause after adjustment for other risk factors, including hypertension. METHODS: In this observational cohort study, consecutive patients underwent polysomnography, and subsequent events (strokes and deaths) were verified. The diagnosis of the obstructive sleep apnea syndrome was based on an apnea-hypopnea index of 5 or higher (five or more events per hour); patients with an apnea-hypopnea index of less than 5 served as the comparison group. Proportional-hazards analysis was used to determine the independent effect of the obstructive sleep apnea syndrome on the composite outcome of stroke or death from any cause. RESULTS: Among 1022 enrolled patients, 697 (68 percent) had the obstructive sleep apnea syndrome. At baseline, the mean apnea-hypopnea index in the patients with the syndrome was 35, as compared with a mean apnea-hypopnea index of 2 in the comparison group. In an unadjusted analysis, the obstructive sleep apnea syndrome was associated with stroke or death from any cause (hazard ratio, 2.24; 95 percent confidence interval, 1.30 to 3.86; P=0.004). After adjustment for age, sex, race, smoking status, alcohol-consumption status, body-mass index, and the presence or absence of diabetes mellitus, hyperlipidemia, atrial fibrillation, and hypertension, the obstructive sleep apnea syndrome retained a statistically significant association with stroke or death (hazard ratio, 1.97; 95 percent confidence interval, 1.12 to 3.48; P=0.01). In a trend analysis, increased severity of sleep apnea at baseline was associated with an increased risk of the development of the composite end point (P=0.005). CONCLUSIONS: The obstructive sleep apnea syndrome significantly increases the risk of stroke or death from any cause, and the increase is independent of other risk factors, including hypertension.	Yale Ctr Sleep Med, Pulm & Crit Care Med Sect, New Haven, CT 06520 USA; Yale Univ, Sch Med, Med Genet Sect, New Haven, CT USA; Yale Univ, Sch Med, Dept Epidemiol & Publ Hlth, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; Vet Affairs Connecticut Healthcare Syst, Pulm & Crit Care Med Sect, West Haven, CT USA; Vet Affairs Connecticut Healthcare Syst, Clin Epidemiol Res Ctr, West Haven, CT USA; Vet Affairs Connecticut Healthcare Syst, Neurol Sect, West Haven, CT USA	Yale University; Yale University; Yale University; Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	Mohsenin, V (corresponding author), Yale Ctr Sleep Med, Pulm & Crit Care Med Sect, 300 Cedar St,TAC 441,POB 208057, New Haven, CT 06520 USA.		Ebben, Matthew R/I-4561-2012	Ebben, Matthew R/0000-0002-4399-7010	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007778] Funding Source: NIH RePORTER; NHLBI NIH HHS [5T32HL07778] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		American Heart Association, 2005, HEART DIS STROKE STA; Bassetti C, 1999, SLEEP, V22, P217, DOI 10.1093/sleep/22.2.217; Becker HF, 2003, CIRCULATION, V107, P68, DOI 10.1161/01.CIR.0000042706.47107.7A; Beelke M, 2002, SLEEP, V25, P856; BOKINSKY G, 1995, CHEST, V108, P625, DOI 10.1378/chest.108.3.625; Broderick J, 1998, STROKE, V29, P415, DOI 10.1161/01.STR.29.2.415; Chin K, 1996, AM J RESP CRIT CARE, V153, P1972, DOI 10.1164/ajrccm.153.6.8665063; Diomedi M, 1998, NEUROLOGY, V51, P1051, DOI 10.1212/WNL.51.4.1051; Dyken ME, 1996, STROKE, V27, P401, DOI 10.1161/01.STR.27.3.401; Flemons WW, 1999, SLEEP, V22, P667, DOI 10.1093/sleep/22.5.667; Franklin KA, 2002, SLEEP MED REV, V6, P429, DOI 10.1053/smrv.2001.0206; Hayashi M, 2003, CHEST, V124, P936, DOI 10.1378/chest.124.3.936; HEDNER J, 1988, J HYPERTENS, V6, pS529, DOI 10.1097/00004872-198812040-00166; JENNUM P, 1989, CHEST, V95, P279, DOI 10.1378/chest.95.2.279; JOHNS MW, 1993, CHEST, V103, P30, DOI 10.1378/chest.103.1.30; Kato M, 2000, CIRCULATION, V102, P2607; LAVIE P, 1995, SLEEP, V18, P149, DOI 10.1093/sleep/18.3.149; Leung RST, 2001, AM J RESP CRIT CARE, V164, P2147, DOI 10.1164/ajrccm.164.12.2107045; Marin JM, 2005, LANCET, V365, P1046, DOI 10.1016/S0140-6736(05)71141-7; Marti S, 2002, EUR RESPIR J, V20, P1511, DOI 10.1183/09031936.02.00306502; Meoli AL, 2001, SLEEP, V24, P469; Meschia JF, 2000, STROKE, V31, P1076, DOI 10.1161/01.STR.31.5.1076; MOHSENIN V, 1995, ARCH PHYS MED REHAB, V76, P71, DOI 10.1016/S0003-9993(95)80046-8; Murray CJL, 1997, LANCET, V349, P1269, DOI 10.1016/S0140-6736(96)07493-4; NEAU JP, 1995, ACTA NEUROL SCAND, V92, P63; Netzer N, 1998, STROKE, V29, P87, DOI 10.1161/01.STR.29.1.87; PALOMAKI H, 1991, STROKE, V22, P1021, DOI 10.1161/01.STR.22.8.1021; Parra O, 2000, AM J RESP CRIT CARE, V161, P375, DOI 10.1164/ajrccm.161.2.9903139; PARTINEN M, 1985, LANCET, V2, P1325; Peppard PE, 2000, NEW ENGL J MED, V342, P1378, DOI 10.1056/NEJM200005113421901; Pepperell JCT, 2002, LANCET, V359, P204, DOI 10.1016/S0140-6736(02)07445-7; Rechtschaffen A., 1968, BRAIN INFORM SERVICE; Schisterman Enrique F, 2004, Popul Health Metr, V2, P2, DOI 10.1186/1478-7954-2-2; Shahar E, 2001, AM J RESP CRIT CARE, V163, P19, DOI 10.1164/ajrccm.163.1.2001008; SMIRNE S, 1993, EUR RESPIR J, V6, P1357; SOMERS VK, 1995, J CLIN INVEST, V96, P1897, DOI 10.1172/JCI118235; SPRIGGS DA, 1992, Q J MED, V83, P555; WHISNANT J P, 1990, Stroke, V21, P637; Yokoe T, 2003, CIRCULATION, V107, P1129, DOI 10.1161/01.CIR.0000052627.99976.18; Young T, 2002, AM J RESP CRIT CARE, V165, P1217, DOI 10.1164/rccm.2109080; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704	41	2000	2109	5	160	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 10	2005	353	19					2034	2041		10.1056/NEJMoa043104	http://dx.doi.org/10.1056/NEJMoa043104			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981WV	16282178				2022-12-28	WOS:000233119600008
J	Lee, DY; Ezhkova, E; Li, B; Pattenden, SG; Tansey, WP; Workman, JL				Lee, DY; Ezhkova, E; Li, B; Pattenden, SG; Tansey, WP; Workman, JL			The proteasome regulatory particle alters the SAGA coactivator to enhance its interactions with transcriptional activators	CELL			English	Article							HISTONE ACETYLTRANSFERASE COMPLEXES; TATA-BINDING PROTEIN; SACCHAROMYCES-CEREVISIAE; IN-VIVO; SWI/SNF COMPLEX; ACTIVE GENES; ACETYLATION; RECRUITMENT; H2B; H3	Promoter recruitment of the Saccharomyces cerevisiae SAGA histone acetyltransferase complex is required for RNA polymerase II-dependent transcription of several genes. SAGA is targeted to promoters through interactions with sequence-specific DNA binding transcriptional activators and facilitates preinitiation-complex assembly and transcription. Here, we show that the 19S proteasome regulatory particle (19S RP) alters SAGA to stimulate its interaction with transcriptional activators. The ATPase components of the 19S RP are required for stimulation of SAGA/activator interactions and enhance SAGA recruitment to promoters. Proteasomal ATPases genetically interact with SAGA, and their inhibition reduces global histone H3 acetylation levels and SAGA recruitment to target promoters in vivo. These results indicate that the 19S RIP modulates SAGA complex using its ATPase components, thereby facilitating subsequent transcription events at promoters.	Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA; Stowers Inst Med Res, Kansas City, MO 64110 USA; Watson Sch Biol Sci, Cold Spring Harbor, NY 11724 USA	Cold Spring Harbor Laboratory; Stowers Institute for Medical Research; Cold Spring Harbor Laboratory	Tansey, WP (corresponding author), Cold Spring Harbor Lab, 1 Bungtown Rd, Cold Spring Harbor, NY 11724 USA.	tansey@cshl.edu; jlw@stowers-institute.org	Lee, Daeyoup/C-1653-2011	Lee, Daeyoup/0000-0003-2006-1823; Ezhkova, Elena/0000-0003-4154-1615	NIGMS NIH HHS [GM067728, GM047867] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM047867, R01GM047867, R01GM067728] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Belotserkovskaya R, 2000, MOL CELL BIOL, V20, P634, DOI 10.1128/MCB.20.2.634-647.2000; Benaroudj N, 2000, NAT CELL BIOL, V2, P833, DOI 10.1038/35041081; Bernstein BE, 2002, P NATL ACAD SCI USA, V99, P8695, DOI 10.1073/pnas.082249499; Bhaumik SR, 2001, GENE DEV, V15, P1935, DOI 10.1101/gad.911401; Bowers JL, 2004, MOL CELL, V16, P967, DOI 10.1016/j.molcel.2004.11.038; Bowman GD, 2004, NATURE, V429, P724, DOI 10.1038/nature02585; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Brown CE, 2001, SCIENCE, V292, P2333, DOI 10.1126/science.1060214; Daniel JA, 2004, J BIOL CHEM, V279, P1867, DOI 10.1074/jbc.C300494200; Davey MJ, 2002, EMBO J, V21, P3148, DOI 10.1093/emboj/cdf308; Deckert J, 2001, MOL CELL BIOL, V21, P2726, DOI 10.1128/MCB.21.8.2726-2735.2001; Dudley AM, 1999, GENE DEV, V13, P2940, DOI 10.1101/gad.13.22.2940; Eberharter A, 1998, METHODS, V15, P315, DOI 10.1006/meth.1998.0635; Ezhkova E, 2004, MOL CELL, V13, P435, DOI 10.1016/S1097-2765(04)00026-7; Ferdous A, 2001, MOL CELL, V7, P981, DOI 10.1016/S1097-2765(01)00250-7; Fishburn J, 2005, MOL CELL, V18, P369, DOI 10.1016/j.molcel.2005.03.029; Funakoshi M, 2004, J CELL SCI, V117, P6447, DOI 10.1242/jcs.01575; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Gonzalez F, 2002, SCIENCE, V296, P548, DOI 10.1126/science.1069490; Grant PA, 1999, J BIOL CHEM, V274, P5895, DOI 10.1074/jbc.274.9.5895; Hassan AH, 2001, CELL, V104, P817, DOI 10.1016/S0092-8674(01)00279-3; Henry KW, 2003, GENE DEV, V17, P2648, DOI 10.1101/gad.1144003; Howe L, 2001, GENE DEV, V15, P3144, DOI 10.1101/gad.931401; Huisinga KL, 2004, MOL CELL, V13, P573, DOI 10.1016/S1097-2765(04)00087-5; Juan LJ, 1997, J BIOL CHEM, V272, P3635, DOI 10.1074/jbc.272.6.3635; Kao CF, 2004, GENE DEV, V18, P184, DOI 10.1101/gad.1149604; Larschan E, 2001, GENE DEV, V15, P1946, DOI 10.1101/gad.911501; Leggett DS, 2002, MOL CELL, V10, P495, DOI 10.1016/S1097-2765(02)00638-X; Lupas AN, 2002, CURR OPIN STRUC BIOL, V12, P746, DOI 10.1016/S0959-440X(02)00388-3; Natarajan K, 1999, MOL CELL, V4, P657, DOI 10.1016/S1097-2765(00)80217-8; Navon A, 2001, MOL CELL, V8, P1339, DOI 10.1016/S1097-2765(01)00407-5; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Neuwald AF, 1999, GENOME RES, V9, P27; Ng HH, 2003, MOL CELL, V11, P709, DOI 10.1016/S1097-2765(03)00092-3; Pray-Grant MG, 2002, MOL CELL BIOL, V22, P8774, DOI 10.1128/MCB.22.24.8774-8786.2002; Pray-Grant MG, 2005, NATURE, V433, P434, DOI 10.1038/nature03242; Robert F, 2004, MOL CELL, V16, P199, DOI 10.1016/j.molcel.2004.09.021; Rodriguez-Navarro S, 2004, CELL, V116, P75, DOI 10.1016/S0092-8674(03)01025-0; Santos-Rosa H, 2002, NATURE, V419, P407, DOI 10.1038/nature01080; Sone T, 2004, J BIOL CHEM, V279, P28807, DOI 10.1074/jbc.M403165200; Stenlund A, 2003, NAT REV MOL CELL BIO, V4, P777, DOI 10.1038/nrm1226; Sterner DE, 2000, MICROBIOL MOL BIOL R, V64, P435, DOI 10.1128/MMBR.64.2.435-459.2000; Sterner DE, 2002, P NATL ACAD SCI USA, V99, P11622, DOI 10.1073/pnas.182021199; Strickland E, 2000, J BIOL CHEM, V275, P5565, DOI 10.1074/jbc.275.8.5565; Sun LP, 2002, BIOCHEM BIOPH RES CO, V296, P991, DOI 10.1016/S0006-291X(02)02026-0; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; Utley RT, 1998, NATURE, V394, P498, DOI 10.1038/28886; Verma R, 2000, MOL BIOL CELL, V11, P3425, DOI 10.1091/mbc.11.10.3425; Wang L, 1998, GENE DEV, V12, P640, DOI 10.1101/gad.12.5.640; Warfield L, 2004, GENE DEV, V18, P1022, DOI 10.1101/gad.1192204; Wu PYJ, 2002, MOL CELL BIOL, V22, P5367, DOI 10.1128/MCB.22.15.5367-5379.2002; XU QL, 1995, MOL CELL BIOL, V15, P6025; Yu VPCC, 2005, MOL CELL, V17, P145, DOI 10.1016/j.molcel.2004.11.020; Zhang WZ, 1998, EMBO J, V17, P3155, DOI 10.1093/emboj/17.11.3155	54	143	148	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 4	2005	123	3					423	436		10.1016/j.cell.2005.08.015	http://dx.doi.org/10.1016/j.cell.2005.08.015			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	983WY	16269334	Bronze			2022-12-28	WOS:000233264300011
J	Spiegelhalter, DJ				Spiegelhalter, DJ			Problems in assessing rates of infection with methicillin resistant Staphylococcus aureus	BRITISH MEDICAL JOURNAL			English	Editorial Material							PERFORMANCE		Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England	MRC Biostatistics Unit; University of Cambridge	Spiegelhalter, DJ (corresponding author), Inst Publ Hlth, MRC, Biostat Unit, Cambridge CB2 2SR, England.	david.spiegelhalter@mrc-bsu.cam.ac.uk						Bird SM, 2005, J ROY STAT SOC A STA, V168, P1, DOI 10.1111/j.1467-985X.2004.00333.x; BLAND JM, 1994, BRIT MED J, V308, P1499, DOI 10.1136/bmj.308.6942.1499; Burgess JF, 2000, J HEALTH ECON, V19, P291, DOI 10.1016/S0167-6296(99)00034-X; *COMM HLTH IMPR, 2003, METH RES STAPH AUR M; Department of Health, 2004, MAND BACT SURV SCHEM; Department of Health, 2004, NAT STAND LOC ACT HL; *HEALTHC COMM, 2004, IND LIST AC TRUSTS; *HEALTHC COMM, 2005, IND LIST AC TRUSTS M; *HLTH PROT AG COMM, 2003, CDR WEEKLY, V13, P1; McCullagh P., 1989, GEN LINEAR MODELS, V2nd; Mohammed MA, 2001, LANCET, V357, P463, DOI 10.1016/S0140-6736(00)04019-8; Spiegelhalter DJ, 2005, STAT MED, V24, P1185, DOI 10.1002/sim.1970; 2004, BBC NEWS        0713; 2004, BBC NEWS        1105	14	23	24	0	1	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 29	2005	331	7523					1013	1015		10.1136/bmj.331.7523.1013	http://dx.doi.org/10.1136/bmj.331.7523.1013			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	981AU	16254304	Green Published			2022-12-28	WOS:000233060200022
J	Kokoeva, MV; Yin, HL; Flier, JS				Kokoeva, MV; Yin, HL; Flier, JS			Neurogenesis in the hypothalamus of adult mice: Potential role in energy balance	SCIENCE			English	Article							CILIARY NEUROTROPHIC FACTOR; NEURAL PROGENITORS; FEEDING CIRCUITS; GENE-EXPRESSION; MAMMALIAN BRAIN; GROWTH-FACTOR; BODY-WEIGHT; LEPTIN; OBESITY; NEURONS	Ciliary neurotrophic factor (CNTF) induces weight loss in obese rodents and humans, and for reasons that are not understood, its effects persist after the cessation of treatment. Here we demonstrate that centrally administered CNTF induces cell proliferation in feeding centers of the murine hypothalamus. Many of the newborn cells express neuronal markers and show functional phenotypes relevant for energy-balance control, including a capacity for leptin-induced phosphorylation of signal transducer and activator of transcription 3 (STAT3). Coadministration of the mitotic blocker cytosine-beta-D-arabinofuranoside (Ara-C) eliminates the proliferation of neural cells and abrogates the tong-term, but not the short-term, effect of CNTF on body weight. These findings link the sustained effect of CNTF on energy balance to hypothalamic neurogenesis and suggest that regulated hypothalamic neurogenesis in adult mice may play a previously unappreciated role in physiology and disease.	Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Flier, JS (corresponding author), Beth Israel Deaconess Med Ctr, Dept Med, Div Endocrinol, 99 Brookline Ave, Boston, MA 02215 USA.	jflier@bidmc.harvard.edu	Flier, jeffrey/AAG-6223-2019		NIDDK NIH HHS [DKR3728082] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK028082] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ahima RS, 2001, TRENDS MOL MED, V7, P205, DOI 10.1016/S1471-4914(01)01989-X; Anderson KD, 1998, SOC NEUR ABSTR, V24, P621; Bates SH, 2003, NATURE, V421, P856, DOI 10.1038/nature01388; Bhat RV, 1996, GLIA, V17, P169; Bjorbaek C, 1999, ENDOCRINOLOGY, V140, P2035, DOI 10.1210/en.140.5.2035; Bouret SG, 2004, SCIENCE, V304, P108, DOI 10.1126/science.1095004; Brown JP, 2003, J COMP NEUROL, V467, P1, DOI 10.1002/cne.10874; Craig CG, 1996, J NEUROSCI, V16, P2649; Doetsch F, 1999, P NATL ACAD SCI USA, V96, P11619, DOI 10.1073/pnas.96.20.11619; Elmquist JK, 1999, NEURON, V22, P221, DOI 10.1016/S0896-6273(00)81084-3; Emsley JG, 2003, EXP NEUROL, V183, P298, DOI 10.1016/S0014-4886(03)00129-8; Ettinger MP, 2003, JAMA-J AM MED ASSOC, V289, P1826, DOI 10.1001/jama.289.14.1826; Gage FH, 2000, SCIENCE, V287, P1433, DOI 10.1126/science.287.5457.1433; Gloaguen I, 1997, P NATL ACAD SCI USA, V94, P6456, DOI 10.1073/pnas.94.12.6456; Gould E, 2002, J NEUROSCI, V22, P619, DOI 10.1523/JNEUROSCI.22-03-00619.2002; Horvath TL, 2004, NAT REV NEUROSCI, V5, P662, DOI 10.1038/nrn1479; Hubschle T, 2001, J NEUROSCI, V21, P2413, DOI 10.1523/JNEUROSCI.21-07-02413.2001; Kelly JF, 2004, DIABETES, V53, P911, DOI 10.2337/diabetes.53.4.911; Kuhn HG, 1997, J NEUROSCI, V17, P5820; Lambert PD, 2001, P NATL ACAD SCI USA, V98, P4652, DOI 10.1073/pnas.061034298; LEE MK, 1990, P NATL ACAD SCI USA, V87, P7195, DOI 10.1073/pnas.87.18.7195; Levison SW, 1996, EXP NEUROL, V141, P256, DOI 10.1006/exnr.1996.0160; LOIS C, 1994, SCIENCE, V264, P1145, DOI 10.1126/science.8178174; Magavi SS, 2000, NATURE, V405, P951, DOI 10.1038/35016083; Markakis EA, 2004, J NEUROSCI, V24, P2886, DOI 10.1523/JNEUROSCI.4161-03.2004; MARUSICH MF, 1994, J NEUROBIOL, V25, P143, DOI 10.1002/neu.480250206; Munzberg H, 2003, ENDOCRINOLOGY, V144, P2121, DOI 10.1210/en.2002-221037; Nakatomi H, 2002, CELL, V110, P429, DOI 10.1016/S0092-8674(02)00862-0; Pencea V, 2001, J NEUROSCI, V21, P6706, DOI 10.1523/JNEUROSCI.21-17-06706.2001; Pinto S, 2004, SCIENCE, V304, P110, DOI 10.1126/science.1089459; SanzRodriguez C, 1997, NEUROSCI LETT, V223, P141, DOI 10.1016/S0304-3940(97)13412-7; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Shimazaki T, 2001, J NEUROSCI, V21, P7642, DOI 10.1523/JNEUROSCI.21-19-07642.2001; Sleeman M W, 2000, Pharm Acta Helv, V74, P265, DOI 10.1016/S0031-6865(99)00050-3; Vaisse C, 1996, NAT GENET, V14, P95, DOI 10.1038/ng0996-95; Weigle DS, 2003, J CLIN ENDOCR METAB, V88, P2462, DOI 10.1210/jc.2003-030151; Xu Y, 2005, EXP NEUROL, V192, P251, DOI 10.1016/j.expneurol.2004.12.021; Yanovski SZ, 2002, NEW ENGL J MED, V346, P591, DOI 10.1056/NEJMra012586; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0	39	518	527	1	37	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					679	683		10.1126/science.1115360	http://dx.doi.org/10.1126/science.1115360			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254185				2022-12-28	WOS:000232997700043
J	Cheung, VG; Spielman, RS; Ewens, KG; Weber, TM; Morley, M; Burdick, JT				Cheung, VG; Spielman, RS; Ewens, KG; Weber, TM; Morley, M; Burdick, JT			Mapping determinants of human gene expression by regional and genome-wide association	NATURE			English	Article							COMPLEX TRAITS; DISEASE; DISSECTION; FUTURE	To study the genetic basis of natural variation in gene expression, we previously carried out genome-wide linkage analysis and mapped the determinants of similar to 1,000 expression phenotypes(1). In the present study, we carried out association analysis with dense sets of single-nucleotide polymorphism ( SNP) markers from the International HapMap Project(2). For 374 phenotypes, the association study was performed with markers only from regions with strong linkage evidence; these regions all mapped close to the expressed gene. For a subset of 27 phenotypes, analysis of genome-wide association was performed with > 770,000 markers. The association analysis with markers under the linkage peaks confirmed the linkage results and narrowed the candidate regulatory regions for many phenotypes with strong linkage evidence. The genome-wide association analysis yielded highly significant results that point to the same locations as the genome scans for about 50% of the phenotypes. For one candidate determinant, we carried out functional analyses and confirmed the variation in cis-acting regulatory activity. Our findings suggest that association studies with dense SNP maps will identify susceptibility loci or other determinants for some complex traits or diseases.	Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia	Cheung, VG (corresponding author), Univ Penn, Dept Pediat, Philadelphia, PA 19104 USA.	vcheung@mail.med.upenn.edu; spielman@pobox.upenn.edu	Cheung, Vivian G./AAT-3115-2020	Morley, Michael/0000-0002-0958-7376	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM081930] Funding Source: NIH RePORTER; NIGMS NIH HHS [R01 GM081930, R01 GM081930-08] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ball RD, 2005, GENETICS, V170, P859, DOI 10.1534/genetics.103.024752; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Brem RB, 2002, SCIENCE, V296, P752, DOI 10.1126/science.1069516; Carlson CS, 2004, NATURE, V429, P446, DOI 10.1038/nature02623; Carrasquillo MM, 2002, NAT GENET, V32, P237, DOI 10.1038/ng998; Cheung VG, 2002, NAT GENET, V32, P522, DOI 10.1038/ng1036; Cheung VG, 2003, NAT GENET, V33, P422, DOI 10.1038/ng1094; Gibbs RA, 2003, NATURE, V426, P789, DOI 10.1038/nature02168; Glazier AM, 2002, SCIENCE, V298, P2345, DOI 10.1126/science.1076641; Hirschhorn JN, 2005, NAT REV GENET, V6, P95, DOI 10.1038/nrg1521; Klein RJ, 2005, SCIENCE, V308, P385, DOI 10.1126/science.1109557; Knight JC, 2003, NAT GENET, V33, P469, DOI 10.1038/ng1124; Komarnitsky P, 2000, GENE DEV, V14, P2452, DOI 10.1101/gad.824700; LANDER ES, 1994, SCIENCE, V265, P2037, DOI 10.1126/science.8091226; Liu XM, 2005, CANCER RES, V65, P99; Monks SA, 2004, AM J HUM GENET, V75, P1094, DOI 10.1086/426461; Morley M, 2004, NATURE, V430, P743, DOI 10.1038/nature02797; Oberley MJ, 2004, METHOD ENZYMOL, V376, P315; Ozaki K, 2002, NAT GENET, V32, P650, DOI 10.1038/ng1047; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; Wang WYS, 2005, NAT REV GENET, V6, P109, DOI 10.1038/nrg1522; Westfall P.H., 1992, RESAMPLING BASED MUL	22	450	474	1	20	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	OCT 27	2005	437	7063					1365	1369		10.1038/nature04244	http://dx.doi.org/10.1038/nature04244			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251966	Bronze, Green Accepted			2022-12-28	WOS:000232829100056
J	Rowe, C; Harris, JM; Roberts, SC				Rowe, C; Harris, JM; Roberts, SC			Sporting contests - Seeing red? Putting sportswear in context	NATURE			English	Editorial Material							COLOR		Newcastle Univ, Sch Biol & Psychol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England; Univ St Andrews, St Marys Coll, Sch Psychol, St Andrews KY16 9JP, Fife, Scotland; Univ Liverpool, Sch Biol Sci, Evolutionary Psychol & Behav Ecol Grp, Liverpool L69 7ZB, Merseyside, England	Newcastle University - UK; University of St Andrews; University of Liverpool	Rowe, C (corresponding author), Newcastle Univ, Sch Biol & Psychol, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England.	candy.rowe@ncl.ac.uk	Roberts, Craig/E-6919-2011; Roberts, S./A-2040-2009	Roberts, Craig/0000-0002-9641-6101; 				Farrow Damian, 2000, Clin Exp Optom, V83, P226; FRANK MG, 1988, J PERS SOC PSYCHOL, V54, P74, DOI 10.1037/0022-3514.54.1.74; Hill RA, 2005, NATURE, V435, P293, DOI 10.1038/435293a; McKeefry DJ, 2003, INVEST OPHTH VIS SCI, V44, P2267, DOI 10.1167/iovs.02-0772; Mills BD, 1996, J HUM MOVEMENT STUD, V31, P47; Regan BC, 2001, PHILOS T R SOC B, V356, P229, DOI 10.1098/rstb.2000.0773; Williams AM, 2000, J SPORT SCI, V18, P737, DOI 10.1080/02640410050120113; Williams M, 2002, PSYCHOLOGIST, V15, P416	8	49	51	1	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					E10	E10		10.1038/nature04306	http://dx.doi.org/10.1038/nature04306			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251904	Bronze			2022-12-28	WOS:000232829100034
J	Bornholdt, S				Bornholdt, S			Less is more in modeling large genetic networks	SCIENCE			English	Editorial Material							EXPRESSION; TOPOLOGY		Univ Bremen, Inst Theoret Phys, D-28359 Bremen, Germany	University of Bremen	Bornholdt, S (corresponding author), Univ Bremen, Inst Theoret Phys, Otto Hahn Allee, D-28359 Bremen, Germany.	bornholdt@itp.uni-bremen.de						Albert R, 2003, J THEOR BIOL, V223, P1, DOI 10.1016/S0022-5193(03)00035-3; Brandman O, 2005, SCIENCE, V310, P496, DOI 10.1126/science.1113834; KAUFFMAN SA, 1969, J THEOR BIOL, V22, P437, DOI 10.1016/0022-5193(69)90015-0; Li FT, 2004, P NATL ACAD SCI USA, V101, P4781, DOI 10.1073/pnas.0305937101; Ma'ayan A, 2005, SCIENCE, V309, P1078, DOI 10.1126/science.1108876; McAdams HH, 1997, P NATL ACAD SCI USA, V94, P814, DOI 10.1073/pnas.94.3.814; Wagner A, 2005, P NATL ACAD SCI USA, V102, P11775, DOI 10.1073/pnas.0501094102	7	216	229	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 21	2005	310	5747					449	+		10.1126/science.1119959	http://dx.doi.org/10.1126/science.1119959			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239464				2022-12-28	WOS:000232786000031
J	Paterson, I; Anderson, EA				Paterson, I; Anderson, EA			The renaissance of natural products as drug candidates	SCIENCE			English	Editorial Material							SCALE SYNTHESIS		Univ Cambridge, Dept Chem, Cambridge CB2 1EW, England	University of Cambridge	Paterson, I (corresponding author), Univ Cambridge, Dept Chem, Lensfield Rd, Cambridge CB2 1EW, England.	ip100@cam.ac.uk	Paterson, Ian/Q-6588-2018	Paterson, Ian/0000-0002-8861-9136				AICHER TD, 1992, J AM CHEM SOC, V114, P3162, DOI 10.1021/ja00034a086; Anantharaman V, 2003, CURR OPIN CHEM BIOL, V7, P12, DOI 10.1016/S1367-5931(02)00018-2; Burke MD, 2004, ANGEW CHEM INT EDIT, V43, P46, DOI 10.1002/anie.200300626; Butler MS, 2005, NAT PROD REP, V22, P162, DOI 10.1039/b402985m; Charest MG, 2005, SCIENCE, V308, P395, DOI 10.1126/science.1109755; Koehn FE, 2005, NAT REV DRUG DISCOV, V4, P206, DOI 10.1038/nrd1657; Mickel SJ, 2004, ORG PROCESS RES DEV, V8, P122, DOI 10.1021/op034134j; Newman DJ, 2003, J NAT PROD, V66, P1022, DOI 10.1021/np030096l; Njardarson JT, 2004, J AM CHEM SOC, V126, P1038, DOI 10.1021/ja039714a; Paterson I, 2003, EUR J ORG CHEM, V2003, P2193, DOI 10.1002/ejoc.200300061; Shaw SJ, 2005, J AM CHEM SOC, V127, P6532, DOI 10.1021/ja051185i; Smith AB, 2000, J AM CHEM SOC, V122, P8654, DOI 10.1021/ja0015287; Wender Paul A, 2004, Curr Drug Discov Technol, V1, P1, DOI 10.2174/1570163043484888; Zhang CO, 1998, J MOL BIOL, V284, P1301, DOI 10.1006/jmbi.1998.2282; Zheng WJ, 2004, BIOORG MED CHEM LETT, V14, P5551, DOI 10.1016/j.bmcl.2004.08.069	15	425	444	0	68	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					451	453		10.1126/science.1116364	http://dx.doi.org/10.1126/science.1116364			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239465				2022-12-28	WOS:000232786000032
J	Wachowiak, A; Yamachika, R; Khoo, KH; Wang, Y; Grobis, M; Lee, DH; Louie, SG; Crommie, MF				Wachowiak, A; Yamachika, R; Khoo, KH; Wang, Y; Grobis, M; Lee, DH; Louie, SG; Crommie, MF			Visualization of the molecular Jahn-Teller effect in an insulating K4C60 monolayer	SCIENCE			English	Article							DOPED C-60 MONOLAYERS; ELECTRONIC-STRUCTURE; ORBITAL DEGENERACY; METAL; FULLERIDES; SUPERCONDUCTIVITY; TRANSITION; DISTORTION; SURFACE; STATES	We present a low-temperature scanning tunneling microscopy (STM) study of KxC60 monolayers on Au(111) for 3 <= x <= 4. The STM spectrum evolves from one that is characteristic of a metal at x = 3 to one that is characteristic of an insulator at x = 4. This electronic transition is accompanied by a dramatic structural rearrangement of the C-60 molecules. The Jahn-Teller effect, a charge-induced mechanical deformation of molecular structure, is directly visualized in the K4C60 monolayer at the single-molecule level. These results, along with theoretical analyses, provide strong evidence that the transition from metal to insulator in KxC60 monolayers is caused by the Jahn-Teller effect.	Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA; Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley	Crommie, MF (corresponding author), Univ Calif Berkeley, Dept Phys, Berkeley, CA 94720 USA.	crommie@berkeley.edu	Khoo, Khoong Hong/G-3983-2012	Khoo, Khoong Hong/0000-0002-4628-1202; Grobis, Michael/0000-0003-0362-6888				Brouet V, 2004, STRUCT BOND, V109, P165, DOI 10.1007/b94382; Capone M, 2000, PHYS REV B, V62, P7619, DOI 10.1103/PhysRevB.62.7619; Cepek C, 2000, SURF SCI, V454, P467, DOI 10.1016/S0039-6028(00)00135-7; CEULEMANS A, 1987, J CHEM PHYS, V87, P5374, DOI 10.1063/1.453656; Chibotaru LF, 1999, PHYS REV B, V59, P12728, DOI 10.1103/PhysRevB.59.R12728; Dahlke P, 2002, CHEM MATER, V14, P1285, DOI 10.1021/cm010386s; Durand P, 2003, NAT MATER, V2, P605, DOI 10.1038/nmat953; Fabrizio M, 1997, PHYS REV B, V55, P13465, DOI 10.1103/PhysRevB.55.13465; GUNNARSSON O, 1991, PHYS REV LETT, V67, P3002, DOI 10.1103/PhysRevLett.67.3002; Gunnarsson O., 2004, ALKALI DOPED FULLERI; HADDON RC, 1991, NATURE, V350, P320, DOI 10.1038/350320a0; Han JE, 2000, PHYS REV LETT, V84, P1276, DOI 10.1103/PhysRevLett.84.1276; HEBARD AF, 1991, NATURE, V350, P600, DOI 10.1038/350600a0; Hesper R, 1997, EUROPHYS LETT, V40, P177, DOI 10.1209/epl/i1997-00442-2; Iwasa Y, 2003, J PHYS-CONDENS MAT, V15, pR495, DOI 10.1088/0953-8984/15/13/202; Jahn HA, 1937, PROC R SOC LON SER-A, V161, P220, DOI 10.1098/rspa.1937.0142; Junquera J, 2001, PHYS REV B, V64, DOI 10.1103/PhysRevB.64.235111; Kamaras K, 2002, PHYS REV B, V65, DOI 10.1103/PhysRevB.65.052103; Kerkoud R, 1996, J PHYS CHEM SOLIDS, V57, P143, DOI 10.1016/0022-3697(95)00113-1; KIEFL RF, 1992, PHYS REV LETT, V69, P2005, DOI 10.1103/PhysRevLett.69.2005; KOGA N, 1992, CHEM PHYS LETT, V196, P191, DOI 10.1016/0009-2614(92)85952-7; Lu XH, 2004, PHYS REV B, V70, DOI 10.1103/PhysRevB.70.115418; MANINI N, 1994, PHYS REV B, V49, P13008, DOI 10.1103/PhysRevB.49.13008; PAUL P, 1994, J AM CHEM SOC, V116, P4145, DOI 10.1021/ja00088a087; STEPNIAK F, 1993, PHYS REV B, V48, P1899, DOI 10.1103/PhysRevB.48.1899; Tjeng LH, 1997, SOLID STATE COMMUN, V103, P31, DOI 10.1016/S0038-1098(97)00126-9; Yang WL, 2003, SCIENCE, V300, P303, DOI 10.1126/science.1082174	27	75	75	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					468	470		10.1126/science.1117303	http://dx.doi.org/10.1126/science.1117303			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239471				2022-12-28	WOS:000232786000039
J	Schroter, D; Cramer, W; Leemans, R; Prentice, IC; Araujo, MB; Arnell, NW; Bondeau, A; Bugmann, H; Carter, TR; Gracia, CA; de la Vega-Leinert, AC; Erhard, M; Ewert, F; Glendining, M; House, JI; Kankaanpaa, S; Klein, RJT; Lavorel, S; Lindner, M; Metzger, MJ; Meyer, J; Mitchell, TD; Reginster, I; Rounsevell, M; Sabate, S; Sitch, S; Smith, B; Smith, J; Smith, P; Sykes, MT; Thonicke, K; Thuiller, W; Tuck, G; Zaehle, S; Zierl, B				Schroter, D; Cramer, W; Leemans, R; Prentice, IC; Araujo, MB; Arnell, NW; Bondeau, A; Bugmann, H; Carter, TR; Gracia, CA; de la Vega-Leinert, AC; Erhard, M; Ewert, F; Glendining, M; House, JI; Kankaanpaa, S; Klein, RJT; Lavorel, S; Lindner, M; Metzger, MJ; Meyer, J; Mitchell, TD; Reginster, I; Rounsevell, M; Sabate, S; Sitch, S; Smith, B; Smith, J; Smith, P; Sykes, MT; Thonicke, K; Thuiller, W; Tuck, G; Zaehle, S; Zierl, B			Ecosystem service supply and vulnerability to global change in Europe	SCIENCE			English	Article							FUTURE SCENARIOS; CLIMATE-CHANGE; CARBON; BIODIVERSITY	Global change will alter the supply of ecosystem services that are vital for human well-being. To investigate ecosystem service supply during the 21st century, we used a range of ecosystem models and scenarios of climate and land-use change to conduct a Europe-wide assessment. Large changes in climate and land use typically resulted in large changes in ecosystem service supply. Some of these trends may be positive (for example, increases in forest area and productivity) or offer opportunities (for example, "surplus land" for agricultural extensification and bioenergy production). However, many changes increase vulnerability as a result of a decreasing supply of ecosystem services (for example, declining soil fertility, declining water availability, increasing risk of forest fires), especially in the Mediterranean and mountain regions.	Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany; Harvard Univ, Ctr Int Dev, Cambridge, MA 02138 USA; Univ Wageningen & Res Ctr, Dept Environm Sci, NL-6700 AA Wageningen, Netherlands; Univ Bristol, Dept Earth Sci, Bristol BS8 1RJ, Avon, England; Univ Oxford, Sch Geog & Environm, Oxford OX1 3TB, England; CSIC, Museo Nacl Ciencias Nat, E-28006 Madrid, Spain; Univ Southampton, Sch Geog, Tyndall Ctr Climate Change Res, Southampton SO17 1BJ, Hants, England; ETH, Dept Environm Sci, CH-8092 Zurich, Switzerland; Finnish Environm Inst, Helsinki 00251, Finland; Univ Barcelona, Ctr Ecol Res & Forestry Applicat, Barcelona 08193, Spain; Forschungszentrum Karlsruhe, Inst Meteorol & Climate Res, D-82467 Garmisch Partenkirchen, Germany; Rothamsted Res, Agr & Environm Div, Harpenden AL5 2JQ, Herts, England; Univ Grenoble 1, CNRS, Lab Ecol Alpine, F-38041 Grenoble, France; CNRS, Ctr Ecol Fonct & Evolut, F-34033 Montpellier, France; European Forest Inst, Joensuu 80100, Finland; Univ E Anglia, Tyndall Ctr Climate Change Res, Norwich NR4 7TJ, Norfolk, England; Catholic Univ Louvain, Dept Geog, B-1348 Louvain, Belgium; Lund Univ, Dept Phys Geog & Ecosyst Anal, S-22362 Lund, Sweden; Univ Aberdeen, Sch Biol Sci, Aberdeen AB24 3UU, Scotland; S African Natl Biodivers Inst, Kirstenbosch Res Ctr, ZA-7735 Cape Town, South Africa	Potsdam Institut fur Klimafolgenforschung; Harvard University; Wageningen University & Research; University of Bristol; University of Oxford; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Museo Nacional de Ciencias Naturales (MNCN); University of Southampton; Swiss Federal Institutes of Technology Domain; ETH Zurich; Finnish Environment Institute; Centro de Investigacion Ecologica y Aplicaciones Forestales (CREAF); University of Barcelona; Helmholtz Association; Karlsruhe Institute of Technology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Rothamsted Research; UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); Centre National de la Recherche Scientifique (CNRS); Universite de Savoie; UDICE-French Research Universities; PSL Research University Paris; Ecole Pratique des Hautes Etudes (EPHE); Institut Agro; Montpellier SupAgro; CIRAD; Centre National de la Recherche Scientifique (CNRS); Institut de Recherche pour le Developpement (IRD); Universite Paul-Valery; Universite de Montpellier; University of East Anglia; Universite Catholique Louvain; Lund University; University of Aberdeen; South African National Biodiversity Institute	Schroter, D (corresponding author), Potsdam Inst Climate Impact Res, D-14473 Potsdam, Germany.	dagmar.schroeter@gmail.com	Sabaté, Santiago/I-3395-2016; Rounsevell, Mark D A/AAC-4498-2021; Smith, Jo U/F-7763-2012; Zaehle, Sönke/C-9528-2017; Bugmann, Harald/A-1252-2008; Smith, Pete/G-1041-2010; Rounsevell, Mark D A/C-5481-2011; Glendining, Margaret/I-1942-2019; Arnell, Nigel/AAC-7331-2020; Metzger, Marc J./B-2510-2010; Bondeau, Alberte/E-9909-2012; Thuiller, Wilfried/G-3283-2010; House, Joanna I/B-6477-2016; Araújo, Miguel B/B-6117-2008; Cramer, Wolfgang/B-8221-2008; Leemans, Rik/A-1548-2009; Klein, Richard J.T./B-1148-2009; Metzger, Marc/S-3976-2019; Sitch, Stephen A/F-8034-2015; Smith, Benjamin/I-1212-2016; Carter, Timothy R/N-4411-2017	Sabaté, Santiago/0000-0003-1854-0761; Rounsevell, Mark D A/0000-0001-7476-9398; Smith, Jo U/0000-0001-6984-6766; Zaehle, Sönke/0000-0001-5602-7956; Smith, Pete/0000-0002-3784-1124; Metzger, Marc J./0000-0002-5119-5894; Bondeau, Alberte/0000-0002-8729-5061; Thuiller, Wilfried/0000-0002-5388-5274; House, Joanna I/0000-0003-4576-3960; Araújo, Miguel B/0000-0002-5107-7265; Cramer, Wolfgang/0000-0002-9205-5812; Leemans, Rik/0000-0002-4001-6301; Klein, Richard J.T./0000-0002-9458-0944; Metzger, Marc/0000-0002-5119-5894; Sitch, Stephen A/0000-0003-1821-8561; Smith, Benjamin/0000-0002-6987-5337; Carter, Timothy R/0000-0002-4026-8859; Bugmann, Harald/0000-0003-4233-0094; de la Vega-Leinert, Anne Cristina/0000-0003-0290-249X; Mitchell, Tim/0000-0003-4071-1977; Lindner, Marcus/0000-0002-0770-003X				Arnell NW, 2004, GLOBAL ENVIRON CHANG, V14, P31, DOI 10.1016/j.gloenvcha.2003.10.006; Elsasser H, 2001, MT RES DEV, V21, P335, DOI 10.1659/0276-4741(2001)021[0335:TVOTSI]2.0.CO;2; Ewert F, 2005, AGR ECOSYST ENVIRON, V107, P101, DOI [10.1016/j.agee.2004.12.003, 10.1016/j.agee.2004.12.002]; FALKENMARK M, 1989, NAT RESOUR FORUM, V13, P258, DOI 10.1111/j.1477-8947.1989.tb00348.x; Fang CM, 2005, NATURE, V433, P57, DOI 10.1038/nature03138; Foley JA, 2005, SCIENCE, V309, P570, DOI 10.1126/science.1111772; Gottfried Michael, 1999, Diversity and Distributions, V5, P241, DOI 10.1046/j.1472-4642.1999.00058.x; Hooper DU, 2005, ECOL MONOGR, V75, P3, DOI 10.1890/04-0922; Knorr W, 2005, NATURE, V433, P298, DOI 10.1038/nature03226; McGuire AD, 2001, GLOBAL BIOGEOCHEM CY, V15, P183, DOI 10.1029/2000GB001298; MEA (Millenium Ecosystem Assessment), 2003, ECOSYSTEMS HUMAN WEL; Nabuurs GJ, 2003, GLOBAL CHANGE BIOL, V9, P152, DOI 10.1046/j.1365-2486.2003.00570.x; Nakieenovie N., 2000, INTERGOVERNMENTAL PA; Palmer M, 2004, SCIENCE, V304, P1251, DOI 10.1126/science.1095780; Reid W.V, 2005, MILLENNIUM ECOSYSTEM; Sala OE, 2000, SCIENCE, V287, P1770, DOI 10.1126/science.287.5459.1770; Schulze ED, 2005, NATURE, V437, P205, DOI 10.1038/437205a; Thuiller W, 2005, P NATL ACAD SCI USA, V102, P8245, DOI 10.1073/pnas.0409902102; Thuiller W, 2004, GLOBAL CHANGE BIOL, V10, P2020, DOI 10.1111/j.1365-2486.2004.00859.x; *UN ENV PROGR, 2002, 3 UNEP EARTHSC; Walther GR, 2002, NATURE, V416, P389, DOI 10.1038/416389a; *WORLD TOUR ORG, 2003, 1 INT C CLIM CHANG T; Zierl B, 2005, WATER RESOUR RES, V41, DOI 10.1029/2004WR003447	23	1130	1217	30	1061	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 25	2005	310	5752					1333	1337		10.1126/science.1115233	http://dx.doi.org/10.1126/science.1115233			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	988KN	16254151				2022-12-28	WOS:000233600200043
J	Perry, JE; Churchill, LR; Kirshner, HS				Perry, JE; Churchill, LR; Kirshner, HS			The Terri Schiavo case: Legal, ethical, and medical perspectives	ANNALS OF INTERNAL MEDICINE			English	Article							VEGETATIVE STATE	Although tragic, the plight of Terri Schiavo provides a valuable case study. The conflicts and misunderstandings surrounding her situation offer important lessons in medicine, law, and ethics. Despite media saturation and intense public interest, widespread confusion lingers regarding the diagnosis of persistent vegetative state, the judicial processes involved, and the appropriateness of the ethical framework used by those entrusted with Terri Schiavo's care. First, the authors review the current medical understanding of persistent vegetative state, including the requirements for patient examination, the differential diagnosis, and the practice guidelines of the American Academy of Neurology regarding artificial nutrition and hydration for patients with this diagnosis. Second, they examine the legal history, including the 2000 trial, the 2002 evidentiary hearing, and the subsequent appeals. The authors argue that the law did not fail Terri Schiavo, but produced the highest-quality evidence and provided the most judicial review of any end-of-life guardianship case in U.S. history. Third, they review alternative ethical frameworks for understanding the Terri Schiavo case and contend that the principle of respect for autonomy is paramount in this case and in similar cases. Far from being unusual, the manner in which Terri Schiavo's case was reviewed and the basis for the decision reflect a broad medical, legal, and ethical consensus. Greater clarity regarding the persistent vegetative state, less apprehension of the presumed mysteries of legal proceedings, and greater appreciation of the ethical principles at work are the chief benefits obtained from studying this provocative case.	Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, Nashville, TN 37232 USA	Vanderbilt University	Perry, JE (corresponding author), Vanderbilt Univ, Med Ctr, Ctr Biomed Eth & Soc, 507B Light Hall, Nashville, TN 37232 USA.							[Anonymous], 1989, NEUROLOGY, V39, P125; ASHWAL S, 1994, NEW ENGL J MED, V330, P1499; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Beauchamp T., 1994, PRINCIPLES BIOMEDICA, P120; Beuthien-Baumann B, 2003, NUCL MED COMMUN, V24, P643, DOI 10.1097/00006231-200306000-00005; BROOKS D, 2005, NY TIMES        0326, pA13; Els T, 2004, ACTA NEUROL SCAND, V110, P361, DOI 10.1111/j.1600-0404.2004.00342.x; FADEN RUTH R., 1986, HIST THEORY INFORM C, P3; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; Laureys S, 2002, NEUROIMAGE, V17, P732, DOI 10.1006/nimg.2002.1236; LYTLE T, 2005, ORLANDO SENTINE 0420, pA18; ROSENBERG JH, 1995, NEUROLOGY, V45, P1015; Snyder L, 2005, ANN INTERN MED, V142, P560, DOI 10.7326/0003-4819-142-7-200504050-00014; THOGMARTIN JR, 2005, CHIEF MED EXAMINER R	14	42	42	1	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 15	2005	143	10					744	748		10.7326/0003-4819-143-10-200511150-00012	http://dx.doi.org/10.7326/0003-4819-143-10-200511150-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	986YY	16287796				2022-12-28	WOS:000233486800007
J	Miller, N; Estoup, A; Toepfer, S; Bourguet, D; Lapchin, L; Derridj, S; Kim, KS; Reynaud, P; Furlan, L; Guillemaud, T				Miller, N; Estoup, A; Toepfer, S; Bourguet, D; Lapchin, L; Derridj, S; Kim, KS; Reynaud, P; Furlan, L; Guillemaud, T			Multiple transatlantic introductions of the western corn rootworm	SCIENCE			English	Article						invasion; introduced species; Approximate Bayesian Computation; colonization; Diabrotica virgifera virgifera; microsatellites; pest species; biological invasion; bioinvasion; multiple introductions; bayesian analysis; ABC; diabrotica virgifera virgifera	INVASIONS		Univ Nice, INRA, UMR 1112, F-06903 Sophia Antipolis, France; Ctr Biol & Gest Populat, F-34988 Montferrier Sur Lez, France; Plant Hlth Serv, CABI Biosci, Switzerland Ctr Field Labs, H-6800 Hodmezovasarhely, Hungary; INRA, UMR 1272, F-78026 Versailles, France; Iowa State Univ, Agr Res Serv, USDA, Corn Insects & Crop Genet Res Unit,Genet Lab, Ames, IA 50011 USA; Lab Natl Protect Vegetaux, F-34060 Montpellier, France; Agripolis, Dipartimento Agron Ambientale & Prod Vegetali, I-35020 Padua, Italy	INRAE; UDICE-French Research Universities; Universite Cote d'Azur; Institut de Recherche pour le Developpement (IRD); INRAE; UDICE-French Research Universities; Universite Paris Saclay; Iowa State University; United States Department of Agriculture (USDA)	Guillemaud, T (corresponding author), Univ Nice, INRA, UMR 1112, 400 Route Chappes, F-06903 Sophia Antipolis, France.	guillem@antibes.inra.fr	guillemaud, thomas/B-4899-2012; Miller, Nicholas/I-4119-2012	guillemaud, thomas/0000-0003-0451-1644; Miller, Nicholas/0000-0001-9827-8286; Bourguet, Denis/0000-0002-2109-5323; Furlan, Lorenzo/0000-0003-4021-4532				Beaumont MA, 2002, GENETICS, V162, P2025; Enserink M, 1999, SCIENCE, V285, P1834, DOI 10.1126/science.285.5435.1834; Kim KS, 2005, MOL ECOL NOTES, V5, P115, DOI 10.1111/j.1471-8286.2004.00853.x; Kiss J, 2005, Western Corn Rootworm: Ecology and Management, P29, DOI 10.1079/9780851998176.0029; Mack RN, 2000, ECOL APPL, V10, P689, DOI 10.1890/1051-0761(2000)010[0689:BICEGC]2.0.CO;2	5	254	270	2	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2005	310	5750					992	992		10.1126/science.1115871	http://dx.doi.org/10.1126/science.1115871			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284172	Green Submitted			2022-12-28	WOS:000233343400035
J	Sakaguchi, H; Matsumura, H; Gong, H; Abouelwafa, AM				Sakaguchi, H; Matsumura, H; Gong, H; Abouelwafa, AM			Direct visualization of the formation of single-molecule conjugated copolymers	SCIENCE			English	Article							SCANNING-TUNNELING-MICROSCOPY; ALKOXY-SUBSTITUTED POLYTHIOPHENES; 2-DIMENSIONAL POLYCRYSTALS; POLYMERS; POLYMERIZATION; CRYSTALS; WIRES	Electrochemical polymerization of two different kinds of thiophene monomers on an iodine-covered gold surface created highly assembled conjugated copolymers with different electronic structures. A scanning tunneling microscope revealed images of several linkage types: diblock, triblock, and multiblock. The single strand of conjugated copolymers exhibited an anomalous swinging motion on the surface. This technique presents the possibility of understanding the copolymerization process from the different monomers on the single-molecular scale and of building single-molecule superlattices on a surface through controlled electropolymerization.	Shizuoka Univ, Elect Res Inst, Hamamatsu, Shizuoka 4328011, Japan; Japan Sci & Technol Agcy, Precursory Res Embryon Sci & Technol PRESTO, Kawaguchi 3320012, Japan	Shizuoka University; Japan Science & Technology Agency (JST)	Sakaguchi, H (corresponding author), Shizuoka Univ, Elect Res Inst, 3-5-1 Johoku, Hamamatsu, Shizuoka 4328011, Japan.	sakaguchi@rie.shizuoka.ac.jp		Sakaguchi, Hiroshi/0000-0003-1942-907X				Akai-Kasaya M, 2003, PHYS REV LETT, V91, DOI 10.1103/PhysRevLett.91.255501; Bakhshi AK, 2000, J MOL STRUC-THEOCHEM, V499, P105, DOI 10.1016/S0166-1280(99)00275-4; BARBARELLA G, 1992, ADV MATER, V4, P282, DOI 10.1002/adma.19920040408; BARNER J, 2003, ANGEW CHEM, V115, P1976; Brun M, 2004, ADV MATER, V16, P2087, DOI 10.1002/adma.200400088; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; Bumm LA, 1999, J PHYS CHEM B, V103, P8122, DOI 10.1021/jp9921699; DAOUST G, 1991, MACROMOLECULES, V24, P455, DOI 10.1021/ma00002a018; Gesquiere A, 2001, NANO LETT, V1, P201, DOI 10.1021/nl015511d; Gigli G, 1998, APPL PHYS LETT, V73, P2414, DOI 10.1063/1.122451; Grevin B, 2003, ADV MATER, V15, P881, DOI 10.1002/adma.200304580; Grevin B, 2003, J CHEM PHYS, V118, P7097, DOI 10.1063/1.1561435; Grobis M, 2005, APPL PHYS LETT, V86, DOI 10.1063/1.1931822; Hla SW, 2000, PHYS REV LETT, V85, P2777, DOI 10.1103/PhysRevLett.85.2777; IYODA T, 1991, J PHYS CHEM-US, V95, P5215, DOI 10.1021/j100166a055; Johansson T, 2003, J MATER CHEM, V13, P1316, DOI 10.1039/b301403g; Leclerc M, 1999, ADV MATER, V11, P1491, DOI 10.1002/(SICI)1521-4095(199912)11:18<1491::AID-ADMA1491>3.0.CO;2-O; LECLERC M, 1990, J CHEM SOC CHEM COMM, P273, DOI 10.1039/c39900000273; McCullough RD, 1998, ADV MATER, V10, P93, DOI 10.1002/(SICI)1521-4095(199801)10:2<93::AID-ADMA93>3.0.CO;2-F; Mena-Osteritz E, 2000, ANGEW CHEM INT EDIT, V39, P2680; Ng MK, 2002, J AM CHEM SOC, V124, P11862, DOI 10.1021/ja026808w; NG MK, 2002, ANGEW CHEM, V114, P3750; Okawa Y, 2001, NATURE, V409, P683, DOI 10.1038/35055625; ROUX C, 1992, MACROMOLECULES, V25, P2141, DOI 10.1021/ma00034a012; Sakaguchi H, 2004, NAT MATER, V3, P551, DOI 10.1038/nmat1176; Sirringhaus H, 2000, APPL PHYS LETT, V77, P406, DOI 10.1063/1.126991; Yamachika R, 2004, SCIENCE, V304, P281, DOI 10.1126/science.1095069	27	103	103	7	64	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 11	2005	310	5750					1002	1006		10.1126/science.1117990	http://dx.doi.org/10.1126/science.1117990			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	984YN	16284175				2022-12-28	WOS:000233343400039
J	Stoleru, D; Peng, Y; Nawathean, P; Rosbash, M				Stoleru, D; Peng, Y; Nawathean, P; Rosbash, M			A resetting signal between Drosophila pacemakers synchronizes morning and evening activity	NATURE			English	Article							CIRCADIAN GENE-EXPRESSION; CLOCK GENE; SUPRACHIASMATIC NUCLEUS; INDIVIDUAL FIBROBLASTS; NERVOUS-SYSTEM; TIMELESS GENES; NEURONS; RHYTHMS; BRAIN; CELLS	The biochemical machinery that underlies circadian rhythms is conserved among animal species and drives self-sustained molecular oscillations and functions, even within individual asynchronous tissue-culture cells(1-3). Yet the rhythm- generating neural centres of higher eukaryotes are usually composed of interconnected cellular networks, which contribute to robustness and synchrony as well as other complex features of rhythmic behaviour(4-7). In mammals, little is known about how individual brain oscillators are organized to orchestrate a complex behavioural pattern. Drosophila is arguably more advanced from this point of view: we and others have recently shown that a group of adult brain clock neurons expresses the neuropeptide PDF8 and controls morning activity ( small LNv cells; M-cells), whereas another group of clock neurons controls evening activity (CRY+, PDF- cells; E-cells)(6,9). We have generated transgenic mosaic animals with different circadian periods in morning and evening cells. Here we show, by behavioural and molecular assays, that the six canonical groups of clock neurons(10) are organized into two separate neuronal circuits. One has no apparent effect on locomotor rhythmicity in darkness, but within the second circuit the molecular and behavioural timing of the evening cells is determined by morning-cell properties. This is due to a daily resetting signal from the morning to the evening cells, which run at their genetically programmed pace between consecutive signals. This neural circuit and oscillator-coupling mechanism ensures a proper relationship between the timing of morning and evening locomotor activity.	Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA; Brandeis Univ, Natl Ctr Behav Genom, Dept Biol, Waltham, MA 02454 USA	Brandeis University; Howard Hughes Medical Institute; Brandeis University	Rosbash, M (corresponding author), Brandeis Univ, Howard Hughes Med Inst, Waltham, MA 02454 USA.	rosbash@brandeis.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007292] Funding Source: NIH RePORTER; NINDS NIH HHS [T32 NS007292] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Aton SJ, 2005, NAT NEUROSCI, V8, P476, DOI 10.1038/nn1419; Balsalobre A, 1998, CELL, V93, P929, DOI 10.1016/S0092-8674(00)81199-X; de la Iglesia HO, 2004, CURR BIOL, V14, P796, DOI 10.1016/j.cub.2004.04.034; Grima B, 2004, NATURE, V431, P869, DOI 10.1038/nature02935; Harmar AJ, 2002, CELL, V109, P497, DOI 10.1016/S0092-8674(02)00736-5; HELFRICHFORSTER C, 1995, P NATL ACAD SCI USA, V92, P612, DOI 10.1073/pnas.92.2.612; Jagota A, 2000, NAT NEUROSCI, V3, P372, DOI 10.1038/73943; Kaneko M, 2000, J COMP NEUROL, V422, P66, DOI 10.1002/(SICI)1096-9861(20000619)422:1<66::AID-CNE5>3.0.CO;2-2; Kaneko M, 1997, J NEUROSCI, V17, P6745; Klarsfeld A, 2004, J NEUROSCI, V24, P1468, DOI 10.1523/JNEUROSCI.3661-03.2004; Levine JD, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-5; Levine JD, 2002, BMC NEUROSCI, V3, DOI 10.1186/1471-2202-3-1; Lin Y, 2004, J NEUROSCI, V24, P7951, DOI 10.1523/JNEUROSCI.2370-04.2004; Martinek S, 2001, CELL, V105, P769, DOI 10.1016/S0092-8674(01)00383-X; Nagoshi E, 2004, CELL, V119, P693, DOI 10.1016/S0092-8674(04)01054-2; Peng Y, 2003, PLOS BIOL, V1, P32, DOI 10.1371/journal.pbio.0000013; Petri B, 1997, J NEUROSCI, V17, P4087; Renn SCP, 1999, CELL, V99, P791, DOI 10.1016/S0092-8674(00)81676-1; Rorth P, 1996, P NATL ACAD SCI USA, V93, P12418, DOI 10.1073/pnas.93.22.12418; Stoleru D, 2004, NATURE, V431, P862, DOI 10.1038/nature02926; Veleri S, 2003, CURR BIOL, V13, P1758, DOI 10.1016/j.cub.2003.09.030; Welsh DK, 2004, CURR BIOL, V14, P2289, DOI 10.1016/j.cub.2004.11.057; Yang ZH, 2001, NEURON, V29, P453, DOI 10.1016/S0896-6273(01)00218-5; Zhao J, 2003, CELL, V113, P755, DOI 10.1016/S0092-8674(03)00400-8	24	231	233	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 10	2005	438	7065					238	242		10.1038/nature04192	http://dx.doi.org/10.1038/nature04192			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	982BV	16281038				2022-12-28	WOS:000233133500052
J	Yusuf, S; Hawken, S; Ounpuu, S; Bautista, L; Franzosi, MG; Commerford, P; Lang, CC; Rumboldt, Z; Onen, CL; Liu, LS; Tanomsup, S; Wangai, P; Razak, F; Sharma, AM; Anand, SS				Yusuf, S; Hawken, S; Ounpuu, S; Bautista, L; Franzosi, MG; Commerford, P; Lang, CC; Rumboldt, Z; Onen, CL; Liu, LS; Tanomsup, S; Wangai, P; Razak, F; Sharma, AM; Anand, SS		INTERHEART Study Investigators	Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study	LANCET			English	Article							BODY-MASS INDEX; CORONARY-HEART-DISEASE; ADIPOSE-TISSUE; HIP CIRCUMFERENCES; ABDOMINAL OBESITY; INSULIN; MORTALITY; FAT; MEN; GLUCOSE	Background Obesity is a major risk factor for cardiovascular disease, but the most predictive measure for different ethnic populations is not clear. We aimed to assess whether markers of obesity, especially waist-to-hip ratio, would be stronger indicators of myocardial infarction than body-mass index (BMI), the conventional measure. Methods We did a standardised case-control study of acute myocardial infarction with 27 098 participants in 52 countries (12461 cases and 14637 controls) representing several major ethnic groups. We assessed the relation between BMI, waist and hip circumferences, and waist-to-hip ratio to myocardial infarction overall and for each group. Findings BMI showed a modest and graded association with myocardial infarction (OR 1.44, 95% CI 1.32-1.57 top quintile vs bottom quintile before adjustment), which was substantially reduced after adjustment for waist-to-hip ratio (1.12, 1.03-1.22), and non-significant after adjustment for other risk factors (0.98, 0.88-1.09). For waist-to-hip ratio, the odds ratios for every successive quintile were significantly greater than that of the previous one (2nd quintile: 1.15, 1.05-1.26; 3rd quintile: 1.39; 1.28-1.52; 4th quintile: 1.90, 1.74-2.07; and 5th quintiles: 2.52, 2.31-2.74 [adjusted for age, sex, region, and smoking]). Waist (adjusted OR 1.77; 1.59-1.97) and hip (0.73; 0.66-0.80) circumferences were both highly significant after adjustment for BMI (p<0.0001 top vs bottom quintiles). Waist-to-hip ratio and waist and hip circumferences were closely (p<0.0001) associated with risk of myocardial infarction even after adjustment for other risk factors (ORs for top quintile vs lowest quintiles were 1.75, 1.33, and 0.76, respectively). The population-attributable risks of myocardial infarction for increased waist-to-hip ratio in the top two quintiles was 24.3% (95% CI 22.5-26.2) compared with only 7.7% (6.0-10.0) for the top two quintiles of BMI. Interpretation Waist-to-hip ratio shows a graded and highly significant association with myocardial infarction risk worldwide. Redefinition of obesity based on waist-to-hip ratio instead of BMI increases the estimate of myocardial infarction attributable to obesity in most ethnic groups.	McMaster Univ, Populat Hlth Res Inst, Hamilton, ON, Canada; Hamilton Hlth Sci, Hamilton, ON, Canada; Univ Wisconsin, Sch Med, Madison, WI 53706 USA; Ist Mario Negri, Milan, Italy; Univ Cape Town, ZA-7700 Rondebosch, South Africa; Univ Dundee, Ninewells Hosp & Med Sch, Dundee DD1 9SY, Scotland; Univ Split, Split, Croatia; Gaborone Private Hosp, Gaborone, Botswana; Cardiovasc Inst, Beijing, Peoples R China; Fu Wai Hosp, Beijing, Peoples R China; Ramathibodi Hosp, Bangkok, Thailand; Nairobi Womens Hosp, Nairobi, Kenya	McMaster University; Population Health Research Institute; McMaster University; University of Wisconsin System; University of Wisconsin Madison; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; University of Cape Town; University of Dundee; University of Split; Chinese Academy of Medical Sciences - Peking Union Medical College; Fu Wai Hospital - CAMS; Mahidol University	Yusuf, S (corresponding author), Hamilton Gen Hosp, Populat Hlth Res Inst, Hamilton, ON L8L 2X2, Canada.	yusufs@mcmaster.ca	Rumboldt, Zvonko/D-6274-2017	Rumboldt, Zvonko/0000-0002-6811-275X; Yusuf, Salim/0000-0003-4776-5601; Hawken, Steven/0000-0002-3341-9022; Bautista, Leonelo/0000-0002-9151-6920; Lang, Chim/0000-0002-4530-3078				AGRESTI A, 2002, CATEGORICAL DATA ANA, P357; Ajani UA, 2004, ANN EPIDEMIOL, V14, P731, DOI 10.1016/j.annepidem.2003.10.008; Baik I, 2000, AM J EPIDEMIOL, V152, P264, DOI 10.1093/aje/152.3.264; BENICHOU J, 1990, BIOMETRICS, V46, P991, DOI 10.2307/2532443; Bjorntorp P, 1996, INT J OBESITY, V20, P291; Chowdhury B, 1996, METABOLISM, V45, P634, DOI 10.1016/S0026-0495(96)90036-0; Dagenais GR, 2005, AM HEART J, V149, P54, DOI 10.1016/j.ahj.2004.07.009; DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595; Deurenberg P, 1998, INT J OBESITY, V22, P1164, DOI 10.1038/sj/ijo/0800741; Engel LS, 2003, J NATL CANCER I, V95, P1404, DOI 10.1093/jnci/djg047; Firth D, 2004, BIOMETRIKA, V91, P65, DOI 10.1093/biomet/91.1.65; Kataria, 2016, SAUDI J SPORTS MED, V16, P139; Klein S, 2004, NEW ENGL J MED, V350, P2549, DOI 10.1056/NEJMoa033179; Lissner L, 2001, OBES RES, V9, P644, DOI 10.1038/oby.2001.85; Livingstone C, 2002, CLIN SCI, V102, P151, DOI 10.1042/cs1020151; McLellan F, 2002, LANCET, V359, P1412, DOI 10.1016/S0140-6736(02)08397-6; Okura T, 2004, ARTERIOSCL THROM VAS, V24, P923, DOI 10.1161/01.ATV.0000125702.26272.f6; Ounpuu S, 2001, AM HEART J, V141, P711, DOI 10.1067/mhj.2001.114974; Pais P, 1996, LANCET, V348, P358, DOI 10.1016/S0140-6736(96)02507-X; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Rexrode KM, 2001, INT J OBESITY, V25, P1047, DOI 10.1038/sj.ijo.0801615; RICHELSEN B, 1991, METABOLISM, V40, P990, DOI 10.1016/0026-0495(91)90078-B; SEIDELL JC, 1989, INT J OBESITY, V13, P289; Seidell JC, 1997, J INTERN MED, V242, P401, DOI 10.1046/j.1365-2796.1997.00235.x; Snijder MB, 2004, INT J OBESITY, V28, P402, DOI 10.1038/sj.ijo.0802567; Snijder MB, 2003, OBES RES, V11, P104, DOI 10.1038/oby.2003.18; Snijder MB, 2005, DIABETOLOGIA, V48, P301, DOI 10.1007/s00125-004-1637-7; Thorne A, 2002, INT J OBESITY, V26, P193, DOI 10.1038/sj.ijo.0801871; Vohl MC, 2004, OBES RES, V12, P1217, DOI 10.1038/oby.2004.153; WHO, 2004, LANCET, V363, P902; WHO Consultation, 2000, WHO TECH REP SER, V894, P1; Widlansky ME, 2004, ARCH INTERN MED, V164, P2326, DOI 10.1001/archinte.164.21.2326; Yusuf S, 2001, CIRCULATION, V104, P2746, DOI 10.1161/hc4601.099487; Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9	34	1964	2065	1	135	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 5	2005	366	9497					1640	1649		10.1016/S0140-6736(05)67663-5	http://dx.doi.org/10.1016/S0140-6736(05)67663-5			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	980VU	16271645				2022-12-28	WOS:000233047100025
J	Montori, VM; Devereaux, PJ; Adhikari, NKJ; Burns, KEA; Eggert, CH; Briel, M; Lacchetti, C; Leung, TW; Darling, E; Bryant, DM; Bucher, HC; Schunemann, H; Meade, MO; Cook, DJ; Erwin, PJ; Sood, A; Sood, R; Lo, B; Thompson, CA; Zhou, Q; Mills, E; Guyatt, GH				Montori, VM; Devereaux, PJ; Adhikari, NKJ; Burns, KEA; Eggert, CH; Briel, M; Lacchetti, C; Leung, TW; Darling, E; Bryant, DM; Bucher, HC; Schunemann, H; Meade, MO; Cook, DJ; Erwin, PJ; Sood, A; Sood, R; Lo, B; Thompson, CA; Zhou, Q; Mills, E; Guyatt, GH			Randomized trials stopped early for benefit - A systematic review	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							NONCARDIAC SURGERY; CLINICAL-TRIALS; RECOMMENDATIONS; GUIDELINE; THERAPY; RISK	Context Randomized clinical trials (RCTs) that stop earlier than planned because of apparent benefit often receive great attention and affect clinical practice. Their prevalence, the magnitude and plausibility of their treatment effects, and the extent to which they report information about how investigators decided to stop early are, however, unknown. Objective To evaluate the epidemiology and reporting quality of RCTs involving interventions stopped early for benefit. Data Sources Systematic review up to November 2004 of MEDLINE, EMBASE, Current Contents, and full-text journal content databases to identify RCTs stopped early for benefit. Study Selection Randomized clinical trials of any intervention reported as having stopped early because of results favoring the intervention. There were no exclusion criteria. Data Extraction Twelve reviewers working independently and in duplicate abstracted data on content area and type of intervention tested, reporting of funding, type of end point driving study termination, treatment effect, length of follow-up, estimated sample size and total sample studied, role of a data and safety monitoring board in stopping the study, number of interim analyses planned and conducted, and existence and type of monitoring methods, statistical boundaries, and adjustment procedures for interim analyses and early stopping. Data Synthesis Of 143 RCTs stopped early for benefit, the majority (92) were published in 5 high-impact medical journals. Typically, these were industry-funded drug trials in cardiology, cancer, and human immunodeficiency virus/AIDS. The proportion of all RCTs published in high-impact journals that were stopped early for benefit increased from 0.5% in 1990-1994 to 1.2% in 2000-2004 (P<.001 for trend). On average, RCTs recruited 63% (SD, 25%) of the planned sample and stopped after a median of 13 (interquartile range [IQR], 3-25) months of follow-up, 1 interim analysis, and when a median of 66 (IQR, 23-195) patients had experienced the end point driving study termination (event). The median risk ratio among truncated RCTs was 0.53 (IQR, 0.28-0.66). One hundred thirty-five (94%) of the 143 RCTs did not report at least 1 of the following: the planned sample size (n =28), the interim analysis after which the trial was stopped (n = 45), whether a stopping rule informed the decision (n = 48), or an adjusted analysis accounting for interim monitoring and truncation (n = 129). Trials with fewer events yielded greater treatment effects (odds ratio, 28; 95% confidence interval, 11-73). Conclusions RCTs stopped early for benefit are becoming more common, often fail to adequately report relevant information about the decision to stop early, and show implausibly large treatment effects, particularly when the number of events is small. These findings suggest clinicians should view the results of such trials with skepticism.	McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Hamilton, ON L8N 325, Canada; McMaster Univ, Bachelor Hlth Sci Programme, Hamilton, ON L8N 325, Canada; McMaster Univ, Dept Med, Hamilton, ON L8N 325, Canada; Mayo Clin Coll Med, Dept Med, Rochester, MN USA; Univ Toronto, Interdepartmental Div Crit Care, Toronto, ON, Canada; Univ Hosp, Basel Inst Clin Epidemiol, Basel, Switzerland; Univ Buffalo, Dept Med, Buffalo, NY 14260 USA; Univ Buffalo, Dept Social & Prevent Med, Buffalo, NY 14260 USA; Italian Natl Canc Inst Regina Elena, Div Clin Res Dev & Informat Translat, Rome, Italy	McMaster University; University of Manitoba; Children's Hospital Research Institute of Manitoba; McMaster University; McMaster University; Mayo Clinic; University of Toronto; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	Guyatt, GH (corresponding author), McMaster Univ, Hlth Sci Ctr, Dept Clin Epidemiol & Biostat, Room 2C12, Hamilton, ON L8N 325, Canada.	guyatt@mcmaster.ca	Bryant, Dianne M/K-6766-2013; Devereaux, PJ/AAY-1757-2021; Zhou, Qi/GSM-9583-2022; Briel, Matthias/AAT-9284-2021; Devereaux, PJ/AAF-2862-2019	Bryant, Dianne M/0000-0002-7535-8707; Schunemann, Holger/0000-0003-3211-8479; Darling, Liz/0000-0003-2675-3222; Montori, Victor/0000-0003-0595-2898; Briel, Matthias/0000-0002-2070-5230; Devereaux, PJ/0000-0003-2935-637X				Cannistra SA, 2004, J CLIN ONCOL, V22, P1542, DOI 10.1200/JCO.2004.02.150; Cook RJ, 1995, CAN J STAT, V23, P333, DOI 10.2307/3315378; Devereaux PJ, 2004, CAN MED ASSOC J, V171, P245, DOI 10.1503/cmaj.1031619; Eagle KA, 2002, J AM COLL CARDIOL, V39, P542, DOI 10.1016/S0735-1097(01)01788-0; Guyatt G., 2015, USERS GUIDES MED LIT; Guyatt Gordon, 2004, ACP J Club, V140, pA11; Juurlink DN, 2004, NEW ENGL J MED, V351, P543, DOI 10.1056/NEJMoa040135; LAN KKG, 1988, BIOMETRICS, V44, P579, DOI 10.2307/2531870; LAN KKG, 1983, BIOMETRIKA, V70, P659, DOI 10.2307/2336502; Moher D, 2001, JAMA-J AM MED ASSOC, V285, P1987, DOI 10.1001/jama.285.15.1987; Montori VM, 2005, BMJ-BRIT MED J, V330, P594, DOI 10.1136/bmj.330.7491.594; Palda VA, 1997, ANN INTERN MED, V127, P313, DOI 10.7326/0003-4819-127-4-199708150-00012; Pocock S, 1999, LANCET, V353, P943, DOI 10.1016/S0140-6736(98)00379-1; POCOCK SJ, 1989, CONTROL CLIN TRIALS, V10, pS209; Poldermans D, 1999, NEW ENGL J MED, V341, P1789, DOI 10.1056/NEJM199912093412402; Prandoni P, 2002, ARCH INTERN MED, V162, P1966, DOI 10.1001/archinte.162.17.1966; Slutsky AS, 2004, NEW ENGL J MED, V350, P1143, DOI 10.1056/NEJMsb033476; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Wheatley K, 2003, CONTROL CLIN TRIALS, V24, P66, DOI 10.1016/S0197-2456(02)00273-8; YANG H, 2004, CAN J ANAESTH, V51, pA7	20	515	523	1	36	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 2	2005	294	17					2203	2209		10.1001/jama.294.17.2203	http://dx.doi.org/10.1001/jama.294.17.2203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	979PQ	16264162				2022-12-28	WOS:000232957700023
J	Sullivan, F; Wyatt, JC				Sullivan, F; Wyatt, JC			ABC of health informatics - How computers help make efficient use of consultations	BRITISH MEDICAL JOURNAL			English	Review							MATTER; CARE		Univ Dundee, Dundee DD1 4HN, Scotland	University of Dundee	Sullivan, F (corresponding author), Univ Dundee, Dundee DD1 4HN, Scotland.		Sullivan, Frank m/A-7767-2009; Sullivan, Frank/L-8286-2019; Wyatt, Jeremy/F-8160-2010	Sullivan, Frank/0000-0002-6623-4964; Wyatt, Jeremy/0000-0001-7008-1473				Bates DW, 2003, J AM MED INFORM ASSN, V10, P523, DOI 10.1197/jamia.M1370; Berwick DM, 1996, BRIT MED J, V312, P619, DOI 10.1136/bmj.312.7031.619; Gardner M, 2003, BRIT MED J, V326, P1101, DOI 10.1136/bmj.326.7399.1101; Guthrie B, 2000, BRIT MED J, V321, P734, DOI 10.1136/bmj.321.7263.734; Schatz M, 2003, AM J MANAG CARE, V9, P538; Wasson JH, 1996, JAMA-J AM MED ASSOC, V275, P641, DOI 10.1001/jama.275.8.641; WYATT JC, 1995, BMJ-BRIT MED J, V311, P1539, DOI 10.1136/bmj.311.7019.1539	7	9	9	0	2	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8146			BRIT MED J	Br. Med. J.	OCT 29	2005	331	7523					1010	1012		10.1136/bmj.331.7523.1010	http://dx.doi.org/10.1136/bmj.331.7523.1010			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	981AU	16254303	Green Published			2022-12-28	WOS:000233060200021
J	Mueller, CA; Broz, P; Muller, SA; Ringler, P; Erne-Brand, F; Sorg, I; Kuhn, M; Engel, A; Cornelis, GR				Mueller, CA; Broz, P; Muller, SA; Ringler, P; Erne-Brand, F; Sorg, I; Kuhn, M; Engel, A; Cornelis, GR			The V-antigen of Yersinia forms a distinct structure at the tip of injectisome needles	SCIENCE			English	Article							PROTEIN SECRETION; VIRULENCE; ENTEROCOLITICA; TRANSLOCON; SYSTEM	Many pathogenic bacteria use injectisomes to deliver effector proteins into host cells through type III secretion. Injectisomes consist of a basal body embedded in the bacterial membranes and a needle. In Yersinia, translocation of effectors requires the YopB and YopD proteins, which form a pore in the target cell membrane, and the LcrV protein, which assists the assembly of the pore. Here we report that LcrV forms a distinct structure at the tip of the needle, the tip complex. This unique localization of LcrV may explain its crucial role in the translocation process and its efficacy as the main protective antigen against plague.	Univ Basel, Biozentrum, CH-4056 Basel, Switzerland; Maurice E Muller Inst, CH-4056 Basel, Switzerland	University of Basel	Cornelis, GR (corresponding author), Univ Basel, Biozentrum, Klingelbergstr 50-70, CH-4056 Basel, Switzerland.	guy.cornelis@unibas.ch	Broz, Petr/AAC-7940-2019	Broz, Petr/0000-0002-2334-7790				BURROWS TW, 1956, NATURE, V177, P426, DOI 10.1038/177426b0; Chakravortty D, 2005, EMBO J, V24, P2043, DOI 10.1038/sj.emboj.7600676; Cordes FS, 2003, J BIOL CHEM, V278, P17103, DOI 10.1074/jbc.M300091200; Cornelis GR, 1997, MOL MICROBIOL, V23, P861, DOI 10.1046/j.1365-2958.1997.2731623.x; Daniell SJ, 2001, CELL MICROBIOL, V3, P865, DOI 10.1046/j.1462-5822.2001.00168.x; Fields KA, 1999, INFECT IMMUN, V67, P5395, DOI 10.1128/IAI.67.10.5395-5408.1999; Galan JE, 1999, SCIENCE, V284, P1322, DOI 10.1126/science.284.5418.1322; Goure J, 2005, J INFECT DIS, V192, P218, DOI 10.1086/430932; Hoiczyk E, 2001, P NATL ACAD SCI USA, V98, P4669, DOI 10.1073/pnas.071065798; Journet L, 2003, SCIENCE, V302, P1757, DOI 10.1126/science.1091422; Kubori T, 1998, SCIENCE, V280, P602, DOI 10.1126/science.280.5363.602; LAWTON WD, 1963, J INFECT DIS, V113, P39, DOI 10.1093/infdis/113.1.39; Marenne MN, 2003, MICROB PATHOGENESIS, V35, P243, DOI 10.1016/S0882-4010(03)00154-2; MUELLER CA, UNPUB; Pettersson J, 1999, MOL MICROBIOL, V32, P961, DOI 10.1046/j.1365-2958.1999.01408.x; Philipovskiy AV, 2005, INFECT IMMUN, V73, P1532, DOI 10.1128/IAI.73.3.1532-1542.2005; Picking WL, 2005, INFECT IMMUN, V73, P1432, DOI 10.1128/IAI.73.3.1432-1440.2005	17	267	278	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 28	2005	310	5748					674	676		10.1126/science.1118476	http://dx.doi.org/10.1126/science.1118476			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	980ET	16254184				2022-12-28	WOS:000232997700041
J	Gibbs, R				Gibbs, R			Deeper into the genome	NATURE			English	Editorial Material									Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Gibbs, R (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.							Altshuler D, 2005, NATURE, V437, P1299, DOI 10.1038/nature04226; Botstein D, 2003, NAT GENET, V33, P228, DOI 10.1038/ng1090; Cohen J, 2005, NAT GENET, V37, P328, DOI 10.1038/ng0305-328c; GIBBS RA, 1990, GENOMICS, V7, P235, DOI 10.1016/0888-7543(90)90545-6; Krizhevsky A, 2017, COMMUN ACM, V60, P84, DOI 10.1145/3065386; Lin Z, 2004, SCIENCE, V305, P183, DOI 10.1126/science.1095019; Pritchard JK, 2002, HUM MOL GENET, V11, P2417, DOI 10.1093/hmg/11.20.2417; Reich DE, 2001, TRENDS GENET, V17, P502, DOI 10.1016/S0168-9525(01)02410-6	8	22	22	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1233	1234		10.1038/4371233a	http://dx.doi.org/10.1038/4371233a			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251930	Bronze			2022-12-28	WOS:000232829100020
J	Hobson, JA				Hobson, JA			Sleep is of the brain, by the brain and for the brain	NATURE			English	Editorial Material								Sleep is a widespread biological phenomenon, and its scientific study is proceeding at multiple levels at the same time. Marked progress is being made in answering three fundamental questions: what is sleep, what are its mechanisms and what are its functions? The most salient answers to these questions have resulted from applying new techniques from basic and applied neuroscience research. The study of sleep is also shedding light on our understanding of consciousness, which undergoes alteration in parallel with sleep-induced changes in the brain.	Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA	Harvard University; Harvard Medical School	Hobson, JA (corresponding author), Harvard Univ, Sch Med, Dept Psychiat, 74 Fenwood Rd,401 Pk Dr,2nd Floor E, Boston, MA 02115 USA.	allan_hobson@hms.harvard.edu	Sanguansri, Luz/B-6630-2011	Sanguansri, Luz/0000-0003-1908-7604				Achermann P, 1997, NEUROSCIENCE, V81, P213, DOI 10.1016/S0306-4522(97)00186-3; ALLISON T, 1976, SCIENCE, V194, P732, DOI 10.1126/science.982039; ASERINSKY E, 1953, SCIENCE, V118, P273, DOI 10.1126/science.118.3062.273; Braun AR, 1997, BRAIN, V120, P1173, DOI 10.1093/brain/120.7.1173; DEMENT W, 1958, J EXP PSYCHOL, V55, P543, DOI 10.1037/h0040031; Fosse MJ, 2003, J COGNITIVE NEUROSCI, V15, P1, DOI 10.1162/089892903321107774; Fosse R, 2001, PSYCHOL SCI, V12, P30, DOI 10.1111/1467-9280.00306; Freud S, 1949, OUTLINE PSYCHOANALYS; Hobson J. A., 1986, HDB PHYSL 1, P701; Hobson J. A., 2002, DREAMING INTRO SCI S; Huber R, 2004, NATURE, V430, P78, DOI 10.1038/nature02663; KETY SS, 1955, T AM NEUROL ASSOC, V80, P125; LIBET B, 1983, BRAIN, V106, P623, DOI 10.1093/brain/106.3.623; Maquet P, 1996, NATURE, V383, P163, DOI 10.1038/383163a0; Metzinger T, 2003, BEING NO ONE; Nofzinger EA, 1997, BRAIN RES, V770, P192, DOI 10.1016/S0006-8993(97)00807-X; Pavlov IP, 1960, CONDITIONED REFLEXES; SHERRINGTON C, 1995, MAN HIS NATURE; Steriade M., 1999, Society for Neuroscience Abstracts, V25, P1661	19	169	175	6	49	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1254	1256		10.1038/nature04283	http://dx.doi.org/10.1038/nature04283			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977UQ	16251949				2022-12-28	WOS:000232829100037
J	Nowak, MA; Sigmund, K				Nowak, MA; Sigmund, K			Evolution of indirect reciprocity	NATURE			English	Review							TIT-FOR-TAT; PRISONERS-DILEMMA; SOCIAL NORMS; NEURAL BASIS; ALTRUISTIC PUNISHMENT; REPEATED GAMES; COOPERATION; REPUTATION; INFORMATION; DYNAMICS	Natural selection is conventionally assumed to favour the strong and selfish who maximize their own resources at the expense of others. But many biological systems, and especially human societies, are organized around altruistic, cooperative interactions. How can natural selection promote unselfish behaviour? Various mechanisms have been proposed, and a rich analysis of indirect reciprocity has recently emerged: I help you and somebody else helps me. The evolution of cooperation by indirect reciprocity leads to reputation building, morality judgement and complex social interactions with ever-increasing cognitive demands.	Univ Vienna, Fac Math, A-1090 Vienna, Austria; IIASA, A-2631 Laxenburg, Austria; Harvard Univ, Dept Math, Dept Organism & Evolutionary Biol, Program Evolutionary Dynam, Cambridge, MA 02138 USA	University of Vienna; International Institute for Applied Systems Analysis (IIASA); Harvard University	Sigmund, K (corresponding author), Univ Vienna, Fac Math, Waehringer Guertel 18, A-1090 Vienna, Austria.	karl.sigmund@univie.ac.at	Nowak, Martin A/A-6977-2008					Alexander R., 1987, BIOL MORAL SYSTEMS; [Anonymous], 1997, MACHIAVELLIAN INTELL; Arrow K. J., 1974, LIMITS ORG; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BERG J, 1995, GAME ECON BEHAV, V10, P122, DOI 10.1006/game.1995.1027; Binmore K., 1992, FUN GAMES TEXT GAME; Binmore K. G., 1994, GAME THEORY SOCIAL C; Bolton GE, 2005, APPL OPTIMIZAT, V92, P195, DOI 10.1007/0-387-23392-X_7; Bolton GE, 2005, J PUBLIC ECON, V89, P1457, DOI 10.1016/j.jpubeco.2004.03.008; Bolton GE, 2004, MANAGE SCI, V50, P1587, DOI 10.1287/mnsc.1030.0199; BOYD R, 1989, SOC NETWORKS, V11, P213, DOI 10.1016/0378-8733(89)90003-8; Brandt H, 2005, P NATL ACAD SCI USA, V102, P2666, DOI 10.1073/pnas.0407370102; Brandt H, 2004, J THEOR BIOL, V231, P475, DOI 10.1016/j.jtbi.2004.06.032; BRANDT H, IN PRESS J THEOR BIO; Brown D. E., 1991, HUMAN UNIVERSALS; Camerer C, 2003, BEHAV GAME THEORY; Colman AM, 2013, GAME THEORY ITS APPL; DAWES RM, 1980, ANNU REV PSYCHOL, V31, P169, DOI 10.1146/annurev.ps.31.020180.001125; de Quervain DJF, 2004, SCIENCE, V305, P1254, DOI 10.1126/science.1100735; DELLAROCAS C, 2003, 429703 MIT SLOAN SCH; Dufwenberg Martin, 2001, HOMO OECON, V18, P19; Dunbar R., 1996, GROOMING GOSSIP EVOL; ELLISON G, 1994, REV ECON STUD, V61, P567, DOI 10.2307/2297904; Engelmann D., 2002, 132 U ZUR; Fehr E, 2002, NATURE, V415, P137, DOI 10.1038/415137a; Fehr E, 2004, TRENDS COGN SCI, V8, P185, DOI 10.1016/j.tics.2004.02.007; Fehr E, 2004, NATURE, V432, P449, DOI 10.1038/432449a; Fehr E, 2004, EVOL HUM BEHAV, V25, P63, DOI 10.1016/S1090-5138(04)00005-4; Fehr E, 2003, NATURE, V425, P785, DOI 10.1038/nature02043; Fehr E, 2000, AM ECON REV, V90, P980, DOI 10.1257/aer.90.4.980; Ferriere R, 1998, NATURE, V393, P517, DOI 10.1038/31102; Fishman MA, 2003, J THEOR BIOL, V225, P285, DOI 10.1016/S0022-5193(03)00246-7; Fishman MA, 2001, J THEOR BIOL, V209, P87, DOI 10.1006/jtbi.2000.2248; FREAN MR, 1994, P ROY SOC B-BIOL SCI, V257, P75, DOI 10.1098/rspb.1994.0096; FUDENBERG D, 1986, ECONOMETRICA, V54, P533, DOI 10.2307/1911307; FUDENBERG D, 1990, AM ECON REV, V80, P274; Gintis H., 2000, GAME THEORY EVOLVING; GREINER B, 2003, 200315 M PLANCK I; Guth Werner, 2001, HOMO OECON, V18, P241; Haley KJ, 2005, EVOL HUM BEHAV, V26, P245, DOI 10.1016/j.evolhumbehav.2005.01.002; Hamilton W.D., 1996, NARROW ROADS GENE LA, V1; Imhof LA, 2005, P NATL ACAD SCI USA, V102, P10797, DOI 10.1073/pnas.0502589102; KANDORI M, 1992, REV ECON STUD, V59, P63, DOI 10.2307/2297925; KESER C, 2002, 2002S75 IBM CIRANO W; Kosfeld M, 2005, NATURE, V435, P673, DOI 10.1038/nature03701; Leimar O, 2001, P ROY SOC B-BIOL SCI, V268, P745, DOI 10.1098/rspb.2000.1573; Lotem A, 1999, NATURE, V400, P226, DOI 10.1038/22247; LOTEM A, 2002, P ROY SOC LOND B BIO, V270, P199; LUCKINGREILEY D, 1999, PENNIES EBAY DETERMI; Milgrom P., 1990, ECON POLIT-OXFORD, V2, P1, DOI DOI 10.1111/J.1468-0343.1990.TB00020.X; Milinski M, 2002, P ROY SOC B-BIOL SCI, V269, P881, DOI 10.1098/rspb.2002.1964; Milinski M, 2002, NATURE, V415, P424, DOI 10.1038/415424a; Milinski M, 2001, P ROY SOC B-BIOL SCI, V268, P2495, DOI 10.1098/rspb.2001.1809; Mohtashemi M, 2003, J THEOR BIOL, V223, P523, DOI 10.1016/S0022-5193(03)00143-7; NOWAK M, 1993, NATURE, V364, P56, DOI 10.1038/364056a0; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; Nowak MA, 2004, SCIENCE, V303, P793, DOI 10.1126/science.1093411; NOWAK MA, 1994, J THEOR BIOL, V168, P219, DOI 10.1006/jtbi.1994.1101; Nowak MA, 1998, J THEOR BIOL, V194, P561, DOI 10.1006/jtbi.1998.0775; Nowak MA, 1998, NATURE, V393, P573, DOI 10.1038/31225; Nowak MA, 2004, NATURE, V428, P646, DOI 10.1038/nature02414; Ohtsuki H, 2004, J THEOR BIOL, V231, P107, DOI 10.1016/j.jtbi.2004.06.005; OHTSUKI H, IN PRESS J THEOR BIO; OKUNOFUJIWARA M, 1995, GAME ECON BEHAV, V9, P79, DOI 10.1006/game.1995.1006; Panchanathan K, 2004, NATURE, V432, P499, DOI 10.1038/nature02978; Panchanathan K, 2003, J THEOR BIOL, V224, P115, DOI 10.1016/S0022-5193(03)00154-1; Pfeiffer T, 2005, P ROY SOC B-BIOL SCI, V272, P1115, DOI 10.1098/rspb.2004.2988; POLLOCK G, 1992, J THEOR BIOL, V159, P25, DOI 10.1016/S0022-5193(05)80765-9; Resnick P, 2000, COMMUN ACM, V43, P45, DOI 10.1145/355112.355122; Rilling JK, 2002, NEURON, V35, P395, DOI 10.1016/S0896-6273(02)00755-9; ROSENTHAL RW, 1979, ECONOMETRICA, V47, P1353, DOI 10.2307/1914005; Sanfey AG, 2003, SCIENCE, V300, P1755, DOI 10.1126/science.1082976; Seabright P, 2004, CO STRANGERS NATURAL; Sigmund K, 2001, P NATL ACAD SCI USA, V98, P10757, DOI 10.1073/pnas.161155698; SINEN I, IN PRESS EUR EC REV; Smith J. M., 1997, MAJOR TRANSITIONS EV; Sugden R, 1986, EC RIGHTS COOPERATIO; Suzuki Y, 2005, J THEOR BIOL, V232, P191, DOI 10.1016/j.jtbi.2004.08.006; Takahashi N., 2003, 29 HOKK U; Trivers R. L., 1985, SOCIAL EVOLUTION; TRIVERS RL, 1971, Q REV BIOL, V46, P35, DOI 10.1086/406755; Wedekind C, 2000, SCIENCE, V288, P850, DOI 10.1126/science.288.5467.850; Wedekind C, 2002, CURR BIOL, V12, P1012, DOI 10.1016/S0960-9822(02)00890-4; Wedekind C, 1998, SCIENCE, V280, P2070; WILSON DS, 1975, P NATL ACAD SCI USA, V72, P143, DOI 10.1073/pnas.72.1.143; Wilson E.O., 1975, P1	87	1456	1505	22	473	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	OCT 27	2005	437	7063					1291	1298		10.1038/nature04131	http://dx.doi.org/10.1038/nature04131			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	977UQ	16251955	Green Submitted			2022-12-28	WOS:000232829100043
J	Gur, I; Fromer, NA; Geier, ML; Alivisatos, AP				Gur, I; Fromer, NA; Geier, ML; Alivisatos, AP			Air-stable all-inorganic nanocrystal solar cells processed from solution	SCIENCE			English	Article							PHOTOVOLTAIC CELLS	We introduce an ultrathin donor-acceptor solar cell composed entirely of inorganic nanocrystals spin-cast from solution. These devices are stable in air, and post-fabrication processing allows for power conversion efficiencies approaching 3% in initial tests. This demonstration elucidates a class of photovoltaic devices with potential for stable, tow-cost power generation.	Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Chem, Berkeley, CA 94720 USA; Univ Calif Berkeley, Dept Mat Sci & Engn, Berkeley, CA 94720 USA	United States Department of Energy (DOE); Lawrence Berkeley National Laboratory; University of California System; University of California Berkeley; University of California System; University of California Berkeley; University of California System; University of California Berkeley	Alivisatos, AP (corresponding author), Univ Calif Berkeley, Lawrence Berkeley Lab, Div Mat Sci, Berkeley, CA 94720 USA.	alivis@berkeley.edu	Alivisatos, Paul/N-8863-2015	Alivisatos, Paul/0000-0001-6895-9048				Alivisatos AP, 1996, J PHYS CHEM-US, V100, P13226, DOI 10.1021/jp9535506; Barker JA, 2003, PHYS REV B, V67, DOI 10.1103/PhysRevB.67.075205; Coakley KM, 2003, APPL PHYS LETT, V83, P3380, DOI 10.1063/1.1616197; Fahrenbruch A.L., 1983, FUNDAMENTALS SOLAR C; Ginger DS, 2000, J APPL PHYS, V87, P1361, DOI 10.1063/1.372021; Gregg BA, 2003, J APPL PHYS, V93, P3605, DOI 10.1063/1.1544413; HALLS JJM, 1995, NATURE, V376, P498, DOI 10.1038/376498a0; Heitmann J, 2004, PHYS REV B, V69, DOI 10.1103/PhysRevB.69.195309; Huynh WU, 2002, SCIENCE, V295, P2425, DOI 10.1126/science.1069156; Kim S, 2003, J AM CHEM SOC, V125, P11466, DOI 10.1021/ja0361749; Li LS, 2001, NANO LETT, V1, P349, DOI 10.1021/nl015559r; McCandless BE, 1997, PROG PHOTOVOLTAICS, V5, P249, DOI 10.1002/(SICI)1099-159X(199707/08)5:4<249::AID-PIP178>3.0.CO;2-S; Milliron DJ, 2004, NATURE, V430, P190, DOI 10.1038/nature02695; Morgan NY, 2002, PHYS REV B, V66, DOI 10.1103/PhysRevB.66.075339; Murray CB, 2000, ANNU REV MATER SCI, V30, P545, DOI 10.1146/annurev.matsci.30.1.545; Nozik AJ, 2002, PHYSICA E, V14, P115, DOI 10.1016/S1386-9477(02)00374-0; Peumans P, 2000, APPL PHYS LETT, V76, P2650, DOI 10.1063/1.126433; Shaheen SE, 2005, MRS BULL, V30, P10, DOI 10.1557/mrs2005.2; Shaheen SE, 2001, APPL PHYS LETT, V78, P841, DOI 10.1063/1.1345834; Shim M, 2001, MRS BULL, V26, P1005, DOI 10.1557/mrs2001.257; Sun BQ, 2005, J APPL PHYS, V97, DOI 10.1063/1.1804613; Sze S., 1981, PHYS SEMICONDUCTOR D, V2nd ed., P85; YU G, 1995, SCIENCE, V270, P1789, DOI 10.1126/science.270.5243.1789	23	1528	1602	7	411	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 21	2005	310	5747					462	465		10.1126/science.1117908	http://dx.doi.org/10.1126/science.1117908			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	977EU	16239470	Green Submitted			2022-12-28	WOS:000232786000037
